abstract_id,relation_id,entity_a_id,entity_b_id,type,novel,sentence,url,Assigned to,True type,True relation,yes For LitCoin,To be studied relation (Y) or title specific (T),Relation word,Relation word 2,"QC (C:correct, W: wrong, Q:qestionable)",ent1 select,ent2 select,Note,3,agree with our labeling,check,Note_from_annotation
1353340,0,D007966,410,Association,FALSE,We report on a new allele at the <ENT2>arylsulfatase A</ENT2> (<ENT2>ARSA</ENT2>) locus causing late-onset <ENT1>metachromatic leukodystrophy</ENT1> (<ENT1>MLD</ENT1>).,,,,T,,,,,c,,,"11,12,21,22",,1.0,,
1353340,0,D007966,410,Association,FALSE,"In contrast to alleles that cause early-onset <ENT1>MLD</ENT1>, the arginine84 to glutamine substitution is associated with some residual <ENT2>ARSA</ENT2> activity.",,,,T,,,,,c,,,,,0.0,,
1353340,0,D007966,410,Association,FALSE,"A comparison of genotypes, <ENT2>ARSA</ENT2> activities, and clinical data on 4 individuals carrying the allele of 81 patients with <ENT1>MLD</ENT1> examined, further validates the concept that different degrees of residual <ENT2>ARSA</ENT2> activity are the basis of phenotypical variation in <ENT1>MLD</ENT1>..",,,,T,,,,,c,,,,,0.25,,
1353340,1,D007966,rs74315458,Positive_Correlation,TRUE,"In contrast to alleles that cause early-onset <ENT1>MLD</ENT1>, the <ENT2>arginine84 to glutamine</ENT2> substitution is associated with some residual ARSA activity.",,,,T,,,,,c,,,,,0.0,,
1671881,4,D010661,5053,Association,FALSE,<ENT1>Classical phenylketonuria</ENT1> is an autosomal recessive disease caused by a deficiency of hepatic phenylalanine hydroxylase (<ENT2>PAH</ENT2>).,,,,T,,,,,c,,,,,1.0,,
1671881,5,OMIM:261600,5053,Negative_Correlation,FALSE,Classical phenylketonuria is an autosomal recessive disease caused by a <ENT1>deficiency of hepatic phenylalanine hydroxylase</ENT1> (<ENT2>PAH</ENT2>).,,,,T,,,,,c,,,,,0.0,,
1848636,9,D007008,D013726,Positive_Correlation,FALSE,The drug effect studied was the antagonism by metoprolol of <ENT2>terbutaline</ENT2>-induced <ENT1>hypokalemia</ENT1>.,,,,T,,,,,c,,,,,1.0,,
1848636,13,D007008,D008790,Negative_Correlation,FALSE,The drug effect studied was the antagonism by <ENT2>metoprolol</ENT2> of terbutaline-induced <ENT1>hypokalemia</ENT1>.,,,,T,,,,,c,,,,,1.0,,
1848636,10,D013034,D008790,Association,FALSE,The metabolism of the cardioselective beta-blocker <ENT2>metoprolol</ENT2> is under genetic control of the debrisoquine/<ENT1>sparteine</ENT1> type.,,,,T,,,,,c,,,,,1.0,,
1848636,8,153,D008790,Negative_Correlation,FALSE,"The two metabolic phenotypes, extensive (EM) and poor metabolizers (PM), show different stereoselective metabolism, resulting in apparently higher <ENT1>beta-1 adrenoceptor</ENT1> antagonistic potency of racemic <ENT2>metoprolol</ENT2> in EMs.",,,,T,,,,,c,,,,,1.0,,
1848636,12,D013726,D008790,Positive_Correlation,TRUE,The drug effect studied was the antagonism by <ENT2>metoprolol</ENT2> of <ENT1>terbutaline</ENT1>-induced hypokalemia.,,,,T,Y,,,,c,,,,,1.0,,
1848636,12,D013726,D008790,Positive_Correlation,TRUE,Six EMs received 0.5 mg of <ENT1>terbutaline</ENT1> s.c. on two different occasions: 1) 1 hr after administration of a placebo and 2) 1 hr after 150 mg of <ENT2>metoprolol</ENT2> p.o.,,,,T,,,,,c,,,,,1.0,,
1848636,12,D013726,D008790,Positive_Correlation,TRUE,"Blood samples for the analysis of plasma potassium, <ENT1>terbutaline</ENT1>, <ENT2>metoprolol</ENT2> (racemic, R- and S-isomer), and alpha-hydroxymetoprolol concentrations were taken at regular time intervals, during 8 hr after <ENT2>metoprolol</ENT2>.",,,,T,,,,,c,,,,,1.0,,
1848636,12,D013726,D008790,Positive_Correlation,TRUE,"In PMs, <ENT2>metoprolol</ENT2> increased the <ENT1>terbutaline</ENT1> area under the plasma concentration vs. time curve (+67%).",,,,T,,,,,c,,,,,1.0,,
1848636,11,D008790,D003647,Association,FALSE,<ENT2>Debrisoquine</ENT2> phenotype and the pharmacokinetics and beta-2 receptor pharmacodynamics of <ENT1>metoprolol</ENT1> and its enantiomers.,,,,T,,,,,c,,,,,0.0,,
1848636,11,D008790,D003647,Association,FALSE,The metabolism of the cardioselective beta-blocker <ENT1>metoprolol</ENT1> is under genetic control of the <ENT2>debrisoquine</ENT2>/sparteine type.,,,,T,,,,,c,,,,,1.0,,
1848636,14,D008790,154,Negative_Correlation,TRUE,Debrisoquine phenotype and the pharmacokinetics and <ENT2>beta-2 receptor</ENT2> pharmacodynamics of <ENT1>metoprolol</ENT1> and its enantiomers.,,,,T,,,,,c,,,,,1.0,,
1848636,14,D008790,154,Negative_Correlation,TRUE,We investigated if the latter also applies to the <ENT2>beta-2 adrenoceptor</ENT2> antagonism by <ENT1>metoprolol</ENT1>.,,,,T,,,,,c,,,,,0.0,,
2422478,15,D008750,D007022,Positive_Correlation,TRUE,Midline B3 serotonin nerves in rat medulla are involved in <ENT2>hypotensive</ENT2> effect of <ENT1>methyldopa</ENT1>.,,,,T,,,,,w,,,,,1.0,,
2422478,15,D008750,D007022,Positive_Correlation,TRUE,Previous experiments in this laboratory have shown that microinjection of <ENT1>methyldopa</ENT1> onto the ventrolateral cells of the B3 serotonin neurons in the medulla elicits a <ENT2>hypotensive</ENT2> response mediated by a projection descending into the spinal cord.,,,,T,,,,,c,,,,,1.0,,
2422478,15,D008750,D007022,Positive_Correlation,TRUE,"In spontaneously hypertensive, stroke-prone rats, microinjection of <ENT1>methyldopa</ENT1> into the area of the midline B3 serotonin cell group in the ventral medulla caused a potent <ENT2>hypotension</ENT2> of 30-40 mm Hg, which was maximal 2-3 h after administration and was abolished by the serotonin neurotoxin 5,7-dihydroxytryptamine (5,7-DHT) injected intracerebroventricularly.",,,,T,,,,,c,,,,,1.0,,
2422478,15,D008750,D007022,Positive_Correlation,TRUE,"It is concluded therefore that, unlike the ventrolateral B3 cells which mediate a <ENT1>methyldopa</ENT1>-induced <ENT2>hypotension</ENT2> via descending projections, the midline serotonin B3 cells in the medulla contribute to the <ENT2>hypotensive</ENT2> action of <ENT1>methyldopa</ENT1>, either by way of an ascending projection which does not pass through the median forebrain bundle, or through a projection restricted to the caudal brainstem.",,,,T,,,,,c,,,"11,22",,0.5,,
2422478,17,D008750,D012701,Positive_Correlation,TRUE,Midline B3 <ENT2>serotonin</ENT2> nerves in rat medulla are involved in hypotensive effect of <ENT1>methyldopa</ENT1>.,,,,T,,,,,w,,,,,1.0,,
2422478,17,D008750,D012701,Positive_Correlation,TRUE,Previous experiments in this laboratory have shown that microinjection of <ENT1>methyldopa</ENT1> onto the ventrolateral cells of the B3 <ENT2>serotonin</ENT2> neurons in the medulla elicits a hypotensive response mediated by a projection descending into the spinal cord.,,,,T,,,,,w,,,,,1.0,,
2422478,17,D008750,D012701,Positive_Correlation,TRUE,"In spontaneously hypertensive, stroke-prone rats, microinjection of <ENT1>methyldopa</ENT1> into the area of the midline B3 <ENT2>serotonin</ENT2> cell group in the ventral medulla caused a potent hypotension of 30-40 mm Hg, which was maximal 2-3 h after administration and was abolished by the <ENT2>serotonin</ENT2> neurotoxin 5,7-dihydroxytryptamine (5,7-DHT) injected intracerebroventricularly.",,,,T,,,,,w,,,,,1.0,,
2422478,17,D008750,D012701,Positive_Correlation,TRUE,"Further, 5,7-DHT lesion of <ENT2>serotonin</ENT2> nerves travelling in the median forebrain bundle, one of the main ascending pathways from the B3 <ENT2>serotonin</ENT2> cells, did not affect the fall in blood pressure associated with a midline B3 <ENT2>serotonin</ENT2> <ENT1>methyldopa</ENT1> injection.",,,,T,,,,,c,,,,,1.0,,
2422478,17,D008750,D012701,Positive_Correlation,TRUE,"It is concluded therefore that, unlike the ventrolateral B3 cells which mediate a <ENT1>methyldopa</ENT1>-induced hypotension via descending projections, the midline <ENT2>serotonin</ENT2> B3 cells in the medulla contribute to the hypotensive action of <ENT1>methyldopa</ENT1>, either by way of an ascending projection which does not pass through the median forebrain bundle, or through a projection restricted to the caudal brainstem.",,,,T,,,,,w,,,,,1.0,,
2422478,16,D015116,D012701,Association,TRUE,"In spontaneously hypertensive, stroke-prone rats, microinjection of methyldopa into the area of the midline B3 <ENT2>serotonin</ENT2> cell group in the ventral medulla caused a potent hypotension of 30-40 mm Hg, which was maximal 2-3 h after administration and was abolished by the <ENT2>serotonin</ENT2> neurotoxin <ENT1>5,7-dihydroxytryptamine</ENT1> (<ENT1>5,7-DHT</ENT1>) injected intracerebroventricularly.",,,,T,,,,,c,,,,,0.75,,
2422478,16,D015116,D012701,Association,TRUE,"However, intraspinal injection of <ENT1>5,7-DHT</ENT1> to produce a more selective lesion of only descending <ENT2>serotonin</ENT2> projections in the spinal cord did not affect this hypotension.",,,,T,,,,,w,,,,,1.0,,
2422478,16,D015116,D012701,Association,TRUE,"Further, <ENT1>5,7-DHT</ENT1> lesion of <ENT2>serotonin</ENT2> nerves travelling in the median forebrain bundle, one of the main ascending pathways from the B3 <ENT2>serotonin</ENT2> cells, did not affect the fall in blood pressure associated with a midline B3 <ENT2>serotonin</ENT2> methyldopa injection.",,,,T,,,,,c,,,,,1.0,,
2422478,18,D007022,D012701,Positive_Correlation,TRUE,Midline B3 <ENT2>serotonin</ENT2> nerves in rat medulla are involved in <ENT1>hypotensive</ENT1> effect of methyldopa.,,,,T,Y,,,,c,,,,,0.0,,
2422478,18,D007022,D012701,Positive_Correlation,TRUE,Previous experiments in this laboratory have shown that microinjection of methyldopa onto the ventrolateral cells of the B3 <ENT2>serotonin</ENT2> neurons in the medulla elicits a <ENT1>hypotensive</ENT1> response mediated by a projection descending into the spinal cord.,,,,T,,,,,w,,,,,1.0,,
2422478,18,D007022,D012701,Positive_Correlation,TRUE,"In spontaneously hypertensive, stroke-prone rats, microinjection of methyldopa into the area of the midline B3 <ENT2>serotonin</ENT2> cell group in the ventral medulla caused a potent <ENT1>hypotension</ENT1> of 30-40 mm Hg, which was maximal 2-3 h after administration and was abolished by the <ENT2>serotonin</ENT2> neurotoxin 5,7-dihydroxytryptamine (5,7-DHT) injected intracerebroventricularly.",,,,T,,,,,w,,,,,0.5,,
2422478,18,D007022,D012701,Positive_Correlation,TRUE,"However, intraspinal injection of 5,7-DHT to produce a more selective lesion of only descending <ENT2>serotonin</ENT2> projections in the spinal cord did not affect this <ENT1>hypotension</ENT1>.",,,,T,,,,,c,,,,,1.0,,
2422478,18,D007022,D012701,Positive_Correlation,TRUE,"It is concluded therefore that, unlike the ventrolateral B3 cells which mediate a methyldopa-induced <ENT1>hypotension</ENT1> via descending projections, the midline <ENT2>serotonin</ENT2> B3 cells in the medulla contribute to the <ENT1>hypotensive</ENT1> action of methyldopa, either by way of an ascending projection which does not pass through the median forebrain bundle, or through a projection restricted to the caudal brainstem.",,,,T,,,,,w,,,,,1.0,,
2491010,19,1756,D020388,Association,TRUE,Eighty unrelated individuals with <ENT2>Duchenne muscular dystrophy</ENT2> (<ENT2>DMD</ENT2>)or <ENT2>Becker muscular dystrophy</ENT2> (<ENT2>BMD</ENT2>) were found to have deletions in the major deletion-rich region of the <ENT1>DMD</ENT1> locus.,,,,T,,,,,w,,,,,0.0,,
7468724,22,D007752,D013726,Negative_Correlation,FALSE,Cardiovascular complications associated with <ENT2>terbutaline</ENT2> treatment for <ENT1>preterm labor</ENT1>.,,,,T,,,,,w,,,,,0.0,,
7468724,22,D007752,D013726,Negative_Correlation,FALSE,Severe cardiovascular complications occurred in eight of 160 patients treated with <ENT2>terbutaline</ENT2> for <ENT1>preterm labor</ENT1>.,,,,T,,,,,c,,,,,1.0,,
7468724,24,D013726,D002318,Association,TRUE,<ENT2>Cardiovascular complications</ENT2> associated with <ENT1>terbutaline</ENT1> treatment for preterm labor.,,,,T,Y,,,,c,,,,,0.0,,
7468724,24,D013726,D002318,Association,TRUE,Severe <ENT2>cardiovascular complications</ENT2> occurred in eight of 160 patients treated with <ENT1>terbutaline</ENT1> for preterm labor.,,,,T,Y,,,,c,,,,,0.0,,
7668252,29,37,D019308,Positive_Correlation,TRUE,"In patient fibroblasts, raising <ENT1>VLCAD</ENT1> activity to approximately 20% of normal control fibroblast activity raised <ENT2>palmitic acid</ENT2> beta-oxidation flux to the level found in control fibroblasts, which may offer important information for the rational design of future somatic gene therapy for VLCAD deficiency..",,,,T,,,,,c,,,,,0.0,,
7668252,27,37,C536353,Negative_Correlation,FALSE,PCR-amplified <ENT1>VLCAD</ENT1> cDNAs were sequenced in cultured fibroblasts from two <ENT2>VLCAD-deficient</ENT2> patients.,,,,T,,,,,c,,,,,0.0,,
7668252,27,37,C536353,Negative_Correlation,FALSE,"Quantitative cDNA expression of normal human <ENT1>VLCAD</ENT1> was performed in the patients fibroblasts, using vaccinia viral system, which demonstrated that the <ENT2>deficiency of the normal VLCAD protein</ENT2> causes impaired long-chain fatty acid beta-oxidation activity in the patients fibroblasts.",,,,T,,,,,c,,,,,1.0,,
7668252,27,37,C536353,Negative_Correlation,FALSE,"In patient fibroblasts, raising <ENT1>VLCAD</ENT1> activity to approximately 20% of normal control fibroblast activity raised palmitic acid beta-oxidation flux to the level found in control fibroblasts, which may offer important information for the rational design of future somatic gene therapy for <ENT2>VLCAD deficiency</ENT2>..",,,,T,Y,,,,c,,,,,0.0,,
7668252,28,D019308,C536353,Association,TRUE,"In patient fibroblasts, raising VLCAD activity to approximately 20% of normal control fibroblast activity raised <ENT1>palmitic acid</ENT1> beta-oxidation flux to the level found in control fibroblasts, which may offer important information for the rational design of future somatic gene therapy for <ENT2>VLCAD deficiency</ENT2>..",,,,T,,,,,w,,,,,0.0,,
7668252,25,C536353,D005227,Negative_Correlation,TRUE,"Quantitative cDNA expression of normal human VLCAD was performed in the patients fibroblasts, using vaccinia viral system, which demonstrated that the <ENT1>deficiency of the normal VLCAD protein</ENT1> causes impaired <ENT2>long-chain fatty acid</ENT2> beta-oxidation activity in the patients fibroblasts.",,,,T,,,,,w,,,,,0.0,,
7905839,34,25601,D053610,Association,TRUE,The expressed <ENT1>mu OR1</ENT1> recognized tested <ENT2>opiate</ENT2> drugs and opioid peptides in a sodium- and GTP-sensitive fashion with affinities virtually identical to those displayed by the rat <ENT1>mu opiate receptor</ENT1>.,,,,T,,,,,c,,,,,0.5,,
7905839,32,25601,D006160,Association,FALSE,The expressed <ENT1>mu OR1</ENT1> recognized tested opiate drugs and opioid peptides in a sodium- and <ENT2>GTP</ENT2>-sensitive fashion with affinities virtually identical to those displayed by the rat <ENT1>mu opiate receptor</ENT1>.,,,,T,,,,,w,,,,,0.0,,
7905839,33,25601,D018847,Association,TRUE,The expressed <ENT1>mu OR1</ENT1> recognized tested opiate drugs and <ENT2>opioid peptides</ENT2> in a sodium- and GTP-sensitive fashion with affinities virtually identical to those displayed by the rat <ENT1>mu opiate receptor</ENT1>.,,,,T,,,,,c,,,,,0.5,,
7905839,35,25601,D012964,Association,FALSE,The expressed <ENT1>mu OR1</ENT1> recognized tested opiate drugs and opioid peptides in a <ENT2>sodium</ENT2>- and GTP-sensitive fashion with affinities virtually identical to those displayed by the rat <ENT1>mu opiate receptor</ENT1>.,,,,T,,,,,w,,,,,0.5,,
7905839,31,25601,D000242,Association,FALSE,Effects on <ENT2>cyclic AMP</ENT2> are similar to those noted for the rat <ENT1>mu opiate receptor</ENT1>.,,,,T,Y,,,,c,,,,,0.0,,
8755918,37,D001260,472,Association,TRUE,We have identified 14 families with <ENT1>ataxia-telangiectasia</ENT1> (<ENT1>A-T</ENT1>) in which mutation of the <ENT2>ATM</ENT2> gene is associated with a less severe clinical and cellular phenotype (approximately 10% -15% of <ENT1>A-T</ENT1> families identified in the United Kingdom).,,,,T,,,,,w,,,,,1.0,,
8829135,43,C534628,1813,Bind,FALSE,"These effects were not mediated by a dopaminergic mechanism as nefiracetam, at millimolar concentrations, failed to displace either [3H]<ENT1>SCH 23390</ENT1> or [3H]spiperone binding from <ENT2>D1 or D2 dopamine receptor</ENT2> subtypes, respectively.",,,,T,,,,,c,,,,,0.0,,
8829135,41,1813,D013134,Bind,FALSE,"These effects were not mediated by a dopaminergic mechanism as nefiracetam, at millimolar concentrations, failed to displace either [3H]SCH 23390 or [3H]<ENT2>spiperone</ENT2> binding from <ENT1>D1 or D2 dopamine receptor</ENT1> subtypes, respectively.",,,,T,,,,,c,,,,,1.0,,
8829135,40,D012601,D007859,Positive_Correlation,FALSE,Nefiracetam is a novel pyrrolidone derivative which attenuates <ENT1>scopolamine</ENT1>-induced <ENT2>learning and post-training consolidation deficits</ENT2>.,,,,T,,,,,c,,,,,1.0,,
8829135,47,D012601,C058876,Negative_Correlation,TRUE,<ENT2>Nefiracetam</ENT2> is a novel pyrrolidone derivative which attenuates <ENT1>scopolamine</ENT1>-induced learning and post-training consolidation deficits.,,,,T,Y,,,,c,,,,,1.0,,
8829135,50,D001058,C058876,Negative_Correlation,TRUE,<ENT2>Nefiracetam</ENT2> (<ENT2>DM-9384</ENT2>) reverses <ENT1>apomorphine</ENT1>-induced amnesia of a passive avoidance response: delayed emergence of the memory retention effects.,,,,T,Y,,,,c,,,,,0.5,,
8829135,50,D001058,C058876,Negative_Correlation,TRUE,"Given that <ENT1>apomorphine</ENT1> inhibits passive avoidance retention when given during training or in a defined 10-12h post-training period, we evaluated the ability of <ENT2>nefiracetam</ENT2> to attenuate amnesia induced by dopaminergic agonism.",,,,T,,,,,c,,,,,1.0,,
8829135,50,D001058,C058876,Negative_Correlation,TRUE,A step-down passive avoidance paradigm was employed and <ENT2>nefiracetam</ENT2> (3 mg/kg) and <ENT1>apomorphine</ENT1> (0.5 mg/kg) were given alone or in combination during training and at the 10-12h post-training period of consolidation.,,,,T,,,,,c,,,,,0.0,,
8829135,50,D001058,C058876,Negative_Correlation,TRUE,Co-administration of <ENT2>nefiracetam</ENT2> and <ENT1>apomorphine</ENT1> during training or 10h thereafter produced no significant anti-amnesic effect.,,,,T,,,,,w,,,,,0.0,,
8829135,50,D001058,C058876,Negative_Correlation,TRUE,"However, administration of <ENT2>nefiracetam</ENT2> during training completely reversed the amnesia induced by <ENT1>apomorphine</ENT1> at the 10h post-training time and the converse was also true.",,,,T,Y,,,,c,,,,,1.0,,
8829135,46,D001058,D000647,Positive_Correlation,FALSE,Nefiracetam (DM-9384) reverses <ENT1>apomorphine</ENT1>-induced <ENT2>amnesia</ENT2> of a passive avoidance response: delayed emergence of the memory retention effects.,,,,T,,,,,c,,,,,1.0,,
8829135,46,D001058,D000647,Positive_Correlation,FALSE,"Given that <ENT1>apomorphine</ENT1> inhibits passive avoidance retention when given during training or in a defined 10-12h post-training period, we evaluated the ability of nefiracetam to attenuate <ENT2>amnesia</ENT2> induced by dopaminergic agonism.",,,,T,,,,,c,,,,,0.0,,
8829135,46,D001058,D000647,Positive_Correlation,FALSE,Co-administration of nefiracetam and <ENT1>apomorphine</ENT1> during training or 10h thereafter produced no significant anti-<ENT2>amnesic</ENT2> effect.,,,,T,,,,,w,,,,,1.0,,
8829135,46,D001058,D000647,Positive_Correlation,FALSE,"However, administration of nefiracetam during training completely reversed the <ENT2>amnesia</ENT2> induced by <ENT1>apomorphine</ENT1> at the 10h post-training time and the converse was also true.",,,,T,,,,,c,,,,,1.0,,
8829135,48,D007859,C058876,Negative_Correlation,TRUE,<ENT2>Nefiracetam</ENT2> is a novel pyrrolidone derivative which attenuates scopolamine-induced <ENT1>learning and post-training consolidation deficits</ENT1>.,,,,T,,,,,c,,,,,1.0,,
8829135,51,C058876,D000647,Negative_Correlation,TRUE,<ENT1>Nefiracetam</ENT1> (<ENT1>DM-9384</ENT1>) reverses apomorphine-induced <ENT2>amnesia</ENT2> of a passive avoidance response: delayed emergence of the memory retention effects.,,,,T,,,,,c,,,,,0.0,,
8829135,51,C058876,D000647,Negative_Correlation,TRUE,"Given that apomorphine inhibits passive avoidance retention when given during training or in a defined 10-12h post-training period, we evaluated the ability of <ENT1>nefiracetam</ENT1> to attenuate <ENT2>amnesia</ENT2> induced by dopaminergic agonism.",,,,T,,Y,,,w,,,,,0.0,,
8829135,51,C058876,D000647,Negative_Correlation,TRUE,Co-administration of <ENT1>nefiracetam</ENT1> and apomorphine during training or 10h thereafter produced no significant anti-<ENT2>amnesic</ENT2> effect.,,,,T,,,,,w,,,,,0.0,,
8829135,51,C058876,D000647,Negative_Correlation,TRUE,"However, administration of <ENT1>nefiracetam</ENT1> during training completely reversed the <ENT2>amnesia</ENT2> induced by apomorphine at the 10h post-training time and the converse was also true.",,,,T,,,,,c,,,,,1.0,,
8829135,49,C058876,D018491,Negative_Correlation,TRUE,"Given that apomorphine inhibits passive avoidance retention when given during training or in a defined 10-12h post-training period, we evaluated the ability of <ENT1>nefiracetam</ENT1> to attenuate amnesia induced by <ENT2>dopaminergic agonism</ENT2>.",,,,T,,Y,,,w,,,,,1.0,,
8829135,45,D000647,D018491,Positive_Correlation,TRUE,"Given that apomorphine inhibits passive avoidance retention when given during training or in a defined 10-12h post-training period, we evaluated the ability of nefiracetam to attenuate <ENT1>amnesia</ENT1> induced by <ENT2>dopaminergic agonism</ENT2>.",,,,T,,,,,c,,,,,1.0,,
9294109,52,D009223,13400,Association,FALSE,"<ENT1>Myotonic dystrophy</ENT1> (<ENT1>DM</ENT1>), the most prevalent muscular disorder in adults, is caused by (CTG) n-repeat expansion in a gene encoding a protein kinase (<ENT2>DM protein kinase</ENT2>; <ENT2>DMPK</ENT2>) and involves changes in cytoarchitecture and ion homeostasis.",,,,T,,,,,c,,,"11,12,21,22",,0.5,,
9294109,53,13400,D002118,Negative_Correlation,TRUE,<ENT1>Myotonic dystrophy protein kinase</ENT1> is involved in the modulation of the <ENT2>Ca2+</ENT2> homeostasis in skeletal muscle cells.,,,,T,,,,,w,,,,,1.0,,
9294109,53,13400,D002118,Negative_Correlation,TRUE,"To obtain clues to the normal biological role of <ENT1>DMPK</ENT1> in cellular ion homeostasis, we have compared the resting [<ENT2>Ca2 +</ENT2>] i, the amplitude and shape of depolarization-induced <ENT2>Ca2 +</ENT2> transients, and the content of ATP-driven ion pumps in cultured skeletal muscle cells of wild-type and <ENT1>DMPK</ENT1> [-/-] knockout mice.",,,,T,,,,,c,,,,,1.0,,
9294109,53,13400,D002118,Negative_Correlation,TRUE,In vitro-differentiated <ENT1>DMPK</ENT1> [-/-] myotubes exhibit a higher resting [<ENT2>Ca2 +</ENT2>] i than do wild-type myotubes because of an altered open probability of voltage-dependent l-type <ENT2>Ca2 +</ENT2> and Na + channels.,,,,T,,,,,c,,,,,1.0,,
9647766,56,4722,1457,Association,TRUE,The NDUFS2 contains a highly conserved protein kinase C phosphorylation site and the <ENT1>NDUFS3</ENT1> subunit contains a highly conserved <ENT2>casein kinase II</ENT2> phosphorylation site which make them strong candidates for future mutation detection studies in enzymatic complex I-deficient patients.,,,,T,,,,,c,,,,,1.0,,
9647766,57,4722,C537475,Association,TRUE,The NDUFS2 contains a highly conserved protein kinase C phosphorylation site and the <ENT1>NDUFS3</ENT1> subunit contains a highly conserved casein kinase II phosphorylation site which make them strong candidates for future mutation detection studies in <ENT2>enzymatic complex I-deficient</ENT2> patients.,,,,T,,,,,w,,,,,0.0,,
9647766,60,4722,4720,Bind,FALSE,"Polymerase chain reaction performed with DNA isolated from somatic human-rodent cell hybrids containing defined human chromosomes as template gave a human-specific signal which mapped the <ENT2>NDUFS2</ENT2> and <ENT1>NDUFS3</ENT1> subunits to chromosomes 1 and 11, respectively.",,,,T,,,,,c,,,,,1.0,,
9647766,60,4722,4720,Bind,FALSE,The <ENT2>NDUFS2</ENT2> contains a highly conserved protein kinase C phosphorylation site and the <ENT1>NDUFS3</ENT1> subunit contains a highly conserved casein kinase II phosphorylation site which make them strong candidates for future mutation detection studies in enzymatic complex I-deficient patients.,,,,T,,,,,c,,,,,1.0,,
9647766,54,1457,C537475,Association,FALSE,The NDUFS2 contains a highly conserved protein kinase C phosphorylation site and the NDUFS3 subunit contains a highly conserved <ENT1>casein kinase II</ENT1> phosphorylation site which make them strong candidates for future mutation detection studies in <ENT2>enzymatic complex I-deficient</ENT2> patients.,,,,T,,,,,w,,,,,0.0,,
9647766,58,C537475,5578,Association,FALSE,The NDUFS2 contains a highly conserved <ENT2>protein kinase C</ENT2> phosphorylation site and the NDUFS3 subunit contains a highly conserved casein kinase II phosphorylation site which make them strong candidates for future mutation detection studies in <ENT1>enzymatic complex I-deficient</ENT1> patients.,,,,T,,,,,w,,,,,0.0,,
9647766,61,C537475,4720,Association,TRUE,The <ENT2>NDUFS2</ENT2> contains a highly conserved protein kinase C phosphorylation site and the NDUFS3 subunit contains a highly conserved casein kinase II phosphorylation site which make them strong candidates for future mutation detection studies in <ENT1>enzymatic complex I-deficient</ENT1> patients.,,,,T,,,,,w,,,,,0.0,,
9647766,62,5578,4720,Association,TRUE,The <ENT2>NDUFS2</ENT2> contains a highly conserved <ENT1>protein kinase C</ENT1> phosphorylation site and the NDUFS3 subunit contains a highly conserved casein kinase II phosphorylation site which make them strong candidates for future mutation detection studies in enzymatic complex I-deficient patients.,,,,T,,,,,c,,,,,0.0,,
9672936,64,D010149,D008614,Negative_Correlation,FALSE,<ENT2>Pethidine</ENT2>-associated seizure in a healthy adolescent receiving <ENT2>pethidine</ENT2> for <ENT1>postoperative pain</ENT1> control.,,,,T,,,,,c,,,,,0.5,,
9672936,64,D010149,D008614,Negative_Correlation,FALSE,A healthy 17-year-old male received standard intermittent doses of <ENT2>pethidine</ENT2> via a patient-controlled analgesia (PCA) pump for management of <ENT1>postoperative pain</ENT1> control.,,,,T,,,,,w,,,,,1.0,,
9672936,64,D010149,D008614,Negative_Correlation,FALSE,The routine use of <ENT2>pethidine</ENT2> via PCA even for a brief <ENT1>postoperative analgesia</ENT1> should be reconsidered.,,,,T,,,,,w,,,,,0.0,,
9672936,63,D008614,D012640,Association,TRUE,<ENT1>Pethidine</ENT1>-associated <ENT2>seizure</ENT2> in a healthy adolescent receiving <ENT1>pethidine</ENT1> for postoperative pain control.,,,,T,Y,,,,c,,,,,0.0,,
9746003,66,D014635,D005013,Cotreatment,TRUE,"Optimal control of the absences was achieved with <ENT1>sodium valproate</ENT1>, lamotrigine, or <ENT2>ethosuximide</ENT2> alone or in combination.",,,,T,,,,,c,,,,,0.0,,
9746003,67,D014635,D000077213,Cotreatment,TRUE,"Optimal control of the absences was achieved with <ENT1>sodium valproate</ENT1>, <ENT2>lamotrigine</ENT2>, or ethosuximide alone or in combination.",,,,T,,,,,c,,,,,0.0,,
9746003,65,D005013,D000077213,Cotreatment,TRUE,"Optimal control of the absences was achieved with sodium valproate, <ENT2>lamotrigine</ENT2>, or <ENT1>ethosuximide</ENT1> alone or in combination.",,,,T,,,,,c,,,,,0.0,,
9746003,73,D020888,D002220,Comparison,FALSE,Inappropriate use of <ENT2>carbamazepine</ENT2> and <ENT1>vigabatrin</ENT1> in typical absence seizures.,,,,T,,,,,c,,,,,1.0,,
9746003,73,D020888,D002220,Comparison,FALSE,<ENT2>Carbamazepine</ENT2> and <ENT1>vigabatrin</ENT1> are contraindicated in typical absence seizures.,,,,T,,,,,w,,,,,1.0,,
9746003,71,D020888,D004832,Positive_Correlation,FALSE,Inappropriate use of carbamazepine and <ENT1>vigabatrin</ENT1> in typical <ENT2>absence seizures</ENT2>.,,,,T,,,,,w,,,,,0.0,,
9746003,71,D020888,D004832,Positive_Correlation,FALSE,Carbamazepine and <ENT1>vigabatrin</ENT1> are contraindicated in typical <ENT2>absence seizures</ENT2>.,,,,T,,,,,w,,,,,0.0,,
9746003,74,D002220,D009207,Positive_Correlation,FALSE,"Frequency of absences increased in four children treated with <ENT1>carbamazepine</ENT1> and two of these developed <ENT2>myoclonic jerks</ENT2>, which resolved on withdrawal of <ENT1>carbamazepine</ENT1>.",,,,T,,,,,w,,,,,1.0,,
9746003,72,D002220,D004832,Positive_Correlation,FALSE,Inappropriate use of <ENT1>carbamazepine</ENT1> and vigabatrin in typical <ENT2>absence seizures</ENT2>.,,,,T,,,,,w,,,,,0.0,,
9746003,72,D002220,D004832,Positive_Correlation,FALSE,<ENT1>Carbamazepine</ENT1> and vigabatrin are contraindicated in typical <ENT2>absence seizures</ENT2>.,,,,T,,,,,w,,,,,0.0,,
10491763,75,3175,D003924,Association,FALSE,<ENT1>Hepatocyte nuclear factor-6</ENT1>: associations between genetic variability and <ENT2>type II diabetes</ENT2> and between genetic variability and estimates of insulin secretion.,,,,T,,,,,w,,,,,0.0,,
10491763,75,3175,D003924,Association,FALSE,The transcription factor <ENT1>hepatocyte nuclear factor (HNF)-6</ENT1> is an upstream regulator of several genes involved in the pathogenesis of <ENT2>maturity-onset diabetes</ENT2> of the young.,,,,T,,,,,w,,,,,1.0,,
10491763,75,3175,D003924,Association,FALSE,We therefore tested the hypothesis that variability in the <ENT1>HNF-6</ENT1> gene is associated with subsets of <ENT2>Type II (non-insulin-dependent) diabetes mellitus</ENT2> and estimates of insulin secretion in glucose tolerant subjects.,,,,T,,Y,,,w,,,,,1.0,,
10491763,75,3175,D003924,Association,FALSE,Mutations in the coding region of the <ENT1>HNF-6</ENT1> gene are not associated with <ENT2>Type II diabetes</ENT2> or with changes in insulin responses to glucose among the Caucasians examined.,,,,T,,,,,w,,,,,1.0,,
10491763,77,D003924,D005947,Association,FALSE,We therefore tested the hypothesis that variability in the HNF-6 gene is associated with subsets of <ENT1>Type II (non-insulin-dependent) diabetes mellitus</ENT1> and estimates of insulin secretion in <ENT2>glucose</ENT2> tolerant subjects.,,,,T,,,,,c,,,,,1.0,,
10491763,77,D003924,D005947,Association,FALSE,"In an association study the allelic frequency of the Pro75Ala polymorphism was 3.2% (95% confidence interval, 1.9-4.5) in 330 patients with <ENT1>Type II diabetes mellitus</ENT1> compared with 4.2% (2.4-6.0) in 238 age-matched <ENT2>glucose</ENT2> tolerant control subjects.",,,,T,,,,,c,,,,,1.0,,
10491763,77,D003924,D005947,Association,FALSE,"Moreover, in studies of 238 middle-aged <ENT2>glucose</ENT2> tolerant subjects, of 226 <ENT2>glucose</ENT2> tolerant offspring of <ENT1>Type II diabetic</ENT1> patients and of 367 young healthy subjects, the carriers of the polymorphism did not differ from non-carriers in <ENT2>glucose</ENT2> induced serum insulin or C-peptide responses.",,,,T,,,,,c,,,,,1.0,,
10491763,77,D003924,D005947,Association,FALSE,Mutations in the coding region of the HNF-6 gene are not associated with <ENT1>Type II diabetes</ENT1> or with changes in insulin responses to <ENT2>glucose</ENT2> among the Caucasians examined.,,,,T,,,,,w,,,,,1.0,,
10491763,76,3630,D005947,Positive_Correlation,FALSE,We therefore tested the hypothesis that variability in the HNF-6 gene is associated with subsets of Type II (non-insulin-dependent) diabetes mellitus and estimates of <ENT1>insulin</ENT1> secretion in <ENT2>glucose</ENT2> tolerant subjects.,,,,T,,,,,c,,,,,1.0,,
10491763,76,3630,D005947,Positive_Correlation,FALSE,"Moreover, in studies of 238 middle-aged <ENT2>glucose</ENT2> tolerant subjects, of 226 <ENT2>glucose</ENT2> tolerant offspring of Type II diabetic patients and of 367 young healthy subjects, the carriers of the polymorphism did not differ from non-carriers in <ENT2>glucose</ENT2> induced serum <ENT1>insulin</ENT1> or <ENT1>C-peptide</ENT1> responses.",,,,T,,,,,c,,,,,0.166666667,,
10491763,76,3630,D005947,Positive_Correlation,FALSE,Mutations in the coding region of the HNF-6 gene are not associated with Type II diabetes or with changes in <ENT1>insulin</ENT1> responses to <ENT2>glucose</ENT2> among the Caucasians examined.,,,,T,Y,,,,w,,,,,0.0,,
10661407,78,D008358,50489,Bind,TRUE,"We have identified a <ENT2>type II Ca2+-dependent lectin</ENT2> displaying <ENT1>mannose</ENT1>-binding specificity, exclusively expressed by Langerhans cells (LC), and named <ENT2>Langerin</ENT2>.",,,,T,,,,,c,,,,,0.0,,
10788334,88,c|INS|5382|C,OMIM:604370,Positive_Correlation,TRUE,"Three <ENT2>BRCA1 abnormalities</ENT2> - <ENT1>5382insC</ENT1>, C61G, and 4153delA - accounted for 51%, 20%, and 11% of the identified mutations, respectively..",,,,T,,,,,c,,,,,0.0,,
10788334,94,672,D061325,Association,FALSE,Founder mutations in the <ENT1>BRCA1</ENT1> gene in Polish families with <ENT2>breast-ovarian cancer</ENT2>.,,,,T,,,,,w,,,,,1.0,,
10788334,90,OMIM:604370,rs28897672,Positive_Correlation,TRUE,"Three <ENT1>BRCA1 abnormalities</ENT1> - 5382insC, <ENT2>C61G</ENT2>, and 4153delA - accounted for 51%, 20%, and 11% of the identified mutations, respectively..",,,,T,,,,,w,,,,,0.0,,
10788334,89,OMIM:604370,c|DEL|4153|A,Positive_Correlation,TRUE,"Three <ENT1>BRCA1 abnormalities</ENT1> - 5382insC, C61G, and <ENT2>4153delA</ENT2> - accounted for 51%, 20%, and 11% of the identified mutations, respectively..",,,,T,,,,,w,,,,,0.0,,
11009181,97,D004409,D001058,Negative_Correlation,TRUE,"In addition, there is convincing clinical evidence that monotherapy with continuous subcutaneous <ENT2>apomorphine</ENT2> infusions is associated with marked reductions of preexisting levodopa-induced <ENT1>dyskinesias</ENT1>.",,,,T,,,,,c,,,,,1.0,,
11009181,95,D004409,D007980,Positive_Correlation,FALSE,"In addition, there is convincing clinical evidence that monotherapy with continuous subcutaneous apomorphine infusions is associated with marked reductions of preexisting <ENT2>levodopa</ENT2>-induced <ENT1>dyskinesias</ENT1>.",,,,T,,,,,c,,,,,1.0,,
11009181,96,D001058,D007980,Negative_Correlation,TRUE,A number of small scale clinical trials have unequivocally shown that intermittent subcutaneous <ENT1>apomorphine</ENT1> injections produce antiparkinsonian benefit close if not identical to that seen with <ENT2>levodopa</ENT2> and that <ENT1>apomorphine</ENT1> rescue injections can reliably revert off-periods even in patients with complex on-off motor swings.,,,,T,,,,,c,,,,,0.0,,
11009181,96,D001058,D007980,Negative_Correlation,TRUE,"In addition, there is convincing clinical evidence that monotherapy with continuous subcutaneous <ENT1>apomorphine</ENT1> infusions is associated with marked reductions of preexisting <ENT2>levodopa</ENT2>-induced dyskinesias.",,,,T,Y,,,,c,,,,,1.0,,
11009181,98,D001058,D010300,Negative_Correlation,TRUE,<ENT1>Apomorphine</ENT1>: an underutilized therapy for <ENT2>Parkinson's disease</ENT2>.,,,,T,,,,,c,,,,,1.0,,
11009181,98,D001058,D010300,Negative_Correlation,TRUE,<ENT1>Apomorphine</ENT1> was the first dopaminergic drug ever used to treat symptoms of <ENT2>Parkinson's disease</ENT2>.,,,,T,,,,,w,,,,,1.0,,
11009181,98,D001058,D010300,Negative_Correlation,TRUE,"While powerful antiparkinsonian effects had been observed as early as 1951, the potential of treating fluctuating <ENT2>Parkinson's disease</ENT2> by subcutaneous administration of <ENT1>apomorphine</ENT1> has only recently become the subject of systematic study.",,,,T,,,,,c,,,,,1.0,,
11009181,98,D001058,D010300,Negative_Correlation,TRUE,"Given the marked degree of efficacy of subcutaneous <ENT1>apomorphine</ENT1> treatment in fluctuating <ENT2>Parkinson's disease</ENT2>, this approach seems to deserve more widespread clinical use.",,,,T,,,,,c,,,,,0.0,,
11054569,102,D017239,84084,Positive_Correlation,TRUE,"MCF7/AdrR cells expressing the exogenous <ENT2>Rab6c</ENT2> exhibited less resistance to several anti-cancer drugs, such as doxorubicin (DOX), <ENT1>taxol</ENT1>, vinblastine, and vincristine, than the control cells containing the empty vector.",,,,T,,,,,c,,,,,0.0,,
11054569,103,84084,D004317,Positive_Correlation,TRUE,"MCF7/AdrR cells expressing the exogenous <ENT1>Rab6c</ENT1> exhibited less resistance to several anti-cancer drugs, such as <ENT2>doxorubicin</ENT2> (<ENT2>DOX</ENT2>), taxol, vinblastine, and vincristine, than the control cells containing the empty vector.",,,,T,,,,,c,,,,,0.0,,
11054569,103,84084,D004317,Positive_Correlation,TRUE,Flow cytometry experiments confirmed that the transfectants' diminished resistance to <ENT2>DOX</ENT2> was caused by increased drug accumulation induced by the exogenous <ENT1>Rab6c</ENT1>.,,,,T,,,,,w,,,,,0.0,,
11054569,100,84084,D014750,Positive_Correlation,TRUE,"MCF7/AdrR cells expressing the exogenous <ENT1>Rab6c</ENT1> exhibited less resistance to several anti-cancer drugs, such as doxorubicin (DOX), taxol, vinblastine, and <ENT2>vincristine</ENT2>, than the control cells containing the empty vector.",,,,T,Y,,,,c,,,,,0.0,,
11054569,101,84084,D014747,Positive_Correlation,TRUE,"MCF7/AdrR cells expressing the exogenous <ENT1>Rab6c</ENT1> exhibited less resistance to several anti-cancer drugs, such as doxorubicin (DOX), taxol, <ENT2>vinblastine</ENT2>, and vincristine, than the control cells containing the empty vector.",,,,T,Y,,,,c,,,,,0.0,,
11054569,99,84084,D014594,Association,TRUE,<ENT1>Rab6c</ENT1> was found to be under-expressed in MCF7/AdrR and MES-SA/Dx5 (a human MDR <ENT2>uterine sarcoma</ENT2> cell line) compared with their non-MDR parental cell lines.,,,,T,,,,,w,,,,,1.0,,
11773892,104,D016559,5530,Negative_Correlation,FALSE,BACKGROUND: The <ENT2>calcineurin</ENT2> inhibitors cyclosporine and <ENT1>tacrolimus</ENT1> are both known to be nephrotoxic.,,,,T,,,,,c,,,,,1.0,,
11773892,107,D016559,D007674,Positive_Correlation,FALSE,BACKGROUND: The calcineurin inhibitors cyclosporine and <ENT1>tacrolimus</ENT1> are both known to be <ENT2>nephrotoxic</ENT2>.,,,,T,,,,,w,,,,,1.0,,
11773892,105,D016572,5530,Negative_Correlation,FALSE,BACKGROUND: The <ENT2>calcineurin</ENT2> inhibitors <ENT1>cyclosporine</ENT1> and tacrolimus are both known to be nephrotoxic.,,,,T,,,,,c,,,,,1.0,,
11773892,109,D016572,D007674,Positive_Correlation,FALSE,BACKGROUND: The calcineurin inhibitors <ENT1>cyclosporine</ENT1> and tacrolimus are both known to be <ENT2>nephrotoxic</ENT2>.,,,,T,,,,,w,,,,,1.0,,
11773892,106,D006530,D003404,Positive_Correlation,TRUE,"Compared with control patients, CRF and ESRD patients had higher preoperative serum <ENT2>creatinine</ENT2> levels, a greater percentage of patients with <ENT1>hepatorenal syndrome</ENT1>, higher percentage requirement for dialysis in the first 3 months postoperatively, and a higher 1-year serum <ENT2>creatinine</ENT2>.",,,,T,,,,,w,,,,,1.0,,
11773892,106,D006530,D003404,Positive_Correlation,TRUE,Patients who develop ESRD have a higher preoperative and 1-year serum <ENT2>creatinine</ENT2> and are more likely to have <ENT1>hepatorenal syndrome</ENT1>.,,,,T,,,,,c,,,,,0.0,,
11773892,108,D007676,D003404,Positive_Correlation,TRUE,"Patients were divided into three groups: Controls, no <ENT1>CRF</ENT1> or <ENT1>ESRD</ENT1>, n=748; <ENT1>CRF</ENT1>, sustained serum <ENT2>creatinine</ENT2> >2.5 mg/dl, n=41; and <ENT1>ESRD</ENT1>, n=45.",,,,T,,,,,c,,,,,0.75,,
11773892,108,D007676,D003404,Positive_Correlation,TRUE,"Compared with control patients, <ENT1>CRF</ENT1> and <ENT1>ESRD</ENT1> patients had higher preoperative serum <ENT2>creatinine</ENT2> levels, a greater percentage of patients with hepatorenal syndrome, higher percentage requirement for dialysis in the first 3 months postoperatively, and a higher 1-year serum <ENT2>creatinine</ENT2>.",,,,T,,,,,c,,,,,0.5,,
11773892,108,D007676,D003404,Positive_Correlation,TRUE,"Multivariate stepwise logistic regression analysis using preoperative and postoperative variables identified that an increase of serum <ENT2>creatinine</ENT2> compared with average at 1 year, 3 months, and 4 weeks postoperatively were independent risk factors for the development of <ENT1>CRF</ENT1> or <ENT1>ESRD</ENT1> with odds ratios of 2.6, 2.2, and 1.6, respectively.",,,,T,,,,,c,,,,,1.0,,
11773892,108,D007676,D003404,Positive_Correlation,TRUE,Patients who develop <ENT1>ESRD</ENT1> have a higher preoperative and 1-year serum <ENT2>creatinine</ENT2> and are more likely to have hepatorenal syndrome.,,,,T,,,,,c,,,,,1.0,,
11773892,108,D007676,D003404,Positive_Correlation,TRUE,"However, an increase of serum <ENT2>creatinine</ENT2> at various times postoperatively is more predictive of the development of <ENT1>CRF</ENT1> or <ENT1>ESRD</ENT1>.",,,,T,,,,,w,,,,,1.0,,
12442272,110,6647,D000690,Association,TRUE,D90A-<ENT1>SOD1</ENT1> mediated <ENT2>amyotrophic lateral sclerosis</ENT2>: a single founder for all cases with evidence for a Cis-acting disease modifier in the recessive haplotype.,,,,T,,,,,c,,,,,1.0,,
12442272,110,6647,D000690,Association,TRUE,"More than 100 different heterozygous mutations in <ENT1>copper/zinc superoxide dismutase</ENT1> (<ENT1>SOD1</ENT1>) have been found in patients with <ENT2>amyotrophic lateral sclerosis</ENT2> (<ENT2>ALS</ENT2>), a fatal neurodegenerative disease.",,,,T,,,,,c,,,"11,12,21,22",,1.0,,
12442272,110,6647,D000690,Association,TRUE,"The frequency of D90A-<ENT1>SOD1</ENT1> is 50 times higher in Scandinavia (2.5%) than elsewhere, though <ENT2>ALS</ENT2> prevalence is not raised there.",,,,T,,,,,c,,,,,1.0,,
12442272,110,6647,D000690,Association,TRUE,"We propose that a cis-acting regulatory polymorphism has arisen close to D90A-<ENT1>SOD1</ENT1> in the recessive founder, which decreases <ENT2>ALS</ENT2> susceptibility in heterozygotes and slows disease progression.",,,,T,,,,,c,,,,,1.0,,
12442272,111,rs80265967,D000690,Negative_Correlation,TRUE,<ENT1>D90A</ENT1>-SOD1 mediated <ENT2>amyotrophic lateral sclerosis</ENT2>: a single founder for all cases with evidence for a Cis-acting disease modifier in the recessive haplotype.,,,,T,,,,,w,,,,,1.0,,
12442272,111,rs80265967,D000690,Negative_Correlation,TRUE,"The frequency of <ENT1>D90A</ENT1>-SOD1 is 50 times higher in Scandinavia (2.5%) than elsewhere, though <ENT2>ALS</ENT2> prevalence is not raised there.",,,,T,,,,,c,,,,,1.0,,
12442272,111,rs80265967,D000690,Negative_Correlation,TRUE,"We propose that a cis-acting regulatory polymorphism has arisen close to <ENT1>D90A</ENT1>-SOD1 in the recessive founder, which decreases <ENT2>ALS</ENT2> susceptibility in heterozygotes and slows disease progression.",,,,T,,,,,c,,,,,0.0,,
14722929,112,C567134,2706,Association,FALSE,A large proportion of <ENT1>non-syndromic autosomal recessive deafness</ENT1> (<ENT1>NSARD</ENT1>) in many populations is caused by variants of the <ENT2>GJB2</ENT2> gene.,,,,T,,,,,c,,,,,1.0,,
15000256,117,D008607,2332,Association,TRUE,Single-strand conformation polymorphism analysis of the <ENT2>FMR1</ENT2> gene in autistic and <ENT1>mentally retarded</ENT1> children in Japan.,,,,T,,T,,,w,,,,,1.0,,
15000256,117,D008607,2332,Association,TRUE,We screened all 17 exons of the <ENT2>FMR1</ENT2> gene for mutations in 90 autistic or <ENT1>mentally retarded</ENT1> children using polymerase chain reaction (PCR)-single strand conformation polymorphism (SSCP) analysis.,,,,T,,Y,,,w,,,,,1.0,,
15000256,117,D008607,2332,Association,TRUE,"Although uncommon, point mutations in the <ENT2>FMR1</ENT2> gene may be a cause of autism and <ENT1>mental retardation</ENT1> in Japanese patients.",,,,T,,,,,c,,,,,1.0,,
15000256,116,D001321,2332,Association,TRUE,Single-strand conformation polymorphism analysis of the <ENT2>FMR1</ENT2> gene in <ENT1>autistic</ENT1> and mentally retarded children in Japan.,,,,T,,T,,,w,,,,,1.0,,
15000256,116,D001321,2332,Association,TRUE,We screened all 17 exons of the <ENT2>FMR1</ENT2> gene for mutations in 90 <ENT1>autistic</ENT1> or mentally retarded children using polymerase chain reaction (PCR)-single strand conformation polymorphism (SSCP) analysis.,,,,T,,Y,,,w,,,,,1.0,,
15000256,116,D001321,2332,Association,TRUE,"Although uncommon, point mutations in the <ENT2>FMR1</ENT2> gene may be a cause of <ENT1>autism</ENT1> and mental retardation in Japanese patients.",,,,T,,,,,c,,,,,1.0,,
15018851,121,D015774,3077517,Association,TRUE,"<ENT2>UL97 protein kinase</ENT2> changes responsible for resistance to <ENT1>ganciclovir</ENT1> were initially detected at residues 591 and 592, and then at position 594.",,,,T,,,,,c,,,,,1.0,,
15018851,124,D015774,p|SUB|L|501|I,Negative_Correlation,TRUE,"Decreased sensitivity to foscarnet coincided with the appearance of amino acid substitution N495K in DNA polymerase, whereas cross-resistance to <ENT1>ganciclovir</ENT1> and cidofovir was due to the <ENT2>L501I</ENT2> substitution.",,,,T,,,,,c,,,,,0.0,,
15018851,123,D000077404,p|SUB|L|501|I,Negative_Correlation,TRUE,"Decreased sensitivity to foscarnet coincided with the appearance of amino acid substitution N495K in DNA polymerase, whereas cross-resistance to ganciclovir and <ENT1>cidofovir</ENT1> was due to the <ENT2>L501I</ENT2> substitution.",,,,T,,,,,c,,,,,0.0,,
15018851,122,p|SUB|N|495|K,D017245,Negative_Correlation,TRUE,"Decreased sensitivity to <ENT2>foscarnet</ENT2> coincided with the appearance of amino acid substitution <ENT1>N495K</ENT1> in DNA polymerase, whereas cross-resistance to ganciclovir and cidofovir was due to the L501I substitution.",,,,T,,,,,w,,,,,0.0,,
15018851,128,D003586,2813,Association,FALSE,"In parallel, we used <ENT2>glycoprotein B</ENT2> (<ENT2>gB</ENT2>) genotyping, and a- and UL10-13-sequence analysis to study <ENT1>CMV</ENT1> interstrain variability.",,,,T,Y,,,,w,,,,,0.0,,
15033202,129,4683,D049932,Association,FALSE,"Most <ENT2>Nijmegen breakage syndrome</ENT2> patients are of Slavonic origin, and all of them known so far carry a founder homozygous 5 nucleotide deletion in the <ENT1>NBS1</ENT1> gene.",,,,T,,,,,c,,,,,1.0,,
15033202,130,D049932,c|DEL||5,Positive_Correlation,FALSE,"Most <ENT1>Nijmegen breakage syndrome</ENT1> patients are of Slavonic origin, and all of them known so far carry a founder homozygous <ENT2>5 nucleotide deletion</ENT2> in the NBS1 gene.",,,,T,,,,,c,,,,,0.0,,
15042318,132,D009136,D004317,Positive_Correlation,TRUE,"The authors describe the unusual association between diffuse B-cell gastric lymphoma and myotonic dystrophy, the most common form of adult <ENT1>muscular dystrophy</ENT1>, and sudden atrial fibrillation following one cycle of <ENT2>doxorubicin</ENT2>-based chemotherapy in the same patient.",,,,T,,,,,w,,,,,1.0,,
15042318,133,C535648,D004317,Negative_Correlation,FALSE,"The authors describe the unusual association between diffuse B-cell <ENT1>gastric lymphoma</ENT1> and myotonic dystrophy, the most common form of adult muscular dystrophy, and sudden atrial fibrillation following one cycle of <ENT2>doxorubicin</ENT2>-based chemotherapy in the same patient.",,,,T,,,,,w,,,,,0.0,,
15042318,131,D004317,D001281,Positive_Correlation,TRUE,"The authors describe the unusual association between diffuse B-cell gastric lymphoma and myotonic dystrophy, the most common form of adult muscular dystrophy, and sudden <ENT2>atrial fibrillation</ENT2> following one cycle of <ENT1>doxorubicin</ENT1>-based chemotherapy in the same patient.",,,,T,,,,,c,,,,,1.0,,
15064320,139,6716,D058490,Association,TRUE,Compound heterozygous mutations in the <ENT1>SRD5A2</ENT1> gene exon 4 in a <ENT2>male pseudohermaphrodite</ENT2> patient of Chinese origin.,,,,T,,,,,w,,,,,1.0,,
15064320,139,6716,D058490,Association,TRUE,The goal of this study was to perform <ENT1>5-alpha-reductase type 2</ENT1> gene (<ENT1>SRD5A2</ENT1>) analysis in a <ENT2>male pseudohermaphrodite</ENT2> (<ENT2>MPH</ENT2>) patient with normal testosterone (T) production and normal androgen receptor (AR) gene coding sequences.,,,,T,,,,,w,,,,,1.0,,
15064320,137,D058490,c|DEL|CODON219|T,Association,TRUE,"The patient showed an R227Q mutation that has been described in an Asian population and <ENT1>MPH</ENT1> patients, along with a novel frameshift mutation, <ENT2>Tdel219</ENT2>.",,,,T,,,,,c,,,,,0.0,,
15064320,138,D058490,rs9332964,Association,TRUE,"The patient showed an <ENT2>R227Q</ENT2> mutation that has been described in an Asian population and <ENT1>MPH</ENT1> patients, along with a novel frameshift mutation, Tdel219.",,,,T,,,,,w,,,,,0.0,,
15064320,136,D013739,D006063,Association,FALSE,"A patient of Chinese origin with ambiguous genitalia at 14 months, a 46,XY karyotype, and normal <ENT1>T</ENT1> secretion under <ENT2>human chorionic gonadotropin</ENT2> (<ENT2>hCG</ENT2>) stimulation underwent a gonadectomy at 20 months.",,,,T,,,,,w,,,,,0.0,,
15069170,141,6559,D053579,Association,FALSE,Four novel mutations in the thiazide-sensitive <ENT1>Na-Cl co-transporter</ENT1> gene in Japanese patients with <ENT2>Gitelman's syndrome</ENT2>.,,,,T,,,,,w,,,,,1.0,,
15069170,141,6559,D053579,Association,FALSE,BACKGROUND: <ENT2>Gitelman's syndrome</ENT2> (<ENT2>GS</ENT2>) is an autosomal recessive disorder resulting from inactivating mutations in the thiazide-sensitive <ENT1>Na-Cl co-transporter</ENT1> (<ENT1>NCCT</ENT1>) gene.,,,,T,,,,,w,,,"11,12,21,22",,1.0,,
15069170,141,6559,D053579,Association,FALSE,"In this study, we analysed mutations in the <ENT1>NCCT</ENT1> gene of seven Japanese patients with <ENT2>GS</ENT2>.",,,,T,,,,,w,,,,,1.0,,
15069170,141,6559,D053579,Association,FALSE,CONCLUSIONS: We found four novel mutations in the <ENT1>NCCT</ENT1> gene in seven Japanese patients with <ENT2>GS</ENT2>.,,,,T,,,,,w,,,,,1.0,,
15069170,141,6559,D053579,Association,FALSE,"Moreover, our study suggests that the distribution of mutations in the <ENT1>NCCT</ENT1> gene in Japanese <ENT2>GS</ENT2> patients potentially differs from that in other populations.",,,,T,,,,,w,,,,,1.0,,
15069170,140,6559,D049971,Positive_Correlation,FALSE,Four novel mutations in the <ENT2>thiazide</ENT2>-sensitive <ENT1>Na-Cl co-transporter</ENT1> gene in Japanese patients with Gitelman's syndrome.,,,,T,,,,,c,,,,,0.0,,
15069170,140,6559,D049971,Positive_Correlation,FALSE,BACKGROUND: Gitelman's syndrome (GS) is an autosomal recessive disorder resulting from inactivating mutations in the <ENT2>thiazide</ENT2>-sensitive <ENT1>Na-Cl co-transporter</ENT1> (<ENT1>NCCT</ENT1>) gene.,,,,T,,,,,c,,,,,0.0,,
15069170,152,D053579,rs371443644,Positive_Correlation,TRUE,"Five of them [<ENT2>c.185C>T</ENT2> (<ENT2>Thr60Met</ENT2>), c.1712C>T (Ala569Val), c.1930C>T (Arg642Cys), c.2552T>A (Leu849His) and c.1932delC] have been reported in Japanese patients, but not in <ENT1>GS</ENT1> patients from other ethnic groups.",,,,T,,,,,w,,,,,1.0,,
15069170,144,D053579,rs200697179,Positive_Correlation,TRUE,"Five of them [c.185C>T (Thr60Met), c.1712C>T (Ala569Val), <ENT2>c.1930C>T</ENT2> (<ENT2>Arg642Cys</ENT2>), c.2552T>A (Leu849His) and c.1932delC] have been reported in Japanese patients, but not in <ENT1>GS</ENT1> patients from other ethnic groups.",,,,T,,,,,w,,,,,1.0,,
15069170,145,D053579,rs79351185,Positive_Correlation,TRUE,"Five of them [c.185C>T (Thr60Met), <ENT2>c.1712C>T</ENT2> (<ENT2>Ala569Val</ENT2>), c.1930C>T (Arg642Cys), c.2552T>A (Leu849His) and c.1932delC] have been reported in Japanese patients, but not in <ENT1>GS</ENT1> patients from other ethnic groups.",,,,T,,,,,w,,,,,1.0,,
15069170,142,D053579,c|DEL|1932|C,Positive_Correlation,TRUE,"Five of them [c.185C>T (Thr60Met), c.1712C>T (Ala569Val), c.1930C>T (Arg642Cys), c.2552T>A (Leu849His) and <ENT2>c.1932delC</ENT2>] have been reported in Japanese patients, but not in <ENT1>GS</ENT1> patients from other ethnic groups.",,,,T,,,,,w,,,,,1.0,,
15069170,143,D053579,rs185927948,Positive_Correlation,TRUE,"Five of them [c.185C>T (Thr60Met), c.1712C>T (Ala569Val), c.1930C>T (Arg642Cys), <ENT2>c.2552T>A</ENT2> (<ENT2>Leu849His</ENT2>) and c.1932delC] have been reported in Japanese patients, but not in <ENT1>GS</ENT1> patients from other ethnic groups.",,,,T,,,,,w,,,,,1.0,,
15086325,159,2153,D005166,Association,FALSE,Identification of three <ENT1>F5</ENT1> gene mutations associated with <ENT2>inherited coagulation factor V deficiency</ENT2> in two Chinese pedigrees.,,,,T,,,,,c,,,,,0.0,,
15086325,159,2153,D005166,Association,FALSE,A 37-year-old male (proband 1) and an 18-month-old boy (proband 2) were diagnosed as <ENT2>inherited coagulation FV deficiency</ENT2> by severely reduced plasma levels of <ENT1>FV</ENT1> activity and antigen.,,,,T,,,,,w,,,,,1.0,,
15086325,159,2153,D005166,Association,FALSE,"Three <ENT1>F5</ENT1> gene mutations, IVS8 -2A>G, 2238-9del AG and G6410T, have been identified in two Chinese pedigree with <ENT2>congenital FV deficiency</ENT2>, respectively.",,,,T,,,,,w,,,,,1.0,,
15086325,154,c|DEL|2238_2239|AG,D005166,Association,TRUE,"Three F5 gene mutations, IVS8 -2A>G, <ENT1>2238-9del AG</ENT1> and G6410T, have been identified in two Chinese pedigree with <ENT2>congenital FV deficiency</ENT2>, respectively.",,,,T,,,,,c,,,,,1.0,,
15086325,153,g|SUB|G|6410|T,D005166,Association,TRUE,"Three F5 gene mutations, IVS8 -2A>G, 2238-9del AG and <ENT1>G6410T</ENT1>, have been identified in two Chinese pedigree with <ENT2>congenital FV deficiency</ENT2>, respectively.",,,,T,,,,,c,,,,,1.0,,
15086325,155,c|SUB|A|IVS8-2|G,D005166,Association,TRUE,"Three F5 gene mutations, <ENT1>IVS8 -2A>G</ENT1>, 2238-9del AG and G6410T, have been identified in two Chinese pedigree with <ENT2>congenital FV deficiency</ENT2>, respectively.",,,,T,,,,,c,,,,,1.0,,
15111599,160,p|DEL|91|G,C565137,Association,TRUE,CONCLUSIONS: The <ENT1>DeltaG91</ENT1> mutation in CRYBA3/A1 is associated with an <ENT2>autosomal dominant congenital nuclear lactescent cataract</ENT2>.,,,,T,,,,,c,,,,,0.0,,
15111599,165,C565137,1411,Association,TRUE,<ENT2>CRYBA3/A1</ENT2> gene mutation associated with suture-sparing <ENT1>autosomal dominant congenital nuclear cataract</ENT1>: a novel phenotype.,,,,T,,,,,c,,,,,1.0,,
15111599,165,C565137,1411,Association,TRUE,CONCLUSIONS: The DeltaG91 mutation in <ENT2>CRYBA3/A1</ENT2> is associated with an <ENT1>autosomal dominant congenital nuclear lactescent cataract</ENT1>.,,,,T,,,,,c,,,,,1.0,,
15111599,163,c|SUB|G|IVS3+1|A,C535342,Association,TRUE,A splice mutation (<ENT1>IVS3+1G/A</ENT1>) in this gene has been reported in a <ENT2>zonular cataract</ENT2> with sutural opacities.,,,,T,,,,,c,,,,,0.0,,
15122711,172,D002549,rs121918047,Association,TRUE,"In two unrelated pedigrees of <ENT1>Alpers' syndrome</ENT1>, each affected child was found to carry a homozygous mutation in exon 17 of the POLG locus that led to a <ENT2>Glu873Stop</ENT2> mutation just upstream of the polymerase domain of the protein.",,,,T,,,,,w,,,,,0.0,,
15122711,174,D002549,5428,Association,FALSE,<ENT2>POLG</ENT2> mutations associated with <ENT1>Alpers' syndrome</ENT1> and mitochondrial DNA depletion.,,,,T,,,,,c,,,,,0.0,,
15122711,174,D002549,5428,Association,FALSE,"In two unrelated pedigrees of <ENT1>Alpers' syndrome</ENT1>, each affected child was found to carry a homozygous mutation in exon 17 of the <ENT2>POLG</ENT2> locus that led to a Glu873Stop mutation just upstream of the polymerase domain of the protein.",,,,T,,,,,w,,,,,1.0,,
15122711,167,D019636,5428,Association,FALSE,"It is an autosomal recessive, developmental mitochondrial DNA depletion disorder characterized by deficiency in mitochondrial <ENT2>DNA polymerase gamma</ENT2> (<ENT2>POLG</ENT2>) catalytic activity, refractory seizures, <ENT1>neurodegeneration</ENT1>, and liver disease.",,,,T,,,,,w,,,,,1.0,,
15122711,173,D028361,5428,Association,FALSE,<ENT2>POLG</ENT2> mutations associated with Alpers' syndrome and <ENT1>mitochondrial DNA depletion</ENT1>.,,,,T,,,,,c,,,,,1.0,,
15122711,173,D028361,5428,Association,FALSE,"It is an autosomal recessive, developmental <ENT1>mitochondrial DNA depletion</ENT1> disorder characterized by deficiency in mitochondrial <ENT2>DNA polymerase gamma</ENT2> (<ENT2>POLG</ENT2>) catalytic activity, refractory seizures, neurodegeneration, and liver disease.",,,,T,,,,,c,,,,,0.0,,
15122711,166,D008107,5428,Association,FALSE,"It is an autosomal recessive, developmental mitochondrial DNA depletion disorder characterized by deficiency in mitochondrial <ENT2>DNA polymerase gamma</ENT2> (<ENT2>POLG</ENT2>) catalytic activity, refractory seizures, neurodegeneration, and <ENT1>liver disease</ENT1>.",,,,T,,,,,w,,,,,1.0,,
15122711,168,D012640,5428,Association,FALSE,"It is an autosomal recessive, developmental mitochondrial DNA depletion disorder characterized by deficiency in mitochondrial <ENT2>DNA polymerase gamma</ENT2> (<ENT2>POLG</ENT2>) catalytic activity, refractory <ENT1>seizures</ENT1>, neurodegeneration, and liver disease.",,,,T,,,,,w,,,,,1.0,,
15130900,175,D003520,D014890,Association,TRUE,Urinary bladder cancer in <ENT2>Wegener's granulomatosis</ENT2>: risks and relation to <ENT1>cyclophosphamide</ENT1>.,,,,T,,T,,,c,,,,,0.0,,
15130900,175,D003520,D014890,Association,TRUE,"OBJECTIVE: To assess and characterise the risk of bladder cancer, and its relation to <ENT1>cyclophosphamide</ENT1>, in patients with <ENT2>Wegener's granulomatosis</ENT2>.",,,,T,,,,,w,,,,,0.0,,
15130900,175,D003520,D014890,Association,TRUE,"CONCLUSION: The results indicate a dose-response relationship between <ENT1>cyclophosphamide</ENT1> and the risk of bladder cancer, high cumulative risks in the entire cohort, and also the possibility of risk factors operating even before <ENT2>Wegener's granulomatosis</ENT2>.",,,,T,,,,,w,,,,,1.0,,
15130900,176,D003520,D001749,Positive_Correlation,TRUE,<ENT2>Urinary bladder cancer</ENT2> in Wegener's granulomatosis: risks and relation to <ENT1>cyclophosphamide</ENT1>.,,,,T,,,,,w,,,,,1.0,,
15130900,176,D003520,D001749,Positive_Correlation,TRUE,"OBJECTIVE: To assess and characterise the risk of <ENT2>bladder cancer</ENT2>, and its relation to <ENT1>cyclophosphamide</ENT1>, in patients with Wegener's granulomatosis.",,,,T,,,,,c,,,,,1.0,,
15130900,176,D003520,D001749,Positive_Correlation,TRUE,"Nested within the cohort, a matched case-control study was performed to estimate the association between <ENT1>cyclophosphamide</ENT1> and <ENT2>bladder cancer</ENT2> using odds ratios (ORs) as relative risk.",,,,T,,,,,c,,,,,1.0,,
15130900,176,D003520,D001749,Positive_Correlation,TRUE,"The risk of <ENT2>bladder cancer</ENT2> doubled for every 10 g increment in <ENT1>cyclophosphamide</ENT1> (OR = 2.0, 95% confidence interval (CI) 0.8 to 4.9).",,,,T,,,,,c,,,,,1.0,,
15130900,176,D003520,D001749,Positive_Correlation,TRUE,"CONCLUSION: The results indicate a dose-response relationship between <ENT1>cyclophosphamide</ENT1> and the risk of <ENT2>bladder cancer</ENT2>, high cumulative risks in the entire cohort, and also the possibility of risk factors operating even before Wegener's granulomatosis.",,,,T,,,,,w,,,,,1.0,,
15177686,177,D004062,7290,Association,TRUE,Altered replication timing of the <ENT2>HIRA</ENT2>/<ENT2>Tuple1</ENT2> locus in the <ENT1>DiGeorge and Velocardiofacial syndromes</ENT1>.,,,,T,,,,,w,,,,,1.0,,
15177686,177,D004062,7290,Association,TRUE,"In this study, we show that the candidate gene <ENT2>HIRA</ENT2>/<ENT2>Tuple1</ENT2> mapping on the non-deleted TDR22, in <ENT1>DGS</ENT1>/<ENT1>VCFS</ENT1> subjects presents a delayed replication timing.",,,,T,,,,,w,,,"11,12,21,22",,1.0,,
15184369,181,D004533,55503,Association,TRUE,Whole cell recordings from non-transfected HEK cells and cells expressing human <ENT2>TRPV6</ENT2> revealed the presence of a basal inward current in both types of cells when the internal solution contained 0.1 mm <ENT1>EGTA</ENT1> and 100 nm (i) or if the cytosolic Ca(2+) buffering remained undisturbed in perforated patch-clamp experiments.,,,,T,,,,,w,,,,,1.0,,
15184369,181,D004533,55503,Association,TRUE,"In contrast, dialyzing 0.5 mm <ENT1>EGTA</ENT1> into <ENT2>TRPV6</ENT2>-expressing cells readily activated Ca(2+) inward currents, which were undetectable in non-transfected cells.",,,,T,,,,,w,,,,,1.0,,
15184369,180,D004533,D002118,Association,TRUE,"Intact cells loaded with fura-2 had an elevated intracellular free <ENT2>Ca(2+)</ENT2> concentration ((i)), which decreased to the same level such as in non-transfected cells if external <ENT2>Ca(2+)</ENT2> was chelated by <ENT1>EGTA</ENT1>.",,,,T,,,,,w,,,,,0.0,,
15184369,180,D004533,D002118,Association,TRUE,Whole cell recordings from non-transfected HEK cells and cells expressing human TRPV6 revealed the presence of a basal inward current in both types of cells when the internal solution contained 0.1 mm <ENT1>EGTA</ENT1> and 100 nm (i) or if the cytosolic <ENT2>Ca(2+)</ENT2> buffering remained undisturbed in perforated patch-clamp experiments.,,,,T,,,,,w,,,,,1.0,,
15184369,180,D004533,D002118,Association,TRUE,"In contrast, dialyzing 0.5 mm <ENT1>EGTA</ENT1> into TRPV6-expressing cells readily activated <ENT2>Ca(2+)</ENT2> inward currents, which were undetectable in non-transfected cells.",,,,T,,,,,c,,,,,0.0,,
15184369,182,55503,D002118,Negative_Correlation,TRUE,<ENT2>Ca2+</ENT2> dependence of the <ENT2>Ca2+</ENT2>-selective <ENT1>TRPV6</ENT1> channel.,,,,T,,,,,w,,,,,0.0,,
15184369,182,55503,D002118,Negative_Correlation,TRUE,Microfluorimetry and patch-clamp experiments were performed on <ENT1>TRPV6</ENT1>-expressing HEK cells to determine whether this <ENT2>Ca(2+)</ENT2>-sensing <ENT2>Ca(2+)</ENT2> channel is constitutively active.,,,,T,,,,,c,,,,,1.0,,
15184369,182,55503,D002118,Negative_Correlation,TRUE,Whole cell recordings from non-transfected HEK cells and cells expressing human <ENT1>TRPV6</ENT1> revealed the presence of a basal inward current in both types of cells when the internal solution contained 0.1 mm EGTA and 100 nm (i) or if the cytosolic <ENT2>Ca(2+)</ENT2> buffering remained undisturbed in perforated patch-clamp experiments.,,,,T,,,,,c,,,,,1.0,,
15184369,182,55503,D002118,Negative_Correlation,TRUE,"If recombinantly expressed <ENT1>TRPV6</ENT1> forms open channels, one would expect <ENT2>Ca(2+)</ENT2>-induced current inhibition, because <ENT1>TRPV6</ENT1> is negatively regulated by internal <ENT2>Ca(2+)</ENT2>.",,,,T,,,,,c,,,,,0.5,,
15184369,182,55503,D002118,Negative_Correlation,TRUE,"In contrast, dialyzing 0.5 mm EGTA into <ENT1>TRPV6</ENT1>-expressing cells readily activated <ENT2>Ca(2+)</ENT2> inward currents, which were undetectable in non-transfected cells.",,,,T,,,,,c,,,,,1.0,,
15184369,182,55503,D002118,Negative_Correlation,TRUE,"Interestingly, monovalent cations permeated the <ENT1>TRPV6</ENT1> channels under conditions where no <ENT2>Ca(2+)</ENT2> permeation was detectable, indicating that divalent cations block <ENT1>TRPV6</ENT1> channels from the extracellular side.",,,,T,,,,,c,,,,,0.0,,
15184369,182,55503,D002118,Negative_Correlation,TRUE,"Like human <ENT1>TRPV6</ENT1>, the truncated human <ENT1>TRPV6</ENT1>(Delta695-725), which lacks the C-terminal domain required for <ENT2>Ca(2+)</ENT2>-calmodulin binding, does not form constitutive active channels, whereas the human <ENT1>TRPV6</ENT1>(D542A), carrying a point mutation in the presumed pore region, does not function as a channel.",,,,T,,,,,w,,,,,0.666666667,,
15184369,178,D016257,D002118,Positive_Correlation,TRUE,"Intact cells loaded with <ENT1>fura-2</ENT1> had an elevated intracellular free <ENT2>Ca(2+)</ENT2> concentration ((i)), which decreased to the same level such as in non-transfected cells if external <ENT2>Ca(2+)</ENT2> was chelated by EGTA.",,,,T,,,,,c,,,,,0.5,,
15184369,179,p|DEL|695-725|,D002118,Association,TRUE,"Like human TRPV6, the truncated human TRPV6(<ENT1>Delta695-725</ENT1>), which lacks the C-terminal domain required for <ENT2>Ca(2+)</ENT2>-calmodulin binding, does not form constitutive active channels, whereas the human TRPV6(D542A), carrying a point mutation in the presumed pore region, does not function as a channel.",,,,T,,,,,c,,,,,0.0,,
15191352,184,D014786,p|SUB|I|280|S,Positive_Correlation,TRUE,"The severe phenotype with seriously impaired intellectual development, hyperkinetic behaviour, tachycardia, <ENT1>hearing and visual impairment</ENT1> is probably due to the dominant negative effect of the <ENT2>I280S</ENT2> mutant protein and the absence of any functional TR-beta.",,,,T,,,,,c,,,,,1.0,,
15191352,194,D014786,7068,Association,TRUE,"The severe phenotype with seriously impaired intellectual development, hyperkinetic behaviour, tachycardia, <ENT1>hearing and visual impairment</ENT1> is probably due to the dominant negative effect of the I280S mutant protein and the absence of any functional <ENT2>TR-beta</ENT2>.",,,,T,,,,,c,,,,,0.0,,
15191352,183,D008607,p|SUB|I|280|S,Positive_Correlation,TRUE,"The severe phenotype with seriously <ENT1>impaired intellectual development</ENT1>, hyperkinetic behaviour, tachycardia, hearing and visual impairment is probably due to the dominant negative effect of the <ENT2>I280S</ENT2> mutant protein and the absence of any functional TR-beta.",,,,T,,,,,c,,,,,1.0,,
15191352,193,D008607,7068,Association,TRUE,"The severe phenotype with seriously <ENT1>impaired intellectual development</ENT1>, hyperkinetic behaviour, tachycardia, hearing and visual impairment is probably due to the dominant negative effect of the I280S mutant protein and the absence of any functional <ENT2>TR-beta</ENT2>.",,,,T,,,,,c,,,,,0.0,,
15191352,187,p|SUB|I|280|S,D006948,Positive_Correlation,TRUE,"The severe phenotype with seriously impaired intellectual development, <ENT2>hyperkinetic</ENT2> behaviour, tachycardia, hearing and visual impairment is probably due to the dominant negative effect of the <ENT1>I280S</ENT1> mutant protein and the absence of any functional TR-beta.",,,,T,,,,,c,,,,,1.0,,
15191352,186,p|SUB|I|280|S,D013610,Positive_Correlation,TRUE,"The severe phenotype with seriously impaired intellectual development, hyperkinetic behaviour, <ENT2>tachycardia</ENT2>, hearing and visual impairment is probably due to the dominant negative effect of the <ENT1>I280S</ENT1> mutant protein and the absence of any functional TR-beta.",,,,T,,,,,c,,,,,1.0,,
15191352,200,D018382,7068,Association,TRUE,Severe form of <ENT1>thyroid hormone resistance</ENT1> in a patient with homozygous/hemizygous mutation of <ENT2>T3 receptor</ENT2> gene.,,,,T,,T,,,w,,,,,1.0,,
15191352,200,D018382,7068,Association,TRUE,We present a patient with <ENT1>RTH</ENT1> found to be homo-/hemizygous for a mutation in the <ENT2>TR-beta</ENT2> gene.,,,,T,,,,,w,,,,,1.0,,
15191352,197,7068,D006948,Association,TRUE,"The severe phenotype with seriously impaired intellectual development, <ENT2>hyperkinetic</ENT2> behaviour, tachycardia, hearing and visual impairment is probably due to the dominant negative effect of the I280S mutant protein and the absence of any functional <ENT1>TR-beta</ENT1>.",,,,T,,,,,c,,,,,0.0,,
15191352,196,7068,D013610,Association,TRUE,"The severe phenotype with seriously impaired intellectual development, hyperkinetic behaviour, <ENT2>tachycardia</ENT2>, hearing and visual impairment is probably due to the dominant negative effect of the I280S mutant protein and the absence of any functional <ENT1>TR-beta</ENT1>.",,,,T,,,,,c,,,,,0.0,,
15198485,202,D009765,rs5370,Association,TRUE,"Another variant in the EDN1 gene in linkage disequilibrium with the <ENT2>Lys198Asn</ENT2> polymorphism may be responsible for the association with BP, or the interaction between the EDN1 <ENT2>Lys198Asn</ENT2> polymorphism and other factors such as <ENT1>obesity</ENT1> may be involved in the mechanisms elevating BP in vivo.",,,,T,,,,,c,,,,,0.0,,
15198485,204,D009765,1906,Association,TRUE,"Another variant in the <ENT2>EDN1</ENT2> gene in linkage disequilibrium with the Lys198Asn polymorphism may be responsible for the association with BP, or the interaction between the <ENT2>EDN1</ENT2> Lys198Asn polymorphism and other factors such as <ENT1>obesity</ENT1> may be involved in the mechanisms elevating BP in vivo.",,,,T,,,,,c,,,,,1.0,,
15198485,201,rs5370,D050177,Association,FALSE,"One is the <ENT1>Lys198Asn</ENT1> polymorphism, which showed a positive association with BP in <ENT2>overweight</ENT2> people.",,,,T,,,,,c,,,,,0.0,,
15200408,209,rs373513519,C564042,Association,TRUE,"However, SNP1 of UP Ia gene affecting a <ENT1>C to T</ENT1> conversion and an <ENT1>Ala7Val</ENT1> change, and SNP7 of UP III affecting a C to G conversion and a Pro154Ala change, were marginally associated with <ENT2>VUR</ENT2> (both P= 0.08).",,,,T,,,,,c,,,,,0.0,,
15200408,211,D006869,22270,Association,FALSE,"Recent studies indicate that genetic ablation of mouse <ENT2>uroplakin (UP) III</ENT2> gene, which encodes a 47 kD urothelial-specific integral membrane protein forming urothelial plaques, causes VUR and <ENT1>hydronephrosis</ENT1>.",,,,T,,,,,c,,,,,1.0,,
15200408,211,D006869,22270,Association,FALSE,"The fact that no truncation or frame shift mutations have been found in any of the VUR patients, coupled with our recent finding that some breeding pairs of <ENT2>UP III</ENT2> knockout mice yield litters that show not only VUR, but also severe <ENT1>hydronephrosis</ENT1> and neonatal death, raises the possibility that major uroplakin mutations could be embryonically or postnatally lethal in humans.",,,,T,,,,,w,,,,,0.0,,
15200408;15200408,208;210,7380;11045,C564042;C564042,Association;Association,TRUE;TRUE,Lack of major involvement of human <ENT1>uroplakin</ENT1> genes in <ENT2>vesicoureteral reflux</ENT2>: implications for disease heterogeneity.,,,,T,,,,,w,,,,,0.0,,
15200408;15200408,208;210,7380;11045,C564042;C564042,Association;Association,TRUE;TRUE,"METHODS: To begin to determine whether mutations in <ENT1>UP</ENT1> genes might play a role in human <ENT2>VUR</ENT2>, we genotyped all four <ENT1>UP</ENT1> genes in 76 patients with radiologically proven primary <ENT2>VUR</ENT2> by polymerase chain reaction (PCR) amplification and sequencing of all their exons plus 50 to 150 bp of flanking intronic sequences.",,,,T,,Y,,,c,,,,,1.0,,
15200408,208,7380,C564042,Association,TRUE,"However, SNP1 of UP Ia gene affecting a C to T conversion and an Ala7Val change, and SNP7 of <ENT1>UP III</ENT1> affecting a C to G conversion and a Pro154Ala change, were marginally associated with <ENT2>VUR</ENT2> (both P= 0.08).",,,,T,,,,,c,,,,,1.0,,
15200408,208,7380,C564042,Association,TRUE,"Studies of additional cases yielded a second set of data that, in combination with the first set, confirmed a weak association of <ENT1>UP III</ENT1> SNP7 in <ENT2>VUR</ENT2> (P= 0.036 adjusted for both subsets of cases vs. controls).",,,,T,,,,,c,,,,,0.0,,
15200408;15200408,208;210,7380;11045,C564042;C564042,Association;Association,TRUE;TRUE,"CONCLUSION: Such a weak association and the lack of families with simple dominant Mendelian inheritance suggest that missense changes of <ENT1>uroplakin</ENT1> genes cannot play a dominant role in causing <ENT2>VUR</ENT2> in humans, although they may be weak risk factors contributing to a complex polygenic disease.",,,,T,,,,,w,,,,,0.0,,
15200408;15200408,208;210,7380;11045,C564042;C564042,Association;Association,TRUE;TRUE,"The fact that no truncation or frame shift mutations have been found in any of the <ENT2>VUR</ENT2> patients, coupled with our recent finding that some breeding pairs of UP III knockout mice yield litters that show not only <ENT2>VUR</ENT2>, but also severe hydronephrosis and neonatal death, raises the possibility that major <ENT1>uroplakin</ENT1> mutations could be embryonically or postnatally lethal in humans.",,,,T,,,,,w,,,,,1.0,,
15200408,207,c|SUB|C||G,C564042,Association,TRUE,"However, SNP1 of UP Ia gene affecting a C to T conversion and an Ala7Val change, and SNP7 of UP III affecting a <ENT1>C to G</ENT1> conversion and a Pro154Ala change, were marginally associated with <ENT2>VUR</ENT2> (both P= 0.08).",,,,T,,,,,c,,,,,0.0,,
15200408,212,22270,C564042,Association,FALSE,"Recent studies indicate that genetic ablation of mouse <ENT1>uroplakin (UP) III</ENT1> gene, which encodes a 47 kD urothelial-specific integral membrane protein forming urothelial plaques, causes <ENT2>VUR</ENT2> and hydronephrosis.",,,,T,,,,,c,,,,,0.0,,
15200408,212,22270,C564042,Association,FALSE,"The fact that no truncation or frame shift mutations have been found in any of the <ENT2>VUR</ENT2> patients, coupled with our recent finding that some breeding pairs of <ENT1>UP III</ENT1> knockout mice yield litters that show not only <ENT2>VUR</ENT2>, but also severe hydronephrosis and neonatal death, raises the possibility that major uroplakin mutations could be embryonically or postnatally lethal in humans.",,,,T,,,,,c,,,,,0.0,,
15200408,205,22270,D066087,Association,FALSE,"The fact that no truncation or frame shift mutations have been found in any of the VUR patients, coupled with our recent finding that some breeding pairs of <ENT1>UP III</ENT1> knockout mice yield litters that show not only VUR, but also severe hydronephrosis and <ENT2>neonatal death</ENT2>, raises the possibility that major uroplakin mutations could be embryonically or postnatally lethal in humans.",,,,T,,,,,c,,,,,0.0,,
15200408,210,11045,C564042,Association,TRUE,"However, SNP1 of <ENT1>UP Ia</ENT1> gene affecting a C to T conversion and an Ala7Val change, and SNP7 of UP III affecting a C to G conversion and a Pro154Ala change, were marginally associated with <ENT2>VUR</ENT2> (both P= 0.08).",,,,T,,,,,c,,,,,1.0,,
15200408,206,p|SUB|P|154|A,C564042,Association,TRUE,"However, SNP1 of UP Ia gene affecting a C to T conversion and an Ala7Val change, and SNP7 of UP III affecting a C to G conversion and a <ENT1>Pro154Ala</ENT1> change, were marginally associated with <ENT2>VUR</ENT2> (both P= 0.08).",,,,T,,,,,c,,,,,0.0,,
15233872,219,C007145,D009203,Negative_Correlation,TRUE,Cardioprotective effect of <ENT1>tincture of Crataegus</ENT1> on isoproterenol-induced <ENT2>myocardial infarction</ENT2> in rats.,,,,T,,,,,w,,,,,0.0,,
15233872,219,C007145,D009203,Negative_Correlation,TRUE,The present study was done to investigate the protective effect of <ENT1>TCR</ENT1> on experimentally induced <ENT2>myocardial infarction</ENT2> in rats.,,,,T,,,,,c,,,,,0.0,,
15233872,218,C007145,D007545,Negative_Correlation,TRUE,Cardioprotective effect of <ENT1>tincture of Crataegus</ENT1> on <ENT2>isoproterenol</ENT2>-induced myocardial infarction in rats.,,,,T,,,,,w,,,,,1.0,,
15233872,218,C007145,D007545,Negative_Correlation,TRUE,"Pretreatment of <ENT1>TCR</ENT1>, at a dose of 0.5 mL/100 g bodyweight per day, orally for 30 days, prevented the increase in lipid peroxidation and activity of marker enzymes observed in <ENT2>isoproterenol</ENT2>-induced rats (85 mg kg(-1) s. c. for 2 days at an interval of 24 h).",,,,T,,,,,w,,,,,0.0,,
15233872,218,C007145,D007545,Negative_Correlation,TRUE,<ENT1>TCR</ENT1> prevented the <ENT2>isoproterenol</ENT2>-induced decrease in antioxidant enzymes in the heart and increased the rate of ADP-stimulated oxygen uptake and respiratory coupling ratio.,,,,T,,,,,c,,,,,0.0,,
15233872,218,C007145,D007545,Negative_Correlation,TRUE,<ENT1>TCR</ENT1> protected against pathological changes induced by <ENT2>isoproterenol</ENT2> in rat heart.,,,,T,Y,,,,c,,,,,1.0,,
15233872,218,C007145,D007545,Negative_Correlation,TRUE,The results show that pretreatment with <ENT1>TCR</ENT1> may be useful in preventing the damage induced by <ENT2>isoproterenol</ENT2> in rat heart.,,,,T,Y,,,,c,,,,,1.0,,
15233872,217,C007145,D008055,Association,TRUE,"Pretreatment of <ENT1>TCR</ENT1>, at a dose of 0.5 mL/100 g bodyweight per day, orally for 30 days, prevented the increase in <ENT2>lipid</ENT2> peroxidation and activity of marker enzymes observed in isoproterenol-induced rats (85 mg kg(-1) s. c. for 2 days at an interval of 24 h).",,,,T,,,,,c,,,,,0.0,,
15233872,215,C007145,D010100,Positive_Correlation,TRUE,<ENT1>TCR</ENT1> prevented the isoproterenol-induced decrease in antioxidant enzymes in the heart and increased the rate of ADP-stimulated <ENT2>oxygen</ENT2> uptake and respiratory coupling ratio.,,,,T,,,,,c,,,,,1.0,,
15233872,216,C007145,D000244,Positive_Correlation,TRUE,<ENT1>TCR</ENT1> prevented the isoproterenol-induced decrease in antioxidant enzymes in the heart and increased the rate of <ENT2>ADP</ENT2>-stimulated oxygen uptake and respiratory coupling ratio.,,,,T,Y,,,,c,,,,,1.0,,
15233872,214,D009203,D007545,Positive_Correlation,FALSE,Cardioprotective effect of tincture of Crataegus on <ENT2>isoproterenol</ENT2>-induced <ENT1>myocardial infarction</ENT1> in rats.,,,,T,,,,,c,,,,,0.0,,
15233872,213,D010100,D000244,Positive_Correlation,FALSE,TCR prevented the isoproterenol-induced decrease in antioxidant enzymes in the heart and increased the rate of <ENT2>ADP</ENT2>-stimulated <ENT1>oxygen</ENT1> uptake and respiratory coupling ratio.,,,,T,,,,,c,,,,,1.0,,
15241482,226,D003327,p|SUB|M|55|L,Association,FALSE,"Two coding polymorphisms, <ENT2>55M/L</ENT2> and 192Q/R, and a promoter variant, -107C/T, has been extensively studied with respect to susceptibility to <ENT1>CHD</ENT1>.",,,,T,,,,,c,,,,,0.0,,
15241482,225,D003327,p|SUB|Q|192|R,Association,FALSE,"Two coding polymorphisms, 55M/L and <ENT2>192Q/R</ENT2>, and a promoter variant, -107C/T, has been extensively studied with respect to susceptibility to <ENT1>CHD</ENT1>.",,,,T,,,,,c,,,,,0.0,,
15241482,225,D003327,p|SUB|Q|192|R,Association,FALSE,"Using self-reported data on ischemic heart disease to evaluate the impact of the PON <ENT2>192Q/R</ENT2> polymorphism on susceptibility to <ENT1>CHD</ENT1>, we found only a nonsignificant trend of 192RR homozygosity in women being a risk factor.",,,,T,,,,,w,,,,,1.0,,
15241482,221,D003327,5444,Association,FALSE,"The antioxidant enzyme <ENT2>paraoxonase 1</ENT2> (<ENT2>PON1</ENT2>) has previously been suggested to confer protection against <ENT1>coronary heart disease</ENT1> (<ENT1>CHD</ENT1>), one of the main causes of death in the Western world.",,,,T,,,,,c,,,"11,12,21,22",,0.5,,
15241482,221,D003327,5444,Association,FALSE,"Using self-reported data on ischemic heart disease to evaluate the impact of the <ENT2>PON</ENT2> 192Q/R polymorphism on susceptibility to <ENT1>CHD</ENT1>, we found only a nonsignificant trend of 192RR homozygosity in women being a risk factor.",,,,T,,,,,w,,,,,1.0,,
15241482,221,D003327,5444,Association,FALSE,Our results thus indicates that <ENT2>PON1</ENT2> 192RR homozygosity is associated with increased mortality in women in the second half of life and that this increased mortality is possibly related to <ENT1>CHD</ENT1> severity and survival after <ENT1>CHD</ENT1> rather than susceptibility to development of <ENT1>CHD</ENT1>.,,,,T,,,,,c,,,,,0.333333333,,
15241482,222,D003327,p|Allele|R|192,Association,TRUE,"Using self-reported data on ischemic heart disease to evaluate the impact of the PON 192Q/R polymorphism on susceptibility to <ENT1>CHD</ENT1>, we found only a nonsignificant trend of <ENT2>192RR</ENT2> homozygosity in women being a risk factor.",,,,T,,,,,c,,,,,0.0,,
15241482,222,D003327,p|Allele|R|192,Association,TRUE,Our results thus indicates that PON1 <ENT2>192RR</ENT2> homozygosity is associated with increased mortality in women in the second half of life and that this increased mortality is possibly related to <ENT1>CHD</ENT1> severity and survival after <ENT1>CHD</ENT1> rather than susceptibility to development of <ENT1>CHD</ENT1>.,,,,T,,,,,c,,,,,0.333333333,,
15241482,220,D003327,c|SUB|C|-107|T,Association,FALSE,"Two coding polymorphisms, 55M/L and 192Q/R, and a promoter variant, <ENT2>-107C/T</ENT2>, has been extensively studied with respect to susceptibility to <ENT1>CHD</ENT1>.",,,,T,,,,,c,,,,,0.0,,
15241482,224,p|SUB|Q|192|R,D017202,Association,FALSE,"Using self-reported data on <ENT2>ischemic heart disease</ENT2> to evaluate the impact of the PON <ENT1>192Q/R</ENT1> polymorphism on susceptibility to CHD, we found only a nonsignificant trend of 192RR homozygosity in women being a risk factor.",,,,T,,,,,w,,,,,1.0,,
15241482,223,5444,D017202,Association,FALSE,"Using self-reported data on <ENT2>ischemic heart disease</ENT2> to evaluate the impact of the <ENT1>PON</ENT1> 192Q/R polymorphism on susceptibility to CHD, we found only a nonsignificant trend of 192RR homozygosity in women being a risk factor.",,,,T,,,,,w,,,,,1.0,,
15266215,227,D013927,D001241,Positive_Correlation,TRUE,"<ENT1>Thrombotic</ENT1> risk was consistently higher for users of <ENT2>aspirin</ENT2> users than nonusers of <ENT2>aspirin</ENT2> (placebo, 1.4% vs. 0%; valdecoxib, 1.7% vs. 0.2%; NSAIDs, 1.9% vs. 0.5%).",,,,T,,,,,c,,,,,0.5,,
15266215,232,5743,C406224,Negative_Correlation,FALSE,Effects of the <ENT1>cyclooxygenase-2</ENT1> specific inhibitor <ENT2>valdecoxib</ENT2> versus nonsteroidal antiinflammatory agents and placebo on cardiovascular thrombotic events in patients with arthritis.,,,,T,,,,,c,,,,,1.0,,
15266215,232,5743,C406224,Negative_Correlation,FALSE,"We evaluated cardiovascular event data for <ENT2>valdecoxib</ENT2>, a new <ENT1>COX-2</ENT1>-specific inhibitor in approximately 8000 patients with osteoarthritis and rheumatoid arthritis treated with this agent in randomized clinical trials.",,,,T,,,,,c,,,,,1.0,,
15266215,230,D000894,C406224,Comparison,TRUE,Effects of the cyclooxygenase-2 specific inhibitor <ENT2>valdecoxib</ENT2> versus <ENT1>nonsteroidal antiinflammatory agents</ENT1> and placebo on cardiovascular thrombotic events in patients with arthritis.,,,,T,,,,,c,,,,,1.0,,
15266215,230,D000894,C406224,Comparison,TRUE,"The incidence of cardiovascular thrombotic events (cardiac, cerebrovascular and peripheral vascular, or arterial thrombotic) was determined by analyzing pooled <ENT2>valdecoxib</ENT2> (10-80 mg daily), nonselective <ENT1>NSAID</ENT1> (diclofenac 75 mg bid, ibuprofen 800 mg tid, or naproxen 500 mg bid) and placebo data from 10 randomized osteoarthritis and rheumatoid arthritis trials that were 6-52 weeks in duration.",,,,T,,,,,w,,,,,1.0,,
15266215,230,D000894,C406224,Comparison,TRUE,"Crude and exposure-adjusted incidences of thrombotic events were similar for <ENT2>valdecoxib</ENT2>, <ENT1>NSAIDs</ENT1>, and placebo.",,,,T,,,,,c,,,,,0.0,,
15266215,230,D000894,C406224,Comparison,TRUE,"Thrombotic risk was consistently higher for users of aspirin users than nonusers of aspirin (placebo, 1.4% vs. 0%; <ENT2>valdecoxib</ENT2>, 1.7% vs. 0.2%; <ENT1>NSAIDs</ENT1>, 1.9% vs. 0.5%).",,,,T,,,,,c,,,,,0.0,,
15266215,230,D000894,C406224,Comparison,TRUE,Short- and intermediate-term treatment with therapeutic (10 or 20 mg daily) and supratherapeutic (40 or 80 mg daily) <ENT2>valdecoxib</ENT2> doses was not associated with an increased incidence of thrombotic events relative to nonselective <ENT1>NSAIDs</ENT1> or placebo in osteoarthritis and rheumatoid arthritis patients in controlled clinical trials.,,,,T,,,,,c,,,,,0.0,,
15266215,231,D001168,C406224,Negative_Correlation,FALSE,Effects of the cyclooxygenase-2 specific inhibitor <ENT2>valdecoxib</ENT2> versus nonsteroidal antiinflammatory agents and placebo on cardiovascular thrombotic events in patients with <ENT1>arthritis</ENT1>.,,,,T,,,,,w,,,,,1.0,,
15266215,228,C406224,D001172,Negative_Correlation,FALSE,"We evaluated cardiovascular event data for <ENT1>valdecoxib</ENT1>, a new COX-2-specific inhibitor in approximately 8000 patients with osteoarthritis and <ENT2>rheumatoid arthritis</ENT2> treated with this agent in randomized clinical trials.",,,,T,,,,,w,,,,,0.0,,
15266215,228,C406224,D001172,Negative_Correlation,FALSE,"The incidence of cardiovascular thrombotic events (cardiac, cerebrovascular and peripheral vascular, or arterial thrombotic) was determined by analyzing pooled <ENT1>valdecoxib</ENT1> (10-80 mg daily), nonselective NSAID (diclofenac 75 mg bid, ibuprofen 800 mg tid, or naproxen 500 mg bid) and placebo data from 10 randomized osteoarthritis and <ENT2>rheumatoid arthritis</ENT2> trials that were 6-52 weeks in duration.",,,,T,,,,,w,,,,,0.0,,
15266215,228,C406224,D001172,Negative_Correlation,FALSE,Short- and intermediate-term treatment with therapeutic (10 or 20 mg daily) and supratherapeutic (40 or 80 mg daily) <ENT1>valdecoxib</ENT1> doses was not associated with an increased incidence of thrombotic events relative to nonselective NSAIDs or placebo in osteoarthritis and <ENT2>rheumatoid arthritis</ENT2> patients in controlled clinical trials.,,,,T,,,,,w,,,,,1.0,,
15266215,229,C406224,D010003,Negative_Correlation,FALSE,"We evaluated cardiovascular event data for <ENT1>valdecoxib</ENT1>, a new COX-2-specific inhibitor in approximately 8000 patients with <ENT2>osteoarthritis</ENT2> and rheumatoid arthritis treated with this agent in randomized clinical trials.",,,,T,,,,,c,,,,,0.0,,
15266215,229,C406224,D010003,Negative_Correlation,FALSE,"The incidence of cardiovascular thrombotic events (cardiac, cerebrovascular and peripheral vascular, or arterial thrombotic) was determined by analyzing pooled <ENT1>valdecoxib</ENT1> (10-80 mg daily), nonselective NSAID (diclofenac 75 mg bid, ibuprofen 800 mg tid, or naproxen 500 mg bid) and placebo data from 10 randomized <ENT2>osteoarthritis</ENT2> and rheumatoid arthritis trials that were 6-52 weeks in duration.",,,,T,,,,,w,,,,,0.0,,
15266215,229,C406224,D010003,Negative_Correlation,FALSE,Short- and intermediate-term treatment with therapeutic (10 or 20 mg daily) and supratherapeutic (40 or 80 mg daily) <ENT1>valdecoxib</ENT1> doses was not associated with an increased incidence of thrombotic events relative to nonselective NSAIDs or placebo in <ENT2>osteoarthritis</ENT2> and rheumatoid arthritis patients in controlled clinical trials.,,,,T,,,,,c,,,,,1.0,,
15459183,236,2213,971,Association,TRUE,<ENT2>CD72</ENT2> polymorphisms associated with alternative splicing modify susceptibility to human systemic lupus erythematosus through epistatic interaction with <ENT1>FCGR2B</ENT1>.,,,,T,,,,,c,,,,,0.0,,
15459183,236,2213,971,Association,TRUE,"Because polymorphism of CD72, another inhibitory receptor of B cells, was associated with murine SLE, we identified human <ENT2>CD72</ENT2> polymorphisms, tested their association with SLE and examined genetic interaction with <ENT1>FCGR2B</ENT1> in the Japanese (160 SLE, 277 controls), Thais (87 SLE, 187 controls) and Caucasians (94 families containing SLE members).",,,,T,,Y,,,w,,,,,0.0,,
15459183,236,2213,971,Association,TRUE,"Using the two Asian cohorts, significant association of <ENT1>FCGR2B</ENT1>-232Thr/Thr with SLE was observed only in the presence of <ENT2>CD72</ENT2>-*1/*1 genotype (OR 4.63, 95% CI 1.47-14.6, P=0.009 versus <ENT1>FCGR2B</ENT1>-232Ile/Ile plus <ENT2>CD72</ENT2>-*2/*2).",,,,T,,,,,c,,,,,0.0,,
15459183,236,2213,971,Association,TRUE,"These results indicated that the presence of <ENT2>CD72</ENT2>-*2 allele decreases risk for human SLE conferred by <ENT1>FCGR2B</ENT1>-232Thr, possibly by increasing the AS isoform of <ENT2>CD72</ENT2>.",,,,T,,,,,c,,,,,0.0,,
15459183,235,2213,D008180,Association,TRUE,CD72 polymorphisms associated with alternative splicing modify susceptibility to human <ENT2>systemic lupus erythematosus</ENT2> through epistatic interaction with <ENT1>FCGR2B</ENT1>.,,,,T,,,,,c,,,,,1.0,,
15459183,235,2213,D008180,Association,TRUE,We previously reported association of <ENT1>FCGR2B</ENT1>-Ile232Thr with <ENT2>systemic lupus erythematosus</ENT2> (<ENT2>SLE</ENT2>) in three Asian populations.,,,,T,,,,,c,,,,,0.5,,
15459183,235,2213,D008180,Association,TRUE,"Because polymorphism of CD72, another inhibitory receptor of B cells, was associated with murine <ENT2>SLE</ENT2>, we identified human CD72 polymorphisms, tested their association with <ENT2>SLE</ENT2> and examined genetic interaction with <ENT1>FCGR2B</ENT1> in the Japanese (160 <ENT2>SLE</ENT2>, 277 controls), Thais (87 <ENT2>SLE</ENT2>, 187 controls) and Caucasians (94 families containing <ENT2>SLE</ENT2> members).",,,,T,,,,,c,,,,,1.0,,
15459183,235,2213,D008180,Association,TRUE,"Using the two Asian cohorts, significant association of <ENT1>FCGR2B</ENT1>-232Thr/Thr with <ENT2>SLE</ENT2> was observed only in the presence of CD72-*1/*1 genotype (OR 4.63, 95% CI 1.47-14.6, P=0.009 versus <ENT1>FCGR2B</ENT1>-232Ile/Ile plus CD72-*2/*2).",,,,T,,,,,c,,,,,0.5,,
15459183,235,2213,D008180,Association,TRUE,"These results indicated that the presence of CD72-*2 allele decreases risk for human <ENT2>SLE</ENT2> conferred by <ENT1>FCGR2B</ENT1>-232Thr, possibly by increasing the AS isoform of CD72.",,,,T,,,,,c,,,,,1.0,,
15459183,233,rs1050501,D008180,Positive_Correlation,TRUE,We previously reported association of FCGR2B-<ENT1>Ile232Thr</ENT1> with <ENT2>systemic lupus erythematosus</ENT2> (<ENT2>SLE</ENT2>) in three Asian populations.,,,,T,,,,,c,,,,,0.5,,
15459183,233,rs1050501,D008180,Positive_Correlation,TRUE,"Using the two Asian cohorts, significant association of FCGR2B-<ENT1>232Thr</ENT1>/Thr with <ENT2>SLE</ENT2> was observed only in the presence of CD72-*1/*1 genotype (OR 4.63, 95% CI 1.47-14.6, P=0.009 versus FCGR2B-<ENT1>232Ile</ENT1>/Ile plus CD72-*2/*2).",,,,T,,,,,c,,,,,0.5,,
15459183,233,rs1050501,D008180,Positive_Correlation,TRUE,"These results indicated that the presence of CD72-*2 allele decreases risk for human <ENT2>SLE</ENT2> conferred by FCGR2B-<ENT1>232Thr</ENT1>, possibly by increasing the AS isoform of CD72.",,,,T,,,,,c,,,,,1.0,,
15459183,237,971,D008180,Association,TRUE,<ENT1>CD72</ENT1> polymorphisms associated with alternative splicing modify susceptibility to human <ENT2>systemic lupus erythematosus</ENT2> through epistatic interaction with FCGR2B.,,,,T,,,,,c,,,,,1.0,,
15459183,237,971,D008180,Association,TRUE,"Because polymorphism of CD72, another inhibitory receptor of B cells, was associated with murine <ENT2>SLE</ENT2>, we identified human <ENT1>CD72</ENT1> polymorphisms, tested their association with <ENT2>SLE</ENT2> and examined genetic interaction with FCGR2B in the Japanese (160 <ENT2>SLE</ENT2>, 277 controls), Thais (87 <ENT2>SLE</ENT2>, 187 controls) and Caucasians (94 families containing <ENT2>SLE</ENT2> members).",,,,T,,,,,c,,,,,1.0,,
15459183,237,971,D008180,Association,TRUE,"Using the two Asian cohorts, significant association of FCGR2B-232Thr/Thr with <ENT2>SLE</ENT2> was observed only in the presence of <ENT1>CD72</ENT1>-*1/*1 genotype (OR 4.63, 95% CI 1.47-14.6, P=0.009 versus FCGR2B-232Ile/Ile plus <ENT1>CD72</ENT1>-*2/*2).",,,,T,,,,,w,,,,,0.0,,
15459183,237,971,D008180,Association,TRUE,"These results indicated that the presence of <ENT1>CD72</ENT1>-*2 allele decreases risk for human <ENT2>SLE</ENT2> conferred by FCGR2B-232Thr, possibly by increasing the AS isoform of <ENT1>CD72</ENT1>.",,,,T,,,,,c,,,,,0.5,,
15459183,238,D008180,12517,Association,FALSE,"Because polymorphism of <ENT2>CD72</ENT2>, another inhibitory receptor of B cells, was associated with murine <ENT1>SLE</ENT1>, we identified human CD72 polymorphisms, tested their association with <ENT1>SLE</ENT1> and examined genetic interaction with FCGR2B in the Japanese (160 <ENT1>SLE</ENT1>, 277 controls), Thais (87 <ENT1>SLE</ENT1>, 187 controls) and Caucasians (94 families containing <ENT1>SLE</ENT1> members).",,,,T,,,,,w,,,,,0.2,,
15459183,238,D008180,12517,Association,FALSE,"The AS isoform lacks exon 8, and is deduced to contain 49 amino acid changes in the membrane-distal portion of the extracellular domain, where considerable amino acid changes are known in <ENT2>CD72</ENT2>(c) allele associated with murine <ENT1>SLE</ENT1>.",,,,T,,,,,c,,,,,1.0,,
15459975,241,p|FS|P|63|P|54,D017499,Association,TRUE,"Upon screening 30 candidate genes, we identified a missense mutation, p.Ser63Asn in SSH1 in one family, a frameshift mutation, p.Ser19CysfsX24 in an alternative variant (isoform f) of SSH1 in another family, and a frameshift mutation, <ENT1>p.Pro27ProfsX54</ENT1> in the same alternative variant in one non-familial case with <ENT2>DSAP</ENT2>.",,,,T,,,,,w,,,,,0.0,,
15459975,242,p|FS|S|19|C|24,D017499,Association,TRUE,"Upon screening 30 candidate genes, we identified a missense mutation, p.Ser63Asn in SSH1 in one family, a frameshift mutation, <ENT1>p.Ser19CysfsX24</ENT1> in an alternative variant (isoform f) of SSH1 in another family, and a frameshift mutation, p.Pro27ProfsX54 in the same alternative variant in one non-familial case with <ENT2>DSAP</ENT2>.",,,,T,,,,,w,,,,,0.0,,
15459975,239,D017499,54434,Association,TRUE,Fine mapping and identification of a candidate gene <ENT2>SSH1</ENT2> in <ENT1>disseminated superficial actinic porokeratosis</ENT1>.,,,,T,,,,,w,,,,,1.0,,
15459975,239,D017499,54434,Association,TRUE,"Upon screening 30 candidate genes, we identified a missense mutation, p.Ser63Asn in <ENT2>SSH1</ENT2> in one family, a frameshift mutation, p.Ser19CysfsX24 in an alternative variant (isoform f) of <ENT2>SSH1</ENT2> in another family, and a frameshift mutation, p.Pro27ProfsX54 in the same alternative variant in one non-familial case with <ENT1>DSAP</ENT1>.",,,,T,,,,,w,,,,,0.0,,
15459975,240,D017499,p|SUB|S|63|N,Association,TRUE,"Upon screening 30 candidate genes, we identified a missense mutation, <ENT2>p.Ser63Asn</ENT2> in SSH1 in one family, a frameshift mutation, p.Ser19CysfsX24 in an alternative variant (isoform f) of SSH1 in another family, and a frameshift mutation, p.Pro27ProfsX54 in the same alternative variant in one non-familial case with <ENT1>DSAP</ENT1>.",,,,T,,,,,w,,,,,0.0,,
15461822,244,D003715,c|DEL||30,Association,TRUE,CONCLUSIONS: The rDEN2<ENT2>Delta30</ENT2> and rDEN2Delta30-4995 viruses can be considered for evaluation in humans and for inclusion in a tetravalent <ENT1>dengue</ENT1> vaccine.,,,,T,,,,,w,,,,,0.0,,
15461822,243,D003715,c|DEL|4995|30,Association,TRUE,CONCLUSIONS: The rDEN2Delta30 and rDEN2<ENT2>Delta30-4995</ENT2> viruses can be considered for evaluation in humans and for inclusion in a tetravalent <ENT1>dengue</ENT1> vaccine.,,,,T,,,,,w,,,,,0.0,,
15461822,245,c|DEL||30,D014766,Association,TRUE,"In rhesus monkeys, rDEN2<ENT1>Delta30</ENT1> appeared to be slightly attenuated when compared to the parent virus as measured by duration and peak of <ENT2>viremia</ENT2> and neutralizing antibody induction.",,,,T,,,,,c,,,,,1.0,,
15464247,247,3593,D014766,Association,TRUE,"However, HCV genotype 1-infected patients with high baseline <ENT2>viremia</ENT2> carrying the <ENT1>IL12B</ENT1> 3'-UTR 1188-C-allele showed significantly higher sustained virologic response (SVR) rates (25.3% vs. 46% vs. 54.5% for A/A, A/C and C/C) due to reduced relapse rates (24.2% vs. 12% vs. zero % for A/A, A/C and C/C).",,,,T,,,,,c,,,,,0.0,,
15464247,246,c|Allele|C|1188,D014766,Association,TRUE,"However, HCV genotype 1-infected patients with high baseline <ENT2>viremia</ENT2> carrying the IL12B 3'-UTR <ENT1>1188-C</ENT1>-allele showed significantly higher sustained virologic response (SVR) rates (25.3% vs. 46% vs. 54.5% for A/A, A/C and C/C) due to reduced relapse rates (24.2% vs. 12% vs. zero % for A/A, A/C and C/C).",,,,T,,,,,c,,,,,0.0,,
15485686,258,p|SUB|V||M,D008133,Association,TRUE,"RESULTS: A novel, spontaneous <ENT2>LQTS</ENT2>-3 mutation was identified in the transmembrane segment 6 of domain IV of the Na(v)1.5 cardiac sodium channel, with a G-->A substitution at codon 1763, which changed a <ENT1>valine (GTG) to a methionine (ATG)</ENT1>.",,,,T,,,,,c,,,,,0.0,,
15485686,256,p|SUB|V|1763|M,D008133,Positive_Correlation,TRUE,CONCLUSIONS: These findings suggest that the Na(v)1.5/<ENT1>V1763M</ENT1> channel dysfunction and possible neighboring mutants contribute to a persistent inward current due to altered inactivation kinetics and clinically congenital <ENT2>LQTS</ENT2> with perinatal onset of arrhythmias that responded to lidocaine and mexiletine.,,,,T,Y,,,,c,,,,,0.0,,
15485686,255,p|SUB|V|1763|M,D001145,Positive_Correlation,TRUE,CONCLUSIONS: These findings suggest that the Na(v)1.5/<ENT1>V1763M</ENT1> channel dysfunction and possible neighboring mutants contribute to a persistent inward current due to altered inactivation kinetics and clinically congenital LQTS with perinatal onset of <ENT2>arrhythmias</ENT2> that responded to lidocaine and mexiletine.,,,,T,Y,,,,c,,,,,0.0,,
15485686,260,D008801,D008133,Negative_Correlation,FALSE,CONCLUSIONS: These findings suggest that the Na(v)1.5/V1763M channel dysfunction and possible neighboring mutants contribute to a persistent inward current due to altered inactivation kinetics and clinically congenital <ENT2>LQTS</ENT2> with perinatal onset of arrhythmias that responded to lidocaine and <ENT1>mexiletine</ENT1>.,,,,T,,,,,c,,,,,0.0,,
15485686,264,D008801,D054537,Negative_Correlation,FALSE,"The 2:1 <ENT2>atrioventricular block</ENT2> improved to 1:1 conduction only after intravenous lidocaine infusion or a high dose of <ENT1>mexiletine</ENT1>, which also controlled the ventricular tachycardia.",,,,T,,,,,c,,,,,0.0,,
15485686,253,D008801,D001145,Negative_Correlation,FALSE,CONCLUSIONS: These findings suggest that the Na(v)1.5/V1763M channel dysfunction and possible neighboring mutants contribute to a persistent inward current due to altered inactivation kinetics and clinically congenital LQTS with perinatal onset of <ENT2>arrhythmias</ENT2> that responded to lidocaine and <ENT1>mexiletine</ENT1>.,,,,T,,,,,c,,,,,1.0,,
15485686,262,D008801,D017180,Negative_Correlation,FALSE,"The 2:1 atrioventricular block improved to 1:1 conduction only after intravenous lidocaine infusion or a high dose of <ENT1>mexiletine</ENT1>, which also controlled the <ENT2>ventricular tachycardia</ENT2>.",,,,T,,,,,c,,,,,1.0,,
15485686,259,c|SUB|G|CODON1763|A,D008133,Association,TRUE,"RESULTS: A novel, spontaneous <ENT2>LQTS</ENT2>-3 mutation was identified in the transmembrane segment 6 of domain IV of the Na(v)1.5 cardiac sodium channel, with a <ENT1>G-->A substitution at codon 1763</ENT1>, which changed a valine (GTG) to a methionine (ATG).",,,,T,,,,,c,,,,,0.0,,
15485686,261,D008012,D008133,Negative_Correlation,FALSE,CONCLUSIONS: These findings suggest that the Na(v)1.5/V1763M channel dysfunction and possible neighboring mutants contribute to a persistent inward current due to altered inactivation kinetics and clinically congenital <ENT2>LQTS</ENT2> with perinatal onset of arrhythmias that responded to <ENT1>lidocaine</ENT1> and mexiletine.,,,,T,,,,,c,,,,,0.0,,
15485686,265,D008012,D054537,Negative_Correlation,FALSE,"The 2:1 <ENT2>atrioventricular block</ENT2> improved to 1:1 conduction only after intravenous <ENT1>lidocaine</ENT1> infusion or a high dose of mexiletine, which also controlled the ventricular tachycardia.",,,,T,,,,,c,,,,,0.0,,
15485686,254,D008012,D001145,Negative_Correlation,FALSE,CONCLUSIONS: These findings suggest that the Na(v)1.5/V1763M channel dysfunction and possible neighboring mutants contribute to a persistent inward current due to altered inactivation kinetics and clinically congenital LQTS with perinatal onset of <ENT2>arrhythmias</ENT2> that responded to <ENT1>lidocaine</ENT1> and mexiletine.,,,,T,,,,,c,,,,,1.0,,
15485686,263,D008012,D017180,Negative_Correlation,FALSE,"The 2:1 atrioventricular block improved to 1:1 conduction only after intravenous <ENT1>lidocaine</ENT1> infusion or a high dose of mexiletine, which also controlled the <ENT2>ventricular tachycardia</ENT2>.",,,,T,,,,,c,,,,,0.0,,
15485686,250,D013610,6331,Association,TRUE,A novel <ENT2>SCN5A</ENT2> mutation manifests as a malignant form of long QT syndrome with perinatal onset of <ENT1>tachycardia</ENT1>/bradycardia.,,,,T,,,,,c,,,,,1.0,,
15485686,257,D008133,6331,Association,TRUE,A novel <ENT2>SCN5A</ENT2> mutation manifests as a malignant form of <ENT1>long QT syndrome</ENT1> with perinatal onset of tachycardia/bradycardia.,,,,T,,,,,c,,,,,1.0,,
15485686,257,D008133,6331,Association,TRUE,"RESULTS: A novel, spontaneous <ENT1>LQTS</ENT1>-3 mutation was identified in the transmembrane segment 6 of domain IV of the <ENT2>Na(v)1.5</ENT2> cardiac sodium channel, with a G-->A substitution at codon 1763, which changed a valine (GTG) to a methionine (ATG).",,,,T,,,,,c,,,,,1.0,,
15485686,257,D008133,6331,Association,TRUE,CONCLUSIONS: These findings suggest that the <ENT2>Na(v)1.5</ENT2>/V1763M channel dysfunction and possible neighboring mutants contribute to a persistent inward current due to altered inactivation kinetics and clinically congenital <ENT1>LQTS</ENT1> with perinatal onset of arrhythmias that responded to lidocaine and mexiletine.,,,,T,Y,,,,c,,,,,1.0,,
15485686,248,6331,D001919,Association,TRUE,A novel <ENT1>SCN5A</ENT1> mutation manifests as a malignant form of long QT syndrome with perinatal onset of tachycardia/<ENT2>bradycardia</ENT2>.,,,,T,,,,,c,,,,,1.0,,
15485686,252,6331,D001145,Association,TRUE,CONCLUSIONS: These findings suggest that the <ENT1>Na(v)1.5</ENT1>/V1763M channel dysfunction and possible neighboring mutants contribute to a persistent inward current due to altered inactivation kinetics and clinically congenital LQTS with perinatal onset of <ENT2>arrhythmias</ENT2> that responded to lidocaine and mexiletine.,,,,T,Y,,,,c,,,,,1.0,,
15523499;15523499;15523499,286;282;284,D009638;D009638;D009638,153;155;154,Positive_Correlation;Positive_Correlation;Positive_Correlation,FALSE;FALSE;FALSE,The <ENT2>beta-adrenergic receptors</ENT2> (<ENT2>beta-AR</ENT2>) are G protein-coupled receptors activated by epinephrine and <ENT1>norepinephrine</ENT1> and are involved in a variety of their physiological functions.,,,,T,,,,,c,,,,,1.0,,
15523499,287,153,D004837,Positive_Correlation,FALSE,The <ENT1>beta-adrenergic receptors</ENT1> (<ENT1>beta-AR</ENT1>) are G protein-coupled receptors activated by <ENT2>epinephrine</ENT2> and norepinephrine and are involved in a variety of their physiological functions.,,,,T,,,,,c,,,,,1.0,,
15523499,281,153,D002318,Association,FALSE,"Previously, three <ENT1>beta-AR</ENT1> genes (<ENT1>ADRB1</ENT1>, ADRB2 and ADRB3) were resequenced, identifying polymorphisms that were used in genetic association studies of <ENT2>cardiovascular and metabolic disorders</ENT2>.",,,,T,,,,,c,,,,,0.5,,
15523499;15523499,283;285,D004837;D004837,155;154,Positive_Correlation;Positive_Correlation,FALSE;FALSE,The <ENT2>beta-adrenergic receptors</ENT2> (<ENT2>beta-AR</ENT2>) are G protein-coupled receptors activated by <ENT1>epinephrine</ENT1> and norepinephrine and are involved in a variety of their physiological functions.,,,,T,,,,,c,,,,,1.0,,
15523499,279,D002318,155,Association,FALSE,"Previously, three <ENT2>beta-AR</ENT2> genes (ADRB1, ADRB2 and <ENT2>ADRB3</ENT2>) were resequenced, identifying polymorphisms that were used in genetic association studies of <ENT1>cardiovascular and metabolic disorders</ENT1>.",,,,T,,,,,c,,,,,0.5,,
15523499,280,D002318,154,Association,FALSE,"Previously, three <ENT2>beta-AR</ENT2> genes (ADRB1, <ENT2>ADRB2</ENT2> and ADRB3) were resequenced, identifying polymorphisms that were used in genetic association studies of <ENT1>cardiovascular and metabolic disorders</ENT1>.",,,,T,,,,,c,,,,,0.5,,
15579441,290,D011692,D009404,Positive_Correlation,FALSE,"With this model, we were able to identify diffuse cortical hypoxia in the <ENT1>puromycin aminonucleoside</ENT1>-induced <ENT2>nephrotic syndrome</ENT2> and focal and segmental hypoxia in the remnant kidney model.",,,,T,,,,,c,,,,,1.0,,
15579441,292,D011692,D000860,Association,TRUE,"With this model, we were able to identify diffuse cortical <ENT2>hypoxia</ENT2> in the <ENT1>puromycin aminonucleoside</ENT1>-induced nephrotic syndrome and focal and segmental <ENT2>hypoxia</ENT2> in the remnant kidney model.",,,,T,,,,,c,,,,,0.0,,
15579441,292,D011692,D000860,Association,TRUE,"Expression of the <ENT2>hypoxia</ENT2>-responsive transgene increased throughout the observation period, reaching 2.2-fold at 2 weeks in the <ENT1>puromycin aminonucleoside</ENT1> model and 2.6-fold at 4 weeks in the remnant kidney model, whereas that of vascular endothelial growth factor showed a mild decrease, reflecting distinct behaviors of the two genes.",,,,T,,,,,w,,,,,1.0,,
15579441,291,83785,D000860,Association,TRUE,"In this study, we developed a new <ENT2>hypoxia</ENT2>-responsive reporter vector using a <ENT2>hypoxia</ENT2>-responsive element of the 5' <ENT1>vascular endothelial growth factor</ENT1> untranslated region and generated a novel <ENT2>hypoxia</ENT2>-sensing transgenic rat.",,,,T,,,,,w,,,,,0.0,,
15579441,291,83785,D000860,Association,TRUE,"Expression of the <ENT2>hypoxia</ENT2>-responsive transgene increased throughout the observation period, reaching 2.2-fold at 2 weeks in the puromycin aminonucleoside model and 2.6-fold at 4 weeks in the remnant kidney model, whereas that of <ENT1>vascular endothelial growth factor</ENT1> showed a mild decrease, reflecting distinct behaviors of the two genes.",,,,T,,,,,c,,,,,1.0,,
15579441,288,302424,D000860,Association,TRUE,"Finally, we identified the localization of proliferating cell nuclear antigen-positive, <ENT1>ED-1</ENT1>-positive, and terminal dUTP nick-end labeled-positive cells in the <ENT2>hypoxic</ENT2> cortical area in the remnant kidney model.",,,,T,,,,,w,,,,,1.0,,
15579441,289,C027078,D000860,Association,TRUE,"Finally, we identified the localization of proliferating cell nuclear antigen-positive, ED-1-positive, and terminal <ENT1>dUTP</ENT1> nick-end labeled-positive cells in the <ENT2>hypoxic</ENT2> cortical area in the remnant kidney model.",,,,T,,,,,w,,,,,1.0,,
15599941,294,c|DUP||G|,D009369,Positive_Correlation,TRUE,"Moreover, we confirm previous results that a short <ENT1>glutamine repeat</ENT1> in conjunction with GG genotype significantly increases the risk of <ENT2>malignant disease</ENT2>.",,,,T,,,,,c,,,,,1.0,,
15599941,296,367,354,Association,FALSE,Polymorphic forms of <ENT2>prostate specific antigen</ENT2> and their interaction with <ENT1>androgen receptor</ENT1> trinucleotide repeats in prostate cancer.,,,,T,,T,,,c,,,,,0.0,,
15599941,296,367,354,Association,FALSE,The effect on PC risks from <ENT2>PSA</ENT2> polymorphisms alone and synergistically with the <ENT1>AR</ENT1> gene was examined in this report.,,,,T,,,,,c,,,,,1.0,,
15599941,299,367,D011471,Association,FALSE,Polymorphic forms of prostate specific antigen and their interaction with <ENT1>androgen receptor</ENT1> trinucleotide repeats in <ENT2>prostate cancer</ENT2>.,,,,T,Y,T,,,w,,,,,0.0,,
15599941,299,367,D011471,Association,FALSE,The <ENT1>androgen receptor</ENT1> (<ENT1>AR</ENT1>) gene has polymorphic regions containing variable length glutamine and glycine repeats and these are believed to be associated with <ENT2>PC</ENT2> risk.,,,,T,,,,,c,,,,,1.0,,
15599941,299,367,D011471,Association,FALSE,The effect on <ENT2>PC</ENT2> risks from PSA polymorphisms alone and synergistically with the <ENT1>AR</ENT1> gene was examined in this report.,,,,T,,Y,,,w,,,,,1.0,,
15599941,298,354,D011471,Association,TRUE,Polymorphic forms of <ENT1>prostate specific antigen</ENT1> and their interaction with androgen receptor trinucleotide repeats in <ENT2>prostate cancer</ENT2>.,,,,T,,T,,,c,,,,,0.0,,
15599941,298,354,D011471,Association,TRUE,BACKGROUND: Recent data has suggested that polymorphisms in the <ENT1>prostate specific antigen</ENT1> (<ENT1>PSA</ENT1>) may increase <ENT2>prostate cancer</ENT2> (<ENT2>PC</ENT2>) risk.,,,,T,,,,,c,,,"11,12,21,22",,1.0,,
15599941,298,354,D011471,Association,TRUE,The effect on <ENT2>PC</ENT2> risks from <ENT1>PSA</ENT1> polymorphisms alone and synergistically with the AR gene was examined in this report.,,,,T,,Y,,,w,,,,,0.0,,
15599941,298,354,D011471,Association,TRUE,RESULTS: We found a significantly higher <ENT1>PSA</ENT1>/GG distribution in <ENT2>PC</ENT2> (30%) than either benign prostatic hyperplasia (BPH) (18%) or population controls (16%) (P = 0.025).,,,,T,,,,,c,,,,,1.0,,
15599941,298,354,D011471,Association,TRUE,CONCLUSIONS: Our results indicate that the <ENT1>PSA</ENT1>/ARE GG genotype confers an increased risk of <ENT2>PC</ENT2> especially among younger men.,,,,T,,,,,w,,,,,1.0,,
15602202,303,D017963,D009395,Positive_Correlation,TRUE,Recurrent acute <ENT2>interstitial nephritis</ENT2> induced by <ENT1>azithromycin</ENT1>.,,,,T,,,,,c,,,,,1.0,,
15602202,303,D017963,D009395,Positive_Correlation,TRUE,"A 14-year-old girl is reported with recurrent, <ENT1>azithromycin</ENT1>-induced, acute <ENT2>interstitial nephritis</ENT2>.",,,,T,,,,,c,,,,,1.0,,
15602202,300,D000900,D007674,Positive_Correlation,TRUE,"Although most cases of <ENT1>antibiotic</ENT1> induced acute interstitial nephritis are benign and self-limited, some patients are at risk for permanent <ENT2>renal injury</ENT2>.",,,,T,,,,,c,,,,,1.0,,
15602202,301,D000900,D009395,Positive_Correlation,TRUE,"Although most cases of <ENT1>antibiotic</ENT1> induced acute <ENT2>interstitial nephritis</ENT2> are benign and self-limited, some patients are at risk for permanent renal injury.",,,,T,,,,,c,,,,,1.0,,
15609295;15609295;15609295,309;304;306,7450;7450;7450,2815;2814;2811,Bind;Bind;Bind,FALSE;FALSE;FALSE,"Bernard-Soulier syndrome (BSS) is a rare inherited bleeding disorder due to quantitative or qualitative abnormalities in the platelet <ENT2>glycoprotein (GP) Ib/IX/V</ENT2> complex, the major <ENT1>von Willebrand factor</ENT1> receptor.",,,,T,,,,,w,,,,,0.0,,
15609295,308,7450,D001606,Association,FALSE,"<ENT2>Bernard-Soulier syndrome</ENT2> (<ENT2>BSS</ENT2>) is a rare inherited bleeding disorder due to quantitative or qualitative abnormalities in the platelet glycoprotein (GP) Ib/IX/V complex, the major <ENT1>von Willebrand factor</ENT1> receptor.",,,,T,,,,,c,,,,,1.0,,
15609295,310,2815,D001606,Association,TRUE,Compound heterozygosity for a novel nine-nucleotide deletion and the Asn45Ser missense mutation in the <ENT1>glycoprotein IX</ENT1> gene in a patient with <ENT2>Bernard-Soulier syndrome</ENT2>.,,,,T,,,,,c,,,,,1.0,,
15609295;15609295;15609295,310;305;307,2815;2814;2811,D001606;D001606;D001606,Association;Association;Association,TRUE;TRUE;TRUE,"<ENT2>Bernard-Soulier syndrome</ENT2> (<ENT2>BSS</ENT2>) is a rare inherited bleeding disorder due to quantitative or qualitative abnormalities in the platelet <ENT1>glycoprotein (GP) Ib/IX/V</ENT1> complex, the major von Willebrand factor receptor.",,,,T,,,,,c,,,,,1.0,,
15609295,310,2815,D001606,Association,TRUE,Our findings suggest that the additive effects of both mutations in the <ENT1>GPIX</ENT1> gene are responsible for the <ENT2>BSS</ENT2> phenotype of the patient.,,,,T,,,,,c,,,,,1.0,,
15609295,305,D001606,2814,Association,FALSE,"Several mutations have been described for each of the subunits, except for <ENT2>GPV</ENT2>, as a cause of <ENT1>BSS</ENT1>.",,,,T,,,,,c,,,,,1.0,,
15609295,311,D001606,rs5030764,Positive_Correlation,TRUE,Compound heterozygosity for a novel nine-nucleotide deletion and the <ENT2>Asn45Ser</ENT2> missense mutation in the glycoprotein IX gene in a patient with <ENT1>Bernard-Soulier syndrome</ENT1>.,,,,T,,,,,w,,,,,0.0,,
15630069,327,D012559,D003024,Negative_Correlation,FALSE,"Thirty-six nonobese subjects with <ENT1>schizophrenia</ENT1> or schizoaffective disorder, matched by body mass index and treated with either <ENT2>clozapine</ENT2>, olanzapine, or risperidone, were included in the analysis.",,,,T,,,,,c,,,,,0.0,,
15630069,326,D012559,C076029,Negative_Correlation,FALSE,"Thirty-six nonobese subjects with <ENT1>schizophrenia</ENT1> or schizoaffective disorder, matched by body mass index and treated with either clozapine, <ENT2>olanzapine</ENT2>, or risperidone, were included in the analysis.",,,,T,,,,,c,,,,,1.0,,
15630069,328,D012559,D014150,Negative_Correlation,FALSE,Glucose metabolism in patients with <ENT1>schizophrenia</ENT1> treated with atypical <ENT2>antipsychotic agents</ENT2>: a frequently sampled intravenous glucose tolerance test and minimal model analysis.,,,,T,,,,,c,,,,,1.0,,
15630069,328,D012559,D014150,Negative_Correlation,FALSE,"BACKGROUND: While the incidence of new-onset diabetes mellitus may be increasing in patients with <ENT1>schizophrenia</ENT1> treated with certain atypical <ENT2>antipsychotic agents</ENT2>, it remains unclear whether atypical agents are directly affecting glucose metabolism or simply increasing known risk factors for diabetes.",,,,T,,,,,c,,,,,0.0,,
15630069,325,D012559,D018967,Negative_Correlation,FALSE,"Thirty-six nonobese subjects with <ENT1>schizophrenia</ENT1> or schizoaffective disorder, matched by body mass index and treated with either clozapine, olanzapine, or <ENT2>risperidone</ENT2>, were included in the analysis.",,,,T,,,,,c,,,,,1.0,,
15630069,324,D005947,D003024,Association,TRUE,OBJECTIVE: To study the 2 drugs most clearly implicated (<ENT2>clozapine</ENT2> and olanzapine) and risperidone using a frequently sampled intravenous <ENT1>glucose</ENT1> tolerance test.,,,,T,,,,,c,,,,,1.0,,
15630069,324,D005947,D003024,Association,TRUE,"There was a significant difference among groups in <ENT1>glucose</ENT1> effectiveness (F(30) = 4.18; P = .02) (<ENT2>clozapine</ENT2><olanzapine<risperidone) with significant differences between <ENT2>clozapine</ENT2> and risperidone (t(30) = -2.59; P = .02) and olanzapine and risperidone (t(30) = -2.34, P = .03).",,,,T,,,,,c,,,,,1.0,,
15630069,324,D005947,D003024,Association,TRUE,CONCLUSIONS: Both nonobese <ENT2>clozapine</ENT2>- and olanzapine-treated groups displayed significant insulin resistance and impairment of <ENT1>glucose</ENT1> effectiveness compared with risperidone-treated subjects.,,,,T,,,,,w,,,,,0.0,,
15630069,320,D005947,C076029,Association,TRUE,OBJECTIVE: To study the 2 drugs most clearly implicated (clozapine and <ENT2>olanzapine</ENT2>) and risperidone using a frequently sampled intravenous <ENT1>glucose</ENT1> tolerance test.,,,,T,,,,,c,,,,,1.0,,
15630069,320,D005947,C076029,Association,TRUE,"There was a significant difference among groups in <ENT1>glucose</ENT1> effectiveness (F(30) = 4.18; P = .02) (clozapine<<ENT2>olanzapine</ENT2><risperidone) with significant differences between clozapine and risperidone (t(30) = -2.59; P = .02) and <ENT2>olanzapine</ENT2> and risperidone (t(30) = -2.34, P = .03).",,,,T,Y,,,,w,,,,,0.0,,
15630069,320,D005947,C076029,Association,TRUE,CONCLUSIONS: Both nonobese clozapine- and <ENT2>olanzapine</ENT2>-treated groups displayed significant insulin resistance and impairment of <ENT1>glucose</ENT1> effectiveness compared with risperidone-treated subjects.,,,,T,,,,,w,,,,,0.0,,
15630069,330,D005947,D014150,Association,TRUE,<ENT1>Glucose</ENT1> metabolism in patients with schizophrenia treated with atypical <ENT2>antipsychotic agents</ENT2>: a frequently sampled intravenous <ENT1>glucose</ENT1> tolerance test and minimal model analysis.,,,,T,Y,T,,,c,,,,,0.5,,
15630069,330,D005947,D014150,Association,TRUE,"BACKGROUND: While the incidence of new-onset diabetes mellitus may be increasing in patients with schizophrenia treated with certain atypical <ENT2>antipsychotic agents</ENT2>, it remains unclear whether atypical agents are directly affecting <ENT1>glucose</ENT1> metabolism or simply increasing known risk factors for diabetes.",,,,T,,,,,c,,,,,1.0,,
15630069,317,D005947,D018967,Association,TRUE,OBJECTIVE: To study the 2 drugs most clearly implicated (clozapine and olanzapine) and <ENT2>risperidone</ENT2> using a frequently sampled intravenous <ENT1>glucose</ENT1> tolerance test.,,,,T,,,,,c,,,,,1.0,,
15630069,317,D005947,D018967,Association,TRUE,"There was a significant difference among groups in <ENT1>glucose</ENT1> effectiveness (F(30) = 4.18; P = .02) (clozapine<olanzapine<<ENT2>risperidone</ENT2>) with significant differences between clozapine and <ENT2>risperidone</ENT2> (t(30) = -2.59; P = .02) and olanzapine and <ENT2>risperidone</ENT2> (t(30) = -2.34, P = .03).",,,,T,Y,,,,w,,,,,0.0,,
15630069,317,D005947,D018967,Association,TRUE,CONCLUSIONS: Both nonobese clozapine- and olanzapine-treated groups displayed significant insulin resistance and impairment of <ENT1>glucose</ENT1> effectiveness compared with <ENT2>risperidone</ENT2>-treated subjects.,,,,T,,,,,w,,,,,1.0,,
15630069,329,D003920,D014150,Positive_Correlation,TRUE,"BACKGROUND: While the incidence of new-onset <ENT1>diabetes mellitus</ENT1> may be increasing in patients with schizophrenia treated with certain atypical <ENT2>antipsychotic agents</ENT2>, it remains unclear whether atypical agents are directly affecting glucose metabolism or simply increasing known risk factors for <ENT1>diabetes</ENT1>.",,,,T,,,,,w,,,,,0.0,,
15630069,323,D003024,C076029,Comparison,TRUE,OBJECTIVE: To study the 2 drugs most clearly implicated (<ENT1>clozapine</ENT1> and <ENT2>olanzapine</ENT2>) and risperidone using a frequently sampled intravenous glucose tolerance test.,,,,T,,,,,w,,,,,0.0,,
15630069,323,D003024,C076029,Comparison,TRUE,"Thirty-six nonobese subjects with schizophrenia or schizoaffective disorder, matched by body mass index and treated with either <ENT1>clozapine</ENT1>, <ENT2>olanzapine</ENT2>, or risperidone, were included in the analysis.",,,,T,,,,,c,,,,,1.0,,
15630069,323,D003024,C076029,Comparison,TRUE,"RESULTS: The mean +/- SD duration of treatment with the identified atypical antipsychotic agent was 68.3 +/- 28.9 months (<ENT1>clozapine</ENT1>), 29.5 +/- 17.5 months (<ENT2>olanzapine</ENT2>), and 40.9 +/- 33.7 (risperidone).",,,,T,,,,,w,,,,,0.0,,
15630069,323,D003024,C076029,Comparison,TRUE,Fasting serum insulin concentrations differed among groups (F(33) = 3.35; P = .047) (<ENT1>clozapine</ENT1>><ENT2>olanzapine</ENT2>>risperidone) with significant differences between <ENT1>clozapine</ENT1> and risperidone (t(33) = 2.32; P = .03) and <ENT2>olanzapine</ENT2> and risperidone (t(33) = 2.15; P = .04).,,,,T,,,,,c,,,,,0.75,,
15630069,323,D003024,C076029,Comparison,TRUE,"There was a significant difference in insulin sensitivity index among groups (F(33) = 10.66; P<.001) (<ENT1>clozapine</ENT1><<ENT2>olanzapine</ENT2><risperidone), with subjects who received <ENT1>clozapine</ENT1> and <ENT2>olanzapine</ENT2> exhibiting significant insulin resistance compared with subjects who were treated with risperidone (<ENT1>clozapine</ENT1> vs risperidone, t(33) = -4.29; P<.001; <ENT2>olanzapine</ENT2> vs risperidone, t(33) = -3.62; P = .001 [P<.001]).",,,,T,,,,,c,,,,,0.111111111,,
15630069,323,D003024,C076029,Comparison,TRUE,"The homeostasis model assessment of insulin resistance also differed significantly among groups (F(33) = 4.92; P = .01) (<ENT1>clozapine</ENT1>><ENT2>olanzapine</ENT2>>risperidone) (<ENT1>clozapine</ENT1> vs risperidone, t(33) = 2.94; P = .006; <ENT2>olanzapine</ENT2> vs risperidone, t(33) = 2.42; P = .02).",,,,T,,,,,c,,,,,0.25,,
15630069,323,D003024,C076029,Comparison,TRUE,"There was a significant difference among groups in glucose effectiveness (F(30) = 4.18; P = .02) (<ENT1>clozapine</ENT1><<ENT2>olanzapine</ENT2><risperidone) with significant differences between <ENT1>clozapine</ENT1> and risperidone (t(30) = -2.59; P = .02) and <ENT2>olanzapine</ENT2> and risperidone (t(30) = -2.34, P = .03).",,,,T,,,,,c,,,,,0.0,,
15630069,323,D003024,C076029,Comparison,TRUE,CONCLUSIONS: Both nonobese <ENT1>clozapine</ENT1>- and <ENT2>olanzapine</ENT2>-treated groups displayed significant insulin resistance and impairment of glucose effectiveness compared with risperidone-treated subjects.,,,,T,,,,,c,,,,,1.0,,
15630069,323,D003024,C076029,Comparison,TRUE,Patients taking <ENT1>clozapine</ENT1> and <ENT2>olanzapine</ENT2> must be examined for insulin resistance and its consequences.,,,,T,,,,,c,,,,,1.0,,
15630069,316,D003024,D011618,Negative_Correlation,FALSE,"Thirty-six nonobese subjects with schizophrenia or <ENT2>schizoaffective disorder</ENT2>, matched by body mass index and treated with either <ENT1>clozapine</ENT1>, olanzapine, or risperidone, were included in the analysis.",,,,T,,,,,c,,,,,1.0,,
15630069,321,D003024,D007333,Positive_Correlation,TRUE,"There was a significant difference in insulin sensitivity index among groups (F(33) = 10.66; P<.001) (<ENT1>clozapine</ENT1><olanzapine<risperidone), with subjects who received <ENT1>clozapine</ENT1> and olanzapine exhibiting significant <ENT2>insulin resistance</ENT2> compared with subjects who were treated with risperidone (<ENT1>clozapine</ENT1> vs risperidone, t(33) = -4.29; P<.001; olanzapine vs risperidone, t(33) = -3.62; P = .001 [P<.001]).",,,,T,,,,,w,,,,,1.0,,
15630069,321,D003024,D007333,Positive_Correlation,TRUE,"The homeostasis model assessment of <ENT2>insulin resistance</ENT2> also differed significantly among groups (F(33) = 4.92; P = .01) (<ENT1>clozapine</ENT1>>olanzapine>risperidone) (<ENT1>clozapine</ENT1> vs risperidone, t(33) = 2.94; P = .006; olanzapine vs risperidone, t(33) = 2.42; P = .02).",,,,T,,,,,c,,,,,0.5,,
15630069,321,D003024,D007333,Positive_Correlation,TRUE,CONCLUSIONS: Both nonobese <ENT1>clozapine</ENT1>- and olanzapine-treated groups displayed significant <ENT2>insulin resistance</ENT2> and impairment of glucose effectiveness compared with risperidone-treated subjects.,,,,T,,,,,c,,,,,1.0,,
15630069,321,D003024,D007333,Positive_Correlation,TRUE,Patients taking <ENT1>clozapine</ENT1> and olanzapine must be examined for <ENT2>insulin resistance</ENT2> and its consequences.,,,,T,Y,,,,w,,,,,0.0,,
15630069,322,D003024,D018967,Comparison,TRUE,OBJECTIVE: To study the 2 drugs most clearly implicated (<ENT1>clozapine</ENT1> and olanzapine) and <ENT2>risperidone</ENT2> using a frequently sampled intravenous glucose tolerance test.,,,,T,,,,,w,,,,,1.0,,
15630069,322,D003024,D018967,Comparison,TRUE,"Thirty-six nonobese subjects with schizophrenia or schizoaffective disorder, matched by body mass index and treated with either <ENT1>clozapine</ENT1>, olanzapine, or <ENT2>risperidone</ENT2>, were included in the analysis.",,,,T,,,,,c,,,,,1.0,,
15630069,322,D003024,D018967,Comparison,TRUE,"RESULTS: The mean +/- SD duration of treatment with the identified atypical antipsychotic agent was 68.3 +/- 28.9 months (<ENT1>clozapine</ENT1>), 29.5 +/- 17.5 months (olanzapine), and 40.9 +/- 33.7 (<ENT2>risperidone</ENT2>).",,,,T,,,,,w,,,,,0.0,,
15630069,322,D003024,D018967,Comparison,TRUE,Fasting serum insulin concentrations differed among groups (F(33) = 3.35; P = .047) (<ENT1>clozapine</ENT1>>olanzapine><ENT2>risperidone</ENT2>) with significant differences between <ENT1>clozapine</ENT1> and <ENT2>risperidone</ENT2> (t(33) = 2.32; P = .03) and olanzapine and <ENT2>risperidone</ENT2> (t(33) = 2.15; P = .04).,,,,T,,,,,c,,,"11,22",,0.166666667,,
15630069,322,D003024,D018967,Comparison,TRUE,"There was a significant difference in insulin sensitivity index among groups (F(33) = 10.66; P<.001) (<ENT1>clozapine</ENT1><olanzapine<<ENT2>risperidone</ENT2>), with subjects who received <ENT1>clozapine</ENT1> and olanzapine exhibiting significant insulin resistance compared with subjects who were treated with <ENT2>risperidone</ENT2> (<ENT1>clozapine</ENT1> vs <ENT2>risperidone</ENT2>, t(33) = -4.29; P<.001; olanzapine vs <ENT2>risperidone</ENT2>, t(33) = -3.62; P = .001 [P<.001]).",,,,T,,,,,c,,,"11,22,33",,0.0,,
15630069,322,D003024,D018967,Comparison,TRUE,"The homeostasis model assessment of insulin resistance also differed significantly among groups (F(33) = 4.92; P = .01) (<ENT1>clozapine</ENT1>>olanzapine><ENT2>risperidone</ENT2>) (<ENT1>clozapine</ENT1> vs <ENT2>risperidone</ENT2>, t(33) = 2.94; P = .006; olanzapine vs <ENT2>risperidone</ENT2>, t(33) = 2.42; P = .02).",,,,T,,,,,c,,,"11,22",,0.0,,
15630069,322,D003024,D018967,Comparison,TRUE,"There was a significant difference among groups in glucose effectiveness (F(30) = 4.18; P = .02) (<ENT1>clozapine</ENT1><olanzapine<<ENT2>risperidone</ENT2>) with significant differences between <ENT1>clozapine</ENT1> and <ENT2>risperidone</ENT2> (t(30) = -2.59; P = .02) and olanzapine and <ENT2>risperidone</ENT2> (t(30) = -2.34, P = .03).",,,,T,,,,,c,,,"11,22",,0.0,,
15630069,322,D003024,D018967,Comparison,TRUE,CONCLUSIONS: Both nonobese <ENT1>clozapine</ENT1>- and olanzapine-treated groups displayed significant insulin resistance and impairment of glucose effectiveness compared with <ENT2>risperidone</ENT2>-treated subjects.,,,,T,,,,,c,,,,,0.0,,
15630069,315,C076029,D011618,Negative_Correlation,FALSE,"Thirty-six nonobese subjects with schizophrenia or <ENT2>schizoaffective disorder</ENT2>, matched by body mass index and treated with either clozapine, <ENT1>olanzapine</ENT1>, or risperidone, were included in the analysis.",,,,T,,,,,c,,,,,1.0,,
15630069,318,C076029,D007333,Positive_Correlation,TRUE,"There was a significant difference in insulin sensitivity index among groups (F(33) = 10.66; P<.001) (clozapine<<ENT1>olanzapine</ENT1><risperidone), with subjects who received clozapine and <ENT1>olanzapine</ENT1> exhibiting significant <ENT2>insulin resistance</ENT2> compared with subjects who were treated with risperidone (clozapine vs risperidone, t(33) = -4.29; P<.001; <ENT1>olanzapine</ENT1> vs risperidone, t(33) = -3.62; P = .001 [P<.001]).",,,,T,,,,,w,,,,,1.0,,
15630069,318,C076029,D007333,Positive_Correlation,TRUE,"The homeostasis model assessment of <ENT2>insulin resistance</ENT2> also differed significantly among groups (F(33) = 4.92; P = .01) (clozapine><ENT1>olanzapine</ENT1>>risperidone) (clozapine vs risperidone, t(33) = 2.94; P = .006; <ENT1>olanzapine</ENT1> vs risperidone, t(33) = 2.42; P = .02).",,,,T,,,,,c,,,,,1.0,,
15630069,318,C076029,D007333,Positive_Correlation,TRUE,CONCLUSIONS: Both nonobese clozapine- and <ENT1>olanzapine</ENT1>-treated groups displayed significant <ENT2>insulin resistance</ENT2> and impairment of glucose effectiveness compared with risperidone-treated subjects.,,,,T,,,,,c,,,,,0.0,,
15630069,318,C076029,D007333,Positive_Correlation,TRUE,Patients taking clozapine and <ENT1>olanzapine</ENT1> must be examined for <ENT2>insulin resistance</ENT2> and its consequences.,,,,T,Y,,,,c,,,,,1.0,,
15630069,319,C076029,D018967,Comparison,TRUE,OBJECTIVE: To study the 2 drugs most clearly implicated (clozapine and <ENT1>olanzapine</ENT1>) and <ENT2>risperidone</ENT2> using a frequently sampled intravenous glucose tolerance test.,,,,T,,,,,w,,,,,1.0,,
15630069,319,C076029,D018967,Comparison,TRUE,"Thirty-six nonobese subjects with schizophrenia or schizoaffective disorder, matched by body mass index and treated with either clozapine, <ENT1>olanzapine</ENT1>, or <ENT2>risperidone</ENT2>, were included in the analysis.",,,,T,,,,,c,,,,,1.0,,
15630069,319,C076029,D018967,Comparison,TRUE,"RESULTS: The mean +/- SD duration of treatment with the identified atypical antipsychotic agent was 68.3 +/- 28.9 months (clozapine), 29.5 +/- 17.5 months (<ENT1>olanzapine</ENT1>), and 40.9 +/- 33.7 (<ENT2>risperidone</ENT2>).",,,,T,,,,,w,,,,,0.0,,
15630069,319,C076029,D018967,Comparison,TRUE,Fasting serum insulin concentrations differed among groups (F(33) = 3.35; P = .047) (clozapine><ENT1>olanzapine</ENT1>><ENT2>risperidone</ENT2>) with significant differences between clozapine and <ENT2>risperidone</ENT2> (t(33) = 2.32; P = .03) and <ENT1>olanzapine</ENT1> and <ENT2>risperidone</ENT2> (t(33) = 2.15; P = .04).,,,,T,,,,,c,,,"11,23",,0.333333333,,
15630069,319,C076029,D018967,Comparison,TRUE,"There was a significant difference in insulin sensitivity index among groups (F(33) = 10.66; P<.001) (clozapine<<ENT1>olanzapine</ENT1><<ENT2>risperidone</ENT2>), with subjects who received clozapine and <ENT1>olanzapine</ENT1> exhibiting significant insulin resistance compared with subjects who were treated with <ENT2>risperidone</ENT2> (clozapine vs <ENT2>risperidone</ENT2>, t(33) = -4.29; P<.001; <ENT1>olanzapine</ENT1> vs <ENT2>risperidone</ENT2>, t(33) = -3.62; P = .001 [P<.001]).",,,,T,,,,,c,,,"11,22,34",,0.0,,
15630069,319,C076029,D018967,Comparison,TRUE,"The homeostasis model assessment of insulin resistance also differed significantly among groups (F(33) = 4.92; P = .01) (clozapine><ENT1>olanzapine</ENT1>><ENT2>risperidone</ENT2>) (clozapine vs <ENT2>risperidone</ENT2>, t(33) = 2.94; P = .006; <ENT1>olanzapine</ENT1> vs <ENT2>risperidone</ENT2>, t(33) = 2.42; P = .02).",,,,T,,,,,c,,,"11,23",,0.0,,
15630069,319,C076029,D018967,Comparison,TRUE,"There was a significant difference among groups in glucose effectiveness (F(30) = 4.18; P = .02) (clozapine<<ENT1>olanzapine</ENT1><<ENT2>risperidone</ENT2>) with significant differences between clozapine and <ENT2>risperidone</ENT2> (t(30) = -2.59; P = .02) and <ENT1>olanzapine</ENT1> and <ENT2>risperidone</ENT2> (t(30) = -2.34, P = .03).",,,,T,,,,,c,,,"11,23",,0.0,,
15630069,319,C076029,D018967,Comparison,TRUE,CONCLUSIONS: Both nonobese clozapine- and <ENT1>olanzapine</ENT1>-treated groups displayed significant insulin resistance and impairment of glucose effectiveness compared with <ENT2>risperidone</ENT2>-treated subjects.,,,,T,,,,,c,,,,,1.0,,
15630069,314,D011618,D018967,Negative_Correlation,FALSE,"Thirty-six nonobese subjects with schizophrenia or <ENT1>schizoaffective disorder</ENT1>, matched by body mass index and treated with either clozapine, olanzapine, or <ENT2>risperidone</ENT2>, were included in the analysis.",,,,T,,,,,c,,,,,1.0,,
15649253,332,D016543,11102,Association,FALSE,<ENT1>Primary malignant lymphoma of the brain</ENT1>: frequent abnormalities and inactivation of <ENT2>p14</ENT2> tumor suppressor gene.,,,,T,,,,,w,,,,,1.0,,
15649253,332,D016543,11102,Association,FALSE,"Ten <ENT1>primary central nervous system lymphomas</ENT1> (<ENT1>PCNSL</ENT1>, <ENT1>brain lymphomas</ENT1>) were examined for <ENT2>p14</ENT2> gene exon 1beta deletion, mutation and methylation by Southern blot analysis, nucleotide analysis of polymerase chain reaction clones and Southern blot-based methylation assay.",,,,T,,,,,c,,,,,1.0,,
15649253,332,D016543,11102,Association,FALSE,"Our observation of frequent <ENT2>p14</ENT2> gene abnormalities (90%) and inactivation (40-60%) was in striking contrast to the same pathological subtype of systemic lymphoma in which <ENT2>p14</ENT2> gene abnormalities and inactivation were infrequent, suggesting a difference in carcinogenesis between <ENT1>PCNSL</ENT1> and systemic lymphoma.",,,,T,Y,,,,w,,,,,1.0,,
15649253,333,11102,D008223,Association,FALSE,"Our observation of frequent <ENT1>p14</ENT1> gene abnormalities (90%) and inactivation (40-60%) was in striking contrast to the same pathological subtype of <ENT2>systemic lymphoma</ENT2> in which <ENT1>p14</ENT1> gene abnormalities and inactivation were infrequent, suggesting a difference in carcinogenesis between PCNSL and <ENT2>systemic lymphoma</ENT2>.",,,,T,,,,,w,,,,,0.75,,
15649253,334,11102,D063646,Association,TRUE,"Our observation of frequent <ENT1>p14</ENT1> gene abnormalities (90%) and inactivation (40-60%) was in striking contrast to the same pathological subtype of systemic lymphoma in which <ENT1>p14</ENT1> gene abnormalities and inactivation were infrequent, suggesting a difference in <ENT2>carcinogenesis</ENT2> between PCNSL and systemic lymphoma.",,,,T,Y,,,,w,,,,,1.0,,
15649253,335,11102,D009369,Negative_Correlation,FALSE,Primary malignant lymphoma of the brain: frequent abnormalities and inactivation of <ENT1>p14</ENT1> <ENT2>tumor</ENT2> suppressor gene.,,,,T,,,,,w,,,,,1.0,,
15668505;15668505,339;338,672;672,D001943;D010051,Association;Association,FALSE;FALSE,Common BRCA2 variants and modification of <ENT2>breast and ovarian cancer</ENT2> risk in <ENT1>BRCA1</ENT1> mutation carriers.,,,,T,,,,,c,,,,,1.0,,
15668505;15668505,339;338,672;672,D001943;D010051,Association;Association,FALSE;FALSE,"As these studies concerned sporadic cancer cases, we investigated whether N372H and another common variant located in the 5'-untranslated region (203G > A) of the BRCA2 gene modify <ENT2>breast or ovarian cancer</ENT2> risk in <ENT1>BRCA1</ENT1> mutation carriers.",,,,T,,,,,c,,,,,1.0,,
15668505,339,672,D001943,Association,FALSE,We found no evidence of a significant modification of <ENT2>breast cancer</ENT2> penetrance in <ENT1>BRCA1</ENT1> mutation carriers by either polymorphism.,,,,T,Y,,,,w,,,,,0.0,,
15668505,340,g|Allele|A|203,D010051,Association,TRUE,"In respect of <ENT2>ovarian cancer</ENT2> risk, we also saw no effect with the N372H variant but we did observe a borderline association with the 5'-untranslated region <ENT1>203A</ENT1> allele (hazard ratio, 1.43; CI, 1.01-2.00).",,,,T,,,,,c,,,,,0.0,,
15668505;15668505,337;336,rs144848;rs144848,D001943;D010051,Positive_Correlation;Positive_Correlation,FALSE;FALSE,The HH genotype of the nonconservative amino acid substitution polymorphism <ENT1>N372H</ENT1> in the BRCA2 gene was reported to be associated with a 1.3- to 1.5-fold increase in risk of both <ENT2>breast and ovarian cancer</ENT2>.,,,,T,,,,,c,,,,,1.0,,
15668505;15668505,337;336,rs144848;rs144848,D001943;D010051,Positive_Correlation;Positive_Correlation,FALSE;FALSE,"As these studies concerned sporadic cancer cases, we investigated whether <ENT1>N372H</ENT1> and another common variant located in the 5'-untranslated region (203G > A) of the BRCA2 gene modify <ENT2>breast or ovarian cancer</ENT2> risk in BRCA1 mutation carriers.",,,,T,,,,,c,,,,,1.0,,
15668505,336,rs144848,D010051,Positive_Correlation,FALSE,"In respect of <ENT2>ovarian cancer</ENT2> risk, we also saw no effect with the <ENT1>N372H</ENT1> variant but we did observe a borderline association with the 5'-untranslated region 203A allele (hazard ratio, 1.43; CI, 1.01-2.00).",,,,T,,,,,c,,,,,1.0,,
15668505,342,D001943,675,Association,FALSE,Common <ENT2>BRCA2</ENT2> variants and modification of <ENT1>breast and ovarian cancer</ENT1> risk in BRCA1 mutation carriers.,,,,T,,T,,,w,,,,,1.0,,
15668505,342,D001943,675,Association,FALSE,The HH genotype of the nonconservative amino acid substitution polymorphism N372H in the <ENT2>BRCA2</ENT2> gene was reported to be associated with a 1.3- to 1.5-fold increase in risk of both <ENT1>breast and ovarian cancer</ENT1>.,,,,T,,,,,c,,,,,1.0,,
15668505,342,D001943,675,Association,FALSE,"As these studies concerned sporadic cancer cases, we investigated whether N372H and another common variant located in the 5'-untranslated region (203G > A) of the <ENT2>BRCA2</ENT2> gene modify <ENT1>breast or ovarian cancer</ENT1> risk in BRCA1 mutation carriers.",,,,T,,Y,,,c,,,,,1.0,,
15668505,341,675,D010051,Association,FALSE,Common <ENT1>BRCA2</ENT1> variants and modification of <ENT2>breast and ovarian cancer</ENT2> risk in BRCA1 mutation carriers.,,,,T,,T,,,w,,,,,1.0,,
15668505,341,675,D010051,Association,FALSE,The HH genotype of the nonconservative amino acid substitution polymorphism N372H in the <ENT1>BRCA2</ENT1> gene was reported to be associated with a 1.3- to 1.5-fold increase in risk of both <ENT2>breast and ovarian cancer</ENT2>.,,,,T,,,,,c,,,,,1.0,,
15668505,341,675,D010051,Association,FALSE,"As these studies concerned sporadic cancer cases, we investigated whether N372H and another common variant located in the 5'-untranslated region (203G > A) of the <ENT1>BRCA2</ENT1> gene modify <ENT2>breast or ovarian cancer</ENT2> risk in BRCA1 mutation carriers.",,,,T,,Y,,,c,,,,,1.0,,
15673851,347,D020258,24408,Association,TRUE,We suggest that opioids may be <ENT1>neurotoxic</ENT1> in the setting of spinal cord ischemia via <ENT2>NMDA receptor</ENT2> activation.,,,,T,,,,,w,,,,,0.0,,
15673851,345,D020258,D000701,Positive_Correlation,TRUE,We suggest that <ENT2>opioids</ENT2> may be <ENT1>neurotoxic</ENT1> in the setting of spinal cord ischemia via NMDA receptor activation.,,,,T,,,,,w,,,,,1.0,,
15673851,352,24408,D009020,Association,TRUE,The activation of spinal <ENT1>N-methyl-D-aspartate receptors</ENT1> may contribute to degeneration of spinal motor neurons induced by neuraxial <ENT2>morphine</ENT2> after a noninjurious interval of spinal cord ischemia.,,,,T,Y,,,,c,,,,,0.0,,
15673851,352,24408,D009020,Association,TRUE,We investigated the relationship between the degeneration of spinal motor neurons and activation of <ENT1>N-methyl-d-aspartate (NMDA) receptors</ENT1> after neuraxial <ENT2>morphine</ENT2> following a noninjurious interval of aortic occlusion in rats.,,,,T,,,,,w,,,,,0.0,,
15673851,352,24408,D009020,Association,TRUE,"These data indicate that IT <ENT2>morphine</ENT2> induces spastic paraparesis with a concomitant increase in CSF glutamate, which is involved in <ENT1>NMDA receptor</ENT1> activation.",,,,T,,,,,c,,,,,0.0,,
15673851,346,24408,D000701,Association,TRUE,We suggest that <ENT2>opioids</ENT2> may be neurotoxic in the setting of spinal cord ischemia via <ENT1>NMDA receptor</ENT1> activation.,,,,T,,,,,c,,,,,1.0,,
15673851,350,24408,D018698,Association,FALSE,"These data indicate that IT morphine induces spastic paraparesis with a concomitant increase in CSF <ENT2>glutamate</ENT2>, which is involved in <ENT1>NMDA receptor</ENT1> activation.",,,,T,,,,,c,,,,,0.0,,
15673851,343,24408,D020760,Association,TRUE,The activation of spinal <ENT1>N-methyl-D-aspartate receptors</ENT1> may contribute to degeneration of spinal motor neurons induced by neuraxial morphine after a noninjurious interval of <ENT2>spinal cord ischemia</ENT2>.,,,,T,,,,,w,,,,,1.0,,
15673851,343,24408,D020760,Association,TRUE,We suggest that opioids may be neurotoxic in the setting of <ENT2>spinal cord ischemia</ENT2> via <ENT1>NMDA receptor</ENT1> activation.,,,,T,Y,,,,c,,,,,0.0,,
15673851,351,24408,D020336,Association,TRUE,"These data indicate that IT morphine induces <ENT2>spastic paraparesis</ENT2> with a concomitant increase in CSF glutamate, which is involved in <ENT1>NMDA receptor</ENT1> activation.",,,,T,,,,,c,,,,,0.0,,
15673851,349,D009020,D016291,Association,TRUE,"Second, we investigated the effect of IT <ENT2>MK-801</ENT2> (30 mug) on the histopathologic changes in the spinal cord after <ENT1>morphine</ENT1>-induced spastic paraparesis.",,,,T,,,,,w,,,,,1.0,,
15673851,349,D009020,D016291,Association,TRUE,IT <ENT2>MK-801</ENT2> significantly reduced the number of dark-stained alpha-motoneurons after <ENT1>morphine</ENT1>-induced spastic paraparesis compared with the saline group.,,,,T,,,,,w,,,,,0.0,,
15673851,353,D009020,D018698,Positive_Correlation,TRUE,"After IT <ENT1>morphine</ENT1>, the cerebrospinal fluid (CSF) <ENT2>glutamate</ENT2> concentration was increased in group M relative to both baseline and group C (P < 0.05).",,,,T,,,,,c,,,,,1.0,,
15673851,353,D009020,D018698,Positive_Correlation,TRUE,"These data indicate that IT <ENT1>morphine</ENT1> induces spastic paraparesis with a concomitant increase in CSF <ENT2>glutamate</ENT2>, which is involved in NMDA receptor activation.",,,,T,,,,,c,,,,,1.0,,
15673851,354,D009020,D020336,Positive_Correlation,FALSE,"Second, we investigated the effect of IT MK-801 (30 mug) on the histopathologic changes in the spinal cord after <ENT1>morphine</ENT1>-induced <ENT2>spastic paraparesis</ENT2>.",,,,T,,,,,c,,,,,1.0,,
15673851,354,D009020,D020336,Positive_Correlation,FALSE,IT MK-801 significantly reduced the number of dark-stained alpha-motoneurons after <ENT1>morphine</ENT1>-induced <ENT2>spastic paraparesis</ENT2> compared with the saline group.,,,,T,,,,,c,,,,,1.0,,
15673851,354,D009020,D020336,Positive_Correlation,FALSE,"These data indicate that IT <ENT1>morphine</ENT1> induces <ENT2>spastic paraparesis</ENT2> with a concomitant increase in CSF glutamate, which is involved in NMDA receptor activation.",,,,T,,,,,c,,,,,1.0,,
15673851,344,D000701,D020760,Association,TRUE,We suggest that <ENT1>opioids</ENT1> may be neurotoxic in the setting of <ENT2>spinal cord ischemia</ENT2> via NMDA receptor activation.,,,,T,Y,,,,c,,,,,0.0,,
15673851,348,D016291,D020336,Association,TRUE,"Second, we investigated the effect of IT <ENT1>MK-801</ENT1> (30 mug) on the histopathologic changes in the spinal cord after morphine-induced <ENT2>spastic paraparesis</ENT2>.",,,,T,,,,,w,,,,,0.0,,
15673851,348,D016291,D020336,Association,TRUE,IT <ENT1>MK-801</ENT1> significantly reduced the number of dark-stained alpha-motoneurons after morphine-induced <ENT2>spastic paraparesis</ENT2> compared with the saline group.,,,,T,Y,,,,c,,,,,0.0,,
15686794,355,D000638,D017116,Positive_Correlation,TRUE,Acute <ENT2>low back pain</ENT2> during intravenous administration of <ENT1>amiodarone</ENT1>: a report of two cases.,,,,T,,,,,c,,,,,1.0,,
15686794,355,D000638,D017116,Positive_Correlation,TRUE,"We briefly describe two patients suffering from recent-onset atrial fibrillation, who experienced an acute devastating <ENT2>low back pain</ENT2> a few minutes after initiation of intravenous <ENT1>amiodarone</ENT1> loading.",,,,T,,,,,c,,,,,0.0,,
15686794,357,D000638,D001281,Negative_Correlation,FALSE,<ENT1>Amiodarone</ENT1> represents an effective antiarrhythmic drug for cardioversion of recent-onset <ENT2>atrial fibrillation</ENT2> (<ENT2>AF</ENT2>) and maintenance of sinus rhythm.,,,,T,,,,,c,,,,,0.5,,
15686794,357,D000638,D001281,Negative_Correlation,FALSE,"We briefly describe two patients suffering from recent-onset <ENT2>atrial fibrillation</ENT2>, who experienced an acute devastating low back pain a few minutes after initiation of intravenous <ENT1>amiodarone</ENT1> loading.",,,,T,,,,,c,,,,,1.0,,
15686794,356,D000889,D001281,Negative_Correlation,FALSE,Amiodarone represents an effective <ENT1>antiarrhythmic drug</ENT1> for cardioversion of recent-onset <ENT2>atrial fibrillation</ENT2> (<ENT2>AF</ENT2>) and maintenance of sinus rhythm.,,,,T,,,,,c,,,,,0.0,,
15748645,359,4953,D012878,Positive_Correlation,FALSE,"All these processes for <ENT2>skin cancer</ENT2> development involve stimulation of DNA synthesis, DNA damage and proliferation, inflammation, immunosuppression, epidermal hyperplasia, cell cycle dysregulation, depletion of antioxidant defenses, impairment of signal transduction pathways, induction of cyclooxygenase, increase in prostaglandin synthesis, and induction of <ENT1>ornithine decarboxylase</ENT1>.",,,,T,,,,,w,,,,,0.0,,
15748645,360,D011453,D012878,Positive_Correlation,FALSE,"All these processes for <ENT2>skin cancer</ENT2> development involve stimulation of DNA synthesis, DNA damage and proliferation, inflammation, immunosuppression, epidermal hyperplasia, cell cycle dysregulation, depletion of antioxidant defenses, impairment of signal transduction pathways, induction of cyclooxygenase, increase in <ENT1>prostaglandin</ENT1> synthesis, and induction of ornithine decarboxylase.",,,,T,,,,,w,,,,,1.0,,
15748645,358,D000975,D012878,Negative_Correlation,FALSE,"All these processes for <ENT2>skin cancer</ENT2> development involve stimulation of DNA synthesis, DNA damage and proliferation, inflammation, immunosuppression, epidermal hyperplasia, cell cycle dysregulation, depletion of <ENT1>antioxidant</ENT1> defenses, impairment of signal transduction pathways, induction of cyclooxygenase, increase in prostaglandin synthesis, and induction of ornithine decarboxylase.",,,,T,,,,,w,,,,,0.0,,
15748645,358,D000975,D012878,Negative_Correlation,FALSE,"Photochemoprevention has been appreciated as a viable approach to reduce the occurrence of <ENT2>skin cancer</ENT2> and in recent years, the use of agents, especially botanical <ENT1>antioxidants</ENT1>, present in the common diet and beverages consumed by human population have gained considerable attention as photochemopreventive agents for human use.",,,,T,,,,,w,,,,,0.0,,
15749661,372,D006432,rs80338886,Association,TRUE,"Two novel mutations, <ENT2>L490R</ENT2> and V561X, of the transferrin receptor 2 gene in Japanese patients with <ENT1>hemochromatosis</ENT1>.",,,,T,,,,,c,,,,,0.0,,
15749661,372,D006432,rs80338886,Association,TRUE,The patient homozygous for both <ENT2>L490R</ENT2> and I238M presented with a mild manifestation of <ENT1>hemochromatosis</ENT1> at the age of 41 years.,,,,T,,,,,c,,,,,1.0,,
15749661,374,D006432,7036,Association,TRUE,"Two novel mutations, L490R and V561X, of the <ENT2>transferrin receptor 2</ENT2> gene in Japanese patients with <ENT1>hemochromatosis</ENT1>.",,,,T,,T,,,c,,,,,1.0,,
15749661,374,D006432,7036,Association,TRUE,This suggests that the <ENT2>TfR2</ENT2> gene is involved in <ENT1>hemochromatosis</ENT1> in Japanese patients.,,,,T,,,,,c,,,,,1.0,,
15749661,374,D006432,7036,Association,TRUE,"INTERPRETATION AND CONCLUSIONS: Taken together with the previous report, 5 of our 12 patients with <ENT1>hemochromatosis</ENT1> manifesting in middle age had mutations in the <ENT2>TfR2</ENT2> gene.",,,,T,,,,,c,,,,,1.0,,
15749661,374,D006432,7036,Association,TRUE,"Thus, <ENT2>TfR2</ENT2> plays a role in the pathogenesis of <ENT1>hemochromatosis</ENT1> in Japan.",,,,T,,,,,c,,,,,1.0,,
15749661,371,D006432,rs80338887,Association,TRUE,"Two novel mutations, L490R and <ENT2>V561X</ENT2>, of the transferrin receptor 2 gene in Japanese patients with <ENT1>hemochromatosis</ENT1>.",,,,T,,T,,,c,,,,,0.0,,
15749661,366,D006432,rs34242818,Association,TRUE,The patient homozygous for both L490R and <ENT2>I238M</ENT2> presented with a mild manifestation of <ENT1>hemochromatosis</ENT1> at the age of 41 years.,,,,T,,,,,c,,,,,0.0,,
15749661,364,D008103,D007501,Association,TRUE,His liver was <ENT1>cirrhotic</ENT1> with parenchymal <ENT2>iron</ENT2> deposits and the result of a glucose tolerance test was compatible with diabetes mellitus.,,,,T,Y,,,,c,,,,,0.0,,
15749661,370,D008103,rs80338887,Association,TRUE,"The patient homozygous for <ENT2>V561X</ENT2> had severe iron overload with the triad of <ENT1>cirrhosis</ENT1>, diabetes mellitus and skin pigmentation at the age of 58 years.",,,,T,,,,,c,,,,,0.0,,
15749661,363,D003920,D005947,Association,TRUE,His liver was cirrhotic with parenchymal iron deposits and the result of a <ENT2>glucose</ENT2> tolerance test was compatible with <ENT1>diabetes mellitus</ENT1>.,,,,T,Y,,,,c,,,,,0.0,,
15749661,369,D003920,rs80338887,Association,TRUE,"The patient homozygous for <ENT2>V561X</ENT2> had severe iron overload with the triad of cirrhosis, <ENT1>diabetes mellitus</ENT1> and skin pigmentation at the age of 58 years.",,,,T,,,,,c,,,,,0.0,,
15749661,368,D010859,rs80338887,Association,TRUE,"The patient homozygous for <ENT2>V561X</ENT2> had severe iron overload with the triad of cirrhosis, diabetes mellitus and <ENT1>skin pigmentation</ENT1> at the age of 58 years.",,,,T,,,,,c,,,,,0.0,,
15749661,367,D019190,rs80338887,Association,TRUE,"The patient homozygous for <ENT2>V561X</ENT2> had severe <ENT1>iron overload</ENT1> with the triad of cirrhosis, diabetes mellitus and skin pigmentation at the age of 58 years.",,,,T,,,,,c,,,,,0.0,,
15754732,400,D010282,4221,Association,TRUE,Somatic mutations of <ENT2>MEN1</ENT2> gene have also been described in sporadic <ENT1>parathyroid tumors</ENT1>.,,,,T,,,,,c,,,,,1.0,,
15754732,400,D010282,4221,Association,TRUE,"In our study, we examined the presence of alterations in <ENT2>MEN1</ENT2> gene in a series of 39 patients who had undergone surgery for sporadic pHPT (35 with <ENT1>parathyroid adenoma or hyperplasia</ENT1>, 4 with a carcinoma).",,,,T,,,,,c,,,,,1.0,,
15754732,400,D010282,4221,Association,TRUE,"In conclusion, our data demonstrate the presence of somatic alterations of the <ENT2>MEN1</ENT2> tumor suppressor gene in about one fifth of benign sporadic <ENT1>parathyroid tumors</ENT1>.",,,,T,,,,,w,,,,,1.0,,
15754732,401,4221,D010279,Association,TRUE,"Somatic <ENT1>MEN1</ENT1> mutations were detected in 6 of the 35 patients with a <ENT2>benign parathyroid lesion</ENT2> examined (17.1%), whereas no alterations were found in the carcinomas.",,,,T,,,,,c,,,,,0.0,,
15754732,399,4221,D009369,Association,FALSE,"In conclusion, our data demonstrate the presence of somatic alterations of the <ENT1>MEN1</ENT1> <ENT2>tumor</ENT2> suppressor gene in about one fifth of benign sporadic parathyroid tumors.",,,,T,,,,,w,,,,,1.0,,
15754732,402,4221,D049950,Association,TRUE,Novel somatic <ENT1>MEN1</ENT1> gene alterations in sporadic <ENT2>primary hyperparathyroidism</ENT2> and correlation with clinical characteristics.,,,,T,,,,,c,,,,,0.0,,
15754732,402,4221,D049950,Association,TRUE,"In our study, we examined the presence of alterations in <ENT1>MEN1</ENT1> gene in a series of 39 patients who had undergone surgery for sporadic <ENT2>pHPT</ENT2> (35 with parathyroid adenoma or hyperplasia, 4 with a carcinoma).",,,,T,,Y,,,w,,,,,1.0,,
15754732,390,4221,D002277,Association,FALSE,"In our study, we examined the presence of alterations in <ENT1>MEN1</ENT1> gene in a series of 39 patients who had undergone surgery for sporadic pHPT (35 with parathyroid adenoma or hyperplasia, 4 with a <ENT2>carcinoma</ENT2>).",,,,T,,,,,w,,,,,1.0,,
15754732,390,4221,D002277,Association,FALSE,"Somatic <ENT1>MEN1</ENT1> mutations were detected in 6 of the 35 patients with a benign parathyroid lesion examined (17.1%), whereas no alterations were found in the <ENT2>carcinomas</ENT2>.",,,,T,,,,,c,,,,,1.0,,
15754732,376,rs2071313,D009369,Association,TRUE,"Moreover, two polymorphisms were also found: one allele carried a R171Q polymorphism (1/39 <ENT2>tumors</ENT2>), while a <ENT1>D418D</ENT1> polymorphism (<ENT1>GAC/GAT</ENT1>) was found in 15 and 8 <ENT2>tumors</ENT2> in hetero (CT) and homozygosity (TT), respectively.",,,,T,,,,,c,,,,,0.5,,
15754732,377,rs607969,D009369,Association,TRUE,"Moreover, two polymorphisms were also found: one allele carried a <ENT1>R171Q</ENT1> polymorphism (1/39 <ENT2>tumors</ENT2>), while a D418D polymorphism (GAC/GAT) was found in 15 and 8 <ENT2>tumors</ENT2> in hetero (CT) and homozygosity (TT), respectively.",,,,T,,,,,c,,,,,0.0,,
15755837,408,D047928,1719,Association,TRUE,Common <ENT2>dihydrofolate reductase</ENT2> 19-base pair deletion allele: a novel risk factor for <ENT1>preterm delivery</ENT1>.,,,,T,,,,,c,,,,,1.0,,
15755837,408,D047928,1719,Association,TRUE,"OBJECTIVE: We aimed to determine whether a common, recently discovered deletion polymorphism in the <ENT2>DHFR</ENT2> gene is a risk factor for <ENT1>preterm delivery</ENT1> or low birth weight.",,,,T,,Y,,,c,,,,,1.0,,
15755837,408,D047928,1719,Association,TRUE,"Women with both a <ENT2>DHFR</ENT2> deletion allele and low folate intake (<400 microg/d from diet plus supplements) had a significantly greater risk of <ENT1>preterm delivery</ENT1> (AOR: 5.5; 95% CI: 1.5, 20.4; P = 0.01) and a significantly greater risk of having an infant with a low birth weight (AOR: 8.3; 95% CI: 1.8, 38.6; P = 0.01) than did women without a deletion allele and with a folate intake >/=400 microg/d.",,,,T,,,,,c,,,,,1.0,,
15755837,408,D047928,1719,Association,TRUE,CONCLUSIONS: The <ENT2>DHFR</ENT2> 19-base pair deletion allele may be a risk factor for <ENT1>preterm delivery</ENT1>.,,,,T,,,,,w,,,,,1.0,,
15755837,405,D047928,c|DEL||19,Positive_Correlation,TRUE,Common dihydrofolate reductase <ENT2>19-base pair deletion</ENT2> allele: a novel risk factor for <ENT1>preterm delivery</ENT1>.,,,,T,,,,,c,,,,,1.0,,
15755837,405,D047928,c|DEL||19,Positive_Correlation,TRUE,CONCLUSIONS: The DHFR <ENT2>19-base pair deletion</ENT2> allele may be a risk factor for <ENT1>preterm delivery</ENT1>.,,,,T,,,,,c,,,,,1.0,,
15755837,404,D047928,D005492,Negative_Correlation,TRUE,"Women with both a DHFR deletion allele and low <ENT2>folate</ENT2> intake (<400 microg/d from diet plus supplements) had a significantly greater risk of <ENT1>preterm delivery</ENT1> (AOR: 5.5; 95% CI: 1.5, 20.4; P = 0.01) and a significantly greater risk of having an infant with a low birth weight (AOR: 8.3; 95% CI: 1.8, 38.6; P = 0.01) than did women without a deletion allele and with a <ENT2>folate</ENT2> intake >/=400 microg/d.",,,,T,,,,,c,,,,,0.5,,
15755837,403,7298,C010920,Positive_Correlation,FALSE,Dihydrofolate reductase (DHFR) is required to convert the folic acid used in supplements and for food fortification and the <ENT2>dihydrofolate</ENT2> produced by <ENT1>thymidylate synthase</ENT1> during DNA synthesis to the reduced folate forms used by the cell.,,,,T,,,,,c,,,,,0.0,,
15755837,406,1719,C010920,Association,FALSE,<ENT1>Dihydrofolate reductase</ENT1> (<ENT1>DHFR</ENT1>) is required to convert the folic acid used in supplements and for food fortification and the <ENT2>dihydrofolate</ENT2> produced by thymidylate synthase during DNA synthesis to the reduced folate forms used by the cell.,,,,T,,,,,w,,,,,1.0,,
15755837,407,1719,D005492,Association,FALSE,<ENT1>Dihydrofolate reductase</ENT1> (<ENT1>DHFR</ENT1>) is required to convert the <ENT2>folic acid</ENT2> used in supplements and for food fortification and the dihydrofolate produced by thymidylate synthase during DNA synthesis to the reduced <ENT2>folate</ENT2> forms used by the cell.,,,,T,,,,,c,,,"11,21,12,22",,1.0,,
15755837,407,1719,D005492,Association,FALSE,"Women with both a <ENT1>DHFR</ENT1> deletion allele and low <ENT2>folate</ENT2> intake (<400 microg/d from diet plus supplements) had a significantly greater risk of preterm delivery (AOR: 5.5; 95% CI: 1.5, 20.4; P = 0.01) and a significantly greater risk of having an infant with a low birth weight (AOR: 8.3; 95% CI: 1.8, 38.6; P = 0.01) than did women without a deletion allele and with a <ENT2>folate</ENT2> intake >/=400 microg/d.",,,,T,,,,,c,,,,,1.0,,
15770495,409,C535830,6716,Association,FALSE,"In this study, sequence abnormalities of the <ENT2>SRD5A2</ENT2> gene were assessed by polymerase chain reaction with specific primers and automated sequencing analysis in DNA samples from 20 patients with suspected <ENT1>steroid 5alpha-reductase type 2 deficiency</ENT1> from 18 Brazilian families.",,,,T,,Y,,,c,,,,,1.0,,
15807692,425,1294,D016108,Association,TRUE,Identification of novel type <ENT1>VII collagen</ENT1> gene mutations resulting in severe <ENT2>recessive dystrophic epidermolysis bullosa</ENT2>.,,,,T,,,,,c,,,,,0.0,,
15807692,425,1294,D016108,Association,TRUE,"In this work, we studied the proband in a small nuclear family of Chinese and Dutch/German descent and identified two novel mutations in the type <ENT1>VII collagen</ENT1> gene leading to <ENT2>recessive dystrophic epidermolysis bullosa</ENT2>, <ENT2>Hallopeau-Siemens</ENT2> variant (<ENT2>HS-RDEB</ENT2>).",,,,T,,,,,c,,,,,1.0,,
15811908,435,D009529,D014700,Cotreatment,FALSE,"Both drugs were immediately discontinued, and the patient recovered after subsequent <ENT1>nicardipine</ENT1> and <ENT2>verapamil</ENT2> treatment.",,,,T,,,,,w,,,,,0.0,,
15811908,429,D010673,D000077582,Association,TRUE,<ENT1>Pheochromocytoma</ENT1> unmasked by <ENT2>amisulpride</ENT2> and tiapride.,,,,T,,,,,c,,,,,0.0,,
15811908,429,D010673,D000077582,Association,TRUE,OBJECTIVE: To describe the unmasking of <ENT1>pheochromocytoma</ENT1> in a patient treated with <ENT2>amisulpride</ENT2> and tiapride.,,,,T,,Y,,,c,,,,,0.0,,
15811908,429,D010673,D000077582,Association,TRUE,"CONCLUSIONS: As of March 24, 2005, this is the first reported case of <ENT2>amisulpride</ENT2>- and tiapride-induced hypertensive crisis in a patient with <ENT1>pheochromocytoma</ENT1>.",,,,T,Y,,,,c,,,,,0.0,,
15811908,431,D010673,D001549,Association,FALSE,"DISCUSSION: Drug-induced symptoms of <ENT1>pheochromocytoma</ENT1> are often associated with the use of substituted <ENT2>benzamide drugs</ENT2>, but the underlying mechanism is unknown.",,,,T,Y,,,,c,,,,,0.0,,
15811908,430,D010673,D063325,Association,TRUE,<ENT1>Pheochromocytoma</ENT1> unmasked by amisulpride and <ENT2>tiapride</ENT2>.,,,,T,,,,,c,,,,,0.0,,
15811908,430,D010673,D063325,Association,TRUE,OBJECTIVE: To describe the unmasking of <ENT1>pheochromocytoma</ENT1> in a patient treated with amisulpride and <ENT2>tiapride</ENT2>.,,,,T,,,,,c,,,,,0.0,,
15811908,430,D010673,D063325,Association,TRUE,"CONCLUSIONS: As of March 24, 2005, this is the first reported case of amisulpride- and <ENT2>tiapride</ENT2>-induced hypertensive crisis in a patient with <ENT1>pheochromocytoma</ENT1>.",,,,T,Y,,,,c,,,,,0.0,,
15811908,441,D000077582,D006261,Positive_Correlation,TRUE,CASE SUMMARY: A 42-year-old white man developed acute hypertension with severe <ENT2>headache</ENT2> and vomiting 2 hours after the first doses of <ENT1>amisulpride</ENT1> 100 mg and tiapride 100 mg.,,,,T,,,,,c,,,,,1.0,,
15811908,439,D000077582,D014839,Positive_Correlation,TRUE,CASE SUMMARY: A 42-year-old white man developed acute hypertension with severe headache and <ENT2>vomiting</ENT2> 2 hours after the first doses of <ENT1>amisulpride</ENT1> 100 mg and tiapride 100 mg.,,,,T,,,,,c,,,,,1.0,,
15811908,443,D000077582,D006973,Positive_Correlation,TRUE,CASE SUMMARY: A 42-year-old white man developed acute <ENT2>hypertension</ENT2> with severe headache and vomiting 2 hours after the first doses of <ENT1>amisulpride</ENT1> 100 mg and tiapride 100 mg.,,,,T,,,,,c,,,,,1.0,,
15811908,443,D000077582,D006973,Positive_Correlation,TRUE,"In our case, use of the Naranjo probability scale indicated a possible relationship between the <ENT2>hypertensive</ENT2> crisis and <ENT1>amisulpride</ENT1> and tiapride therapy.",,,,T,,,,,c,,,,,1.0,,
15811908,443,D000077582,D006973,Positive_Correlation,TRUE,"CONCLUSIONS: As of March 24, 2005, this is the first reported case of <ENT1>amisulpride</ENT1>- and tiapride-induced <ENT2>hypertensive</ENT2> crisis in a patient with pheochromocytoma.",,,,T,,,,,c,,,,,1.0,,
15811908,428,D000077582,D063325,Drug_Interaction,FALSE,Pheochromocytoma unmasked by <ENT1>amisulpride</ENT1> and <ENT2>tiapride</ENT2>.,,,,T,,,,,c,,,,,1.0,,
15811908,428,D000077582,D063325,Drug_Interaction,FALSE,OBJECTIVE: To describe the unmasking of pheochromocytoma in a patient treated with <ENT1>amisulpride</ENT1> and <ENT2>tiapride</ENT2>.,,,,T,,,,,c,,,,,1.0,,
15811908,428,D000077582,D063325,Drug_Interaction,FALSE,CASE SUMMARY: A 42-year-old white man developed acute hypertension with severe headache and vomiting 2 hours after the first doses of <ENT1>amisulpride</ENT1> 100 mg and <ENT2>tiapride</ENT2> 100 mg.,,,,T,,,,,c,,,,,1.0,,
15811908,428,D000077582,D063325,Drug_Interaction,FALSE,"In our case, use of the Naranjo probability scale indicated a possible relationship between the hypertensive crisis and <ENT1>amisulpride</ENT1> and <ENT2>tiapride</ENT2> therapy.",,,,T,,,,,w,,,,,0.0,,
15811908,428,D000077582,D063325,Drug_Interaction,FALSE,"CONCLUSIONS: As of March 24, 2005, this is the first reported case of <ENT1>amisulpride</ENT1>- and <ENT2>tiapride</ENT2>-induced hypertensive crisis in a patient with pheochromocytoma.",,,,T,,,,,w,,,,,0.0,,
15811908,428,D000077582,D063325,Drug_Interaction,FALSE,Physicians and other healthcare professionals should be aware of this potential adverse effect of <ENT2>tiapride</ENT2> and <ENT1>amisulpride</ENT1>.,,,,T,,,,,w,,,,,0.0,,
15811908,442,D006261,D063325,Positive_Correlation,TRUE,CASE SUMMARY: A 42-year-old white man developed acute hypertension with severe <ENT1>headache</ENT1> and vomiting 2 hours after the first doses of amisulpride 100 mg and <ENT2>tiapride</ENT2> 100 mg.,,,,T,,,,,c,,,,,1.0,,
15811908,440,D014839,D063325,Positive_Correlation,TRUE,CASE SUMMARY: A 42-year-old white man developed acute hypertension with severe headache and <ENT1>vomiting</ENT1> 2 hours after the first doses of amisulpride 100 mg and <ENT2>tiapride</ENT2> 100 mg.,,,,T,,,,,c,,,,,1.0,,
15811908,444,D006973,D063325,Positive_Correlation,TRUE,CASE SUMMARY: A 42-year-old white man developed acute <ENT1>hypertension</ENT1> with severe headache and vomiting 2 hours after the first doses of amisulpride 100 mg and <ENT2>tiapride</ENT2> 100 mg.,,,,T,,,,,c,,,,,1.0,,
15811908,444,D006973,D063325,Positive_Correlation,TRUE,"In our case, use of the Naranjo probability scale indicated a possible relationship between the <ENT1>hypertensive</ENT1> crisis and amisulpride and <ENT2>tiapride</ENT2> therapy.",,,,T,,,,,c,,,,,1.0,,
15811908,444,D006973,D063325,Positive_Correlation,TRUE,"CONCLUSIONS: As of March 24, 2005, this is the first reported case of amisulpride- and <ENT2>tiapride</ENT2>-induced <ENT1>hypertensive</ENT1> crisis in a patient with pheochromocytoma.",,,,T,,,,,c,,,,,1.0,,
15814629,445,D012685,1636,Association,FALSE,Amplified <ENT2>ACE</ENT2> gene fragments were separated on <ENT1>agarose</ENT1> gels.,,,,T,Y,,,,c,,,,,0.0,,
15814629,448,D009362,1636,Association,TRUE,The number of <ENT1>lymph node metastases</ENT1> in gastric cancer correlates with the <ENT2>angiotensin I-converting enzyme</ENT2> gene insertion/deletion polymorphism.,,,,T,,,,,c,,,,,0.0,,
15814629,448,D009362,1636,Association,TRUE,"However, the <ENT2>ACE</ENT2> genotypes correlated with the number of <ENT1>lymph node metastases</ENT1> and the Unio Internationale Contra Cancrum (UICC) tumor stage.",,,,T,,,,,c,,,,,0.0,,
15814629,448,D009362,1636,Association,TRUE,"No correlation was found between tumor type, tumor location, local tumor growth, distant <ENT1>metastases</ENT1>, and the <ENT2>ACE</ENT2> genotype.",,,,T,,,,,c,,,,,1.0,,
15814629,447,1636,D009369,Association,TRUE,"However, the <ENT1>ACE</ENT1> genotypes correlated with the number of lymph node metastases and the Unio Internationale Contra Cancrum (UICC) <ENT2>tumor</ENT2> stage.",,,,T,,,,,c,,,,,0.0,,
15814629,447,1636,D009369,Association,TRUE,"No correlation was found between <ENT2>tumor</ENT2> type, <ENT2>tumor</ENT2> location, local <ENT2>tumor</ENT2> growth, distant metastases, and the <ENT1>ACE</ENT1> genotype.",,,,T,,,,,c,,,,,1.0,,
15814629,447,1636,D009369,Association,TRUE,<ENT1>ACE</ENT1> was expressed by endothelial cells in all (100%) specimens and by <ENT2>tumor</ENT2> cells in 56 (56%) specimens.,,,,T,Y,,,,c,,,,,0.0,,
15814629,446,1636,D013274,Association,TRUE,The number of lymph node metastases in <ENT2>gastric cancer</ENT2> correlates with the <ENT1>angiotensin I-converting enzyme</ENT1> gene insertion/deletion polymorphism.,,,,T,Y,,,,c,,,,,0.0,,
15814629,446,1636,D013274,Association,TRUE,"PURPOSE: In the present study, we aimed to substantiate the putative significance of <ENT1>angiotensin I-converting enzyme</ENT1> (<ENT1>ACE</ENT1>) on <ENT2>gastric cancer</ENT2> biology by investigating the influence of its gene polymorphism on <ENT2>gastric cancer</ENT2> progression.",,,,T,,Y,,,w,,,,,1.0,,
15814629,446,1636,D013274,Association,TRUE,The distribution of the <ENT1>ACE</ENT1> genotypes did not differ significantly from the control group of 189 patients without <ENT2>gastric cancer</ENT2>.,,,,T,,,,,c,,,,,1.0,,
15814629,446,1636,D013274,Association,TRUE,The expression of <ENT1>ACE</ENT1> in <ENT2>gastric cancer</ENT2> was investigated by immunohistochemistry in 100 of 113 patients.,,,,T,,Y,,,w,,,,,1.0,,
15814629,446,1636,D013274,Association,TRUE,CONCLUSIONS: Our study shows that <ENT1>ACE</ENT1> is expressed locally in <ENT2>gastric cancer</ENT2> and that the gene polymorphism influences metastatic behavior.,,,,T,,,,,w,,,,,0.0,,
15817013,450,D006470,D014859,Positive_Correlation,TRUE,People aged over 75 in atrial fibrillation on <ENT2>warfarin</ENT2>: the rate of major <ENT1>hemorrhage</ENT1> and stroke in more than 500 patient-years of follow-up.,,,,T,,Y,,,w,,,,,1.0,,
15817013,450,D006470,D014859,Positive_Correlation,TRUE,OBJECTIVES: To determine the incidence of major <ENT1>hemorrhage</ENT1> and stroke in people aged 76 and older with atrial fibrillation on adjusted-dose <ENT2>warfarin</ENT2> who had been recently been admitted to hospital.,,,,T,,Y,,,c,,,,,1.0,,
15817013,450,D006470,D014859,Positive_Correlation,TRUE,"MEASUREMENTS: Information regarding major <ENT1>bleeding</ENT1> episodes, strokes, and <ENT2>warfarin</ENT2> use was obtained from patients, relatives, primary physicians, and medical records.",,,,T,,Y,,,w,,,,,1.0,,
15817013,450,D006470,D014859,Positive_Correlation,TRUE,"CONCLUSION: The rate of major <ENT1>hemorrhage</ENT1> was high in this old, frail group, but excluding fatalities, resulted in no long-term sequelae, and the stroke rate on <ENT2>warfarin</ENT2> was low, demonstrating how effective <ENT2>warfarin</ENT2> treatment is.",,,,T,,,,,w,,,,,0.0,TRUE,
15817013,451,D014859,D001281,Negative_Correlation,FALSE,People aged over 75 in <ENT2>atrial fibrillation</ENT2> on <ENT1>warfarin</ENT1>: the rate of major hemorrhage and stroke in more than 500 patient-years of follow-up.,,,,T,,T,,,w,,,,,1.0,,
15817013,451,D014859,D001281,Negative_Correlation,FALSE,OBJECTIVES: To determine the incidence of major hemorrhage and stroke in people aged 76 and older with <ENT2>atrial fibrillation</ENT2> on adjusted-dose <ENT1>warfarin</ENT1> who had been recently been admitted to hospital.,,,,T,,,,,w,,,,,1.0,,
15817013,451,D014859,D001281,Negative_Correlation,FALSE,"PARTICIPANTS: Two hundred thirty-five patients aged 76 and older admitted to a major healthcare network between July 1, 2001, and June 30, 2002, with <ENT2>atrial fibrillation</ENT2> on <ENT1>warfarin</ENT1> were enrolled.",,,,T,,,,,c,,,,,1.0,,
15817013,449,D014859,D020521,Negative_Correlation,TRUE,People aged over 75 in atrial fibrillation on <ENT1>warfarin</ENT1>: the rate of major hemorrhage and <ENT2>stroke</ENT2> in more than 500 patient-years of follow-up.,,,,T,,Y,,,c,,,,,1.0,,
15817013,449,D014859,D020521,Negative_Correlation,TRUE,OBJECTIVES: To determine the incidence of major hemorrhage and <ENT2>stroke</ENT2> in people aged 76 and older with atrial fibrillation on adjusted-dose <ENT1>warfarin</ENT1> who had been recently been admitted to hospital.,,,,T,,Y,,,w,,,,,1.0,,
15817013,449,D014859,D020521,Negative_Correlation,TRUE,"MEASUREMENTS: Information regarding major bleeding episodes, <ENT2>strokes</ENT2>, and <ENT1>warfarin</ENT1> use was obtained from patients, relatives, primary physicians, and medical records.",,,,T,,Y,,,c,,,,,1.0,,
15817013,449,D014859,D020521,Negative_Correlation,TRUE,The annual <ENT2>stroke</ENT2> rate after initiation of <ENT1>warfarin</ENT1> was 2.6%.,,,,T,,,,,c,,,,,0.0,,
15817013,449,D014859,D020521,Negative_Correlation,TRUE,"CONCLUSION: The rate of major hemorrhage was high in this old, frail group, but excluding fatalities, resulted in no long-term sequelae, and the <ENT2>stroke</ENT2> rate on <ENT1>warfarin</ENT1> was low, demonstrating how effective <ENT1>warfarin</ENT1> treatment is.",,,,T,,,,,c,,,,,1.0,,
15820770,456,5798,D003920,Association,TRUE,RESULTS: The frequencies of the Asp/Glu and Glu/Glu were significantly increased in <ENT2>diabetic</ENT2> subjects with detectable <ENT1>IA-2</ENT1> antibodies (P < 0.01).,,,,T,Y,,,,w,,,,,0.0,,
15820770,457,5798,D003922,Association,FALSE,Vitamin D-binding protein gene polymorphism association with <ENT1>IA-2</ENT1> autoantibodies in <ENT2>type 1 diabetes</ENT2>.,,,,T,Y,,,,w,,,,,1.0,,
15820770,460,5798,2638,Association,FALSE,<ENT2>Vitamin D-binding protein</ENT2> gene polymorphism association with <ENT1>IA-2</ENT1> autoantibodies in type 1 diabetes.,,,,T,,T,,,c,,,,,1.0,,
15820770,458,D002117,2638,Association,FALSE,BACKGROUND: <ENT2>Vitamin D-binding protein</ENT2> (<ENT2>DBP</ENT2>) is the main systemic transporter of <ENT1>1.25(OH)2D3</ENT1> and is essential for its cellular endocytosis.,,,,T,,,,,c,,,,,0.0,,
15820770,458,D002117,2638,Association,FALSE,These <ENT2>DBP</ENT2> variants lead to differences in the affinity for <ENT1>1.25(OH)2D3</ENT1>.,,,,T,,,,,c,,,,,0.0,,
15820770,459,D003922,2638,Association,FALSE,<ENT2>Vitamin D-binding protein</ENT2> gene polymorphism association with IA-2 autoantibodies in <ENT1>type 1 diabetes</ENT1>.,,,,T,Y,T,,,c,,,,,1.0,,
15820770,459,D003922,2638,Association,FALSE,Correlations between <ENT2>DBP</ENT2> alleles and <ENT1>type 1 diabetes</ENT1> have been described in different populations.,,,,T,,,,,c,,,,,1.0,,
15820770,459,D003922,2638,Association,FALSE,"Therefore, we investigated the polymorphism in codon 416 of the <ENT2>DBP</ENT2> gene for an association with autoimmune markers of <ENT1>type 1 diabetes</ENT1>.",,,,T,,Y,,,w,,,,,1.0,,
15820770,455,D003922,D014807,Association,TRUE,These finding supports a role of the <ENT2>vitamin D</ENT2> endocrine system in the autoimmune process of <ENT1>type 1 diabetes</ENT1>.,,,,T,,,,,c,,,,,1.0,,
15858223,464,D014635,C075750,Positive_Correlation,TRUE,"A single dose of <ENT1>valproic acid</ENT1> (<ENT1>VPA</ENT1>), which is a widely used antiepileptic drug, is associated with oxidative stress in rats, as recently demonstrated by elevated levels of <ENT2>15-F(2t)-isoprostane</ENT2> (<ENT2>15-F(2t)-IsoP</ENT2>).",,,,T,,,,,c,,,"11,12,21,22",,1.0,,
15858223,464,D014635,C075750,Positive_Correlation,TRUE,Plasma and liver <ENT2>15-F(2t)-IsoP</ENT2> were elevated and reached a plateau after day 2 of <ENT1>VPA</ENT1> treatment compared to control.,,,,T,,,,,c,,,,,1.0,,
15858223,464,D014635,C075750,Positive_Correlation,TRUE,"Overall, these findings indicate that <ENT1>VPA</ENT1> treatment results in oxidative stress, as measured by levels of <ENT2>15-F(2t)-IsoP</ENT2>, which precedes the onset of necrosis, steatosis, and elevated levels of serum alpha-GST.",,,,T,,,,,w,,,,,0.0,,
15858223,469,D014635,D056486,Association,FALSE,"<ENT1>Valproic acid</ENT1> I: time course of lipid peroxidation biomarkers, <ENT2>liver toxicity</ENT2>, and <ENT1>valproic acid</ENT1> metabolite levels in rats.",,,,T,,T,,,w,,,,,0.0,,
15858223,469,D014635,D056486,Association,FALSE,"To determine whether there was a temporal relationship between <ENT1>VPA</ENT1>-associated oxidative stress and <ENT2>hepatotoxicity</ENT2>, adult male Sprague-Dawley rats were treated ip with <ENT1>VPA</ENT1> (500 mg/kg) or 0.9% saline (vehicle) once daily for 2, 4, 7, 10, or 14 days.",,,,T,,,,,w,,,,,0.0,,
15858223,468,D014635,24421,Positive_Correlation,TRUE,"Overall, these findings indicate that <ENT1>VPA</ENT1> treatment results in oxidative stress, as measured by levels of 15-F(2t)-IsoP, which precedes the onset of necrosis, steatosis, and elevated levels of serum <ENT2>alpha-GST</ENT2>.",,,,T,,,,,w,,,,,0.0,,
15858223,467,D014635,D009336,Positive_Correlation,TRUE,"Overall, these findings indicate that <ENT1>VPA</ENT1> treatment results in oxidative stress, as measured by levels of 15-F(2t)-IsoP, which precedes the onset of <ENT2>necrosis</ENT2>, steatosis, and elevated levels of serum alpha-GST.",,,,T,,,,,w,,,,,1.0,,
15858223,466,D014635,D005234,Positive_Correlation,TRUE,"Overall, these findings indicate that <ENT1>VPA</ENT1> treatment results in oxidative stress, as measured by levels of 15-F(2t)-IsoP, which precedes the onset of necrosis, <ENT2>steatosis</ENT2>, and elevated levels of serum alpha-GST.",,,,T,,,,,w,,,,,1.0,,
15858223,461,D006505,24421,Positive_Correlation,TRUE,"Serum <ENT2>alpha-GST</ENT2> levels were significantly elevated by day 4, which corresponded to hepatotoxicity as shown by the increasing incidence of <ENT1>inflammation of the liver capsule</ENT1>, necrosis, and steatosis throughout the study.",,,,T,,,,,w,,,,,0.0,,
15858223,465,D056486,24421,Positive_Correlation,TRUE,<ENT1>Liver toxicity</ENT1> was evaluated based on serum levels of <ENT2>alpha-glutathione S-transferase</ENT2> (<ENT2>alpha-GST</ENT2>) and by histology.,,,,T,,,,,c,,,,,0.0,,
15858223,465,D056486,24421,Positive_Correlation,TRUE,"Serum <ENT2>alpha-GST</ENT2> levels were significantly elevated by day 4, which corresponded to <ENT1>hepatotoxicity</ENT1> as shown by the increasing incidence of inflammation of the liver capsule, necrosis, and steatosis throughout the study.",,,,T,,,,,c,,,,,1.0,,
15858223,463,24421,D009336,Positive_Correlation,TRUE,"Serum <ENT1>alpha-GST</ENT1> levels were significantly elevated by day 4, which corresponded to hepatotoxicity as shown by the increasing incidence of inflammation of the liver capsule, <ENT2>necrosis</ENT2>, and steatosis throughout the study.",,,,T,,,,,w,,,,,0.0,,
15858223,463,24421,D009336,Positive_Correlation,TRUE,"Overall, these findings indicate that VPA treatment results in oxidative stress, as measured by levels of 15-F(2t)-IsoP, which precedes the onset of <ENT2>necrosis</ENT2>, steatosis, and elevated levels of serum <ENT1>alpha-GST</ENT1>.",,,,T,,,,,c,,,,,1.0,,
15858223,462,24421,D005234,Positive_Correlation,TRUE,"Serum <ENT1>alpha-GST</ENT1> levels were significantly elevated by day 4, which corresponded to hepatotoxicity as shown by the increasing incidence of inflammation of the liver capsule, necrosis, and <ENT2>steatosis</ENT2> throughout the study.",,,,T,,,,,w,,,,,0.0,,
15858223,462,24421,D005234,Positive_Correlation,TRUE,"Overall, these findings indicate that VPA treatment results in oxidative stress, as measured by levels of 15-F(2t)-IsoP, which precedes the onset of necrosis, <ENT2>steatosis</ENT2>, and elevated levels of serum <ENT1>alpha-GST</ENT1>.",,,,T,,,,,c,,,,,1.0,,
15859361,473,D003875,D000082,Positive_Correlation,TRUE,Safety of celecoxib in patients with adverse <ENT1>skin reactions</ENT1> to <ENT2>acetaminophen</ENT2> (<ENT2>paracetamol</ENT2>) and nimesulide associated or not with common non-steroidal anti-inflammatory drugs.,,,,T,,,,,c,,,,,0.5,,
15859361,473,D003875,D000082,Positive_Correlation,TRUE,OBJECTIVE: We evaluated the tolerability of CE in a group of patients with documented history of adverse <ENT1>cutaneous reactions</ENT1> to <ENT2>P</ENT2> and N associated or not to classic NSAIDs.,,,,T,,Y,,,w,,,,,0.0,,
15859361,473,D003875,D000082,Positive_Correlation,TRUE,The diagnosis of <ENT2>P</ENT2> and N-induced <ENT1>skin reactions</ENT1> was based in vivo challenge.,,,,T,,,,,c,,,,,1.0,,
15859361,470,D003875,C012655,Positive_Correlation,TRUE,Safety of celecoxib in patients with adverse <ENT1>skin reactions</ENT1> to acetaminophen (paracetamol) and <ENT2>nimesulide</ENT2> associated or not with common non-steroidal anti-inflammatory drugs.,,,,T,,,,,c,,,,,0.0,,
15859361,470,D003875,C012655,Positive_Correlation,TRUE,OBJECTIVE: We evaluated the tolerability of CE in a group of patients with documented history of adverse <ENT1>cutaneous reactions</ENT1> to P and <ENT2>N</ENT2> associated or not to classic NSAIDs.,,,,T,,Y,,,w,,,,,0.0,,
15859361,470,D003875,C012655,Positive_Correlation,TRUE,The diagnosis of P and <ENT2>N</ENT2>-induced <ENT1>skin reactions</ENT1> was based in vivo challenge.,,,,T,,,,,c,,,,,1.0,,
15859361,472,D000894,D004342,Positive_Correlation,TRUE,METHODS: We studied 9 patients with <ENT2>hypersensitivity</ENT2> to P and N with or without associated reactions to classic <ENT1>NSAIDs</ENT1>.,,,,T,,,,,c,,,,,1.0,,
15859361,472,D000894,D004342,Positive_Correlation,TRUE,CONCLUSION: Only one <ENT2>hypersensitivity</ENT2> reaction to CE was documented among 9 P and N-highly <ENT1>NSAIDs</ENT1> intolerant patients.,,,,T,,,,,c,,,,,0.0,,
15859361,478,C105934,4513,Positive_Correlation,FALSE,"<ENT1>Celecoxib</ENT1> (<ENT1>CE</ENT1>) is a novel drug, with high selectivity and affinity for <ENT2>COX-2</ENT2> enzyme.",,,,T,,,,,c,,,,,0.0,,
15859361,477,C105934,D000082,Comparison,TRUE,Safety of <ENT1>celecoxib</ENT1> in patients with adverse skin reactions to <ENT2>acetaminophen</ENT2> (<ENT2>paracetamol</ENT2>) and nimesulide associated or not with common non-steroidal anti-inflammatory drugs.,,,,T,,,,,c,,,,,1.0,,
15859361,477,C105934,D000082,Comparison,TRUE,OBJECTIVE: We evaluated the tolerability of <ENT1>CE</ENT1> in a group of patients with documented history of adverse cutaneous reactions to <ENT2>P</ENT2> and N associated or not to classic NSAIDs.,,,,T,,,,,w,,,,,1.0,,
15859361,477,C105934,D000082,Comparison,TRUE,CONCLUSION: Only one hypersensitivity reaction to <ENT1>CE</ENT1> was documented among 9 <ENT2>P</ENT2> and N-highly NSAIDs intolerant patients.,,,,T,,,,,c,,,,,0.0,,
15859361,477,C105934,D000082,Comparison,TRUE,"Thus, we conclude that <ENT1>CE</ENT1> is a reasonably safe alternative to be used in subjects who do not tolerate <ENT2>P</ENT2> and N.",,,,T,,,,,w,,,,,0.0,,
15859361,476,C105934,C012655,Comparison,TRUE,Safety of <ENT1>celecoxib</ENT1> in patients with adverse skin reactions to acetaminophen (paracetamol) and <ENT2>nimesulide</ENT2> associated or not with common non-steroidal anti-inflammatory drugs.,,,,T,,,,,c,,,,,1.0,,
15859361,476,C105934,C012655,Comparison,TRUE,OBJECTIVE: We evaluated the tolerability of <ENT1>CE</ENT1> in a group of patients with documented history of adverse cutaneous reactions to P and <ENT2>N</ENT2> associated or not to classic NSAIDs.,,,,T,,,,,w,,,,,1.0,,
15859361,476,C105934,C012655,Comparison,TRUE,CONCLUSION: Only one hypersensitivity reaction to <ENT1>CE</ENT1> was documented among 9 P and <ENT2>N</ENT2>-highly NSAIDs intolerant patients.,,,,T,,,,,c,,,,,0.0,,
15859361,476,C105934,C012655,Comparison,TRUE,"Thus, we conclude that <ENT1>CE</ENT1> is a reasonably safe alternative to be used in subjects who do not tolerate P and <ENT2>N</ENT2>.",,,,T,,,,,w,,,,,0.0,,
15859361,474,D000082,D004342,Positive_Correlation,TRUE,METHODS: We studied 9 patients with <ENT2>hypersensitivity</ENT2> to <ENT1>P</ENT1> and N with or without associated reactions to classic NSAIDs.,,,,T,,Y,,,w,,,,,1.0,,
15859361,474,D000082,D004342,Positive_Correlation,TRUE,CONCLUSION: Only one <ENT2>hypersensitivity</ENT2> reaction to CE was documented among 9 <ENT1>P</ENT1> and N-highly NSAIDs intolerant patients.,,,,T,,,,,c,,,,,1.0,,
15859361,471,C012655,D004342,Positive_Correlation,TRUE,METHODS: We studied 9 patients with <ENT2>hypersensitivity</ENT2> to P and <ENT1>N</ENT1> with or without associated reactions to classic NSAIDs.,,,,T,,Y,,,w,,,,,1.0,,
15859361,471,C012655,D004342,Positive_Correlation,TRUE,CONCLUSION: Only one <ENT2>hypersensitivity</ENT2> reaction to CE was documented among 9 P and <ENT1>N</ENT1>-highly NSAIDs intolerant patients.,,,,T,,,,,c,,,,,0.0,,
15867855,483,D001249,26762,Association,TRUE,Genetic variants of the <ENT2>T-cell immunoglobulin mucin 1</ENT2> but not the T-cell immunoglobulin mucin 3 gene are associated with <ENT1>asthma</ENT1> in an African American population.,,,,T,,,,,c,,,,,0.0,,
15867855,483,D001249,26762,Association,TRUE,OBJECTIVE: Genetic association of the sequence variants for <ENT2>TIM-1</ENT2> and TIM-3 genes with <ENT1>asthma</ENT1> in an African American population was investigated.,,,,T,,Y,,,w,,,,,0.0,,
15867855,483,D001249,26762,Association,TRUE,"RESULTS: In the case-control design, the frequencies of the TT genotype for SNP rs2277025 and the homozygous deletion variant (157delMTTTVP) in the fourth exon of the <ENT2>TIM-1</ENT2> gene were higher among patients with patients with <ENT1>asthma</ENT1> compared with the controls (odds ratio [OR], 2.779, P = .016; and OR, 3.09, P = .022, respectively).",,,,T,,,,,w,,,,,1.0,,
15867855,483,D001249,26762,Association,TRUE,CONCLUSION: Our findings suggest that the genetic variants of the <ENT2>TIM-1</ENT2> but not the TIM-3 gene contribute to <ENT1>asthma</ENT1> susceptibility in this African-American population.,,,,T,,,,,c,,,,,1.0,,
15867855,480,D001249,p|DEL|157|MTTTVP,Positive_Correlation,TRUE,"RESULTS: In the case-control design, the frequencies of the TT genotype for SNP rs2277025 and the homozygous deletion variant (<ENT2>157delMTTTVP</ENT2>) in the fourth exon of the TIM-1 gene were higher among patients with patients with <ENT1>asthma</ENT1> compared with the controls (odds ratio [OR], 2.779, P = .016; and OR, 3.09, P = .022, respectively).",,,,T,,,,,c,,,,,1.0,,
15867855,481,D001249,rs2277025,Positive_Correlation,TRUE,"RESULTS: In the case-control design, the frequencies of the TT genotype for SNP <ENT2>rs2277025</ENT2> and the homozygous deletion variant (157delMTTTVP) in the fourth exon of the TIM-1 gene were higher among patients with patients with <ENT1>asthma</ENT1> compared with the controls (odds ratio [OR], 2.779, P = .016; and OR, 3.09, P = .022, respectively).",,,,T,,,,,w,,,,,1.0,,
15867855;15867855,482;479,26762;84868,D004342;D004342,Association;Association,FALSE;FALSE,BACKGROUND: The <ENT1>T-cell immunoglobulin mucin</ENT1> ( <ENT1>TIM</ENT1> ) proteins and their genetic variants have been suggested to play a role in regulating <ENT2>allergic diseases</ENT2>.,,,,T,,,,,w,,,,,1.0,,
15893386,484,D013390,D014313,Positive_Correlation,TRUE,<ENT1>Succinylcholine</ENT1>-induced <ENT2>masseter muscle rigidity</ENT2> during bronchoscopic removal of a tracheal foreign body.,,,,T,,,,,c,,,,,1.0,,
15893386,484,D013390,D014313,Positive_Correlation,TRUE,"Here, we describe a case of severe <ENT2>masseter muscle rigidity</ENT2> (<ENT2>jaw of steel</ENT2>) after <ENT1>succinylcholine</ENT1> (<ENT1>Sch</ENT1>) administration during general anesthetic management for rigid bronchoscopic removal of a tracheal foreign body.",,,,T,,,,,c,,,"11,12,21,22",,0.5,,
15897593,487,D066126,D011034,Positive_Correlation,FALSE,"PURPOSE: The anthracyclines daunorubicin and doxorubicin and the <ENT2>epipodophyllotoxin</ENT2> etoposide are potent DNA cleavage-enhancing drugs that are widely used in clinical oncology; however, myelosuppression and <ENT1>cardiac toxicity</ENT1> limit their use.",,,,T,,,,,c,,,,,0.0,,
15897593,503,D066126,D064730,Negative_Correlation,FALSE,<ENT2>Dexrazoxane</ENT2> (<ENT2>ICRF-187</ENT2>) is recommended for protection against anthracycline-induced <ENT1>cardiotoxicity</ENT1>.,,,,T,,,,,c,,,,,1.0,,
15897593,493,D066126,D004317,Positive_Correlation,FALSE,"PURPOSE: The anthracyclines daunorubicin and <ENT2>doxorubicin</ENT2> and the epipodophyllotoxin etoposide are potent DNA cleavage-enhancing drugs that are widely used in clinical oncology; however, myelosuppression and <ENT1>cardiac toxicity</ENT1> limit their use.",,,,T,,,,,c,,,,,0.0,,
15897593,495,D066126,D003630,Positive_Correlation,FALSE,"PURPOSE: The anthracyclines <ENT2>daunorubicin</ENT2> and doxorubicin and the epipodophyllotoxin etoposide are potent DNA cleavage-enhancing drugs that are widely used in clinical oncology; however, myelosuppression and <ENT1>cardiac toxicity</ENT1> limit their use.",,,,T,,,,,c,,,,,0.0,,
15897593,489,D066126,D018943,Positive_Correlation,FALSE,"PURPOSE: The <ENT2>anthracyclines</ENT2> daunorubicin and doxorubicin and the epipodophyllotoxin etoposide are potent DNA cleavage-enhancing drugs that are widely used in clinical oncology; however, myelosuppression and <ENT1>cardiac toxicity</ENT1> limit their use.",,,,T,,,,,c,,,,,0.0,,
15897593,489,D066126,D018943,Positive_Correlation,FALSE,Dexrazoxane (ICRF-187) is recommended for protection against <ENT2>anthracycline</ENT2>-induced <ENT1>cardiotoxicity</ENT1>.,,,,T,,,,,c,,,,,1.0,,
15897593,497,D066126,D005047,Positive_Correlation,FALSE,"PURPOSE: The anthracyclines daunorubicin and doxorubicin and the epipodophyllotoxin <ENT2>etoposide</ENT2> are potent DNA cleavage-enhancing drugs that are widely used in clinical oncology; however, myelosuppression and <ENT1>cardiac toxicity</ENT1> limit their use.",,,,T,,,,,c,,,,,0.0,,
15897593,488,D011034,D001855,Positive_Correlation,FALSE,"PURPOSE: The anthracyclines daunorubicin and doxorubicin and the <ENT1>epipodophyllotoxin</ENT1> etoposide are potent DNA cleavage-enhancing drugs that are widely used in clinical oncology; however, <ENT2>myelosuppression</ENT2> and cardiac toxicity limit their use.",,,,T,,,,,c,,,,,0.0,,
15897593,491,D064420,D004317,Positive_Correlation,FALSE,"RESULTS: Nontoxic doses of dexrazoxane reduced myelosuppression and weight loss from daunorubicin and etoposide in mice and antagonized their antiproliferative effects in the colony assay; however, dexrazoxane neither reduced myelosuppression, weight loss, nor the in vitro <ENT1>cytotoxicity</ENT1> from <ENT2>doxorubicin</ENT2>.",,,,T,,,,,w,,,,,1.0,,
15897593,502,D006402,D064730,Negative_Correlation,FALSE,"EXPERIMENTAL DESIGN: Because of their widespread use, the <ENT1>hematologic toxicity</ENT1> following coadministration of <ENT2>dexrazoxane</ENT2> and these three structurally different DNA cleavage enhancers was investigated: Sensitivity of human and murine blood progenitor cells to etoposide, daunorubicin, and doxorubicin +/- <ENT2>dexrazoxane</ENT2> was determined in granulocyte-macrophage colony forming assays.",,,,T,,Y,,,c,,,,,0.5,TRUE,
15897593,502,D006402,D064730,Negative_Correlation,FALSE,Clinical trials in patients with brain metastases combining <ENT2>dexrazoxane</ENT2> and high doses of etoposide is ongoing with the aim of improving efficacy without aggravating <ENT1>hematologic toxicity</ENT1>.,,,,T,,,,,c,,,,,0.0,,
15897593,507,D064730,D001855,Negative_Correlation,TRUE,<ENT1>Dexrazoxane</ENT1> protects against <ENT2>myelosuppression</ENT2> from the DNA cleavage-enhancing drugs etoposide and daunorubicin but not doxorubicin.,,,,T,,,,,c,,,,,1.0,,
15897593,507,D064730,D001855,Negative_Correlation,TRUE,"RESULTS: Nontoxic doses of <ENT1>dexrazoxane</ENT1> reduced <ENT2>myelosuppression</ENT2> and weight loss from daunorubicin and etoposide in mice and antagonized their antiproliferative effects in the colony assay; however, <ENT1>dexrazoxane</ENT1> neither reduced <ENT2>myelosuppression</ENT2>, weight loss, nor the in vitro cytotoxicity from doxorubicin.",,,,T,,,,,c,,,,,0.25,,
15897593,501,D064730,D015431,Negative_Correlation,TRUE,"RESULTS: Nontoxic doses of <ENT1>dexrazoxane</ENT1> reduced myelosuppression and <ENT2>weight loss</ENT2> from daunorubicin and etoposide in mice and antagonized their antiproliferative effects in the colony assay; however, <ENT1>dexrazoxane</ENT1> neither reduced myelosuppression, <ENT2>weight loss</ENT2>, nor the in vitro cytotoxicity from doxorubicin.",,,,T,,,,,c,,,,,0.25,,
15897593,505,D064730,D003630,Negative_Correlation,TRUE,<ENT1>Dexrazoxane</ENT1> protects against myelosuppression from the DNA cleavage-enhancing drugs etoposide and <ENT2>daunorubicin</ENT2> but not doxorubicin.,,,,T,,,,,c,,,,,1.0,,
15897593,505,D064730,D003630,Negative_Correlation,TRUE,"EXPERIMENTAL DESIGN: Because of their widespread use, the hematologic toxicity following coadministration of <ENT1>dexrazoxane</ENT1> and these three structurally different DNA cleavage enhancers was investigated: Sensitivity of human and murine blood progenitor cells to etoposide, <ENT2>daunorubicin</ENT2>, and doxorubicin +/- <ENT1>dexrazoxane</ENT1> was determined in granulocyte-macrophage colony forming assays.",,,,T,,,,,c,,,,,1.0,,
15897593,505,D064730,D003630,Negative_Correlation,TRUE,"Likewise, in vivo, B6D2F1 mice were treated with etoposide, <ENT2>daunorubicin</ENT2>, and doxorubicin, with or without <ENT1>dexrazoxane</ENT1> over a wide range of doses: posttreatment, a full hematologic evaluation was done.",,,,T,,,,,c,,,,,1.0,,
15897593,505,D064730,D003630,Negative_Correlation,TRUE,"RESULTS: Nontoxic doses of <ENT1>dexrazoxane</ENT1> reduced myelosuppression and weight loss from <ENT2>daunorubicin</ENT2> and etoposide in mice and antagonized their antiproliferative effects in the colony assay; however, <ENT1>dexrazoxane</ENT1> neither reduced myelosuppression, weight loss, nor the in vitro cytotoxicity from doxorubicin.",,,,T,,,,,c,,,,,0.5,,
15897593,505,D064730,D003630,Negative_Correlation,TRUE,"CONCLUSION: Although our findings support the observation that <ENT1>dexrazoxane</ENT1> reduces neither hematologic activity nor antitumor activity from doxorubicin clinically, the potent antagonism of <ENT2>daunorubicin</ENT2> activity raises concern; a possible interference with anticancer efficacy certainly would call for renewed attention.",,,,T,,,,,c,,,,,0.0,,
15897593,504,D064730,D018943,Negative_Correlation,FALSE,<ENT1>Dexrazoxane</ENT1> (<ENT1>ICRF-187</ENT1>) is recommended for protection against <ENT2>anthracycline</ENT2>-induced cardiotoxicity.,,,,T,Y,,,,c,,,,,1.0,,
15897593,506,D064730,D005047,Negative_Correlation,TRUE,<ENT1>Dexrazoxane</ENT1> protects against myelosuppression from the DNA cleavage-enhancing drugs <ENT2>etoposide</ENT2> and daunorubicin but not doxorubicin.,,,,T,,,,,c,,,,,1.0,,
15897593,506,D064730,D005047,Negative_Correlation,TRUE,"EXPERIMENTAL DESIGN: Because of their widespread use, the hematologic toxicity following coadministration of <ENT1>dexrazoxane</ENT1> and these three structurally different DNA cleavage enhancers was investigated: Sensitivity of human and murine blood progenitor cells to <ENT2>etoposide</ENT2>, daunorubicin, and doxorubicin +/- <ENT1>dexrazoxane</ENT1> was determined in granulocyte-macrophage colony forming assays.",,,,T,,,,,c,,,,,1.0,,
15897593,506,D064730,D005047,Negative_Correlation,TRUE,"Likewise, in vivo, B6D2F1 mice were treated with <ENT2>etoposide</ENT2>, daunorubicin, and doxorubicin, with or without <ENT1>dexrazoxane</ENT1> over a wide range of doses: posttreatment, a full hematologic evaluation was done.",,,,T,,,,,c,,,,,1.0,,
15897593,506,D064730,D005047,Negative_Correlation,TRUE,"RESULTS: Nontoxic doses of <ENT1>dexrazoxane</ENT1> reduced myelosuppression and weight loss from daunorubicin and <ENT2>etoposide</ENT2> in mice and antagonized their antiproliferative effects in the colony assay; however, <ENT1>dexrazoxane</ENT1> neither reduced myelosuppression, weight loss, nor the in vitro cytotoxicity from doxorubicin.",,,,T,,,,,c,,,,,0.0,,
15897593,506,D064730,D005047,Negative_Correlation,TRUE,Our data also suggest that significant <ENT2>etoposide</ENT2> dose escalation is perhaps possible by the use of <ENT1>dexrazoxane</ENT1>.,,,,T,,,,,c,,,,,1.0,,
15897593,506,D064730,D005047,Negative_Correlation,TRUE,Clinical trials in patients with brain metastases combining <ENT1>dexrazoxane</ENT1> and high doses of <ENT2>etoposide</ENT2> is ongoing with the aim of improving efficacy without aggravating hematologic toxicity.,,,,T,,,,,w,,,,,0.0,,
15897593,494,D001855,D004317,Positive_Correlation,FALSE,Dexrazoxane protects against <ENT1>myelosuppression</ENT1> from the DNA cleavage-enhancing drugs etoposide and daunorubicin but not <ENT2>doxorubicin</ENT2>.,,,,T,,,,,c,,,,,1.0,,
15897593,494,D001855,D004317,Positive_Correlation,FALSE,"PURPOSE: The anthracyclines daunorubicin and <ENT2>doxorubicin</ENT2> and the epipodophyllotoxin etoposide are potent DNA cleavage-enhancing drugs that are widely used in clinical oncology; however, <ENT1>myelosuppression</ENT1> and cardiac toxicity limit their use.",,,,T,,,,,c,,,,,0.0,,
15897593,494,D001855,D004317,Positive_Correlation,FALSE,"RESULTS: Nontoxic doses of dexrazoxane reduced <ENT1>myelosuppression</ENT1> and weight loss from daunorubicin and etoposide in mice and antagonized their antiproliferative effects in the colony assay; however, dexrazoxane neither reduced <ENT1>myelosuppression</ENT1>, weight loss, nor the in vitro cytotoxicity from <ENT2>doxorubicin</ENT2>.",,,,T,,,,,c,,,,,1.0,,
15897593,499,D001855,D003630,Positive_Correlation,FALSE,Dexrazoxane protects against <ENT1>myelosuppression</ENT1> from the DNA cleavage-enhancing drugs etoposide and <ENT2>daunorubicin</ENT2> but not doxorubicin.,,,,T,,,,,w,,,,,0.0,,
15897593,499,D001855,D003630,Positive_Correlation,FALSE,"PURPOSE: The anthracyclines <ENT2>daunorubicin</ENT2> and doxorubicin and the epipodophyllotoxin etoposide are potent DNA cleavage-enhancing drugs that are widely used in clinical oncology; however, <ENT1>myelosuppression</ENT1> and cardiac toxicity limit their use.",,,,T,,,,,c,,,,,0.0,,
15897593,499,D001855,D003630,Positive_Correlation,FALSE,"RESULTS: Nontoxic doses of dexrazoxane reduced <ENT1>myelosuppression</ENT1> and weight loss from <ENT2>daunorubicin</ENT2> and etoposide in mice and antagonized their antiproliferative effects in the colony assay; however, dexrazoxane neither reduced <ENT1>myelosuppression</ENT1>, weight loss, nor the in vitro cytotoxicity from doxorubicin.",,,,T,,,,,w,,,,,0.5,TRUE,
15897593,490,D001855,D018943,Positive_Correlation,FALSE,"PURPOSE: The <ENT2>anthracyclines</ENT2> daunorubicin and doxorubicin and the epipodophyllotoxin etoposide are potent DNA cleavage-enhancing drugs that are widely used in clinical oncology; however, <ENT1>myelosuppression</ENT1> and cardiac toxicity limit their use.",,,,T,,,,,c,,,,,0.0,,
15897593,500,D001855,D005047,Positive_Correlation,FALSE,Dexrazoxane protects against <ENT1>myelosuppression</ENT1> from the DNA cleavage-enhancing drugs <ENT2>etoposide</ENT2> and daunorubicin but not doxorubicin.,,,,T,,,,,w,,,,,1.0,,
15897593,500,D001855,D005047,Positive_Correlation,FALSE,"PURPOSE: The anthracyclines daunorubicin and doxorubicin and the epipodophyllotoxin <ENT2>etoposide</ENT2> are potent DNA cleavage-enhancing drugs that are widely used in clinical oncology; however, <ENT1>myelosuppression</ENT1> and cardiac toxicity limit their use.",,,,T,,,,,c,,,,,0.0,,
15897593,500,D001855,D005047,Positive_Correlation,FALSE,"RESULTS: Nontoxic doses of dexrazoxane reduced <ENT1>myelosuppression</ENT1> and weight loss from daunorubicin and <ENT2>etoposide</ENT2> in mice and antagonized their antiproliferative effects in the colony assay; however, dexrazoxane neither reduced <ENT1>myelosuppression</ENT1>, weight loss, nor the in vitro cytotoxicity from doxorubicin.",,,,T,,,,,w,,,,,0.5,TRUE,
15897593,492,D015431,D004317,Positive_Correlation,FALSE,"RESULTS: Nontoxic doses of dexrazoxane reduced myelosuppression and <ENT1>weight loss</ENT1> from daunorubicin and etoposide in mice and antagonized their antiproliferative effects in the colony assay; however, dexrazoxane neither reduced myelosuppression, <ENT1>weight loss</ENT1>, nor the in vitro cytotoxicity from <ENT2>doxorubicin</ENT2>.",,,,T,,,,,w,,,,,0.0,,
15897593,485,D015431,D003630,Positive_Correlation,FALSE,"RESULTS: Nontoxic doses of dexrazoxane reduced myelosuppression and <ENT1>weight loss</ENT1> from <ENT2>daunorubicin</ENT2> and etoposide in mice and antagonized their antiproliferative effects in the colony assay; however, dexrazoxane neither reduced myelosuppression, <ENT1>weight loss</ENT1>, nor the in vitro cytotoxicity from doxorubicin.",,,,T,,,,,w,,,,,0.5,,
15897593,486,D015431,D005047,Positive_Correlation,FALSE,"RESULTS: Nontoxic doses of dexrazoxane reduced myelosuppression and <ENT1>weight loss</ENT1> from daunorubicin and <ENT2>etoposide</ENT2> in mice and antagonized their antiproliferative effects in the colony assay; however, dexrazoxane neither reduced myelosuppression, <ENT1>weight loss</ENT1>, nor the in vitro cytotoxicity from doxorubicin.",,,,T,,,,,w,,,,,0.5,,
15897593,496,D004317,D003630,Comparison,TRUE,Dexrazoxane protects against myelosuppression from the DNA cleavage-enhancing drugs etoposide and <ENT2>daunorubicin</ENT2> but not <ENT1>doxorubicin</ENT1>.,,,,T,,,,,c,,,,,0.0,,
15897593,496,D004317,D003630,Comparison,TRUE,"PURPOSE: The anthracyclines <ENT2>daunorubicin</ENT2> and <ENT1>doxorubicin</ENT1> and the epipodophyllotoxin etoposide are potent DNA cleavage-enhancing drugs that are widely used in clinical oncology; however, myelosuppression and cardiac toxicity limit their use.",,,,T,,,,,c,,,,,1.0,,
15897593,496,D004317,D003630,Comparison,TRUE,"EXPERIMENTAL DESIGN: Because of their widespread use, the hematologic toxicity following coadministration of dexrazoxane and these three structurally different DNA cleavage enhancers was investigated: Sensitivity of human and murine blood progenitor cells to etoposide, <ENT2>daunorubicin</ENT2>, and <ENT1>doxorubicin</ENT1> +/- dexrazoxane was determined in granulocyte-macrophage colony forming assays.",,,,T,,,,,c,,,,,1.0,,
15897593,496,D004317,D003630,Comparison,TRUE,"Likewise, in vivo, B6D2F1 mice were treated with etoposide, <ENT2>daunorubicin</ENT2>, and <ENT1>doxorubicin</ENT1>, with or without dexrazoxane over a wide range of doses: posttreatment, a full hematologic evaluation was done.",,,,T,,,,,c,,,,,1.0,,
15897593,496,D004317,D003630,Comparison,TRUE,"RESULTS: Nontoxic doses of dexrazoxane reduced myelosuppression and weight loss from <ENT2>daunorubicin</ENT2> and etoposide in mice and antagonized their antiproliferative effects in the colony assay; however, dexrazoxane neither reduced myelosuppression, weight loss, nor the in vitro cytotoxicity from <ENT1>doxorubicin</ENT1>.",,,,T,,,,,c,,,,,1.0,,
15897593,496,D004317,D003630,Comparison,TRUE,"CONCLUSION: Although our findings support the observation that dexrazoxane reduces neither hematologic activity nor antitumor activity from <ENT1>doxorubicin</ENT1> clinically, the potent antagonism of <ENT2>daunorubicin</ENT2> activity raises concern; a possible interference with anticancer efficacy certainly would call for renewed attention.",,,,T,,,,,c,,,,,1.0,,
15897593,498,D004317,D005047,Comparison,TRUE,Dexrazoxane protects against myelosuppression from the DNA cleavage-enhancing drugs <ENT2>etoposide</ENT2> and daunorubicin but not <ENT1>doxorubicin</ENT1>.,,,,T,,,,,c,,,,,0.0,,
15897593,498,D004317,D005047,Comparison,TRUE,"PURPOSE: The anthracyclines daunorubicin and <ENT1>doxorubicin</ENT1> and the epipodophyllotoxin <ENT2>etoposide</ENT2> are potent DNA cleavage-enhancing drugs that are widely used in clinical oncology; however, myelosuppression and cardiac toxicity limit their use.",,,,T,,,,,c,,,,,1.0,,
15897593,498,D004317,D005047,Comparison,TRUE,"EXPERIMENTAL DESIGN: Because of their widespread use, the hematologic toxicity following coadministration of dexrazoxane and these three structurally different DNA cleavage enhancers was investigated: Sensitivity of human and murine blood progenitor cells to <ENT2>etoposide</ENT2>, daunorubicin, and <ENT1>doxorubicin</ENT1> +/- dexrazoxane was determined in granulocyte-macrophage colony forming assays.",,,,T,,,,,c,,,,,1.0,,
15897593,498,D004317,D005047,Comparison,TRUE,"Likewise, in vivo, B6D2F1 mice were treated with <ENT2>etoposide</ENT2>, daunorubicin, and <ENT1>doxorubicin</ENT1>, with or without dexrazoxane over a wide range of doses: posttreatment, a full hematologic evaluation was done.",,,,T,,,,,c,,,,,1.0,,
15897593,498,D004317,D005047,Comparison,TRUE,"RESULTS: Nontoxic doses of dexrazoxane reduced myelosuppression and weight loss from daunorubicin and <ENT2>etoposide</ENT2> in mice and antagonized their antiproliferative effects in the colony assay; however, dexrazoxane neither reduced myelosuppression, weight loss, nor the in vitro cytotoxicity from <ENT1>doxorubicin</ENT1>.",,,,T,,,,,c,,,,,1.0,,
15951966,508,4292,D003123,Association,FALSE,"BACKGROUND: Exonic deletions in MSH2 and <ENT1>MLH1</ENT1> are significant contributors to the mutation spectrum in <ENT2>HNPCC</ENT2>, and heterozygous changes in exon copy number are not detected by conventional mutation screening methods.",,,,T,,,,,c,,,,,1.0,,
15951966,508,4292,D003123,Association,FALSE,CONCLUSIONS: MAPH can detect exonic copy number changes in <ENT1>MLH1</ENT1> and MSH2 in DNA from <ENT2>HNPCC</ENT2> patients.,,,,T,,,,,c,,,,,1.0,,
15951966,509,4436,D003123,Association,FALSE,"BACKGROUND: Exonic deletions in <ENT1>MSH2</ENT1> and MLH1 are significant contributors to the mutation spectrum in <ENT2>HNPCC</ENT2>, and heterozygous changes in exon copy number are not detected by conventional mutation screening methods.",,,,T,,,,,c,,,,,1.0,,
15951966,509,4436,D003123,Association,FALSE,CONCLUSIONS: MAPH can detect exonic copy number changes in MLH1 and <ENT1>MSH2</ENT1> in DNA from <ENT2>HNPCC</ENT2> patients.,,,,T,,,,,c,,,,,1.0,,
15983230,517,D003924,6514,Association,TRUE,Polymorphisms in the <ENT2>SLC2A2</ENT2> (<ENT2>GLUT2</ENT2>) gene are associated with the conversion from impaired glucose tolerance to <ENT1>type 2 diabetes</ENT1>: the Finnish Diabetes Prevention Study.,,,,T,,,,,c,,,,,1.0,,
15983230,517,D003924,6514,Association,TRUE,"The aim of this study was to investigate whether single nucleotide polymorphisms (SNPs) in the genes regulating insulin secretion (<ENT2>SLC2A2</ENT2> [encoding <ENT2>GLUT2</ENT2>], GCK, TCF1 [encoding HNF-1alpha], HNF4A, GIP, and GLP1R) are associated with the conversion from impaired glucose tolerance (IGT) to <ENT1>type 2 diabetes</ENT1> in participants of the Finnish Diabetes Prevention Study.",,,,T,,Y,,,c,,,,,1.0,,
15983230,517,D003924,6514,Association,TRUE,"With the exception of <ENT2>SLC2A2</ENT2>, other genes were not associated with the risk of <ENT1>type 2 diabetes</ENT1>.",,,,T,,,,,c,,,,,0.0,,
15983230,517,D003924,6514,Association,TRUE,"All four SNPs of <ENT2>SLC2A2</ENT2> predicted the conversion to diabetes, and rs5393 (AA genotype) increased the risk of <ENT1>type 2 diabetes</ENT1> in the entire study population by threefold (odds ratio 3.04, 95% CI 1.34-6.88, P = 0.008).",,,,T,,,,,w,,,,,0.0,,
15983230,513,D003924,rs5393,Positive_Correlation,TRUE,"All four SNPs of SLC2A2 predicted the conversion to diabetes, and <ENT2>rs5393</ENT2> (AA genotype) increased the risk of <ENT1>type 2 diabetes</ENT1> in the entire study population by threefold (odds ratio 3.04, 95% CI 1.34-6.88, P = 0.008).",,,,T,,,,,c,,,,,1.0,,
15983230,515,D009765,6514,Association,TRUE,We conclude that the SNPs of <ENT2>SLC2A2</ENT2> predict the conversion to diabetes in <ENT1>obese</ENT1> subjects with IGT.,,,,T,,,,,c,,,,,1.0,,
15983230,522,6927,3630,Association,FALSE,"The aim of this study was to investigate whether single nucleotide polymorphisms (SNPs) in the genes regulating <ENT2>insulin</ENT2> secretion (SLC2A2 [encoding GLUT2], GCK, <ENT1>TCF1</ENT1> [encoding <ENT1>HNF-1alpha</ENT1>], HNF4A, GIP, and GLP1R) are associated with the conversion from impaired glucose tolerance (IGT) to type 2 diabetes in participants of the Finnish Diabetes Prevention Study.",,,,T,,,,,w,,,,,0.0,,
15983230,516,6514,D003920,Association,TRUE,Polymorphisms in the <ENT1>SLC2A2</ENT1> (<ENT1>GLUT2</ENT1>) gene are associated with the conversion from impaired glucose tolerance to type 2 diabetes: the Finnish <ENT2>Diabetes</ENT2> Prevention Study.,,,,T,,,,,c,,,,,1.0,,
15983230,516,6514,D003920,Association,TRUE,"The aim of this study was to investigate whether single nucleotide polymorphisms (SNPs) in the genes regulating insulin secretion (<ENT1>SLC2A2</ENT1> [encoding <ENT1>GLUT2</ENT1>], GCK, TCF1 [encoding HNF-1alpha], HNF4A, GIP, and GLP1R) are associated with the conversion from impaired glucose tolerance (IGT) to type 2 diabetes in participants of the Finnish <ENT2>Diabetes</ENT2> Prevention Study.",,,,T,,,,,c,,,,,1.0,,
15983230,516,6514,D003920,Association,TRUE,"All four SNPs of <ENT1>SLC2A2</ENT1> predicted the conversion to <ENT2>diabetes</ENT2>, and rs5393 (AA genotype) increased the risk of type 2 diabetes in the entire study population by threefold (odds ratio 3.04, 95% CI 1.34-6.88, P = 0.008).",,,,T,,,,,c,,,,,1.0,,
15983230,516,6514,D003920,Association,TRUE,We conclude that the SNPs of <ENT1>SLC2A2</ENT1> predict the conversion to <ENT2>diabetes</ENT2> in obese subjects with IGT.,,,,T,,,,,c,,,,,1.0,,
15983230,514,6514,D018149,Association,TRUE,Polymorphisms in the <ENT1>SLC2A2</ENT1> (<ENT1>GLUT2</ENT1>) gene are associated with the conversion from <ENT2>impaired glucose tolerance</ENT2> to type 2 diabetes: the Finnish Diabetes Prevention Study.,,,,T,,,,,c,,,,,0.5,,
15983230,514,6514,D018149,Association,TRUE,"The aim of this study was to investigate whether single nucleotide polymorphisms (SNPs) in the genes regulating insulin secretion (<ENT1>SLC2A2</ENT1> [encoding <ENT1>GLUT2</ENT1>], GCK, TCF1 [encoding HNF-1alpha], HNF4A, GIP, and GLP1R) are associated with the conversion from <ENT2>impaired glucose tolerance</ENT2> (<ENT2>IGT</ENT2>) to type 2 diabetes in participants of the Finnish Diabetes Prevention Study.",,,,T,,Y,,,w,,,,,1.0,,
15983230,514,6514,D018149,Association,TRUE,We conclude that the SNPs of <ENT1>SLC2A2</ENT1> predict the conversion to diabetes in obese subjects with <ENT2>IGT</ENT2>.,,,,T,Y,,,,w,,,,,0.0,,
15983230,518,6514,3630,Association,FALSE,"The aim of this study was to investigate whether single nucleotide polymorphisms (SNPs) in the genes regulating <ENT2>insulin</ENT2> secretion (<ENT1>SLC2A2</ENT1> [encoding <ENT1>GLUT2</ENT1>], GCK, TCF1 [encoding HNF-1alpha], HNF4A, GIP, and GLP1R) are associated with the conversion from impaired glucose tolerance (IGT) to type 2 diabetes in participants of the Finnish Diabetes Prevention Study.",,,,T,,,,,w,,,,,0.0,,
15983230,512,D003920,rs5393,Association,TRUE,"All four SNPs of SLC2A2 predicted the conversion to <ENT1>diabetes</ENT1>, and <ENT2>rs5393</ENT2> (AA genotype) increased the risk of type 2 diabetes in the entire study population by threefold (odds ratio 3.04, 95% CI 1.34-6.88, P = 0.008).",,,,T,,,,,w,,,,,0.0,,
15983230,521,3172,3630,Association,FALSE,"The aim of this study was to investigate whether single nucleotide polymorphisms (SNPs) in the genes regulating <ENT2>insulin</ENT2> secretion (SLC2A2 [encoding GLUT2], GCK, TCF1 [encoding HNF-1alpha], <ENT1>HNF4A</ENT1>, GIP, and GLP1R) are associated with the conversion from impaired glucose tolerance (IGT) to type 2 diabetes in participants of the Finnish Diabetes Prevention Study.",,,,T,,,,,w,,,,,0.0,,
15983230,523,2645,3630,Association,FALSE,"The aim of this study was to investigate whether single nucleotide polymorphisms (SNPs) in the genes regulating <ENT2>insulin</ENT2> secretion (SLC2A2 [encoding GLUT2], <ENT1>GCK</ENT1>, TCF1 [encoding HNF-1alpha], HNF4A, GIP, and GLP1R) are associated with the conversion from impaired glucose tolerance (IGT) to type 2 diabetes in participants of the Finnish Diabetes Prevention Study.",,,,T,,,,,w,,,,,0.0,,
15983230,519,3630,2740,Association,FALSE,"The aim of this study was to investigate whether single nucleotide polymorphisms (SNPs) in the genes regulating <ENT1>insulin</ENT1> secretion (SLC2A2 [encoding GLUT2], GCK, TCF1 [encoding HNF-1alpha], HNF4A, GIP, and <ENT2>GLP1R</ENT2>) are associated with the conversion from impaired glucose tolerance (IGT) to type 2 diabetes in participants of the Finnish Diabetes Prevention Study.",,,,T,,,,,w,,,,,0.0,,
15983230,520,3630,2695,Association,FALSE,"The aim of this study was to investigate whether single nucleotide polymorphisms (SNPs) in the genes regulating <ENT1>insulin</ENT1> secretion (SLC2A2 [encoding GLUT2], GCK, TCF1 [encoding HNF-1alpha], HNF4A, <ENT2>GIP</ENT2>, and GLP1R) are associated with the conversion from impaired glucose tolerance (IGT) to type 2 diabetes in participants of the Finnish Diabetes Prevention Study.",,,,T,,,,,w,,,,,0.0,,
15991002,527,D002110,D009538,Negative_Correlation,TRUE,<ENT2>Nicotine</ENT2> antagonizes <ENT1>caffeine</ENT1>- but not pentylenetetrazole-induced anxiogenic effect in mice.,,,,T,,,,,c,,,,,0.0,,
15991002,527,D002110,D009538,Negative_Correlation,TRUE,RATIONALE: <ENT2>Nicotine</ENT2> and <ENT1>caffeine</ENT1> are widely consumed licit psychoactive drugs worldwide.,,,,T,,,,,c,,,,,1.0,,
15991002,527,D002110,D009538,Negative_Correlation,TRUE,"OBJECTIVES: The present study investigates the effects of <ENT2>nicotine</ENT2> on anxiety induced by <ENT1>caffeine</ENT1> and another anxiogenic drug, pentylenetetrazole, in mice.",,,,T,,Y,,,c,,,,,1.0,,
15991002,527,D002110,D009538,Negative_Correlation,TRUE,METHODS: Adult male Swiss Webster mice (25-32 g) were given <ENT2>nicotine</ENT2> (0.05-0.25 mg/kg s.c.) or saline 10 min before <ENT1>caffeine</ENT1> (70 mg/kg i.p.) or pentylenetetrazole (15 and 30 mg/kg i.p.) injections.,,,,T,,,,,c,,,,,1.0,,
15991002,527,D002110,D009538,Negative_Correlation,TRUE,"RESULTS: <ENT2>Nicotine</ENT2> (0.05-0.25 mg/kg) itself did not produce any significant effect in the EPM test, whereas <ENT1>caffeine</ENT1> (70 mg/kg) and pentylenetetrazole (30 mg/kg) produced an anxiogenic effect, apparent with decreases in open-arm time and entry.",,,,T,,,,,c,,,,,1.0,,
15991002,527,D002110,D009538,Negative_Correlation,TRUE,<ENT2>Nicotine</ENT2> (0.25 mg/kg) pretreatment blocked the <ENT1>caffeine</ENT1>- but not pentylenetetrazole-induced anxiety.,,,,T,,,,,c,,,,,1.0,,
15991002,527,D002110,D009538,Negative_Correlation,TRUE,"CONCLUSIONS: Our results suggest that the antagonistic effect of <ENT2>nicotine</ENT2> on <ENT1>caffeine</ENT1>-induced anxiety is specific to <ENT1>caffeine</ENT1>, instead of a non-specific anxiolytic effect.",,,,T,Y,,,,w,,,,,0.0,TRUE,
15991002,527,D002110,D009538,Negative_Correlation,TRUE,"Thus, it may extend the current findings on the interaction between <ENT2>nicotine</ENT2> and <ENT1>caffeine</ENT1>.",,,,T,,,,,c,,,,,0.0,,
15991002,525,D002110,D001008,Positive_Correlation,FALSE,Nicotine antagonizes <ENT1>caffeine</ENT1>- but not pentylenetetrazole-induced <ENT2>anxiogenic effect</ENT2> in mice.,,,,T,,,,,c,,,,,0.0,,
15991002,525,D002110,D001008,Positive_Correlation,FALSE,"OBJECTIVES: The present study investigates the effects of nicotine on <ENT2>anxiety</ENT2> induced by <ENT1>caffeine</ENT1> and another anxiogenic drug, pentylenetetrazole, in mice.",,,,T,,,,,c,,,,,1.0,,
15991002,525,D002110,D001008,Positive_Correlation,FALSE,"RESULTS: Nicotine (0.05-0.25 mg/kg) itself did not produce any significant effect in the EPM test, whereas <ENT1>caffeine</ENT1> (70 mg/kg) and pentylenetetrazole (30 mg/kg) produced an <ENT2>anxiogenic effect</ENT2>, apparent with decreases in open-arm time and entry.",,,,T,,,,,c,,,,,1.0,,
15991002,525,D002110,D001008,Positive_Correlation,FALSE,Nicotine (0.25 mg/kg) pretreatment blocked the <ENT1>caffeine</ENT1>- but not pentylenetetrazole-induced <ENT2>anxiety</ENT2>.,,,,T,,,,,w,,,,,0.0,,
15991002,525,D002110,D001008,Positive_Correlation,FALSE,"CONCLUSIONS: Our results suggest that the antagonistic effect of nicotine on <ENT1>caffeine</ENT1>-induced <ENT2>anxiety</ENT2> is specific to <ENT1>caffeine</ENT1>, instead of a non-specific anxiolytic effect.",,,,T,,,,,c,,,,,1.0,,
15991002,524,D010433,D001008,Positive_Correlation,FALSE,Nicotine antagonizes caffeine- but not <ENT1>pentylenetetrazole</ENT1>-induced <ENT2>anxiogenic effect</ENT2> in mice.,,,,T,,,,,c,,,,,1.0,,
15991002,524,D010433,D001008,Positive_Correlation,FALSE,"OBJECTIVES: The present study investigates the effects of nicotine on <ENT2>anxiety</ENT2> induced by caffeine and another anxiogenic drug, <ENT1>pentylenetetrazole</ENT1>, in mice.",,,,T,,,,,c,,,,,1.0,,
15991002,524,D010433,D001008,Positive_Correlation,FALSE,"RESULTS: Nicotine (0.05-0.25 mg/kg) itself did not produce any significant effect in the EPM test, whereas caffeine (70 mg/kg) and <ENT1>pentylenetetrazole</ENT1> (30 mg/kg) produced an <ENT2>anxiogenic effect</ENT2>, apparent with decreases in open-arm time and entry.",,,,T,,,,,c,,,,,1.0,,
15991002,524,D010433,D001008,Positive_Correlation,FALSE,Nicotine (0.25 mg/kg) pretreatment blocked the caffeine- but not <ENT1>pentylenetetrazole</ENT1>-induced <ENT2>anxiety</ENT2>.,,,,T,,,,,c,,,,,1.0,,
15991002,526,D009538,D001008,Negative_Correlation,TRUE,<ENT1>Nicotine</ENT1> antagonizes caffeine- but not pentylenetetrazole-induced <ENT2>anxiogenic effect</ENT2> in mice.,,,,T,,,,,w,,,,,0.0,,
15991002,526,D009538,D001008,Negative_Correlation,TRUE,"OBJECTIVES: The present study investigates the effects of <ENT1>nicotine</ENT1> on <ENT2>anxiety</ENT2> induced by caffeine and another anxiogenic drug, pentylenetetrazole, in mice.",,,,T,,Y,,,w,,,,,0.0,,
15991002,526,D009538,D001008,Negative_Correlation,TRUE,"RESULTS: <ENT1>Nicotine</ENT1> (0.05-0.25 mg/kg) itself did not produce any significant effect in the EPM test, whereas caffeine (70 mg/kg) and pentylenetetrazole (30 mg/kg) produced an <ENT2>anxiogenic effect</ENT2>, apparent with decreases in open-arm time and entry.",,,,T,,,,,c,,,,,1.0,,
15991002,526,D009538,D001008,Negative_Correlation,TRUE,<ENT1>Nicotine</ENT1> (0.25 mg/kg) pretreatment blocked the caffeine- but not pentylenetetrazole-induced <ENT2>anxiety</ENT2>.,,,,T,,,,,w,,,,,0.0,,
15991002,526,D009538,D001008,Negative_Correlation,TRUE,"CONCLUSIONS: Our results suggest that the antagonistic effect of <ENT1>nicotine</ENT1> on caffeine-induced <ENT2>anxiety</ENT2> is specific to caffeine, instead of a non-specific anxiolytic effect.",,,,T,,,,,c,,,,,1.0,,
16000134,531,D020152,C031942,Negative_Correlation,TRUE,Successful therapy with <ENT2>argatroban</ENT2> for superior mesenteric vein thrombosis in a patient with <ENT1>congenital antithrombin deficiency</ENT1>.,,,,T,Y,,,,w,,,,,0.0,,
16000134,531,D020152,C031942,Negative_Correlation,TRUE,<ENT2>Argatroban</ENT2> administration would be effective in the treatment of <ENT1>congenital antithrombin deficiency</ENT1> with SMV thrombosis.,,,,T,,,,,c,,,,,1.0,,
16000134,534,D025861,462,Association,FALSE,Family studies of <ENT2>antithrombin</ENT2> activity revealed that she had <ENT1>type I congenital antithrombin deficiency</ENT1>.,,,,T,,,,,c,,,,,0.0,,
16000134,530,D020246,C031942,Negative_Correlation,TRUE,Successful therapy with <ENT2>argatroban</ENT2> for superior mesenteric <ENT1>vein thrombosis</ENT1> in a patient with congenital antithrombin deficiency.,,,,T,,,,,c,,,,,1.0,,
16000134,530,D020246,C031942,Negative_Correlation,TRUE,<ENT2>Argatroban</ENT2> administration would be effective in the treatment of congenital antithrombin deficiency with <ENT1>SMV thrombosis</ENT1>.,,,,T,,,,,w,,,,,0.0,,
16000134,528,2147,C031942,Negative_Correlation,FALSE,"However, successful anticoagulation was achieved by administration of direct <ENT1>thrombin</ENT1> inhibitor, <ENT2>argatroban</ENT2>.",,,,T,,,,,w,,,,,0.0,,
16005363,536,7466,D014929,Association,TRUE,Identification of a novel <ENT1>WFS1</ENT1> mutation (AFF344-345ins) in Japanese patients with <ENT2>Wolfram syndrome</ENT2>.,,,,T,,,,,w,,,,,0.0,,
16005363,536,7466,D014929,Association,TRUE,<ENT1>WFS1</ENT1> encoding a transmembrane protein was identified as the gene responsible for <ENT2>WFS</ENT2>.,,,,T,,,,,c,,,,,1.0,,
16005363,537,p|INS|344_345|AFF,D014929,Positive_Correlation,TRUE,Identification of a novel WFS1 mutation (<ENT1>AFF344-345ins</ENT1>) in Japanese patients with <ENT2>Wolfram syndrome</ENT2>.,,,,T,,,,,c,,,,,0.0,,
16018252,539,6736,OMIM:400044,Association,TRUE,Two novel mutations in <ENT1>SRY</ENT1> gene form Chinese <ENT2>sex reversal XY</ENT2> females.,,,,T,,,,,c,,,,,1.0,,
16018252,539,6736,OMIM:400044,Association,TRUE,Deletion and inactivating mutations of <ENT1>SRY</ENT1> are among the known causes of <ENT2>XY sex reversal</ENT2>.,,,,T,,,,,c,,,,,0.0,,
16018252,539,6736,OMIM:400044,Association,TRUE,"Here, we described the screening of 10 patients who presented with <ENT2>46,XY sex reversal</ENT2> for mutations in open reading frame (ORF) of <ENT1>SRY</ENT1> gene.",,,,T,,Y,,,w,,,,,0.0,,
16018252,539,6736,OMIM:400044,Association,TRUE,"The two novel mutations in <ENT1>SRY</ENT1> gene provided valuable information for understanding the molecular mechanism of the patient with <ENT2>46,XY female sex reversal</ENT2>.",,,,T,,,,,c,,,,,1.0,,
16046395,543,D010146,4988,Association,FALSE,"As a primary target for opioid drugs and peptides, the <ENT2>mu opioid receptor</ENT2> (<ENT2>OPRM1</ENT2>) plays a key role in <ENT1>pain</ENT1> perception and addiction.",,,,T,,,,,c,,,,,1.0,,
16046395,545,rs1799971,D019966,Association,TRUE,"Genetic variants of OPRM1 have been implicated in predisposition to <ENT2>drug addiction</ENT2>, in particular the single nucleotide polymorphism <ENT1>A118G</ENT1>, leading to an <ENT1>N40D</ENT1> substitution, with an allele frequency of 10-32%, and uncertain functions.",,,,T,,,,,w,,,,,0.0,,
16046395,544,D019966,4988,Association,FALSE,"Genetic variants of <ENT2>OPRM1</ENT2> have been implicated in predisposition to <ENT1>drug addiction</ENT1>, in particular the single nucleotide polymorphism A118G, leading to an N40D substitution, with an allele frequency of 10-32%, and uncertain functions.",,,,T,,,,,c,,,,,1.0,,
16051693,549,10400,D010713,Positive_Correlation,FALSE,<ENT1>Phosphatidylethanolamine N-methyltransferase</ENT1> (<ENT1>PEMT</ENT1>) catalyzes <ENT2>phosphatidylcholine</ENT2> synthesis.,,,,T,,,,,c,,,,,0.0,,
16051693,550,10400,D065626,Association,TRUE,Polymorphism of the <ENT1>PEMT</ENT1> gene and susceptibility to <ENT2>nonalcoholic fatty liver disease</ENT2> (<ENT2>NAFLD</ENT2>).,,,,T,,,,,c,,,,,0.0,,
16051693,550,10400,D065626,Association,TRUE,"PEMT knockout mice have fatty livers, and it is possible that, in humans, <ENT2>nonalcoholic fatty liver disease</ENT2> (<ENT2>NAFLD</ENT2>) might be associated with <ENT1>PEMT</ENT1> gene polymorphisms.",,,,T,,,,,c,,,,,1.0,,
16051693,550,10400,D065626,Association,TRUE,"DNA samples from 59 humans without fatty liver and from 28 humans with <ENT2>NAFLD</ENT2> were genotyped for a single nucleotide polymorphism in exon 8 of <ENT1>PEMT</ENT1>, which leads to a V175M substitution.",,,,T,,Y,,,c,,,,,1.0,,
16051693,550,10400,D065626,Association,TRUE,For the first time we report that a polymorphism of the human <ENT1>PEMT</ENT1> gene (V175M) is associated with diminished activity and may confer susceptibility to <ENT2>NAFLD</ENT2>.,,,,T,,,,,c,,,,,1.0,,
16051693,548,rs7946,D065626,Positive_Correlation,TRUE,"DNA samples from 59 humans without fatty liver and from 28 humans with <ENT2>NAFLD</ENT2> were genotyped for a single nucleotide polymorphism in exon 8 of PEMT, which leads to a <ENT1>V175M</ENT1> substitution.",,,,T,,Y,,,c,,,,,1.0,,
16051693,548,rs7946,D065626,Positive_Correlation,TRUE,<ENT1>Met/Met at residue 175</ENT1> (loss of function SNP) occurred in 67.9% of the <ENT2>NAFLD</ENT2> subjects and in only 40.7% of control subjects (P<0.03).,,,,T,,,,,c,,,,,0.0,,
16051693,548,rs7946,D065626,Positive_Correlation,TRUE,For the first time we report that a polymorphism of the human PEMT gene (<ENT1>V175M</ENT1>) is associated with diminished activity and may confer susceptibility to <ENT2>NAFLD</ENT2>.,,,,T,,,,,c,,,,,1.0,,
16051693,546,18618,D005234,Negative_Correlation,FALSE,"<ENT1>PEMT</ENT1> knockout mice have <ENT2>fatty livers</ENT2>, and it is possible that, in humans, nonalcoholic fatty liver disease (NAFLD) might be associated with PEMT gene polymorphisms.",,,,T,,,,,c,,,,,0.0,,
16112787,560,D001284,D014640,Positive_Correlation,TRUE,"There were a significant dilatation of tubular lumens, extensive epithelial cell vacuolization, <ENT1>atrophy</ENT1>, desquamation, and necrosis in <ENT2>VCM</ENT2>-treated rats more than those of the control and the erdosteine groups.",,,,T,,,,,c,,,,,1.0,,
16112787,564,D008315,D014640,Positive_Correlation,TRUE,"<ENT2>VCM</ENT2> administration to control rats significantly increased renal <ENT1>malondialdehyde</ENT1> (<ENT1>MDA</ENT1>) and urinary N-acetyl-beta-d-glucosaminidase (NAG, a marker of renal tubular injury) excretion but decreased superoxide dismutase (SOD) and catalase (CAT) activities.",,,,T,,,,,c,,,,,1.0,,
16112787,564,D008315,D014640,Positive_Correlation,TRUE,"Erdosteine administration with <ENT2>VCM</ENT2> injections caused significantly decreased renal <ENT1>MDA</ENT1> and urinary NAG excretion, and increased SOD activity, but not CAT activity in renal tissue when compared with <ENT2>VCM</ENT2> alone.",,,,T,,,,,c,,,,,1.0,,
16112787,556,D008315,C048498,Negative_Correlation,TRUE,"<ENT2>Erdosteine</ENT2> administration with VCM injections caused significantly decreased renal <ENT1>MDA</ENT1> and urinary NAG excretion, and increased SOD activity, but not CAT activity in renal tissue when compared with VCM alone.",,,,T,,,,,c,,,,,1.0,,
16112787,557,D017382,D014640,Association,FALSE,"The aims of this study were to examine <ENT2>vancomycin</ENT2> (<ENT2>VCM</ENT2>)-induced oxidative stress that promotes production of <ENT1>reactive oxygen species</ENT1> (<ENT1>ROS</ENT1>) and to investigate the role of erdosteine, an expectorant agent, which has also antioxidant properties, on kidney tissue against the possible <ENT2>VCM</ENT2>-induced renal impairment in rats.",,,,T,,,,,c,,,"11,12,21,22",,0.0,,
16112787,565,D014640,C048498,Negative_Correlation,TRUE,In vivo evidences suggesting the role of oxidative stress in pathogenesis of <ENT1>vancomycin</ENT1>-induced nephrotoxicity: protection by <ENT2>erdosteine</ENT2>.,,,,T,,,,,c,,,,,1.0,,
16112787,565,D014640,C048498,Negative_Correlation,TRUE,"The aims of this study were to examine <ENT1>vancomycin</ENT1> (<ENT1>VCM</ENT1>)-induced oxidative stress that promotes production of reactive oxygen species (ROS) and to investigate the role of <ENT2>erdosteine</ENT2>, an expectorant agent, which has also antioxidant properties, on kidney tissue against the possible <ENT1>VCM</ENT1>-induced renal impairment in rats.",,,,T,,Y,,,c,,,,,1.0,,
16112787,565,D014640,C048498,Negative_Correlation,TRUE,"Rats were divided into three groups: sham, <ENT1>VCM</ENT1> and <ENT1>VCM</ENT1> plus <ENT2>erdosteine</ENT2>.",,,,T,,,,,c,,,,,1.0,,
16112787,565,D014640,C048498,Negative_Correlation,TRUE,"<ENT2>Erdosteine</ENT2> administration with <ENT1>VCM</ENT1> injections caused significantly decreased renal MDA and urinary NAG excretion, and increased SOD activity, but not CAT activity in renal tissue when compared with <ENT1>VCM</ENT1> alone.",,,,T,,,,,c,,,,,1.0,,
16112787,565,D014640,C048498,Negative_Correlation,TRUE,<ENT2>Erdosteine</ENT2> showed histopathological protection against <ENT1>VCM</ENT1>-induced nephrotoxicity.,,,,T,Y,,,,w,,,,,0.0,,
16112787,565,D014640,C048498,Negative_Correlation,TRUE,"There were a significant dilatation of tubular lumens, extensive epithelial cell vacuolization, atrophy, desquamation, and necrosis in <ENT1>VCM</ENT1>-treated rats more than those of the control and the <ENT2>erdosteine</ENT2> groups.",,,,T,,,,,c,,,,,1.0,,
16112787,565,D014640,C048498,Negative_Correlation,TRUE,It is concluded that oxidative tubular damage plays an important role in the <ENT1>VCM</ENT1>-induced nephrotoxicity and the modulation of oxidative stress with <ENT2>erdosteine</ENT2> reduces the <ENT1>VCM</ENT1>-induced kidney damage both at the biochemical and histological levels.,,,,T,Y,,,,c,,,,,0.0,,
16112787,562,D014640,D013482,Negative_Correlation,TRUE,"<ENT1>VCM</ENT1> administration to control rats significantly increased renal malondialdehyde (MDA) and urinary N-acetyl-beta-d-glucosaminidase (NAG, a marker of renal tubular injury) excretion but decreased <ENT2>superoxide dismutase</ENT2> (<ENT2>SOD</ENT2>) and catalase (CAT) activities.",,,,T,,,,,c,,,,,1.0,,
16112787,562,D014640,D013482,Negative_Correlation,TRUE,"Erdosteine administration with <ENT1>VCM</ENT1> injections caused significantly decreased renal MDA and urinary NAG excretion, and increased <ENT2>SOD</ENT2> activity, but not CAT activity in renal tissue when compared with <ENT1>VCM</ENT1> alone.",,,,T,,,,,c,,,,,1.0,,
16112787,552,D014640,24248,Negative_Correlation,TRUE,"<ENT1>VCM</ENT1> administration to control rats significantly increased renal malondialdehyde (MDA) and urinary N-acetyl-beta-d-glucosaminidase (NAG, a marker of renal tubular injury) excretion but decreased superoxide dismutase (SOD) and <ENT2>catalase</ENT2> (<ENT2>CAT</ENT2>) activities.",,,,T,,,,,c,,,,,1.0,,
16112787,552,D014640,24248,Negative_Correlation,TRUE,"Erdosteine administration with <ENT1>VCM</ENT1> injections caused significantly decreased renal MDA and urinary NAG excretion, and increased SOD activity, but not <ENT2>CAT</ENT2> activity in renal tissue when compared with <ENT1>VCM</ENT1> alone.",,,,T,,,,,c,,,,,1.0,,
16112787,558,D014640,D009336,Positive_Correlation,TRUE,"There were a significant dilatation of tubular lumens, extensive epithelial cell vacuolization, atrophy, desquamation, and <ENT2>necrosis</ENT2> in <ENT1>VCM</ENT1>-treated rats more than those of the control and the erdosteine groups.",,,,T,,,,,c,,,,,0.0,,
16112787,559,D014640,D012871,Positive_Correlation,TRUE,"There were a significant dilatation of tubular lumens, extensive epithelial cell vacuolization, atrophy, <ENT2>desquamation</ENT2>, and necrosis in <ENT1>VCM</ENT1>-treated rats more than those of the control and the erdosteine groups.",,,,T,,,,,c,,,,,1.0,,
16112787,563,D014640,154968,Positive_Correlation,TRUE,"<ENT1>VCM</ENT1> administration to control rats significantly increased renal malondialdehyde (MDA) and urinary <ENT2>N-acetyl-beta-d-glucosaminidase</ENT2> (<ENT2>NAG</ENT2>, a marker of renal tubular injury) excretion but decreased superoxide dismutase (SOD) and catalase (CAT) activities.",,,,T,,,,,c,,,,,1.0,,
16112787,563,D014640,154968,Positive_Correlation,TRUE,"Erdosteine administration with <ENT1>VCM</ENT1> injections caused significantly decreased renal MDA and urinary <ENT2>NAG</ENT2> excretion, and increased SOD activity, but not CAT activity in renal tissue when compared with <ENT1>VCM</ENT1> alone.",,,,T,,,,,c,,,,,1.0,,
16112787,561,D014640,D007674,Positive_Correlation,FALSE,In vivo evidences suggesting the role of oxidative stress in pathogenesis of <ENT1>vancomycin</ENT1>-induced <ENT2>nephrotoxicity</ENT2>: protection by erdosteine.,,,,T,,,,,c,,,,,1.0,,
16112787,561,D014640,D007674,Positive_Correlation,FALSE,"The aims of this study were to examine <ENT1>vancomycin</ENT1> (<ENT1>VCM</ENT1>)-induced oxidative stress that promotes production of reactive oxygen species (ROS) and to investigate the role of erdosteine, an expectorant agent, which has also antioxidant properties, on kidney tissue against the possible <ENT1>VCM</ENT1>-induced <ENT2>renal impairment</ENT2> in rats.",,,,T,,,,,c,,,,,0.0,,
16112787,561,D014640,D007674,Positive_Correlation,FALSE,"<ENT1>VCM</ENT1> administration to control rats significantly increased renal malondialdehyde (MDA) and urinary N-acetyl-beta-d-glucosaminidase (NAG, a marker of <ENT2>renal tubular injury</ENT2>) excretion but decreased superoxide dismutase (SOD) and catalase (CAT) activities.",,,,T,,,,,w,,,,,0.0,,
16112787,561,D014640,D007674,Positive_Correlation,FALSE,Erdosteine showed histopathological protection against <ENT1>VCM</ENT1>-induced <ENT2>nephrotoxicity</ENT2>.,,,,T,,,,,c,,,,,1.0,,
16112787,561,D014640,D007674,Positive_Correlation,FALSE,It is concluded that oxidative tubular damage plays an important role in the <ENT1>VCM</ENT1>-induced <ENT2>nephrotoxicity</ENT2> and the modulation of oxidative stress with erdosteine reduces the <ENT1>VCM</ENT1>-induced <ENT2>kidney damage</ENT2> both at the biochemical and histological levels.,,,,T,,,,,c,,,"11,22",,0.75,,
16112787,551,C048498,D013482,Positive_Correlation,TRUE,"<ENT1>Erdosteine</ENT1> administration with VCM injections caused significantly decreased renal MDA and urinary NAG excretion, and increased <ENT2>SOD</ENT2> activity, but not CAT activity in renal tissue when compared with VCM alone.",,,,T,,,,,c,,,,,1.0,,
16112787,555,C048498,154968,Negative_Correlation,TRUE,"<ENT1>Erdosteine</ENT1> administration with VCM injections caused significantly decreased renal MDA and urinary <ENT2>NAG</ENT2> excretion, and increased SOD activity, but not CAT activity in renal tissue when compared with VCM alone.",,,,T,,,,,c,,,,,0.0,,
16112787,554,C048498,D007674,Negative_Correlation,TRUE,In vivo evidences suggesting the role of oxidative stress in pathogenesis of vancomycin-induced <ENT2>nephrotoxicity</ENT2>: protection by <ENT1>erdosteine</ENT1>.,,,,T,,T,,,w,,,,,1.0,,
16112787,554,C048498,D007674,Negative_Correlation,TRUE,"The aims of this study were to examine vancomycin (VCM)-induced oxidative stress that promotes production of reactive oxygen species (ROS) and to investigate the role of <ENT1>erdosteine</ENT1>, an expectorant agent, which has also antioxidant properties, on kidney tissue against the possible VCM-induced <ENT2>renal impairment</ENT2> in rats.",,,,T,,Y,,,w,,,,,1.0,,
16112787,554,C048498,D007674,Negative_Correlation,TRUE,<ENT1>Erdosteine</ENT1> showed histopathological protection against VCM-induced <ENT2>nephrotoxicity</ENT2>.,,,,T,,,,,c,,,,,1.0,,
16112787,554,C048498,D007674,Negative_Correlation,TRUE,It is concluded that oxidative tubular damage plays an important role in the VCM-induced <ENT2>nephrotoxicity</ENT2> and the modulation of oxidative stress with <ENT1>erdosteine</ENT1> reduces the VCM-induced <ENT2>kidney damage</ENT2> both at the biochemical and histological levels.,,,,T,,,,,c,,,,,0.0,,
16112787,553,154968,D007674,Association,FALSE,"VCM administration to control rats significantly increased renal malondialdehyde (MDA) and urinary <ENT1>N-acetyl-beta-d-glucosaminidase</ENT1> (<ENT1>NAG</ENT1>, a marker of <ENT2>renal tubular injury</ENT2>) excretion but decreased superoxide dismutase (SOD) and catalase (CAT) activities.",,,,T,,,,,c,,,,,0.5,,
16116131,566,D004409,D001058,Positive_Correlation,TRUE,"Using repetitive transcranial magnetic stimulation (rTMS) over the supplementary motor area (SMA) in a group of patients with advanced Parkinson disease, the authors investigated whether modulation of SMA excitability may result in a modification of a <ENT1>dyskinetic</ENT1> state induced by continuous <ENT2>apomorphine</ENT2> infusion.",,,,T,,,,,c,,,,,1.0,,
16116131,567,D004409,D007980,Positive_Correlation,FALSE,The neural mechanisms and circuitry involved in <ENT2>levodopa</ENT2>-induced <ENT1>dyskinesia</ENT1> are unclear.,,,,T,,,,,c,,,,,1.0,,
16120104,568,C565789,c|Allele|G|111,Positive_Correlation,TRUE,The PER2 <ENT2>111G</ENT2> allele associates with morning preference and is a potential candidate allele for <ENT1>ASPS</ENT1>.,,,,T,,,,,c,,,,,0.0,,
16120104,569,C565789,8864,Association,TRUE,A missense mutation in the human <ENT2>PER2</ENT2> gene has previously been linked to <ENT1>advanced sleep phase syndrome</ENT1> (<ENT1>ASPS</ENT1>).,,,,T,,,,,c,,,,,1.0,,
16120104,569,C565789,8864,Association,TRUE,The <ENT2>PER2</ENT2> 111G allele associates with morning preference and is a potential candidate allele for <ENT1>ASPS</ENT1>.,,,,T,,,,,w,,,,,1.0,,
16152606,571,p|SUB|R|215|W,D054198,Association,FALSE,"In addition, the substitution 643C>T (<ENT1>R215W</ENT1>) has also been found in excess among children with <ENT2>acute lymphoblastic leukemia</ENT2> (<ENT2>ALL</ENT2>).",,,,T,,,,,c,,,,,1.0,,
16152606,577,4683,D008223,Association,FALSE,Carrier frequency of mutation 657del5 in the <ENT1>NBS1</ENT1> gene in a population of Polish pediatric patients with <ENT2>sporadic lymphoid malignancies</ENT2>.,,,,T,,T,,,c,,,,,1.0,,
16152606,577,4683,D008223,Association,FALSE,"Recently, significantly higher frequencies of heterozygous carriers of the Slavic founder <ENT1>NBS1</ENT1> mutation, 657del5, were found in Russian children with <ENT2>sporadic lymphoid malignancies</ENT2>, and in Polish adults with non-Hodgkin lymphoma (NHL).",,,,T,,,,,w,,,,,0.0,,
16152606,577,4683,D008223,Association,FALSE,"Nonetheless, <ENT1>NBS1</ENT1> gene heterozygosity is not a major risk factor for <ENT2>lymphoid malignancies</ENT2> in childhood and adolescence.",,,,T,,,,,c,,,,,0.0,,
16152606,576,4683,D054198,Association,FALSE,The <ENT1>NBS1</ENT1> mutation 657del5 on one allele was found in 3 of 270 patients with <ENT2>ALL</ENT2> and 2 of 212 children and adolescents with NHL; no carrier was found among 63 patients with Hodgkin lymphoma (HL).,,,,T,Y,,,,w,,,,,1.0,,
16152606,575,4683,D008228,Association,FALSE,"Recently, significantly higher frequencies of heterozygous carriers of the Slavic founder <ENT1>NBS1</ENT1> mutation, 657del5, were found in Russian children with sporadic lymphoid malignancies, and in Polish adults with <ENT2>non-Hodgkin lymphoma</ENT2> (<ENT2>NHL</ENT2>).",,,,T,,,,,w,,,,,1.0,,
16152606,575,4683,D008228,Association,FALSE,The <ENT1>NBS1</ENT1> mutation 657del5 on one allele was found in 3 of 270 patients with ALL and 2 of 212 children and adolescents with <ENT2>NHL</ENT2>; no carrier was found among 63 patients with Hodgkin lymphoma (HL).,,,,T,,,,,w,,,,,0.0,,
16152606,579,D008223,c|DEL|657|5,Association,TRUE,Carrier frequency of mutation <ENT2>657del5</ENT2> in the NBS1 gene in a population of Polish pediatric patients with <ENT1>sporadic lymphoid malignancies</ENT1>.,,,,T,,T,,,c,,,,,0.0,,
16152606,579,D008223,c|DEL|657|5,Association,TRUE,"Recently, significantly higher frequencies of heterozygous carriers of the Slavic founder NBS1 mutation, <ENT2>657del5</ENT2>, were found in Russian children with <ENT1>sporadic lymphoid malignancies</ENT1>, and in Polish adults with non-Hodgkin lymphoma (NHL).",,,,T,,,,,c,,,,,1.0,,
16152606,573,D054198,c|DEL|657|5,Association,TRUE,The NBS1 mutation <ENT2>657del5</ENT2> on one allele was found in 3 of 270 patients with <ENT1>ALL</ENT1> and 2 of 212 children and adolescents with NHL; no carrier was found among 63 patients with Hodgkin lymphoma (HL).,,,,T,,,,,c,,,,,1.0,,
16152606,572,D054198,c|SUB|C|643|T,Association,FALSE,"In addition, the substitution <ENT2>643C>T</ENT2> (R215W) has also been found in excess among children with <ENT1>acute lymphoblastic leukemia</ENT1> (<ENT1>ALL</ENT1>).",,,,T,,,,,c,,,,,1.0,,
16152606,578,c|DEL|657|5,D008228,Association,FALSE,"Recently, significantly higher frequencies of heterozygous carriers of the Slavic founder NBS1 mutation, <ENT1>657del5</ENT1>, were found in Russian children with sporadic lymphoid malignancies, and in Polish adults with <ENT2>non-Hodgkin lymphoma</ENT2> (<ENT2>NHL</ENT2>).",,,,T,,,,,c,,,,,1.0,,
16152606,578,c|DEL|657|5,D008228,Association,FALSE,The NBS1 mutation <ENT1>657del5</ENT1> on one allele was found in 3 of 270 patients with ALL and 2 of 212 children and adolescents with <ENT2>NHL</ENT2>; no carrier was found among 63 patients with Hodgkin lymphoma (HL).,,,,T,,,,,c,,,,,1.0,,
16152606,570,c|DEL|657|5,D009369,Association,TRUE,"In the analyzed population with <ENT2>malignancies</ENT2>, an increased odds ratio for the occurrence of mutation <ENT1>657del5</ENT1> was found in comparison with the control Polish population (OR range 1.48-1.85, 95% confidence interval 1.18-2.65).",,,,T,,,,,c,,,,,0.0,,
16157158,581,D016574,3358,Association,FALSE,A Cys 23-Ser 23 substitution in the <ENT2>5-HT(2C) receptor</ENT2> gene influences body weight regulation in females with <ENT1>seasonal affective disorder</ENT1>: an Austrian-Canadian collaborative study.,,,,T,,,,,w,,,,,0.0,,
16157158,580,D016574,rs6318,Association,TRUE,A <ENT2>Cys 23-Ser 23</ENT2> substitution in the 5-HT(2C) receptor gene influences body weight regulation in females with <ENT1>seasonal affective disorder</ENT1>: an Austrian-Canadian collaborative study.,,,,T,,,,,c,,,,,0.0,,
16157158,580,D016574,rs6318,Association,TRUE,We hypothesized that <ENT2>Cys 23 Ser</ENT2> influences weight regulation in females with <ENT1>SAD</ENT1>.,,,,T,,,,,c,,,,,0.0,,
16157158,580,D016574,rs6318,Association,TRUE,"Two independent samples from Austria (162 females with <ENT1>SAD</ENT1>, 119 controls), and Canada (90 females with <ENT1>SAD</ENT1>, 42 controls) were genotyped for <ENT2>Cys 23 Ser</ENT2>.",,,,T,,Y,,,c,,,,,1.0,,
16157158,580,D016574,rs6318,Association,TRUE,"Our data provide evidence that <ENT2>Cys 23 Ser</ENT2> mediates severity of weight regulation disturbances in females with <ENT1>SAD</ENT1>, and the gene-dose effect-like differences suggest a direct functional role of <ENT2>Cys 23 Ser</ENT2> in the behavioral regulation of body weight.",,,,T,,,,,c,,,,,0.5,,
16158428,584,D008607,4983,Association,FALSE,Recent reports have demonstrated that mutations in the <ENT2>OPHN1</ENT2> gene were responsible for a syndromic rather than non-specific <ENT1>mental retardation</ENT1>.,,,,T,,,,,w,,,,,1.0,,
16158428,582,4983,D038901,Association,TRUE,"We report here a new family with <ENT2>X-linked mental retardation</ENT2> due to mutation in <ENT1>OPHN1</ENT1> and present unpublished data about two families previously reported, concerning the facial and psychological phenotype of affected males and carrier females.",,,,T,,,,,c,,,,,1.0,,
16167916,586,D054556,D020849,Positive_Correlation,TRUE,"CONCLUSION: We suggest that the increased risk of <ENT1>venous thromboembolism</ENT1> due to <ENT2>raloxifene</ENT2> treatment may be related to increased tPA levels, but not TAFI levels.",,,,T,,,,,c,,,,,1.0,,
16167916,585,D054556,5327,Positive_Correlation,TRUE,"CONCLUSION: We suggest that the increased risk of <ENT1>venous thromboembolism</ENT1> due to raloxifene treatment may be related to increased <ENT2>tPA</ENT2> levels, but not TAFI levels.",,,,T,,,,,c,,,,,0.0,,
16167916,591,D020849,5054,Association,FALSE,"The effects of short-term <ENT1>raloxifene</ENT1> therapy on fibrinolysis markers: TAFI, tPA, and <ENT2>PAI-1</ENT2>.",,,,T,Y,T,,,c,,,,,0.0,,
16167916,591,D020849,5054,Association,FALSE,"BACKGROUND: Markers of fibrinolysis, thrombin-activatable fibrinolysis inhibitor (TAFI), tissue-type plasminogen activator (tPA), and <ENT2>plasminogen activator inhibitor-1</ENT2> (<ENT2>PAI-1</ENT2>) levels were studied for the evaluation of short-term effects of <ENT1>raloxifene</ENT1> administration in postmenopausal women.",,,,T,,Y,,,w,,,,,1.0,,
16167916,588,D020849,5327,Positive_Correlation,TRUE,"The effects of short-term <ENT1>raloxifene</ENT1> therapy on fibrinolysis markers: TAFI, <ENT2>tPA</ENT2>, and PAI-1.",,,,T,,,,,c,,,,,1.0,,
16167916,588,D020849,5327,Positive_Correlation,TRUE,"BACKGROUND: Markers of fibrinolysis, thrombin-activatable fibrinolysis inhibitor (TAFI), <ENT2>tissue-type plasminogen activator</ENT2> (<ENT2>tPA</ENT2>), and plasminogen activator inhibitor-1 (PAI-1) levels were studied for the evaluation of short-term effects of <ENT1>raloxifene</ENT1> administration in postmenopausal women.",,,,T,,,,,c,,,,,1.0,,
16167916,588,D020849,5327,Positive_Correlation,TRUE,"RESULTS: Three months of <ENT1>raloxifene</ENT1> treatment was associated with a significant decrease in the plasma TAFI antigen concentrations (16% change, P < 0.01), and a significant increase in <ENT2>tPA</ENT2> antigen concentrations (25% change, P < 0.05).",,,,T,,,,,c,,,,,0.0,,
16167916,588,D020849,5327,Positive_Correlation,TRUE,"CONCLUSION: We suggest that the increased risk of venous thromboembolism due to <ENT1>raloxifene</ENT1> treatment may be related to increased <ENT2>tPA</ENT2> levels, but not TAFI levels.",,,,T,,,,,w,,,,,1.0,,
16167916,589,D020849,1361,Negative_Correlation,TRUE,"The effects of short-term <ENT1>raloxifene</ENT1> therapy on fibrinolysis markers: <ENT2>TAFI</ENT2>, tPA, and PAI-1.",,,,T,,,,,c,,,,,1.0,,
16167916,589,D020849,1361,Negative_Correlation,TRUE,"BACKGROUND: Markers of fibrinolysis, <ENT2>thrombin-activatable fibrinolysis inhibitor</ENT2> (<ENT2>TAFI</ENT2>), tissue-type plasminogen activator (tPA), and plasminogen activator inhibitor-1 (PAI-1) levels were studied for the evaluation of short-term effects of <ENT1>raloxifene</ENT1> administration in postmenopausal women.",,,,T,,,,,c,,,,,1.0,,
16167916,589,D020849,1361,Negative_Correlation,TRUE,"RESULTS: Three months of <ENT1>raloxifene</ENT1> treatment was associated with a significant decrease in the plasma <ENT2>TAFI</ENT2> antigen concentrations (16% change, P < 0.01), and a significant increase in tPA antigen concentrations (25% change, P < 0.05).",,,,T,,,,,c,,,,,1.0,,
16167916,589,D020849,1361,Negative_Correlation,TRUE,"CONCLUSION: We suggest that the increased risk of venous thromboembolism due to <ENT1>raloxifene</ENT1> treatment may be related to increased tPA levels, but not <ENT2>TAFI</ENT2> levels.",,,,T,,,,,c,,,,,1.0,,
16181814,592,D002549,rs113994095,Association,TRUE,We studied the skin fibroblasts of a patient with <ENT1>Alpers syndrome</ENT1> having the genotype E873stop/<ENT2>A467T</ENT2>.,,,,T,,,,,c,,,,,0.0,,
16181814,593,D002549,rs121918047,Association,TRUE,We studied the skin fibroblasts of a patient with <ENT1>Alpers syndrome</ENT1> having the genotype <ENT2>E873stop</ENT2>/A467T.,,,,T,,,,,c,,,,,0.0,,
16181814,594,D002549,5428,Association,TRUE,Mono-allelic <ENT2>POLG</ENT2> expression resulting from nonsense-mediated decay and alternative splicing in a patient with <ENT1>Alpers syndrome</ENT1>.,,,,T,,,,,c,,,,,1.0,,
16181814,594,D002549,5428,Association,TRUE,"Most patients with <ENT1>Alpers syndrome</ENT1> have been found to be compound heterozygotes, carrying two pathogenic mutations in trans at the <ENT2>POLG</ENT2> locus.",,,,T,,,,,c,,,,,1.0,,
16186368,598,285440,C535440,Association,FALSE,Characterization of <ENT2>Bietti crystalline dystrophy</ENT2> patients with <ENT1>CYP4V2</ENT1> mutations.,,,,T,,T,,,w,,,,,0.0,,
16186368,598,285440,C535440,Association,FALSE,"PURPOSE: Mutations of the <ENT1>CYP4V2</ENT1> gene, a novel family member of the <ENT1>cytochrome P450</ENT1> genes on chromosome 4q35, have recently been identified in patients with <ENT2>Bietti crystalline dystrophy</ENT2> (<ENT2>BCD</ENT2>).",,,,T,,,,,c,,,,,1.0,,
16186368,598,285440,C535440,Association,FALSE,CONCLUSIONS: This study identified novel mutations in the <ENT1>CYP4V2</ENT1> gene as a cause of <ENT2>BCD</ENT2>.,,,,T,,,,,c,,,,,1.0,,
16200390,599,D008881,D012701,Positive_Correlation,FALSE,The brain neurotransmitter <ENT2>5-hydroxytryptamine</ENT2> (<ENT2>5-HT</ENT2>; <ENT2>serotonin</ENT2>) is involved in nociceptive pathways and has been implicated in the pathophysiology of <ENT1>migraine</ENT1>.,,,,T,,,,,c,,,,,0.0,,
16200390,599,D008881,D012701,Positive_Correlation,FALSE,"With few genetic studies investigating biosynthetic and metabolic enzymes governing the rate of <ENT2>5-HT</ENT2> activity and their relationship to <ENT1>migraine</ENT1>, it was the objective of this study to assess genetic variants within the human tryptophan hydroxylase (TPH), amino acid decarboxylase (AADC) and monoamine oxidase A (MAOA) genes in <ENT1>migraine</ENT1> susceptibility.",,,,T,,,,,w,,,,,0.0,TRUE,
16225977,608,D012559,D000077582,Negative_Correlation,FALSE,<ENT2>Amisulpride</ENT2> related tic-like symptoms in an adolescent <ENT1>schizophrenic</ENT1>.,,,,T,,,,,w,,,,,1.0,,
16225977,608,D012559,D000077582,Negative_Correlation,FALSE,We present a 15-year-old girl <ENT1>schizophrenic</ENT1> who developed frequent involuntary eye-blinking movements after 5 months of <ENT2>amisulpride</ENT2> treatment (1000 mg per day).,,,,T,,,,,w,,,,,1.0,,
16225977,606,D000069348,D000077582,Cotreatment,TRUE,"Together with previously reported cases, our patient suggests that tic-like symptoms might occur in certain vulnerable individuals during treatment with atypical antipsychotics such as <ENT1>quetiapine</ENT1>, clozapine, or <ENT2>amisulpride</ENT2>.",,,,T,,,,,c,,,,,1.0,,
16225977,605,D000077582,D020820,Positive_Correlation,FALSE,We present a 15-year-old girl schizophrenic who developed frequent <ENT2>involuntary eye-blinking movements</ENT2> after 5 months of <ENT1>amisulpride</ENT1> treatment (1000 mg per day).,,,,T,,,,,c,,,,,1.0,,
16225977,600,D013981,C092292,Negative_Correlation,FALSE,"<ENT1>Tic disorders</ENT1> can be effectively treated by atypical antipsychotics such as risperidone, olanzapine and <ENT2>ziprasidone</ENT2>.",,,,T,,,,,c,,,,,1.0,,
16225977,603,D013981,D014150,Negative_Correlation,TRUE,"<ENT1>Tic disorders</ENT1> can be effectively treated by atypical <ENT2>antipsychotics</ENT2> such as risperidone, olanzapine and ziprasidone.",,,,T,,,,,c,,,,,1.0,,
16225977,601,D013981,D000077152,Negative_Correlation,FALSE,"<ENT1>Tic disorders</ENT1> can be effectively treated by atypical antipsychotics such as risperidone, <ENT2>olanzapine</ENT2> and ziprasidone.",,,,T,,,,,c,,,,,1.0,,
16225977,602,D013981,D018967,Negative_Correlation,FALSE,"<ENT1>Tic disorders</ENT1> can be effectively treated by atypical antipsychotics such as <ENT2>risperidone</ENT2>, olanzapine and ziprasidone.",,,,T,,,,,c,,,,,0.0,,
16252083,613,4436,D001943,Association,TRUE,Polymorphisms of the DNA <ENT1>mismatch repair</ENT1> gene <ENT1>HMSH2</ENT1> in <ENT2>breast cancer</ENT2> occurence and progression.,,,,T,,T,,,c,,,,,0.5,,
16252083,613,4436,D001943,Association,TRUE,"The importance of genetic variability of the components of <ENT1>mismatch repair</ENT1> (<ENT1>MMR</ENT1>) genes is well documented in colorectal cancer, but little is known about its role in <ENT2>breast cancer</ENT2>.",,,,T,,Y,,,w,,,,,1.0,,
16252083,613,4436,D001943,Association,TRUE,We performed a case-control study to test the association between two polymorphisms in the <ENT1>hMSH2</ENT1> gene: an A --> G transition at 127 position producing an Asn --> Ser substitution at codon 127 (the Asn127Ser polymorphism) and a G --> A transition at 1032 position resulting in a Gly --> Asp change at codon 322 (the Gly322Asp polymorphism) and <ENT2>breast cancer</ENT2> risk and cancer progression.,,,,T,,Y,,,w,,,,,0.0,,
16252083,613,4436,D001943,Association,TRUE,"Therefore, <ENT1>MMR</ENT1> may play a role in the <ENT2>breast carcinogenesis</ENT2> and the Gly322Asp polymorphism of the <ENT1>hMSH2</ENT1> gene may be considered as a potential marker in <ENT2>breast cancer</ENT2>.",,,,T,,,,,c,,,"11,22",,1.0,,
16252083,612,4436,D015179,Association,FALSE,"The importance of genetic variability of the components of <ENT1>mismatch repair</ENT1> (<ENT1>MMR</ENT1>) genes is well documented in <ENT2>colorectal cancer</ENT2>, but little is known about its role in breast cancer.",,,,T,,,,,c,,,,,1.0,,
16252083,614,4436,D009369,Association,TRUE,We performed a case-control study to test the association between two polymorphisms in the <ENT1>hMSH2</ENT1> gene: an A --> G transition at 127 position producing an Asn --> Ser substitution at codon 127 (the Asn127Ser polymorphism) and a G --> A transition at 1032 position resulting in a Gly --> Asp change at codon 322 (the Gly322Asp polymorphism) and breast cancer risk and <ENT2>cancer</ENT2> progression.,,,,T,,Y,,,w,,,,,0.0,,
16252083,609,rs4987188,D001943,Association,TRUE,We performed a case-control study to test the association between two polymorphisms in the hMSH2 gene: an A --> G transition at 127 position producing an Asn --> Ser substitution at codon 127 (the Asn127Ser polymorphism) and a <ENT1>G --> A transition at 1032 position</ENT1> resulting in a <ENT1>Gly --> Asp change at codon 322</ENT1> (the <ENT1>Gly322Asp</ENT1> polymorphism) and <ENT2>breast cancer</ENT2> risk and cancer progression.,,,,T,,Y,,,c,,,,,1.0,,
16252083,609,rs4987188,D001943,Association,TRUE,A strong association between <ENT2>breast cancer</ENT2> occurrence and the Gly/Gly phenotype of the <ENT1>Gly322Asp</ENT1> polymorphism (odds ratio 8.39; 95% confidence interval 1.44-48.8) was found.,,,,T,,,,,c,,,,,0.0,,
16252083,609,rs4987188,D001943,Association,TRUE,"Therefore, MMR may play a role in the <ENT2>breast carcinogenesis</ENT2> and the <ENT1>Gly322Asp</ENT1> polymorphism of the hMSH2 gene may be considered as a potential marker in <ENT2>breast cancer</ENT2>.",,,,T,,,,,c,,,,,0.0,,
16252083,610,D001943,rs17217772,Association,TRUE,We performed a case-control study to test the association between two polymorphisms in the hMSH2 gene: an <ENT2>A --> G transition at 127 position</ENT2> producing an <ENT2>Asn --> Ser substitution at codon 127</ENT2> (the <ENT2>Asn127Ser</ENT2> polymorphism) and a G --> A transition at 1032 position resulting in a Gly --> Asp change at codon 322 (the Gly322Asp polymorphism) and <ENT1>breast cancer</ENT1> risk and cancer progression.,,,,T,,Y,,,w,,,,,1.0,,
16252083,611,rs17217772,D009369,Association,TRUE,We performed a case-control study to test the association between two polymorphisms in the hMSH2 gene: an <ENT1>A --> G transition at 127 position</ENT1> producing an <ENT1>Asn --> Ser substitution at codon 127</ENT1> (the <ENT1>Asn127Ser</ENT1> polymorphism) and a G --> A transition at 1032 position resulting in a Gly --> Asp change at codon 322 (the Gly322Asp polymorphism) and breast cancer risk and <ENT2>cancer</ENT2> progression.,,,,T,,Y,,,w,,,,,1.0,,
16277682,617,D005357,rs771966860,Association,FALSE,"Of the five clinically ascertained affected members of the family, four possessed the <ENT2>M404V</ENT2> mutation and exhibited the polyostotic form of PDB, except one patient with a single X-ray-assessed skeletal localization and one with a <ENT1>polyostotic disease</ENT1> who had died several years before the DNA analysis.",,,,T,,,,,w,,,,,0.0,,
16277682,618,C538098,rs771966860,Positive_Correlation,TRUE,Segregation of a <ENT2>M404V</ENT2> mutation of the p62/sequestosome 1 (p62/SQSTM1) gene with polyostotic <ENT1>Paget's disease of bone</ENT1> in an Italian family.,,,,T,,T,,,w,,,,,0.0,,
16277682,618,C538098,rs771966860,Positive_Correlation,TRUE,"We originally described a <ENT2>methionine-->valine substitution at codon 404</ENT2> (<ENT2>M404V</ENT2>) of exon 8, in the ubiquitin protein-binding domain of p62/SQSTM1 gene in an Italian <ENT1>PDB</ENT1> patient.",,,,T,,,,,w,,,,,0.5,TRUE,
16277682,618,C538098,rs771966860,Positive_Correlation,TRUE,Extension of the genetic analysis to other relatives in this family demonstrated segregation of the <ENT2>M404V</ENT2> mutation with the polyostotic <ENT1>PDB</ENT1> phenotype and provided the identification of six asymptomatic gene carriers.,,,,T,,,,,w,,,,,0.0,,
16277682,618,C538098,rs771966860,Positive_Correlation,TRUE,"Of the five clinically ascertained affected members of the family, four possessed the <ENT2>M404V</ENT2> mutation and exhibited the polyostotic form of <ENT1>PDB</ENT1>, except one patient with a single X-ray-assessed skeletal localization and one with a polyostotic disease who had died several years before the DNA analysis.",,,,T,,,,,c,,,,,1.0,,
16277682,618,C538098,rs771966860,Positive_Correlation,TRUE,"Taken together, these results support a genotype-phenotype correlation between the <ENT2>M404V</ENT2> mutation in the p62/SQSTM1 gene and a polyostotic form of <ENT1>PDB</ENT1> in this family.",,,,T,,,,,c,,,,,0.0,,
16277682,616,C538098,8878,Association,TRUE,Segregation of a M404V mutation of the <ENT2>p62</ENT2>/<ENT2>sequestosome 1</ENT2> (<ENT2>p62</ENT2>/<ENT2>SQSTM1</ENT2>) gene with polyostotic <ENT1>Paget's disease of bone</ENT1> in an Italian family.,,,,T,,,,,w,,,,,0.0,TRUE,
16277682,616,C538098,8878,Association,TRUE,Mutations of the <ENT2>p62</ENT2>/<ENT2>Sequestosome 1</ENT2> gene (<ENT2>p62</ENT2>/<ENT2>SQSTM1</ENT2>) account for both sporadic and familial forms of <ENT1>Paget's disease of bone</ENT1> (<ENT1>PDB</ENT1>).,,,,T,,,,,c,,,"11,12,13,14,21,22,23,24",,1.0,,
16277682,616,C538098,8878,Association,TRUE,"We originally described a methionine-->valine substitution at codon 404 (M404V) of exon 8, in the ubiquitin protein-binding domain of <ENT2>p62</ENT2>/<ENT2>SQSTM1</ENT2> gene in an Italian <ENT1>PDB</ENT1> patient.",,,,T,,,,,c,,,,,0.5,,
16277682,616,C538098,8878,Association,TRUE,"Taken together, these results support a genotype-phenotype correlation between the M404V mutation in the <ENT2>p62</ENT2>/<ENT2>SQSTM1</ENT2> gene and a polyostotic form of <ENT1>PDB</ENT1> in this family.",,,,T,,,,,w,,,,,0.5,TRUE,
16277682,616,C538098,8878,Association,TRUE,The high penetrance of the <ENT1>PDB</ENT1> trait in this family together with the study of the asymptomatic gene carriers will allow us to confirm the proposed genotype-phenotype correlation and to evaluate the potential use of mutational analysis of the <ENT2>p62</ENT2>/<ENT2>SQSTM1</ENT2> gene in the early detection of relatives at risk for <ENT1>PDB</ENT1>.,,,,T,Y,Y,,,c,,,,,1.0,,
16288197,624,C537550,rs74315339,Association,TRUE,"Data presented here supports the hypothesis that <ENT1>congenital microcoria</ENT1> is a potential risk factor for glaucoma, although this observation is complicated by the partial segregation of MYOC <ENT2>Q48H</ENT2> (1q24.3-q25.2), a mutation known to be associated with glaucoma in India.",,,,T,,,,,w,,,,,0.0,,
16288197,624,C537550,rs74315339,Association,TRUE,"The relationship between <ENT1>microcoria</ENT1>, glaucoma, and the MYOC <ENT2>Q48H</ENT2> mutation in this family is discussed.",,,,T,,,,,c,,,,,0.0,,
16288197,623,C537550,8104,Association,FALSE,CONCLUSIONS: We have confirmed the localization of the <ENT1>congenital microcoria</ENT1> locus (<ENT2>MCOR</ENT2>) to 13q31-q32 in a large Asian Indian family and conclude that current information suggests this is a single locus disorder and genetically homogeneous.,,,,T,,,,,c,,,,,1.0,,
16288197,623,C537550,8104,Association,FALSE,Fine mapping and candidate gene analysis continues with the hope that characterizing the <ENT2>micocoria</ENT2> gene will lead to a better understanding of <ENT1>microcoria</ENT1> and glaucoma causation.,,,,T,,,,,w,,,,,0.0,,
16288197,627,C537550,4653,Association,TRUE,"In addition, eight individuals who had both <ENT1>microcoria</ENT1> and glaucoma were screened for glaucoma genes: <ENT2>myocilin</ENT2> (<ENT2>MYOC</ENT2>), optineurin (OPTN) and CYP1B1.",,,,T,Y,,,,c,,,,,0.0,,
16288197,627,C537550,4653,Association,TRUE,"Data presented here supports the hypothesis that <ENT1>congenital microcoria</ENT1> is a potential risk factor for glaucoma, although this observation is complicated by the partial segregation of <ENT2>MYOC</ENT2> Q48H (1q24.3-q25.2), a mutation known to be associated with glaucoma in India.",,,,T,,,,,w,,,,,0.0,,
16288197,627,C537550,4653,Association,TRUE,"The relationship between <ENT1>microcoria</ENT1>, glaucoma, and the <ENT2>MYOC</ENT2> Q48H mutation in this family is discussed.",,,,T,,,,,c,,,,,0.0,,
16288197,626,C537550,10133,Association,FALSE,"In addition, eight individuals who had both <ENT1>microcoria</ENT1> and glaucoma were screened for glaucoma genes: myocilin (MYOC), <ENT2>optineurin</ENT2> (<ENT2>OPTN</ENT2>) and CYP1B1.",,,,T,Y,,,,c,,,,,0.0,,
16288197,625,C537550,1545,Association,FALSE,"In addition, eight individuals who had both <ENT1>microcoria</ENT1> and glaucoma were screened for glaucoma genes: myocilin (MYOC), optineurin (OPTN) and <ENT2>CYP1B1</ENT2>.",,,,T,,,,,w,,,,,0.0,,
16288197,620,rs74315339,D005901,Positive_Correlation,TRUE,"Using direct sequencing a point mutation (<ENT1>144 G>A</ENT1>) resulting in a <ENT1>Q48H</ENT1> substitution in exon 1 of the MYOC gene was observed in five of the eight <ENT2>glaucoma</ENT2> patients, but not in unaffected family members and 100 unrelated controls.",,,,T,,,,,c,,,,,0.0,,
16288197,620,rs74315339,D005901,Positive_Correlation,TRUE,"Data presented here supports the hypothesis that congenital microcoria is a potential risk factor for <ENT2>glaucoma</ENT2>, although this observation is complicated by the partial segregation of MYOC <ENT1>Q48H</ENT1> (1q24.3-q25.2), a mutation known to be associated with <ENT2>glaucoma</ENT2> in India.",,,,T,,,,,c,,,,,0.5,,
16288197,620,rs74315339,D005901,Positive_Correlation,TRUE,"The relationship between microcoria, <ENT2>glaucoma</ENT2>, and the MYOC <ENT1>Q48H</ENT1> mutation in this family is discussed.",,,,T,,,,,w,,,,,1.0,,
16288197,628,D005901,4653,Association,FALSE,"In addition, eight individuals who had both microcoria and <ENT1>glaucoma</ENT1> were screened for <ENT1>glaucoma</ENT1> genes: <ENT2>myocilin</ENT2> (<ENT2>MYOC</ENT2>), optineurin (OPTN) and CYP1B1.",,,,T,,,,,c,,,"11,12,21,22",,0.0,,
16288197,628,D005901,4653,Association,FALSE,"Using direct sequencing a point mutation (144 G>A) resulting in a Q48H substitution in exon 1 of the <ENT2>MYOC</ENT2> gene was observed in five of the eight <ENT1>glaucoma</ENT1> patients, but not in unaffected family members and 100 unrelated controls.",,,,T,Y,,,,w,,,,,0.0,,
16288197,628,D005901,4653,Association,FALSE,"Data presented here supports the hypothesis that congenital microcoria is a potential risk factor for <ENT1>glaucoma</ENT1>, although this observation is complicated by the partial segregation of <ENT2>MYOC</ENT2> Q48H (1q24.3-q25.2), a mutation known to be associated with <ENT1>glaucoma</ENT1> in India.",,,,T,,,,,c,,,,,0.5,,
16288197,628,D005901,4653,Association,FALSE,"The relationship between microcoria, <ENT1>glaucoma</ENT1>, and the <ENT2>MYOC</ENT2> Q48H mutation in this family is discussed.",,,,T,,,,,c,,,,,0.0,,
16288197,622,D005901,10133,Association,FALSE,"In addition, eight individuals who had both microcoria and <ENT1>glaucoma</ENT1> were screened for <ENT1>glaucoma</ENT1> genes: myocilin (MYOC), <ENT2>optineurin</ENT2> (<ENT2>OPTN</ENT2>) and CYP1B1.",,,,T,Y,,,,c,,,"11,12,21,22",,0.0,,
16288197,621,D005901,1545,Association,FALSE,"In addition, eight individuals who had both microcoria and <ENT1>glaucoma</ENT1> were screened for <ENT1>glaucoma</ENT1> genes: myocilin (MYOC), optineurin (OPTN) and <ENT2>CYP1B1</ENT2>.",,,,T,Y,,,,c,,,,,0.0,,
16288197,619,1638,D010859,Association,FALSE,"The <ENT1>DCT</ENT1> locus, a member of the tyrosinase family involved in <ENT2>pigmentation</ENT2>, maps within this region.",,,,T,,,,,c,,,,,1.0,,
16288199,631,c|DUP||CCTTT|13,D005902,Association,TRUE,"(CCTTT)14, which has been reported to have a higher activity in a reporter-construct, was significantly more abundant in <ENT2>POAG</ENT2> patients, while (CCTTT)10 and <ENT1>(CCTTT)13</ENT1> were less common.",,,,T,,,,,w,,,,,1.0,,
16288199,629,D009422,D009569,Association,FALSE,"PURPOSE: <ENT2>Nitric oxide</ENT2> has many beneficial functions in the human body at the right amounts, but it can also be hazardous if it is produced in amounts more than needed and has therefore been studied in relation to several <ENT1>neurological and non-neurological disorders</ENT1>.",,,,T,,,,,c,,,,,0.0,,
16288199,634,D005901,4843,Association,FALSE,The promoter of inducible <ENT2>nitric oxide synthase</ENT2> implicated in <ENT1>glaucoma</ENT1> based on genetic analysis and nuclear factor binding.,,,,T,,,,,c,,,,,1.0,,
16288199,634,D005901,4843,Association,FALSE,"In vitro and in vivo studies demonstrate a connection between the inducible form of <ENT2>Nitric Oxide Synthase</ENT2>, <ENT2>iNOS</ENT2>, and the <ENT1>neuropathological disorder glaucoma</ENT1>, one of the major causes of blindness in the world.",,,,T,,,,,c,,,,,1.0,,
16288199,632,c|DUP||CCTTT|10,D005902,Association,TRUE,"(CCTTT)14, which has been reported to have a higher activity in a reporter-construct, was significantly more abundant in <ENT2>POAG</ENT2> patients, while <ENT1>(CCTTT)10</ENT1> and (CCTTT)13 were less common.",,,,T,,,,,w,,,,,1.0,,
16288199,635,D005902,4843,Association,FALSE,"In this study, we sought to establish the genetic association between <ENT2>iNOS</ENT2> and <ENT1>primary open angle glaucoma</ENT1>, <ENT1>POAG</ENT1>, and to find the functional element(s) connected with the pathogenesis of the disease.",,,,T,,,,,c,,,,,0.0,,
16288199,635,D005902,4843,Association,FALSE,"METHODS: Two microsatellites, 1 insertion/deletion, and 8 single nucleotide polymorphisms (SNPs) in the regulatory region of <ENT2>iNOS</ENT2> were genotyped in 200 <ENT1>POAG</ENT1> patients and 200 age-matched controls.",,,,T,,Y,,,w,,,,,0.0,,
16288199,635,D005902,4843,Association,FALSE,"CONCLUSIONS: These results, together with other studies on this gene and the CCTTT-microsatellite, establish, for the first time, a genetic association of <ENT2>iNOS</ENT2> with <ENT1>POAG</ENT1> and suggest a regulatory function for the microsatellite.",,,,T,,,,,c,,,,,1.0,,
16288199,630,D005902,c|DUP||CCTTT|14,Association,TRUE,"<ENT2>(CCTTT)14</ENT2>, which has been reported to have a higher activity in a reporter-construct, was significantly more abundant in <ENT1>POAG</ENT1> patients, while (CCTTT)10 and (CCTTT)13 were less common.",,,,T,,,,,c,,,,,1.0,,
16288199,633,D001766,4843,Association,FALSE,"In vitro and in vivo studies demonstrate a connection between the inducible form of <ENT2>Nitric Oxide Synthase</ENT2>, <ENT2>iNOS</ENT2>, and the neuropathological disorder glaucoma, one of the major causes of <ENT1>blindness</ENT1> in the world.",,,,T,Y,,,,w,,,,,1.0,,
16309808,642,D004294,1813,Negative_Correlation,FALSE,"To our knowledge, there is no previous report regarding whether <ENT1>domperidone</ENT1>, a peripheral <ENT2>dopamine D2 receptor</ENT2> antagonist, can also induce or aggravate symptoms of RLS.",,,,T,,,,,w,,,,,1.0,,
16309808,639,D004294,D012148,Positive_Correlation,TRUE,Does <ENT1>domperidone</ENT1> potentiate mirtazapine-associated <ENT2>restless legs syndrome</ENT2>?,,,,T,,Y,,,w,,,,,1.0,,
16309808,639,D004294,D012148,Positive_Correlation,TRUE,"To our knowledge, there is no previous report regarding whether <ENT1>domperidone</ENT1>, a peripheral dopamine D2 receptor antagonist, can also induce or aggravate symptoms of <ENT2>RLS</ENT2>.",,,,T,,,,,c,,,,,1.0,,
16309808,639,D004294,D012148,Positive_Correlation,TRUE,The authors report here a depressed patient comorbid with postprandial dyspepsia who developed <ENT2>RLS</ENT2> after mirtazapine had been added to his <ENT1>domperidone</ENT1> therapy.,,,,T,,,,,c,,,,,0.0,,
16309808,639,D004294,D012148,Positive_Correlation,TRUE,Such a temporal relationship between the use of mirtazapine and the symptoms of <ENT2>RLS</ENT2> in our patient did not support a potentiating effect of <ENT1>domperione</ENT1> on mirtazapine-associated <ENT2>RLS</ENT2>.,,,,T,,,,,c,,,,,1.0,,
16309808,641,D004294,D000078785,Drug_Interaction,TRUE,Does <ENT1>domperidone</ENT1> potentiate <ENT2>mirtazapine</ENT2>-associated restless legs syndrome?,,,,T,,Y,,,w,,,,,0.0,,
16309808,641,D004294,D000078785,Drug_Interaction,TRUE,The authors report here a depressed patient comorbid with postprandial dyspepsia who developed RLS after <ENT2>mirtazapine</ENT2> had been added to his <ENT1>domperidone</ENT1> therapy.,,,,T,,,,,w,,,,,0.0,,
16309808,641,D004294,D000078785,Drug_Interaction,TRUE,Such a temporal relationship between the use of <ENT2>mirtazapine</ENT2> and the symptoms of RLS in our patient did not support a potentiating effect of <ENT1>domperione</ENT1> on <ENT2>mirtazapine</ENT2>-associated RLS.,,,,T,,,,,c,,,,,1.0,,
16309808,637,D012148,D000928,Association,FALSE,"Mirtazapine, the first <ENT2>noradrenergic and specific serotonergic antidepressant</ENT2> (<ENT2>NaSSA</ENT2>), has been associated with <ENT1>RLS</ENT1> in several recent publications.",,,,T,,,,,c,,,,,0.0,,
16309808,640,D012148,D000078785,Positive_Correlation,TRUE,Does domperidone potentiate <ENT2>mirtazapine</ENT2>-associated <ENT1>restless legs syndrome</ENT1>?,,,,T,,,,,w,,,,,0.0,,
16309808,640,D012148,D000078785,Positive_Correlation,TRUE,"<ENT2>Mirtazapine</ENT2>, the first noradrenergic and specific serotonergic antidepressant (NaSSA), has been associated with <ENT1>RLS</ENT1> in several recent publications.",,,,T,,,,,w,,,,,0.0,,
16309808,640,D012148,D000078785,Positive_Correlation,TRUE,The authors report here a depressed patient comorbid with postprandial dyspepsia who developed <ENT1>RLS</ENT1> after <ENT2>mirtazapine</ENT2> had been added to his domperidone therapy.,,,,T,,,,,c,,,,,1.0,,
16309808,640,D012148,D000078785,Positive_Correlation,TRUE,"Our patient started to have symptoms of <ENT1>RLS</ENT1> only after he had been treated with <ENT2>mirtazapine</ENT2>, and his <ENT1>RLS</ENT1> symptoms resolved completely upon discontinuation of his <ENT2>mirtazapine</ENT2>.",,,,T,,,,,c,,,,,1.0,,
16309808,640,D012148,D000078785,Positive_Correlation,TRUE,Such a temporal relationship between the use of <ENT2>mirtazapine</ENT2> and the symptoms of <ENT1>RLS</ENT1> in our patient did not support a potentiating effect of domperione on <ENT2>mirtazapine</ENT2>-associated <ENT1>RLS</ENT1>.,,,,T,,,,,c,,,"11,22",,0.5,,
16309808,640,D012148,D000078785,Positive_Correlation,TRUE,"However, physicians should be aware of the possibility that <ENT2>mirtazapine</ENT2> can be associated with <ENT1>RLS</ENT1> in some individuals, especially those receiving concomitant dopamine D2 receptor antagonists.",,,,T,,,,,c,,,,,0.0,,
16309808,638,D012148,D007980,Negative_Correlation,FALSE,"For example, the symptoms of <ENT1>RLS</ENT1> can be dramatically improved by <ENT2>levodopa</ENT2> and dopamine agonists, whereas central dopamine D2 receptor antagonists can induce or aggravate <ENT1>RLS</ENT1> symptoms.",,,,T,,,,,c,,,,,0.5,,
16309808,636,D012148,D065127,Positive_Correlation,TRUE,"For example, the symptoms of <ENT1>RLS</ENT1> can be dramatically improved by levodopa and dopamine agonists, whereas central <ENT2>dopamine D2 receptor antagonists</ENT2> can induce or aggravate <ENT1>RLS</ENT1> symptoms.",,,,T,,,,,c,,,,,0.0,,
16309808,636,D012148,D065127,Positive_Correlation,TRUE,"However, physicians should be aware of the possibility that mirtazapine can be associated with <ENT1>RLS</ENT1> in some individuals, especially those receiving concomitant <ENT2>dopamine D2 receptor antagonists</ENT2>.",,,,T,,,,,w,,,,,0.0,,
16364460,645,D016713,D012601,Negative_Correlation,TRUE,Microinjection of <ENT1>ritanserin</ENT1> into the CA1 region of hippocampus improves <ENT2>scopolamine</ENT2>-induced amnesia in adult male rats.,,,,T,Y,,,,w,,,,,0.0,,
16364460,645,D016713,D012601,Negative_Correlation,TRUE,The effect of <ENT1>ritanserin</ENT1> (5-HT2 antagonist) on <ENT2>scopolamine</ENT2> (muscarinic cholinergic antagonist)-induced amnesia in Morris water maze (MWM) was investigated.,,,,T,,Y,,,w,,,,,0.0,,
16364460,645,D016713,D012601,Negative_Correlation,TRUE,"One week later, they received repeatedly vehicles (saline, DMSO, saline+DMSO), <ENT2>scopolamine</ENT2> (2 microg/0.5 microl saline/side; 30 min before training), <ENT1>ritanserin</ENT1> (2, 4 and 8 microg/0.5 microl DMSO/side; 20 min before training) and <ENT2>scopolamine</ENT2> (2 microg/0.5 microl; 30 min before <ENT1>ritanserin</ENT1> injection)+<ENT1>ritanserin</ENT1> (4 microg/0.5 microl DMSO) through cannulae each day.",,,,T,,,,,w,,,,,1.0,TRUE,
16364460,645,D016713,D012601,Negative_Correlation,TRUE,"However, <ENT2>scopolamine</ENT2> and <ENT1>ritanserin</ENT1> co-administration resulted in a significant decrease in escape latencies and traveled distances as compared to the <ENT2>scopolamine</ENT2>-treated rats.",,,,T,,,,,c,,,,,1.0,,
16364460,645,D016713,D012601,Negative_Correlation,TRUE,Our findings show that microinjection of <ENT1>ritanserin</ENT1> into the CA1 region of the hippocampus improves the <ENT2>scopolamine</ENT2>-induced amnesia.,,,,T,Y,,,,w,,,,,1.0,,
16364460,643,D016713,29595,Negative_Correlation,FALSE,The effect of <ENT1>ritanserin</ENT1> (<ENT2>5-HT2</ENT2> antagonist) on scopolamine (muscarinic cholinergic antagonist)-induced amnesia in Morris water maze (MWM) was investigated.,,,,T,,,,,w,,,,,1.0,,
16364460,644,D016713,D000647,Negative_Correlation,TRUE,Microinjection of <ENT1>ritanserin</ENT1> into the CA1 region of hippocampus improves scopolamine-induced <ENT2>amnesia</ENT2> in adult male rats.,,,,T,,,,,c,,,,,0.0,,
16364460,644,D016713,D000647,Negative_Correlation,TRUE,The effect of <ENT1>ritanserin</ENT1> (5-HT2 antagonist) on scopolamine (muscarinic cholinergic antagonist)-induced <ENT2>amnesia</ENT2> in Morris water maze (MWM) was investigated.,,,,T,,Y,,,w,,,,,0.0,,
16364460,644,D016713,D000647,Negative_Correlation,TRUE,Our findings show that microinjection of <ENT1>ritanserin</ENT1> into the CA1 region of the hippocampus improves the scopolamine-induced <ENT2>amnesia</ENT2>.,,,,T,,,,,c,,,,,1.0,,
16364460,646,D012601,25229,Negative_Correlation,FALSE,The effect of ritanserin (5-HT2 antagonist) on <ENT1>scopolamine</ENT1> (<ENT2>muscarinic cholinergic</ENT2> antagonist)-induced amnesia in Morris water maze (MWM) was investigated.,,,,T,,,,,w,,,,,0.0,,
16364460,647,D012601,D000647,Positive_Correlation,FALSE,Microinjection of ritanserin into the CA1 region of hippocampus improves <ENT1>scopolamine</ENT1>-induced <ENT2>amnesia</ENT2> in adult male rats.,,,,T,,,,,c,,,,,1.0,,
16364460,647,D012601,D000647,Positive_Correlation,FALSE,The effect of ritanserin (5-HT2 antagonist) on <ENT1>scopolamine</ENT1> (muscarinic cholinergic antagonist)-induced <ENT2>amnesia</ENT2> in Morris water maze (MWM) was investigated.,,,,T,,,,,c,,,,,1.0,,
16364460,647,D012601,D000647,Positive_Correlation,FALSE,Our findings show that microinjection of ritanserin into the CA1 region of the hippocampus improves the <ENT1>scopolamine</ENT1>-induced <ENT2>amnesia</ENT2>.,,,,T,,,,,c,,,,,1.0,,
16369751,651,D066126,C032348,Positive_Correlation,TRUE,5-Fluorouracil <ENT1>cardiotoxicity</ENT1> induced by <ENT2>alpha-fluoro-beta-alanine</ENT2>.,,,,T,,,,,c,,,,,1.0,,
16369751,651,D066126,C032348,Positive_Correlation,TRUE,"We herein report the case of a 70-year-old man with 5-FU-induced <ENT1>cardiotoxicity</ENT1>, in whom a high serum level of <ENT2>alpha-fluoro-beta-alanine</ENT2> (<ENT2>FBAL</ENT2>) was observed.",,,,T,,,,,c,,,,,0.5,,
16369751,651,D066126,C032348,Positive_Correlation,TRUE,"The experience of this case, together with a review of the literature, suggests that <ENT2>FBAL</ENT2> is related to 5-FU-induced <ENT1>cardiotoxicity</ENT1>.",,,,T,,,,,c,,,,,1.0,,
16369751,650,D066126,C079198,Negative_Correlation,TRUE,<ENT2>S-1</ENT2> may be administered safely to patients with 5-FU-induced <ENT1>cardiotoxicity</ENT1>.,,,,T,,,,,c,,,,,0.0,,
16369751,657,D066126,D005472,Positive_Correlation,TRUE,<ENT2>5-Fluorouracil</ENT2> <ENT1>cardiotoxicity</ENT1> induced by alpha-fluoro-beta-alanine.,,,,T,,,,,w,,,,,0.0,,
16369751,657,D066126,D005472,Positive_Correlation,TRUE,<ENT1>Cardiotoxicity</ENT1> is a rare complication occurring during <ENT2>5-fluorouracil</ENT2> (<ENT2>5-FU</ENT2>) treatment for malignancies.,,,,T,,,,,c,,,,,1.0,,
16369751,657,D066126,D005472,Positive_Correlation,TRUE,"We herein report the case of a 70-year-old man with <ENT2>5-FU</ENT2>-induced <ENT1>cardiotoxicity</ENT1>, in whom a high serum level of alpha-fluoro-beta-alanine (FBAL) was observed.",,,,T,,,,,c,,,,,1.0,,
16369751,657,D066126,D005472,Positive_Correlation,TRUE,"As the precordial pain in this patient was considered to have been due to <ENT2>5-FU</ENT2>-induced <ENT1>cardiotoxicity</ENT1>, the administration of <ENT2>5-FU</ENT2> was abandoned.",,,,T,,,,,c,,,,,0.5,,
16369751,657,D066126,D005472,Positive_Correlation,TRUE,"The experience of this case, together with a review of the literature, suggests that FBAL is related to <ENT2>5-FU</ENT2>-induced <ENT1>cardiotoxicity</ENT1>.",,,,T,,,,,c,,,,,1.0,,
16369751,657,D066126,D005472,Positive_Correlation,TRUE,S-1 may be administered safely to patients with <ENT2>5-FU</ENT2>-induced <ENT1>cardiotoxicity</ENT1>.,,,,T,,,,,c,,,,,0.0,,
16369751,655,D002037,C032348,Positive_Correlation,TRUE,"After admission, the patient received a continuous intravenous infusion of 5-FU (1000 mg/day), during which precordial pain with <ENT1>right bundle branch block</ENT1> occurred concomitantly with a high serum <ENT2>FBAL</ENT2> concentration of 1955 ng/ml.",,,,T,,,,,c,,,,,0.0,,
16369751,659,D002037,D005472,Positive_Correlation,TRUE,"After admission, the patient received a continuous intravenous infusion of <ENT2>5-FU</ENT2> (1000 mg/day), during which precordial pain with <ENT1>right bundle branch block</ENT1> occurred concomitantly with a high serum FBAL concentration of 1955 ng/ml.",,,,T,,,,,w,,,,,1.0,,
16369751,654,C032348,C079198,Negative_Correlation,TRUE,"Instead, oral administration of <ENT2>S-1</ENT2> (a derivative of 5-FU), at 200 mg/day twice a week, was instituted, because <ENT2>S-1</ENT2> has a strong inhibitory effect on dihydropyrimidine dehydrogenase, which catalyzes the degradative of 5-FU into <ENT1>FBAL</ENT1>.",,,,T,,,,,c,,,,,0.0,,
16369751,654,C032348,C079198,Negative_Correlation,TRUE,"The serum <ENT1>FBAL</ENT1> concentration subsequently decreased to 352 ng/ml, the same as the value measured on the first day of <ENT2>S-1</ENT2> administration.",,,,T,,,,,w,,,,,0.0,,
16369751,658,C032348,D005472,Positive_Correlation,TRUE,<ENT2>5-Fluorouracil</ENT2> cardiotoxicity induced by <ENT1>alpha-fluoro-beta-alanine</ENT1>.,,,,T,,,,,c,,,,,0.0,,
16369751,658,C032348,D005472,Positive_Correlation,TRUE,"We herein report the case of a 70-year-old man with <ENT2>5-FU</ENT2>-induced cardiotoxicity, in whom a high serum level of <ENT1>alpha-fluoro-beta-alanine</ENT1> (<ENT1>FBAL</ENT1>) was observed.",,,,T,,,,,c,,,,,1.0,,
16369751,658,C032348,D005472,Positive_Correlation,TRUE,"After admission, the patient received a continuous intravenous infusion of <ENT2>5-FU</ENT2> (1000 mg/day), during which precordial pain with right bundle branch block occurred concomitantly with a high serum <ENT1>FBAL</ENT1> concentration of 1955 ng/ml.",,,,T,,,,,c,,,,,1.0,,
16369751,658,C032348,D005472,Positive_Correlation,TRUE,"Instead, oral administration of S-1 (a derivative of <ENT2>5-FU</ENT2>), at 200 mg/day twice a week, was instituted, because S-1 has a strong inhibitory effect on dihydropyrimidine dehydrogenase, which catalyzes the degradative of <ENT2>5-FU</ENT2> into <ENT1>FBAL</ENT1>.",,,,T,,,,,c,,,,,0.0,,
16369751,658,C032348,D005472,Positive_Correlation,TRUE,"The experience of this case, together with a review of the literature, suggests that <ENT1>FBAL</ENT1> is related to <ENT2>5-FU</ENT2>-induced cardiotoxicity.",,,,T,,,,,c,,,,,0.0,,
16369751,652,C032348,D002637,Positive_Correlation,TRUE,"After admission, the patient received a continuous intravenous infusion of 5-FU (1000 mg/day), during which <ENT2>precordial pain</ENT2> with right bundle branch block occurred concomitantly with a high serum <ENT1>FBAL</ENT1> concentration of 1955 ng/ml.",,,,T,,,,,w,,,,,1.0,,
16369751,648,C079198,D005472,Comparison,TRUE,"Instead, oral administration of <ENT1>S-1</ENT1> (a derivative of <ENT2>5-FU</ENT2>), at 200 mg/day twice a week, was instituted, because <ENT1>S-1</ENT1> has a strong inhibitory effect on dihydropyrimidine dehydrogenase, which catalyzes the degradative of <ENT2>5-FU</ENT2> into FBAL.",,,,T,Y,,,,c,,,,,1.0,,
16369751,648,C079198,D005472,Comparison,TRUE,<ENT1>S-1</ENT1> may be administered safely to patients with <ENT2>5-FU</ENT2>-induced cardiotoxicity.,,,,T,Y,,,,w,,,,,0.0,,
16369751,653,D005472,D002637,Positive_Correlation,TRUE,"After admission, the patient received a continuous intravenous infusion of <ENT1>5-FU</ENT1> (1000 mg/day), during which <ENT2>precordial pain</ENT2> with right bundle branch block occurred concomitantly with a high serum FBAL concentration of 1955 ng/ml.",,,,T,,,,,c,,,,,1.0,,
16369751,653,D005472,D002637,Positive_Correlation,TRUE,Both the <ENT2>precordial pain</ENT2> and the electrocardiographic changes disappeared spontaneously after the discontinuation of <ENT1>5-FU</ENT1>.,,,,T,,,,,c,,,,,1.0,,
16369751,653,D005472,D002637,Positive_Correlation,TRUE,"As the <ENT2>precordial pain</ENT2> in this patient was considered to have been due to <ENT1>5-FU</ENT1>-induced cardiotoxicity, the administration of <ENT1>5-FU</ENT1> was abandoned.",,,,T,,,,,c,,,,,0.5,,
16369751,656,D005472,D009369,Negative_Correlation,FALSE,Cardiotoxicity is a rare complication occurring during <ENT1>5-fluorouracil</ENT1> (<ENT1>5-FU</ENT1>) treatment for <ENT2>malignancies</ENT2>.,,,,T,,,,,c,,,,,0.5,,
16391785,662,D000077209,D008175,Negative_Correlation,TRUE,<ENT1>5-Aza-2'-deoxy-cytidine</ENT1> and/or Trichostatin A treatments induced DOCK8 expression in <ENT2>lung cancer</ENT2> cell lines with reduced DOCK8 expression.,,,,T,,,,,w,,,,,0.0,,
16391785,663,D000077209,81704,Positive_Correlation,TRUE,<ENT1>5-Aza-2'-deoxy-cytidine</ENT1> and/or Trichostatin A treatments induced <ENT2>DOCK8</ENT2> expression in lung cancer cell lines with reduced <ENT2>DOCK8</ENT2> expression.,,,,T,,,,,c,,,,,0.5,,
16391785,660,D008175,C012589,Negative_Correlation,TRUE,5-Aza-2'-deoxy-cytidine and/or <ENT2>Trichostatin A</ENT2> treatments induced DOCK8 expression in <ENT1>lung cancer</ENT1> cell lines with reduced DOCK8 expression.,,,,T,,,,,w,,,,,0.0,,
16391785,666,D008175,81704,Negative_Correlation,TRUE,Homozygous deletion and reduced expression of the <ENT2>DOCK8</ENT2> gene in human <ENT1>lung cancer</ENT1>.,,,,T,,,,,w,,,,,0.0,,
16391785,666,D008175,81704,Negative_Correlation,TRUE,A homozygous deletion of the <ENT2>DOCK8</ENT2> (<ENT2>dedicator of cytokinesis 8</ENT2>) locus at chromosome 9p24 was found in a <ENT1>lung cancer</ENT1> cell line by array-CGH analysis.,,,,T,,,,,w,,,,,0.0,TRUE,
16391785,666,D008175,81704,Negative_Correlation,TRUE,"<ENT2>DOCK8</ENT2> was expressed in a variety of human organs, including the lungs, and was also expressed in type II alveolar, bronchiolar epithelial and bronchial epithelial cells, which are considered as being progenitors for <ENT1>lung cancer</ENT1> cells.",,,,T,,,,,c,,,,,0.0,,
16391785,666,D008175,81704,Negative_Correlation,TRUE,"<ENT2>DOCK8</ENT2> expression was reduced in 62/71 (87%) primary <ENT1>lung cancers</ENT1> compared with normal lung tissue, and the reduction occurred irrespective of the histological type of <ENT1>lung cancer</ENT1>.",,,,T,,,,,c,,,,,0.5,,
16391785,666,D008175,81704,Negative_Correlation,TRUE,5-Aza-2'-deoxy-cytidine and/or Trichostatin A treatments induced <ENT2>DOCK8</ENT2> expression in <ENT1>lung cancer</ENT1> cell lines with reduced <ENT2>DOCK8</ENT2> expression.,,,,T,,,,,w,,,,,0.0,,
16391785,666,D008175,81704,Negative_Correlation,TRUE,"Therefore, epigenetic mechanisms, including DNA methylation and histone deacetylation, were indicated to be involved in <ENT2>DOCK8</ENT2> down-regulation in <ENT1>lung cancer</ENT1> cells.",,,,T,,,,,w,,,,,0.0,,
16391785,666,D008175,81704,Negative_Correlation,TRUE,"Thus, the present results suggest that genetic and epigenetic inactivation of <ENT2>DOCK8</ENT2> is involved in the development and/or progression of <ENT1>lung and other cancers</ENT1> by disturbing such regulations.",,,,T,,,,,w,,,,,0.0,,
16391785,665,D001943,81704,Negative_Correlation,TRUE,Further screening revealed homozygous deletions of the <ENT2>DOCK8</ENT2> gene in a gastric and a <ENT1>breast cancer</ENT1> cell line.,,,,T,,,,,w,,,,,0.0,,
16391785,661,C012589,81704,Positive_Correlation,TRUE,5-Aza-2'-deoxy-cytidine and/or <ENT1>Trichostatin A</ENT1> treatments induced <ENT2>DOCK8</ENT2> expression in lung cancer cell lines with reduced <ENT2>DOCK8</ENT2> expression.,,,,T,,,,,c,,,,,0.5,,
16391785,664,81704,D009369,Association,TRUE,"Thus, the present results suggest that genetic and epigenetic inactivation of <ENT1>DOCK8</ENT1> is involved in the development and/or progression of <ENT2>lung and other cancers</ENT2> by disturbing such regulations.",,,,T,,,,,c,,,,,0.0,,
16410744,669,7157,1029,Positive_Correlation,FALSE,"As previously observed for glioblastomas in Europe, there was a positive association between EGFR amplification and <ENT2>p16</ENT2> deletion (p=0.009), whereas there was an inverse association between <ENT1>TP53</ENT1> mutations and <ENT2>p16</ENT2> deletion (p=0.049) in glioblastomas in Japan.",,,,T,Y,,,,w,,,,,0.0,,
16410744,670,7157,D005909,Association,TRUE,SSCP followed by DNA sequencing revealed <ENT1>TP53</ENT1> mutations in 16 of 73 (22%) <ENT2>glioblastomas</ENT2> and PTEN mutations in 13 of 63 (21%) cases analyzed.,,,,T,,,,,c,,,,,1.0,,
16410744,670,7157,D005909,Association,TRUE,"As previously observed for <ENT2>glioblastomas</ENT2> in Europe, there was a positive association between EGFR amplification and p16 deletion (p=0.009), whereas there was an inverse association between <ENT1>TP53</ENT1> mutations and p16 deletion (p=0.049) in <ENT2>glioblastomas</ENT2> in Japan.",,,,T,,,,,c,,,,,0.0,,
16410744,668,p|SUB|Q|787|Q,D005909,Association,TRUE,"The allele frequencies of polymorphisms at <ENT1>codon 787 CAG/CAA</ENT1> (Gln/Gln) in <ENT2>glioblastomas</ENT2> in Japan were G/G (82.4%), G/A (10.8%), A/A (6.8%), corresponding to G 0.878 versus A 0.122, significantly different from those in <ENT2>glioblastomas</ENT2> in Switzerland: G/G (27.2%), G/A (28.4%), A/A (44.4%), corresponding to G 0.414 versus A 0.586 (p < 0.0001).",,,,T,,,,,c,,,,,0.5,,
16410744,671,1029,1956,Negative_Correlation,FALSE,Polymerase chain reaction (PCR) showed <ENT2>EGFR</ENT2> amplification in 25 of 77 (32%) cases and <ENT1>p16</ENT1> homozygous deletion in 32 of 77 (42%) cases.,,,,T,,,,,c,,,,,1.0,,
16410744,671,1029,1956,Negative_Correlation,FALSE,"As previously observed for glioblastomas in Europe, there was a positive association between <ENT2>EGFR</ENT2> amplification and <ENT1>p16</ENT1> deletion (p=0.009), whereas there was an inverse association between TP53 mutations and <ENT1>p16</ENT1> deletion (p=0.049) in glioblastomas in Japan.",,,,T,,,,,c,,,,,0.0,,
16410744,672,1029,D005909,Association,TRUE,"As previously observed for <ENT2>glioblastomas</ENT2> in Europe, there was a positive association between EGFR amplification and <ENT1>p16</ENT1> deletion (p=0.009), whereas there was an inverse association between TP53 mutations and <ENT1>p16</ENT1> deletion (p=0.049) in <ENT2>glioblastomas</ENT2> in Japan.",,,,T,,,,,w,,,,,0.0,,
16410744,673,1956,D005909,Association,TRUE,"As previously observed for <ENT2>glioblastomas</ENT2> in Europe, there was a positive association between <ENT1>EGFR</ENT1> amplification and p16 deletion (p=0.009), whereas there was an inverse association between TP53 mutations and p16 deletion (p=0.049) in <ENT2>glioblastomas</ENT2> in Japan.",,,,T,,,,,c,,,,,0.5,,
16410744,673,1956,D005909,Association,TRUE,SSCP followed by DNA sequencing of the kinase domain (exons 18-21) of the <ENT1>EGFR</ENT1> gene revealed mutations in 2 ou of 69 (3%) <ENT2>glioblastomas</ENT2> in Japan and in 4 of 81 (5%) <ENT2>glioblastomas</ENT2> in Switzerland.,,,,T,,,,,c,,,,,0.0,,
16410744,673,1956,D005909,Association,TRUE,"These results suggest that primary <ENT2>glioblastomas</ENT2> in Japan show genetic alterations similar to those in Switzerland, suggesting a similar molecular basis in caucasians and Asians, despite different genetic backgrounds, including different status of a polymorphism in the <ENT1>EGFR</ENT1> gene.",,,,T,,,,,w,,,,,1.0,,
16410744,667,p|SUB|Q||Q,D005909,Association,TRUE,"The allele frequencies of polymorphisms at codon 787 CAG/CAA (<ENT1>Gln/Gln</ENT1>) in <ENT2>glioblastomas</ENT2> in Japan were G/G (82.4%), G/A (10.8%), A/A (6.8%), corresponding to G 0.878 versus A 0.122, significantly different from those in <ENT2>glioblastomas</ENT2> in Switzerland: G/G (27.2%), G/A (28.4%), A/A (44.4%), corresponding to G 0.414 versus A 0.586 (p < 0.0001).",,,,T,,,,,c,,,,,1.0,,
16412238,676,D052496,5468,Negative_Correlation,FALSE,<ENT2>Peroxisomal proliferator activated receptor-gamma</ENT2> deficiency in a Canadian kindred with <ENT1>familial partial lipodystrophy type 3</ENT1> (<ENT1>FPLD3</ENT1>).,,,,T,,,,,w,,,,,1.0,TRUE,
16412238,676,D052496,5468,Negative_Correlation,FALSE,"BACKGROUND: <ENT1>Familial partial lipodystrophy (Dunnigan) type 3</ENT1> (<ENT1>FPLD3</ENT1>, <ENT1>Mendelian Inheritance in Man [MIM] 604367</ENT1>) results from heterozygous mutations in <ENT2>PPARG</ENT2> encoding <ENT2>peroxisomal proliferator-activated receptor-gamma</ENT2>.",,,,T,,,,,c,,,"11,12,21,22,31,32",,0.0,,
16412238,676,D052496,5468,Negative_Correlation,FALSE,"CONCLUSION: Taken together with previous studies of human <ENT2>PPARG</ENT2> mutations, these findings suggest that <ENT2>PPAR-gamma</ENT2> deficiency due either to haploinsufficiency or to substantial activity loss due to dominant negative interference of the normal allele product's function can each contribute to the <ENT1>FPLD3</ENT1> phenotype.",,,,T,,,,,w,,,,,0.0,TRUE,
16418600,687,C563856,c|INS|457_458|G,Positive_Correlation,FALSE,The reported mutation associated with <ENT1>SIDDT</ENT1> (<ENT2>457_458insG</ENT2>) was not detectable in our cohort.,,,,T,,,,,w,,,,,0.0,,
16418600,688,C563856,7259,Association,FALSE,"Recently, a lethal phenotype characterized by <ENT1>sudden infant death with dysgenesis of the testes syndrome</ENT1> (<ENT1>SIDDT</ENT1>) was identified to be caused by loss of function mutations in the <ENT2>TSPYL1</ENT2> gene.",,,,T,,,,,c,,,,,1.0,,
16418600,688,C563856,7259,Association,FALSE,"Because <ENT1>SIDDT</ENT1> is the result of homozygous <ENT2>TSPYL1</ENT2> mutations, this heterozygous exchange cannot solely explain the sudden death in this child.",,,,T,,,,,c,,,,,0.0,,
16506214,695,D010146,4513,Association,FALSE,The prostaglandins produced by <ENT2>COX-2</ENT2> are involved in inflammation and <ENT1>pain</ENT1> response in different tissues in the body.,,,,T,Y,,,,w,,,,,1.0,,
16506214,692,D010146,D011453,Association,FALSE,The <ENT2>prostaglandins</ENT2> produced by COX-2 are involved in inflammation and <ENT1>pain</ENT1> response in different tissues in the body.,,,,T,,,,,c,,,,,1.0,,
16506214,697,4513,D011453,Positive_Correlation,FALSE,<ENT1>COX-2</ENT1> is a key enzyme in the conversion of arachidonic acid to <ENT2>prostaglandins</ENT2>.,,,,T,,,,,w,,,,,1.0,,
16506214,697,4513,D011453,Positive_Correlation,FALSE,The <ENT2>prostaglandins</ENT2> produced by <ENT1>COX-2</ENT1> are involved in inflammation and pain response in different tissues in the body.,,,,T,,,,,c,,,,,1.0,,
16506214,698,4513,D016718,Association,FALSE,<ENT1>COX-2</ENT1> is a key enzyme in the conversion of <ENT2>arachidonic acid</ENT2> to prostaglandins.,,,,T,,,,,w,,,,,1.0,,
16506214,700,4513,D009369,Association,FALSE,"Accumulating evidence from epidemiologic studies, chemical carcinogen-induced rodent models and clinical trials indicate that <ENT1>COX-2</ENT1> plays a role in human <ENT2>carcinogenesis</ENT2> and is overexpressed in prostate cancer tissue.",,,,T,,,,,c,,,,,1.0,,
16506214,699,4513,D011471,Positive_Correlation,TRUE,Genetic variation in the <ENT1>COX-2</ENT1> gene and the association with <ENT2>prostate cancer</ENT2> risk.,,,,T,,,,,w,,,,,0.0,,
16506214,699,4513,D011471,Positive_Correlation,TRUE,"Accumulating evidence from epidemiologic studies, chemical carcinogen-induced rodent models and clinical trials indicate that <ENT1>COX-2</ENT1> plays a role in human carcinogenesis and is overexpressed in <ENT2>prostate cancer</ENT2> tissue.",,,,T,,,,,c,,,,,0.0,,
16506214,699,4513,D011471,Positive_Correlation,TRUE,We examined whether sequence variants in the <ENT1>COX-2</ENT1> gene are associated with <ENT2>prostate cancer</ENT2> risk.,,,,T,,Y,,,c,,,,,1.0,,
16506214,699,4513,D011471,Positive_Correlation,TRUE,This study supports the hypothesis that inflammation is involved in <ENT2>prostate carcinogenesis</ENT2> and that sequence variation within the <ENT1>COX-2</ENT1> gene influence the risk of <ENT2>prostate cancer</ENT2>.,,,,T,,,,,c,,,,,0.0,,
16506214,696,4513,D007249,Association,FALSE,The prostaglandins produced by <ENT1>COX-2</ENT1> are involved in <ENT2>inflammation</ENT2> and pain response in different tissues in the body.,,,,T,Y,,,,w,,,,,1.0,,
16506214,696,4513,D007249,Association,FALSE,This study supports the hypothesis that <ENT2>inflammation</ENT2> is involved in prostate carcinogenesis and that sequence variation within the <ENT1>COX-2</ENT1> gene influence the risk of prostate cancer.,,,,T,,,,,c,,,,,1.0,,
16506214,694,D011453,D016718,Conversion,FALSE,COX-2 is a key enzyme in the conversion of <ENT2>arachidonic acid</ENT2> to <ENT1>prostaglandins</ENT1>.,,,,T,,,,,c,,,,,0.0,,
16506214,693,D011453,D007249,Association,FALSE,The <ENT1>prostaglandins</ENT1> produced by COX-2 are involved in <ENT2>inflammation</ENT2> and pain response in different tissues in the body.,,,,T,,,,,c,,,,,1.0,,
16506214,691,D011471,c|SUB|T|+3100|G,Negative_Correlation,TRUE,"In the haplotype analysis, 1 haplotype carrying the variant allele from both <ENT2>+3100 T/G</ENT2> and +8365 C/T, with a population frequency of 3%, was also significantly associated with decreased risk of <ENT1>prostate cancer</ENT1> (p=0.036, global simulated p-value=0.046).",,,,T,,,,,w,,,,,0.0,,
16506214,689,D011471,c|SUB|C|+8365|T,Negative_Correlation,TRUE,"In the haplotype analysis, 1 haplotype carrying the variant allele from both +3100 T/G and <ENT2>+8365 C/T</ENT2>, with a population frequency of 3%, was also significantly associated with decreased risk of <ENT1>prostate cancer</ENT1> (p=0.036, global simulated p-value=0.046).",,,,T,,,,,w,,,,,0.0,,
16506214,690,c|SUB|T|+3100|G,c|SUB|C|+8365|T,Association,TRUE,"A statistically significant difference in allele frequency between cases and controls was observed for 2 of the SNPs (<ENT1>+3100 T/G</ENT1> and <ENT2>+8365 C/T</ENT2>), with an odds ratio of 0.78 (95% CI=0.64-0.96) and 0.65 (95% CI=0.45-0.94) respectively.",,,,T,,,,,c,,,,,1.0,,
16506214,690,c|SUB|T|+3100|G,c|SUB|C|+8365|T,Association,TRUE,"In the haplotype analysis, 1 haplotype carrying the variant allele from both <ENT1>+3100 T/G</ENT1> and <ENT2>+8365 C/T</ENT2>, with a population frequency of 3%, was also significantly associated with decreased risk of prostate cancer (p=0.036, global simulated p-value=0.046).",,,,T,,,,,c,,,,,1.0,,
16541406,702,4292,D003123,Association,TRUE,Distinct patterns of germ-line deletions in <ENT1>MLH1</ENT1> and MSH2: the implication of Alu repetitive element in the genetic etiology of <ENT2>Lynch syndrome</ENT2> (<ENT2>HNPCC</ENT2>).,,,,T,,,,,w,,,,,1.0,,
16541406,702,4292,D003123,Association,TRUE,A relatively high frequency of germ-line genomic rearrangements in <ENT1>MLH1</ENT1> and MSH2 has been reported among <ENT2>Lynch Syndrome</ENT2> (<ENT2>HNPCC</ENT2>) patients from different ethnic populations.,,,,T,,,,,c,,,,,1.0,,
16541406,701,4436,D003123,Association,TRUE,Distinct patterns of germ-line deletions in MLH1 and <ENT1>MSH2</ENT1>: the implication of Alu repetitive element in the genetic etiology of <ENT2>Lynch syndrome</ENT2> (<ENT2>HNPCC</ENT2>).,,,,T,,,,,w,,,,,0.0,,
16541406,701,4436,D003123,Association,TRUE,A relatively high frequency of germ-line genomic rearrangements in MLH1 and <ENT1>MSH2</ENT1> has been reported among <ENT2>Lynch Syndrome</ENT2> (<ENT2>HNPCC</ENT2>) patients from different ethnic populations.,,,,T,,,,,c,,,,,1.0,,
16574712,704,D003072,D018817,Positive_Correlation,TRUE,<ENT2>MDMA</ENT2> polydrug users show process-specific central executive impairments coupled with <ENT1>impaired social and emotional judgement processes</ENT1>.,,,,T,,,,,c,,,,,0.0,,
16574712,703,D008569,D018817,Positive_Correlation,FALSE,"In recent years working <ENT1>memory deficits</ENT1> have been reported in users of <ENT2>MDMA</ENT2> (<ENT2>3,4-methylenedioxymethamphetamine</ENT2>, <ENT2>ecstasy</ENT2>).",,,,T,,,,,c,,,,,0.666666667,,
16574713,710,D020258,D012701,Positive_Correlation,FALSE,"Although 3,4-methylenedioxymethamphetamine (MDMA or ecstasy) has been shown to damage brain <ENT2>serotonin</ENT2> (<ENT2>5-HT</ENT2>) neurons in animals and possibly humans, little is known about the long-term consequences of MDMA-induced <ENT2>5-HT</ENT2> <ENT1>neurotoxic lesions</ENT1> on functions in which <ENT2>5-HT</ENT2> is involved, such as cognitive function.",,,,T,Y,,,,w,,,,,0.0,,
16574713,707,D020258,D018817,Positive_Correlation,FALSE,"Although <ENT2>3,4-methylenedioxymethamphetamine</ENT2> (<ENT2>MDMA</ENT2> or <ENT2>ecstasy</ENT2>) has been shown to damage brain serotonin (5-HT) neurons in animals and possibly humans, little is known about the long-term consequences of <ENT2>MDMA</ENT2>-induced 5-HT <ENT1>neurotoxic lesions</ENT1> on functions in which 5-HT is involved, such as cognitive function.",,,,T,,,,,c,,,,,0.5,,
16574713,709,6532,D012701,Association,FALSE,Because <ENT2>5-HT</ENT2> transporters play a key element in the regulation of synaptic <ENT2>5-HT</ENT2> transmission it may be important to control for the potential covariance effect of a polymorphism in the <ENT1>5-HT transporter promoter gene region</ENT1> (<ENT1>5-HTTLPR</ENT1>) when studying the effects of MDMA as well as cognitive functioning.,,,,T,,,,,c,,,,,0.0,,
16574713,705,6532,D018817,Association,TRUE,Memory function and <ENT1>serotonin transporter</ENT1> promoter gene polymorphism in <ENT2>ecstasy</ENT2> (<ENT2>MDMA</ENT2>) users.,,,,T,,T,,,w,,,,,0.0,,
16574713,705,6532,D018817,Association,TRUE,Because 5-HT transporters play a key element in the regulation of synaptic 5-HT transmission it may be important to control for the potential covariance effect of a polymorphism in the <ENT1>5-HT transporter promoter gene region</ENT1> (<ENT1>5-HTTLPR</ENT1>) when studying the effects of <ENT2>MDMA</ENT2> as well as cognitive functioning.,,,,T,,,,,c,,,,,1.0,,
16574713,705,6532,D018817,Association,TRUE,"The aim of the study was to investigate the effects of moderate and heavy <ENT2>MDMA</ENT2> use on cognitive function, as well as the effects of long-term abstention from <ENT2>MDMA</ENT2>, in subjects genotyped for <ENT1>5-HTTLPR</ENT1>.",,,,T,,,,,c,,,,,1.0,,
16574713,705,6532,D018817,Association,TRUE,No effect of <ENT1>5-HTTLPR</ENT1> or gender on memory function or <ENT2>MDMA</ENT2> use was observed.,,,,T,,,,,c,,,,,1.0,,
16574713,706,D008569,D018817,Positive_Correlation,TRUE,"In contrast, no evidence of <ENT1>memory impairment</ENT1> was observed in moderate <ENT2>MDMA</ENT2> users.",,,,T,,,,,c,,,,,0.0,,
16574713,706,D008569,D018817,Positive_Correlation,TRUE,"While the use of <ENT2>MDMA</ENT2> in quantities that may be considered ""moderate"" is not associated with <ENT1>impaired memory functioning</ENT1>, heavy use of <ENT2>MDMA</ENT2> use may lead to long lasting <ENT1>memory impairments</ENT1>.",,,,T,,,,,c,,,,,0.25,,
16574713,708,D012701,D018817,Positive_Correlation,FALSE,"Although <ENT2>3,4-methylenedioxymethamphetamine</ENT2> (<ENT2>MDMA</ENT2> or <ENT2>ecstasy</ENT2>) has been shown to damage brain <ENT1>serotonin</ENT1> (<ENT1>5-HT</ENT1>) neurons in animals and possibly humans, little is known about the long-term consequences of <ENT2>MDMA</ENT2>-induced <ENT1>5-HT</ENT1> neurotoxic lesions on functions in which <ENT1>5-HT</ENT1> is involved, such as cognitive function.",,,,T,Y,,,,w,,,,,0.0,,
16574713,708,D012701,D018817,Positive_Correlation,FALSE,Because <ENT1>5-HT</ENT1> transporters play a key element in the regulation of synaptic <ENT1>5-HT</ENT1> transmission it may be important to control for the potential covariance effect of a polymorphism in the 5-HT transporter promoter gene region (5-HTTLPR) when studying the effects of <ENT2>MDMA</ENT2> as well as cognitive functioning.,,,,T,,,,,c,,,,,1.0,,
16575011,712,c|DEL|1494|6,D015179,Association,TRUE,Tumor thymidylate synthase <ENT1>1494del6</ENT1> genotype as a prognostic factor in <ENT2>colorectal cancer</ENT2> patients receiving fluorouracil-based adjuvant treatment.,,,,T,,,,,c,,,,,1.0,,
16575011,712,c|DEL|1494|6,D015179,Association,TRUE,CONCLUSION: Tumor TS <ENT1>1494del6</ENT1> genotype may be a prognostic factor in FU-based adjuvant treatment of <ENT2>colorectal cancer</ENT2> patients.,,,,T,,,,,c,,,,,1.0,,
16575011,711,c|DEL|1494|6,D009369,Association,TRUE,<ENT2>Tumor</ENT2> thymidylate synthase <ENT1>1494del6</ENT1> genotype as a prognostic factor in colorectal cancer patients receiving fluorouracil-based adjuvant treatment.,,,,T,,T,,,c,,,,,0.0,,
16575011,711,c|DEL|1494|6,D009369,Association,TRUE,"TS enhancer region, 3R G > C single nucleotide polymorphism (SNP), and TS <ENT1>1494del6</ENT1> polymorphisms were assessed in both fresh-frozen normal mucosa and <ENT2>tumor</ENT2>.",,,,T,,Y,,,w,,,,,0.0,,
16575011,711,c|DEL|1494|6,D009369,Association,TRUE,"<ENT2>Tumor</ENT2> TS <ENT1>1494del6</ENT1> allele (frequency of allelic loss, 36%) was protective (for each allele with the deletion, based on an additive model, HR = 0.42; 95% CI, 0.22 to 0.82; P = .0034).",,,,T,Y,,,,w,,,,,1.0,,
16575011,711,c|DEL|1494|6,D009369,Association,TRUE,CONCLUSION: <ENT2>Tumor</ENT2> TS <ENT1>1494del6</ENT1> genotype may be a prognostic factor in FU-based adjuvant treatment of colorectal cancer patients.,,,,T,,,,,c,,,,,1.0,,
16575011,715,7298,D015179,Association,FALSE,Tumor <ENT1>thymidylate synthase</ENT1> 1494del6 genotype as a prognostic factor in <ENT2>colorectal cancer</ENT2> patients receiving fluorouracil-based adjuvant treatment.,,,,T,,,,,c,,,,,1.0,,
16575011,715,7298,D015179,Association,FALSE,PURPOSE: The purpose of this study was to analyze the value of germline and tumor <ENT1>thymidylate synthase</ENT1> (<ENT1>TS</ENT1>) genotyping as a prognostic marker in a series of <ENT2>colorectal cancer</ENT2> patients receiving adjuvant fluorouracil (FU) -based treatment.,,,,T,,,,,c,,,,,0.0,,
16575011,715,7298,D015179,Association,FALSE,CONCLUSION: Tumor <ENT1>TS</ENT1> 1494del6 genotype may be a prognostic factor in FU-based adjuvant treatment of <ENT2>colorectal cancer</ENT2> patients.,,,,T,,,,,w,,,,,0.0,,
16575011,713,7298,D009362,Association,FALSE,Mutational analyses of <ENT1>TS</ENT1> and allelic imbalances were studied in all primary tumors and in 18 additional metachronic <ENT2>metastases</ENT2>.,,,,T,Y,,,,w,,,,,0.0,,
16575011,713,7298,D009362,Association,FALSE,No <ENT1>TS</ENT1> point mutation was detected in primary tumors or <ENT2>metastases</ENT2>.,,,,T,,,,,c,,,,,1.0,,
16575011,714,7298,D009369,Association,FALSE,<ENT2>Tumor</ENT2> <ENT1>thymidylate synthase</ENT1> 1494del6 genotype as a prognostic factor in colorectal cancer patients receiving fluorouracil-based adjuvant treatment.,,,,T,,T,,,w,,,,,1.0,,
16575011,714,7298,D009369,Association,FALSE,PURPOSE: The purpose of this study was to analyze the value of germline and <ENT2>tumor</ENT2> <ENT1>thymidylate synthase</ENT1> (<ENT1>TS</ENT1>) genotyping as a prognostic marker in a series of colorectal cancer patients receiving adjuvant fluorouracil (FU) -based treatment.,,,,T,,Y,,,c,,,,,1.0,,
16575011,714,7298,D009369,Association,FALSE,"<ENT1>TS</ENT1> enhancer region, 3R G > C single nucleotide polymorphism (SNP), and <ENT1>TS</ENT1> 1494del6 polymorphisms were assessed in both fresh-frozen normal mucosa and <ENT2>tumor</ENT2>.",,,,T,,Y,,,c,,,,,1.0,,
16575011,714,7298,D009369,Association,FALSE,Mutational analyses of <ENT1>TS</ENT1> and allelic imbalances were studied in all primary <ENT2>tumors</ENT2> and in 18 additional metachronic metastases.,,,,T,,Y,,,c,,,,,1.0,,
16575011,714,7298,D009369,Association,FALSE,<ENT1>TS</ENT1> protein immunostaining was assessed in an expanded series of 214 <ENT2>tumors</ENT2>.,,,,T,,Y,,,w,,,,,0.0,,
16575011,714,7298,D009369,Association,FALSE,"<ENT2>Tumor</ENT2> <ENT1>TS</ENT1> 1494del6 allele (frequency of allelic loss, 36%) was protective (for each allele with the deletion, based on an additive model, HR = 0.42; 95% CI, 0.22 to 0.82; P = .0034).",,,,T,,,,,w,,,,,1.0,,
16575011,714,7298,D009369,Association,FALSE,No <ENT1>TS</ENT1> point mutation was detected in primary <ENT2>tumors</ENT2> or metastases.,,,,T,,,,,c,,,,,1.0,,
16575011,714,7298,D009369,Association,FALSE,CONCLUSION: <ENT2>Tumor</ENT2> <ENT1>TS</ENT1> 1494del6 genotype may be a prognostic factor in FU-based adjuvant treatment of colorectal cancer patients.,,,,T,,,,,w,,,,,1.0,,
16575011,720,D015179,D007978,Negative_Correlation,FALSE,PATIENTS AND METHODS: One hundred twenty-nine <ENT1>colorectal cancer</ENT1> patients homogeneously treated with FU plus <ENT2>levamisole</ENT2> or leucovorin in the adjuvant setting were included.,,,,T,,,,,c,,,,,1.0,,
16575011,718,D015179,D005472,Negative_Correlation,FALSE,Tumor thymidylate synthase 1494del6 genotype as a prognostic factor in <ENT1>colorectal cancer</ENT1> patients receiving <ENT2>fluorouracil</ENT2>-based adjuvant treatment.,,,,T,,,,,c,,,,,1.0,,
16575011,718,D015179,D005472,Negative_Correlation,FALSE,PURPOSE: The purpose of this study was to analyze the value of germline and tumor thymidylate synthase (TS) genotyping as a prognostic marker in a series of <ENT1>colorectal cancer</ENT1> patients receiving adjuvant <ENT2>fluorouracil</ENT2> (<ENT2>FU</ENT2>) -based treatment.,,,,T,,,,,c,,,,,1.0,,
16575011,718,D015179,D005472,Negative_Correlation,FALSE,PATIENTS AND METHODS: One hundred twenty-nine <ENT1>colorectal cancer</ENT1> patients homogeneously treated with <ENT2>FU</ENT2> plus levamisole or leucovorin in the adjuvant setting were included.,,,,T,,,,,c,,,,,1.0,,
16575011,718,D015179,D005472,Negative_Correlation,FALSE,CONCLUSION: Tumor TS 1494del6 genotype may be a prognostic factor in <ENT2>FU</ENT2>-based adjuvant treatment of <ENT1>colorectal cancer</ENT1> patients.,,,,T,,,,,c,,,,,1.0,,
16575011,719,D015179,D002955,Negative_Correlation,FALSE,PATIENTS AND METHODS: One hundred twenty-nine <ENT1>colorectal cancer</ENT1> patients homogeneously treated with FU plus levamisole or <ENT2>leucovorin</ENT2> in the adjuvant setting were included.,,,,T,,,,,c,,,,,1.0,,
16575011,717,D007978,D005472,Cotreatment,FALSE,PATIENTS AND METHODS: One hundred twenty-nine colorectal cancer patients homogeneously treated with <ENT2>FU</ENT2> plus <ENT1>levamisole</ENT1> or leucovorin in the adjuvant setting were included.,,,,T,,,,,c,,,,,0.0,,
16575011,716,D005472,D002955,Cotreatment,FALSE,PATIENTS AND METHODS: One hundred twenty-nine colorectal cancer patients homogeneously treated with <ENT1>FU</ENT1> plus levamisole or <ENT2>leucovorin</ENT2> in the adjuvant setting were included.,,,,T,,,,,c,,,,,0.0,,
16596970,722,D001308,D010862,Positive_Correlation,TRUE,<ENT2>Pilocarpine</ENT2> seizures cause age-dependent <ENT1>impairment in auditory location discrimination</ENT1>.,,,,T,,,,,c,,,,,0.0,,
16596970,721,D013226,D010862,Positive_Correlation,TRUE,"<ENT2>Pilocarpine</ENT2> on either day induced <ENT1>status epilepticus</ENT1>; <ENT1>status epilepticus</ENT1> at P45 resulted in CA3 cell loss and spontaneous seizures, whereas P20 rats had no cell loss or spontaneous seizures.",,,,T,,,,,c,,,,,0.5,,
16596970,723,D012640,D010862,Positive_Correlation,FALSE,<ENT2>Pilocarpine</ENT2> <ENT1>seizures</ENT1> cause age-dependent impairment in auditory location discrimination.,,,,T,,,,,c,,,,,0.0,,
16596970,723,D012640,D010862,Positive_Correlation,FALSE,"<ENT2>Pilocarpine</ENT2> on either day induced status epilepticus; status epilepticus at P45 resulted in CA3 cell loss and spontaneous <ENT1>seizures</ENT1>, whereas P20 rats had no cell loss or spontaneous <ENT1>seizures</ENT1>.",,,,T,,,,,c,,,,,0.0,,
16611040,724,D003550,1080,Association,FALSE,"However, despite the cloning of the <ENT2>cystic fibrosis transmembrane conductance regulator</ENT2> gene in 1989, over 15 years later a practical gene therapy for <ENT1>CF</ENT1> has not eventuated.",,,,T,,,,,c,,,,,0.0,,
16720068,761,D011596,D017374,Positive_Correlation,TRUE,"On the 10th day of <ENT2>paroxetine</ENT2> and alprazolam treatment, the patient exhibited marked <ENT1>psychomotor retardation</ENT1>, disorientation, and severe muscle rigidity with tremors.",,,,T,,,,,c,,,,,1.0,,
16720068,756,D011596,D000525,Positive_Correlation,TRUE,"On the 10th day of paroxetine and <ENT2>alprazolam</ENT2> treatment, the patient exhibited marked <ENT1>psychomotor retardation</ENT1>, disorientation, and severe muscle rigidity with tremors.",,,,T,,,,,c,,,,,1.0,,
16720068,763,D017374,D009459,Positive_Correlation,TRUE,Possible <ENT2>neuroleptic malignant syndrome</ENT2> related to concomitant treatment with <ENT1>paroxetine</ENT1> and alprazolam.,,,,T,,,,,c,,,,,0.0,,
16720068,763,D017374,D009459,Positive_Correlation,TRUE,"This patient presented with symptoms of <ENT2>neuroleptic malignant syndrome</ENT2> (<ENT2>NMS</ENT2>), thus demonstrating that <ENT2>NMS</ENT2>-like symptoms can occur after combined <ENT1>paroxetine</ENT1> and alprazolam treatment.",,,,T,,,,,c,,,,,0.666666667,,
16720068,760,D017374,D009127,Positive_Correlation,TRUE,"On the 10th day of <ENT1>paroxetine</ENT1> and alprazolam treatment, the patient exhibited marked psychomotor retardation, disorientation, and severe <ENT2>muscle rigidity</ENT2> with tremors.",,,,T,,,,,c,,,,,1.0,,
16720068,759,D017374,D014202,Positive_Correlation,TRUE,"On the 10th day of <ENT1>paroxetine</ENT1> and alprazolam treatment, the patient exhibited marked psychomotor retardation, disorientation, and severe muscle rigidity with <ENT2>tremors</ENT2>.",,,,T,,,,,c,,,,,1.0,,
16720068,762,D017374,D000525,Drug_Interaction,FALSE,Possible neuroleptic malignant syndrome related to concomitant treatment with <ENT1>paroxetine</ENT1> and <ENT2>alprazolam</ENT2>.,,,,T,,,,,c,,,,,0.0,,
16720068,762,D017374,D000525,Drug_Interaction,FALSE,Medical treatment was initiated at a daily dose of 20 mg <ENT1>paroxetine</ENT1> and 1.2 mg <ENT2>alprazolam</ENT2>.,,,,T,,,,,c,,,,,1.0,,
16720068,762,D017374,D000525,Drug_Interaction,FALSE,"On the 10th day of <ENT1>paroxetine</ENT1> and <ENT2>alprazolam</ENT2> treatment, the patient exhibited marked psychomotor retardation, disorientation, and severe muscle rigidity with tremors.",,,,T,,,,,w,,,,,1.0,,
16720068,762,D017374,D000525,Drug_Interaction,FALSE,"This patient presented with symptoms of neuroleptic malignant syndrome (NMS), thus demonstrating that NMS-like symptoms can occur after combined <ENT1>paroxetine</ENT1> and <ENT2>alprazolam</ENT2> treatment.",,,,T,,,,,c,,,,,0.0,,
16720068,757,D009459,D000525,Positive_Correlation,TRUE,Possible <ENT1>neuroleptic malignant syndrome</ENT1> related to concomitant treatment with paroxetine and <ENT2>alprazolam</ENT2>.,,,,T,,,,,c,,,,,1.0,,
16720068,757,D009459,D000525,Positive_Correlation,TRUE,"This patient presented with symptoms of <ENT1>neuroleptic malignant syndrome</ENT1> (<ENT1>NMS</ENT1>), thus demonstrating that <ENT1>NMS</ENT1>-like symptoms can occur after combined paroxetine and <ENT2>alprazolam</ENT2> treatment.",,,,T,,,,,c,,,,,1.0,,
16720068,744,D003402,D005334,Positive_Correlation,TRUE,"7 days later, the <ENT2>fever</ENT2> disappeared and the patient's serum <ENT1>CPK</ENT1> levels were normalized (175 IU/L).",,,,T,,,,,w,,,,,1.0,,
16720068,755,D009127,D000525,Positive_Correlation,TRUE,"On the 10th day of paroxetine and <ENT2>alprazolam</ENT2> treatment, the patient exhibited marked psychomotor retardation, disorientation, and severe <ENT1>muscle rigidity</ENT1> with tremors.",,,,T,,,,,c,,,,,1.0,,
16720068,754,D014202,D000525,Positive_Correlation,TRUE,"On the 10th day of paroxetine and <ENT2>alprazolam</ENT2> treatment, the patient exhibited marked psychomotor retardation, disorientation, and severe muscle rigidity with <ENT1>tremors</ENT1>.",,,,T,,,,,c,,,,,1.0,,
16781314,765,5317,D012873,Association,FALSE,This mutation differs from the <ENT1>PKP1</ENT1> gene pathology reported in 8 previously published individuals with this rare <ENT2>genodermatosis</ENT2>.,,,,T,,,,,w,,,,,0.0,,
16781314,767,5317,C536183,Association,TRUE,"<ENT2>Ectodermal dysplasia-skin fragility syndrome</ENT2> resulting from a new homozygous mutation, 888delC, in the desmosomal protein <ENT1>plakophilin 1</ENT1>.",,,,T,,,,,c,,,,,1.0,,
16781314,767,5317,C536183,Association,TRUE,"We report an unusual case of an inherited disorder of the desmosomal protein <ENT1>plakophilin 1</ENT1>, resulting in <ENT2>ectodermal dysplasia-skin fragility syndrome</ENT2>.",,,,T,,,,,c,,,,,1.0,,
16781314,764,5317,D030342,Association,TRUE,"We report an unusual case of an <ENT2>inherited disorder</ENT2> of the desmosomal protein <ENT1>plakophilin 1</ENT1>, resulting in ectodermal dysplasia-skin fragility syndrome.",,,,T,,,,,c,,,,,0.0,,
16781314,768,c|DEL888|C,C536183,Positive_Correlation,TRUE,"<ENT2>Ectodermal dysplasia-skin fragility syndrome</ENT2> resulting from a new homozygous mutation, <ENT1>888delC</ENT1>, in the desmosomal protein plakophilin 1.",,,,T,,,,,c,,,,,1.0,,
16801510,772,D008691,D016171,Association,TRUE,Six patients (3.6%) in the <ENT1>methadone</ENT1> group presented <ENT2>torsades de pointes</ENT2>.,,,,T,,,,,c,,,,,0.0,,
16801510,773,D008691,D008133,Positive_Correlation,TRUE,Drug-induced <ENT2>long QT syndrome</ENT2> in injection drug users receiving <ENT1>methadone</ENT1>: high frequency in hospitalized patients and risk factors.,,,,T,,,,,c,,,,,1.0,,
16801510,773,D008691,D008133,Positive_Correlation,TRUE,"In the inpatient setting, the frequency of <ENT2>QT interval prolongation</ENT2> with <ENT1>methadone</ENT1> treatment, its dose dependence, and the importance of cofactors such as drug-drug interactions remain unknown.",,,,T,,,,,c,,,,,1.0,,
16801510,773,D008691,D008133,Positive_Correlation,TRUE,"In addition to <ENT1>methadone</ENT1> dose, 15 demographic, biological, and pharmacological variables were considered as potential risk factors for <ENT2>QT prolongation</ENT2>.",,,,T,,,,,c,,,,,1.0,,
16801510,773,D008691,D008133,Positive_Correlation,TRUE,"RESULTS: Among 167 <ENT1>methadone</ENT1> maintenance patients, the prevalence of <ENT2>QTc prolongation</ENT2> to 0.50 second((1/2)) or longer was 16.2% compared with 0% in 80 control subjects.",,,,T,,,,,w,,,,,0.0,,
16801510,773,D008691,D008133,Positive_Correlation,TRUE,CONCLUSIONS: <ENT2>QT interval prolongation</ENT2> in <ENT1>methadone</ENT1> maintenance patients hospitalized in a tertiary care center is a frequent finding.,,,,T,,,,,c,,,,,1.0,,
16801510,773,D008691,D008133,Positive_Correlation,TRUE,"<ENT1>Methadone</ENT1> dose, presence of cytochrome P-450 3A4 inhibitors, potassium level, and liver function contribute to <ENT2>QT prolongation</ENT2>.",,,,T,,,,,c,,,,,1.0,,
16801510,773,D008691,D008133,Positive_Correlation,TRUE,<ENT2>Long QT syndrome</ENT2> can occur with low doses of <ENT1>methadone</ENT1>.,,,,T,,,,,c,,,,,1.0,,
16801510,771,D011188,D008133,Association,TRUE,"Methadone dose, presence of cytochrome P-450 3A4 inhibitors, <ENT1>potassium</ENT1> level, and liver function contribute to <ENT2>QT prolongation</ENT2>.",,,,T,,,,,c,,,,,0.0,,
16801510,769,D008133,D065692,Association,TRUE,"Methadone dose, presence of <ENT2>cytochrome P-450 3A4 inhibitors</ENT2>, potassium level, and liver function contribute to <ENT1>QT prolongation</ENT1>.",,,,T,,,,,c,,,,,0.0,,
16810074,778,D009638,D019335,Negative_Correlation,TRUE,Maximal contraction to <ENT1>norepinephrine</ENT1> was modestly reduced in arteries from <ENT2>LNNA</ENT2> compared with control rats whereas the maximum contraction to ET-1 was significantly reduced (54% control).,,,,T,,,,,c,,,,,1.0,,
16810074,774,D018738,D019335,Association,TRUE,"Similarly, ganglionic blockade with <ENT1>hexamethonium</ENT1> caused a significantly greater fall in <ENT2>LNNA</ENT2> hypertensive rats (76 +/- 9 mm Hg) compared with control rats (35 +/- 10 mm Hg).",,,,T,,,,,c,,,,,0.0,,
16810074,775,D018738,D006973,Association,TRUE,"Similarly, ganglionic blockade with <ENT1>hexamethonium</ENT1> caused a significantly greater fall in LNNA <ENT2>hypertensive</ENT2> rats (76 +/- 9 mm Hg) compared with control rats (35 +/- 10 mm Hg).",,,,T,,,,,c,,,,,0.0,,
16810074,783,D009569,D018754,Negative_Correlation,FALSE,Loss of endothelial cell-derived <ENT1>nitric oxide</ENT1> (<ENT1>NO</ENT1>) in hypertension is a hallmark of <ENT2>arterial dysfunction</ENT2>.,,,,T,,,,,c,,,,,0.0,,
16810074,785,D009569,D006973,Negative_Correlation,FALSE,Mechanisms of <ENT2>hypertension</ENT2> induced by <ENT1>nitric oxide</ENT1> (<ENT1>NO</ENT1>) deficiency: focus on venous function.,,,,T,,,,,c,,,,,0.0,,
16810074,785,D009569,D006973,Negative_Correlation,FALSE,Loss of endothelial cell-derived <ENT1>nitric oxide</ENT1> (<ENT1>NO</ENT1>) in <ENT2>hypertension</ENT2> is a hallmark of arterial dysfunction.,,,,T,,,,,c,,,,,1.0,,
16810074,785,D009569,D006973,Negative_Correlation,FALSE,"Experimental <ENT2>hypertension</ENT2> created by the removal of <ENT1>NO</ENT1>, however, involves mechanisms in addition to decreased arterial vasodilator activity.",,,,T,,,,,c,,,,,1.0,,
16810074,785,D009569,D006973,Negative_Correlation,FALSE,"These data suggest that while <ENT1>NO</ENT1> deficiency increases oxidative stress and sympathetic activity in both arterial and venous vessels, the impact on veins does not make a major contribution to this form of <ENT2>hypertension</ENT2>.",,,,T,,,,,c,,,,,1.0,,
16810074,779,D019335,24598,Negative_Correlation,FALSE,Rats were treated with the <ENT2>NO synthase</ENT2> inhibitor <ENT1>LNNA</ENT1> (0.5 g/L in drinking water) for 2 weeks.,,,,T,,,,,c,,,,,1.0,,
16810074,776,D019335,C001803,Negative_Correlation,TRUE,"The superoxide scavenger <ENT2>tempol</ENT2> (30, 100, and 300 micromol kg(-1), IV) did not change arterial pressure in control rats but caused a dose-dependent decrease in <ENT1>LNNA</ENT1> rats (-18 +/- 8, -26 +/- 15, and -54 +/- 11 mm Hg).",,,,T,,,,,c,,,,,1.0,,
16810074,782,D019335,D006973,Positive_Correlation,FALSE,We hypothesized that increased venous smooth muscle (venomotor) tone plays a role in <ENT1>Nomega-nitro-L-arginine</ENT1> (<ENT1>LNNA</ENT1>) <ENT2>hypertension</ENT2> through these mechanisms.,,,,T,,,,,c,,,,,0.0,,
16810074,782,D019335,D006973,Positive_Correlation,FALSE,"Mean circulatory filling pressure, an in vivo measure of venomotor tone, was not elevated in <ENT1>LNNA</ENT1> <ENT2>hypertension</ENT2> at 1 or 2 weeks after <ENT1>LNNA</ENT1>.",,,,T,,,,,c,,,,,0.5,,
16810074,782,D019335,D006973,Positive_Correlation,FALSE,"Similarly, ganglionic blockade with hexamethonium caused a significantly greater fall in <ENT1>LNNA</ENT1> <ENT2>hypertensive</ENT2> rats (76 +/- 9 mm Hg) compared with control rats (35 +/- 10 mm Hg).",,,,T,,,,,c,,,,,1.0,,
16810074,781,D019335,24323,Negative_Correlation,TRUE,Maximal contraction to norepinephrine was modestly reduced in arteries from <ENT1>LNNA</ENT1> compared with control rats whereas the maximum contraction to <ENT2>ET-1</ENT2> was significantly reduced (54% control).,,,,T,,,,,c,,,,,0.0,,
16810074,780,D019335,D013481,Positive_Correlation,TRUE,"The <ENT2>superoxide</ENT2> scavenger tempol (30, 100, and 300 micromol kg(-1), IV) did not change arterial pressure in control rats but caused a dose-dependent decrease in <ENT1>LNNA</ENT1> rats (-18 +/- 8, -26 +/- 15, and -54 +/- 11 mm Hg).",,,,T,,,,,w,,,,,0.0,,
16810074,780,D019335,D013481,Positive_Correlation,TRUE,"Carotid arteries, vena cava, and sympathetic ganglia from <ENT1>LNNA</ENT1> rats had higher basal levels of <ENT2>superoxide</ENT2> compared with those from control rats.",,,,T,,,,,c,,,,,1.0,,
16810074,777,C001803,D013481,Negative_Correlation,FALSE,"The <ENT2>superoxide</ENT2> scavenger <ENT1>tempol</ENT1> (30, 100, and 300 micromol kg(-1), IV) did not change arterial pressure in control rats but caused a dose-dependent decrease in LNNA rats (-18 +/- 8, -26 +/- 15, and -54 +/- 11 mm Hg).",,,,T,,,,,c,,,,,0.0,,
16820346,788,D009566,D003907,Negative_Correlation,TRUE,"Plasma <ENT1>nitrate</ENT1>/nitrite (NOx) was decreased in <ENT2>dex</ENT2>-treated rats compared to saline-treated rats (11.2 +/- 1.08 microm, 15.3 +/- 1.17 microm, respectively, P < 0.05).",,,,T,,,,,c,,,,,1.0,,
16820346,792,D000069059,D003907,Negative_Correlation,TRUE,<ENT1>Atorvastatin</ENT1> prevented and reversed <ENT2>dexamethasone</ENT2>-induced hypertension in the rat.,,,,T,,,,,c,,,,,1.0,,
16820346,792,D000069059,D003907,Negative_Correlation,TRUE,"To assess the antioxidant effects of <ENT1>atorvastatin</ENT1> (<ENT1>atorva</ENT1>) on <ENT2>dexamethasone</ENT2> (<ENT2>dex</ENT2>)-induced hypertension, 60 male Sprague-Dawley rats were treated with <ENT1>atorva</ENT1> 30 mg/kg/day or tap water for 15 days.",,,,T,Y,,,,c,,,"11,12,21,22",,0.0,,
16820346,792,D000069059,D003907,Negative_Correlation,TRUE,"In this prevention study, SBP in the <ENT1>atorva</ENT1> + <ENT2>dex</ENT2> group was increased from 115 +/- 0.4 to 124 +/- 1.5 mmHg, but this was significantly lower than in the <ENT2>dex</ENT2>-only group (P' < 0.05).",,,,T,,,,,c,,,,,1.0,,
16820346,792,D000069059,D003907,Negative_Correlation,TRUE,"<ENT1>Atorva</ENT1> reversed <ENT2>dex</ENT2>-induced hypertension (129 +/- 0.6 mmHg, vs. 135 +/- 0.6 mmHg P' < 0.05) and decreased plasma superoxide (7931 +/- 392.8 <ENT2>dex</ENT2>, 1187 +/- 441.2 <ENT1>atorva</ENT1> + <ENT2>dex</ENT2>, P < 0.0001).",,,,T,,,,,c,,,,,0.166666667,,
16820346,792,D000069059,D003907,Negative_Correlation,TRUE,"Thus, <ENT1>atorvastatin</ENT1> prevented and reversed <ENT2>dexamethasone</ENT2>-induced hypertension in the rat.",,,,T,,,,,c,,,,,1.0,,
16820346,791,D000069059,D006973,Negative_Correlation,TRUE,<ENT1>Atorvastatin</ENT1> prevented and reversed dexamethasone-induced <ENT2>hypertension</ENT2> in the rat.,,,,T,,,,,c,,,,,1.0,,
16820346,791,D000069059,D006973,Negative_Correlation,TRUE,"To assess the antioxidant effects of <ENT1>atorvastatin</ENT1> (<ENT1>atorva</ENT1>) on dexamethasone (dex)-induced <ENT2>hypertension</ENT2>, 60 male Sprague-Dawley rats were treated with <ENT1>atorva</ENT1> 30 mg/kg/day or tap water for 15 days.",,,,T,,Y,,,c,,,,,1.0,,
16820346,791,D000069059,D006973,Negative_Correlation,TRUE,"<ENT1>Atorva</ENT1> reversed dex-induced <ENT2>hypertension</ENT2> (129 +/- 0.6 mmHg, vs. 135 +/- 0.6 mmHg P' < 0.05) and decreased plasma superoxide (7931 +/- 392.8 dex, 1187 +/- 441.2 <ENT1>atorva</ENT1> + dex, P < 0.0001).",,,,T,,,,,c,,,,,0.5,,
16820346,791,D000069059,D006973,Negative_Correlation,TRUE,"Thus, <ENT1>atorvastatin</ENT1> prevented and reversed dexamethasone-induced <ENT2>hypertension</ENT2> in the rat.",,,,T,,,,,c,,,,,1.0,,
16820346,787,D003907,D009573,Negative_Correlation,TRUE,"Plasma nitrate/<ENT2>nitrite</ENT2> (NOx) was decreased in <ENT1>dex</ENT1>-treated rats compared to saline-treated rats (11.2 +/- 1.08 microm, 15.3 +/- 1.17 microm, respectively, P < 0.05).",,,,T,,,,,c,,,,,1.0,,
16820346,790,D003907,D006973,Positive_Correlation,FALSE,Atorvastatin prevented and reversed <ENT1>dexamethasone</ENT1>-induced <ENT2>hypertension</ENT2> in the rat.,,,,T,,,,,c,,,,,1.0,,
16820346,790,D003907,D006973,Positive_Correlation,FALSE,"To assess the antioxidant effects of atorvastatin (atorva) on <ENT1>dexamethasone</ENT1> (<ENT1>dex</ENT1>)-induced <ENT2>hypertension</ENT2>, 60 male Sprague-Dawley rats were treated with atorva 30 mg/kg/day or tap water for 15 days.",,,,T,,,,,c,,,,,1.0,,
16820346,790,D003907,D006973,Positive_Correlation,FALSE,"Atorva reversed <ENT1>dex</ENT1>-induced <ENT2>hypertension</ENT2> (129 +/- 0.6 mmHg, vs. 135 +/- 0.6 mmHg P' < 0.05) and decreased plasma superoxide (7931 +/- 392.8 <ENT1>dex</ENT1>, 1187 +/- 441.2 atorva + <ENT1>dex</ENT1>, P < 0.0001).",,,,T,,,,,c,,,,,0.333333333,,
16820346,790,D003907,D006973,Positive_Correlation,FALSE,"Thus, atorvastatin prevented and reversed <ENT1>dexamethasone</ENT1>-induced <ENT2>hypertension</ENT2> in the rat.",,,,T,,,,,c,,,,,1.0,,
16820346,786,D003907,D009589,Negative_Correlation,TRUE,"Plasma nitrate/nitrite (<ENT2>NOx</ENT2>) was decreased in <ENT1>dex</ENT1>-treated rats compared to saline-treated rats (11.2 +/- 1.08 microm, 15.3 +/- 1.17 microm, respectively, P < 0.05).",,,,T,,,,,c,,,,,1.0,,
16820346,789,D003907,D013481,Positive_Correlation,TRUE,"<ENT1>Dex</ENT1> increased systolic blood pressure (SBP) from 109 +/- 1.8 to 135 +/- 0.6 mmHg and plasma <ENT2>superoxide</ENT2> (5711 +/- 284.9 saline, 7931 +/- 392.8 U/ml <ENT1>dex</ENT1>, P < 0.001).",,,,T,,,,,c,,,,,1.0,,
16820346,789,D003907,D013481,Positive_Correlation,TRUE,"Atorva reversed <ENT1>dex</ENT1>-induced hypertension (129 +/- 0.6 mmHg, vs. 135 +/- 0.6 mmHg P' < 0.05) and decreased plasma <ENT2>superoxide</ENT2> (7931 +/- 392.8 <ENT1>dex</ENT1>, 1187 +/- 441.2 atorva + <ENT1>dex</ENT1>, P < 0.0001).",,,,T,,,,,c,,,,,1.0,,
16838170,802,D003924,D020909,Negative_Correlation,TRUE,This trial aimed at evaluating the effect of <ENT2>acarbose</ENT2> compared to placebo in the prevention of <ENT1>type 2 diabetes mellitus</ENT1>.,,,,T,,Y,,,w,,,,,1.0,,
16838170,805,D003924,rs4810424,Positive_Correlation,TRUE,"Haplotype analysis based on three SNPs (<ENT2>rs4810424</ENT2>, rs2071197, and rs3818247) representing the linkage disequilibrium blocks in our study population indicated that the conversion to <ENT1>type 2 diabetes mellitus</ENT1> was dependent on the number of risk alleles in different haplotypes in women.",,,,T,,,,,c,,,,,1.0,,
16838170,806,D003924,3172,Association,TRUE,Single nucleotide polymorphisms of the <ENT2>HNF4alpha</ENT2> gene are associated with the conversion to <ENT1>type 2 diabetes mellitus</ENT1>: the STOP-NIDDM trial.,,,,T,,,,,c,,,,,1.0,,
16838170,806,D003924,3172,Association,TRUE,"We investigated whether single nucleotide polymorphisms (SNPs) of <ENT2>HNF4A</ENT2>, encoding <ENT2>HNF4alpha</ENT2>, influenced the conversion from impaired glucose tolerance (IGT) to <ENT1>type 2 diabetes mellitus</ENT1> in subjects of the STOP-NIDDM trial.",,,,T,,Y,,,w,,,,,0.5,,
16838170,806,D003924,3172,Association,TRUE,Our results suggest that SNPs of <ENT2>HNF4A</ENT2> and their haplotypes predispose to <ENT1>type 2 diabetes mellitus</ENT1> in female subjects of the STOP-NIDDM study population.,,,,T,,,,,c,,,,,0.0,,
16838170,804,D003924,rs2071197,Positive_Correlation,TRUE,"Haplotype analysis based on three SNPs (rs4810424, <ENT2>rs2071197</ENT2>, and rs3818247) representing the linkage disequilibrium blocks in our study population indicated that the conversion to <ENT1>type 2 diabetes mellitus</ENT1> was dependent on the number of risk alleles in different haplotypes in women.",,,,T,,,,,c,,,,,1.0,,
16838170,803,D003924,rs3818247,Positive_Correlation,TRUE,"Haplotype analysis based on three SNPs (rs4810424, rs2071197, and <ENT2>rs3818247</ENT2>) representing the linkage disequilibrium blocks in our study population indicated that the conversion to <ENT1>type 2 diabetes mellitus</ENT1> was dependent on the number of risk alleles in different haplotypes in women.",,,,T,,,,,c,,,,,1.0,,
16838170,796,rs4810424,D003920,Positive_Correlation,TRUE,"Female carriers of the less frequent C allele of <ENT1>rs4810424</ENT1> had a 1.7-fold elevated risk [95% confidence interval (CI) 1.09-2.66; P=0.020] for the conversion to <ENT2>diabetes</ENT2> compared to women with the common genotype after the adjustment for age, treatment group (placebo or acarbose), smoking, weight at baseline, and weight change.",,,,T,,,,,c,,,,,1.0,,
16838170,795,rs4810424,rs2071197,Association,TRUE,"Haplotype analysis based on three SNPs (<ENT1>rs4810424</ENT1>, <ENT2>rs2071197</ENT2>, and rs3818247) representing the linkage disequilibrium blocks in our study population indicated that the conversion to type 2 diabetes mellitus was dependent on the number of risk alleles in different haplotypes in women.",,,,T,,,,,c,,,,,1.0,,
16838170,794,rs4810424,rs3818247,Association,TRUE,"Haplotype analysis based on three SNPs (<ENT1>rs4810424</ENT1>, rs2071197, and <ENT2>rs3818247</ENT2>) representing the linkage disequilibrium blocks in our study population indicated that the conversion to type 2 diabetes mellitus was dependent on the number of risk alleles in different haplotypes in women.",,,,T,,,,,c,,,,,1.0,,
16838170,793,rs2071197,rs3818247,Association,TRUE,"Haplotype analysis based on three SNPs (rs4810424, <ENT1>rs2071197</ENT1>, and <ENT2>rs3818247</ENT2>) representing the linkage disequilibrium blocks in our study population indicated that the conversion to type 2 diabetes mellitus was dependent on the number of risk alleles in different haplotypes in women.",,,,T,,,,,c,,,,,1.0,,
16840830,811,D018761,4221,Association,TRUE,Two novel mutations in the <ENT2>MEN1</ENT2> gene in subjects with <ENT1>multiple endocrine neoplasia-1</ENT1>.,,,,T,,,,,w,,,,,0.0,,
16840830,811,D018761,4221,Association,TRUE,"<ENT1>Multiple endocrine neoplasia type 1</ENT1> (<ENT1>MEN1</ENT1>) is characterized by parathyroid, enteropancreatic endocrine and pituitary adenomas as well as germline mutation of the <ENT2>MEN1</ENT2> gene.",,,,T,,,,,c,,,,,1.0,,
16843501,815,5888,D013274,Association,TRUE,DNA damage and repair in <ENT2>gastric cancer</ENT2>--a correlation with the hOGG1 and <ENT1>RAD51</ENT1> genes polymorphisms.,,,,T,,,,,c,,,,,1.0,,
16843501,815,5888,D013274,Association,TRUE,"We observed a strong association between <ENT2>gastric cancer</ENT2> occurrence, impaired DNA repair in human lymphocytes and the G/C genotype of the G135C polymorphism of the <ENT1>RAD51</ENT1> gene.",,,,T,,,,,c,,,,,1.0,,
16843501,815,5888,D013274,Association,TRUE,"Therefore, our result suggest that the G135C polymorphism of the <ENT1>RAD51</ENT1> gene may be linked with <ENT2>gastric cancer</ENT2> by the modulation of the cellular response to oxidative stress and this polymorphism may be a useful additional marker in this disease along with the genetic or/and environmental indicators of oxidative stress.",,,,T,,,,,c,,,,,1.0,,
16843501,812,4968,D013274,Association,TRUE,DNA damage and repair in <ENT2>gastric cancer</ENT2>--a correlation with the <ENT1>hOGG1</ENT1> and RAD51 genes polymorphisms.,,,,T,,,,,c,,,,,1.0,,
16843501,812,4968,D013274,Association,TRUE,"We did not observe any correlation between the Ser1245Cys polymorphism of the <ENT1>hOGG1</ENT1> gene and <ENT2>gastric cancer</ENT2>, including subjects with impaired DNA repair and/or high levels of endogenous oxidative DNA lesions.",,,,T,,,,,c,,,,,1.0,,
16843501,813,g|SUB|G|135|C,D013274,Association,TRUE,"We observed a strong association between <ENT2>gastric cancer</ENT2> occurrence, impaired DNA repair in human lymphocytes and the G/C genotype of the <ENT1>G135C</ENT1> polymorphism of the RAD51 gene.",,,,T,,,,,c,,,,,1.0,,
16843501,813,g|SUB|G|135|C,D013274,Association,TRUE,"Therefore, our result suggest that the <ENT1>G135C</ENT1> polymorphism of the RAD51 gene may be linked with <ENT2>gastric cancer</ENT2> by the modulation of the cellular response to oxidative stress and this polymorphism may be a useful additional marker in this disease along with the genetic or/and environmental indicators of oxidative stress.",,,,T,,,,,c,,,,,1.0,,
16843501,814,g|SUB|G||C,D013274,Association,TRUE,"We observed a strong association between <ENT2>gastric cancer</ENT2> occurrence, impaired DNA repair in human lymphocytes and the <ENT1>G/C</ENT1> genotype of the G135C polymorphism of the RAD51 gene.",,,,T,,,,,c,,,,,1.0,,
16849419,819,c|DEL||85,C562793,Positive_Correlation,TRUE,An unrelated individual with <ENT2>HHRH</ENT2> was a compound heterozygote for an <ENT1>85-bp deletion</ENT1> in intron 10 and a G-to-A substitution at the last nucleotide in exon 7.,,,,T,Y,,,,w,,,,,1.0,,
16849419,816,C097949,D053565,Positive_Correlation,FALSE,"CONTEXT: Hereditary hypophosphatemic rickets with hypercalciuria (HHRH) is a rare metabolic disorder, characterized by hypophosphatemia and rickets/osteomalacia with increased serum <ENT1>1,25-dihydroxyvitamin D</ENT1> [<ENT1>1,25-(OH)(2)D</ENT1>] resulting in <ENT2>hypercalciuria</ENT2>.",,,,T,,,,,c,,,,,1.0,,
16849419,817,C097949,C562793,Positive_Correlation,FALSE,"CONTEXT: <ENT2>Hereditary hypophosphatemic rickets with hypercalciuria</ENT2> (<ENT2>HHRH</ENT2>) is a rare metabolic disorder, characterized by hypophosphatemia and rickets/osteomalacia with increased serum <ENT1>1,25-dihydroxyvitamin D</ENT1> [<ENT1>1,25-(OH)(2)D</ENT1>] resulting in hypercalciuria.",,,,T,,,,,c,,,"11,12,21,22",,0.75,,
16849419,818,c|SUB|G||A,C562793,Association,TRUE,An unrelated individual with <ENT2>HHRH</ENT2> was a compound heterozygote for an 85-bp deletion in intron 10 and a <ENT1>G-to-A</ENT1> substitution at the last nucleotide in exon 7.,,,,T,Y,,,,w,,,,,0.0,,
16849419,821,142680,C562793,Association,TRUE,Intronic deletions in the <ENT1>SLC34A3</ENT1> gene cause <ENT2>hereditary hypophosphatemic rickets with hypercalciuria</ENT2>.,,,,T,,,,,c,,,,,1.0,,
16849419,821,142680,C562793,Association,TRUE,"OBJECTIVE: Our objective was to determine whether mutations in the <ENT1>SLC34A3</ENT1> gene, which encodes <ENT1>sodium-phosphate cotransporter type IIc</ENT1>, are responsible for the occurrence of <ENT2>HHRH</ENT2>.",,,,T,,Y,,,c,,,,,1.0,,
16849419,821,142680,C562793,Association,TRUE,CONCLUSION: <ENT2>HHRH</ENT2> is caused by biallelic mutations in the <ENT1>SLC34A3</ENT1> gene.,,,,T,,,,,c,,,,,1.0,,
16867021,826,C069357,C052075,Negative_Correlation,TRUE,"<ENT1>(R)-alpha-methylhistamine</ENT1> (<ENT1>RAMH</ENT1>) (5 microg i.c.v.) and <ENT2>thioperamide</ENT2> (<ENT2>THP</ENT2>) (15 mg/kg i.p.), per se did not cause catalepsy.",,,,T,,,,,c,,,,,1.0,,
16867021,826,C069357,C052075,Negative_Correlation,TRUE,"However, pretreatment with <ENT1>RAMH</ENT1> significantly reversed such an effect of <ENT2>THP</ENT2> (15 mg/kg i.p.).",,,,T,,,,,c,,,,,1.0,,
16867021,826,C069357,C052075,Negative_Correlation,TRUE,"<ENT1>RAMH</ENT1> per se showed significant reduction in locomotor time, distance traveled and average speed but <ENT2>THP</ENT2> (15 mg/kg i.p.) per se had no effect on these parameters.",,,,T,,,,,c,,,,,1.0,,
16867021,826,C069357,C052075,Negative_Correlation,TRUE,Pretreatment with <ENT1>RAMH</ENT1> (5 microg i.c.v.) could partially reverse such effects of <ENT2>THP</ENT2> (3.75 mg/kg i.p.).,,,,T,,,,,c,,,,,0.0,,
16867021,826,C069357,C052075,Negative_Correlation,TRUE,Such effects of <ENT2>THP</ENT2> were reversed by <ENT1>RAMH</ENT1> indicating the involvement of histamine H(3)-receptors.,,,,T,,,,,c,,,,,1.0,,
16867021,827,C069357,99296,Association,TRUE,Such effects of THP were reversed by <ENT1>RAMH</ENT1> indicating the involvement of <ENT2>histamine H(3)-receptors</ENT2>.,,,,T,,,,,c,,,,,1.0,,
16867021,822,D012559,D054828,Negative_Correlation,TRUE,Findings suggest a potential for <ENT2>H(3)-receptor antagonists</ENT2> in improving the refractory cases of <ENT1>schizophrenia</ENT1>.,,,,T,,,,,c,,,,,1.0,,
16867021,832,D000661,C052075,Negative_Correlation,TRUE,"On <ENT1>amphetamine</ENT1>-induced hyperactivity, <ENT2>THP</ENT2> (3.75 and 7.5 mg/kg i.p.) reduced locomotor time, distance traveled and average speed (P < 0.05).",,,,T,,,,,c,,,,,0.0,,
16867021,832,D000661,C052075,Negative_Correlation,TRUE,"<ENT2>THP</ENT2> exhibited an antipsychotic-like profile by potentiating haloperidol-induced catalepsy, reducing <ENT1>amphetamine</ENT1>-induced hyperactivity and reducing apomorphine-induced climbing in mice.",,,,T,Y,,,,c,,,,,1.0,,
16867021,825,D000661,D006948,Positive_Correlation,FALSE,"On <ENT1>amphetamine</ENT1>-induced <ENT2>hyperactivity</ENT2>, THP (3.75 and 7.5 mg/kg i.p.) reduced locomotor time, distance traveled and average speed (P < 0.05).",,,,T,,,,,c,,,,,1.0,,
16867021,825,D000661,D006948,Positive_Correlation,FALSE,"THP exhibited an antipsychotic-like profile by potentiating haloperidol-induced catalepsy, reducing <ENT1>amphetamine</ENT1>-induced <ENT2>hyperactivity</ENT2> and reducing apomorphine-induced climbing in mice.",,,,T,,,,,c,,,,,1.0,,
16867021,830,C052075,D006220,Positive_Correlation,TRUE,"Administration of <ENT1>THP</ENT1> (3.75, 7.5 and 15 mg/kg i.p.) 1 h prior to <ENT2>haloperidol</ENT2> resulted in a dose-dependent increase in the catalepsy times (P < 0.05).",,,,T,,,,,c,,,,,1.0,,
16867021,830,C052075,D006220,Positive_Correlation,TRUE,"<ENT1>THP</ENT1> exhibited an antipsychotic-like profile by potentiating <ENT2>haloperidol</ENT2>-induced catalepsy, reducing amphetamine-induced hyperactivity and reducing apomorphine-induced climbing in mice.",,,,T,Y,,,,c,,,,,0.0,,
16867021,828,C052075,D001058,Negative_Correlation,TRUE,Climbing behavior induced by <ENT2>apomorphine</ENT2> was reduced in animals treated with <ENT1>THP</ENT1>.,,,,T,,,,,c,,,,,1.0,,
16867021,828,C052075,D001058,Negative_Correlation,TRUE,"<ENT1>THP</ENT1> exhibited an antipsychotic-like profile by potentiating haloperidol-induced catalepsy, reducing amphetamine-induced hyperactivity and reducing <ENT2>apomorphine</ENT2>-induced climbing in mice.",,,,T,Y,,,,c,,,,,1.0,,
16867021,833,C052075,99296,Negative_Correlation,TRUE,"Antipsychotic-like profile of <ENT1>thioperamide</ENT1>, a selective <ENT2>H3-receptor</ENT2> antagonist in mice.",,,,T,,,,,c,,,,,1.0,,
16867021,833,C052075,99296,Negative_Correlation,TRUE,Such effects of <ENT1>THP</ENT1> were reversed by RAMH indicating the involvement of <ENT2>histamine H(3)-receptors</ENT2>.,,,,T,,,,,w,,,,,0.0,,
16867021,829,C052075,D002375,Positive_Correlation,TRUE,"(R)-alpha-methylhistamine (RAMH) (5 microg i.c.v.) and <ENT1>thioperamide</ENT1> (<ENT1>THP</ENT1>) (15 mg/kg i.p.), per se did not cause <ENT2>catalepsy</ENT2>.",,,,T,,,,,c,,,,,1.0,,
16867021,829,C052075,D002375,Positive_Correlation,TRUE,"Administration of <ENT1>THP</ENT1> (3.75, 7.5 and 15 mg/kg i.p.) 1 h prior to haloperidol resulted in a dose-dependent increase in the <ENT2>catalepsy</ENT2> times (P < 0.05).",,,,T,,,,,c,,,,,1.0,,
16867021,829,C052075,D002375,Positive_Correlation,TRUE,"<ENT1>THP</ENT1> exhibited an antipsychotic-like profile by potentiating haloperidol-induced <ENT2>catalepsy</ENT2>, reducing amphetamine-induced hyperactivity and reducing apomorphine-induced climbing in mice.",,,,T,,,,,c,,,,,1.0,,
16867021,831,C052075,D006948,Negative_Correlation,TRUE,"On amphetamine-induced <ENT2>hyperactivity</ENT2>, <ENT1>THP</ENT1> (3.75 and 7.5 mg/kg i.p.) reduced locomotor time, distance traveled and average speed (P < 0.05).",,,,T,,,,,c,,,,,1.0,,
16867021,831,C052075,D006948,Negative_Correlation,TRUE,"<ENT1>THP</ENT1> exhibited an antipsychotic-like profile by potentiating haloperidol-induced catalepsy, reducing amphetamine-induced <ENT2>hyperactivity</ENT2> and reducing apomorphine-induced climbing in mice.",,,,T,,,,,c,,,,,0.0,,
16867021,824,D006220,D002375,Positive_Correlation,FALSE,"<ENT2>Catalepsy</ENT2> was induced by <ENT1>haloperidol</ENT1> (2 mg/kg p.o.), while apomorphine (1.5 mg/kg s.c.) and amphetamine (2 mg/kg s.c.) were used for studying climbing behavior and locomotor activities, respectively.",,,,T,,,,,c,,,,,1.0,,
16867021,824,D006220,D002375,Positive_Correlation,FALSE,"Administration of THP (3.75, 7.5 and 15 mg/kg i.p.) 1 h prior to <ENT1>haloperidol</ENT1> resulted in a dose-dependent increase in the <ENT2>catalepsy</ENT2> times (P < 0.05).",,,,T,,,,,c,,,,,0.0,,
16867021,824,D006220,D002375,Positive_Correlation,FALSE,"THP exhibited an antipsychotic-like profile by potentiating <ENT1>haloperidol</ENT1>-induced <ENT2>catalepsy</ENT2>, reducing amphetamine-induced hyperactivity and reducing apomorphine-induced climbing in mice.",,,,T,,,,,c,,,,,1.0,,
16867021,823,D002375,D014150,Positive_Correlation,FALSE,"The present study was designed to study the effect of histamine H(3)-receptor ligands on <ENT2>neuroleptic</ENT2>-induced <ENT1>catalepsy</ENT1>, apomorphine-induced climbing behavior and amphetamine-induced locomotor activities in mice.",,,,T,,,,,c,,,,,0.0,,
16867021,823,D002375,D014150,Positive_Correlation,FALSE,"THP exhibited an <ENT2>antipsychotic</ENT2>-like profile by potentiating haloperidol-induced <ENT1>catalepsy</ENT1>, reducing amphetamine-induced hyperactivity and reducing apomorphine-induced climbing in mice.",,,,T,,,,,w,,,,,0.0,,
16867246,834,D012559,1813,Association,TRUE,Association of <ENT2>DRD2</ENT2> polymorphisms and chlorpromazine-induced extrapyramidal syndrome in Chinese <ENT1>schizophrenic</ENT1> patients.,,,,T,,,,,c,,,,,0.0,,
16867246,834,D012559,1813,Association,TRUE,"Recently, many research groups have reported on the positive relationship between the genetic variations in the <ENT2>DRD2</ENT2> gene and the therapeutic response in <ENT1>schizophrenia</ENT1> patients as a result of the role of variations in the receptor in modulating receptor expression.",,,,T,,,,,c,,,,,1.0,,
16867246,834,D012559,1813,Association,TRUE,"In this study, we evaluate the role <ENT2>DRD2</ENT2> plays in chlorpromazine-induced EPS in <ENT1>schizophrenic</ENT1> patients.",,,,T,,,,,w,,,,,0.0,,
16867246,834,D012559,1813,Association,TRUE,"METHODS: We identified seven SNP(single nucleotide polymorphism) (-141Cins>del, TaqIB, TaqID, Ser311Cys, rs6275, rs6277 and TaqIA) in the <ENT2>DRD2</ENT2> gene in 146 <ENT1>schizophrenic</ENT1> inpatients (59 with EPS and 87 without EPS according to the Simpson-Angus Scale) treated with chlorpromazine after 8 weeks.",,,,T,,,,,c,,,,,1.0,,
16867246,834,D012559,1813,Association,TRUE,"CONCLUSION: Our results did not lend strong support to the view that the genetic variation of the <ENT2>DRD2</ENT2> gene plays a major role in the individually variable adverse effect induced by chlorpromazine, at least in Chinese patients with <ENT1>schizophrenia</ENT1>.",,,,T,,,,,w,,,,,0.0,,
16867246,836,D012559,D002746,Negative_Correlation,FALSE,Association of DRD2 polymorphisms and <ENT2>chlorpromazine</ENT2>-induced extrapyramidal syndrome in Chinese <ENT1>schizophrenic</ENT1> patients.,,,,T,,,,,c,,,,,0.0,,
16867246,836,D012559,D002746,Negative_Correlation,FALSE,"In this study, we evaluate the role DRD2 plays in <ENT2>chlorpromazine</ENT2>-induced EPS in <ENT1>schizophrenic</ENT1> patients.",,,,T,,,,,c,,,,,0.0,,
16867246,836,D012559,D002746,Negative_Correlation,FALSE,"METHODS: We identified seven SNP(single nucleotide polymorphism) (-141Cins>del, TaqIB, TaqID, Ser311Cys, rs6275, rs6277 and TaqIA) in the DRD2 gene in 146 <ENT1>schizophrenic</ENT1> inpatients (59 with EPS and 87 without EPS according to the Simpson-Angus Scale) treated with <ENT2>chlorpromazine</ENT2> after 8 weeks.",,,,T,,,,,c,,,,,1.0,,
16867246,836,D012559,D002746,Negative_Correlation,FALSE,"CONCLUSION: Our results did not lend strong support to the view that the genetic variation of the DRD2 gene plays a major role in the individually variable adverse effect induced by <ENT2>chlorpromazine</ENT2>, at least in Chinese patients with <ENT1>schizophrenia</ENT1>.",,,,T,,,,,c,,,,,0.0,,
16867246,837,1813,D001480,Association,FALSE,Association of <ENT1>DRD2</ENT1> polymorphisms and chlorpromazine-induced <ENT2>extrapyramidal syndrome</ENT2> in Chinese schizophrenic patients.,,,,T,,,,,c,,,,,1.0,,
16867246,837,1813,D001480,Association,FALSE,AIM: <ENT2>Extrapyramidal syndrome</ENT2> (<ENT2>EPS</ENT2>) is most commonly affected by typical antipsychotic drugs that have a high affinity with the <ENT1>D2 receptor</ENT1>.,,,,T,,,,,w,,,,,0.0,TRUE,
16867246,837,1813,D001480,Association,FALSE,"In this study, we evaluate the role <ENT1>DRD2</ENT1> plays in chlorpromazine-induced <ENT2>EPS</ENT2> in schizophrenic patients.",,,,T,,Y,,,c,,,,,0.0,,
16867246,837,1813,D001480,Association,FALSE,"METHODS: We identified seven SNP(single nucleotide polymorphism) (-141Cins>del, TaqIB, TaqID, Ser311Cys, rs6275, rs6277 and TaqIA) in the <ENT1>DRD2</ENT1> gene in 146 schizophrenic inpatients (59 with <ENT2>EPS</ENT2> and 87 without <ENT2>EPS</ENT2> according to the Simpson-Angus Scale) treated with chlorpromazine after 8 weeks.",,,,T,,,,,c,,,,,1.0,,
16867246,837,1813,D001480,Association,FALSE,Our results confirmed a previous study on the relationship between <ENT1>DRD2</ENT1> and <ENT2>EPS</ENT2> in Caucasians.,,,,T,,,,,c,,,,,1.0,,
16867246,835,1813,D014150,Association,FALSE,AIM: Extrapyramidal syndrome (EPS) is most commonly affected by typical <ENT2>antipsychotic drugs</ENT2> that have a high affinity with the <ENT1>D2 receptor</ENT1>.,,,,T,,,,,w,,,,,0.0,,
16867246,839,D002746,D001480,Positive_Correlation,FALSE,Association of DRD2 polymorphisms and <ENT1>chlorpromazine</ENT1>-induced <ENT2>extrapyramidal syndrome</ENT2> in Chinese schizophrenic patients.,,,,T,,,,,c,,,,,1.0,,
16867246,839,D002746,D001480,Positive_Correlation,FALSE,"In this study, we evaluate the role DRD2 plays in <ENT1>chlorpromazine</ENT1>-induced <ENT2>EPS</ENT2> in schizophrenic patients.",,,,T,,,,,c,,,,,1.0,,
16867246,839,D002746,D001480,Positive_Correlation,FALSE,"METHODS: We identified seven SNP(single nucleotide polymorphism) (-141Cins>del, TaqIB, TaqID, Ser311Cys, rs6275, rs6277 and TaqIA) in the DRD2 gene in 146 schizophrenic inpatients (59 with <ENT2>EPS</ENT2> and 87 without <ENT2>EPS</ENT2> according to the Simpson-Angus Scale) treated with <ENT1>chlorpromazine</ENT1> after 8 weeks.",,,,T,,,,,c,,,,,1.0,,
16867246,838,D001480,D014150,Positive_Correlation,FALSE,AIM: <ENT1>Extrapyramidal syndrome</ENT1> (<ENT1>EPS</ENT1>) is most commonly affected by typical <ENT2>antipsychotic drugs</ENT2> that have a high affinity with the D2 receptor.,,,,T,,,,,c,,,,,1.0,,
16920333,841,D010852,D012640,Positive_Correlation,FALSE,Anticonvulsant effect of eslicarbazepine acetate (BIA 2-093) on <ENT2>seizures</ENT2> induced by microperfusion of <ENT1>picrotoxin</ENT1> in the hippocampus of freely moving rats.,,,,T,,,,,c,,,,,1.0,,
16920333,841,D010852,D012640,Positive_Correlation,FALSE,"In the animals treated with threshold doses of <ENT1>picrotoxin</ENT1>, the average number of <ENT2>seizures</ENT2> was 2.3+/-1.2, and average <ENT2>seizure</ENT2> duration was 39.5+/-8.4s.",,,,T,,,,,c,,,,,0.0,,
16920333,841,D010852,D012640,Positive_Correlation,FALSE,Pre-treatment with a dose of 30 mg/kg 2h before <ENT1>picrotoxin</ENT1> microperfusion prevented <ENT2>seizures</ENT2> in the 75% of the rats.,,,,T,,,,,w,,,,,0.0,,
16920333,844,D010852,C416835,Negative_Correlation,TRUE,Anticonvulsant effect of <ENT2>eslicarbazepine acetate</ENT2> (<ENT2>BIA 2-093</ENT2>) on seizures induced by microperfusion of <ENT1>picrotoxin</ENT1> in the hippocampus of freely moving rats.,,,,T,Y,,,,w,,,,,0.0,,
16920333,840,D002220,C036006,Comparison,TRUE,"Eslicarbazepine acetate (BIA 2-093, S-(-)-10-acetoxy-10,11-dihydro-5H-dibenzo/b,f/azepine-5-carboxamide) is a novel antiepileptic drug, now in Phase III clinical trials, designed with the aim of improving efficacy and safety in comparison with the structurally related drugs <ENT1>carbamazepine</ENT1> (<ENT1>CBZ</ENT1>) and <ENT2>oxcarbazepine</ENT2> (<ENT2>OXC</ENT2>).",,,,T,Y,,,,w,,,"11,12,21,22",,0.0,,
16920333,842,D002220,C416835,Comparison,TRUE,"<ENT2>Eslicarbazepine acetate</ENT2> (<ENT2>BIA 2-093</ENT2>, <ENT2>S-(-)-10-acetoxy-10,11-dihydro-5H-dibenzo/b,f/azepine-5-carboxamide</ENT2>) is a novel antiepileptic drug, now in Phase III clinical trials, designed with the aim of improving efficacy and safety in comparison with the structurally related drugs <ENT1>carbamazepine</ENT1> (<ENT1>CBZ</ENT1>) and oxcarbazepine (OXC).",,,,T,,,,,c,,,"11,12,13,21,22,23",,0.666666667,,
16920333,845,D012640,C416835,Negative_Correlation,TRUE,Anticonvulsant effect of <ENT2>eslicarbazepine acetate</ENT2> (<ENT2>BIA 2-093</ENT2>) on <ENT1>seizures</ENT1> induced by microperfusion of picrotoxin in the hippocampus of freely moving rats.,,,,T,,T,,,w,,,,,0.0,TRUE,
16920333,845,D012640,C416835,Negative_Correlation,TRUE,We have studied the effects of oral treatment with <ENT2>eslicarbazepine acetate</ENT2> on a whole-animal model in which partial <ENT1>seizures</ENT1> can be elicited repeatedly on different days without changes in threshold or <ENT1>seizure</ENT1> patterns.,,,,T,,,,,c,,,,,0.0,,
16920333,843,C036006,C416835,Comparison,TRUE,"<ENT2>Eslicarbazepine acetate</ENT2> (<ENT2>BIA 2-093</ENT2>, <ENT2>S-(-)-10-acetoxy-10,11-dihydro-5H-dibenzo/b,f/azepine-5-carboxamide</ENT2>) is a novel antiepileptic drug, now in Phase III clinical trials, designed with the aim of improving efficacy and safety in comparison with the structurally related drugs carbamazepine (CBZ) and <ENT1>oxcarbazepine</ENT1> (<ENT1>OXC</ENT1>).",,,,T,,,,,c,,,"11,12,13,21,22,23",,0.833333333,,
17003357,846,rs2476601,D003922,Positive_Correlation,TRUE,"However, evidence supporting a role for PTPN22 in <ENT2>type 1 diabetes</ENT2> derives entirely from the study of just one coding single nucleotide polymorphism, <ENT1>1858C/T</ENT1>.",,,,T,,,,,c,,,,,0.0,,
17003357,846,rs2476601,D003922,Positive_Correlation,TRUE,The <ENT1>1858T</ENT1> risk allele occurred on only a single haplotype that was strongly associated with <ENT2>type 1 diabetes</ENT2> (P = 7.9 x 10(-5)).,,,,T,,,,,c,,,,,1.0,,
17003357,846,rs2476601,D003922,Positive_Correlation,TRUE,"These results support the conclusion that the <ENT1>1858C/T</ENT1> allele is the major risk variant for <ENT2>type 1 diabetes</ENT2> in the PTPN22 locus, but they suggest that additional infrequent coding variants at PTPN22 may also contribute to <ENT2>type 1 diabetes</ENT2> risk.",,,,T,,,,,c,,,,,1.0,,
17003357,847,D003922,26191,Association,TRUE,A haplotype-based analysis of the <ENT2>PTPN22</ENT2> locus in <ENT1>type 1 diabetes</ENT1>.,,,,T,Y,,,,w,,,,,1.0,,
17003357,847,D003922,26191,Association,TRUE,A recent addition to the list of widely confirmed <ENT1>type 1 diabetes</ENT1> risk loci is the <ENT2>PTPN22</ENT2> gene encoding a <ENT2>lymphoid-specific phosphatase</ENT2> (<ENT2>Lyp</ENT2>).,,,,T,,,,,c,,,,,1.0,,
17003357,847,D003922,26191,Association,TRUE,"However, evidence supporting a role for <ENT2>PTPN22</ENT2> in <ENT1>type 1 diabetes</ENT1> derives entirely from the study of just one coding single nucleotide polymorphism, 1858C/T.",,,,T,,,,,w,,,,,0.0,,
17003357,847,D003922,26191,Association,TRUE,"In the current study, the haplotype structure of the <ENT2>PTPN22</ENT2> region was determined, and individual haplotypes were tested for association with <ENT1>type 1 diabetes</ENT1> in family-based tests.",,,,T,,Y,,,c,,,,,1.0,,
17003357,847,D003922,26191,Association,TRUE,"These results support the conclusion that the 1858C/T allele is the major risk variant for <ENT1>type 1 diabetes</ENT1> in the <ENT2>PTPN22</ENT2> locus, but they suggest that additional infrequent coding variants at <ENT2>PTPN22</ENT2> may also contribute to <ENT1>type 1 diabetes</ENT1> risk.",,,,T,,,,,c,,,"11,22",,1.0,,
17006606,849,rs1143627,rs1143634,Association,TRUE,"Proinflammatory cytokine gene polymorphisms have been demonstrated to associate with gastric cancer risk, of which IL1B<ENT1>-31T/C</ENT1> and <ENT2>-511C/T</ENT2> changes have been well investigated due to the possibility that they may alter the IL1B transcription.",,,,T,,,,,c,,,,,1.0,,
17006606,849,rs1143627,rs1143634,Association,TRUE,We observed strong linkage disequilibrium between the <ENT2>T allele at -511</ENT2> and the <ENT1>C allele at -31</ENT1> and between the <ENT2>C allele at -511</ENT2> and the <ENT1>T allele at -31</ENT1> in IL1B in both the cases and controls (R (2)=0.94).,,,,T,,,,,c,,,"11,22",,0.0,,
17006606,849,rs1143627,rs1143634,Association,TRUE,"Though FAS-670 polymorphisms did not show any significant difference, the proportion of subjects with IL1B<ENT1>-31TT</ENT1> (or IL1B<ENT2>-511CC</ENT2>) increased according to stage (trend P=0.019).",,,,T,,,,,c,,,,,1.0,,
17006606,849,rs1143627,rs1143634,Association,TRUE,"In particular, subjects with stage IV had a two times higher probability of having either IL1B<ENT1>-31TT</ENT1> (or IL1B<ENT2>-511CC</ENT2>) genotype compared with stage I subjects.",,,,T,,,,,c,,,,,1.0,,
17006606,849,rs1143627,rs1143634,Association,TRUE,These observations suggest that IL1B<ENT1>-31TT</ENT1> and IL1B<ENT2>-511CC</ENT2> are associated with disease progression.,,,,T,,,,,c,,,,,1.0,,
17006606,855,rs1143627,D013274,Positive_Correlation,TRUE,A polymorphism of <ENT1>C-to-T substitution at -31</ENT1> IL1B is associated with the risk of advanced <ENT2>gastric adenocarcinoma</ENT2> in a Japanese population.,,,,T,,,,,c,,,,,0.0,,
17006606,855,rs1143627,D013274,Positive_Correlation,TRUE,"Proinflammatory cytokine gene polymorphisms have been demonstrated to associate with <ENT2>gastric cancer</ENT2> risk, of which IL1B<ENT1>-31T/C</ENT1> and -511C/T changes have been well investigated due to the possibility that they may alter the IL1B transcription.",,,,T,,,,,c,,,,,0.0,,
17006606,852,3553,4790,Association,FALSE,"The signal transduction target upon <ENT1>interleukin 1 beta</ENT1> (<ENT1>IL1beta</ENT1>) stimulation, the <ENT2>nuclear factor of kappa B</ENT2> (<ENT2>NFkappaB</ENT2>) activation, supports cancer development, signal transduction in which is mediated by FS-7 cell-associated cell surface antigen (FAS) signaling.",,,,T,,,,,c,,,,,0.0,,
17006606,852,3553,4790,Association,FALSE,"Based on recent papers describing the prognostic roles of the polymorphisms and the <ENT2>NFkappaB</ENT2> functions on cancer development, we sought to determine if Japanese gastric cancer patients were affected by the <ENT1>IL1B</ENT1> -31/-511 and FAS-670 polymorphisms.",,,,T,,,,,c,,,,,1.0,,
17006606,851,3553,D009369,Association,FALSE,"The signal transduction target upon <ENT1>interleukin 1 beta</ENT1> (<ENT1>IL1beta</ENT1>) stimulation, the nuclear factor of kappa B (NFkappaB) activation, supports <ENT2>cancer</ENT2> development, signal transduction in which is mediated by FS-7 cell-associated cell surface antigen (FAS) signaling.",,,,T,,,,,w,,,,,1.0,,
17006606,851,3553,D009369,Association,FALSE,"Based on recent papers describing the prognostic roles of the polymorphisms and the NFkappaB functions on <ENT2>cancer</ENT2> development, we sought to determine if Japanese gastric cancer patients were affected by the <ENT1>IL1B</ENT1> -31/-511 and FAS-670 polymorphisms.",,,,T,,Y,,,c,,,,,1.0,,
17006606,853,3553,D013274,Association,TRUE,A polymorphism of C-to-T substitution at -31 <ENT1>IL1B</ENT1> is associated with the risk of advanced <ENT2>gastric adenocarcinoma</ENT2> in a Japanese population.,,,,T,,,,,w,,,,,0.0,,
17006606,853,3553,D013274,Association,TRUE,"<ENT1>Proinflammatory cytokine</ENT1> gene polymorphisms have been demonstrated to associate with <ENT2>gastric cancer</ENT2> risk, of which <ENT1>IL1B</ENT1>-31T/C and -511C/T changes have been well investigated due to the possibility that they may alter the <ENT1>IL1B</ENT1> transcription.",,,,T,,,,,c,,,,,0.333333333,,
17006606,853,3553,D013274,Association,TRUE,"Based on recent papers describing the prognostic roles of the polymorphisms and the NFkappaB functions on cancer development, we sought to determine if Japanese <ENT2>gastric cancer</ENT2> patients were affected by the <ENT1>IL1B</ENT1> -31/-511 and FAS-670 polymorphisms.",,,,T,,Y,,,c,,,,,1.0,,
17006606,853,3553,D013274,Association,TRUE,"Neither <ENT1>IL1B</ENT1>-31, -511 nor FAS-670 polymorphisms showed significantly different risks of <ENT2>gastric adenocarcinoma</ENT2>.",,,,T,,,,,c,,,,,1.0,,
17006606,850,4790,D009369,Association,FALSE,"The signal transduction target upon interleukin 1 beta (IL1beta) stimulation, the <ENT1>nuclear factor of kappa B</ENT1> (<ENT1>NFkappaB</ENT1>) activation, supports <ENT2>cancer</ENT2> development, signal transduction in which is mediated by FS-7 cell-associated cell surface antigen (FAS) signaling.",,,,T,,,,,w,,,,,0.5,TRUE,
17006606,850,4790,D009369,Association,FALSE,"Based on recent papers describing the prognostic roles of the polymorphisms and the <ENT1>NFkappaB</ENT1> functions on <ENT2>cancer</ENT2> development, we sought to determine if Japanese gastric cancer patients were affected by the IL1B -31/-511 and FAS-670 polymorphisms.",,,,T,,,,,w,,,,,0.0,,
17006606,854,rs1143634,D013274,Positive_Correlation,FALSE,"Proinflammatory cytokine gene polymorphisms have been demonstrated to associate with <ENT2>gastric cancer</ENT2> risk, of which IL1B-31T/C and <ENT1>-511C/T</ENT1> changes have been well investigated due to the possibility that they may alter the IL1B transcription.",,,,T,,,,,w,,,,,0.0,,
17033686,864,D008850,10084,Association,TRUE,"A two base pair deletion in the <ENT2>PQBP1</ENT2> gene is associated with <ENT1>microphthalmia</ENT1>, microcephaly, and mental retardation.",,,,T,,,,,c,,,,,1.0,,
17033686,864,D008850,10084,Association,TRUE,"In summary, our findings demonstrate for the first time that mutations in <ENT2>PQBP1</ENT2> are associated with an S-XLMR phenotype including <ENT1>microphthalmia</ENT1>, thereby further extending the clinical spectrum of phenotypes associated with <ENT2>PQBP1</ENT2> mutations.",,,,T,,,,,c,,,,,1.0,,
17033686,862,D008607,10084,Association,TRUE,"A two base pair deletion in the <ENT2>PQBP1</ENT2> gene is associated with microphthalmia, microcephaly, and <ENT1>mental retardation</ENT1>.",,,,T,,,,,c,,,,,1.0,,
17033686,863,10084,D008831,Association,TRUE,"A two base pair deletion in the <ENT1>PQBP1</ENT1> gene is associated with microphthalmia, <ENT2>microcephaly</ENT2>, and mental retardation.",,,,T,,,,,c,,,,,1.0,,
17033686,860,10084,D038901,Association,TRUE,"<ENT2>X-linked mental retardation</ENT2> has been traditionally divided into syndromic (S-<ENT2>XLMR</ENT2>) and non-syndromic forms (NS-<ENT2>XLMR</ENT2>), although the borderlines between these phenotypes begin to vanish and mutations in a single gene, for example <ENT1>PQBP1</ENT1>, can cause S-<ENT2>XLMR</ENT2> as well as NS-<ENT2>XLMR</ENT2>.",,,,T,,,,,c,,,,,1.0,,
17033686,860,10084,D038901,Association,TRUE,"In summary, our findings demonstrate for the first time that mutations in <ENT1>PQBP1</ENT1> are associated with an S-<ENT2>XLMR</ENT2> phenotype including microphthalmia, thereby further extending the clinical spectrum of phenotypes associated with <ENT1>PQBP1</ENT1> mutations.",,,,T,,,,,c,,,,,1.0,,
17033686,858,54880,C537464,Association,FALSE,"A missense mutation in <ENT1>BCOR</ENT1> was described in a family with <ENT2>Lenz microphthalmia syndrome</ENT2>, a phenotype showing substantial overlapping features with that described in the two cousins.",,,,T,,,,,c,,,,,0.0,,
17035713,872,D013438,C004656,Negative_Correlation,TRUE,<ENT2>Chloroacetaldehyde</ENT2> as a sulfhydryl reagent: the role of critical <ENT1>thiol</ENT1> groups in ifosfamide nephropathy.,,,,T,,,,,c,,,,,1.0,,
17035713,872,D013438,C004656,Negative_Correlation,TRUE,"<ENT2>CAA</ENT2> reduced hRPTEC cell number and protein, induced a loss in free intracellular <ENT1>thiols</ENT1> and an increase in necrosis markers.",,,,T,,,,,c,,,,,1.0,,
17035713,872,D013438,C004656,Negative_Correlation,TRUE,The effects of <ENT2>CAA</ENT2> on cysteine protease activities and <ENT1>thiols</ENT1> could be reproduced in cell lysate.,,,,T,,,,,w,,,,,1.0,,
17035713,872,D013438,C004656,Negative_Correlation,TRUE,"Acidification, which slowed the reaction of <ENT2>CAA</ENT2> with <ENT1>thiol</ENT1> donors, could also attenuate effects of <ENT2>CAA</ENT2> on necrosis markers, <ENT1>thiol</ENT1> depletion and cysteine protease inhibition in living cells.",,,,T,,,,,w,,,,,0.75,TRUE,
17035713,872,D013438,C004656,Negative_Correlation,TRUE,"Thus, <ENT2>CAA</ENT2> directly reacts with cellular protein and non-protein <ENT1>thiols</ENT1>, mediating its toxicity on hRPTEC.",,,,T,,,,,w,,,,,0.0,,
17035713,874,D007069,D007674,Positive_Correlation,FALSE,Chloroacetaldehyde as a sulfhydryl reagent: the role of critical thiol groups in <ENT1>ifosfamide</ENT1> <ENT2>nephropathy</ENT2>.,,,,T,,,,,c,,,,,0.0,,
17035713,874,D007069,D007674,Positive_Correlation,FALSE,Chloroacetaldehyde (CAA) is a metabolite of the alkylating agent <ENT1>ifosfamide</ENT1> (<ENT1>IFO</ENT1>) and putatively responsible for <ENT2>renal damage</ENT2> following anti-tumor therapy with <ENT1>IFO</ENT1>.,,,,T,,,,,c,,,,,1.0,,
17035713,874,D007069,D007674,Positive_Correlation,FALSE,"Therefore, urinary acidification could be an option to prevent <ENT1>IFO</ENT1> <ENT2>nephropathy</ENT2> in patients.",,,,T,,,,,c,,,,,0.0,,
17035713,875,D007069,D009369,Negative_Correlation,FALSE,Chloroacetaldehyde (CAA) is a metabolite of the alkylating agent <ENT1>ifosfamide</ENT1> (<ENT1>IFO</ENT1>) and putatively responsible for renal damage following anti-<ENT2>tumor</ENT2> therapy with <ENT1>IFO</ENT1>.,,,,T,,,,,w,,,,,0.333333333,,
17035713,868,C004656,1508,Negative_Correlation,TRUE,"<ENT1>CAA</ENT1> but not acrolein inhibited the <ENT2>cysteine proteases</ENT2> caspase-3, caspase-8 and <ENT2>cathepsin B</ENT2>. Caspase activation by cisplatin was inhibited by <ENT1>CAA</ENT1>.",,,,T,,,,,c,,,,,0.5,,
17035713;17035713;17035713,868;869;870,C004656;C004656;C004656,1508;841;836,Negative_Correlation;Negative_Correlation;Negative_Correlation,TRUE;TRUE;TRUE,The effects of <ENT1>CAA</ENT1> on <ENT2>cysteine protease</ENT2> activities and thiols could be reproduced in cell lysate.,,,,T,,,,,w,,,,,0.0,,
17035713;17035713;17035713,868;869;870,C004656;C004656;C004656,1508;841;836,Negative_Correlation;Negative_Correlation;Negative_Correlation,TRUE;TRUE;TRUE,"Acidification, which slowed the reaction of <ENT1>CAA</ENT1> with thiol donors, could also attenuate effects of <ENT1>CAA</ENT1> on necrosis markers, thiol depletion and <ENT2>cysteine protease</ENT2> inhibition in living cells.",,,,T,,,,,w,,,,,0.5,TRUE,
17035713,865,C004656,D002945,Negative_Correlation,TRUE,"<ENT1>CAA</ENT1> but not acrolein inhibited the cysteine proteases caspase-3, caspase-8 and cathepsin B. Caspase activation by <ENT2>cisplatin</ENT2> was inhibited by <ENT1>CAA</ENT1>.",,,,T,,,,,c,,,,,0.5,,
17035713,869,C004656,841,Negative_Correlation,TRUE,"<ENT1>CAA</ENT1> but not acrolein inhibited the <ENT2>cysteine proteases</ENT2> caspase-3, <ENT2>caspase-8</ENT2> and cathepsin B. <ENT2>Caspase</ENT2> activation by cisplatin was inhibited by <ENT1>CAA</ENT1>.",,,,T,,,,,c,,,"11,12,23",,0.333333333,,
17035713,870,C004656,836,Negative_Correlation,TRUE,"Toxicity of <ENT1>CAA</ENT1> was determined by protein content, cell number, LDH release, trypan blue exclusion assay and <ENT2>caspase-3</ENT2> activity.",,,,T,,,,,w,,,,,0.0,,
17035713,870,C004656,836,Negative_Correlation,TRUE,"<ENT1>CAA</ENT1> but not acrolein inhibited the <ENT2>cysteine proteases</ENT2> <ENT2>caspase-3</ENT2>, caspase-8 and cathepsin B. <ENT2>Caspase</ENT2> activation by cisplatin was inhibited by <ENT1>CAA</ENT1>.",,,,T,,,,,c,,,"11,12,23",,0.5,,
17035713,873,C004656,D007674,Positive_Correlation,FALSE,<ENT1>Chloroacetaldehyde</ENT1> as a sulfhydryl reagent: the role of critical thiol groups in ifosfamide <ENT2>nephropathy</ENT2>.,,,,T,,,,,c,,,,,0.0,,
17035713,873,C004656,D007674,Positive_Correlation,FALSE,<ENT1>Chloroacetaldehyde</ENT1> (<ENT1>CAA</ENT1>) is a metabolite of the alkylating agent ifosfamide (IFO) and putatively responsible for <ENT2>renal damage</ENT2> following anti-tumor therapy with IFO.,,,,T,,,,,c,,,,,0.5,,
17035713,871,C004656,D009336,Positive_Correlation,TRUE,"<ENT1>CAA</ENT1> reduced hRPTEC cell number and protein, induced a loss in free intracellular thiols and an increase in <ENT2>necrosis</ENT2> markers.",,,,T,,,,,c,,,,,1.0,,
17035713,871,C004656,D009336,Positive_Correlation,TRUE,"Acidification, which slowed the reaction of <ENT1>CAA</ENT1> with thiol donors, could also attenuate effects of <ENT1>CAA</ENT1> on <ENT2>necrosis</ENT2> markers, thiol depletion and cysteine protease inhibition in living cells.",,,,T,,,,,w,,,,,0.5,TRUE,
17035713,866,D002945,841,Positive_Correlation,FALSE,"CAA but not acrolein inhibited the <ENT2>cysteine proteases</ENT2> caspase-3, <ENT2>caspase-8</ENT2> and cathepsin B. <ENT2>Caspase</ENT2> activation by <ENT1>cisplatin</ENT1> was inhibited by CAA.",,,,T,,,,,w,,,,,0.666666667,,
17035713,867,D002945,836,Positive_Correlation,FALSE,"CAA but not acrolein inhibited the <ENT2>cysteine proteases</ENT2> <ENT2>caspase-3</ENT2>, caspase-8 and cathepsin B. <ENT2>Caspase</ENT2> activation by <ENT1>cisplatin</ENT1> was inhibited by CAA.",,,,T,,,,,w,,,,,0.666666667,,
17059986,881,rs148038173,D053579,Association,TRUE,"However, mutation analysis showed that the proband is a compound heterozygote for 2 mutations in SLC12A3: a substitution of <ENT1>serine by leucine at amino acid position 555</ENT1> (<ENT1>p.Ser555Leu</ENT1>) and a novel guanine to cytosine transition at the 5' splice site of intron 22 (c.2633+1G>C), providing the molecular diagnosis of <ENT2>GS</ENT2>.",,,,T,,,,,c,,,,,0.5,,
17059986,880,D053579,c|SUB|G||C,Association,TRUE,"However, mutation analysis showed that the proband is a compound heterozygote for 2 mutations in SLC12A3: a substitution of serine by leucine at amino acid position 555 (p.Ser555Leu) and a novel <ENT2>guanine to cytosine</ENT2> transition at the 5' splice site of intron 22 (c.2633+1G>C), providing the molecular diagnosis of <ENT1>GS</ENT1>.",,,,T,,,,,c,,,,,0.0,,
17059986,886,D053579,6559,Association,TRUE,A novel splicing mutation in <ENT2>SLC12A3</ENT2> associated with <ENT1>Gitelman syndrome</ENT1> and idiopathic intracranial hypertension.,,,,T,,,,,c,,,,,1.0,,
17059986,886,D053579,6559,Association,TRUE,"However, mutation analysis showed that the proband is a compound heterozygote for 2 mutations in <ENT2>SLC12A3</ENT2>: a substitution of serine by leucine at amino acid position 555 (p.Ser555Leu) and a novel guanine to cytosine transition at the 5' splice site of intron 22 (c.2633+1G>C), providing the molecular diagnosis of <ENT1>GS</ENT1>.",,,,T,,,,,c,,,,,1.0,,
17059986,878,D053579,c|SUB|G|2633+1|C,Association,TRUE,"However, mutation analysis showed that the proband is a compound heterozygote for 2 mutations in SLC12A3: a substitution of serine by leucine at amino acid position 555 (p.Ser555Leu) and a novel guanine to cytosine transition at the 5' splice site of intron 22 (<ENT2>c.2633+1G>C</ENT2>), providing the molecular diagnosis of <ENT1>GS</ENT1>.",,,,T,,,,,c,,,,,0.0,,
17059986,885,6559,D011559,Association,TRUE,A novel splicing mutation in <ENT1>SLC12A3</ENT1> associated with Gitelman syndrome and <ENT2>idiopathic intracranial hypertension</ENT2>.,,,,T,,,,,c,,,,,1.0,,
17059986,876,D008274,D011188,Cotreatment,FALSE,"Supplementation with <ENT2>potassium</ENT2> and <ENT1>magnesium</ENT1> improved clinical symptoms and resulted in catch-up growth, but vision remained impaired.",,,,T,,,,,c,,,,,0.0,,
17065198,887,D012878,7157,Association,TRUE,Analysis of <ENT1>skin cancer</ENT1> risk factors in immunosuppressed renal transplant patients shows high levels of UV-specific tandem CC to TT mutations of the <ENT2>p53</ENT2> gene.,,,,T,,,,,c,,,,,1.0,,
17065198,887,D012878,7157,Association,TRUE,"We detected 24 <ENT2>p53</ENT2> mutations in 15/25 (60%) <ENT1>NMSCs</ENT1>, 1 deletion and 23 base substitutions, the majority (78%) being UV-specific C to T transitions at bipyrimidine sites.",,,,T,,,,,w,,,,,1.0,,
17065198,887,D012878,7157,Association,TRUE,"We found 8 <ENT2>p53</ENT2> mutations in 7/17 (41%) precancerous actinic keratosis (AK), suggesting that <ENT2>p53</ENT2> mutations are early events in RTR <ENT1>skin carcinogenesis</ENT1>.",,,,T,,,,,c,,,,,1.0,,
17065198,887,D012878,7157,Association,TRUE,"The <ENT2>p53</ENT2> mutation spectrum, presenting a high level of CC to TT mutations, shows that the UV component of sunlight is the major risk factor and modulated DNA repair by immunosuppressive drug treatment may be significant in the <ENT1>skin carcinogenesis</ENT1> of RTRs.",,,,T,,,,,c,,,,,0.0,,
17065198,890,D012878,c|SUB|C||T,Positive_Correlation,TRUE,Analysis of <ENT1>skin cancer</ENT1> risk factors in immunosuppressed renal transplant patients shows high levels of UV-specific tandem <ENT2>CC to TT</ENT2> mutations of the p53 gene.,,,,T,,,,,c,,,,,0.0,,
17065198,890,D012878,c|SUB|C||T,Positive_Correlation,TRUE,"We detected 24 p53 mutations in 15/25 (60%) <ENT1>NMSCs</ENT1>, 1 deletion and 23 base substitutions, the majority (78%) being UV-specific <ENT2>C to T</ENT2> transitions at bipyrimidine sites.",,,,T,,,,,w,,,,,1.0,,
17065198,890,D012878,c|SUB|C||T,Positive_Correlation,TRUE,"The p53 mutation spectrum, presenting a high level of <ENT2>CC to TT</ENT2> mutations, shows that the UV component of sunlight is the major risk factor and modulated DNA repair by immunosuppressive drug treatment may be significant in the <ENT1>skin carcinogenesis</ENT1> of RTRs.",,,,T,,,,,w,,,,,0.0,,
17065198,891,D016572,c|SUB|C||T,Association,TRUE,"Importantly, 35% (6/17) are tandem mutations, including 4 UV signature <ENT2>CC to TT</ENT2> transitions possibly linked to modulated DNA repair caused by the immunosuppressive drug <ENT1>cyclosporin A</ENT1> (<ENT1>CsA</ENT1>).",,,,T,,,,,c,,,,,0.0,,
17065198,888,7157,D055623,Association,TRUE,"We found 8 <ENT1>p53</ENT1> mutations in 7/17 (41%) precancerous <ENT2>actinic keratosis</ENT2> (<ENT2>AK</ENT2>), suggesting that <ENT1>p53</ENT1> mutations are early events in RTR skin carcinogenesis.",,,,T,,,,,w,,,,,1.0,,
17074608,893,D014635,D001927,Positive_Correlation,FALSE,<ENT1>Valproate</ENT1>-induced chorea and <ENT2>encephalopathy</ENT2> in atypical nonketotic hyperglycinemia.,,,,T,,,,,w,,,,,0.0,,
17074608,893,D014635,D001927,Positive_Correlation,FALSE,"This report describes a patient with mild language delay and mental retardation, who was found to have nonketotic hyperglycinemia following her presentation with acute <ENT2>encephalopathy</ENT2> and chorea shortly after initiation of <ENT1>valproate</ENT1> therapy.",,,,T,,,,,c,,,,,1.0,,
17074608,894,D014635,D002819,Positive_Correlation,FALSE,<ENT1>Valproate</ENT1>-induced <ENT2>chorea</ENT2> and encephalopathy in atypical nonketotic hyperglycinemia.,,,,T,,,,,c,,,,,1.0,,
17074608,894,D014635,D002819,Positive_Correlation,FALSE,"This report describes a patient with mild language delay and mental retardation, who was found to have nonketotic hyperglycinemia following her presentation with acute encephalopathy and <ENT2>chorea</ENT2> shortly after initiation of <ENT1>valproate</ENT1> therapy.",,,,T,,,,,c,,,,,1.0,,
17074608,892,D005998,D020158,Positive_Correlation,FALSE,<ENT2>Nonketotic hyperglycinemia</ENT2> is a disorder of amino acid metabolism in which a defect in the <ENT1>glycine</ENT1> cleavage system leads to an accumulation of <ENT1>glycine</ENT1> in the brain and other body compartments.,,,,T,,,,,c,,,,,0.5,,
17083016,897,653509,D000073893,Bind,FALSE,<ENT1>Surfactant protein (SP)-A</ENT1> and SP-D are pattern-recognition molecules of the respiratory tract that activate inflammatory and phagocytic defences after binding to microbial <ENT2>sugars</ENT2>.,,,,T,,,,,c,,,,,0.0,,
17083016;17083016,898;905,653509;729238,D007249;D007249,Association;Association,FALSE;FALSE,<ENT1>Surfactant protein (SP)-A</ENT1> and SP-D are pattern-recognition molecules of the respiratory tract that activate <ENT2>inflammatory</ENT2> and phagocytic defences after binding to microbial sugars.,,,,T,,,,,c,,,,,1.0,,
17083016,899,c|Allele|K|223,D003643,Association,TRUE,"Carriage of alleles encoding <ENT1>lysine at residue 223</ENT1> was found in 61% of patients who <ENT2>died</ENT2>, compared with 35% of those who survived (OR adjusted for age, 2.9; 95% CI, 1.1-7.7).",,,,T,,,,,c,,,,,0.0,,
17083016,904,D000073893,729238,Bind,FALSE,<ENT2>Surfactant protein (SP)-A</ENT2> and SP-D are pattern-recognition molecules of the respiratory tract that activate inflammatory and phagocytic defences after binding to microbial <ENT1>sugars</ENT1>.,,,,T,,,,,c,,,,,0.0,,
17083016,895,D000073893,6441,Bind,FALSE,Surfactant protein (SP)-A and <ENT2>SP-D</ENT2> are pattern-recognition molecules of the respiratory tract that activate inflammatory and phagocytic defences after binding to microbial <ENT1>sugars</ENT1>.,,,,T,,,,,c,,,,,0.0,,
17083016,903,D008589,c|SUB|Q|223|K,Positive_Correlation,TRUE,"An analysis of the multiple single-nucleotide polymorphisms in SP-A demonstrated that homozygosity for alleles encoding <ENT2>lysine (in 1A1) rather than glutamine (in 1A5) at amino acid 223</ENT2> in the carbohydrate recognition domain was associated with an increased risk of <ENT1>meningococcal disease</ENT1> (OR, 6.7; 95% CI, 1.4-31.5).",,,,T,,,,,c,,,,,1.0,,
17083016,903,D008589,c|SUB|Q|223|K,Positive_Correlation,TRUE,"CONCLUSIONS: Gene polymorphism resulting in the substitution of <ENT2>glutamine with lysine at residue 223</ENT2> in the carbohydrate recognition domain of SP-A2 increases susceptibility to <ENT1>meningococcal disease</ENT1>, as well as the risk of death.",,,,T,,,,,c,,,,,1.0,,
17083016,907,D008589,729238,Association,TRUE,Genetic polymorphism of the binding domain of <ENT2>surfactant protein-A2</ENT2> increases susceptibility to <ENT1>meningococcal disease</ENT1>.,,,,T,,,,,c,,,,,1.0,,
17083016,907,D008589,729238,Association,TRUE,"METHODS: Allele frequencies of SP-A1, <ENT2>SP-A2</ENT2>, and SP-D were determined by polymerase chain reaction in 303 patients with microbiologically proven <ENT1>meningococcal disease</ENT1>, including 18 patients who died, and 222 healthy control subjects.",,,,T,,Y,,,c,,,,,1.0,,
17083016,907,D008589,729238,Association,TRUE,"RESULTS: Homozygosity of allele 1A1 of <ENT2>SP-A2</ENT2> increased the risk of <ENT1>meningococcal disease</ENT1> (odds ratio [OR], 7.4; 95% confidence interval [CI], 1.3-42.4); carriage of 1A5 reduced the risk (OR, 0.3; 95% CI, 0.1-0.97).",,,,T,,,,,c,,,,,1.0,,
17083016,907,D008589,729238,Association,TRUE,"An analysis of the multiple single-nucleotide polymorphisms in <ENT2>SP-A</ENT2> demonstrated that homozygosity for alleles encoding lysine (in 1A1) rather than glutamine (in 1A5) at amino acid 223 in the carbohydrate recognition domain was associated with an increased risk of <ENT1>meningococcal disease</ENT1> (OR, 6.7; 95% CI, 1.4-31.5).",,,,T,,,,,c,,,,,1.0,,
17083016,907,D008589,729238,Association,TRUE,"CONCLUSIONS: Gene polymorphism resulting in the substitution of glutamine with lysine at residue 223 in the carbohydrate recognition domain of <ENT2>SP-A2</ENT2> increases susceptibility to <ENT1>meningococcal disease</ENT1>, as well as the risk of death.",,,,T,,,,,c,,,,,1.0,,
17083016,901,c|SUB|Q|223|K,D003643,Positive_Correlation,TRUE,"CONCLUSIONS: Gene polymorphism resulting in the substitution of <ENT1>glutamine with lysine at residue 223</ENT1> in the carbohydrate recognition domain of SP-A2 increases susceptibility to meningococcal disease, as well as the risk of <ENT2>death</ENT2>.",,,,T,,,,,c,,,,,1.0,,
17083016,902,c|SUB|Q|223|K,D002241,Association,TRUE,"An analysis of the multiple single-nucleotide polymorphisms in SP-A demonstrated that homozygosity for alleles encoding <ENT1>lysine (in 1A1) rather than glutamine (in 1A5) at amino acid 223</ENT1> in the <ENT2>carbohydrate</ENT2> recognition domain was associated with an increased risk of meningococcal disease (OR, 6.7; 95% CI, 1.4-31.5).",,,,T,,,,,c,,,,,0.0,,
17083016,902,c|SUB|Q|223|K,D002241,Association,TRUE,"CONCLUSIONS: Gene polymorphism resulting in the substitution of <ENT1>glutamine with lysine at residue 223</ENT1> in the <ENT2>carbohydrate</ENT2> recognition domain of SP-A2 increases susceptibility to meningococcal disease, as well as the risk of death.",,,,T,,,,,c,,,,,0.0,,
17083016,906,729238,D003643,Association,TRUE,"METHODS: Allele frequencies of SP-A1, <ENT1>SP-A2</ENT1>, and SP-D were determined by polymerase chain reaction in 303 patients with microbiologically proven meningococcal disease, including 18 patients who <ENT2>died</ENT2>, and 222 healthy control subjects.",,,,T,,,,,w,,,,,0.0,,
17083016,906,729238,D003643,Association,TRUE,"CONCLUSIONS: Gene polymorphism resulting in the substitution of glutamine with lysine at residue 223 in the carbohydrate recognition domain of <ENT1>SP-A2</ENT1> increases susceptibility to meningococcal disease, as well as the risk of <ENT2>death</ENT2>.",,,,T,,,,,c,,,,,1.0,,
17083016,900,729238,D002241,Association,FALSE,"An analysis of the multiple single-nucleotide polymorphisms in <ENT1>SP-A</ENT1> demonstrated that homozygosity for alleles encoding lysine (in 1A1) rather than glutamine (in 1A5) at amino acid 223 in the <ENT2>carbohydrate</ENT2> recognition domain was associated with an increased risk of meningococcal disease (OR, 6.7; 95% CI, 1.4-31.5).",,,,T,,,,,w,,,,,1.0,,
17083016,900,729238,D002241,Association,FALSE,"CONCLUSIONS: Gene polymorphism resulting in the substitution of glutamine with lysine at residue 223 in the <ENT2>carbohydrate</ENT2> recognition domain of <ENT1>SP-A2</ENT1> increases susceptibility to meningococcal disease, as well as the risk of death.",,,,T,,,,,c,,,,,1.0,,
17083016,896,D007249,6441,Association,FALSE,Surfactant protein (SP)-A and <ENT2>SP-D</ENT2> are pattern-recognition molecules of the respiratory tract that activate <ENT1>inflammatory</ENT1> and phagocytic defences after binding to microbial sugars.,,,,T,,,,,c,,,,,1.0,,
17151160,914,D012559,C076029,Negative_Correlation,TRUE,Randomized comparison of <ENT2>olanzapine</ENT2> versus risperidone for the treatment of first-episode <ENT1>schizophrenia</ENT1>: 4-month outcomes.,,,,T,,,,,w,,,,,1.0,,
17151160,914,D012559,C076029,Negative_Correlation,TRUE,OBJECTIVE: The authors compared 4-month treatment outcomes for <ENT2>olanzapine</ENT2> versus risperidone in patients with first-episode <ENT1>schizophrenia</ENT1> spectrum disorders.,,,,T,,,,,w,,,,,0.0,,
17151160,914,D012559,C076029,Negative_Correlation,TRUE,"METHOD: One hundred twelve subjects (70% male; mean age=23.3 years [SD = 5.1]) with first-episode <ENT1>schizophrenia</ENT1> (75%), schizophreniform disorder (17%), or schizoaffective disorder (8%) were randomly assigned to treatment with <ENT2>olanzapine</ENT2> (2.5-20 mg/day) or risperidone (1-6 mg/day).",,,,T,,,,,w,,,,,1.0,,
17151160,913,D012559,D018967,Negative_Correlation,TRUE,Randomized comparison of olanzapine versus <ENT2>risperidone</ENT2> for the treatment of first-episode <ENT1>schizophrenia</ENT1>: 4-month outcomes.,,,,T,,,,,w,,,,,0.0,,
17151160,913,D012559,D018967,Negative_Correlation,TRUE,OBJECTIVE: The authors compared 4-month treatment outcomes for olanzapine versus <ENT2>risperidone</ENT2> in patients with first-episode <ENT1>schizophrenia</ENT1> spectrum disorders.,,,,T,,,,,w,,,,,0.0,,
17151160,913,D012559,D018967,Negative_Correlation,TRUE,"METHOD: One hundred twelve subjects (70% male; mean age=23.3 years [SD = 5.1]) with first-episode <ENT1>schizophrenia</ENT1> (75%), schizophreniform disorder (17%), or schizoaffective disorder (8%) were randomly assigned to treatment with olanzapine (2.5-20 mg/day) or <ENT2>risperidone</ENT2> (1-6 mg/day).",,,,T,,,,,w,,,,,0.0,,
17151160,908,D015430,C076029,Positive_Correlation,TRUE,Significantly more <ENT1>weight gain</ENT1> occurred with <ENT2>olanzapine</ENT2> than with risperidone: the increase in weight at 4 months relative to baseline weight was 17.3% (95% CI=14.2%-20.5%) with <ENT2>olanzapine</ENT2> and 11.3% (95% CI=8.4%-14.3%) with risperidone.,,,,T,,,,,c,,,,,1.0,,
17151160,908,D015430,C076029,Positive_Correlation,TRUE,"Both medications caused substantial rapid <ENT1>weight gain</ENT1>, but <ENT1>weight gain</ENT1> was greater with <ENT2>olanzapine</ENT2>.",,,,T,,,,,c,,,,,1.0,,
17151160,915,D015430,D018967,Positive_Correlation,TRUE,Significantly more <ENT1>weight gain</ENT1> occurred with olanzapine than with <ENT2>risperidone</ENT2>: the increase in weight at 4 months relative to baseline weight was 17.3% (95% CI=14.2%-20.5%) with olanzapine and 11.3% (95% CI=8.4%-14.3%) with <ENT2>risperidone</ENT2>.,,,,T,,,,,c,,,,,0.0,,
17151160,912,C076029,D011618,Negative_Correlation,TRUE,"METHOD: One hundred twelve subjects (70% male; mean age=23.3 years [SD = 5.1]) with first-episode schizophrenia (75%), <ENT2>schizophreniform disorder</ENT2> (17%), or <ENT2>schizoaffective disorder</ENT2> (8%) were randomly assigned to treatment with <ENT1>olanzapine</ENT1> (2.5-20 mg/day) or risperidone (1-6 mg/day).",,,,T,,,,,w,,,,,0.0,,
17151160,910,C076029,D001480,Association,TRUE,<ENT2>Extrapyramidal symptom</ENT2> severity scores were 1.4 (95% CI=1.2-1.6) with risperidone and 1.2 (95% CI=1.0-1.4) with <ENT1>olanzapine</ENT1>.,,,,T,,,,,w,,,,,0.0,,
17151160,916,C076029,D018967,Comparison,TRUE,Randomized comparison of <ENT1>olanzapine</ENT1> versus <ENT2>risperidone</ENT2> for the treatment of first-episode schizophrenia: 4-month outcomes.,,,,T,,,,,c,,,,,0.0,,
17151160,916,C076029,D018967,Comparison,TRUE,OBJECTIVE: The authors compared 4-month treatment outcomes for <ENT1>olanzapine</ENT1> versus <ENT2>risperidone</ENT2> in patients with first-episode schizophrenia spectrum disorders.,,,,T,,,,,c,,,,,0.0,,
17151160,916,C076029,D018967,Comparison,TRUE,"METHOD: One hundred twelve subjects (70% male; mean age=23.3 years [SD = 5.1]) with first-episode schizophrenia (75%), schizophreniform disorder (17%), or schizoaffective disorder (8%) were randomly assigned to treatment with <ENT1>olanzapine</ENT1> (2.5-20 mg/day) or <ENT2>risperidone</ENT2> (1-6 mg/day).",,,,T,,,,,w,,,,,0.0,,
17151160,916,C076029,D018967,Comparison,TRUE,"RESULTS: Response rates did not significantly differ between <ENT1>olanzapine</ENT1> (43.7%, 95% CI=28.8%-58.6%) and <ENT2>risperidone</ENT2> (54.3%, 95% CI=39.9%-68.7%).",,,,T,,,,,c,,,,,0.0,,
17151160,916,C076029,D018967,Comparison,TRUE,"Among those responding to treatment, more subjects in the <ENT1>olanzapine</ENT1> group (40.9%, 95% CI=16.8%-65.0%) than in the <ENT2>risperidone</ENT2> group (18.9%, 95% CI=0%-39.2%) had subsequent ratings not meeting response criteria.",,,,T,,,,,c,,,,,0.0,,
17151160,916,C076029,D018967,Comparison,TRUE,Extrapyramidal symptom severity scores were 1.4 (95% CI=1.2-1.6) with <ENT2>risperidone</ENT2> and 1.2 (95% CI=1.0-1.4) with <ENT1>olanzapine</ENT1>.,,,,T,,,,,w,,,,,0.0,,
17151160,916,C076029,D018967,Comparison,TRUE,Significantly more weight gain occurred with <ENT1>olanzapine</ENT1> than with <ENT2>risperidone</ENT2>: the increase in weight at 4 months relative to baseline weight was 17.3% (95% CI=14.2%-20.5%) with <ENT1>olanzapine</ENT1> and 11.3% (95% CI=8.4%-14.3%) with <ENT2>risperidone</ENT2>.,,,,T,,,,,c,,,,,0.0,,
17151160,916,C076029,D018967,Comparison,TRUE,Body mass index at baseline and at 4 months was 24.3 (95% CI=22.8-25.7) versus 28.2 (95% CI=26.7-29.7) with <ENT1>olanzapine</ENT1> and 23.9 (95% CI=22.5-25.3) versus 26.7 (95% CI=25.2-28.2) with <ENT2>risperidone</ENT2>.,,,,T,,,,,c,,,,,0.0,,
17151160,916,C076029,D018967,Comparison,TRUE,"CONCLUSIONS: Clinical outcomes with <ENT2>risperidone</ENT2> were equal to those with <ENT1>olanzapine</ENT1>, and response may be more stable.",,,,T,,,,,c,,,,,0.0,,
17151160,911,D011618,D018967,Negative_Correlation,TRUE,"METHOD: One hundred twelve subjects (70% male; mean age=23.3 years [SD = 5.1]) with first-episode schizophrenia (75%), <ENT1>schizophreniform disorder</ENT1> (17%), or <ENT1>schizoaffective disorder</ENT1> (8%) were randomly assigned to treatment with olanzapine (2.5-20 mg/day) or <ENT2>risperidone</ENT2> (1-6 mg/day).",,,,T,,,,,w,,,,,0.0,,
17151160,909,D001480,D018967,Association,TRUE,<ENT1>Extrapyramidal symptom</ENT1> severity scores were 1.4 (95% CI=1.2-1.6) with <ENT2>risperidone</ENT2> and 1.2 (95% CI=1.0-1.4) with olanzapine.,,,,T,,,,,w,,,,,0.0,,
17166870,917,D000081029,2022,Association,TRUE,Association between an <ENT2>endoglin</ENT2> gene polymorphism and systemic sclerosis-related <ENT1>pulmonary arterial hypertension</ENT1>.,,,,T,,,,,c,,,,,1.0,,
17166870,917,D000081029,2022,Association,TRUE,"CONCLUSIONS: Thus the frequency of 6bINS differs between SSc patients with or without <ENT1>PAH</ENT1>, suggesting the implication of <ENT2>ENG</ENT2> in this devastating vascular complication of SSc.",,,,T,,,,,c,,,,,1.0,,
17166870,918,D000081029,c|INS||6,Negative_Correlation,TRUE,OBJECTIVES: Our objective was to investigate the relationship between <ENT2>6bINS</ENT2> and the vascular complication <ENT1>pulmonary arterial hypertension</ENT1> (<ENT1>PAH</ENT1>) in SSc in a French Caucasian population.,,,,T,,Y,,,c,,,,,1.0,,
17166870,918,D000081029,c|INS||6,Negative_Correlation,TRUE,"We observed a significant lower frequency of <ENT2>6bINS</ENT2> allele in SSc patients with associated <ENT1>PAH</ENT1> compared with controls [10.3 vs 23.9%, P = 0.01; odds ratio (OR) 0.37, 95% confidence interval (CI) 0.15-0.89], and a trend in comparison with SSc patients without <ENT1>PAH</ENT1> (10.3 vs 20.3%, P = 0.05; OR: 0.45, 95% CI: 0.19-1.08).",,,,T,,,,,c,,,,,0.0,,
17166870,918,D000081029,c|INS||6,Negative_Correlation,TRUE,"Genotypes carrying allele <ENT2>6bINS</ENT2> were also less frequent in SSc patients with <ENT1>PAH</ENT1> than in controls (20.7 vs 42.9%, P = 0.02).",,,,T,,,,,c,,,,,0.0,,
17166870,918,D000081029,c|INS||6,Negative_Correlation,TRUE,"CONCLUSIONS: Thus the frequency of <ENT2>6bINS</ENT2> differs between SSc patients with or without <ENT1>PAH</ENT1>, suggesting the implication of ENG in this devastating vascular complication of SSc.",,,,T,,,,,w,,,,,0.0,,
17166870,923,2022,D014652,Association,TRUE,"CONCLUSIONS: Thus the frequency of 6bINS differs between SSc patients with or without PAH, suggesting the implication of <ENT1>ENG</ENT1> in this devastating <ENT2>vascular complication</ENT2> of SSc.",,,,T,,,,,c,,,,,0.0,,
17166870,922,2022,D012595,Association,TRUE,Association between an <ENT1>endoglin</ENT1> gene polymorphism and <ENT2>systemic sclerosis</ENT2>-related pulmonary arterial hypertension.,,,,T,,,,,c,,,,,1.0,,
17166870,922,2022,D012595,Association,TRUE,"CONCLUSIONS: Thus the frequency of 6bINS differs between <ENT2>SSc</ENT2> patients with or without PAH, suggesting the implication of <ENT1>ENG</ENT1> in this devastating vascular complication of <ENT2>SSc</ENT2>.",,,,T,,,,,c,,,,,0.5,,
17166870,921,2022,7040,Bind,FALSE,"<ENT1>Endoglin</ENT1> gene (<ENT1>ENG</ENT1>) encodes a transmembrane glycoprotein which acts as an accessory receptor for the <ENT2>transforming growth factor-beta</ENT2> (<ENT2>TGF-beta</ENT2>) superfamily, and is crucial for maintaining vascular integrity.",,,,T,,,,,c,,,"11,12,21,22",,0.0,,
17166870,920,D014652,c|INS||6,Association,TRUE,OBJECTIVES: Our objective was to investigate the relationship between <ENT2>6bINS</ENT2> and the <ENT1>vascular complication</ENT1> pulmonary arterial hypertension (PAH) in SSc in a French Caucasian population.,,,,T,,Y,,,c,,,,,1.0,,
17166870,920,D014652,c|INS||6,Association,TRUE,"CONCLUSIONS: Thus the frequency of <ENT2>6bINS</ENT2> differs between SSc patients with or without PAH, suggesting the implication of ENG in this devastating <ENT1>vascular complication</ENT1> of SSc.",,,,T,Y,,,,w,,,,,0.0,,
17166870,919,D012595,c|INS||6,Association,TRUE,OBJECTIVES: Our objective was to investigate the relationship between <ENT2>6bINS</ENT2> and the vascular complication pulmonary arterial hypertension (PAH) in <ENT1>SSc</ENT1> in a French Caucasian population.,,,,T,,Y,,,c,,,,,1.0,,
17166870,919,D012595,c|INS||6,Association,TRUE,"We observed a significant lower frequency of <ENT2>6bINS</ENT2> allele in <ENT1>SSc</ENT1> patients with associated PAH compared with controls [10.3 vs 23.9%, P = 0.01; odds ratio (OR) 0.37, 95% confidence interval (CI) 0.15-0.89], and a trend in comparison with <ENT1>SSc</ENT1> patients without PAH (10.3 vs 20.3%, P = 0.05; OR: 0.45, 95% CI: 0.19-1.08).",,,,T,,,,,c,,,,,0.5,,
17166870,919,D012595,c|INS||6,Association,TRUE,"Genotypes carrying allele <ENT2>6bINS</ENT2> were also less frequent in <ENT1>SSc</ENT1> patients with PAH than in controls (20.7 vs 42.9%, P = 0.02).",,,,T,Y,,,,w,,,,,1.0,,
17166870,919,D012595,c|INS||6,Association,TRUE,"CONCLUSIONS: Thus the frequency of <ENT2>6bINS</ENT2> differs between <ENT1>SSc</ENT1> patients with or without PAH, suggesting the implication of ENG in this devastating vascular complication of <ENT1>SSc</ENT1>.",,,,T,Y,,,,w,,,,,0.0,,
17177139,928,D014284,p|SUB|E|333|D,Positive_Correlation,TRUE,We found that the <ENT2>E333D</ENT2> mutation neither significantly affected the affinity of the receptor for <ENT1>T3</ENT1> nor modified heterodimer formation with retinoid X receptor (RXR) when bound to DNA.,,,,T,,,,,c,,,,,1.0,,
17177139,930,D018382,6955,Association,TRUE,A novel mutation (E333D) in the <ENT2>thyroid hormone beta receptor</ENT2> causing <ENT1>resistance to thyroid hormone syndrome</ENT1>.,,,,T,,,,,c,,,,,1.0,,
17177139,930,D018382,6955,Association,TRUE,"Here, we report a novel natural <ENT1>RTH</ENT1> mutation (E333D) located in the large carboxy-terminal ligand binding domain of <ENT2>TRbeta</ENT2>.",,,,T,,,,,c,,,,,0.0,,
17177139,930,D018382,6955,Association,TRUE,These results strongly suggest that the E333D <ENT2>TRbeta</ENT2> mutation is responsible for the <ENT1>RTH</ENT1> phenotype in the proposita's family.,,,,T,,,,,c,,,,,1.0,,
17177139,936,D018382,p|SUB|E|333|D,Positive_Correlation,TRUE,A novel mutation (<ENT2>E333D</ENT2>) in the thyroid hormone beta receptor causing <ENT1>resistance to thyroid hormone syndrome</ENT1>.,,,,T,,,,,c,,,,,1.0,,
17177139,936,D018382,p|SUB|E|333|D,Positive_Correlation,TRUE,"Here, we report a novel natural <ENT1>RTH</ENT1> mutation (<ENT2>E333D</ENT2>) located in the large carboxy-terminal ligand binding domain of TRbeta.",,,,T,,,,,w,,,,,1.0,,
17177139,936,D018382,p|SUB|E|333|D,Positive_Correlation,TRUE,These results strongly suggest that the <ENT2>E333D</ENT2> TRbeta mutation is responsible for the <ENT1>RTH</ENT1> phenotype in the proposita's family.,,,,T,,,,,c,,,,,0.0,,
17177139,934,D018382,1081,Association,FALSE,"<ENT1>Resistance to thyroid hormone</ENT1> (<ENT1>RTH</ENT1>) is an inherited syndrome characterized by elevated serum thyroid hormones (TH), failure to suppress pituitary <ENT2>thyroid stimulating hormone</ENT2> (<ENT2>TSH</ENT2>) secretion, and variable peripheral tissue responsiveness to TH.",,,,T,,,,,c,,,"11,12,21,22",,0.25,,
17177139,931,D018382,D013963,Positive_Correlation,FALSE,"<ENT1>Resistance to thyroid hormone</ENT1> (<ENT1>RTH</ENT1>) is an inherited syndrome characterized by elevated serum <ENT2>thyroid hormones</ENT2> (<ENT2>TH</ENT2>), failure to suppress pituitary thyroid stimulating hormone (TSH) secretion, and variable peripheral tissue responsiveness to <ENT2>TH</ENT2>.",,,,T,,,,,c,,,"11,12,21,22",,0.166666667,,
17177139,929,6955,1081,Positive_Correlation,FALSE,"However, in transient transfection assays, the E333D <ENT1>TRbeta</ENT1> mutant exhibited impaired transcriptional regulation on two distinct positively regulated thyroid response elements (F2- and DR4-TREs) as well as on the negatively regulated human <ENT2>TSHalpha</ENT2> promoter.",,,,T,,,,,w,,,,,0.0,,
17177139,929,6955,1081,Positive_Correlation,FALSE,"Moreover, a dominant inhibition of the wild-type <ENT1>TRbeta</ENT1> counterpart transactivation function was observed on both a positive (F2-TRE) and a negative (<ENT2>TSHalpha</ENT2>) promoter.",,,,T,,,,,w,,,,,0.0,,
17177139,935,p|SUB|E|333|D,1081,Positive_Correlation,TRUE,"However, in transient transfection assays, the <ENT1>E333D</ENT1> TRbeta mutant exhibited impaired transcriptional regulation on two distinct positively regulated thyroid response elements (F2- and DR4-TREs) as well as on the negatively regulated human <ENT2>TSHalpha</ENT2> promoter.",,,,T,,,,,w,,,,,0.0,,
17185386,937,54820,D012559,Association,TRUE,"Families with the risk allele of DISC1 reveal a link between <ENT2>schizophrenia</ENT2> and another component of the same molecular pathway, <ENT1>NDE1</ENT1>.",,,,T,,,,,c,,,,,0.0,,
17185386,937,54820,D012559,Association,TRUE,"Although none of the observed linkages remained significant after multiple test correction through simulation, further analysis of <ENT1>NDE1</ENT1> revealed an association between a tag-haplotype and <ENT2>schizophrenia</ENT2> (P = 0.00046) specific to females, which proved to be significant (P = 0.011) after multiple test correction.",,,,T,,,,,c,,,,,1.0,,
17185386,938,54820,27185,Association,FALSE,"Families with the risk allele of <ENT2>DISC1</ENT2> reveal a link between schizophrenia and another component of the same molecular pathway, <ENT1>NDE1</ENT1>.",,,,T,,,,,c,,,,,0.0,,
17185386,938,54820,27185,Association,FALSE,"Two additional loci displayed an evidence of linkage (LOD > 3) and included a locus on 16p13, proximal to the gene encoding <ENT1>NDE1</ENT1>, which has been shown to biologically interact with <ENT2>DISC1</ENT2>.",,,,T,,,,,c,,,,,1.0,,
17185386,939,D012559,27185,Association,TRUE,"Families with the risk allele of <ENT2>DISC1</ENT2> reveal a link between <ENT1>schizophrenia</ENT1> and another component of the same molecular pathway, NDE1.",,,,T,,,,,c,,,,,0.0,,
17185386,939,D012559,27185,Association,TRUE,We have previously reported a robust association between an allelic haplotype of '<ENT2>Disrupted in Schizophrenia 1</ENT2>' (<ENT2>DISC1</ENT2>) and <ENT1>schizophrenia</ENT1> in a nationwide collection of Finnish <ENT1>schizophrenia</ENT1> families.,,,,T,,,,,c,,,,,1.0,,
17185386,939,D012559,27185,Association,TRUE,<ENT2>DISC1</ENT2> association to <ENT1>schizophrenia</ENT1> has since been replicated in multiple independent study samples from different populations.,,,,T,,,,,c,,,,,1.0,,
17185386,939,D012559,27185,Association,TRUE,"Notably, this and other converging lines of evidence underline the importance of <ENT2>DISC1</ENT2>-related functional pathways in the etiology of <ENT1>schizophrenia</ENT1>.",,,,T,,,,,w,,,,,0.0,,
17192049,940,rs1048943,D011471,Negative_Correlation,TRUE,"To evaluate this phenomenon, the association between two single nucleotide polymorphisms (<ENT1>A to G</ENT1> transition in exon7 leading to amino acid substitution <ENT1>Ile462Val</ENT1> and T3801C at 3'UTR) of CYP1A1 gene in <ENT2>prostate cancer</ENT2> were analyzed in a case-control study of 100 individuals in South Indian population.",,,,T,,Y,,,c,,,,,1.0,,
17192049,940,rs1048943,D011471,Negative_Correlation,TRUE,The estimated relative risk was significantly high for individuals with w1/m1 genotype at 3'UTR of CYP1A1 gene (OR-4.64; 95%CI = 1.51-14.86; P < 0.01) whereas the CYP1A1 <ENT1>Ile/Val</ENT1> genotype (w2/m2) on exon 7 was found to be associated with a decreased risk for <ENT2>prostate cancer</ENT2> (OR-0.17; 95%CI = 0.02-0.89; P=0.03).,,,,T,,,,,c,,,,,1.0,,
17192049,941,D011471,g|SUB|T|3801|C,Association,TRUE,"To evaluate this phenomenon, the association between two single nucleotide polymorphisms (A to G transition in exon7 leading to amino acid substitution Ile462Val and <ENT2>T3801C</ENT2> at 3'UTR) of CYP1A1 gene in <ENT1>prostate cancer</ENT1> were analyzed in a case-control study of 100 individuals in South Indian population.",,,,T,Y,,,,w,,,,,0.0,,
17192049,942,D011471,1543,Association,TRUE,<ENT2>Cytochrome p4501A1</ENT2> gene variants as susceptibility marker for <ENT1>prostate cancer</ENT1>.,,,,T,,,,,c,,,,,1.0,,
17192049,942,D011471,1543,Association,TRUE,<ENT2>CYP1A1</ENT2> activates environmental procarcinogens and catalyzes oxidative metabolism of estrogens and is likely to play an important role in the etiology of <ENT1>prostate cancer</ENT1>.,,,,T,,,,,c,,,,,1.0,,
17192049,942,D011471,1543,Association,TRUE,"To evaluate this phenomenon, the association between two single nucleotide polymorphisms (A to G transition in exon7 leading to amino acid substitution Ile462Val and T3801C at 3'UTR) of <ENT2>CYP1A1</ENT2> gene in <ENT1>prostate cancer</ENT1> were analyzed in a case-control study of 100 individuals in South Indian population.",,,,T,,Y,,,c,,,,,1.0,,
17192049,942,D011471,1543,Association,TRUE,The estimated relative risk was significantly high for individuals with w1/m1 genotype at 3'UTR of <ENT2>CYP1A1</ENT2> gene (OR-4.64; 95%CI = 1.51-14.86; P < 0.01) whereas the <ENT2>CYP1A1</ENT2> Ile/Val genotype (w2/m2) on exon 7 was found to be associated with a decreased risk for <ENT1>prostate cancer</ENT1> (OR-0.17; 95%CI = 0.02-0.89; P=0.03).,,,,T,,,,,c,,,,,1.0,,
17194457,951,D006897,D010134,Negative_Correlation,TRUE,<ENT2>PCPA</ENT2> significantly and substantially depleted 5-HT and <ENT1>5-HIAA</ENT1> in all brain regions examined.,,,,T,,,,,c,,,,,1.0,,
17194457,951,D006897,D010134,Negative_Correlation,TRUE,"Chronic T treatment significantly decreased 5-HT and <ENT1>5-HIAA</ENT1> in certain brain areas, but to a much lesser extent than <ENT2>PCPA</ENT2>.",,,,T,,,,,w,,,,,1.0,,
17194457,946,D006897,D013739,Negative_Correlation,TRUE,"Chronic <ENT2>T</ENT2> treatment significantly decreased 5-HT and <ENT1>5-HIAA</ENT1> in certain brain areas, but to a much lesser extent than PCPA.",,,,T,,,,,c,,,,,1.0,,
17194457,952,D010134,D012701,Negative_Correlation,TRUE,"<ENT2>Serotonin</ENT2> was depleted beginning on postnatal day 26 with <ENT1>parachlorophenylalanine</ENT1> (<ENT1>PCPA</ENT1> 100 mg/kg, every other day); controls received saline.",,,,T,,,,,c,,,,,1.0,,
17194457,952,D010134,D012701,Negative_Correlation,TRUE,<ENT1>PCPA</ENT1> significantly and substantially depleted <ENT2>5-HT</ENT2> and 5-HIAA in all brain regions examined.,,,,T,,,,,c,,,,,1.0,,
17194457,952,D010134,D012701,Negative_Correlation,TRUE,"Chronic T treatment significantly decreased <ENT2>5-HT</ENT2> and 5-HIAA in certain brain areas, but to a much lesser extent than <ENT1>PCPA</ENT1>.",,,,T,,,,,w,,,,,1.0,,
17194457,948,D010134,D013739,Association,TRUE,"At puberty (P40), half the <ENT1>PCPA</ENT1>-treated rats and half the saline-treated rats began treatment with <ENT2>testosterone</ENT2> (<ENT2>T</ENT2>, 5 mg/kg, 5 days/week).",,,,T,,,,,c,,,,,1.0,,
17194457,948,D010134,D013739,Association,TRUE,"Chronic <ENT2>T</ENT2> treatment significantly decreased 5-HT and 5-HIAA in certain brain areas, but to a much lesser extent than <ENT1>PCPA</ENT1>.",,,,T,,,,,c,,,,,1.0,,
17194457,948,D010134,D013739,Association,TRUE,"The most striking effect of combining <ENT2>T</ENT2>+<ENT1>PCPA</ENT1> was a significant increase in attack frequency as well as a significant decrease in the latency to attack, particularly following physical provocation.",,,,T,,,,,w,,,,,0.0,,
17194457,950,D010134,D001523,Positive_Correlation,TRUE,"Chronic exposure to <ENT1>PCPA</ENT1> alone significantly decreased locomotor activity and increased <ENT2>irritability</ENT2> but had no effect on sexual behavior, partner preference, or <ENT2>aggression</ENT2>.",,,,T,,,,,c,,,,,0.5,,
17194457,944,D045165,D012701,Association,FALSE,Behavioral effects of pubertal <ENT1>anabolic androgenic steroid</ENT1> exposure in male rats with low <ENT2>serotonin</ENT2>.,,,,T,Y,T,,,w,,,,,1.0,,
17194457,944,D045165,D012701,Association,FALSE,"The goal of this study was to assess the interactive effects of chronic <ENT1>anabolic androgenic steroid</ENT1> (<ENT1>AAS</ENT1>) exposure and brain <ENT2>serotonin</ENT2> (<ENT2>5-hydroxytryptamine</ENT2>, <ENT2>5-HT</ENT2>) depletion on behavior of pubertal male rats.",,,,T,,Y,,,c,,,,,1.0,,
17194457,944,D045165,D012701,Association,FALSE,"Based on these data, it can be speculated that pubertal <ENT1>AAS</ENT1> users with low central <ENT2>5-HT</ENT2> may be especially prone to exhibit aggressive behavior.",,,,T,,,,,w,,,,,0.0,,
17194457,943,D045165,D001523,Positive_Correlation,TRUE,"Based on these data, it can be speculated that pubertal <ENT1>AAS</ENT1> users with low central 5-HT may be especially prone to exhibit <ENT2>aggressive behavior</ENT2>.",,,,T,,,,,c,,,,,1.0,,
17194457,947,D012701,D013739,Negative_Correlation,TRUE,"Chronic <ENT2>T</ENT2> treatment significantly decreased <ENT1>5-HT</ENT1> and 5-HIAA in certain brain areas, but to a much lesser extent than PCPA.",,,,T,,,,,c,,,,,1.0,,
17194457,949,D012701,D001523,Association,TRUE,"Based on these data, it can be speculated that pubertal AAS users with low central <ENT1>5-HT</ENT1> may be especially prone to exhibit <ENT2>aggressive behavior</ENT2>.",,,,T,,,,,c,,,,,0.0,,
17194457,945,D013739,D001523,Positive_Correlation,TRUE,"<ENT1>T</ENT1> alone had no effect on locomotion, <ENT2>irritability</ENT2>, or sexual behavior but increased partner preference and <ENT2>aggression</ENT2>.",,,,T,,,,,c,,,,,0.5,,
17221831,957,rs1049564,D003072,Positive_Correlation,TRUE,The <ENT1>G51S</ENT1> purine nucleoside phosphorylase polymorphism is associated with <ENT2>cognitive decline</ENT2> in Alzheimer's disease patients.,,,,T,,,,,c,,,,,0.0,,
17221831,957,rs1049564,D003072,Positive_Correlation,TRUE,"Our findings suggest that the <ENT1>G51S</ENT1> PNP polymorphism is associated with a faster rate of <ENT2>cognitive decline</ENT2> in AD patients, highlighting the important role of purine metabolism in the progression of this neurodegenerative disorder.",,,,T,,,,,c,,,,,1.0,,
17221831,955,rs1049564,D019636,Association,TRUE,"Our findings suggest that the <ENT1>G51S</ENT1> PNP polymorphism is associated with a faster rate of cognitive decline in AD patients, highlighting the important role of purine metabolism in the progression of this <ENT2>neurodegenerative disorder</ENT2>.",,,,T,,,,,c,,,,,0.0,,
17221831,958,rs1049564,D000544,Association,TRUE,The <ENT1>G51S</ENT1> purine nucleoside phosphorylase polymorphism is associated with cognitive decline in <ENT2>Alzheimer's disease</ENT2> patients.,,,,T,,,,,c,,,,,1.0,,
17221831,958,rs1049564,D000544,Association,TRUE,"In this report the distribution of the exonic <ENT1>G/A</ENT1> single nucleotide polymorphism (SNP) in purine nucleoside phosphorylase (PNP) gene, resulting in the amino acid substitution <ENT1>serine to glycine at position 51</ENT1> (<ENT1>G51S</ENT1>), was investigated in a large population of <ENT2>AD</ENT2> patients (n=321) and non-demented control (n=208).",,,,T,,Y,,,c,,,,,1.0,,
17221831,958,rs1049564,D000544,Association,TRUE,"Our findings suggest that the <ENT1>G51S</ENT1> PNP polymorphism is associated with a faster rate of cognitive decline in <ENT2>AD</ENT2> patients, highlighting the important role of purine metabolism in the progression of this neurodegenerative disorder.",,,,T,,,,,c,,,,,0.0,,
17221831,956,D003072,4860,Association,TRUE,The G51S <ENT2>purine nucleoside phosphorylase</ENT2> polymorphism is associated with <ENT1>cognitive decline</ENT1> in Alzheimer's disease patients.,,,,T,,,,,c,,,,,1.0,,
17221831,956,D003072,4860,Association,TRUE,An increased representation of the <ENT2>PNP</ENT2> AA genotype was observed in AD patients with fast <ENT1>cognitive deterioration</ENT1> in comparison with that from patients with slow deterioration rate.,,,,T,,,,,c,,,,,1.0,,
17221831,956,D003072,4860,Association,TRUE,"Our findings suggest that the G51S <ENT2>PNP</ENT2> polymorphism is associated with a faster rate of <ENT1>cognitive decline</ENT1> in AD patients, highlighting the important role of purine metabolism in the progression of this neurodegenerative disorder.",,,,T,,,,,c,,,,,1.0,,
17221831,954,D019636,4860,Association,TRUE,"Our findings suggest that the G51S <ENT2>PNP</ENT2> polymorphism is associated with a faster rate of cognitive decline in AD patients, highlighting the important role of purine metabolism in the progression of this <ENT1>neurodegenerative disorder</ENT1>.",,,,T,,,,,c,,,,,1.0,,
17221831,953,D000544,4860,Association,TRUE,The G51S <ENT2>purine nucleoside phosphorylase</ENT2> polymorphism is associated with cognitive decline in <ENT1>Alzheimer's disease</ENT1> patients.,,,,T,,,,,c,,,,,1.0,,
17221831,953,D000544,4860,Association,TRUE,"In this report the distribution of the exonic G/A single nucleotide polymorphism (SNP) in <ENT2>purine nucleoside phosphorylase</ENT2> (<ENT2>PNP</ENT2>) gene, resulting in the amino acid substitution serine to glycine at position 51 (G51S), was investigated in a large population of <ENT1>AD</ENT1> patients (n=321) and non-demented control (n=208).",,,,T,,Y,,,c,,,,,1.0,,
17221831,953,D000544,4860,Association,TRUE,An increased representation of the <ENT2>PNP</ENT2> AA genotype was observed in <ENT1>AD</ENT1> patients with fast cognitive deterioration in comparison with that from patients with slow deterioration rate.,,,,T,,,,,c,,,,,0.0,,
17221831,953,D000544,4860,Association,TRUE,"Our findings suggest that the G51S <ENT2>PNP</ENT2> polymorphism is associated with a faster rate of cognitive decline in <ENT1>AD</ENT1> patients, highlighting the important role of purine metabolism in the progression of this neurodegenerative disorder.",,,,T,,,,,c,,,,,0.0,,
17255138,969,C116926,D009203,Association,TRUE,"Among non-users of aspirin, the adjusted hazard ratios (95% confidence interval) of hospitalization for <ENT2>AMI</ENT2>/GI vs the acetaminophen (with no aspirin) group were: <ENT1>rofecoxib</ENT1> 1.27 (1.13, 1.42), celecoxib 0.93 (0.83, 1.03), naproxen 1.59 (1.31, 1.93), diclofenac 1.17 (0.99, 1.38) and ibuprofen 1.05 (0.74, 1.51).",,,,T,,,,,c,,,,,1.0,,
17255138,969,C116926,D009203,Association,TRUE,The <ENT2>AMI</ENT2>/GI toxicity of celecoxib was similar to that of acetaminophen and seemed to be better than those of <ENT1>rofecoxib</ENT1> and NS-NSAIDs.,,,,T,,,,,w,,,,,0.0,,
17255138,960,C116926,D005767,Association,TRUE,The AMI/<ENT2>GI toxicity</ENT2> of celecoxib was similar to that of acetaminophen and seemed to be better than those of <ENT1>rofecoxib</ENT1> and NS-NSAIDs.,,,,T,,,,,w,,,,,0.0,,
17255138,973,C116926,D001241,Negative_Correlation,TRUE,"RESULTS: Person-years of exposure among non-users of <ENT2>aspirin</ENT2> were: 75,761 to acetaminophen, 42,671 to <ENT1>rofecoxib</ENT1> 65,860 to celecoxib, and 37,495 to NS-NSAIDs.",,,,T,,,,,w,,,,,1.0,,
17255138,973,C116926,D001241,Negative_Correlation,TRUE,"Among users of <ENT2>aspirin</ENT2>, they were: 14,671 to <ENT1>rofecoxib</ENT1>, 22,875 to celecoxib, 9,832 to NS-NSAIDs and 38,048 to acetaminophen.",,,,T,,,,,w,,,,,1.0,,
17255138,973,C116926,D001241,Negative_Correlation,TRUE,"Among non-users of <ENT2>aspirin</ENT2>, the adjusted hazard ratios (95% confidence interval) of hospitalization for AMI/GI vs the acetaminophen (with no <ENT2>aspirin</ENT2>) group were: <ENT1>rofecoxib</ENT1> 1.27 (1.13, 1.42), celecoxib 0.93 (0.83, 1.03), naproxen 1.59 (1.31, 1.93), diclofenac 1.17 (0.99, 1.38) and ibuprofen 1.05 (0.74, 1.51).",,,,T,,,,,w,,,,,1.0,,
17255138,973,C116926,D001241,Negative_Correlation,TRUE,"Among users of <ENT2>aspirin</ENT2>, they were: <ENT1>rofecoxib</ENT1> 1.73 (1.52, 1.98), celecoxib 1.34 (1.19, 1.52), ibuprofen 1.51 (0.95, 2.41), diclofenac 1.69 (1.35, 2.10), naproxen 1.35 (0.97, 1.88) and acetaminophen 1.29 (1.17, 1.42).",,,,T,,,,,w,,,,,1.0,,
17255138,979,D000894,D052246,Comparison,TRUE,Risks and benefits of <ENT2>COX-2 inhibitors</ENT2> vs non-selective <ENT1>NSAIDs</ENT1>: does their cardiovascular risk exceed their gastrointestinal benefit? A retrospective cohort study.,,,,T,,,,,c,,,,,0.0,,
17255138,979,D000894,D052246,Comparison,TRUE,OBJECTIVES: The risk of acute myocardial infarction (AMI) with <ENT2>COX-2 inhibitors</ENT2> may offset their gastrointestinal (GI) benefit compared with non-selective (NS) <ENT1>non-steroidal anti-inflammatory drugs</ENT1> (<ENT1>NSAIDs</ENT1>).,,,,T,,,,,c,,,,,0.0,,
17255138,979,D000894,D052246,Comparison,TRUE,"We aimed to compare the risks of hospitalization for AMI and GI bleeding among elderly patients using <ENT2>COX-2 inhibitors</ENT2>, NS-<ENT1>NSAIDs</ENT1> and acetaminophen.",,,,T,,Y,,,c,,,,,0.0,,
17255138,976,D000894,D009203,Association,TRUE,OBJECTIVES: The risk of <ENT2>acute myocardial infarction</ENT2> (<ENT2>AMI</ENT2>) with COX-2 inhibitors may offset their gastrointestinal (GI) benefit compared with non-selective (NS) <ENT1>non-steroidal anti-inflammatory drugs</ENT1> (<ENT1>NSAIDs</ENT1>).,,,,T,,,,,c,,,,,1.0,,
17255138,976,D000894,D009203,Association,TRUE,"We aimed to compare the risks of hospitalization for <ENT2>AMI</ENT2> and GI bleeding among elderly patients using COX-2 inhibitors, NS-<ENT1>NSAIDs</ENT1> and acetaminophen.",,,,T,,,,,w,,,,,0.0,,
17255138,976,D000894,D009203,Association,TRUE,The <ENT2>AMI</ENT2>/GI toxicity of celecoxib was similar to that of acetaminophen and seemed to be better than those of rofecoxib and NS-<ENT1>NSAIDs</ENT1>.,,,,T,,,,,w,,,,,0.0,,
17255138,977,D000894,D000082,Comparison,TRUE,"We aimed to compare the risks of hospitalization for AMI and GI bleeding among elderly patients using COX-2 inhibitors, NS-<ENT1>NSAIDs</ENT1> and <ENT2>acetaminophen</ENT2>.",,,,T,,Y,,,c,,,,,0.0,,
17255138,977,D000894,D000082,Comparison,TRUE,METHODS: We conducted a retrospective cohort study using administrative data of patients > or =65 years of age who filled a prescription for <ENT1>NSAID</ENT1> or <ENT2>acetaminophen</ENT2> during 1999-2002.,,,,T,,,,,c,,,,,1.0,,
17255138,977,D000894,D000082,Comparison,TRUE,"RESULTS: Person-years of exposure among non-users of aspirin were: 75,761 to <ENT2>acetaminophen</ENT2>, 42,671 to rofecoxib 65,860 to celecoxib, and 37,495 to NS-<ENT1>NSAIDs</ENT1>.",,,,T,,,,,c,,,,,0.0,,
17255138,977,D000894,D000082,Comparison,TRUE,"Among users of aspirin, they were: 14,671 to rofecoxib, 22,875 to celecoxib, 9,832 to NS-<ENT1>NSAIDs</ENT1> and 38,048 to <ENT2>acetaminophen</ENT2>.",,,,T,,,,,c,,,,,0.0,,
17255138,977,D000894,D000082,Comparison,TRUE,The AMI/GI toxicity of celecoxib was similar to that of <ENT2>acetaminophen</ENT2> and seemed to be better than those of rofecoxib and NS-<ENT1>NSAIDs</ENT1>.,,,,T,,,,,c,,,,,0.0,,
17255138,962,D000894,D005767,Association,TRUE,The AMI/<ENT2>GI toxicity</ENT2> of celecoxib was similar to that of acetaminophen and seemed to be better than those of rofecoxib and NS-<ENT1>NSAIDs</ENT1>.,,,,T,,,,,w,,,,,0.0,,
17255138,975,D000894,D001241,Negative_Correlation,TRUE,"RESULTS: Person-years of exposure among non-users of <ENT2>aspirin</ENT2> were: 75,761 to acetaminophen, 42,671 to rofecoxib 65,860 to celecoxib, and 37,495 to NS-<ENT1>NSAIDs</ENT1>.",,,,T,,,,,w,,,,,1.0,,
17255138,975,D000894,D001241,Negative_Correlation,TRUE,"Among users of <ENT2>aspirin</ENT2>, they were: 14,671 to rofecoxib, 22,875 to celecoxib, 9,832 to NS-<ENT1>NSAIDs</ENT1> and 38,048 to acetaminophen.",,,,T,,,,,w,,,,,1.0,,
17255138,970,D006471,D000082,Association,TRUE,"We aimed to compare the risks of hospitalization for AMI and <ENT1>GI bleeding</ENT1> among elderly patients using COX-2 inhibitors, NS-NSAIDs and <ENT2>acetaminophen</ENT2>.",,,,T,,,,,w,,,,,0.0,,
17255138,963,D006471,D009288,Positive_Correlation,TRUE,"CONCLUSION: Among non-users of aspirin, <ENT2>naproxen</ENT2> seemed to carry the highest risk for AMI/<ENT1>GI bleeding</ENT1>.",,,,T,,,,,c,,,,,1.0,,
17255138,967,C105934,D009203,Association,TRUE,"Among non-users of aspirin, the adjusted hazard ratios (95% confidence interval) of hospitalization for <ENT2>AMI</ENT2>/GI vs the acetaminophen (with no aspirin) group were: rofecoxib 1.27 (1.13, 1.42), <ENT1>celecoxib</ENT1> 0.93 (0.83, 1.03), naproxen 1.59 (1.31, 1.93), diclofenac 1.17 (0.99, 1.38) and ibuprofen 1.05 (0.74, 1.51).",,,,T,,,,,c,,,,,1.0,,
17255138,967,C105934,D009203,Association,TRUE,The <ENT2>AMI</ENT2>/GI toxicity of <ENT1>celecoxib</ENT1> was similar to that of acetaminophen and seemed to be better than those of rofecoxib and NS-NSAIDs.,,,,T,,,,,w,,,,,0.0,,
17255138,959,C105934,D005767,Association,TRUE,The AMI/<ENT2>GI toxicity</ENT2> of <ENT1>celecoxib</ENT1> was similar to that of acetaminophen and seemed to be better than those of rofecoxib and NS-NSAIDs.,,,,T,,,,,w,,,,,0.0,,
17255138,972,C105934,D001241,Negative_Correlation,TRUE,"RESULTS: Person-years of exposure among non-users of <ENT2>aspirin</ENT2> were: 75,761 to acetaminophen, 42,671 to rofecoxib 65,860 to <ENT1>celecoxib</ENT1>, and 37,495 to NS-NSAIDs.",,,,T,,,,,w,,,,,1.0,,
17255138,972,C105934,D001241,Negative_Correlation,TRUE,"Among users of <ENT2>aspirin</ENT2>, they were: 14,671 to rofecoxib, 22,875 to <ENT1>celecoxib</ENT1>, 9,832 to NS-NSAIDs and 38,048 to acetaminophen.",,,,T,,,,,w,,,,,1.0,,
17255138,972,C105934,D001241,Negative_Correlation,TRUE,"Among non-users of <ENT2>aspirin</ENT2>, the adjusted hazard ratios (95% confidence interval) of hospitalization for AMI/GI vs the acetaminophen (with no <ENT2>aspirin</ENT2>) group were: rofecoxib 1.27 (1.13, 1.42), <ENT1>celecoxib</ENT1> 0.93 (0.83, 1.03), naproxen 1.59 (1.31, 1.93), diclofenac 1.17 (0.99, 1.38) and ibuprofen 1.05 (0.74, 1.51).",,,,T,,,,,w,,,,,1.0,,
17255138,972,C105934,D001241,Negative_Correlation,TRUE,"Among users of <ENT2>aspirin</ENT2>, they were: rofecoxib 1.73 (1.52, 1.98), <ENT1>celecoxib</ENT1> 1.34 (1.19, 1.52), ibuprofen 1.51 (0.95, 2.41), diclofenac 1.69 (1.35, 2.10), naproxen 1.35 (0.97, 1.88) and acetaminophen 1.29 (1.17, 1.42).",,,,T,,,,,w,,,,,1.0,,
17255138,972,C105934,D001241,Negative_Correlation,TRUE,"Among users of <ENT2>aspirin</ENT2>, both <ENT1>celecoxib</ENT1> and naproxen seemed to be the least toxic.",,,,T,,,,,w,,,,,1.0,,
17255138,965,D052246,D009203,Positive_Correlation,FALSE,OBJECTIVES: The risk of <ENT2>acute myocardial infarction</ENT2> (<ENT2>AMI</ENT2>) with <ENT1>COX-2 inhibitors</ENT1> may offset their gastrointestinal (GI) benefit compared with non-selective (NS) non-steroidal anti-inflammatory drugs (NSAIDs).,,,,T,,,,,w,,,,,0.0,,
17255138,965,D052246,D009203,Positive_Correlation,FALSE,"We aimed to compare the risks of hospitalization for <ENT2>AMI</ENT2> and GI bleeding among elderly patients using <ENT1>COX-2 inhibitors</ENT1>, NS-NSAIDs and acetaminophen.",,,,T,,,,,w,,,,,0.0,,
17255138,978,D052246,D000082,Comparison,TRUE,"We aimed to compare the risks of hospitalization for AMI and GI bleeding among elderly patients using <ENT1>COX-2 inhibitors</ENT1>, NS-NSAIDs and <ENT2>acetaminophen</ENT2>.",,,,T,,Y,,,c,,,,,0.0,,
17255138,971,D009203,D000082,Association,TRUE,"We aimed to compare the risks of hospitalization for <ENT1>AMI</ENT1> and GI bleeding among elderly patients using COX-2 inhibitors, NS-NSAIDs and <ENT2>acetaminophen</ENT2>.",,,,T,,,,,w,,,,,0.0,,
17255138,971,D009203,D000082,Association,TRUE,"Among non-users of aspirin, the adjusted hazard ratios (95% confidence interval) of hospitalization for <ENT1>AMI</ENT1>/GI vs the <ENT2>acetaminophen</ENT2> (with no aspirin) group were: rofecoxib 1.27 (1.13, 1.42), celecoxib 0.93 (0.83, 1.03), naproxen 1.59 (1.31, 1.93), diclofenac 1.17 (0.99, 1.38) and ibuprofen 1.05 (0.74, 1.51).",,,,T,,,,,c,,,,,1.0,,
17255138,971,D009203,D000082,Association,TRUE,The <ENT1>AMI</ENT1>/GI toxicity of celecoxib was similar to that of <ENT2>acetaminophen</ENT2> and seemed to be better than those of rofecoxib and NS-NSAIDs.,,,,T,,,,,w,,,,,0.0,,
17255138,964,D009203,D009288,Positive_Correlation,TRUE,"Among non-users of aspirin, the adjusted hazard ratios (95% confidence interval) of hospitalization for <ENT1>AMI</ENT1>/GI vs the acetaminophen (with no aspirin) group were: rofecoxib 1.27 (1.13, 1.42), celecoxib 0.93 (0.83, 1.03), <ENT2>naproxen</ENT2> 1.59 (1.31, 1.93), diclofenac 1.17 (0.99, 1.38) and ibuprofen 1.05 (0.74, 1.51).",,,,T,,,,,w,,,,,1.0,,
17255138,964,D009203,D009288,Positive_Correlation,TRUE,"CONCLUSION: Among non-users of aspirin, <ENT2>naproxen</ENT2> seemed to carry the highest risk for <ENT1>AMI</ENT1>/GI bleeding.",,,,T,,,,,c,,,,,1.0,,
17255138,961,D000082,D005767,Association,TRUE,The AMI/<ENT2>GI toxicity</ENT2> of celecoxib was similar to that of <ENT1>acetaminophen</ENT1> and seemed to be better than those of rofecoxib and NS-NSAIDs.,,,,T,,,,,w,,,,,0.0,,
17255138,974,D000082,D001241,Negative_Correlation,TRUE,"RESULTS: Person-years of exposure among non-users of <ENT2>aspirin</ENT2> were: 75,761 to <ENT1>acetaminophen</ENT1>, 42,671 to rofecoxib 65,860 to celecoxib, and 37,495 to NS-NSAIDs.",,,,T,,,,,c,,,,,1.0,,
17255138,974,D000082,D001241,Negative_Correlation,TRUE,"Among users of <ENT2>aspirin</ENT2>, they were: 14,671 to rofecoxib, 22,875 to celecoxib, 9,832 to NS-NSAIDs and 38,048 to <ENT1>acetaminophen</ENT1>.",,,,T,,,,,c,,,,,1.0,,
17255138,974,D000082,D001241,Negative_Correlation,TRUE,"Among non-users of <ENT2>aspirin</ENT2>, the adjusted hazard ratios (95% confidence interval) of hospitalization for AMI/GI vs the <ENT1>acetaminophen</ENT1> (with no <ENT2>aspirin</ENT2>) group were: rofecoxib 1.27 (1.13, 1.42), celecoxib 0.93 (0.83, 1.03), naproxen 1.59 (1.31, 1.93), diclofenac 1.17 (0.99, 1.38) and ibuprofen 1.05 (0.74, 1.51).",,,,T,,,,,w,,,,,1.0,,
17255138,974,D000082,D001241,Negative_Correlation,TRUE,"Among users of <ENT2>aspirin</ENT2>, they were: rofecoxib 1.73 (1.52, 1.98), celecoxib 1.34 (1.19, 1.52), ibuprofen 1.51 (0.95, 2.41), diclofenac 1.69 (1.35, 2.10), naproxen 1.35 (0.97, 1.88) and <ENT1>acetaminophen</ENT1> 1.29 (1.17, 1.42).",,,,T,,,,,w,,,,,1.0,,
17297207,982,D007565,D011803,Negative_Correlation,FALSE,It was reported that there was a case of severe malaria patient with <ENT1>jaundice</ENT1> who presented with arrhythmia (premature ventricular contraction) while getting <ENT2>quinine</ENT2> infusion was reported.,,,,T,,,,,w,,,,,1.0,,
17297207,982,D007565,D011803,Negative_Correlation,FALSE,"On admission, laboratory examination showed Plasmodium falciparum (++++), total bilirubin 8.25 mg/dL, conjugated bilirubin 4.36 mg/dL, unconjugated bilirubin 3.89 mg/dL, potassium 3.52 meq/L Patient was diagnosed as severe malaria with <ENT1>jaundice</ENT1> and got <ENT2>quinine</ENT2> infusion in dextrose 5% 500 mg/8 hour.",,,,T,,,,,w,,,,,0.0,,
17297207,983,D016778,D011803,Negative_Correlation,FALSE,<ENT2>Quinine</ENT2>-induced arrhythmia in a patient with <ENT1>severe malaria</ENT1>.,,,,T,,T,,,c,,,,,1.0,,
17297207,983,D016778,D011803,Negative_Correlation,FALSE,It was reported that there was a case of <ENT1>severe malaria</ENT1> patient with jaundice who presented with arrhythmia (premature ventricular contraction) while getting <ENT2>quinine</ENT2> infusion was reported.,,,,T,,,,,c,,,,,0.0,,
17297207,983,D016778,D011803,Negative_Correlation,FALSE,"On admission, laboratory examination showed Plasmodium falciparum (++++), total bilirubin 8.25 mg/dL, conjugated bilirubin 4.36 mg/dL, unconjugated bilirubin 3.89 mg/dL, potassium 3.52 meq/L Patient was diagnosed as <ENT1>severe malaria</ENT1> with jaundice and got <ENT2>quinine</ENT2> infusion in dextrose 5% 500 mg/8 hour.",,,,T,,,,,w,,,,,1.0,,
17297207,984,D012848,D011803,Positive_Correlation,TRUE,"After 30 hours of <ENT2>quinine</ENT2> infusion the patient felt palpitation and electrocardiography (ECG) recording showed premature ventricular contraction (PVC) > 5 x/minute, trigemini, constant type--<ENT1>sinoatrial block</ENT1>, positive U wave.",,,,T,,,,,w,,,,,1.0,,
17297207,987,D001145,D011803,Positive_Correlation,FALSE,<ENT2>Quinine</ENT2>-induced <ENT1>arrhythmia</ENT1> in a patient with severe malaria.,,,,T,,,,,c,,,,,1.0,,
17297207,987,D001145,D011803,Positive_Correlation,FALSE,It was reported that there was a case of severe malaria patient with jaundice who presented with <ENT1>arrhythmia</ENT1> (premature ventricular contraction) while getting <ENT2>quinine</ENT2> infusion was reported.,,,,T,,,,,c,,,,,1.0,,
17297207,987,D001145,D011803,Positive_Correlation,FALSE,"<ENT2>Quinine</ENT2>, like quinidine, is a chincona alkaloid that has anti-<ENT1>arrhythmic</ENT1> property, although it also pro-<ENT1>arrhythmic</ENT1> that can cause various <ENT1>arrhythmias</ENT1>, including severe <ENT1>arrhythmia</ENT1> such as multiple PVC.",,,,T,,,,,c,,,,,0.75,,
17297207,987,D001145,D011803,Positive_Correlation,FALSE,"Administration of parenteral <ENT2>quinine</ENT2> must be done carefully and with good observation because of its pro-<ENT1>arrhythmic</ENT1> effect, especially in older patients who have heart diseases or patients with electrolyte disorder (hypokalemia) which frequently occurs due to vomiting and or diarrhea in malaria cases.",,,,T,,,,,w,,,,,1.0,,
17297207,986,D011803,D006331,Positive_Correlation,TRUE,"After 30 hours of <ENT1>quinine</ENT1> infusion the patient felt <ENT2>palpitation</ENT2> and electrocardiography (ECG) recording showed premature ventricular contraction (PVC) > 5 x/minute, trigemini, constant type--sinoatrial block, positive U wave.",,,,T,,,,,w,,,,,1.0,,
17297207,986,D011803,D006331,Positive_Correlation,TRUE,"Administration of parenteral <ENT1>quinine</ENT1> must be done carefully and with good observation because of its pro-arrhythmic effect, especially in older patients who have <ENT2>heart diseases</ENT2> or patients with electrolyte disorder (hypokalemia) which frequently occurs due to vomiting and or diarrhea in malaria cases.",,,,T,,,,,w,,,,,1.0,,
17297207,985,D011803,D018879,Positive_Correlation,TRUE,It was reported that there was a case of severe malaria patient with jaundice who presented with arrhythmia (<ENT2>premature ventricular contraction</ENT2>) while getting <ENT1>quinine</ENT1> infusion was reported.,,,,T,,,,,w,,,,,1.0,,
17297207,985,D011803,D018879,Positive_Correlation,TRUE,"After 30 hours of <ENT1>quinine</ENT1> infusion the patient felt palpitation and electrocardiography (ECG) recording showed <ENT2>premature ventricular contraction</ENT2> (<ENT2>PVC</ENT2>) > 5 x/minute, trigemini, constant type--sinoatrial block, positive U wave.",,,,T,,,,,c,,,,,1.0,,
17297207,985,D011803,D018879,Positive_Correlation,TRUE,"<ENT1>Quinine</ENT1>, like quinidine, is a chincona alkaloid that has anti-arrhythmic property, although it also pro-arrhythmic that can cause various arrhythmias, including severe arrhythmia such as multiple <ENT2>PVC</ENT2>.",,,,T,,,,,c,,,,,1.0,,
17304550,993,D009421,255928,Association,TRUE,Disruption of a <ENT2>synaptotagmin</ENT2> (<ENT2>SYT14</ENT2>) associated with <ENT1>neurodevelopmental abnormalities</ENT1>.,,,,T,,,,,c,,,,,1.0,,
17304550,992,255928,D002118,Association,FALSE,"Because members of the <ENT1>synaptotagmin</ENT1> family of proteins function as sensors that link changes in <ENT2>calcium</ENT2> levels with a variety of biological processes, including neurotransmission and hormone-responsiveness, <ENT1>SYT14</ENT1> is an intriguing candidate gene for the abnormal development in this child.",,,,T,,,,,w,,,,,1.0,,
17344330,1000,D013575,D008691,Positive_Correlation,TRUE,<ENT1>Syncope</ENT1> and QT prolongation among patients treated with <ENT2>methadone</ENT2> for heroin dependence in the city of Copenhagen.,,,,T,,T,,,c,,,,,1.0,,
17344330,1000,D013575,D008691,Positive_Correlation,TRUE,"As heroin addicts sometimes faint while using illicit drugs, doctors might attribute too many episodes of <ENT1>syncope</ENT1> to illicit drug use and thereby underestimate the incidence of TdP in this special population, and the high mortality in this population may, in part, be caused by the proarrhythmic effect of <ENT2>methadone</ENT2>.",,,,T,,,,,c,,,,,1.0,,
17344330,1000,D013575,D008691,Positive_Correlation,TRUE,"The association between opioid dose and QT, and <ENT2>methadone</ENT2> dose and reporting of <ENT1>syncope</ENT1> was assessed using multivariate linear regression and logistic regression, respectively.",,,,T,,Y,,,c,,,,,1.0,,
17344330,1000,D013575,D008691,Positive_Correlation,TRUE,A 50 mg higher <ENT2>methadone</ENT2> dose was associated with a 1.2 (95% CI 1.1 to 1.4) times higher odds for <ENT1>syncope</ENT1>.,,,,T,,,,,c,,,,,1.0,,
17344330,1000,D013575,D008691,Positive_Correlation,TRUE,CONCLUSIONS: <ENT2>Methadone</ENT2> is associated with QT prolongation and higher reporting of <ENT1>syncope</ENT1> in a population of heroin addicts.,,,,T,,,,,c,,,,,1.0,,
17344330,996,D008691,D002047,Comparison,FALSE,"METHODS: In this cross-sectional study interview, ECGs and blood samples were collected in a population of adult heroin addicts treated with <ENT1>methadone</ENT1> or <ENT2>buprenorphine</ENT2> on a daily basis.",,,,T,,,,,c,,,,,1.0,,
17344330,997,D008691,D000701,Association,FALSE,BACKGROUND: <ENT1>Methadone</ENT1> is prescribed to heroin addicts to decrease illicit <ENT2>opioid</ENT2> use.,,,,T,,,,,w,,,,,0.0,,
17344330,997,D008691,D000701,Association,FALSE,"The association between <ENT2>opioid</ENT2> dose and QT, and <ENT1>methadone</ENT1> dose and reporting of syncope was assessed using multivariate linear regression and logistic regression, respectively.",,,,T,,,,,c,,,,,0.0,,
17344330,994,D008691,D016171,Positive_Correlation,FALSE,Prolongation of the QT interval in the ECG of patients with <ENT2>torsade de pointes</ENT2> (<ENT2>TdP</ENT2>) has been reported in <ENT1>methadone</ENT1> users.,,,,T,,,,,w,,,,,0.0,,
17344330,994,D008691,D016171,Positive_Correlation,FALSE,"As heroin addicts sometimes faint while using illicit drugs, doctors might attribute too many episodes of syncope to illicit drug use and thereby underestimate the incidence of <ENT2>TdP</ENT2> in this special population, and the high mortality in this population may, in part, be caused by the proarrhythmic effect of <ENT1>methadone</ENT1>.",,,,T,,,,,c,,,,,1.0,,
17344330,999,D008691,D008133,Positive_Correlation,TRUE,Syncope and <ENT2>QT prolongation</ENT2> among patients treated with <ENT1>methadone</ENT1> for heroin dependence in the city of Copenhagen.,,,,T,,,,,w,,,,,0.0,,
17344330,999,D008691,D008133,Positive_Correlation,TRUE,<ENT2>Prolongation of the QT interval</ENT2> in the ECG of patients with torsade de pointes (TdP) has been reported in <ENT1>methadone</ENT1> users.,,,,T,,,,,c,,,,,1.0,,
17344330,999,D008691,D008133,Positive_Correlation,TRUE,RESULTS: <ENT1>Methadone</ENT1> dose was associated with <ENT2>longer QT interval</ENT2> of 0.140 ms/mg (p = 0.002).,,,,T,,,,,c,,,,,1.0,,
17344330,999,D008691,D008133,Positive_Correlation,TRUE,"Among the subjects treated with <ENT1>methadone</ENT1>, 28% men and 32% women had <ENT2>prolonged QTc interval</ENT2>.",,,,T,,,,,c,,,,,1.0,,
17344330,999,D008691,D008133,Positive_Correlation,TRUE,CONCLUSIONS: <ENT1>Methadone</ENT1> is associated with <ENT2>QT prolongation</ENT2> and higher reporting of syncope in a population of heroin addicts.,,,,T,,,,,c,,,,,1.0,,
17344330,998,D008691,D006556,Negative_Correlation,FALSE,Syncope and QT prolongation among patients treated with <ENT1>methadone</ENT1> for <ENT2>heroin dependence</ENT2> in the city of Copenhagen.,,,,T,,,,,c,,,,,1.0,,
17344330,998,D008691,D006556,Negative_Correlation,FALSE,BACKGROUND: <ENT1>Methadone</ENT1> is prescribed to <ENT2>heroin addicts</ENT2> to decrease illicit opioid use.,,,,T,,,,,c,,,,,1.0,,
17344330,998,D008691,D006556,Negative_Correlation,FALSE,"As <ENT2>heroin addicts</ENT2> sometimes faint while using illicit drugs, doctors might attribute too many episodes of syncope to illicit drug use and thereby underestimate the incidence of TdP in this special population, and the high mortality in this population may, in part, be caused by the proarrhythmic effect of <ENT1>methadone</ENT1>.",,,,T,,,,,w,,,,,0.0,,
17344330,998,D008691,D006556,Negative_Correlation,FALSE,"METHODS: In this cross-sectional study interview, ECGs and blood samples were collected in a population of adult <ENT2>heroin addicts</ENT2> treated with <ENT1>methadone</ENT1> or buprenorphine on a daily basis.",,,,T,,,,,w,,,,,0.0,,
17344330,998,D008691,D006556,Negative_Correlation,FALSE,CONCLUSIONS: <ENT1>Methadone</ENT1> is associated with QT prolongation and higher reporting of syncope in a population of <ENT2>heroin addicts</ENT2>.,,,,T,,,,,w,,,,,0.0,,
17344330,995,D002047,D006556,Negative_Correlation,FALSE,"METHODS: In this cross-sectional study interview, ECGs and blood samples were collected in a population of adult <ENT2>heroin addicts</ENT2> treated with methadone or <ENT1>buprenorphine</ENT1> on a daily basis.",,,,T,,,,,w,,,,,0.0,,
17345627,1012,D009999,652,Association,TRUE,Over-expression of <ENT2>BMP4</ENT2> and BMP5 in a child with axial skeletal malformations and <ENT1>heterotopic ossification</ENT1>: a new syndrome.,,,,T,,,,,c,,,,,1.0,,
17345627,1012,D009999,652,Association,TRUE,"<ENT2>Bone morphogenetic proteins</ENT2> (<ENT2>BMPs</ENT2>) are a highly conserved class of signaling molecules that induce ectopic cartilage and bone formation in vivo. Dysregulated expression of <ENT2>bone morphogenetic protein 4</ENT2> (<ENT2>BMP4</ENT2>) is found in the cells of patients who have fibrodysplasia ossificans progressiva (FOP), a genetic disorder of axial and appendicular skeletal malformation and progressive <ENT1>heterotopic ossification</ENT1>.",,,,T,,,,,w,,,,,1.0,,
17345627,1011,D009999,653,Association,TRUE,Over-expression of BMP4 and <ENT2>BMP5</ENT2> in a child with axial skeletal malformations and <ENT1>heterotopic ossification</ENT1>: a new syndrome.,,,,T,,,,,c,,,,,1.0,,
17345627,1011,D009999,653,Association,TRUE,"<ENT2>Bone morphogenetic proteins</ENT2> (<ENT2>BMPs</ENT2>) are a highly conserved class of signaling molecules that induce ectopic cartilage and bone formation in vivo. Dysregulated expression of bone morphogenetic protein 4 (BMP4) is found in the cells of patients who have fibrodysplasia ossificans progressiva (FOP), a genetic disorder of axial and appendicular skeletal malformation and progressive <ENT1>heterotopic ossification</ENT1>.",,,,T,,,,,c,,,,,0.0,,
17345627,1001,650,D002357,Association,FALSE,"<ENT1>Bone morphogenetic proteins</ENT1> (<ENT1>BMPs</ENT1>) are a highly conserved class of signaling molecules that induce <ENT2>ectopic cartilage and bone formation</ENT2> in vivo. Dysregulated expression of bone morphogenetic protein 4 (BMP4) is found in the cells of patients who have fibrodysplasia ossificans progressiva (FOP), a genetic disorder of axial and appendicular skeletal malformation and progressive heterotopic ossification.",,,,T,,,,,c,,,,,0.0,,
17345627,1004,652,D002357,Association,FALSE,"<ENT1>Bone morphogenetic proteins</ENT1> (<ENT1>BMPs</ENT1>) are a highly conserved class of signaling molecules that induce <ENT2>ectopic cartilage and bone formation</ENT2> in vivo. Dysregulated expression of <ENT1>bone morphogenetic protein 4</ENT1> (<ENT1>BMP4</ENT1>) is found in the cells of patients who have fibrodysplasia ossificans progressiva (FOP), a genetic disorder of axial and appendicular skeletal malformation and progressive heterotopic ossification.",,,,T,,,,,c,,,,,0.0,,
17345627,1016,652,D001848,Association,TRUE,Over-expression of <ENT1>BMP4</ENT1> and BMP5 in a child with <ENT2>axial skeletal malformations</ENT2> and heterotopic ossification: a new syndrome.,,,,T,,T,,,c,,,,,1.0,,
17345627,1016,652,D001848,Association,TRUE,"<ENT1>Bone morphogenetic proteins</ENT1> (<ENT1>BMPs</ENT1>) are a highly conserved class of signaling molecules that induce ectopic cartilage and bone formation in vivo. Dysregulated expression of <ENT1>bone morphogenetic protein 4</ENT1> (<ENT1>BMP4</ENT1>) is found in the cells of patients who have fibrodysplasia ossificans progressiva (FOP), a genetic disorder of <ENT2>axial and appendicular skeletal malformation</ENT2> and progressive heterotopic ossification.",,,,T,,,,,c,,,,,1.0,,
17345627,1016,652,D001848,Association,TRUE,Our data suggest that dysregulated expression of <ENT1>BMP4</ENT1> and BMP5 genes is associated with an array of human <ENT2>axial skeletal abnormalities</ENT2> similar to the short ear mouse and FOP.,,,,T,,,,,c,,,,,1.0,,
17345627,1013,652,D009221,Association,TRUE,"<ENT1>Bone morphogenetic proteins</ENT1> (<ENT1>BMPs</ENT1>) are a highly conserved class of signaling molecules that induce ectopic cartilage and bone formation in vivo. Dysregulated expression of <ENT1>bone morphogenetic protein 4</ENT1> (<ENT1>BMP4</ENT1>) is found in the cells of patients who have <ENT2>fibrodysplasia ossificans progressiva</ENT2> (<ENT2>FOP</ENT2>), a genetic disorder of axial and appendicular skeletal malformation and progressive heterotopic ossification.",,,,T,,,,,c,,,,,0.875,,
17345627,1013,652,D009221,Association,TRUE,Our data suggest that dysregulated expression of <ENT1>BMP4</ENT1> and BMP5 genes is associated with an array of human axial skeletal abnormalities similar to the short ear mouse and <ENT2>FOP</ENT2>.,,,,T,,,,,c,,,,,1.0,,
17345627;17345627,1002;1003,D002357;D002357,649;653,Association;Association,FALSE;FALSE,"<ENT2>Bone morphogenetic proteins</ENT2> (<ENT2>BMPs</ENT2>) are a highly conserved class of signaling molecules that induce <ENT1>ectopic cartilage and bone formation</ENT1> in vivo. Dysregulated expression of bone morphogenetic protein 4 (BMP4) is found in the cells of patients who have fibrodysplasia ossificans progressiva (FOP), a genetic disorder of axial and appendicular skeletal malformation and progressive heterotopic ossification.",,,,T,,,,,c,,,,,0.0,,
17345627,1015,653,D001848,Association,TRUE,Over-expression of BMP4 and <ENT1>BMP5</ENT1> in a child with <ENT2>axial skeletal malformations</ENT2> and heterotopic ossification: a new syndrome.,,,,T,,,,,c,,,,,1.0,,
17345627,1015,653,D001848,Association,TRUE,"<ENT1>Bone morphogenetic proteins</ENT1> (<ENT1>BMPs</ENT1>) are a highly conserved class of signaling molecules that induce ectopic cartilage and bone formation in vivo. Dysregulated expression of bone morphogenetic protein 4 (BMP4) is found in the cells of patients who have fibrodysplasia ossificans progressiva (FOP), a genetic disorder of <ENT2>axial and appendicular skeletal malformation</ENT2> and progressive heterotopic ossification.",,,,T,,,,,w,,,,,0.0,,
17345627,1015,653,D001848,Association,TRUE,"Loss of function mutations in the <ENT1>bone morphogenetic protein 5</ENT1> (<ENT1>bmp5</ENT1>) gene leading to under-expression of <ENT1>BMP5</ENT1> cause the murine short ear syndrome, characterized by small malformed ears and a broad range of <ENT2>axial skeletal malformations</ENT2>.",,,,T,,,,,c,,,,,1.0,,
17345627,1015,653,D001848,Association,TRUE,Our data suggest that dysregulated expression of BMP4 and <ENT1>BMP5</ENT1> genes is associated with an array of human <ENT2>axial skeletal abnormalities</ENT2> similar to the short ear mouse and FOP.,,,,T,,,,,c,,,,,1.0,,
17345627,1009,653,D009221,Association,TRUE,"<ENT1>Bone morphogenetic proteins</ENT1> (<ENT1>BMPs</ENT1>) are a highly conserved class of signaling molecules that induce ectopic cartilage and bone formation in vivo. Dysregulated expression of bone morphogenetic protein 4 (BMP4) is found in the cells of patients who have <ENT2>fibrodysplasia ossificans progressiva</ENT2> (<ENT2>FOP</ENT2>), a genetic disorder of axial and appendicular skeletal malformation and progressive heterotopic ossification.",,,,T,,,,,w,,,,,0.0,,
17345627,1009,653,D009221,Association,TRUE,Our data suggest that dysregulated expression of BMP4 and <ENT1>BMP5</ENT1> genes is associated with an array of human axial skeletal abnormalities similar to the short ear mouse and <ENT2>FOP</ENT2>.,,,,T,,,,,c,,,,,1.0,,
17345627,1010,653,D004427,Association,TRUE,"Loss of function mutations in the <ENT1>bone morphogenetic protein 5</ENT1> (<ENT1>bmp5</ENT1>) gene leading to under-expression of <ENT1>BMP5</ENT1> cause the murine <ENT2>short ear syndrome</ENT2>, characterized by small malformed ears and a broad range of axial skeletal malformations.",,,,T,,,,,c,,,,,1.0,,
17395743,1022,D003924,5820,Association,TRUE,Identification of <ENT2>PVT1</ENT2> as a candidate gene for end-stage renal disease in <ENT1>type 2 diabetes</ENT1> using a pooling-based genome-wide single nucleotide polymorphism association study.,,,,T,,,,,c,,,,,1.0,,
17395743,1021,D003920,5820,Association,TRUE,"Together, these results suggest that <ENT2>PVT1</ENT2> may contribute to ESRD susceptibility in <ENT1>diabetes</ENT1>.",,,,T,Y,,,,c,,,,,0.0,,
17395743,1023,5820,D007676,Association,TRUE,Identification of <ENT1>PVT1</ENT1> as a candidate gene for <ENT2>end-stage renal disease</ENT2> in type 2 diabetes using a pooling-based genome-wide single nucleotide polymorphism association study.,,,,T,,,,,c,,,,,1.0,,
17395743,1023,5820,D007676,Association,TRUE,"Together, these results suggest that <ENT1>PVT1</ENT1> may contribute to <ENT2>ESRD</ENT2> susceptibility in diabetes.",,,,T,,,,,c,,,,,1.0,,
17395743,1018,D007676,rs2720709,Positive_Correlation,TRUE,We subsequently genotyped these 11 variants and an additional 87 SNPs identified through public databases in 319-kb flanking <ENT2>rs2720709</ENT2> ( approximately 1 SNP/3.5 kb); 23 markers were associated with <ENT1>ESRD</ENT1> at P < 0.01.,,,,T,,,,,w,,,,,0.0,,
17491223,1024,D007511,D004280,Association,FALSE,"OBJECTIVES: To assess the added diagnostic value of a new cardiac performance index (dP/dtejc) measurement, based on brachial artery flow changes, as compared to standard 12-lead ECG, for detecting <ENT2>dobutamine</ENT2>-induced myocardial ischemia, using Tc99m-Sestamibi single-photon emission computed tomography as the gold standard of comparison to assess the presence or absence of <ENT1>ischemia</ENT1>.",,,,T,,,,,w,,,,,0.0,,
17491223,1025,D004280,D017202,Positive_Correlation,FALSE,Assessment of a new non-invasive index of cardiac performance for detection of <ENT1>dobutamine</ENT1>-induced <ENT2>myocardial ischemia</ENT2>.,,,,T,,,,,c,,,,,1.0,,
17491223,1025,D004280,D017202,Positive_Correlation,FALSE,BACKGROUND: Electrocardiography has a very low sensitivity in detecting <ENT1>dobutamine</ENT1>-induced <ENT2>myocardial ischemia</ENT2>.,,,,T,,,,,c,,,,,1.0,,
17491223,1025,D004280,D017202,Positive_Correlation,FALSE,"OBJECTIVES: To assess the added diagnostic value of a new cardiac performance index (dP/dtejc) measurement, based on brachial artery flow changes, as compared to standard 12-lead ECG, for detecting <ENT1>dobutamine</ENT1>-induced <ENT2>myocardial ischemia</ENT2>, using Tc99m-Sestamibi single-photon emission computed tomography as the gold standard of comparison to assess the presence or absence of ischemia.",,,,T,,,,,c,,,,,1.0,,
17549393,1027,3664,C536528,Association,FALSE,A novel <ENT1>IRF6</ENT1> nonsense mutation (Y67X) in a German family with <ENT2>Van der Woude syndrome</ENT2>.,,,,T,,T,,,c,,,,,1.0,,
17549393,1027,3664,C536528,Association,FALSE,<ENT2>VWS</ENT2> arises as the result of mutations in the gene encoding <ENT1>interferon regulatory factor 6</ENT1> (<ENT1>IRF6</ENT1>).,,,,T,,,,,c,,,,,1.0,,
17549393,1027,3664,C536528,Association,FALSE,"Very recently, mutations of the <ENT1>IRF6</ENT1> gene in exons 2-9 have been found in <ENT2>VWS</ENT2> patients, suggesting that this gene plays an important role in orofacial development.",,,,T,,,,,c,,,,,1.0,,
17549393,1026,3664,4086,Bind,FALSE,The premature stop codon was responsible for a truncated protein lacking parts of the DNA- binding domain and the complete <ENT2>Smad</ENT2>-<ENT1>interferon regulatory factor</ENT1>-binding domain probably essential for interactions with the <ENT2>Smad</ENT2> transcription factors.,,,,T,,,,,c,,,,,0.0,,
17549393,1029,C536528,p|SUB|Y|67|X,Positive_Correlation,TRUE,A novel IRF6 nonsense mutation (<ENT2>Y67X</ENT2>) in a German family with <ENT1>Van der Woude syndrome</ENT1>.,,,,T,,,,,c,,,,,0.0,,
17595233,1034,D015212,64127,Association,TRUE,"The aim of this study was therefore to investigate the influence of mutations in these <ENT2>innate immune receptor</ENT2> genes (<ENT2>nucleotide oligomerisation domain (NOD) 2</ENT2>/<ENT2>caspase recruitment domain (CARD) 15</ENT2>, NOD1/CARD4, TUCAN/CARDINAL/CARD8, Toll-like receptor (TLR) 4, TLR2, TLR1 and TLR6) on the development of antimicrobial and antiglycan antibodies in <ENT1>inflammatory bowel disease</ENT1> (<ENT1>IBD</ENT1>).",,,,T,,Y,,,c,,,,,1.0,,
17595233,1034,D015212,64127,Association,TRUE,"Materials and METHODS: A cohort of 1163 unrelated patients with <ENT1>IBD</ENT1> (874 Crohn's disease, 259 ulcerative colitis, 30 indeterminate colitis) and 312 controls were analysed for anti-Saccharomyces cerevisiae antibodies (gASCA) IgG, anti-laminaribioside antibodies (ALCA) IgG, anti-chitobioside antibodies (ACCA) IgA, anti-mannobioside antibodies (AMCA) IgG and outer membrane porin (Omp) IgA and were genotyped for variants in <ENT2>NOD2</ENT2>/<ENT2>CARD15</ENT2>, TUCAN/CARDINAL/CARD8, NOD1/CARD4, TLR4, TLR1, TLR2 and TLR6.",,,,T,,,,,c,,,,,1.0,,
17595233,1030,D015212,7097,Association,TRUE,"The aim of this study was therefore to investigate the influence of mutations in these <ENT2>innate immune receptor</ENT2> genes (nucleotide oligomerisation domain (NOD) 2/caspase recruitment domain (CARD) 15, NOD1/CARD4, TUCAN/CARDINAL/CARD8, Toll-like receptor (TLR) 4, <ENT2>TLR2</ENT2>, TLR1 and TLR6) on the development of antimicrobial and antiglycan antibodies in <ENT1>inflammatory bowel disease</ENT1> (<ENT1>IBD</ENT1>).",,,,T,,Y,,,c,,,,,1.0,,
17595233,1030,D015212,7097,Association,TRUE,"Materials and METHODS: A cohort of 1163 unrelated patients with <ENT1>IBD</ENT1> (874 Crohn's disease, 259 ulcerative colitis, 30 indeterminate colitis) and 312 controls were analysed for anti-Saccharomyces cerevisiae antibodies (gASCA) IgG, anti-laminaribioside antibodies (ALCA) IgG, anti-chitobioside antibodies (ACCA) IgA, anti-mannobioside antibodies (AMCA) IgG and outer membrane porin (Omp) IgA and were genotyped for variants in NOD2/CARD15, TUCAN/CARDINAL/CARD8, NOD1/CARD4, TLR4, TLR1, <ENT2>TLR2</ENT2> and TLR6.",,,,T,,,,,c,,,,,1.0,,
17595233,1031,D015212,7099,Association,TRUE,"The aim of this study was therefore to investigate the influence of mutations in these <ENT2>innate immune receptor</ENT2> genes (nucleotide oligomerisation domain (NOD) 2/caspase recruitment domain (CARD) 15, NOD1/CARD4, TUCAN/CARDINAL/CARD8, <ENT2>Toll-like receptor (TLR) 4</ENT2>, TLR2, TLR1 and TLR6) on the development of antimicrobial and antiglycan antibodies in <ENT1>inflammatory bowel disease</ENT1> (<ENT1>IBD</ENT1>).",,,,T,,Y,,,c,,,,,1.0,,
17595233,1031,D015212,7099,Association,TRUE,"Materials and METHODS: A cohort of 1163 unrelated patients with <ENT1>IBD</ENT1> (874 Crohn's disease, 259 ulcerative colitis, 30 indeterminate colitis) and 312 controls were analysed for anti-Saccharomyces cerevisiae antibodies (gASCA) IgG, anti-laminaribioside antibodies (ALCA) IgG, anti-chitobioside antibodies (ACCA) IgA, anti-mannobioside antibodies (AMCA) IgG and outer membrane porin (Omp) IgA and were genotyped for variants in NOD2/CARD15, TUCAN/CARDINAL/CARD8, NOD1/CARD4, <ENT2>TLR4</ENT2>, TLR1, TLR2 and TLR6.",,,,T,,,,,c,,,,,1.0,,
17595233,1036,10392,D003424,Association,TRUE,"Materials and METHODS: A cohort of 1163 unrelated patients with IBD (874 <ENT2>Crohn's disease</ENT2>, 259 ulcerative colitis, 30 indeterminate colitis) and 312 controls were analysed for anti-Saccharomyces cerevisiae antibodies (gASCA) IgG, anti-laminaribioside antibodies (ALCA) IgG, anti-chitobioside antibodies (ACCA) IgA, anti-mannobioside antibodies (AMCA) IgG and outer membrane porin (Omp) IgA and were genotyped for variants in NOD2/CARD15, TUCAN/CARDINAL/CARD8, <ENT1>NOD1</ENT1>/<ENT1>CARD4</ENT1>, TLR4, TLR1, TLR2 and TLR6.",,,,T,,Y,,,c,,,,,1.0,,
17595233,1036,10392,D003424,Association,TRUE,"Similarly, <ENT2>Crohn's disease</ENT2> patients carrying <ENT1>NOD1</ENT1>/<ENT1>CARD4</ENT1> indel had a higher prevalence of gASCA antibodies than wild-type patients (63.8% versus 55.2%, p = 0.014), also with a gene dosage effect.",,,,T,,,,,c,,,,,1.0,,
17595233,1035,64127,D003424,Association,TRUE,"Materials and METHODS: A cohort of 1163 unrelated patients with IBD (874 <ENT2>Crohn's disease</ENT2>, 259 ulcerative colitis, 30 indeterminate colitis) and 312 controls were analysed for anti-Saccharomyces cerevisiae antibodies (gASCA) IgG, anti-laminaribioside antibodies (ALCA) IgG, anti-chitobioside antibodies (ACCA) IgA, anti-mannobioside antibodies (AMCA) IgG and outer membrane porin (Omp) IgA and were genotyped for variants in <ENT1>NOD2</ENT1>/<ENT1>CARD15</ENT1>, TUCAN/CARDINAL/CARD8, NOD1/CARD4, TLR4, TLR1, TLR2 and TLR6.",,,,T,,Y,,,c,,,,,1.0,,
17595233,1035,64127,D003424,Association,TRUE,"RESULTS: When compared with <ENT2>Crohn's disease</ENT2> patients without <ENT1>CARD15</ENT1> mutations, the presence of at least one <ENT1>CARD15</ENT1> variant in <ENT2>Crohn's disease</ENT2> patients more frequently led to gASCA positivity (66.1% versus 51.5%, p < 0.0001) and ALCA positivity (43.3% versus 34.9%, p = 0.018) and higher gASCA titers (85.7 versus 51.8 ELISA units, p < 0.0001), independent of ileal involvement.",,,,T,,,,,c,,,,,1.0,,
17600377,1048,D003704,C524754,Association,TRUE,"A novel compound, <ENT2>maltolyl p-coumarate</ENT2>, attenuates cognitive deficits and shows neuroprotective effects in vitro and in vivo <ENT1>dementia</ENT1> models.",,,,T,,,,,w,,,,,0.0,,
17600377,1039,C544092,D003072,Positive_Correlation,FALSE,"In the present study, we investigated whether maltolyl p-coumarate could improve <ENT2>cognitive decline</ENT2> in scopolamine-injected rats and in <ENT1>amyloid beta peptide(1-42)</ENT1>-infused rats.",,,,T,,,,,c,,,,,1.0,,
17600377,1039,C544092,D003072,Positive_Correlation,FALSE,Maltolyl p-coumarate was found to attenuate <ENT2>cognitive deficits</ENT2> in both rat models using passive avoidance test and to reduce apoptotic cell death observed in the hippocampus of the <ENT1>amyloid beta peptide(1-42)</ENT1>-infused rats.,,,,T,,,,,w,,,,,0.0,,
17600377,1047,C544092,C524754,Association,TRUE,"In the present study, we investigated whether <ENT2>maltolyl p-coumarate</ENT2> could improve cognitive decline in scopolamine-injected rats and in <ENT1>amyloid beta peptide(1-42)</ENT1>-infused rats.",,,,T,,,,,c,,,,,1.0,,
17600377,1047,C544092,C524754,Association,TRUE,<ENT2>Maltolyl p-coumarate</ENT2> was found to attenuate cognitive deficits in both rat models using passive avoidance test and to reduce apoptotic cell death observed in the hippocampus of the <ENT1>amyloid beta peptide(1-42)</ENT1>-infused rats.,,,,T,,,,,w,,,,,0.0,,
17600377,1047,C544092,C524754,Association,TRUE,"Cells were pretreated with <ENT2>maltolyl p-coumarate</ENT2>, before exposed to <ENT1>amyloid beta peptide(1-42)</ENT1>, glutamate or H2O2.",,,,T,,,,,c,,,,,1.0,,
17600377,1049,D003072,C524754,Negative_Correlation,TRUE,"A novel compound, <ENT2>maltolyl p-coumarate</ENT2>, attenuates <ENT1>cognitive deficits</ENT1> and shows neuroprotective effects in vitro and in vivo dementia models.",,,,T,,,,,c,,,,,1.0,,
17600377,1049,D003072,C524754,Negative_Correlation,TRUE,"In the present study, we investigated whether <ENT2>maltolyl p-coumarate</ENT2> could improve <ENT1>cognitive decline</ENT1> in scopolamine-injected rats and in amyloid beta peptide(1-42)-infused rats.",,,,T,,Y,,,c,,,,,1.0,,
17600377,1049,D003072,C524754,Negative_Correlation,TRUE,<ENT2>Maltolyl p-coumarate</ENT2> was found to attenuate <ENT1>cognitive deficits</ENT1> in both rat models using passive avoidance test and to reduce apoptotic cell death observed in the hippocampus of the amyloid beta peptide(1-42)-infused rats.,,,,T,,,,,c,,,,,1.0,,
17600377,1049,D003072,C524754,Negative_Correlation,TRUE,"Taking these in vitro and in vivo results together, our study suggests that <ENT2>maltolyl p-coumarate</ENT2> is a potentially effective candidate against Alzheimer's disease that is characterized by wide spread neuronal death and progressive <ENT1>decline of cognitive function</ENT1>.",,,,T,,,,,c,,,,,1.0,,
17600377,1038,D003072,D012601,Positive_Correlation,FALSE,"In the present study, we investigated whether maltolyl p-coumarate could improve <ENT1>cognitive decline</ENT1> in <ENT2>scopolamine</ENT2>-injected rats and in amyloid beta peptide(1-42)-infused rats.",,,,T,,,,,w,,,,,1.0,,
17600377,1046,C524754,D017382,Negative_Correlation,TRUE,"We found that <ENT1>maltolyl p-coumarate</ENT1> significantly decreased apoptotic cell death and reduced <ENT2>reactive oxygen species</ENT2>, cytochrome c release, and caspase 3 activation.",,,,T,,,,,c,,,,,1.0,,
17600377,1040,C524754,C495469,Association,TRUE,"To develop a novel and effective drug that could enhance cognitive function and neuroprotection, we newly synthesized <ENT1>maltolyl p-coumarate</ENT1> by the esterification of maltol and <ENT2>p-coumaric acid</ENT2>.",,,,T,,,,,w,,,,,0.0,,
17600377,1043,C524754,D000544,Negative_Correlation,TRUE,"Taking these in vitro and in vivo results together, our study suggests that <ENT1>maltolyl p-coumarate</ENT1> is a potentially effective candidate against <ENT2>Alzheimer's disease</ENT2> that is characterized by wide spread neuronal death and progressive decline of cognitive function.",,,,T,,,,,c,,,,,1.0,,
17600377,1044,C524754,D045304,Negative_Correlation,TRUE,"We found that <ENT1>maltolyl p-coumarate</ENT1> significantly decreased apoptotic cell death and reduced reactive oxygen species, <ENT2>cytochrome c</ENT2> release, and caspase 3 activation.",,,,T,,,,,c,,,,,1.0,,
17600377,1045,C524754,25402,Negative_Correlation,TRUE,"We found that <ENT1>maltolyl p-coumarate</ENT1> significantly decreased apoptotic cell death and reduced reactive oxygen species, cytochrome c release, and <ENT2>caspase 3</ENT2> activation.",,,,T,,,,,c,,,,,1.0,,
17600377,1042,C524754,D009410,Negative_Correlation,TRUE,"Taking these in vitro and in vivo results together, our study suggests that <ENT1>maltolyl p-coumarate</ENT1> is a potentially effective candidate against Alzheimer's disease that is characterized by wide spread <ENT2>neuronal death</ENT2> and progressive decline of cognitive function.",,,,T,,,,,c,,,,,1.0,,
17600377,1041,C524754,C008316,Association,TRUE,"To develop a novel and effective drug that could enhance cognitive function and neuroprotection, we newly synthesized <ENT1>maltolyl p-coumarate</ENT1> by the esterification of <ENT2>maltol</ENT2> and p-coumaric acid.",,,,T,,,,,w,,,,,0.0,,
17600377,1037,C495469,C008316,Association,TRUE,"To develop a novel and effective drug that could enhance cognitive function and neuroprotection, we newly synthesized maltolyl p-coumarate by the esterification of <ENT2>maltol</ENT2> and <ENT1>p-coumaric acid</ENT1>.",,,,T,,,,,w,,,,,0.0,,
17628794,1050,p|SUB|V|16|A,D052878,Positive_Correlation,TRUE,"A <ENT1>valine (Val) to alanine (Ala) substitution at amino acid 16</ENT1>, occurring in the mitochondrial targeting sequence of the MnSOD gene, has been associated with an increase in <ENT2>urolithiasis</ENT2> risk.",,,,T,,,,,c,,,,,1.0,,
17628794,1052,D002137,6648,Association,FALSE,We investigated the <ENT2>MnSOD</ENT2> in 66 <ENT1>stone-forming</ENT1> adults and 72 healthy volunteers.,,,,T,,Y,,,c,,,,,1.0,,
17628794,1051,6648,D052878,Association,FALSE,<ENT1>Manganese superoxide dismutase</ENT1> (<ENT1>Mn-SOD</ENT1>) gene polymorphisms in <ENT2>urolithiasis</ENT2>.,,,,T,,T,,,w,,,,,0.5,TRUE,
17628794,1051,6648,D052878,Association,FALSE,Polymorphism in <ENT1>manganese superoxide dismutase</ENT1> gene (<ENT1>Mn-SOD</ENT1>) is a new approach to identify its probable association with <ENT2>urolithiasis</ENT2>.,,,,T,,,,,w,,,,,0.0,TRUE,
17628794,1051,6648,D052878,Association,FALSE,"A valine (Val) to alanine (Ala) substitution at amino acid 16, occurring in the mitochondrial targeting sequence of the <ENT1>MnSOD</ENT1> gene, has been associated with an increase in <ENT2>urolithiasis</ENT2> risk.",,,,T,,,,,c,,,,,0.0,,
17628794,1051,6648,D052878,Association,FALSE,This study was conducted to investigate the association of <ENT1>MnSOD</ENT1> gene polymorphism with the risk of <ENT2>urolithiasis</ENT2>.,,,,T,,Y,,,c,,,,,1.0,,
17628794,1051,6648,D052878,Association,FALSE,<ENT1>MnSOD</ENT1> genotype determination may provide a tool to identify individuals who are at risk of <ENT2>urolithiasis</ENT2>.,,,,T,,,,,w,,,,,0.0,,
17634480,1055,D001943,2879,Association,TRUE,"PATIENTS AND METHODS: We examined associations between 54 polymorphisms that tag the known common variants (minor allele frequency > 0.05) in 10 genes involved in oxidative damage repair (CAT, SOD1, SOD2, GPX1, <ENT2>GPX4</ENT2>, GSR, TXN, TXN2, TXNRD1, and TXNRD2) and survival in 4,470 women with <ENT1>breast cancer</ENT1>.",,,,T,,Y,,,c,,,,,1.0,,
17634480,1055,D001943,2879,Association,TRUE,"We found that the common allele is preferentially expressed in normal lymphocytes, normal breast, and <ENT1>breast tumors</ENT1> compared with the rare allele, but there were no differences in total levels of <ENT2>GPX4</ENT2> mRNA across genotypes.",,,,T,,,,,c,,,,,1.0,,
17634480,1055,D001943,2879,Association,TRUE,CONCLUSION: These data provide strong support for the hypothesis that common variation in <ENT2>GPX4</ENT2> is associated with prognosis after a diagnosis of <ENT1>breast cancer</ENT1>.,,,,T,,,,,c,,,,,1.0,,
17634480,1056,rs713041,D003643,Positive_Correlation,TRUE,"GPX4 <ENT1>rs713041</ENT1> is located near the selenocysteine insertion sequence element in the GPX4 3' untranslated region, and the rare allele of this SNP is associated with an increased risk of <ENT2>death</ENT2>, with a hazard ratio of 1.27 per rare allele carried (95% CI, 1.13 to 11.43).",,,,T,,,,,c,,,,,1.0,,
17634480,1053,D017382,D009369,Positive_Correlation,FALSE,Of particular interest are genes involved in defense against <ENT1>reactive oxygen species</ENT1> (<ENT1>ROS</ENT1>) because <ENT1>ROS</ENT1> are thought to cause DNA damage and contribute to the pathogenesis of <ENT2>cancer</ENT2>.,,,,T,,,,,c,,,,,0.333333333,,
17634480,1054,D003643,2879,Association,TRUE,"<ENT2>GPX4</ENT2> rs713041 is located near the selenocysteine insertion sequence element in the <ENT2>GPX4</ENT2> 3' untranslated region, and the rare allele of this SNP is associated with an increased risk of <ENT1>death</ENT1>, with a hazard ratio of 1.27 per rare allele carried (95% CI, 1.13 to 11.43).",,,,T,,,,,c,,,,,1.0,,
17671735,1059,rs80338939,D034381,Positive_Correlation,FALSE,Our results suggest the importance of routine screening for the rather frequent -3170G>A mutation (in addition to <ENT1>c.35delG</ENT1>) in patients with <ENT2>hearing impairment</ENT2>.,,,,T,,,,,w,,,,,1.0,,
17671735,1061,D034381,2706,Association,FALSE,Mutations in the <ENT2>GJB2</ENT2> gene are the most common cause of hereditary prelingual <ENT1>sensorineural hearing impairment</ENT1> in Europe.,,,,T,,,,,c,,,,,1.0,,
17671735,1061,D034381,2706,Association,FALSE,"Therefore, we screened 47 Hungarian <ENT2>GJB2</ENT2>- heterozygous (one mutation in coding exon of the <ENT2>GJB2</ENT2> gene) patients with <ENT1>hearing impairment</ENT1> for DNA changes in two further connexin genes (GJB6 and GJB3) and in the 5' non-coding region of <ENT2>GJB2</ENT2> including the splice sites.",,,,T,,Y,,,c,,,,,0.0,,
17671735,1060,D034381,c|SUB|G|-3170|A,Positive_Correlation,TRUE,Our results suggest the importance of routine screening for the rather frequent <ENT2>-3170G>A</ENT2> mutation (in addition to c.35delG) in patients with <ENT1>hearing impairment</ENT1>.,,,,T,,,,,w,,,,,1.0,,
17683901,1063,rs28931614,D000130,Positive_Correlation,FALSE,An improved tetra-primer PCR approach for the detection of the FGFR3 <ENT1>G380R</ENT1> mutation responsible for <ENT2>achondroplasia</ENT2>.,,,,T,,,,,c,,,,,1.0,,
17683901,1063,rs28931614,D000130,Positive_Correlation,FALSE,"The assay has been tested in 50 healthy controls, 3 known patients with <ENT2>achondroplasia</ENT2>, and 5 amniotic fluids suspected of having <ENT2>achondroplasia</ENT2> and for whom we had previously determined the genotypes for the <ENT1>c.1138G>A</ENT1> mutation by PCR-RFLP.",,,,T,,,,,c,,,,,0.5,,
17683901,1062,D000130,2261,Association,FALSE,An improved tetra-primer PCR approach for the detection of the <ENT2>FGFR3</ENT2> G380R mutation responsible for <ENT1>achondroplasia</ENT1>.,,,,T,,,,,c,,,,,1.0,,
17854040,1065,D006509,D019259,Negative_Correlation,FALSE,Mutations associated with <ENT2>lamivudine</ENT2>-resistance in therapy-na  ve <ENT1>hepatitis B virus (HBV) infected</ENT1> patients with and without HIV co-infection: implications for antiretroviral therapy in <ENT1>HBV and HIV co-infected</ENT1> South African patients.,,,,T,,,,,w,,,,,0.0,,
17854040,1065,D006509,D019259,Negative_Correlation,FALSE,Thirty-five <ENT2>lamivudine</ENT2>-na  ve <ENT1>HBV infected</ENT1> patients with or without HIV co-infection were studied: 15 chronic <ENT1>HBV mono-infected</ENT1> patients and 20 <ENT1>HBV-HIV co-infected</ENT1> patients.,,,,T,,,,,w,,,,,0.0,,
17854040,1065,D006509,D019259,Negative_Correlation,FALSE,HBV <ENT2>lamivudine</ENT2>-resistant strains were detected in 3 of 15 mono-infected chronic <ENT1>hepatitis B</ENT1> patients and 10 of 20 <ENT1>HBV-HIV co-infected</ENT1> patients.,,,,T,,,,,w,,,,,1.0,,
17854040;17854040,1065;1064,D006509;D015658,D019259;D019259,Association;Association,FALSE;FALSE,"To the best of our knowledge, this constitutes the first report of HBV <ENT2>lamivudine</ENT2>-resistant strains in therapy-na  ve <ENT1>HBV-HIV co-infected</ENT1> patients.",,,,T,,,,,w,,,,,0.0,,
17854040;17854040,1065;1064,D006509;D015658,D019259;D019259,Association;Association,FALSE;FALSE,"It remains to be seen whether such pre-existing antiviral mutations could result in widespread emergence of HBV resistant strains when <ENT2>lamivudine</ENT2>-containing highly active antiretroviral (ARV) treatment (HAART) regimens become widely applied in South Africa, as this is likely to have potential implications in the management of <ENT1>HBV-HIV co-infected</ENT1> patients.",,,,T,,,,,w,,,,,0.0,,
17854040,1064,D015658,D019259,Association,FALSE,Mutations associated with <ENT2>lamivudine</ENT2>-resistance in therapy-na  ve hepatitis B virus (HBV) infected patients with and without <ENT1>HIV co-infection</ENT1>: implications for antiretroviral therapy in <ENT1>HBV and HIV co-infected</ENT1> South African patients.,,,,T,,,,,c,,,,,1.0,,
17854040,1064,D015658,D019259,Association,FALSE,This was an exploratory study to investigate <ENT2>lamivudine</ENT2>-resistant hepatitis B virus (HBV) strains in selected <ENT2>lamivudine</ENT2>-na  ve HBV carriers with and without <ENT1>human immunodeficiency virus (HIV) co-infection</ENT1> in South African patients.,,,,T,,,,,c,,,,,1.0,,
17854040,1064,D015658,D019259,Association,FALSE,Thirty-five <ENT2>lamivudine</ENT2>-na  ve HBV infected patients with or without <ENT1>HIV co-infection</ENT1> were studied: 15 chronic HBV mono-infected patients and 20 <ENT1>HBV-HIV co-infected</ENT1> patients.,,,,T,,,,,c,,,,,1.0,,
17854040,1064,D015658,D019259,Association,FALSE,HBV <ENT2>lamivudine</ENT2>-resistant strains were detected in 3 of 15 mono-infected chronic hepatitis B patients and 10 of 20 <ENT1>HBV-HIV co-infected</ENT1> patients.,,,,T,,,,,w,,,,,0.0,,
17879945,1073,D050197,D019438,Positive_Correlation,FALSE,We have previously demonstrated that <ENT2>ritonavir</ENT2> treatment increases <ENT1>atherosclerotic lesion</ENT1> formation in male mice to a greater extent than in female mice.,,,,T,,,,,c,,,,,1.0,,
17879945,1069,D002788,D004958,Negative_Correlation,TRUE,<ENT2>E2</ENT2> decreased the accumulation of <ENT1>cholesteryl esters</ENT1> in macrophages following ritonavir treatment.,,,,T,,,,,c,,,,,1.0,,
17879945,1069,D002788,D004958,Negative_Correlation,TRUE,This data suggests that <ENT2>E2</ENT2> modifies the expression of CD36 at the level of protein expression in monocyte-derived macrophages resulting in reduced <ENT1>cholesteryl ester</ENT1> accumulation following ritonavir treatment.,,,,T,,,,,c,,,,,1.0,,
17879945,1074,D002788,D019438,Negative_Correlation,TRUE,Estrogen prevents <ENT1>cholesteryl ester</ENT1> accumulation in macrophages induced by the HIV protease inhibitor <ENT2>ritonavir</ENT2>.,,,,T,,,,,w,,,,,1.0,,
17879945,1074,D002788,D019438,Negative_Correlation,TRUE,"Furthermore, peripheral blood monocytes isolated from <ENT2>ritonavir</ENT2>-treated females had less <ENT1>cholesteryl ester</ENT1> accumulation.",,,,T,,,,,w,,,,,0.0,,
17879945,1074,D002788,D019438,Positive_Correlation,TRUE,E2 decreased the accumulation of <ENT1>cholesteryl esters</ENT1> in macrophages following <ENT2>ritonavir</ENT2> treatment.,,,,T,,,,,w,,,,,0.0,,
17879945,1074,D002788,D019438,Positive_Correlation,TRUE,This data suggests that E2 modifies the expression of CD36 at the level of protein expression in monocyte-derived macrophages resulting in reduced <ENT1>cholesteryl ester</ENT1> accumulation following <ENT2>ritonavir</ENT2> treatment.,,,,T,,,,,w,,,,,0.0,,
17879945,1067,D002788,948,Association,TRUE,This data suggests that E2 modifies the expression of <ENT2>CD36</ENT2> at the level of protein expression in monocyte-derived macrophages resulting in reduced <ENT1>cholesteryl ester</ENT1> accumulation following ritonavir treatment.,,,,T,Y,,,,c,,,,,0.0,,
17879945,1075,D002788,D004967,Negative_Correlation,TRUE,<ENT2>Estrogen</ENT2> prevents <ENT1>cholesteryl ester</ENT1> accumulation in macrophages induced by the HIV protease inhibitor ritonavir.,,,,T,,,,,c,,,,,1.0,,
17879945,1072,D004958,D019438,Association,TRUE,<ENT1>E2</ENT1> decreased the accumulation of cholesteryl esters in macrophages following <ENT2>ritonavir</ENT2> treatment.,,,,T,,,,,w,,,,,0.0,,
17879945,1072,D004958,D019438,Association,TRUE,This data suggests that <ENT1>E2</ENT1> modifies the expression of CD36 at the level of protein expression in monocyte-derived macrophages resulting in reduced cholesteryl ester accumulation following <ENT2>ritonavir</ENT2> treatment.,,,,T,Y,,,,c,,,,,0.0,,
17879945,1068,D004958,948,Negative_Correlation,TRUE,"<ENT1>E2</ENT1> did, however, significantly suppress <ENT2>CD36</ENT2> protein levels as measured by fluorescent immunocytochemistry.",,,,T,,,,,c,,,,,1.0,,
17879945,1068,D004958,948,Negative_Correlation,TRUE,This data suggests that <ENT1>E2</ENT1> modifies the expression of <ENT2>CD36</ENT2> at the level of protein expression in monocyte-derived macrophages resulting in reduced cholesteryl ester accumulation following ritonavir treatment.,,,,T,,,,,w,,,,,1.0,,
17879945,1070,D019438,5468,Positive_Correlation,TRUE,"Additionally, <ENT1>ritonavir</ENT1> treatment selectively increased the relative levels of <ENT2>PPARgamma</ENT2> mRNA, a transcription factor responsible for the regulation of CD36 mRNA expression.",,,,T,,,,,c,,,,,1.0,,
17879945,1071,D019438,948,Positive_Correlation,TRUE,"<ENT1>Ritonavir</ENT1> increased the expression of the scavenger receptor, <ENT2>CD36</ENT2> mRNA, responsible for the uptake of LDL.",,,,T,,,,,c,,,,,1.0,,
17879945,1071,D019438,948,Positive_Correlation,TRUE,"Additionally, <ENT1>ritonavir</ENT1> treatment selectively increased the relative levels of PPARgamma mRNA, a transcription factor responsible for the regulation of <ENT2>CD36</ENT2> mRNA expression.",,,,T,,,,,c,,,,,0.0,,
17879945,1071,D019438,948,Positive_Correlation,TRUE,This data suggests that E2 modifies the expression of <ENT2>CD36</ENT2> at the level of protein expression in monocyte-derived macrophages resulting in reduced cholesteryl ester accumulation following <ENT1>ritonavir</ENT1> treatment.,,,,T,,,,,c,,,,,1.0,,
17879945,1066,5468,948,Association,FALSE,"Additionally, ritonavir treatment selectively increased the relative levels of <ENT1>PPARgamma</ENT1> mRNA, a transcription factor responsible for the regulation of <ENT2>CD36</ENT2> mRNA expression.",,,,T,,,,,c,,,,,1.0,,
17910065,1076,4487,C538049,Association,FALSE,We screened one family with <ENT2>nonsyndromic oligodontia</ENT2> for mutations in PAX9 and <ENT1>MSX1</ENT1>.,,,,T,,Y,,,w,,,,,0.0,,
17910065,1078,C538049,5083,Association,TRUE,A novel missense mutation in the paired domain of human <ENT2>PAX9</ENT2> causes <ENT1>oligodontia</ENT1>.,,,,T,,,,,c,,,,,1.0,,
17910065,1078,C538049,5083,Association,TRUE,We screened one family with <ENT1>nonsyndromic oligodontia</ENT1> for mutations in <ENT2>PAX9</ENT2> and MSX1.,,,,T,,Y,,,w,,,,,0.0,,
17910065,1078,C538049,5083,Association,TRUE,"To elucidate the pathogenic mechanism producing <ENT1>oligodontia phenotype</ENT1> caused by this mutation, we analyzed the binding of wild-type and mutant <ENT2>PAX9</ENT2> paired domain protein to double-stranded DNA targets.",,,,T,,Y,,,w,,,,,1.0,,
17951029,1081,D005489,64840,Association,TRUE,"<ENT1>Focal dermal hypoplasia</ENT1> resulting from a new nonsense mutation, p.E300X, in the <ENT2>PORCN</ENT2> gene.",,,,T,,,,,c,,,,,1.0,,
17951029,1081,D005489,64840,Association,TRUE,"The molecular basis of <ENT1>FDH</ENT1> involves mutations in the <ENT2>PORCN</ENT2> gene, which encodes an enzyme that allows membrane targeting and secretion of several Wnt proteins critical for normal tissue development.",,,,T,,,,,c,,,,,1.0,,
17951029,1081,D005489,64840,Association,TRUE,CONCLUSION: Identification of this new de novo nonsense mutation confirms the diagnosis of <ENT1>FDH</ENT1> in this child and highlights the clinical importance of <ENT2>PORCN</ENT2> and Wnt signalling pathways in embryogenesis.,,,,T,,,,,w,,,,,0.0,,
17951029,1082,D005489,p|SUB|E|300|X,Positive_Correlation,TRUE,"<ENT1>Focal dermal hypoplasia</ENT1> resulting from a new nonsense mutation, <ENT2>p.E300X</ENT2>, in the PORCN gene.",,,,T,,,,,w,,,,,0.0,,
17959715,1083,rs1800734,D009369,Positive_Correlation,TRUE,"We hypothesised that a common substitution in the basal promoter of MLH1 (position -93, <ENT1>rs1800734</ENT1>) modifies the risk of <ENT2>cancer</ENT2> after methylating chemotherapy.",,,,T,,,,,w,,,,,1.0,,
17959715,1088,D006689,4292,Association,TRUE,Polymorphic <ENT2>MLH1</ENT2> and risk of cancer after methylating chemotherapy for <ENT1>Hodgkin lymphoma</ENT1>.,,,,T,,,,,w,,,,,0.0,,
17959715,1088,D006689,4292,Association,TRUE,"METHODS: 133 patients who developed cancer following chemotherapy and/or radiotherapy (n = 133), 420 patients diagnosed with de novo myeloid leukaemia, 242 patients diagnosed with <ENT1>primary Hodgkin lymphoma</ENT1>, and 1177 healthy controls were genotyped for the <ENT2>MLH1</ENT2> -93 polymorphism by allelic discrimination polymerase chain reaction (PCR) and restriction fragment length polymorphism assay.",,,,T,,,,,c,,,,,1.0,,
17959715,1088,D006689,4292,Association,TRUE,CONCLUSIONS: These data support the hypothesis that the common polymorphism at position -93 in the core promoter of <ENT2>MLH1</ENT2> defines a risk allele for the development of cancer after methylating chemotherapy for <ENT1>Hodgkin lymphoma</ENT1>.,,,,T,,,,,w,,,,,1.0,,
17959715,1089,D001943,4292,Association,TRUE,"RESULTS: Carrier frequency of the <ENT2>MLH1</ENT2> -93 variant was higher in patients who developed therapy related acute myeloid leukaemia (t-AML) (75.0%, n = 12) or <ENT1>breast cancer</ENT1> (53.3%.",,,,T,,,,,c,,,,,1.0,,
17959715,1090,D015470,4292,Association,TRUE,"RESULTS: Carrier frequency of the <ENT2>MLH1</ENT2> -93 variant was higher in patients who developed therapy related <ENT1>acute myeloid leukaemia</ENT1> (t-<ENT1>AML</ENT1>) (75.0%, n = 12) or breast cancer (53.3%.",,,,T,,,,,c,,,,,1.0,,
17959715,1090,D015470,4292,Association,TRUE,"The <ENT2>MLH1</ENT2> -93 variant allele was also over-represented in t-<ENT1>AML</ENT1> cases when compared to de novo <ENT1>AML</ENT1> cases (36.9%, n = 420) and healthy controls (36.3%, n = 952), and was associated with a significantly increased risk of developing t-<ENT1>AML</ENT1> (odds ratio 5.31, 95% confidence interval 1.40 to 20.15), but only in patients previously treated with a methylating agent.",,,,T,,,,,c,,,,,0.333333333,,
17959715,1087,4292,D009369,Association,TRUE,Polymorphic <ENT1>MLH1</ENT1> and risk of <ENT2>cancer</ENT2> after methylating chemotherapy for Hodgkin lymphoma.,,,,T,,,,,w,,,,,0.0,,
17959715,1087,4292,D009369,Association,TRUE,"We hypothesised that a common substitution in the basal promoter of <ENT1>MLH1</ENT1> (position -93, rs1800734) modifies the risk of <ENT2>cancer</ENT2> after methylating chemotherapy.",,,,T,,,,,c,,,,,1.0,,
17959715,1087,4292,D009369,Association,TRUE,"METHODS: 133 patients who developed <ENT2>cancer</ENT2> following chemotherapy and/or radiotherapy (n = 133), 420 patients diagnosed with de novo myeloid leukaemia, 242 patients diagnosed with primary Hodgkin lymphoma, and 1177 healthy controls were genotyped for the <ENT1>MLH1</ENT1> -93 polymorphism by allelic discrimination polymerase chain reaction (PCR) and restriction fragment length polymorphism assay.",,,,T,,,,,c,,,,,1.0,,
17959715,1087,4292,D009369,Association,TRUE,"Odds ratios and 95% confidence intervals for <ENT2>cancer</ENT2> risk by <ENT1>MLH1</ENT1> -93 polymorphism status, and stratified by previous exposure to methylating chemotherapy, were calculated using unconditional logistic regression.",,,,T,,Y,,,w,,,,,0.0,,
17959715,1087,4292,D009369,Association,TRUE,CONCLUSIONS: These data support the hypothesis that the common polymorphism at position -93 in the core promoter of <ENT1>MLH1</ENT1> defines a risk allele for the development of <ENT2>cancer</ENT2> after methylating chemotherapy for Hodgkin lymphoma.,,,,T,,,,,c,,,,,1.0,,
17965424,1095,D004008,D005767,Positive_Correlation,FALSE,"The cumulative discontinuation rate due to <ENT2>GI AEs</ENT2> was significantly lower with etoricoxib than <ENT1>diclofenac</ENT1> (5.2 vs 8.5 events per 100 patient-years, respectively; hazard ratio 0.62 (95% CI: 0.47, 0.81; p<or=0.001)).",,,,T,,,,,c,,,,,0.0,,
17965424,1095,D004008,D005767,Positive_Correlation,FALSE,"CONCLUSIONS: Etoricoxib 90 mg demonstrated a significantly lower risk for discontinuing treatment due to <ENT2>GI AEs</ENT2> compared with <ENT1>diclofenac</ENT1> 150 mg. Discontinuations from renovascular AEs, although less common than discontinuations from <ENT2>GI AEs</ENT2>, were significantly higher with etoricoxib.",,,,T,,,,,w,,,,,0.0,,
17965424,1098,D004008,D001172,Negative_Correlation,FALSE,Gastrointestinal tolerability of etoricoxib in <ENT2>rheumatoid arthritis</ENT2> patients: results of the etoricoxib vs <ENT1>diclofenac sodium</ENT1> gastrointestinal tolerability and effectiveness trial (EDGE-II).,,,,T,,T,,,w,,,,,1.0,,
17965424,1098,D004008,D001172,Negative_Correlation,FALSE,"OBJECTIVE: A randomised, double-blind study to compare the gastrointestinal (GI) tolerability, safety and efficacy of etoricoxib and <ENT1>diclofenac</ENT1> in patients with <ENT2>rheumatoid arthritis</ENT2> (<ENT2>RA</ENT2>).",,,,T,,,,,w,,,,,0.0,,
17965424,1098,D004008,D001172,Negative_Correlation,FALSE,PATIENTS AND METHODS: A total of 4086 patients (mean age 60.8 years) diagnosed with <ENT2>RA</ENT2> were enrolled and received etoricoxib 90 mg daily (n = 2032) or <ENT1>diclofenac</ENT1> 75 mg twice daily (n = 2054).,,,,T,,,,,w,,,,,0.0,,
17965424,1093,D004008,D006973,Positive_Correlation,FALSE,The incidence of discontinuations for <ENT2>hypertension</ENT2>-related and oedema-related AEs were significantly higher with etoricoxib (2.5% and 1.1% respectively) compared with <ENT1>diclofenac</ENT1> (1.5% and 0.4% respectively; p<0.001 for <ENT2>hypertension</ENT2> and p<0.01 for oedema).,,,,T,,,,,w,,,,,0.0,,
17965424,1091,D004008,D004487,Positive_Correlation,FALSE,The incidence of discontinuations for hypertension-related and <ENT2>oedema</ENT2>-related AEs were significantly higher with etoricoxib (2.5% and 1.1% respectively) compared with <ENT1>diclofenac</ENT1> (1.5% and 0.4% respectively; p<0.001 for hypertension and p<0.01 for <ENT2>oedema</ENT2>).,,,,T,,,,,w,,,,,0.0,,
17965424,1099,D004008,D000077613,Comparison,TRUE,Gastrointestinal tolerability of <ENT2>etoricoxib</ENT2> in rheumatoid arthritis patients: results of the <ENT2>etoricoxib</ENT2> vs <ENT1>diclofenac sodium</ENT1> gastrointestinal tolerability and effectiveness trial (EDGE-II).,,,,T,,,,,c,,,,,0.0,,
17965424,1099,D004008,D000077613,Comparison,TRUE,"OBJECTIVE: A randomised, double-blind study to compare the gastrointestinal (GI) tolerability, safety and efficacy of <ENT2>etoricoxib</ENT2> and <ENT1>diclofenac</ENT1> in patients with rheumatoid arthritis (RA).",,,,T,,,,,c,,,,,1.0,,
17965424,1099,D004008,D000077613,Comparison,TRUE,PATIENTS AND METHODS: A total of 4086 patients (mean age 60.8 years) diagnosed with RA were enrolled and received <ENT2>etoricoxib</ENT2> 90 mg daily (n = 2032) or <ENT1>diclofenac</ENT1> 75 mg twice daily (n = 2054).,,,,T,,,,,w,,,,,0.0,,
17965424,1099,D004008,D000077613,Comparison,TRUE,"RESULTS: Mean (SD; maximum) duration of treatment was 19.3 (10.3; 32.9) and 19.1 (10.4; 33.1) months in the <ENT2>etoricoxib</ENT2> and <ENT1>diclofenac</ENT1> groups, respectively.",,,,T,,,,,c,,,,,1.0,,
17965424,1099,D004008,D000077613,Comparison,TRUE,"The cumulative discontinuation rate due to GI AEs was significantly lower with <ENT2>etoricoxib</ENT2> than <ENT1>diclofenac</ENT1> (5.2 vs 8.5 events per 100 patient-years, respectively; hazard ratio 0.62 (95% CI: 0.47, 0.81; p<or=0.001)).",,,,T,,,,,c,,,,,1.0,,
17965424,1099,D004008,D000077613,Comparison,TRUE,The incidence of discontinuations for hypertension-related and oedema-related AEs were significantly higher with <ENT2>etoricoxib</ENT2> (2.5% and 1.1% respectively) compared with <ENT1>diclofenac</ENT1> (1.5% and 0.4% respectively; p<0.001 for hypertension and p<0.01 for oedema).,,,,T,,,,,c,,,,,1.0,,
17965424,1099,D004008,D000077613,Comparison,TRUE,"<ENT2>Etoricoxib</ENT2> and <ENT1>diclofenac</ENT1> treatment resulted in similar efficacy (PGADS mean changes from baseline -0.62 vs -0.58, respectively).",,,,T,,,,,c,,,,,1.0,,
17965424,1099,D004008,D000077613,Comparison,TRUE,"CONCLUSIONS: <ENT2>Etoricoxib</ENT2> 90 mg demonstrated a significantly lower risk for discontinuing treatment due to GI AEs compared with <ENT1>diclofenac</ENT1> 150 mg. Discontinuations from renovascular AEs, although less common than discontinuations from GI AEs, were significantly higher with <ENT2>etoricoxib</ENT2>.",,,,T,,,,,c,,,,,1.0,,
17965424,1096,D005767,D000077613,Positive_Correlation,FALSE,"The cumulative discontinuation rate due to <ENT1>GI AEs</ENT1> was significantly lower with <ENT2>etoricoxib</ENT2> than diclofenac (5.2 vs 8.5 events per 100 patient-years, respectively; hazard ratio 0.62 (95% CI: 0.47, 0.81; p<or=0.001)).",,,,T,,,,,c,,,,,0.0,,
17965424,1096,D005767,D000077613,Positive_Correlation,FALSE,"CONCLUSIONS: <ENT2>Etoricoxib</ENT2> 90 mg demonstrated a significantly lower risk for discontinuing treatment due to <ENT1>GI AEs</ENT1> compared with diclofenac 150 mg. Discontinuations from renovascular AEs, although less common than discontinuations from <ENT1>GI AEs</ENT1>, were significantly higher with <ENT2>etoricoxib</ENT2>.",,,,T,,,,,c,,,"11,22",,0.0,,
17965424,1100,D001172,D000077613,Negative_Correlation,FALSE,Gastrointestinal tolerability of <ENT2>etoricoxib</ENT2> in <ENT1>rheumatoid arthritis</ENT1> patients: results of the <ENT2>etoricoxib</ENT2> vs diclofenac sodium gastrointestinal tolerability and effectiveness trial (EDGE-II).,,,,T,,,,,w,,,,,0.5,,
17965424,1100,D001172,D000077613,Negative_Correlation,FALSE,"OBJECTIVE: A randomised, double-blind study to compare the gastrointestinal (GI) tolerability, safety and efficacy of <ENT2>etoricoxib</ENT2> and diclofenac in patients with <ENT1>rheumatoid arthritis</ENT1> (<ENT1>RA</ENT1>).",,,,T,,,,,w,,,,,0.5,,
17965424,1100,D001172,D000077613,Negative_Correlation,FALSE,PATIENTS AND METHODS: A total of 4086 patients (mean age 60.8 years) diagnosed with <ENT1>RA</ENT1> were enrolled and received <ENT2>etoricoxib</ENT2> 90 mg daily (n = 2032) or diclofenac 75 mg twice daily (n = 2054).,,,,T,,,,,w,,,,,1.0,,
17965424,1094,D006973,D000077613,Positive_Correlation,FALSE,The incidence of discontinuations for <ENT1>hypertension</ENT1>-related and oedema-related AEs were significantly higher with <ENT2>etoricoxib</ENT2> (2.5% and 1.1% respectively) compared with diclofenac (1.5% and 0.4% respectively; p<0.001 for <ENT1>hypertension</ENT1> and p<0.01 for oedema).,,,,T,,,,,c,,,,,1.0,,
17965424,1092,D004487,D000077613,Positive_Correlation,FALSE,The incidence of discontinuations for hypertension-related and <ENT1>oedema</ENT1>-related AEs were significantly higher with <ENT2>etoricoxib</ENT2> (2.5% and 1.1% respectively) compared with diclofenac (1.5% and 0.4% respectively; p<0.001 for hypertension and p<0.01 for <ENT1>oedema</ENT1>).,,,,T,,,,,c,,,,,1.0,,
17975693,1101,D009643,D001008,Positive_Correlation,TRUE,<ENT2>Anxiogenic</ENT2> potential of ciprofloxacin and <ENT1>norfloxacin</ENT1> in rats.,,,,T,Y,T,,,w,,,,,1.0,,
17975693,1101,D009643,D001008,Positive_Correlation,TRUE,"INTRODUCTION: The possible <ENT2>anxiogenic</ENT2> effects of fluoroquinolones, namely ciprofloxacin and <ENT1>norfloxacin</ENT1>, were investigated in adult Charles Foster albino rats of either sex, weighing 150-200 g. METHODS: The drugs were given orally, in doses of 50 mg/kg for five consecutive days and the experiments were performed on the fifth day.",,,,T,,,,,w,,,,,1.0,,
17975693,1101,D009643,D001008,Positive_Correlation,TRUE,RESULTS: The results indicate that ciprofloxacin- and <ENT1>norfloxacin</ENT1>-treated rats showed <ENT2>anxious behaviour</ENT2> in comparison to control rats in all the parameters studied.,,,,T,,,,,c,,,,,1.0,,
17975693,1101,D009643,D001008,Positive_Correlation,TRUE,CONCLUSION: The present experimental findings substantiate the clinically observed <ENT2>anxiogenic</ENT2> potential of ciprofloxacin and <ENT1>norfloxacin</ENT1>.,,,,T,,,,,w,,,,,1.0,,
17975693,1102,D024841,D001008,Positive_Correlation,TRUE,"INTRODUCTION: The possible <ENT2>anxiogenic</ENT2> effects of <ENT1>fluoroquinolones</ENT1>, namely ciprofloxacin and norfloxacin, were investigated in adult Charles Foster albino rats of either sex, weighing 150-200 g. METHODS: The drugs were given orally, in doses of 50 mg/kg for five consecutive days and the experiments were performed on the fifth day.",,,,T,,Y,,,w,,,,,0.0,,
17975693,1103,D002939,D001008,Positive_Correlation,TRUE,<ENT2>Anxiogenic</ENT2> potential of <ENT1>ciprofloxacin</ENT1> and norfloxacin in rats.,,,,T,,,,,c,,,,,0.0,,
17975693,1103,D002939,D001008,Positive_Correlation,TRUE,"INTRODUCTION: The possible <ENT2>anxiogenic</ENT2> effects of fluoroquinolones, namely <ENT1>ciprofloxacin</ENT1> and norfloxacin, were investigated in adult Charles Foster albino rats of either sex, weighing 150-200 g. METHODS: The drugs were given orally, in doses of 50 mg/kg for five consecutive days and the experiments were performed on the fifth day.",,,,T,,Y,,,w,,,,,0.0,,
17975693,1103,D002939,D001008,Positive_Correlation,TRUE,RESULTS: The results indicate that <ENT1>ciprofloxacin</ENT1>- and norfloxacin-treated rats showed <ENT2>anxious behaviour</ENT2> in comparison to control rats in all the parameters studied.,,,,T,,,,,c,,,,,1.0,,
17975693,1103,D002939,D001008,Positive_Correlation,TRUE,CONCLUSION: The present experimental findings substantiate the clinically observed <ENT2>anxiogenic</ENT2> potential of <ENT1>ciprofloxacin</ENT1> and norfloxacin.,,,,T,,,,,c,,,,,1.0,,
18046082,1106,C567089,348,Association,FALSE,"Identification of <ENT2>apolipoprotein E</ENT2> Guangzhou (arginine 150 proline), a new variant associated with <ENT1>lipoprotein glomerulopathy</ENT1>.",,,,T,,,,,c,,,,,1.0,,
18046082,1106,C567089,348,Association,FALSE,BACKGROUND/AIMS: <ENT1>Lipoprotein glomerulopathy</ENT1> (<ENT1>LPG</ENT1>) is a rare disease characterized by thrombus-like substances in markedly dilated glomerular capillaries and elevated plasma levels of <ENT2>apolipoprotein E</ENT2> (<ENT2>apoE</ENT2>).,,,,T,,,,,c,,,"11,12,21,22",,0.0,,
18046082,1106,C567089,348,Association,FALSE,"Previous studies have shown that genetic disorders of <ENT2>apoE</ENT2> may contribute to the pathogenesis of <ENT1>LPG</ENT1>, but <ENT1>LPG</ENT1> may not be caused by <ENT2>apoE</ENT2> gene mutations in Chinese patients.",,,,T,,,,,c,,,,,0.25,,
18046082,1106,C567089,348,Association,FALSE,This study investigated the association of a new variant of <ENT2>apoE</ENT2> with <ENT1>LPG</ENT1> in a Chinese family.,,,,T,,Y,,,c,,,,,1.0,,
18046082,1106,C567089,348,Association,FALSE,METHODS: The <ENT2>apoE</ENT2> gene in a family with 4 <ENT1>LPG</ENT1> patients was sequenced.,,,,T,,Y,,,w,,,,,0.0,,
18046082,1106,C567089,348,Association,FALSE,RESULTS: A novel point mutation in exon 4 of the <ENT2>apoE</ENT2> gene was identified in all 4 <ENT1>LPG</ENT1> patients and 1 asymptomatic family member.,,,,T,,,,,c,,,,,1.0,,
18046082,1106,C567089,348,Association,FALSE,CONCLUSION: The results of this study suggest that <ENT2>apoE</ENT2> (arginine 150 proline) is a novel <ENT2>apoE</ENT2> variant that etiologically related to <ENT1>LPG</ENT1>.,,,,T,,,,,c,,,,,0.0,,
18046082,1108,C567089,p|SUB|R|150|P,Association,TRUE,"Identification of apolipoprotein E Guangzhou (<ENT2>arginine 150 proline</ENT2>), a new variant associated with <ENT1>lipoprotein glomerulopathy</ENT1>.",,,,T,,,,,c,,,,,1.0,,
18046082,1108,C567089,p|SUB|R|150|P,Association,TRUE,CONCLUSION: The results of this study suggest that apoE (<ENT2>arginine 150 proline</ENT2>) is a novel apoE variant that etiologically related to <ENT1>LPG</ENT1>.,,,,T,,,,,c,,,,,1.0,,
18046082,1105,348,D008055,Bind,FALSE,This variant (<ENT1>apoE</ENT1> Guangzhou) may cause a marked molecular conformational change of the <ENT1>apoE</ENT1> and thus impair its binding ability to <ENT2>lipids</ENT2>.,,,,T,,,,,c,,,,,0.0,,
18050247,1112,3654,D008180,Association,TRUE,RESULTS: Family-based TDT showed a significant association of <ENT2>SLE</ENT2> with a N673S polymorphism in the P-selectin gene (SELP) (P = 5.74 x 10(-6)) and a C203S polymorphism in the <ENT1>interleukin-1 receptor-associated kinase 1</ENT1> gene (<ENT1>IRAK1</ENT1>) (P = 9.58 x 10(-6)).,,,,T,,,,,w,,,,,0.0,TRUE,
18050247,1112,3654,D008180,Association,TRUE,"CONCLUSION: SELP and <ENT1>IRAK1</ENT1> were identified as novel <ENT2>SLE</ENT2>-associated genes with a high degree of significance, suggesting new directions in understanding the pathogenesis of <ENT2>SLE</ENT2>.",,,,T,,,,,c,,,,,1.0,,
18050247,1114,6403,D008180,Association,TRUE,RESULTS: Family-based TDT showed a significant association of <ENT2>SLE</ENT2> with a N673S polymorphism in the <ENT1>P-selectin</ENT1> gene (<ENT1>SELP</ENT1>) (P = 5.74 x 10(-6)) and a C203S polymorphism in the interleukin-1 receptor-associated kinase 1 gene (IRAK1) (P = 9.58 x 10(-6)).,,,,T,,,,,c,,,,,1.0,,
18050247,1114,6403,D008180,Association,TRUE,"CONCLUSION: <ENT1>SELP</ENT1> and IRAK1 were identified as novel <ENT2>SLE</ENT2>-associated genes with a high degree of significance, suggesting new directions in understanding the pathogenesis of <ENT2>SLE</ENT2>.",,,,T,,,,,c,,,,,1.0,,
18050247,1110,3663,D008180,Association,TRUE,"These additional genes notably included TNFRSF6 (Fas) and <ENT1>IRF5</ENT1>, supporting previous findings of their association with <ENT2>SLE</ENT2> pathogenesis.",,,,T,,,,,c,,,,,1.0,,
18050247,1113,D008180,rs10127175,Positive_Correlation,TRUE,RESULTS: Family-based TDT showed a significant association of <ENT1>SLE</ENT1> with a N673S polymorphism in the P-selectin gene (SELP) (P = 5.74 x 10(-6)) and a <ENT2>C203S</ENT2> polymorphism in the interleukin-1 receptor-associated kinase 1 gene (IRAK1) (P = 9.58 x 10(-6)).,,,,T,,,,,w,,,,,1.0,,
18050247,1111,D008180,355,Association,TRUE,"These additional genes notably included <ENT2>TNFRSF6</ENT2> (<ENT2>Fas</ENT2>) and IRF5, supporting previous findings of their association with <ENT1>SLE</ENT1> pathogenesis.",,,,T,,,,,c,,,,,0.5,,
18050247,1109,D008180,rs3917815,Positive_Correlation,TRUE,RESULTS: Family-based TDT showed a significant association of <ENT1>SLE</ENT1> with a <ENT2>N673S</ENT2> polymorphism in the P-selectin gene (SELP) (P = 5.74 x 10(-6)) and a C203S polymorphism in the interleukin-1 receptor-associated kinase 1 gene (IRAK1) (P = 9.58 x 10(-6)).,,,,T,,,,,w,,,,,1.0,,
18165598,1121,C116926,D010146,Negative_Correlation,TRUE,"RESULTS: The bupivacaine/<ENT1>rofecoxib</ENT1> group reported significantly less <ENT2>pain</ENT2>, as assessed by a visual analog scale, compared with the other three treatment groups over the first 4 h. However, the bupivacaine/placebo group reported significantly more <ENT2>pain</ENT2> at 24 h and PGE2 levels during the first 4 h were significantly higher than the other three treatment groups.",,,,T,,,,,c,,,,,0.5,,
18165598,1128,C116926,D002045,Cotreatment,TRUE,METHODS: Subjects (n = 114) undergoing extraction of impacted third molars received either 2% lidocaine or 0.5% <ENT2>bupivacaine</ENT2> before surgery and either <ENT1>rofecoxib</ENT1> 50 mg or placebo orally 90 min before surgery and for the following 48 h.,,,,T,,,,,c,,,,,0.0,,
18165598,1128,C116926,D002045,Cotreatment,TRUE,"RESULTS: The <ENT2>bupivacaine</ENT2>/<ENT1>rofecoxib</ENT1> group reported significantly less pain, as assessed by a visual analog scale, compared with the other three treatment groups over the first 4 h. However, the <ENT2>bupivacaine</ENT2>/placebo group reported significantly more pain at 24 h and PGE2 levels during the first 4 h were significantly higher than the other three treatment groups.",,,,T,,,,,w,,,,,0.5,,
18165598,1127,D010146,D002045,Positive_Correlation,TRUE,"The differential effects of <ENT2>bupivacaine</ENT2> and lidocaine on prostaglandin E2 release, cyclooxygenase gene expression and <ENT1>pain</ENT1> in a clinical <ENT1>pain</ENT1> model.",,,,T,,,,,w,,,,,1.0,TRUE,
18165598,1127,D010146,D002045,Positive_Correlation,TRUE,"RESULTS: The <ENT2>bupivacaine</ENT2>/rofecoxib group reported significantly less <ENT1>pain</ENT1>, as assessed by a visual analog scale, compared with the other three treatment groups over the first 4 h. However, the <ENT2>bupivacaine</ENT2>/placebo group reported significantly more <ENT1>pain</ENT1> at 24 h and PGE2 levels during the first 4 h were significantly higher than the other three treatment groups.",,,,T,,,,,c,,,,,0.25,,
18165598,1127,D010146,D002045,Positive_Correlation,TRUE,"CONCLUSIONS: These results suggest that <ENT2>bupivacaine</ENT2> stimulates COX-2 gene expression after tissue injury, which is associated with higher PGE2 production and <ENT1>pain</ENT1> after the local anesthetic effect dissipates.",,,,T,,,,,w,,,,,1.0,,
18165598,1119,D010146,4513,Association,TRUE,"The differential effects of bupivacaine and lidocaine on prostaglandin E2 release, <ENT2>cyclooxygenase</ENT2> gene expression and <ENT1>pain</ENT1> in a clinical <ENT1>pain</ENT1> model.",,,,T,,,,,c,,,,,1.0,,
18165598,1119,D010146,4513,Association,TRUE,"CONCLUSIONS: These results suggest that bupivacaine stimulates <ENT2>COX-2</ENT2> gene expression after tissue injury, which is associated with higher PGE2 production and <ENT1>pain</ENT1> after the local anesthetic effect dissipates.",,,,T,,,,,c,,,,,1.0,,
18165598;18165598,1125;1123,D002045;D002045,4513;4512,Association;Association,TRUE;TRUE,"The differential effects of <ENT1>bupivacaine</ENT1> and lidocaine on prostaglandin E2 release, <ENT2>cyclooxygenase</ENT2> gene expression and pain in a clinical pain model.",,,,T,,,,,c,,,,,1.0,,
18165598;18165598,1125;1123,D002045;D002045,4513;4512,Association;Association,TRUE;TRUE,"In the present study, we describe the proinflammatory effects of <ENT1>bupivacaine</ENT1> on local prostaglandin E2 (PGE2) production and <ENT2>cyclooxygenase</ENT2> (<ENT2>COX</ENT2>) gene expression that increases postoperative pain in human subjects.",,,,T,,,,,w,,,,,0.0,,
18165598,1125,D002045,4513,Positive_Correlation,TRUE,"Moreover, <ENT1>bupivacaine</ENT1> significantly increased <ENT2>COX-2</ENT2> gene expression at 48 h as compared with the lidocaine/placebo group.",,,,T,,,,,c,,,,,1.0,,
18165598,1125,D002045,4513,Positive_Correlation,TRUE,"CONCLUSIONS: These results suggest that <ENT1>bupivacaine</ENT1> stimulates <ENT2>COX-2</ENT2> gene expression after tissue injury, which is associated with higher PGE2 production and pain after the local anesthetic effect dissipates.",,,,T,,,,,c,,,,,1.0,,
18165598,1122,D002045,D010149,Positive_Correlation,TRUE,"In the present study, we describe the proinflammatory effects of <ENT1>bupivacaine</ENT1> on local prostaglandin E2 (PGE2) production and cyclooxygenase (COX) gene expression that increases <ENT2>postoperative pain</ENT2> in human subjects.",,,,T,,,,,c,,,,,0.0,,
18165598,1124,D002045,D017695,Association,TRUE,"CONCLUSIONS: These results suggest that <ENT1>bupivacaine</ENT1> stimulates COX-2 gene expression after <ENT2>tissue injury</ENT2>, which is associated with higher PGE2 production and pain after the local anesthetic effect dissipates.",,,,T,,,,,w,,,,,0.0,,
18165598,1129,D002045,D008012,Comparison,TRUE,"The differential effects of <ENT1>bupivacaine</ENT1> and <ENT2>lidocaine</ENT2> on prostaglandin E2 release, cyclooxygenase gene expression and pain in a clinical pain model.",,,,T,,,,,c,,,,,0.0,,
18165598,1129,D002045,D008012,Comparison,TRUE,METHODS: Subjects (n = 114) undergoing extraction of impacted third molars received either 2% <ENT2>lidocaine</ENT2> or 0.5% <ENT1>bupivacaine</ENT1> before surgery and either rofecoxib 50 mg or placebo orally 90 min before surgery and for the following 48 h.,,,,T,,,,,w,,,,,0.0,,
18165598,1129,D002045,D008012,Comparison,TRUE,"Moreover, <ENT1>bupivacaine</ENT1> significantly increased COX-2 gene expression at 48 h as compared with the <ENT2>lidocaine</ENT2>/placebo group.",,,,T,,,,,c,,,,,0.0,,
18165598,1126,D002045,5732,Positive_Correlation,TRUE,"The differential effects of <ENT1>bupivacaine</ENT1> and lidocaine on <ENT2>prostaglandin E2</ENT2> release, cyclooxygenase gene expression and pain in a clinical pain model.",,,,T,,,,,w,,,,,1.0,,
18165598,1126,D002045,5732,Positive_Correlation,TRUE,"In the present study, we describe the proinflammatory effects of <ENT1>bupivacaine</ENT1> on local <ENT2>prostaglandin E2</ENT2> (<ENT2>PGE2</ENT2>) production and cyclooxygenase (COX) gene expression that increases postoperative pain in human subjects.",,,,T,,,,,w,,,,,0.0,,
18165598,1126,D002045,5732,Positive_Correlation,TRUE,"RESULTS: The <ENT1>bupivacaine</ENT1>/rofecoxib group reported significantly less pain, as assessed by a visual analog scale, compared with the other three treatment groups over the first 4 h. However, the <ENT1>bupivacaine</ENT1>/placebo group reported significantly more pain at 24 h and <ENT2>PGE2</ENT2> levels during the first 4 h were significantly higher than the other three treatment groups.",,,,T,,,,,c,,,,,0.0,,
18165598,1126,D002045,5732,Positive_Correlation,TRUE,"CONCLUSIONS: These results suggest that <ENT1>bupivacaine</ENT1> stimulates COX-2 gene expression after tissue injury, which is associated with higher <ENT2>PGE2</ENT2> production and pain after the local anesthetic effect dissipates.",,,,T,,,,,c,,,,,1.0,,
18165598,1117,4513,D010149,Association,TRUE,"In the present study, we describe the proinflammatory effects of bupivacaine on local prostaglandin E2 (PGE2) production and <ENT1>cyclooxygenase</ENT1> (<ENT1>COX</ENT1>) gene expression that increases <ENT2>postoperative pain</ENT2> in human subjects.",,,,T,,,,,c,,,,,0.0,,
18165598,1116,4513,D013931,Negative_Correlation,TRUE,"<ENT2>Thromboxane</ENT2> levels were not significantly affected by any of the treatments, indicating that the effects seen were attributable to inhibition of <ENT1>COX-2</ENT1>, but not COX-1.",,,,T,,,,,c,,,,,1.0,,
18165598,1118,4513,5732,Positive_Correlation,TRUE,"The differential effects of bupivacaine and lidocaine on <ENT2>prostaglandin E2</ENT2> release, <ENT1>cyclooxygenase</ENT1> gene expression and pain in a clinical pain model.",,,,T,,,,,w,,,,,1.0,,
18165598,1118,4513,5732,Positive_Correlation,TRUE,"In the present study, we describe the proinflammatory effects of bupivacaine on local <ENT2>prostaglandin E2</ENT2> (<ENT2>PGE2</ENT2>) production and <ENT1>cyclooxygenase</ENT1> (<ENT1>COX</ENT1>) gene expression that increases postoperative pain in human subjects.",,,,T,,,,,c,,,,,1.0,,
18165598,1118,4513,5732,Positive_Correlation,TRUE,"CONCLUSIONS: These results suggest that bupivacaine stimulates <ENT1>COX-2</ENT1> gene expression after tissue injury, which is associated with higher <ENT2>PGE2</ENT2> production and pain after the local anesthetic effect dissipates.",,,,T,,,,,c,,,,,1.0,,
18165598,1115,D010149,4512,Association,TRUE,"In the present study, we describe the proinflammatory effects of bupivacaine on local prostaglandin E2 (PGE2) production and <ENT2>cyclooxygenase</ENT2> (<ENT2>COX</ENT2>) gene expression that increases <ENT1>postoperative pain</ENT1> in human subjects.",,,,T,,,,,c,,,,,0.0,,
18165598,1120,D010149,5732,Positive_Correlation,TRUE,"In the present study, we describe the proinflammatory effects of bupivacaine on local <ENT2>prostaglandin E2</ENT2> (<ENT2>PGE2</ENT2>) production and cyclooxygenase (COX) gene expression that increases <ENT1>postoperative pain</ENT1> in human subjects.",,,,T,,,,,c,,,,,0.0,,
18166824,1132,D016649,4439,Association,TRUE,"OBJECTIVE: The goal of this study was to determine whether mutations of meiotic genes, such as disrupted meiotic cDNA (DMC1), MutS homolog (MSH4), <ENT2>MSH5</ENT2>, and S. cerevisiae homolog (SPO11), were associated with <ENT1>premature ovarian failure</ENT1> (<ENT1>POF</ENT1>).",,,,T,,Y,,,c,,,,,1.0,,
18166824,1132,D016649,4439,Association,TRUE,"RESULTS: A single heterozygous missense mutation, substitution of a cytosine residue with thymidine in exon 2 of <ENT2>MSH5</ENT2>, was found in two Caucasian women in whom <ENT1>POF</ENT1> developed at 18 and 36 years of age.",,,,T,Y,,,,c,,,,,1.0,,
18166824,1132,D016649,4439,Association,TRUE,"<ENT2>MSH5</ENT2> and DMC1 mutations may be one explanation for <ENT1>POF</ENT1>, albeit uncommon.",,,,T,,,,,c,,,,,1.0,,
18166824,1136,D016649,rs2227914,Association,TRUE,Another <ENT1>POF</ENT1> patient of African origin showed a homozygous nucleotide change in the tenth of DMC1 gene that led to an alteration of the amino acid composition of the protein (<ENT2>M200V</ENT2>).,,,,T,Y,,,,c,,,,,0.0,,
18166824,1137,D016649,rs2075789,Association,TRUE,"RESULTS: A single heterozygous missense mutation, substitution of a <ENT2>cytosine residue with thymidine</ENT2> in exon 2 of MSH5, was found in two Caucasian women in whom <ENT1>POF</ENT1> developed at 18 and 36 years of age.",,,,T,Y,,,,c,,,,,0.0,,
18166824,1131,D016649,11144,Association,TRUE,"OBJECTIVE: The goal of this study was to determine whether mutations of meiotic genes, such as disrupted meiotic cDNA (<ENT2>DMC1</ENT2>), MutS homolog (MSH4), MSH5, and S. cerevisiae homolog (SPO11), were associated with <ENT1>premature ovarian failure</ENT1> (<ENT1>POF</ENT1>).",,,,T,,Y,,,c,,,,,1.0,,
18166824,1131,D016649,11144,Association,TRUE,Another <ENT1>POF</ENT1> patient of African origin showed a homozygous nucleotide change in the tenth of <ENT2>DMC1</ENT2> gene that led to an alteration of the amino acid composition of the protein (M200V).,,,,T,,,,,c,,,,,1.0,,
18166824,1131,D016649,11144,Association,TRUE,"MSH5 and <ENT2>DMC1</ENT2> mutations may be one explanation for <ENT1>POF</ENT1>, albeit uncommon.",,,,T,,,,,c,,,,,0.0,,
18166824,1133,4439,D007247,Association,TRUE,CONCLUSIONS: The symptoms of <ENT2>infertility</ENT2> observed in the DMC1 homozygote mutation carrier and in both patients with a heterozygous substitution in exon 2 of the <ENT1>MSH5</ENT1> gene provide indirect evidence of the role of genes involved in meiotic recombination in the regulation of ovarian function.,,,,T,,,,,c,,,,,0.0,,
18166824,1130,D007247,11144,Association,TRUE,CONCLUSIONS: The symptoms of <ENT1>infertility</ENT1> observed in the <ENT2>DMC1</ENT2> homozygote mutation carrier and in both patients with a heterozygous substitution in exon 2 of the MSH5 gene provide indirect evidence of the role of genes involved in meiotic recombination in the regulation of ovarian function.,,,,T,,,,,c,,,,,1.0,,
18179903,1138,c|DEL|1177_1178|AA,C536647,Positive_Correlation,TRUE,"No CHRNA1, CHRNB1, or CHRND mutations were detected, but a homozygous RAPSN frameshift mutation, <ENT1>c.1177-1178delAA</ENT1>, was identified in a family with three children affected with lethal <ENT2>fetal akinesia sequence</ENT2>.",,,,T,Y,,,,c,,,,,0.0,,
18179903,1140,5913,C536647,Negative_Correlation,TRUE,"Mutation analysis of CHRNA1, CHRNB1, CHRND, and <ENT1>RAPSN</ENT1> genes in multiple pterygium syndrome/<ENT2>fetal akinesia</ENT2> patients.",,,,T,,,,,c,,,,,1.0,,
18179903,1140,5913,C536647,Negative_Correlation,TRUE,"We hypothesized that mutations in acetylcholine receptor-related genes might also result in a MPS/<ENT2>fetal akinesia</ENT2> phenotype and so we analyzed 15 cases of lethal MPS/<ENT2>fetal akinesia</ENT2> without CHRNG mutations for mutations in the CHRNA1, CHRNB1, CHRND, and <ENT1>rapsyn</ENT1> (<ENT1>RAPSN</ENT1>) genes.",,,,T,,,,,c,,,,,1.0,,
18179903,1140,5913,C536647,Negative_Correlation,TRUE,"No CHRNA1, CHRNB1, or CHRND mutations were detected, but a homozygous <ENT1>RAPSN</ENT1> frameshift mutation, c.1177-1178delAA, was identified in a family with three children affected with lethal <ENT2>fetal akinesia sequence</ENT2>.",,,,T,,,,,w,,,,,0.0,,
18179903,1140,5913,C536647,Negative_Correlation,TRUE,"Functional studies were consistent with the hypothesis that whereas incomplete loss of <ENT1>rapsyn</ENT1> function may cause congenital myasthenia, more severe loss of function can result in a lethal <ENT2>fetal akinesia</ENT2> phenotype.",,,,T,,,,,c,,,,,0.0,,
18179903,1139,5913,D020294,Negative_Correlation,TRUE,"Previously, <ENT1>RAPSN</ENT1> mutations have been reported in <ENT2>congenital myasthenia</ENT2>.",,,,T,,,,,w,,,,,0.0,,
18179903,1139,5913,D020294,Negative_Correlation,TRUE,"Functional studies were consistent with the hypothesis that whereas incomplete loss of <ENT1>rapsyn</ENT1> function may cause <ENT2>congenital myasthenia</ENT2>, more severe loss of function can result in a lethal fetal akinesia phenotype.",,,,T,,,,,c,,,,,0.0,,
18179903,1141,C537377,1146,Association,FALSE,"Previously, we and others reported that recessive mutations in the <ENT2>embryonal acetylcholine receptor g subunit</ENT2> (<ENT2>CHRNG</ENT2>) can cause both lethal and nonlethal <ENT1>MPS</ENT1>, thus demonstrating that pterygia resulted from fetal akinesia.",,,,T,,,,,c,,,,,1.0,,
18179903,1141,C537377,1146,Association,FALSE,"We hypothesized that mutations in acetylcholine receptor-related genes might also result in a <ENT1>MPS</ENT1>/fetal akinesia phenotype and so we analyzed 15 cases of lethal <ENT1>MPS</ENT1>/fetal akinesia without <ENT2>CHRNG</ENT2> mutations for mutations in the CHRNA1, CHRNB1, CHRND, and rapsyn (RAPSN) genes.",,,,T,,,,,c,,,,,1.0,,
18189233,1144,rs486907,D011471,Association,FALSE,METHODS: We resequenced the positional candidate gene RNASEL in 48 <ENT2>prostate cancer</ENT2> cases and genotyped the previously reported <ENT1>R462Q</ENT1> and D541E polymorphisms in 230 <ENT2>prostate cancer</ENT2> cases and 458 controls.,,,,T,,Y,,,c,,,,,0.0,,
18189233,1144,rs486907,D011471,Association,FALSE,RESULTS: We found no evidence of association between <ENT1>R462Q</ENT1> and D541E polymorphisms and <ENT2>prostate cancer</ENT2> risk in our case/control analysis.,,,,T,,,,,c,,,,,1.0,,
18189233,1145,6059,6041,Negative_Correlation,FALSE,We also examined the inhibitor of <ENT2>RNASEL</ENT2> (<ENT1>ABCE1</ENT1>) for variation associated with prostate cancer risk.,,,,T,,,,,c,,,,,1.0,,
18189233,1146,6041,D011471,Association,TRUE,<ENT1>RNASEL</ENT1> and <ENT1>RNASEL</ENT1>-inhibitor variation and <ENT2>prostate cancer</ENT2> risk in Afro-Caribbeans.,,,,T,,T,,,w,,,,,1.0,TRUE,
18189233,1146,6041,D011471,Association,TRUE,Variation in the <ENT1>ribonuclease L</ENT1> (<ENT1>RNASEL</ENT1>) gene has recently been reported to be associated with an increased risk of <ENT2>prostate cancer</ENT2>.,,,,T,,,,,c,,,,,0.5,,
18189233,1146,6041,D011471,Association,TRUE,"However, whether <ENT1>RNASEL</ENT1> variation contributes to the increased risk of <ENT2>prostate cancer</ENT2> observed in populations of African ancestry remains unclear.",,,,T,,,,,c,,,,,1.0,,
18189233,1146,6041,D011471,Association,TRUE,METHODS: We resequenced the positional candidate gene <ENT1>RNASEL</ENT1> in 48 <ENT2>prostate cancer</ENT2> cases and genotyped the previously reported R462Q and D541E polymorphisms in 230 <ENT2>prostate cancer</ENT2> cases and 458 controls.,,,,T,,,,,c,,,,,0.0,,
18189233,1146,6041,D011471,Association,TRUE,We also examined the inhibitor of <ENT1>RNASEL</ENT1> (ABCE1) for variation associated with <ENT2>prostate cancer</ENT2> risk.,,,,T,,Y,,,w,,,,,0.0,,
18189233,1146,6041,D011471,Association,TRUE,"CONCLUSIONS: Our results suggest that common variation in the putative <ENT2>prostate cancer</ENT2> susceptibility gene, <ENT1>RNASEL</ENT1>, or its inhibitor does not contribute significantly to <ENT2>prostate cancer</ENT2> risk in this Afro-Caribbean population.",,,,T,,,,,c,,,,,0.0,,
18189233,1142,rs143544690,D011471,Association,TRUE,A novel variant (<ENT1>K294E</ENT1>) was identified in a single heterozygous individual with <ENT2>prostate cancer</ENT2>.,,,,T,Y,,,,c,,,,,0.0,,
18189233,1143,rs627928,D011471,Association,FALSE,METHODS: We resequenced the positional candidate gene RNASEL in 48 <ENT2>prostate cancer</ENT2> cases and genotyped the previously reported R462Q and <ENT1>D541E</ENT1> polymorphisms in 230 <ENT2>prostate cancer</ENT2> cases and 458 controls.,,,,T,,,,,c,,,,,0.0,,
18189233,1143,rs627928,D011471,Association,FALSE,RESULTS: We found no evidence of association between R462Q and <ENT1>D541E</ENT1> polymorphisms and <ENT2>prostate cancer</ENT2> risk in our case/control analysis.,,,,T,,,,,c,,,,,1.0,,
18310445,1167,443538,14714,Positive_Correlation,TRUE,"BMP-4 alone had no effect on <ENT1>FSH</ENT1> production, but enhanced the activin+<ENT2>GnRH</ENT2>-induced stimulation of FSHbeta mRNA and <ENT1>FSH</ENT1> secretion, without any effect on follistatin mRNA.",,,,T,,,,,c,,,,,1.0,,
18310445,1167,443538,14714,Positive_Correlation,TRUE,"BMP-4 reduced LHbeta mRNA up-regulation in response to <ENT2>GnRH</ENT2> (+/-activin) and decreased GnRH receptor expression, which would favour <ENT1>FSH</ENT1>, rather than LH, synthesis and secretion.",,,,T,,,,,c,,,,,1.0,,
18310445,1147,443538,443502,Negative_Correlation,FALSE,"We have shown previously that, in sheep primary pituitary cells, <ENT2>bone morphogenetic proteins (BMP)-4</ENT2> inhibits FSHbeta mRNA expression and <ENT1>FSH</ENT1> release.",,,,T,,,,,c,,,,,1.0,,
18310445;18310445,1158;1159,443538;443387,16323;16323,Positive_Correlation;Positive_Correlation,TRUE;TRUE,"BMP-4 alone had no effect on <ENT1>FSH</ENT1> production, but enhanced the <ENT2>activin</ENT2>+GnRH-induced stimulation of FSHbeta mRNA and <ENT1>FSH</ENT1> secretion, without any effect on follistatin mRNA.",,,,T,,,,,c,,,,,1.0,,
18310445;18310445,1158;1159,443538;443387,16323;16323,Positive_Correlation;Positive_Correlation,TRUE;TRUE,"BMP-4 reduced LHbeta mRNA up-regulation in response to GnRH (+/-<ENT2>activin</ENT2>) and decreased GnRH receptor expression, which would favour <ENT1>FSH</ENT1>, rather than LH, synthesis and secretion.",,,,T,,,,,c,,,,,1.0,,
18310445,1150,12159,17129,Association,TRUE,"<ENT2>Smad1/5</ENT2> phosphorylation induced by BMP-4, indicating activation of <ENT1>BMP</ENT1> signalling, was the same whether BMP-4 was used alone or combined with activin+/-GnRH.",,,,T,,,,,c,,,,,1.0,,
18310445,1164,12912,14714,Association,TRUE,"We hypothesized that activin and/or <ENT2>GnRH</ENT2> pathways may be modulated by BMP-4, but neither the activin-stimulated phosphorylation of Smad2/3 nor the <ENT2>GnRH</ENT2>-induced ERK1/2 or <ENT1>cAMP response element-binding</ENT1> phosphorylation were modified.",,,,T,,,,,w,,,,,0.0,,
18310445,1155,16866,14714,Positive_Correlation,TRUE,"BMP-4 reduced <ENT1>LHbeta</ENT1> mRNA up-regulation in response to <ENT2>GnRH</ENT2> (+/-activin) and decreased GnRH receptor expression, which would favour FSH, rather than <ENT1>LH</ENT1>, synthesis and secretion.",,,,T,,,,,c,,,,,0.5,,
18310445,1176,16866,652,Negative_Correlation,TRUE,"<ENT2>BMP-4</ENT2> reduced <ENT1>LHbeta</ENT1> mRNA up-regulation in response to GnRH (+/-activin) and decreased GnRH receptor expression, which would favour FSH, rather than <ENT1>LH</ENT1>, synthesis and secretion.",,,,T,,,,,c,,,,,0.5,,
18310445,1154,16866,14715,Positive_Correlation,TRUE,"BMP-4 reduced <ENT1>LHbeta</ENT1> mRNA up-regulation in response to GnRH (+/-activin) and decreased <ENT2>GnRH receptor</ENT2> expression, which would favour FSH, rather than <ENT1>LH</ENT1>, synthesis and secretion.",,,,T,,,,,w,,,,,1.0,,
18310445,1151,17129,652,Association,TRUE,"<ENT1>Smad1/5</ENT1> phosphorylation induced by <ENT2>BMP-4</ENT2>, indicating activation of BMP signalling, was the same whether <ENT2>BMP-4</ENT2> was used alone or combined with activin+/-GnRH.",,,,T,,,,,c,,,,,0.0,,
18310445,1163,14714,26416,Positive_Correlation,TRUE,"However, the <ENT1>GnRH</ENT1>-induced activation of <ENT2>p38 MAPK</ENT2> was decreased by BMP-4.",,,,T,,,,,c,,,,,1.0,,
18310445,1180,14714,652,Positive_Correlation,TRUE,<ENT2>Bone morphogenetic protein-4</ENT2> interacts with activin and <ENT1>GnRH</ENT1> to modulate gonadotrophin secretion in LbetaT2 gonadotrophs.,,,,T,,,,,w,,,,,0.0,,
18310445,1180,14714,652,Positive_Correlation,TRUE,"As a species comparison with our previous results, we used LbetaT2 cells to investigate the effects of <ENT2>BMP-4</ENT2> on gonadotrophin mRNA and secretion modulated by activin and <ENT1>GnRH</ENT1>.",,,,T,,,,,c,,,,,1.0,,
18310445,1180,14714,652,Positive_Correlation,TRUE,"<ENT2>BMP-4</ENT2> alone had no effect on FSH production, but enhanced the activin+<ENT1>GnRH</ENT1>-induced stimulation of FSHbeta mRNA and FSH secretion, without any effect on follistatin mRNA.",,,,T,,,,,c,,,,,1.0,,
18310445,1180,14714,652,Positive_Correlation,TRUE,"<ENT2>BMP-4</ENT2> reduced LHbeta mRNA up-regulation in response to <ENT1>GnRH</ENT1> (+/-activin) and decreased GnRH receptor expression, which would favour FSH, rather than LH, synthesis and secretion.",,,,T,,,,,c,,,,,0.0,,
18310445,1180,14714,652,Positive_Correlation,TRUE,"Smad1/5 phosphorylation induced by <ENT2>BMP-4</ENT2>, indicating activation of BMP signalling, was the same whether <ENT2>BMP-4</ENT2> was used alone or combined with activin+/-<ENT1>GnRH</ENT1>.",,,,T,,,,,c,,,,,1.0,,
18310445,1180,14714,652,Positive_Correlation,TRUE,"We hypothesized that activin and/or <ENT1>GnRH</ENT1> pathways may be modulated by <ENT2>BMP-4</ENT2>, but neither the activin-stimulated phosphorylation of Smad2/3 nor the <ENT1>GnRH</ENT1>-induced ERK1/2 or cAMP response element-binding phosphorylation were modified.",,,,T,,,,,w,,,,,0.0,,
18310445,1180,14714,652,Positive_Correlation,TRUE,"However, the <ENT1>GnRH</ENT1>-induced activation of p38 MAPK was decreased by <ENT2>BMP-4</ENT2>.",,,,T,,,,,c,,,,,0.0,,
18310445,1180,14714,652,Positive_Correlation,TRUE,"<ENT2>BMPs</ENT2> as important modulators of activin and/or <ENT1>GnRH</ENT1>-stimulated gonadotrophin synthesis and release and 2. important species differences in these effects, which could relate to differences in BMP receptor expression in gonadotrophs.",,,,T,,,,,w,,,,,0.0,,
18310445;18310445,1169;1170,14714;14714,14308;12640,Association;Association,FALSE;FALSE,Bone morphogenetic protein-4 interacts with activin and <ENT1>GnRH</ENT1> to modulate <ENT2>gonadotrophin</ENT2> secretion in LbetaT2 gonadotrophs.,,,,T,,,,,c,,,,,0.0,,
18310445;18310445,1169;1170,14714;14714,14308;12640,Positive_Correlation;Positive_Correlation,TRUE;TRUE,"As a species comparison with our previous results, we used LbetaT2 cells to investigate the effects of BMP-4 on <ENT2>gonadotrophin</ENT2> mRNA and secretion modulated by activin and <ENT1>GnRH</ENT1>.",,,,T,,,,,w,,,,,0.0,,
18310445,1169,14714,14308,Positive_Correlation,TRUE,"BMP-4 alone had no effect on FSH production, but enhanced the activin+<ENT1>GnRH</ENT1>-induced stimulation of <ENT2>FSHbeta</ENT2> mRNA and FSH secretion, without any effect on follistatin mRNA.",,,,T,,,,,c,,,,,1.0,,
18310445;18310445,1169;1170,14714;14714,14308;12640,Positive_Correlation;Positive_Correlation,TRUE;TRUE,"BMPs as important modulators of activin and/or <ENT1>GnRH</ENT1>-stimulated <ENT2>gonadotrophin</ENT2> synthesis and release and 2. important species differences in these effects, which could relate to differences in BMP receptor expression in gonadotrophs.",,,,T,,,,,c,,,,,1.0,,
18310445,1165,14714,26417,Association,TRUE,"We hypothesized that activin and/or <ENT1>GnRH</ENT1> pathways may be modulated by BMP-4, but neither the activin-stimulated phosphorylation of Smad2/3 nor the <ENT1>GnRH</ENT1>-induced <ENT2>ERK1/2</ENT2> or cAMP response element-binding phosphorylation were modified.",,,,T,,,,,c,,,,,0.0,,
18310445,1168,14714,443387,Positive_Correlation,TRUE,"BMP-4 alone had no effect on <ENT2>FSH</ENT2> production, but enhanced the activin+<ENT1>GnRH</ENT1>-induced stimulation of FSHbeta mRNA and <ENT2>FSH</ENT2> secretion, without any effect on follistatin mRNA.",,,,T,,,,,c,,,,,1.0,,
18310445,1168,14714,443387,Positive_Correlation,TRUE,"BMP-4 reduced LHbeta mRNA up-regulation in response to <ENT1>GnRH</ENT1> (+/-activin) and decreased GnRH receptor expression, which would favour <ENT2>FSH</ENT2>, rather than LH, synthesis and secretion.",,,,T,,,,,c,,,,,1.0,,
18310445,1170,14714,12640,Association,FALSE,"BMP-4 reduced LHbeta mRNA up-regulation in response to <ENT1>GnRH</ENT1> (+/-activin) and decreased GnRH receptor expression, which would favour FSH, rather than <ENT2>LH</ENT2>, synthesis and secretion.",,,,T,,,,,c,,,,,1.0,,
18310445,1162,14714,16323,Association,FALSE,"As a species comparison with our previous results, we used LbetaT2 cells to investigate the effects of BMP-4 on gonadotrophin mRNA and secretion modulated by <ENT2>activin</ENT2> and <ENT1>GnRH</ENT1>.",,,,T,,,,,c,,,,,1.0,,
18310445,1162,14714,16323,Association,FALSE,"BMP-4 alone had no effect on FSH production, but enhanced the <ENT2>activin</ENT2>+<ENT1>GnRH</ENT1>-induced stimulation of FSHbeta mRNA and FSH secretion, without any effect on follistatin mRNA.",,,,T,,,,,w,,,,,0.0,,
18310445,1162,14714,16323,Association,FALSE,"BMP-4 reduced LHbeta mRNA up-regulation in response to <ENT1>GnRH</ENT1> (+/-<ENT2>activin</ENT2>) and decreased GnRH receptor expression, which would favour FSH, rather than LH, synthesis and secretion.",,,,T,Y,,,,w,,,,,0.0,,
18310445,1162,14714,16323,Association,FALSE,"Smad1/5 phosphorylation induced by BMP-4, indicating activation of BMP signalling, was the same whether BMP-4 was used alone or combined with <ENT2>activin</ENT2>+/-<ENT1>GnRH</ENT1>.",,,,T,Y,,,,w,,,,,0.0,,
18310445,1162,14714,16323,Association,FALSE,"We hypothesized that <ENT2>activin</ENT2> and/or <ENT1>GnRH</ENT1> pathways may be modulated by BMP-4, but neither the <ENT2>activin</ENT2>-stimulated phosphorylation of Smad2/3 nor the <ENT1>GnRH</ENT1>-induced ERK1/2 or cAMP response element-binding phosphorylation were modified.",,,,T,,,,,c,,,,,1.0,,
18310445,1162,14714,16323,Association,FALSE,"BMPs as important modulators of <ENT2>activin</ENT2> and/or <ENT1>GnRH</ENT1>-stimulated gonadotrophin synthesis and release and 2. important species differences in these effects, which could relate to differences in BMP receptor expression in gonadotrophs.",,,,T,,,,,c,,,,,1.0,,
18310445,1149,26416,652,Negative_Correlation,TRUE,"However, the GnRH-induced activation of <ENT1>p38 MAPK</ENT1> was decreased by <ENT2>BMP-4</ENT2>.",,,,T,,,,,c,,,,,0.0,,
18310445,1148,443502,443387,Negative_Correlation,FALSE,"We have shown previously that, in sheep primary pituitary cells, <ENT1>bone morphogenetic proteins (BMP)-4</ENT1> inhibits <ENT2>FSHbeta</ENT2> mRNA expression and <ENT2>FSH</ENT2> release.",,,,T,,,,,c,,,,,1.0,,
18310445;18310445,1178;1179,652;652,14308;12640,Association;Association,TRUE;TRUE,<ENT1>Bone morphogenetic protein-4</ENT1> interacts with activin and GnRH to modulate <ENT2>gonadotrophin</ENT2> secretion in LbetaT2 gonadotrophs.,,,,T,,,,,c,,,,,1.0,,
18310445,1178,652,14308,Association,TRUE,"In contrast, in mouse LbetaT2 gonadotrophs, others have shown a stimulatory effect of <ENT1>BMPs</ENT1> on basal or activin-stimulated <ENT2>FSHbeta</ENT2> promoter-driven transcription.",,,,T,,,,,c,,,,,0.0,,
18310445;18310445,1178;1179,652;652,14308;12640,Association;Association,TRUE;TRUE,"As a species comparison with our previous results, we used LbetaT2 cells to investigate the effects of <ENT1>BMP-4</ENT1> on <ENT2>gonadotrophin</ENT2> mRNA and secretion modulated by activin and GnRH.",,,,T,,Y,,,w,,,,,1.0,,
18310445,1178,652,14308,Association,TRUE,"<ENT1>BMP-4</ENT1> alone had no effect on FSH production, but enhanced the activin+GnRH-induced stimulation of <ENT2>FSHbeta</ENT2> mRNA and FSH secretion, without any effect on follistatin mRNA.",,,,T,,,,,c,,,,,0.0,,
18310445;18310445,1178;1179,652;652,14308;12640,Association;Association,TRUE;TRUE,"<ENT1>BMPs</ENT1> as important modulators of activin and/or GnRH-stimulated <ENT2>gonadotrophin</ENT2> synthesis and release and 2. important species differences in these effects, which could relate to differences in BMP receptor expression in gonadotrophs.",,,,T,,,,,c,,,,,1.0,,
18310445,1181,652,83729,Association,FALSE,<ENT1>Bone morphogenetic protein-4</ENT1> interacts with <ENT2>activin</ENT2> and GnRH to modulate gonadotrophin secretion in LbetaT2 gonadotrophs.,,,,T,,,,,c,,,,,1.0,,
18310445,1179,652,12640,Association,TRUE,"<ENT1>BMP-4</ENT1> reduced LHbeta mRNA up-regulation in response to GnRH (+/-activin) and decreased GnRH receptor expression, which would favour FSH, rather than <ENT2>LH</ENT2>, synthesis and secretion.",,,,T,,,,,c,,,,,0.0,,
18310445,1177,652,16323,Positive_Correlation,TRUE,"In contrast, in mouse LbetaT2 gonadotrophs, others have shown a stimulatory effect of <ENT1>BMPs</ENT1> on basal or <ENT2>activin</ENT2>-stimulated FSHbeta promoter-driven transcription.",,,,T,,,,,w,,,,,0.0,,
18310445,1177,652,16323,Positive_Correlation,TRUE,"As a species comparison with our previous results, we used LbetaT2 cells to investigate the effects of <ENT1>BMP-4</ENT1> on gonadotrophin mRNA and secretion modulated by <ENT2>activin</ENT2> and GnRH.",,,,T,,,,,c,,,,,1.0,,
18310445,1177,652,16323,Positive_Correlation,TRUE,"<ENT1>BMP-4</ENT1> alone had no effect on FSH production, but enhanced the <ENT2>activin</ENT2>+GnRH-induced stimulation of FSHbeta mRNA and FSH secretion, without any effect on follistatin mRNA.",,,,T,Y,,,,c,,,,,1.0,,
18310445,1177,652,16323,Positive_Correlation,TRUE,"<ENT1>BMP-4</ENT1> reduced LHbeta mRNA up-regulation in response to GnRH (+/-<ENT2>activin</ENT2>) and decreased GnRH receptor expression, which would favour FSH, rather than LH, synthesis and secretion.",,,,T,,,,,c,,,,,1.0,,
18310445,1177,652,16323,Positive_Correlation,TRUE,"Smad1/5 phosphorylation induced by <ENT1>BMP-4</ENT1>, indicating activation of BMP signalling, was the same whether <ENT1>BMP-4</ENT1> was used alone or combined with <ENT2>activin</ENT2>+/-GnRH.",,,,T,,,,,c,,,,,1.0,,
18310445,1177,652,16323,Positive_Correlation,TRUE,"We hypothesized that <ENT2>activin</ENT2> and/or GnRH pathways may be modulated by <ENT1>BMP-4</ENT1>, but neither the <ENT2>activin</ENT2>-stimulated phosphorylation of Smad2/3 nor the GnRH-induced ERK1/2 or cAMP response element-binding phosphorylation were modified.",,,,T,,,,,w,,,,,0.5,TRUE,
18310445,1177,652,16323,Positive_Correlation,TRUE,"<ENT1>BMPs</ENT1> as important modulators of <ENT2>activin</ENT2> and/or GnRH-stimulated gonadotrophin synthesis and release and 2. important species differences in these effects, which could relate to differences in BMP receptor expression in gonadotrophs.",,,,T,,,,,w,,,,,0.0,,
18310445,1175,652,14715,Negative_Correlation,TRUE,"<ENT1>BMP-4</ENT1> reduced LHbeta mRNA up-regulation in response to GnRH (+/-activin) and decreased <ENT2>GnRH receptor</ENT2> expression, which would favour FSH, rather than LH, synthesis and secretion.",,,,T,,,,,c,,,,,1.0,,
18310445,1171,14308,83729,Association,FALSE,Bone morphogenetic protein-4 interacts with <ENT2>activin</ENT2> and GnRH to modulate <ENT1>gonadotrophin</ENT1> secretion in LbetaT2 gonadotrophs.,,,,T,,,,,c,,,,,1.0,,
18310445,1160,14308,16323,Positive_Correlation,TRUE,"In contrast, in mouse LbetaT2 gonadotrophs, others have shown a stimulatory effect of BMPs on basal or <ENT2>activin</ENT2>-stimulated <ENT1>FSHbeta</ENT1> promoter-driven transcription.",,,,T,,,,,c,,,,,1.0,,
18310445;18310445,1160;1161,14308;12640,16323;16323,Positive_Correlation;Association,TRUE;FALSE,"As a species comparison with our previous results, we used LbetaT2 cells to investigate the effects of BMP-4 on <ENT1>gonadotrophin</ENT1> mRNA and secretion modulated by <ENT2>activin</ENT2> and GnRH.",,,,T,,,,,w,,,,,1.0,,
18310445,1160,14308,16323,Positive_Correlation,TRUE,"BMP-4 alone had no effect on FSH production, but enhanced the <ENT2>activin</ENT2>+GnRH-induced stimulation of <ENT1>FSHbeta</ENT1> mRNA and FSH secretion, without any effect on follistatin mRNA.",,,,T,,,,,c,,,,,1.0,,
18310445;18310445,1160;1161,14308;12640,16323;16323,Positive_Correlation;Positive_Correlation,TRUE;TRUE,"BMPs as important modulators of <ENT2>activin</ENT2> and/or GnRH-stimulated <ENT1>gonadotrophin</ENT1> synthesis and release and 2. important species differences in these effects, which could relate to differences in BMP receptor expression in gonadotrophs.",,,,T,,,,,c,,,,,1.0,,
18310445,1172,83729,12640,Association,FALSE,Bone morphogenetic protein-4 interacts with <ENT1>activin</ENT1> and GnRH to modulate <ENT2>gonadotrophin</ENT2> secretion in LbetaT2 gonadotrophs.,,,,T,,,,,c,,,,,1.0,,
18310445,1156,17127,16323,Association,TRUE,"We hypothesized that <ENT2>activin</ENT2> and/or GnRH pathways may be modulated by BMP-4, but neither the <ENT2>activin</ENT2>-stimulated phosphorylation of <ENT1>Smad2/3</ENT1> nor the GnRH-induced ERK1/2 or cAMP response element-binding phosphorylation were modified.",,,,T,,,,,c,,,,,0.5,,
18310445,1161,12640,16323,Association,FALSE,"BMP-4 reduced LHbeta mRNA up-regulation in response to GnRH (+/-<ENT2>activin</ENT2>) and decreased GnRH receptor expression, which would favour FSH, rather than <ENT1>LH</ENT1>, synthesis and secretion.",,,,T,,,,,c,,,,,1.0,,
18356633,1187,D003404,D007674,Positive_Correlation,FALSE,The occurrence of <ENT2>nephrotoxicity</ENT2> by means of an increase in serum <ENT1>creatinine</ENT1> and evaluation of efficacy via amikacin serum concentrations with respective pathogens were assessed.,,,,T,,,,,c,,,,,1.0,,
18356633,1186,D000583,D006402,Negative_Correlation,TRUE,Forty patients with a diagnosis consistent with a <ENT2>hematologic/oncologic disorder</ENT2> that required treatment with an aminoglycoside were randomized to either conventional or extended-interval <ENT1>amikacin</ENT1>.,,,,T,,,,,w,,,,,0.0,,
18356633,1190,D000583,D007674,Positive_Correlation,TRUE,An evaluation of <ENT1>amikacin</ENT1> <ENT2>nephrotoxicity</ENT2> in the hematology/oncology population.,,,,T,,,,,c,,,,,1.0,,
18356633,1190,D000583,D007674,Positive_Correlation,TRUE,"To evaluate <ENT1>amikacin</ENT1>-associated <ENT2>nephrotoxicity</ENT2> in an adult hematology/oncology population, a prospective, randomized, open-label trial was conducted at a university-affiliated medical center.",,,,T,,,,,w,,,,,0.0,,
18356633,1190,D000583,D007674,Positive_Correlation,TRUE,The occurrence of <ENT2>nephrotoxicity</ENT2> by means of an increase in serum creatinine and evaluation of efficacy via <ENT1>amikacin</ENT1> serum concentrations with respective pathogens were assessed.,,,,T,,,,,c,,,,,1.0,,
18356633,1189,D000583,D009503,Negative_Correlation,FALSE,<ENT1>Amikacin</ENT1> is an aminoglycoside commonly used to provide empirical double gram-negative treatment for <ENT2>febrile neutropenia</ENT2> and other suspected infections.,,,,T,,,,,c,,,,,0.0,,
18356633,1188,D000583,D007239,Negative_Correlation,FALSE,<ENT1>Amikacin</ENT1> is an aminoglycoside commonly used to provide empirical double gram-negative treatment for febrile neutropenia and other suspected <ENT2>infections</ENT2>.,,,,T,,,,,c,,,,,0.0,,
18356633,1185,D006402,D000617,Negative_Correlation,TRUE,Forty patients with a diagnosis consistent with a <ENT1>hematologic/oncologic disorder</ENT1> that required treatment with an <ENT2>aminoglycoside</ENT2> were randomized to either conventional or extended-interval amikacin.,,,,T,,,,,c,,,,,1.0,,
18366737,1194,2271,C535516,Association,TRUE,The <ENT1>FH</ENT1> mutation database: an online database of <ENT1>fumarate hydratase</ENT1> mutations involved in the <ENT2>MCUL</ENT2> (<ENT2>HLRCC</ENT2>) tumor syndrome and congenital fumarase deficiency.,,,,T,,,,,c,,,,,0.5,,
18366737,1194,2271,C535516,Association,TRUE,"In 2002, the Multiple Leiomyoma Consortium identified heterozygous germline mutations of <ENT1>FH</ENT1> in patients with <ENT2>multiple cutaneous and uterine leiomyomas</ENT2>, (<ENT2>MCUL</ENT2>: <ENT2>OMIM 150800</ENT2>).",,,,T,,,,,c,,,,,0.333333333,,
18366737,1194,2271,C535516,Association,TRUE,"Since the first molecular characterization of an <ENT1>FH</ENT1> mutation by Bourgeron et al in 1994, a series of reports of both FH deficiency patients and patients with <ENT2>MCUL</ENT2>/<ENT2>HLRRC</ENT2> have described 107 variants, of which 93 are thought to be pathogenic.",,,,T,,,,,c,,,,,0.0,,
18366737,1191,2271,D014233,Association,FALSE,"BACKGROUND: <ENT1>Fumarate hydratase</ENT1> (HGNC approved gene symbol - <ENT1>FH</ENT1>), also known as <ENT1>fumarase</ENT1>, is an enzyme of the <ENT2>tricarboxylic acid</ENT2> (<ENT2>TCA</ENT2>) cycle, involved in fundamental cellular energy production.",,,,T,,,,,c,,,"11,12,21,22,31,32",,1.0,,
18366737,1191,2271,D014233,Association,FALSE,DESCRIPTION: The <ENT1>FH</ENT1> mutation database is a part of the <ENT2>TCA</ENT2> cycle gene mutation database (formerly the succinate dehydrogenase gene mutation database) and is based on the Leiden Open (source) Variation Database (LOVD) system.,,,,T,,,,,w,,,,,0.0,,
18366737,1193,2271,D009369,Association,TRUE,The <ENT1>FH</ENT1> mutation database: an online database of <ENT1>fumarate hydratase</ENT1> mutations involved in the MCUL (HLRCC) <ENT2>tumor syndrome</ENT2> and congenital fumarase deficiency.,,,,T,,T,,,c,,,,,0.5,,
18366737,1193,2271,D009369,Association,TRUE,"The identification of <ENT1>FH</ENT1> as a <ENT2>tumor</ENT2> suppressor was an unexpected finding and following the identification of subunits of succinate dehydrogenase in 2000 and 2001, was only the second description of the involvement of an enzyme of intermediary metabolism in <ENT2>tumorigenesis</ENT2>.",,,,T,,,,,c,,,,,0.5,,
18366737,1192,2271,C538191,Association,TRUE,The <ENT1>FH</ENT1> mutation database: an online database of <ENT1>fumarate hydratase</ENT1> mutations involved in the MCUL (HLRCC) tumor syndrome and congenital <ENT2>fumarase deficiency</ENT2>.,,,,T,,T,,,c,,,,,0.0,,
18366737,1192,2271,C538191,Association,TRUE,"Since the first molecular characterization of an <ENT1>FH</ENT1> mutation by Bourgeron et al in 1994, a series of reports of both <ENT2>FH deficiency</ENT2> patients and patients with MCUL/HLRRC have described 107 variants, of which 93 are thought to be pathogenic.",,,,T,,,,,w,,,,,0.0,,
18385794,1198,D008850,6657,Association,FALSE,Identification of novel mutations and sequence variants in the <ENT2>SOX2</ENT2> and CHX10 genes in patients with anophthalmia/<ENT1>microphthalmia</ENT1>.,,,,T,,,,,c,,,,,1.0,,
18385794,1198,D008850,6657,Association,FALSE,PURPOSE: Mutations in the <ENT2>SOX2</ENT2> and CHX10 genes have been reported in patients with anophthalmia and/or <ENT1>microphthalmia</ENT1>.,,,,T,,,,,c,,,,,1.0,,
18385794,1198,D008850,6657,Association,FALSE,"In this study, we evaluated 34 anophthalmic/<ENT1>microphthalmic</ENT1> patient DNA samples (two sets of siblings included) for mutations and sequence variants in <ENT2>SOX2</ENT2> and CHX10.",,,,T,,Y,,,w,,,,,0.0,,
18385794,1196,D008850,338917,Association,FALSE,Identification of novel mutations and sequence variants in the SOX2 and <ENT2>CHX10</ENT2> genes in patients with anophthalmia/<ENT1>microphthalmia</ENT1>.,,,,T,,,,,c,,,,,1.0,,
18385794,1196,D008850,338917,Association,FALSE,PURPOSE: Mutations in the SOX2 and <ENT2>CHX10</ENT2> genes have been reported in patients with anophthalmia and/or <ENT1>microphthalmia</ENT1>.,,,,T,,,,,c,,,,,1.0,,
18385794,1196,D008850,338917,Association,FALSE,"In this study, we evaluated 34 anophthalmic/<ENT1>microphthalmic</ENT1> patient DNA samples (two sets of siblings included) for mutations and sequence variants in SOX2 and <ENT2>CHX10</ENT2>.",,,,T,,Y,,,w,,,,,0.0,,
18385794,1196,D008850,338917,Association,FALSE,<ENT2>CHX10</ENT2> was not implicated with <ENT1>microphthalmia</ENT1>/anophthalmia in our patient cohort.,,,,T,,,,,c,,,,,1.0,,
18385794,1199,D000853,6657,Association,FALSE,Identification of novel mutations and sequence variants in the <ENT2>SOX2</ENT2> and CHX10 genes in patients with <ENT1>anophthalmia</ENT1>/microphthalmia.,,,,T,,,,,c,,,,,1.0,,
18385794,1199,D000853,6657,Association,FALSE,PURPOSE: Mutations in the <ENT2>SOX2</ENT2> and CHX10 genes have been reported in patients with <ENT1>anophthalmia</ENT1> and/or microphthalmia.,,,,T,,,,,c,,,,,1.0,,
18385794,1199,D000853,6657,Association,FALSE,"In this study, we evaluated 34 <ENT1>anophthalmic</ENT1>/microphthalmic patient DNA samples (two sets of siblings included) for mutations and sequence variants in <ENT2>SOX2</ENT2> and CHX10.",,,,T,,Y,,,w,,,,,0.0,,
18385794,1197,D000853,338917,Association,FALSE,Identification of novel mutations and sequence variants in the SOX2 and <ENT2>CHX10</ENT2> genes in patients with <ENT1>anophthalmia</ENT1>/microphthalmia.,,,,T,,,,,c,,,,,1.0,,
18385794,1197,D000853,338917,Association,FALSE,PURPOSE: Mutations in the SOX2 and <ENT2>CHX10</ENT2> genes have been reported in patients with <ENT1>anophthalmia</ENT1> and/or microphthalmia.,,,,T,,,,,c,,,,,1.0,,
18385794,1197,D000853,338917,Association,FALSE,"In this study, we evaluated 34 <ENT1>anophthalmic</ENT1>/microphthalmic patient DNA samples (two sets of siblings included) for mutations and sequence variants in SOX2 and <ENT2>CHX10</ENT2>.",,,,T,,Y,,,w,,,,,0.0,,
18385794,1197,D000853,338917,Association,FALSE,<ENT2>CHX10</ENT2> was not implicated with microphthalmia/<ENT1>anophthalmia</ENT1> in our patient cohort.,,,,T,,,,,c,,,,,1.0,,
18385794,1200,6657,D005124,Negative_Correlation,FALSE,Loss of <ENT1>SOX2</ENT1> function results in severe <ENT2>eye malformation</ENT2>.,,,,T,,,,,c,,,,,0.0,,
18410548,1221,D049912,rs267606574,Association,TRUE,RESULTS: A heterozygous in-frame deletion <ENT2>Y248del</ENT2> (<ENT2>c.742_744delTAC</ENT2>) was identified in one <ENT1>GH-secreting adenoma</ENT1> patient.,,,,T,Y,,,,c,,,,,1.0,,
18410548,1220,D049912,9049,Association,TRUE,"CONCLUSIONS: While mutations were absent in non-<ENT1>GH-secreting adenoma</ENT1> patients, germline <ENT2>AIP</ENT2> mutations can be found in children and adolescents with <ENT1>GH-secreting tumours</ENT1>, even in the absence of family history.",,,,T,,,,,c,,,,,0.0,,
18410548,1219,D010911,9049,Association,FALSE,<ENT2>Aryl hydrocarbon receptor interacting protein</ENT2> (<ENT2>AIP</ENT2>) gene mutation analysis in children and adolescents with sporadic <ENT1>pituitary adenomas</ENT1>.,,,,T,,T,,,c,,,,,0.0,,
18410548,1219,D010911,9049,Association,FALSE,<ENT1>Pituitary adenoma</ENT1> predisposition (PAP) has been recently associated with germline mutations in the <ENT2>aryl hydrocarbon receptor interacting protein</ENT2> (<ENT2>AIP</ENT2>) gene.,,,,T,,,,,c,,,,,1.0,,
18410548,1219,D010911,9049,Association,FALSE,The aim of the study was to examine the proportion of germline <ENT2>AIP</ENT2> mutations in apparently sporadic paediatric <ENT1>pituitary adenomas</ENT1>.,,,,T,,,,,c,,,,,0.0,,
18410548,1219,D010911,9049,Association,FALSE,"Clearly, further studies are needed to improve our knowledge on the role of <ENT2>AIP</ENT2> in paediatric <ENT1>pituitary adenomas</ENT1>.",,,,T,,,,,c,,,,,0.0,,
18439317,1224,c|Allele|D|-1607,D055959,Positive_Correlation,TRUE,CONCLUSION: We demonstrated that individuals with the presence of <ENT1>D allele for the -1607</ENT1> promoter polymorphism of MMP1 are about 1.5 times more susceptible to develop <ENT2>DDD</ENT2> when compared with those having G allele only.,,,,T,,,,,c,,,,,1.0,,
18439317,1226,4312,C535531,Association,TRUE,Association between promoter -1607 polymorphism of <ENT1>MMP1</ENT1> and <ENT2>lumbar disc disease</ENT2> in Southern Chinese.,,,,T,,,,,c,,,,,1.0,,
18439317,1225,4312,D055959,Association,TRUE,RESULTS: Our results showed substantial evidence of association between -1607 promoter polymorphism of <ENT1>MMP1</ENT1> and <ENT2>DDD</ENT2> in the Southern Chinese subjects.,,,,T,,,,,c,,,,,1.0,,
18439317,1225,4312,D055959,Association,TRUE,CONCLUSION: We demonstrated that individuals with the presence of D allele for the -1607 promoter polymorphism of <ENT1>MMP1</ENT1> are about 1.5 times more susceptible to develop <ENT2>DDD</ENT2> when compared with those having G allele only.,,,,T,,,,,c,,,,,0.0,,
18439803,1234,D014635,C108761,Comparison,TRUE,"The present study aimed to investigate the anticonvulsant activity as well as the effects on the level of hippocampal amino acid neurotransmitters (glutamate, aspartate, glycine and GABA) of <ENT2>N-(2-propylpentanoyl)urea</ENT2> (<ENT2>VPU</ENT2>) in comparison to its parent compound, <ENT1>valproic acid</ENT1> (<ENT1>VPA</ENT1>).",,,,T,,,,,c,,,"11,12,21,22",,0.0,,
18439803,1234,D014635,C108761,Comparison,TRUE,"<ENT2>VPU</ENT2> was more potent than <ENT1>VPA</ENT1>, exhibiting the median effective dose (ED(50)) of 49 mg/kg in protecting rats against pilocarpine-induced seizure whereas the corresponding value for <ENT1>VPA</ENT1> was 322 mg/kg.",,,,T,,,,,c,,,,,0.0,,
18439803,1234,D014635,C108761,Comparison,TRUE,Pretreatment with either <ENT2>VPU</ENT2> (50 and 100 mg/kg) or <ENT1>VPA</ENT1> (300 and 600 mg/kg) completely abolished pilocarpine-evoked increases in extracellular glutamate and aspartate.,,,,T,,,,,c,,,,,1.0,,
18439803,1234,D014635,C108761,Comparison,TRUE,Based on the finding that <ENT2>VPU</ENT2> and <ENT1>VPA</ENT1> could protect the animals against pilocarpine-induced seizure it is suggested that the reduction of inhibitory amino acid neurotransmitters was comparatively minor and offset by a pronounced reduction of glutamate and aspartate.,,,,T,,,,,c,,,,,1.0,,
18439803,1234,D014635,C108761,Comparison,TRUE,"Therefore, like <ENT1>VPA</ENT1>, the finding that <ENT2>VPU</ENT2> could drastically reduce pilocarpine-induced increases in glutamate and aspartate should account, at least partly, for its anticonvulsant activity observed in pilocarpine-induced seizure in experimental animals.",,,,T,,,,,c,,,,,0.0,,
18439803,1237,D014635,D012640,Negative_Correlation,TRUE,"VPU was more potent than <ENT1>VPA</ENT1>, exhibiting the median effective dose (ED(50)) of 49 mg/kg in protecting rats against pilocarpine-induced <ENT2>seizure</ENT2> whereas the corresponding value for <ENT1>VPA</ENT1> was 322 mg/kg.",,,,T,,,,,c,,,,,0.5,,
18439803,1237,D014635,D012640,Negative_Correlation,TRUE,Based on the finding that VPU and <ENT1>VPA</ENT1> could protect the animals against pilocarpine-induced <ENT2>seizure</ENT2> it is suggested that the reduction of inhibitory amino acid neurotransmitters was comparatively minor and offset by a pronounced reduction of glutamate and aspartate.,,,,T,,,,,c,,,,,1.0,,
18439803,1237,D014635,D012640,Negative_Correlation,TRUE,"Therefore, like <ENT1>VPA</ENT1>, the finding that VPU could drastically reduce pilocarpine-induced increases in glutamate and aspartate should account, at least partly, for its anticonvulsant activity observed in pilocarpine-induced <ENT2>seizure</ENT2> in experimental animals.",,,,T,,,,,c,,,,,0.0,,
18439803,1227,D014635,D001224,Negative_Correlation,TRUE,"The present study aimed to investigate the anticonvulsant activity as well as the effects on the level of hippocampal amino acid neurotransmitters (glutamate, <ENT2>aspartate</ENT2>, glycine and GABA) of N-(2-propylpentanoyl)urea (VPU) in comparison to its parent compound, <ENT1>valproic acid</ENT1> (<ENT1>VPA</ENT1>).",,,,T,,,,,c,,,,,1.0,,
18439803,1227,D014635,D001224,Negative_Correlation,TRUE,Pretreatment with either VPU (50 and 100 mg/kg) or <ENT1>VPA</ENT1> (300 and 600 mg/kg) completely abolished pilocarpine-evoked increases in extracellular glutamate and <ENT2>aspartate</ENT2>.,,,,T,,,,,c,,,,,1.0,,
18439803,1227,D014635,D001224,Negative_Correlation,TRUE,Based on the finding that VPU and <ENT1>VPA</ENT1> could protect the animals against pilocarpine-induced seizure it is suggested that the reduction of inhibitory amino acid neurotransmitters was comparatively minor and offset by a pronounced reduction of glutamate and <ENT2>aspartate</ENT2>.,,,,T,,,,,c,,,,,0.0,,
18439803,1227,D014635,D001224,Negative_Correlation,TRUE,"Therefore, like <ENT1>VPA</ENT1>, the finding that VPU could drastically reduce pilocarpine-induced increases in glutamate and <ENT2>aspartate</ENT2> should account, at least partly, for its anticonvulsant activity observed in pilocarpine-induced seizure in experimental animals.",,,,T,,,,,c,,,,,0.0,,
18439803,1229,D014635,D010862,Negative_Correlation,TRUE,"VPU was more potent than <ENT1>VPA</ENT1>, exhibiting the median effective dose (ED(50)) of 49 mg/kg in protecting rats against <ENT2>pilocarpine</ENT2>-induced seizure whereas the corresponding value for <ENT1>VPA</ENT1> was 322 mg/kg.",,,,T,Y,,,,c,,,,,0.0,,
18439803,1229,D014635,D010862,Negative_Correlation,TRUE,Pretreatment with either VPU (50 and 100 mg/kg) or <ENT1>VPA</ENT1> (300 and 600 mg/kg) completely abolished <ENT2>pilocarpine</ENT2>-evoked increases in extracellular glutamate and aspartate.,,,,T,,,,,c,,,,,1.0,,
18439803,1229,D014635,D010862,Negative_Correlation,TRUE,Based on the finding that VPU and <ENT1>VPA</ENT1> could protect the animals against <ENT2>pilocarpine</ENT2>-induced seizure it is suggested that the reduction of inhibitory amino acid neurotransmitters was comparatively minor and offset by a pronounced reduction of glutamate and aspartate.,,,,T,,,,,c,,,,,0.0,,
18439803,1229,D014635,D010862,Negative_Correlation,TRUE,"Therefore, like <ENT1>VPA</ENT1>, the finding that VPU could drastically reduce <ENT2>pilocarpine</ENT2>-induced increases in glutamate and aspartate should account, at least partly, for its anticonvulsant activity observed in <ENT2>pilocarpine</ENT2>-induced seizure in experimental animals.",,,,T,Y,,,,c,,,,,0.5,,
18439803,1228,D014635,D018698,Negative_Correlation,TRUE,"The present study aimed to investigate the anticonvulsant activity as well as the effects on the level of hippocampal amino acid neurotransmitters (<ENT2>glutamate</ENT2>, aspartate, glycine and GABA) of N-(2-propylpentanoyl)urea (VPU) in comparison to its parent compound, <ENT1>valproic acid</ENT1> (<ENT1>VPA</ENT1>).",,,,T,,,,,c,,,,,1.0,,
18439803,1228,D014635,D018698,Negative_Correlation,TRUE,Pretreatment with either VPU (50 and 100 mg/kg) or <ENT1>VPA</ENT1> (300 and 600 mg/kg) completely abolished pilocarpine-evoked increases in extracellular <ENT2>glutamate</ENT2> and aspartate.,,,,T,,,,,w,,,,,1.0,,
18439803,1228,D014635,D018698,Negative_Correlation,TRUE,Based on the finding that VPU and <ENT1>VPA</ENT1> could protect the animals against pilocarpine-induced seizure it is suggested that the reduction of inhibitory amino acid neurotransmitters was comparatively minor and offset by a pronounced reduction of <ENT2>glutamate</ENT2> and aspartate.,,,,T,,,,,c,,,,,0.0,,
18439803,1228,D014635,D018698,Negative_Correlation,TRUE,"Therefore, like <ENT1>VPA</ENT1>, the finding that VPU could drastically reduce pilocarpine-induced increases in <ENT2>glutamate</ENT2> and aspartate should account, at least partly, for its anticonvulsant activity observed in pilocarpine-induced seizure in experimental animals.",,,,T,,,,,w,,,,,1.0,,
18439803,1231,D005998,C108761,Association,FALSE,"The present study aimed to investigate the anticonvulsant activity as well as the effects on the level of hippocampal amino acid neurotransmitters (glutamate, aspartate, <ENT1>glycine</ENT1> and GABA) of <ENT2>N-(2-propylpentanoyl)urea</ENT2> (<ENT2>VPU</ENT2>) in comparison to its parent compound, valproic acid (VPA).",,,,T,,Y,,,w,,,,,0.0,TRUE,
18439803,1235,C108761,D012640,Negative_Correlation,TRUE,Acute effects of <ENT1>N-(2-propylpentanoyl)urea</ENT1> on hippocampal amino acid neurotransmitters in pilocarpine-induced <ENT2>seizure</ENT2> in rats.,,,,T,,,,,w,,,,,1.0,,
18439803,1235,C108761,D012640,Negative_Correlation,TRUE,"<ENT1>VPU</ENT1> was more potent than VPA, exhibiting the median effective dose (ED(50)) of 49 mg/kg in protecting rats against pilocarpine-induced <ENT2>seizure</ENT2> whereas the corresponding value for VPA was 322 mg/kg.",,,,T,,,,,c,,,,,1.0,,
18439803,1235,C108761,D012640,Negative_Correlation,TRUE,Based on the finding that <ENT1>VPU</ENT1> and VPA could protect the animals against pilocarpine-induced <ENT2>seizure</ENT2> it is suggested that the reduction of inhibitory amino acid neurotransmitters was comparatively minor and offset by a pronounced reduction of glutamate and aspartate.,,,,T,,,,,c,,,,,1.0,,
18439803,1235,C108761,D012640,Negative_Correlation,TRUE,"Therefore, like VPA, the finding that <ENT1>VPU</ENT1> could drastically reduce pilocarpine-induced increases in glutamate and aspartate should account, at least partly, for its anticonvulsant activity observed in pilocarpine-induced <ENT2>seizure</ENT2> in experimental animals.",,,,T,,,,,c,,,,,1.0,,
18439803,1232,C108761,D001224,Negative_Correlation,TRUE,"The present study aimed to investigate the anticonvulsant activity as well as the effects on the level of hippocampal amino acid neurotransmitters (glutamate, <ENT2>aspartate</ENT2>, glycine and GABA) of <ENT1>N-(2-propylpentanoyl)urea</ENT1> (<ENT1>VPU</ENT1>) in comparison to its parent compound, valproic acid (VPA).",,,,T,,Y,,,c,,,,,1.0,,
18439803,1232,C108761,D001224,Negative_Correlation,TRUE,Pretreatment with either <ENT1>VPU</ENT1> (50 and 100 mg/kg) or VPA (300 and 600 mg/kg) completely abolished pilocarpine-evoked increases in extracellular glutamate and <ENT2>aspartate</ENT2>.,,,,T,,,,,w,,,,,0.0,,
18439803,1232,C108761,D001224,Negative_Correlation,TRUE,Based on the finding that <ENT1>VPU</ENT1> and VPA could protect the animals against pilocarpine-induced seizure it is suggested that the reduction of inhibitory amino acid neurotransmitters was comparatively minor and offset by a pronounced reduction of glutamate and <ENT2>aspartate</ENT2>.,,,,T,,,,,w,,,,,0.0,,
18439803,1232,C108761,D001224,Negative_Correlation,TRUE,"Therefore, like VPA, the finding that <ENT1>VPU</ENT1> could drastically reduce pilocarpine-induced increases in glutamate and <ENT2>aspartate</ENT2> should account, at least partly, for its anticonvulsant activity observed in pilocarpine-induced seizure in experimental animals.",,,,T,,,,,w,,,,,0.0,,
18439803,1236,C108761,D010862,Negative_Correlation,TRUE,Acute effects of <ENT1>N-(2-propylpentanoyl)urea</ENT1> on hippocampal amino acid neurotransmitters in <ENT2>pilocarpine</ENT2>-induced seizure in rats.,,,,T,,,,,c,,,,,1.0,,
18439803,1236,C108761,D010862,Negative_Correlation,TRUE,"<ENT1>VPU</ENT1> was more potent than VPA, exhibiting the median effective dose (ED(50)) of 49 mg/kg in protecting rats against <ENT2>pilocarpine</ENT2>-induced seizure whereas the corresponding value for VPA was 322 mg/kg.",,,,T,,,,,c,,,,,1.0,,
18439803,1236,C108761,D010862,Negative_Correlation,TRUE,Pretreatment with either <ENT1>VPU</ENT1> (50 and 100 mg/kg) or VPA (300 and 600 mg/kg) completely abolished <ENT2>pilocarpine</ENT2>-evoked increases in extracellular glutamate and aspartate.,,,,T,,,,,c,,,,,1.0,,
18439803,1236,C108761,D010862,Negative_Correlation,TRUE,Based on the finding that <ENT1>VPU</ENT1> and VPA could protect the animals against <ENT2>pilocarpine</ENT2>-induced seizure it is suggested that the reduction of inhibitory amino acid neurotransmitters was comparatively minor and offset by a pronounced reduction of glutamate and aspartate.,,,,T,Y,,,,c,,,,,1.0,,
18439803,1236,C108761,D010862,Negative_Correlation,TRUE,"Therefore, like VPA, the finding that <ENT1>VPU</ENT1> could drastically reduce <ENT2>pilocarpine</ENT2>-induced increases in glutamate and aspartate should account, at least partly, for its anticonvulsant activity observed in <ENT2>pilocarpine</ENT2>-induced seizure in experimental animals.",,,,T,,,,,c,,,,,1.0,,
18439803,1233,C108761,D018698,Negative_Correlation,TRUE,"The present study aimed to investigate the anticonvulsant activity as well as the effects on the level of hippocampal amino acid neurotransmitters (<ENT2>glutamate</ENT2>, aspartate, glycine and GABA) of <ENT1>N-(2-propylpentanoyl)urea</ENT1> (<ENT1>VPU</ENT1>) in comparison to its parent compound, valproic acid (VPA).",,,,T,,Y,,,c,,,,,1.0,,
18439803,1233,C108761,D018698,Negative_Correlation,TRUE,Pretreatment with either <ENT1>VPU</ENT1> (50 and 100 mg/kg) or VPA (300 and 600 mg/kg) completely abolished pilocarpine-evoked increases in extracellular <ENT2>glutamate</ENT2> and aspartate.,,,,T,,,,,w,,,,,1.0,,
18439803,1233,C108761,D018698,Negative_Correlation,TRUE,Based on the finding that <ENT1>VPU</ENT1> and VPA could protect the animals against pilocarpine-induced seizure it is suggested that the reduction of inhibitory amino acid neurotransmitters was comparatively minor and offset by a pronounced reduction of <ENT2>glutamate</ENT2> and aspartate.,,,,T,,,,,w,,,,,0.0,,
18439803,1233,C108761,D018698,Negative_Correlation,TRUE,"Therefore, like VPA, the finding that <ENT1>VPU</ENT1> could drastically reduce pilocarpine-induced increases in <ENT2>glutamate</ENT2> and aspartate should account, at least partly, for its anticonvulsant activity observed in pilocarpine-induced seizure in experimental animals.",,,,T,,,,,w,,,,,0.0,,
18439803,1230,C108761,D005680,Association,FALSE,"The present study aimed to investigate the anticonvulsant activity as well as the effects on the level of hippocampal amino acid neurotransmitters (glutamate, aspartate, glycine and <ENT2>GABA</ENT2>) of <ENT1>N-(2-propylpentanoyl)urea</ENT1> (<ENT1>VPU</ENT1>) in comparison to its parent compound, valproic acid (VPA).",,,,T,,Y,,,w,,,,,0.0,TRUE,
18439803,1240,D012640,D010862,Positive_Correlation,FALSE,Acute effects of N-(2-propylpentanoyl)urea on hippocampal amino acid neurotransmitters in <ENT2>pilocarpine</ENT2>-induced <ENT1>seizure</ENT1> in rats.,,,,T,,,,,c,,,,,1.0,,
18439803,1240,D012640,D010862,Positive_Correlation,FALSE,"VPU was more potent than VPA, exhibiting the median effective dose (ED(50)) of 49 mg/kg in protecting rats against <ENT2>pilocarpine</ENT2>-induced <ENT1>seizure</ENT1> whereas the corresponding value for VPA was 322 mg/kg.",,,,T,,,,,c,,,,,1.0,,
18439803,1240,D012640,D010862,Positive_Correlation,FALSE,Based on the finding that VPU and VPA could protect the animals against <ENT2>pilocarpine</ENT2>-induced <ENT1>seizure</ENT1> it is suggested that the reduction of inhibitory amino acid neurotransmitters was comparatively minor and offset by a pronounced reduction of glutamate and aspartate.,,,,T,,,,,c,,,,,1.0,,
18439803,1240,D012640,D010862,Positive_Correlation,FALSE,"Therefore, like VPA, the finding that VPU could drastically reduce <ENT2>pilocarpine</ENT2>-induced increases in glutamate and aspartate should account, at least partly, for its anticonvulsant activity observed in <ENT2>pilocarpine</ENT2>-induced <ENT1>seizure</ENT1> in experimental animals.",,,,T,,,,,c,,,,,1.0,,
18439803,1238,D001224,D010862,Positive_Correlation,TRUE,In vivo microdialysis demonstrated that an intraperitoneal administration of <ENT2>pilocarpine</ENT2> induced a pronounced increment of hippocampal glutamate and <ENT1>aspartate</ENT1> whereas no significant change was observed on the level of glycine and GABA.,,,,T,,,,,c,,,,,1.0,,
18439803,1238,D001224,D010862,Positive_Correlation,TRUE,Pretreatment with either VPU (50 and 100 mg/kg) or VPA (300 and 600 mg/kg) completely abolished <ENT2>pilocarpine</ENT2>-evoked increases in extracellular glutamate and <ENT1>aspartate</ENT1>.,,,,T,,,,,c,,,,,1.0,,
18439803,1238,D001224,D010862,Positive_Correlation,TRUE,Based on the finding that VPU and VPA could protect the animals against <ENT2>pilocarpine</ENT2>-induced seizure it is suggested that the reduction of inhibitory amino acid neurotransmitters was comparatively minor and offset by a pronounced reduction of glutamate and <ENT1>aspartate</ENT1>.,,,,T,,,,,w,,,,,0.0,,
18439803,1238,D001224,D010862,Positive_Correlation,TRUE,"Therefore, like VPA, the finding that VPU could drastically reduce <ENT2>pilocarpine</ENT2>-induced increases in glutamate and <ENT1>aspartate</ENT1> should account, at least partly, for its anticonvulsant activity observed in <ENT2>pilocarpine</ENT2>-induced seizure in experimental animals.",,,,T,,,,,c,,,,,0.5,,
18439803,1239,D010862,D018698,Positive_Correlation,TRUE,In vivo microdialysis demonstrated that an intraperitoneal administration of <ENT1>pilocarpine</ENT1> induced a pronounced increment of hippocampal <ENT2>glutamate</ENT2> and aspartate whereas no significant change was observed on the level of glycine and GABA.,,,,T,,,,,c,,,,,1.0,,
18439803,1239,D010862,D018698,Positive_Correlation,TRUE,Pretreatment with either VPU (50 and 100 mg/kg) or VPA (300 and 600 mg/kg) completely abolished <ENT1>pilocarpine</ENT1>-evoked increases in extracellular <ENT2>glutamate</ENT2> and aspartate.,,,,T,,,,,c,,,,,1.0,,
18439803,1239,D010862,D018698,Positive_Correlation,TRUE,Based on the finding that VPU and VPA could protect the animals against <ENT1>pilocarpine</ENT1>-induced seizure it is suggested that the reduction of inhibitory amino acid neurotransmitters was comparatively minor and offset by a pronounced reduction of <ENT2>glutamate</ENT2> and aspartate.,,,,T,,,,,c,,,,,0.0,,
18439803,1239,D010862,D018698,Positive_Correlation,TRUE,"Therefore, like VPA, the finding that VPU could drastically reduce <ENT1>pilocarpine</ENT1>-induced increases in <ENT2>glutamate</ENT2> and aspartate should account, at least partly, for its anticonvulsant activity observed in <ENT1>pilocarpine</ENT1>-induced seizure in experimental animals.",,,,T,,,,,c,,,,,0.5,,
18457324,1243,rs1056892,D000438,Association,TRUE,CONCLUSIONS: The functional CBR3 <ENT1>V244M</ENT1> polymorphism may have an impact on the risk of anthracycline-related CHF among childhood cancer survivors by modulating the intracardiac formation of cardiotoxic <ENT2>anthracycline alcohol</ENT2> metabolites.,,,,T,,,,,c,,,,,1.0,,
18457324,1244,rs1056892,C010013,Association,TRUE,"In line, recombinant CBR3 <ENT1>V244</ENT1> (G allele) synthesized 2.6-fold more cardiotoxic <ENT2>doxorubicinol</ENT2> per unit of time than CBR3 <ENT1>M244</ENT1> (A allele; CBR3 <ENT1>V244</ENT1> [8.26+/-3.57 nmol/hour.mg] vs CBR3 <ENT1>M244</ENT1> [3.22+/-0.67 nmol/hour.mg]; P=.01).",,,,T,,,,,c,,,,,0.0,,
18457324,1245,rs1056892,D006333,Positive_Correlation,TRUE,Thirty patients with <ENT2>CHF</ENT2> (cases) and 115 matched controls were genotyped for polymorphisms in NQO1 (NQO1*2) and CBR3 (the CBR3 <ENT1>valine [V] to methionine [M] substitution at position 244</ENT1> [<ENT1>V244M</ENT1>]).,,,,T,,,,,c,,,,,1.0,,
18457324,1245,rs1056892,D006333,Positive_Correlation,TRUE,RESULTS: Multivariate analyses adjusted for sex and primary disease recurrence were used to test for associations between the candidate genetic polymorphisms (NQO1*2 and CBR3 <ENT1>V244M</ENT1>) and the risk of <ENT2>CHF</ENT2>.,,,,T,,,,,c,,,,,0.0,,
18457324,1245,rs1056892,D006333,Positive_Correlation,TRUE,"There was a trend toward an association between the CBR3 <ENT1>V244M</ENT1> polymorphism and the risk of <ENT2>CHF</ENT2> (OR, 8.16; P=.056 for G/G vs A/A; OR, 5.44; P=.092 for G/A vs A/A).",,,,T,,,,,w,,,,,1.0,,
18457324,1245,rs1056892,D006333,Positive_Correlation,TRUE,CONCLUSIONS: The functional CBR3 <ENT1>V244M</ENT1> polymorphism may have an impact on the risk of anthracycline-related <ENT2>CHF</ENT2> among childhood cancer survivors by modulating the intracardiac formation of cardiotoxic anthracycline alcohol metabolites.,,,,T,,,,,w,,,,,1.0,,
18457324,1246,rs1056892,D018943,Association,TRUE,Enzyme activity assays with recombinant CBR3 isoforms (CBR3 <ENT1>V244</ENT1> and CBR3 <ENT1>M244</ENT1>) and the <ENT2>anthracycline</ENT2> substrate doxorubicin were used to investigate the functional impact of the CBR3 <ENT1>V244M</ENT1> polymorphism.,,,,T,,,,,c,,,,,1.0,,
18457324,1246,rs1056892,D018943,Association,TRUE,CONCLUSIONS: The functional CBR3 <ENT1>V244M</ENT1> polymorphism may have an impact on the risk of <ENT2>anthracycline</ENT2>-related CHF among childhood cancer survivors by modulating the intracardiac formation of cardiotoxic <ENT2>anthracycline alcohol</ENT2> metabolites.,,,,T,,,,,c,,,,,0.0,,
18457324,1242,D000438,D066126,Positive_Correlation,FALSE,CONCLUSIONS: The functional CBR3 V244M polymorphism may have an impact on the risk of anthracycline-related CHF among childhood cancer survivors by modulating the intracardiac formation of <ENT2>cardiotoxic</ENT2> <ENT1>anthracycline alcohol</ENT1> metabolites.,,,,T,Y,,,,c,,,,,0.0,,
18457324,1247,D000438,D006333,Association,TRUE,CONCLUSIONS: The functional CBR3 V244M polymorphism may have an impact on the risk of anthracycline-related <ENT2>CHF</ENT2> among childhood cancer survivors by modulating the intracardiac formation of cardiotoxic <ENT1>anthracycline alcohol</ENT1> metabolites.,,,,T,,,,,c,,,,,0.0,,
18457324,1252,D000438,874,Association,TRUE,CONCLUSIONS: The functional <ENT2>CBR3</ENT2> V244M polymorphism may have an impact on the risk of anthracycline-related CHF among childhood cancer survivors by modulating the intracardiac formation of cardiotoxic <ENT1>anthracycline alcohol</ENT1> metabolites.,,,,T,,,,,c,,,,,1.0,,
18457324,1241,D066126,C010013,Positive_Correlation,FALSE,"In line, recombinant CBR3 V244 (G allele) synthesized 2.6-fold more <ENT1>cardiotoxic</ENT1> <ENT2>doxorubicinol</ENT2> per unit of time than CBR3 M244 (A allele; CBR3 V244 [8.26+/-3.57 nmol/hour.mg] vs CBR3 M244 [3.22+/-0.67 nmol/hour.mg]; P=.01).",,,,T,,,,,c,,,,,1.0,,
18457324,1249,D066126,D018943,Positive_Correlation,FALSE,CONCLUSIONS: The functional CBR3 V244M polymorphism may have an impact on the risk of <ENT2>anthracycline</ENT2>-related CHF among childhood cancer survivors by modulating the intracardiac formation of <ENT1>cardiotoxic</ENT1> <ENT2>anthracycline alcohol</ENT2> metabolites.,,,,T,,,,,c,,,,,0.5,,
18457324,1251,D066126,874,Association,TRUE,"In line, recombinant <ENT2>CBR3</ENT2> V244 (G allele) synthesized 2.6-fold more <ENT1>cardiotoxic</ENT1> doxorubicinol per unit of time than <ENT2>CBR3</ENT2> M244 (A allele; <ENT2>CBR3</ENT2> V244 [8.26+/-3.57 nmol/hour.mg] vs <ENT2>CBR3</ENT2> M244 [3.22+/-0.67 nmol/hour.mg]; P=.01).",,,,T,,,,,c,,,,,0.0,,
18457324,1251,D066126,874,Association,TRUE,CONCLUSIONS: The functional <ENT2>CBR3</ENT2> V244M polymorphism may have an impact on the risk of anthracycline-related CHF among childhood cancer survivors by modulating the intracardiac formation of <ENT1>cardiotoxic</ENT1> anthracycline alcohol metabolites.,,,,T,,,,,w,,,,,1.0,,
18457324,1253,C010013,874,Association,TRUE,"In line, recombinant <ENT2>CBR3</ENT2> V244 (G allele) synthesized 2.6-fold more cardiotoxic <ENT1>doxorubicinol</ENT1> per unit of time than <ENT2>CBR3</ENT2> M244 (A allele; <ENT2>CBR3</ENT2> V244 [8.26+/-3.57 nmol/hour.mg] vs <ENT2>CBR3</ENT2> M244 [3.22+/-0.67 nmol/hour.mg]; P=.01).",,,,T,,,,,c,,,,,0.25,,
18457324,1250,D006333,D018943,Positive_Correlation,TRUE,Genetic polymorphisms in the carbonyl reductase 3 gene CBR3 and the NAD(P)H:quinone oxidoreductase 1 gene NQO1 in patients who developed <ENT2>anthracycline</ENT2>-related <ENT1>congestive heart failure</ENT1> after childhood cancer.,,,,T,,,,,c,,,,,1.0,,
18457324,1250,D006333,D018943,Positive_Correlation,TRUE,BACKGROUND: Exposure to <ENT2>anthracyclines</ENT2> as part of cancer therapy has been associated with the development of <ENT1>congestive heart failure</ENT1> (<ENT1>CHF</ENT1>).,,,,T,,,,,c,,,,,1.0,,
18457324,1250,D006333,D018943,Positive_Correlation,TRUE,The potential role of genetic risk factors in <ENT2>anthracycline</ENT2>-related <ENT1>CHF</ENT1> remains to be defined.,,,,T,,,,,c,,,,,1.0,,
18457324,1250,D006333,D018943,Positive_Correlation,TRUE,"Thus, in this study, the authors examined whether common polymorphisms in candidate genes involved in the pharmacodynamics of <ENT2>anthracyclines</ENT2> (in particular, the nicotinamide adenine dinucleotide phosphate:quinone oxidoreductase 1 gene NQO1 and the carbonyl reductase 3 gene CBR3) had an impact on the risk of <ENT2>anthracycline</ENT2>-related <ENT1>CHF</ENT1>.",,,,T,,,,,c,,,,,1.0,,
18457324,1250,D006333,D018943,Positive_Correlation,TRUE,"Analyses indicated no association between the NQO1*2 polymorphism and the risk of <ENT2>anthracycline</ENT2>-related <ENT1>CHF</ENT1> (odds ratio [OR], 1.04; P=.97).",,,,T,,,,,c,,,,,0.0,,
18457324,1250,D006333,D018943,Positive_Correlation,TRUE,CONCLUSIONS: The functional CBR3 V244M polymorphism may have an impact on the risk of <ENT2>anthracycline</ENT2>-related <ENT1>CHF</ENT1> among childhood cancer survivors by modulating the intracardiac formation of cardiotoxic <ENT2>anthracycline alcohol</ENT2> metabolites.,,,,T,,,,,c,,,,,0.5,,
18457324,1254,D006333,874,Association,TRUE,Genetic polymorphisms in the <ENT2>carbonyl reductase 3</ENT2> gene <ENT2>CBR3</ENT2> and the NAD(P)H:quinone oxidoreductase 1 gene NQO1 in patients who developed anthracycline-related <ENT1>congestive heart failure</ENT1> after childhood cancer.,,,,T,,,,,w,,,,,1.0,,
18457324,1254,D006333,874,Association,TRUE,"Thus, in this study, the authors examined whether common polymorphisms in candidate genes involved in the pharmacodynamics of anthracyclines (in particular, the nicotinamide adenine dinucleotide phosphate:quinone oxidoreductase 1 gene NQO1 and the <ENT2>carbonyl reductase 3</ENT2> gene <ENT2>CBR3</ENT2>) had an impact on the risk of anthracycline-related <ENT1>CHF</ENT1>.",,,,T,,Y,,,w,,,,,0.0,TRUE,
18457324,1254,D006333,874,Association,TRUE,Thirty patients with <ENT1>CHF</ENT1> (cases) and 115 matched controls were genotyped for polymorphisms in NQO1 (NQO1*2) and <ENT2>CBR3</ENT2> (the <ENT2>CBR3</ENT2> valine [V] to methionine [M] substitution at position 244 [V244M]).,,,,T,,Y,,,w,,,,,0.0,TRUE,
18457324,1254,D006333,874,Association,TRUE,RESULTS: Multivariate analyses adjusted for sex and primary disease recurrence were used to test for associations between the candidate genetic polymorphisms (NQO1*2 and <ENT2>CBR3</ENT2> V244M) and the risk of <ENT1>CHF</ENT1>.,,,,T,,Y,,,w,,,,,1.0,,
18457324,1254,D006333,874,Association,TRUE,"There was a trend toward an association between the <ENT2>CBR3</ENT2> V244M polymorphism and the risk of <ENT1>CHF</ENT1> (OR, 8.16; P=.056 for G/G vs A/A; OR, 5.44; P=.092 for G/A vs A/A).",,,,T,,,,,c,,,,,1.0,,
18457324,1254,D006333,874,Association,TRUE,CONCLUSIONS: The functional <ENT2>CBR3</ENT2> V244M polymorphism may have an impact on the risk of anthracycline-related <ENT1>CHF</ENT1> among childhood cancer survivors by modulating the intracardiac formation of cardiotoxic anthracycline alcohol metabolites.,,,,T,,,,,c,,,,,1.0,,
18457324,1248,D018943,D009369,Negative_Correlation,FALSE,Genetic polymorphisms in the carbonyl reductase 3 gene CBR3 and the NAD(P)H:quinone oxidoreductase 1 gene NQO1 in patients who developed <ENT1>anthracycline</ENT1>-related congestive heart failure after childhood <ENT2>cancer</ENT2>.,,,,T,,,,,c,,,,,1.0,,
18457324,1248,D018943,D009369,Negative_Correlation,FALSE,BACKGROUND: Exposure to <ENT1>anthracyclines</ENT1> as part of <ENT2>cancer</ENT2> therapy has been associated with the development of congestive heart failure (CHF).,,,,T,,,,,c,,,,,0.0,,
18457324,1248,D018943,D009369,Negative_Correlation,FALSE,CONCLUSIONS: The functional CBR3 V244M polymorphism may have an impact on the risk of <ENT1>anthracycline</ENT1>-related CHF among childhood <ENT2>cancer</ENT2> survivors by modulating the intracardiac formation of cardiotoxic <ENT1>anthracycline alcohol</ENT1> metabolites.,,,,T,,,,,w,,,,,0.5,,
18457324,1255,D018943,874,Association,TRUE,Genetic polymorphisms in the <ENT2>carbonyl reductase 3</ENT2> gene <ENT2>CBR3</ENT2> and the NAD(P)H:quinone oxidoreductase 1 gene NQO1 in patients who developed <ENT1>anthracycline</ENT1>-related congestive heart failure after childhood cancer.,,,,T,Y,,,,c,,,,,1.0,,
18457324,1255,D018943,874,Association,TRUE,"Thus, in this study, the authors examined whether common polymorphisms in candidate genes involved in the pharmacodynamics of <ENT1>anthracyclines</ENT1> (in particular, the nicotinamide adenine dinucleotide phosphate:quinone oxidoreductase 1 gene NQO1 and the <ENT2>carbonyl reductase 3</ENT2> gene <ENT2>CBR3</ENT2>) had an impact on the risk of <ENT1>anthracycline</ENT1>-related CHF.",,,,T,,,,,c,,,,,0.25,,
18457324,1255,D018943,874,Association,TRUE,Enzyme activity assays with recombinant <ENT2>CBR3</ENT2> isoforms (<ENT2>CBR3</ENT2> V244 and <ENT2>CBR3</ENT2> M244) and the <ENT1>anthracycline</ENT1> substrate doxorubicin were used to investigate the functional impact of the <ENT2>CBR3</ENT2> V244M polymorphism.,,,,T,,,,,c,,,,,0.75,,
18457324,1255,D018943,874,Association,TRUE,CONCLUSIONS: The functional <ENT2>CBR3</ENT2> V244M polymorphism may have an impact on the risk of <ENT1>anthracycline</ENT1>-related CHF among childhood cancer survivors by modulating the intracardiac formation of cardiotoxic <ENT1>anthracycline alcohol</ENT1> metabolites.,,,,T,,,,,c,,,,,1.0,,
18470323,1257,rs121909210,C537881,Association,TRUE,Anticipation in familial <ENT2>lattice corneal dystrophy type I</ENT2> with <ENT1>R124C</ENT1> mutation in the TGFBI (BIGH3) gene.,,,,T,,,,,c,,,,,1.0,,
18470323,1257,rs121909210,C537881,Association,TRUE,CONCLUSIONS: The <ENT1>R124C</ENT1> mutation in TGFBI cosegregated with <ENT2>LCD type I</ENT2> in the investigated family.,,,,T,,,,,c,,,,,0.0,,
18470323,1256,C537881,7045,Association,TRUE,Anticipation in familial <ENT1>lattice corneal dystrophy type I</ENT1> with R124C mutation in the <ENT2>TGFBI</ENT2> (<ENT2>BIGH3</ENT2>) gene.,,,,T,,,,,c,,,,,0.5,,
18470323,1256,C537881,7045,Association,TRUE,CONCLUSIONS: The R124C mutation in <ENT2>TGFBI</ENT2> cosegregated with <ENT1>LCD type I</ENT1> in the investigated family.,,,,T,,,,,c,,,,,0.0,,
18483878,1264,D003520,22353,Association,FALSE,Exaggerated expression of inflammatory mediators in <ENT2>vasoactive intestinal polypeptide</ENT2> knockout (<ENT2>VIP</ENT2>-/-) mice with <ENT1>cyclophosphamide</ENT1> (<ENT1>CYP</ENT1>)-induced cystitis.,,,,T,,,,,c,,,,,1.0,,
18483878,1264,D003520,22353,Association,FALSE,<ENT2>VIP</ENT2>(-/-) mice exhibit altered bladder function and neurochemical properties in micturition pathways after <ENT1>cyclophosphamide</ENT1> (<ENT1>CYP</ENT1>)-induced cystitis.,,,,T,,,,,w,,,,,0.0,,
18483878,1264,D003520,22353,Association,FALSE,A mouse inflammatory cytokine and receptor RT2 profiler array was used to determine regulated transcripts in the urinary bladder of wild type (WT) and <ENT2>VIP</ENT2>(-/-) mice with or without <ENT1>CYP</ENT1>-induced cystitis (150 mg/kg; i.p.; 48 h).,,,,T,,,,,w,,,,,1.0,,
18483878,1264,D003520,22353,Association,FALSE,"Four binary comparisons were made: WT control versus <ENT1>CYP</ENT1> treatment (48 h), <ENT2>VIP</ENT2>(-/-) control versus <ENT1>CYP</ENT1> treatment (48 h), WT control versus <ENT2>VIP</ENT2>(-/-) control, and WT with <ENT1>CYP</ENT1> treatment (48 h) versus <ENT2>VIP</ENT2>(-/-) with <ENT1>CYP</ENT1> treatment (48 h).",,,,T,,,,,w,,,,,1.0,,
18483878,1264,D003520,22353,Association,FALSE,"<ENT1>CYP</ENT1> treatment significantly (p < or = 0.001) increased expression of CXCL1 and IL-1beta in the urinary bladder of WT and <ENT2>VIP</ENT2>(-/-) mice, but expression in <ENT2>VIP</ENT2>(-/-) mice with <ENT1>CYP</ENT1> treatment was significantly (p < or = 0.001) greater (4.2- to 13-fold increase) than that observed in WT urinary bladder (3.6- to 5-fold increase).",,,,T,,,,,w,,,,,1.0,,
18483878,1264,D003520,22353,Association,FALSE,"The data suggest that in <ENT2>VIP</ENT2>(-/-) mice with bladder inflammation, inflammatory mediators are increased above that observed in WT with <ENT1>CYP</ENT1>.",,,,T,,,,,w,,,,,0.0,,
18483878,1258,D003520,16176,Positive_Correlation,TRUE,"<ENT1>CYP</ENT1> treatment significantly (p < or = 0.001) increased expression of CXCL1 and <ENT2>IL-1beta</ENT2> in the urinary bladder of WT and VIP(-/-) mice, but expression in VIP(-/-) mice with <ENT1>CYP</ENT1> treatment was significantly (p < or = 0.001) greater (4.2- to 13-fold increase) than that observed in WT urinary bladder (3.6- to 5-fold increase).",,,,T,,,,,c,,,,,0.5,,
18483878,1261,D003520,D003556,Positive_Correlation,FALSE,Exaggerated expression of inflammatory mediators in vasoactive intestinal polypeptide knockout (VIP-/-) mice with <ENT1>cyclophosphamide</ENT1> (<ENT1>CYP</ENT1>)-induced <ENT2>cystitis</ENT2>.,,,,T,,,,,c,,,,,0.5,,
18483878,1261,D003520,D003556,Positive_Correlation,FALSE,VIP(-/-) mice exhibit altered bladder function and neurochemical properties in micturition pathways after <ENT1>cyclophosphamide</ENT1> (<ENT1>CYP</ENT1>)-induced <ENT2>cystitis</ENT2>.,,,,T,,,,,c,,,,,1.0,,
18483878,1261,D003520,D003556,Positive_Correlation,FALSE,A mouse inflammatory cytokine and receptor RT2 profiler array was used to determine regulated transcripts in the urinary bladder of wild type (WT) and VIP(-/-) mice with or without <ENT1>CYP</ENT1>-induced <ENT2>cystitis</ENT2> (150 mg/kg; i.p.; 48 h).,,,,T,,,,,c,,,,,1.0,,
18483878,1261,D003520,D003556,Positive_Correlation,FALSE,"The data suggest that in VIP(-/-) mice with <ENT2>bladder inflammation</ENT2>, inflammatory mediators are increased above that observed in WT with <ENT1>CYP</ENT1>.",,,,T,,,,,w,,,,,1.0,,
18483878,1260,D003520,D007249,Association,TRUE,Exaggerated expression of <ENT2>inflammatory</ENT2> mediators in vasoactive intestinal polypeptide knockout (VIP-/-) mice with <ENT1>cyclophosphamide</ENT1> (<ENT1>CYP</ENT1>)-induced cystitis.,,,,T,,,,,w,,,,,1.0,,
18483878,1260,D003520,D007249,Association,TRUE,A mouse <ENT2>inflammatory</ENT2> cytokine and receptor RT2 profiler array was used to determine regulated transcripts in the urinary bladder of wild type (WT) and VIP(-/-) mice with or without <ENT1>CYP</ENT1>-induced cystitis (150 mg/kg; i.p.; 48 h).,,,,T,,,,,w,,,,,1.0,,
18483878,1260,D003520,D007249,Association,TRUE,"The data suggest that in VIP(-/-) mice with bladder inflammation, <ENT2>inflammatory</ENT2> mediators are increased above that observed in WT with <ENT1>CYP</ENT1>.",,,,T,,,,,w,,,,,0.0,,
18483878,1259,D003520,14825,Positive_Correlation,TRUE,"<ENT1>CYP</ENT1> treatment significantly (p < or = 0.001) increased expression of <ENT2>CXCL1</ENT2> and IL-1beta in the urinary bladder of WT and VIP(-/-) mice, but expression in VIP(-/-) mice with <ENT1>CYP</ENT1> treatment was significantly (p < or = 0.001) greater (4.2- to 13-fold increase) than that observed in WT urinary bladder (3.6- to 5-fold increase).",,,,T,,,,,c,,,,,1.0,,
18483878,1263,22353,D003556,Negative_Correlation,FALSE,Exaggerated expression of inflammatory mediators in <ENT1>vasoactive intestinal polypeptide</ENT1> knockout (<ENT1>VIP</ENT1>-/-) mice with cyclophosphamide (CYP)-induced <ENT2>cystitis</ENT2>.,,,,T,,,,,c,,,,,0.5,,
18483878,1263,22353,D003556,Negative_Correlation,FALSE,<ENT1>VIP</ENT1>(-/-) mice exhibit altered bladder function and neurochemical properties in micturition pathways after cyclophosphamide (CYP)-induced <ENT2>cystitis</ENT2>.,,,,T,,,,,c,,,,,1.0,,
18483878,1263,22353,D003556,Negative_Correlation,FALSE,"Given <ENT1>VIP</ENT1>'s role as an anti-inflammatory mediator, we hypothesized that <ENT1>VIP</ENT1>(-/-) mice would exhibit enhanced inflammatory mediator expression after <ENT2>cystitis</ENT2>.",,,,T,,Y,,,c,,,,,1.0,,
18483878,1263,22353,D003556,Negative_Correlation,FALSE,A mouse inflammatory cytokine and receptor RT2 profiler array was used to determine regulated transcripts in the urinary bladder of wild type (WT) and <ENT1>VIP</ENT1>(-/-) mice with or without CYP-induced <ENT2>cystitis</ENT2> (150 mg/kg; i.p.; 48 h).,,,,T,,,,,c,,,,,1.0,,
18483878,1263,22353,D003556,Negative_Correlation,FALSE,"The data suggest that in <ENT1>VIP</ENT1>(-/-) mice with <ENT2>bladder inflammation</ENT2>, inflammatory mediators are increased above that observed in WT with CYP.",,,,T,,,,,w,,,,,0.0,,
18483878,1263,22353,D003556,Negative_Correlation,FALSE,This shift in balance may contribute to increased bladder dysfunction in <ENT1>VIP</ENT1>(-/-) mice with <ENT2>bladder inflammation</ENT2> and altered neurochemical expression in micturition pathways.,,,,T,,,,,w,,,,,1.0,,
18483878,1262,22353,D007249,Negative_Correlation,FALSE,Exaggerated expression of <ENT2>inflammatory</ENT2> mediators in <ENT1>vasoactive intestinal polypeptide</ENT1> knockout (<ENT1>VIP</ENT1>-/-) mice with cyclophosphamide (CYP)-induced cystitis.,,,,T,,,,,c,,,,,0.5,,
18483878,1262,22353,D007249,Negative_Correlation,FALSE,"Given <ENT1>VIP</ENT1>'s role as an anti-<ENT2>inflammatory</ENT2> mediator, we hypothesized that <ENT1>VIP</ENT1>(-/-) mice would exhibit enhanced <ENT2>inflammatory</ENT2> mediator expression after cystitis.",,,,T,,,,,c,,,,,0.75,,
18483878,1262,22353,D007249,Negative_Correlation,FALSE,A mouse <ENT2>inflammatory</ENT2> cytokine and receptor RT2 profiler array was used to determine regulated transcripts in the urinary bladder of wild type (WT) and <ENT1>VIP</ENT1>(-/-) mice with or without CYP-induced cystitis (150 mg/kg; i.p.; 48 h).,,,,T,,,,,c,,,,,1.0,,
18483878,1262,22353,D007249,Negative_Correlation,FALSE,"The data suggest that in <ENT1>VIP</ENT1>(-/-) mice with bladder inflammation, <ENT2>inflammatory</ENT2> mediators are increased above that observed in WT with CYP.",,,,T,,,,,c,,,,,0.0,,
18503483,1269,D000068338,D016559,Conversion,FALSE,Recovery of <ENT2>tacrolimus</ENT2>-associated brachial neuritis after conversion to <ENT1>everolimus</ENT1> in a pediatric renal transplant recipient--case report and review of the literature.,,,,T,,,,,c,,,,,0.0,,
18503483,1269,D000068338,D016559,Conversion,FALSE,Improvement and eventually full recovery only occurred after <ENT2>TAC</ENT2> was completely discontinued and successfully replaced by <ENT1>everolimus</ENT1>.,,,,T,,,,,c,,,,,0.0,,
18503483,1267,D000068338,D020968,Negative_Correlation,TRUE,Recovery of tacrolimus-associated <ENT2>brachial neuritis</ENT2> after conversion to <ENT1>everolimus</ENT1> in a pediatric renal transplant recipient--case report and review of the literature.,,,,T,,,,,c,,,,,1.0,,
18503483,1270,D016559,D020968,Positive_Correlation,TRUE,Recovery of <ENT1>tacrolimus</ENT1>-associated <ENT2>brachial neuritis</ENT2> after conversion to everolimus in a pediatric renal transplant recipient--case report and review of the literature.,,,,T,,,,,c,,,,,1.0,,
18507837,1280,rs2479717,D001943,Association,TRUE,"CONCLUSION: It is possible that CCND3 <ENT1>rs2479717</ENT1>, or another variant it tags, is associated with prognosis after a diagnosis of <ENT2>breast cancer</ENT2>.",,,,T,,,,,c,,,,,0.0,,
18507837,1281,rs2479717,D003643,Positive_Correlation,TRUE,"RESULTS: The rare allele of the tagging single nucleotide polymorphism (SNP) <ENT1>rs2479717</ENT1> is associated with an increased risk of <ENT2>death</ENT2> (hazard ratio = 1.26 per rare allele carried, 95% confidence interval: 1.12 to 1.42; P = 0.0001), which was not attenuated after adjusting for tumour stage, grade, and treatment.",,,,T,,,,,c,,,,,1.0,,
18507837,1272,D001943,896,Association,TRUE,"METHODS: We examined associations between common germline genetic variation in 13 genes involved in cell cycle control (CCND1, CCND2, <ENT2>CCND3</ENT2>, CCNE1, CDK2 [p33], CDK4, CDK6, CDKN1A [p21, Cip1], CDKN1B [p27, Kip1], CDKN2A [p16], CDKN2B [p15], CDKN2C [p18], and CDKN2D [p19]) and survival among women diagnosed with <ENT1>invasive breast cancer</ENT1> participating in the SEARCH (Studies of Epidemiology and Risk factors in Cancer Heredity) <ENT1>breast cancer</ENT1> study.",,,,T,,Y,,,c,,,,,1.0,,
18507837,1272,D001943,896,Association,TRUE,"CONCLUSION: It is possible that <ENT2>CCND3</ENT2> rs2479717, or another variant it tags, is associated with prognosis after a diagnosis of <ENT1>breast cancer</ENT1>.",,,,T,,,,,c,,,,,0.0,,
18507837,1271,D001943,29964,Association,TRUE,"Elevated expression of the <ENT2>C6orf49</ENT2> transcript was associated with <ENT1>breast cancer</ENT1> survival, adding biological interest to the finding.",,,,T,,,,,c,,,,,1.0,,
18507837,1278,705,896,Association,FALSE,"This SNP is part of a large linkage disequilibrium block, which contains <ENT2>CCND3</ENT2>, <ENT1>BYSL</ENT1>, TRFP, USP49, C6ofr49, FRS3, and PGC.",,,,T,Y,,,,w,,,,,0.0,,
18507837,1274,896,10817,Association,FALSE,"This SNP is part of a large linkage disequilibrium block, which contains <ENT1>CCND3</ENT1>, BYSL, TRFP, USP49, C6ofr49, <ENT2>FRS3</ENT2>, and PGC.",,,,T,Y,,,,w,,,,,0.0,,
18507837,1277,896,55031,Association,FALSE,"This SNP is part of a large linkage disequilibrium block, which contains <ENT1>CCND3</ENT1>, BYSL, <ENT2>TRFP</ENT2>, USP49, C6ofr49, FRS3, and PGC.",,,,T,Y,,,,w,,,,,0.0,,
18507837,1273,896,5225,Association,FALSE,"This SNP is part of a large linkage disequilibrium block, which contains <ENT1>CCND3</ENT1>, BYSL, TRFP, USP49, C6ofr49, FRS3, and <ENT2>PGC</ENT2>.",,,,T,Y,,,,w,,,,,0.0,,
18507837,1276,896,25862,Association,FALSE,"This SNP is part of a large linkage disequilibrium block, which contains <ENT1>CCND3</ENT1>, BYSL, TRFP, <ENT2>USP49</ENT2>, C6ofr49, FRS3, and PGC.",,,,T,Y,,,,w,,,,,0.0,,
18507837,1275,896,29964,Association,FALSE,"This SNP is part of a large linkage disequilibrium block, which contains <ENT1>CCND3</ENT1>, BYSL, TRFP, USP49, <ENT2>C6ofr49</ENT2>, FRS3, and PGC.",,,,T,Y,,,,w,,,,,0.0,,
18541230,1287,D011692,D006402,Positive_Correlation,FALSE,Treatment with antithrombin attenuated the <ENT1>puromycin aminonucleoside</ENT1>-induced <ENT2>hematological abnormalities</ENT2>.,,,,T,,,,,c,,,,,1.0,,
18541230,1288,D011692,D009401,Positive_Correlation,FALSE,Protective effects of antithrombin on <ENT1>puromycin aminonucleoside</ENT1> <ENT2>nephrosis</ENT2> in rats.,,,,T,,,,,c,,,,,1.0,,
18541230,1288,D011692,D009401,Positive_Correlation,FALSE,"We investigated the effects of antithrombin, a plasma inhibitor of coagulation factors, in rats with <ENT1>puromycin aminonucleoside</ENT1>-induced <ENT2>nephrosis</ENT2>, which is an experimental model of human nephrotic syndrome.",,,,T,,,,,c,,,,,1.0,,
18541230,1284,D011692,D009404,Positive_Correlation,FALSE,"We investigated the effects of antithrombin, a plasma inhibitor of coagulation factors, in rats with <ENT1>puromycin aminonucleoside</ENT1>-induced nephrosis, which is an experimental model of human <ENT2>nephrotic syndrome</ENT2>.",,,,T,,,,,c,,,,,1.0,,
18541230,1284,D011692,D009404,Positive_Correlation,FALSE,These findings suggest that thrombin plays an important role in the pathogenesis of <ENT1>puromycin aminonucleoside</ENT1>-induced <ENT2>nephrotic syndrome</ENT2>.,,,,T,,,,,c,,,,,1.0,,
18541230,1283,D011692,29251,Association,TRUE,These findings suggest that <ENT2>thrombin</ENT2> plays an important role in the pathogenesis of <ENT1>puromycin aminonucleoside</ENT1>-induced nephrotic syndrome.,,,,T,,,,,c,,,,,1.0,,
18541230,1294,D011692,D000991,Negative_Correlation,TRUE,Protective effects of <ENT2>antithrombin</ENT2> on <ENT1>puromycin aminonucleoside</ENT1> nephrosis in rats.,,,,T,,,,,c,,,,,0.0,,
18541230,1294,D011692,D000991,Negative_Correlation,TRUE,"We investigated the effects of <ENT2>antithrombin</ENT2>, a plasma inhibitor of coagulation factors, in rats with <ENT1>puromycin aminonucleoside</ENT1>-induced nephrosis, which is an experimental model of human nephrotic syndrome.",,,,T,,Y,,,w,,,,,0.0,,
18541230,1294,D011692,D000991,Negative_Correlation,TRUE,<ENT2>Antithrombin</ENT2> (50 or 500 IU/kg/i.v.) was administered to rats once a day for 10 days immediately after the injection of <ENT1>puromycin aminonucleoside</ENT1> (50 mg/kg/i.v.).,,,,T,,,,,c,,,,,0.0,,
18541230,1294,D011692,D000991,Negative_Correlation,TRUE,Treatment with <ENT2>antithrombin</ENT2> attenuated the <ENT1>puromycin aminonucleoside</ENT1>-induced hematological abnormalities.,,,,T,Y,,,,c,,,,,0.0,,
18541230,1294,D011692,D000991,Negative_Correlation,TRUE,"In addition, <ENT2>antithrombin</ENT2> treatment markedly suppressed <ENT1>puromycin aminonucleoside</ENT1>-induced apoptosis of renal tubular epithelial cells.",,,,T,,,,,c,,,,,0.0,,
18541230,1286,D011692,D007674,Positive_Correlation,FALSE,<ENT1>Puromycin aminonucleoside</ENT1>-induced <ENT2>renal dysfunction</ENT2> and hyperlipidemia were also suppressed.,,,,T,,,,,c,,,,,1.0,,
18541230,1285,D011692,D006949,Positive_Correlation,FALSE,<ENT1>Puromycin aminonucleoside</ENT1>-induced renal dysfunction and <ENT2>hyperlipidemia</ENT2> were also suppressed.,,,,T,,,,,c,,,,,0.0,,
18541230,1292,D006402,D000991,Negative_Correlation,TRUE,Treatment with <ENT2>antithrombin</ENT2> attenuated the puromycin aminonucleoside-induced <ENT1>hematological abnormalities</ENT1>.,,,,T,,,,,c,,,,,1.0,,
18541230,1293,D009401,D000991,Negative_Correlation,TRUE,Protective effects of <ENT2>antithrombin</ENT2> on puromycin aminonucleoside <ENT1>nephrosis</ENT1> in rats.,,,,T,,,,,c,,,,,0.0,,
18541230,1293,D009401,D000991,Negative_Correlation,TRUE,"We investigated the effects of <ENT2>antithrombin</ENT2>, a plasma inhibitor of coagulation factors, in rats with puromycin aminonucleoside-induced <ENT1>nephrosis</ENT1>, which is an experimental model of human nephrotic syndrome.",,,,T,,Y,,,w,,,,,0.0,,
18541230,1282,D009404,29251,Association,TRUE,These findings suggest that <ENT2>thrombin</ENT2> plays an important role in the pathogenesis of puromycin aminonucleoside-induced <ENT1>nephrotic syndrome</ENT1>.,,,,T,,,,,c,,,,,1.0,,
18541230,1289,D009404,D000991,Negative_Correlation,TRUE,"We investigated the effects of <ENT2>antithrombin</ENT2>, a plasma inhibitor of coagulation factors, in rats with puromycin aminonucleoside-induced nephrosis, which is an experimental model of human <ENT1>nephrotic syndrome</ENT1>.",,,,T,,,,,c,,,,,1.0,,
18541230,1289,D009404,D000991,Negative_Correlation,TRUE,Treatment with <ENT2>antithrombin</ENT2> may be clinically effective in patients with <ENT1>nephrotic syndrome</ENT1>.,,,,T,,,,,c,,,,,1.0,,
18541230,1291,D000991,D007674,Negative_Correlation,TRUE,"Histopathological examination revealed severe <ENT2>renal damage</ENT2> such as proteinaceous casts in tubuli and tubular expansion in the kidney of control rats, while an improvement of the damage was seen in <ENT1>antithrombin</ENT1>-treated rats.",,,,T,,,,,c,,,,,1.0,,
18544179;18544179,1296;1295,C009250;C009250,D010149;D020250,Positive_Correlation;Positive_Correlation,FALSE;FALSE,METHODS: This double-blind study examined the incidence and severity of <ENT2>postoperative nausea and vomiting and pain</ENT2> in the first 24 h after <ENT1>sevoflurane</ENT1> anaesthesia in 216 adult day surgery patients.,,,,T,,,,,c,,,,,0.0,,
18544179,1296,C009250,D010149,Positive_Correlation,FALSE,"CONCLUSION: As fentanyl exacerbated postoperative nausea and vomiting without an improvement in <ENT2>postoperative pain</ENT2> and also had adverse cardiorespiratory effects, it appears to be an unnecessary and possibly detrimental supplement to <ENT1>sevoflurane</ENT1> in day surgery.",,,,T,,,,,c,,,,,1.0,,
18544179,1295,C009250,D020250,Positive_Correlation,FALSE,"BACKGROUND AND OBJECTIVE: Despite advantages of induction and maintenance of anaesthesia with <ENT1>sevoflurane</ENT1>, <ENT2>postoperative nausea and vomiting</ENT2> occurs frequently.",,,,T,,,,,w,,,,,0.0,,
18544179,1295,C009250,D020250,Positive_Correlation,FALSE,"CONCLUSION: As fentanyl exacerbated <ENT2>postoperative nausea and vomiting</ENT2> without an improvement in postoperative pain and also had adverse cardiorespiratory effects, it appears to be an unnecessary and possibly detrimental supplement to <ENT1>sevoflurane</ENT1> in day surgery.",,,,T,,,,,c,,,,,1.0,,
18544179,1304,C009250,D005283,Cotreatment,TRUE,"Omitting <ENT2>fentanyl</ENT2> reduces nausea and vomiting, without increasing pain, after <ENT1>sevoflurane</ENT1> for day surgery.",,,,T,,,,,w,,,,,1.0,,
18544179,1304,C009250,D005283,Cotreatment,TRUE,"<ENT2>Fentanyl</ENT2> did reduce minor intraoperative movement but had no <ENT1>sevoflurane</ENT1>-sparing effect and increased respiratory depression, hypotension and bradycardia.",,,,T,,,,,w,,,,,1.0,,
18544179,1304,C009250,D005283,Cotreatment,TRUE,"CONCLUSION: As <ENT2>fentanyl</ENT2> exacerbated postoperative nausea and vomiting without an improvement in postoperative pain and also had adverse cardiorespiratory effects, it appears to be an unnecessary and possibly detrimental supplement to <ENT1>sevoflurane</ENT1> in day surgery.",,,,T,,,,,c,,,,,0.0,,
18544179,1299,D012131,D005283,Positive_Correlation,TRUE,"<ENT2>Fentanyl</ENT2> did reduce minor intraoperative movement but had no sevoflurane-sparing effect and increased <ENT1>respiratory depression</ENT1>, hypotension and bradycardia.",,,,T,,,,,c,,,,,1.0,,
18544179,1303,D020250,D005283,Positive_Correlation,TRUE,"RESULTS: Omission of <ENT2>fentanyl</ENT2> did not reduce the overall incidence of <ENT1>postoperative nausea and vomiting</ENT1>, but did reduce the incidence of vomiting and/or moderate to severe nausea prior to discharge from 20% and 17% with <ENT2>fentanyl</ENT2> and <ENT2>fentanyl</ENT2>-dexamethasone, respectively, to 5% (P = 0.013).",,,,T,,,,,w,,,,,0.666666667,,
18544179,1303,D020250,D005283,Positive_Correlation,TRUE,"Combining the two <ENT2>fentanyl</ENT2> groups revealed further significant benefits from the avoidance of opioids, reducing <ENT1>postoperative nausea and vomiting</ENT1> and nausea prior to discharge from 35% and 33% to 22% and 19% (P = 0.049 and P = 0.035), respectively, while nausea in the first 24 h was decreased from 42% to 27% (P = 0.034).",,,,T,,,,,c,,,,,0.0,,
18544179,1303,D020250,D005283,Positive_Correlation,TRUE,"CONCLUSION: As <ENT2>fentanyl</ENT2> exacerbated <ENT1>postoperative nausea and vomiting</ENT1> without an improvement in postoperative pain and also had adverse cardiorespiratory effects, it appears to be an unnecessary and possibly detrimental supplement to sevoflurane in day surgery.",,,,T,,,,,c,,,,,1.0,,
18544179,1300,D005283,D003907,Cotreatment,FALSE,"Patients were randomly allocated to either receive or not receive 1 1 <ENT1>fentanyl</ENT1>, while a third group received <ENT2>dexamethasone</ENT2> in addition to <ENT1>fentanyl</ENT1>.",,,,T,,,,,c,,,,,0.0,,
18544179,1300,D005283,D003907,Cotreatment,FALSE,"RESULTS: Omission of <ENT1>fentanyl</ENT1> did not reduce the overall incidence of postoperative nausea and vomiting, but did reduce the incidence of vomiting and/or moderate to severe nausea prior to discharge from 20% and 17% with <ENT1>fentanyl</ENT1> and <ENT1>fentanyl</ENT1>-<ENT2>dexamethasone</ENT2>, respectively, to 5% (P = 0.013).",,,,T,,,,,w,,,,,0.333333333,,
18544179,1298,D005283,D007022,Positive_Correlation,TRUE,"<ENT1>Fentanyl</ENT1> did reduce minor intraoperative movement but had no sevoflurane-sparing effect and increased respiratory depression, <ENT2>hypotension</ENT2> and bradycardia.",,,,T,,,,,c,,,,,1.0,,
18544179,1302,D005283,D014839,Positive_Correlation,TRUE,"Omitting <ENT1>fentanyl</ENT1> reduces nausea and <ENT2>vomiting</ENT2>, without increasing pain, after sevoflurane for day surgery.",,,,T,,,,,c,,,,,1.0,,
18544179,1302,D005283,D014839,Positive_Correlation,TRUE,"RESULTS: Omission of <ENT1>fentanyl</ENT1> did not reduce the overall incidence of postoperative nausea and vomiting, but did reduce the incidence of <ENT2>vomiting</ENT2> and/or moderate to severe nausea prior to discharge from 20% and 17% with <ENT1>fentanyl</ENT1> and <ENT1>fentanyl</ENT1>-dexamethasone, respectively, to 5% (P = 0.013).",,,,T,,,,,c,,,,,1.0,,
18544179,1301,D005283,D009325,Positive_Correlation,TRUE,"Omitting <ENT1>fentanyl</ENT1> reduces <ENT2>nausea</ENT2> and vomiting, without increasing pain, after sevoflurane for day surgery.",,,,T,,,,,c,,,,,1.0,,
18544179,1301,D005283,D009325,Positive_Correlation,TRUE,"RESULTS: Omission of <ENT1>fentanyl</ENT1> did not reduce the overall incidence of postoperative nausea and vomiting, but did reduce the incidence of vomiting and/or moderate to severe <ENT2>nausea</ENT2> prior to discharge from 20% and 17% with <ENT1>fentanyl</ENT1> and <ENT1>fentanyl</ENT1>-dexamethasone, respectively, to 5% (P = 0.013).",,,,T,,,,,c,,,,,1.0,,
18544179,1301,D005283,D009325,Positive_Correlation,TRUE,"Combining the two <ENT1>fentanyl</ENT1> groups revealed further significant benefits from the avoidance of opioids, reducing postoperative nausea and vomiting and <ENT2>nausea</ENT2> prior to discharge from 35% and 33% to 22% and 19% (P = 0.049 and P = 0.035), respectively, while <ENT2>nausea</ENT2> in the first 24 h was decreased from 42% to 27% (P = 0.034).",,,,T,,,,,c,,,,,0.5,,
18544179,1297,D005283,D001919,Positive_Correlation,TRUE,"<ENT1>Fentanyl</ENT1> did reduce minor intraoperative movement but had no sevoflurane-sparing effect and increased respiratory depression, hypotension and <ENT2>bradycardia</ENT2>.",,,,T,,,,,c,,,,,1.0,,
18593936,1346,595,D003474,Negative_Correlation,TRUE,"Moreover, using RNA interference with small inhibitory RNAs for Sp1, Sp3, and Sp4, we observed that <ENT2>curcumin</ENT2>-dependent inhibition of nuclear factor kappaB (NF-kappaB)-dependent genes, such as bcl-2, survivin, and <ENT1>cyclin D1</ENT1>, was also due, in part, to loss of Sp proteins.",,,,T,,,,,c,,,,,1.0,,
18593936,1328,595,6671,Association,TRUE,"Moreover, using RNA interference with small inhibitory RNAs for Sp1, Sp3, and <ENT2>Sp4</ENT2>, we observed that curcumin-dependent inhibition of nuclear factor kappaB (NF-kappaB)-dependent genes, such as bcl-2, survivin, and <ENT1>cyclin D1</ENT1>, was also due, in part, to loss of <ENT2>Sp</ENT2> proteins.",,,,T,,,,,c,,,,,0.0,,
18593936,1315,595,4790,Association,FALSE,"Moreover, using RNA interference with small inhibitory RNAs for Sp1, Sp3, and Sp4, we observed that curcumin-dependent inhibition of <ENT2>nuclear factor kappaB</ENT2> (<ENT2>NF-kappaB</ENT2>)-dependent genes, such as bcl-2, survivin, and <ENT1>cyclin D1</ENT1>, was also due, in part, to loss of Sp proteins.",,,,T,,,,,w,,,,,0.0,,
18593936,1333,595,6670,Association,TRUE,"Moreover, using RNA interference with small inhibitory RNAs for Sp1, <ENT2>Sp3</ENT2>, and Sp4, we observed that curcumin-dependent inhibition of nuclear factor kappaB (NF-kappaB)-dependent genes, such as bcl-2, survivin, and <ENT1>cyclin D1</ENT1>, was also due, in part, to loss of <ENT2>Sp</ENT2> proteins.",,,,T,,,,,c,,,,,0.0,,
18593936,1338,595,6667,Association,TRUE,"Moreover, using RNA interference with small inhibitory RNAs for <ENT2>Sp1</ENT2>, Sp3, and Sp4, we observed that curcumin-dependent inhibition of nuclear factor kappaB (NF-kappaB)-dependent genes, such as bcl-2, survivin, and <ENT1>cyclin D1</ENT1>, was also due, in part, to loss of <ENT2>Sp</ENT2> proteins.",,,,T,,,,,c,,,,,0.0,,
18593936,1342,20688,D003474,Negative_Correlation,TRUE,"<ENT2>Curcumin</ENT2> also decreased bladder tumor growth in athymic nude mice bearing KU7 cells as xenografts and this was accompanied by decreased Sp1, Sp3, and <ENT1>Sp4</ENT1> protein levels in tumors.",,,,T,,,,,c,,,,,1.0,,
18593936,1309,20688,D001749,Association,TRUE,"Curcumin also decreased <ENT2>bladder tumor</ENT2> growth in athymic nude mice bearing KU7 cells as xenografts and this was accompanied by decreased Sp1, Sp3, and <ENT1>Sp4</ENT1> protein levels in tumors.",,,,T,,,,,c,,,,,0.0,,
18593936,1306,20688,D009369,Association,FALSE,"Curcumin also decreased bladder tumor growth in athymic nude mice bearing KU7 cells as xenografts and this was accompanied by decreased Sp1, Sp3, and <ENT1>Sp4</ENT1> protein levels in <ENT2>tumors</ENT2>.",,,,T,,,,,c,,,,,0.0,,
18593936,1352,D003474,7422,Negative_Correlation,TRUE,"In this study, 10 to 25 micromol/L <ENT1>curcumin</ENT1> inhibited 253JB-V and KU7 bladder cancer cell growth, and this was accompanied by induction of apoptosis and decreased expression of the proapoptotic protein survivin and the <ENT2>angiogenic proteins</ENT2> <ENT2>vascular endothelial growth factor</ENT2> (<ENT2>VEGF</ENT2>) and VEGF receptor 1 (VEGFR1).",,,,T,,,,,c,,,,,0.333333333,,
18593936,1352,D003474,7422,Negative_Correlation,TRUE,"Because expression of survivin, <ENT2>VEGF</ENT2>, and VEGFR1 are dependent on specificity protein (Sp) transcription factors, we also investigated the effects of <ENT1>curcumin</ENT1> on Sp protein expression as an underlying mechanism for the apoptotic and antiangiogenic activity of this compound.",,,,T,,,,,c,,,,,1.0,,
18593936,1345,D003474,D001749,Negative_Correlation,TRUE,<ENT1>Curcumin</ENT1> decreases specificity protein expression in <ENT2>bladder cancer</ENT2> cells.,,,,T,,,,,c,,,,,1.0,,
18593936,1345,D003474,D001749,Negative_Correlation,TRUE,"In this study, 10 to 25 micromol/L <ENT1>curcumin</ENT1> inhibited 253JB-V and KU7 <ENT2>bladder cancer</ENT2> cell growth, and this was accompanied by induction of apoptosis and decreased expression of the proapoptotic protein survivin and the angiogenic proteins vascular endothelial growth factor (VEGF) and VEGF receptor 1 (VEGFR1).",,,,T,,,,,c,,,,,1.0,,
18593936,1345,D003474,D001749,Negative_Correlation,TRUE,"<ENT1>Curcumin</ENT1> also decreased <ENT2>bladder tumor</ENT2> growth in athymic nude mice bearing KU7 cells as xenografts and this was accompanied by decreased Sp1, Sp3, and Sp4 protein levels in tumors.",,,,T,,,,,c,,,,,1.0,,
18593936,1345,D003474,D001749,Negative_Correlation,TRUE,"These results show for the first time that one of the underlying mechanisms of action of <ENT1>curcumin</ENT1> as a cancer chemotherapeutic agent is due, in part, to decreased expression of Sp transcription factors in <ENT2>bladder cancer</ENT2> cells.",,,,T,,,,,c,,,,,1.0,,
18593936,1350,D003474,332,Negative_Correlation,TRUE,"In this study, 10 to 25 micromol/L <ENT1>curcumin</ENT1> inhibited 253JB-V and KU7 bladder cancer cell growth, and this was accompanied by induction of apoptosis and decreased expression of the <ENT2>proapoptotic protein</ENT2> <ENT2>survivin</ENT2> and the angiogenic proteins vascular endothelial growth factor (VEGF) and VEGF receptor 1 (VEGFR1).",,,,T,,,,,c,,,,,1.0,,
18593936,1350,D003474,332,Negative_Correlation,TRUE,"Because expression of <ENT2>survivin</ENT2>, VEGF, and VEGFR1 are dependent on specificity protein (Sp) transcription factors, we also investigated the effects of <ENT1>curcumin</ENT1> on Sp protein expression as an underlying mechanism for the apoptotic and antiangiogenic activity of this compound.",,,,T,,,,,c,,,,,1.0,,
18593936,1350,D003474,332,Negative_Correlation,TRUE,"Moreover, using RNA interference with small inhibitory RNAs for Sp1, Sp3, and Sp4, we observed that <ENT1>curcumin</ENT1>-dependent inhibition of nuclear factor kappaB (NF-kappaB)-dependent genes, such as bcl-2, <ENT2>survivin</ENT2>, and cyclin D1, was also due, in part, to loss of Sp proteins.",,,,T,,,,,c,,,,,1.0,,
18593936,1349,D003474,5698,Association,TRUE,"The results show that <ENT1>curcumin</ENT1> induced <ENT2>proteasome</ENT2>-dependent down-regulation of Sp1, Sp3, and Sp4 in 253JB-V and KU7 cells.",,,,T,Y,,,,c,,,,,0.0,,
18593936;18593936;18593936,1353;1354;1355,D003474;D003474;D003474,6671;6670;6667,Negative_Correlation;Negative_Correlation;Negative_Correlation,TRUE;TRUE;TRUE,<ENT1>Curcumin</ENT1> decreases <ENT2>specificity protein</ENT2> expression in bladder cancer cells.,,,,T,,,,,c,,,,,1.0,,
18593936;18593936;18593936,1353;1354;1355,D003474;D003474;D003474,6671;6670;6667,Negative_Correlation;Negative_Correlation;Negative_Correlation,TRUE;TRUE;TRUE,"Because expression of survivin, VEGF, and VEGFR1 are dependent on <ENT2>specificity protein (Sp) transcription factors</ENT2>, we also investigated the effects of <ENT1>curcumin</ENT1> on <ENT2>Sp</ENT2> protein expression as an underlying mechanism for the apoptotic and antiangiogenic activity of this compound.",,,,T,,,,,c,,,,,1.0,,
18593936,1353,D003474,6671,Negative_Correlation,TRUE,"The results show that <ENT1>curcumin</ENT1> induced proteasome-dependent down-regulation of Sp1, Sp3, and <ENT2>Sp4</ENT2> in 253JB-V and KU7 cells.",,,,T,,,,,c,,,,,1.0,,
18593936,1353,D003474,6671,Negative_Correlation,TRUE,"Moreover, using RNA interference with small inhibitory RNAs for Sp1, Sp3, and <ENT2>Sp4</ENT2>, we observed that <ENT1>curcumin</ENT1>-dependent inhibition of nuclear factor kappaB (NF-kappaB)-dependent genes, such as bcl-2, survivin, and cyclin D1, was also due, in part, to loss of <ENT2>Sp</ENT2> proteins.",,,,T,,,,,c,,,,,1.0,,
18593936;18593936;18593936,1353;1354;1355,D003474;D003474;D003474,6671;6670;6667,Negative_Correlation;Negative_Correlation;Negative_Correlation,TRUE;TRUE;TRUE,"These results show for the first time that one of the underlying mechanisms of action of <ENT1>curcumin</ENT1> as a cancer chemotherapeutic agent is due, in part, to decreased expression of <ENT2>Sp transcription factors</ENT2> in bladder cancer cells.",,,,T,,,,,c,,,,,1.0,,
18593936,1348,D003474,4790,Association,FALSE,"Moreover, using RNA interference with small inhibitory RNAs for Sp1, Sp3, and Sp4, we observed that <ENT1>curcumin</ENT1>-dependent inhibition of <ENT2>nuclear factor kappaB</ENT2> (<ENT2>NF-kappaB</ENT2>)-dependent genes, such as bcl-2, survivin, and cyclin D1, was also due, in part, to loss of Sp proteins.",,,,T,,,,,w,,,,,0.0,,
18593936,1354,D003474,6670,Negative_Correlation,TRUE,"The results show that <ENT1>curcumin</ENT1> induced proteasome-dependent down-regulation of Sp1, <ENT2>Sp3</ENT2>, and Sp4 in 253JB-V and KU7 cells.",,,,T,,,,,c,,,,,1.0,,
18593936,1354,D003474,6670,Negative_Correlation,TRUE,"Moreover, using RNA interference with small inhibitory RNAs for Sp1, <ENT2>Sp3</ENT2>, and Sp4, we observed that <ENT1>curcumin</ENT1>-dependent inhibition of nuclear factor kappaB (NF-kappaB)-dependent genes, such as bcl-2, survivin, and cyclin D1, was also due, in part, to loss of <ENT2>Sp</ENT2> proteins.",,,,T,,,,,c,,,,,1.0,,
18593936,1355,D003474,6667,Negative_Correlation,TRUE,"The results show that <ENT1>curcumin</ENT1> induced proteasome-dependent down-regulation of <ENT2>Sp1</ENT2>, Sp3, and Sp4 in 253JB-V and KU7 cells.",,,,T,,,,,c,,,,,1.0,,
18593936,1355,D003474,6667,Negative_Correlation,TRUE,"Moreover, using RNA interference with small inhibitory RNAs for <ENT2>Sp1</ENT2>, Sp3, and Sp4, we observed that <ENT1>curcumin</ENT1>-dependent inhibition of nuclear factor kappaB (NF-kappaB)-dependent genes, such as bcl-2, survivin, and cyclin D1, was also due, in part, to loss of <ENT2>Sp</ENT2> proteins.",,,,T,,,,,c,,,,,1.0,,
18593936,1344,D003474,20683,Negative_Correlation,TRUE,"<ENT1>Curcumin</ENT1> also decreased bladder tumor growth in athymic nude mice bearing KU7 cells as xenografts and this was accompanied by decreased <ENT2>Sp1</ENT2>, Sp3, and Sp4 protein levels in tumors.",,,,T,,,,,c,,,,,1.0,,
18593936,1305,D003474,D009369,Negative_Correlation,TRUE,"<ENT1>Curcumin</ENT1> also decreased bladder tumor growth in athymic nude mice bearing KU7 cells as xenografts and this was accompanied by decreased Sp1, Sp3, and Sp4 protein levels in <ENT2>tumors</ENT2>.",,,,T,,,,,w,,,,,0.0,,
18593936,1305,D003474,D009369,Negative_Correlation,TRUE,"These results show for the first time that one of the underlying mechanisms of action of <ENT1>curcumin</ENT1> as a <ENT2>cancer</ENT2> chemotherapeutic agent is due, in part, to decreased expression of Sp transcription factors in bladder cancer cells.",,,,T,,,,,c,,,,,1.0,,
18593936,1351,D003474,2321,Negative_Correlation,TRUE,"In this study, 10 to 25 micromol/L <ENT1>curcumin</ENT1> inhibited 253JB-V and KU7 bladder cancer cell growth, and this was accompanied by induction of apoptosis and decreased expression of the proapoptotic protein survivin and the <ENT2>angiogenic proteins</ENT2> vascular endothelial growth factor (VEGF) and <ENT2>VEGF receptor 1</ENT2> (<ENT2>VEGFR1</ENT2>).",,,,T,,,,,c,,,,,0.666666667,,
18593936,1351,D003474,2321,Negative_Correlation,TRUE,"Because expression of survivin, VEGF, and <ENT2>VEGFR1</ENT2> are dependent on specificity protein (Sp) transcription factors, we also investigated the effects of <ENT1>curcumin</ENT1> on Sp protein expression as an underlying mechanism for the apoptotic and antiangiogenic activity of this compound.",,,,T,,,,,c,,,,,1.0,,
18593936,1347,D003474,596,Negative_Correlation,TRUE,"Moreover, using RNA interference with small inhibitory RNAs for Sp1, Sp3, and Sp4, we observed that <ENT1>curcumin</ENT1>-dependent inhibition of nuclear factor kappaB (NF-kappaB)-dependent genes, such as <ENT2>bcl-2</ENT2>, survivin, and cyclin D1, was also due, in part, to loss of Sp proteins.",,,,T,,,,,c,,,,,1.0,,
18593936,1343,D003474,20687,Negative_Correlation,TRUE,"<ENT1>Curcumin</ENT1> also decreased bladder tumor growth in athymic nude mice bearing KU7 cells as xenografts and this was accompanied by decreased Sp1, <ENT2>Sp3</ENT2>, and Sp4 protein levels in tumors.",,,,T,,,,,c,,,,,1.0,,
18593936,1314,7422,D001749,Association,TRUE,"In this study, 10 to 25 micromol/L curcumin inhibited 253JB-V and KU7 <ENT2>bladder cancer</ENT2> cell growth, and this was accompanied by induction of apoptosis and decreased expression of the proapoptotic protein survivin and the <ENT1>angiogenic proteins</ENT1> <ENT1>vascular endothelial growth factor</ENT1> (<ENT1>VEGF</ENT1>) and VEGF receptor 1 (VEGFR1).",,,,T,Y,,,,c,,,,,0.0,,
18593936;18593936;18593936,1324;1325;1326,7422;7422;7422,6671;6670;6667,Association;Association;Association,FALSE;FALSE;FALSE,"Because expression of survivin, <ENT1>VEGF</ENT1>, and VEGFR1 are dependent on <ENT2>specificity protein (Sp) transcription factors</ENT2>, we also investigated the effects of curcumin on <ENT2>Sp</ENT2> protein expression as an underlying mechanism for the apoptotic and antiangiogenic activity of this compound.",,,,T,,,,,c,,,,,0.5,,
18593936,1312,D001749,332,Association,TRUE,"In this study, 10 to 25 micromol/L curcumin inhibited 253JB-V and KU7 <ENT1>bladder cancer</ENT1> cell growth, and this was accompanied by induction of apoptosis and decreased expression of the <ENT2>proapoptotic protein</ENT2> <ENT2>survivin</ENT2> and the angiogenic proteins vascular endothelial growth factor (VEGF) and VEGF receptor 1 (VEGFR1).",,,,T,,,,,c,,,,,0.0,,
18593936;18593936;18593936,1327;1332;1337,D001749;D001749;D001749,6671;6670;6667,Association;Association;Association,FALSE;FALSE;FALSE,Curcumin decreases <ENT2>specificity protein</ENT2> expression in <ENT1>bladder cancer</ENT1> cells.,,,,T,,,,,w,,,,,1.0,,
18593936;18593936;18593936,1327;1332;1337,D001749;D001749;D001749,6671;6670;6667,Association;Association;Association,FALSE;FALSE;FALSE,"These results show for the first time that one of the underlying mechanisms of action of curcumin as a cancer chemotherapeutic agent is due, in part, to decreased expression of <ENT2>Sp transcription factors</ENT2> in <ENT1>bladder cancer</ENT1> cells.",,,,T,,,,,c,,,,,0.0,,
18593936,1311,D001749,20683,Association,TRUE,"Curcumin also decreased <ENT1>bladder tumor</ENT1> growth in athymic nude mice bearing KU7 cells as xenografts and this was accompanied by decreased <ENT2>Sp1</ENT2>, Sp3, and Sp4 protein levels in tumors.",,,,T,,,,,c,,,,,0.0,,
18593936,1313,D001749,2321,Association,TRUE,"In this study, 10 to 25 micromol/L curcumin inhibited 253JB-V and KU7 <ENT1>bladder cancer</ENT1> cell growth, and this was accompanied by induction of apoptosis and decreased expression of the proapoptotic protein survivin and the <ENT2>angiogenic proteins</ENT2> vascular endothelial growth factor (VEGF) and <ENT2>VEGF receptor 1</ENT2> (<ENT2>VEGFR1</ENT2>).",,,,T,Y,,,,c,,,,,0.0,,
18593936,1310,D001749,20687,Association,TRUE,"Curcumin also decreased <ENT1>bladder tumor</ENT1> growth in athymic nude mice bearing KU7 cells as xenografts and this was accompanied by decreased Sp1, <ENT2>Sp3</ENT2>, and Sp4 protein levels in tumors.",,,,T,,,,,c,,,,,0.0,,
18593936;18593936;18593936,1331;1336;1341,332;332;332,6671;6670;6667,Association;Association;Association,TRUE;TRUE;TRUE,"Because expression of <ENT1>survivin</ENT1>, VEGF, and VEGFR1 are dependent on <ENT2>specificity protein (Sp) transcription factors</ENT2>, we also investigated the effects of curcumin on <ENT2>Sp</ENT2> protein expression as an underlying mechanism for the apoptotic and antiangiogenic activity of this compound.",,,,T,,,,,c,,,,,0.5,,
18593936,1331,332,6671,Association,TRUE,"Moreover, using RNA interference with small inhibitory RNAs for Sp1, Sp3, and <ENT2>Sp4</ENT2>, we observed that curcumin-dependent inhibition of nuclear factor kappaB (NF-kappaB)-dependent genes, such as bcl-2, <ENT1>survivin</ENT1>, and cyclin D1, was also due, in part, to loss of <ENT2>Sp</ENT2> proteins.",,,,T,,,,,c,,,,,0.0,,
18593936,1317,332,4790,Association,FALSE,"Moreover, using RNA interference with small inhibitory RNAs for Sp1, Sp3, and Sp4, we observed that curcumin-dependent inhibition of <ENT2>nuclear factor kappaB</ENT2> (<ENT2>NF-kappaB</ENT2>)-dependent genes, such as bcl-2, <ENT1>survivin</ENT1>, and cyclin D1, was also due, in part, to loss of Sp proteins.",,,,T,,,,,c,,,,,0.0,,
18593936,1336,332,6670,Association,TRUE,"Moreover, using RNA interference with small inhibitory RNAs for Sp1, <ENT2>Sp3</ENT2>, and Sp4, we observed that curcumin-dependent inhibition of nuclear factor kappaB (NF-kappaB)-dependent genes, such as bcl-2, <ENT1>survivin</ENT1>, and cyclin D1, was also due, in part, to loss of <ENT2>Sp</ENT2> proteins.",,,,T,,,,,c,,,,,0.0,,
18593936,1341,332,6667,Association,TRUE,"Moreover, using RNA interference with small inhibitory RNAs for <ENT2>Sp1</ENT2>, Sp3, and Sp4, we observed that curcumin-dependent inhibition of nuclear factor kappaB (NF-kappaB)-dependent genes, such as bcl-2, <ENT1>survivin</ENT1>, and cyclin D1, was also due, in part, to loss of <ENT2>Sp</ENT2> proteins.",,,,T,,,,,c,,,,,0.0,,
18593936,1318,5698,6671,Association,FALSE,"The results show that curcumin induced <ENT1>proteasome</ENT1>-dependent down-regulation of Sp1, Sp3, and <ENT2>Sp4</ENT2> in 253JB-V and KU7 cells.",,,,T,,,,,c,,,,,0.0,,
18593936,1319,5698,6670,Association,FALSE,"The results show that curcumin induced <ENT1>proteasome</ENT1>-dependent down-regulation of Sp1, <ENT2>Sp3</ENT2>, and Sp4 in 253JB-V and KU7 cells.",,,,T,,,,,c,,,,,0.0,,
18593936,1320,5698,6667,Association,FALSE,"The results show that curcumin induced <ENT1>proteasome</ENT1>-dependent down-regulation of <ENT2>Sp1</ENT2>, Sp3, and Sp4 in 253JB-V and KU7 cells.",,,,T,,,,,c,,,,,0.0,,
18593936,1330,6671,4790,Association,TRUE,"Moreover, using RNA interference with small inhibitory RNAs for Sp1, Sp3, and <ENT1>Sp4</ENT1>, we observed that curcumin-dependent inhibition of <ENT2>nuclear factor kappaB</ENT2> (<ENT2>NF-kappaB</ENT2>)-dependent genes, such as bcl-2, survivin, and cyclin D1, was also due, in part, to loss of <ENT1>Sp</ENT1> proteins.",,,,T,,,,,c,,,,,0.0,,
18593936;18593936;18593936,1321;1322;1323,6671;6670;6667,2321;2321;2321,Association;Association;Association,FALSE;FALSE;FALSE,"Because expression of survivin, VEGF, and <ENT2>VEGFR1</ENT2> are dependent on <ENT1>specificity protein (Sp) transcription factors</ENT1>, we also investigated the effects of curcumin on <ENT1>Sp</ENT1> protein expression as an underlying mechanism for the apoptotic and antiangiogenic activity of this compound.",,,,T,,,,,c,,,,,0.5,,
18593936,1329,6671,596,Association,TRUE,"Moreover, using RNA interference with small inhibitory RNAs for Sp1, Sp3, and <ENT1>Sp4</ENT1>, we observed that curcumin-dependent inhibition of nuclear factor kappaB (NF-kappaB)-dependent genes, such as <ENT2>bcl-2</ENT2>, survivin, and cyclin D1, was also due, in part, to loss of <ENT1>Sp</ENT1> proteins.",,,,T,,,,,c,,,,,0.0,,
18593936,1335,4790,6670,Association,TRUE,"Moreover, using RNA interference with small inhibitory RNAs for Sp1, <ENT2>Sp3</ENT2>, and Sp4, we observed that curcumin-dependent inhibition of <ENT1>nuclear factor kappaB</ENT1> (<ENT1>NF-kappaB</ENT1>)-dependent genes, such as bcl-2, survivin, and cyclin D1, was also due, in part, to loss of <ENT2>Sp</ENT2> proteins.",,,,T,,,,,c,,,,,0.25,,
18593936,1340,4790,6667,Association,TRUE,"Moreover, using RNA interference with small inhibitory RNAs for <ENT2>Sp1</ENT2>, Sp3, and Sp4, we observed that curcumin-dependent inhibition of <ENT1>nuclear factor kappaB</ENT1> (<ENT1>NF-kappaB</ENT1>)-dependent genes, such as bcl-2, survivin, and cyclin D1, was also due, in part, to loss of <ENT2>Sp</ENT2> proteins.",,,,T,,,,,c,,,,,0.0,,
18593936,1316,4790,596,Association,FALSE,"Moreover, using RNA interference with small inhibitory RNAs for Sp1, Sp3, and Sp4, we observed that curcumin-dependent inhibition of <ENT1>nuclear factor kappaB</ENT1> (<ENT1>NF-kappaB</ENT1>)-dependent genes, such as <ENT2>bcl-2</ENT2>, survivin, and cyclin D1, was also due, in part, to loss of Sp proteins.",,,,T,,,,,c,,,,,0.0,,
18593936,1334,6670,596,Association,TRUE,"Moreover, using RNA interference with small inhibitory RNAs for Sp1, <ENT1>Sp3</ENT1>, and Sp4, we observed that curcumin-dependent inhibition of nuclear factor kappaB (NF-kappaB)-dependent genes, such as <ENT2>bcl-2</ENT2>, survivin, and cyclin D1, was also due, in part, to loss of <ENT1>Sp</ENT1> proteins.",,,,T,,,,,c,,,,,0.0,,
18593936,1339,6667,596,Association,TRUE,"Moreover, using RNA interference with small inhibitory RNAs for <ENT1>Sp1</ENT1>, Sp3, and Sp4, we observed that curcumin-dependent inhibition of nuclear factor kappaB (NF-kappaB)-dependent genes, such as <ENT2>bcl-2</ENT2>, survivin, and cyclin D1, was also due, in part, to loss of <ENT1>Sp</ENT1> proteins.",,,,T,,,,,c,,,,,0.0,,
18593936,1308,20683,D009369,Association,FALSE,"Curcumin also decreased bladder tumor growth in athymic nude mice bearing KU7 cells as xenografts and this was accompanied by decreased <ENT1>Sp1</ENT1>, Sp3, and Sp4 protein levels in <ENT2>tumors</ENT2>.",,,,T,,,,,c,,,,,0.0,,
18593936,1307,D009369,20687,Association,FALSE,"Curcumin also decreased bladder tumor growth in athymic nude mice bearing KU7 cells as xenografts and this was accompanied by decreased Sp1, <ENT2>Sp3</ENT2>, and Sp4 protein levels in <ENT1>tumors</ENT1>.",,,,T,,,,,c,,,,,0.0,,
18657397,1356,D004827,D010400,Positive_Correlation,FALSE,"After a short period of basal activity recording, <ENT1>epileptic</ENT1> focus was induced by injecting 400IU/2 microl <ENT2>penicillin-G potassium</ENT2> into the left lateral ventricle while the cortical activity was continuously recorded.",,,,T,,,,,c,,,,,1.0,,
18657397,1357,D004827,D010406,Positive_Correlation,FALSE,Detailed spectral profile analysis of <ENT2>penicillin</ENT2>-induced <ENT1>epileptiform activity</ENT1> in anesthetized rats.,,,,T,,,,,c,,,,,1.0,,
18657397,1357,D004827,D010406,Positive_Correlation,FALSE,<ENT2>Penicillin</ENT2> model is a widely used experimental model for <ENT1>epilepsy</ENT1> research.,,,,T,,,,,w,,,,,1.0,,
18657397,1357,D004827,D010406,Positive_Correlation,FALSE,In the present study we aimed to portray a detailed spectral analysis of <ENT2>penicillin</ENT2>-induced <ENT1>epileptiform activity</ENT1> in comparison with basal brain activity in anesthetized Wistar rats.,,,,T,,,,,c,,,,,1.0,,
18657397,1357,D004827,D010406,Positive_Correlation,FALSE,"Basal activity, latent period and the <ENT2>penicillin</ENT2>-induced <ENT1>epileptiform activity</ENT1> periods were then analyzed using both conventional methods and spectral analysis.",,,,T,,,,,c,,,,,0.0,,
18672102,1365,rs146017816,D006345,Association,TRUE,"Nine distinct mutations including one small deletion mutation (46delS), two small insertion mutations (118-119insA and 125-126insAA), and six non-synonymous mutations (A6V, P163S, E359K, P407Q, S429T and <ENT1>A442V</ENT1>) were identified in 12 of the 486 patients (nine with <ENT2>ventricular septal defect</ENT2>, two with Tetralogy of Fallot, and one with endocardial cushion defect).",,,,T,Y,,,,c,,,,,0.0,,
18672102,1364,rs146017816,D013771,Association,TRUE,"Nine distinct mutations including one small deletion mutation (46delS), two small insertion mutations (118-119insA and 125-126insAA), and six non-synonymous mutations (A6V, P163S, E359K, P407Q, S429T and <ENT1>A442V</ENT1>) were identified in 12 of the 486 patients (nine with ventricular septal defect, two with <ENT2>Tetralogy of Fallot</ENT2>, and one with endocardial cushion defect).",,,,T,Y,,,,c,,,,,0.0,,
18672102,1363,rs146017816,D004694,Association,TRUE,"Nine distinct mutations including one small deletion mutation (46delS), two small insertion mutations (118-119insA and 125-126insAA), and six non-synonymous mutations (A6V, P163S, E359K, P407Q, S429T and <ENT1>A442V</ENT1>) were identified in 12 of the 486 patients (nine with ventricular septal defect, two with Tetralogy of Fallot, and one with <ENT2>endocardial cushion defect</ENT2>).",,,,T,Y,,,,c,,,,,0.0,,
18672102,1358,c|INS|1146+25|A,D006345,Association,TRUE,"Interestingly, a nucleotide insertion of <ENT1>c.1146+25insA</ENT1> in exon 6 was detected in five <ENT2>VSD</ENT2> patients, but not in 486 normal healthy controls.",,,,T,Y,,,,c,,,,,0.0,,
18672102,1362,2626,D006331,Association,FALSE,<ENT1>GATA4</ENT1> mutations in 486 Chinese patients with <ENT2>congenital heart disease</ENT2>.,,,,T,,T,,,c,,,,,0.0,,
18672102,1362,2626,D006331,Association,FALSE,Recent studies have reported germline mutations in <ENT1>GATA4</ENT1> gene in some types of <ENT2>congenital heart disease</ENT2> (<ENT2>CHD</ENT2>).,,,,T,,,,,c,,,,,1.0,,
18672102,1362,2626,D006331,Association,FALSE,"However, the prevalence of <ENT1>GATA4</ENT1> mutations in <ENT2>CHD</ENT2> and the correlation between the <ENT1>GATA4</ENT1> genotype and <ENT2>CHD</ENT2> phenotype have not been extensively studied.",,,,T,,,,,c,,,"11,22",,0.0,,
18672102,1362,2626,D006331,Association,FALSE,"We screened germline mutations in the coding exons and the flanking intron sequences of the <ENT1>GATA4</ENT1> gene in 486 <ENT2>CHD</ENT2> patients by denaturing high-performance liquid chromatography (DHPLC), and confirmed the mutations by sequencing.",,,,T,,Y,,,w,,,,,0.0,,
18672102,1362,2626,D006331,Association,FALSE,Our findings are useful in understanding the prevalence of <ENT1>GATA4</ENT1> mutations and the correlation between the <ENT1>GATA4</ENT1> genotype and the <ENT2>CHD</ENT2> phenotype in Chinese patients.,,,,T,,,,,c,,,,,1.0,,
18672102,1383,D006345,|INS|125_126|AA,Association,TRUE,"Nine distinct mutations including one small deletion mutation (46delS), two small insertion mutations (118-119insA and <ENT2>125-126insAA</ENT2>), and six non-synonymous mutations (A6V, P163S, E359K, P407Q, S429T and A442V) were identified in 12 of the 486 patients (nine with <ENT1>ventricular septal defect</ENT1>, two with Tetralogy of Fallot, and one with endocardial cushion defect).",,,,T,Y,,,,c,,,,,0.0,,
18672102,1377,D006345,rs387906769,Association,TRUE,"Nine distinct mutations including one small deletion mutation (46delS), two small insertion mutations (118-119insA and 125-126insAA), and six non-synonymous mutations (A6V, <ENT2>P163S</ENT2>, E359K, P407Q, S429T and A442V) were identified in 12 of the 486 patients (nine with <ENT1>ventricular septal defect</ENT1>, two with Tetralogy of Fallot, and one with endocardial cushion defect).",,,,T,Y,,,,c,,,,,0.0,,
18672102,1386,D006345,|INS|118_119|A,Association,TRUE,"Nine distinct mutations including one small deletion mutation (46delS), two small insertion mutations (<ENT2>118-119insA</ENT2> and 125-126insAA), and six non-synonymous mutations (A6V, P163S, E359K, P407Q, S429T and A442V) were identified in 12 of the 486 patients (nine with <ENT1>ventricular septal defect</ENT1>, two with Tetralogy of Fallot, and one with endocardial cushion defect).",,,,T,Y,,,,c,,,,,0.0,,
18672102,1368,D006345,p|SUB|S|429|T,Association,TRUE,"Nine distinct mutations including one small deletion mutation (46delS), two small insertion mutations (118-119insA and 125-126insAA), and six non-synonymous mutations (A6V, P163S, E359K, P407Q, <ENT2>S429T</ENT2> and A442V) were identified in 12 of the 486 patients (nine with <ENT1>ventricular septal defect</ENT1>, two with Tetralogy of Fallot, and one with endocardial cushion defect).",,,,T,Y,,,,c,,,,,0.0,,
18672102,1389,D006345,|DEL|46|S,Association,TRUE,"Nine distinct mutations including one small deletion mutation (<ENT2>46delS</ENT2>), two small insertion mutations (118-119insA and 125-126insAA), and six non-synonymous mutations (A6V, P163S, E359K, P407Q, S429T and A442V) were identified in 12 of the 486 patients (nine with <ENT1>ventricular septal defect</ENT1>, two with Tetralogy of Fallot, and one with endocardial cushion defect).",,,,T,Y,,,,c,,,,,0.0,,
18672102,1371,D006345,rs115099192,Association,TRUE,"Nine distinct mutations including one small deletion mutation (46delS), two small insertion mutations (118-119insA and 125-126insAA), and six non-synonymous mutations (A6V, P163S, E359K, <ENT2>P407Q</ENT2>, S429T and A442V) were identified in 12 of the 486 patients (nine with <ENT1>ventricular septal defect</ENT1>, two with Tetralogy of Fallot, and one with endocardial cushion defect).",,,,T,Y,,,,c,,,,,0.0,,
18672102,1380,D006345,rs199922907,Association,TRUE,"Nine distinct mutations including one small deletion mutation (46delS), two small insertion mutations (118-119insA and 125-126insAA), and six non-synonymous mutations (<ENT2>A6V</ENT2>, P163S, E359K, P407Q, S429T and A442V) were identified in 12 of the 486 patients (nine with <ENT1>ventricular septal defect</ENT1>, two with Tetralogy of Fallot, and one with endocardial cushion defect).",,,,T,Y,,,,c,,,,,0.0,,
18672102,1374,D006345,rs368489876,Association,TRUE,"Nine distinct mutations including one small deletion mutation (46delS), two small insertion mutations (118-119insA and 125-126insAA), and six non-synonymous mutations (A6V, P163S, <ENT2>E359K</ENT2>, P407Q, S429T and A442V) were identified in 12 of the 486 patients (nine with <ENT1>ventricular septal defect</ENT1>, two with Tetralogy of Fallot, and one with endocardial cushion defect).",,,,T,Y,,,,c,,,,,0.0,,
18672102,1374,D006345,rs368489876,Association,TRUE,"Of them, two patients carrying <ENT2>E359K</ENT2> mutation were from two generations in one family with <ENT1>ventricular septal defect</ENT1> (<ENT1>VSD</ENT1>).",,,,T,Y,,,,c,,,,,0.0,,
18672102,1382,|INS|125_126|AA,D013771,Association,TRUE,"Nine distinct mutations including one small deletion mutation (46delS), two small insertion mutations (118-119insA and <ENT1>125-126insAA</ENT1>), and six non-synonymous mutations (A6V, P163S, E359K, P407Q, S429T and A442V) were identified in 12 of the 486 patients (nine with ventricular septal defect, two with <ENT2>Tetralogy of Fallot</ENT2>, and one with endocardial cushion defect).",,,,T,Y,,,,c,,,,,0.0,,
18672102,1381,|INS|125_126|AA,D004694,Association,TRUE,"Nine distinct mutations including one small deletion mutation (46delS), two small insertion mutations (118-119insA and <ENT1>125-126insAA</ENT1>), and six non-synonymous mutations (A6V, P163S, E359K, P407Q, S429T and A442V) were identified in 12 of the 486 patients (nine with ventricular septal defect, two with Tetralogy of Fallot, and one with <ENT2>endocardial cushion defect</ENT2>).",,,,T,Y,,,,c,,,,,0.0,,
18672102,1376,rs387906769,D013771,Association,TRUE,"Nine distinct mutations including one small deletion mutation (46delS), two small insertion mutations (118-119insA and 125-126insAA), and six non-synonymous mutations (A6V, <ENT1>P163S</ENT1>, E359K, P407Q, S429T and A442V) were identified in 12 of the 486 patients (nine with ventricular septal defect, two with <ENT2>Tetralogy of Fallot</ENT2>, and one with endocardial cushion defect).",,,,T,Y,,,,c,,,,,0.0,,
18672102,1375,rs387906769,D004694,Association,TRUE,"Nine distinct mutations including one small deletion mutation (46delS), two small insertion mutations (118-119insA and 125-126insAA), and six non-synonymous mutations (A6V, <ENT1>P163S</ENT1>, E359K, P407Q, S429T and A442V) were identified in 12 of the 486 patients (nine with ventricular septal defect, two with Tetralogy of Fallot, and one with <ENT2>endocardial cushion defect</ENT2>).",,,,T,Y,,,,c,,,,,0.0,,
18672102,1385,|INS|118_119|A,D013771,Association,TRUE,"Nine distinct mutations including one small deletion mutation (46delS), two small insertion mutations (<ENT1>118-119insA</ENT1> and 125-126insAA), and six non-synonymous mutations (A6V, P163S, E359K, P407Q, S429T and A442V) were identified in 12 of the 486 patients (nine with ventricular septal defect, two with <ENT2>Tetralogy of Fallot</ENT2>, and one with endocardial cushion defect).",,,,T,Y,,,,c,,,,,0.0,,
18672102,1384,|INS|118_119|A,D004694,Association,TRUE,"Nine distinct mutations including one small deletion mutation (46delS), two small insertion mutations (<ENT1>118-119insA</ENT1> and 125-126insAA), and six non-synonymous mutations (A6V, P163S, E359K, P407Q, S429T and A442V) were identified in 12 of the 486 patients (nine with ventricular septal defect, two with Tetralogy of Fallot, and one with <ENT2>endocardial cushion defect</ENT2>).",,,,T,Y,,,,c,,,,,0.0,,
18672102,1367,p|SUB|S|429|T,D013771,Association,TRUE,"Nine distinct mutations including one small deletion mutation (46delS), two small insertion mutations (118-119insA and 125-126insAA), and six non-synonymous mutations (A6V, P163S, E359K, P407Q, <ENT1>S429T</ENT1> and A442V) were identified in 12 of the 486 patients (nine with ventricular septal defect, two with <ENT2>Tetralogy of Fallot</ENT2>, and one with endocardial cushion defect).",,,,T,Y,,,,c,,,,,0.0,,
18672102,1366,p|SUB|S|429|T,D004694,Association,TRUE,"Nine distinct mutations including one small deletion mutation (46delS), two small insertion mutations (118-119insA and 125-126insAA), and six non-synonymous mutations (A6V, P163S, E359K, P407Q, <ENT1>S429T</ENT1> and A442V) were identified in 12 of the 486 patients (nine with ventricular septal defect, two with Tetralogy of Fallot, and one with <ENT2>endocardial cushion defect</ENT2>).",,,,T,Y,,,,c,,,,,0.0,,
18672102,1388,|DEL|46|S,D013771,Association,TRUE,"Nine distinct mutations including one small deletion mutation (<ENT1>46delS</ENT1>), two small insertion mutations (118-119insA and 125-126insAA), and six non-synonymous mutations (A6V, P163S, E359K, P407Q, S429T and A442V) were identified in 12 of the 486 patients (nine with ventricular septal defect, two with <ENT2>Tetralogy of Fallot</ENT2>, and one with endocardial cushion defect).",,,,T,Y,,,,c,,,,,0.0,,
18672102,1387,|DEL|46|S,D004694,Association,TRUE,"Nine distinct mutations including one small deletion mutation (<ENT1>46delS</ENT1>), two small insertion mutations (118-119insA and 125-126insAA), and six non-synonymous mutations (A6V, P163S, E359K, P407Q, S429T and A442V) were identified in 12 of the 486 patients (nine with ventricular septal defect, two with Tetralogy of Fallot, and one with <ENT2>endocardial cushion defect</ENT2>).",,,,T,Y,,,,c,,,,,0.0,,
18672102,1370,D013771,rs115099192,Association,TRUE,"Nine distinct mutations including one small deletion mutation (46delS), two small insertion mutations (118-119insA and 125-126insAA), and six non-synonymous mutations (A6V, P163S, E359K, <ENT2>P407Q</ENT2>, S429T and A442V) were identified in 12 of the 486 patients (nine with ventricular septal defect, two with <ENT1>Tetralogy of Fallot</ENT1>, and one with endocardial cushion defect).",,,,T,Y,,,,c,,,,,0.0,,
18672102,1379,D013771,rs199922907,Association,TRUE,"Nine distinct mutations including one small deletion mutation (46delS), two small insertion mutations (118-119insA and 125-126insAA), and six non-synonymous mutations (<ENT2>A6V</ENT2>, P163S, E359K, P407Q, S429T and A442V) were identified in 12 of the 486 patients (nine with ventricular septal defect, two with <ENT1>Tetralogy of Fallot</ENT1>, and one with endocardial cushion defect).",,,,T,Y,,,,c,,,,,0.0,,
18672102,1373,D013771,rs368489876,Association,TRUE,"Nine distinct mutations including one small deletion mutation (46delS), two small insertion mutations (118-119insA and 125-126insAA), and six non-synonymous mutations (A6V, P163S, <ENT2>E359K</ENT2>, P407Q, S429T and A442V) were identified in 12 of the 486 patients (nine with ventricular septal defect, two with <ENT1>Tetralogy of Fallot</ENT1>, and one with endocardial cushion defect).",,,,T,Y,,,,c,,,,,0.0,,
18672102,1369,D004694,rs115099192,Association,TRUE,"Nine distinct mutations including one small deletion mutation (46delS), two small insertion mutations (118-119insA and 125-126insAA), and six non-synonymous mutations (A6V, P163S, E359K, <ENT2>P407Q</ENT2>, S429T and A442V) were identified in 12 of the 486 patients (nine with ventricular septal defect, two with Tetralogy of Fallot, and one with <ENT1>endocardial cushion defect</ENT1>).",,,,T,Y,,,,c,,,,,0.0,,
18672102,1378,D004694,rs199922907,Association,TRUE,"Nine distinct mutations including one small deletion mutation (46delS), two small insertion mutations (118-119insA and 125-126insAA), and six non-synonymous mutations (<ENT2>A6V</ENT2>, P163S, E359K, P407Q, S429T and A442V) were identified in 12 of the 486 patients (nine with ventricular septal defect, two with Tetralogy of Fallot, and one with <ENT1>endocardial cushion defect</ENT1>).",,,,T,Y,,,,c,,,,,0.0,,
18672102,1372,D004694,rs368489876,Association,TRUE,"Nine distinct mutations including one small deletion mutation (46delS), two small insertion mutations (118-119insA and 125-126insAA), and six non-synonymous mutations (A6V, P163S, <ENT2>E359K</ENT2>, P407Q, S429T and A442V) were identified in 12 of the 486 patients (nine with ventricular septal defect, two with Tetralogy of Fallot, and one with <ENT1>endocardial cushion defect</ENT1>).",,,,T,Y,,,,c,,,,,0.0,,
18674790,1415,D009765,25708,Association,TRUE,"Mechanistic studies revealed that <ENT1>OB</ENT1> rats are sensitized due to: (1) higher oxyradical stress leading to upregulation of <ENT2>uncoupling proteins 2 and 3</ENT2>, (2) downregulation of cardiac peroxisome proliferators activated receptor-alpha, (3) decreased plasma adiponectin levels, (4) decreased cardiac fatty-acid oxidation (666.9+/-14.0 nmol/min/g heart in ND versus 400.2+/-11.8 nmol/min/g heart in <ENT1>OB</ENT1>), (5) decreased mitochondrial AMP-alpha2 protein kinase, and (6) 86% drop in cardiac ATP levels accompanied by decreased ATP/ADP ratio after doxorubicin administration.",,,,T,Y,,,,c,,,,,0.5,,
18674790,1405,D009765,D004041,Positive_Correlation,TRUE,High <ENT2>fat</ENT2> diet-fed <ENT1>obese</ENT1> rats are highly sensitive to doxorubicin-induced cardiotoxicity.,,,,T,,,,,w,,,,,1.0,,
18674790,1405,D009765,D004041,Positive_Correlation,TRUE,"In the current study, we investigated whether a physiological intervention by feeding 40% high <ENT2>fat</ENT2> diet (HFD), which induces <ENT1>obesity</ENT1> in male Sprague-Dawley rats (250-275 g), sensitizes to doxorubicin-induced cardiotoxicity.",,,,T,,,,,c,,,,,1.0,,
18674790,1413,D009765,25747,Association,TRUE,"Mechanistic studies revealed that <ENT1>OB</ENT1> rats are sensitized due to: (1) higher oxyradical stress leading to upregulation of uncoupling proteins 2 and 3, (2) downregulation of cardiac <ENT2>peroxisome proliferators activated receptor-alpha</ENT2>, (3) decreased plasma adiponectin levels, (4) decreased cardiac fatty-acid oxidation (666.9+/-14.0 nmol/min/g heart in ND versus 400.2+/-11.8 nmol/min/g heart in <ENT1>OB</ENT1>), (5) decreased mitochondrial AMP-alpha2 protein kinase, and (6) 86% drop in cardiac ATP levels accompanied by decreased ATP/ADP ratio after doxorubicin administration.",,,,T,Y,,,,c,,,,,0.0,,
18674790,1411,D009765,D000255,Negative_Correlation,TRUE,"Mechanistic studies revealed that <ENT1>OB</ENT1> rats are sensitized due to: (1) higher oxyradical stress leading to upregulation of uncoupling proteins 2 and 3, (2) downregulation of cardiac peroxisome proliferators activated receptor-alpha, (3) decreased plasma adiponectin levels, (4) decreased cardiac fatty-acid oxidation (666.9+/-14.0 nmol/min/g heart in ND versus 400.2+/-11.8 nmol/min/g heart in <ENT1>OB</ENT1>), (5) decreased mitochondrial AMP-alpha2 protein kinase, and (6) 86% drop in cardiac <ENT2>ATP</ENT2> levels accompanied by decreased <ENT2>ATP</ENT2>/ADP ratio after doxorubicin administration.",,,,T,Y,,,,c,,,,,0.75,,
18674790,1411,D009765,D000255,Negative_Correlation,TRUE,"In conclusion, HFD-induced <ENT1>obese</ENT1> rats are highly sensitized to doxorubicin-induced cardiotoxicity by substantially downregulating cardiac mitochondrial <ENT2>ATP</ENT2> generation, increasing oxidative stress and downregulating the JAK/STAT3 pathway.",,,,T,,,,,c,,,,,0.0,,
18674790,1416,D009765,246253,Association,TRUE,"Mechanistic studies revealed that <ENT1>OB</ENT1> rats are sensitized due to: (1) higher oxyradical stress leading to upregulation of uncoupling proteins 2 and 3, (2) downregulation of cardiac peroxisome proliferators activated receptor-alpha, (3) decreased plasma <ENT2>adiponectin</ENT2> levels, (4) decreased cardiac fatty-acid oxidation (666.9+/-14.0 nmol/min/g heart in ND versus 400.2+/-11.8 nmol/min/g heart in <ENT1>OB</ENT1>), (5) decreased mitochondrial AMP-alpha2 protein kinase, and (6) 86% drop in cardiac ATP levels accompanied by decreased ATP/ADP ratio after doxorubicin administration.",,,,T,Y,,,,c,,,,,0.0,,
18674790,1417,D009765,D004317,Positive_Correlation,TRUE,High fat diet-fed <ENT1>obese</ENT1> rats are highly sensitive to <ENT2>doxorubicin</ENT2>-induced cardiotoxicity.,,,,T,,,,,c,,,,,0.0,,
18674790,1417,D009765,D004317,Positive_Correlation,TRUE,"In the current study, we investigated whether a physiological intervention by feeding 40% high fat diet (HFD), which induces <ENT1>obesity</ENT1> in male Sprague-Dawley rats (250-275 g), sensitizes to <ENT2>doxorubicin</ENT2>-induced cardiotoxicity.",,,,T,,Y,,,c,,,,,1.0,,
18674790,1417,D009765,D004317,Positive_Correlation,TRUE,"A LD(10) dose (8 mg <ENT2>doxorubicin</ENT2>/kg, ip) administered on day 43 of the HFD feeding regimen led to higher cardiotoxicity, cardiac dysfunction, lipid peroxidation, and 80% mortality in the <ENT1>obese</ENT1> (<ENT1>OB</ENT1>) rats in the absence of any significant renal or hepatic toxicity.",,,,T,,,,,c,,,,,1.0,,
18674790,1417,D009765,D004317,Positive_Correlation,TRUE,<ENT2>Doxorubicin</ENT2> toxicokinetics studies revealed no change in accumulation of <ENT2>doxorubicin</ENT2> and doxorubicinol (toxic metabolite) in the normal diet-fed (ND) and <ENT1>OB</ENT1> hearts.,,,,T,,,,,c,,,,,1.0,,
18674790,1417,D009765,D004317,Positive_Correlation,TRUE,"Mechanistic studies revealed that <ENT1>OB</ENT1> rats are sensitized due to: (1) higher oxyradical stress leading to upregulation of uncoupling proteins 2 and 3, (2) downregulation of cardiac peroxisome proliferators activated receptor-alpha, (3) decreased plasma adiponectin levels, (4) decreased cardiac fatty-acid oxidation (666.9+/-14.0 nmol/min/g heart in ND versus 400.2+/-11.8 nmol/min/g heart in <ENT1>OB</ENT1>), (5) decreased mitochondrial AMP-alpha2 protein kinase, and (6) 86% drop in cardiac ATP levels accompanied by decreased ATP/ADP ratio after <ENT2>doxorubicin</ENT2> administration.",,,,T,Y,,,,c,,,,,0.5,,
18674790,1417,D009765,D004317,Positive_Correlation,TRUE,"In conclusion, HFD-induced <ENT1>obese</ENT1> rats are highly sensitized to <ENT2>doxorubicin</ENT2>-induced cardiotoxicity by substantially downregulating cardiac mitochondrial ATP generation, increasing oxidative stress and downregulating the JAK/STAT3 pathway.",,,,T,,,,,c,,,,,1.0,,
18674790,1404,D009765,D005227,Association,TRUE,"Mechanistic studies revealed that <ENT1>OB</ENT1> rats are sensitized due to: (1) higher oxyradical stress leading to upregulation of uncoupling proteins 2 and 3, (2) downregulation of cardiac peroxisome proliferators activated receptor-alpha, (3) decreased plasma adiponectin levels, (4) decreased cardiac <ENT2>fatty-acid</ENT2> oxidation (666.9+/-14.0 nmol/min/g heart in ND versus 400.2+/-11.8 nmol/min/g heart in <ENT1>OB</ENT1>), (5) decreased mitochondrial AMP-alpha2 protein kinase, and (6) 86% drop in cardiac ATP levels accompanied by decreased ATP/ADP ratio after doxorubicin administration.",,,,T,Y,,,,c,,,,,0.0,,
18674790,1412,D009765,65248,Association,TRUE,"Mechanistic studies revealed that <ENT1>OB</ENT1> rats are sensitized due to: (1) higher oxyradical stress leading to upregulation of uncoupling proteins 2 and 3, (2) downregulation of cardiac peroxisome proliferators activated receptor-alpha, (3) decreased plasma adiponectin levels, (4) decreased cardiac fatty-acid oxidation (666.9+/-14.0 nmol/min/g heart in ND versus 400.2+/-11.8 nmol/min/g heart in <ENT1>OB</ENT1>), (5) decreased mitochondrial <ENT2>AMP-alpha2 protein kinase</ENT2>, and (6) 86% drop in cardiac ATP levels accompanied by decreased ATP/ADP ratio after doxorubicin administration.",,,,T,Y,,,,c,,,,,0.0,,
18674790,1402,89829,84598,Negative_Correlation,TRUE,Decreased cardiac erythropoietin and increased <ENT1>SOCS3</ENT1> further downregulated the cardioprotective <ENT2>JAK</ENT2>/STAT3 pathway.,,,,T,,,,,c,,,,,1.0,,
18674790,1403,89829,25125,Negative_Correlation,TRUE,Decreased cardiac erythropoietin and increased <ENT1>SOCS3</ENT1> further downregulated the cardioprotective JAK/<ENT2>STAT3</ENT2> pathway.,,,,T,,,,,c,,,,,0.0,,
18674790,1401,84598,25125,Association,FALSE,"This cardioprotection is accompanied by decreased cardiac oxidative stress and triglycerides and increased cardiac fatty-acid oxidation, ATP synthesis, and upregulated <ENT1>JAK</ENT1>/<ENT2>STAT3</ENT2> pathway.",,,,T,,,,,w,,,,,0.0,,
18674790,1401,84598,25125,Association,FALSE,Decreased cardiac erythropoietin and increased SOCS3 further downregulated the cardioprotective <ENT1>JAK</ENT1>/<ENT2>STAT3</ENT2> pathway.,,,,T,,,,,w,,,,,0.0,,
18674790,1401,84598,25125,Association,FALSE,"In conclusion, HFD-induced obese rats are highly sensitized to doxorubicin-induced cardiotoxicity by substantially downregulating cardiac mitochondrial ATP generation, increasing oxidative stress and downregulating the <ENT1>JAK</ENT1>/<ENT2>STAT3</ENT2> pathway.",,,,T,,,,,w,,,,,1.0,,
18674790,1399,84598,24335,Positive_Correlation,TRUE,Decreased cardiac <ENT2>erythropoietin</ENT2> and increased SOCS3 further downregulated the cardioprotective <ENT1>JAK</ENT1>/STAT3 pathway.,,,,T,,,,,c,,,,,0.0,,
18674790,1400,25125,24335,Positive_Correlation,TRUE,Decreased cardiac <ENT2>erythropoietin</ENT2> and increased SOCS3 further downregulated the cardioprotective JAK/<ENT1>STAT3</ENT1> pathway.,,,,T,,,,,c,,,,,0.0,,
18674790,1410,D066126,D004317,Positive_Correlation,FALSE,High fat diet-fed obese rats are highly sensitive to <ENT2>doxorubicin</ENT2>-induced <ENT1>cardiotoxicity</ENT1>.,,,,T,,,,,c,,,,,1.0,,
18674790,1410,D066126,D004317,Positive_Correlation,FALSE,"Often, chemotherapy by <ENT2>doxorubicin</ENT2> (<ENT2>Adriamycin</ENT2>) is limited due to life threatening <ENT1>cardiotoxicity</ENT1> in patients during and posttherapy.",,,,T,,,,,w,,,,,0.0,TRUE,
18674790,1410,D066126,D004317,Positive_Correlation,FALSE,"Recently, we have shown that moderate diet restriction remarkably protects against <ENT2>doxorubicin</ENT2>-induced <ENT1>cardiotoxicity</ENT1>.",,,,T,,,,,c,,,,,1.0,,
18674790,1410,D066126,D004317,Positive_Correlation,FALSE,"In the current study, we investigated whether a physiological intervention by feeding 40% high fat diet (HFD), which induces obesity in male Sprague-Dawley rats (250-275 g), sensitizes to <ENT2>doxorubicin</ENT2>-induced <ENT1>cardiotoxicity</ENT1>.",,,,T,,,,,c,,,,,1.0,,
18674790,1410,D066126,D004317,Positive_Correlation,FALSE,"A LD(10) dose (8 mg <ENT2>doxorubicin</ENT2>/kg, ip) administered on day 43 of the HFD feeding regimen led to higher <ENT1>cardiotoxicity</ENT1>, cardiac dysfunction, lipid peroxidation, and 80% mortality in the obese (OB) rats in the absence of any significant renal or hepatic toxicity.",,,,T,,,,,c,,,,,1.0,,
18674790,1410,D066126,D004317,Positive_Correlation,FALSE,"In conclusion, HFD-induced obese rats are highly sensitized to <ENT2>doxorubicin</ENT2>-induced <ENT1>cardiotoxicity</ENT1> by substantially downregulating cardiac mitochondrial ATP generation, increasing oxidative stress and downregulating the JAK/STAT3 pathway.",,,,T,,,,,c,,,,,1.0,,
18674790,1408,D008055,D004317,Association,TRUE,"A LD(10) dose (8 mg <ENT2>doxorubicin</ENT2>/kg, ip) administered on day 43 of the HFD feeding regimen led to higher cardiotoxicity, cardiac dysfunction, <ENT1>lipid</ENT1> peroxidation, and 80% mortality in the obese (OB) rats in the absence of any significant renal or hepatic toxicity.",,,,T,Y,,,,c,,,,,1.0,,
18674790,1409,D006331,D004317,Positive_Correlation,TRUE,"A LD(10) dose (8 mg <ENT2>doxorubicin</ENT2>/kg, ip) administered on day 43 of the HFD feeding regimen led to higher cardiotoxicity, <ENT1>cardiac dysfunction</ENT1>, lipid peroxidation, and 80% mortality in the obese (OB) rats in the absence of any significant renal or hepatic toxicity.",,,,T,,,,,c,,,,,1.0,,
18674790,1407,D000255,D004317,Negative_Correlation,TRUE,"Mechanistic studies revealed that OB rats are sensitized due to: (1) higher oxyradical stress leading to upregulation of uncoupling proteins 2 and 3, (2) downregulation of cardiac peroxisome proliferators activated receptor-alpha, (3) decreased plasma adiponectin levels, (4) decreased cardiac fatty-acid oxidation (666.9+/-14.0 nmol/min/g heart in ND versus 400.2+/-11.8 nmol/min/g heart in OB), (5) decreased mitochondrial AMP-alpha2 protein kinase, and (6) 86% drop in cardiac <ENT1>ATP</ENT1> levels accompanied by decreased <ENT1>ATP</ENT1>/ADP ratio after <ENT2>doxorubicin</ENT2> administration.",,,,T,,,,,w,,,,,0.5,,
18674790,1407,D000255,D004317,Negative_Correlation,TRUE,"In conclusion, HFD-induced obese rats are highly sensitized to <ENT2>doxorubicin</ENT2>-induced cardiotoxicity by substantially downregulating cardiac mitochondrial <ENT1>ATP</ENT1> generation, increasing oxidative stress and downregulating the JAK/STAT3 pathway.",,,,T,,,,,c,,,,,0.0,,
18674790,1406,D004317,D000244,Association,TRUE,"Mechanistic studies revealed that OB rats are sensitized due to: (1) higher oxyradical stress leading to upregulation of uncoupling proteins 2 and 3, (2) downregulation of cardiac peroxisome proliferators activated receptor-alpha, (3) decreased plasma adiponectin levels, (4) decreased cardiac fatty-acid oxidation (666.9+/-14.0 nmol/min/g heart in ND versus 400.2+/-11.8 nmol/min/g heart in OB), (5) decreased mitochondrial AMP-alpha2 protein kinase, and (6) 86% drop in cardiac ATP levels accompanied by decreased ATP/<ENT2>ADP</ENT2> ratio after <ENT1>doxorubicin</ENT1> administration.",,,,T,,,,,c,,,,,0.0,,
18681856,1420,D006849,7253,Association,FALSE,CONCLUSIONS: <ENT1>Ventriculomegaly</ENT1> and bilateral shortening of the fifth metacarpal bones and the middle phalanges of the fifth fingers might be characteristic features of NAH because of an activating <ENT2>TSHR</ENT2> germline mutation.,,,,T,,,,,c,,,,,1.0,,
18681856,1423,rs121908864,C563786,Positive_Correlation,TRUE,"Expanding clinical spectrum of <ENT2>non-autoimmune hyperthyroidism</ENT2> due to an activating germline mutation, <ENT1>p.M453T</ENT1>, in the thyrotropin receptor gene.",,,,T,,,,,c,,,,,1.0,,
18681856,1422,7253,C563786,Association,FALSE,"Expanding clinical spectrum of <ENT2>non-autoimmune hyperthyroidism</ENT2> due to an activating germline mutation, p.M453T, in the <ENT1>thyrotropin receptor</ENT1> gene.",,,,T,,,,,c,,,,,1.0,,
18681856,1422,7253,C563786,Association,FALSE,OBJECTIVE: To describe clinical and genetic features of a Thai family with <ENT2>non-autoimmune hyperthyroidism</ENT2> (<ENT2>NAH</ENT2>) caused by an activating germline mutation in the <ENT1>thyrotropin receptor</ENT1> (<ENT1>TSHR</ENT1>) gene.,,,,T,,,,,c,,,"11,12,21,22",,1.0,,
18681856,1422,7253,C563786,Association,FALSE,CONCLUSIONS: Ventriculomegaly and bilateral shortening of the fifth metacarpal bones and the middle phalanges of the fifth fingers might be characteristic features of <ENT2>NAH</ENT2> because of an activating <ENT1>TSHR</ENT1> germline mutation.,,,,T,,,,,c,,,,,1.0,,
18779591,1425,D018226,rs72478580,Positive_Correlation,TRUE,"In a prospective study involving 74 <ENT1>MFA</ENT1> patients and 170 control subjects, we identified four patients harboring a heterozygous single nucleotide polymorphism in exon 6 of the PrlR gene, encoding <ENT2>Ile(146)-->Leu</ENT2> substitution in its extracellular domain.",,,,T,,,,,w,,,,,0.0,,
18779591,1430,D018226,5617,Association,TRUE,"<ENT1>Multiple fibroadenomas</ENT1> (<ENT1>MFA</ENT1>) are benign breast tumors which appear most frequently in young women, including at puberty, when <ENT2>Prl</ENT2> has well-recognized proliferative actions on the breast.",,,,T,,,,,c,,,,,0.0,,
18779591,1426,D018226,5618,Association,TRUE,"In a prospective study involving 74 <ENT1>MFA</ENT1> patients and 170 control subjects, we identified four patients harboring a heterozygous single nucleotide polymorphism in exon 6 of the <ENT2>PrlR</ENT2> gene, encoding Ile(146)-->Leu substitution in its extracellular domain.",,,,T,,,,,w,,,,,1.0,,
18779591,1432,D001941,5617,Association,TRUE,"Given the essential role of this hormonal system in breast physiology, we reasoned that genetic anomalies of <ENT2>Prl</ENT2>/PrlR genes may be related to the occurrence of <ENT1>breast diseases</ENT1> with high proliferative potential.",,,,T,,,,,c,,,,,1.0,,
18779591,1428,D001941,5618,Association,TRUE,"Given the essential role of this hormonal system in breast physiology, we reasoned that genetic anomalies of Prl/<ENT2>PrlR</ENT2> genes may be related to the occurrence of <ENT1>breast diseases</ENT1> with high proliferative potential.",,,,T,,,,,c,,,,,1.0,,
18779591,1429,D001943,5617,Association,TRUE,"Multiple fibroadenomas (MFA) are <ENT1>benign breast tumors</ENT1> which appear most frequently in young women, including at puberty, when <ENT2>Prl</ENT2> has well-recognized proliferative actions on the breast.",,,,T,,,,,c,,,,,1.0,,
18779591,1424,D001943,5618,Association,TRUE,Identification of a gain-of-function mutation of the <ENT2>prolactin receptor</ENT2> in women with <ENT1>benign breast tumors</ENT1>.,,,,T,,,,,w,,,,,1.0,,
18779591,1431,5617,5618,Bind,FALSE,There is currently no known genetic disease linked to <ENT1>prolactin</ENT1> (<ENT1>Prl</ENT1>) or its receptor (<ENT2>PrlR</ENT2>) in humans.,,,,T,,,,,c,,,,,0.5,,
18779591,1431,5617,5618,Bind,FALSE,"Given the essential role of this hormonal system in breast physiology, we reasoned that genetic anomalies of <ENT1>Prl</ENT1>/<ENT2>PrlR</ENT2> genes may be related to the occurrence of breast diseases with high proliferative potential.",,,,T,Y,,,,w,,,,,0.0,,
18779591,1431,5617,5618,Bind,FALSE,"This sole substitution was sufficient to confer constitutive activity to the receptor variant (PrlR(I146L)), as assessed in three reconstituted cell models (Ba/F3, HEK293 and MCF-7 cells) by <ENT1>Prl</ENT1>-independent (i) <ENT2>PrlR</ENT2> tyrosine phosphorylation, (ii) activation of signal transducer and activator of transcription 5 (STAT5) signaling, (iii) transcriptional activity toward a <ENT1>Prl</ENT1>-responsive reporter gene, and (iv) cell proliferation and protection from cell death.",,,,T,,,,,c,,,,,1.0,,
18779591,1427,5618,6776,Association,TRUE,"This sole substitution was sufficient to confer constitutive activity to the receptor variant (PrlR(I146L)), as assessed in three reconstituted cell models (Ba/F3, HEK293 and MCF-7 cells) by Prl-independent (i) <ENT1>PrlR</ENT1> tyrosine phosphorylation, (ii) activation of <ENT2>signal transducer and activator of transcription 5</ENT2> (<ENT2>STAT5</ENT2>) signaling, (iii) transcriptional activity toward a Prl-responsive reporter gene, and (iv) cell proliferation and protection from cell death.",,,,T,,,,,c,,,,,1.0,,
18779591,1427,5618,6776,Association,TRUE,Constitutive activity of <ENT1>PrlR</ENT1>(I146L) in the breast sample from a patient was supported by increased <ENT2>STAT5</ENT2> signaling.,,,,T,,,,,c,,,,,1.0,,
18808529,1440,24907,11820,Association,FALSE,"Taking into account that the sarcolemmal integrity is stabilized by the <ENT1>dystrophin</ENT1>-<ENT2>glycoprotein</ENT2> complex (DGC) that connects actin and laminin in contractile machinery and extracellular matrix and by integrins, this study tests the hypothesis that isoproterenol affects sarcolemmal stability through changes in the DGC and integrins.",,,,T,,,,,c,,,,,0.0,,
18808529,1444,24907,D007545,Negative_Correlation,TRUE,<ENT2>Isoproterenol</ENT2> induces primary loss of <ENT1>dystrophin</ENT1> in rat hearts: correlation with myocardial injury.,,,,T,,,,,c,,,,,1.0,,
18808529,1444,24907,D007545,Negative_Correlation,TRUE,"Taking into account that the sarcolemmal integrity is stabilized by the <ENT1>dystrophin</ENT1>-glycoprotein complex (DGC) that connects actin and laminin in contractile machinery and extracellular matrix and by integrins, this study tests the hypothesis that <ENT2>isoproterenol</ENT2> affects sarcolemmal stability through changes in the DGC and integrins.",,,,T,,,,,c,,,,,1.0,,
18808529,1444,24907,D007545,Negative_Correlation,TRUE,"In conclusion, administration of <ENT2>isoproterenol</ENT2> to rats results in primary loss of <ENT1>dystrophin</ENT1>, the most sensitive among the structural proteins that form the DGC that connects the extracellular matrix and the cytoskeleton in cardiomyocyte.",,,,T,,,,,c,,,,,1.0,,
18808529,1436,24907,309368,Positive_Correlation,TRUE,"Taking into account that the sarcolemmal integrity is stabilized by the <ENT1>dystrophin</ENT1>-glycoprotein complex (DGC) that connects actin and <ENT2>laminin</ENT2> in contractile machinery and extracellular matrix and by integrins, this study tests the hypothesis that isoproterenol affects sarcolemmal stability through changes in the DGC and integrins.",,,,T,,,,,w,,,,,0.0,,
18808529,1441,24907,D009202,Association,TRUE,Isoproterenol induces primary loss of <ENT1>dystrophin</ENT1> in rat hearts: correlation with <ENT2>myocardial injury</ENT2>.,,,,T,,T,,,c,,,,,0.0,,
18808529,1442,D007545,D007511,Positive_Correlation,FALSE,"These changes, related to <ENT2>ischaemic injury</ENT2>, explain the severe alterations in the structural integrity of the sarcolemma of cardiomyocytes and hence severe and irreversible injury induced by <ENT1>isoproterenol</ENT1>.",,,,T,,,,,c,,,,,0.0,,
18808529,1443,D007545,D009202,Positive_Correlation,FALSE,<ENT1>Isoproterenol</ENT1> induces primary loss of dystrophin in rat hearts: correlation with <ENT2>myocardial injury</ENT2>.,,,,T,,,,,c,,,,,1.0,,
18808529,1443,D007545,D009202,Positive_Correlation,FALSE,"The mechanism of <ENT1>isoproterenol</ENT1>-induced <ENT2>myocardial damage</ENT2> is unknown, but a mismatch of oxygen supply vs. demand following coronary hypotension and <ENT2>myocardial hyperactivity</ENT2> is the best explanation for the complex morphological alterations observed.",,,,T,,,,,c,,,,,1.0,,
18808529,1433,D007022,D010100,Association,FALSE,"The mechanism of isoproterenol-induced myocardial damage is unknown, but a mismatch of <ENT2>oxygen</ENT2> supply vs. demand following coronary <ENT1>hypotension</ENT1> and myocardial hyperactivity is the best explanation for the complex morphological alterations observed.",,,,T,,,,,w,,,,,0.0,,
18808529,1434,D010100,D009202,Association,FALSE,"The mechanism of isoproterenol-induced <ENT2>myocardial damage</ENT2> is unknown, but a mismatch of <ENT1>oxygen</ENT1> supply vs. demand following coronary hypotension and <ENT2>myocardial hyperactivity</ENT2> is the best explanation for the complex morphological alterations observed.",,,,T,,,,,w,,,,,0.5,,
18945288,1447,p|FS|R|58||,D000474,Association,TRUE,<ENT1>R58fs</ENT1> mutation in the HGD gene in a family with <ENT2>alkaptonuria</ENT2> in the UAE.,,,,T,,T,,,w,,,,,0.0,,
18945288,1446,D000474,3081,Association,TRUE,R58fs mutation in the <ENT2>HGD</ENT2> gene in a family with <ENT1>alkaptonuria</ENT1> in the UAE.,,,,T,,T,,,w,,,,,0.0,,
19037252,1449,51196,C537346,Association,FALSE,Mutations in <ENT1>phospholipase C epsilon 1</ENT1> are not sufficient to cause <ENT2>diffuse mesangial sclerosis</ENT2>.,,,,T,,,,,c,,,,,1.0,,
19037252,1449,51196,C537346,Association,FALSE,We conclude this nonpenetrance may be due to compensatory mutations at a second locus and that mutation within <ENT1>PLCE1</ENT1> is not always sufficient to cause <ENT2>diffuse mesangial sclerosis</ENT2>.,,,,T,Y,,,,w,,,,,0.0,,
19048115,1462,7157,4763,Association,TRUE,<ENT2>Neurofibromin 1</ENT2> (<ENT2>NF1</ENT2>) defects are common in human ovarian serous carcinomas and co-occur with <ENT1>TP53</ENT1> mutations.,,,,T,,,,,c,,,,,0.0,,
19048115,1462,7157,4763,Association,TRUE,"The <ENT1>TP53</ENT1> tumor-suppressor gene was mutated in all OSCs with documented <ENT2>NF1</ENT2> mutation, suggesting that the pathways regulated by these two tumor-suppressor proteins often cooperate in the development of ovarian carcinomas with serous differentiation.",,,,T,,,,,c,,,,,0.0,,
19048115,1460,7157,D010051,Association,TRUE,Neurofibromin 1 (NF1) defects are common in human <ENT2>ovarian serous carcinomas</ENT2> and co-occur with <ENT1>TP53</ENT1> mutations.,,,,T,,,,,c,,,,,0.0,,
19048115,1460,7157,D010051,Association,TRUE,"Mutations of <ENT1>TP53</ENT1> and dysfunction of the Brca1 and/or Brca2 tumor-suppressor proteins have been implicated in the molecular pathogenesis of a large fraction of <ENT2>OSCs</ENT2>, but frequent somatic mutations in other well-established tumor-suppressor genes have not been identified.",,,,T,,,,,c,,,,,1.0,,
19048115,1460,7157,D010051,Association,TRUE,"The <ENT1>TP53</ENT1> tumor-suppressor gene was mutated in all <ENT2>OSCs</ENT2> with documented NF1 mutation, suggesting that the pathways regulated by these two tumor-suppressor proteins often cooperate in the development of <ENT2>ovarian carcinomas</ENT2> with serous differentiation.",,,,T,,,,,c,,,,,1.0,,
19048115,1461,7157,D009369,Association,FALSE,"Mutations of <ENT1>TP53</ENT1> and dysfunction of the Brca1 and/or Brca2 <ENT2>tumor</ENT2>-suppressor proteins have been implicated in the molecular pathogenesis of a large fraction of OSCs, but frequent somatic mutations in other well-established <ENT2>tumor</ENT2>-suppressor genes have not been identified.",,,,T,,,,,w,,,,,1.0,,
19048115,1461,7157,D009369,Association,FALSE,"The <ENT1>TP53</ENT1> <ENT2>tumor</ENT2>-suppressor gene was mutated in all OSCs with documented NF1 mutation, suggesting that the pathways regulated by these two <ENT2>tumor</ENT2>-suppressor proteins often cooperate in the development of ovarian carcinomas with serous differentiation.",,,,T,,,,,c,,,,,1.0,,
19048115,1455,672,D010051,Association,FALSE,"Mutations of TP53 and dysfunction of the <ENT1>Brca1</ENT1> and/or Brca2 tumor-suppressor proteins have been implicated in the molecular pathogenesis of a large fraction of <ENT2>OSCs</ENT2>, but frequent somatic mutations in other well-established tumor-suppressor genes have not been identified.",,,,T,,,,,c,,,,,1.0,,
19048115,1458,672,D009369,Association,FALSE,"Mutations of TP53 and dysfunction of the <ENT1>Brca1</ENT1> and/or Brca2 <ENT2>tumor</ENT2>-suppressor proteins have been implicated in the molecular pathogenesis of a large fraction of OSCs, but frequent somatic mutations in other well-established <ENT2>tumor</ENT2>-suppressor genes have not been identified.",,,,T,,,,,c,,,,,0.5,,
19048115,1453,4763,D010051,Association,TRUE,<ENT1>Neurofibromin 1</ENT1> (<ENT1>NF1</ENT1>) defects are common in human <ENT2>ovarian serous carcinomas</ENT2> and co-occur with TP53 mutations.,,,,T,,,,,w,,,,,1.0,,
19048115,1453,4763,D010051,Association,TRUE,"Using a genome-wide screen of DNA copy number alterations in 36 primary <ENT2>OSCs</ENT2>, we identified two tumors with apparent homozygous deletions of the <ENT1>NF1</ENT1> gene.",,,,T,Y,,,,w,,,,,0.0,,
19048115,1453,4763,D010051,Association,TRUE,"Subsequently, 18 <ENT2>ovarian carcinoma</ENT2>-derived cell lines and 41 primary <ENT2>OSCs</ENT2> were evaluated for <ENT1>NF1</ENT1> alterations.",,,,T,,Y,,,c,,,,,1.0,,
19048115,1453,4763,D010051,Association,TRUE,"Similarly, <ENT1>NF1</ENT1> alterations including homozygous deletions and splicing mutations were identified in 9 (22%) of 41 primary <ENT2>OSCs</ENT2>.",,,,T,Y,,,,w,,,,,0.0,,
19048115,1453,4763,D010051,Association,TRUE,"The TP53 tumor-suppressor gene was mutated in all <ENT2>OSCs</ENT2> with documented <ENT1>NF1</ENT1> mutation, suggesting that the pathways regulated by these two tumor-suppressor proteins often cooperate in the development of <ENT2>ovarian carcinomas</ENT2> with serous differentiation.",,,,T,,,,,c,,,,,1.0,,
19048115,1459,4763,D009369,Association,TRUE,"Using a genome-wide screen of DNA copy number alterations in 36 primary OSCs, we identified two <ENT2>tumors</ENT2> with apparent homozygous deletions of the <ENT1>NF1</ENT1> gene.",,,,T,,,,,c,,,,,1.0,,
19048115,1459,4763,D009369,Association,TRUE,"As expected, <ENT2>tumors</ENT2> and cell lines with <ENT1>NF1</ENT1> defects lacked mutations in KRAS or BRAF but showed Ras pathway activation based on immunohistochemical detection of phosphorylated MAPK (primary <ENT2>tumors</ENT2>) or increased levels of GTP-bound Ras (cell lines).",,,,T,,,,,w,,,,,0.5,TRUE,
19048115,1459,4763,D009369,Association,TRUE,"The TP53 <ENT2>tumor</ENT2>-suppressor gene was mutated in all OSCs with documented <ENT1>NF1</ENT1> mutation, suggesting that the pathways regulated by these two <ENT2>tumor</ENT2>-suppressor proteins often cooperate in the development of ovarian carcinomas with serous differentiation.",,,,T,,,,,c,,,,,0.0,,
19048115,1451,5594,D009369,Association,FALSE,"As expected, <ENT2>tumors</ENT2> and cell lines with NF1 defects lacked mutations in KRAS or BRAF but showed Ras pathway activation based on immunohistochemical detection of phosphorylated <ENT1>MAPK</ENT1> (primary <ENT2>tumors</ENT2>) or increased levels of GTP-bound Ras (cell lines).",,,,T,,,,,c,,,,,0.0,,
19048115,1452,D006160,3845,Bind,FALSE,"As expected, tumors and cell lines with NF1 defects lacked mutations in <ENT2>KRAS</ENT2> or BRAF but showed <ENT2>Ras</ENT2> pathway activation based on immunohistochemical detection of phosphorylated MAPK (primary tumors) or increased levels of <ENT1>GTP</ENT1>-bound <ENT2>Ras</ENT2> (cell lines).",,,,T,,,,,c,,,,,0.333333333,,
19048115,1456,3845,D009369,Association,FALSE,"As expected, <ENT2>tumors</ENT2> and cell lines with NF1 defects lacked mutations in <ENT1>KRAS</ENT1> or BRAF but showed <ENT1>Ras</ENT1> pathway activation based on immunohistochemical detection of phosphorylated MAPK (primary <ENT2>tumors</ENT2>) or increased levels of GTP-bound <ENT1>Ras</ENT1> (cell lines).",,,,T,,,,,c,,,,,0.166666667,,
19048115,1454,675,D010051,Association,FALSE,"Mutations of TP53 and dysfunction of the Brca1 and/or <ENT1>Brca2</ENT1> tumor-suppressor proteins have been implicated in the molecular pathogenesis of a large fraction of <ENT2>OSCs</ENT2>, but frequent somatic mutations in other well-established tumor-suppressor genes have not been identified.",,,,T,,,,,c,,,,,1.0,,
19048115,1457,675,D009369,Association,FALSE,"Mutations of TP53 and dysfunction of the Brca1 and/or <ENT1>Brca2</ENT1> <ENT2>tumor</ENT2>-suppressor proteins have been implicated in the molecular pathogenesis of a large fraction of OSCs, but frequent somatic mutations in other well-established <ENT2>tumor</ENT2>-suppressor genes have not been identified.",,,,T,,,,,c,,,,,0.5,,
19067809,1465,D013575,185,Association,TRUE,"RESULTS: AA genotype of A 1166C polymorphism was associated with lower minimal systolic blood pressure (SBP) and diastolic blood pressure (DBP) during HUT compared with other genotypes (minimal SBP: AA 59.6+/-21,8, AC 79.9+/-22.7, CC 65.4+/-22.7 mmHg, P=0.007), (minimal DBP: AA 36.4+/-22.7, AC 52.3+/-22.9, CC 45.4+/-19.5 mmHg, P=0.007).AA genotype was also associated with higher SDNN compared to other genotypes in the early phase of HUT (SDNN in 5 minutes of tilt: AA 59.7+/-24.6, AC 50.6+/-20.6, CC 46.0+/-13.2, P=0.01) and at <ENT1>syncope</ENT1> occurrence (SDNN: AA 71.0+/-20.9, AC 58.2+/-17.9, CC 58+/-10, P=0.04) CONCLUSION: AA genotype of A 1166C polymorphism in the <ENT2>ATR1</ENT2> gene may be associated with hypotension and decline in sympathetic tone during HUT.",,,,T,,,,,w,,,,,1.0,,
19067809,1466,D013575,rs5186,Association,TRUE,"RESULTS: AA genotype of <ENT2>A 1166C</ENT2> polymorphism was associated with lower minimal systolic blood pressure (SBP) and diastolic blood pressure (DBP) during HUT compared with other genotypes (minimal SBP: AA 59.6+/-21,8, AC 79.9+/-22.7, CC 65.4+/-22.7 mmHg, P=0.007), (minimal DBP: AA 36.4+/-22.7, AC 52.3+/-22.9, CC 45.4+/-19.5 mmHg, P=0.007).AA genotype was also associated with higher SDNN compared to other genotypes in the early phase of HUT (SDNN in 5 minutes of tilt: AA 59.7+/-24.6, AC 50.6+/-20.6, CC 46.0+/-13.2, P=0.01) and at <ENT1>syncope</ENT1> occurrence (SDNN: AA 71.0+/-20.9, AC 58.2+/-17.9, CC 58+/-10, P=0.04) CONCLUSION: AA genotype of <ENT2>A 1166C</ENT2> polymorphism in the ATR1 gene may be associated with hypotension and decline in sympathetic tone during HUT.",,,,T,,,,,w,,,,,1.0,,
19067809,1464,185,D007022,Association,TRUE,"RESULTS: AA genotype of A 1166C polymorphism was associated with lower minimal systolic blood pressure (SBP) and diastolic blood pressure (DBP) during HUT compared with other genotypes (minimal SBP: AA 59.6+/-21,8, AC 79.9+/-22.7, CC 65.4+/-22.7 mmHg, P=0.007), (minimal DBP: AA 36.4+/-22.7, AC 52.3+/-22.9, CC 45.4+/-19.5 mmHg, P=0.007).AA genotype was also associated with higher SDNN compared to other genotypes in the early phase of HUT (SDNN in 5 minutes of tilt: AA 59.7+/-24.6, AC 50.6+/-20.6, CC 46.0+/-13.2, P=0.01) and at syncope occurrence (SDNN: AA 71.0+/-20.9, AC 58.2+/-17.9, CC 58+/-10, P=0.04) CONCLUSION: AA genotype of A 1166C polymorphism in the <ENT1>ATR1</ENT1> gene may be associated with <ENT2>hypotension</ENT2> and decline in sympathetic tone during HUT.",,,,T,,,,,c,,,,,1.0,,
19067809,1468,D007022,rs5186,Association,TRUE,"RESULTS: AA genotype of <ENT2>A 1166C</ENT2> polymorphism was associated with lower minimal systolic blood pressure (SBP) and diastolic blood pressure (DBP) during HUT compared with other genotypes (minimal SBP: AA 59.6+/-21,8, AC 79.9+/-22.7, CC 65.4+/-22.7 mmHg, P=0.007), (minimal DBP: AA 36.4+/-22.7, AC 52.3+/-22.9, CC 45.4+/-19.5 mmHg, P=0.007).AA genotype was also associated with higher SDNN compared to other genotypes in the early phase of HUT (SDNN in 5 minutes of tilt: AA 59.7+/-24.6, AC 50.6+/-20.6, CC 46.0+/-13.2, P=0.01) and at syncope occurrence (SDNN: AA 71.0+/-20.9, AC 58.2+/-17.9, CC 58+/-10, P=0.04) CONCLUSION: AA genotype of <ENT2>A 1166C</ENT2> polymorphism in the ATR1 gene may be associated with <ENT1>hypotension</ENT1> and decline in sympathetic tone during HUT.",,,,T,,,,,c,,,,,1.0,,
19082493,1471,D012004,c|INDEL||6,Association,TRUE,"VNTR and <ENT2>ins/del 6 bp</ENT2> genotypes varied with tumour anatomical site: 2R/2R genotype was rare in left-sided tumours (7.0% vs. 26.3% of right-sided and 24.1% of <ENT1>rectal cancers</ENT1>; P<0.01), where the variant allele 6- was very frequent (69.0%).",,,,T,,,,,w,,,,,1.0,,
19082493,1474,7298,D015179,Association,TRUE,Combination of polymorphisms within 5' and 3' untranslated regions of <ENT1>thymidylate synthase</ENT1> gene modulates survival in 5 fluorouracil-treated <ENT2>colorectal cancer</ENT2> patients.,,,,T,,,,,c,,,,,1.0,,
19082493,1474,7298,D015179,Association,TRUE,In the present study we explored the effect of three polymorphisms of the <ENT1>TS</ENT1> gene on overall and progression- free survival of <ENT2>colorectal cancer</ENT2> (<ENT2>CRC</ENT2>) patients subjected to 5FU chemotherapy.,,,,T,,Y,,,c,,,,,0.0,,
19082493,1474,7298,D015179,Association,TRUE,In our study the combination of high <ENT1>TS</ENT1> expression genotypes G_6+/6+ identifies a group of high risk within <ENT2>CRC</ENT2> patients treated with 5FU.,,,,T,,,,,c,,,,,1.0,,
19082493,1473,7298,D005472,Positive_Correlation,TRUE,Combination of polymorphisms within 5' and 3' untranslated regions of <ENT1>thymidylate synthase</ENT1> gene modulates survival in <ENT2>5 fluorouracil</ENT2>-treated colorectal cancer patients.,,,,T,,,,,w,,,,,0.0,,
19082493,1473,7298,D005472,Positive_Correlation,TRUE,In the present study we explored the effect of three polymorphisms of the <ENT1>TS</ENT1> gene on overall and progression- free survival of colorectal cancer (CRC) patients subjected to <ENT2>5FU</ENT2> chemotherapy.,,,,T,,,,,c,,,,,1.0,,
19082493,1473,7298,D005472,Positive_Correlation,TRUE,In our study the combination of high <ENT1>TS</ENT1> expression genotypes G_6+/6+ identifies a group of high risk within CRC patients treated with <ENT2>5FU</ENT2>.,,,,T,,,,,w,,,,,0.0,,
19082493,1479,D015179,D005472,Negative_Correlation,FALSE,Combination of polymorphisms within 5' and 3' untranslated regions of thymidylate synthase gene modulates survival in <ENT2>5 fluorouracil</ENT2>-treated <ENT1>colorectal cancer</ENT1> patients.,,,,T,,,,,c,,,,,1.0,,
19082493,1479,D015179,D005472,Negative_Correlation,FALSE,In the present study we explored the effect of three polymorphisms of the TS gene on overall and progression- free survival of <ENT1>colorectal cancer</ENT1> (<ENT1>CRC</ENT1>) patients subjected to <ENT2>5FU</ENT2> chemotherapy.,,,,T,,,,,c,,,,,1.0,,
19082493,1479,D015179,D005472,Negative_Correlation,FALSE,In our study the combination of high TS expression genotypes G_6+/6+ identifies a group of high risk within <ENT1>CRC</ENT1> patients treated with <ENT2>5FU</ENT2>.,,,,T,,,,,c,,,,,1.0,,
19082493,1475,c|INDEL||6,D009369,Association,TRUE,"VNTR and <ENT1>ins/del 6 bp</ENT1> genotypes varied with <ENT2>tumour</ENT2> anatomical site: 2R/2R genotype was rare in left-sided <ENT2>tumours</ENT2> (7.0% vs. 26.3% of right-sided and 24.1% of rectal cancers; P<0.01), where the variant allele 6- was very frequent (69.0%).",,,,T,,,,,c,,,,,1.0,,
19101703,1485,c|SUB|(GCG)6(GCA)3GCG||(GCG)6(GCA)(GCG)4(GCA)3GCG,D039141,Positive_Correlation,TRUE,The normal <ENT1>(GCG)6(GCA)3GCG sequence was replaced by (GCG)6(GCA)(GCG)4(GCA)3GCG</ENT1> due to an insertion of (GCG)4GCA into the normal allele in the Taiwanese <ENT2>OPMD</ENT2> subjects.,,,,T,,,,,w,,,,,0.0,,
19101703,1484,c|INS|(GCG)4GCA,D039141,Positive_Correlation,TRUE,The normal (GCG)6(GCA)3GCG sequence was replaced by (GCG)6(GCA)(GCG)4(GCA)3GCG due to an <ENT1>insertion of (GCG)4GCA</ENT1> into the normal allele in the Taiwanese <ENT2>OPMD</ENT2> subjects.,,,,T,,,,,w,,,,,0.0,,
19101703,1484,c|INS|(GCG)4GCA,D039141,Positive_Correlation,TRUE,"CONCLUSIONS: In contrast to a single GCG expansion in most of <ENT2>OPMD</ENT2> patients in the literature, an <ENT1>insertion of (GCG)4GCA</ENT1> in the PABPN1 gene was found in the Taiwanese <ENT2>OPMD</ENT2> subjects.",,,,T,,,,,w,,,,,0.0,,
19101703,1481,8106,D039141,Association,FALSE,<ENT2>OPMD</ENT2> is caused by a short trinucleotide repeat expansion encoding an expanded polyalanine tract in the <ENT1>polyadenylate binding-protein nuclear 1</ENT1> (<ENT1>PABPN1</ENT1>) gene.,,,,T,,,,,c,,,,,1.0,,
19101703,1481,8106,D039141,Association,FALSE,We identified and characterized a <ENT1>PABPN1</ENT1> mutation in a Taiwanese family with <ENT2>OPMD</ENT2>.,,,,T,,,,,c,,,,,1.0,,
19101703,1481,8106,D039141,Association,FALSE,RESULTS: Ten subjects with <ENT2>OPMD</ENT2> (6 symptomatic and 4 asymptomatic) within the Taiwanese family carried a novel mutation in the <ENT1>PABPN1</ENT1> gene.,,,,T,,,,,c,,,,,1.0,,
19101703,1481,8106,D039141,Association,FALSE,"CONCLUSIONS: In contrast to a single GCG expansion in most of <ENT2>OPMD</ENT2> patients in the literature, an insertion of (GCG)4GCA in the <ENT1>PABPN1</ENT1> gene was found in the Taiwanese <ENT2>OPMD</ENT2> subjects.",,,,T,,,,,c,,,,,0.5,,
19101703,1482,8106,C019529,Association,FALSE,OPMD is caused by a short trinucleotide repeat expansion encoding an expanded <ENT2>polyalanine</ENT2> tract in the <ENT1>polyadenylate binding-protein nuclear 1</ENT1> (<ENT1>PABPN1</ENT1>) gene.,,,,T,,,,,c,,,,,0.0,,
19101703,1483,D039141,C019529,Association,FALSE,<ENT1>OPMD</ENT1> is caused by a short trinucleotide repeat expansion encoding an expanded <ENT2>polyalanine</ENT2> tract in the polyadenylate binding-protein nuclear 1 (PABPN1) gene.,,,,T,Y,,,,c,,,,,0.0,,
19108278,1491,D004837,D011433,Negative_Correlation,TRUE,"Both isomers of <ENT2>propranolol</ENT2> were capable of preventing <ENT1>adrenaline</ENT1>-induced cardiac arrhythmias in cats anaesthetized with halothane, but the mean dose of (-)-<ENT2>propranolol</ENT2> was 0.09+/-0.02 mg/kg whereas that of (+)-<ENT2>propranolol</ENT2> was 4.2+/-1.2 mg/kg.",,,,T,Y,,,,c,,,,,0.0,,
19108278,1487,D004837,D001145,Positive_Correlation,FALSE,"Both isomers of propranolol were capable of preventing <ENT1>adrenaline</ENT1>-induced <ENT2>cardiac arrhythmias</ENT2> in cats anaesthetized with halothane, but the mean dose of (-)-propranolol was 0.09+/-0.02 mg/kg whereas that of (+)-propranolol was 4.2+/-1.2 mg/kg.",,,,T,,,,,c,,,,,0.0,,
19108278,1487,D004837,D001145,Positive_Correlation,FALSE,Blockade of <ENT2>arrhythmias</ENT2> with both isomers was surmountable by increasing the dose of <ENT1>adrenaline</ENT1>.7.,,,,T,,,,,c,,,,,0.0,,
19108278,1494,D007545,D011433,Negative_Correlation,TRUE,"In blocking the positive inotropic and chronotropic responses to <ENT1>isoprenaline</ENT1>, (+)-<ENT2>propranolol</ENT2> had less than one hundredth the potency of (-)-<ENT2>propranolol</ENT2>.",,,,T,,,,,c,,,,,0.5,,
19108278,1494,D007545,D011433,Negative_Correlation,TRUE,"At dose levels of (+)-<ENT2>propranolol</ENT2> which attenuated the responses to <ENT1>isoprenaline</ENT1>, there was a significant prolongation of the PR interval of the electrocardiogram.3.",,,,T,,,,,c,,,,,1.0,,
19108278,1494,D007545,D011433,Negative_Correlation,TRUE,"The metabolic responses to <ENT1>isoprenaline</ENT1> in dogs (an increase in circulating glucose, lactate and free fatty acids) were all blocked by (-)-<ENT2>propranolol</ENT2>.",,,,T,,,,,c,,,,,1.0,,
19108278,1496,D007545,D019344,Positive_Correlation,FALSE,"The metabolic responses to <ENT1>isoprenaline</ENT1> in dogs (an increase in circulating glucose, <ENT2>lactate</ENT2> and free fatty acids) were all blocked by (-)-propranolol.",,,,T,,,,,c,,,,,0.0,,
19108278,1497,D007545,D005947,Positive_Correlation,FALSE,"The metabolic responses to <ENT1>isoprenaline</ENT1> in dogs (an increase in circulating <ENT2>glucose</ENT2>, lactate and free fatty acids) were all blocked by (-)-propranolol.",,,,T,,,,,c,,,,,1.0,,
19108278,1495,D007545,D005227,Positive_Correlation,FALSE,"The metabolic responses to <ENT1>isoprenaline</ENT1> in dogs (an increase in circulating glucose, lactate and free <ENT2>fatty acids</ENT2>) were all blocked by (-)-propranolol.",,,,T,,,,,c,,,,,0.0,,
19108278,1492,D011433,D019344,Negative_Correlation,TRUE,"The metabolic responses to isoprenaline in dogs (an increase in circulating glucose, <ENT2>lactate</ENT2> and free fatty acids) were all blocked by (-)-<ENT1>propranolol</ENT1>.",,,,T,,,,,c,,,,,1.0,,
19108278,1492,D011433,D019344,Negative_Correlation,TRUE,(+)-<ENT1>Propranolol</ENT1> had no effect on fatty acid mobilization but significantly reduced the increments in both <ENT2>lactate</ENT2> and glucose.4.,,,,T,,,,,c,,,,,1.0,,
19108278,1488,D011433,D010042,Negative_Correlation,TRUE,Both isomers of <ENT1>propranolol</ENT1> were also capable of reversing ventricular tachycardia caused by <ENT2>ouabain</ENT2> in anaesthetized cats and dogs.,,,,T,,,,,c,,,,,0.0,,
19108278,1493,D011433,D005947,Negative_Correlation,TRUE,"The metabolic responses to isoprenaline in dogs (an increase in circulating <ENT2>glucose</ENT2>, lactate and free fatty acids) were all blocked by (-)-<ENT1>propranolol</ENT1>.",,,,T,,,,,c,,,,,1.0,,
19108278,1493,D011433,D005947,Negative_Correlation,TRUE,(+)-<ENT1>Propranolol</ENT1> had no effect on fatty acid mobilization but significantly reduced the increments in both lactate and <ENT2>glucose</ENT2>.4.,,,,T,,,,,c,,,,,1.0,,
19108278,1490,D011433,D001145,Negative_Correlation,TRUE,The biological properties of the optical isomers of <ENT1>propranolol</ENT1> and their effects on <ENT2>cardiac arrhythmias</ENT2>.,,,,T,,,,,c,,,,,0.0,,
19108278,1490,D011433,D001145,Negative_Correlation,TRUE,"Both isomers of <ENT1>propranolol</ENT1> were capable of preventing adrenaline-induced <ENT2>cardiac arrhythmias</ENT2> in cats anaesthetized with halothane, but the mean dose of (-)-<ENT1>propranolol</ENT1> was 0.09+/-0.02 mg/kg whereas that of (+)-<ENT1>propranolol</ENT1> was 4.2+/-1.2 mg/kg.",,,,T,,,,,c,,,,,1.0,,
19108278,1489,D011433,D017180,Negative_Correlation,TRUE,Both isomers of <ENT1>propranolol</ENT1> were also capable of reversing <ENT2>ventricular tachycardia</ENT2> caused by ouabain in anaesthetized cats and dogs.,,,,T,,,,,c,,,,,1.0,,
19108278,1486,D010042,D017180,Positive_Correlation,FALSE,Both isomers of propranolol were also capable of reversing <ENT2>ventricular tachycardia</ENT2> caused by <ENT1>ouabain</ENT1> in anaesthetized cats and dogs.,,,,T,,,,,c,,,,,1.0,,
19160446;19160446,1499;1498,D001714;D003866,5027;5027,Association;Association,FALSE;FALSE,<ENT2>P2RX7</ENT2>: A <ENT1>bipolar and unipolar disorder</ENT1> candidate susceptibility gene?,,,,T,,T,,,c,,,,,1.0,,
19160446,1499,D001714,5027,Association,FALSE,The gene <ENT2>P2RX7</ENT2> is located in this chromosomal region and has been recently reported as a susceptibility gene for <ENT1>bipolar disorder</ENT1> and unipolar depression.,,,,T,,,,,w,,,,,1.0,,
19160446;19160446,1499;1498,D001714;D003866,5027;5027,Association;Association,FALSE;FALSE,"Neither rs2230912 nor any of 8 other SNPs genotyped across <ENT2>P2RX7</ENT2> was found to be associated with mood disorder in general, nor specifically with <ENT1>bipolar or unipolar disorder</ENT1>.",,,,T,,,,,c,,,,,1.0,,
19160446,1498,D003866,5027,Association,FALSE,The gene <ENT2>P2RX7</ENT2> is located in this chromosomal region and has been recently reported as a susceptibility gene for bipolar disorder and <ENT1>unipolar depression</ENT1>.,,,,T,,,,,w,,,,,1.0,,
19207031,1501,D004393,2688,Negative_Correlation,FALSE,<ENT2>Growth hormone</ENT2> dose in <ENT1>growth hormone-deficient</ENT1> adults is not associated with IGF-1 gene polymorphisms.,,,,T,,,,,w,,,,,0.0,,
19207031,1501,D004393,2688,Negative_Correlation,FALSE,"Variance in IGF-1 concentrations due to genetic variations may affect different response to <ENT2>growth hormone</ENT2> (<ENT2>GH</ENT2>) treatment, resulting in different individually required <ENT2>GH</ENT2>-doses in <ENT1>GH-deficient</ENT1> patients.",,,,T,,,,,w,,,,,0.0,,
19207031,1501,D004393,2688,Negative_Correlation,FALSE,The aim of this study was to test if the IGF-1 gene polymorphisms are associated with the <ENT2>GH</ENT2>-dose of <ENT1>GH-deficient</ENT1> adults.,,,,T,,,,,w,,,,,0.0,,
19207031,1501,D004393,2688,Negative_Correlation,FALSE,CONCLUSION: IGF-1 gene polymorphisms were not associated with the responsiveness to exogenous <ENT2>GH</ENT2> in <ENT1>GHD</ENT1>.,,,,T,,,,,c,,,,,1.0,,
19207031,1500,2688,3479,Association,TRUE,<ENT1>Growth hormone</ENT1> dose in growth hormone-deficient adults is not associated with <ENT2>IGF-1</ENT2> gene polymorphisms.,,,,T,,,,,c,,,,,1.0,,
19207031,1500,2688,3479,Association,TRUE,"Variance in <ENT2>IGF-1</ENT2> concentrations due to genetic variations may affect different response to <ENT1>growth hormone</ENT1> (<ENT1>GH</ENT1>) treatment, resulting in different individually required <ENT1>GH</ENT1>-doses in GH-deficient patients.",,,,T,,,,,c,,,,,0.0,,
19207031,1500,2688,3479,Association,TRUE,The aim of this study was to test if the <ENT2>IGF-1</ENT2> gene polymorphisms are associated with the <ENT1>GH</ENT1>-dose of GH-deficient adults.,,,,T,,Y,,,c,,,,,1.0,,
19207031,1500,2688,3479,Association,TRUE,Patients received <ENT1>GH</ENT1>-treatment for 12 months with finished dose-titration of <ENT1>GH</ENT1> and centralized <ENT2>IGF-1</ENT2> measurements.,,,,T,,,,,c,,,,,1.0,,
19207031,1500,2688,3479,Association,TRUE,"<ENT1>GH</ENT1>-dose after 1 year of treatment, <ENT2>IGF-1</ENT2> concentrations, <ENT2>IGF-1</ENT2>-standard deviation score (SDS), the <ENT2>IGF-1</ENT2>:<ENT1>GH</ENT1> ratio and anthropometric data were analyzed by genotype.",,,,T,,,,,c,,,,,1.0,,
19207031,1500,2688,3479,Association,TRUE,"RESULTS: Except for rs1019731, which showed a significant difference of <ENT2>IGF-1</ENT2>-SDS by genotypes (p = 0.02), all polymorphisms showed no associations with the <ENT1>GH</ENT1>-doses, <ENT2>IGF-1</ENT2> concentrations, <ENT2>IGF-1</ENT2>-SDS and <ENT2>IGF-1</ENT2>:<ENT1>GH</ENT1> ratio after adjusting for the confounding variables gender, age and BMI.",,,,T,,,,,c,,,,,1.0,,
19207031,1500,2688,3479,Association,TRUE,CONCLUSION: <ENT2>IGF-1</ENT2> gene polymorphisms were not associated with the responsiveness to exogenous <ENT1>GH</ENT1> in GHD.,,,,T,,,,,c,,,,,1.0,,
19207031,1500,2688,3479,Association,TRUE,"Therefore, genetic variations of the <ENT2>IGF-1</ENT2> gene seem not to be major influencing factors of the <ENT1>GH</ENT1>-<ENT2>IGF</ENT2>-axis causing variable response to exogenous <ENT1>GH</ENT1>-treatment.",,,,T,,,,,c,,,,,1.0,,
19208385,1502,D009140,1278,Association,TRUE,These observations suggest that mutations in this region of the <ENT2>collagen type I alpha 2</ENT2> chain carry a high risk of <ENT1>abnormal limb development</ENT1> and intracranial bleeding.,,,,T,,,,,c,,,,,0.0,,
19208385,1503,D020300,1278,Association,TRUE,Osteogenesis imperfecta type III with <ENT1>intracranial hemorrhage</ENT1> and brachydactyly associated with mutations in exon 49 of <ENT2>COL1A2</ENT2>.,,,,T,,,,,c,,,,,1.0,,
19208385,1503,D020300,1278,Association,TRUE,These observations suggest that mutations in this region of the <ENT2>collagen type I alpha 2</ENT2> chain carry a high risk of abnormal limb development and <ENT1>intracranial bleeding</ENT1>.,,,,T,,,,,c,,,,,1.0,,
19208385,1505,1278,C536044,Association,TRUE,<ENT2>Osteogenesis imperfecta type III</ENT2> with intracranial hemorrhage and brachydactyly associated with mutations in exon 49 of <ENT1>COL1A2</ENT1>.,,,,T,,,,,c,,,,,1.0,,
19208385,1506,1278,D059327,Association,TRUE,Osteogenesis imperfecta type III with intracranial hemorrhage and <ENT2>brachydactyly</ENT2> associated with mutations in exon 49 of <ENT1>COL1A2</ENT1>.,,,,T,,,,,c,,,,,1.0,,
19208385,1504,1278,D010013,Association,TRUE,"In all of these patients, <ENT2>OI</ENT2> was caused by glycine mutations affecting exon 49 of the <ENT1>COL1A2</ENT1> gene, which codes for the most carboxy-terminal part of the triple-helical domain of the <ENT1>collagen type I alpha 2</ENT1> chain.",,,,T,,,,,c,,,,,1.0,,
19234905,1507,D004409,D007980,Positive_Correlation,FALSE,"Ten consecutive patients (mean age, 58.4 +/- 6.8 years; 7 men, 3 women) with similar characteristics at the duration of disease (mean disease time, 8.4 +/- 3.5 years), disabling motor fluctuations (Hoehn _ Yahr stage 3-5 in off-drug phases) and <ENT2>levodopa</ENT2>-induced <ENT1>dyskinesias</ENT1> were selected.",,,,T,,,,,c,,,,,0.0,,
19276632,1523,C537540,14238,Association,FALSE,"Moreover, <ENT2>Foxf2</ENT2> knockout mice present with cleft palate in combination with <ENT1>hypoplasia of the genital tubercle</ENT1>.",,,,T,,,,,c,,,,,1.0,,
19276632,1522,D002972,2295,Association,FALSE,Mutation analysis of <ENT2>FOXF2</ENT2> in patients with disorders of sex development (DSD) in combination with <ENT1>cleft palate</ENT1>.,,,,T,,T,,,c,,,,,1.0,,
19276632,1522,D002972,2295,Association,FALSE,We hypothesized that humans with disorders of sex development (DSD) in combination with <ENT1>cleft palate</ENT1> could have mutations in the <ENT2>FOXF2</ENT2> gene.,,,,T,,,,,c,,,,,1.0,,
19276632,1524,D002972,14238,Association,FALSE,"Moreover, <ENT2>Foxf2</ENT2> knockout mice present with <ENT1>cleft palate</ENT1> in combination with hypoplasia of the genital tubercle.",,,,T,,,,,c,,,,,1.0,,
19276632,1518,D012734,D000728,Negative_Correlation,FALSE,"In contrast to <ENT1>disorders of sexual differentiation</ENT1> caused by lack of <ENT2>androgen</ENT2> production or inhibited <ENT2>androgen</ENT2> action, defects affecting development of the bipotent genital anlagen have rarely been investigated in humans.",,,,T,,,,,c,,,,,0.0,,
19276632,1517,D012734,2295,Association,FALSE,Mutation analysis of <ENT2>FOXF2</ENT2> in patients with <ENT1>disorders of sex development</ENT1> (<ENT1>DSD</ENT1>) in combination with cleft palate.,,,,T,,T,,,w,,,,,0.0,TRUE,
19276632,1517,D012734,2295,Association,FALSE,We hypothesized that humans with <ENT1>disorders of sex development</ENT1> (<ENT1>DSD</ENT1>) in combination with cleft palate could have mutations in the <ENT2>FOXF2</ENT2> gene.,,,,T,,,,,c,,,,,0.5,,
19306381,1549,20779,3084,Positive_Correlation,TRUE,"Both baseline and <ENT2>NRG-1 beta</ENT2>-induced migration were erbB-dependent and required the action of MEK 1/2, SAPK/JNK, PI-3 kinase, <ENT1>Src family kinases</ENT1> and ROCK-I/II.",,,,T,,,,,w,,,,,1.0,,
19306381,1549,20779,3084,Positive_Correlation,TRUE,"While <ENT2>NRG-1 beta</ENT2> potently and persistently activated Erk 1/2, SAPK/JNK, Akt and <ENT1>Src family kinases</ENT1>, <ENT2>NRG-1 alpha</ENT2> did not activate Akt and activated these other kinases with kinetics distinct from those evident in <ENT2>NRG-1 beta</ENT2>-stimulated cells.",,,,T,,,,,c,,,,,0.666666667,,
19306381,1552,5599,3084,Positive_Correlation,TRUE,"Both baseline and <ENT2>NRG-1 beta</ENT2>-induced migration were erbB-dependent and required the action of MEK 1/2, <ENT1>SAPK</ENT1>/<ENT1>JNK</ENT1>, PI-3 kinase, Src family kinases and ROCK-I/II.",,,,T,,,,,w,,,,,1.0,TRUE,
19306381,1552,5599,3084,Positive_Correlation,TRUE,"While <ENT2>NRG-1 beta</ENT2> potently and persistently activated Erk 1/2, <ENT1>SAPK</ENT1>/<ENT1>JNK</ENT1>, Akt and Src family kinases, <ENT2>NRG-1 alpha</ENT2> did not activate Akt and activated these other kinases with kinetics distinct from those evident in <ENT2>NRG-1 beta</ENT2>-stimulated cells.",,,,T,,,,,c,,,,,0.666666667,,
19306381,1545,6093,3084,Association,TRUE,"Both baseline and <ENT2>NRG-1 beta</ENT2>-induced migration were erbB-dependent and required the action of MEK 1/2, SAPK/JNK, PI-3 kinase, Src family kinases and <ENT1>ROCK-I/II</ENT1>.",,,,T,,,,,w,,,,,0.0,,
19306381,1561,3084,13867,Bind,TRUE,"The <ENT1>NRG-1</ENT1> receptors <ENT2>erbB3</ENT2> and erbB4 were present in MPNST invadopodia (processes mediating invasion), partially colocalized with focal adhesion kinase and the laminin receptor beta(1)-integrin and coimmunoprecipitated with beta(1)-integrin.",,,,T,,,,,c,,,,,0.0,,
19306381;19306381,1561;1558,3084;3084,13867;2066,Bind;Bind,TRUE;TRUE,"Both baseline and <ENT1>NRG-1 beta</ENT1>-induced migration were <ENT2>erbB</ENT2>-dependent and required the action of MEK 1/2, SAPK/JNK, PI-3 kinase, Src family kinases and ROCK-I/II.",,,,T,,,,,w,,,,,0.0,,
19306381,1541,3084,5594,Positive_Correlation,TRUE,"While <ENT1>NRG-1 beta</ENT1> potently and persistently activated <ENT2>Erk 1/2</ENT2>, SAPK/JNK, Akt and Src family kinases, <ENT1>NRG-1 alpha</ENT1> did not activate Akt and activated these other kinases with kinetics distinct from those evident in <ENT1>NRG-1 beta</ENT1>-stimulated cells.",,,,T,,,,,c,,,,,0.666666667,,
19306381,1556,3084,26396,Association,TRUE,"Both baseline and <ENT1>NRG-1 beta</ENT1>-induced migration were erbB-dependent and required the action of <ENT2>MEK 1/2</ENT2>, SAPK/JNK, PI-3 kinase, Src family kinases and ROCK-I/II.",,,,T,,,,,w,,,,,0.0,,
19306381,1562,3084,16777,Association,TRUE,"Hypothesizing that <ENT1>NRG-1 beta</ENT1> and/or <ENT1>NRG-1 alpha</ENT1> promote MPNST invasion, we found that <ENT1>NRG-1 beta</ENT1> promoted MPNST migration in a substrate-specific manner, markedly enhancing migration on <ENT2>laminin</ENT2> but not on collagen type I or fibronectin.",,,,T,,,,,c,,,,,0.0,,
19306381,1551,3084,30955,Association,TRUE,"Both baseline and <ENT1>NRG-1 beta</ENT1>-induced migration were erbB-dependent and required the action of MEK 1/2, SAPK/JNK, <ENT2>PI-3 kinase</ENT2>, Src family kinases and ROCK-I/II.",,,,T,,,,,w,,,,,0.0,,
19306381,1567,3084,D018319,Association,TRUE,<ENT1>Neuregulin-1 beta</ENT1> and <ENT1>neuregulin-1 alpha</ENT1> differentially affect the migration and invasion of <ENT2>malignant peripheral nerve sheath tumor</ENT2> cells.,,,,T,,,,,c,,,,,0.5,,
19306381,1567,3084,D018319,Association,TRUE,"We have shown that <ENT2>MPNSTs</ENT2> express <ENT1>neuregulin-1 (NRG-1) beta</ENT1> isoforms, which promote Schwann cell migration during development, and <ENT1>NRG-1 alpha</ENT1> isoforms, whose effects on Schwann cells are poorly understood.",,,,T,,,,,c,,,,,1.0,,
19306381,1567,3084,D018319,Association,TRUE,"Hypothesizing that <ENT1>NRG-1 beta</ENT1> and/or <ENT1>NRG-1 alpha</ENT1> promote <ENT2>MPNST</ENT2> invasion, we found that <ENT1>NRG-1 beta</ENT1> promoted <ENT2>MPNST</ENT2> migration in a substrate-specific manner, markedly enhancing migration on laminin but not on collagen type I or fibronectin.",,,,T,,,,,c,,,,,0.0,,
19306381,1567,3084,D018319,Association,TRUE,"The <ENT1>NRG-1</ENT1> receptors erbB3 and erbB4 were present in <ENT2>MPNST</ENT2> invadopodia (processes mediating invasion), partially colocalized with focal adhesion kinase and the laminin receptor beta(1)-integrin and coimmunoprecipitated with beta(1)-integrin.",,,,T,,,,,w,,,,,1.0,,
19306381,1567,3084,D018319,Association,TRUE,"<ENT1>NRG-1 beta</ENT1> stimulated human and murine <ENT2>MPNST</ENT2> cell migration and invasion in a concentration-dependent manner in three-dimensional migration assays, acting as a chemotactic factor.",,,,T,,,,,c,,,,,0.0,,
19306381,1567,3084,D018319,Association,TRUE,"In contrast, <ENT1>NRG-1 alpha</ENT1> had no effect on the migration and invasion of some <ENT2>MPNST</ENT2> lines and inhibited the migration of others.",,,,T,,,,,c,,,,,1.0,,
19306381,1567,3084,D018319,Association,TRUE,These findings suggest that <ENT1>NRG-1 beta</ENT1> enhances <ENT2>MPNST</ENT2> migration and that <ENT1>NRG-1 beta</ENT1> and <ENT1>NRG-1 alpha</ENT1> differentially modulate this process.,,,,T,,,,,c,,,,,0.0,,
19306381,1558,3084,2066,Bind,TRUE,"The <ENT1>NRG-1</ENT1> receptors erbB3 and <ENT2>erbB4</ENT2> were present in MPNST invadopodia (processes mediating invasion), partially colocalized with focal adhesion kinase and the laminin receptor beta(1)-integrin and coimmunoprecipitated with beta(1)-integrin.",,,,T,,,,,c,,,,,0.0,,
19306381,1539,3084,11651,Positive_Correlation,TRUE,"While <ENT1>NRG-1 beta</ENT1> potently and persistently activated Erk 1/2, SAPK/JNK, <ENT2>Akt</ENT2> and Src family kinases, <ENT1>NRG-1 alpha</ENT1> did not activate <ENT2>Akt</ENT2> and activated these other kinases with kinetics distinct from those evident in <ENT1>NRG-1 beta</ENT1>-stimulated cells.",,,,T,,,,,c,,,,,0.666666667,,
19306381,1526,5747,13867,Association,TRUE,"The NRG-1 receptors <ENT2>erbB3</ENT2> and erbB4 were present in MPNST invadopodia (processes mediating invasion), partially colocalized with <ENT1>focal adhesion kinase</ENT1> and the laminin receptor beta(1)-integrin and coimmunoprecipitated with beta(1)-integrin.",,,,T,,,,,c,,,,,0.0,,
19306381,1564,5747,D018319,Association,TRUE,"The NRG-1 receptors erbB3 and erbB4 were present in <ENT2>MPNST</ENT2> invadopodia (processes mediating invasion), partially colocalized with <ENT1>focal adhesion kinase</ENT1> and the laminin receptor beta(1)-integrin and coimmunoprecipitated with beta(1)-integrin.",,,,T,,,,,w,,,,,0.0,,
19306381,1527,5747,2066,Association,TRUE,"The NRG-1 receptors erbB3 and <ENT2>erbB4</ENT2> were present in MPNST invadopodia (processes mediating invasion), partially colocalized with <ENT1>focal adhesion kinase</ENT1> and the laminin receptor beta(1)-integrin and coimmunoprecipitated with beta(1)-integrin.",,,,T,,,,,c,,,,,0.0,,
19306381,1535,13867,3688,Association,TRUE,"The NRG-1 receptors <ENT1>erbB3</ENT1> and erbB4 were present in MPNST invadopodia (processes mediating invasion), partially colocalized with focal adhesion kinase and the <ENT2>laminin receptor</ENT2> <ENT2>beta(1)-integrin</ENT2> and coimmunoprecipitated with <ENT2>beta(1)-integrin</ENT2>.",,,,T,,,,,c,,,,,0.0,,
19306381,1536,13867,D018319,Association,TRUE,"The NRG-1 receptors <ENT1>erbB3</ENT1> and erbB4 were present in <ENT2>MPNST</ENT2> invadopodia (processes mediating invasion), partially colocalized with focal adhesion kinase and the laminin receptor beta(1)-integrin and coimmunoprecipitated with beta(1)-integrin.",,,,T,,,,,c,,,,,1.0,,
19306381,1566,16777,D018319,Association,TRUE,"Hypothesizing that NRG-1 beta and/or NRG-1 alpha promote <ENT2>MPNST</ENT2> invasion, we found that NRG-1 beta promoted <ENT2>MPNST</ENT2> migration in a substrate-specific manner, markedly enhancing migration on <ENT1>laminin</ENT1> but not on collagen type I or fibronectin.",,,,T,,,,,c,,,,,0.0,,
19306381,1565,3688,D018319,Association,TRUE,"The NRG-1 receptors erbB3 and erbB4 were present in <ENT2>MPNST</ENT2> invadopodia (processes mediating invasion), partially colocalized with focal adhesion kinase and the <ENT1>laminin receptor</ENT1> <ENT1>beta(1)-integrin</ENT1> and coimmunoprecipitated with <ENT1>beta(1)-integrin</ENT1>.",,,,T,,,,,w,,,,,0.666666667,,
19306381,1528,3688,2066,Association,TRUE,"The NRG-1 receptors erbB3 and <ENT2>erbB4</ENT2> were present in MPNST invadopodia (processes mediating invasion), partially colocalized with focal adhesion kinase and the <ENT1>laminin receptor</ENT1> <ENT1>beta(1)-integrin</ENT1> and coimmunoprecipitated with <ENT1>beta(1)-integrin</ENT1>.",,,,T,,,,,c,,,,,0.0,,
19306381,1529,D018319,2066,Association,TRUE,"The NRG-1 receptors erbB3 and <ENT2>erbB4</ENT2> were present in <ENT1>MPNST</ENT1> invadopodia (processes mediating invasion), partially colocalized with focal adhesion kinase and the laminin receptor beta(1)-integrin and coimmunoprecipitated with beta(1)-integrin.",,,,T,,,,,c,,,,,1.0,,
19306381,1563,D018319,4763,Association,FALSE,<ENT1>Malignant peripheral nerve sheath tumors</ENT1> (<ENT1>MPNSTs</ENT1>) are the most common malignancy associated with <ENT2>neurofibromatosis Type 1</ENT2> (<ENT2>NF1</ENT2>).,,,,T,,,,,c,,,"11,12,21,22",,0.0,,
19319147,1570,C025667,D002543,Negative_Correlation,TRUE,We provide experimental data suggesting <ENT1>PCC</ENT1> to be an effective acute treatment for W-<ENT2>ICH</ENT2> in terms of reducing hemorrhagic blood volume.,,,,T,,,,,c,,,,,1.0,,
19319147,1569,C025667,D014859,Negative_Correlation,TRUE,We provide experimental data suggesting <ENT1>PCC</ENT1> to be an effective acute treatment for <ENT2>W</ENT2>-ICH in terms of reducing hemorrhagic blood volume.,,,,T,,,,,c,,,,,0.0,,
19319147,1572,D006470,D017364,Positive_Correlation,FALSE,"Second, a stereotactic injection of <ENT2>collagenase</ENT2> was administered to induce <ENT1>hemorrhage</ENT1> in the right striatum.",,,,T,,,,,c,,,,,0.0,,
19319147,1568,D002543,D014859,Association,FALSE,Rapid reversal of anticoagulation reduces hemorrhage volume in a mouse model of <ENT2>warfarin</ENT2>-associated <ENT1>intracerebral hemorrhage</ENT1>.,,,,T,Y,,,,c,,,,,0.0,,
19319147,1568,D002543,D014859,Association,FALSE,<ENT2>Warfarin</ENT2>-associated <ENT1>intracerebral hemorrhage</ENT1> (<ENT2>W</ENT2>-<ENT1>ICH</ENT1>) is a severe type of stroke.,,,,T,,,,,c,,,"11,22",,0.0,,
19319147,1568,D002543,D014859,Association,FALSE,There is no consensus on the optimal treatment for <ENT2>W</ENT2>-<ENT1>ICH</ENT1>.,,,,T,,,,,w,,,,,0.0,,
19319147,1568,D002543,D014859,Association,FALSE,We provide experimental data suggesting PCC to be an effective acute treatment for <ENT2>W</ENT2>-<ENT1>ICH</ENT1> in terms of reducing hemorrhagic blood volume.,,,,T,,,,,w,,,,,0.0,,
19319147,1568,D002543,D014859,Association,FALSE,Future studies are needed to assess the therapeutic potential emerging from our finding for human <ENT2>W</ENT2>-<ENT1>ICH</ENT1>.,,,,T,,,,,w,,,,,0.0,,
19346865,1574,D008795,D001927,Positive_Correlation,TRUE,Reversible <ENT2>inferior colliculus lesion</ENT2> in <ENT1>metronidazole</ENT1>-induced <ENT2>encephalopathy</ENT2>: magnetic resonance findings on diffusion-weighted and fluid attenuated inversion recovery imaging.,,,,T,,,,,c,,,,,0.5,,
19346865,1574,D008795,D001927,Positive_Correlation,TRUE,"OBJECTIVE: This is to present reversible <ENT2>inferior colliculus lesions</ENT2> in <ENT1>metronidazole</ENT1>-induced <ENT2>encephalopathy</ENT2>, to focus on the diffusion-weighted imaging (DWI) and fluid attenuated inversion recovery (FLAIR) imaging.",,,,T,,,,,c,,,,,0.5,,
19346865,1574,D008795,D001927,Positive_Correlation,TRUE,"MATERIALS AND METHODS: From November 2005 to September 2007, 8 patients (5 men and 3 women) were diagnosed as having <ENT1>metronidazole</ENT1>-induced <ENT2>encephalopathy</ENT2> (age range; 43-78 years).",,,,T,,,,,c,,,,,1.0,,
19346865,1574,D008795,D001927,Positive_Correlation,TRUE,"CONCLUSIONS: Reversible <ENT2>inferior colliculus lesions</ENT2> could be considered as the characteristic for <ENT1>metronidazole</ENT1>-induced <ENT2>encephalopathy</ENT2>, next to the dentate nucleus involvement.",,,,T,,,,,c,,,,,1.0,,
19346865,1573,D008795,D007239,Negative_Correlation,FALSE,"They had been taking <ENT1>metronidazole</ENT1> (total dosage, 45-120 g; duration, 30 days to 2 months) to treat the <ENT2>infection</ENT2> in various organs.",,,,T,,,,,c,,,,,1.0,,
19365571,1577,4166,D003317,Association,FALSE,<ENT2>Macular corneal dystrophy</ENT2> in a Chinese family related with novel mutations of <ENT1>CHST6</ENT1>.,,,,T,,,,,c,,,,,1.0,,
19365571,1577,4166,D003317,Association,FALSE,PURPOSE: To identify mutations in the <ENT1>carbohydrate sulfotransferase gene</ENT1> (<ENT1>CHST6</ENT1>) for a Chinese family with <ENT2>macular corneal dystrophy</ENT2> (<ENT2>MCD</ENT2>) and to investigate the histopathological changes in the affected cornea.,,,,T,,Y,,,c,,,,,0.25,,
19365571,1582,4166,D007632,Association,TRUE,"CONCLUSIONS: Those novel compound heterozygous mutations were thought to contribute to the loss of <ENT1>CHST6</ENT1> function, which induced the abnormal metabolism of <ENT2>keratan sulfate</ENT2> (<ENT2>KS</ENT2>) that deposited in the corneal stroma.",,,,T,,,,,c,,,,,1.0,,
19370764,1597,C565367,84572,Association,TRUE,Identification and molecular characterization of six novel mutations in the <ENT2>UDP-N-acetylglucosamine-1-phosphotransferase gamma subunit</ENT2> (<ENT2>GNPTG</ENT2>) gene in patients with <ENT1>mucolipidosis III gamma</ENT1>.,,,,T,,T,,,w,,,,,1.0,,
19370764,1596,D009081,84572,Negative_Correlation,TRUE,"In a study of 10 patients from seven families with a clinical phenotype and enzymatic diagnosis of <ENT1>MLIII</ENT1>, six novel <ENT2>GNPTG</ENT2> gene mutations were identified.",,,,T,Y,,,,w,,,,,0.0,,
19394258,1598,C580039,1716,Association,TRUE,The first founder <ENT2>DGUOK</ENT2> mutation associated with <ENT1>hepatocerebral mitochondrial DNA depletion syndrome</ENT1>.,,,,T,,,,,c,,,,,1.0,,
19394258,1598,C580039,1716,Association,TRUE,This new <ENT2>DGUOK</ENT2> homozygous mutation (c.444-62C>A) was identified in three patients from two North-African consanguineous families with combined respiratory chain deficiencies and <ENT1>mitochondrial DNA depletion</ENT1> in the liver.,,,,T,,,,,c,,,,,1.0,,
19394258,1600,C580039,c|SUB|C|444-62|A,Association,TRUE,This new DGUOK homozygous mutation (<ENT2>c.444-62C>A</ENT2>) was identified in three patients from two North-African consanguineous families with combined respiratory chain deficiencies and <ENT1>mitochondrial DNA depletion</ENT1> in the liver.,,,,T,,,,,c,,,,,0.0,,
19394258,1599,1716,D028361,Association,TRUE,This new <ENT1>DGUOK</ENT1> homozygous mutation (c.444-62C>A) was identified in three patients from two North-African consanguineous families with combined <ENT2>respiratory chain deficiencies</ENT2> and mitochondrial DNA depletion in the liver.,,,,T,,,,,c,,,,,1.0,,
19394258,1601,D028361,c|SUB|C|444-62|A,Association,TRUE,This new DGUOK homozygous mutation (<ENT2>c.444-62C>A</ENT2>) was identified in three patients from two North-African consanguineous families with combined <ENT1>respiratory chain deficiencies</ENT1> and mitochondrial DNA depletion in the liver.,,,,T,,,,,c,,,,,0.0,,
19445921,1616,D008315,D007545,Positive_Correlation,TRUE,"<ENT2>Isoproterenol</ENT2>-treated rats showed significant increases in the levels of lactate dehydrogenase, aspartate transaminase, creatine kinase and <ENT1>malondialdehyde</ENT1> and significant decreases in the activities of superoxide dismutase, catalase and glutathione peroxidase in serum and heart.",,,,T,,,,,c,,,,,1.0,,
19445921,1610,24264,D007545,Positive_Correlation,TRUE,"<ENT2>Isoproterenol</ENT2>-treated rats showed significant increases in the levels of lactate dehydrogenase, aspartate transaminase, <ENT1>creatine kinase</ENT1> and malondialdehyde and significant decreases in the activities of superoxide dismutase, catalase and glutathione peroxidase in serum and heart.",,,,T,,,,,c,,,,,1.0,,
19445921,1606,D000244,D028361,Association,TRUE,"In addition, <ENT2>mitochondrial respiratory dysfunction</ENT2> characterized by decreased respiratory control ratio and <ENT1>ADP</ENT1>/O was observed in isoproterenol-treated rats.",,,,T,,,,,c,,,,,0.0,,
19445921,1617,D009203,D007545,Positive_Correlation,FALSE,Cardioprotective effect of salvianolic acid A on <ENT2>isoproterenol</ENT2>-induced <ENT1>myocardial infarction</ENT1> in rats.,,,,T,,,,,c,,,,,1.0,,
19445921,1617,D009203,D007545,Positive_Correlation,FALSE,The present study was designed to evaluate the cardioprotective potential of salvianolic acid A on <ENT2>isoproterenol</ENT2>-induced <ENT1>myocardial infarction</ENT1> in rats.,,,,T,,,,,c,,,,,1.0,,
19445921,1617,D009203,D007545,Positive_Correlation,FALSE,The results of our study suggest that salvianolic acid A possessing antioxidant activity has a significant protective effect against <ENT2>isoproterenol</ENT2>-induced <ENT1>myocardial infarction</ENT1>.,,,,T,,,,,c,,,,,0.0,,
19445921,1604,D009203,C066201,Negative_Correlation,TRUE,Cardioprotective effect of <ENT2>salvianolic acid A</ENT2> on isoproterenol-induced <ENT1>myocardial infarction</ENT1> in rats.,,,,T,,T,,,w,,,,,0.0,,
19445921,1604,D009203,C066201,Negative_Correlation,TRUE,The present study was designed to evaluate the cardioprotective potential of <ENT2>salvianolic acid A</ENT2> on isoproterenol-induced <ENT1>myocardial infarction</ENT1> in rats.,,,,T,,Y,,,w,,,,,1.0,,
19445921,1604,D009203,C066201,Negative_Correlation,TRUE,The results of our study suggest that <ENT2>salvianolic acid A</ENT2> possessing antioxidant activity has a significant protective effect against isoproterenol-induced <ENT1>myocardial infarction</ENT1>.,,,,T,,,,,c,,,,,1.0,,
19445921,1607,D028361,D007545,Positive_Correlation,TRUE,"In addition, <ENT1>mitochondrial respiratory dysfunction</ENT1> characterized by decreased respiratory control ratio and ADP/O was observed in <ENT2>isoproterenol</ENT2>-treated rats.",,,,T,,,,,c,,,,,1.0,,
19445921,1612,D007545,24533,Positive_Correlation,TRUE,"<ENT1>Isoproterenol</ENT1>-treated rats showed significant increases in the levels of <ENT2>lactate dehydrogenase</ENT2>, aspartate transaminase, creatine kinase and malondialdehyde and significant decreases in the activities of superoxide dismutase, catalase and glutathione peroxidase in serum and heart.",,,,T,,,,,c,,,,,1.0,,
19445921,1611,D007545,25721,Positive_Correlation,TRUE,"<ENT1>Isoproterenol</ENT1>-treated rats showed significant increases in the levels of lactate dehydrogenase, <ENT2>aspartate transaminase</ENT2>, creatine kinase and malondialdehyde and significant decreases in the activities of superoxide dismutase, catalase and glutathione peroxidase in serum and heart.",,,,T,,,,,c,,,,,1.0,,
19445921,1609,D007545,24786,Negative_Correlation,TRUE,"<ENT1>Isoproterenol</ENT1>-treated rats showed significant increases in the levels of lactate dehydrogenase, aspartate transaminase, creatine kinase and malondialdehyde and significant decreases in the activities of <ENT2>superoxide dismutase</ENT2>, catalase and glutathione peroxidase in serum and heart.",,,,T,,,,,c,,,,,1.0,,
19445921,1615,D007545,24248,Negative_Correlation,TRUE,"<ENT1>Isoproterenol</ENT1>-treated rats showed significant increases in the levels of lactate dehydrogenase, aspartate transaminase, creatine kinase and malondialdehyde and significant decreases in the activities of superoxide dismutase, <ENT2>catalase</ENT2> and glutathione peroxidase in serum and heart.",,,,T,,,,,c,,,,,1.0,,
19445921,1613,D007545,D009202,Positive_Correlation,TRUE,Administration of salvianolic acid A for a period of 8 days significantly attenuated <ENT1>isoproterenol</ENT1>-induced cardiac dysfunction and <ENT2>myocardial injury</ENT2> and improved mitochondrial respiratory function.,,,,T,,,,,w,,,,,0.0,,
19445921,1613,D007545,D009202,Positive_Correlation,TRUE,The protective role of salvianolic acid A against <ENT1>isoproterenol</ENT1>-induced <ENT2>myocardial damage</ENT2> was further confirmed by histopathological examination.,,,,T,,,,,c,,,,,1.0,,
19445921,1608,D007545,24404,Negative_Correlation,TRUE,"<ENT1>Isoproterenol</ENT1>-treated rats showed significant increases in the levels of lactate dehydrogenase, aspartate transaminase, creatine kinase and malondialdehyde and significant decreases in the activities of superoxide dismutase, catalase and <ENT2>glutathione peroxidase</ENT2> in serum and heart.",,,,T,,,,,c,,,,,1.0,,
19445921,1605,D007545,C066201,Negative_Correlation,TRUE,Cardioprotective effect of <ENT2>salvianolic acid A</ENT2> on <ENT1>isoproterenol</ENT1>-induced myocardial infarction in rats.,,,,T,,T,,,w,,,,,0.0,,
19445921,1605,D007545,C066201,Negative_Correlation,TRUE,The present study was designed to evaluate the cardioprotective potential of <ENT2>salvianolic acid A</ENT2> on <ENT1>isoproterenol</ENT1>-induced myocardial infarction in rats.,,,,T,,Y,,,c,,,,,1.0,,
19445921,1605,D007545,C066201,Negative_Correlation,TRUE,Administration of <ENT2>salvianolic acid A</ENT2> for a period of 8 days significantly attenuated <ENT1>isoproterenol</ENT1>-induced cardiac dysfunction and myocardial injury and improved mitochondrial respiratory function.,,,,T,Y,,,,c,,,,,1.0,,
19445921,1605,D007545,C066201,Negative_Correlation,TRUE,The protective role of <ENT2>salvianolic acid A</ENT2> against <ENT1>isoproterenol</ENT1>-induced myocardial damage was further confirmed by histopathological examination.,,,,T,,,,,c,,,,,1.0,,
19445921,1605,D007545,C066201,Negative_Correlation,TRUE,The results of our study suggest that <ENT2>salvianolic acid A</ENT2> possessing antioxidant activity has a significant protective effect against <ENT1>isoproterenol</ENT1>-induced myocardial infarction.,,,,T,,,,,c,,,,,1.0,,
19445921,1614,D007545,D006331,Positive_Correlation,FALSE,Administration of salvianolic acid A for a period of 8 days significantly attenuated <ENT1>isoproterenol</ENT1>-induced <ENT2>cardiac dysfunction</ENT2> and myocardial injury and improved mitochondrial respiratory function.,,,,T,,,,,c,,,,,1.0,,
19445921,1602,D009202,C066201,Negative_Correlation,TRUE,Administration of <ENT2>salvianolic acid A</ENT2> for a period of 8 days significantly attenuated isoproterenol-induced cardiac dysfunction and <ENT1>myocardial injury</ENT1> and improved mitochondrial respiratory function.,,,,T,,,,,c,,,,,1.0,,
19445921,1602,D009202,C066201,Negative_Correlation,TRUE,The protective role of <ENT2>salvianolic acid A</ENT2> against isoproterenol-induced <ENT1>myocardial damage</ENT1> was further confirmed by histopathological examination.,,,,T,,,,,c,,,,,1.0,,
19445921,1603,C066201,D006331,Negative_Correlation,TRUE,Administration of <ENT1>salvianolic acid A</ENT1> for a period of 8 days significantly attenuated isoproterenol-induced <ENT2>cardiac dysfunction</ENT2> and myocardial injury and improved mitochondrial respiratory function.,,,,T,,,,,c,,,,,1.0,,
19463742;19463742;19463742,1664;1652;1650,116554;116554;5599,17202;4160;4160,Negative_Correlation;Negative_Correlation;Negative_Correlation,TRUE;TRUE;TRUE,<ENT2>Melanocortin-4 receptor</ENT2> activation inhibits <ENT1>c-Jun N-terminal kinase</ENT1> activity and promotes insulin signaling.,,,,T,,,,,c,,,,,0.0,,
19463742;19463742;19463742;19463742;19463742;19463742,1643;1646;1639;1641;1644;1637,116554;116554;116554;5599;5599;5599,24505;16333;3630;24505;16333;3630,Association;Association;Association;Association;Association;Association,TRUE;TRUE;TRUE;TRUE;TRUE;TRUE,Melanocortin-4 receptor activation inhibits <ENT1>c-Jun N-terminal kinase</ENT1> activity and promotes <ENT2>insulin</ENT2> signaling.,,,,T,,,,,c,,,,,0.0,,
19463742;19463742;19463742;19463742;19463742;19463742,1643;1646;1639;1641;1644;1637,116554;116554;116554;5599;5599;5599,24505;16333;3630;24505;16333;3630,Association;Association;Association;Association;Association;Association,TRUE;TRUE;TRUE;TRUE;TRUE;TRUE,The current study shows that the melanocortinergic system interacts with <ENT2>insulin</ENT2> signaling via novel effects on <ENT1>JNK</ENT1> activity.,,,,T,,,,,c,,,,,1.0,,
19463742,1635,C027756,5599,Negative_Correlation,TRUE,The melanocortin agonist <ENT1>NDP-MSH</ENT1> dose-dependently inhibited <ENT2>JNK</ENT2> activity in HEK293 cells stably expressing the human MC4R; effects were reversed by melanocortin receptor antagonist.,,,,T,,,,,c,,,,,1.0,,
19463742,1624,C027756,5443,Positive_Correlation,FALSE,The <ENT2>melanocortin</ENT2> agonist <ENT1>NDP-MSH</ENT1> dose-dependently inhibited JNK activity in HEK293 cells stably expressing the human MC4R; effects were reversed by melanocortin receptor antagonist.,,,,T,,,,,c,,,,,1.0,,
19463742,1624,C027756,5443,Positive_Correlation,FALSE,The <ENT2>melanocortin</ENT2> agonist melanotan II increased insulin-stimulated AKT phosphorylation in the rat hypothalamus in vivo. <ENT1>NDP-MSH</ENT1> increased insulin-stimulated glucose uptake in hypothalamic GT1-1 cells.,,,,T,,,,,w,,,,,0.0,,
19463742,1630,C027756,p|Allele|S|307,Association,TRUE,"<ENT1>NDP-MSH</ENT1> time- and dose-dependently inhibited IRS-1(<ENT2>ser307</ENT2>) phosphorylation, effects also reversed by a specific melanocortin receptor antagonist.",,,,T,,,,,c,,,,,0.0,,
19463742,1631,C027756,3667,Association,TRUE,"<ENT1>NDP-MSH</ENT1> time- and dose-dependently inhibited <ENT2>IRS-1</ENT2>(ser307) phosphorylation, effects also reversed by a specific melanocortin receptor antagonist.",,,,T,,,,,c,,,,,0.0,,
19463742,1629,C027756,207,Association,TRUE,<ENT1>NDP-MSH</ENT1> augmented insulin-stimulated <ENT2>AKT</ENT2> phosphorylation in vitro.,,,,T,,,,,c,,,,,0.0,,
19463742,1628,C027756,D005947,Positive_Correlation,TRUE,The melanocortin agonist melanotan II increased insulin-stimulated AKT phosphorylation in the rat hypothalamus in vivo. <ENT1>NDP-MSH</ENT1> increased insulin-stimulated <ENT2>glucose</ENT2> uptake in hypothalamic GT1-1 cells.,,,,T,,,,,c,,,,,1.0,,
19463742,1633,C027756,16333,Association,TRUE,The melanocortin agonist melanotan II increased insulin-stimulated AKT phosphorylation in the rat hypothalamus in vivo. <ENT1>NDP-MSH</ENT1> increased <ENT2>insulin</ENT2>-stimulated glucose uptake in hypothalamic GT1-1 cells.,,,,T,Y,,,,c,,,,,0.0,,
19463742,1634,C027756,4160,Association,TRUE,The melanocortin agonist <ENT1>NDP-MSH</ENT1> dose-dependently inhibited JNK activity in HEK293 cells stably expressing the human <ENT2>MC4R</ENT2>; effects were reversed by <ENT2>melanocortin receptor</ENT2> antagonist.,,,,T,Y,,,,w,,,,,0.0,TRUE,
19463742,1634,C027756,4160,Association,TRUE,"<ENT1>NDP-MSH</ENT1> time- and dose-dependently inhibited IRS-1(ser307) phosphorylation, effects also reversed by a specific <ENT2>melanocortin receptor</ENT2> antagonist.",,,,T,,,,,c,,,,,1.0,,
19463742,1632,C027756,3630,Association,TRUE,<ENT1>NDP-MSH</ENT1> augmented <ENT2>insulin</ENT2>-stimulated AKT phosphorylation in vitro.,,,,T,Y,,,,c,,,,,0.0,,
19463742,1662,17202,5599,Negative_Correlation,TRUE,<ENT1>Melanocortin-4 receptor</ENT1> activation inhibits <ENT2>c-Jun N-terminal kinase</ENT2> activity and promotes insulin signaling.,,,,T,,,,,c,,,,,0.0,,
19463742;19463742;19463742;19463742,1660;1661;1659;1647,17202;17202;17202;4160,24505;16333;3630;3630,Positive_Correlation;Positive_Correlation;Positive_Correlation;Positive_Correlation,TRUE;TRUE;TRUE;TRUE,<ENT1>Melanocortin-4 receptor</ENT1> activation inhibits c-Jun N-terminal kinase activity and promotes <ENT2>insulin</ENT2> signaling.,,,,T,,,,,c,,,,,1.0,,
19463742,1627,5599,5443,Negative_Correlation,TRUE,The <ENT2>melanocortin</ENT2> agonist NDP-MSH dose-dependently inhibited <ENT1>JNK</ENT1> activity in HEK293 cells stably expressing the human MC4R; effects were reversed by melanocortin receptor antagonist.,,,,T,,,,,c,,,,,1.0,,
19463742,1650,5599,4160,Negative_Correlation,TRUE,The <ENT2>melanocortin receptor type 4</ENT2> (<ENT2>MC4R</ENT2>) modulates insulin signaling via effects on <ENT1>c-Jun N-terminal kinase</ENT1> (<ENT1>JNK</ENT1>).,,,,T,,,,,w,,,"11,12,21,22",,0.0,,
19463742,1650,5599,4160,Negative_Correlation,TRUE,The melanocortin agonist NDP-MSH dose-dependently inhibited <ENT1>JNK</ENT1> activity in HEK293 cells stably expressing the human <ENT2>MC4R</ENT2>; effects were reversed by <ENT2>melanocortin receptor</ENT2> antagonist.,,,,T,,,,,w,,,,,1.0,,
19463742,1637,5599,3630,Association,TRUE,The melanocortin receptor type 4 (MC4R) modulates <ENT2>insulin</ENT2> signaling via effects on <ENT1>c-Jun N-terminal kinase</ENT1> (<ENT1>JNK</ENT1>).,,,,T,,,,,c,,,,,0.5,,
19463742,1625,5443,24505,Association,TRUE,The <ENT1>melanocortin</ENT1> agonist melanotan II increased <ENT2>insulin</ENT2>-stimulated AKT phosphorylation in the rat hypothalamus in vivo. NDP-MSH increased insulin-stimulated glucose uptake in hypothalamic GT1-1 cells.,,,,T,,,,,c,,,,,1.0,,
19463742,1623,5443,24185,Association,TRUE,The <ENT1>melanocortin</ENT1> agonist melanotan II increased insulin-stimulated <ENT2>AKT</ENT2> phosphorylation in the rat hypothalamus in vivo. NDP-MSH increased insulin-stimulated glucose uptake in hypothalamic GT1-1 cells.,,,,T,,,,,c,,,,,0.0,,
19463742,1626,5443,4160,Bind,FALSE,The <ENT1>melanocortin</ENT1> agonist NDP-MSH dose-dependently inhibited JNK activity in HEK293 cells stably expressing the human <ENT2>MC4R</ENT2>; effects were reversed by <ENT2>melanocortin receptor</ENT2> antagonist.,,,,T,,,,,w,,,,,0.5,,
19463742,1622,5443,C079282,Positive_Correlation,FALSE,The <ENT1>melanocortin</ENT1> agonist <ENT2>melanotan II</ENT2> increased insulin-stimulated AKT phosphorylation in the rat hypothalamus in vivo. NDP-MSH increased insulin-stimulated glucose uptake in hypothalamic GT1-1 cells.,,,,T,,,,,c,,,,,1.0,,
19463742,1640,24505,24185,Association,FALSE,The melanocortin agonist melanotan II increased <ENT1>insulin</ENT1>-stimulated <ENT2>AKT</ENT2> phosphorylation in the rat hypothalamus in vivo. NDP-MSH increased insulin-stimulated glucose uptake in hypothalamic GT1-1 cells.,,,,T,Y,,,,c,,,,,0.0,,
19463742;19463742,1648;1649,24505;16333,4160;4160,Positive_Correlation;Positive_Correlation,TRUE;TRUE,<ENT2>Melanocortin-4 receptor</ENT2> activation inhibits c-Jun N-terminal kinase activity and promotes <ENT1>insulin</ENT1> signaling.,,,,T,,,,,c,,,,,1.0,,
19463742,1620,24505,C079282,Association,TRUE,The melanocortin agonist <ENT2>melanotan II</ENT2> increased <ENT1>insulin</ENT1>-stimulated AKT phosphorylation in the rat hypothalamus in vivo. NDP-MSH increased insulin-stimulated glucose uptake in hypothalamic GT1-1 cells.,,,,T,,,,,c,,,,,0.0,,
19463742,1621,3667,4160,Association,TRUE,"NDP-MSH time- and dose-dependently inhibited <ENT1>IRS-1</ENT1>(ser307) phosphorylation, effects also reversed by a specific <ENT2>melanocortin receptor</ENT2> antagonist.",,,,T,,,,,w,,,,,0.0,,
19463742,1636,207,3630,Association,FALSE,NDP-MSH augmented <ENT2>insulin</ENT2>-stimulated <ENT1>AKT</ENT1> phosphorylation in vitro.,,,,T,,,,,c,,,,,0.0,,
19463742,1618,D005947,16333,Positive_Correlation,FALSE,The melanocortin agonist melanotan II increased insulin-stimulated AKT phosphorylation in the rat hypothalamus in vivo. NDP-MSH increased <ENT2>insulin</ENT2>-stimulated <ENT1>glucose</ENT1> uptake in hypothalamic GT1-1 cells.,,,,T,,,,,c,,,,,1.0,,
19463742,1619,24185,C079282,Association,TRUE,The melanocortin agonist <ENT2>melanotan II</ENT2> increased insulin-stimulated <ENT1>AKT</ENT1> phosphorylation in the rat hypothalamus in vivo. NDP-MSH increased insulin-stimulated glucose uptake in hypothalamic GT1-1 cells.,,,,T,,,,,c,,,,,1.0,,
19463742,1647,4160,3630,Positive_Correlation,TRUE,The <ENT1>melanocortin receptor type 4</ENT1> (<ENT1>MC4R</ENT1>) modulates <ENT2>insulin</ENT2> signaling via effects on c-Jun N-terminal kinase (JNK).,,,,T,,,,,w,,,,,0.0,,
19484664,1665,D001249,1636,Association,FALSE,<ENT2>Angiotensin converting enzyme</ENT2> gene polymorphism in Turkish <ENT1>asthmatic</ENT1> patients.,,,,T,,T,,,w,,,,,1.0,,
19484664,1665,D001249,1636,Association,FALSE,"Several candidate genes have been identified with a potential role in the pathogenesis of <ENT1>asthma</ENT1>, including the <ENT2>angiotensin converting enzyme</ENT2> (<ENT2>ACE</ENT2>) gene.",,,,T,,,,,w,,,,,0.0,TRUE,
19484664,1665,D001249,1636,Association,FALSE,We aimed to investigate the frequency of an <ENT2>ACE</ENT2> gene polymorphism in Turkish <ENT1>asthmatic</ENT1> patients and to determine its impact on clinical parameters and disease severity.,,,,T,,Y,,,c,,,,,1.0,,
19484664,1665,D001249,1636,Association,FALSE,"The frequency of the <ENT2>ACE</ENT2> genotypes (I = insertion and D = deletion) among <ENT1>asthmatics</ENT1> and controls were compared: <ENT1>asthmatics</ENT1> showed a 40.2% prevalence of the DD genotype (n = 39), ID was 45.4% (n = 44), and II was 14.4% (n = 14.4).",,,,T,,,,,w,,,,,1.0,,
19484664,1665,D001249,1636,Association,FALSE,The DD <ENT2>ACE</ENT2> genotype was significantly more frequent in <ENT1>asthmatics</ENT1> compared with controls (p < 0.001).,,,,T,,,,,c,,,,,1.0,,
19484664,1665,D001249,1636,Association,FALSE,"<ENT1>Asthmatics</ENT1> with the ID <ENT2>ACE</ENT2> genotype showed a higher frequency of drug allergies, although this was not statistically significant (p = 0.08).",,,,T,,,,,w,,,,,0.0,,
19484664,1665,D001249,1636,Association,FALSE,"We found a higher frequency of the <ENT2>ACE</ENT2> DD gene mutation in Turkish <ENT1>asthmatic</ENT1> patients compared with non-<ENT1>asthmatics</ENT1>, suggesting that this <ENT2>ACE</ENT2> gene polymorphism may be a risk factor for <ENT1>asthma</ENT1> but does not increase the severity of the disease.",,,,T,,,,,c,,,"11,32",,0.666666667,,
19508969,1675,D008103,rs267607116,Positive_Correlation,TRUE,"When examining a worldwide cohort of 62 independent patients with NPHP and associated <ENT1>liver fibrosis</ENT1> we identified altogether four novel mutations (p.W290L, p.C615R, <ENT2>p.G821S</ENT2>, and <ENT2>p.G821R</ENT2>) in five of them.",,,,T,,,,,c,,,,,0.0,,
19508969,1683,D008103,rs267607117,Positive_Correlation,TRUE,"When examining a worldwide cohort of 62 independent patients with NPHP and associated <ENT1>liver fibrosis</ENT1> we identified altogether four novel mutations (<ENT2>p.W290L</ENT2>, p.C615R, p.G821S, and p.G821R) in five of them.",,,,T,,,,,c,,,,,0.0,,
19508969,1679,D008103,rs201893408,Positive_Correlation,TRUE,"When examining a worldwide cohort of 62 independent patients with NPHP and associated <ENT1>liver fibrosis</ENT1> we identified altogether four novel mutations (p.W290L, <ENT2>p.C615R</ENT2>, p.G821S, and p.G821R) in five of them.",,,,T,,,,,c,,,,,0.0,,
19508969,1692,D008103,91147,Association,TRUE,"Additionally, mutation analysis for <ENT2>MKS3</ENT2>/<ENT2>TMEM67</ENT2> in 120 patients with JBTS yielded seven different (four novel) mutations in five patients, four of whom also presented with congenital <ENT1>liver fibrosis</ENT1>.",,,,T,,,,,c,,,,,1.0,,
19508969,1693,OMIM:613550,91147,Association,TRUE,Hypomorphic mutations in <ENT2>meckelin</ENT2> (<ENT2>MKS3</ENT2>/<ENT2>TMEM67</ENT2>) cause <ENT1>nephronophthisis with liver fibrosis</ENT1> (<ENT1>NPHP11</ENT1>).,,,,T,,,,,c,,,"11,12,13,21,22,23",,1.0,,
19508969,1693,OMIM:613550,91147,Association,TRUE,CONCLUSIONS: Hypomorphic <ENT2>MKS3</ENT2>/<ENT2>TMEM67</ENT2> mutations cause <ENT1>NPHP with liver fibrosis</ENT1> (<ENT1>NPHP11</ENT1>).,,,,T,,,,,c,,,"11,12,21,22",,0.5,,
19508969,1672,rs267607116,C537699,Positive_Correlation,TRUE,"When examining a worldwide cohort of 62 independent patients with <ENT2>NPHP</ENT2> and associated liver fibrosis we identified altogether four novel mutations (p.W290L, p.C615R, <ENT1>p.G821S</ENT1>, and <ENT1>p.G821R</ENT1>) in five of them.",,,,T,,,,,c,,,,,0.0,,
19508969,1688,C536132,91147,Association,FALSE,"Mutations of <ENT2>MKS3</ENT2>/<ENT2>TMEM67</ENT2>, found recently in <ENT1>Meckel-Gruber syndrome (MKS) type 3</ENT1> and Joubert syndrome (JBTS) type 6, are predominantly truncating mutations.",,,,T,,,,,c,,,,,1.0,,
19508969,1680,rs267607117,C537699,Positive_Correlation,TRUE,"When examining a worldwide cohort of 62 independent patients with <ENT2>NPHP</ENT2> and associated liver fibrosis we identified altogether four novel mutations (<ENT1>p.W290L</ENT1>, p.C615R, p.G821S, and p.G821R) in five of them.",,,,T,,,,,c,,,,,0.0,,
19508969,1691,C536293,91147,Association,FALSE,"Additionally, mutation analysis for <ENT2>MKS3</ENT2>/<ENT2>TMEM67</ENT2> in 120 patients with <ENT1>JBTS</ENT1> yielded seven different (four novel) mutations in five patients, four of whom also presented with congenital liver fibrosis.",,,,T,Y,,,,w,,,,,0.5,,
19508969,1676,C537699,rs201893408,Positive_Correlation,TRUE,"When examining a worldwide cohort of 62 independent patients with <ENT1>NPHP</ENT1> and associated liver fibrosis we identified altogether four novel mutations (p.W290L, <ENT2>p.C615R</ENT2>, p.G821S, and p.G821R) in five of them.",,,,T,,,,,c,,,,,0.0,,
19508969,1687,91147,C537689,Association,FALSE,"Mutations of <ENT1>MKS3</ENT1>/<ENT1>TMEM67</ENT1>, found recently in Meckel-Gruber syndrome (MKS) type 3 and <ENT2>Joubert syndrome (JBTS) type 6</ENT2>, are predominantly truncating mutations.",,,,T,,,,,c,,,,,1.0,,
19536134,1713,26419,26409,Association,TRUE,BMPR signalling was markedly impaired in <ENT2>TAK1</ENT2>-deficient chondrocytes as evidenced by reduced expression of known BMP target genes as well as reduced phosphorylation of Smad1/5/8 and p38/<ENT1>Jnk</ENT1>/Erk <ENT1>MAP kinases</ENT1>.,,,,T,,,,,c,,,,,0.5,,
19536134,1713,26419,26409,Association,TRUE,These findings provide the first in vivo evidence in a mammalian system that <ENT2>TAK1</ENT2> is required for BMP signalling and functions as an upstream activating kinase for Smad1/5/8 in addition to its known role in regulating <ENT1>MAP kinase</ENT1> pathways.,,,,T,,,,,c,,,,,1.0,,
19536134,1707,26419,12159,Association,FALSE,BMPR signalling was markedly impaired in TAK1-deficient chondrocytes as evidenced by reduced expression of known <ENT2>BMP</ENT2> target genes as well as reduced phosphorylation of Smad1/5/8 and p38/<ENT1>Jnk</ENT1>/Erk <ENT1>MAP kinases</ENT1>.,,,,T,,,,,c,,,,,0.5,,
19536134;19536134,1707;1708,26419;26416,12159;12159,Association;Association,FALSE;FALSE,These findings provide the first in vivo evidence in a mammalian system that TAK1 is required for <ENT2>BMP</ENT2> signalling and functions as an upstream activating kinase for Smad1/5/8 in addition to its known role in regulating <ENT1>MAP kinase</ENT1> pathways.,,,,T,,,,,w,,,,,0.0,,
19536134,1695,26419,12166,Association,FALSE,<ENT2>BMPR</ENT2> signalling was markedly impaired in TAK1-deficient chondrocytes as evidenced by reduced expression of known BMP target genes as well as reduced phosphorylation of Smad1/5/8 and p38/<ENT1>Jnk</ENT1>/Erk <ENT1>MAP kinases</ENT1>.,,,,T,,,,,c,,,,,0.0,,
19536134,1720,D004204,26409,Association,TRUE,"<ENT2>Tak1</ENT2>(col2) mice displayed severe chondrodysplasia with runting, impaired formation of secondary centres of ossification, and joint abnormalities including <ENT1>elbow dislocation</ENT1> and tarsal fusion.",,,,T,,,,,c,,,,,1.0,,
19536134,1703,D004204,12824,Association,TRUE,"Tak1(<ENT2>col2</ENT2>) mice displayed severe chondrodysplasia with runting, impaired formation of secondary centres of ossification, and joint abnormalities including <ENT1>elbow dislocation</ENT1> and tarsal fusion.",,,,T,,,,,c,,,,,0.0,,
19536134,1717,17125,26409,Association,TRUE,BMPR signalling was markedly impaired in <ENT2>TAK1</ENT2>-deficient chondrocytes as evidenced by reduced expression of known BMP target genes as well as reduced phosphorylation of <ENT1>Smad1/5/8</ENT1> and p38/Jnk/Erk MAP kinases.,,,,T,,,,,w,,,,,0.0,,
19536134,1717,17125,26409,Association,TRUE,<ENT2>TAK1</ENT2> mediates <ENT1>Smad1</ENT1> phosphorylation at C-terminal serine residues.,,,,T,,,,,c,,,,,1.0,,
19536134,1717,17125,26409,Association,TRUE,These findings provide the first in vivo evidence in a mammalian system that <ENT2>TAK1</ENT2> is required for BMP signalling and functions as an upstream activating kinase for <ENT1>Smad1/5/8</ENT1> in addition to its known role in regulating MAP kinase pathways.,,,,T,,,,,c,,,,,0.0,,
19536134;19536134,1711;1710,17125;17129,12159;12159,Association;Association,FALSE;FALSE,BMPR signalling was markedly impaired in TAK1-deficient chondrocytes as evidenced by reduced expression of known <ENT2>BMP</ENT2> target genes as well as reduced phosphorylation of <ENT1>Smad1/5/8</ENT1> and p38/Jnk/Erk MAP kinases.,,,,T,,,,,c,,,,,1.0,,
19536134;19536134,1711;1710,17125;17129,12159;12159,Association;Association,FALSE;FALSE,These findings provide the first in vivo evidence in a mammalian system that TAK1 is required for <ENT2>BMP</ENT2> signalling and functions as an upstream activating kinase for <ENT1>Smad1/5/8</ENT1> in addition to its known role in regulating MAP kinase pathways.,,,,T,,,,,w,,,,,1.0,,
19536134;19536134,1699;1698,17125;17129,12166;12166,Association;Association,FALSE;FALSE,<ENT2>BMPR</ENT2> signalling was markedly impaired in TAK1-deficient chondrocytes as evidenced by reduced expression of known BMP target genes as well as reduced phosphorylation of <ENT1>Smad1/5/8</ENT1> and p38/Jnk/Erk MAP kinases.,,,,T,,,,,c,,,,,0.0,,
19536134,1716,26409,17129,Association,TRUE,BMPR signalling was markedly impaired in <ENT1>TAK1</ENT1>-deficient chondrocytes as evidenced by reduced expression of known BMP target genes as well as reduced phosphorylation of <ENT2>Smad1/5/8</ENT2> and p38/Jnk/Erk MAP kinases.,,,,T,,,,,w,,,,,0.0,,
19536134,1716,26409,17129,Association,TRUE,These findings provide the first in vivo evidence in a mammalian system that <ENT1>TAK1</ENT1> is required for BMP signalling and functions as an upstream activating kinase for <ENT2>Smad1/5/8</ENT2> in addition to its known role in regulating MAP kinase pathways.,,,,T,,,,,c,,,,,0.0,,
19536134,1714,26409,26416,Association,TRUE,BMPR signalling was markedly impaired in <ENT1>TAK1</ENT1>-deficient chondrocytes as evidenced by reduced expression of known BMP target genes as well as reduced phosphorylation of Smad1/5/8 and <ENT2>p38</ENT2>/Jnk/Erk <ENT2>MAP kinases</ENT2>.,,,,T,,,,,c,,,,,0.0,,
19536134;19536134,1714;1712,26409;26409,26416;26413,Association;Association,TRUE;TRUE,These findings provide the first in vivo evidence in a mammalian system that <ENT1>TAK1</ENT1> is required for BMP signalling and functions as an upstream activating kinase for Smad1/5/8 in addition to its known role in regulating <ENT2>MAP kinase</ENT2> pathways.,,,,T,,,,,c,,,,,1.0,,
19536134,1723,26409,12159,Positive_Correlation,TRUE,<ENT1>TAK1</ENT1> is an essential regulator of <ENT2>BMP</ENT2> signalling in cartilage.,,,,T,,,,,w,,,,,0.0,,
19536134,1723,26409,12159,Positive_Correlation,TRUE,BMPR signalling was markedly impaired in <ENT1>TAK1</ENT1>-deficient chondrocytes as evidenced by reduced expression of known <ENT2>BMP</ENT2> target genes as well as reduced phosphorylation of Smad1/5/8 and p38/Jnk/Erk MAP kinases.,,,,T,,,,,c,,,,,1.0,,
19536134,1723,26409,12159,Positive_Correlation,TRUE,These findings provide the first in vivo evidence in a mammalian system that <ENT1>TAK1</ENT1> is required for <ENT2>BMP</ENT2> signalling and functions as an upstream activating kinase for Smad1/5/8 in addition to its known role in regulating MAP kinase pathways.,,,,T,,,,,c,,,,,0.0,,
19536134,1719,26409,D000070604,Association,TRUE,"<ENT1>Tak1</ENT1>(col2) mice displayed severe chondrodysplasia with runting, impaired formation of secondary centres of ossification, and joint abnormalities including elbow dislocation and <ENT2>tarsal fusion</ENT2>.",,,,T,,,,,c,,,,,1.0,,
19536134,1701,26409,12166,Association,TRUE,<ENT2>BMPR</ENT2> signalling was markedly impaired in <ENT1>TAK1</ENT1>-deficient chondrocytes as evidenced by reduced expression of known BMP target genes as well as reduced phosphorylation of Smad1/5/8 and p38/Jnk/Erk MAP kinases.,,,,T,,,,,c,,,,,0.0,,
19536134,1712,26409,26413,Association,TRUE,BMPR signalling was markedly impaired in <ENT1>TAK1</ENT1>-deficient chondrocytes as evidenced by reduced expression of known BMP target genes as well as reduced phosphorylation of Smad1/5/8 and p38/Jnk/<ENT2>Erk</ENT2> <ENT2>MAP kinases</ENT2>.,,,,T,,,,,c,,,,,0.0,,
19536134,1718,26409,12824,Association,FALSE,"To analyse the in vivo function of <ENT1>TAK1</ENT1> in cartilage, we generated mice with a conditional deletion of <ENT1>Tak1</ENT1> driven by the <ENT2>collagen 2</ENT2> promoter.",,,,T,Y,,,,c,,,,,0.0,,
19536134,1718,26409,12824,Association,FALSE,"<ENT1>Tak1</ENT1>(<ENT2>col2</ENT2>) mice displayed severe chondrodysplasia with runting, impaired formation of secondary centres of ossification, and joint abnormalities including elbow dislocation and tarsal fusion.",,,,T,Y,,,,w,,,,,1.0,,
19536134,1722,26409,D010009,Association,TRUE,"<ENT1>Tak1</ENT1>(col2) mice displayed severe <ENT2>chondrodysplasia</ENT2> with runting, impaired formation of secondary centres of ossification, and joint abnormalities including elbow dislocation and tarsal fusion.",,,,T,,,,,c,,,,,1.0,,
19536134,1721,26409,D007592,Association,TRUE,"<ENT1>Tak1</ENT1>(col2) mice displayed severe chondrodysplasia with runting, impaired formation of secondary centres of ossification, and <ENT2>joint abnormalities</ENT2> including elbow dislocation and tarsal fusion.",,,,T,,,,,c,,,,,1.0,,
19536134,1708,26416,12159,Association,FALSE,BMPR signalling was markedly impaired in TAK1-deficient chondrocytes as evidenced by reduced expression of known <ENT2>BMP</ENT2> target genes as well as reduced phosphorylation of Smad1/5/8 and <ENT1>p38</ENT1>/Jnk/Erk <ENT1>MAP kinases</ENT1>.,,,,T,,,,,c,,,,,0.5,,
19536134,1696,26416,12166,Association,FALSE,<ENT2>BMPR</ENT2> signalling was markedly impaired in TAK1-deficient chondrocytes as evidenced by reduced expression of known BMP target genes as well as reduced phosphorylation of Smad1/5/8 and <ENT1>p38</ENT1>/Jnk/Erk <ENT1>MAP kinases</ENT1>.,,,,T,,,,,c,,,,,0.0,,
19536134,1700,12159,12166,Bind,FALSE,<ENT2>BMPR</ENT2> signalling was markedly impaired in TAK1-deficient chondrocytes as evidenced by reduced expression of known <ENT1>BMP</ENT1> target genes as well as reduced phosphorylation of Smad1/5/8 and p38/Jnk/Erk MAP kinases.,,,,T,,,,,w,,,,,0.0,,
19536134,1706,12159,26413,Association,FALSE,BMPR signalling was markedly impaired in TAK1-deficient chondrocytes as evidenced by reduced expression of known <ENT1>BMP</ENT1> target genes as well as reduced phosphorylation of Smad1/5/8 and p38/Jnk/<ENT2>Erk</ENT2> <ENT2>MAP kinases</ENT2>.,,,,T,,,,,c,,,,,1.0,,
19536134,1706,12159,26413,Association,FALSE,These findings provide the first in vivo evidence in a mammalian system that TAK1 is required for <ENT1>BMP</ENT1> signalling and functions as an upstream activating kinase for Smad1/5/8 in addition to its known role in regulating <ENT2>MAP kinase</ENT2> pathways.,,,,T,,,,,c,,,,,1.0,,
19536134,1702,D000070604,12824,Association,TRUE,"Tak1(<ENT2>col2</ENT2>) mice displayed severe chondrodysplasia with runting, impaired formation of secondary centres of ossification, and joint abnormalities including elbow dislocation and <ENT1>tarsal fusion</ENT1>.",,,,T,,,,,c,,,,,1.0,,
19536134,1694,12166,26413,Association,FALSE,<ENT1>BMPR</ENT1> signalling was markedly impaired in TAK1-deficient chondrocytes as evidenced by reduced expression of known BMP target genes as well as reduced phosphorylation of Smad1/5/8 and p38/Jnk/<ENT2>Erk</ENT2> <ENT2>MAP kinases</ENT2>.,,,,T,,,,,c,,,,,0.0,,
19536134,1705,12824,D010009,Association,TRUE,"Tak1(<ENT1>col2</ENT1>) mice displayed severe <ENT2>chondrodysplasia</ENT2> with runting, impaired formation of secondary centres of ossification, and joint abnormalities including elbow dislocation and tarsal fusion.",,,,T,,,,,c,,,,,1.0,,
19536134,1704,12824,D007592,Association,TRUE,"Tak1(<ENT1>col2</ENT1>) mice displayed severe chondrodysplasia with runting, impaired formation of secondary centres of ossification, and <ENT2>joint abnormalities</ENT2> including elbow dislocation and tarsal fusion.",,,,T,,,,,c,,,,,1.0,,
19549709,1725,D000068338,2475,Negative_Correlation,FALSE,"<ENT1>RAD001</ENT1>, an oral inhibitor of the <ENT2>mammalian target of rapamycin</ENT2> (<ENT2>mTOR</ENT2>), has shown phase I efficacy in NSCLC.",,,,T,,,,,c,,,,,1.0,,
19549709,1726,D000068338,D002289,Negative_Correlation,FALSE,Efficacy of <ENT1>everolimus</ENT1> (<ENT1>RAD001</ENT1>) in patients with advanced <ENT2>NSCLC</ENT2> previously treated with chemotherapy alone or with chemotherapy and EGFR inhibitors.,,,,T,,T,,,w,,,,,0.0,TRUE,
19549709,1726,D000068338,D002289,Negative_Correlation,FALSE,"<ENT1>RAD001</ENT1>, an oral inhibitor of the mammalian target of rapamycin (mTOR), has shown phase I efficacy in <ENT2>NSCLC</ENT2>.",,,,T,,,,,c,,,,,1.0,,
19549709,1726,D000068338,D002289,Negative_Correlation,FALSE,"METHODS: Stage IIIb or IV <ENT2>NSCLC</ENT2> patients, with two or fewer prior chemotherapy regimens, one platinum based (stratum 1) or both chemotherapy and epidermal growth factor receptor tyrosine kinase inhibitors (stratum 2), received <ENT1>RAD001</ENT1> 10 mg/day until progression or unacceptable toxicity.",,,,T,,,,,w,,,,,0.0,,
19549709,1726,D000068338,D002289,Negative_Correlation,FALSE,"CONCLUSIONS: <ENT1>RAD001</ENT1> 10 mg/day was well tolerated, showing modest clinical activity in pretreated <ENT2>NSCLC</ENT2>.",,,,T,,,,,w,,,,,0.0,,
19549709,1726,D000068338,D002289,Negative_Correlation,FALSE,Evaluation of <ENT1>RAD001</ENT1> plus standard therapy for metastatic <ENT2>NSCLC</ENT2> continues.,,,,T,,,,,w,,,,,0.0,,
19549709,1728,D010984,D002289,Negative_Correlation,FALSE,"METHODS: Stage IIIb or IV <ENT2>NSCLC</ENT2> patients, with two or fewer prior chemotherapy regimens, one <ENT1>platinum</ENT1> based (stratum 1) or both chemotherapy and epidermal growth factor receptor tyrosine kinase inhibitors (stratum 2), received RAD001 10 mg/day until progression or unacceptable toxicity.",,,,T,,,,,c,,,,,0.0,,
19549709,1724,2475,D002289,Association,FALSE,"RAD001, an oral inhibitor of the <ENT1>mammalian target of rapamycin</ENT1> (<ENT1>mTOR</ENT1>), has shown phase I efficacy in <ENT2>NSCLC</ENT2>.",,,,T,,,,,c,,,,,0.0,,
19549709,1727,D002289,1956,Association,FALSE,Efficacy of everolimus (RAD001) in patients with advanced <ENT1>NSCLC</ENT1> previously treated with chemotherapy alone or with chemotherapy and <ENT2>EGFR</ENT2> inhibitors.,,,,T,,,,,w,,,,,0.0,,
19549709,1727,D002289,1956,Association,FALSE,"METHODS: Stage IIIb or IV <ENT1>NSCLC</ENT1> patients, with two or fewer prior chemotherapy regimens, one platinum based (stratum 1) or both chemotherapy and <ENT2>epidermal growth factor receptor tyrosine kinase</ENT2> inhibitors (stratum 2), received RAD001 10 mg/day until progression or unacceptable toxicity.",,,,T,,,,,w,,,,,0.0,,
19565319,1739,D001321,135,Association,TRUE,<ENT2>Adenosine A(2A) receptor</ENT2> gene (<ENT2>ADORA2A</ENT2>) variants may increase <ENT1>autistic symptoms</ENT1> and anxiety in autism spectrum disorder.,,,,T,,,,,c,,,,,1.0,,
19565319,1739,D001321,135,Association,TRUE,"As <ENT1>autistic symptoms</ENT1> are increased in individuals with 22q11.2 deletion syndrome, and large 22q11.2 deletions and duplications have been observed in ASD individuals, in this study, 98 individuals with ASD and 234 control individuals were genotyped for eight single-nucleotide polymorphisms in <ENT2>ADORA2A</ENT2>.",,,,T,,,,,w,,,,,1.0,,
19565319,1736,D016584,135,Association,FALSE,The <ENT2>adenosine A(2A) receptor</ENT2> gene (<ENT2>ADORA2A</ENT2>) is associated with <ENT1>panic disorder</ENT1> and is located on chromosome 22q11.23.,,,,T,,,,,c,,,,,1.0,,
19565319,1732,rs2236624,D000067877,Association,TRUE,"Nominal association with the disorder was observed for <ENT1>rs2236624</ENT1>-CC, and phenotypic variability in <ENT2>ASD</ENT2> symptoms was influenced by rs3761422, rs5751876 and rs35320474.",,,,T,,,,,w,,,,,1.0,,
19565319,1738,135,D001008,Association,TRUE,<ENT1>Adenosine A(2A) receptor</ENT1> gene (<ENT1>ADORA2A</ENT1>) variants may increase autistic symptoms and <ENT2>anxiety</ENT2> in autism spectrum disorder.,,,,T,,,,,c,,,,,1.0,,
19565319,1738,135,D001008,Association,TRUE,"In addition, association of <ENT1>ADORA2A</ENT1> variants with <ENT2>anxiety</ENT2> was replicated for individuals with ASD.",,,,T,,,,,c,,,,,1.0,,
19565319,1737,135,D000067877,Association,TRUE,<ENT1>Adenosine A(2A) receptor</ENT1> gene (<ENT1>ADORA2A</ENT1>) variants may increase autistic symptoms and anxiety in <ENT2>autism spectrum disorder</ENT2>.,,,,T,,,,,c,,,,,1.0,,
19565319,1737,135,D000067877,Association,TRUE,"Its gene product, the <ENT1>adenosine A(2A) receptor</ENT1>, is strongly expressed in the caudate nucleus, which also is involved in <ENT2>ASD</ENT2>.",,,,T,,,,,c,,,,,1.0,,
19565319,1737,135,D000067877,Association,TRUE,"As autistic symptoms are increased in individuals with 22q11.2 deletion syndrome, and large 22q11.2 deletions and duplications have been observed in <ENT2>ASD</ENT2> individuals, in this study, 98 individuals with <ENT2>ASD</ENT2> and 234 control individuals were genotyped for eight single-nucleotide polymorphisms in <ENT1>ADORA2A</ENT1>.",,,,T,,,,,w,,,,,1.0,,
19565319,1737,135,D000067877,Association,TRUE,"In addition, association of <ENT1>ADORA2A</ENT1> variants with anxiety was replicated for individuals with <ENT2>ASD</ENT2>.",,,,T,Y,,,,c,,,,,1.0,,
19565319,1737,135,D000067877,Association,TRUE,Findings point toward a possible mediating role of <ENT1>ADORA2A</ENT1> variants on phenotypic expression in <ENT2>ASD</ENT2> that need to be replicated in a larger sample.,,,,T,,,,,c,,,,,0.0,,
19631624,1740,D020258,D018817,Positive_Correlation,TRUE,These <ENT2>ecstasy</ENT2>-specific effects may be related to the vulnerability of isocortical and allocortical regions to the <ENT1>neurotoxic</ENT1> effects of <ENT2>ecstasy</ENT2>.,,,,T,,,,,c,,,,,1.0,,
19631624,1747,D002188,D007859,Positive_Correlation,TRUE,<ENT2>Deficits in learning and memory</ENT2>: parahippocampal hyperactivity and frontocortical hypoactivity in <ENT1>cannabis</ENT1> users.,,,,T,,T,,,w,,,,,0.0,,
19631624,1745,D002188,D006948,Positive_Correlation,TRUE,Deficits in learning and memory: parahippocampal <ENT2>hyperactivity</ENT2> and frontocortical hypoactivity in <ENT1>cannabis</ENT1> users.,,,,T,,T,,,w,,,,,0.0,,
19631624,1743,D002188,D018817,Association,TRUE,"To address the potential confounding effects of the <ENT1>cannabis</ENT1> use of the <ENT2>ecstasy</ENT2> using group, a second analysis included 14 previously tested <ENT1>cannabis</ENT1> users (Nestor, L., Roberts, G., Garavan, H., Hester, R., 2008.",,,,T,,,,,c,,,,,0.0,,
19631624,1743,D002188,D018817,Association,TRUE,<ENT2>Ecstasy</ENT2> users performed significantly worse in learning and memory compared to controls and <ENT1>cannabis</ENT1> users.,,,,T,,,,,c,,,,,1.0,,
19631624,1743,D002188,D018817,Association,TRUE,"In both <ENT2>ecstasy</ENT2> and <ENT1>cannabis</ENT1> groups brain activation was decreased in the right medial frontal gyrus, left parahippocampal gyrus, left dorsal cingulate gyrus, and left caudate.",,,,T,,,,,c,,,,,1.0,,
19631624,1743,D002188,D018817,Association,TRUE,"These results elucidated <ENT2>ecstasy</ENT2>-related deficits, only some of which might be attributed to <ENT1>cannabis</ENT1> use.",,,,T,,,,,w,,,,,0.0,,
19631624,1744,D007859,D018817,Positive_Correlation,FALSE,<ENT1>Learning and memory deficits</ENT1> in <ENT2>ecstasy</ENT2> users and their neural correlates during a face-learning task.,,,,T,,T,,,w,,,,,0.0,,
19631624,1744,D007859,D018817,Positive_Correlation,FALSE,It has been consistently shown that <ENT2>ecstasy</ENT2> users display <ENT1>impairments in learning and memory</ENT1> performance.,,,,T,,,,,c,,,,,1.0,,
19631624,1741,D006948,D018817,Positive_Correlation,FALSE,"A conjunction analysis of the encode and recall phases of the task revealed <ENT2>ecstasy</ENT2>-specific <ENT1>hyperactivity</ENT1> in bilateral frontal regions, left temporal, right parietal, bilateral temporal, and bilateral occipital brain regions.",,,,T,,,,,c,,,,,0.0,,
19672862,1758,1027,5594,Association,TRUE,"p21 and <ENT1>p27</ENT1> expression was not increased by treatment of Ishikawa cells with <ENT2>ERK</ENT2> and Akt inhibitors, suggesting that PKCalpha regulates CDK expression independently of Akt and <ENT2>ERK</ENT2>.",,,,T,,,,,c,,,,,1.0,,
19672862,1758,1027,5594,Association,TRUE,These studies demonstrate a critical role for PKCalpha signaling in endometrial tumorigenesis by regulating expression of CDK inhibitors p21 and <ENT1>p27</ENT1> and activation of Akt and <ENT2>ERK</ENT2>-dependent proliferative pathways.,,,,T,,,,,c,,,,,1.0,,
19672862,1768,1027,5578,Negative_Correlation,TRUE,"Consistent with impaired growth, <ENT2>PKCalpha</ENT2> knockdown increased levels of the cyclin-dependent kinase (CDK) inhibitors p21(Cip1/WAF1) (p21) and <ENT1>p27</ENT1>(<ENT1>Kip1</ENT1>) (<ENT1>p27</ENT1>).",,,,T,,,,,c,,,,,1.0,,
19672862,1768,1027,5578,Negative_Correlation,TRUE,"p21 and <ENT1>p27</ENT1> expression was not increased by treatment of Ishikawa cells with ERK and Akt inhibitors, suggesting that <ENT2>PKCalpha</ENT2> regulates CDK expression independently of Akt and ERK.",,,,T,,,,,c,,,,,1.0,,
19672862,1768,1027,5578,Negative_Correlation,TRUE,These studies demonstrate a critical role for <ENT2>PKCalpha</ENT2> signaling in endometrial tumorigenesis by regulating expression of CDK inhibitors p21 and <ENT1>p27</ENT1> and activation of Akt and ERK-dependent proliferative pathways.,,,,T,,,,,c,,,,,0.0,,
19672862,1756,1027,983,Negative_Correlation,TRUE,"Consistent with impaired growth, PKCalpha knockdown increased levels of the <ENT2>cyclin-dependent kinase</ENT2> (<ENT2>CDK</ENT2>) inhibitors p21(Cip1/WAF1) (p21) and <ENT1>p27</ENT1>(<ENT1>Kip1</ENT1>) (<ENT1>p27</ENT1>).",,,,T,,,,,c,,,"11,12,21,22,31,32",,0.333333333,,
19672862,1756,1027,983,Negative_Correlation,TRUE,"p21 and <ENT1>p27</ENT1> expression was not increased by treatment of Ishikawa cells with ERK and Akt inhibitors, suggesting that PKCalpha regulates <ENT2>CDK</ENT2> expression independently of Akt and ERK.",,,,T,,,,,c,,,,,1.0,,
19672862,1756,1027,983,Negative_Correlation,TRUE,These studies demonstrate a critical role for PKCalpha signaling in endometrial tumorigenesis by regulating expression of <ENT2>CDK</ENT2> inhibitors p21 and <ENT1>p27</ENT1> and activation of Akt and ERK-dependent proliferative pathways.,,,,T,,,,,c,,,,,1.0,,
19672862,1759,1027,207,Association,TRUE,"p21 and <ENT1>p27</ENT1> expression was not increased by treatment of Ishikawa cells with ERK and <ENT2>Akt</ENT2> inhibitors, suggesting that PKCalpha regulates CDK expression independently of <ENT2>Akt</ENT2> and ERK.",,,,T,,,,,c,,,,,1.0,,
19672862,1759,1027,207,Association,TRUE,These studies demonstrate a critical role for PKCalpha signaling in endometrial tumorigenesis by regulating expression of CDK inhibitors p21 and <ENT1>p27</ENT1> and activation of <ENT2>Akt</ENT2> and ERK-dependent proliferative pathways.,,,,T,,,,,c,,,,,1.0,,
19672862,1751,1027,D009369,Association,TRUE,These studies demonstrate a critical role for PKCalpha signaling in endometrial <ENT2>tumorigenesis</ENT2> by regulating expression of CDK inhibitors p21 and <ENT1>p27</ENT1> and activation of Akt and ERK-dependent proliferative pathways.,,,,T,,,,,c,,,,,1.0,,
19672862,1765,2932,5578,Association,TRUE,"Despite the absence of functional phosphatase and tensin homolog (PTEN) protein in Ishikawa cells, <ENT2>PKCalpha</ENT2> knockdown reduced Akt phosphorylation at serine 473 and concomitantly inhibited phosphorylation of the Akt target, <ENT1>glycogen synthase kinase-3beta</ENT1> (<ENT1>GSK-3beta</ENT1>).",,,,T,,,,,c,,,,,0.0,,
19672862,1755,2932,207,Association,TRUE,"Despite the absence of functional phosphatase and tensin homolog (PTEN) protein in Ishikawa cells, PKCalpha knockdown reduced <ENT2>Akt</ENT2> phosphorylation at serine 473 and concomitantly inhibited phosphorylation of the <ENT2>Akt</ENT2> target, <ENT1>glycogen synthase kinase-3beta</ENT1> (<ENT1>GSK-3beta</ENT1>).",,,,T,,,,,c,,,,,0.0,,
19672862,1764,5594,5578,Positive_Correlation,TRUE,<ENT2>PKCalpha</ENT2> knockdown also resulted in decreased basal <ENT1>ERK</ENT1> phosphorylation and attenuated <ENT1>ERK</ENT1> activation following EGF stimulation.,,,,T,,,,,c,,,,,1.0,,
19672862,1764,5594,5578,Positive_Correlation,TRUE,"p21 and p27 expression was not increased by treatment of Ishikawa cells with <ENT1>ERK</ENT1> and Akt inhibitors, suggesting that <ENT2>PKCalpha</ENT2> regulates CDK expression independently of Akt and <ENT1>ERK</ENT1>.",,,,T,,,,,w,,,,,1.0,,
19672862,1764,5594,5578,Positive_Correlation,TRUE,These studies demonstrate a critical role for <ENT2>PKCalpha</ENT2> signaling in endometrial tumorigenesis by regulating expression of CDK inhibitors p21 and p27 and activation of Akt and <ENT1>ERK</ENT1>-dependent proliferative pathways.,,,,T,,,,,w,,,,,1.0,,
19672862,1748,5594,D009369,Association,TRUE,These studies demonstrate a critical role for PKCalpha signaling in endometrial <ENT2>tumorigenesis</ENT2> by regulating expression of CDK inhibitors p21 and p27 and activation of Akt and <ENT1>ERK</ENT1>-dependent proliferative pathways.,,,,T,Y,,,,c,,,,,1.0,,
19672862,1760,5594,1026,Association,TRUE,"<ENT2>p21</ENT2> and p27 expression was not increased by treatment of Ishikawa cells with <ENT1>ERK</ENT1> and Akt inhibitors, suggesting that PKCalpha regulates CDK expression independently of Akt and <ENT1>ERK</ENT1>.",,,,T,,,,,c,,,,,1.0,,
19672862,1760,5594,1026,Association,TRUE,These studies demonstrate a critical role for PKCalpha signaling in endometrial tumorigenesis by regulating expression of CDK inhibitors <ENT2>p21</ENT2> and p27 and activation of Akt and <ENT1>ERK</ENT1>-dependent proliferative pathways.,,,,T,,,,,c,,,,,1.0,,
19672862,1754,5594,1950,Positive_Correlation,TRUE,PKCalpha knockdown also resulted in decreased basal <ENT1>ERK</ENT1> phosphorylation and attenuated <ENT1>ERK</ENT1> activation following <ENT2>EGF</ENT2> stimulation.,,,,T,,,,,c,,,,,0.5,,
19672862,1753,5578,D016889,Association,TRUE,<ENT1>Protein kinase C alpha</ENT1>-dependent signaling mediates <ENT2>endometrial cancer</ENT2> cell growth and tumorigenesis.,,,,T,,,,,c,,,,,1.0,,
19672862,1753,5578,D016889,Association,TRUE,"We sought to define a functional role for the <ENT1>protein kinase C</ENT1> (<ENT1>PKC</ENT1>) isoform, <ENT1>PKCalpha</ENT1>, in an established cell model of <ENT2>endometrial adenocarcinoma</ENT2>.",,,,T,,Y,,,c,,,,,1.0,,
19672862,1753,5578,D016889,Association,TRUE,"Immunohistochemical analysis of Grade 1 <ENT2>endometrioid adenocarcinoma</ENT2> revealed aberrant <ENT1>PKCalpha</ENT1> expression, with foci of elevated <ENT1>PKCalpha</ENT1> staining, not observed in normal endometrium.",,,,T,,,,,c,,,,,1.0,,
19672862,1753,5578,D016889,Association,TRUE,"Thus, targeting <ENT1>PKCalpha</ENT1> may provide novel therapeutic options in <ENT2>endometrial tumors</ENT2>.",,,,T,,,,,c,,,,,0.0,,
19672862,1767,5578,983,Association,TRUE,"Consistent with impaired growth, <ENT1>PKCalpha</ENT1> knockdown increased levels of the <ENT2>cyclin-dependent kinase</ENT2> (<ENT2>CDK</ENT2>) inhibitors p21(Cip1/WAF1) (p21) and p27(Kip1) (p27).",,,,T,,,,,c,,,,,0.5,,
19672862,1767,5578,983,Association,TRUE,"p21 and p27 expression was not increased by treatment of Ishikawa cells with ERK and Akt inhibitors, suggesting that <ENT1>PKCalpha</ENT1> regulates <ENT2>CDK</ENT2> expression independently of Akt and ERK.",,,,T,,,,,c,,,,,0.0,,
19672862,1767,5578,983,Association,TRUE,These studies demonstrate a critical role for <ENT1>PKCalpha</ENT1> signaling in endometrial tumorigenesis by regulating expression of <ENT2>CDK</ENT2> inhibitors p21 and p27 and activation of Akt and ERK-dependent proliferative pathways.,,,,T,,,,,c,,,,,1.0,,
19672862,1766,5578,207,Association,TRUE,"Despite the absence of functional phosphatase and tensin homolog (PTEN) protein in Ishikawa cells, <ENT1>PKCalpha</ENT1> knockdown reduced <ENT2>Akt</ENT2> phosphorylation at serine 473 and concomitantly inhibited phosphorylation of the <ENT2>Akt</ENT2> target, glycogen synthase kinase-3beta (GSK-3beta).",,,,T,,,,,c,,,,,0.0,,
19672862,1766,5578,207,Association,TRUE,"p21 and p27 expression was not increased by treatment of Ishikawa cells with ERK and <ENT2>Akt</ENT2> inhibitors, suggesting that <ENT1>PKCalpha</ENT1> regulates CDK expression independently of <ENT2>Akt</ENT2> and ERK.",,,,T,,,,,c,,,,,1.0,,
19672862,1766,5578,207,Association,TRUE,These studies demonstrate a critical role for <ENT1>PKCalpha</ENT1> signaling in endometrial tumorigenesis by regulating expression of CDK inhibitors p21 and p27 and activation of <ENT2>Akt</ENT2> and ERK-dependent proliferative pathways.,,,,T,,,,,c,,,,,0.0,,
19672862,1762,5578,D009369,Association,TRUE,<ENT1>Protein kinase C alpha</ENT1>-dependent signaling mediates endometrial cancer cell growth and <ENT2>tumorigenesis</ENT2>.,,,,T,,,,,c,,,,,1.0,,
19672862,1762,5578,D009369,Association,TRUE,"Ishikawa cells depleted of <ENT1>PKCalpha</ENT1> protein grew slower, formed fewer colonies in anchorage-independent growth assays and exhibited impaired xenograft <ENT2>tumor</ENT2> formation in nude mice.",,,,T,,,,,c,,,,,0.0,,
19672862,1762,5578,D009369,Association,TRUE,These studies demonstrate a critical role for <ENT1>PKCalpha</ENT1> signaling in endometrial <ENT2>tumorigenesis</ENT2> by regulating expression of CDK inhibitors p21 and p27 and activation of Akt and ERK-dependent proliferative pathways.,,,,T,,,,,c,,,,,1.0,,
19672862,1769,5578,1026,Negative_Correlation,TRUE,"Consistent with impaired growth, <ENT1>PKCalpha</ENT1> knockdown increased levels of the cyclin-dependent kinase (CDK) inhibitors <ENT2>p21</ENT2>(<ENT2>Cip1</ENT2>/<ENT2>WAF1</ENT2>) (<ENT2>p21</ENT2>) and p27(Kip1) (p27).",,,,T,,,,,c,,,,,1.0,,
19672862,1769,5578,1026,Negative_Correlation,TRUE,"<ENT2>p21</ENT2> and p27 expression was not increased by treatment of Ishikawa cells with ERK and Akt inhibitors, suggesting that <ENT1>PKCalpha</ENT1> regulates CDK expression independently of Akt and ERK.",,,,T,,,,,c,,,,,1.0,,
19672862,1769,5578,1026,Negative_Correlation,TRUE,These studies demonstrate a critical role for <ENT1>PKCalpha</ENT1> signaling in endometrial tumorigenesis by regulating expression of CDK inhibitors <ENT2>p21</ENT2> and p27 and activation of Akt and ERK-dependent proliferative pathways.,,,,T,,,,,w,,,,,0.0,,
19672862,1763,5578,1950,Association,TRUE,<ENT1>PKCalpha</ENT1> knockdown also resulted in decreased basal ERK phosphorylation and attenuated ERK activation following <ENT2>EGF</ENT2> stimulation.,,,,T,,,,,c,,,,,0.0,,
19672862,1750,983,D009369,Association,TRUE,These studies demonstrate a critical role for PKCalpha signaling in endometrial <ENT2>tumorigenesis</ENT2> by regulating expression of <ENT1>CDK</ENT1> inhibitors p21 and p27 and activation of Akt and ERK-dependent proliferative pathways.,,,,T,,,,,c,,,,,0.0,,
19672862,1757,983,1026,Negative_Correlation,TRUE,"Consistent with impaired growth, PKCalpha knockdown increased levels of the <ENT1>cyclin-dependent kinase</ENT1> (<ENT1>CDK</ENT1>) inhibitors <ENT2>p21</ENT2>(<ENT2>Cip1</ENT2>/<ENT2>WAF1</ENT2>) (<ENT2>p21</ENT2>) and p27(Kip1) (p27).",,,,T,,,,,c,,,"11,12,13,14,21,22,23,24",,0.5,,
19672862,1757,983,1026,Negative_Correlation,TRUE,"<ENT2>p21</ENT2> and p27 expression was not increased by treatment of Ishikawa cells with ERK and Akt inhibitors, suggesting that PKCalpha regulates <ENT1>CDK</ENT1> expression independently of Akt and ERK.",,,,T,,,,,w,,,,,0.0,,
19672862,1757,983,1026,Negative_Correlation,TRUE,These studies demonstrate a critical role for PKCalpha signaling in endometrial tumorigenesis by regulating expression of <ENT1>CDK</ENT1> inhibitors <ENT2>p21</ENT2> and p27 and activation of Akt and ERK-dependent proliferative pathways.,,,,T,,,,,c,,,,,0.0,,
19672862,1749,207,D009369,Association,TRUE,These studies demonstrate a critical role for PKCalpha signaling in endometrial <ENT2>tumorigenesis</ENT2> by regulating expression of CDK inhibitors p21 and p27 and activation of <ENT1>Akt</ENT1> and ERK-dependent proliferative pathways.,,,,T,,,,,c,,,,,1.0,,
19672862,1761,207,1026,Association,TRUE,"<ENT2>p21</ENT2> and p27 expression was not increased by treatment of Ishikawa cells with ERK and <ENT1>Akt</ENT1> inhibitors, suggesting that PKCalpha regulates CDK expression independently of <ENT1>Akt</ENT1> and ERK.",,,,T,,,,,c,,,,,1.0,,
19672862,1761,207,1026,Association,TRUE,These studies demonstrate a critical role for PKCalpha signaling in endometrial tumorigenesis by regulating expression of CDK inhibitors <ENT2>p21</ENT2> and p27 and activation of <ENT1>Akt</ENT1> and ERK-dependent proliferative pathways.,,,,T,,,,,c,,,,,1.0,,
19672862,1752,D009369,1026,Association,TRUE,These studies demonstrate a critical role for PKCalpha signaling in endometrial <ENT1>tumorigenesis</ENT1> by regulating expression of CDK inhibitors <ENT2>p21</ENT2> and p27 and activation of Akt and ERK-dependent proliferative pathways.,,,,T,,,,,c,,,,,1.0,,
19681452,1777,D002544,D003042,Positive_Correlation,FALSE,<ENT2>Cocaine</ENT2> is a risk factor for both <ENT1>ischemic and haemorrhagic stroke</ENT1>.,,,,T,,,,,c,,,,,1.0,,
19681452,1775,D003932,D020520,Positive_Correlation,FALSE,Drug-related <ENT2>globus pallidus infarctions</ENT2> are most often associated with <ENT1>heroin</ENT1>.,,,,T,,,,,c,,,,,0.0,,
19681452,1775,D003932,D020520,Positive_Correlation,FALSE,"Bilateral <ENT2>basal ganglia infarcts</ENT2> after the use of cocaine, without concurrent <ENT1>heroin</ENT1> use, have never been reported.",,,,T,,,,,c,,,,,1.0,,
19681452,1771,D012131,D000431,Positive_Correlation,TRUE,"In our patient, transient cardiac arrhythmia or <ENT1>respiratory dysfunction</ENT1> related to cocaine and/or <ENT2>ethanol</ENT2> use were the most likely causes of cerebral hypoperfusion.",,,,T,,,,,c,,,,,1.0,,
19681452,1779,D012131,D003042,Positive_Correlation,TRUE,"In our patient, transient cardiac arrhythmia or <ENT1>respiratory dysfunction</ENT1> related to <ENT2>cocaine</ENT2> and/or ethanol use were the most likely causes of cerebral hypoperfusion.",,,,T,,,,,c,,,,,1.0,,
19681452;19681452,1774;1773,D002543;D020520,D000431;D000431,Positive_Correlation;Positive_Correlation,TRUE;TRUE,Bilateral <ENT1>haemorrhagic infarction of the globus pallidus</ENT1> after cocaine and <ENT2>alcohol</ENT2> intoxication.,,,,T,,T,,,w,,,,,0.0,,
19681452;19681452,1782;1781,D002543;D020520,D003042;D003042,Positive_Correlation;Positive_Correlation,TRUE;TRUE,Bilateral <ENT1>haemorrhagic infarction of the globus pallidus</ENT1> after <ENT2>cocaine</ENT2> and alcohol intoxication.,,,,T,,T,,,w,,,,,1.0,,
19681452,1770,D002545,D000431,Positive_Correlation,TRUE,We present the case of a 31-year-old man with bilateral <ENT1>ischemia of the globus pallidus</ENT1> after excessive <ENT2>alcohol</ENT2> and intranasal cocaine use.,,,,T,,,,,c,,,,,1.0,,
19681452,1770,D002545,D000431,Positive_Correlation,TRUE,"In our patient, transient cardiac arrhythmia or respiratory dysfunction related to cocaine and/or <ENT2>ethanol</ENT2> use were the most likely causes of <ENT1>cerebral hypoperfusion</ENT1>.",,,,T,,,,,c,,,,,1.0,,
19681452,1778,D002545,D003042,Positive_Correlation,TRUE,We present the case of a 31-year-old man with bilateral <ENT1>ischemia of the globus pallidus</ENT1> after excessive alcohol and intranasal <ENT2>cocaine</ENT2> use.,,,,T,,,,,c,,,,,1.0,,
19681452,1778,D002545,D003042,Positive_Correlation,TRUE,"In our patient, transient cardiac arrhythmia or respiratory dysfunction related to <ENT2>cocaine</ENT2> and/or ethanol use were the most likely causes of <ENT1>cerebral hypoperfusion</ENT1>.",,,,T,,,,,c,,,,,1.0,,
19681452,1781,D020520,D003042,Positive_Correlation,TRUE,"Bilateral <ENT1>basal ganglia infarcts</ENT1> after the use of <ENT2>cocaine</ENT2>, without concurrent heroin use, have never been reported.",,,,T,,Y,,,w,,,,,1.0,,
19681452,1772,D000431,D001145,Positive_Correlation,TRUE,"In our patient, transient <ENT2>cardiac arrhythmia</ENT2> or respiratory dysfunction related to cocaine and/or <ENT1>ethanol</ENT1> use were the most likely causes of cerebral hypoperfusion.",,,,T,,,,,c,,,,,1.0,,
19681452,1780,D001145,D003042,Positive_Correlation,TRUE,"In our patient, transient <ENT1>cardiac arrhythmia</ENT1> or respiratory dysfunction related to <ENT2>cocaine</ENT2> and/or ethanol use were the most likely causes of cerebral hypoperfusion.",,,,T,,,,,c,,,,,1.0,,
19707748,1783,1544,D064704,Association,TRUE,"PURPOSE: We present a case of a patient who developed seizures shortly after initiating treatment with <ENT2>levofloxacin</ENT2> and to discuss the potential drug-drug interactions related to the inhibition of <ENT1>cytochrome P450 (CYP) 1A2</ENT1> in this case, as well as in other cases, of <ENT2>levofloxacin</ENT2>-induced seizures.",,,,T,,,,,c,,,,,1.0,,
19707748,1783,1544,D064704,Association,TRUE,Drug-drug interactions related to the inhibition of <ENT1>CYP1A2</ENT1> by <ENT2>levofloxacin</ENT2> are likely involved in the clinical outcome of these cases.,,,,T,,,,,w,,,,,0.0,,
19707748,1783,1544,D064704,Association,TRUE,CONCLUSIONS: Clinicians are exhorted to pay close attention when initiating <ENT2>levofloxacin</ENT2> therapy in patients taking medications with epileptogenic properties that are <ENT1>CYP1A2</ENT1> substrates.,,,,T,,,,,w,,,,,0.0,,
19707748,1784,D012640,D064704,Positive_Correlation,TRUE,<ENT1>Seizures</ENT1> associated with <ENT2>levofloxacin</ENT2>: case presentation and literature review.,,,,T,,T,,,c,,,,,1.0,,
19707748,1784,D012640,D064704,Positive_Correlation,TRUE,"PURPOSE: We present a case of a patient who developed <ENT1>seizures</ENT1> shortly after initiating treatment with <ENT2>levofloxacin</ENT2> and to discuss the potential drug-drug interactions related to the inhibition of cytochrome P450 (CYP) 1A2 in this case, as well as in other cases, of <ENT2>levofloxacin</ENT2>-induced <ENT1>seizures</ENT1>.",,,,T,,,,,c,,,"11,22",,1.0,,
19707748,1784,D012640,D064704,Positive_Correlation,TRUE,RESULTS: Six cases of <ENT2>levofloxacin</ENT2>-induced <ENT1>seizures</ENT1> have been reported in the literature.,,,,T,,,,,c,,,,,1.0,,
19721134,1789,100379235,C042375,Negative_Correlation,FALSE,"Moreover, <ENT1>M(3)-muscarinic acetylcholine receptor</ENT1> (<ENT1>mAChR</ENT1>) antagonist <ENT2>4-DAMP</ENT2> (<ENT2>4-diphenylacetoxy-N-methylpiperidine-methiodide</ENT2>) partially abolished the beneficial effects of pilocarpine.",,,,T,,,,,c,,,"11,12,21,22",,0.75,,
19721134,1790,100379235,D010042,Association,TRUE,These data suggest that pilocarpine produced antiarrhythmic actions on arrhythmic rat and guinea pig models induced by aconitine or <ENT2>ouabain</ENT2> via stimulating the cardiac <ENT1>M(3)-mAChR</ENT1>.,,,,T,,,,,c,,,,,0.0,,
19721134,1791,100379235,D000157,Association,TRUE,These data suggest that pilocarpine produced antiarrhythmic actions on arrhythmic rat and guinea pig models induced by <ENT2>aconitine</ENT2> or ouabain via stimulating the cardiac <ENT1>M(3)-mAChR</ENT1>.,,,,T,,,,,w,,,,,0.0,,
19721134,1800,100379235,D010862,Association,TRUE,"Moreover, <ENT1>M(3)-muscarinic acetylcholine receptor</ENT1> (<ENT1>mAChR</ENT1>) antagonist 4-DAMP (4-diphenylacetoxy-N-methylpiperidine-methiodide) partially abolished the beneficial effects of <ENT2>pilocarpine</ENT2>.",,,,T,,,,,c,,,,,0.0,,
19721134,1800,100379235,D010862,Association,TRUE,These data suggest that <ENT2>pilocarpine</ENT2> produced antiarrhythmic actions on arrhythmic rat and guinea pig models induced by aconitine or ouabain via stimulating the cardiac <ENT1>M(3)-mAChR</ENT1>.,,,,T,,,,,w,,,,,0.0,,
19721134,1792,100379235,D001145,Association,TRUE,These data suggest that pilocarpine produced antiarrhythmic actions on <ENT2>arrhythmic</ENT2> rat and guinea pig models induced by aconitine or ouabain via stimulating the cardiac <ENT1>M(3)-mAChR</ENT1>.,,,,T,,,,,c,,,,,0.0,,
19721134,1793,C042375,D010862,Negative_Correlation,TRUE,"Moreover, M(3)-muscarinic acetylcholine receptor (mAChR) antagonist <ENT1>4-DAMP</ENT1> (<ENT1>4-diphenylacetoxy-N-methylpiperidine-methiodide</ENT1>) partially abolished the beneficial effects of <ENT2>pilocarpine</ENT2>.",,,,T,,,,,c,,,,,0.5,,
19721134,1801,D010042,D010862,Negative_Correlation,TRUE,"This study was designed to evaluate the effects of <ENT2>pilocarpine</ENT2> and explore the underlying ionic mechanism, using both aconitine-induced rat and <ENT1>ouabain</ENT1>-induced guinea pig arrhythmia models.",,,,T,,,,,c,,,,,1.0,,
19721134,1801,D010042,D010862,Negative_Correlation,TRUE,[Ca(2+)](i) overload induced by aconitine or <ENT1>ouabain</ENT1> was reduced in isolated myocytes pretreated with <ENT2>pilocarpine</ENT2>.,,,,T,,,,,c,,,,,1.0,,
19721134,1801,D010042,D010862,Negative_Correlation,TRUE,These data suggest that <ENT2>pilocarpine</ENT2> produced antiarrhythmic actions on arrhythmic rat and guinea pig models induced by aconitine or <ENT1>ouabain</ENT1> via stimulating the cardiac M(3)-mAChR.,,,,T,,,,,w,,,,,0.0,,
19721134,1797,D010042,D001145,Positive_Correlation,FALSE,"This study was designed to evaluate the effects of pilocarpine and explore the underlying ionic mechanism, using both aconitine-induced rat and <ENT1>ouabain</ENT1>-induced guinea pig <ENT2>arrhythmia</ENT2> models.",,,,T,,,,,c,,,,,0.0,,
19721134,1797,D010042,D001145,Positive_Correlation,FALSE,These data suggest that pilocarpine produced antiarrhythmic actions on <ENT2>arrhythmic</ENT2> rat and guinea pig models induced by aconitine or <ENT1>ouabain</ENT1> via stimulating the cardiac M(3)-mAChR.,,,,T,,,,,c,,,,,0.0,,
19721134,1794,D010042,D002118,Positive_Correlation,FALSE,[<ENT2>Ca(2+)</ENT2>](i) overload induced by aconitine or <ENT1>ouabain</ENT1> was reduced in isolated myocytes pretreated with pilocarpine.,,,,T,,,,,c,,,,,1.0,,
19721134,1802,D000157,D010862,Negative_Correlation,TRUE,"This study was designed to evaluate the effects of <ENT2>pilocarpine</ENT2> and explore the underlying ionic mechanism, using both <ENT1>aconitine</ENT1>-induced rat and ouabain-induced guinea pig arrhythmia models.",,,,T,,,,,c,,,,,1.0,,
19721134,1802,D000157,D010862,Negative_Correlation,TRUE,[Ca(2+)](i) overload induced by <ENT1>aconitine</ENT1> or ouabain was reduced in isolated myocytes pretreated with <ENT2>pilocarpine</ENT2>.,,,,T,,,,,c,,,,,1.0,,
19721134,1802,D000157,D010862,Negative_Correlation,TRUE,These data suggest that <ENT2>pilocarpine</ENT2> produced antiarrhythmic actions on arrhythmic rat and guinea pig models induced by <ENT1>aconitine</ENT1> or ouabain via stimulating the cardiac M(3)-mAChR.,,,,T,Y,,,,c,,,,,0.0,,
19721134,1798,D000157,D001145,Positive_Correlation,FALSE,"This study was designed to evaluate the effects of pilocarpine and explore the underlying ionic mechanism, using both <ENT1>aconitine</ENT1>-induced rat and ouabain-induced guinea pig <ENT2>arrhythmia</ENT2> models.",,,,T,,,,,c,,,,,1.0,,
19721134,1798,D000157,D001145,Positive_Correlation,FALSE,These data suggest that pilocarpine produced antiarrhythmic actions on <ENT2>arrhythmic</ENT2> rat and guinea pig models induced by <ENT1>aconitine</ENT1> or ouabain via stimulating the cardiac M(3)-mAChR.,,,,T,,,,,c,,,,,1.0,,
19721134,1795,D000157,D002118,Positive_Correlation,FALSE,[<ENT2>Ca(2+)</ENT2>](i) overload induced by <ENT1>aconitine</ENT1> or ouabain was reduced in isolated myocytes pretreated with pilocarpine.,,,,T,,,,,c,,,,,1.0,,
19721134,1804,D010862,D017180|D014693,Negative_Correlation,TRUE,"The current data showed that <ENT1>pilocarpine</ENT1> significantly delayed onset of arrhythmias, decreased the time course of <ENT2>ventricular tachycardia and fibrillation</ENT2>, reduced arrhythmia score, and increased the survival time of arrhythmic rats and guinea pigs.",,,,T,,,,,c,,,,,1.0,,
19721134,1803,D010862,D001145,Negative_Correlation,TRUE,"This study was designed to evaluate the effects of <ENT1>pilocarpine</ENT1> and explore the underlying ionic mechanism, using both aconitine-induced rat and ouabain-induced guinea pig <ENT2>arrhythmia</ENT2> models.",,,,T,,Y,,,c,,,,,1.0,,
19721134,1803,D010862,D001145,Negative_Correlation,TRUE,"The current data showed that <ENT1>pilocarpine</ENT1> significantly delayed onset of <ENT2>arrhythmias</ENT2>, decreased the time course of ventricular tachycardia and fibrillation, reduced <ENT2>arrhythmia</ENT2> score, and increased the survival time of <ENT2>arrhythmic</ENT2> rats and guinea pigs.",,,,T,,,,,c,,,,,1.0,,
19721134,1803,D010862,D001145,Negative_Correlation,TRUE,These data suggest that <ENT1>pilocarpine</ENT1> produced antiarrhythmic actions on <ENT2>arrhythmic</ENT2> rat and guinea pig models induced by aconitine or ouabain via stimulating the cardiac M(3)-mAChR.,,,,T,,,,,c,,,,,0.0,,
19721134,1796,D010862,D002118,Negative_Correlation,TRUE,[<ENT2>Ca(2+)</ENT2>](i) overload induced by aconitine or ouabain was reduced in isolated myocytes pretreated with <ENT1>pilocarpine</ENT1>.,,,,T,,,,,c,,,,,1.0,,
19759529,1818,14810,D012559,Association,FALSE,"However, the observation that antagonists of the <ENT1>glutamate N-methyl-D-aspartate (NMDA) receptor</ENT1> produce <ENT2>schizophrenic</ENT2>-like symptoms in humans has led to the idea of a dysfunctioning of the glutamatergic system via its <ENT1>NMDA receptor</ENT1>.",,,,T,,,,,c,,,,,0.0,,
19759529,1820,14810,D005998,Positive_Correlation,TRUE,"Among them are glycine transporter-1 (GlyT1) inhibitors such as SSR103800, which indirectly enhance <ENT1>NMDA receptor</ENT1> function by increasing the <ENT2>glycine</ENT2> (a co-agonist for the <ENT1>NMDA receptor</ENT1>) levels in the synapse.",,,,T,,,,,c,,,,,0.5,,
19759529,1822,14810,-1,Positive_Correlation,TRUE,"Among them are glycine transporter-1 (GlyT1) inhibitors such as <ENT2>SSR103800</ENT2>, which indirectly enhance <ENT1>NMDA receptor</ENT1> function by increasing the glycine (a co-agonist for the <ENT1>NMDA receptor</ENT1>) levels in the synapse.",,,,T,,,,,c,,,,,0.5,,
19759529,1822,14810,-1,Positive_Correlation,TRUE,"This study aimed at investigating the potential antipsychotic-like properties of <ENT2>SSR103800</ENT2>, with a particular focus on models of hyperactivity, involving either drug challenge (ie, amphetamine and MK-801) or transgenic mice (ie, <ENT1>NMDA Nr1</ENT1>(neo-/-) and DAT(-/-)).",,,,T,,,,,c,,,,,1.0,,
19759529,1822,14810,-1,Positive_Correlation,TRUE,"Results showed that <ENT2>SSR103800</ENT2> (10-30 mg/kg p.o.) blocked hyperactivity induced by the non-competitive <ENT1>NMDA receptor</ENT1> antagonist, MK-801 and partially reversed spontaneous hyperactivity of <ENT1>NMDA Nr1</ENT1>(neo-/-) mice.",,,,T,Y,,,,w,,,,,0.5,,
19759529,1817,14810,D006948,Association,TRUE,"This study aimed at investigating the potential antipsychotic-like properties of SSR103800, with a particular focus on models of <ENT2>hyperactivity</ENT2>, involving either drug challenge (ie, amphetamine and MK-801) or transgenic mice (ie, <ENT1>NMDA Nr1</ENT1>(neo-/-) and DAT(-/-)).",,,,T,,,,,w,,,,,0.0,,
19759529,1817,14810,D006948,Association,TRUE,"Results showed that SSR103800 (10-30 mg/kg p.o.) blocked <ENT2>hyperactivity</ENT2> induced by the non-competitive <ENT1>NMDA receptor</ENT1> antagonist, MK-801 and partially reversed spontaneous <ENT2>hyperactivity</ENT2> of <ENT1>NMDA Nr1</ENT1>(neo-/-) mice.",,,,T,,,,,c,,,"11,22",,0.0,,
19759529,1819,14810,D016291,Negative_Correlation,TRUE,"This study aimed at investigating the potential antipsychotic-like properties of SSR103800, with a particular focus on models of hyperactivity, involving either drug challenge (ie, amphetamine and <ENT2>MK-801</ENT2>) or transgenic mice (ie, <ENT1>NMDA Nr1</ENT1>(neo-/-) and DAT(-/-)).",,,,T,,,,,c,,,,,1.0,,
19759529,1819,14810,D016291,Negative_Correlation,TRUE,"Results showed that SSR103800 (10-30 mg/kg p.o.) blocked hyperactivity induced by the non-competitive <ENT1>NMDA receptor</ENT1> antagonist, <ENT2>MK-801</ENT2> and partially reversed spontaneous hyperactivity of <ENT1>NMDA Nr1</ENT1>(neo-/-) mice.",,,,T,,,,,c,,,,,0.5,,
19759529,1813,D012559,D004298,Association,FALSE,<ENT1>Schizophrenia</ENT1> has been initially associated with dysfunction in <ENT2>dopamine</ENT2> neurotransmission.,,,,T,,,,,c,,,,,1.0,,
19759529,1823,D005998,-1,Positive_Correlation,TRUE,"Among them are glycine transporter-1 (GlyT1) inhibitors such as <ENT2>SSR103800</ENT2>, which indirectly enhance NMDA receptor function by increasing the <ENT1>glycine</ENT1> (a co-agonist for the NMDA receptor) levels in the synapse.",,,,T,,,,,c,,,,,1.0,,
19759529,1824,14664,-1,Negative_Correlation,TRUE,The <ENT1>glycine transporter-1</ENT1> inhibitor <ENT2>SSR103800</ENT2> displays a selective and specific antipsychotic-like profile in normal and transgenic mice.,,,,T,,,,,c,,,,,1.0,,
19759529,1824,14664,-1,Negative_Correlation,TRUE,"Among them are <ENT1>glycine transporter-1</ENT1> (<ENT1>GlyT1</ENT1>) inhibitors such as <ENT2>SSR103800</ENT2>, which indirectly enhance NMDA receptor function by increasing the glycine (a co-agonist for the NMDA receptor) levels in the synapse.",,,,T,,,,,c,,,,,1.0,,
19759529,1824,14664,-1,Negative_Correlation,TRUE,"Together these findings show that the <ENT1>GlyT1</ENT1> inhibitor, <ENT2>SSR103800</ENT2>, produces antipsychotic-like effects, which differ from those observed with compounds primarily targeting the dopaminergic system, and has a reduced side-effect potential as compared with these latter drugs.",,,,T,,,,,c,,,,,1.0,,
19759529,1815,D000661,D006948,Positive_Correlation,FALSE,"This study aimed at investigating the potential antipsychotic-like properties of SSR103800, with a particular focus on models of <ENT2>hyperactivity</ENT2>, involving either drug challenge (ie, <ENT1>amphetamine</ENT1> and MK-801) or transgenic mice (ie, NMDA Nr1(neo-/-) and DAT(-/-)).",,,,T,,,,,w,,,,,0.0,,
19759529,1815,D000661,D006948,Positive_Correlation,FALSE,"In contrast, SSR103800 failed to affect <ENT2>hyperactivity</ENT2> induced by <ENT1>amphetamine</ENT1> or naturally observed in dopamine transporter (DAT(-/-)) knockout mice (10-30 mg/kg p.o.).",,,,T,,,,,c,,,,,0.0,,
19759529,1806,C094645,D006948,Negative_Correlation,TRUE,"Importantly, both classical (haloperidol) and atypical (olanzapine, clozapine and <ENT1>aripiprazole</ENT1>) antipsychotics were effective in all these models of <ENT2>hyperactivity</ENT2>.",,,,T,,,,,c,,,,,0.0,,
19759529,1812,D006220,D006948,Negative_Correlation,TRUE,"Importantly, both classical (<ENT1>haloperidol</ENT1>) and atypical (olanzapine, clozapine and aripiprazole) antipsychotics were effective in all these models of <ENT2>hyperactivity</ENT2>.",,,,T,,,,,c,,,,,0.0,,
19759529,1808,D003024,D006948,Negative_Correlation,TRUE,"Importantly, both classical (haloperidol) and atypical (olanzapine, <ENT1>clozapine</ENT1> and aripiprazole) antipsychotics were effective in all these models of <ENT2>hyperactivity</ENT2>.",,,,T,,,,,c,,,,,0.0,,
19759529,1821,-1,D006948,Negative_Correlation,TRUE,"This study aimed at investigating the potential antipsychotic-like properties of <ENT1>SSR103800</ENT1>, with a particular focus on models of <ENT2>hyperactivity</ENT2>, involving either drug challenge (ie, amphetamine and MK-801) or transgenic mice (ie, NMDA Nr1(neo-/-) and DAT(-/-)).",,,,T,,Y,,,c,,,,,1.0,,
19759529,1821,-1,D006948,Negative_Correlation,TRUE,"Results showed that <ENT1>SSR103800</ENT1> (10-30 mg/kg p.o.) blocked <ENT2>hyperactivity</ENT2> induced by the non-competitive NMDA receptor antagonist, MK-801 and partially reversed spontaneous <ENT2>hyperactivity</ENT2> of NMDA Nr1(neo-/-) mice.",,,,T,,,,,c,,,,,1.0,,
19759529,1821,-1,D006948,Negative_Correlation,TRUE,"In contrast, <ENT1>SSR103800</ENT1> failed to affect <ENT2>hyperactivity</ENT2> induced by amphetamine or naturally observed in dopamine transporter (DAT(-/-)) knockout mice (10-30 mg/kg p.o.).",,,,T,,,,,c,,,,,1.0,,
19759529,1814,-1,D016291,Negative_Correlation,TRUE,"This study aimed at investigating the potential antipsychotic-like properties of <ENT1>SSR103800</ENT1>, with a particular focus on models of hyperactivity, involving either drug challenge (ie, amphetamine and <ENT2>MK-801</ENT2>) or transgenic mice (ie, NMDA Nr1(neo-/-) and DAT(-/-)).",,,,T,,,,,w,,,,,0.0,,
19759529,1814,-1,D016291,Negative_Correlation,TRUE,"Results showed that <ENT1>SSR103800</ENT1> (10-30 mg/kg p.o.) blocked hyperactivity induced by the non-competitive NMDA receptor antagonist, <ENT2>MK-801</ENT2> and partially reversed spontaneous hyperactivity of NMDA Nr1(neo-/-) mice.",,,,T,,,,,c,,,,,1.0,,
19759529,1810,D006948,C076029,Negative_Correlation,TRUE,"Importantly, both classical (haloperidol) and atypical (<ENT2>olanzapine</ENT2>, clozapine and aripiprazole) antipsychotics were effective in all these models of <ENT1>hyperactivity</ENT1>.",,,,T,,,,,c,,,,,0.0,,
19759529,1816,D006948,D016291,Positive_Correlation,TRUE,"This study aimed at investigating the potential antipsychotic-like properties of SSR103800, with a particular focus on models of <ENT1>hyperactivity</ENT1>, involving either drug challenge (ie, amphetamine and <ENT2>MK-801</ENT2>) or transgenic mice (ie, NMDA Nr1(neo-/-) and DAT(-/-)).",,,,T,,,,,w,,,,,0.0,,
19759529,1816,D006948,D016291,Positive_Correlation,TRUE,"Results showed that SSR103800 (10-30 mg/kg p.o.) blocked <ENT1>hyperactivity</ENT1> induced by the non-competitive NMDA receptor antagonist, <ENT2>MK-801</ENT2> and partially reversed spontaneous <ENT1>hyperactivity</ENT1> of NMDA Nr1(neo-/-) mice.",,,,T,,,,,c,,,,,0.0,,
19779499,1829,rs267606698,D003643,Positive_Correlation,TRUE,"Clinical analysis indicates that mutation <ENT1>V876E</ENT1> is associated with a severe outcome as characterized by a very early age of onset, complete penetrance and a severe prognosis including <ENT2>death</ENT2>.",,,,T,,,,,c,,,,,1.0,,
19779499,1828,rs267606698,D020514,Positive_Correlation,TRUE,"Genetic analysis identified a novel <ENT1>V876E</ENT1> mutation in all <ENT2>HypoPP</ENT2> patients in the family, but not in normal family members or 160 control people.",,,,T,,,,,w,,,,,0.0,,
19779499,1825,D011188,D018908,Association,FALSE,"Hypokalaemic periodic paralysis (HypoPP) is an autosomal dominant disorder, which is characterized by periodic attacks of <ENT2>muscle weakness</ENT2> associated with a decrease in the serum <ENT1>potassium</ENT1> level.",,,,T,,,,,w,,,,,0.0,,
19779499,1826,D020514,779,Association,FALSE,Novel <ENT2>CACNA1S</ENT2> mutation causes autosomal dominant <ENT1>hypokalemic periodic paralysis</ENT1> in a South American family.,,,,T,,T,,,c,,,,,1.0,,
19779499,1826,D020514,779,Association,FALSE,"A major disease-causing gene for <ENT1>HypoPP</ENT1> has been identified as <ENT2>CACNA1S</ENT2>, which encodes the <ENT2>skeletal muscle calcium channel alpha-subunit</ENT2> with four transmembrane domains (I-IV), each with six transmembrane segments (S1-S6).",,,,T,,,,,c,,,,,1.0,,
19779499,1826,D020514,779,Association,FALSE,"To date, all <ENT2>CACNA1S</ENT2> mutations identified in <ENT1>HypoPP</ENT1> patients are located within the voltage-sensor S4 segment.",,,,T,,,,,w,,,,,0.0,,
19779499,1826,D020514,779,Association,FALSE,These results identify a new mutation in <ENT2>CACNA1S</ENT2> and expand the spectrum of <ENT2>CACNA1S</ENT2> mutations associated with <ENT1>HypoPP</ENT1>.,,,,T,,,,,c,,,,,1.0,,
19789368,1833,D015179,3845,Association,TRUE,Vitamin D receptor expression is associated with PIK3CA and <ENT2>KRAS</ENT2> mutations in <ENT1>colorectal cancer</ENT1>.,,,,T,,,,,w,,,,,1.0,,
19789368,1833,D015179,3845,Association,TRUE,"In conclusion, VDR overexpression in <ENT1>colorectal cancer</ENT1> is independently associated with PIK3CA and <ENT2>KRAS</ENT2> mutations.",,,,T,,,,,c,,,,,0.0,,
19789368,1830,D015179,D014807,Negative_Correlation,FALSE,"<ENT2>Vitamin D</ENT2> is associated with decreased risks of various cancers, including <ENT1>colon cancer</ENT1>.",,,,T,,,,,c,,,,,1.0,,
19789368,1837,D015179,7421,Positive_Correlation,TRUE,<ENT2>Vitamin D receptor</ENT2> expression is associated with PIK3CA and KRAS mutations in <ENT1>colorectal cancer</ENT1>.,,,,T,,T,,,c,,,,,0.0,,
19789368,1837,D015179,7421,Positive_Correlation,TRUE,"Among 619 <ENT1>colorectal cancers</ENT1> in two prospective cohort studies, 233 (38%) tumors showed <ENT2>VDR</ENT2> overexpression by immunohistochemistry.",,,,T,,,,,w,,,,,0.0,,
19789368,1837,D015179,7421,Positive_Correlation,TRUE,"<ENT2>VDR</ENT2> was not independently associated with body mass index, family history of <ENT1>colorectal cancer</ENT1>, tumor location (colon versus rectum), stage, tumor grade, signet ring cells, CIMP, MSI, LINE-1 hypomethylation, BRAF, p53, p21, beta-catenin, or cyclooxygenase-2.",,,,T,,,,,c,,,,,1.0,,
19789368,1837,D015179,7421,Positive_Correlation,TRUE,"In conclusion, <ENT2>VDR</ENT2> overexpression in <ENT1>colorectal cancer</ENT1> is independently associated with PIK3CA and KRAS mutations.",,,,T,,,,,c,,,,,0.0,,
19789368,1835,D015179,5290,Association,TRUE,Vitamin D receptor expression is associated with <ENT2>PIK3CA</ENT2> and KRAS mutations in <ENT1>colorectal cancer</ENT1>.,,,,T,Y,,,,w,,,,,1.0,,
19789368,1835,D015179,5290,Association,TRUE,"In conclusion, VDR overexpression in <ENT1>colorectal cancer</ENT1> is independently associated with <ENT2>PIK3CA</ENT2> and KRAS mutations.",,,,T,,,,,c,,,,,1.0,,
19789368,1834,3845,1432,Association,FALSE,A link between VDR and the <ENT1>RAS</ENT1>-<ENT2>mitogen-activated protein kinase</ENT2> (<ENT2>MAPK</ENT2>) or phosphatidylinositol 3-kinase (PI3K)-AKT pathway has been suggested.,,,,T,,,,,w,,,,,0.5,,
19789368,1834,3845,1432,Association,FALSE,"Our data support potential interactions between the VDR, <ENT1>RAS</ENT1>-<ENT2>MAPK</ENT2> and PI3K-AKT pathways, and possible influence by <ENT1>KRAS</ENT1> or PIK3CA mutation on therapy or chemoprevention targeting VDR.",,,,T,,,,,w,,,,,0.5,,
19789368,1839,3845,7421,Association,TRUE,<ENT2>Vitamin D receptor</ENT2> expression is associated with PIK3CA and <ENT1>KRAS</ENT1> mutations in colorectal cancer.,,,,T,,,,,c,,,,,0.0,,
19789368,1839,3845,7421,Association,TRUE,A link between <ENT2>VDR</ENT2> and the <ENT1>RAS</ENT1>-mitogen-activated protein kinase (MAPK) or phosphatidylinositol 3-kinase (PI3K)-AKT pathway has been suggested.,,,,T,,,,,c,,,,,0.0,,
19789368,1839,3845,7421,Association,TRUE,"However, the prognostic role of <ENT2>VDR</ENT2> expression or its relationship with PIK3CA or <ENT1>KRAS</ENT1> mutation remains uncertain.",,,,T,,Y,,,c,,,,,1.0,,
19789368,1839,3845,7421,Association,TRUE,"<ENT2>VDR</ENT2> overexpression was significantly associated with <ENT1>KRAS</ENT1> mutation (odds ratio, 1.55; 95% confidence interval, 1.11-2.16) and PIK3CA mutation (odds ratio, 2.17; 95% confidence interval, 1.36-3.47), both of which persisted in multivariate logistic regression analysis.",,,,T,,,,,c,,,,,0.0,,
19789368,1839,3845,7421,Association,TRUE,"In conclusion, <ENT2>VDR</ENT2> overexpression in colorectal cancer is independently associated with PIK3CA and <ENT1>KRAS</ENT1> mutations.",,,,T,,,,,c,,,,,1.0,,
19789368,1839,3845,7421,Association,TRUE,"Our data support potential interactions between the <ENT2>VDR</ENT2>, <ENT1>RAS</ENT1>-MAPK and PI3K-AKT pathways, and possible influence by <ENT1>KRAS</ENT1> or PIK3CA mutation on therapy or chemoprevention targeting <ENT2>VDR</ENT2>.",,,,T,,,,,c,,,"11,22",,0.25,,
19789368,1831,D014807,D009369,Negative_Correlation,FALSE,"<ENT1>Vitamin D</ENT1> is associated with decreased risks of various <ENT2>cancers</ENT2>, including colon cancer.",,,,T,,,,,c,,,,,0.0,,
19789368,1836,207,5290,Association,FALSE,A link between VDR and the RAS-mitogen-activated protein kinase (MAPK) or <ENT2>phosphatidylinositol 3-kinase</ENT2> (<ENT2>PI3K</ENT2>)-<ENT1>AKT</ENT1> pathway has been suggested.,,,,T,,,,,w,,,,,0.0,,
19789368,1836,207,5290,Association,FALSE,"Our data support potential interactions between the VDR, RAS-MAPK and <ENT2>PI3K</ENT2>-<ENT1>AKT</ENT1> pathways, and possible influence by KRAS or <ENT2>PIK3CA</ENT2> mutation on therapy or chemoprevention targeting VDR.",,,,T,,,,,w,,,,,0.0,,
19789368,1840,7421,5290,Association,TRUE,<ENT1>Vitamin D receptor</ENT1> expression is associated with <ENT2>PIK3CA</ENT2> and KRAS mutations in colorectal cancer.,,,,T,,T,,,c,,,,,1.0,,
19789368,1840,7421,5290,Association,TRUE,A link between <ENT1>VDR</ENT1> and the RAS-mitogen-activated protein kinase (MAPK) or <ENT2>phosphatidylinositol 3-kinase</ENT2> (<ENT2>PI3K</ENT2>)-AKT pathway has been suggested.,,,,T,,,,,c,,,,,1.0,,
19789368,1840,7421,5290,Association,TRUE,"However, the prognostic role of <ENT1>VDR</ENT1> expression or its relationship with <ENT2>PIK3CA</ENT2> or KRAS mutation remains uncertain.",,,,T,,Y,,,c,,,,,1.0,,
19789368,1840,7421,5290,Association,TRUE,"<ENT1>VDR</ENT1> overexpression was significantly associated with KRAS mutation (odds ratio, 1.55; 95% confidence interval, 1.11-2.16) and <ENT2>PIK3CA</ENT2> mutation (odds ratio, 2.17; 95% confidence interval, 1.36-3.47), both of which persisted in multivariate logistic regression analysis.",,,,T,,,,,c,,,,,1.0,,
19789368,1840,7421,5290,Association,TRUE,"In conclusion, <ENT1>VDR</ENT1> overexpression in colorectal cancer is independently associated with <ENT2>PIK3CA</ENT2> and KRAS mutations.",,,,T,,,,,c,,,,,1.0,,
19789368,1840,7421,5290,Association,TRUE,"Our data support potential interactions between the <ENT1>VDR</ENT1>, RAS-MAPK and <ENT2>PI3K</ENT2>-AKT pathways, and possible influence by KRAS or <ENT2>PIK3CA</ENT2> mutation on therapy or chemoprevention targeting <ENT1>VDR</ENT1>.",,,,T,,,,,c,,,"11,22",,0.0,,
19789368,1832,7421,D009369,Positive_Correlation,TRUE,"Among 619 colorectal cancers in two prospective cohort studies, 233 (38%) <ENT2>tumors</ENT2> showed <ENT1>VDR</ENT1> overexpression by immunohistochemistry.",,,,T,,,,,w,,,,,0.0,,
19789368,1832,7421,D009369,Positive_Correlation,TRUE,"<ENT1>VDR</ENT1> was not independently associated with body mass index, family history of colorectal cancer, <ENT2>tumor</ENT2> location (colon versus rectum), stage, <ENT2>tumor</ENT2> grade, signet ring cells, CIMP, MSI, LINE-1 hypomethylation, BRAF, p53, p21, beta-catenin, or cyclooxygenase-2.",,,,T,,,,,c,,,,,1.0,,
19825989,1842,D015544,D018281,Association,FALSE,"The <ENT1>d-myo-inositol 1,4,5-trisphosphate</ENT1> (<ENT1>IP(3)</ENT1>)/Ca(2+)/protein kinase C (PKC)/mitogen-activated protein kinase pathway regulates <ENT2>cholangiocarcinoma</ENT2> growth.",,,,T,,,,,c,,,,,1.0,,
19825989,1852,D015544,C069357,Positive_Correlation,TRUE,"In Mz-ChA-1 cells stimulated with <ENT2>(R)-(alpha)-(-)-methylhistamine dihydrobromide</ENT2> (<ENT2>RAMH</ENT2>), we measured (a) cell growth, (b) <ENT1>IP(3)</ENT1> and cyclic AMP levels, and (c) phosphorylation of PKC and mitogen-activated protein kinase isoforms.",,,,T,,Y,,,c,,,,,1.0,,
19825989,1852,D015544,C069357,Positive_Correlation,TRUE,<ENT2>RAMH</ENT2> increased <ENT1>IP(3)</ENT1> levels and PKCalpha phosphorylation and decreased ERK1/2 phosphorylation.,,,,T,,,,,c,,,,,1.0,,
19825989,1864,5578,5594,Association,TRUE,"The d-myo-inositol 1,4,5-trisphosphate (IP(3))/Ca(2+)/<ENT1>protein kinase C</ENT1> (<ENT1>PKC</ENT1>)/<ENT2>mitogen-activated protein kinase</ENT2> pathway regulates cholangiocarcinoma growth.",,,,T,,,,,w,,,,,0.0,,
19825989,1864,5578,5594,Association,TRUE,"In Mz-ChA-1 cells stimulated with (R)-(alpha)-(-)-methylhistamine dihydrobromide (RAMH), we measured (a) cell growth, (b) IP(3) and cyclic AMP levels, and (c) phosphorylation of <ENT1>PKC</ENT1> and <ENT2>mitogen-activated protein kinase</ENT2> isoforms.",,,,T,,,,,c,,,,,1.0,,
19825989,1865,5578,D018281,Negative_Correlation,FALSE,H3 histamine receptor-mediated activation of <ENT1>protein kinase Calpha</ENT1> inhibits the growth of <ENT2>cholangiocarcinoma</ENT2> in vitro and in vivo.,,,,T,,T,,,c,,,,,1.0,,
19825989,1865,5578,D018281,Negative_Correlation,FALSE,"The d-myo-inositol 1,4,5-trisphosphate (IP(3))/Ca(2+)/<ENT1>protein kinase C</ENT1> (<ENT1>PKC</ENT1>)/mitogen-activated protein kinase pathway regulates <ENT2>cholangiocarcinoma</ENT2> growth.",,,,T,,,,,c,,,,,0.0,,
19825989,1865,5578,D018281,Negative_Correlation,FALSE,RAMH inhibits <ENT2>cholangiocarcinoma</ENT2> growth by <ENT1>PKCalpha</ENT1>-dependent ERK1/2 dephosphorylation.,,,,T,,,,,c,,,,,0.0,,
19825989,1865,5578,D018281,Negative_Correlation,FALSE,Modulation of <ENT1>PKCalpha</ENT1> by histamine receptors may be important in regulating <ENT2>cholangiocarcinoma</ENT2> growth.,,,,T,,,,,c,,,,,0.0,,
19825989;19825989;19825989;19825989,1860;1859;1861;1867,5578;5578;5578;5578,3274;59340;3269;11255,Association;Association;Association;Association,TRUE;TRUE;TRUE;TRUE,Modulation of <ENT1>PKCalpha</ENT1> by <ENT2>histamine receptors</ENT2> may be important in regulating cholangiocarcinoma growth.,,,,T,,,,,c,,,,,0.0,,
19825989,1867,5578,11255,Positive_Correlation,TRUE,<ENT2>H3 histamine receptor</ENT2>-mediated activation of <ENT1>protein kinase Calpha</ENT1> inhibits the growth of cholangiocarcinoma in vitro and in vivo.,,,,T,,,,,c,,,,,1.0,,
19825989,1862,5578,C069357,Positive_Correlation,TRUE,"In Mz-ChA-1 cells stimulated with <ENT2>(R)-(alpha)-(-)-methylhistamine dihydrobromide</ENT2> (<ENT2>RAMH</ENT2>), we measured (a) cell growth, (b) IP(3) and cyclic AMP levels, and (c) phosphorylation of <ENT1>PKC</ENT1> and mitogen-activated protein kinase isoforms.",,,,T,,Y,,,c,,,,,1.0,,
19825989,1862,5578,C069357,Positive_Correlation,TRUE,"Following knockdown of <ENT1>PKCalpha</ENT1>, Mz-ChA-1 cells were stimulated with <ENT2>RAMH</ENT2> before evaluating cell growth and extracellular signal-regulated kinase (ERK)-1/2 phosphorylation.",,,,T,,Y,,,c,,,,,1.0,,
19825989,1862,5578,C069357,Positive_Correlation,TRUE,<ENT2>RAMH</ENT2> increased IP(3) levels and <ENT1>PKCalpha</ENT1> phosphorylation and decreased ERK1/2 phosphorylation.,,,,T,,,,,c,,,,,0.0,,
19825989,1862,5578,C069357,Positive_Correlation,TRUE,<ENT2>RAMH</ENT2> induced a shift in the localization of <ENT1>PKCalpha</ENT1> expression from the cytosolic domain into the membrane region of Mz-ChA-1 cells.,,,,T,,,,,c,,,,,1.0,,
19825989,1862,5578,C069357,Positive_Correlation,TRUE,Silencing of <ENT1>PKCalpha</ENT1> prevented <ENT2>RAMH</ENT2> inhibition of Mz-ChA-1 cell growth and ablated <ENT2>RAMH</ENT2> effects on ERK1/2 phosphorylation.,,,,T,,,,,w,,,,,0.0,,
19825989,1862,5578,C069357,Positive_Correlation,TRUE,"In vivo, <ENT2>RAMH</ENT2> decreased tumor growth and expression of VEGF and its receptors; <ENT1>PKCalpha</ENT1> expression was increased.",,,,T,,,,,w,,,,,0.0,,
19825989,1862,5578,C069357,Positive_Correlation,TRUE,<ENT2>RAMH</ENT2> inhibits cholangiocarcinoma growth by <ENT1>PKCalpha</ENT1>-dependent ERK1/2 dephosphorylation.,,,,T,,,,,w,,,,,0.0,,
19825989,1858,5594,D018281,Association,FALSE,"The d-myo-inositol 1,4,5-trisphosphate (IP(3))/Ca(2+)/protein kinase C (PKC)/<ENT1>mitogen-activated protein kinase</ENT1> pathway regulates <ENT2>cholangiocarcinoma</ENT2> growth.",,,,T,,,,,c,,,,,1.0,,
19825989,1855,5594,C069357,Negative_Correlation,TRUE,"In Mz-ChA-1 cells stimulated with <ENT2>(R)-(alpha)-(-)-methylhistamine dihydrobromide</ENT2> (<ENT2>RAMH</ENT2>), we measured (a) cell growth, (b) IP(3) and cyclic AMP levels, and (c) phosphorylation of PKC and <ENT1>mitogen-activated protein kinase</ENT1> isoforms.",,,,T,,,,,c,,,,,0.5,,
19825989,1847,D006632,3274,Bind,FALSE,"<ENT1>Histamine</ENT1> regulates functions via four receptors (HRH1, <ENT2>HRH2</ENT2>, HRH3, and HRH4).",,,,T,,,,,c,,,,,0.0,,
19825989,1849,D006632,11255,Bind,FALSE,"<ENT1>Histamine</ENT1> regulates functions via four receptors (HRH1, HRH2, <ENT2>HRH3</ENT2>, and HRH4).",,,,T,,,,,c,,,,,0.0,,
19825989,1846,D006632,59340,Bind,FALSE,"<ENT1>Histamine</ENT1> regulates functions via four receptors (HRH1, HRH2, HRH3, and <ENT2>HRH4</ENT2>).",,,,T,,,,,c,,,,,0.0,,
19825989,1848,D006632,3269,Bind,FALSE,"<ENT1>Histamine</ENT1> regulates functions via four receptors (<ENT2>HRH1</ENT2>, HRH2, HRH3, and HRH4).",,,,T,,,,,c,,,,,0.0,,
19825989;19825989;19825989;19825989,1844;1866;1843;1845,D018281;D018281;D018281;D018281,3274;11255;59340;3269,Association;Association;Association;Association,TRUE;TRUE;TRUE;TRUE,Modulation of PKCalpha by <ENT2>histamine receptors</ENT2> may be important in regulating <ENT1>cholangiocarcinoma</ENT1> growth.,,,,T,,,,,w,,,,,0.0,,
19825989,1866,D018281,11255,Association,TRUE,<ENT2>H3 histamine receptor</ENT2>-mediated activation of protein kinase Calpha inhibits the growth of <ENT1>cholangiocarcinoma</ENT1> in vitro and in vivo.,,,,T,,,,,w,,,,,0.0,,
19825989,1866,D018281,11255,Association,TRUE,We evaluated the role of <ENT2>HRH3</ENT2> in the regulation of <ENT1>cholangiocarcinoma</ENT1> growth.,,,,T,,Y,,,w,,,,,0.0,,
19825989,1856,D018281,C069357,Negative_Correlation,TRUE,<ENT2>RAMH</ENT2> inhibited the growth of <ENT1>cholangiocarcinoma</ENT1> cells.,,,,T,,,,,c,,,,,0.0,,
19825989,1856,D018281,C069357,Negative_Correlation,TRUE,<ENT2>RAMH</ENT2> inhibits <ENT1>cholangiocarcinoma</ENT1> growth by PKCalpha-dependent ERK1/2 dephosphorylation.,,,,T,,,,,w,,,,,0.0,,
19825989,1841,D018281,D002118,Association,FALSE,"The d-myo-inositol 1,4,5-trisphosphate (IP(3))/<ENT2>Ca(2+)</ENT2>/protein kinase C (PKC)/mitogen-activated protein kinase pathway regulates <ENT1>cholangiocarcinoma</ENT1> growth.",,,,T,,,,,c,,,,,1.0,,
19825989,1853,D009369,C069357,Negative_Correlation,TRUE,Mice were treated with saline or <ENT2>RAMH</ENT2> for 44 days and <ENT1>tumor</ENT1> volume was measured.,,,,T,,Y,,,c,,,,,1.0,,
19825989,1853,D009369,C069357,Negative_Correlation,TRUE,"In vivo, <ENT2>RAMH</ENT2> decreased <ENT1>tumor</ENT1> growth and expression of VEGF and its receptors; PKCalpha expression was increased.",,,,T,,,,,c,,,,,1.0,,
19841052,1868,D006679,D016578,Positive_Correlation,TRUE,"To determine whether the risk of <ENT1>HIV seroconversion</ENT1> among daily smokers of <ENT2>crack cocaine</ENT2> changed over time, we used Cox proportional hazards regression and divided the study into 3 periods: May 1, 1996-Nov. 30, 1999 (period 1), Dec. 1, 1999-Nov. 30, 2002 (period 2), and Dec. 1, 2002-Dec. 30, 2005 (period 3).",,,,T,,Y,,,w,,,,,0.0,,
19841052,1868,D006679,D016578,Positive_Correlation,TRUE,"After adjusting for potential confounders, we found that the risk of <ENT1>HIV seroconversion</ENT1> among participants who were daily smokers of <ENT2>crack cocaine</ENT2> increased over time (period 1: hazard ratio [HR] 1.03, 95% confidence interval [CI] 0.57-1.85; period 2: HR 1.68, 95% CI 1.01-2.80; and period 3: HR 2.74, 95% CI 1.06-7.11).",,,,T,,,,,w,,,,,0.0,,
19841052,1868,D006679,D016578,Positive_Correlation,TRUE,INTERPRETATION: Smoking of <ENT2>crack cocaine</ENT2> was found to be an independent risk factor for <ENT1>HIV seroconversion</ENT1> among people who were injection drug users.,,,,T,,,,,w,,,,,1.0,,
19841052,1869,D016578,D015658,Positive_Correlation,TRUE,Smoking of <ENT1>crack cocaine</ENT1> as a risk factor for <ENT2>HIV infection</ENT2> among people who use injection drugs.,,,,T,,,,,w,,,,,1.0,,
19841052,1869,D016578,D015658,Positive_Correlation,TRUE,BACKGROUND: Little is known about the possible role that smoking <ENT1>crack cocaine</ENT1> has on the incidence of <ENT2>HIV infection</ENT2>.,,,,T,,Y,,,c,,,,,1.0,,
19841052,1869,D016578,D015658,Positive_Correlation,TRUE,"Given the increasing use of <ENT1>crack cocaine</ENT1>, we sought to examine whether use of this illicit drug has become a risk factor for <ENT2>HIV infection</ENT2>.",,,,T,,Y,,,c,,,,,1.0,,
19880293,1873,D011565,c|Allele|AC|-3297,Positive_Correlation,TRUE,"RESULTS: We found that increased risk of <ENT1>psoriasis</ENT1> was associated with the FOXP3 <ENT2>-3279 AC</ENT2> genotype (adjusted OR, 1.32; 95% CI, 1.01-1.74) and the combined AC+AA genotype (adjusted OR, 1.38; 95% CI, 1.07-1.78), compared with the -3279 CC genotype.",,,,T,,,,,c,,,,,0.0,,
19880293,1872,D011565,c|Allele|GG|IVS9+459,Positive_Correlation,TRUE,"We also found that an increased risk of <ENT1>psoriasis</ENT1> was associated with the FOXP3 <ENT2>IVS9+459 GG</ENT2> genotype (adjusted OR, 2.24; 95% CI, 1.41-3.58).",,,,T,,,,,c,,,,,1.0,,
19880293,1874,D011565,50943,Association,TRUE,Polymorphisms in the <ENT2>FOXP3</ENT2> gene in Han Chinese <ENT1>psoriasis</ENT1> patients.,,,,T,,,,,w,,,,,0.0,,
19880293,1874,D011565,50943,Association,TRUE,"However, information about <ENT2>FOXP3</ENT2> gene in <ENT1>psoriasis</ENT1> is limited.",,,,T,,Y,,,c,,,,,1.0,,
19880293,1874,D011565,50943,Association,TRUE,OBJECTIVE: This study evaluated the association between <ENT2>FOXP3</ENT2> gene SNPs and susceptibility to <ENT1>psoriasis</ENT1> in a Han Chinese population.,,,,T,,Y,,,c,,,,,1.0,,
19880293,1874,D011565,50943,Association,TRUE,"We investigated four SNPs in the <ENT2>FOXP3</ENT2> gene (-6054, deletion/ATT; -3279, A/C; -924, A/G; IVS9+459, A/G) in <ENT1>psoriatic</ENT1> patients, and assessed allele and genotype frequencies in <ENT1>psoriatic</ENT1> patients (237 females, 287 males) and normal controls (272 females, 277 males).",,,,T,,Y,,,c,,,,,1.0,,
19880293,1874,D011565,50943,Association,TRUE,"RESULTS: We found that increased risk of <ENT1>psoriasis</ENT1> was associated with the <ENT2>FOXP3</ENT2> -3279 AC genotype (adjusted OR, 1.32; 95% CI, 1.01-1.74) and the combined AC+AA genotype (adjusted OR, 1.38; 95% CI, 1.07-1.78), compared with the -3279 CC genotype.",,,,T,,,,,c,,,,,1.0,,
19880293,1874,D011565,50943,Association,TRUE,"We also found that an increased risk of <ENT1>psoriasis</ENT1> was associated with the <ENT2>FOXP3</ENT2> IVS9+459 GG genotype (adjusted OR, 2.24; 95% CI, 1.41-3.58).",,,,T,,,,,c,,,,,1.0,,
19880293,1874,D011565,50943,Association,TRUE,"In combined genotype analyses, the <ENT2>FOXP3</ENT2>-3279 AC+AA genotype was more obviously associated in males (adjusted OR=1.60, 95% CI=1.11-2.31) and severe <ENT1>psoriasis</ENT1> patients (PASI score >20; adjusted OR=1.97, 95% CI=1.41-2.75).",,,,T,,,,,c,,,,,1.0,,
19880293,1874,D011565,50943,Association,TRUE,"Meanwhile, the <ENT2>FOXP3</ENT2> IVS9+459 GA+GG genotype was also associated with severe <ENT1>psoriasis</ENT1> patients (adjusted OR=1.69, 95% CI=1.21-2.36).",,,,T,,,,,c,,,,,1.0,,
19880293,1874,D011565,50943,Association,TRUE,CONCLUSIONS: <ENT2>FOXP3</ENT2> polymorphisms appear to contribute to the risk of <ENT1>psoriasis</ENT1> in a Han Chinese population.,,,,T,,,,,c,,,,,1.0,,
19880293,1871,D011565,c|Allele|AC|-3279,Association,TRUE,"In combined genotype analyses, the FOXP3<ENT2>-3279 AC+AA</ENT2> genotype was more obviously associated in males (adjusted OR=1.60, 95% CI=1.11-2.31) and severe <ENT1>psoriasis</ENT1> patients (PASI score >20; adjusted OR=1.97, 95% CI=1.41-2.75).",,,,T,,,,,c,,,,,1.0,,
19880293,1870,D011565,c|Allele|GA|IVS9+459,Positive_Correlation,TRUE,"Meanwhile, the FOXP3 <ENT2>IVS9+459 GA+GG</ENT2> genotype was also associated with severe <ENT1>psoriasis</ENT1> patients (adjusted OR=1.69, 95% CI=1.21-2.36).",,,,T,,,,,c,,,,,1.0,,
19880293,1875,D001327,50943,Association,FALSE,Studies have found that single-nucleotide polymorphisms (SNPs) in the <ENT2>FOXP3</ENT2> gene contribute to susceptibility to some <ENT1>autoimmune disorders</ENT1>.,,,,T,,,,,c,,,,,1.0,,
19881468,1887,4968,D008175,Association,TRUE,<ENT1>hOGG1</ENT1> Ser326Cys polymorphism and risk of <ENT2>lung cancer</ENT2> by histological type.,,,,T,,T,,,w,,,,,0.0,,
19881468,1880,4968,C024829,Association,FALSE,"Human <ENT1>8-oxoguanine DNA glycosylase 1</ENT1> (<ENT1>hOGG1</ENT1>) has a major role in the repair of <ENT2>8-hydroxyguanine</ENT2>, a major promutagenic DNA lesion.",,,,T,,,,,c,,,,,1.0,,
19881468,1888,D008175,rs1052133,Positive_Correlation,TRUE,hOGG1 <ENT2>Ser326Cys</ENT2> polymorphism and risk of <ENT1>lung cancer</ENT1> by histological type.,,,,T,,,,,w,,,,,0.0,,
19881468,1888,D008175,rs1052133,Positive_Correlation,TRUE,"Although several studies have investigated the association between <ENT2>rs1052133</ENT2> and <ENT1>lung cancer</ENT1> susceptibility, the effect of this locus on <ENT1>lung cancer</ENT1> according to histology remains unclear.",,,,T,,,,,w,,,,,0.0,,
19881468,1881,rs1052133,D000077192,Positive_Correlation,TRUE,These results indicate that <ENT1>rs1052133</ENT1> contributes to the risk of <ENT2>adenocarcinoma of lung</ENT2>.,,,,T,,,,,c,,,,,1.0,,
19889778,1898,p|SUB|G|145|R,D006513,Association,FALSE,Differential impact of immune escape mutations <ENT1>G145R</ENT1> and P120T on the replication of lamivudine-resistant <ENT2>hepatitis B virus e antigen</ENT2>-positive and -negative strains.,,,,T,,,,,w,,,,,0.0,,
19889778,1898,p|SUB|G|145|R,D006513,Association,FALSE,"We therefore systematically analyzed the functional impact of the most prevalent immune escape variants, the s<ENT1>G145R</ENT1> and sP120T mutants, on the viral replication efficacy and antiviral drug susceptibility of common treatment-associated mutants with resistance to lamivudine (LAM) and/or <ENT2>HBeAg</ENT2> negativity.",,,,T,,,,,c,,,,,1.0,,
19889778,1898,p|SUB|G|145|R,D006513,Association,FALSE,Replication-competent HBV strains with s<ENT1>G145R</ENT1> or sP120T and LAM resistance (rtM204I or rtL180M/rtM204V) were generated on an <ENT2>HBeAg</ENT2>-positive and an <ENT2>HBeAg</ENT2>-negative background with precore (PC) and basal core promoter (BCP) mutants.,,,,T,,,,,c,,,,,1.0,,
19889778,1897,p|SUB|G|145|R,D019259,Association,FALSE,Differential impact of immune escape mutations <ENT1>G145R</ENT1> and P120T on the replication of <ENT2>lamivudine</ENT2>-resistant hepatitis B virus e antigen-positive and -negative strains.,,,,T,Y,T,,,w,,,,,0.0,,
19889778,1897,p|SUB|G|145|R,D019259,Association,FALSE,"We therefore systematically analyzed the functional impact of the most prevalent immune escape variants, the s<ENT1>G145R</ENT1> and sP120T mutants, on the viral replication efficacy and antiviral drug susceptibility of common treatment-associated mutants with resistance to <ENT2>lamivudine</ENT2> (<ENT2>LAM</ENT2>) and/or HBeAg negativity.",,,,T,,Y,,,c,,,,,1.0,,
19889778,1897,p|SUB|G|145|R,D019259,Association,FALSE,Replication-competent HBV strains with s<ENT1>G145R</ENT1> or sP120T and <ENT2>LAM</ENT2> resistance (rtM204I or rtL180M/rtM204V) were generated on an HBeAg-positive and an HBeAg-negative background with precore (PC) and basal core promoter (BCP) mutants.,,,,T,,,,,c,,,,,1.0,,
19889778,1897,p|SUB|G|145|R,D019259,Association,FALSE,"The s<ENT1>G145R</ENT1> mutation strongly reduced HBsAg levels and was able to fully restore the impaired replication of <ENT2>LAM</ENT2>-resistant HBV mutants to the levels of wild-type HBV, and PC or BCP mutations further enhanced viral replication.",,,,T,,,,,w,,,,,0.0,,
19889778,1896,p|SUB|G|145|R,D006514,Negative_Correlation,TRUE,"The s<ENT1>G145R</ENT1> mutation strongly reduced <ENT2>HBsAg</ENT2> levels and was able to fully restore the impaired replication of LAM-resistant HBV mutants to the levels of wild-type HBV, and PC or BCP mutations further enhanced viral replication.",,,,T,,,,,c,,,,,0.0,,
19889778,1893,c|SUB|P|120|T,D006513,Association,FALSE,Differential impact of immune escape mutations G145R and <ENT1>P120T</ENT1> on the replication of lamivudine-resistant <ENT2>hepatitis B virus e antigen</ENT2>-positive and -negative strains.,,,,T,,,,,w,,,,,0.0,,
19889778,1893,c|SUB|P|120|T,D006513,Association,FALSE,"We therefore systematically analyzed the functional impact of the most prevalent immune escape variants, the sG145R and s<ENT1>P120T</ENT1> mutants, on the viral replication efficacy and antiviral drug susceptibility of common treatment-associated mutants with resistance to lamivudine (LAM) and/or <ENT2>HBeAg</ENT2> negativity.",,,,T,,,,,c,,,,,1.0,,
19889778,1893,c|SUB|P|120|T,D006513,Association,FALSE,Replication-competent HBV strains with sG145R or s<ENT1>P120T</ENT1> and LAM resistance (rtM204I or rtL180M/rtM204V) were generated on an <ENT2>HBeAg</ENT2>-positive and an <ENT2>HBeAg</ENT2>-negative background with precore (PC) and basal core promoter (BCP) mutants.,,,,T,,,,,c,,,,,1.0,,
19889778,1893,c|SUB|P|120|T,D006513,Association,FALSE,"However, the concomitant occurrence of <ENT2>HBeAg</ENT2> negativity (PC/BCP), s<ENT1>P120T</ENT1>, and LAM resistance resulted in the restoration of replication to levels of wild-type HBV.",,,,T,Y,,,,w,,,,,0.0,,
19889778,1894,c|SUB|P|120|T,D019259,Association,FALSE,Differential impact of immune escape mutations G145R and <ENT1>P120T</ENT1> on the replication of <ENT2>lamivudine</ENT2>-resistant hepatitis B virus e antigen-positive and -negative strains.,,,,T,,,,,c,,,,,1.0,,
19889778,1894,c|SUB|P|120|T,D019259,Association,FALSE,"We therefore systematically analyzed the functional impact of the most prevalent immune escape variants, the sG145R and s<ENT1>P120T</ENT1> mutants, on the viral replication efficacy and antiviral drug susceptibility of common treatment-associated mutants with resistance to <ENT2>lamivudine</ENT2> (<ENT2>LAM</ENT2>) and/or HBeAg negativity.",,,,T,,,,,c,,,,,1.0,,
19889778,1894,c|SUB|P|120|T,D019259,Association,FALSE,Replication-competent HBV strains with sG145R or s<ENT1>P120T</ENT1> and <ENT2>LAM</ENT2> resistance (rtM204I or rtL180M/rtM204V) were generated on an HBeAg-positive and an HBeAg-negative background with precore (PC) and basal core promoter (BCP) mutants.,,,,T,,,,,c,,,,,1.0,,
19889778,1894,c|SUB|P|120|T,D019259,Association,FALSE,"Although the s<ENT1>P120T</ENT1> substitution also impaired HBsAg secretion, it did not enhance the replication of <ENT2>LAM</ENT2>-resistant clones.",,,,T,,,,,c,,,,,1.0,,
19889778,1894,c|SUB|P|120|T,D019259,Association,FALSE,"However, the concomitant occurrence of HBeAg negativity (PC/BCP), s<ENT1>P120T</ENT1>, and <ENT2>LAM</ENT2> resistance resulted in the restoration of replication to levels of wild-type HBV.",,,,T,Y,,,,w,,,,,0.0,,
19889778,1892,c|SUB|P|120|T,D006514,Association,TRUE,"Although the s<ENT1>P120T</ENT1> substitution also impaired <ENT2>HBsAg</ENT2> secretion, it did not enhance the replication of LAM-resistant clones.",,,,T,,,,,c,,,,,0.0,,
19889778,1891,D006513,944568,Association,FALSE,Replication-competent HBV strains with sG145R or sP120T and LAM resistance (rtM204I or rtL180M/rtM204V) were generated on an <ENT1>HBeAg</ENT1>-positive and an <ENT1>HBeAg</ENT1>-negative background with <ENT2>precore</ENT2> (<ENT2>PC</ENT2>) and basal core promoter (BCP) mutants.,,,,T,,,,,c,,,,,1.0,,
19889778,1891,D006513,944568,Association,FALSE,"However, the concomitant occurrence of <ENT1>HBeAg</ENT1> negativity (<ENT2>PC</ENT2>/BCP), sP120T, and LAM resistance resulted in the restoration of replication to levels of wild-type HBV.",,,,T,Y,,,,w,,,,,0.0,,
19889778,1895,D006513,D019259,Association,FALSE,Differential impact of immune escape mutations G145R and P120T on the replication of <ENT2>lamivudine</ENT2>-resistant <ENT1>hepatitis B virus e antigen</ENT1>-positive and -negative strains.,,,,T,,T,,,c,,,,,0.0,,
19889778,1895,D006513,D019259,Association,FALSE,"We therefore systematically analyzed the functional impact of the most prevalent immune escape variants, the sG145R and sP120T mutants, on the viral replication efficacy and antiviral drug susceptibility of common treatment-associated mutants with resistance to <ENT2>lamivudine</ENT2> (<ENT2>LAM</ENT2>) and/or <ENT1>HBeAg</ENT1> negativity.",,,,T,,,,,c,,,,,1.0,,
19889778,1895,D006513,D019259,Association,FALSE,Replication-competent HBV strains with sG145R or sP120T and <ENT2>LAM</ENT2> resistance (rtM204I or rtL180M/rtM204V) were generated on an <ENT1>HBeAg</ENT1>-positive and an <ENT1>HBeAg</ENT1>-negative background with precore (PC) and basal core promoter (BCP) mutants.,,,,T,,Y,,,c,,,,,1.0,,
19889778,1895,D006513,D019259,Association,FALSE,"However, the concomitant occurrence of <ENT1>HBeAg</ENT1> negativity (PC/BCP), sP120T, and <ENT2>LAM</ENT2> resistance resulted in the restoration of replication to levels of wild-type HBV.",,,,T,,,,,w,,,,,1.0,,
19889778,1890,944568,D019259,Association,TRUE,Replication-competent HBV strains with sG145R or sP120T and <ENT2>LAM</ENT2> resistance (rtM204I or rtL180M/rtM204V) were generated on an HBeAg-positive and an HBeAg-negative background with <ENT1>precore</ENT1> (<ENT1>PC</ENT1>) and basal core promoter (BCP) mutants.,,,,T,,,,,c,,,,,1.0,,
19889778,1890,944568,D019259,Association,TRUE,"The sG145R mutation strongly reduced HBsAg levels and was able to fully restore the impaired replication of <ENT2>LAM</ENT2>-resistant HBV mutants to the levels of wild-type HBV, and <ENT1>PC</ENT1> or BCP mutations further enhanced viral replication.",,,,T,,,,,c,,,,,1.0,,
19889778,1890,944568,D019259,Association,TRUE,"However, the concomitant occurrence of HBeAg negativity (<ENT1>PC</ENT1>/BCP), sP120T, and <ENT2>LAM</ENT2> resistance resulted in the restoration of replication to levels of wild-type HBV.",,,,T,Y,,,,w,,,,,0.0,,
19889778,1889,944568,D006514,Association,TRUE,"The sG145R mutation strongly reduced <ENT2>HBsAg</ENT2> levels and was able to fully restore the impaired replication of LAM-resistant HBV mutants to the levels of wild-type HBV, and <ENT1>PC</ENT1> or BCP mutations further enhanced viral replication.",,,,T,,,,,c,,,,,1.0,,
19891556,1900,D003324,D000077144,Negative_Correlation,FALSE,Antiplatelet therapy with <ENT2>clopidogrel</ENT2> is the current standard of care for <ENT1>coronary artery disease</ENT1> patients undergoing a percutaneous coronary intervention.,,,,T,,,,,c,,,,,1.0,,
19891556,1899,1557,D000077144,Association,TRUE,<ENT2>Clopidogrel</ENT2> is a prodrug that undergoes hepatic biotransformation by <ENT1>CYP2C19</ENT1> into its active metabolite.,,,,T,,,,,c,,,,,1.0,,
19891556,1899,1557,D000077144,Association,TRUE,"Several studies have reported that, compared with wild-type individuals, <ENT1>CYP2C19</ENT1> variant allele carriers exhibit a significantly lower capacity to metabolize <ENT2>clopidogrel</ENT2> into its active metabolite and inhibit platelet activation, and are therefore at significantly higher risk of adverse cardiovascular events.",,,,T,,,,,w,,,,,1.0,,
19891556,1899,1557,D000077144,Association,TRUE,"Consequently, the US FDA has recently changed <ENT2>clopidogrel</ENT2>'s prescribing information to highlight the impact of <ENT1>CYP2C19</ENT1> genotype on <ENT2>clopidogrel</ENT2> pharmacokinetics, pharmacodynamics and clinical response.",,,,T,,,,,c,,,,,0.0,,
19891556,1899,1557,D000077144,Association,TRUE,Future studies remain necessary to develop effective personalized therapeutic strategies for <ENT1>CYP2C19</ENT1> variant allele carriers and other individuals at risk for <ENT2>clopidogrel</ENT2> nonresponsiveness.,,,,T,,Y,,,c,,,,,0.0,,
19914299,1902,D005472,D008569,Positive_Correlation,FALSE,Fluoxetine improves the <ENT2>memory deficits</ENT2> caused by the chemotherapy agent <ENT1>5-fluorouracil</ENT1>.,,,,T,,,,,c,,,,,1.0,,
19914299,1903,D005472,D005473,Negative_Correlation,TRUE,<ENT2>Fluoxetine</ENT2> improves the memory deficits caused by the chemotherapy agent <ENT1>5-fluorouracil</ENT1>.,,,,T,Y,,,,w,,,,,1.0,,
19914299,1903,D005472,D005473,Negative_Correlation,TRUE,In this investigation the behavioural effects of chronic (two week) treatment with <ENT1>5-FU</ENT1> and (three weeks) with <ENT2>Fluoxetine</ENT2> either separately or in combination with <ENT1>5-FU</ENT1> were tested on adult Lister hooded rats.,,,,T,,,,,c,,,,,0.0,,
19914299,1903,D005472,D005473,Negative_Correlation,TRUE,Animals treated only with <ENT1>5-FU</ENT1> showed significant deficits in their ability to carry out the OLR task but co administration of <ENT2>Fluoxetine</ENT2> improved their performance.,,,,T,Y,,,,w,,,,,0.0,,
19914299,1903,D005472,D005473,Negative_Correlation,TRUE,This reduction was eliminated when <ENT2>Fluoxetine</ENT2> was co administered with <ENT1>5-FU</ENT1>.,,,,T,Y,,,,w,,,,,0.0,,
19914299,1903,D005472,D005473,Negative_Correlation,TRUE,These findings suggest that <ENT1>5-FU</ENT1> can negatively affect both cell proliferation and hippocampal dependent working memory and that these deficits can be reversed by the simultaneous administration of the antidepressant <ENT2>Fluoxetine</ENT2>.,,,,T,Y,,,,w,,,,,0.0,,
19914299,1904,D008569,D005473,Negative_Correlation,TRUE,<ENT2>Fluoxetine</ENT2> improves the <ENT1>memory deficits</ENT1> caused by the chemotherapy agent 5-fluorouracil.,,,,T,,,,,c,,,,,1.0,,
19957053,1908,D004809,D010656,Comparison,FALSE,<ENT2>Phenylephrine</ENT2> but not <ENT1>ephedrine</ENT1> reduces frontal lobe oxygenation following anesthesia-induced hypotension.,,,,T,,T,,,c,,,,,0.0,,
19957053,1908,D004809,D010656,Comparison,FALSE,We describe the effect of <ENT2>phenylephrine</ENT2> and <ENT1>ephedrine</ENT1> on frontal lobe oxygenation (S(c)O(2)) following anesthesia-induced hypotension.,,,,T,,Y,,,c,,,,,1.0,,
19957053,1908,D004809,D010656,Comparison,FALSE,"METHODS: Following induction of anesthesia by fentanyl (0.15 mg kg(-1)) and propofol (2.0 mg kg(-1)), 13 patients received <ENT2>phenylephrine</ENT2> (0.1 mg iv) and 12 patients received <ENT1>ephedrine</ENT1> (10 mg iv) to restore mean arterial pressure (MAP).",,,,T,,Y,,,w,,,,,0.0,,
19957053,1908,D004809,D010656,Comparison,FALSE,CONCLUSIONS: The utilization of <ENT2>phenylephrine</ENT2> to correct hypotension induced by anesthesia has a negative impact on S(c)O(2) while <ENT1>ephedrine</ENT1> maintains frontal lobe oxygenation potentially related to an increase in CO.,,,,T,,,,,c,,,,,0.0,,
19957053,1905,D004809,D007022,Negative_Correlation,FALSE,Phenylephrine but not <ENT1>ephedrine</ENT1> reduces frontal lobe oxygenation following anesthesia-induced <ENT2>hypotension</ENT2>.,,,,T,,T,,,w,,,,,0.0,,
19957053,1905,D004809,D007022,Negative_Correlation,FALSE,We describe the effect of phenylephrine and <ENT1>ephedrine</ENT1> on frontal lobe oxygenation (S(c)O(2)) following anesthesia-induced <ENT2>hypotension</ENT2>.,,,,T,,Y,,,c,,,,,1.0,,
19957053,1905,D004809,D007022,Negative_Correlation,FALSE,CONCLUSIONS: The utilization of phenylephrine to correct <ENT2>hypotension</ENT2> induced by anesthesia has a negative impact on S(c)O(2) while <ENT1>ephedrine</ENT1> maintains frontal lobe oxygenation potentially related to an increase in CO.,,,,T,,,,,c,,,,,1.0,,
19957053,1909,D010656,D007022,Negative_Correlation,FALSE,<ENT1>Phenylephrine</ENT1> but not ephedrine reduces frontal lobe oxygenation following anesthesia-induced <ENT2>hypotension</ENT2>.,,,,T,,T,,,c,,,,,0.0,,
19957053,1909,D010656,D007022,Negative_Correlation,FALSE,We describe the effect of <ENT1>phenylephrine</ENT1> and ephedrine on frontal lobe oxygenation (S(c)O(2)) following anesthesia-induced <ENT2>hypotension</ENT2>.,,,,T,,Y,,,c,,,,,1.0,,
19957053,1909,D010656,D007022,Negative_Correlation,FALSE,CONCLUSIONS: The utilization of <ENT1>phenylephrine</ENT1> to correct <ENT2>hypotension</ENT2> induced by anesthesia has a negative impact on S(c)O(2) while ephedrine maintains frontal lobe oxygenation potentially related to an increase in CO.,,,,T,,,,,w,,,,,1.0,,
19996135,1910,D014148,D012640,Positive_Correlation,TRUE,High-dose <ENT1>tranexamic Acid</ENT1> is associated with nonischemic clinical <ENT2>seizures</ENT2> in cardiac surgical patients.,,,,T,Y,,,,w,,,,,1.0,,
19996135,1910,D014148,D012640,Positive_Correlation,TRUE,The purpose of this review was to perform a retrospective analysis to examine whether there was a relation between <ENT1>TXA</ENT1> usage and <ENT2>seizures</ENT2> after cardiac surgery.,,,,T,,Y,,,w,,,,,1.0,,
19996135,1910,D014148,D012640,Positive_Correlation,TRUE,"All 24 patients with <ENT2>seizures</ENT2> received high doses of <ENT1>TXA</ENT1> intraoperatively ranging from 61 to 259 mg/kg, had a mean age of 69.9 years, and 21 of 24 had undergone open chamber rather than coronary bypass procedures.",,,,T,,,,,w,,,,,1.0,,
19996135,1910,D014148,D012640,Positive_Correlation,TRUE,CONCLUSION: Our results suggest that use of high-dose <ENT1>TXA</ENT1> in older patients in conjunction with cardiopulmonary bypass and open-chamber cardiac surgery is associated with clinical <ENT2>seizures</ENT2> in susceptible patients.,,,,T,,,,,w,,,,,1.0,,
20005218,1912,16591,D001161,Association,FALSE,BACKGROUND: Mice with defects in the <ENT1>Klotho</ENT1> gene exhibit multiple aging phenotypes including <ENT2>arteriosclerosis</ENT2>.,,,,T,,,,,c,,,,,1.0,,
20005218,1911,9365,D000075222,Association,TRUE,A potential regulatory single nucleotide polymorphism in the promoter of the <ENT1>Klotho</ENT1> gene may be associated with <ENT2>essential hypertension</ENT2> in the Chinese Han population.,,,,T,,,,,c,,,,,1.0,,
20005218,1911,9365,D000075222,Association,TRUE,We hypothesised that the G-395A polymorphism in the promoter region of the human <ENT1>Klotho</ENT1> gene may contribute to the prevalence of <ENT2>Essential Hypertension</ENT2> (<ENT2>EH</ENT2>).,,,,T,,,,,c,,,,,0.0,,
20005218,1911,9365,D000075222,Association,TRUE,METHODS: We investigate whether the G-395A polymorphism of <ENT1>Klotho</ENT1> is associated with <ENT2>EH</ENT2> in a population consisting of 215 patients with <ENT2>EH</ENT2> and 220 non-hypertensive subjects.,,,,T,,Y,,,c,,,,,1.0,,
20005218,1911,9365,D000075222,Association,TRUE,CONCLUSIONS: The G-395A polymorphism of the human <ENT1>Klotho</ENT1> gene is associated with <ENT2>EH</ENT2> and may be a potential regulatory site.,,,,T,,,,,c,,,,,1.0,,
20005218,1914,rs1207568,D000075222,Positive_Correlation,TRUE,We hypothesised that the <ENT1>G-395A</ENT1> polymorphism in the promoter region of the human Klotho gene may contribute to the prevalence of <ENT2>Essential Hypertension</ENT2> (<ENT2>EH</ENT2>).,,,,T,,,,,c,,,,,0.5,,
20005218,1914,rs1207568,D000075222,Positive_Correlation,TRUE,METHODS: We investigate whether the <ENT1>G-395A</ENT1> polymorphism of Klotho is associated with <ENT2>EH</ENT2> in a population consisting of 215 patients with <ENT2>EH</ENT2> and 220 non-hypertensive subjects.,,,,T,,Y,,,c,,,,,1.0,,
20005218,1914,rs1207568,D000075222,Positive_Correlation,TRUE,RESULTS: Differences in the genotype distributions of the <ENT1>G-395A</ENT1> polymorphism between the <ENT2>EH</ENT2> and non-hypertension groups are statistically significant (P=0.032).,,,,T,,,,,w,,,,,1.0,,
20005218,1914,rs1207568,D000075222,Positive_Correlation,TRUE,"There are differential effects of age, gender and smoking status on the association of the <ENT1>G-395A</ENT1> polymorphism with <ENT2>EH</ENT2>; the <ENT1>G-395A</ENT1> polymorphism is significantly associated with <ENT2>EH</ENT2> in subjects over 60years old, in females and in nonsmokers.",,,,T,,,,,w,,,"11,22",,0.0,TRUE,"11,22"
20005218,1914,rs1207568,D000075222,Positive_Correlation,TRUE,A multiple logistic regression analysis indicated that the odds ratio for <ENT2>EH</ENT2> in the <ENT1>-395A</ENT1> allele carriers as compared with the control group was 0.593 (P=0.024) after adjusting for current traditional risk factors.,,,,T,,,,,c,,,,,1.0,,
20005218,1914,rs1207568,D000075222,Positive_Correlation,TRUE,CONCLUSIONS: The <ENT1>G-395A</ENT1> polymorphism of the human Klotho gene is associated with <ENT2>EH</ENT2> and may be a potential regulatory site.,,,,T,,,,,w,,,,,0.0,,
20034406,1917,24770,D013226,Positive_Correlation,TRUE,Chemokine <ENT1>CCL2</ENT1> and its receptor CCR2 are increased in the hippocampus following pilocarpine-induced <ENT2>status epilepticus</ENT2>.,,,,T,,,,,c,,,,,0.0,,
20034406,1917,24770,D013226,Positive_Correlation,TRUE,In this work CCR2 and <ENT1>CCL2</ENT1> expression were examined following <ENT2>status epilepticus</ENT2> (<ENT2>SE</ENT2>) induced by pilocarpine injection.,,,,T,,Y,,,c,,,,,0.5,,
20034406,1917,24770,D013226,Positive_Correlation,TRUE,Examination of <ENT1>CCL2</ENT1> expression showed that it was elevated in the hippocampus following <ENT2>SE</ENT2>.,,,,T,,,,,c,,,,,0.0,,
20034406,1917,24770,D013226,Positive_Correlation,TRUE,CONCLUSION: The data show that CCR2 and <ENT1>CCL2</ENT1> are up-regulated in the hippocampus after pilocarpine-induced <ENT2>SE</ENT2>.,,,,T,,,,,c,,,,,1.0,,
20034406,1922,24770,60463,Bind,FALSE,Chemokine <ENT1>CCL2</ENT1> and its receptor <ENT2>CCR2</ENT2> are increased in the hippocampus following pilocarpine-induced status epilepticus.,,,,T,,,,,c,,,,,1.0,,
20034406,1922,24770,60463,Bind,FALSE,<ENT2>CCR2</ENT2> is a <ENT2>chemokine receptor</ENT2> for <ENT1>CCL2</ENT1> and their interaction mediates monocyte infiltration in the neuroinflammatory cascade triggered in different brain pathologies.,,,,T,,,,,c,,,,,1.0,,
20034406,1922,24770,60463,Bind,FALSE,In this work <ENT2>CCR2</ENT2> and <ENT1>CCL2</ENT1> expression were examined following status epilepticus (SE) induced by pilocarpine injection.,,,,T,,,,,c,,,,,1.0,,
20034406,1922,24770,60463,Bind,FALSE,CONCLUSION: The data show that <ENT2>CCR2</ENT2> and <ENT1>CCL2</ENT1> are up-regulated in the hippocampus after pilocarpine-induced SE.,,,,T,,,,,c,,,,,1.0,,
20034406,1920,24770,D010862,Positive_Correlation,TRUE,Chemokine <ENT1>CCL2</ENT1> and its receptor CCR2 are increased in the hippocampus following <ENT2>pilocarpine</ENT2>-induced status epilepticus.,,,,T,,,,,c,,,,,1.0,,
20034406,1920,24770,D010862,Positive_Correlation,TRUE,In this work CCR2 and <ENT1>CCL2</ENT1> expression were examined following status epilepticus (SE) induced by <ENT2>pilocarpine</ENT2> injection.,,,,T,,Y,,,c,,,,,1.0,,
20034406,1920,24770,D010862,Positive_Correlation,TRUE,CONCLUSION: The data show that CCR2 and <ENT1>CCL2</ENT1> are up-regulated in the hippocampus after <ENT2>pilocarpine</ENT2>-induced SE.,,,,T,,,,,c,,,,,1.0,,
20034406,1916,D013226,60463,Positive_Correlation,TRUE,Chemokine CCL2 and its receptor <ENT2>CCR2</ENT2> are increased in the hippocampus following pilocarpine-induced <ENT1>status epilepticus</ENT1>.,,,,T,,,,,c,,,,,0.0,,
20034406,1916,D013226,60463,Positive_Correlation,TRUE,In this work <ENT2>CCR2</ENT2> and CCL2 expression were examined following <ENT1>status epilepticus</ENT1> (<ENT1>SE</ENT1>) induced by pilocarpine injection.,,,,T,,Y,,,c,,,,,1.0,,
20034406,1916,D013226,60463,Positive_Correlation,TRUE,"Five days after <ENT1>SE</ENT1>, <ENT2>CCR2</ENT2> staining in neurons and glial cells was examined using imunohistochemical analyses.",,,,T,,,,,c,,,,,1.0,,
20034406,1916,D013226,60463,Positive_Correlation,TRUE,RESULTS: Increased <ENT2>CCR2</ENT2> was observed in the hippocampus after <ENT1>SE</ENT1>.,,,,T,,,,,c,,,,,0.0,,
20034406,1916,D013226,60463,Positive_Correlation,TRUE,Increased numbers of neurons that expressed <ENT2>CCR2</ENT2> was observed following <ENT1>SE</ENT1>.,,,,T,,,,,w,,,,,0.0,,
20034406,1916,D013226,60463,Positive_Correlation,TRUE,Microglial cells were more closely apposed to the <ENT2>CCR2</ENT2>-labeled cells in <ENT1>SE</ENT1> rats.,,,,T,,,,,c,,,,,0.0,,
20034406,1916,D013226,60463,Positive_Correlation,TRUE,"In addition, rats that experienced <ENT1>SE</ENT1> exhibited <ENT2>CCR2</ENT2>-labeling in populations of hypertrophied astrocytes, especially in CA1 and dentate gyrus.",,,,T,,,,,w,,,,,0.0,,
20034406,1916,D013226,60463,Positive_Correlation,TRUE,CONCLUSION: The data show that <ENT2>CCR2</ENT2> and CCL2 are up-regulated in the hippocampus after pilocarpine-induced <ENT1>SE</ENT1>.,,,,T,,,,,c,,,,,1.0,,
20034406,1918,D013226,D010862,Positive_Correlation,FALSE,Chemokine CCL2 and its receptor CCR2 are increased in the hippocampus following <ENT2>pilocarpine</ENT2>-induced <ENT1>status epilepticus</ENT1>.,,,,T,,,,,c,,,,,1.0,,
20034406,1918,D013226,D010862,Positive_Correlation,FALSE,In this work CCR2 and CCL2 expression were examined following <ENT1>status epilepticus</ENT1> (<ENT1>SE</ENT1>) induced by <ENT2>pilocarpine</ENT2> injection.,,,,T,,,,,c,,,,,1.0,,
20034406,1918,D013226,D010862,Positive_Correlation,FALSE,METHODS: <ENT1>SE</ENT1> was induced by <ENT2>pilocarpine</ENT2> injection.,,,,T,,,,,c,,,,,1.0,,
20034406,1918,D013226,D010862,Positive_Correlation,FALSE,CONCLUSION: The data show that CCR2 and CCL2 are up-regulated in the hippocampus after <ENT2>pilocarpine</ENT2>-induced <ENT1>SE</ENT1>.,,,,T,,,,,c,,,,,1.0,,
20034406,1915,D012640,60463,Association,TRUE,<ENT1>Seizures</ENT1> also resulted in alterations to the cell types expressing <ENT2>CCR2</ENT2>.,,,,T,,,,,c,,,,,1.0,,
20034406,1915,D012640,60463,Association,TRUE,<ENT1>Seizures</ENT1> also result in changes to <ENT2>CCR2</ENT2> receptor expression in neurons and astrocytes.,,,,T,,,,,c,,,,,1.0,,
20034406,1919,60463,D010862,Positive_Correlation,TRUE,Chemokine CCL2 and its receptor <ENT1>CCR2</ENT1> are increased in the hippocampus following <ENT2>pilocarpine</ENT2>-induced status epilepticus.,,,,T,,,,,c,,,,,0.0,,
20034406,1919,60463,D010862,Positive_Correlation,TRUE,In this work <ENT1>CCR2</ENT1> and CCL2 expression were examined following status epilepticus (SE) induced by <ENT2>pilocarpine</ENT2> injection.,,,,T,,,,,c,,,,,1.0,,
20034406,1919,60463,D010862,Positive_Correlation,TRUE,CONCLUSION: The data show that <ENT1>CCR2</ENT1> and CCL2 are up-regulated in the hippocampus after <ENT2>pilocarpine</ENT2>-induced SE.,,,,T,,,,,c,,,,,1.0,,
20034406,1921,60463,D007249,Association,TRUE,<ENT1>CCR2</ENT1> is a <ENT1>chemokine receptor</ENT1> for CCL2 and their interaction mediates monocyte infiltration in the <ENT2>neuroinflammatory</ENT2> cascade triggered in different brain pathologies.,,,,T,Y,,,,w,,,,,1.0,,
20046642,1931,D008315,D008668,Negative_Correlation,TRUE,"Also, BCNU administration increased serum tumor necrosis factor-alpha (TNFalpha), hippocampal <ENT2>MT</ENT2> and <ENT1>malondialdehyde</ENT1> (<ENT1>MDA</ENT1>) contents as well as caspase-3 activity in addition to histological alterations.",,,,T,,,,,c,,,,,1.0,,
20046642,1931,D008315,D008668,Negative_Correlation,TRUE,"In conclusion, <ENT2>MT</ENT2> induction halts BCNU-induced hippocampal toxicity as it prevented GR inhibition and GSH depletion and counteracted the increased levels of TNFalpha, <ENT1>MDA</ENT1> and caspase-3 activity with subsequent preservation of cognition.",,,,T,,,,,c,,,,,1.0,,
20046642,1924,D008315,D019287,Negative_Correlation,TRUE,<ENT2>ZnSO(4)</ENT2> pretreatment counteracted BCNU-induced inhibition of GR and depletion of GSH and resulted in significant reduction in the levels of <ENT1>MDA</ENT1> and TNFalpha as well as the activity of caspase-3.,,,,T,,,,,c,,,,,1.0,,
20046642,1937,D008315,D002330,Positive_Correlation,TRUE,"Also, <ENT2>BCNU</ENT2> administration increased serum tumor necrosis factor-alpha (TNFalpha), hippocampal MT and <ENT1>malondialdehyde</ENT1> (<ENT1>MDA</ENT1>) contents as well as caspase-3 activity in addition to histological alterations.",,,,T,,,,,c,,,,,1.0,,
20046642,1937,D008315,D002330,Positive_Correlation,TRUE,ZnSO(4) pretreatment counteracted <ENT2>BCNU</ENT2>-induced inhibition of GR and depletion of GSH and resulted in significant reduction in the levels of <ENT1>MDA</ENT1> and TNFalpha as well as the activity of caspase-3.,,,,T,,,,,c,,,,,0.0,,
20046642,1937,D008315,D002330,Positive_Correlation,TRUE,"In conclusion, MT induction halts <ENT2>BCNU</ENT2>-induced hippocampal toxicity as it prevented GR inhibition and GSH depletion and counteracted the increased levels of TNFalpha, <ENT1>MDA</ENT1> and caspase-3 activity with subsequent preservation of cognition.",,,,T,,,,,w,,,,,0.0,,
20046642,1935,D003072,D008668,Negative_Correlation,TRUE,The present study aimed to explore the effect of <ENT2>MT</ENT2> induction on carmustine (BCNU)-induced hippocampal <ENT1>cognitive dysfunction</ENT1> in rats.,,,,T,,Y,,,w,,,,,1.0,,
20046642,1944,D003072,D002330,Positive_Correlation,FALSE,The present study aimed to explore the effect of MT induction on <ENT2>carmustine</ENT2> (<ENT2>BCNU</ENT2>)-induced hippocampal <ENT1>cognitive dysfunction</ENT1> in rats.,,,,T,,,,,c,,,,,1.0,,
20046642,1929,D008668,25402,Negative_Correlation,TRUE,<ENT1>Metallothionein</ENT1> induction reduces <ENT2>caspase-3</ENT2> activity and TNFalpha levels with preservation of cognitive function and intact hippocampal neurons in carmustine-treated rats.,,,,T,,,,,c,,,,,1.0,,
20046642,1929,D008668,25402,Negative_Correlation,TRUE,"Also, BCNU administration increased serum tumor necrosis factor-alpha (TNFalpha), hippocampal <ENT1>MT</ENT1> and malondialdehyde (MDA) contents as well as <ENT2>caspase-3</ENT2> activity in addition to histological alterations.",,,,T,,,,,c,,,,,1.0,,
20046642,1929,D008668,25402,Negative_Correlation,TRUE,"In conclusion, <ENT1>MT</ENT1> induction halts BCNU-induced hippocampal toxicity as it prevented GR inhibition and GSH depletion and counteracted the increased levels of TNFalpha, MDA and <ENT2>caspase-3</ENT2> activity with subsequent preservation of cognition.",,,,T,,,,,c,,,,,1.0,,
20046642,1930,D008668,D019287,Positive_Correlation,FALSE,"On the other hand, induction of <ENT1>metallothionein</ENT1> (<ENT1>MT</ENT1>) by <ENT2>ZnSO(4)</ENT2> and its role in neuroprotection has been documented.",,,,T,,,,,c,,,,,1.0,,
20046642,1932,D008668,24835,Negative_Correlation,TRUE,<ENT1>Metallothionein</ENT1> induction reduces caspase-3 activity and <ENT2>TNFalpha</ENT2> levels with preservation of cognitive function and intact hippocampal neurons in carmustine-treated rats.,,,,T,,,,,c,,,,,1.0,,
20046642,1932,D008668,24835,Negative_Correlation,TRUE,"Also, BCNU administration increased serum <ENT2>tumor necrosis factor-alpha</ENT2> (<ENT2>TNFalpha</ENT2>), hippocampal <ENT1>MT</ENT1> and malondialdehyde (MDA) contents as well as caspase-3 activity in addition to histological alterations.",,,,T,,,,,c,,,,,1.0,,
20046642,1932,D008668,24835,Negative_Correlation,TRUE,"In conclusion, <ENT1>MT</ENT1> induction halts BCNU-induced hippocampal toxicity as it prevented GR inhibition and GSH depletion and counteracted the increased levels of <ENT2>TNFalpha</ENT2>, MDA and caspase-3 activity with subsequent preservation of cognition.",,,,T,,,,,c,,,,,0.0,,
20046642,1933,D008668,D005978,Positive_Correlation,TRUE,"In conclusion, <ENT1>MT</ENT1> induction halts BCNU-induced hippocampal toxicity as it prevented GR inhibition and <ENT2>GSH</ENT2> depletion and counteracted the increased levels of TNFalpha, MDA and caspase-3 activity with subsequent preservation of cognition.",,,,T,,,,,c,,,,,0.0,,
20046642,1943,D008668,D002330,Positive_Correlation,TRUE,<ENT1>Metallothionein</ENT1> induction reduces caspase-3 activity and TNFalpha levels with preservation of cognitive function and intact hippocampal neurons in <ENT2>carmustine</ENT2>-treated rats.,,,,T,,,,,c,,,,,1.0,,
20046642,1943,D008668,D002330,Positive_Correlation,TRUE,The present study aimed to explore the effect of <ENT1>MT</ENT1> induction on <ENT2>carmustine</ENT2> (<ENT2>BCNU</ENT2>)-induced hippocampal cognitive dysfunction in rats.,,,,T,,Y,,,c,,,,,1.0,,
20046642,1943,D008668,D002330,Positive_Correlation,TRUE,"Also, <ENT2>BCNU</ENT2> administration increased serum tumor necrosis factor-alpha (TNFalpha), hippocampal <ENT1>MT</ENT1> and malondialdehyde (MDA) contents as well as caspase-3 activity in addition to histological alterations.",,,,T,,,,,c,,,,,1.0,,
20046642,1943,D008668,D002330,Positive_Correlation,TRUE,"In conclusion, <ENT1>MT</ENT1> induction halts <ENT2>BCNU</ENT2>-induced hippocampal toxicity as it prevented GR inhibition and GSH depletion and counteracted the increased levels of TNFalpha, MDA and caspase-3 activity with subsequent preservation of cognition.",,,,T,Y,,,,w,,,,,0.0,,
20046642,1934,D008668,116686,Positive_Correlation,TRUE,"In conclusion, <ENT1>MT</ENT1> induction halts BCNU-induced hippocampal toxicity as it prevented <ENT2>GR</ENT2> inhibition and GSH depletion and counteracted the increased levels of TNFalpha, MDA and caspase-3 activity with subsequent preservation of cognition.",,,,T,,,,,c,,,,,0.0,,
20046642,1942,D007859,D002330,Positive_Correlation,FALSE,"The obtained data revealed that <ENT2>BCNU</ENT2> administration resulted in <ENT1>deterioration of learning and short-term memory</ENT1> (STM), as measured by using radial arm water maze, accompanied with decreased hippocampal glutathione reductase (GR) activity and reduced glutathione (GSH) content.",,,,T,,,,,c,,,,,1.0,,
20046642,1923,25402,D019287,Negative_Correlation,TRUE,<ENT2>ZnSO(4)</ENT2> pretreatment counteracted BCNU-induced inhibition of GR and depletion of GSH and resulted in significant reduction in the levels of MDA and TNFalpha as well as the activity of <ENT1>caspase-3</ENT1>.,,,,T,,,,,c,,,,,1.0,,
20046642,1936,25402,D002330,Positive_Correlation,TRUE,Metallothionein induction reduces <ENT1>caspase-3</ENT1> activity and TNFalpha levels with preservation of cognitive function and intact hippocampal neurons in <ENT2>carmustine</ENT2>-treated rats.,,,,T,,,,,c,,,,,1.0,,
20046642,1936,25402,D002330,Positive_Correlation,TRUE,"Also, <ENT2>BCNU</ENT2> administration increased serum tumor necrosis factor-alpha (TNFalpha), hippocampal MT and malondialdehyde (MDA) contents as well as <ENT1>caspase-3</ENT1> activity in addition to histological alterations.",,,,T,,,,,c,,,,,1.0,,
20046642,1936,25402,D002330,Positive_Correlation,TRUE,ZnSO(4) pretreatment counteracted <ENT2>BCNU</ENT2>-induced inhibition of GR and depletion of GSH and resulted in significant reduction in the levels of MDA and TNFalpha as well as the activity of <ENT1>caspase-3</ENT1>.,,,,T,,,,,c,,,,,0.0,,
20046642,1936,25402,D002330,Positive_Correlation,TRUE,"In conclusion, MT induction halts <ENT2>BCNU</ENT2>-induced hippocampal toxicity as it prevented GR inhibition and GSH depletion and counteracted the increased levels of TNFalpha, MDA and <ENT1>caspase-3</ENT1> activity with subsequent preservation of cognition.",,,,T,,,,,c,,,,,0.0,,
20046642,1925,D019287,24835,Negative_Correlation,TRUE,<ENT1>ZnSO(4)</ENT1> pretreatment counteracted BCNU-induced inhibition of GR and depletion of GSH and resulted in significant reduction in the levels of MDA and <ENT2>TNFalpha</ENT2> as well as the activity of caspase-3.,,,,T,,,,,c,,,,,1.0,,
20046642,1926,D019287,D005978,Positive_Correlation,TRUE,<ENT1>ZnSO(4)</ENT1> pretreatment counteracted BCNU-induced inhibition of GR and depletion of <ENT2>GSH</ENT2> and resulted in significant reduction in the levels of MDA and TNFalpha as well as the activity of caspase-3.,,,,T,,,,,c,,,,,0.0,,
20046642,1928,D019287,D002330,Cotreatment,FALSE,"The second group administered <ENT1>ZnSO(4)</ENT1> (0.1 micromol/10 microl normal saline, i.c.v, once) then <ENT2>BCNU</ENT2> solvent (i.v) after 24 h.",,,,T,,,,,c,,,,,0.0,,
20046642,1928,D019287,D002330,Cotreatment,FALSE,"Fourth group received a single dose of <ENT1>ZnSO(4)</ENT1> (0.1 micromol/10 microl normal saline, i.c.v) then <ENT2>BCNU</ENT2> (20 mg/kg, i.v, once) after 24 h.",,,,T,,,,,c,,,,,0.0,,
20046642,1928,D019287,D002330,Cotreatment,FALSE,<ENT1>ZnSO(4)</ENT1> pretreatment counteracted <ENT2>BCNU</ENT2>-induced inhibition of GR and depletion of GSH and resulted in significant reduction in the levels of MDA and TNFalpha as well as the activity of caspase-3.,,,,T,,,,,w,,,,,0.0,,
20046642,1928,D019287,D002330,Cotreatment,FALSE,The histological features were improved in hippocampus of rats treated with <ENT1>ZnSO(4)</ENT1> + <ENT2>BCNU</ENT2> compared to only <ENT2>BCNU</ENT2>-treated animals.,,,,T,,,,,c,,,,,1.0,,
20046642,1927,D019287,116686,Positive_Correlation,TRUE,<ENT1>ZnSO(4)</ENT1> pretreatment counteracted BCNU-induced inhibition of <ENT2>GR</ENT2> and depletion of GSH and resulted in significant reduction in the levels of MDA and TNFalpha as well as the activity of caspase-3.,,,,T,,,,,c,,,,,0.0,,
20046642,1938,24835,D002330,Positive_Correlation,TRUE,Metallothionein induction reduces caspase-3 activity and <ENT1>TNFalpha</ENT1> levels with preservation of cognitive function and intact hippocampal neurons in <ENT2>carmustine</ENT2>-treated rats.,,,,T,,,,,c,,,,,1.0,,
20046642,1938,24835,D002330,Positive_Correlation,TRUE,"Also, <ENT2>BCNU</ENT2> administration increased serum <ENT1>tumor necrosis factor-alpha</ENT1> (<ENT1>TNFalpha</ENT1>), hippocampal MT and malondialdehyde (MDA) contents as well as caspase-3 activity in addition to histological alterations.",,,,T,,,,,c,,,,,1.0,,
20046642,1938,24835,D002330,Positive_Correlation,TRUE,ZnSO(4) pretreatment counteracted <ENT2>BCNU</ENT2>-induced inhibition of GR and depletion of GSH and resulted in significant reduction in the levels of MDA and <ENT1>TNFalpha</ENT1> as well as the activity of caspase-3.,,,,T,,,,,c,,,,,1.0,,
20046642,1938,24835,D002330,Positive_Correlation,TRUE,"In conclusion, MT induction halts <ENT2>BCNU</ENT2>-induced hippocampal toxicity as it prevented GR inhibition and GSH depletion and counteracted the increased levels of <ENT1>TNFalpha</ENT1>, MDA and caspase-3 activity with subsequent preservation of cognition.",,,,T,,,,,c,,,,,1.0,,
20046642,1939,D005978,D002330,Negative_Correlation,TRUE,"The obtained data revealed that <ENT2>BCNU</ENT2> administration resulted in deterioration of learning and short-term memory (STM), as measured by using radial arm water maze, accompanied with decreased hippocampal glutathione reductase (GR) activity and reduced <ENT1>glutathione</ENT1> (<ENT1>GSH</ENT1>) content.",,,,T,,,,,c,,,,,1.0,,
20046642,1939,D005978,D002330,Negative_Correlation,TRUE,ZnSO(4) pretreatment counteracted <ENT2>BCNU</ENT2>-induced inhibition of GR and depletion of <ENT1>GSH</ENT1> and resulted in significant reduction in the levels of MDA and TNFalpha as well as the activity of caspase-3.,,,,T,,,,,c,,,,,1.0,,
20046642,1939,D005978,D002330,Negative_Correlation,TRUE,"In conclusion, MT induction halts <ENT2>BCNU</ENT2>-induced hippocampal toxicity as it prevented GR inhibition and <ENT1>GSH</ENT1> depletion and counteracted the increased levels of TNFalpha, MDA and caspase-3 activity with subsequent preservation of cognition.",,,,T,,,,,c,,,,,1.0,,
20046642,1940,D002330,116686,Negative_Correlation,TRUE,"The obtained data revealed that <ENT1>BCNU</ENT1> administration resulted in deterioration of learning and short-term memory (STM), as measured by using radial arm water maze, accompanied with decreased hippocampal <ENT2>glutathione reductase</ENT2> (<ENT2>GR</ENT2>) activity and reduced glutathione (GSH) content.",,,,T,,,,,c,,,,,1.0,,
20046642,1940,D002330,116686,Negative_Correlation,TRUE,ZnSO(4) pretreatment counteracted <ENT1>BCNU</ENT1>-induced inhibition of <ENT2>GR</ENT2> and depletion of GSH and resulted in significant reduction in the levels of MDA and TNFalpha as well as the activity of caspase-3.,,,,T,,,,,c,,,,,1.0,,
20046642,1940,D002330,116686,Negative_Correlation,TRUE,"In conclusion, MT induction halts <ENT1>BCNU</ENT1>-induced hippocampal toxicity as it prevented <ENT2>GR</ENT2> inhibition and GSH depletion and counteracted the increased levels of TNFalpha, MDA and caspase-3 activity with subsequent preservation of cognition.",,,,T,,,,,c,,,,,0.0,,
20080916,1946,3663,D008180,Association,TRUE,"Promoter insertion/deletion in the <ENT1>IRF5</ENT1> gene is highly associated with susceptibility to <ENT2>systemic lupus erythematosus</ENT2> in distinct populations, but exerts a modest effect on gene expression in peripheral blood mononuclear cells.",,,,T,,,,,w,,,,,1.0,,
20080916,1946,3663,D008180,Association,TRUE,OBJECTIVE: We examined the genetic association of the promoter insertion/deletion (indel) in <ENT1>IRF5</ENT1> gene with <ENT2>systemic lupus erythematosus</ENT2> (<ENT2>SLE</ENT2>) in distinct populations and assessed its role in gene expression.,,,,T,,,,,c,,,,,1.0,,
20080916,1946,3663,D008180,Association,TRUE,METHODS: Four <ENT1>IRF5</ENT1> polymorphisms were genotyped in 1488 <ENT2>SLE</ENT2> patients and 1466 controls.,,,,T,,Y,,,c,,,,,1.0,,
20080916,1946,3663,D008180,Association,TRUE,CONCLUSION: We corroborated the association of the promoter indel with <ENT2>SLE</ENT2> in 5 different populations and revealed that rs10954213 is the main single-nucleotide polymorphism responsible for altered <ENT1>IRF5</ENT1> expression in PBMC.,,,,T,,,,,w,,,,,0.0,,
20080916,1945,rs10954213,rs2004640,Association,TRUE,"RESULTS: The promoter indel and rs2070197 had independent genetic effects, which accounted for the association of <ENT2>rs2004640</ENT2> and <ENT1>rs10954213</ENT1>.",,,,T,,,,,c,,,,,0.0,,
20080916,1947,rs10954213,D008180,Association,TRUE,CONCLUSION: We corroborated the association of the promoter indel with <ENT2>SLE</ENT2> in 5 different populations and revealed that <ENT1>rs10954213</ENT1> is the main single-nucleotide polymorphism responsible for altered IRF5 expression in PBMC.,,,,T,,,,,c,,,,,0.0,,
20105310,1959,D009765,9370,Association,FALSE,"However, <ENT1>obese</ENT1> subjects differ in insulin resistance, <ENT2>adipokine</ENT2> production and co-morbidities.",,,,T,,,,,w,,,,,0.0,,
20105310,1960,D009765,D014280,Positive_Correlation,TRUE,"Based on fasting plasma analysis, <ENT1>obese</ENT1> subjects were grouped as Low Acylation Stimulating protein (ASP) and <ENT2>Triglyceride</ENT2> (<ENT2>TG</ENT2>) (LAT) vs High ASP and <ENT2>TG</ENT2> (HAT).",,,,T,,,,,c,,,,,1.0,,
20105310,1960,D009765,D014280,Positive_Correlation,TRUE,"CONCLUSION: Taken together, the profile of C5L2 receptor, ASP gene expression and metabolic factors in adipose tissue from morbidly <ENT1>obese</ENT1> HAT subjects suggests a compensatory response associated with the increased plasma ASP and <ENT2>TG</ENT2>.",,,,T,,,,,c,,,,,0.0,,
20105310,1958,D009765,718,Association,TRUE,Association of adipocyte genes with <ENT2>ASP</ENT2> expression: a microarray analysis of subcutaneous and omental adipose tissue in morbidly <ENT1>obese</ENT1> subjects.,,,,T,,,,,c,,,,,1.0,,
20105310,1958,D009765,718,Association,TRUE,"Based on fasting plasma analysis, <ENT1>obese</ENT1> subjects were grouped as Low <ENT2>Acylation Stimulating protein</ENT2> (<ENT2>ASP</ENT2>) and Triglyceride (TG) (LAT) vs High <ENT2>ASP</ENT2> and TG (HAT).",,,,T,,,,,c,,,,,1.0,,
20105310,1958,D009765,718,Association,TRUE,"CONCLUSION: Taken together, the profile of C5L2 receptor, <ENT2>ASP</ENT2> gene expression and metabolic factors in adipose tissue from morbidly <ENT1>obese</ENT1> HAT subjects suggests a compensatory response associated with the increased plasma <ENT2>ASP</ENT2> and TG.",,,,T,,,,,c,,,,,1.0,,
20105310,1966,5346,D008055,Association,TRUE,"RESULTS: HAT adipose tissue demonstrated increased <ENT2>lipid</ENT2> related genes for storage (CD36, DGAT1, DGAT2, SCD1, FASN, and LPL), lipolysis (HSL, CES1, <ENT1>perilipin</ENT1>), fatty acid binding proteins (FABP1, FABP3) and adipocyte differentiation markers (CEBPalpha, CEBPbeta, PPARgamma).",,,,T,,,,,c,,,,,0.0,,
20105310,1965,2168,D008055,Association,TRUE,"RESULTS: HAT adipose tissue demonstrated increased <ENT2>lipid</ENT2> related genes for storage (CD36, DGAT1, DGAT2, SCD1, FASN, and LPL), lipolysis (HSL, CES1, perilipin), <ENT1>fatty acid binding proteins</ENT1> (<ENT1>FABP1</ENT1>, FABP3) and adipocyte differentiation markers (CEBPalpha, CEBPbeta, PPARgamma).",,,,T,,,,,c,,,,,0.5,,
20105310,1976,D014280,27202,Positive_Correlation,FALSE,"Increased <ENT2>C5L2</ENT2> (p < 0.01), an <ENT2>ASP receptor</ENT2>, in HAT suggests a compensatory ASP pathway, associated with increased <ENT1>TG</ENT1> storage.",,,,T,,,,,c,,,,,0.0,,
20105310,1976,D014280,27202,Positive_Correlation,FALSE,"CONCLUSION: Taken together, the profile of <ENT2>C5L2</ENT2> receptor, ASP gene expression and metabolic factors in adipose tissue from morbidly obese HAT subjects suggests a compensatory response associated with the increased plasma ASP and <ENT1>TG</ENT1>.",,,,T,,,,,w,,,,,0.0,,
20105310,1957,D014280,718,Positive_Correlation,TRUE,"Based on fasting plasma analysis, obese subjects were grouped as Low <ENT2>Acylation Stimulating protein</ENT2> (<ENT2>ASP</ENT2>) and <ENT1>Triglyceride</ENT1> (<ENT1>TG</ENT1>) (LAT) vs High <ENT2>ASP</ENT2> and <ENT1>TG</ENT1> (HAT).",,,,T,,,,,c,,,,,1.0,,
20105310,1957,D014280,718,Positive_Correlation,TRUE,"Increased C5L2 (p < 0.01), an ASP receptor, in HAT suggests a compensatory <ENT2>ASP</ENT2> pathway, associated with increased <ENT1>TG</ENT1> storage.",,,,T,,,,,w,,,,,0.0,,
20105310,1957,D014280,718,Positive_Correlation,TRUE,"CONCLUSION: Taken together, the profile of C5L2 receptor, <ENT2>ASP</ENT2> gene expression and metabolic factors in adipose tissue from morbidly obese HAT subjects suggests a compensatory response associated with the increased plasma <ENT2>ASP</ENT2> and <ENT1>TG</ENT1>.",,,,T,,,,,w,,,,,1.0,,
20105310,1953,7040,D007249,Association,FALSE,"HAT subjects had increased anti-<ENT2>inflammatory</ENT2> genes <ENT1>TGFB1</ENT1>, TIMP1, TIMP3, and TIMP4 while <ENT2>proinflammatory</ENT2> PIG7 and MMP2 were also significantly increased; all genes, p < 0.025.",,,,T,,,,,w,,,,,0.5,,
20105310,1968,3991,D008055,Association,TRUE,"RESULTS: HAT adipose tissue demonstrated increased <ENT2>lipid</ENT2> related genes for storage (CD36, DGAT1, DGAT2, SCD1, FASN, and LPL), lipolysis (<ENT1>HSL</ENT1>, CES1, perilipin), fatty acid binding proteins (FABP1, FABP3) and adipocyte differentiation markers (CEBPalpha, CEBPbeta, PPARgamma).",,,,T,,,,,c,,,,,1.0,,
20105310,1948,4313,D007249,Association,FALSE,"HAT subjects had increased anti-<ENT2>inflammatory</ENT2> genes TGFB1, TIMP1, TIMP3, and TIMP4 while <ENT2>proinflammatory</ENT2> PIG7 and <ENT1>MMP2</ENT1> were also significantly increased; all genes, p < 0.025.",,,,T,,,,,w,,,,,0.0,,
20105310,1949,9516,D007249,Association,FALSE,"HAT subjects had increased anti-<ENT2>inflammatory</ENT2> genes TGFB1, TIMP1, TIMP3, and TIMP4 while <ENT2>proinflammatory</ENT2> <ENT1>PIG7</ENT1> and MMP2 were also significantly increased; all genes, p < 0.025.",,,,T,,,,,w,,,,,0.0,,
20105310,1975,27202,718,Bind,FALSE,"Increased <ENT1>C5L2</ENT1> (p < 0.01), an <ENT1>ASP receptor</ENT1>, in HAT suggests a compensatory <ENT2>ASP</ENT2> pathway, associated with increased TG storage.",,,,T,,,,,w,,,,,1.0,TRUE,
20105310,1975,27202,718,Bind,FALSE,"CONCLUSION: Taken together, the profile of <ENT1>C5L2</ENT1> receptor, <ENT2>ASP</ENT2> gene expression and metabolic factors in adipose tissue from morbidly obese HAT subjects suggests a compensatory response associated with the increased plasma <ENT2>ASP</ENT2> and TG.",,,,T,,,,,w,,,,,1.0,,
20105310,1956,629,718,Positive_Correlation,FALSE,"<ENT2>ASP</ENT2> related genes tended to be increased in the HAT group and were correlated (<ENT1>factor B</ENT1>, adipsin, <ENT2>complement C3</ENT2>, p < 0.01 each).",,,,T,Y,,,,w,,,,,0.0,,
20105310,1955,629,1675,Positive_Correlation,FALSE,"ASP related genes tended to be increased in the HAT group and were correlated (<ENT1>factor B</ENT1>, <ENT2>adipsin</ENT2>, complement C3, p < 0.01 each).",,,,T,Y,,,,w,,,,,0.0,,
20105310,1978,3643,3630,Association,FALSE,"METHODS: LAT and HAT groups were matched in age, obesity, <ENT2>insulin</ENT2>, and glucose, and had similar expression of <ENT2>insulin</ENT2>-related genes (<ENT1>InsR</ENT1>, IRS-1).",,,,T,,,,,c,,,,,0.5,,
20105310,1961,5468,D008055,Association,TRUE,"RESULTS: HAT adipose tissue demonstrated increased <ENT2>lipid</ENT2> related genes for storage (CD36, DGAT1, DGAT2, SCD1, FASN, and LPL), lipolysis (HSL, CES1, perilipin), fatty acid binding proteins (FABP1, FABP3) and adipocyte differentiation markers (CEBPalpha, CEBPbeta, <ENT1>PPARgamma</ENT1>).",,,,T,,,,,c,,,,,0.0,,
20105310,1954,718,1675,Positive_Correlation,FALSE,"<ENT1>ASP</ENT1> related genes tended to be increased in the HAT group and were correlated (factor B, <ENT2>adipsin</ENT2>, <ENT1>complement C3</ENT1>, p < 0.01 each).",,,,T,Y,,,,w,,,,,0.0,,
20105310,1970,2194,D008055,Association,TRUE,"RESULTS: HAT adipose tissue demonstrated increased <ENT2>lipid</ENT2> related genes for storage (CD36, DGAT1, DGAT2, SCD1, <ENT1>FASN</ENT1>, and LPL), lipolysis (HSL, CES1, perilipin), fatty acid binding proteins (FABP1, FABP3) and adipocyte differentiation markers (CEBPalpha, CEBPbeta, PPARgamma).",,,,T,,,,,c,,,,,1.0,,
20105310,1969,4023,D008055,Association,TRUE,"RESULTS: HAT adipose tissue demonstrated increased <ENT2>lipid</ENT2> related genes for storage (CD36, DGAT1, DGAT2, SCD1, FASN, and <ENT1>LPL</ENT1>), lipolysis (HSL, CES1, perilipin), fatty acid binding proteins (FABP1, FABP3) and adipocyte differentiation markers (CEBPalpha, CEBPbeta, PPARgamma).",,,,T,,,,,c,,,,,1.0,,
20105310,1977,3667,3630,Association,FALSE,"METHODS: LAT and HAT groups were matched in age, obesity, <ENT2>insulin</ENT2>, and glucose, and had similar expression of <ENT2>insulin</ENT2>-related genes (InsR, <ENT1>IRS-1</ENT1>).",,,,T,,,,,c,,,,,0.0,,
20105310,1963,1050,D008055,Association,TRUE,"RESULTS: HAT adipose tissue demonstrated increased <ENT2>lipid</ENT2> related genes for storage (CD36, DGAT1, DGAT2, SCD1, FASN, and LPL), lipolysis (HSL, CES1, perilipin), fatty acid binding proteins (FABP1, FABP3) and adipocyte differentiation markers (<ENT1>CEBPalpha</ENT1>, CEBPbeta, PPARgamma).",,,,T,,,,,c,,,,,0.0,,
20105310,1950,D007249,7079,Association,FALSE,"HAT subjects had increased anti-<ENT1>inflammatory</ENT1> genes TGFB1, TIMP1, TIMP3, and <ENT2>TIMP4</ENT2> while <ENT1>proinflammatory</ENT1> PIG7 and MMP2 were also significantly increased; all genes, p < 0.025.",,,,T,,,,,w,,,,,0.0,,
20105310,1951,D007249,7078,Association,FALSE,"HAT subjects had increased anti-<ENT1>inflammatory</ENT1> genes TGFB1, TIMP1, <ENT2>TIMP3</ENT2>, and TIMP4 while <ENT1>proinflammatory</ENT1> PIG7 and MMP2 were also significantly increased; all genes, p < 0.025.",,,,T,,,,,w,,,,,0.5,,
20105310,1952,D007249,7076,Association,FALSE,"HAT subjects had increased anti-<ENT1>inflammatory</ENT1> genes TGFB1, <ENT2>TIMP1</ENT2>, TIMP3, and TIMP4 while <ENT1>proinflammatory</ENT1> PIG7 and MMP2 were also significantly increased; all genes, p < 0.025.",,,,T,,,,,w,,,,,0.5,,
20105310,1962,1051,D008055,Association,TRUE,"RESULTS: HAT adipose tissue demonstrated increased <ENT2>lipid</ENT2> related genes for storage (CD36, DGAT1, DGAT2, SCD1, FASN, and LPL), lipolysis (HSL, CES1, perilipin), fatty acid binding proteins (FABP1, FABP3) and adipocyte differentiation markers (CEBPalpha, <ENT1>CEBPbeta</ENT1>, PPARgamma).",,,,T,,,,,c,,,,,0.0,,
20105310,1967,1066,D008055,Association,TRUE,"RESULTS: HAT adipose tissue demonstrated increased <ENT2>lipid</ENT2> related genes for storage (CD36, DGAT1, DGAT2, SCD1, FASN, and LPL), lipolysis (HSL, <ENT1>CES1</ENT1>, perilipin), fatty acid binding proteins (FABP1, FABP3) and adipocyte differentiation markers (CEBPalpha, CEBPbeta, PPARgamma).",,,,T,,,,,c,,,,,0.0,,
20105310,1971,6319,D008055,Association,TRUE,"RESULTS: HAT adipose tissue demonstrated increased <ENT2>lipid</ENT2> related genes for storage (CD36, DGAT1, DGAT2, <ENT1>SCD1</ENT1>, FASN, and LPL), lipolysis (HSL, CES1, perilipin), fatty acid binding proteins (FABP1, FABP3) and adipocyte differentiation markers (CEBPalpha, CEBPbeta, PPARgamma).",,,,T,,,,,c,,,,,1.0,,
20105310,1974,D008055,948,Association,TRUE,"RESULTS: HAT adipose tissue demonstrated increased <ENT1>lipid</ENT1> related genes for storage (<ENT2>CD36</ENT2>, DGAT1, DGAT2, SCD1, FASN, and LPL), lipolysis (HSL, CES1, perilipin), fatty acid binding proteins (FABP1, FABP3) and adipocyte differentiation markers (CEBPalpha, CEBPbeta, PPARgamma).",,,,T,,,,,c,,,,,1.0,,
20105310,1973,D008055,8694,Association,TRUE,"RESULTS: HAT adipose tissue demonstrated increased <ENT1>lipid</ENT1> related genes for storage (CD36, <ENT2>DGAT1</ENT2>, DGAT2, SCD1, FASN, and LPL), lipolysis (HSL, CES1, perilipin), fatty acid binding proteins (FABP1, FABP3) and adipocyte differentiation markers (CEBPalpha, CEBPbeta, PPARgamma).",,,,T,,,,,c,,,,,1.0,,
20105310,1972,D008055,84649,Association,TRUE,"RESULTS: HAT adipose tissue demonstrated increased <ENT1>lipid</ENT1> related genes for storage (CD36, DGAT1, <ENT2>DGAT2</ENT2>, SCD1, FASN, and LPL), lipolysis (HSL, CES1, perilipin), fatty acid binding proteins (FABP1, FABP3) and adipocyte differentiation markers (CEBPalpha, CEBPbeta, PPARgamma).",,,,T,,,,,c,,,,,1.0,,
20105310,1964,D008055,2170,Association,TRUE,"RESULTS: HAT adipose tissue demonstrated increased <ENT1>lipid</ENT1> related genes for storage (CD36, DGAT1, DGAT2, SCD1, FASN, and LPL), lipolysis (HSL, CES1, perilipin), <ENT2>fatty acid binding proteins</ENT2> (FABP1, <ENT2>FABP3</ENT2>) and adipocyte differentiation markers (CEBPalpha, CEBPbeta, PPARgamma).",,,,T,,,,,c,,,,,0.5,,
20129423,1980,D006967,D002220,Positive_Correlation,FALSE,"Fatal <ENT2>carbamazepine</ENT2> induced fulminant eosinophilic (<ENT1>hypersensitivity</ENT1>) myocarditis: emphasis on anatomical and histological characteristics, mechanisms and genetics of drug hypersensitivity and differential diagnosis.",,,,T,,,,,c,,,,,1.0,,
20129423,1980,D006967,D002220,Positive_Correlation,FALSE,"A frequently fatal, although exceptionally rare side effect of <ENT2>carbamazepine</ENT2> is necrotizing eosinophilic (<ENT1>hypersensitivity</ENT1>) myocarditis.",,,,T,,,,,w,,,,,1.0,,
20129423,1980,D006967,D002220,Positive_Correlation,FALSE,We report a case of <ENT1>hypersensitivity</ENT1> myocarditis secondary to administration of <ENT2>carbamazepine</ENT2>.,,,,T,,,,,c,,,,,0.0,,
20129423,1981,D002220,D009205,Positive_Correlation,TRUE,"Fatal <ENT1>carbamazepine</ENT1> induced fulminant eosinophilic (hypersensitivity) <ENT2>myocarditis</ENT2>: emphasis on anatomical and histological characteristics, mechanisms and genetics of drug hypersensitivity and differential diagnosis.",,,,T,,,,,c,,,,,1.0,,
20129423,1981,D002220,D009205,Positive_Correlation,TRUE,"A frequently fatal, although exceptionally rare side effect of <ENT1>carbamazepine</ENT1> is necrotizing eosinophilic (hypersensitivity) <ENT2>myocarditis</ENT2>.",,,,T,,,,,w,,,,,1.0,,
20129423,1981,D002220,D009205,Positive_Correlation,TRUE,We report a case of hypersensitivity <ENT2>myocarditis</ENT2> secondary to administration of <ENT1>carbamazepine</ENT1>.,,,,T,,,,,c,,,,,1.0,,
20129423,1981,D002220,D009205,Positive_Correlation,TRUE,To best of our knowledge this is the second case of fatal <ENT1>carbamazepine</ENT1> induced <ENT2>myocarditis</ENT2> reported in English literature.,,,,T,,,,,c,,,,,1.0,,
20143913,1984,p|SUB|R|315|X,D009087,Association,FALSE,Apparent homozygosity for the mutation <ENT1>p.R315X</ENT1> present on exon 5 of the arylsulfatase B (ARSB) gene in a <ENT2>mucopolysaccharidosis type VI</ENT2> patient was solved in this study by further testing for a second mutation.,,,,T,Y,,,,w,,,,,0.0,,
20143913,1983,D009087,411,Association,FALSE,Large deletion involving exon 5 of the <ENT2>arylsulfatase B</ENT2> gene caused apparent homozygosity in a <ENT1>mucopolysaccharidosis type VI</ENT1> patient.,,,,T,,,,,c,,,,,1.0,,
20143913,1983,D009087,411,Association,FALSE,Apparent homozygosity for the mutation p.R315X present on exon 5 of the <ENT2>arylsulfatase B</ENT2> (<ENT2>ARSB</ENT2>) gene in a <ENT1>mucopolysaccharidosis type VI</ENT1> patient was solved in this study by further testing for a second mutation.,,,,T,,,,,w,,,,,0.0,TRUE,
20226780,1989,25884,563085,Association,TRUE,Inability to identify a separate zebrafish gene corresponding to the mammalian CHL1 gene suggests that <ENT2>Chl</ENT2> may serve roles in zebrafish distributed between CHL1 and <ENT1>CHL2</ENT1> in other species.,,,,T,,,,,c,,,,,0.0,,
20226780,1990,91851,563085,Association,TRUE,Inability to identify a separate zebrafish gene corresponding to the mammalian <ENT1>CHL1</ENT1> gene suggests that <ENT2>Chl</ENT2> may serve roles in zebrafish distributed between <ENT1>CHL1</ENT1> and CHL2 in other species.,,,,T,Y,,,,w,,,,,0.0,,
20226780,1991,69121,563085,Association,TRUE,The <ENT2>chl</ENT2> gene is on a region of chromosome 21 syntenic with the area of murine chromosome 7 bearing the <ENT1>CHL2</ENT1> gene.,,,,T,,,,,c,,,,,1.0,,
20226780,1986,30161,30204,Negative_Correlation,FALSE,"Chl, like <ENT1>Chd</ENT1>, dorsalizes embryos upon overexpression and is cleaved by <ENT2>BMP1</ENT2>, which antagonizes this activity.",,,,T,,,,,c,,,,,0.0,,
20226780,1986,30161,30204,Negative_Correlation,FALSE,Loss-of-function experiments demonstrate that Chl serves as a <ENT2>BMP</ENT2> antagonist with functions that overlap and are redundant with those of <ENT1>Chd</ENT1> in forming the dorsoventral axis.,,,,T,,,,,c,,,,,1.0,,
20226780,1987,30161,359834,Association,FALSE,<ENT1>Chordin</ENT1> is the prototype of a group of <ENT1>cysteine-rich domain-containing proteins</ENT1> that bind and modulate signaling of various <ENT2>TGFbeta</ENT2>-like ligands.,,,,T,,,,,c,,,,,0.0,,
20226780,1988,563085,30204,Negative_Correlation,TRUE,"<ENT1>Chl</ENT1>, like Chd, dorsalizes embryos upon overexpression and is cleaved by <ENT2>BMP1</ENT2>, which antagonizes this activity.",,,,T,,,,,c,,,,,0.0,,
20226780,1988,563085,30204,Negative_Correlation,TRUE,Loss-of-function experiments demonstrate that <ENT1>Chl</ENT1> serves as a <ENT2>BMP</ENT2> antagonist with functions that overlap and are redundant with those of Chd in forming the dorsoventral axis.,,,,T,,,,,c,,,,,1.0,,
20331935,1993,D017367,D050723,Positive_Correlation,TRUE,"Of 13 documented <ENT2>fractures</ENT2>, 3 occurred after risperidone and <ENT1>SSRIs</ENT1> were started, and none occurred in patients with hyperprolactinemia.",,,,T,Y,,,,w,,,,,1.0,,
20331935,1994,D050723,D018967,Positive_Correlation,TRUE,"Of 13 documented <ENT1>fractures</ENT1>, 3 occurred after <ENT2>risperidone</ENT2> and SSRIs were started, and none occurred in patients with hyperprolactinemia.",,,,T,Y,,,,w,,,,,1.0,,
20331935,1992,D006966,D018967,Positive_Correlation,FALSE,OBJECTIVE: The aim of the present study was to investigate the effect of <ENT2>risperidone</ENT2>-induced <ENT1>hyperprolactinemia</ENT1> on trabecular bone mineral density (BMD) in children and adolescents.,,,,T,,,,,c,,,,,1.0,,
20331935,1992,D006966,D018967,Positive_Correlation,FALSE,RESULTS: <ENT1>Hyperprolactinemia</ENT1> was present in 49% of 83 boys (n = 41) treated with <ENT2>risperidone</ENT2> for a mean of 2.9 years.,,,,T,,,,,w,,,,,0.0,,
20331935,1992,D006966,D018967,Positive_Correlation,FALSE,"Of 13 documented fractures, 3 occurred after <ENT2>risperidone</ENT2> and SSRIs were started, and none occurred in patients with <ENT1>hyperprolactinemia</ENT1>.",,,,T,,,,,c,,,,,1.0,,
20331935,1992,D006966,D018967,Positive_Correlation,FALSE,CONCLUSIONS: This is the first study to link <ENT2>risperidone</ENT2>-induced <ENT1>hyperprolactinemia</ENT1> and SSRI treatment to lower BMD in children and adolescents.,,,,T,,,,,c,,,,,1.0,,
20335448,2013,C564221,2908,Association,TRUE,A novel point mutation in helix 10 of the human <ENT2>glucocorticoid receptor</ENT2> causes generalized <ENT1>glucocorticoid resistance</ENT1> by disrupting the structure of the ligand-binding domain.,,,,T,,,,,c,,,,,1.0,,
20335448,2013,C564221,2908,Association,TRUE,"CONTEXT: Generalized <ENT1>glucocorticoid resistance</ENT1> syndrome is a rare familial or sporadic condition characterized by partial insensitivity to glucocorticoids, caused by mutations in the <ENT2>glucocorticoid receptor</ENT2> (<ENT2>GR</ENT2>) gene.",,,,T,,,,,c,,,,,0.5,,
20335448,2006,C564221,D005938,Negative_Correlation,FALSE,"CONTEXT: Generalized <ENT1>glucocorticoid resistance</ENT1> syndrome is a rare familial or sporadic condition characterized by partial insensitivity to <ENT2>glucocorticoids</ENT2>, caused by mutations in the glucocorticoid receptor (GR) gene.",,,,T,,,,,c,,,,,0.0,,
20335448,1996,D007003,c|Allele|R|714,Association,TRUE,"CONCLUSIONS: Dexamethasone treatment is effective in controlling the premature pubarche, <ENT1>hypoglycemia</ENT1>, hypertension, and hypokalemia in this child case, wherein <ENT2>arginine 714</ENT2> plays a key role in the proper formation of the ligand-binding pocket and the AF-2 surface of the GR alpha LBD.",,,,T,,,,,c,,,,,1.0,,
20335448,2003,D007003,D003907,Negative_Correlation,TRUE,"CONCLUSIONS: <ENT2>Dexamethasone</ENT2> treatment is effective in controlling the premature pubarche, <ENT1>hypoglycemia</ENT1>, hypertension, and hypokalemia in this child case, wherein arginine 714 plays a key role in the proper formation of the ligand-binding pocket and the AF-2 surface of the GR alpha LBD.",,,,T,,,,,c,,,,,1.0,,
20335448,2010,D007003,2908,Association,TRUE,"CONCLUSIONS: Dexamethasone treatment is effective in controlling the premature pubarche, <ENT1>hypoglycemia</ENT1>, hypertension, and hypokalemia in this child case, wherein arginine 714 plays a key role in the proper formation of the ligand-binding pocket and the AF-2 surface of the <ENT2>GR alpha</ENT2> LBD.",,,,T,,,,,c,,,,,1.0,,
20335448,1999,C567552,c|Allele|R|714,Association,TRUE,"CONCLUSIONS: Dexamethasone treatment is effective in controlling the <ENT1>premature pubarche</ENT1>, hypoglycemia, hypertension, and hypokalemia in this child case, wherein <ENT2>arginine 714</ENT2> plays a key role in the proper formation of the ligand-binding pocket and the AF-2 surface of the GR alpha LBD.",,,,T,,,,,c,,,,,0.0,,
20335448,2000,C567552,D003907,Negative_Correlation,TRUE,"She also had hypertension and <ENT1>premature pubarche</ENT1>, whereas <ENT2>dexamethasone</ENT2> effectively suppressed these clinical manifestations.",,,,T,,,,,c,,,,,1.0,,
20335448,2000,C567552,D003907,Negative_Correlation,TRUE,"CONCLUSIONS: <ENT2>Dexamethasone</ENT2> treatment is effective in controlling the <ENT1>premature pubarche</ENT1>, hypoglycemia, hypertension, and hypokalemia in this child case, wherein arginine 714 plays a key role in the proper formation of the ligand-binding pocket and the AF-2 surface of the GR alpha LBD.",,,,T,,,,,c,,,,,1.0,,
20335448,2001,C567552,2908,Association,TRUE,"CONCLUSIONS: Dexamethasone treatment is effective in controlling the <ENT1>premature pubarche</ENT1>, hypoglycemia, hypertension, and hypokalemia in this child case, wherein arginine 714 plays a key role in the proper formation of the ligand-binding pocket and the AF-2 surface of the <ENT2>GR alpha</ENT2> LBD.",,,,T,,,,,c,,,,,0.0,,
20335448,1997,c|Allele|R|714,D006973,Association,TRUE,"CONCLUSIONS: Dexamethasone treatment is effective in controlling the premature pubarche, hypoglycemia, <ENT2>hypertension</ENT2>, and hypokalemia in this child case, wherein <ENT1>arginine 714</ENT1> plays a key role in the proper formation of the ligand-binding pocket and the AF-2 surface of the GR alpha LBD.",,,,T,,,,,c,,,,,1.0,,
20335448,1995,c|Allele|R|714,D007008,Association,TRUE,"CONCLUSIONS: Dexamethasone treatment is effective in controlling the premature pubarche, hypoglycemia, hypertension, and <ENT2>hypokalemia</ENT2> in this child case, wherein <ENT1>arginine 714</ENT1> plays a key role in the proper formation of the ligand-binding pocket and the AF-2 surface of the GR alpha LBD.",,,,T,,,,,c,,,,,1.0,,
20335448,2005,D003907,D006973,Negative_Correlation,TRUE,"She also had <ENT2>hypertension</ENT2> and premature pubarche, whereas <ENT1>dexamethasone</ENT1> effectively suppressed these clinical manifestations.",,,,T,,,,,c,,,,,0.0,,
20335448,2005,D003907,D006973,Negative_Correlation,TRUE,"CONCLUSIONS: <ENT1>Dexamethasone</ENT1> treatment is effective in controlling the premature pubarche, hypoglycemia, <ENT2>hypertension</ENT2>, and hypokalemia in this child case, wherein arginine 714 plays a key role in the proper formation of the ligand-binding pocket and the AF-2 surface of the GR alpha LBD.",,,,T,,,,,c,,,,,0.0,,
20335448,2002,D003907,D007008,Negative_Correlation,TRUE,"CONCLUSIONS: <ENT1>Dexamethasone</ENT1> treatment is effective in controlling the premature pubarche, hypoglycemia, hypertension, and <ENT2>hypokalemia</ENT2> in this child case, wherein arginine 714 plays a key role in the proper formation of the ligand-binding pocket and the AF-2 surface of the GR alpha LBD.",,,,T,,,,,c,,,,,1.0,,
20335448,2012,2908,D006973,Association,TRUE,"CONCLUSIONS: Dexamethasone treatment is effective in controlling the premature pubarche, hypoglycemia, <ENT2>hypertension</ENT2>, and hypokalemia in this child case, wherein arginine 714 plays a key role in the proper formation of the ligand-binding pocket and the AF-2 surface of the <ENT1>GR alpha</ENT1> LBD.",,,,T,,,,,c,,,,,1.0,,
20335448,2009,2908,D007008,Association,TRUE,"CONCLUSIONS: Dexamethasone treatment is effective in controlling the premature pubarche, hypoglycemia, hypertension, and <ENT2>hypokalemia</ENT2> in this child case, wherein arginine 714 plays a key role in the proper formation of the ligand-binding pocket and the AF-2 surface of the <ENT1>GR alpha</ENT1> LBD.",,,,T,,,,,c,,,,,1.0,,
20401977,2014,196,D004147,Association,TRUE,"BACKGROUND: The effects of 2,3,7,8-tetrachlorodibenzo-p-dioxin and related <ENT2>dioxin</ENT2>-like chemicals are mediated through binding-dependent activation of the cytosolic <ENT1>aryl hydrocarbon receptor</ENT1> (<ENT1>AHR</ENT1>).",,,,T,,,,,c,,,,,1.0,,
20401977,2014,196,D004147,Association,TRUE,"The human <ENT1>AHR</ENT1> is a low-affinity receptor relative to most rodents, but some reports suggest that there may be individuals with polymorphic high-affinity receptors, thereby possibly increasing the sensitivity to <ENT2>dioxins</ENT2> in such people.",,,,T,,,,,w,,,,,1.0,,
20401977,2015,196,D000072317,Association,FALSE,"BACKGROUND: The effects of <ENT2>2,3,7,8-tetrachlorodibenzo-p-dioxin</ENT2> and related dioxin-like chemicals are mediated through binding-dependent activation of the cytosolic <ENT1>aryl hydrocarbon receptor</ENT1> (<ENT1>AHR</ENT1>).",,,,T,,,,,w,,,,,0.5,,
20401977,2016,D004147,D000072317,Association,FALSE,"BACKGROUND: The effects of <ENT2>2,3,7,8-tetrachlorodibenzo-p-dioxin</ENT2> and related <ENT1>dioxin</ENT1>-like chemicals are mediated through binding-dependent activation of the cytosolic aryl hydrocarbon receptor (AHR).",,,,T,Y,,,,w,,,,,0.0,,
20415560,2017,D003920,3240,Association,TRUE,Vitamin E reduces cardiovascular disease in individuals with <ENT1>diabetes mellitus</ENT1> and the <ENT2>haptoglobin</ENT2> 2-2 genotype.,,,,T,,,,,c,,,,,1.0,,
20415560,2017,D003920,3240,Association,TRUE,AIMS: Individuals with both <ENT1>diabetes mellitus</ENT1> (<ENT1>DM</ENT1>) and the <ENT2>Haptoglobin</ENT2> (<ENT2>Hp</ENT2>) 2-2 genotype are at increased risk of cardiovascular disease.,,,,T,,Y,,,c,,,,,1.0,,
20415560,2017,D003920,3240,Association,TRUE,"As the antioxidant function of the <ENT2>Hp</ENT2> 2-2 protein is impaired, we sought to test the pharmacogenomic hypothesis that antioxidant vitamin E supplementation would provide cardiovascular protection to <ENT2>Hp</ENT2> 2-2 <ENT1>DM</ENT1> individuals.",,,,T,,,,,c,,,,,1.0,,
20415560,2017,D003920,3240,Association,TRUE,"MATERIALS & METHODS: We determined the <ENT2>Hp</ENT2> genotype on <ENT1>DM</ENT1> participants from two trials (HOPE and ICARE) and assessed the effect of vitamin E by <ENT2>Hp</ENT2> genotype on their common prespecified outcome, the composite of stroke, myocardial infarction and cardiovascular death.",,,,T,,,,,c,,,,,1.0,,
20415560,2017,D003920,3240,Association,TRUE,RESULTS: Meta-analysis of the two trials demonstrated a significant overall reduction in the composite end point in <ENT2>Hp</ENT2> 2-2 <ENT1>DM</ENT1> individuals with vitamin E (odds ratio: 0.58; 95% CI: 0.40-0.86; p = 0.006).,,,,T,,,,,c,,,,,1.0,,
20415560,2017,D003920,3240,Association,TRUE,"In these trials, <ENT2>Hp</ENT2> typing of 69 <ENT1>DM</ENT1> individuals and treating those with the <ENT2>Hp</ENT2> 2-2 with vitamin E prevented one myocardial infarct, stroke or cardiovascular death.",,,,T,,,,,c,,,,,1.0,,
20415560,2017,D003920,3240,Association,TRUE,Lifelong administration of vitamin E to <ENT2>Hp</ENT2> 2-2 <ENT1>DM</ENT1> individuals in the Kaiser population would increase their life expectancy by 3 years.,,,,T,Y,,,,w,,,,,0.0,,
20415560,2017,D003920,3240,Association,TRUE,CONCLUSION: A pharmacogenomic strategy of screening <ENT1>DM</ENT1> individuals for the <ENT2>Hp</ENT2> genotype and treating those with <ENT2>Hp</ENT2> 2-2 with vitamin E appears to be highly clinically effective.,,,,T,,,,,w,,,,,0.0,,
20415560,2021,D003920,D014810,Negative_Correlation,TRUE,<ENT2>Vitamin E</ENT2> reduces cardiovascular disease in individuals with <ENT1>diabetes mellitus</ENT1> and the haptoglobin 2-2 genotype.,,,,T,Y,,,,w,,,,,0.0,,
20415560,2021,D003920,D014810,Negative_Correlation,TRUE,"As the antioxidant function of the Hp 2-2 protein is impaired, we sought to test the pharmacogenomic hypothesis that antioxidant <ENT2>vitamin E</ENT2> supplementation would provide cardiovascular protection to Hp 2-2 <ENT1>DM</ENT1> individuals.",,,,T,,Y,,,c,,,,,1.0,,
20415560,2021,D003920,D014810,Negative_Correlation,TRUE,"MATERIALS & METHODS: We determined the Hp genotype on <ENT1>DM</ENT1> participants from two trials (HOPE and ICARE) and assessed the effect of <ENT2>vitamin E</ENT2> by Hp genotype on their common prespecified outcome, the composite of stroke, myocardial infarction and cardiovascular death.",,,,T,,Y,,,c,,,,,1.0,,
20415560,2021,D003920,D014810,Negative_Correlation,TRUE,RESULTS: Meta-analysis of the two trials demonstrated a significant overall reduction in the composite end point in Hp 2-2 <ENT1>DM</ENT1> individuals with <ENT2>vitamin E</ENT2> (odds ratio: 0.58; 95% CI: 0.40-0.86; p = 0.006).,,,,T,,,,,w,,,,,0.0,,
20415560,2021,D003920,D014810,Negative_Correlation,TRUE,"In these trials, Hp typing of 69 <ENT1>DM</ENT1> individuals and treating those with the Hp 2-2 with <ENT2>vitamin E</ENT2> prevented one myocardial infarct, stroke or cardiovascular death.",,,,T,,,,,w,,,,,1.0,,
20415560,2021,D003920,D014810,Negative_Correlation,TRUE,Lifelong administration of <ENT2>vitamin E</ENT2> to Hp 2-2 <ENT1>DM</ENT1> individuals in the Kaiser population would increase their life expectancy by 3 years.,,,,T,,,,,w,,,,,0.0,,
20415560,2021,D003920,D014810,Negative_Correlation,TRUE,CONCLUSION: A pharmacogenomic strategy of screening <ENT1>DM</ENT1> individuals for the Hp genotype and treating those with Hp 2-2 with <ENT2>vitamin E</ENT2> appears to be highly clinically effective.,,,,T,,,,,w,,,,,1.0,,
20415560,2018,D002318,3240,Association,FALSE,Vitamin E reduces <ENT1>cardiovascular disease</ENT1> in individuals with diabetes mellitus and the <ENT2>haptoglobin</ENT2> 2-2 genotype.,,,,T,Y,,,,w,,,,,1.0,,
20415560,2018,D002318,3240,Association,FALSE,AIMS: Individuals with both diabetes mellitus (DM) and the <ENT2>Haptoglobin</ENT2> (<ENT2>Hp</ENT2>) 2-2 genotype are at increased risk of <ENT1>cardiovascular disease</ENT1>.,,,,T,,,,,c,,,,,0.5,,
20415560,2018,D002318,3240,Association,FALSE,"MATERIALS & METHODS: We determined the <ENT2>Hp</ENT2> genotype on DM participants from two trials (HOPE and ICARE) and assessed the effect of vitamin E by <ENT2>Hp</ENT2> genotype on their common prespecified outcome, the composite of stroke, myocardial infarction and <ENT1>cardiovascular death</ENT1>.",,,,T,,Y,,,c,,,,,1.0,,
20415560,2018,D002318,3240,Association,FALSE,"In these trials, <ENT2>Hp</ENT2> typing of 69 DM individuals and treating those with the <ENT2>Hp</ENT2> 2-2 with vitamin E prevented one myocardial infarct, stroke or <ENT1>cardiovascular death</ENT1>.",,,,T,,,,,w,,,,,0.5,TRUE,
20415560,2023,D002318,D014810,Negative_Correlation,TRUE,<ENT2>Vitamin E</ENT2> reduces <ENT1>cardiovascular disease</ENT1> in individuals with diabetes mellitus and the haptoglobin 2-2 genotype.,,,,T,,,,,c,,,,,1.0,,
20415560,2023,D002318,D014810,Negative_Correlation,TRUE,"MATERIALS & METHODS: We determined the Hp genotype on DM participants from two trials (HOPE and ICARE) and assessed the effect of <ENT2>vitamin E</ENT2> by Hp genotype on their common prespecified outcome, the composite of stroke, myocardial infarction and <ENT1>cardiovascular death</ENT1>.",,,,T,,Y,,,c,,,,,1.0,,
20415560,2023,D002318,D014810,Negative_Correlation,TRUE,"In these trials, Hp typing of 69 DM individuals and treating those with the Hp 2-2 with <ENT2>vitamin E</ENT2> prevented one myocardial infarct, stroke or <ENT1>cardiovascular death</ENT1>.",,,,T,,,,,c,,,,,0.0,,
20415560,2020,D009203,D014810,Negative_Correlation,TRUE,"MATERIALS & METHODS: We determined the Hp genotype on DM participants from two trials (HOPE and ICARE) and assessed the effect of <ENT2>vitamin E</ENT2> by Hp genotype on their common prespecified outcome, the composite of stroke, <ENT1>myocardial infarction</ENT1> and cardiovascular death.",,,,T,,Y,,,c,,,,,1.0,,
20415560,2020,D009203,D014810,Negative_Correlation,TRUE,"In these trials, Hp typing of 69 DM individuals and treating those with the Hp 2-2 with <ENT2>vitamin E</ENT2> prevented one <ENT1>myocardial infarct</ENT1>, stroke or cardiovascular death.",,,,T,,,,,c,,,,,1.0,,
20415560,2022,3240,D014810,Association,TRUE,<ENT2>Vitamin E</ENT2> reduces cardiovascular disease in individuals with diabetes mellitus and the <ENT1>haptoglobin</ENT1> 2-2 genotype.,,,,T,Y,,,,w,,,,,0.0,,
20415560,2022,3240,D014810,Association,TRUE,"As the antioxidant function of the <ENT1>Hp</ENT1> 2-2 protein is impaired, we sought to test the pharmacogenomic hypothesis that antioxidant <ENT2>vitamin E</ENT2> supplementation would provide cardiovascular protection to <ENT1>Hp</ENT1> 2-2 DM individuals.",,,,T,,Y,,,c,,,,,1.0,,
20415560,2022,3240,D014810,Association,TRUE,"MATERIALS & METHODS: We determined the <ENT1>Hp</ENT1> genotype on DM participants from two trials (HOPE and ICARE) and assessed the effect of <ENT2>vitamin E</ENT2> by <ENT1>Hp</ENT1> genotype on their common prespecified outcome, the composite of stroke, myocardial infarction and cardiovascular death.",,,,T,,Y,,,c,,,,,1.0,,
20415560,2022,3240,D014810,Association,TRUE,RESULTS: Meta-analysis of the two trials demonstrated a significant overall reduction in the composite end point in <ENT1>Hp</ENT1> 2-2 DM individuals with <ENT2>vitamin E</ENT2> (odds ratio: 0.58; 95% CI: 0.40-0.86; p = 0.006).,,,,T,,,,,w,,,,,1.0,,
20415560,2022,3240,D014810,Association,TRUE,There was a statistically significant interaction between the <ENT1>Hp</ENT1> genotype and <ENT2>vitamin E</ENT2> on the composite end point.,,,,T,,,,,c,,,,,1.0,,
20415560,2022,3240,D014810,Association,TRUE,"In these trials, <ENT1>Hp</ENT1> typing of 69 DM individuals and treating those with the <ENT1>Hp</ENT1> 2-2 with <ENT2>vitamin E</ENT2> prevented one myocardial infarct, stroke or cardiovascular death.",,,,T,,,,,w,,,,,0.5,TRUE,
20415560,2022,3240,D014810,Association,TRUE,Lifelong administration of <ENT2>vitamin E</ENT2> to <ENT1>Hp</ENT1> 2-2 DM individuals in the Kaiser population would increase their life expectancy by 3 years.,,,,T,,,,,w,,,,,1.0,,
20415560,2022,3240,D014810,Association,TRUE,CONCLUSION: A pharmacogenomic strategy of screening DM individuals for the <ENT1>Hp</ENT1> genotype and treating those with <ENT1>Hp</ENT1> 2-2 with <ENT2>vitamin E</ENT2> appears to be highly clinically effective.,,,,T,,,,,w,,,,,0.5,TRUE,
20415560,2019,D014810,D020521,Negative_Correlation,TRUE,"MATERIALS & METHODS: We determined the Hp genotype on DM participants from two trials (HOPE and ICARE) and assessed the effect of <ENT1>vitamin E</ENT1> by Hp genotype on their common prespecified outcome, the composite of <ENT2>stroke</ENT2>, myocardial infarction and cardiovascular death.",,,,T,,,,,c,,,,,1.0,,
20415560,2019,D014810,D020521,Negative_Correlation,TRUE,"In these trials, Hp typing of 69 DM individuals and treating those with the Hp 2-2 with <ENT1>vitamin E</ENT1> prevented one myocardial infarct, <ENT2>stroke</ENT2> or cardiovascular death.",,,,T,,,,,c,,,,,1.0,,
20428796;20428796;20428796,2034;2028;2031,D007627;D007627;D007627,7043;7042;7040,Negative_Correlation;Positive_Correlation;Positive_Correlation,TRUE;TRUE;TRUE,The aim of this study was to investigate the effect of TGF-beta1 targeting by antisense oligonucleotides on the RNA synthesis and protein expression of <ENT2>TGF-beta</ENT2> isoforms and their receptors in <ENT1>keloid</ENT1>-derived fibroblasts.,,,,T,,,,,c,,,,,1.0,,
20428796,2034,D007627,7043,Negative_Correlation,TRUE,"In tissue samples with normal fibroblasts (NFs) serving as control samples, expression of TGF-beta1 and -beta2 was decreased when compared to <ENT1>keloid</ENT1> fibroblasts (KFs), while expression of <ENT2>TGF-beta3</ENT2> and of TGF-betaRII was significantly higher in NFs.",,,,T,,,,,c,,,,,0.0,,
20428796;20428796;20428796,2034;2028;2031,D007627;D007627;D007627,7043;7042;7040,Negative_Correlation;Positive_Correlation;Positive_Correlation,TRUE;TRUE;TRUE,Improving the understanding of <ENT2>TGF-beta</ENT2> in <ENT1>keloid disease</ENT1> could lead to the development of clinically useful therapeutic modalities for treatment of <ENT1>keloid disease</ENT1> or even allow identification of preventive strategies.,,,,T,,,,,c,,,,,1.0,,
20428796;20428796,2028;2037,D007627;D007627,7042;4052,Positive_Correlation;Positive_Correlation,TRUE;TRUE,"In tissue samples with normal fibroblasts (NFs) serving as control samples, expression of <ENT2>TGF-beta1 and -beta2</ENT2> was decreased when compared to <ENT1>keloid</ENT1> fibroblasts (KFs), while expression of TGF-beta3 and of TGF-betaRII was significantly higher in NFs.",,,,T,,,,,c,,,,,0.0,,
20428796;20428796,2033;2032,D007627;D007627,7046;7048,Association;Negative_Correlation,FALSE;TRUE,Effect of the abrogation of TGF-beta1 by antisense oligonucleotides on the expression of <ENT2>TGF-beta-isoforms and their receptors I and II</ENT2> in isolated fibroblasts from <ENT1>keloid scars</ENT1>.,,,,T,,,,,c,,,,,1.0,,
20428796,2037,D007627,4052,Positive_Correlation,TRUE,Effect of the abrogation of <ENT2>TGF-beta1</ENT2> by antisense oligonucleotides on the expression of TGF-beta-isoforms and their receptors I and II in isolated fibroblasts from <ENT1>keloid scars</ENT1>.,,,,T,,,,,c,,,,,1.0,,
20428796,2037,D007627,4052,Positive_Correlation,TRUE,The aim of this study was to investigate the effect of <ENT2>TGF-beta1</ENT2> targeting by antisense oligonucleotides on the RNA synthesis and protein expression of TGF-beta isoforms and their receptors in <ENT1>keloid</ENT1>-derived fibroblasts.,,,,T,,,,,c,,,,,1.0,,
20428796,2032,D007627,7048,Negative_Correlation,TRUE,"In tissue samples with normal fibroblasts (NFs) serving as control samples, expression of TGF-beta1 and -beta2 was decreased when compared to <ENT1>keloid</ENT1> fibroblasts (KFs), while expression of TGF-beta3 and of <ENT2>TGF-betaRII</ENT2> was significantly higher in NFs.",,,,T,Y,,,,w,,,,,0.0,,
20428796;20428796;20428796;20428796;20428796,2025;2024;2027;2026;2029,7043;7043;7042;7042;7040,7046;7048;7046;7048;7048,Bind;Bind;Bind;Bind;Bind,FALSE;FALSE;FALSE;FALSE;FALSE,"<ENT1>TGF-beta</ENT1> exerts its influence by binding to <ENT2>type I and type II TGF-beta receptors</ENT2>, thereby forming a complex and activating specific downstream effector molecules.",,,,T,,,,,c,,,,,1.0,,
20428796,2025,7043,7046,Bind,FALSE,Expression of <ENT1>TGF-beta3</ENT1> mRNA revealed contrary patterns in KFs from different patients while expression of <ENT2>TGF-betaRI</ENT2> was found to be equal during the measurement period.,,,,T,,,,,c,,,,,1.0,,
20428796,2024,7043,7048,Bind,FALSE,"In tissue samples with normal fibroblasts (NFs) serving as control samples, expression of TGF-beta1 and -beta2 was decreased when compared to keloid fibroblasts (KFs), while expression of <ENT1>TGF-beta3</ENT1> and of <ENT2>TGF-betaRII</ENT2> was significantly higher in NFs.",,,,T,,,,,c,,,,,1.0,,
20428796,2038,D009841,4052,Association,FALSE,Effect of the abrogation of <ENT2>TGF-beta1</ENT2> by antisense <ENT1>oligonucleotides</ENT1> on the expression of TGF-beta-isoforms and their receptors I and II in isolated fibroblasts from keloid scars.,,,,T,Y,,,,w,,,,,1.0,,
20428796,2038,D009841,4052,Association,FALSE,The aim of this study was to investigate the effect of <ENT2>TGF-beta1</ENT2> targeting by antisense <ENT1>oligonucleotides</ENT1> on the RNA synthesis and protein expression of TGF-beta isoforms and their receptors in keloid-derived fibroblasts.,,,,T,,,,,c,,,,,0.0,,
20428796,2035,7042,4052,Positive_Correlation,TRUE,"The isoforms <ENT2>TGF-beta1</ENT2> and <ENT1>TGF-beta2</ENT1> have profibrotic properties, whereas TGF-beta3 may have antifibrotic functions.",,,,T,,,,,c,,,,,1.0,,
20428796,2035,7042,4052,Positive_Correlation,TRUE,The aim of this study was to investigate the effect of <ENT2>TGF-beta1</ENT2> targeting by antisense oligonucleotides on the RNA synthesis and protein expression of <ENT1>TGF-beta</ENT1> isoforms and their receptors in keloid-derived fibroblasts.,,,,T,,,,,c,,,,,1.0,,
20428796,2035,7042,4052,Positive_Correlation,TRUE,"In the ELISA assay, abrogation of <ENT2>TGF-beta1</ENT2> led to a significant decrease in <ENT2><ENT1>TGF-beta1 and -beta2</ENT2></ENT1> (p<0.05).",,,,T,,,,,c,,,,,0.5,,
20428796,2026,7042,7048,Bind,FALSE,"In tissue samples with normal fibroblasts (NFs) serving as control samples, expression of <ENT1>TGF-beta1 and -beta2</ENT1> was decreased when compared to keloid fibroblasts (KFs), while expression of TGF-beta3 and of <ENT2>TGF-betaRII</ENT2> was significantly higher in NFs.",,,,T,,,,,c,,,,,1.0,,
20428796,2036,7046,4052,Bind,FALSE,Effect of the abrogation of <ENT2>TGF-beta1</ENT2> by antisense oligonucleotides on the expression of <ENT1>TGF-beta-isoforms and their receptors I and II</ENT1> in isolated fibroblasts from keloid scars.,,,,T,,T,,,w,,,,,0.0,,
20428796,2030,7046,7040,Bind,FALSE,"<ENT2>TGF-beta</ENT2> exerts its influence by binding to <ENT1>type I and type II TGF-beta receptors</ENT1>, thereby forming a complex and activating specific downstream effector molecules.",,,,T,,,,,c,,,,,0.0,,
20431083,2040,D002543,D005343,Association,FALSE,"<ENT2>Antithrombotic drug</ENT2> use, <ENT1>cerebral microbleeds</ENT1>, and <ENT1>intracerebral hemorrhage</ENT1>: a systematic review of published and unpublished studies.",,,,T,,,,,w,,,,,0.0,,
20431083,2040,D002543,D005343,Association,FALSE,"BACKGROUND AND PURPOSE: <ENT1>Cerebral microbleeds</ENT1> (<ENT1>MB</ENT1>) are potential risk factors for <ENT1>intracerebral hemorrhage</ENT1> (<ENT1>ICH</ENT1>), but it is unclear if they are a contraindication to using <ENT2>antithrombotic drugs</ENT2>.",,,,T,,,,,c,,,,,1.0,,
20431083,2041,D002543,D014859,Association,TRUE,"RESULTS: In a pooled analysis of 1460 <ENT1>ICH</ENT1> and 3817 IS/TIA, <ENT1>MB</ENT1> were more frequent in <ENT1>ICH</ENT1> vs IS/TIA in all treatment groups, but the excess increased from 2.8 (odds ratio; range, 2.3-3.5) in nonantithrombotic users to 5.7 (range, 3.4-9.7) in antiplatelet users and 8.0 (range, 3.5-17.8) in <ENT2>warfarin</ENT2> users (P difference=0.01).",,,,T,,,,,c,,,,,1.0,,
20431083,2041,D002543,D014859,Association,TRUE,"There was also an excess of <ENT1>MB</ENT1> in <ENT2>warfarin</ENT2> users vs nonusers with <ENT1>ICH</ENT1> (OR, 2.7; 95% CI, 1.6-4.4; P<0.001) but none in <ENT2>warfarin</ENT2> users with IS/TIA (OR, 1.3; 95% CI, 0.9-1.7; P=0.33; P difference=0.01).",,,,T,Y,,,,w,,,,,0.75,TRUE,
20431083,2041,D002543,D014859,Association,TRUE,CONCLUSIONS: The excess of <ENT1>MB</ENT1> in <ENT2>warfarin</ENT2> users with <ENT1>ICH</ENT1> compared to other groups suggests that <ENT1>MB</ENT1> increase the risk of <ENT2>warfarin</ENT2>-associated <ENT1>ICH</ENT1>.,,,,T,,,,,c,,,,,0.125,,
20477932,2044,81736,24598,Negative_Correlation,TRUE,"Therefore <ENT1>NFkappaB</ENT1> activity, oxidative stress, <ENT2>neuronal nitric oxide synthase</ENT2> (<ENT2>nNOS</ENT2>) activity, spatial learning and memory as well as the effect of topiramate, a previously proposed therapy for cocaine addiction, were evaluated in an experimental model of cocaine administration in rats.",,,,T,,,,,c,,,,,1.0,,
20477932,2044,81736,24598,Negative_Correlation,TRUE,"<ENT1>NFkappaB</ENT1> activity was decreased in the frontal cortex of cocaine treated rats, as well as GSH concentration and glutathione peroxidase activity in the hippocampus, whereas <ENT2>nNOS</ENT2> activity in the hippocampus was increased.",,,,T,,,,,c,,,,,1.0,,
20477932,2046,81736,D005978,Association,TRUE,"<ENT1>NFkappaB</ENT1> activity was decreased in the frontal cortex of cocaine treated rats, as well as <ENT2>GSH</ENT2> concentration and <ENT2>glutathione</ENT2> peroxidase activity in the hippocampus, whereas nNOS activity in the hippocampus was increased.",,,,T,,,,,c,,,,,1.0,,
20477932,2045,81736,D003042,Negative_Correlation,TRUE,"<ENT2>Cocaine</ENT2> causes memory and learning impairments in rats: involvement of <ENT1>nuclear factor kappa B</ENT1> and oxidative stress, and prevention by topiramate.",,,,T,Y,T,,,w,,,,,0.0,,
20477932,2045,81736,D003042,Negative_Correlation,TRUE,"Therefore <ENT1>NFkappaB</ENT1> activity, oxidative stress, neuronal nitric oxide synthase (nNOS) activity, spatial learning and memory as well as the effect of topiramate, a previously proposed therapy for cocaine addiction, were evaluated in an experimental model of <ENT2>cocaine</ENT2> administration in rats.",,,,T,,Y,,,c,,,,,1.0,,
20477932,2045,81736,D003042,Negative_Correlation,TRUE,"<ENT1>NFkappaB</ENT1> activity was decreased in the frontal cortex of <ENT2>cocaine</ENT2> treated rats, as well as GSH concentration and glutathione peroxidase activity in the hippocampus, whereas nNOS activity in the hippocampus was increased.",,,,T,,,,,c,,,,,1.0,,
20477932,2045,81736,D003042,Negative_Correlation,TRUE,Memory retrieval of experiences acquired prior to <ENT2>cocaine</ENT2> administration was impaired and negatively correlated with <ENT1>NFkappaB</ENT1> activity in the frontal cortex.,,,,T,,,,,c,,,,,0.0,,
20477932,2045,81736,D003042,Negative_Correlation,TRUE,These results provide evidence for a possible mechanistic role of oxidative and nitrosative stress and <ENT1>NFkappaB</ENT1> in the alterations induced by <ENT2>cocaine</ENT2>.,,,,T,Y,,,,w,,,,,0.0,,
20477932,2049,D000077236,D007859,Negative_Correlation,TRUE,"Cocaine causes <ENT2>memory and learning impairments</ENT2> in rats: involvement of nuclear factor kappa B and oxidative stress, and prevention by <ENT1>topiramate</ENT1>.",,,,T,,,,,w,,,,,1.0,,
20477932,2047,D000077236,D019970,Negative_Correlation,FALSE,"Therefore NFkappaB activity, oxidative stress, neuronal nitric oxide synthase (nNOS) activity, spatial learning and memory as well as the effect of <ENT1>topiramate</ENT1>, a previously proposed therapy for <ENT2>cocaine addiction</ENT2>, were evaluated in an experimental model of cocaine administration in rats.",,,,T,,,,,c,,,,,1.0,,
20477932,2051,D000077236,D003042,Negative_Correlation,TRUE,"<ENT2>Cocaine</ENT2> causes memory and learning impairments in rats: involvement of nuclear factor kappa B and oxidative stress, and prevention by <ENT1>topiramate</ENT1>.",,,,T,Y,T,,,c,,,,,1.0,,
20477932,2051,D000077236,D003042,Negative_Correlation,TRUE,"Therefore NFkappaB activity, oxidative stress, neuronal nitric oxide synthase (nNOS) activity, spatial learning and memory as well as the effect of <ENT1>topiramate</ENT1>, a previously proposed therapy for cocaine addiction, were evaluated in an experimental model of <ENT2>cocaine</ENT2> administration in rats.",,,,T,,Y,,,c,,,,,1.0,,
20477932,2042,24598,D005978,Association,TRUE,"NFkappaB activity was decreased in the frontal cortex of cocaine treated rats, as well as <ENT2>GSH</ENT2> concentration and <ENT2>glutathione</ENT2> peroxidase activity in the hippocampus, whereas <ENT1>nNOS</ENT1> activity in the hippocampus was increased.",,,,T,,,,,c,,,,,1.0,,
20477932,2042,24598,D005978,Association,TRUE,"In contrast, learning of new tasks was enhanced and correlated with the increase of <ENT1>nNOS</ENT1> activity and the decrease of <ENT2>glutathione</ENT2> peroxidase.",,,,T,,,,,c,,,,,1.0,,
20477932,2043,24598,D003042,Positive_Correlation,TRUE,"Therefore NFkappaB activity, oxidative stress, <ENT1>neuronal nitric oxide synthase</ENT1> (<ENT1>nNOS</ENT1>) activity, spatial learning and memory as well as the effect of topiramate, a previously proposed therapy for cocaine addiction, were evaluated in an experimental model of <ENT2>cocaine</ENT2> administration in rats.",,,,T,,Y,,,c,,,,,1.0,,
20477932,2043,24598,D003042,Positive_Correlation,TRUE,"NFkappaB activity was decreased in the frontal cortex of <ENT2>cocaine</ENT2> treated rats, as well as GSH concentration and glutathione peroxidase activity in the hippocampus, whereas <ENT1>nNOS</ENT1> activity in the hippocampus was increased.",,,,T,,,,,c,,,,,0.0,,
20477932,2053,D007859,D003042,Positive_Correlation,FALSE,"<ENT2>Cocaine</ENT2> causes <ENT1>memory and learning impairments</ENT1> in rats: involvement of nuclear factor kappa B and oxidative stress, and prevention by topiramate.",,,,T,,,,,c,,,,,1.0,,
20477932,2050,D005978,D003042,Association,TRUE,"NFkappaB activity was decreased in the frontal cortex of <ENT2>cocaine</ENT2> treated rats, as well as <ENT1>GSH</ENT1> concentration and <ENT1>glutathione</ENT1> peroxidase activity in the hippocampus, whereas nNOS activity in the hippocampus was increased.",,,,T,,,,,c,,,,,0.0,,
20510337,2054,D015032,D002945,Negative_Correlation,TRUE,"Coenzyme Q10 significantly compensated deficits in the antioxidant defense mechanisms (reduced glutathione level and superoxide dismutase activity), suppressed lipid peroxidation, decreased the elevations of tumor necrosis factor-alpha, nitric oxide and platinum ion concentration, and attenuated the reductions of selenium and <ENT1>zinc</ENT1> ions in renal tissue resulted from <ENT2>cisplatin</ENT2> administration.",,,,T,,,,,w,,,,,0.0,,
20510337,2071,D015032,C024989,Positive_Correlation,TRUE,"<ENT2>Coenzyme Q10</ENT2> significantly compensated deficits in the antioxidant defense mechanisms (reduced glutathione level and superoxide dismutase activity), suppressed lipid peroxidation, decreased the elevations of tumor necrosis factor-alpha, nitric oxide and platinum ion concentration, and attenuated the reductions of selenium and <ENT1>zinc</ENT1> ions in renal tissue resulted from cisplatin administration.",,,,T,,,,,c,,,,,0.0,,
20510337,2056,D002945,D058186,Positive_Correlation,FALSE,The nephroprotective effect of coenzyme Q10 was investigated in mice with <ENT2>acute renal injury</ENT2> induced by a single i.p. injection of <ENT1>cisplatin</ENT1> (5 mg/kg).,,,,T,,,,,w,,,,,1.0,,
20510337,2063,D002945,D007674,Positive_Correlation,FALSE,Coenzyme Q10 treatment ameliorates acute <ENT1>cisplatin</ENT1> <ENT2>nephrotoxicity</ENT2> in mice.,,,,T,,,,,c,,,,,1.0,,
20510337,2063,D002945,D007674,Positive_Correlation,FALSE,"Also, histopathological <ENT2>renal tissue damage</ENT2> mediated by <ENT1>cisplatin</ENT1> was ameliorated by coenzyme Q10 treatment.",,,,T,,,,,w,,,,,1.0,,
20510337,2063,D002945,D007674,Positive_Correlation,FALSE,It was concluded that coenzyme Q10 represents a potential therapeutic option to protect against acute <ENT1>cisplatin</ENT1> <ENT2>nephrotoxicity</ENT2> commonly encountered in clinical practice.,,,,T,,,,,c,,,,,1.0,,
20510337,2057,D002945,18125,Positive_Correlation,TRUE,"Immunohistochemical analysis revealed that coenzyme Q10 significantly decreased the <ENT1>cisplatin</ENT1>-induced overexpression of inducible <ENT2>nitric oxide synthase</ENT2>, nuclear factor-kappaB, caspase-3 and p53 in renal tissue.",,,,T,,,,,w,,,,,0.0,,
20510337,2061,D002945,D003404,Positive_Correlation,TRUE,Coenzyme Q10 significantly reduced blood urea nitrogen and serum <ENT2>creatinine</ENT2> levels which were increased by <ENT1>cisplatin</ENT1>.,,,,T,,,,,w,,,,,0.0,,
20510337,2079,D002945,C024989,Negative_Correlation,TRUE,<ENT2>Coenzyme Q10</ENT2> treatment ameliorates acute <ENT1>cisplatin</ENT1> nephrotoxicity in mice.,,,,T,,,,,c,,,,,1.0,,
20510337,2079,D002945,C024989,Negative_Correlation,TRUE,The nephroprotective effect of <ENT2>coenzyme Q10</ENT2> was investigated in mice with acute renal injury induced by a single i.p. injection of <ENT1>cisplatin</ENT1> (5 mg/kg).,,,,T,,Y,,,w,,,,,0.0,,
20510337,2079,D002945,C024989,Negative_Correlation,TRUE,"<ENT2>Coenzyme Q10</ENT2> treatment (10 mg/kg/day, i.p.) was applied for 6 consecutive days, starting 1 day before <ENT1>cisplatin</ENT1> administration.",,,,T,,,,,c,,,,,1.0,,
20510337,2079,D002945,C024989,Negative_Correlation,TRUE,<ENT2>Coenzyme Q10</ENT2> significantly reduced blood urea nitrogen and serum creatinine levels which were increased by <ENT1>cisplatin</ENT1>.,,,,T,,,,,w,,,,,0.0,,
20510337,2079,D002945,C024989,Negative_Correlation,TRUE,"<ENT2>Coenzyme Q10</ENT2> significantly compensated deficits in the antioxidant defense mechanisms (reduced glutathione level and superoxide dismutase activity), suppressed lipid peroxidation, decreased the elevations of tumor necrosis factor-alpha, nitric oxide and platinum ion concentration, and attenuated the reductions of selenium and zinc ions in renal tissue resulted from <ENT1>cisplatin</ENT1> administration.",,,,T,,,,,w,,,,,0.0,,
20510337,2079,D002945,C024989,Negative_Correlation,TRUE,"Also, histopathological renal tissue damage mediated by <ENT1>cisplatin</ENT1> was ameliorated by <ENT2>coenzyme Q10</ENT2> treatment.",,,,T,,,,,w,,,,,0.0,,
20510337,2079,D002945,C024989,Negative_Correlation,TRUE,"Immunohistochemical analysis revealed that <ENT2>coenzyme Q10</ENT2> significantly decreased the <ENT1>cisplatin</ENT1>-induced overexpression of inducible nitric oxide synthase, nuclear factor-kappaB, caspase-3 and p53 in renal tissue.",,,,T,,,,,c,,,,,1.0,,
20510337,2079,D002945,C024989,Negative_Correlation,TRUE,It was concluded that <ENT2>coenzyme Q10</ENT2> represents a potential therapeutic option to protect against acute <ENT1>cisplatin</ENT1> nephrotoxicity commonly encountered in clinical practice.,,,,T,Y,,,,w,,,,,0.0,,
20510337,2059,D002945,22060,Positive_Correlation,TRUE,"Immunohistochemical analysis revealed that coenzyme Q10 significantly decreased the <ENT1>cisplatin</ENT1>-induced overexpression of inducible nitric oxide synthase, nuclear factor-kappaB, caspase-3 and <ENT2>p53</ENT2> in renal tissue.",,,,T,,,,,c,,,,,1.0,,
20510337,2060,D002945,12367,Positive_Correlation,TRUE,"Immunohistochemical analysis revealed that coenzyme Q10 significantly decreased the <ENT1>cisplatin</ENT1>-induced overexpression of inducible nitric oxide synthase, nuclear factor-kappaB, <ENT2>caspase-3</ENT2> and p53 in renal tissue.",,,,T,,,,,w,,,,,1.0,,
20510337,2062,D002945,D001806,Positive_Correlation,FALSE,Coenzyme Q10 significantly reduced <ENT2>blood urea nitrogen</ENT2> and serum creatinine levels which were increased by <ENT1>cisplatin</ENT1>.,,,,T,,,,,w,,,,,1.0,,
20510337,2055,D002945,D012643,Negative_Correlation,TRUE,"Coenzyme Q10 significantly compensated deficits in the antioxidant defense mechanisms (reduced glutathione level and superoxide dismutase activity), suppressed lipid peroxidation, decreased the elevations of tumor necrosis factor-alpha, nitric oxide and platinum ion concentration, and attenuated the reductions of <ENT2>selenium</ENT2> and zinc ions in renal tissue resulted from <ENT1>cisplatin</ENT1> administration.",,,,T,,,,,c,,,,,0.0,,
20510337,2058,D002945,18033,Positive_Correlation,TRUE,"Immunohistochemical analysis revealed that coenzyme Q10 significantly decreased the <ENT1>cisplatin</ENT1>-induced overexpression of inducible nitric oxide synthase, <ENT2>nuclear factor-kappaB</ENT2>, caspase-3 and p53 in renal tissue.",,,,T,,,,,w,,,,,0.0,,
20510337,2078,D007674,C024989,Negative_Correlation,TRUE,<ENT2>Coenzyme Q10</ENT2> treatment ameliorates acute cisplatin <ENT1>nephrotoxicity</ENT1> in mice.,,,,T,,,,,w,,,,,0.0,,
20510337,2078,D007674,C024989,Negative_Correlation,TRUE,"Also, histopathological <ENT1>renal tissue damage</ENT1> mediated by cisplatin was ameliorated by <ENT2>coenzyme Q10</ENT2> treatment.",,,,T,,,,,c,,,,,1.0,,
20510337,2078,D007674,C024989,Negative_Correlation,TRUE,It was concluded that <ENT2>coenzyme Q10</ENT2> represents a potential therapeutic option to protect against acute cisplatin <ENT1>nephrotoxicity</ENT1> commonly encountered in clinical practice.,,,,T,,,,,c,,,,,1.0,,
20510337,2064,18125,C024989,Negative_Correlation,TRUE,"Immunohistochemical analysis revealed that <ENT2>coenzyme Q10</ENT2> significantly decreased the cisplatin-induced overexpression of inducible <ENT1>nitric oxide synthase</ENT1>, nuclear factor-kappaB, caspase-3 and p53 in renal tissue.",,,,T,,,,,c,,,,,1.0,,
20510337,2076,D003404,C024989,Negative_Correlation,TRUE,<ENT2>Coenzyme Q10</ENT2> significantly reduced blood urea nitrogen and serum <ENT1>creatinine</ENT1> levels which were increased by cisplatin.,,,,T,,,,,c,,,,,1.0,,
20510337,2070,21926,C024989,Negative_Correlation,TRUE,"<ENT2>Coenzyme Q10</ENT2> significantly compensated deficits in the antioxidant defense mechanisms (reduced glutathione level and superoxide dismutase activity), suppressed lipid peroxidation, decreased the elevations of <ENT1>tumor necrosis factor-alpha</ENT1>, nitric oxide and platinum ion concentration, and attenuated the reductions of selenium and zinc ions in renal tissue resulted from cisplatin administration.",,,,T,,,,,c,,,,,0.0,,
20510337,2074,D009569,C024989,Negative_Correlation,TRUE,"<ENT2>Coenzyme Q10</ENT2> significantly compensated deficits in the antioxidant defense mechanisms (reduced glutathione level and superoxide dismutase activity), suppressed lipid peroxidation, decreased the elevations of tumor necrosis factor-alpha, <ENT1>nitric oxide</ENT1> and platinum ion concentration, and attenuated the reductions of selenium and zinc ions in renal tissue resulted from cisplatin administration.",,,,T,,,,,c,,,,,1.0,,
20510337,2066,C024989,22060,Negative_Correlation,TRUE,"Immunohistochemical analysis revealed that <ENT1>coenzyme Q10</ENT1> significantly decreased the cisplatin-induced overexpression of inducible nitric oxide synthase, nuclear factor-kappaB, caspase-3 and <ENT2>p53</ENT2> in renal tissue.",,,,T,,,,,c,,,,,1.0,,
20510337,2067,C024989,12367,Negative_Correlation,TRUE,"Immunohistochemical analysis revealed that <ENT1>coenzyme Q10</ENT1> significantly decreased the cisplatin-induced overexpression of inducible nitric oxide synthase, nuclear factor-kappaB, <ENT2>caspase-3</ENT2> and p53 in renal tissue.",,,,T,,,,,c,,,,,1.0,,
20510337,2077,C024989,D001806,Negative_Correlation,TRUE,<ENT1>Coenzyme Q10</ENT1> significantly reduced <ENT2>blood urea nitrogen</ENT2> and serum creatinine levels which were increased by cisplatin.,,,,T,,,,,c,,,,,1.0,,
20510337,2069,C024989,20655,Negative_Correlation,TRUE,"<ENT1>Coenzyme Q10</ENT1> significantly compensated deficits in the antioxidant defense mechanisms (reduced glutathione level and <ENT2>superoxide dismutase</ENT2> activity), suppressed lipid peroxidation, decreased the elevations of tumor necrosis factor-alpha, nitric oxide and platinum ion concentration, and attenuated the reductions of selenium and zinc ions in renal tissue resulted from cisplatin administration.",,,,T,,,,,c,,,,,1.0,,
20510337,2075,C024989,D008055,Negative_Correlation,TRUE,"<ENT1>Coenzyme Q10</ENT1> significantly compensated deficits in the antioxidant defense mechanisms (reduced glutathione level and superoxide dismutase activity), suppressed <ENT2>lipid</ENT2> peroxidation, decreased the elevations of tumor necrosis factor-alpha, nitric oxide and platinum ion concentration, and attenuated the reductions of selenium and zinc ions in renal tissue resulted from cisplatin administration.",,,,T,Y,,,,w,,,,,0.0,,
20510337,2072,C024989,D012643,Positive_Correlation,TRUE,"<ENT1>Coenzyme Q10</ENT1> significantly compensated deficits in the antioxidant defense mechanisms (reduced glutathione level and superoxide dismutase activity), suppressed lipid peroxidation, decreased the elevations of tumor necrosis factor-alpha, nitric oxide and platinum ion concentration, and attenuated the reductions of <ENT2>selenium</ENT2> and zinc ions in renal tissue resulted from cisplatin administration.",,,,T,,,,,c,,,,,0.0,,
20510337,2073,C024989,D010984,Negative_Correlation,TRUE,"<ENT1>Coenzyme Q10</ENT1> significantly compensated deficits in the antioxidant defense mechanisms (reduced glutathione level and superoxide dismutase activity), suppressed lipid peroxidation, decreased the elevations of tumor necrosis factor-alpha, nitric oxide and <ENT2>platinum</ENT2> ion concentration, and attenuated the reductions of selenium and zinc ions in renal tissue resulted from cisplatin administration.",,,,T,,,,,c,,,,,1.0,,
20510337,2065,C024989,18033,Negative_Correlation,TRUE,"Immunohistochemical analysis revealed that <ENT1>coenzyme Q10</ENT1> significantly decreased the cisplatin-induced overexpression of inducible nitric oxide synthase, <ENT2>nuclear factor-kappaB</ENT2>, caspase-3 and p53 in renal tissue.",,,,T,,,,,c,,,,,0.0,,
20510337,2068,C024989,D005978,Negative_Correlation,TRUE,"<ENT1>Coenzyme Q10</ENT1> significantly compensated deficits in the antioxidant defense mechanisms (reduced <ENT2>glutathione</ENT2> level and superoxide dismutase activity), suppressed lipid peroxidation, decreased the elevations of tumor necrosis factor-alpha, nitric oxide and platinum ion concentration, and attenuated the reductions of selenium and zinc ions in renal tissue resulted from cisplatin administration.",,,,T,,,,,w,,,,,1.0,,
20523265,2080,3075,D008268,Association,TRUE,"Association study of <ENT1>complement factor H</ENT1>, C2, CFB, and C3 and <ENT2>age-related macular degeneration</ENT2> in a Han Chinese population.",,,,T,Y,T,,,w,,,,,1.0,,
20523265,2080,3075,D008268,Association,TRUE,"PURPOSE: Genes in the complement pathway, including <ENT1>complement factor H</ENT1> (<ENT1>CFH</ENT1>), C2/BF, and C3, have been reported to be associated with <ENT2>age-related macular degeneration</ENT2> (<ENT2>AMD</ENT2>).",,,,T,,,,,c,,,"11,12,21,22",,1.0,,
20523265,2080,3075,D008268,Association,TRUE,"RESULTS: Four SNPs, including rs3753394 (P = 0.0276), rs800292 (P = 0.0266), rs1061170 (P = 0.00514), and rs1329428 (P = 0.0089), in <ENT1>CFH</ENT1> showed a significant association with wet <ENT2>AMD</ENT2> in the cohort of this study.",,,,T,,,,,c,,,,,1.0,,
20523265,2080,3075,D008268,Association,TRUE,"None of the SNPs in <ENT1>CFH</ENT1> showed a significant association with drusen, and none of the SNPs in <ENT1>CFH</ENT1>, C2, CFB, and C3 showed a significant association with either wet <ENT2>AMD</ENT2> or drusen in the cohort of this study.",,,,T,,,,,c,,,,,1.0,,
20523265,2080,3075,D008268,Association,TRUE,"CONCLUSION: This study showed that SNPs rs3753394 (P = 0.0276), rs800292 (P = 0.0266), rs1061170 (P = 0.00514), and rs1329428 (P = 0.0089), but not rs7535263, rs1410996, or rs2274700, in <ENT1>CFH</ENT1> were significantly associated with wet <ENT2>AMD</ENT2> in a mainland Han Chinese population.",,,,T,,,,,c,,,,,1.0,,
20523265,2080,3075,D008268,Association,TRUE,"This study showed that <ENT1>CFH</ENT1> was more likely to be <ENT2>AMD</ENT2> susceptibility gene at Chr.1q31 based on the finding that the CFHR1 and CFHR3 deletion was not polymorphic in the cohort of this study, and none of the SNPs that were significantly associated with <ENT2>AMD</ENT2> in a white population in C2, CFB, and C3 genes showed a significant association with <ENT2>AMD</ENT2>.",,,,T,,,,,c,,,,,1.0,,
20523265,2083,rs800292,D008268,Positive_Correlation,TRUE,"RESULTS: Four SNPs, including rs3753394 (P = 0.0276), <ENT1>rs800292</ENT1> (P = 0.0266), rs1061170 (P = 0.00514), and rs1329428 (P = 0.0089), in CFH showed a significant association with wet <ENT2>AMD</ENT2> in the cohort of this study.",,,,T,,,,,w,,,,,1.0,,
20523265,2083,rs800292,D008268,Positive_Correlation,TRUE,"CONCLUSION: This study showed that SNPs rs3753394 (P = 0.0276), <ENT1>rs800292</ENT1> (P = 0.0266), rs1061170 (P = 0.00514), and rs1329428 (P = 0.0089), but not rs7535263, rs1410996, or rs2274700, in CFH were significantly associated with wet <ENT2>AMD</ENT2> in a mainland Han Chinese population.",,,,T,,,,,w,,,,,1.0,,
20523265,2087,629,D008268,Association,TRUE,"Association study of complement factor H, C2, <ENT1>CFB</ENT1>, and C3 and <ENT2>age-related macular degeneration</ENT2> in a Han Chinese population.",,,,T,Y,T,,,w,,,,,1.0,,
20523265,2087,629,D008268,Association,TRUE,"PURPOSE: Genes in the complement pathway, including complement factor H (CFH), <ENT1>C2/BF</ENT1>, and C3, have been reported to be associated with <ENT2>age-related macular degeneration</ENT2> (<ENT2>AMD</ENT2>).",,,,T,,,,,c,,,,,1.0,,
20523265,2087,629,D008268,Association,TRUE,"None of the SNPs in CFH showed a significant association with drusen, and none of the SNPs in CFH, C2, <ENT1>CFB</ENT1>, and C3 showed a significant association with either wet <ENT2>AMD</ENT2> or drusen in the cohort of this study.",,,,T,,,,,c,,,,,1.0,,
20523265,2087,629,D008268,Association,TRUE,"This study showed that CFH was more likely to be <ENT2>AMD</ENT2> susceptibility gene at Chr.1q31 based on the finding that the CFHR1 and CFHR3 deletion was not polymorphic in the cohort of this study, and none of the SNPs that were significantly associated with <ENT2>AMD</ENT2> in a white population in C2, <ENT1>CFB</ENT1>, and C3 genes showed a significant association with <ENT2>AMD</ENT2>.",,,,T,,,,,c,,,,,0.0,,
20523265,2081,D008268,rs1329428,Positive_Correlation,TRUE,"RESULTS: Four SNPs, including rs3753394 (P = 0.0276), rs800292 (P = 0.0266), rs1061170 (P = 0.00514), and <ENT2>rs1329428</ENT2> (P = 0.0089), in CFH showed a significant association with wet <ENT1>AMD</ENT1> in the cohort of this study.",,,,T,,,,,w,,,,,1.0,,
20523265,2081,D008268,rs1329428,Positive_Correlation,TRUE,"CONCLUSION: This study showed that SNPs rs3753394 (P = 0.0276), rs800292 (P = 0.0266), rs1061170 (P = 0.00514), and <ENT2>rs1329428</ENT2> (P = 0.0089), but not rs7535263, rs1410996, or rs2274700, in CFH were significantly associated with wet <ENT1>AMD</ENT1> in a mainland Han Chinese population.",,,,T,,,,,w,,,,,1.0,,
20523265,2086,D008268,718,Association,TRUE,"Association study of complement factor H, C2, CFB, and <ENT2>C3</ENT2> and <ENT1>age-related macular degeneration</ENT1> in a Han Chinese population.",,,,T,Y,T,,,w,,,,,1.0,,
20523265,2086,D008268,718,Association,TRUE,"PURPOSE: Genes in the complement pathway, including complement factor H (CFH), C2/BF, and <ENT2>C3</ENT2>, have been reported to be associated with <ENT1>age-related macular degeneration</ENT1> (<ENT1>AMD</ENT1>).",,,,T,,,,,c,,,,,1.0,,
20523265,2086,D008268,718,Association,TRUE,"None of the SNPs in CFH showed a significant association with drusen, and none of the SNPs in CFH, C2, CFB, and <ENT2>C3</ENT2> showed a significant association with either wet <ENT1>AMD</ENT1> or drusen in the cohort of this study.",,,,T,,,,,c,,,,,1.0,,
20523265,2086,D008268,718,Association,TRUE,"This study showed that CFH was more likely to be <ENT1>AMD</ENT1> susceptibility gene at Chr.1q31 based on the finding that the CFHR1 and CFHR3 deletion was not polymorphic in the cohort of this study, and none of the SNPs that were significantly associated with <ENT1>AMD</ENT1> in a white population in C2, CFB, and <ENT2>C3</ENT2> genes showed a significant association with <ENT1>AMD</ENT1>.",,,,T,,,,,c,,,,,0.0,,
20523265,2082,D008268,rs1061170,Positive_Correlation,TRUE,"RESULTS: Four SNPs, including rs3753394 (P = 0.0276), rs800292 (P = 0.0266), <ENT2>rs1061170</ENT2> (P = 0.00514), and rs1329428 (P = 0.0089), in CFH showed a significant association with wet <ENT1>AMD</ENT1> in the cohort of this study.",,,,T,,,,,w,,,,,1.0,,
20523265,2082,D008268,rs1061170,Positive_Correlation,TRUE,"CONCLUSION: This study showed that SNPs rs3753394 (P = 0.0276), rs800292 (P = 0.0266), <ENT2>rs1061170</ENT2> (P = 0.00514), and rs1329428 (P = 0.0089), but not rs7535263, rs1410996, or rs2274700, in CFH were significantly associated with wet <ENT1>AMD</ENT1> in a mainland Han Chinese population.",,,,T,,,,,w,,,,,0.0,,
20523265,2084,D008268,rs3753394,Positive_Correlation,TRUE,"RESULTS: Four SNPs, including <ENT2>rs3753394</ENT2> (P = 0.0276), rs800292 (P = 0.0266), rs1061170 (P = 0.00514), and rs1329428 (P = 0.0089), in CFH showed a significant association with wet <ENT1>AMD</ENT1> in the cohort of this study.",,,,T,,,,,w,,,,,1.0,,
20523265,2084,D008268,rs3753394,Positive_Correlation,TRUE,"CONCLUSION: This study showed that SNPs <ENT2>rs3753394</ENT2> (P = 0.0276), rs800292 (P = 0.0266), rs1061170 (P = 0.00514), and rs1329428 (P = 0.0089), but not rs7535263, rs1410996, or rs2274700, in CFH were significantly associated with wet <ENT1>AMD</ENT1> in a mainland Han Chinese population.",,,,T,,,,,w,,,,,1.0,,
20523265,2085,D008268,717,Association,TRUE,"Association study of complement factor H, <ENT2>C2</ENT2>, CFB, and C3 and <ENT1>age-related macular degeneration</ENT1> in a Han Chinese population.",,,,T,Y,T,,,w,,,,,1.0,,
20523265,2085,D008268,717,Association,TRUE,"PURPOSE: Genes in the complement pathway, including complement factor H (CFH), <ENT2>C2/BF</ENT2>, and C3, have been reported to be associated with <ENT1>age-related macular degeneration</ENT1> (<ENT1>AMD</ENT1>).",,,,T,,,,,c,,,,,1.0,,
20523265,2085,D008268,717,Association,TRUE,"None of the SNPs in CFH showed a significant association with drusen, and none of the SNPs in CFH, <ENT2>C2</ENT2>, CFB, and C3 showed a significant association with either wet <ENT1>AMD</ENT1> or drusen in the cohort of this study.",,,,T,,,,,c,,,,,1.0,,
20523265,2085,D008268,717,Association,TRUE,"This study showed that CFH was more likely to be <ENT1>AMD</ENT1> susceptibility gene at Chr.1q31 based on the finding that the CFHR1 and CFHR3 deletion was not polymorphic in the cohort of this study, and none of the SNPs that were significantly associated with <ENT1>AMD</ENT1> in a white population in <ENT2>C2</ENT2>, CFB, and C3 genes showed a significant association with <ENT1>AMD</ENT1>.",,,,T,,,,,c,,,,,0.0,,
20534142,2096,D011384,D009765,Association,FALSE,Association of <ENT2>obesity</ENT2> risk SNPs in PCSK1 with insulin sensitivity and <ENT1>proinsulin</ENT1> conversion.,,,,T,,T,,,w,,,,,1.0,,
20534142,2096,D011384,D009765,Association,FALSE,"Rare mutations in gene PCSK1, encoding this enzyme, cause childhood <ENT2>obesity</ENT2> and abnormal glucose homeostasis with elevated <ENT1>proinsulin</ENT1> concentrations.",,,,T,Y,,,,w,,,,,1.0,,
20534142,2088,D011384,D044882,Association,FALSE,"Rare mutations in gene PCSK1, encoding this enzyme, cause childhood obesity and <ENT2>abnormal glucose homeostasis</ENT2> with elevated <ENT1>proinsulin</ENT1> concentrations.",,,,T,Y,,,,w,,,,,0.0,,
20534142,2094,D011384,5122,Association,FALSE,Association of obesity risk SNPs in <ENT2>PCSK1</ENT2> with insulin sensitivity and <ENT1>proinsulin</ENT1> conversion.,,,,T,Y,T,,,w,,,,,0.0,,
20534142,2094,D011384,5122,Association,FALSE,"Rare mutations in gene <ENT2>PCSK1</ENT2>, encoding this enzyme, cause childhood obesity and abnormal glucose homeostasis with elevated <ENT1>proinsulin</ENT1> concentrations.",,,,T,,,,,w,,,,,1.0,,
20534142,2094,D011384,5122,Association,FALSE,"CONCLUSIONS: Like rare mutations in <ENT2>PCSK1</ENT2>, the more common variants tested determine glucose-stimulated <ENT1>proinsulin</ENT1> conversion, but not insulin secretion.",,,,T,,,,,w,,,,,0.0,,
20534142,2090,D011384,D005947,Association,FALSE,"The subjects were metabolically characterized by oral <ENT2>glucose</ENT2> tolerance test with <ENT2>glucose</ENT2>, insulin, <ENT1>proinsulin</ENT1>, and C-peptide measurements.",,,,T,,,,,c,,,,,1.0,,
20534142,2090,D011384,D005947,Association,FALSE,"The minor allele of SNP rs6232 was additionally associated with 15% higher OGTT-derived and 19% higher clamp-derived insulin sensitivity (pdom <or= 0.0047), 4.5% lower HOMAIR (pdom = 0.02) and 3.5% lower 120-min <ENT2>glucose</ENT2> (pdom = 0.0003) independently of BMI and <ENT1>proinsulin</ENT1> conversion.",,,,T,,,,,c,,,,,1.0,,
20534142,2090,D011384,D005947,Association,FALSE,"CONCLUSIONS: Like rare mutations in PCSK1, the more common variants tested determine <ENT2>glucose</ENT2>-stimulated <ENT1>proinsulin</ENT1> conversion, but not insulin secretion.",,,,T,,,,,c,,,,,0.0,,
20534142,2100,D011384,3630,Association,FALSE,Association of obesity risk SNPs in PCSK1 with <ENT2>insulin</ENT2> sensitivity and <ENT1>proinsulin</ENT1> conversion.,,,,T,,,,,c,,,,,1.0,,
20534142,2100,D011384,3630,Association,FALSE,"The subjects were metabolically characterized by oral glucose tolerance test with glucose, <ENT2>insulin</ENT2>, <ENT1>proinsulin</ENT1>, and C-peptide measurements.",,,,T,,,,,c,,,,,0.0,,
20534142,2100,D011384,3630,Association,FALSE,"Both minor alleles, adjusted for sex, age, BMI and <ENT2>insulin</ENT2> sensitivity were associated with elevated AUC<ENT1>proinsulin</ENT1> and AUC<ENT1>proinsulin</ENT1>/AUC<ENT2>insulin</ENT2> (rs6235: p(additive) model <or= 0.009, effect sizes 8/8%, rs6232: pdominant model <or= 0.01, effect sizes 10/21%).",,,,T,,,,,c,,,,,0.25,,
20534142,2100,D011384,3630,Association,FALSE,"The minor allele of SNP rs6232 was additionally associated with 15% higher OGTT-derived and 19% higher clamp-derived <ENT2>insulin</ENT2> sensitivity (pdom <or= 0.0047), 4.5% lower HOMAIR (pdom = 0.02) and 3.5% lower 120-min glucose (pdom = 0.0003) independently of BMI and <ENT1>proinsulin</ENT1> conversion.",,,,T,,,,,c,,,,,1.0,,
20534142,2100,D011384,3630,Association,FALSE,"CONCLUSIONS: Like rare mutations in PCSK1, the more common variants tested determine glucose-stimulated <ENT1>proinsulin</ENT1> conversion, but not <ENT2>insulin</ENT2> secretion.",,,,T,,,,,c,,,,,1.0,,
20534142,2097,D009765,5122,Association,FALSE,Association of <ENT1>obesity</ENT1> risk SNPs in <ENT2>PCSK1</ENT2> with insulin sensitivity and proinsulin conversion.,,,,T,,,,,w,,,,,0.0,,
20534142,2097,D009765,5122,Association,FALSE,"Rare mutations in gene <ENT2>PCSK1</ENT2>, encoding this enzyme, cause childhood <ENT1>obesity</ENT1> and abnormal glucose homeostasis with elevated proinsulin concentrations.",,,,T,,,,,c,,,,,1.0,,
20534142,2092,D009765,rs6232,Association,FALSE,"Common single nucleotide polymorphisms (SNPs) within this gene, <ENT2>rs6232</ENT2> and rs6235, are associated with <ENT1>obesity</ENT1>.",,,,T,,,,,c,,,,,0.0,,
20534142,2095,D009765,rs6235,Association,FALSE,"Common single nucleotide polymorphisms (SNPs) within this gene, rs6232 and <ENT2>rs6235</ENT2>, are associated with <ENT1>obesity</ENT1>.",,,,T,,,,,c,,,,,0.0,,
20534142,2101,D009765,3630,Association,FALSE,Association of <ENT1>obesity</ENT1> risk SNPs in PCSK1 with <ENT2>insulin</ENT2> sensitivity and proinsulin conversion.,,,,T,Y,,,,w,,,,,0.0,,
20534142,2093,D044882,5122,Association,FALSE,"Rare mutations in gene <ENT2>PCSK1</ENT2>, encoding this enzyme, cause childhood obesity and <ENT1>abnormal glucose homeostasis</ENT1> with elevated proinsulin concentrations.",,,,T,,,,,c,,,,,1.0,,
20534142,2089,5122,D005947,Association,TRUE,"CONCLUSIONS: Like rare mutations in <ENT1>PCSK1</ENT1>, the more common variants tested determine <ENT2>glucose</ENT2>-stimulated proinsulin conversion, but not insulin secretion.",,,,T,,,,,c,,,,,0.0,,
20534142,2099,5122,3630,Association,TRUE,Association of obesity risk SNPs in <ENT1>PCSK1</ENT1> with <ENT2>insulin</ENT2> sensitivity and proinsulin conversion.,,,,T,,,,,w,,,,,1.0,,
20534142,2099,5122,3630,Association,TRUE,"CONCLUSIONS: Like rare mutations in <ENT1>PCSK1</ENT1>, the more common variants tested determine glucose-stimulated proinsulin conversion, but not <ENT2>insulin</ENT2> secretion.",,,,T,,,,,c,,,,,0.0,,
20534142,2091,rs6232,D005947,Association,TRUE,"The minor allele of SNP <ENT1>rs6232</ENT1> was additionally associated with 15% higher OGTT-derived and 19% higher clamp-derived insulin sensitivity (pdom <or= 0.0047), 4.5% lower HOMAIR (pdom = 0.02) and 3.5% lower 120-min <ENT2>glucose</ENT2> (pdom = 0.0003) independently of BMI and proinsulin conversion.",,,,T,,,,,c,,,,,0.0,,
20534142,2091,rs6232,D005947,Association,TRUE,"In addition, <ENT1>rs6232</ENT1>, encoding the amino acid exchange <ENT1>N221D</ENT1>, influences insulin sensitivity and <ENT2>glucose</ENT2> homeostasis.",,,,T,,,,,c,,,,,1.0,,
20534142,2098,rs6232,3630,Association,TRUE,"Both minor alleles, adjusted for sex, age, BMI and <ENT2>insulin</ENT2> sensitivity were associated with elevated AUCproinsulin and AUCproinsulin/AUC<ENT2>insulin</ENT2> (rs6235: p(additive) model <or= 0.009, effect sizes 8/8%, <ENT1>rs6232</ENT1>: pdominant model <or= 0.01, effect sizes 10/21%).",,,,T,,,,,w,,,,,1.0,,
20534142,2098,rs6232,3630,Association,TRUE,"The minor allele of SNP <ENT1>rs6232</ENT1> was additionally associated with 15% higher OGTT-derived and 19% higher clamp-derived <ENT2>insulin</ENT2> sensitivity (pdom <or= 0.0047), 4.5% lower HOMAIR (pdom = 0.02) and 3.5% lower 120-min glucose (pdom = 0.0003) independently of BMI and proinsulin conversion.",,,,T,,,,,c,,,,,0.0,,
20534142,2098,rs6232,3630,Association,TRUE,"In addition, <ENT1>rs6232</ENT1>, encoding the amino acid exchange <ENT1>N221D</ENT1>, influences <ENT2>insulin</ENT2> sensitivity and glucose homeostasis.",,,,T,,,,,c,,,,,0.5,,
20534762,2102,D003409,7252,Association,TRUE,Two novel mutations of the <ENT2>TSH-beta</ENT2> subunit gene underlying <ENT1>congenital central hypothyroidism</ENT1> undetectable in neonatal <ENT2>TSH</ENT2> screening.,,,,T,,T,,,c,,,,,1.0,,
20534762,2102,D003409,7252,Association,TRUE,CONTEXT: Patients with <ENT2>TSH-beta</ENT2> subunit defects and <ENT1>congenital hypothyroidism</ENT1> are missed by <ENT2>TSH</ENT2>-based neonatal screening.,,,,T,Y,,,,w,,,,,0.5,TRUE,
20534762,2102,D003409,7252,Association,TRUE,OBJECTIVE: Our objective was to report the molecular consequences of a novel splice-junction mutation and a novel missense mutation in the <ENT2>TSH-beta</ENT2> subunit gene found in two patients with <ENT1>congenital central hypothyroidism</ENT1> and conventional treatment-resistant anemia.,,,,T,,,,,w,,,,,1.0,,
20534762,2109,7252,D000740,Association,TRUE,OBJECTIVE: Our objective was to report the molecular consequences of a novel splice-junction mutation and a novel missense mutation in the <ENT1>TSH-beta</ENT1> subunit gene found in two patients with congenital central hypothyroidism and conventional treatment-resistant <ENT2>anemia</ENT2>.,,,,T,,,,,w,,,,,1.0,,
20540798,2117,D050197,5144,Association,TRUE,"CONCLUSIONS: The present study demonstrates a sex-differential effect of <ENT2>PDE4D</ENT2> on IMT, plaque index and stroke, which highlights its influence on various aspects of <ENT1>atherogenesis</ENT1>.",,,,T,,,,,c,,,,,1.0,,
20540798,2119,D002340,5144,Association,TRUE,Sex-differential genetic effect of <ENT2>phosphodiesterase 4D</ENT2> (<ENT2>PDE4D</ENT2>) on <ENT1>carotid atherosclerosis</ENT1>.,,,,T,,T,,,w,,,,,1.0,,
20540798,2118,5144,D020521,Association,FALSE,BACKGROUND: The <ENT1>phosphodiesterase 4D</ENT1> (<ENT1>PDE4D</ENT1>) gene was reported as a susceptibility gene to <ENT2>stroke</ENT2>.,,,,T,,,,,c,,,,,1.0,,
20540798,2118,5144,D020521,Association,FALSE,Rs702553 at the <ENT1>PDE4D</ENT1> gene was selected because it conferred a risk for young <ENT2>stroke</ENT2> in our previous report.,,,,T,,,,,w,,,,,0.0,,
20540798,2118,5144,D020521,Association,FALSE,"CONCLUSIONS: The present study demonstrates a sex-differential effect of <ENT1>PDE4D</ENT1> on IMT, plaque index and <ENT2>stroke</ENT2>, which highlights its influence on various aspects of atherogenesis.",,,,T,,,,,w,,,,,0.0,,
20540798,2116,rs702553,D020521,Positive_Correlation,TRUE,<ENT1>Rs702553</ENT1> at the PDE4D gene was selected because it conferred a risk for young <ENT2>stroke</ENT2> in our previous report.,,,,T,,,,,c,,,,,1.0,,
20540798,2116,rs702553,D020521,Positive_Correlation,TRUE,"Similarly, SNP <ENT1>rs702553</ENT1> was only significant in young <ENT2>stroke</ENT2> men (OR = 1.8, p = 0.025) but not in women (p = 0.27).",,,,T,,,,,w,,,,,0.0,,
20558148,2127,24408,D016202,Positive_Correlation,FALSE,"Haloperidol-induced catalepsy was challenged with prior intracollicular microinjections of <ENT1>glutamate NMDA receptor</ENT1> antagonists, MK-801 (15 or 30 mmol/0.5 microl) and AP7 (10 or 20 nmol/0.5 microl), or of the <ENT1>NMDA receptor</ENT1> agonist <ENT2>N-methyl-d-aspartate</ENT2> (<ENT2>NMDA</ENT2>, 20 or 30 nmol/0.5 microl).",,,,T,,,,,c,,,,,1.0,,
20558148,2128,24408,C031231,Negative_Correlation,FALSE,"Haloperidol-induced catalepsy was challenged with prior intracollicular microinjections of <ENT1>glutamate NMDA receptor</ENT1> antagonists, MK-801 (15 or 30 mmol/0.5 microl) and <ENT2>AP7</ENT2> (10 or 20 nmol/0.5 microl), or of the <ENT1>NMDA receptor</ENT1> agonist N-methyl-d-aspartate (NMDA, 20 or 30 nmol/0.5 microl).",,,,T,,,,,c,,,,,0.0,,
20558148,2130,24408,D002375,Association,TRUE,Glutamatergic neurotransmission mediated by <ENT1>NMDA receptors</ENT1> in the inferior colliculus can modulate haloperidol-induced <ENT2>catalepsy</ENT2>.,,,,T,,,,,c,,,,,1.0,,
20558148,2130,24408,D002375,Association,TRUE,"Haloperidol-induced <ENT2>catalepsy</ENT2> was challenged with prior intracollicular microinjections of <ENT1>glutamate NMDA receptor</ENT1> antagonists, MK-801 (15 or 30 mmol/0.5 microl) and AP7 (10 or 20 nmol/0.5 microl), or of the <ENT1>NMDA receptor</ENT1> agonist N-methyl-d-aspartate (NMDA, 20 or 30 nmol/0.5 microl).",,,,T,Y,,,,w,,,,,1.0,TRUE,
20558148,2129,24408,D016291,Negative_Correlation,FALSE,"Haloperidol-induced catalepsy was challenged with prior intracollicular microinjections of <ENT1>glutamate NMDA receptor</ENT1> antagonists, <ENT2>MK-801</ENT2> (15 or 30 mmol/0.5 microl) and AP7 (10 or 20 nmol/0.5 microl), or of the <ENT1>NMDA receptor</ENT1> agonist N-methyl-d-aspartate (NMDA, 20 or 30 nmol/0.5 microl).",,,,T,,,,,c,,,,,0.5,,
20558148,2124,D006220,C031231,Negative_Correlation,TRUE,"<ENT1>Haloperidol</ENT1>-induced catalepsy was challenged with prior intracollicular microinjections of glutamate NMDA receptor antagonists, MK-801 (15 or 30 mmol/0.5 microl) and <ENT2>AP7</ENT2> (10 or 20 nmol/0.5 microl), or of the NMDA receptor agonist N-methyl-d-aspartate (NMDA, 20 or 30 nmol/0.5 microl).",,,,T,Y,,,,w,,,,,0.0,,
20558148,2124,D006220,C031231,Negative_Correlation,TRUE,"The results showed that intracollicular microinjection of MK-801 and <ENT2>AP7</ENT2> previous to systemic injections of <ENT1>haloperidol</ENT1> significantly attenuated the catalepsy, as indicated by a reduced latency to step down from a horizontal bar.",,,,T,,,,,c,,,,,1.0,,
20558148,2131,D006220,D002375,Positive_Correlation,FALSE,Glutamatergic neurotransmission mediated by NMDA receptors in the inferior colliculus can modulate <ENT1>haloperidol</ENT1>-induced <ENT2>catalepsy</ENT2>.,,,,T,,,,,c,,,,,1.0,,
20558148,2131,D006220,D002375,Positive_Correlation,FALSE,The present study examined the influence of excitatory amino acid-mediated mechanisms in the IC on the <ENT2>catalepsy</ENT2> induced by the dopamine receptor blocker <ENT1>haloperidol</ENT1> administered systemically (1 or 0.5 mg/kg) in rats.,,,,T,,,,,c,,,,,1.0,,
20558148,2131,D006220,D002375,Positive_Correlation,FALSE,"<ENT1>Haloperidol</ENT1>-induced <ENT2>catalepsy</ENT2> was challenged with prior intracollicular microinjections of glutamate NMDA receptor antagonists, MK-801 (15 or 30 mmol/0.5 microl) and AP7 (10 or 20 nmol/0.5 microl), or of the NMDA receptor agonist N-methyl-d-aspartate (NMDA, 20 or 30 nmol/0.5 microl).",,,,T,,,,,c,,,,,0.0,,
20558148,2131,D006220,D002375,Positive_Correlation,FALSE,"The results showed that intracollicular microinjection of MK-801 and AP7 previous to systemic injections of <ENT1>haloperidol</ENT1> significantly attenuated the <ENT2>catalepsy</ENT2>, as indicated by a reduced latency to step down from a horizontal bar.",,,,T,,,,,w,,,,,0.0,,
20558148,2131,D006220,D002375,Positive_Correlation,FALSE,These findings suggest that glutamate-mediated mechanisms in the neural circuits at the IC level influence <ENT1>haloperidol</ENT1>-induced <ENT2>catalepsy</ENT2> and participate in the regulation of motor activity.,,,,T,,,,,c,,,,,1.0,,
20558148,2126,D006220,D016291,Negative_Correlation,TRUE,"<ENT1>Haloperidol</ENT1>-induced catalepsy was challenged with prior intracollicular microinjections of glutamate NMDA receptor antagonists, <ENT2>MK-801</ENT2> (15 or 30 mmol/0.5 microl) and AP7 (10 or 20 nmol/0.5 microl), or of the NMDA receptor agonist N-methyl-d-aspartate (NMDA, 20 or 30 nmol/0.5 microl).",,,,T,,,,,c,,,,,0.0,,
20558148,2126,D006220,D016291,Negative_Correlation,TRUE,"The results showed that intracollicular microinjection of <ENT2>MK-801</ENT2> and AP7 previous to systemic injections of <ENT1>haloperidol</ENT1> significantly attenuated the catalepsy, as indicated by a reduced latency to step down from a horizontal bar.",,,,T,Y,,,,w,,,,,0.0,,
20558148,2122,D006220,D018698,Association,TRUE,These findings suggest that <ENT2>glutamate</ENT2>-mediated mechanisms in the neural circuits at the IC level influence <ENT1>haloperidol</ENT1>-induced catalepsy and participate in the regulation of motor activity.,,,,T,,,,,c,,,,,1.0,,
20558148,2120,D006220,24316,Negative_Correlation,FALSE,The present study examined the influence of excitatory amino acid-mediated mechanisms in the IC on the catalepsy induced by the <ENT2>dopamine receptor</ENT2> blocker <ENT1>haloperidol</ENT1> administered systemically (1 or 0.5 mg/kg) in rats.,,,,T,,,,,w,,,,,1.0,,
20558148,2123,C031231,D002375,Negative_Correlation,TRUE,"Haloperidol-induced <ENT2>catalepsy</ENT2> was challenged with prior intracollicular microinjections of glutamate NMDA receptor antagonists, MK-801 (15 or 30 mmol/0.5 microl) and <ENT1>AP7</ENT1> (10 or 20 nmol/0.5 microl), or of the NMDA receptor agonist N-methyl-d-aspartate (NMDA, 20 or 30 nmol/0.5 microl).",,,,T,,,,,c,,,,,0.0,,
20558148,2123,C031231,D002375,Negative_Correlation,TRUE,"The results showed that intracollicular microinjection of MK-801 and <ENT1>AP7</ENT1> previous to systemic injections of haloperidol significantly attenuated the <ENT2>catalepsy</ENT2>, as indicated by a reduced latency to step down from a horizontal bar.",,,,T,,,,,c,,,,,0.0,,
20558148,2125,D002375,D016291,Negative_Correlation,TRUE,"Haloperidol-induced <ENT1>catalepsy</ENT1> was challenged with prior intracollicular microinjections of glutamate NMDA receptor antagonists, <ENT2>MK-801</ENT2> (15 or 30 mmol/0.5 microl) and AP7 (10 or 20 nmol/0.5 microl), or of the NMDA receptor agonist N-methyl-d-aspartate (NMDA, 20 or 30 nmol/0.5 microl).",,,,T,,,,,c,,,,,0.0,,
20558148,2125,D002375,D016291,Negative_Correlation,TRUE,"The results showed that intracollicular microinjection of <ENT2>MK-801</ENT2> and AP7 previous to systemic injections of haloperidol significantly attenuated the <ENT1>catalepsy</ENT1>, as indicated by a reduced latency to step down from a horizontal bar.",,,,T,,,,,c,,,,,1.0,,
20558148,2121,D002375,D018698,Association,TRUE,These findings suggest that <ENT2>glutamate</ENT2>-mediated mechanisms in the neural circuits at the IC level influence haloperidol-induced <ENT1>catalepsy</ENT1> and participate in the regulation of motor activity.,,,,T,,,,,c,,,,,1.0,,
20583543,2133,C536649,rs121434250,Association,TRUE,Another patient with <ENT1>isolated micropenis</ENT1> harbored a heterozygous <ENT2>p.G196S</ENT2> missense mutation.,,,,T,,,,,c,,,,,1.0,,
20583543,2140,c|DEL||8,D058490,Association,TRUE,"Molecular diagnosis of <ENT2>46,XY DSD</ENT2> and identification of a novel <ENT1>8 nucleotide deletion</ENT1> in exon 1 of the SRD5A2 gene.",,,,T,,T,,,w,,,,,0.0,,
20583543,2139,D058490,6716,Association,TRUE,"Molecular diagnosis of <ENT1>46,XY DSD</ENT1> and identification of a novel 8 nucleotide deletion in exon 1 of the <ENT2>SRD5A2</ENT2> gene.",,,,T,,T,,,w,,,,,0.0,,
20583543,2139,D058490,6716,Association,TRUE,"Mutational analysis of androgen receptor (AR) and <ENT2>SRD5A2</ENT2> genes was performed in 29 patients with <ENT1>46,XY DSD</ENT1>, by PCR-SSCP.",,,,T,,Y,,,c,,,,,1.0,,
20583543,2135,D007021,6716,Association,TRUE,"Also, it records a novel deletion in exon 1 of <ENT2>SRD5A2</ENT2> gene in a patient with severe <ENT1>hypospadias</ENT1>.",,,,T,,,,,c,,,,,1.0,,
20588063,2141,D011692,D009401,Positive_Correlation,FALSE,"Permeability, ultrastructural changes, and distribution of novel proteins in the glomerular barrier in early <ENT1>puromycin aminonucleoside</ENT1> <ENT2>nephrosis</ENT2>.",,,,T,,,,,w,,,,,0.0,,
20588063,2141,D011692,D009401,Positive_Correlation,FALSE,"Using <ENT1>puromycin aminonucleoside</ENT1> <ENT2>nephrosis</ENT2> (<ENT2>PAN</ENT2>) rats, we studied early ultrastructural and permeability changes in relation to the expression of the podocyte-associated molecules nephrin, a-actinin, dendrin, and plekhh2, the last two of which were only recently discovered in podocytes.",,,,T,,,,,w,,,,,0.0,,
20588063,2142,25113,D009401,Association,TRUE,"Using puromycin aminonucleoside <ENT2>nephrosis</ENT2> (<ENT2>PAN</ENT2>) rats, we studied early ultrastructural and permeability changes in relation to the expression of the podocyte-associated molecules nephrin, a-actinin, <ENT1>dendrin</ENT1>, and plekhh2, the last two of which were only recently discovered in podocytes.",,,,T,,,,,w,,,,,1.0,,
20588063,2142,25113,D009401,Association,TRUE,"The novel proteins <ENT1>dendrin</ENT1> and plekhh2 were both reduced, suggesting roles in <ENT2>PAN</ENT2>, whereas a-actinin was unchanged.",,,,T,,,,,c,,,,,1.0,,
20588063,2143,D009401,313866,Association,TRUE,"Using puromycin aminonucleoside <ENT1>nephrosis</ENT1> (<ENT1>PAN</ENT1>) rats, we studied early ultrastructural and permeability changes in relation to the expression of the podocyte-associated molecules nephrin, a-actinin, dendrin, and <ENT2>plekhh2</ENT2>, the last two of which were only recently discovered in podocytes.",,,,T,,,,,w,,,,,1.0,,
20588063,2143,D009401,313866,Association,TRUE,"The novel proteins dendrin and <ENT2>plekhh2</ENT2> were both reduced, suggesting roles in <ENT1>PAN</ENT1>, whereas a-actinin was unchanged.",,,,T,,,,,c,,,,,0.0,,
20588063,2144,D009401,64563,Association,TRUE,"Using puromycin aminonucleoside <ENT1>nephrosis</ENT1> (<ENT1>PAN</ENT1>) rats, we studied early ultrastructural and permeability changes in relation to the expression of the podocyte-associated molecules <ENT2>nephrin</ENT2>, a-actinin, dendrin, and plekhh2, the last two of which were only recently discovered in podocytes.",,,,T,,Y,,,w,,,,,1.0,,
20606392,2150,D046150,2690,Association,TRUE,"Atypical <ENT1>GH insensitivity syndrome</ENT1> and severe insulin-like growth factor-I deficiency resulting from compound heterozygous mutations of the <ENT2>GH receptor</ENT2>, including a novel frameshift mutation affecting the intracellular domain.",,,,T,,T,,,c,,,,,1.0,,
20606392,2150,D046150,2690,Association,TRUE,BACKGROUND/AIMS: <ENT1>GH insensitivity</ENT1> and IGF deficiency may result from aberrations of the <ENT2>GH receptor</ENT2> (<ENT2>GHR</ENT2>).,,,,T,,,,,c,,,,,1.0,,
20606392,2150,D046150,2690,Association,TRUE,"We describe a 4-year-old child with modest growth failure and normal serum concentrations of <ENT2>GH-binding protein</ENT2> (<ENT2>GHBP</ENT2>), but clinical evidence of <ENT1>GH insensitivity</ENT1>.",,,,T,Y,,,,w,,,,,0.0,TRUE,
20606392,2150,D046150,2690,Association,TRUE,"CONCLUSION: Mutations affecting the intracellular domain of the <ENT2>GHR</ENT2> can result in <ENT1>GH insensitivity</ENT1> and IGF deficiency, despite normal serum concentrations of <ENT2>GHBP</ENT2>.",,,,T,,,,,c,,,,,0.5,,
20606392,2153,C563867,2690,Association,TRUE,"Atypical GH insensitivity syndrome and severe <ENT1>insulin-like growth factor-I deficiency</ENT1> resulting from compound heterozygous mutations of the <ENT2>GH receptor</ENT2>, including a novel frameshift mutation affecting the intracellular domain.",,,,T,,T,,,c,,,,,1.0,,
20606392,2153,C563867,2690,Association,TRUE,BACKGROUND/AIMS: GH insensitivity and <ENT1>IGF deficiency</ENT1> may result from aberrations of the <ENT2>GH receptor</ENT2> (<ENT2>GHR</ENT2>).,,,,T,,,,,c,,,,,1.0,,
20606392,2153,C563867,2690,Association,TRUE,"CONCLUSION: Mutations affecting the intracellular domain of the <ENT2>GHR</ENT2> can result in GH insensitivity and <ENT1>IGF deficiency</ENT1>, despite normal serum concentrations of <ENT2>GHBP</ENT2>.",,,,T,,,,,c,,,,,0.5,,
20621845,2158,81686,D002122,Positive_Correlation,TRUE,"Elevation of ADAM10, ADAM17, <ENT1>MMP-2</ENT1> and MMP-9 expression with media degeneration features <ENT2>CaCl2</ENT2>-induced thoracic aortic aneurysm in a rat model.",,,,T,Y,T,,,w,,,,,0.0,,
20621845,2158,81686,D002122,Positive_Correlation,TRUE,"<ENT1>MMP-2</ENT1>, MMP-9, ADAM-10 and ADAM-17 mRNA levels were increased in <ENT2>CaCl(2)</ENT2>-treated segments (all p<0.01), with trends of elevation in <ENT2>CaCl(2)</ENT2>-untreated segments, as compared with NaCl-treated segments.",,,,T,,,,,c,,,,,0.0,,
20621845,2158,81686,D002122,Positive_Correlation,TRUE,"Immunohistochemistry displayed significantly increased expressions of <ENT1>MMP-2</ENT1>, MMP-9, ADAM-10 and ADAM-17 (all p<0.01) in intima and media for <ENT2>CaCl(2)</ENT2>-treated segments.",,,,T,,,,,c,,,,,1.0,,
20621845,2158,81686,D002122,Positive_Correlation,TRUE,"CONCLUSION: This study establishes a TAA model by periarterial <ENT2>CaCl(2)</ENT2> exposure in rats, and demonstrates a significant elevation of expression of <ENT1>MMP-2</ENT1>, MMP-9, ADAM10 and ADAM17 in the pathogenesis of vascular remodeling.",,,,T,,,,,c,,,,,1.0,,
20621845,2159,81686,D017545,Association,TRUE,"Elevation of ADAM10, ADAM17, <ENT1>MMP-2</ENT1> and MMP-9 expression with media degeneration features CaCl2-induced <ENT2>thoracic aortic aneurysm</ENT2> in a rat model.",,,,T,,T,,,c,,,,,1.0,,
20621845,2159,81686,D017545,Association,TRUE,"CONCLUSION: This study establishes a <ENT2>TAA</ENT2> model by periarterial CaCl(2) exposure in rats, and demonstrates a significant elevation of expression of <ENT1>MMP-2</ENT1>, MMP-9, ADAM10 and ADAM17 in the pathogenesis of vascular remodeling.",,,,T,,,,,c,,,,,1.0,,
20621845,2160,57027,D002122,Positive_Correlation,TRUE,"Elevation of ADAM10, <ENT1>ADAM17</ENT1>, MMP-2 and MMP-9 expression with media degeneration features <ENT2>CaCl2</ENT2>-induced thoracic aortic aneurysm in a rat model.",,,,T,Y,T,,,c,,,,,0.0,,
20621845,2160,57027,D002122,Positive_Correlation,TRUE,"PURPOSE: This study was designed to establish a rat model of thoracic aortic aneurysm (TAA) by <ENT2>calcium chloride</ENT2> (<ENT2>CaCl(2)</ENT2>)-induced arterial injury and to explore the potential role of <ENT1>a disintegrin and metalloproteinase</ENT1> (<ENT1>ADAM</ENT1>), matrix metalloproteinases (MMPs) and their endogenous inhibitors (TIMPs) in TAA formation.",,,,T,,Y,,,c,,,,,1.0,,
20621845,2160,57027,D002122,Positive_Correlation,TRUE,"MMP-2, MMP-9, ADAM-10 and <ENT1>ADAM-17</ENT1> mRNA levels were increased in <ENT2>CaCl(2)</ENT2>-treated segments (all p<0.01), with trends of elevation in <ENT2>CaCl(2)</ENT2>-untreated segments, as compared with NaCl-treated segments.",,,,T,,,,,c,,,,,0.5,,
20621845,2160,57027,D002122,Positive_Correlation,TRUE,"Immunohistochemistry displayed significantly increased expressions of MMP-2, MMP-9, ADAM-10 and <ENT1>ADAM-17</ENT1> (all p<0.01) in intima and media for <ENT2>CaCl(2)</ENT2>-treated segments.",,,,T,,,,,c,,,,,1.0,,
20621845,2160,57027,D002122,Positive_Correlation,TRUE,"CONCLUSION: This study establishes a TAA model by periarterial <ENT2>CaCl(2)</ENT2> exposure in rats, and demonstrates a significant elevation of expression of MMP-2, MMP-9, ADAM10 and <ENT1>ADAM17</ENT1> in the pathogenesis of vascular remodeling.",,,,T,,,,,c,,,,,0.0,,
20621845,2161,57027,D017545,Association,TRUE,"Elevation of ADAM10, <ENT1>ADAM17</ENT1>, MMP-2 and MMP-9 expression with media degeneration features CaCl2-induced <ENT2>thoracic aortic aneurysm</ENT2> in a rat model.",,,,T,,,,,c,,,,,1.0,,
20621845;20621845,2161;2163,57027;29650,D017545;D017545,Association;Association,TRUE;TRUE,"PURPOSE: This study was designed to establish a rat model of <ENT2>thoracic aortic aneurysm</ENT2> (<ENT2>TAA</ENT2>) by calcium chloride (CaCl(2))-induced arterial injury and to explore the potential role of <ENT1>a disintegrin and metalloproteinase</ENT1> (<ENT1>ADAM</ENT1>), matrix metalloproteinases (MMPs) and their endogenous inhibitors (TIMPs) in <ENT2>TAA</ENT2> formation.",,,,T,,Y,,,c,,,,,1.0,,
20621845,2161,57027,D017545,Association,TRUE,"CONCLUSION: This study establishes a <ENT2>TAA</ENT2> model by periarterial CaCl(2) exposure in rats, and demonstrates a significant elevation of expression of MMP-2, MMP-9, ADAM10 and <ENT1>ADAM17</ENT1> in the pathogenesis of vascular remodeling.",,,,T,,,,,c,,,,,1.0,,
20621845,2156,81687,D002122,Positive_Correlation,TRUE,"Elevation of ADAM10, ADAM17, MMP-2 and <ENT1>MMP-9</ENT1> expression with media degeneration features <ENT2>CaCl2</ENT2>-induced thoracic aortic aneurysm in a rat model.",,,,T,Y,T,,,c,,,,,0.0,,
20621845,2156,81687,D002122,Positive_Correlation,TRUE,"MMP-2, <ENT1>MMP-9</ENT1>, ADAM-10 and ADAM-17 mRNA levels were increased in <ENT2>CaCl(2)</ENT2>-treated segments (all p<0.01), with trends of elevation in <ENT2>CaCl(2)</ENT2>-untreated segments, as compared with NaCl-treated segments.",,,,T,,,,,c,,,,,0.5,,
20621845,2156,81687,D002122,Positive_Correlation,TRUE,"Immunohistochemistry displayed significantly increased expressions of MMP-2, <ENT1>MMP-9</ENT1>, ADAM-10 and ADAM-17 (all p<0.01) in intima and media for <ENT2>CaCl(2)</ENT2>-treated segments.",,,,T,,,,,c,,,,,1.0,,
20621845,2156,81687,D002122,Positive_Correlation,TRUE,"CONCLUSION: This study establishes a TAA model by periarterial <ENT2>CaCl(2)</ENT2> exposure in rats, and demonstrates a significant elevation of expression of MMP-2, <ENT1>MMP-9</ENT1>, ADAM10 and ADAM17 in the pathogenesis of vascular remodeling.",,,,T,,,,,c,,,,,1.0,,
20621845,2157,81687,D017545,Association,TRUE,"Elevation of ADAM10, ADAM17, MMP-2 and <ENT1>MMP-9</ENT1> expression with media degeneration features CaCl2-induced <ENT2>thoracic aortic aneurysm</ENT2> in a rat model.",,,,T,,,,,c,,,,,0.0,,
20621845,2157,81687,D017545,Association,TRUE,"CONCLUSION: This study establishes a <ENT2>TAA</ENT2> model by periarterial CaCl(2) exposure in rats, and demonstrates a significant elevation of expression of MMP-2, <ENT1>MMP-9</ENT1>, ADAM10 and ADAM17 in the pathogenesis of vascular remodeling.",,,,T,,,,,c,,,,,0.0,,
20621845,2154,D002122,D014652,Positive_Correlation,FALSE,"PURPOSE: This study was designed to establish a rat model of thoracic aortic aneurysm (TAA) by <ENT1>calcium chloride</ENT1> (<ENT1>CaCl(2)</ENT1>)-induced <ENT2>arterial injury</ENT2> and to explore the potential role of a disintegrin and metalloproteinase (ADAM), matrix metalloproteinases (MMPs) and their endogenous inhibitors (TIMPs) in TAA formation.",,,,T,,,,,c,,,,,0.5,,
20621845,2162,D002122,29650,Positive_Correlation,TRUE,"Elevation of <ENT2>ADAM10</ENT2>, ADAM17, MMP-2 and MMP-9 expression with media degeneration features <ENT1>CaCl2</ENT1>-induced thoracic aortic aneurysm in a rat model.",,,,T,Y,,,,c,,,,,0.0,,
20621845,2162,D002122,29650,Positive_Correlation,TRUE,"PURPOSE: This study was designed to establish a rat model of thoracic aortic aneurysm (TAA) by <ENT1>calcium chloride</ENT1> (<ENT1>CaCl(2)</ENT1>)-induced arterial injury and to explore the potential role of <ENT2>a disintegrin and metalloproteinase</ENT2> (<ENT2>ADAM</ENT2>), matrix metalloproteinases (MMPs) and their endogenous inhibitors (TIMPs) in TAA formation.",,,,T,,Y,,,c,,,,,1.0,,
20621845,2162,D002122,29650,Positive_Correlation,TRUE,"MMP-2, MMP-9, <ENT2>ADAM-10</ENT2> and ADAM-17 mRNA levels were increased in <ENT1>CaCl(2)</ENT1>-treated segments (all p<0.01), with trends of elevation in <ENT1>CaCl(2)</ENT1>-untreated segments, as compared with NaCl-treated segments.",,,,T,,,,,c,,,,,0.5,,
20621845,2162,D002122,29650,Positive_Correlation,TRUE,"Immunohistochemistry displayed significantly increased expressions of MMP-2, MMP-9, <ENT2>ADAM-10</ENT2> and ADAM-17 (all p<0.01) in intima and media for <ENT1>CaCl(2)</ENT1>-treated segments.",,,,T,,,,,c,,,,,1.0,,
20621845,2162,D002122,29650,Positive_Correlation,TRUE,"CONCLUSION: This study establishes a TAA model by periarterial <ENT1>CaCl(2)</ENT1> exposure in rats, and demonstrates a significant elevation of expression of MMP-2, MMP-9, <ENT2>ADAM10</ENT2> and ADAM17 in the pathogenesis of vascular remodeling.",,,,T,,,,,c,,,,,0.0,,
20621845,2155,D002122,D017545,Positive_Correlation,FALSE,"Elevation of ADAM10, ADAM17, MMP-2 and MMP-9 expression with media degeneration features <ENT1>CaCl2</ENT1>-induced <ENT2>thoracic aortic aneurysm</ENT2> in a rat model.",,,,T,,,,,c,,,,,1.0,,
20621845,2155,D002122,D017545,Positive_Correlation,FALSE,"PURPOSE: This study was designed to establish a rat model of <ENT2>thoracic aortic aneurysm</ENT2> (<ENT2>TAA</ENT2>) by <ENT1>calcium chloride</ENT1> (<ENT1>CaCl(2)</ENT1>)-induced arterial injury and to explore the potential role of a disintegrin and metalloproteinase (ADAM), matrix metalloproteinases (MMPs) and their endogenous inhibitors (TIMPs) in <ENT2>TAA</ENT2> formation.",,,,T,,Y,,,c,,,,,0.666666667,,
20621845,2155,D002122,D017545,Positive_Correlation,FALSE,"CONCLUSION: This study establishes a <ENT2>TAA</ENT2> model by periarterial <ENT1>CaCl(2)</ENT1> exposure in rats, and demonstrates a significant elevation of expression of MMP-2, MMP-9, ADAM10 and ADAM17 in the pathogenesis of vascular remodeling.",,,,T,,,,,w,,,,,1.0,,
20621845,2163,29650,D017545,Association,TRUE,"Elevation of <ENT1>ADAM10</ENT1>, ADAM17, MMP-2 and MMP-9 expression with media degeneration features CaCl2-induced <ENT2>thoracic aortic aneurysm</ENT2> in a rat model.",,,,T,,,,,c,,,,,0.0,,
20621845,2163,29650,D017545,Association,TRUE,"CONCLUSION: This study establishes a <ENT2>TAA</ENT2> model by periarterial CaCl(2) exposure in rats, and demonstrates a significant elevation of expression of MMP-2, MMP-9, <ENT1>ADAM10</ENT1> and ADAM17 in the pathogenesis of vascular remodeling.",,,,T,,,,,c,,,,,1.0,,
20682662,2164,1234,D007249,Association,FALSE,OBJECTIVE: <ENT1>C-C chemokine receptor 5</ENT1> (<ENT1>CCR5</ENT1>) plays an important role in <ENT2>inflammation</ENT2>.,,,,T,,,,,c,,,,,1.0,,
20705401,2170,D008694,rs1805054,Association,TRUE,"METHOD: Using five tagging SNPs (rs6693503, <ENT2>rs1805054</ENT2>, rs4912138, rs3790757 and rs9659997), we conducted a genetic association analysis of case-control samples (197 <ENT1>METH</ENT1>-induced psychosis patients and 337 controls) in the Japanese population.",,,,T,,Y,,,w,,,,,1.0,,
20705401,2170,D008694,rs1805054,Association,TRUE,"In the haplotype-wise analysis, we detected an association between two markers (rs6693503 and <ENT2>rs1805054</ENT2>) and three markers (rs6693503, <ENT2>rs1805054</ENT2> and rs4912138) in HTR6 and <ENT1>METH</ENT1>-induced psychosis patients, respectively.",,,,T,Y,,,,c,,,,,1.0,,
20705401,2185,D008694,D011605,Positive_Correlation,FALSE,Serotonin 6 receptor gene is associated with <ENT1>methamphetamine</ENT1>-induced <ENT2>psychosis</ENT2> in a Japanese population.,,,,T,,T,,,c,,,,,1.0,,
20705401,2185,D008694,D011605,Positive_Correlation,FALSE,The symptoms of <ENT1>methamphetamine</ENT1> (<ENT1>METH</ENT1>)-induced <ENT2>psychosis</ENT2> are similar to those of paranoid type schizophrenia.,,,,T,,,,,c,,,,,1.0,,
20705401,2185,D008694,D011605,Positive_Correlation,FALSE,"Therefore, we conducted an analysis of the association of the 5-HT6 gene (HTR6) with <ENT1>METH</ENT1>-induced <ENT2>psychosis</ENT2>.",,,,T,,,,,c,,,,,1.0,,
20705401,2185,D008694,D011605,Positive_Correlation,FALSE,"METHOD: Using five tagging SNPs (rs6693503, rs1805054, rs4912138, rs3790757 and rs9659997), we conducted a genetic association analysis of case-control samples (197 <ENT1>METH</ENT1>-induced <ENT2>psychosis</ENT2> patients and 337 controls) in the Japanese population.",,,,T,,,,,c,,,,,1.0,,
20705401,2185,D008694,D011605,Positive_Correlation,FALSE,RESULTS: rs6693503 was associated with <ENT1>METH</ENT1>-induced <ENT2>psychosis</ENT2> patients in the allele/genotype-wise analysis.,,,,T,,,,,c,,,,,1.0,,
20705401,2185,D008694,D011605,Positive_Correlation,FALSE,"In the haplotype-wise analysis, we detected an association between two markers (rs6693503 and rs1805054) and three markers (rs6693503, rs1805054 and rs4912138) in HTR6 and <ENT1>METH</ENT1>-induced <ENT2>psychosis</ENT2> patients, respectively.",,,,T,,,,,c,,,,,1.0,,
20705401,2185,D008694,D011605,Positive_Correlation,FALSE,CONCLUSION: HTR6 may play an important role in the pathophysiology of <ENT1>METH</ENT1>-induced <ENT2>psychosis</ENT2> in the Japanese population.,,,,T,,,,,c,,,,,1.0,,
20705401,2182,D008694,3362,Association,TRUE,<ENT2>Serotonin 6 receptor</ENT2> gene is associated with <ENT1>methamphetamine</ENT1>-induced psychosis in a Japanese population.,,,,T,Y,T,,,c,,,,,1.0,,
20705401,2182,D008694,3362,Association,TRUE,"Therefore, we conducted an analysis of the association of the <ENT2>5-HT6</ENT2> gene (<ENT2>HTR6</ENT2>) with <ENT1>METH</ENT1>-induced psychosis.",,,,T,,Y,,,c,,,,,0.0,,
20705401,2182,D008694,3362,Association,TRUE,"In the haplotype-wise analysis, we detected an association between two markers (rs6693503 and rs1805054) and three markers (rs6693503, rs1805054 and rs4912138) in <ENT2>HTR6</ENT2> and <ENT1>METH</ENT1>-induced psychosis patients, respectively.",,,,T,,,,,w,,,,,1.0,,
20705401,2182,D008694,3362,Association,TRUE,CONCLUSION: <ENT2>HTR6</ENT2> may play an important role in the pathophysiology of <ENT1>METH</ENT1>-induced psychosis in the Japanese population.,,,,T,,,,,c,,,,,1.0,,
20705401,2172,D008694,rs6693503,Association,TRUE,"METHOD: Using five tagging SNPs (<ENT2>rs6693503</ENT2>, rs1805054, rs4912138, rs3790757 and rs9659997), we conducted a genetic association analysis of case-control samples (197 <ENT1>METH</ENT1>-induced psychosis patients and 337 controls) in the Japanese population.",,,,T,,Y,,,w,,,,,1.0,,
20705401,2172,D008694,rs6693503,Association,TRUE,RESULTS: <ENT2>rs6693503</ENT2> was associated with <ENT1>METH</ENT1>-induced psychosis patients in the allele/genotype-wise analysis.,,,,T,,,,,c,,,,,0.0,,
20705401,2172,D008694,rs6693503,Association,TRUE,"In the haplotype-wise analysis, we detected an association between two markers (<ENT2>rs6693503</ENT2> and rs1805054) and three markers (<ENT2>rs6693503</ENT2>, rs1805054 and rs4912138) in HTR6 and <ENT1>METH</ENT1>-induced psychosis patients, respectively.",,,,T,Y,,,,c,,,,,1.0,,
20705401,2168,D008694,rs4912138,Association,TRUE,"METHOD: Using five tagging SNPs (rs6693503, rs1805054, <ENT2>rs4912138</ENT2>, rs3790757 and rs9659997), we conducted a genetic association analysis of case-control samples (197 <ENT1>METH</ENT1>-induced psychosis patients and 337 controls) in the Japanese population.",,,,T,,Y,,,w,,,,,1.0,,
20705401,2168,D008694,rs4912138,Association,TRUE,"In the haplotype-wise analysis, we detected an association between two markers (rs6693503 and rs1805054) and three markers (rs6693503, rs1805054 and <ENT2>rs4912138</ENT2>) in HTR6 and <ENT1>METH</ENT1>-induced psychosis patients, respectively.",,,,T,,,,,c,,,,,1.0,,
20705401,2178,D003024,3362,Association,FALSE,"The <ENT2>serotonin 6 (5-HT6) receptor</ENT2> is therapeutically targeted by several second generation antipsychotics, such as <ENT1>clozapine</ENT1> and olanzapine, and d-amphetamine-induced hyperactivity in rats is corrected with the use of a selective 5-HT6 receptor antagonist.",,,,T,,,,,c,,,,,1.0,,
20705401,2176,D006948,D003913,Positive_Correlation,FALSE,"The serotonin 6 (5-HT6) receptor is therapeutically targeted by several second generation antipsychotics, such as clozapine and olanzapine, and <ENT2>d-amphetamine</ENT2>-induced <ENT1>hyperactivity</ENT1> in rats is corrected with the use of a selective 5-HT6 receptor antagonist.",,,,T,,,,,c,,,,,1.0,,
20705401,2180,D006948,3362,Association,FALSE,"The <ENT2>serotonin 6 (5-HT6) receptor</ENT2> is therapeutically targeted by several second generation antipsychotics, such as clozapine and olanzapine, and d-amphetamine-induced <ENT1>hyperactivity</ENT1> in rats is corrected with the use of a selective 5-HT6 receptor antagonist.",,,,T,,,,,w,,,,,1.0,,
20705401,2179,D014150,3362,Association,FALSE,"The <ENT2>serotonin 6 (5-HT6) receptor</ENT2> is therapeutically targeted by several second generation <ENT1>antipsychotics</ENT1>, such as clozapine and olanzapine, and d-amphetamine-induced hyperactivity in rats is corrected with the use of a selective 5-HT6 receptor antagonist.",,,,T,,,,,c,,,,,1.0,,
20705401,2169,rs1805054,D011605,Association,TRUE,"METHOD: Using five tagging SNPs (rs6693503, <ENT1>rs1805054</ENT1>, rs4912138, rs3790757 and rs9659997), we conducted a genetic association analysis of case-control samples (197 METH-induced <ENT2>psychosis</ENT2> patients and 337 controls) in the Japanese population.",,,,T,,Y,,,w,,,,,1.0,,
20705401,2169,rs1805054,D011605,Association,TRUE,"In the haplotype-wise analysis, we detected an association between two markers (rs6693503 and <ENT1>rs1805054</ENT1>) and three markers (rs6693503, <ENT1>rs1805054</ENT1> and rs4912138) in HTR6 and METH-induced <ENT2>psychosis</ENT2> patients, respectively.",,,,T,,,,,c,,,,,0.0,,
20705401,2175,D003913,D012702,Association,FALSE,"The serotonin 6 (5-HT6) receptor is therapeutically targeted by several second generation antipsychotics, such as clozapine and olanzapine, and <ENT1>d-amphetamine</ENT1>-induced hyperactivity in rats is corrected with the use of a selective <ENT2>5-HT6 receptor antagonist</ENT2>.",,,,T,,,,,c,,,,,0.0,,
20705401,2175,D003913,D012702,Association,FALSE,"In addition, the disrupted prepulse inhibition induced by <ENT1>d-amphetamine</ENT1> or phencyclidine was restored by <ENT2>5-HT6 receptor antagonist</ENT2> in an animal study using rats.",,,,T,,,,,c,,,,,0.0,,
20705401,2181,D011605,3362,Association,TRUE,<ENT2>Serotonin 6 receptor</ENT2> gene is associated with methamphetamine-induced <ENT1>psychosis</ENT1> in a Japanese population.,,,,T,,T,,,c,,,,,1.0,,
20705401,2181,D011605,3362,Association,TRUE,"These animal models were considered to reflect the positive symptoms of schizophrenia, and the above evidence suggests that altered <ENT2>5-HT6 receptors</ENT2> are involved in the pathophysiology of <ENT1>psychotic disorders</ENT1>.",,,,T,,,,,c,,,,,1.0,,
20705401,2181,D011605,3362,Association,TRUE,"Therefore, we conducted an analysis of the association of the <ENT2>5-HT6</ENT2> gene (<ENT2>HTR6</ENT2>) with METH-induced <ENT1>psychosis</ENT1>.",,,,T,,Y,,,w,,,,,1.0,,
20705401,2181,D011605,3362,Association,TRUE,"In the haplotype-wise analysis, we detected an association between two markers (rs6693503 and rs1805054) and three markers (rs6693503, rs1805054 and rs4912138) in <ENT2>HTR6</ENT2> and METH-induced <ENT1>psychosis</ENT1> patients, respectively.",,,,T,Y,,,,w,,,,,1.0,,
20705401,2181,D011605,3362,Association,TRUE,CONCLUSION: <ENT2>HTR6</ENT2> may play an important role in the pathophysiology of METH-induced <ENT1>psychosis</ENT1> in the Japanese population.,,,,T,,,,,c,,,,,1.0,,
20705401,2171,D011605,rs6693503,Association,TRUE,"METHOD: Using five tagging SNPs (<ENT2>rs6693503</ENT2>, rs1805054, rs4912138, rs3790757 and rs9659997), we conducted a genetic association analysis of case-control samples (197 METH-induced <ENT1>psychosis</ENT1> patients and 337 controls) in the Japanese population.",,,,T,,Y,,,w,,,,,1.0,,
20705401,2171,D011605,rs6693503,Association,TRUE,RESULTS: <ENT2>rs6693503</ENT2> was associated with METH-induced <ENT1>psychosis</ENT1> patients in the allele/genotype-wise analysis.,,,,T,,,,,c,,,,,0.0,,
20705401,2171,D011605,rs6693503,Association,TRUE,"In the haplotype-wise analysis, we detected an association between two markers (<ENT2>rs6693503</ENT2> and rs1805054) and three markers (<ENT2>rs6693503</ENT2>, rs1805054 and rs4912138) in HTR6 and METH-induced <ENT1>psychosis</ENT1> patients, respectively.",,,,T,,,,,c,,,,,0.0,,
20705401,2167,D011605,rs4912138,Association,TRUE,"METHOD: Using five tagging SNPs (rs6693503, rs1805054, <ENT2>rs4912138</ENT2>, rs3790757 and rs9659997), we conducted a genetic association analysis of case-control samples (197 METH-induced <ENT1>psychosis</ENT1> patients and 337 controls) in the Japanese population.",,,,T,,Y,,,w,,,,,1.0,,
20705401,2167,D011605,rs4912138,Association,TRUE,"In the haplotype-wise analysis, we detected an association between two markers (rs6693503 and rs1805054) and three markers (rs6693503, rs1805054 and <ENT2>rs4912138</ENT2>) in HTR6 and METH-induced <ENT1>psychosis</ENT1> patients, respectively.",,,,T,,,,,c,,,,,0.0,,
20705401,2177,3362,D000077152,Association,FALSE,"The <ENT1>serotonin 6 (5-HT6) receptor</ENT1> is therapeutically targeted by several second generation antipsychotics, such as clozapine and <ENT2>olanzapine</ENT2>, and d-amphetamine-induced hyperactivity in rats is corrected with the use of a selective 5-HT6 receptor antagonist.",,,,T,,,,,c,,,,,1.0,,
20705401,2173,D012702,D010622,Association,FALSE,"In addition, the disrupted prepulse inhibition induced by d-amphetamine or <ENT2>phencyclidine</ENT2> was restored by <ENT1>5-HT6 receptor antagonist</ENT1> in an animal study using rats.",,,,T,,,,,c,,,,,0.0,,
20708777,2186,1584,D006973,Association,FALSE,Association of DNA polymorphisms within the CYP11B2/<ENT1>CYP11B1</ENT1> locus and postoperative <ENT2>hypertension</ENT2> risk in the patients with aldosterone-producing adenomas.,,,,T,,T,,,c,,,,,1.0,,
20708777,2186,1584,D006973,Association,FALSE,"The aim of this study was to investigate the association of DNA polymorphisms within <ENT1>steroid synthesis genes</ENT1> (CYP11B2, <ENT1>CYP11B1</ENT1>) and the postoperative resolution of <ENT2>hypertension</ENT2> in Chinese patients undergoing adrenalectomy for aldosterone-producing adenomas (APA).",,,,T,,Y,,,w,,,,,1.0,TRUE,
20708777,2186,1584,D006973,Association,FALSE,The associations between CYPB11B2/<ENT1>CYP11B1</ENT1> polymorphisms and persistent postoperative <ENT2>hypertension</ENT2> were assessed by multivariate analysis.,,,,T,,Y,,,w,,,,,1.0,,
20708777,2186,1584,D006973,Association,FALSE,RESULTS: CYP11B2-<ENT1>CYP11B1</ENT1> haplotype was associated with persistent postoperative <ENT2>hypertension</ENT2> in Chinese patients undergoing adrenalectomy with APA (P = .006).,,,,T,,,,,c,,,,,1.0,,
20708777,2186,1584,D006973,Association,FALSE,DNA polymorphisms at <ENT1>CYP11B2/B1</ENT1> locus may confer susceptibility to postoperative <ENT2>hypertension</ENT2> of patients with APA.,,,,T,,,,,c,,,,,1.0,,
20708777,2192,1584,D000236,Association,FALSE,Association of DNA polymorphisms within the CYP11B2/<ENT1>CYP11B1</ENT1> locus and postoperative hypertension risk in the patients with <ENT2>aldosterone-producing adenomas</ENT2>.,,,,T,,T,,,c,,,,,0.0,,
20708777,2192,1584,D000236,Association,FALSE,"The aim of this study was to investigate the association of DNA polymorphisms within <ENT1>steroid synthesis genes</ENT1> (CYP11B2, <ENT1>CYP11B1</ENT1>) and the postoperative resolution of hypertension in Chinese patients undergoing adrenalectomy for <ENT2>aldosterone-producing adenomas</ENT2> (<ENT2>APA</ENT2>).",,,,T,,Y,,,w,,,"11,12,21,22",,1.0,TRUE,
20708777,2192,1584,D000236,Association,FALSE,RESULTS: CYP11B2-<ENT1>CYP11B1</ENT1> haplotype was associated with persistent postoperative hypertension in Chinese patients undergoing adrenalectomy with <ENT2>APA</ENT2> (P = .006).,,,,T,,,,,c,,,,,0.0,,
20708777,2192,1584,D000236,Association,FALSE,DNA polymorphisms at <ENT1>CYP11B2/B1</ENT1> locus may confer susceptibility to postoperative hypertension of patients with <ENT2>APA</ENT2>.,,,,T,,,,,c,,,,,0.0,,
20708777,2190,D006973,rs4539,Positive_Correlation,TRUE,"Specifically, the <ENT2>rs4539</ENT2> (AA) polymorphism was associated with persistent postoperative <ENT1>hypertension</ENT1> (P = .002).",,,,T,,,,,c,,,,,1.0,,
20708777,2190,D006973,rs4539,Positive_Correlation,TRUE,"CONCLUSIONS: The <ENT2>rs4539</ENT2> (AA), H1, H2, and H3 are genetic predictors for postoperative persistence of <ENT1>hypertension</ENT1> for Chinese patients treated by adrenalectomy with APA.",,,,T,,,,,c,,,,,0.0,,
20708777,2187,D006973,1585,Association,FALSE,Association of DNA polymorphisms within the <ENT2>CYP11B2</ENT2>/CYP11B1 locus and postoperative <ENT1>hypertension</ENT1> risk in the patients with aldosterone-producing adenomas.,,,,T,,T,,,c,,,,,0.0,,
20708777,2187,D006973,1585,Association,FALSE,"The aim of this study was to investigate the association of DNA polymorphisms within <ENT2>steroid synthesis genes</ENT2> (<ENT2>CYP11B2</ENT2>, CYP11B1) and the postoperative resolution of <ENT1>hypertension</ENT1> in Chinese patients undergoing adrenalectomy for aldosterone-producing adenomas (APA).",,,,T,,Y,,,w,,,,,1.0,TRUE,
20708777,2187,D006973,1585,Association,FALSE,The associations between <ENT2>CYPB11B2</ENT2>/CYP11B1 polymorphisms and persistent postoperative <ENT1>hypertension</ENT1> were assessed by multivariate analysis.,,,,T,,Y,,,w,,,,,1.0,,
20708777,2187,D006973,1585,Association,FALSE,RESULTS: <ENT2>CYP11B2</ENT2>-CYP11B1 haplotype was associated with persistent postoperative <ENT1>hypertension</ENT1> in Chinese patients undergoing adrenalectomy with APA (P = .006).,,,,T,,,,,c,,,,,1.0,,
20708777,2187,D006973,1585,Association,FALSE,DNA polymorphisms at <ENT2>CYP11B2/B1</ENT2> locus may confer susceptibility to postoperative <ENT1>hypertension</ENT1> of patients with APA.,,,,T,,,,,c,,,,,1.0,,
20708777,2196,D000236,rs4539,Association,TRUE,"CONCLUSIONS: The <ENT2>rs4539</ENT2> (AA), H1, H2, and H3 are genetic predictors for postoperative persistence of hypertension for Chinese patients treated by adrenalectomy with <ENT1>APA</ENT1>.",,,,T,,,,,c,,,,,0.0,,
20708777,2193,D000236,1585,Association,FALSE,Association of DNA polymorphisms within the <ENT2>CYP11B2</ENT2>/CYP11B1 locus and postoperative hypertension risk in the patients with <ENT1>aldosterone-producing adenomas</ENT1>.,,,,T,,T,,,c,,,,,0.0,,
20708777,2193,D000236,1585,Association,FALSE,"The aim of this study was to investigate the association of DNA polymorphisms within <ENT2>steroid synthesis genes</ENT2> (<ENT2>CYP11B2</ENT2>, CYP11B1) and the postoperative resolution of hypertension in Chinese patients undergoing adrenalectomy for <ENT1>aldosterone-producing adenomas</ENT1> (<ENT1>APA</ENT1>).",,,,T,,Y,,,w,,,"11,12,21,22",,1.0,TRUE,
20708777,2193,D000236,1585,Association,FALSE,RESULTS: <ENT2>CYP11B2</ENT2>-CYP11B1 haplotype was associated with persistent postoperative hypertension in Chinese patients undergoing adrenalectomy with <ENT1>APA</ENT1> (P = .006).,,,,T,,,,,c,,,,,0.0,,
20708777,2193,D000236,1585,Association,FALSE,DNA polymorphisms at <ENT2>CYP11B2/B1</ENT2> locus may confer susceptibility to postoperative hypertension of patients with <ENT1>APA</ENT1>.,,,,T,,,,,c,,,,,0.0,,
20709368,2199,D020246,rs2066865,Association,FALSE,"A functional single nucleotide polymorphism (SNP) in the 3' untranslated region of the FGG gene (FGG <ENT2>10034C>T</ENT2>, <ENT2>rs2066865</ENT2>) has been associated with <ENT1>deep venous thrombosis</ENT1> and myocardial infarction.",,,,T,,,,,c,,,,,0.0,,
20709368,2201,D020246,2266,Association,FALSE,"A functional single nucleotide polymorphism (SNP) in the 3' untranslated region of the <ENT2>FGG</ENT2> gene (<ENT2>FGG</ENT2> 10034C>T, rs2066865) has been associated with <ENT1>deep venous thrombosis</ENT1> and myocardial infarction.",,,,T,,,,,c,,,,,0.5,,
20709368,2198,rs2066865,D009203,Association,FALSE,"A functional single nucleotide polymorphism (SNP) in the 3' untranslated region of the FGG gene (FGG <ENT1>10034C>T</ENT1>, <ENT1>rs2066865</ENT1>) has been associated with deep venous thrombosis and <ENT2>myocardial infarction</ENT2>.",,,,T,,,,,c,,,,,0.0,,
20709368,2200,D009203,2266,Association,FALSE,"A functional single nucleotide polymorphism (SNP) in the 3' untranslated region of the <ENT2>FGG</ENT2> gene (<ENT2>FGG</ENT2> 10034C>T, rs2066865) has been associated with deep venous thrombosis and <ENT1>myocardial infarction</ENT1>.",,,,T,,,,,c,,,,,1.0,,
20722491,2211,D060831,D000069287,Positive_Correlation,FALSE,"The most commonly reported toxic effects of <ENT2>capecitabine</ENT2> are diarrhea, nausea, vomiting, stomatitis and <ENT1>hand-foot syndrome</ENT1>.",,,,T,,,,,c,,,,,1.0,,
20722491,2212,D013280,D000069287,Positive_Correlation,FALSE,"The most commonly reported toxic effects of <ENT2>capecitabine</ENT2> are diarrhea, nausea, vomiting, <ENT1>stomatitis</ENT1> and hand-foot syndrome.",,,,T,,,,,c,,,,,1.0,,
20722491;20722491,2209;2210,D000069287;D000069287,D008107;D007674,Association;Association,TRUE;TRUE,"<ENT1>Capecitabine</ENT1> has a well-established safety profile and can be given safely to patients with advanced age, <ENT2>hepatic and renal dysfunctions</ENT2>.",,,,T,,,,,c,,,,,1.0,,
20722491,2215,D000069287,D003967,Positive_Correlation,FALSE,"The most commonly reported toxic effects of <ENT1>capecitabine</ENT1> are <ENT2>diarrhea</ENT2>, nausea, vomiting, stomatitis and hand-foot syndrome.",,,,T,,,,,c,,,,,1.0,,
20722491,2214,D000069287,D009325,Positive_Correlation,FALSE,"The most commonly reported toxic effects of <ENT1>capecitabine</ENT1> are diarrhea, <ENT2>nausea</ENT2>, vomiting, stomatitis and hand-foot syndrome.",,,,T,,,,,c,,,,,1.0,,
20722491,2213,D000069287,D014839,Positive_Correlation,FALSE,"The most commonly reported toxic effects of <ENT1>capecitabine</ENT1> are diarrhea, nausea, <ENT2>vomiting</ENT2>, stomatitis and hand-foot syndrome.",,,,T,,,,,c,,,,,1.0,,
20722491,2210,D000069287,D007674,Association,TRUE,"WHAT THE READER WILL GAIN: The reader will gain better insight into the safety of <ENT1>capecitabine</ENT1> in special populations such as patients with advanced age, <ENT2>renal and kidney disease</ENT2>.",,,,T,,,,,c,,,,,1.0,,
20722491,2205,D015179,D005472,Negative_Correlation,FALSE,"IMPORTANCE OF THE FIELD: Fluoropyrimidines, in particular <ENT2>5-fluorouracil</ENT2> (<ENT2>5-FU</ENT2>), have been the mainstay of treatment for several solid tumors, including <ENT1>colorectal, breast and head and neck cancers</ENT1>, for > 40 years.",,,,T,,,,,w,,,,,1.0,,
20722491,2208,D005472,D009369,Negative_Correlation,FALSE,"IMPORTANCE OF THE FIELD: Fluoropyrimidines, in particular <ENT1>5-fluorouracil</ENT1> (<ENT1>5-FU</ENT1>), have been the mainstay of treatment for several solid <ENT2>tumors</ENT2>, including colorectal, breast and head and neck cancers, for > 40 years.",,,,T,,,,,w,,,,,0.5,,
20801104,2227,D012559,1815,Association,TRUE,"Association study of polymorphisms in the promoter region of <ENT2>DRD4</ENT2> with <ENT1>schizophrenia</ENT1>, depression, and heroin addiction.",,,,T,,T,,,c,,,,,0.0,,
20801104,2227,D012559,1815,Association,TRUE,"This study investigated the possible association between three functional polymorphisms in the promoter region of the <ENT2>dopamine D4 receptor</ENT2> (<ENT2>DRD4</ENT2>) gene and <ENT1>schizophrenia</ENT1>, depression, and heroin addiction.",,,,T,,Y,,,w,,,,,1.0,TRUE,
20801104,2227,D012559,1815,Association,TRUE,These observations strongly suggest that the -120-bp duplication polymorphism of <ENT2>DRD4</ENT2> is associated with <ENT1>schizophrenia</ENT1> and that the -521 C/T polymorphism is associated with heroin addiction.,,,,T,,,,,c,,,,,1.0,,
20801104,2224,D012559,c|DUP|-120||,Positive_Correlation,TRUE,Results of this analysis indicated that there is a strong finding of <ENT2>-120 bp duplication</ENT2> allele frequencies with <ENT1>schizophrenia</ENT1> (p=0.008) and weak finding with -1240 L/S and for paranoid schizophrenia (p=0.022).,,,,T,,,,,w,,,,,0.0,,
20801104,2224,D012559,c|DUP|-120||,Positive_Correlation,TRUE,These observations strongly suggest that the <ENT2>-120-bp duplication</ENT2> polymorphism of DRD4 is associated with <ENT1>schizophrenia</ENT1> and that the -521 C/T polymorphism is associated with heroin addiction.,,,,T,,,,,c,,,,,1.0,,
20801104,2222,rs1800955,D006556,Positive_Correlation,TRUE,"Interestingly, there is a stronger finding with <ENT1>-521 C/T</ENT1> allele frequencies with <ENT2>heroin dependence</ENT2> (p=0.0002).",,,,T,,,,,w,,,,,0.0,,
20801104,2222,rs1800955,D006556,Positive_Correlation,TRUE,These observations strongly suggest that the -120-bp duplication polymorphism of DRD4 is associated with schizophrenia and that the <ENT1>-521 C/T</ENT1> polymorphism is associated with <ENT2>heroin addiction</ENT2>.,,,,T,,,,,c,,,,,0.0,,
20801104,2223,p|SUB|L|-1240|S,D012563,Positive_Correlation,TRUE,Results of this analysis indicated that there is a strong finding of -120 bp duplication allele frequencies with schizophrenia (p=0.008) and weak finding with <ENT1>-1240 L/S</ENT1> and for <ENT2>paranoid schizophrenia</ENT2> (p=0.022).,,,,T,,,,,w,,,,,0.0,,
20801104,2225,D006556,1815,Association,TRUE,"Association study of polymorphisms in the promoter region of <ENT2>DRD4</ENT2> with schizophrenia, depression, and <ENT1>heroin addiction</ENT1>.",,,,T,,T,,,c,,,,,0.0,,
20801104,2225,D006556,1815,Association,TRUE,"This study investigated the possible association between three functional polymorphisms in the promoter region of the <ENT2>dopamine D4 receptor</ENT2> (<ENT2>DRD4</ENT2>) gene and schizophrenia, depression, and <ENT1>heroin addiction</ENT1>.",,,,T,,Y,,,w,,,,,1.0,TRUE,
20801104,2225,D006556,1815,Association,TRUE,These observations strongly suggest that the -120-bp duplication polymorphism of <ENT2>DRD4</ENT2> is associated with schizophrenia and that the -521 C/T polymorphism is associated with <ENT1>heroin addiction</ENT1>.,,,,T,,,,,w,,,,,1.0,,
20801540,2233,c|SUB|G|2554+1|T,C536004,Positive_Correlation,TRUE,"RESULTS: A novel homozygous ceruloplasmin gene mutation, <ENT1>c.2554+1G>T</ENT1>, was identified as the cause of <ENT2>aceruloplasminemia</ENT2> in three affected siblings.",,,,T,,,,,c,,,,,1.0,,
20801540,2238,C536004,57817,Association,TRUE,"<ENT1>Aceruloplasminemia</ENT1> was associated with severe brain and liver iron overload, where hepatic mRNA expression of the iron hormone <ENT2>hepcidin</ENT2> was increased, corresponding to the degree of iron overload.",,,,T,,,,,c,,,,,0.0,,
20801540,2238,C536004,57817,Association,TRUE,"Iron accumulation in <ENT1>aceruloplasminemia</ENT1> is a result of defective cellular iron export, where <ENT2>hepcidin</ENT2> regulation is appropriate for the degree of iron overload.",,,,T,,,,,c,,,,,1.0,,
20801540,2239,C536004,D007501,Positive_Correlation,TRUE,Hepatic but not brain <ENT2>iron</ENT2> is rapidly chelated by deferasirox in <ENT1>aceruloplasminemia</ENT1> due to a novel gene mutation.,,,,T,,T,,,w,,,,,1.0,,
20801540,2239,C536004,D007501,Positive_Correlation,TRUE,"BACKGROUND _#38; AIMS: <ENT1>Aceruloplasminemia</ENT1> is a rare autosomal recessive neurodegenerative disease associated with brain and liver <ENT2>iron</ENT2> accumulation which typically presents with movement disorders, retinal degeneration, and diabetes mellitus.",,,,T,,,,,c,,,,,1.0,,
20801540,2239,C536004,D007501,Positive_Correlation,TRUE,"<ENT1>Aceruloplasminemia</ENT1> was associated with severe brain and liver iron overload, where hepatic mRNA expression of the <ENT2>iron</ENT2> hormone hepcidin was increased, corresponding to the degree of iron overload.",,,,T,,,,,w,,,,,0.0,,
20801540,2239,C536004,D007501,Positive_Correlation,TRUE,CONCLUSIONS: <ENT1>Aceruloplasminemia</ENT1> can show an incomplete clinical penetrance but is invariably associated with <ENT2>iron</ENT2> accumulation in the liver and in the brain.,,,,T,,,,,c,,,,,1.0,,
20801540,2239,C536004,D007501,Positive_Correlation,TRUE,"<ENT2>Iron</ENT2> accumulation in <ENT1>aceruloplasminemia</ENT1> is a result of defective cellular <ENT2>iron</ENT2> export, where hepcidin regulation is appropriate for the degree of iron overload.",,,,T,,,,,w,,,,,0.5,,
20801540,2241,C536004,D000077588,Negative_Correlation,TRUE,Hepatic but not brain iron is rapidly chelated by <ENT2>deferasirox</ENT2> in <ENT1>aceruloplasminemia</ENT1> due to a novel gene mutation.,,,,T,Y,T,,,w,,,,,1.0,,
20801540,2236,C536004,1356,Association,TRUE,"RESULTS: A novel homozygous <ENT2>ceruloplasmin</ENT2> gene mutation, c.2554+1G>T, was identified as the cause of <ENT1>aceruloplasminemia</ENT1> in three affected siblings.",,,,T,,,,,c,,,,,0.0,,
20801540,2243,D003920,D007501,Positive_Correlation,FALSE,"BACKGROUND _#38; AIMS: Aceruloplasminemia is a rare autosomal recessive neurodegenerative disease associated with brain and liver <ENT2>iron</ENT2> accumulation which typically presents with movement disorders, retinal degeneration, and <ENT1>diabetes mellitus</ENT1>.",,,,T,,,,,c,,,,,0.0,,
20801540,2228,57817,D019190,Negative_Correlation,TRUE,"Aceruloplasminemia was associated with severe brain and liver <ENT2>iron overload</ENT2>, where hepatic mRNA expression of the iron hormone <ENT1>hepcidin</ENT1> was increased, corresponding to the degree of <ENT2>iron overload</ENT2>.",,,,T,,,,,w,,,,,0.0,,
20801540,2228,57817,D019190,Negative_Correlation,TRUE,"Iron accumulation in aceruloplasminemia is a result of defective cellular iron export, where <ENT1>hepcidin</ENT1> regulation is appropriate for the degree of <ENT2>iron overload</ENT2>.",,,,T,,,,,w,,,,,0.0,,
20801540,2230,D007501,D019190,Positive_Correlation,FALSE,"Aceruloplasminemia was associated with severe brain and liver <ENT2>iron overload</ENT2>, where hepatic mRNA expression of the <ENT1>iron</ENT1> hormone hepcidin was increased, corresponding to the degree of <ENT2>iron overload</ENT2>.",,,,T,,,,,c,,,,,0.0,,
20801540,2230,D007501,D019190,Positive_Correlation,FALSE,"<ENT1>Iron</ENT1> accumulation in aceruloplasminemia is a result of defective cellular <ENT1>iron</ENT1> export, where hepcidin regulation is appropriate for the degree of <ENT2>iron overload</ENT2>.",,,,T,,,,,c,,,,,0.5,,
20801540,2244,D007501,D009069,Positive_Correlation,FALSE,"BACKGROUND _#38; AIMS: Aceruloplasminemia is a rare autosomal recessive neurodegenerative disease associated with brain and liver <ENT1>iron</ENT1> accumulation which typically presents with <ENT2>movement disorders</ENT2>, retinal degeneration, and diabetes mellitus.",,,,T,,,,,c,,,,,0.0,,
20801540,2246,D007501,D000077588,Bind,TRUE,Hepatic but not brain <ENT1>iron</ENT1> is rapidly chelated by <ENT2>deferasirox</ENT2> in aceruloplasminemia due to a novel gene mutation.,,,,T,,T,,,c,,,,,0.0,,
20801540,2246,D007501,D000077588,Bind,TRUE,"Hepatic <ENT1>iron</ENT1> concentration normalized after 3 and 5months of <ENT1>iron</ENT1> chelation therapy with <ENT2>deferasirox</ENT2>, which was also associated with reduced insulin demands.",,,,T,,,,,c,,,,,0.0,,
20801540,2246,D007501,D000077588,Bind,TRUE,<ENT1>Iron</ENT1> chelation with <ENT2>deferasirox</ENT2> was effective in mobilizing hepatic <ENT1>iron</ENT1> but has no effect on brain <ENT1>iron</ENT1>.,,,,T,,,,,c,,,,,0.0,,
20801540,2242,D007501,D012162,Positive_Correlation,FALSE,"BACKGROUND _#38; AIMS: Aceruloplasminemia is a rare autosomal recessive neurodegenerative disease associated with brain and liver <ENT1>iron</ENT1> accumulation which typically presents with movement disorders, <ENT2>retinal degeneration</ENT2>, and diabetes mellitus.",,,,T,,,,,c,,,,,0.0,,
20801540,2237,D007501,1356,Association,FALSE,<ENT2>Ceruloplasmin</ENT2> is a multi-copper ferroxidase that is secreted into plasma and facilitates cellular <ENT1>iron</ENT1> export and <ENT1>iron</ENT1> binding to transferrin.,,,,T,,,,,c,,,,,0.0,,
20801540,2245,D007501,7018,Bind,FALSE,Ceruloplasmin is a multi-copper ferroxidase that is secreted into plasma and facilitates cellular <ENT1>iron</ENT1> export and <ENT1>iron</ENT1> binding to <ENT2>transferrin</ENT2>.,,,,T,,,,,c,,,,,0.5,,
20801540,2240,D000077588,3630,Negative_Correlation,TRUE,"Hepatic iron concentration normalized after 3 and 5months of iron chelation therapy with <ENT1>deferasirox</ENT1>, which was also associated with reduced <ENT2>insulin</ENT2> demands.",,,,T,,,,,c,,,,,1.0,,
20828385,2249,C401859,7422,Negative_Correlation,TRUE,"Apart from this cytostatic effect, <ENT1>temsirolimus</ENT1> had an antiangiogenic effect with decrease of tumor microvessel density and of <ENT2>VEGF</ENT2> expression.",,,,T,,,,,c,,,,,1.0,,
20828385,2251,C401859,D020522,Negative_Correlation,TRUE,Cytostatic and anti-angiogenic effects of <ENT1>temsirolimus</ENT1> in refractory <ENT2>mantle cell lymphoma</ENT2>.,,,,T,,T,,,w,,,,,1.0,,
20828385,2251,C401859,D020522,Negative_Correlation,TRUE,"However, a 38% remission rate has been recently reported in refractory <ENT2>MCL</ENT2> treated with <ENT1>temsirolimus</ENT1>, a mTOR inhibitor.Here we had the opportunity to study a case of refractory <ENT2>MCL</ENT2> who had tumor regression two months after <ENT1>temsirolimus</ENT1> treatment, and a progression-free survival of 10 months.",,,,T,,,,,c,,,"11,22",,1.0,,
20828385,2251,C401859,D020522,Negative_Correlation,TRUE,"Thus, <ENT1>temsirolimus</ENT1> reduced tumor burden through associated cytostatic and anti-angiogenic effects.This dual effect of <ENT1>temsirolimus</ENT1> on tumor tissue could contribute to its recently reported efficiency in refractory <ENT2>MCL</ENT2> resistant to conventional chemotherapy.",,,,T,,,,,w,,,,,1.0,,
20828385,2248,C401859,2475,Negative_Correlation,FALSE,"However, a 38% remission rate has been recently reported in refractory MCL treated with <ENT1>temsirolimus</ENT1>, a <ENT2>mTOR</ENT2> inhibitor.Here we had the opportunity to study a case of refractory MCL who had tumor regression two months after <ENT1>temsirolimus</ENT1> treatment, and a progression-free survival of 10 months.",,,,T,,,,,w,,,,,0.5,,
20828385,2250,C401859,D009369,Negative_Correlation,TRUE,"However, a 38% remission rate has been recently reported in refractory MCL treated with <ENT1>temsirolimus</ENT1>, a mTOR inhibitor.Here we had the opportunity to study a case of refractory MCL who had <ENT2>tumor</ENT2> regression two months after <ENT1>temsirolimus</ENT1> treatment, and a progression-free survival of 10 months.",,,,T,,,,,c,,,,,1.0,,
20828385,2250,C401859,D009369,Negative_Correlation,TRUE,"Comparison of the two biopsies showed that <ENT1>temsirolimus</ENT1> inhibited <ENT2>tumor</ENT2> cell proliferation through cell cycle arrest, but did not induce any change in the number of apoptotic <ENT2>tumor</ENT2> cells.",,,,T,,,,,w,,,,,0.5,,
20828385,2250,C401859,D009369,Negative_Correlation,TRUE,"Apart from this cytostatic effect, <ENT1>temsirolimus</ENT1> had an antiangiogenic effect with decrease of <ENT2>tumor</ENT2> microvessel density and of VEGF expression.",,,,T,,,,,c,,,,,0.0,,
20828385,2250,C401859,D009369,Negative_Correlation,TRUE,"Thus, <ENT1>temsirolimus</ENT1> reduced <ENT2>tumor</ENT2> burden through associated cytostatic and anti-angiogenic effects.This dual effect of <ENT1>temsirolimus</ENT1> on <ENT2>tumor</ENT2> tissue could contribute to its recently reported efficiency in refractory MCL resistant to conventional chemotherapy.",,,,T,,,,,c,,,"11,22",,0.75,,
20828385,2247,C401859,D009336,Negative_Correlation,TRUE,"Moreover, numerous patchy, well-limited fibrotic areas, compatible with post-<ENT2>necrotic</ENT2> tissue repair, were found after 6-month <ENT1>temsirolimus</ENT1> therapy.",,,,T,,,,,w,,,,,0.0,,
20846357,2255,C536168,2706,Association,TRUE,A novel mutation in the <ENT2>connexin 26</ENT2> gene (<ENT2>GJB2</ENT2>) in a child with clinical and histological features of <ENT1>keratitis-ichthyosis-deafness (KID) syndrome</ENT1>.,,,,T,,T,,,w,,,,,0.0,TRUE,
20846357,2255,C536168,2706,Association,TRUE,"BACKGROUND: <ENT1>Keratitis-ichthyosis-deafness (KID) syndrome</ENT1> is a rare congenital ectodermal disorder, caused by heterozygous missense mutation in <ENT2>GJB2</ENT2>, encoding the gap junction protein <ENT2>connexin 26</ENT2>.",,,,T,,,,,c,,,,,1.0,,
20846357,2255,C536168,2706,Association,TRUE,CONCLUSIONS: This study has identified a new heterozygous de novo mutation in the <ENT2>Cx26</ENT2> gene (c.263C>T; p.Ala88Val) leading to <ENT1>KID syndrome</ENT1>.,,,,T,,,,,c,,,,,1.0,,
20846357,2254,C536168,c|SUB|C|263|T,Positive_Correlation,TRUE,CONCLUSIONS: This study has identified a new heterozygous de novo mutation in the Cx26 gene (<ENT2>c.263C>T</ENT2>; p.Ala88Val) leading to <ENT1>KID syndrome</ENT1>.,,,,T,,,,,c,,,,,0.0,,
20846357,2253,C536168,p|SUB|A|88|V,Positive_Correlation,TRUE,CONCLUSIONS: This study has identified a new heterozygous de novo mutation in the Cx26 gene (c.263C>T; <ENT2>p.Ala88Val</ENT2>) leading to <ENT1>KID syndrome</ENT1>.,,,,T,,,,,c,,,,,0.0,,
20854438,2264,D014777,57152,Association,FALSE,"Among the family members, patients with the homozygous <ENT2>SLURP1</ENT2> (previously known as ARS component B) mutation are prone to melanoma and <ENT1>viral infection</ENT1>, which might link to defective T-cell function as well as a derangement of epidermal homeostasis.",,,,T,,,,,c,,,,,1.0,,
20854438,2266,57152,1137,Positive_Correlation,FALSE,<ENT1>SLURP-1</ENT1> is an allosteric agonist to the <ENT2>nicotinic acetylcholine receptor</ENT2> (<ENT2>nAchR</ENT2>) and it regulates epidermal homeostasis.,,,,T,,,,,c,,,,,1.0,,
20854438,2261,57152,D007645,Association,FALSE,<ENT1>SLURP1</ENT1> mutation-impaired T-cell activation in a family with <ENT2>mal de Meleda</ENT2>.,,,,T,,T,,,w,,,,,1.0,,
20854438,2261,57152,D007645,Association,FALSE,BACKGROUND: <ENT2>Mal de Meleda</ENT2> (<ENT2>MDM</ENT2>) is palmoplantar erythrokeratoderma with an autosomal recessive inheritance and is caused by a mutation in the gene encoding <ENT1>SLURP-1</ENT1> (<ENT1>lymphocyte antigen 6</ENT1>/<ENT1>urokinase-type plasminogen activator receptor related protein-1</ENT1>).,,,,T,,,,,c,,,"11,12,21,22,31,32",,0.666666667,,
20854438,2261,57152,D007645,Association,FALSE,OBJECTIVES: To investigate the association of the <ENT1>SLURP1</ENT1> gene mutation with T-cell activation in a Taiwanese family with <ENT2>MDM</ENT2>.,,,,T,,Y,,,w,,,,,0.0,,
20854438,2261,57152,D007645,Association,FALSE,"METHODS: Human peripheral blood mononuclear cells (PBMCs) were isolated from a Taiwanese <ENT2>MDM</ENT2> family bearing the G to A substitution in nucleotide 256 in the <ENT1>SLURP1</ENT1> gene, corresponding to a glycine to arginine substitution at amino acid 86 (G86R) in the <ENT1>SLURP-1</ENT1> protein.",,,,T,Y,,,,c,,,,,0.0,,
20854438,2261,57152,D007645,Association,FALSE,CONCLUSIONS: Patients with <ENT2>MDM</ENT2> with the homozygous <ENT1>SLURP-1</ENT1> G86R mutation may have an impaired T-cell activation.,,,,T,,,,,w,,,,,0.0,,
20854438,2265,57152,D008545,Association,FALSE,"Among the family members, patients with the homozygous <ENT1>SLURP1</ENT1> (previously known as ARS component B) mutation are prone to <ENT2>melanoma</ENT2> and viral infection, which might link to defective T-cell function as well as a derangement of epidermal homeostasis.",,,,T,,,,,c,,,,,1.0,,
20854438,2260,rs28937888,D007645,Positive_Correlation,FALSE,"METHODS: Human peripheral blood mononuclear cells (PBMCs) were isolated from a Taiwanese <ENT2>MDM</ENT2> family bearing the <ENT1>G to A substitution in nucleotide 256</ENT1> in the SLURP1 gene, corresponding to a <ENT1>glycine to arginine substitution at amino acid 86</ENT1> (<ENT1>G86R</ENT1>) in the SLURP-1 protein.",,,,T,,,,,c,,,,,0.0,,
20854438,2260,rs28937888,D007645,Positive_Correlation,FALSE,CONCLUSIONS: Patients with <ENT2>MDM</ENT2> with the homozygous SLURP-1 <ENT1>G86R</ENT1> mutation may have an impaired T-cell activation.,,,,T,,,,,w,,,,,1.0,,
20859899,2282,D013575,D013148,Positive_Correlation,TRUE,<ENT1>Syncope</ENT1> caused by hyperkalemia during use of a combined therapy with the angiotensin-converting enzyme inhibitor and <ENT2>spironolactone</ENT2>.,,,,T,Y,T,,,w,,,,,1.0,,
20859899,2283,D013575,D000806,Positive_Correlation,TRUE,<ENT1>Syncope</ENT1> caused by hyperkalemia during use of a combined therapy with the <ENT2>angiotensin-converting enzyme inhibitor</ENT2> and spironolactone.,,,,T,Y,T,,,w,,,,,0.0,,
20859899,2276,D013148,D000450,Negative_Correlation,FALSE,"The cause of hyperkalemia was considered to be several doses of <ENT1>spiranolactone</ENT1>, an <ENT2>aldosterone</ENT2> antagonist, in addition to the long-term intake of ramipril, an ACE inhibitor.",,,,T,,,,,c,,,,,1.0,,
20859899,2279,D013148,D006947,Negative_Correlation,TRUE,Syncope caused by <ENT2>hyperkalemia</ENT2> during use of a combined therapy with the angiotensin-converting enzyme inhibitor and <ENT1>spironolactone</ENT1>.,,,,T,,,,,w,,,,,1.0,,
20859899,2279,D013148,D006947,Negative_Correlation,TRUE,"The cause of <ENT2>hyperkalemia</ENT2> was considered to be several doses of <ENT1>spiranolactone</ENT1>, an aldosterone antagonist, in addition to the long-term intake of ramipril, an ACE inhibitor.",,,,T,,,,,w,,,,,1.0,,
20859899,2281,D013148,D000806,Cotreatment,TRUE,Syncope caused by hyperkalemia during use of a combined therapy with the <ENT2>angiotensin-converting enzyme inhibitor</ENT2> and <ENT1>spironolactone</ENT1>.,,,,T,,T,,,c,,,,,0.0,,
20859899,2268,D057911,D011188,Cotreatment,TRUE,"Clinicians should be alert to the possibility of hyperkalemia, especially in elderly patients using ACE/<ENT1>ARB</ENT1> in combination with <ENT2>potassium</ENT2> sparing agents and who have mild renal disturbance.",,,,T,,,,,c,,,,,0.0,,
20859899,2269,D057911,D006947,Association,TRUE,"Clinicians should be alert to the possibility of <ENT2>hyperkalemia</ENT2>, especially in elderly patients using ACE/<ENT1>ARB</ENT1> in combination with potassium sparing agents and who have mild renal disturbance.",,,,T,,,,,w,,,,,0.0,,
20859899,2273,D057911,1636,Cotreatment,TRUE,"Clinicians should be alert to the possibility of hyperkalemia, especially in elderly patients using <ENT2>ACE</ENT2>/<ENT1>ARB</ENT1> in combination with potassium sparing agents and who have mild renal disturbance.",,,,T,,,,,w,,,,,0.0,,
20859899,2267,D057911,D007674,Association,TRUE,"Clinicians should be alert to the possibility of hyperkalemia, especially in elderly patients using ACE/<ENT1>ARB</ENT1> in combination with potassium sparing agents and who have mild <ENT2>renal disturbance</ENT2>.",,,,T,,,,,c,,,,,1.0,,
20859899,2271,D011188,D006947,Positive_Correlation,TRUE,"Clinicians should be alert to the possibility of <ENT2>hyperkalemia</ENT2>, especially in elderly patients using ACE/ARB in combination with <ENT1>potassium</ENT1> sparing agents and who have mild renal disturbance.",,,,T,,,,,w,,,,,0.0,,
20859899,2274,D011188,1636,Cotreatment,TRUE,"Clinicians should be alert to the possibility of hyperkalemia, especially in elderly patients using <ENT2>ACE</ENT2>/ARB in combination with <ENT1>potassium</ENT1> sparing agents and who have mild renal disturbance.",,,,T,,,,,c,,,,,0.0,,
20859899,2270,D011188,D007674,Association,TRUE,"Clinicians should be alert to the possibility of hyperkalemia, especially in elderly patients using ACE/ARB in combination with <ENT1>potassium</ENT1> sparing agents and who have mild <ENT2>renal disturbance</ENT2>.",,,,T,,,,,c,,,,,1.0,,
20859899,2278,D017257,D006947,Positive_Correlation,TRUE,"The cause of <ENT2>hyperkalemia</ENT2> was considered to be several doses of spiranolactone, an aldosterone antagonist, in addition to the long-term intake of <ENT1>ramipril</ENT1>, an ACE inhibitor.",,,,T,,,,,c,,,,,1.0,,
20859899,2277,D017257,1636,Negative_Correlation,FALSE,"The cause of hyperkalemia was considered to be several doses of spiranolactone, an aldosterone antagonist, in addition to the long-term intake of <ENT1>ramipril</ENT1>, an <ENT2>ACE</ENT2> inhibitor.",,,,T,,,,,c,,,,,1.0,,
20859899,2275,D006947,1636,Association,TRUE,"The cause of <ENT1>hyperkalemia</ENT1> was considered to be several doses of spiranolactone, an aldosterone antagonist, in addition to the long-term intake of ramipril, an <ENT2>ACE</ENT2> inhibitor.",,,,T,Y,,,,c,,,,,0.0,,
20859899,2275,D006947,1636,Association,TRUE,"Clinicians should be alert to the possibility of <ENT1>hyperkalemia</ENT1>, especially in elderly patients using <ENT2>ACE</ENT2>/ARB in combination with potassium sparing agents and who have mild renal disturbance.",,,,T,,,,,w,,,,,0.0,,
20859899,2280,D006947,D000806,Negative_Correlation,TRUE,Syncope caused by <ENT1>hyperkalemia</ENT1> during use of a combined therapy with the <ENT2>angiotensin-converting enzyme inhibitor</ENT2> and spironolactone.,,,,T,,,,,w,,,,,0.0,,
20859899,2272,1636,D007674,Association,TRUE,"Clinicians should be alert to the possibility of hyperkalemia, especially in elderly patients using <ENT1>ACE</ENT1>/ARB in combination with potassium sparing agents and who have mild <ENT2>renal disturbance</ENT2>.",,,,T,,,,,c,,,,,1.0,,
20949073,2285,D003550,rs397508387,Association,TRUE,We identified such a mechanism as the origin of the mild to asymptomatic phenotype observed in <ENT1>cystic fibrosis</ENT1> patients homozygous for the <ENT2>E831X</ENT2> mutation (<ENT2>2623G>T</ENT2>) in the CFTR gene.,,,,T,,,,,c,,,,,0.0,,
20949073,2284,D003550,1080,Association,FALSE,We identified such a mechanism as the origin of the mild to asymptomatic phenotype observed in <ENT1>cystic fibrosis</ENT1> patients homozygous for the E831X mutation (2623G>T) in the <ENT2>CFTR</ENT2> gene.,,,,T,,,,,c,,,,,1.0,,
20959502,2290,D017576,D009395,Negative_Correlation,FALSE,DISCUSSION: <ENT1>Daptomycin</ENT1> was initiated in our patient secondary to possible nafcillin-induced acute <ENT2>interstitial nephritis</ENT2> and relapsing bacteremia.,,,,T,,,,,w,,,,,1.0,,
20959502,2291,D017576,D016470,Negative_Correlation,TRUE,OBJECTIVE: To report a case of methicillin-sensitive Staphylococcus aureus (MSSA) <ENT2>bacteremia</ENT2> with suspected MSSA meningitis treated with high-dose <ENT1>daptomycin</ENT1> assessed with concurrent serum and cerebrospinal fluid (CSF) concentrations.,,,,T,,,,,c,,,,,1.0,,
20959502,2291,D017576,D016470,Negative_Correlation,TRUE,DISCUSSION: <ENT1>Daptomycin</ENT1> was initiated in our patient secondary to possible nafcillin-induced acute interstitial nephritis and relapsing <ENT2>bacteremia</ENT2>.,,,,T,,,,,w,,,,,0.0,,
20959502,2291,D017576,D016470,Negative_Correlation,TRUE,CONCLUSIONS: High-dose <ENT1>daptomycin</ENT1> may be an alternative option for MSSA <ENT2>bacteremia</ENT2> with or without a CNS source in patients who have failed or cannot tolerate standard therapy.,,,,T,,,,,w,,,,,0.0,,
20959502,2292,D017576,D008581,Negative_Correlation,TRUE,Cerebrospinal fluid penetration of high-dose <ENT1>daptomycin</ENT1> in suspected Staphylococcus aureus <ENT2>meningitis</ENT2>.,,,,T,,,,,c,,,,,0.0,,
20959502,2292,D017576,D008581,Negative_Correlation,TRUE,OBJECTIVE: To report a case of methicillin-sensitive Staphylococcus aureus (MSSA) bacteremia with suspected MSSA <ENT2>meningitis</ENT2> treated with high-dose <ENT1>daptomycin</ENT1> assessed with concurrent serum and cerebrospinal fluid (CSF) concentrations.,,,,T,,,,,c,,,,,1.0,,
20959502,2292,D017576,D008581,Negative_Correlation,TRUE,Nafcillin was discontinued and <ENT1>daptomycin</ENT1> 9 mg/kg daily was initiated for suspected <ENT2>meningitis</ENT2> and was continued until the patient's death on day 16.,,,,T,,,,,w,,,,,0.0,,
20959502,2302,D014640,D064704,Cotreatment,FALSE,"Treatment was empirically initiated with <ENT1>vancomycin</ENT1>, <ENT2>levofloxacin</ENT2>, and piperacillin/tazobactam.",,,,T,,,,,c,,,,,0.0,,
20959502,2301,D014640,D000077725,Cotreatment,FALSE,"Treatment was empirically initiated with <ENT1>vancomycin</ENT1>, levofloxacin, and <ENT2>piperacillin/tazobactam</ENT2>.",,,,T,,,,,c,,,,,0.0,,
20959502,2293,D058186,D003404,Positive_Correlation,FALSE,"On day 8, the patient developed <ENT1>acute renal failure</ENT1> (serum <ENT2>creatinine</ENT2> 1.9 mg/dL, increased from 1.2 mg/dL the previous day and 0.8 mg/dL on admission).",,,,T,,,,,c,,,,,1.0,,
20959502,2289,D008712,D016470,Association,FALSE,OBJECTIVE: To report a case of <ENT1>methicillin</ENT1>-sensitive Staphylococcus aureus (MSSA) <ENT2>bacteremia</ENT2> with suspected MSSA meningitis treated with high-dose daptomycin assessed with concurrent serum and cerebrospinal fluid (CSF) concentrations.,,,,T,,,,,w,,,,,0.0,,
20959502,2287,D009395,D009254,Positive_Correlation,FALSE,DISCUSSION: Daptomycin was initiated in our patient secondary to possible <ENT2>nafcillin</ENT2>-induced acute <ENT1>interstitial nephritis</ENT1> and relapsing bacteremia.,,,,T,,,,,c,,,,,1.0,,
20959502,2288,D016470,D009254,Positive_Correlation,FALSE,DISCUSSION: Daptomycin was initiated in our patient secondary to possible <ENT2>nafcillin</ENT2>-induced acute interstitial nephritis and relapsing <ENT1>bacteremia</ENT1>.,,,,T,,,,,c,,,,,0.0,,
20959502,2300,D064704,D000077725,Cotreatment,FALSE,"Treatment was empirically initiated with vancomycin, <ENT1>levofloxacin</ENT1>, and <ENT2>piperacillin/tazobactam</ENT2>.",,,,T,,,,,c,,,,,0.0,,
20973483,2309,D004409,D012110,Positive_Correlation,FALSE,"Compound 1 is a potent A(2A)/A(1) receptor antagonist in vitro (A(2A) K(i) = 4.1 nM; A(1) K(i) = 17.0 nM) that has excellent activity, after oral administration, across a number of animal models of Parkinson's disease including mouse and rat models of haloperidol-induced catalepsy, mouse model of <ENT2>reserpine</ENT2>-induced <ENT1>akinesia</ENT1>, rat 6-hydroxydopamine (6-OHDA) lesion model of drug-induced rotation, and MPTP-treated non-human primate model.",,,,T,,,,,c,,,,,1.0,,
20973483,2303,D006220,D002375,Positive_Correlation,FALSE,"Compound 1 is a potent A(2A)/A(1) receptor antagonist in vitro (A(2A) K(i) = 4.1 nM; A(1) K(i) = 17.0 nM) that has excellent activity, after oral administration, across a number of animal models of Parkinson's disease including mouse and rat models of <ENT1>haloperidol</ENT1>-induced <ENT2>catalepsy</ENT2>, mouse model of reserpine-induced akinesia, rat 6-hydroxydopamine (6-OHDA) lesion model of drug-induced rotation, and MPTP-treated non-human primate model.",,,,T,,,,,c,,,,,1.0,,
20973483,2305,D006220,D010300,Association,FALSE,"Compound 1 is a potent A(2A)/A(1) receptor antagonist in vitro (A(2A) K(i) = 4.1 nM; A(1) K(i) = 17.0 nM) that has excellent activity, after oral administration, across a number of animal models of <ENT2>Parkinson's disease</ENT2> including mouse and rat models of <ENT1>haloperidol</ENT1>-induced catalepsy, mouse model of reserpine-induced akinesia, rat 6-hydroxydopamine (6-OHDA) lesion model of drug-induced rotation, and MPTP-treated non-human primate model.",,,,T,Y,,,,c,,,,,0.0,,
20973483,2308,D012110,D010300,Association,FALSE,"Compound 1 is a potent A(2A)/A(1) receptor antagonist in vitro (A(2A) K(i) = 4.1 nM; A(1) K(i) = 17.0 nM) that has excellent activity, after oral administration, across a number of animal models of <ENT2>Parkinson's disease</ENT2> including mouse and rat models of haloperidol-induced catalepsy, mouse model of <ENT1>reserpine</ENT1>-induced akinesia, rat 6-hydroxydopamine (6-OHDA) lesion model of drug-induced rotation, and MPTP-treated non-human primate model.",,,,T,Y,,,,c,,,,,0.0,,
20973483,2306,D015632,D010300,Association,FALSE,"Compound 1 is a potent A(2A)/A(1) receptor antagonist in vitro (A(2A) K(i) = 4.1 nM; A(1) K(i) = 17.0 nM) that has excellent activity, after oral administration, across a number of animal models of <ENT2>Parkinson's disease</ENT2> including mouse and rat models of haloperidol-induced catalepsy, mouse model of reserpine-induced akinesia, rat 6-hydroxydopamine (6-OHDA) lesion model of drug-induced rotation, and <ENT1>MPTP</ENT1>-treated non-human primate model.",,,,T,Y,,,,c,,,,,0.0,,
20973483,2304,D058915,D010300,Association,FALSE,In vivo characterization of a dual <ENT1>adenosine A2A/A1 receptor antagonist</ENT1> in animal models of <ENT2>Parkinson's disease</ENT2>.,,,,T,,T,,,c,,,,,1.0,,
20973483,2304,D058915,D010300,Association,FALSE,The in vivo characterization of a dual <ENT1>adenosine A(2A)/A(1) receptor antagonist</ENT1> in several animal models of <ENT2>Parkinson's disease</ENT2> is described.,,,,T,,Y,,,c,,,,,0.0,,
20973483,2304,D058915,D010300,Association,FALSE,"Compound 1 is a potent <ENT1>A(2A)/A(1) receptor antagonist</ENT1> in vitro (A(2A) K(i) = 4.1 nM; A(1) K(i) = 17.0 nM) that has excellent activity, after oral administration, across a number of animal models of <ENT2>Parkinson's disease</ENT2> including mouse and rat models of haloperidol-induced catalepsy, mouse model of reserpine-induced akinesia, rat 6-hydroxydopamine (6-OHDA) lesion model of drug-induced rotation, and MPTP-treated non-human primate model.",,,,T,,,,,w,,,,,0.0,,
20973483,2307,D016627,D010300,Association,FALSE,"Compound 1 is a potent A(2A)/A(1) receptor antagonist in vitro (A(2A) K(i) = 4.1 nM; A(1) K(i) = 17.0 nM) that has excellent activity, after oral administration, across a number of animal models of <ENT2>Parkinson's disease</ENT2> including mouse and rat models of haloperidol-induced catalepsy, mouse model of reserpine-induced akinesia, rat <ENT1>6-hydroxydopamine</ENT1> (<ENT1>6-OHDA</ENT1>) lesion model of drug-induced rotation, and MPTP-treated non-human primate model.",,,,T,Y,,,,c,,,,,0.0,,
21042587,2328,4306,2908,Association,TRUE,<ENT2>GR</ENT2> haploinsufficiency leads to hypertension due to illicit occupation of renal <ENT1>mineralocorticoid receptor</ENT1> by elevated cortisol rather than to increased mineralocorticoid production reported in primary glucocorticoid resistance.,,,,T,,,,,c,,,,,1.0,,
21042587,2312,4306,D006854,Association,TRUE,GR haploinsufficiency leads to hypertension due to illicit occupation of renal <ENT1>mineralocorticoid receptor</ENT1> by elevated <ENT2>cortisol</ENT2> rather than to increased mineralocorticoid production reported in primary glucocorticoid resistance.,,,,T,,,,,w,,,,,0.0,,
21042587,2318,4306,D006973,Association,TRUE,GR haploinsufficiency leads to <ENT2>hypertension</ENT2> due to illicit occupation of renal <ENT1>mineralocorticoid receptor</ENT1> by elevated cortisol rather than to increased mineralocorticoid production reported in primary glucocorticoid resistance.,,,,T,,,,,c,,,,,0.0,,
21042587,2330,2289,2908,Positive_Correlation,TRUE,"This reduced <ENT2>GR</ENT2> expression leads to a significantly below-normal induction of glucocorticoid-induced target genes, <ENT1>FKBP5</ENT1> in fibroblasts.",,,,T,,,,,c,,,,,0.0,,
21042587,2315,2289,D005938,Positive_Correlation,FALSE,"This reduced GR expression leads to a significantly below-normal induction of <ENT2>glucocorticoid</ENT2>-induced target genes, <ENT1>FKBP5</ENT1> in fibroblasts.",,,,T,,,,,c,,,,,1.0,,
21042587,2326,C564221,2908,Association,FALSE,"Primary <ENT1>glucocorticoid resistance</ENT1> (OMIM 138040) is a rare hereditary disease that causes a generalized partial insensitivity to glucocorticoid action, due to genetic alterations of the <ENT2>glucocorticoid receptor</ENT2> (<ENT2>GR</ENT2>).",,,,T,,,,,c,,,,,0.5,,
21042587,2326,C564221,2908,Association,FALSE,<ENT2>GR</ENT2> haploinsufficiency leads to hypertension due to illicit occupation of renal mineralocorticoid receptor by elevated cortisol rather than to increased mineralocorticoid production reported in primary <ENT1>glucocorticoid resistance</ENT1>.,,,,T,,,,,w,,,,,1.0,,
21042587,2310,C564221,D005938,Association,FALSE,"Primary <ENT1>glucocorticoid resistance</ENT1> (OMIM 138040) is a rare hereditary disease that causes a generalized partial insensitivity to <ENT2>glucocorticoid</ENT2> action, due to genetic alterations of the glucocorticoid receptor (GR).",,,,T,,,,,c,,,,,1.0,,
21042587,2325,D013761,C537422,Association,TRUE,"Indeed, <ENT2>apparent mineralocorticoid excess</ENT2> was demonstrated by a decrease in urinary <ENT1>tetrahydrocortisone</ENT1>-tetrahydrocortisol ratio in affected patients, revealing reduced glucocorticoid degradation by renal activity of the 11b-hydroxysteroid dehydrogenase type 2, a GR regulated gene.",,,,T,,,,,c,,,,,1.0,,
21042587,2329,2908,D005938,Bind,TRUE,"Primary glucocorticoid resistance (OMIM 138040) is a rare hereditary disease that causes a generalized partial insensitivity to <ENT2>glucocorticoid</ENT2> action, due to genetic alterations of the <ENT1>glucocorticoid receptor</ENT1> (<ENT1>GR</ENT1>).",,,,T,,,,,w,,,,,0.0,,
21042587,2329,2908,D005938,Bind,TRUE,"This reduced <ENT1>GR</ENT1> expression leads to a significantly below-normal induction of <ENT2>glucocorticoid</ENT2>-induced target genes, FKBP5 in fibroblasts.",,,,T,,,,,c,,,,,1.0,,
21042587,2329,2908,D005938,Bind,TRUE,We demonstrated that the molecular mechanisms of <ENT2>glucocorticoid</ENT2> signaling dysfunction involved <ENT1>GR</ENT1> haploinsufficiency due to the selective degradation of the mutated <ENT1>GR</ENT1> transcript through a nonsense-mediated mRNA Decay that was experimentally validated on emetine-treated propositus' fibroblasts.,,,,T,,,,,w,,,,,0.0,,
21042587,2329,2908,D005938,Bind,TRUE,"Indeed, apparent mineralocorticoid excess was demonstrated by a decrease in urinary tetrahydrocortisone-tetrahydrocortisol ratio in affected patients, revealing reduced <ENT2>glucocorticoid</ENT2> degradation by renal activity of the 11b-hydroxysteroid dehydrogenase type 2, a <ENT1>GR</ENT1> regulated gene.",,,,T,,,,,c,,,,,1.0,,
21042587,2329,2908,D005938,Bind,TRUE,"We propose thus that <ENT1>GR</ENT1> haploinsufficiency compromises <ENT2>glucocorticoid</ENT2> sensitivity and may represent a novel genetic cause of subclinical hypercortisolism, incidentally revealed bilateral adrenal hyperplasia and mineralocorticoid-independent hypertension.",,,,T,,,,,w,,,,,0.0,,
21042587,2336,2908,C537422,Association,TRUE,"Familial <ENT1>glucocorticoid receptor</ENT1> haploinsufficiency by non-sense mediated mRNA decay, adrenal hyperplasia and <ENT2>apparent mineralocorticoid excess</ENT2>.",,,,T,,T,,,w,,,,,1.0,,
21042587,2336,2908,C537422,Association,TRUE,"Indeed, <ENT2>apparent mineralocorticoid excess</ENT2> was demonstrated by a decrease in urinary tetrahydrocortisone-tetrahydrocortisol ratio in affected patients, revealing reduced glucocorticoid degradation by renal activity of the 11b-hydroxysteroid dehydrogenase type 2, a <ENT1>GR</ENT1> regulated gene.",,,,T,Y,,,,c,,,,,0.0,,
21042587,2331,2908,D000312,Association,TRUE,"Familial <ENT1>glucocorticoid receptor</ENT1> haploinsufficiency by non-sense mediated mRNA decay, <ENT2>adrenal hyperplasia</ENT2> and apparent mineralocorticoid excess.",,,,T,,T,,,w,,,,,0.0,,
21042587,2331,2908,D000312,Association,TRUE,"We propose thus that <ENT1>GR</ENT1> haploinsufficiency compromises glucocorticoid sensitivity and may represent a novel genetic cause of subclinical hypercortisolism, incidentally revealed <ENT2>bilateral adrenal hyperplasia</ENT2> and mineralocorticoid-independent hypertension.",,,,T,,,,,c,,,,,1.0,,
21042587,2311,2908,3291,Association,FALSE,"Indeed, apparent mineralocorticoid excess was demonstrated by a decrease in urinary tetrahydrocortisone-tetrahydrocortisol ratio in affected patients, revealing reduced glucocorticoid degradation by renal activity of the <ENT2>11b-hydroxysteroid dehydrogenase type 2</ENT2>, a <ENT1>GR</ENT1> regulated gene.",,,,T,,,,,w,,,,,0.0,,
21042587,2327,2908,D003480,Association,TRUE,"We propose thus that <ENT1>GR</ENT1> haploinsufficiency compromises glucocorticoid sensitivity and may represent a novel genetic cause of subclinical <ENT2>hypercortisolism</ENT2>, incidentally revealed bilateral adrenal hyperplasia and mineralocorticoid-independent hypertension.",,,,T,,,,,c,,,,,0.0,,
21042587,2335,2908,D006973,Association,TRUE,<ENT1>GR</ENT1> haploinsufficiency leads to <ENT2>hypertension</ENT2> due to illicit occupation of renal mineralocorticoid receptor by elevated cortisol rather than to increased mineralocorticoid production reported in primary glucocorticoid resistance.,,,,T,,,,,c,,,,,1.0,,
21042587,2335,2908,D006973,Association,TRUE,"We propose thus that <ENT1>GR</ENT1> haploinsufficiency compromises glucocorticoid sensitivity and may represent a novel genetic cause of subclinical hypercortisolism, incidentally revealed bilateral adrenal hyperplasia and mineralocorticoid-independent <ENT2>hypertension</ENT2>.",,,,T,,,,,c,,,,,1.0,,
21042587,2317,D006854,D006973,Association,TRUE,GR haploinsufficiency leads to <ENT2>hypertension</ENT2> due to illicit occupation of renal mineralocorticoid receptor by elevated <ENT1>cortisol</ENT1> rather than to increased mineralocorticoid production reported in primary glucocorticoid resistance.,,,,T,,,,,c,,,,,0.0,,
21042587,2316,D005938,D000312,Association,TRUE,"We propose thus that GR haploinsufficiency compromises <ENT1>glucocorticoid</ENT1> sensitivity and may represent a novel genetic cause of subclinical hypercortisolism, incidentally revealed <ENT2>bilateral adrenal hyperplasia</ENT2> and mineralocorticoid-independent hypertension.",,,,T,,,,,c,,,,,1.0,,
21042587,2314,D005938,3291,Positive_Correlation,TRUE,"Indeed, apparent mineralocorticoid excess was demonstrated by a decrease in urinary tetrahydrocortisone-tetrahydrocortisol ratio in affected patients, revealing reduced <ENT1>glucocorticoid</ENT1> degradation by renal activity of the <ENT2>11b-hydroxysteroid dehydrogenase type 2</ENT2>, a GR regulated gene.",,,,T,,,,,w,,,,,1.0,,
21042587,2313,D005938,D003480,Association,TRUE,"We propose thus that GR haploinsufficiency compromises <ENT1>glucocorticoid</ENT1> sensitivity and may represent a novel genetic cause of subclinical <ENT2>hypercortisolism</ENT2>, incidentally revealed bilateral adrenal hyperplasia and mineralocorticoid-independent hypertension.",,,,T,,,,,c,,,,,0.0,,
21042587,2324,C537422,D013760,Association,TRUE,"Indeed, <ENT1>apparent mineralocorticoid excess</ENT1> was demonstrated by a decrease in urinary tetrahydrocortisone-<ENT2>tetrahydrocortisol</ENT2> ratio in affected patients, revealing reduced glucocorticoid degradation by renal activity of the 11b-hydroxysteroid dehydrogenase type 2, a GR regulated gene.",,,,T,,,,,c,,,,,1.0,,
21054465,2337,1558,D006973,Association,TRUE,Mutational analysis of <ENT1>CYP2C8</ENT1> in <ENT2>hypertensive</ENT2> patients using denaturing high performance liquid chromatography.,,,,T,,T,,,w,,,,,0.0,,
21054465,2337,1558,D006973,Association,TRUE,METHODS: DNA samples from 200 subjects (<ENT2>hypertensive</ENT2> patients and healthy controls) were screened for SNPs in <ENT1>CYP2C8</ENT1> using DHPLC.,,,,T,,Y,,,w,,,,,1.0,,
21054465,2337,1558,D006973,Association,TRUE,Genotypes and allelic frequencies of <ENT1>CYP2C8</ENT1> between the healthy controls and patients with <ENT2>hypertension</ENT2> were compared.,,,,T,,Y,,,w,,,,,1.0,,
21054465,2339,D006973,c|SUB|C|35322|T,Positive_Correlation,TRUE,A higher frequency of the <ENT2>C35322T</ENT2> SNP was observed among <ENT1>hypertensive</ENT1> patients than control subjects.,,,,T,,,,,c,,,,,1.0,,
21054465,2338,D006973,D016718,Association,FALSE,"<ENT2>Arachidonic acid</ENT2> metabolites such as epoxyeicosatrienenoic acids and hydroxyeicosatetrenoic acids, produced may have a role in <ENT1>hypertension</ENT1>.",,,,T,,,,,c,,,,,1.0,,
21054465,2341,D006973,c|SUB|C|35322|C,Association,TRUE,Having homozygous <ENT2>C35322C</ENT2> could be a protective factor for <ENT1>hypertension</ENT1>.,,,,T,,,,,c,,,,,0.0,,
21070631,2343,D009638,D004298,Conversion,FALSE,Dopamine b-hydroxylase (DBH) catalyses the conversion of <ENT2>dopamine</ENT2> to <ENT1>noradrenaline</ENT1>.,,,,T,,,,,c,,,,,0.0,,
21070631,2353,D009638,1621,Association,FALSE,<ENT2>Dopamine b-hydroxylase</ENT2> (<ENT2>DBH</ENT2>) catalyses the conversion of dopamine to <ENT1>noradrenaline</ENT1>.,,,,T,,,,,c,,,,,1.0,,
21070631,2344,D009638,D007249,Negative_Correlation,FALSE,"CONCLUSIONS: Extensive, previous evidence (reviewed here) indicates an important role for <ENT1>noradrenaline</ENT1> in the control of <ENT2>inflammation</ENT2> in the brain.",,,,T,,,,,c,,,,,0.0,,
21070631,2345,3569,D000544,Association,FALSE,"Interactions have been reported between the low-activity -1021T allele (rs1611115) of DBH and polymorphisms of the pro-inflammatory cytokine genes, IL1A and <ENT1>IL6</ENT1>, contributing to the risk of <ENT2>AD</ENT2>.",,,,T,,,,,c,,,,,1.0,,
21070631,2354,3569,1621,Association,FALSE,"Interactions have been reported between the low-activity -1021T allele (rs1611115) of <ENT2>DBH</ENT2> and polymorphisms of the pro-inflammatory cytokine genes, IL1A and <ENT1>IL6</ENT1>, contributing to the risk of AD.",,,,T,,,,,c,,,,,0.0,,
21070631,2354,3569,1621,Association,FALSE,"METHODS: We genotyped eight single nucleotide polymorphisms (SNPs) in the three genes, <ENT2>DBH</ENT2>, IL1A and <ENT1>IL6</ENT1>.",,,,T,,Y,,,c,,,,,1.0,,
21070631,2347,3569,D007249,Association,FALSE,"Interactions have been reported between the low-activity -1021T allele (rs1611115) of DBH and polymorphisms of the pro-<ENT2>inflammatory</ENT2> cytokine genes, IL1A and <ENT1>IL6</ENT1>, contributing to the risk of AD.",,,,T,,,,,w,,,,,1.0,,
21070631,2352,D004298,1621,Association,FALSE,<ENT2>Dopamine b-hydroxylase</ENT2> (<ENT2>DBH</ENT2>) catalyses the conversion of <ENT1>dopamine</ENT1> to noradrenaline.,,,,T,,,,,c,,,,,1.0,,
21070631,2346,D000544,3552,Association,FALSE,"Interactions have been reported between the low-activity -1021T allele (rs1611115) of DBH and polymorphisms of the pro-inflammatory cytokine genes, <ENT2>IL1A</ENT2> and IL6, contributing to the risk of <ENT1>AD</ENT1>.",,,,T,,,,,c,,,,,1.0,,
21070631,2357,D000544,1621,Association,TRUE,The <ENT2>dopamine b-hydroxylase</ENT2> -1021C/T polymorphism is associated with the risk of <ENT1>Alzheimer's disease</ENT1> in the Epistasis Project.,,,,T,,T,,,c,,,,,1.0,,
21070631,2357,D000544,1621,Association,TRUE,"Interactions have been reported between the low-activity -1021T allele (rs1611115) of <ENT2>DBH</ENT2> and polymorphisms of the pro-inflammatory cytokine genes, IL1A and IL6, contributing to the risk of <ENT1>AD</ENT1>.",,,,T,,,,,c,,,,,1.0,,
21070631,2357,D000544,1621,Association,TRUE,"We therefore examined the associations with <ENT1>AD</ENT1> of the <ENT2>DBH</ENT2> -1021T allele and of the above interactions in the Epistasis Project, with 1757 cases of <ENT1>AD</ENT1> and 6294 elderly controls.",,,,T,,Y,,,w,,,,,1.0,,
21070631,2350,D000544,rs1611115,Positive_Correlation,TRUE,The dopamine b-hydroxylase <ENT2>-1021C/T</ENT2> polymorphism is associated with the risk of <ENT1>Alzheimer's disease</ENT1> in the Epistasis Project.,,,,T,,,,,c,,,,,1.0,,
21070631,2350,D000544,rs1611115,Positive_Correlation,TRUE,"Interactions have been reported between the low-activity <ENT2>-1021T</ENT2> allele (<ENT2>rs1611115</ENT2>) of DBH and polymorphisms of the pro-inflammatory cytokine genes, IL1A and IL6, contributing to the risk of <ENT1>AD</ENT1>.",,,,T,,,,,w,,,,,1.0,,
21070631,2350,D000544,rs1611115,Positive_Correlation,TRUE,"We therefore examined the associations with <ENT1>AD</ENT1> of the DBH <ENT2>-1021T</ENT2> allele and of the above interactions in the Epistasis Project, with 1757 cases of <ENT1>AD</ENT1> and 6294 elderly controls.",,,,T,,,,,c,,,,,1.0,,
21070631,2350,D000544,rs1611115,Positive_Correlation,TRUE,"RESULTS: We found that the presence of the <ENT2>-1021T</ENT2> allele was associated with <ENT1>AD</ENT1>: odds ratio = 1.2 (95% confidence interval: 1.06-1.4, p = 0.005).",,,,T,,,,,c,,,,,0.0,,
21070631,2350,D000544,rs1611115,Positive_Correlation,TRUE,"Thus, the <ENT2>-1021T</ENT2> allele with presumed low activity may be associated with misregulation of inflammation, which could contribute to the onset of <ENT1>AD</ENT1>.",,,,T,,,,,w,,,,,1.0,,
21070631,2355,3552,1621,Association,TRUE,"Interactions have been reported between the low-activity -1021T allele (rs1611115) of <ENT2>DBH</ENT2> and polymorphisms of the pro-inflammatory cytokine genes, <ENT1>IL1A</ENT1> and IL6, contributing to the risk of AD.",,,,T,,,,,c,,,,,1.0,,
21070631,2355,3552,1621,Association,TRUE,"METHODS: We genotyped eight single nucleotide polymorphisms (SNPs) in the three genes, <ENT2>DBH</ENT2>, <ENT1>IL1A</ENT1> and IL6.",,,,T,,Y,,,c,,,,,1.0,,
21070631,2355,3552,1621,Association,TRUE,"We also found an interaction between the presence of <ENT2>DBH</ENT2> -1021T and the -889TT genotype (rs1800587) of <ENT1>IL1A</ENT1>: synergy factor = 1.9 (1.2-3.1, 0.005).",,,,T,,,,,c,,,,,1.0,,
21070631,2348,3552,D007249,Association,FALSE,"Interactions have been reported between the low-activity -1021T allele (rs1611115) of DBH and polymorphisms of the pro-<ENT2>inflammatory</ENT2> cytokine genes, <ENT1>IL1A</ENT1> and IL6, contributing to the risk of AD.",,,,T,,,,,w,,,,,1.0,,
21070631,2356,1621,D007249,Association,FALSE,"Interactions have been reported between the low-activity -1021T allele (rs1611115) of <ENT1>DBH</ENT1> and polymorphisms of the pro-<ENT2>inflammatory</ENT2> cytokine genes, IL1A and IL6, contributing to the risk of AD.",,,,T,,,,,c,,,,,1.0,,
21070631,2349,rs1611115,D007249,Association,FALSE,"Interactions have been reported between the low-activity <ENT1>-1021T</ENT1> allele (<ENT1>rs1611115</ENT1>) of DBH and polymorphisms of the pro-<ENT2>inflammatory</ENT2> cytokine genes, IL1A and IL6, contributing to the risk of AD.",,,,T,,,,,c,,,,,1.0,,
21070631,2349,rs1611115,D007249,Association,FALSE,"Thus, the <ENT1>-1021T</ENT1> allele with presumed low activity may be associated with misregulation of <ENT2>inflammation</ENT2>, which could contribute to the onset of AD.",,,,T,,,,,c,,,,,1.0,,
21080147,2371,78987,C562831,Association,TRUE,Novel <ENT1>CRELD1</ENT1> gene mutations in patients with <ENT2>atrioventricular septal defect</ENT2>.,,,,T,,T,,,w,,,,,0.0,,
21080147,2371,78987,C562831,Association,TRUE,"<ENT1>CRELD1</ENT1> gene, a novel cell adhesion molecule, is a candidate gene for <ENT2>AVSD</ENT2>.",,,,T,,,,,c,,,,,1.0,,
21080147,2371,78987,C562831,Association,TRUE,CONCLUSIONS: Two novel <ENT1>CRELD1</ENT1> mutations were identified in the calcium-binding EGF domain in patients with <ENT2>AVSD</ENT2>.,,,,T,,,,,c,,,,,1.0,,
21080147,2371,78987,C562831,Association,TRUE,<ENT1>CRELD1</ENT1> is likely to be an <ENT2>AVSD</ENT2>-susceptibility gene and <ENT1>CRELD1</ENT1> mutations may increase the risk of developing a heart defect rather than being a direct causative mutation.,,,,T,,,,,w,,,,,1.0,,
21080147,2369,78987,D002118,Association,TRUE,CONCLUSIONS: Two novel <ENT1>CRELD1</ENT1> mutations were identified in the <ENT2>calcium</ENT2>-binding EGF domain in patients with AVSD.,,,,T,,,,,c,,,,,0.0,,
21080147,2368,78987,1950,Association,TRUE,CONCLUSIONS: Two novel <ENT1>CRELD1</ENT1> mutations were identified in the calcium-binding <ENT2>EGF</ENT2> domain in patients with AVSD.,,,,T,,,,,c,,,,,0.0,,
21080147,2370,78987,D006331,Association,TRUE,<ENT1>CRELD1</ENT1> is likely to be an AVSD-susceptibility gene and <ENT1>CRELD1</ENT1> mutations may increase the risk of developing a <ENT2>heart defect</ENT2> rather than being a direct causative mutation.,,,,T,,,,,c,,,,,1.0,,
21080147,2358,C562831,1950,Association,FALSE,CONCLUSIONS: Two novel CRELD1 mutations were identified in the calcium-binding <ENT2>EGF</ENT2> domain in patients with <ENT1>AVSD</ENT1>.,,,,T,,,,,w,,,,,1.0,,
21080147,2359,D002118,1950,Bind,FALSE,"RESULTS: In a patient, a C-to-G transition was identified at nucleotide 857 in exon 8 that resulted in a substitution of alanine for proline at amino acid 286 in the first <ENT1>calcium</ENT1>-binding <ENT2>EGF</ENT2> domain.",,,,T,,,,,c,,,,,1.0,,
21080147,2359,D002118,1950,Bind,FALSE,The heterozygous c.973G>A transition in exon 9 resulted in a substitution of lysine for glutamic acid at amino acid 325 (E325K) in the second <ENT1>calcium</ENT1>-binding <ENT2>EGF</ENT2> domain.,,,,T,,,,,c,,,,,1.0,,
21080147,2359,D002118,1950,Bind,FALSE,CONCLUSIONS: Two novel CRELD1 mutations were identified in the <ENT1>calcium</ENT1>-binding <ENT2>EGF</ENT2> domain in patients with AVSD.,,,,T,,,,,c,,,,,1.0,,
21126715,2375,D008607,26580,Association,FALSE,"Mutations in the <ENT2>BSCL2</ENT2> gene are known to result in CGL2, a more severe phenotype than CGL1, with earlier onset, more extensive fat loss and biochemical changes, more severe <ENT1>intellectual impairment</ENT1>, and more severe cardiomyopathy.",,,,T,,,,,c,,,,,0.0,,
21126715,2378,D052497,p|FS|I|262||,Positive_Correlation,TRUE,A Taiwanese boy with <ENT1>congenital generalized lipodystrophy</ENT1> caused by homozygous <ENT2>Ile262fs</ENT2> mutation in the BSCL2 gene.,,,,T,,T,,,c,,,,,1.0,,
21126715,2377,D052497,26580,Association,TRUE,A Taiwanese boy with <ENT1>congenital generalized lipodystrophy</ENT1> caused by homozygous Ile262fs mutation in the <ENT2>BSCL2</ENT2> gene.,,,,T,,,,,c,,,,,1.0,,
21126715,2377,D052497,26580,Association,TRUE,"Mutations in the <ENT2>BSCL2</ENT2> gene are known to result in <ENT1>CGL2</ENT1>, a more severe phenotype than <ENT1>CGL1</ENT1>, with earlier onset, more extensive fat loss and biochemical changes, more severe intellectual impairment, and more severe cardiomyopathy.",,,,T,,,,,c,,,,,0.5,,
21126715,2377,D052497,26580,Association,TRUE,"We reviewed the genotype of <ENT1>CGL</ENT1> cases from Japan, India, China and Taiwan, and found that <ENT2>BSCL2</ENT2> is a major causative gene for <ENT1>CGL</ENT1> in Asian.",,,,T,,,,,c,,,,,1.0,,
21126715,2376,26580,D009202,Association,FALSE,"Mutations in the <ENT1>BSCL2</ENT1> gene are known to result in CGL2, a more severe phenotype than CGL1, with earlier onset, more extensive fat loss and biochemical changes, more severe intellectual impairment, and more severe <ENT2>cardiomyopathy</ENT2>.",,,,T,,,,,c,,,,,1.0,,
21130517,2383,D008175,1956,Association,FALSE,Detection of <ENT2>EGFR</ENT2> mutations in plasma DNA from <ENT1>lung cancer</ENT1> patients by mass spectrometry genotyping is predictive of tumor <ENT2>EGFR</ENT2> status and response to <ENT2>EGFR</ENT2> inhibitors.,,,,T,,T,,,c,,,,,0.666666667,,
21130517,2383,D008175,1956,Association,FALSE,AIMS: <ENT2>EGFR</ENT2> mutations now guide the clinical use of <ENT2>EGFR</ENT2>-targeted therapy in <ENT1>lung cancer</ENT1>.,,,,T,,,,,c,,,,,0.0,,
21130517,2383,D008175,1956,Association,FALSE,"In this study, we combined a mass spectrometry genotyping assay (Sequenom) with a mutant-enriched PCR (ME-PCR) to detect <ENT2>EGFR</ENT2> mutations in free plasma DNA from patients with <ENT1>lung cancer</ENT1>.",,,,T,,Y,,,w,,,,,0.0,,
21130517,2382,D000069347,1956,Association,TRUE,"For patients treated with <ENT1>erlotinib</ENT1>, overall survival was correlated with the presence of <ENT2>EGFR</ENT2> mutation in plasma and/or tumor tissue (p=0.002), with the two patients positive only in plasma DNA showing responses and favorable outcomes.",,,,T,,,,,c,,,,,0.0,,
21130517,2381,D000069347,D009369,Negative_Correlation,FALSE,"For patients treated with <ENT1>erlotinib</ENT1>, overall survival was correlated with the presence of EGFR mutation in plasma and/or <ENT2>tumor</ENT2> tissue (p=0.002), with the two patients positive only in plasma DNA showing responses and favorable outcomes.",,,,T,Y,,,,w,,,,,0.0,,
21130517,2379,rs121434568,D009369,Association,FALSE,"By mass spectrometry genotyping, the plasma samples contained mutant DNA corresponding to 5/14 EGFR Exon 19 deletions and 3/4 EGFR <ENT1>L858R</ENT1> mutations previously diagnosed in the matched <ENT2>tumors</ENT2>.",,,,T,,,,,c,,,,,0.0,,
21130517,2384,1956,D009369,Association,FALSE,Detection of <ENT1>EGFR</ENT1> mutations in plasma DNA from lung cancer patients by mass spectrometry genotyping is predictive of <ENT2>tumor</ENT2> <ENT1>EGFR</ENT1> status and response to <ENT1>EGFR</ENT1> inhibitors.,,,,T,,,,,c,,,,,0.333333333,,
21130517,2384,1956,D009369,Association,FALSE,"However, standard <ENT1>EGFR</ENT1> mutation analysis requires a minimum amount of <ENT2>tumor</ENT2> tissue, which may not be available in certain situations.",,,,T,,,,,c,,,,,0.0,,
21130517,2384,1956,D009369,Association,FALSE,Results in plasma DNA samples were compared with <ENT1>EGFR</ENT1> mutation status obtained in <ENT2>tumor</ENT2> DNA (18/31 <ENT1>EGFR</ENT1> mutant).,,,,T,Y,,,,c,,,,,0.0,,
21130517,2384,1956,D009369,Association,FALSE,The relationship of <ENT1>EGFR</ENT1> mutation status in <ENT2>tumor</ENT2> and/or plasma samples to overall survival was assessed.,,,,T,,Y,,,w,,,,,0.0,,
21130517,2384,1956,D009369,Association,FALSE,RESULTS: The <ENT1>EGFR</ENT1> mutation status in plasma DNA was identical to the primary <ENT2>tumor</ENT2> in 61% of patients (19/31).,,,,T,,,,,c,,,,,0.0,,
21130517,2384,1956,D009369,Association,FALSE,"By mass spectrometry genotyping, the plasma samples contained mutant DNA corresponding to 5/14 <ENT1>EGFR</ENT1> Exon 19 deletions and 3/4 <ENT1>EGFR</ENT1> L858R mutations previously diagnosed in the matched <ENT2>tumors</ENT2>.",,,,T,,,,,c,,,,,0.0,,
21130517,2384,1956,D009369,Association,FALSE,"For patients treated with erlotinib, overall survival was correlated with the presence of <ENT1>EGFR</ENT1> mutation in plasma and/or <ENT2>tumor</ENT2> tissue (p=0.002), with the two patients positive only in plasma DNA showing responses and favorable outcomes.",,,,T,,,,,c,,,,,0.0,,
21130517,2384,1956,D009369,Association,FALSE,A positive <ENT1>EGFR</ENT1> result in plasma DNA has a high predictive value for <ENT2>tumor</ENT2> <ENT1>EGFR</ENT1> status and for favorable clinical course on <ENT1>EGFR</ENT1>-targeted therapy and could therefore be useful in guiding clinical decisions in patients with insufficient or unavailable <ENT2>tumor</ENT2> specimens.,,,,T,,,,,c,,,,,0.166666667,,
21135151,2386,1234,D015658,Association,TRUE,"To clarify the role of <ENT1>CCR5</ENT1> host genetic background and disease progression on viral evolutionary patterns, we obtain gp120 envelope sequences from clonal HIV-1 variants isolated at multiple time points in the course of infection from populations of <ENT2>HIV-1-infected</ENT2> individuals who only harbored <ENT1>CCR5</ENT1>-using HIV-1 variants at all time points.",,,,T,,,,,c,,,,,0.0,,
21163864,2388,D002312,rs699,Positive_Correlation,TRUE,The <ENT2>M235T</ENT2> polymorphism of the angiotensinogen gene in South Indian patients of <ENT1>hypertrophic cardiomyopathy</ENT1>.,,,,T,,T,,,w,,,,,0.0,,
21163864,2388,D002312,rs699,Positive_Correlation,TRUE,The objective of the present study was to examine the association of the <ENT2>T704C</ENT2> polymorphism of exon 2 of the angiotensinogen (AGT) gene with <ENT1>HCM</ENT1> in a South Indian population from Andhra Pradesh.,,,,T,,Y,,,w,,,,,1.0,,
21163864,2387,D002312,183,Association,TRUE,The M235T polymorphism of the <ENT2>angiotensinogen</ENT2> gene in South Indian patients of <ENT1>hypertrophic cardiomyopathy</ENT1>.,,,,T,,T,,,c,,,,,1.0,,
21163864,2387,D002312,183,Association,TRUE,The objective of the present study was to examine the association of the T704C polymorphism of exon 2 of the <ENT2>angiotensinogen</ENT2> (<ENT2>AGT</ENT2>) gene with <ENT1>HCM</ENT1> in a South Indian population from Andhra Pradesh.,,,,T,,Y,,,w,,,,,0.0,TRUE,
21163864,2387,D002312,183,Association,TRUE,CONCLUSION: Our results suggest that the T allele of the <ENT2>AGT</ENT2> gene is significantly associated with <ENT1>SHCM</ENT1> in a South Indian population from Andhra Pradesh.,,,,T,,,,,c,,,,,1.0,,
21219851,2389,1281,D004535,Association,FALSE,"<ENT2>Ehlers-Danlos syndrome, vascular type</ENT2> (<ENT2>vEDS</ENT2>) (<ENT2>MIM #130050</ENT2>) is an autosomal dominant disorder caused by <ENT1>type III procollagen</ENT1> gene (<ENT1>COL3A1</ENT1>) mutations.",,,,T,,,,,c,,,"11,12,13,21,22,23",,1.0,,
21238926,2400,42297,35197,Association,TRUE,"Here, we identify <ENT2>Brain Tumor</ENT2> (<ENT2>Brat</ENT2>) as a potent differentiation factor and target of Pum-<ENT1>Nos</ENT1> regulation.",,,,T,,,,,c,,,,,1.0,,
21238926,2400,42297,35197,Association,TRUE,"<ENT2>Brat</ENT2> is excluded from GSCs by Pum-<ENT1>Nos</ENT1> but functions with Pum in CBs to translationally repress distinct targets, including the Mad and dMyc mRNAs.",,,,T,,,,,c,,,,,0.0,,
21238926,2399,35197,33529,Negative_Correlation,TRUE,"<ENT1>Brat</ENT1> is excluded from GSCs by Pum-Nos but functions with Pum in CBs to translationally repress distinct targets, including the <ENT2>Mad</ENT2> and dMyc mRNAs.",,,,T,,,,,c,,,,,1.0,,
21238926,2398,35197,31310,Negative_Correlation,TRUE,"<ENT1>Brat</ENT1> is excluded from GSCs by Pum-Nos but functions with Pum in CBs to translationally repress distinct targets, including the Mad and <ENT2>dMyc</ENT2> mRNAs.",,,,T,,,,,c,,,,,1.0,,
21238926,2397,35197,33432,Association,TRUE,<ENT1>Brat</ENT1> promotes stem cell differentiation via control of a bistable switch that restricts <ENT2>BMP</ENT2> signaling.,,,,T,,,,,c,,,,,0.0,,
21238926,2397,35197,33432,Association,TRUE,"Mathematical modeling elucidates bistability of cell fate in the <ENT1>Brat</ENT1>-mediated system, revealing how autoregulation of GSC number can arise from <ENT1>Brat</ENT1> coupling extracellular <ENT2>Dpp</ENT2> regulation to intracellular interpretation.",,,,T,,,,,c,,,,,1.0,,
21238926,2401,35197,41094,Association,TRUE,"Here, we identify <ENT1>Brain Tumor</ENT1> (<ENT1>Brat</ENT1>) as a potent differentiation factor and target of <ENT2>Pum</ENT2>-Nos regulation.",,,,T,,,,,c,,,,,1.0,,
21238926,2401,35197,41094,Association,TRUE,"<ENT1>Brat</ENT1> is excluded from GSCs by <ENT2>Pum</ENT2>-Nos but functions with <ENT2>Pum</ENT2> in CBs to translationally repress distinct targets, including the Mad and dMyc mRNAs.",,,,T,,,,,c,,,,,0.5,,
21238926,2396,33529,41094,Negative_Correlation,TRUE,"Brat is excluded from GSCs by <ENT2>Pum</ENT2>-Nos but functions with <ENT2>Pum</ENT2> in CBs to translationally repress distinct targets, including the <ENT1>Mad</ENT1> and dMyc mRNAs.",,,,T,,,,,c,,,,,0.0,,
21238926,2395,31310,41094,Negative_Correlation,TRUE,"Brat is excluded from GSCs by <ENT2>Pum</ENT2>-Nos but functions with <ENT2>Pum</ENT2> in CBs to translationally repress distinct targets, including the Mad and <ENT1>dMyc</ENT1> mRNAs.",,,,T,,,,,c,,,,,0.5,,
21325775,2403,C567089,p|SUB|R|158|P,Association,TRUE,"A novel apolipoprotein E mutation, ApoE Osaka (<ENT2>Arg158 Pro</ENT2>), in a dyslipidemic patient with <ENT1>lipoprotein glomerulopathy</ENT1>.",,,,T,,T,,,w,,,,,0.0,,
21325775,2404,C567089,348,Positive_Correlation,TRUE,"A novel <ENT2>apolipoprotein E</ENT2> mutation, <ENT2>ApoE</ENT2> Osaka (Arg158 Pro), in a dyslipidemic patient with <ENT1>lipoprotein glomerulopathy</ENT1>.",,,,T,,T,,,w,,,,,0.0,TRUE,
21325775,2404,C567089,348,Positive_Correlation,TRUE,<ENT1>Lipoprotein glomerulopathy</ENT1> (<ENT1>LPG</ENT1>) is a rare disease characterized by the presence of thrombuslike deposition in markedly dilated glomerular capillaries and is often accompanied by an increased serum <ENT2>apolipoprotein E</ENT2> (<ENT2>apoE</ENT2>) level.,,,,T,,,,,c,,,"11,12,21,22",,0.0,,
21325775,2404,C567089,348,Positive_Correlation,TRUE,Several gene mutations of <ENT2>apoE</ENT2> have been reported to be associated with <ENT1>LPG</ENT1>.,,,,T,,,,,w,,,,,0.0,,
21325775,2404,C567089,348,Positive_Correlation,TRUE,"In the current study, we report an <ENT1>LPG</ENT1> patient with a novel <ENT2>apoE</ENT2> mutation, <ENT2>apoE</ENT2> Osaka.",,,,T,,,,,w,,,,,0.0,TRUE,
21325775,2404,C567089,348,Positive_Correlation,TRUE,"The precise mechanism of <ENT1>LPG</ENT1> related with <ENT2>apoE</ENT2> Osaka, however, remains to be elucidated.",,,,T,,Y,,,c,,,,,0.0,,
21325775,2405,p|SUB|R|158|P,D050171,Association,TRUE,"A novel apolipoprotein E mutation, ApoE Osaka (<ENT1>Arg158 Pro</ENT1>), in a <ENT2>dyslipidemic</ENT2> patient with lipoprotein glomerulopathy.",,,,T,,T,,,w,,,,,1.0,,
21325775,2406,348,D050171,Association,TRUE,"A novel <ENT1>apolipoprotein E</ENT1> mutation, <ENT1>ApoE</ENT1> Osaka (Arg158 Pro), in a <ENT2>dyslipidemic</ENT2> patient with lipoprotein glomerulopathy.",,,,T,,T,,,w,,,,,1.0,,
21325775,2406,348,D050171,Association,TRUE,His <ENT1>apoE</ENT1> phenotype was <ENT1>apoE3/2</ENT1> and he had mild <ENT2>dyslipidemia</ENT2> with a mid-band on polyacrylamide gel electrophoresis.,,,,T,,,,,c,,,,,1.0,,
21405999,2418,2979,D012164,Association,FALSE,"However, the role of <ENT1>GUCA1B</ENT1> gene mutations in inherited <ENT2>retinal disease</ENT2> has been controversial.",,,,T,Y,,,,w,,,,,0.0,,
21405999;21405999,2420;2421,2979;2979,D000077765;D000071700,Association;Association,TRUE;TRUE,Mutation screening of the <ENT1>GUCA1B</ENT1> gene in patients with autosomal dominant <ENT2>cone and cone rod dystrophy</ENT2>.,,,,T,Y,T,,,w,,,,,0.0,,
21405999,2420,2979,D000077765,Association,TRUE,We therefore performed a mutation analysis of the <ENT1>GUCA1B</ENT1> gene in a clinically well characterized group of patients of European and North-American geographical origin with autosomal dominantly inherited <ENT2>cone dystrophy</ENT2> and cone rod dystrophy.,,,,T,,Y,,,w,,,,,1.0,,
21405999,2419,2979,D012162,Association,TRUE,Conclusion: The absence of clearly pathogenic mutations in the selected patient group suggests that the <ENT1>GUCA1B</ENT1> gene is a minor cause for <ENT2>retinal degenerations</ENT2> in Europeans or North-Americans.,,,,T,,,,,c,,,,,0.0,,
21405999,2421,2979,D000071700,Association,TRUE,We therefore performed a mutation analysis of the <ENT1>GUCA1B</ENT1> gene in a clinically well characterized group of patients of European and North-American geographical origin with autosomal dominantly inherited cone dystrophy and <ENT2>cone rod dystrophy</ENT2>.,,,,T,,Y,,,w,,,,,1.0,,
21405999,2408,2979,D002118,Bind,FALSE,"The sequence variant c.465G>T encodes a conservative amino acid substitution, p.Glu155Asp, located in EF-hand 4, the <ENT2>calcium</ENT2> binding site of <ENT1>GCAP2</ENT1> protein.",,,,T,,,,,c,,,,,1.0,,
21405999,2407,2978,D008268,Association,FALSE,"Background: Heterozygous mutations in <ENT1>GUCA1A</ENT1> (MIM # 600364) have been identified to cause autosomal dominantly inherited cone dystrophy, cone rod dystrophy and <ENT2>macular dystrophy</ENT2>.",,,,T,,,,,c,,,,,1.0,,
21405999,2410,2978,D000077765,Association,FALSE,"Background: Heterozygous mutations in <ENT1>GUCA1A</ENT1> (MIM # 600364) have been identified to cause autosomal dominantly inherited <ENT2>cone dystrophy</ENT2>, cone rod dystrophy and macular dystrophy.",,,,T,,,,,c,,,,,1.0,,
21405999,2414,2978,D000071700,Association,FALSE,"Background: Heterozygous mutations in <ENT1>GUCA1A</ENT1> (MIM # 600364) have been identified to cause autosomal dominantly inherited cone dystrophy, <ENT2>cone rod dystrophy</ENT2> and macular dystrophy.",,,,T,,,,,c,,,,,1.0,,
21405999,2409,rs139923590,D002118,Association,TRUE,"The sequence variant <ENT1>c.465G>T</ENT1> encodes a conservative amino acid substitution, <ENT1>p.Glu155Asp</ENT1>, located in EF-hand 4, the <ENT2>calcium</ENT2> binding site of GCAP2 protein.",,,,T,Y,,,,c,,,,,0.0,,
21615796,2426,rs763780,D016553,Association,TRUE,"We investigated the association between <ENT2>chronic ITP</ENT2> and the frequency of the single-nucleotide polymorphism <ENT1>rs763780</ENT1> (<ENT1>7488T/C</ENT1>), which causes a <ENT1>His-to-Arg substitution at amino acid 161</ENT1>.",,,,T,,Y,,,c,,,,,1.0,,
21615796,2426,rs763780,D016553,Association,TRUE,"RESULTS: Compared with the control group, patients with <ENT2>chronic ITP</ENT2> had a significantly lower frequency of the IL-17F <ENT1>7488CC</ENT1> genotype (0% vs. 4.8%, P<0.05).",,,,T,,,,,c,,,,,0.0,,
21615796,2426,rs763780,D016553,Association,TRUE,"The number of IL-17F <ENT1>7488C</ENT1> alleles among the patients with <ENT2>chronic ITP</ENT2> was also significantly lower than in the control group (8.7% vs. 15.2% OR=0.48, 95%CI=0.27-0.84, P=0.016).",,,,T,,,,,c,,,,,0.0,,
21615796,2426,rs763780,D016553,Association,TRUE,"CONCLUSION: These findings suggest that the IL-17F <ENT1>7488 T</ENT1> allele is significantly associated with the development of <ENT2>chronic ITP</ENT2>, suggesting a role for IL-17F in the pathogenesis of <ENT2>chronic ITP</ENT2>.",,,,T,,,,,c,,,,,0.0,,
21615796,2425,rs763780,D011696,Association,TRUE,"Furthermore, patients with the IL-17F <ENT1>7488TT</ENT1> genotype showed a severe <ENT2>thrombocytopenic</ENT2> state (platelet count<10 10(9) /L) at diagnosis than those with the IL-17F <ENT1>7488TC</ENT1> genotype (20.9% vs. 0%, P=0.04).",,,,T,,,,,c,,,,,0.0,,
21615796,2424,D001327,112744,Association,FALSE,INTRODUCTION: <ENT2>IL-17F</ENT2> is a novel <ENT2>inflammatory cytokine</ENT2> and plays an important role in some <ENT1>autoimmune diseases</ENT1>.,,,,T,,,,,c,,,,,0.5,,
21615796,2423,112744,D016553,Association,TRUE,<ENT1>Interleukin-17F</ENT1> gene polymorphism in patients with <ENT2>chronic immune thrombocytopenia</ENT2>.,,,,T,,T,,,w,,,,,1.0,,
21615796,2423,112744,D016553,Association,TRUE,"RESULTS: Compared with the control group, patients with <ENT2>chronic ITP</ENT2> had a significantly lower frequency of the <ENT1>IL-17F</ENT1> 7488CC genotype (0% vs. 4.8%, P<0.05).",,,,T,,,,,c,,,,,0.0,,
21615796,2423,112744,D016553,Association,TRUE,"The number of <ENT1>IL-17F</ENT1> 7488C alleles among the patients with <ENT2>chronic ITP</ENT2> was also significantly lower than in the control group (8.7% vs. 15.2% OR=0.48, 95%CI=0.27-0.84, P=0.016).",,,,T,,,,,c,,,,,0.0,,
21615796,2423,112744,D016553,Association,TRUE,"CONCLUSION: These findings suggest that the <ENT1>IL-17F</ENT1> 7488 T allele is significantly associated with the development of <ENT2>chronic ITP</ENT2>, suggesting a role for <ENT1>IL-17F</ENT1> in the pathogenesis of <ENT2>chronic ITP</ENT2>.",,,,T,,,,,c,,,"11,22",,0.75,,
21615796,2422,112744,D011696,Association,TRUE,"Furthermore, patients with the <ENT1>IL-17F</ENT1> 7488TT genotype showed a severe <ENT2>thrombocytopenic</ENT2> state (platelet count<10 10(9) /L) at diagnosis than those with the <ENT1>IL-17F</ENT1> 7488TC genotype (20.9% vs. 0%, P=0.04).",,,,T,,,,,c,,,,,0.0,,
21666969,2427,3569,D015431,Association,FALSE,"CONCLUSION: The novel finding of this study is the association of the mutant allele (A1359) with a decrease of resistin, leptin and <ENT1>interleukin-6</ENT1> secondary to <ENT2>weight loss</ENT2>.",,,,T,,,,,c,,,,,0.0,,
21666969,2430,D009765,1268,Association,FALSE,OBJECTIVE: We decided to investigate the role of the polymorphism (G1359A) of <ENT2>CB1 receptor</ENT2> gene on adipocytokines response and weight loss secondary to a lifestyle modification (Mediterranean hypocaloric diet and exercise) in <ENT1>obese</ENT1> patients.,,,,T,,Y,,,w,,,,,0.0,,
21666969,2431,1268,D015431,Association,FALSE,Roles of G1359A polymorphism of the <ENT1>cannabinoid receptor</ENT1> gene (<ENT1>CNR1</ENT1>) on <ENT2>weight loss</ENT2> and adipocytokines after a hypocaloric diet.,,,,T,,T,,,c,,,,,0.0,,
21666969,2431,1268,D015431,Association,FALSE,OBJECTIVE: We decided to investigate the role of the polymorphism (G1359A) of <ENT1>CB1 receptor</ENT1> gene on adipocytokines response and <ENT2>weight loss</ENT2> secondary to a lifestyle modification (Mediterranean hypocaloric diet and exercise) in obese patients.,,,,T,,Y,,,w,,,,,0.0,,
21666969,2429,D015431,56729,Association,FALSE,"CONCLUSION: The novel finding of this study is the association of the mutant allele (A1359) with a decrease of <ENT2>resistin</ENT2>, leptin and interleukin-6 secondary to <ENT1>weight loss</ENT1>.",,,,T,,,,,c,,,,,0.0,,
21666969,2432,D015431,rs1049353,Association,TRUE,Roles of <ENT2>G1359A</ENT2> polymorphism of the cannabinoid receptor gene (CNR1) on <ENT1>weight loss</ENT1> and adipocytokines after a hypocaloric diet.,,,,T,,T,,,c,,,,,0.0,,
21666969,2432,D015431,rs1049353,Association,TRUE,OBJECTIVE: We decided to investigate the role of the polymorphism (<ENT2>G1359A</ENT2>) of CB1 receptor gene on adipocytokines response and <ENT1>weight loss</ENT1> secondary to a lifestyle modification (Mediterranean hypocaloric diet and exercise) in obese patients.,,,,T,,Y,,,w,,,,,0.0,,
21666969,2432,D015431,rs1049353,Association,TRUE,"CONCLUSION: The novel finding of this study is the association of the mutant allele (<ENT2>A1359</ENT2>) with a decrease of resistin, leptin and interleukin-6 secondary to <ENT1>weight loss</ENT1>.",,,,T,,,,,c,,,,,1.0,,
21666969,2428,D015431,3952,Association,FALSE,"CONCLUSION: The novel finding of this study is the association of the mutant allele (A1359) with a decrease of resistin, <ENT2>leptin</ENT2> and interleukin-6 secondary to <ENT1>weight loss</ENT1>.",,,,T,,,,,c,,,,,0.0,,
21682595,2433,7515,D008180,Association,TRUE,<ENT1>XRCC1</ENT1> Arg399Gln gene polymorphism and the risk of <ENT2>systemic lupus erythematosus</ENT2> in the Polish population.,,,,T,,T,,,w,,,,,0.0,,
21682595,2433,7515,D008180,Association,TRUE,It has been shown that DNA repair is reduced in patients with <ENT2>systemic lupus erythematosus</ENT2> (<ENT2>SLE</ENT2>) and that the <ENT1>X-ray repair cross-complementing</ENT1> (<ENT1>XRCC1</ENT1>) Arg399Gln (rs25487) polymorphism may contribute to DNA repair.,,,,T,Y,,,,w,,,"11,12,21,22",,1.0,TRUE,
21682595,2433,7515,D008180,Association,TRUE,We evaluated the frequency of the <ENT1>XRCC1</ENT1> Arg399Gln substitution in patients with <ENT2>SLE</ENT2> (n=265) and controls (n=360) in a sample of the Polish population.,,,,T,,Y,,,c,,,,,1.0,,
21682595,2433,7515,D008180,Association,TRUE,Our studies may confirm that the <ENT1>XRCC1</ENT1> Arg399Gln polymorphism may increase the risk of incidence of <ENT2>SLE</ENT2> and the occurrence of some <ENT2>SLE</ENT2> manifestations.,,,,T,,,,,c,,,,,1.0,,
21682595,2435,D008180,rs25487,Positive_Correlation,TRUE,XRCC1 <ENT2>Arg399Gln</ENT2> gene polymorphism and the risk of <ENT1>systemic lupus erythematosus</ENT1> in the Polish population.,,,,T,,T,,,c,,,,,0.0,,
21682595,2435,D008180,rs25487,Positive_Correlation,TRUE,It has been shown that DNA repair is reduced in patients with <ENT1>systemic lupus erythematosus</ENT1> (<ENT1>SLE</ENT1>) and that the X-ray repair cross-complementing (XRCC1) <ENT2>Arg399Gln</ENT2> (<ENT2>rs25487</ENT2>) polymorphism may contribute to DNA repair.,,,,T,,,,,c,,,"11,12,21,22",,1.0,,
21682595,2435,D008180,rs25487,Positive_Correlation,TRUE,We evaluated the frequency of the XRCC1 <ENT2>Arg399Gln</ENT2> substitution in patients with <ENT1>SLE</ENT1> (n=265) and controls (n=360) in a sample of the Polish population.,,,,T,,Y,,,c,,,,,1.0,,
21682595,2435,D008180,rs25487,Positive_Correlation,TRUE,"The OR for the <ENT2>399 Gln</ENT2> allele in patients with <ENT1>SLE</ENT1> was 1.406 (95% CI=1.111-1.779, p=0.0045).",,,,T,,,,,c,,,,,0.0,,
21682595,2435,D008180,rs25487,Positive_Correlation,TRUE,Our studies may confirm that the XRCC1 <ENT2>Arg399Gln</ENT2> polymorphism may increase the risk of incidence of <ENT1>SLE</ENT1> and the occurrence of some <ENT1>SLE</ENT1> manifestations.,,,,T,,,,,c,,,,,1.0,,
21684788,2440,218,D016111,Association,TRUE,"A 24-year-old <ENT2>SLS</ENT2> female was homozygous for a 352-kb deletion involving ALDH3A2 and 4 contiguous genes including <ENT1>ALDH3A1</ENT1>, which codes for the major soluble protein in cornea.",,,,T,,,,,c,,,,,1.0,,
21684788,2441,c|DEL||352K,D016111,Association,TRUE,"A 24-year-old <ENT2>SLS</ENT2> female was homozygous for a <ENT1>352-kb deletion</ENT1> involving ALDH3A2 and 4 contiguous genes including ALDH3A1, which codes for the major soluble protein in cornea.",,,,T,,,,,c,,,,,1.0,,
21684788,2442,224,D016111,Association,TRUE,"<ENT2>Sjogren-Larsson syndrome</ENT2> (<ENT2>SLS</ENT2>) is an autosomal recessive disorder characterized by ichthyosis, mental retardation, spasticity and mutations in the <ENT1>ALDH3A2</ENT1> gene for <ENT1>fatty aldehyde dehydrogenase</ENT1>, an enzyme that catalyzes the oxidation of fatty aldehyde to fatty acid.",,,,T,,,,,c,,,"11,12,21,22",,1.0,,
21684788,2442,224,D016111,Association,TRUE,We now describe 2 <ENT2>SLS</ENT2> patients whose disease is caused by large contiguous gene deletions of the <ENT1>ALDH3A2</ENT1> locus on 17p11.2.,,,,T,,,,,c,,,,,1.0,,
21684788,2442,224,D016111,Association,TRUE,"A 24-year-old <ENT2>SLS</ENT2> female was homozygous for a 352-kb deletion involving <ENT1>ALDH3A2 and 4</ENT1> contiguous genes including ALDH3A1, which codes for the major soluble protein in cornea.",,,,T,,,,,c,,,,,1.0,,
21684788,2444,224,D005227,Association,FALSE,"Sjogren-Larsson syndrome (SLS) is an autosomal recessive disorder characterized by ichthyosis, mental retardation, spasticity and mutations in the <ENT1>ALDH3A2</ENT1> gene for <ENT1>fatty aldehyde dehydrogenase</ENT1>, an enzyme that catalyzes the oxidation of fatty aldehyde to <ENT2>fatty acid</ENT2>.",,,,T,,,,,w,,,,,0.5,,
21684788,2443,224,C001634,Association,FALSE,"Sjogren-Larsson syndrome (SLS) is an autosomal recessive disorder characterized by ichthyosis, mental retardation, spasticity and mutations in the <ENT1>ALDH3A2</ENT1> gene for <ENT1>fatty aldehyde dehydrogenase</ENT1>, an enzyme that catalyzes the oxidation of <ENT2>fatty aldehyde</ENT2> to fatty acid.",,,,T,,,,,w,,,,,1.0,,
21695597;21695597,2445;2446,720;3123,D008180;D008180,Association;Association,FALSE;FALSE,<ENT1>MHC</ENT1> region and risk of <ENT2>systemic lupus erythematosus</ENT2> in African American women.,,,,T,,T,,,w,,,,,0.0,,
21695597;21695597,2445;2446,720;3123,D008180;D008180,Association;Association,FALSE;FALSE,The <ENT1>major histocompatibility complex</ENT1> (<ENT1>MHC</ENT1>) on chromosome 6p21 is a key contributor to the genetic basis of <ENT2>systemic lupus erythematosus</ENT2> (<ENT2>SLE</ENT2>).,,,,T,,,,,c,,,"11,12,21,22",,0.5,,
21695597;21695597,2445;2446,720;3123,D008180;D008180,Association;Association,FALSE;FALSE,"Although <ENT2>SLE</ENT2> affects African Americans disproportionately compared to European Americans, there has been no comprehensive analysis of the <ENT1>MHC</ENT1> region in relationship to <ENT2>SLE</ENT2> in African Americans.",,,,T,,Y,,,w,,,,,1.0,,
21695597,2445,720,D008180,Association,FALSE,"We conducted a screening of the <ENT1>MHC</ENT1> region for 1,536 single nucleotide polymorphisms (SNPs) and the deletion of the <ENT1>C4A</ENT1> gene in a <ENT2>SLE</ENT2> case-control study (380 cases, 765 age-matched controls) nested within the prospective Black Women's Health Study.",,,,T,,Y,,,c,,,,,1.0,,
21695597;21695597,2445;2446,720;3123,D008180;D008180,Association;Association,FALSE;FALSE,"In summary, we found four independent signals in the <ENT1>MHC</ENT1> region associated with risk of <ENT2>SLE</ENT2> in African American women.",,,,T,,,,,c,,,,,1.0,,
21695597,2446,3123,D008180,Association,FALSE,"We conducted a screening of the <ENT1>MHC</ENT1> region for 1,536 single nucleotide polymorphisms (SNPs) and the deletion of the C4A gene in a <ENT2>SLE</ENT2> case-control study (380 cases, 765 age-matched controls) nested within the prospective Black Women's Health Study.",,,,T,,Y,,,c,,,,,1.0,,
21695597,2446,3123,D008180,Association,FALSE,"The most strongly associated SNP with <ENT2>SLE</ENT2> was the rs9271366 (odds ratio, OR = 1.70, p = 5.6 10(-5)) near the <ENT1>HLA-DRB1</ENT1> gene.",,,,T,Y,,,,c,,,,,1.0,,
21695597,2450,D008180,rs9271366,Positive_Correlation,TRUE,"The most strongly associated SNP with <ENT1>SLE</ENT1> was the <ENT2>rs9271366</ENT2> (odds ratio, OR = 1.70, p = 5.6 10(-5)) near the HLA-DRB1 gene.",,,,T,,,,,c,,,,,1.0,,
21695597,2450,D008180,rs9271366,Positive_Correlation,TRUE,"Conditional haplotype analysis revealed three other SNPs, rs204890 (OR = 1.86, p = 1.2 10(-4)), rs2071349 (OR = 1.53, p = 1.0 10(-3)), and rs2844580 (OR = 1.43, p = 1.3 10(-3)), to be associated with <ENT1>SLE</ENT1> independent of the <ENT2>rs9271366</ENT2> SNP.",,,,T,,,,,c,,,,,0.0,,
21695597,2450,D008180,rs9271366,Positive_Correlation,TRUE,"Our strongest signal, the <ENT2>rs9271366</ENT2> SNP, was also associated with higher risk of <ENT1>SLE</ENT1> in a previous Chinese genome-wide association study (GWAS).",,,,T,,,,,c,,,,,1.0,,
21695597,2447,D008180,rs2844580,Positive_Correlation,TRUE,"Conditional haplotype analysis revealed three other SNPs, rs204890 (OR = 1.86, p = 1.2 10(-4)), rs2071349 (OR = 1.53, p = 1.0 10(-3)), and <ENT2>rs2844580</ENT2> (OR = 1.43, p = 1.3 10(-3)), to be associated with <ENT1>SLE</ENT1> independent of the rs9271366 SNP.",,,,T,,,,,c,,,,,0.0,,
21695597,2448,D008180,rs2071349,Positive_Correlation,TRUE,"Conditional haplotype analysis revealed three other SNPs, rs204890 (OR = 1.86, p = 1.2 10(-4)), <ENT2>rs2071349</ENT2> (OR = 1.53, p = 1.0 10(-3)), and rs2844580 (OR = 1.43, p = 1.3 10(-3)), to be associated with <ENT1>SLE</ENT1> independent of the rs9271366 SNP.",,,,T,,,,,c,,,,,0.0,,
21695597,2449,D008180,rs204890,Positive_Correlation,TRUE,"Conditional haplotype analysis revealed three other SNPs, <ENT2>rs204890</ENT2> (OR = 1.86, p = 1.2 10(-4)), rs2071349 (OR = 1.53, p = 1.0 10(-3)), and rs2844580 (OR = 1.43, p = 1.3 10(-3)), to be associated with <ENT1>SLE</ENT1> independent of the rs9271366 SNP.",,,,T,,,,,c,,,,,0.0,,
21750150,2454,D004318,1602,Positive_Correlation,TRUE,"We then generated U87TR-Da glioma cells, where <ENT2>DACH1</ENT2> expression could be activated by exposure of the cells to <ENT1>doxycycline</ENT1>.",,,,T,,,,,c,,,,,1.0,,
21750150,2455,10763,1602,Association,TRUE,U87-<ENT2>DACH1</ENT2>-low cells form spheroids with CD133 and <ENT1>Nestin</ENT1> expression in serum-free medium but U87-<ENT2>DACH1</ENT2>-high cells do not.,,,,T,,,,,w,,,,,0.5,,
21750150,2453,2247,1602,Negative_Correlation,TRUE,"Gene expression analysis and chromatin immunoprecipitation assay reveal that <ENT1>fibroblast growth factor 2</ENT1> (<ENT1>FGF2</ENT1>/<ENT1>bFGF</ENT1>) is transcriptionally repressed by <ENT2>DACH1</ENT2>, especially in cells cultured in serum-free medium.",,,,T,,,,,c,,,,,1.0,,
21750150,2453,2247,1602,Negative_Correlation,TRUE,"Exogenous <ENT1>bFGF</ENT1> rescues spheroid-forming activity and tumorigenicity of the U87-<ENT2>DACH1</ENT2>-high cells, suggesting that loss of <ENT2>DACH1</ENT2> increases the number of tumor-initiating cells through transcriptional activation of <ENT1>bFGF</ENT1>.",,,,T,,,,,c,,,,,0.5,,
21750150,2453,2247,1602,Negative_Correlation,TRUE,"These results illustrate that <ENT2>DACH1</ENT2> is a distinctive tumor suppressor, which does not only suppress growth of tumor cells but also regulates <ENT1>bFGF</ENT1>-mediated tumor-initiating activity of glioma cells.",,,,T,,,,,c,,,,,0.0,,
21750150,2451,2247,D005910,Association,FALSE,"These results illustrate that DACH1 is a distinctive tumor suppressor, which does not only suppress growth of tumor cells but also regulates <ENT1>bFGF</ENT1>-mediated tumor-initiating activity of <ENT2>glioma</ENT2> cells.",,,,T,,,,,c,,,,,1.0,,
21750150,2452,2247,D009369,Association,FALSE,"Exogenous <ENT1>bFGF</ENT1> rescues spheroid-forming activity and tumorigenicity of the U87-DACH1-high cells, suggesting that loss of DACH1 increases the number of <ENT2>tumor</ENT2>-initiating cells through transcriptional activation of <ENT1>bFGF</ENT1>.",,,,T,,,,,c,,,,,1.0,,
21750150,2452,2247,D009369,Association,FALSE,"These results illustrate that DACH1 is a distinctive <ENT2>tumor</ENT2> suppressor, which does not only suppress growth of <ENT2>tumor</ENT2> cells but also regulates <ENT1>bFGF</ENT1>-mediated <ENT2>tumor</ENT2>-initiating activity of glioma cells.",,,,T,,,,,c,,,,,0.333333333,,
21750150,2457,1602,D005910,Association,TRUE,Homozygously deleted gene <ENT1>DACH1</ENT1> regulates tumor-initiating activity of <ENT2>glioma</ENT2> cells.,,,,T,,,,,c,,,,,1.0,,
21750150,2457,1602,D005910,Association,TRUE,We found decreased cell proliferation of a series of <ENT2>glioma</ENT2> cell lines by forced expression of <ENT1>DACH1</ENT1>.,,,,T,,,,,c,,,,,0.0,,
21750150,2457,1602,D005910,Association,TRUE,"We then generated U87TR-Da <ENT2>glioma</ENT2> cells, where <ENT1>DACH1</ENT1> expression could be activated by exposure of the cells to doxycycline.",,,,T,,,,,c,,,,,1.0,,
21750150,2457,1602,D005910,Association,TRUE,"These results illustrate that <ENT1>DACH1</ENT1> is a distinctive tumor suppressor, which does not only suppress growth of tumor cells but also regulates bFGF-mediated tumor-initiating activity of <ENT2>glioma</ENT2> cells.",,,,T,,,,,c,,,,,1.0,,
21750150,2458,1602,D009369,Association,TRUE,Homozygously deleted gene <ENT1>DACH1</ENT1> regulates <ENT2>tumor</ENT2>-initiating activity of glioma cells.,,,,T,,T,,,c,,,,,1.0,,
21750150,2458,1602,D009369,Association,TRUE,"Both ex vivo cellular proliferation and in vivo growth of s.c. transplanted <ENT2>tumors</ENT2> in mice are reduced in U87TR-Da cells with <ENT1>DACH1</ENT1> expression (U87-<ENT1>DACH1</ENT1>-high), compared with <ENT1>DACH1</ENT1>-nonexpressing U87TR-Da cells (U87-<ENT1>DACH1</ENT1>-low).",,,,T,,,,,c,,,,,0.0,,
21750150,2458,1602,D009369,Association,TRUE,"Compared with spheroid-forming U87-<ENT1>DACH1</ENT1>-low cells, adherent U87-<ENT1>DACH1</ENT1>-high cells display lower tumorigenicity, indicating <ENT1>DACH1</ENT1> decreases the number of <ENT2>tumor</ENT2>-initiating cells.",,,,T,,,,,c,,,,,0.0,,
21750150,2458,1602,D009369,Association,TRUE,"Exogenous bFGF rescues spheroid-forming activity and tumorigenicity of the U87-<ENT1>DACH1</ENT1>-high cells, suggesting that loss of <ENT1>DACH1</ENT1> increases the number of <ENT2>tumor</ENT2>-initiating cells through transcriptional activation of bFGF.",,,,T,,,,,c,,,,,0.5,,
21750150,2458,1602,D009369,Association,TRUE,"These results illustrate that <ENT1>DACH1</ENT1> is a distinctive <ENT2>tumor</ENT2> suppressor, which does not only suppress growth of <ENT2>tumor</ENT2> cells but also regulates bFGF-mediated <ENT2>tumor</ENT2>-initiating activity of glioma cells.",,,,T,,,,,c,,,,,0.0,,
21750150,2456,1602,8842,Association,TRUE,U87-<ENT1>DACH1</ENT1>-low cells form spheroids with <ENT2>CD133</ENT2> and Nestin expression in serum-free medium but U87-<ENT1>DACH1</ENT1>-high cells do not.,,,,T,,,,,c,,,,,0.0,,
21879313,2469,D006526,3439,Negative_Correlation,FALSE,"Serum levels of lipid are associated with the response to <ENT2>pegylated interferon</ENT2> plus ribavirin (<ENT2>PEG-IFN</ENT2>/RBV) therapy, while single nucleotide polymorphisms (SNPs) around the human interleukin 28B (IL28B) gene locus and amino acid substitutions in the core region of the HCV have been reported to affect the efficacy of <ENT2>PEG-IFN</ENT2>/RBV therapy in chronic hepatitis with <ENT1>HCV genotype 1b infection</ENT1>.",,,,T,Y,,,,w,,,,,0.333333333,,
21879313,2469,D006526,3439,Negative_Correlation,FALSE,"The aim of this study was to elucidate the relationship between serum lipid and factors that are able to predict the efficacy of <ENT2>PEG-IFN</ENT2>/RB therapy, with specific focus on apolipoprotein B-100 (apoB-100) in 148 subjects with chronic <ENT1>HCV G1b infection</ENT1>.",,,,T,,,,,w,,,,,1.0,,
21879313,2462,D006526,338,Association,TRUE,"The aim of this study was to elucidate the relationship between serum lipid and factors that are able to predict the efficacy of PEG-IFN/RB therapy, with specific focus on <ENT2>apolipoprotein B-100</ENT2> (<ENT2>apoB-100</ENT2>) in 148 subjects with chronic <ENT1>HCV G1b infection</ENT1>.",,,,T,,Y,,,c,,,,,1.0,,
21879313,2462,D006526,338,Association,TRUE,Our results suggest that <ENT2>apoB-100</ENT2> and LDL cholesterol are markers of impaired cellular lipoprotein pathways and/or host endogenous interferon response to HCV in chronic <ENT1>HCV infection</ENT1>.,,,,T,,,,,c,,,,,0.0,,
21879313,2467,D006526,D012254,Negative_Correlation,FALSE,"Serum levels of lipid are associated with the response to pegylated interferon plus <ENT2>ribavirin</ENT2> (PEG-IFN/<ENT2>RBV</ENT2>) therapy, while single nucleotide polymorphisms (SNPs) around the human interleukin 28B (IL28B) gene locus and amino acid substitutions in the core region of the HCV have been reported to affect the efficacy of PEG-IFN/<ENT2>RBV</ENT2> therapy in chronic hepatitis with <ENT1>HCV genotype 1b infection</ENT1>.",,,,T,,,,,w,,,,,0.0,,
21879313,2467,D006526,D012254,Negative_Correlation,FALSE,"The aim of this study was to elucidate the relationship between serum lipid and factors that are able to predict the efficacy of PEG-IFN/<ENT2>RB</ENT2> therapy, with specific focus on apolipoprotein B-100 (apoB-100) in 148 subjects with chronic <ENT1>HCV G1b infection</ENT1>.",,,,T,,,,,w,,,,,0.0,,
21879313,2466,D006526,D008078,Association,TRUE,Our results suggest that apoB-100 and <ENT2>LDL cholesterol</ENT2> are markers of impaired cellular lipoprotein pathways and/or host endogenous interferon response to HCV in chronic <ENT1>HCV infection</ENT1>.,,,,T,,,,,c,,,,,0.0,,
21879313,2463,D006526,282617,Association,TRUE,"Serum levels of lipid are associated with the response to pegylated interferon plus ribavirin (PEG-IFN/RBV) therapy, while single nucleotide polymorphisms (SNPs) around the human <ENT2>interleukin 28B</ENT2> (<ENT2>IL28B</ENT2>) gene locus and amino acid substitutions in the core region of the HCV have been reported to affect the efficacy of PEG-IFN/RBV therapy in chronic hepatitis with <ENT1>HCV genotype 1b infection</ENT1>.",,,,T,Y,,,,c,,,,,0.0,,
21879313,2465,p|Allele|R|70,D008078,Positive_Correlation,TRUE,A significant association was noted between higher levels of apoB-100 (P = 1.1 10(-3)) and <ENT2>LDL cholesterol</ENT2> (P = 0.02) and the subjects having <ENT1>Arg70</ENT1>.,,,,T,,,,,c,,,,,1.0,,
21879313,2481,rs8099917,D019698,Association,TRUE,Genotype <ENT1>rs8099917</ENT1> near the IL28B gene and amino acid substitution at position 70 in the core region of the hepatitis C virus are determinants of serum apolipoprotein B-100 concentration in <ENT2>chronic hepatitis C</ENT2>.,,,,T,,,,,c,,,,,0.0,,
21879313,2478,rs8099917,D008078,Positive_Correlation,TRUE,Our results demonstrated that both the aa 70 substitution in the core region of the HCV and the <ENT1>rs8099917</ENT1> SNP located proximal to the IL28B were independent factors in determining serum apoB-100 and <ENT2>low-density lipoprotein (LDL) cholesterol</ENT2> levels.,,,,T,,,,,c,,,,,1.0,,
21879313,2478,rs8099917,D008078,Positive_Correlation,TRUE,A significant association was also observed between subjects carrying the <ENT1>rs8099917</ENT1> TT responder genotype and higher levels of apoB-100 (P = 6.4 10(-3)) and <ENT2>LDL cholesterol</ENT2> (P = 4.2 10(-3)).,,,,T,,,,,c,,,,,1.0,,
21879313,2460,3439,D008055,Association,FALSE,"Serum levels of <ENT2>lipid</ENT2> are associated with the response to <ENT1>pegylated interferon</ENT1> plus ribavirin (<ENT1>PEG-IFN</ENT1>/RBV) therapy, while single nucleotide polymorphisms (SNPs) around the human interleukin 28B (IL28B) gene locus and amino acid substitutions in the core region of the HCV have been reported to affect the efficacy of <ENT1>PEG-IFN</ENT1>/RBV therapy in chronic hepatitis with HCV genotype 1b infection.",,,,T,,,,,c,,,,,0.333333333,,
21879313,2460,3439,D008055,Association,FALSE,"The aim of this study was to elucidate the relationship between serum <ENT2>lipid</ENT2> and factors that are able to predict the efficacy of <ENT1>PEG-IFN</ENT1>/RB therapy, with specific focus on apolipoprotein B-100 (apoB-100) in 148 subjects with chronic HCV G1b infection.",,,,T,,Y,,,w,,,,,0.0,,
21879313,2471,3439,D012254,Cotreatment,FALSE,"Serum levels of lipid are associated with the response to <ENT1>pegylated interferon</ENT1> plus <ENT2>ribavirin</ENT2> (<ENT1>PEG-IFN</ENT1>/<ENT2>RBV</ENT2>) therapy, while single nucleotide polymorphisms (SNPs) around the human interleukin 28B (IL28B) gene locus and amino acid substitutions in the core region of the HCV have been reported to affect the efficacy of <ENT1>PEG-IFN</ENT1>/<ENT2>RBV</ENT2> therapy in chronic hepatitis with HCV genotype 1b infection.",,,,T,,,,,c,,,"11,22,33",,0.666666667,,
21879313,2471,3439,D012254,Cotreatment,FALSE,"The aim of this study was to elucidate the relationship between serum lipid and factors that are able to predict the efficacy of <ENT1>PEG-IFN</ENT1>/<ENT2>RB</ENT2> therapy, with specific focus on apolipoprotein B-100 (apoB-100) in 148 subjects with chronic HCV G1b infection.",,,,T,,,,,w,,,,,0.0,,
21879313,2470,3439,D006521,Negative_Correlation,FALSE,"Serum levels of lipid are associated with the response to <ENT1>pegylated interferon</ENT1> plus ribavirin (<ENT1>PEG-IFN</ENT1>/RBV) therapy, while single nucleotide polymorphisms (SNPs) around the human interleukin 28B (IL28B) gene locus and amino acid substitutions in the core region of the HCV have been reported to affect the efficacy of <ENT1>PEG-IFN</ENT1>/RBV therapy in <ENT2>chronic hepatitis</ENT2> with HCV genotype 1b infection.",,,,T,,,,,w,,,,,1.0,,
21879313,2476,3439,282617,Association,FALSE,"Serum levels of lipid are associated with the response to <ENT1>pegylated interferon</ENT1> plus ribavirin (<ENT1>PEG-IFN</ENT1>/RBV) therapy, while single nucleotide polymorphisms (SNPs) around the human <ENT2>interleukin 28B</ENT2> (<ENT2>IL28B</ENT2>) gene locus and amino acid substitutions in the core region of the HCV have been reported to affect the efficacy of <ENT1>PEG-IFN</ENT1>/RBV therapy in chronic hepatitis with HCV genotype 1b infection.",,,,T,,,,,w,,,,,0.0,,
21879313,2479,338,D019698,Association,TRUE,Genotype rs8099917 near the IL28B gene and amino acid substitution at position 70 in the core region of the hepatitis C virus are determinants of serum <ENT1>apolipoprotein B-100</ENT1> concentration in <ENT2>chronic hepatitis C</ENT2>.,,,,T,,T,,,c,,,,,1.0,,
21879313,2472,338,D008078,Association,TRUE,Our results demonstrated that both the aa 70 substitution in the core region of the HCV and the rs8099917 SNP located proximal to the IL28B were independent factors in determining serum <ENT1>apoB-100</ENT1> and <ENT2>low-density lipoprotein (LDL) cholesterol</ENT2> levels.,,,,T,,,,,c,,,,,1.0,,
21879313,2472,338,D008078,Association,TRUE,A significant association was noted between higher levels of <ENT1>apoB-100</ENT1> (P = 1.1 10(-3)) and <ENT2>LDL cholesterol</ENT2> (P = 0.02) and the subjects having Arg70.,,,,T,,,,,c,,,,,0.0,,
21879313,2472,338,D008078,Association,TRUE,A significant association was also observed between subjects carrying the rs8099917 TT responder genotype and higher levels of <ENT1>apoB-100</ENT1> (P = 6.4 10(-3)) and <ENT2>LDL cholesterol</ENT2> (P = 4.2 10(-3)).,,,,T,Y,,,,w,,,,,1.0,,
21879313,2472,338,D008078,Association,TRUE,Our results suggest that <ENT1>apoB-100</ENT1> and <ENT2>LDL cholesterol</ENT2> are markers of impaired cellular lipoprotein pathways and/or host endogenous interferon response to HCV in chronic HCV infection.,,,,T,,,,,c,,,,,1.0,,
21879313,2477,338,282617,Association,TRUE,Genotype rs8099917 near the <ENT2>IL28B</ENT2> gene and amino acid substitution at position 70 in the core region of the hepatitis C virus are determinants of serum <ENT1>apolipoprotein B-100</ENT1> concentration in chronic hepatitis C.,,,,T,,T,,,c,,,,,1.0,,
21879313,2477,338,282617,Association,TRUE,Our results demonstrated that both the aa 70 substitution in the core region of the HCV and the rs8099917 SNP located proximal to the <ENT2>IL28B</ENT2> were independent factors in determining serum <ENT1>apoB-100</ENT1> and low-density lipoprotein (LDL) cholesterol levels.,,,,T,,,,,c,,,,,1.0,,
21879313,2480,D019698,282617,Association,FALSE,Genotype rs8099917 near the <ENT2>IL28B</ENT2> gene and amino acid substitution at position 70 in the core region of the hepatitis C virus are determinants of serum apolipoprotein B-100 concentration in <ENT1>chronic hepatitis C</ENT1>.,,,,T,,T,,,c,,,,,0.0,,
21879313,2459,D008055,D012254,Association,FALSE,"Serum levels of <ENT1>lipid</ENT1> are associated with the response to pegylated interferon plus <ENT2>ribavirin</ENT2> (PEG-IFN/<ENT2>RBV</ENT2>) therapy, while single nucleotide polymorphisms (SNPs) around the human interleukin 28B (IL28B) gene locus and amino acid substitutions in the core region of the HCV have been reported to affect the efficacy of PEG-IFN/<ENT2>RBV</ENT2> therapy in chronic hepatitis with HCV genotype 1b infection.",,,,T,,,,,c,,,,,0.0,,
21879313,2459,D008055,D012254,Association,FALSE,"The aim of this study was to elucidate the relationship between serum <ENT1>lipid</ENT1> and factors that are able to predict the efficacy of PEG-IFN/<ENT2>RB</ENT2> therapy, with specific focus on apolipoprotein B-100 (apoB-100) in 148 subjects with chronic HCV G1b infection.",,,,T,,Y,,,w,,,,,0.0,,
21879313,2468,D012254,D006521,Negative_Correlation,FALSE,"Serum levels of lipid are associated with the response to pegylated interferon plus <ENT1>ribavirin</ENT1> (PEG-IFN/<ENT1>RBV</ENT1>) therapy, while single nucleotide polymorphisms (SNPs) around the human interleukin 28B (IL28B) gene locus and amino acid substitutions in the core region of the HCV have been reported to affect the efficacy of PEG-IFN/<ENT1>RBV</ENT1> therapy in <ENT2>chronic hepatitis</ENT2> with HCV genotype 1b infection.",,,,T,,,,,w,,,,,1.0,,
21879313,2475,D012254,282617,Association,FALSE,"Serum levels of lipid are associated with the response to pegylated interferon plus <ENT1>ribavirin</ENT1> (PEG-IFN/<ENT1>RBV</ENT1>) therapy, while single nucleotide polymorphisms (SNPs) around the human <ENT2>interleukin 28B</ENT2> (<ENT2>IL28B</ENT2>) gene locus and amino acid substitutions in the core region of the HCV have been reported to affect the efficacy of PEG-IFN/<ENT1>RBV</ENT1> therapy in chronic hepatitis with HCV genotype 1b infection.",,,,T,,,,,c,,,,,0.0,,
21879313,2473,D008078,282617,Association,TRUE,Our results demonstrated that both the aa 70 substitution in the core region of the HCV and the rs8099917 SNP located proximal to the <ENT2>IL28B</ENT2> were independent factors in determining serum apoB-100 and <ENT1>low-density lipoprotein (LDL) cholesterol</ENT1> levels.,,,,T,,,,,c,,,,,1.0,,
21879313,2474,D006521,282617,Association,FALSE,"Serum levels of lipid are associated with the response to pegylated interferon plus ribavirin (PEG-IFN/RBV) therapy, while single nucleotide polymorphisms (SNPs) around the human <ENT2>interleukin 28B</ENT2> (<ENT2>IL28B</ENT2>) gene locus and amino acid substitutions in the core region of the HCV have been reported to affect the efficacy of PEG-IFN/RBV therapy in <ENT1>chronic hepatitis</ENT1> with HCV genotype 1b infection.",,,,T,,,,,c,,,,,0.0,,
21903317,2488,C537048,5972,Association,FALSE,"Homozygous or compound heterozygous mutations in <ENT2>renin</ENT2> (<ENT2>REN</ENT2>) cause <ENT1>renal tubular dysgenesis</ENT1>, which is characterized by death in utero due to kidney failure and pulmonary hypoplasia.",,,,T,,,,,c,,,,,1.0,,
21903317,2492,D057911,C576203,Positive_Correlation,FALSE,The phenotype resembles the <ENT2>fetopathy</ENT2> caused by angiotensin-converting enzyme inhibitor or <ENT1>angiotensin receptor blocker</ENT1> intake during pregnancy.,,,,T,,,,,c,,,,,1.0,,
21903317,2493,C576203,D000806,Positive_Correlation,FALSE,The phenotype resembles the <ENT1>fetopathy</ENT1> caused by <ENT2>angiotensin-converting enzyme inhibitor</ENT2> or angiotensin receptor blocker intake during pregnancy.,,,,T,,,,,c,,,,,1.0,,
21903317,2489,D051436,5972,Association,FALSE,"Autosomal dominant mutation in the signal peptide of <ENT2>renin</ENT2> in a kindred with anemia, hyperuricemia, and <ENT1>CKD</ENT1>.",,,,T,Y,T,,,w,,,,,1.0,,
21903317,2489,D051436,5972,Association,FALSE,"Recently, heterozygous <ENT2>REN</ENT2> mutations were shown to result in early-onset hyperuricemia, anemia, and <ENT1>chronic kidney disease</ENT1> (<ENT1>CKD</ENT1>).",,,,T,,,,,c,,,,,1.0,,
21903317,2489,D051436,5972,Association,FALSE,We report mutation analysis of the <ENT2>REN</ENT2> gene in 39 kindreds with hyperuricemia and <ENT1>CKD</ENT1> who previously tested negative for mutations in the UMOD (uromodulin) and HNF1B (hepatocyte nuclear factor 1b) genes.,,,,T,,Y,,,c,,,,,1.0,,
21903317,2489,D051436,5972,Association,FALSE,"On this basis, we conclude that <ENT2>REN</ENT2> mutations are rare events in patients with <ENT1>CKD</ENT1>.",,,,T,,,,,w,,,,,1.0,,
21903317,2489,D051436,5972,Association,FALSE,"Within the kindred, we found affected individuals over 4 generations who carried the novel <ENT2>REN</ENT2> mutation and were characterized by significant anemia, hyperuricemia, and <ENT1>CKD</ENT1>.",,,,T,,,,,w,,,,,0.0,,
21903317,2489,D051436,5972,Association,FALSE,"Because all heterozygous <ENT2>REN</ENT2> mutations that have been described are localized in the signal sequence, screening of the <ENT2>REN</ENT2> gene for patients with <ENT1>CKD</ENT1> with hyperuricemia and anemia may best be focused on sequencing of exon 1, which encodes the signal peptide.",,,,T,,Y,,,c,,,,,0.5,,
21903317,2491,5972,D033461,Association,FALSE,"Autosomal dominant mutation in the signal peptide of <ENT1>renin</ENT1> in a kindred with anemia, <ENT2>hyperuricemia</ENT2>, and CKD.",,,,T,,T,,,w,,,,,0.0,,
21903317,2491,5972,D033461,Association,FALSE,"Recently, heterozygous <ENT1>REN</ENT1> mutations were shown to result in early-onset <ENT2>hyperuricemia</ENT2>, anemia, and chronic kidney disease (CKD).",,,,T,,,,,c,,,,,1.0,,
21903317,2491,5972,D033461,Association,FALSE,We report mutation analysis of the <ENT1>REN</ENT1> gene in 39 kindreds with <ENT2>hyperuricemia</ENT2> and CKD who previously tested negative for mutations in the UMOD (uromodulin) and HNF1B (hepatocyte nuclear factor 1b) genes.,,,,T,,Y,,,c,,,,,0.0,,
21903317,2491,5972,D033461,Association,FALSE,"Within the kindred, we found affected individuals over 4 generations who carried the novel <ENT1>REN</ENT1> mutation and were characterized by significant anemia, <ENT2>hyperuricemia</ENT2>, and CKD.",,,,T,,,,,w,,,,,0.0,,
21903317,2491,5972,D033461,Association,FALSE,"Because all heterozygous <ENT1>REN</ENT1> mutations that have been described are localized in the signal sequence, screening of the <ENT1>REN</ENT1> gene for patients with CKD with <ENT2>hyperuricemia</ENT2> and anemia may best be focused on sequencing of exon 1, which encodes the signal peptide.",,,,T,,Y,,,c,,,,,0.0,,
21903317,2490,5972,D000740,Association,FALSE,"Autosomal dominant mutation in the signal peptide of <ENT1>renin</ENT1> in a kindred with <ENT2>anemia</ENT2>, hyperuricemia, and CKD.",,,,T,,T,,,w,,,,,0.0,,
21903317,2490,5972,D000740,Association,FALSE,"Recently, heterozygous <ENT1>REN</ENT1> mutations were shown to result in early-onset hyperuricemia, <ENT2>anemia</ENT2>, and chronic kidney disease (CKD).",,,,T,,,,,c,,,,,1.0,,
21903317,2490,5972,D000740,Association,FALSE,"Within the kindred, we found affected individuals over 4 generations who carried the novel <ENT1>REN</ENT1> mutation and were characterized by significant <ENT2>anemia</ENT2>, hyperuricemia, and CKD.",,,,T,,,,,w,,,,,0.0,,
21903317,2490,5972,D000740,Association,FALSE,"Because all heterozygous <ENT1>REN</ENT1> mutations that have been described are localized in the signal sequence, screening of the <ENT1>REN</ENT1> gene for patients with CKD with hyperuricemia and <ENT2>anemia</ENT2> may best be focused on sequencing of exon 1, which encodes the signal peptide.",,,,T,,Y,,,c,,,,,0.0,,
21904390,2502,D015783,5080,Association,TRUE,PURPOSE: <ENT1>Aniridia</ENT1> (<ENT1>AN</ENT1>) is a rare congenital panocular disorder caused by the mutations of the <ENT2>paired box homeotic gene 6</ENT2>(<ENT2>PAX6</ENT2>) gene.,,,,T,,,,,c,,,"11,12,21,22",,1.0,,
21904390,2502,D015783,5080,Association,TRUE,"We studied the <ENT2>PAX6</ENT2> gene mutations in a cohort of affected individuals with different clinical phenotype including <ENT1>AN</ENT1>, coloboma of iris and choroid, or anterior segment malformations.",,,,T,,Y,,,c,,,,,1.0,,
21904390,2502,D015783,5080,Association,TRUE,"Sequencing of the <ENT2>PAX6</ENT2> gene, three intragenic mutations including a novel heterozygous splicing-site mutations c.357-3C>G (p.Ser119fsX) were identified in the patients of the <ENT1>AN</ENT1> group.",,,,T,,,,,c,,,,,1.0,,
21904390,2502,D015783,5080,Association,TRUE,"Through MLPA analysis, a large deletion including the whole <ENT2>PAX6</ENT2> gene and DKFZ p686k1684 gene was detected in one sporadic patient from the <ENT1>AN</ENT1> group.",,,,T,,,,,c,,,,,1.0,,
21904390,2499,D015783,p|FS|S|119||,Positive_Correlation,TRUE,"Sequencing of the PAX6 gene, three intragenic mutations including a novel heterozygous splicing-site mutations c.357-3C>G (<ENT2>p.Ser119fsX</ENT2>) were identified in the patients of the <ENT1>AN</ENT1> group.",,,,T,,,,,c,,,,,0.0,,
21904390,2498,D015783,c|SUB|C|357-3|G,Positive_Correlation,TRUE,"Sequencing of the PAX6 gene, three intragenic mutations including a novel heterozygous splicing-site mutations <ENT2>c.357-3C>G</ENT2> (p.Ser119fsX) were identified in the patients of the <ENT1>AN</ENT1> group.",,,,T,,,,,c,,,,,0.0,,
21904390,2501,5080,C537775,Association,TRUE,The <ENT1>PAX6</ENT1> gene is also involved in other <ENT2>anterior segment malformations</ENT2> including Peters anomaly.,,,,T,,,,,c,,,,,1.0,,
21904390,2501,5080,C537775,Association,TRUE,"We studied the <ENT1>PAX6</ENT1> gene mutations in a cohort of affected individuals with different clinical phenotype including AN, coloboma of iris and choroid, or <ENT2>anterior segment malformations</ENT2>.",,,,T,,Y,,,c,,,,,1.0,,
21904390,2500,5080,C537884,Association,TRUE,The <ENT1>PAX6</ENT1> gene is also involved in other anterior segment malformations including <ENT2>Peters anomaly</ENT2>.,,,,T,,,,,c,,,,,1.0,,
21904390,2500,5080,C537884,Association,TRUE,The mutation p.S216P located in the homeodomain region of the <ENT1>PAX6</ENT1> caused the phenotype of <ENT2>Peters anomaly</ENT2> in family A6 with different expressing.,,,,T,,,,,c,,,,,1.0,,
21904390,2497,p|SUB|S|216|P,C537775,Positive_Correlation,TRUE,A novel missense mutation c.643T>C (<ENT1>p.S216P</ENT1>) was detected in the <ENT2>anterior segment malformation</ENT2> group.,,,,T,,,,,c,,,,,0.0,,
21904390,2496,p|SUB|S|216|P,C537884,Positive_Correlation,TRUE,The mutation <ENT1>p.S216P</ENT1> located in the homeodomain region of the PAX6 caused the phenotype of <ENT2>Peters anomaly</ENT2> in family A6 with different expressing.,,,,T,,,,,c,,,,,0.0,,
21904390,2495,C537775,c|SUB|T|643|C,Positive_Correlation,TRUE,A novel missense mutation <ENT2>c.643T>C</ENT2> (p.S216P) was detected in the <ENT1>anterior segment malformation</ENT1> group.,,,,T,,,,,c,,,,,0.0,,
21976953,2503,2200,D008382,Association,TRUE,Identification of a novel <ENT1>FBN1</ENT1> gene mutation in a Chinese family with <ENT2>Marfan syndrome</ENT2>.,,,,T,,T,,,w,,,,,0.0,,
21976953,2503,2200,D008382,Association,TRUE,PURPOSE: To identify the mutation in the <ENT1>fibrillin-1</ENT1> gene (<ENT1>FBN1</ENT1>) in a Chinese family with <ENT2>Marfan syndrome</ENT2> (<ENT2>MFS</ENT2>).,,,,T,,Y,,,c,,,"11,12,21,22",,1.0,,
21976953,2503,2200,D008382,Association,TRUE,"CONCLUSIONS: We indentified a novel p.S1235P mutation in <ENT1>FBN1</ENT1>, which is the causative mutation for <ENT2>MFS</ENT2> in this family.",,,,T,,,,,c,,,,,1.0,,
21976953,2503,2200,D008382,Association,TRUE,Our result expands the mutation spectrum of <ENT1>FBN1</ENT1> and contributes to the study of the molecular pathogenesis of <ENT2>Marfan syndrome</ENT2>.,,,,T,,,,,c,,,,,1.0,,
21976953,2505,D008382,p|SUB|S|1235|P,Positive_Correlation,TRUE,"CONCLUSIONS: We indentified a novel <ENT2>p.S1235P</ENT2> mutation in FBN1, which is the causative mutation for <ENT1>MFS</ENT1> in this family.",,,,T,,,,,c,,,,,1.0,,
22051099,2506,D055113,3579,Association,FALSE,Previous studies of our group found association of haplotypes in the IL8 and in the <ENT2>CXCR2</ENT2> genes with the multifactorial disease <ENT1>chronic periodontitis</ENT1>.,,,,T,,,,,c,,,,,1.0,,
22051099,2508,D055113,3576,Association,FALSE,Previous studies of our group found association of haplotypes in the <ENT2>IL8</ENT2> and in the CXCR2 genes with the multifactorial disease <ENT1>chronic periodontitis</ENT1>.,,,,T,,,,,c,,,,,1.0,,
22051099,2510,3577,3576,Bind,FALSE,"BACKGROUND: The <ENT1>chemokine receptor 1 CXCR-1</ENT1> (or <ENT1>IL8R-alpha</ENT1>) is a specific receptor for the <ENT2>interleukin 8</ENT2> (<ENT2>IL-8</ENT2>), which is chemoattractant for neutrophils and has an important role in the inflammatory response.",,,,T,,,,,c,,,"11,12,21,22",,0.5,,
22051099,2509,3577,D007249,Association,FALSE,"BACKGROUND: The <ENT1>chemokine receptor 1 CXCR-1</ENT1> (or <ENT1>IL8R-alpha</ENT1>) is a specific receptor for the interleukin 8 (IL-8), which is chemoattractant for neutrophils and has an important role in the <ENT2>inflammatory</ENT2> response.",,,,T,,,,,c,,,,,1.0,,
22051099,2507,3576,D007249,Association,FALSE,"BACKGROUND: The chemokine receptor 1 CXCR-1 (or IL8R-alpha) is a specific receptor for the <ENT1>interleukin 8</ENT1> (<ENT1>IL-8</ENT1>), which is chemoattractant for neutrophils and has an important role in the <ENT2>inflammatory</ENT2> response.",,,,T,,,,,c,,,,,1.0,,
22711886,2518,26419,21939,Association,TRUE,"Moreover, consistent with previous results, we also show that TRAF2 was required for efficient <ENT1>JNK</ENT1> and ERK activation in response to <ENT2>CD40</ENT2> engagement.",,,,T,,,,,c,,,,,0.0,,
22711886,2526,26419,22030,Positive_Correlation,TRUE,"Moreover, consistent with previous results, we also show that <ENT2>TRAF2</ENT2> was required for efficient <ENT1>JNK</ENT1> and ERK activation in response to CD40 engagement.",,,,T,,,,,c,,,,,0.0,,
22711886,2514,D015451,596,Association,TRUE,We have previously shown that transgenic (tg) mice expressing in B lymphocytes both <ENT2>BCL-2</ENT2> and a TNFR-associated factor 2 (TRAF2) mutant lacking the really interesting new gene and zinc finger domains (TRAF2DN) develop <ENT1>small lymphocytic lymphoma</ENT1> and <ENT1>chronic lymphocytic leukemia</ENT1> with high incidence (Zapata et al. 2004.,,,,T,,,,,c,,,,,1.0,,
22711886,2514,D015451,596,Association,TRUE,"Altogether, our results suggest that TRAF2 deficiency cooperates with <ENT2>BCL-2</ENT2> in promoting <ENT1>chronic lymphocytic leukemia</ENT1>/<ENT1>small lymphocytic lymphoma</ENT1> in mice, possibly by specifically enforcing marginal zone B cell accumulation, increasing X-linked inhibitor of apoptosis expression, and rendering B cells independent of B cell activating factor for survival.",,,,T,,,,,c,,,,,1.0,,
22711886,2527,D015451,22030,Negative_Correlation,TRUE,<ENT2>TNFR-associated factor 2</ENT2> deficiency in B lymphocytes predisposes to <ENT1>chronic lymphocytic leukemia</ENT1>/<ENT1>small lymphocytic lymphoma</ENT1> in mice.,,,,T,,,,,c,,,,,0.0,,
22711886,2527,D015451,22030,Negative_Correlation,TRUE,We have previously shown that transgenic (tg) mice expressing in B lymphocytes both BCL-2 and a <ENT2>TNFR-associated factor 2</ENT2> (<ENT2>TRAF2</ENT2>) mutant lacking the really interesting new gene and zinc finger domains (TRAF2DN) develop <ENT1>small lymphocytic lymphoma</ENT1> and <ENT1>chronic lymphocytic leukemia</ENT1> with high incidence (Zapata et al. 2004.,,,,T,,,,,c,,,"11,12,21,22",,0.0,,
22711886,2527,D015451,22030,Negative_Correlation,TRUE,"Altogether, our results suggest that <ENT2>TRAF2</ENT2> deficiency cooperates with BCL-2 in promoting <ENT1>chronic lymphocytic leukemia</ENT1>/<ENT1>small lymphocytic lymphoma</ENT1> in mice, possibly by specifically enforcing marginal zone B cell accumulation, increasing X-linked inhibitor of apoptosis expression, and rendering B cells independent of B cell activating factor for survival.",,,,T,,,,,c,,,,,0.0,,
22711886,2516,26416,21939,Association,FALSE,"In contrast, TRAF2 deficiency had no effect on <ENT2>CD40</ENT2>-mediated <ENT1>p38 MAPK</ENT1> activation but significantly reduced BCR-mediated <ENT1>p38</ENT1> activation.",,,,T,,,,,c,,,,,0.0,,
22711886,2522,26416,22030,Positive_Correlation,TRUE,"In contrast, <ENT2>TRAF2</ENT2> deficiency had no effect on CD40-mediated <ENT1>p38 MAPK</ENT1> activation but significantly reduced BCR-mediated <ENT1>p38</ENT1> activation.",,,,T,,,,,c,,,,,0.5,,
22711886,2515,26416,12518,Association,FALSE,"In contrast, TRAF2 deficiency had no effect on CD40-mediated <ENT1>p38 MAPK</ENT1> activation but significantly reduced <ENT2>BCR</ENT2>-mediated <ENT1>p38</ENT1> activation.",,,,T,,,,,w,,,,,0.0,,
22711886,2524,21939,22030,Association,TRUE,"Moreover, consistent with previous results, we also show that <ENT2>TRAF2</ENT2> was required for efficient JNK and ERK activation in response to <ENT1>CD40</ENT1> engagement.",,,,T,Y,,,,c,,,,,0.0,,
22711886,2524,21939,22030,Association,TRUE,"In contrast, <ENT2>TRAF2</ENT2> deficiency had no effect on <ENT1>CD40</ENT1>-mediated p38 MAPK activation but significantly reduced BCR-mediated p38 activation.",,,,T,,,,,w,,,,,0.0,,
22711886,2524,21939,22030,Association,TRUE,"Finally, we further confirm that <ENT2>TRAF2</ENT2> was required for <ENT1>CD40</ENT1>-mediated proliferation, but its absence relieved B cells of the need for B cell activating factor for survival.",,,,T,,,,,c,,,,,0.0,,
22711886,2517,21939,26413,Association,TRUE,"Moreover, consistent with previous results, we also show that TRAF2 was required for efficient JNK and <ENT2>ERK</ENT2> activation in response to <ENT1>CD40</ENT1> engagement.",,,,T,,,,,c,,,,,0.0,,
22711886,2513,596,11798,Association,TRUE,"Altogether, our results suggest that TRAF2 deficiency cooperates with <ENT1>BCL-2</ENT1> in promoting chronic lymphocytic leukemia/small lymphocytic lymphoma in mice, possibly by specifically enforcing marginal zone B cell accumulation, increasing <ENT2>X-linked inhibitor of apoptosis</ENT2> expression, and rendering B cells independent of B cell activating factor for survival.",,,,T,,,,,c,,,,,0.0,,
22711886,2521,596,22030,Association,TRUE,We have previously shown that transgenic (tg) mice expressing in B lymphocytes both <ENT1>BCL-2</ENT1> and a <ENT2>TNFR-associated factor 2</ENT2> (<ENT2>TRAF2</ENT2>) mutant lacking the really interesting new gene and zinc finger domains (TRAF2DN) develop small lymphocytic lymphoma and chronic lymphocytic leukemia with high incidence (Zapata et al. 2004.,,,,T,,,,,c,,,,,0.0,,
22711886,2521,596,22030,Association,TRUE,"Altogether, our results suggest that <ENT2>TRAF2</ENT2> deficiency cooperates with <ENT1>BCL-2</ENT1> in promoting chronic lymphocytic leukemia/small lymphocytic lymphoma in mice, possibly by specifically enforcing marginal zone B cell accumulation, increasing X-linked inhibitor of apoptosis expression, and rendering B cells independent of B cell activating factor for survival.",,,,T,,,,,c,,,,,0.0,,
22711886,2520,11798,22030,Negative_Correlation,TRUE,"Altogether, our results suggest that <ENT2>TRAF2</ENT2> deficiency cooperates with BCL-2 in promoting chronic lymphocytic leukemia/small lymphocytic lymphoma in mice, possibly by specifically enforcing marginal zone B cell accumulation, increasing <ENT1>X-linked inhibitor of apoptosis</ENT1> expression, and rendering B cells independent of B cell activating factor for survival.",,,,T,,,,,c,,,,,1.0,,
22711886,2525,22030,26413,Positive_Correlation,TRUE,"Moreover, consistent with previous results, we also show that <ENT1>TRAF2</ENT1> was required for efficient JNK and <ENT2>ERK</ENT2> activation in response to CD40 engagement.",,,,T,,,,,c,,,,,1.0,,
22711886,2523,22030,12518,Association,TRUE,"However, <ENT1>TRAF2</ENT1> was deleterious for <ENT2>BCR</ENT2>-mediated activation of these kinases.",,,,T,,,,,c,,,,,0.0,,
22711886,2523,22030,12518,Association,TRUE,"In contrast, <ENT1>TRAF2</ENT1> deficiency had no effect on CD40-mediated p38 MAPK activation but significantly reduced <ENT2>BCR</ENT2>-mediated p38 activation.",,,,T,,,,,c,,,,,0.0,,
22711886,2519,22030,24099,Association,TRUE,"Finally, we further confirm that <ENT1>TRAF2</ENT1> was required for CD40-mediated proliferation, but its absence relieved B cells of the need for <ENT2>B cell activating factor</ENT2> for survival.",,,,T,,,,,w,,,,,0.0,,
22711886,2519,22030,24099,Association,TRUE,"Altogether, our results suggest that <ENT1>TRAF2</ENT1> deficiency cooperates with BCL-2 in promoting chronic lymphocytic leukemia/small lymphocytic lymphoma in mice, possibly by specifically enforcing marginal zone B cell accumulation, increasing X-linked inhibitor of apoptosis expression, and rendering B cells independent of <ENT2>B cell activating factor</ENT2> for survival.",,,,T,Y,,,,w,,,,,0.0,,
22808010,2552,D011086,13857,Association,FALSE,"Certain concepts concerning EPO/<ENT2>EPOR</ENT2> action modes have been challenged by in vivo studies: Bcl-x levels are elevated in maturing erythroblasts, but not in their progenitors; truncated <ENT2>EPOR</ENT2> alleles that lack a major p85/PI3K recruitment site nonetheless promote <ENT1>polycythemia</ENT1>; and Erk1 disruption unexpectedly bolsters erythropoiesis.",,,,T,,,,,c,,,,,0.5,,
22808010,2559,12530,13857,Association,TRUE,"EPO/<ENT2>EPOR</ENT2>-modulated cell cycle mediators included <ENT1>Cdc25a</ENT1>, Btg3, Cyclin-d2, p27-kip1, Cyclin-g2 and CyclinB1-IP-1.",,,,T,,,,,c,,,,,1.0,,
22808010,2542,12530,13856,Association,TRUE,"<ENT2>EPO</ENT2>/EPOR-modulated cell cycle mediators included <ENT1>Cdc25a</ENT1>, Btg3, Cyclin-d2, p27-kip1, Cyclin-g2 and CyclinB1-IP-1.",,,,T,,,,,c,,,,,1.0,,
22808010,2557,12444,13857,Association,FALSE,"EPO/<ENT2>EPOR</ENT2>-modulated cell cycle mediators included Cdc25a, Btg3, <ENT1>Cyclin-d2</ENT1>, p27-kip1, Cyclin-g2 and CyclinB1-IP-1.",,,,T,,,,,c,,,,,1.0,,
22808010,2540,12444,13856,Association,FALSE,"<ENT2>EPO</ENT2>/EPOR-modulated cell cycle mediators included Cdc25a, Btg3, <ENT1>Cyclin-d2</ENT1>, p27-kip1, Cyclin-g2 and CyclinB1-IP-1.",,,,T,,,,,c,,,,,0.0,,
22808010,2548,14455,13856,Association,TRUE,"A unique set of <ENT2>EPO</ENT2>-regulated survival factors included Lyl1, <ENT1>Gas5</ENT1>, Pim3, Pim1, Bim, Trib3 and Serpina 3g.",,,,T,,,,,c,,,,,1.0,,
22808010,2535,12702,13856,Positive_Correlation,FALSE,"For example, not only <ENT1>Socs3</ENT1> plus Socs2 but also Spred2, Spred1 and Eaf1 were <ENT2>EPO</ENT2>-induced as negative-feedback components.",,,,T,,,,,c,,,,,1.0,,
22808010,2528,D000740,20850,Association,TRUE,"Socs2, plus five additional targets, further proved to comprise new EPOR/Jak2/<ENT2>Stat5</ENT2> response genes (which are important for erythropoiesis during <ENT1>anemia</ENT1>).",,,,T,,,,,c,,,,,1.0,,
22808010,2529,D000740,16452,Association,TRUE,"Socs2, plus five additional targets, further proved to comprise new EPOR/<ENT2>Jak2</ENT2>/Stat5 response genes (which are important for erythropoiesis during <ENT1>anemia</ENT1>).",,,,T,,,,,c,,,,,1.0,,
22808010,2533,D000740,216233,Association,TRUE,"<ENT2>Socs2</ENT2>, plus five additional targets, further proved to comprise new EPOR/Jak2/Stat5 response genes (which are important for erythropoiesis during <ENT1>anemia</ENT1>).",,,,T,,,,,c,,,,,1.0,,
22808010,2553,D000740,13857,Association,TRUE,"Socs2, plus five additional targets, further proved to comprise new <ENT2>EPOR</ENT2>/Jak2/Stat5 response genes (which are important for erythropoiesis during <ENT1>anemia</ENT1>).",,,,T,,,,,c,,,,,0.0,,
22808010,2545,12125,13856,Association,FALSE,"A unique set of <ENT2>EPO</ENT2>-regulated survival factors included Lyl1, Gas5, Pim3, Pim1, <ENT1>Bim</ENT1>, Trib3 and Serpina 3g.",,,,T,,,,,c,,,,,0.0,,
22808010,2551,18708,13857,Association,FALSE,"Certain concepts concerning EPO/<ENT2>EPOR</ENT2> action modes have been challenged by in vivo studies: Bcl-x levels are elevated in maturing erythroblasts, but not in their progenitors; truncated <ENT2>EPOR</ENT2> alleles that lack a major <ENT1>p85/PI3K</ENT1> recruitment site nonetheless promote polycythemia; and Erk1 disruption unexpectedly bolsters erythropoiesis.",,,,T,,,,,c,,,,,0.0,,
22808010,2558,12228,13857,Association,TRUE,"EPO/<ENT2>EPOR</ENT2>-modulated cell cycle mediators included Cdc25a, <ENT1>Btg3</ENT1>, Cyclin-d2, p27-kip1, Cyclin-g2 and CyclinB1-IP-1.",,,,T,,,,,c,,,,,1.0,,
22808010,2541,12228,13856,Association,TRUE,"<ENT2>EPO</ENT2>/EPOR-modulated cell cycle mediators included Cdc25a, <ENT1>Btg3</ENT1>, Cyclin-d2, p27-kip1, Cyclin-g2 and CyclinB1-IP-1.",,,,T,,,,,c,,,,,1.0,,
22808010,2555,12452,13857,Association,FALSE,"EPO/<ENT2>EPOR</ENT2>-modulated cell cycle mediators included Cdc25a, Btg3, Cyclin-d2, p27-kip1, <ENT1>Cyclin-g2</ENT1> and CyclinB1-IP-1.",,,,T,,,,,c,,,,,1.0,,
22808010,2538,12452,13856,Association,FALSE,"<ENT2>EPO</ENT2>/EPOR-modulated cell cycle mediators included Cdc25a, Btg3, Cyclin-d2, p27-kip1, <ENT1>Cyclin-g2</ENT1> and CyclinB1-IP-1.",,,,T,,,,,c,,,,,1.0,,
22808010,2554,239083,13857,Association,TRUE,"EPO/<ENT2>EPOR</ENT2>-modulated cell cycle mediators included Cdc25a, Btg3, Cyclin-d2, p27-kip1, Cyclin-g2 and <ENT1>CyclinB1-IP-1</ENT1>.",,,,T,,,,,c,,,,,1.0,,
22808010,2537,239083,13856,Association,TRUE,"<ENT2>EPO</ENT2>/EPOR-modulated cell cycle mediators included Cdc25a, Btg3, Cyclin-d2, p27-kip1, Cyclin-g2 and <ENT1>CyclinB1-IP-1</ENT1>.",,,,T,,,,,c,,,,,0.0,,
22808010,2547,223775,13856,Association,FALSE,"A unique set of <ENT2>EPO</ENT2>-regulated survival factors included Lyl1, Gas5, <ENT1>Pim3</ENT1>, Pim1, Bim, Trib3 and Serpina 3g.",,,,T,,,,,c,,,,,0.0,,
22808010,2534,216233,13856,Positive_Correlation,FALSE,"For example, not only Socs3 plus <ENT1>Socs2</ENT1> but also Spred2, Spred1 and Eaf1 were <ENT2>EPO</ENT2>-induced as negative-feedback components.",,,,T,,,,,c,,,,,1.0,,
22808010,2556,13857,12576,Association,FALSE,"EPO/<ENT1>EPOR</ENT1>-modulated cell cycle mediators included Cdc25a, Btg3, Cyclin-d2, <ENT2>p27-kip1</ENT2>, Cyclin-g2 and CyclinB1-IP-1.",,,,T,,,,,c,,,,,1.0,,
22808010,2560,13857,72049,Association,TRUE,"Defining an <ENT1>EPOR</ENT1>- regulated transcriptome for primary progenitors, including <ENT2>Tnfr-sf13c</ENT2> as a novel mediator of EPO- dependent erythroblast formation.",,,,T,,T,,,c,,,,,1.0,,
22808010,2560,13857,72049,Association,TRUE,"The <ENT1>EPOR</ENT1> therefore engages a sophisticated set of transcriptome response circuits, with <ENT2>Tnfr-sf13c</ENT2> deployed as one novel positive regulator of proerythroblast formation.",,,,T,,,,,c,,,,,0.0,,
22808010,2549,13857,13856,Bind,FALSE,"Defining an <ENT1>EPOR</ENT1>- regulated transcriptome for primary progenitors, including Tnfr-sf13c as a novel mediator of <ENT2>EPO</ENT2>- dependent erythroblast formation.",,,,T,,T,,,c,,,,,1.0,,
22808010,2549,13857,13856,Bind,FALSE,"Certain concepts concerning <ENT2>EPO</ENT2>/<ENT1>EPOR</ENT1> action modes have been challenged by in vivo studies: Bcl-x levels are elevated in maturing erythroblasts, but not in their progenitors; truncated <ENT1>EPOR</ENT1> alleles that lack a major p85/PI3K recruitment site nonetheless promote polycythemia; and Erk1 disruption unexpectedly bolsters erythropoiesis.",,,,T,,,,,w,,,,,0.0,,
22808010,2549,13857,13856,Bind,FALSE,"To discover novel <ENT2>EPO</ENT2>/<ENT1>EPOR</ENT1> action routes, global transcriptome analyses presently are applied to interrogate <ENT2>EPO</ENT2>/<ENT1>EPOR</ENT1> effects on primary bone marrow-derived CFUe-like progenitors.",,,,T,,,,,w,,,"11,22",,0.0,,
22808010,2549,13857,13856,Bind,FALSE,"Overall, 160 <ENT2>EPO</ENT2>/<ENT1>EPOR</ENT1> target transcripts were significantly modulated 2-to 21.8-fold.",,,,T,,,,,w,,,,,0.0,,
22808010,2549,13857,13856,Bind,FALSE,"<ENT2>EPO</ENT2>/<ENT1>EPOR</ENT1>-modulated cell cycle mediators included Cdc25a, Btg3, Cyclin-d2, p27-kip1, Cyclin-g2 and CyclinB1-IP-1.",,,,T,,,,,w,,,,,0.0,,
22808010,2536,17095,13856,Association,TRUE,"A unique set of <ENT2>EPO</ENT2>-regulated survival factors included <ENT1>Lyl1</ENT1>, Gas5, Pim3, Pim1, Bim, Trib3 and Serpina 3g.",,,,T,,,,,c,,,,,1.0,,
22808010,2539,12576,13856,Association,FALSE,"<ENT2>EPO</ENT2>/EPOR-modulated cell cycle mediators included Cdc25a, Btg3, Cyclin-d2, <ENT1>p27-kip1</ENT1>, Cyclin-g2 and CyclinB1-IP-1.",,,,T,,,,,c,,,,,1.0,,
22808010,2532,114716,13856,Positive_Correlation,TRUE,"For example, not only Socs3 plus Socs2 but also <ENT1>Spred2</ENT1>, Spred1 and Eaf1 were <ENT2>EPO</ENT2>-induced as negative-feedback components.",,,,T,,,,,c,,,,,0.0,,
22808010,2550,72049,13856,Positive_Correlation,TRUE,"Defining an EPOR- regulated transcriptome for primary progenitors, including <ENT1>Tnfr-sf13c</ENT1> as a novel mediator of <ENT2>EPO</ENT2>- dependent erythroblast formation.",,,,T,Y,,,,c,,,,,0.0,,
22808010,2550,72049,13856,Positive_Correlation,TRUE,"Among receptors, an atypical <ENT1>TNF-receptor</ENT1> <ENT1>Tnfr-sf13c</ENT1> was up-modulated    >5-fold by <ENT2>EPO</ENT2>.",,,,T,,,,,c,,,,,1.0,,
22808010,2544,228775,13856,Association,FALSE,"A unique set of <ENT2>EPO</ENT2>-regulated survival factors included Lyl1, Gas5, Pim3, Pim1, Bim, <ENT1>Trib3</ENT1> and Serpina 3g.",,,,T,,,,,c,,,,,1.0,,
22808010,2543,20715,13856,Association,FALSE,"A unique set of <ENT2>EPO</ENT2>-regulated survival factors included Lyl1, Gas5, Pim3, Pim1, Bim, Trib3 and <ENT1>Serpina 3g</ENT1>.",,,,T,,,,,c,,,,,1.0,,
22808010,2531,13856,114715,Positive_Correlation,TRUE,"For example, not only Socs3 plus Socs2 but also Spred2, <ENT2>Spred1</ENT2> and Eaf1 were <ENT1>EPO</ENT1>-induced as negative-feedback components.",,,,T,,,,,c,,,,,1.0,,
22808010,2530,13856,74427,Positive_Correlation,TRUE,"For example, not only Socs3 plus Socs2 but also Spred2, Spred1 and <ENT2>Eaf1</ENT2> were <ENT1>EPO</ENT1>-induced as negative-feedback components.",,,,T,,,,,c,,,,,1.0,,
22808010,2546,13856,18712,Association,FALSE,"A unique set of <ENT1>EPO</ENT1>-regulated survival factors included Lyl1, Gas5, Pim3, <ENT2>Pim1</ENT2>, Bim, Trib3 and Serpina 3g.",,,,T,,,,,c,,,,,1.0,,
22836123,2564,D016559,D012595,Negative_Correlation,TRUE,The aim of this work is to call attention to the risk of <ENT1>tacrolimus</ENT1> use in patients with <ENT2>SSc</ENT2>.,,,,T,,,,,w,,,,,0.0,,
22836123,2566,D016559,D007674,Positive_Correlation,TRUE,Late-onset <ENT2>scleroderma renal crisis</ENT2> induced by <ENT1>tacrolimus</ENT1> and prednisolone: a case report.,,,,T,,T,,,c,,,,,1.0,,
22836123,2566,D016559,D007674,Positive_Correlation,TRUE,"In this article, we report a patient with <ENT2>SRC</ENT2> induced by <ENT1>tacrolimus</ENT1> and corticosteroids.",,,,T,,,,,c,,,,,1.0,,
22836123,2562,D016572,D057049,Positive_Correlation,FALSE,"Furthermore, there have been reports of <ENT2>thrombotic microangiopathy</ENT2> precipitated by <ENT1>cyclosporine</ENT1> in patients with SSc.",,,,T,,,,,c,,,,,1.0,,
22836123,2563,D016572,D012595,Negative_Correlation,FALSE,"Furthermore, there have been reports of thrombotic microangiopathy precipitated by <ENT1>cyclosporine</ENT1> in patients with <ENT2>SSc</ENT2>.",,,,T,,,,,w,,,,,0.0,,
22836123,2561,D000305,D007674,Positive_Correlation,TRUE,Moderate to high dose <ENT1>corticosteroid</ENT1> use is recognized as a major risk factor for <ENT2>SRC</ENT2>.,,,,T,,,,,c,,,,,1.0,,
22836123,2561,D000305,D007674,Positive_Correlation,TRUE,"In this article, we report a patient with <ENT2>SRC</ENT2> induced by tacrolimus and <ENT1>corticosteroids</ENT1>.",,,,T,,,,,c,,,,,1.0,,
22836123,2565,D011239,D007674,Positive_Correlation,TRUE,Late-onset <ENT2>scleroderma renal crisis</ENT2> induced by tacrolimus and <ENT1>prednisolone</ENT1>: a case report.,,,,T,,T,,,c,,,,,1.0,,
22859398,2572,3586,D011471,Association,TRUE,Variation in <ENT1>IL10</ENT1> and other genes involved in the immune response and in oxidation and <ENT2>prostate cancer</ENT2> recurrence.,,,,T,,T,,,c,,,,,1.0,,
22859398,2572,3586,D011471,Association,TRUE,"BACKGROUND: To evaluate the association of variation in genes involved in immune response, including <ENT1>IL10</ENT1>, production and detoxification of reactive oxygen species, and repair of oxidative DNA damage with risk of recurrence after surgery for localized <ENT2>prostate cancer</ENT2>.",,,,T,,Y,,,c,,,,,1.0,,
22859398,2572,3586,D011471,Association,TRUE,"CONCLUSION: Variation in <ENT1>IL10</ENT1>, CRP, GSTP1, IL1B, and NOS2 was associated with <ENT2>prostate cancer</ENT2> recurrence independent of pathologic prognostic factors.",,,,T,,,,,c,,,,,1.0,,
22859398,2570,2950,D011471,Association,TRUE,"CONCLUSION: Variation in IL10, CRP, <ENT1>GSTP1</ENT1>, IL1B, and NOS2 was associated with <ENT2>prostate cancer</ENT2> recurrence independent of pathologic prognostic factors.",,,,T,,,,,c,,,,,1.0,,
22859398,2569,3553,D011471,Association,TRUE,"CONCLUSION: Variation in IL10, CRP, GSTP1, <ENT1>IL1B</ENT1>, and NOS2 was associated with <ENT2>prostate cancer</ENT2> recurrence independent of pathologic prognostic factors.",,,,T,,,,,c,,,,,1.0,,
22859398,2573,4843,D011471,Association,TRUE,"CONCLUSION: Variation in IL10, CRP, GSTP1, IL1B, and <ENT1>NOS2</ENT1> was associated with <ENT2>prostate cancer</ENT2> recurrence independent of pathologic prognostic factors.",,,,T,,,,,c,,,,,1.0,,
22859398,2571,1401,D011471,Association,TRUE,"CONCLUSION: Variation in IL10, <ENT1>CRP</ENT1>, GSTP1, IL1B, and NOS2 was associated with <ENT2>prostate cancer</ENT2> recurrence independent of pathologic prognostic factors.",,,,T,,,,,c,,,,,1.0,,
23069675,2576,13063,D009410,Association,TRUE,"In contrast, in NP1-KO neurons there was no translocation of Bad and Bax from cytosol to the mitochondria, and no evidence of D (m) loss, increased <ENT1>Cyt C</ENT1> release and caspase-3 activation following OGD; which resulted in significantly reduced <ENT2>neuronal death</ENT2>.",,,,T,,,,,c,,,,,0.0,,
23069675,2578,13063,12028,Association,TRUE,Immunofluorescence staining and subcellular fractionation analyses revealed increased mitochondrial translocation of Bad and <ENT2>Bax</ENT2> proteins from cytoplasm following OGD (4 h) and simultaneously increased release of <ENT1>Cyt C</ENT1> from mitochondria followed by activation of caspase-3.,,,,T,,,,,c,,,,,0.0,,
23069675,2578,13063,12028,Association,TRUE,"In contrast, in NP1-KO neurons there was no translocation of Bad and <ENT2>Bax</ENT2> from cytosol to the mitochondria, and no evidence of D (m) loss, increased <ENT1>Cyt C</ENT1> release and caspase-3 activation following OGD; which resulted in significantly reduced neuronal death.",,,,T,Y,,,,w,,,,,0.0,,
23069675,2578,13063,12028,Association,TRUE,Our results indicate a regulatory role of NP1 in Bad/<ENT2>Bax</ENT2>-dependent mitochondrial release of <ENT1>Cyt C</ENT1> and caspase-3 activation.,,,,T,,,,,c,,,,,1.0,,
23069675,2581,13063,12015,Association,TRUE,Immunofluorescence staining and subcellular fractionation analyses revealed increased mitochondrial translocation of <ENT2>Bad</ENT2> and Bax proteins from cytoplasm following OGD (4 h) and simultaneously increased release of <ENT1>Cyt C</ENT1> from mitochondria followed by activation of caspase-3.,,,,T,,,,,c,,,,,0.0,,
23069675,2581,13063,12015,Association,TRUE,"In contrast, in NP1-KO neurons there was no translocation of <ENT2>Bad</ENT2> and Bax from cytosol to the mitochondria, and no evidence of D (m) loss, increased <ENT1>Cyt C</ENT1> release and caspase-3 activation following OGD; which resulted in significantly reduced neuronal death.",,,,T,Y,,,,w,,,,,1.0,,
23069675,2581,13063,12015,Association,TRUE,Our results indicate a regulatory role of NP1 in <ENT2>Bad</ENT2>/Bax-dependent mitochondrial release of <ENT1>Cyt C</ENT1> and caspase-3 activation.,,,,T,,,,,c,,,,,0.0,,
23069675,2579,D009410,12028,Association,TRUE,"In contrast, in NP1-KO neurons there was no translocation of Bad and <ENT2>Bax</ENT2> from cytosol to the mitochondria, and no evidence of D (m) loss, increased Cyt C release and caspase-3 activation following OGD; which resulted in significantly reduced <ENT1>neuronal death</ENT1>.",,,,T,,,,,c,,,,,0.0,,
23069675,2585,D009410,18164,Association,TRUE,"In contrast, in <ENT2>NP1</ENT2>-KO neurons there was no translocation of Bad and Bax from cytosol to the mitochondria, and no evidence of D (m) loss, increased Cyt C release and caspase-3 activation following OGD; which resulted in significantly reduced <ENT1>neuronal death</ENT1>.",,,,T,,,,,c,,,,,0.0,,
23069675,2575,D009410,12367,Association,TRUE,"In contrast, in NP1-KO neurons there was no translocation of Bad and Bax from cytosol to the mitochondria, and no evidence of D (m) loss, increased Cyt C release and <ENT2>caspase-3</ENT2> activation following OGD; which resulted in significantly reduced <ENT1>neuronal death</ENT1>.",,,,T,,,,,c,,,,,0.0,,
23069675,2582,D009410,12015,Association,TRUE,"In contrast, in NP1-KO neurons there was no translocation of <ENT2>Bad</ENT2> and Bax from cytosol to the mitochondria, and no evidence of D (m) loss, increased Cyt C release and caspase-3 activation following OGD; which resulted in significantly reduced <ENT1>neuronal death</ENT1>.",,,,T,,,,,c,,,,,0.0,,
23069675,2583,56637,19211,Association,TRUE,We also found increased <ENT2>PTEN</ENT2> activity concurrent with OGD time-dependent (4-8 h) dephosphorylation of Akt (Ser473) and <ENT1>GSK-3b</ENT1> (Ser9).,,,,T,,,,,c,,,,,0.0,,
23069675,2586,12028,18164,Association,TRUE,"<ENT2>NP1</ENT2> protein was immunoprecipitated with Bad and <ENT1>Bax</ENT1> proteins; OGD caused increased interactions of <ENT2>NP1</ENT2> with Bad and <ENT1>Bax</ENT1>, thereby, facilitating their mitochondrial translocation and dissipation of mitochondrial membrane potential (D (m)).",,,,T,,,,,c,,,"11,22",,0.5,,
23069675,2586,12028,18164,Association,TRUE,"In contrast, in <ENT2>NP1</ENT2>-KO neurons there was no translocation of Bad and <ENT1>Bax</ENT1> from cytosol to the mitochondria, and no evidence of D (m) loss, increased Cyt C release and caspase-3 activation following OGD; which resulted in significantly reduced neuronal death.",,,,T,Y,,,,w,,,,,0.0,,
23069675,2586,12028,18164,Association,TRUE,Our results indicate a regulatory role of <ENT2>NP1</ENT2> in Bad/<ENT1>Bax</ENT1>-dependent mitochondrial release of Cyt C and caspase-3 activation.,,,,T,,,,,c,,,,,0.0,,
23069675,2577,12028,12367,Association,TRUE,Immunofluorescence staining and subcellular fractionation analyses revealed increased mitochondrial translocation of Bad and <ENT1>Bax</ENT1> proteins from cytoplasm following OGD (4 h) and simultaneously increased release of Cyt C from mitochondria followed by activation of <ENT2>caspase-3</ENT2>.,,,,T,Y,,,,w,,,,,0.0,,
23069675,2577,12028,12367,Association,TRUE,"In contrast, in NP1-KO neurons there was no translocation of Bad and <ENT1>Bax</ENT1> from cytosol to the mitochondria, and no evidence of D (m) loss, increased Cyt C release and <ENT2>caspase-3</ENT2> activation following OGD; which resulted in significantly reduced neuronal death.",,,,T,Y,,,,c,,,,,0.0,,
23069675,2577,12028,12367,Association,TRUE,Our results indicate a regulatory role of NP1 in Bad/<ENT1>Bax</ENT1>-dependent mitochondrial release of Cyt C and <ENT2>caspase-3</ENT2> activation.,,,,T,,,,,w,,,,,0.0,,
23069675,2574,266777,D020925,Association,TRUE,"Previously, we have reported induction of <ENT1>neuronal pentraxin 1</ENT1> (<ENT1>NP1</ENT1>), a novel neuronal protein of long-pentraxin family, following <ENT2>HI neuronal injury</ENT2>.",,,,T,,,,,c,,,,,0.0,,
23069675,2587,18164,12015,Association,TRUE,"<ENT1>NP1</ENT1> protein was immunoprecipitated with <ENT2>Bad</ENT2> and Bax proteins; OGD caused increased interactions of <ENT1>NP1</ENT1> with <ENT2>Bad</ENT2> and Bax, thereby, facilitating their mitochondrial translocation and dissipation of mitochondrial membrane potential (D (m)).",,,,T,,,,,c,,,"11,22",,0.25,,
23069675,2587,18164,12015,Association,TRUE,"In contrast, in <ENT1>NP1</ENT1>-KO neurons there was no translocation of <ENT2>Bad</ENT2> and Bax from cytosol to the mitochondria, and no evidence of D (m) loss, increased Cyt C release and caspase-3 activation following OGD; which resulted in significantly reduced neuronal death.",,,,T,Y,,,,w,,,,,0.0,,
23069675,2587,18164,12015,Association,TRUE,Our results indicate a regulatory role of <ENT1>NP1</ENT1> in <ENT2>Bad</ENT2>/Bax-dependent mitochondrial release of Cyt C and caspase-3 activation.,,,,T,,,,,c,,,,,0.0,,
23069675,2588,18164,D020925,Association,TRUE,Critical role of <ENT1>neuronal pentraxin 1</ENT1> in mitochondria-mediated <ENT2>hypoxic-ischemic neuronal injury</ENT2>.,,,,T,,T,,,c,,,,,1.0,,
23069675,2588,18164,D020925,Association,TRUE,"We used wild-type (WT) and <ENT1>NP1</ENT1> knockout (<ENT1>NP1</ENT1>-KO) mouse hippocampal cultures, modeled in vitro following exposure to oxygen glucose deprivation (OGD), and in vivo neonatal (P9-10) mouse model of <ENT2>HI brain injury</ENT2>.",,,,T,,,,,c,,,,,1.0,,
23069675,2588,18164,D020925,Association,TRUE,Together our findings demonstrate a novel mechanism by which <ENT1>NP1</ENT1> regulates mitochondria-driven hippocampal cell death; suggesting <ENT1>NP1</ENT1> as a potential therapeutic target against <ENT2>HI brain injury</ENT2> in neonates.,,,,T,,,,,c,,,,,0.0,,
23069675,2584,19211,11651,Association,TRUE,We also found increased <ENT1>PTEN</ENT1> activity concurrent with OGD time-dependent (4-8 h) dephosphorylation of <ENT2>Akt</ENT2> (Ser473) and GSK-3b (Ser9).,,,,T,,,,,c,,,,,0.0,,
23069675,2580,12367,12015,Association,TRUE,Immunofluorescence staining and subcellular fractionation analyses revealed increased mitochondrial translocation of <ENT2>Bad</ENT2> and Bax proteins from cytoplasm following OGD (4 h) and simultaneously increased release of Cyt C from mitochondria followed by activation of <ENT1>caspase-3</ENT1>.,,,,T,,,,,c,,,,,1.0,,
23069675,2580,12367,12015,Association,TRUE,"In contrast, in NP1-KO neurons there was no translocation of <ENT2>Bad</ENT2> and Bax from cytosol to the mitochondria, and no evidence of D (m) loss, increased Cyt C release and <ENT1>caspase-3</ENT1> activation following OGD; which resulted in significantly reduced neuronal death.",,,,T,,,,,c,,,,,1.0,,
23069675,2580,12367,12015,Association,TRUE,Our results indicate a regulatory role of NP1 in <ENT2>Bad</ENT2>/Bax-dependent mitochondrial release of Cyt C and <ENT1>caspase-3</ENT1> activation.,,,,T,Y,,,,w,,,,,0.0,,
23285048,2590,19264,54485,Positive_Correlation,TRUE,"Besides its effects in the BM vascular niche, anti-<ENT2>Dll4</ENT2> treatment perturbed hematopoiesis, as evidenced by increased myeloid (CD11b(+)), decreased B (<ENT1>B220</ENT1>(+)) and T (CD3(+)) lymphoid BM content of treated mice, with a corresponding increase in myeloid circulating cells.",,,,T,,,,,c,,,,,0.0,,
23285048,2604,18613,54485,Association,TRUE,"Here we show that <ENT2>Dll4</ENT2> blockade with monoclonal antibodies perturbs the BM vascular niche of sub-lethally irradiated mice, resulting in increased <ENT1>CD31</ENT1>(+), VE-Cadherin(+) and c-kit(+) vessel density, and also increased megakaryocytes, whereas CD105(+), VEGFR3(+), SMA(+) and lectin(+) vessel density remained unaltered.",,,,T,,,,,c,,,,,0.0,,
23285048,2591,16409,54485,Negative_Correlation,TRUE,"Besides its effects in the BM vascular niche, anti-<ENT2>Dll4</ENT2> treatment perturbed hematopoiesis, as evidenced by increased myeloid (<ENT1>CD11b</ENT1>(+)), decreased B (B220(+)) and T (CD3(+)) lymphoid BM content of treated mice, with a corresponding increase in myeloid circulating cells.",,,,T,,,,,c,,,,,1.0,,
23285048,2589,12501,54485,Positive_Correlation,TRUE,"Besides its effects in the BM vascular niche, anti-<ENT2>Dll4</ENT2> treatment perturbed hematopoiesis, as evidenced by increased myeloid (CD11b(+)), decreased B (B220(+)) and T (<ENT1>CD3</ENT1>(+)) lymphoid BM content of treated mice, with a corresponding increase in myeloid circulating cells.",,,,T,,,,,c,,,,,0.0,,
23285048,2603,12562,54485,Association,TRUE,"Here we show that <ENT2>Dll4</ENT2> blockade with monoclonal antibodies perturbs the BM vascular niche of sub-lethally irradiated mice, resulting in increased CD31(+), <ENT1>VE-Cadherin</ENT1>(+) and c-kit(+) vessel density, and also increased megakaryocytes, whereas CD105(+), VEGFR3(+), SMA(+) and lectin(+) vessel density remained unaltered.",,,,T,,,,,c,,,,,0.0,,
23285048,2596,14164,54485,Positive_Correlation,TRUE,"We investigated also the expression of angiocrine genes upon <ENT2>Dll4</ENT2> treatment in vivo, and demonstrate that IGFbp2, IGFbp3, Angpt2, <ENT2>Dll4</ENT2>, DHH and VEGF-A are upregulated, while <ENT1>FGF1</ENT1> and CSF2 are reduced.",,,,T,,,,,w,,,,,0.5,,
23285048,2601,16008,54485,Positive_Correlation,TRUE,"We investigated also the expression of angiocrine genes upon <ENT2>Dll4</ENT2> treatment in vivo, and demonstrate that <ENT1>IGFbp2</ENT1>, IGFbp3, Angpt2, <ENT2>Dll4</ENT2>, DHH and VEGF-A are upregulated, while FGF1 and CSF2 are reduced.",,,,T,,,,,w,,,,,0.5,,
23285048,2594,18128,54485,Association,TRUE,"<ENT2>Delta-like 4</ENT2> (<ENT2>Dll4</ENT2>) is a ligand of the <ENT1>Notch</ENT1> pathway family which has been widely studied in the context of tumor angiogenesis, its blockade shown to result in non-productive angiogenesis and halted tumor growth.",,,,T,,,,,c,,,,,0.0,,
23285048,2594,18128,54485,Association,TRUE,"As <ENT2>Dll4</ENT2> inhibitors enter the clinic, there is an emerging need to understand their side effects, namely the systemic consequences of <ENT2>Dll4</ENT2>:<ENT1>Notch</ENT1> blockade in tissues other than tumors.",,,,T,,,,,w,,,,,1.0,,
23285048,2594,18128,54485,Association,TRUE,"Moreover, anti-<ENT2>Dll4</ENT2> treatment also increased the number of CFU-M and -G colonies in methylcellulose assays, independently of <ENT1>Notch1</ENT1>.",,,,T,,,,,c,,,,,1.0,,
23285048,2597,22339,54485,Positive_Correlation,TRUE,"We investigated also the expression of angiocrine genes upon <ENT2>Dll4</ENT2> treatment in vivo, and demonstrate that IGFbp2, IGFbp3, Angpt2, <ENT2>Dll4</ENT2>, DHH and <ENT1>VEGF-A</ENT1> are upregulated, while FGF1 and CSF2 are reduced.",,,,T,,,,,w,,,,,0.5,,
23285048,2598,54485,13363,Positive_Correlation,TRUE,"We investigated also the expression of angiocrine genes upon <ENT1>Dll4</ENT1> treatment in vivo, and demonstrate that IGFbp2, IGFbp3, Angpt2, <ENT1>Dll4</ENT1>, <ENT2>DHH</ENT2> and VEGF-A are upregulated, while FGF1 and CSF2 are reduced.",,,,T,,,,,w,,,,,0.0,,
23285048,2600,54485,16009,Positive_Correlation,TRUE,"We investigated also the expression of angiocrine genes upon <ENT1>Dll4</ENT1> treatment in vivo, and demonstrate that IGFbp2, <ENT2>IGFbp3</ENT2>, Angpt2, <ENT1>Dll4</ENT1>, DHH and VEGF-A are upregulated, while FGF1 and CSF2 are reduced.",,,,T,,,,,w,,,,,0.5,,
23285048,2599,54485,11601,Positive_Correlation,TRUE,"We investigated also the expression of angiocrine genes upon <ENT1>Dll4</ENT1> treatment in vivo, and demonstrate that IGFbp2, IGFbp3, <ENT2>Angpt2</ENT2>, <ENT1>Dll4</ENT1>, DHH and VEGF-A are upregulated, while FGF1 and CSF2 are reduced.",,,,T,,,,,w,,,,,0.5,,
23285048,2593,54485,D009369,Association,FALSE,"<ENT1>Delta-like 4</ENT1> (<ENT1>Dll4</ENT1>) is a ligand of the Notch pathway family which has been widely studied in the context of <ENT2>tumor</ENT2> angiogenesis, its blockade shown to result in non-productive angiogenesis and halted <ENT2>tumor</ENT2> growth.",,,,T,,,,,c,,,"11,12,21,22",,1.0,,
23285048,2593,54485,D009369,Association,FALSE,"As <ENT1>Dll4</ENT1> inhibitors enter the clinic, there is an emerging need to understand their side effects, namely the systemic consequences of <ENT1>Dll4</ENT1>:Notch blockade in tissues other than <ENT2>tumors</ENT2>.",,,,T,Y,,,,w,,,,,1.0,,
23285048,2602,54485,16590,Association,TRUE,"Here we show that <ENT1>Dll4</ENT1> blockade with monoclonal antibodies perturbs the BM vascular niche of sub-lethally irradiated mice, resulting in increased CD31(+), VE-Cadherin(+) and <ENT2>c-kit</ENT2>(+) vessel density, and also increased megakaryocytes, whereas CD105(+), VEGFR3(+), SMA(+) and lectin(+) vessel density remained unaltered.",,,,T,,,,,c,,,,,0.0,,
23285048,2595,54485,12981,Positive_Correlation,TRUE,"We investigated also the expression of angiocrine genes upon <ENT1>Dll4</ENT1> treatment in vivo, and demonstrate that IGFbp2, IGFbp3, Angpt2, <ENT1>Dll4</ENT1>, DHH and VEGF-A are upregulated, while FGF1 and <ENT2>CSF2</ENT2> are reduced.",,,,T,,,,,w,,,,,0.5,,
23285048,2592,54485,11651,Association,TRUE,In vitro treatment of endothelial cells with anti-<ENT1>Dll4</ENT1> reduced <ENT2>Akt</ENT2> phosphorylation while maintaining similar levels of Erk 1/2 phosphorylation.,,,,T,,,,,c,,,,,0.0,,
23791840,2612,13198,D016640,Positive_Correlation,TRUE,"RESULTS: <ENT2>Maternal diabetes</ENT2> significantly increased the levels of <ENT1>CHOP</ENT1>, calnexin, phosphorylated (p)-eIF2a, p-PERK, and p-IRE1a; triggered XBP1 mRNA splicing; and enhanced ER chaperone gene expression in WT embryos.",,,,T,,,,,c,,,,,1.0,,
23791840,2618,13198,20655,Association,TRUE,"STUDY DESIGN: Wild-type (WT) and <ENT2>superoxide dismutase 1</ENT2> (<ENT2>SOD1</ENT2>)-overexpressing day 8.75 embryos from nondiabetic WT control with <ENT2>SOD1</ENT2> transgenic male and diabetic WT female with <ENT2>SOD1</ENT2> transgenic male were analyzed for ER stress markers: <ENT1>C/EBP-homologous protein</ENT1> (<ENT1>CHOP</ENT1>), calnexin, eukaryotic initiation factor 2a (eIF2a), protein kinase ribonucleic acid (RNA)-like ER kinase (PERK), binding immunoglobulin protein, protein disulfide isomerase family A member 3, kinases inositol-requiring protein-1a (IRE1a), and the X-box binding protein (XBP1) messenger RNA (mRNA) splicing.",,,,T,,Y,,,c,,,,,1.0,,
23791840,2609,D016640,78943,Association,TRUE,"RESULTS: <ENT1>Maternal diabetes</ENT1> significantly increased the levels of CHOP, calnexin, phosphorylated (p)-eIF2a, p-PERK, and p-<ENT2>IRE1a</ENT2>; triggered XBP1 mRNA splicing; and enhanced ER chaperone gene expression in WT embryos.",,,,T,,,,,c,,,,,1.0,,
23791840,2611,D016640,229317,Association,TRUE,"RESULTS: <ENT1>Maternal diabetes</ENT1> significantly increased the levels of CHOP, calnexin, phosphorylated (p)-<ENT2>eIF2a</ENT2>, p-PERK, and p-IRE1a; triggered XBP1 mRNA splicing; and enhanced ER chaperone gene expression in WT embryos.",,,,T,,,,,c,,,,,0.0,,
23791840,2619,D016640,20655,Association,TRUE,<ENT2>Superoxide dismutase 1</ENT2> overexpression in mice abolishes <ENT1>maternal diabetes</ENT1>-induced endoplasmic reticulum stress in diabetic embryopathy.,,,,T,Y,,,,w,,,,,0.0,,
23791840,2619,D016640,20655,Association,TRUE,CONCLUSION: Mitigating oxidative stress via <ENT2>SOD1</ENT2> overexpression blocks <ENT1>maternal diabetes</ENT1>-induced ER stress in vivo.,,,,T,Y,,,,w,,,,,0.0,,
23791840,2608,D016640,22433,Association,TRUE,"RESULTS: <ENT1>Maternal diabetes</ENT1> significantly increased the levels of CHOP, calnexin, phosphorylated (p)-eIF2a, p-PERK, and p-IRE1a; triggered <ENT2>XBP1</ENT2> mRNA splicing; and enhanced ER chaperone gene expression in WT embryos.",,,,T,,,,,c,,,,,1.0,,
23791840,2606,D016640,12330,Positive_Correlation,TRUE,"RESULTS: <ENT1>Maternal diabetes</ENT1> significantly increased the levels of CHOP, <ENT2>calnexin</ENT2>, phosphorylated (p)-eIF2a, p-PERK, and p-IRE1a; triggered XBP1 mRNA splicing; and enhanced ER chaperone gene expression in WT embryos.",,,,T,,,,,c,,,,,1.0,,
23791840,2610,D016640,13666,Association,TRUE,"RESULTS: <ENT1>Maternal diabetes</ENT1> significantly increased the levels of CHOP, calnexin, phosphorylated (p)-eIF2a, p-<ENT2>PERK</ENT2>, and p-IRE1a; triggered XBP1 mRNA splicing; and enhanced ER chaperone gene expression in WT embryos.",,,,T,,,,,c,,,,,0.0,,
23791840,2607,D003920,20655,Association,TRUE,<ENT2>Superoxide dismutase 1</ENT2> overexpression in mice abolishes maternal diabetes-induced endoplasmic reticulum stress in <ENT1>diabetic</ENT1> embryopathy.,,,,T,,,,,w,,,,,0.0,,
23791840,2607,D003920,20655,Association,TRUE,"STUDY DESIGN: Wild-type (WT) and <ENT2>superoxide dismutase 1</ENT2> (<ENT2>SOD1</ENT2>)-overexpressing day 8.75 embryos from nondiabetic WT control with <ENT2>SOD1</ENT2> transgenic male and <ENT1>diabetic</ENT1> WT female with <ENT2>SOD1</ENT2> transgenic male were analyzed for ER stress markers: C/EBP-homologous protein (CHOP), calnexin, eukaryotic initiation factor 2a (eIF2a), protein kinase ribonucleic acid (RNA)-like ER kinase (PERK), binding immunoglobulin protein, protein disulfide isomerase family A member 3, kinases inositol-requiring protein-1a (IRE1a), and the X-box binding protein (XBP1) messenger RNA (mRNA) splicing.",,,,T,,,,,c,,,,,1.0,,
23791840,2607,D003920,20655,Association,TRUE,<ENT2>SOD1</ENT2> overexpression blocked these <ENT1>diabetes</ENT1>-induced ER stress markers.,,,,T,Y,,,,w,,,,,0.0,,
23791840,2615,78943,20655,Association,TRUE,"STUDY DESIGN: Wild-type (WT) and <ENT2>superoxide dismutase 1</ENT2> (<ENT2>SOD1</ENT2>)-overexpressing day 8.75 embryos from nondiabetic WT control with <ENT2>SOD1</ENT2> transgenic male and diabetic WT female with <ENT2>SOD1</ENT2> transgenic male were analyzed for ER stress markers: C/EBP-homologous protein (CHOP), calnexin, eukaryotic initiation factor 2a (eIF2a), protein kinase ribonucleic acid (RNA)-like ER kinase (PERK), binding immunoglobulin protein, protein disulfide isomerase family A member 3, <ENT1>kinases inositol-requiring protein-1a</ENT1> (<ENT1>IRE1a</ENT1>), and the X-box binding protein (XBP1) messenger RNA (mRNA) splicing.",,,,T,,Y,,,w,,,,,1.0,,
23791840,2617,229317,20655,Association,TRUE,"STUDY DESIGN: Wild-type (WT) and <ENT2>superoxide dismutase 1</ENT2> (<ENT2>SOD1</ENT2>)-overexpressing day 8.75 embryos from nondiabetic WT control with <ENT2>SOD1</ENT2> transgenic male and diabetic WT female with <ENT2>SOD1</ENT2> transgenic male were analyzed for ER stress markers: C/EBP-homologous protein (CHOP), calnexin, <ENT1>eukaryotic initiation factor 2a</ENT1> (<ENT1>eIF2a</ENT1>), protein kinase ribonucleic acid (RNA)-like ER kinase (PERK), binding immunoglobulin protein, protein disulfide isomerase family A member 3, kinases inositol-requiring protein-1a (IRE1a), and the X-box binding protein (XBP1) messenger RNA (mRNA) splicing.",,,,T,,Y,,,w,,,,,1.0,,
23791840,2614,20655,22433,Association,TRUE,"STUDY DESIGN: Wild-type (WT) and <ENT1>superoxide dismutase 1</ENT1> (<ENT1>SOD1</ENT1>)-overexpressing day 8.75 embryos from nondiabetic WT control with <ENT1>SOD1</ENT1> transgenic male and diabetic WT female with <ENT1>SOD1</ENT1> transgenic male were analyzed for ER stress markers: C/EBP-homologous protein (CHOP), calnexin, eukaryotic initiation factor 2a (eIF2a), protein kinase ribonucleic acid (RNA)-like ER kinase (PERK), binding immunoglobulin protein, protein disulfide isomerase family A member 3, kinases inositol-requiring protein-1a (IRE1a), and the <ENT2>X-box binding protein</ENT2> (<ENT2>XBP1</ENT2>) messenger RNA (mRNA) splicing.",,,,T,,Y,,,w,,,,,1.0,,
23791840,2613,20655,12330,Association,TRUE,"STUDY DESIGN: Wild-type (WT) and <ENT1>superoxide dismutase 1</ENT1> (<ENT1>SOD1</ENT1>)-overexpressing day 8.75 embryos from nondiabetic WT control with <ENT1>SOD1</ENT1> transgenic male and diabetic WT female with <ENT1>SOD1</ENT1> transgenic male were analyzed for ER stress markers: C/EBP-homologous protein (CHOP), <ENT2>calnexin</ENT2>, eukaryotic initiation factor 2a (eIF2a), protein kinase ribonucleic acid (RNA)-like ER kinase (PERK), binding immunoglobulin protein, protein disulfide isomerase family A member 3, kinases inositol-requiring protein-1a (IRE1a), and the X-box binding protein (XBP1) messenger RNA (mRNA) splicing.",,,,T,,Y,,,w,,,,,1.0,,
23791840,2616,20655,13666,Association,TRUE,"STUDY DESIGN: Wild-type (WT) and <ENT1>superoxide dismutase 1</ENT1> (<ENT1>SOD1</ENT1>)-overexpressing day 8.75 embryos from nondiabetic WT control with <ENT1>SOD1</ENT1> transgenic male and diabetic WT female with <ENT1>SOD1</ENT1> transgenic male were analyzed for ER stress markers: C/EBP-homologous protein (CHOP), calnexin, eukaryotic initiation factor 2a (eIF2a), <ENT2>protein kinase ribonucleic acid (RNA)-like ER kinase</ENT2> (<ENT2>PERK</ENT2>), binding immunoglobulin protein, protein disulfide isomerase family A member 3, kinases inositol-requiring protein-1a (IRE1a), and the X-box binding protein (XBP1) messenger RNA (mRNA) splicing.",,,,T,,Y,,,w,,,,,1.0,,
23791840,2605,20655,D005315,Association,TRUE,<ENT1>Superoxide dismutase 1</ENT1> overexpression in mice abolishes maternal diabetes-induced endoplasmic reticulum stress in diabetic <ENT2>embryopathy</ENT2>.,,,,T,,T,,,c,,,,,0.0,,
23864035,2621,D009101,D003907,Negative_Correlation,FALSE,Bortezomib and <ENT2>dexamethasone</ENT2> as salvage therapy in patients with relapsed/refractory <ENT1>multiple myeloma</ENT1>: analysis of long-term clinical outcomes.,,,,T,,T,,,c,,,,,1.0,,
23864035,2621,D009101,D003907,Negative_Correlation,FALSE,Bortezomib (bort)-<ENT2>dexamethasone</ENT2> (<ENT2>dex</ENT2>) is an effective therapy for relapsed/refractory (R/R) <ENT1>multiple myeloma</ENT1> (<ENT1>MM</ENT1>).,,,,T,,,,,c,,,"11,12,21,22",,0.5,,
23864035,2621,D009101,D003907,Negative_Correlation,FALSE,"This retrospective study investigated the combination of bort (1.3 mg/m(2) on days 1, 4, 8, and 11 every 3 weeks) and <ENT2>dex</ENT2> (20 mg on the day of and the day after bort) as salvage treatment in 85 patients with R/R <ENT1>MM</ENT1> after prior autologous stem cell transplantation or conventional chemotherapy.",,,,T,,,,,c,,,,,1.0,,
23864035,2621,D009101,D003907,Negative_Correlation,FALSE,"Bort-<ENT2>dex</ENT2> was an effective salvage treatment for <ENT1>MM</ENT1> patients, particularly for those in first relapse.",,,,T,,,,,c,,,,,1.0,,
23864035,2624,D009101,D000069286,Negative_Correlation,FALSE,<ENT2>Bortezomib</ENT2> and dexamethasone as salvage therapy in patients with relapsed/refractory <ENT1>multiple myeloma</ENT1>: analysis of long-term clinical outcomes.,,,,T,,T,,,c,,,,,1.0,,
23864035,2624,D009101,D000069286,Negative_Correlation,FALSE,<ENT2>Bortezomib</ENT2> (<ENT2>bort</ENT2>)-dexamethasone (dex) is an effective therapy for relapsed/refractory (R/R) <ENT1>multiple myeloma</ENT1> (<ENT1>MM</ENT1>).,,,,T,,,,,c,,,"11,12,21,22",,1.0,,
23864035,2624,D009101,D000069286,Negative_Correlation,FALSE,"This retrospective study investigated the combination of <ENT2>bort</ENT2> (1.3 mg/m(2) on days 1, 4, 8, and 11 every 3 weeks) and dex (20 mg on the day of and the day after <ENT2>bort</ENT2>) as salvage treatment in 85 patients with R/R <ENT1>MM</ENT1> after prior autologous stem cell transplantation or conventional chemotherapy.",,,,T,,,,,c,,,,,0.5,,
23864035,2624,D009101,D000069286,Negative_Correlation,FALSE,"<ENT2>Bort</ENT2>-dex was an effective salvage treatment for <ENT1>MM</ENT1> patients, particularly for those in first relapse.",,,,T,,,,,c,,,,,1.0,,
23864035,2623,D003907,D000069286,Cotreatment,FALSE,<ENT2>Bortezomib</ENT2> and <ENT1>dexamethasone</ENT1> as salvage therapy in patients with relapsed/refractory multiple myeloma: analysis of long-term clinical outcomes.,,,,T,,T,,,c,,,,,1.0,,
23864035,2623,D003907,D000069286,Cotreatment,FALSE,<ENT2>Bortezomib</ENT2> (<ENT2>bort</ENT2>)-<ENT1>dexamethasone</ENT1> (<ENT1>dex</ENT1>) is an effective therapy for relapsed/refractory (R/R) multiple myeloma (MM).,,,,T,,,,,c,,,"11,12,21,22",,0.75,,
23864035,2623,D003907,D000069286,Cotreatment,FALSE,"This retrospective study investigated the combination of <ENT2>bort</ENT2> (1.3 mg/m(2) on days 1, 4, 8, and 11 every 3 weeks) and <ENT1>dex</ENT1> (20 mg on the day of and the day after <ENT2>bort</ENT2>) as salvage treatment in 85 patients with R/R MM after prior autologous stem cell transplantation or conventional chemotherapy.",,,,T,,,,,c,,,,,0.5,,
23864035,2623,D003907,D000069286,Cotreatment,FALSE,Eighty-seven percent of the patients had received immunomodulatory drugs included in some line of therapy before <ENT2>bort</ENT2>-<ENT1>dex</ENT1>.,,,,T,,,,,w,,,,,0.0,,
23864035,2623,D003907,D000069286,Cotreatment,FALSE,"The median number of <ENT2>bort</ENT2>-<ENT1>dex</ENT1> cycles was 6, up to a maximum of 12 cycles.",,,,T,,,,,c,,,,,1.0,,
23864035,2623,D003907,D000069286,Cotreatment,FALSE,Prolonged PFS and OS were observed in patients achieving CR and receiving <ENT2>bort</ENT2>-<ENT1>dex</ENT1> a single line of prior therapy.,,,,T,,,,,w,,,,,1.0,,
23864035,2623,D003907,D000069286,Cotreatment,FALSE,"<ENT2>Bort</ENT2>-<ENT1>dex</ENT1> was an effective salvage treatment for MM patients, particularly for those in first relapse.",,,,T,,,,,c,,,,,1.0,,
23949582,2627,D007069,D030342,Positive_Correlation,FALSE,"Mesna significantly reduces <ENT1>IFO</ENT1>'s <ENT2>genotoxicity</ENT2>, while when administered in high concentrations it acts in an inhibitory fashion on the cytostatic action of the drug.",,,,T,,,,,w,,,,,1.0,,
23949582,2629,D007069,D015080,Negative_Correlation,TRUE,"The cytogenetic action of <ENT1>ifosfamide</ENT1>, <ENT2>mesna</ENT2>, and their combination on peripheral rabbit lymphocytes: an in vivo/in vitro cytogenetic study.",,,,T,,T,,,w,,,,,0.0,,
23949582,2629,D007069,D015080,Negative_Correlation,TRUE,This side effect of <ENT1>IFO</ENT1> raises the requirement for the co-administration with <ENT2>sodium 2-sulfanylethanesulfonate</ENT2> (<ENT2>Mesna</ENT2>) aiming to avoid or minimize this effect.,,,,T,Y,,,,c,,,,,0.0,,
23949582,2629,D007069,D015080,Negative_Correlation,TRUE,"<ENT1>IFO</ENT1> and <ENT2>Mesna</ENT2> were administrated separately on rabbit's lymphocytes in vivo, which were later developed in vitro.",,,,T,,,,,c,,,,,1.0,,
23949582,2629,D007069,D015080,Negative_Correlation,TRUE,"<ENT2>Mesna</ENT2>'s action, in conjunction with <ENT1>IFO</ENT1> reduces the frequency of SCEs, in comparison with the SCEs recordings obtained when <ENT1>IFO</ENT1> is administered alone.",,,,T,Y,,,,w,,,,,0.0,,
23949582,2629,D007069,D015080,Negative_Correlation,TRUE,"In addition to this, when high concentrations of <ENT2>Mesna</ENT2> were administered alone significant reductions of the PRI were noted, than with <ENT1>IFO</ENT1> acting at the same concentration on the lymphocytes.",,,,T,,,,,w,,,,,0.0,,
23949582,2629,D007069,D015080,Negative_Correlation,TRUE,"<ENT2>Mesna</ENT2> significantly reduces <ENT1>IFO</ENT1>'s genotoxicity, while when administered in high concentrations it acts in an inhibitory fashion on the cytostatic action of the drug.",,,,T,,,,,c,,,,,1.0,,
23949582,2628,D030342,D015080,Negative_Correlation,TRUE,"<ENT2>Mesna</ENT2> significantly reduces IFO's <ENT1>genotoxicity</ENT1>, while when administered in high concentrations it acts in an inhibitory fashion on the cytostatic action of the drug.",,,,T,,,,,c,,,,,1.0,,
23952588,2630,D010300,D007980,Negative_Correlation,FALSE,Risk factors and predictors of <ENT2>levodopa</ENT2>-induced dyskinesia among multiethnic Malaysians with <ENT1>Parkinson's disease</ENT1>.,,,,T,Y,T,,,w,,,,,0.0,,
23952588,2630,D010300,D007980,Negative_Correlation,FALSE,Chronic pulsatile <ENT2>levodopa</ENT2> therapy for <ENT1>Parkinson's disease</ENT1> (<ENT1>PD</ENT1>) leads to the development of motor fluctuations and dyskinesia.,,,,T,,,,,c,,,,,1.0,,
23952588,2630,D010300,D007980,Negative_Correlation,FALSE,We studied the prevalence and predictors of <ENT2>levodopa</ENT2>-induced dyskinesia among multiethnic Malaysian patients with <ENT1>PD</ENT1>.,,,,T,Y,,,,w,,,,,1.0,,
23952588,2630,D010300,D007980,Negative_Correlation,FALSE,METHODS: This is a cross-sectional study involving 95 patients with <ENT1>PD</ENT1> on uninterrupted <ENT2>levodopa</ENT2> therapy for at least 6 months.,,,,T,,,,,w,,,,,1.0,,
23952588,2631,D004409,D007980,Positive_Correlation,FALSE,Risk factors and predictors of <ENT2>levodopa</ENT2>-induced <ENT1>dyskinesia</ENT1> among multiethnic Malaysians with Parkinson's disease.,,,,T,,,,,c,,,,,1.0,,
23952588,2631,D004409,D007980,Positive_Correlation,FALSE,Chronic pulsatile <ENT2>levodopa</ENT2> therapy for Parkinson's disease (PD) leads to the development of motor fluctuations and <ENT1>dyskinesia</ENT1>.,,,,T,,,,,w,,,,,1.0,,
23952588,2631,D004409,D007980,Positive_Correlation,FALSE,We studied the prevalence and predictors of <ENT2>levodopa</ENT2>-induced <ENT1>dyskinesia</ENT1> among multiethnic Malaysian patients with PD.,,,,T,,,,,c,,,,,1.0,,
23952588,2631,D004409,D007980,Positive_Correlation,FALSE,<ENT1>Dyskinesia</ENT1> was present in 44% (n = 42) with median <ENT2>levodopa</ENT2> therapy of 3 years.,,,,T,,,,,w,,,,,1.0,,
23952588,2631,D004409,D007980,Positive_Correlation,FALSE,"Patients with <ENT1>dyskinesia</ENT1> had lower onset age ( p < 0.001), longer duration of <ENT2>levodopa</ENT2> therapy ( p < 0.001), longer disease duration ( p < 0.001), higher total daily <ENT2>levodopa</ENT2> dose ( p < 0.001), and higher total UPDRS scores ( p = 0.005) than patients without <ENT1>dyskinesia</ENT1>.",,,,T,,,,,c,,,"11,22",,0.5,,
23952588,2631,D004409,D007980,Positive_Correlation,FALSE,"The three significant predictors of <ENT1>dyskinesia</ENT1> were duration of <ENT2>levodopa</ENT2> therapy, onset age, and total daily <ENT2>levodopa</ENT2> dose.",,,,T,,,,,w,,,,,1.0,,
23952588,2631,D004409,D007980,Positive_Correlation,FALSE,CONCLUSIONS: The prevalence of <ENT2>levodopa</ENT2>-induced <ENT1>dyskinesia</ENT1> in our patients was 44%.,,,,T,,,,,c,,,,,0.0,,
24014394,2639,852104,856689,Association,TRUE,"In a <ENT1>mzm1D</ENT1> yeast strain, the expression of a <ENT1>mzm1</ENT1>(D25N) mutant allele caused temperature-sensitive respiratory growth defect, decreased oxygen consumption, impaired maturation/stabilization of the <ENT2>Rieske Fe-S protein</ENT2>, and reduced complex III activity and amount.",,,,T,,,,,c,,,,,0.0,,
24014394,2640,852104,D012131,Association,TRUE,"In a <ENT1>mzm1D</ENT1> yeast strain, the expression of a <ENT1>mzm1</ENT1>(D25N) mutant allele caused temperature-sensitive <ENT2>respiratory growth defect</ENT2>, decreased oxygen consumption, impaired maturation/stabilization of the Rieske Fe-S protein, and reduced complex III activity and amount.",,,,T,,,,,c,,,,,0.0,,
24014394,2638,852104,D010100,Association,TRUE,"In a <ENT1>mzm1D</ENT1> yeast strain, the expression of a <ENT1>mzm1</ENT1>(D25N) mutant allele caused temperature-sensitive respiratory growth defect, decreased <ENT2>oxygen</ENT2> consumption, impaired maturation/stabilization of the Rieske Fe-S protein, and reduced complex III activity and amount.",,,,T,,,,,c,,,,,0.5,,
24014394,2637,852104,617,Negative_Correlation,TRUE,"Recently, human LYRM7/MZM1L, the ortholog of yeast <ENT1>MZM1</ENT1>, has been identified as a new assembly factor for <ENT2>cIII</ENT2>.",,,,T,Y,,,,w,,,,,0.0,,
24014394,2637,852104,617,Negative_Correlation,TRUE,"In a <ENT1>mzm1D</ENT1> yeast strain, the expression of a <ENT1>mzm1</ENT1>(D25N) mutant allele caused temperature-sensitive respiratory growth defect, decreased oxygen consumption, impaired maturation/stabilization of the Rieske Fe-S protein, and reduced <ENT2>complex III</ENT2> activity and amount.",,,,T,,,,,c,,,,,0.0,,
24014394,2635,D001927,rs587777433,Positive_Correlation,TRUE,"In a baby patient with early onset, severe <ENT1>encephalopathy</ENT1>, lactic acidosis and profound, isolated cIII deficiency in skeletal muscle, we identified a disease-segregating homozygous mutation (<ENT2>c.73G>A</ENT2>) in LYRM7/MZM1L, predicting a drastic change in a highly conserved amino-acid residue (<ENT2>p.Asp25Asn</ENT2>).",,,,T,,,,,w,,,,,0.0,,
24014394,2648,D001927,90624,Association,TRUE,"A homozygous mutation in <ENT2>LYRM7</ENT2>/<ENT2>MZM1L</ENT2> associated with early onset <ENT1>encephalopathy</ENT1>, lactic acidosis, and severe reduction of mitochondrial complex III activity.",,,,T,,,,,c,,,,,0.5,,
24014394,2648,D001927,90624,Association,TRUE,"In a baby patient with early onset, severe <ENT1>encephalopathy</ENT1>, lactic acidosis and profound, isolated cIII deficiency in skeletal muscle, we identified a disease-segregating homozygous mutation (c.73G>A) in <ENT2>LYRM7</ENT2>/<ENT2>MZM1L</ENT2>, predicting a drastic change in a highly conserved amino-acid residue (p.Asp25Asn).",,,,T,,,,,c,,,,,1.0,,
24014394,2644,C538525,90624,Association,TRUE,"<ENT2>LYRM7</ENT2>/<ENT2>MZM1L</ENT2> is a novel disease gene, causing cIII-defective, early onset, severe <ENT1>mitochondrial encephalopathy</ENT1>.",,,,T,,,,,c,,,,,1.0,,
24014394,2634,D012131,rs587777433,Positive_Correlation,TRUE,"In a mzm1D yeast strain, the expression of a mzm1(<ENT2>D25N</ENT2>) mutant allele caused temperature-sensitive <ENT1>respiratory growth defect</ENT1>, decreased oxygen consumption, impaired maturation/stabilization of the Rieske Fe-S protein, and reduced complex III activity and amount.",,,,T,,,,,c,,,,,1.0,,
24014394,2641,D000140,rs587777433,Positive_Correlation,TRUE,"In a baby patient with early onset, severe encephalopathy, <ENT1>lactic acidosis</ENT1> and profound, isolated cIII deficiency in skeletal muscle, we identified a disease-segregating homozygous mutation (<ENT2>c.73G>A</ENT2>) in LYRM7/MZM1L, predicting a drastic change in a highly conserved amino-acid residue (<ENT2>p.Asp25Asn</ENT2>).",,,,T,,,,,w,,,,,0.0,,
24014394,2646,D000140,90624,Association,TRUE,"A homozygous mutation in <ENT2>LYRM7</ENT2>/<ENT2>MZM1L</ENT2> associated with early onset encephalopathy, <ENT1>lactic acidosis</ENT1>, and severe reduction of mitochondrial complex III activity.",,,,T,,T,,,c,,,,,1.0,,
24014394,2646,D000140,90624,Association,TRUE,"In a baby patient with early onset, severe encephalopathy, <ENT1>lactic acidosis</ENT1> and profound, isolated cIII deficiency in skeletal muscle, we identified a disease-segregating homozygous mutation (c.73G>A) in <ENT2>LYRM7</ENT2>/<ENT2>MZM1L</ENT2>, predicting a drastic change in a highly conserved amino-acid residue (p.Asp25Asn).",,,,T,,,,,w,,,,,1.0,,
24014394,2642,C565128,rs587777433,Positive_Correlation,TRUE,"In a baby patient with early onset, severe encephalopathy, lactic acidosis and profound, isolated <ENT1>cIII deficiency</ENT1> in skeletal muscle, we identified a disease-segregating homozygous mutation (<ENT2>c.73G>A</ENT2>) in LYRM7/MZM1L, predicting a drastic change in a highly conserved amino-acid residue (<ENT2>p.Asp25Asn</ENT2>).",,,,T,,,,,w,,,,,0.0,,
24014394,2647,C565128,90624,Association,TRUE,"A homozygous mutation in <ENT2>LYRM7</ENT2>/<ENT2>MZM1L</ENT2> associated with early onset encephalopathy, lactic acidosis, and severe <ENT1>reduction of mitochondrial complex III</ENT1> activity.",,,,T,,T,,,c,,,,,1.0,,
24014394,2647,C565128,90624,Association,TRUE,"In a baby patient with early onset, severe encephalopathy, lactic acidosis and profound, isolated <ENT1>cIII deficiency</ENT1> in skeletal muscle, we identified a disease-segregating homozygous mutation (c.73G>A) in <ENT2>LYRM7</ENT2>/<ENT2>MZM1L</ENT2>, predicting a drastic change in a highly conserved amino-acid residue (p.Asp25Asn).",,,,T,,,,,w,,,,,1.0,,
24014394,2647,C565128,90624,Association,TRUE,"<ENT2>LYRM7</ENT2>/<ENT2>MZM1L</ENT2> is a novel disease gene, causing <ENT1>cIII-defective</ENT1>, early onset, severe mitochondrial encephalopathy.",,,,T,,,,,c,,,,,1.0,,
24014394,2643,C565128,617,Negative_Correlation,FALSE,"Mutations in nuclear genes associated with <ENT1>defective complex III (cIII) of the mitochondrial</ENT1> respiratory chain are rare, having been found in only two <ENT2>cIII</ENT2> assembly factors and, as private changes in single families, three <ENT2>cIII</ENT2> structural subunits.",,,,T,,,,,w,,,,,0.0,,
24014394,2633,D010100,rs587777433,Association,TRUE,"In a mzm1D yeast strain, the expression of a mzm1(<ENT2>D25N</ENT2>) mutant allele caused temperature-sensitive respiratory growth defect, decreased <ENT1>oxygen</ENT1> consumption, impaired maturation/stabilization of the Rieske Fe-S protein, and reduced complex III activity and amount.",,,,T,,,,,c,,,,,0.0,,
24014394,2632,rs587777433,617,Negative_Correlation,TRUE,"In a mzm1D yeast strain, the expression of a mzm1(<ENT1>D25N</ENT1>) mutant allele caused temperature-sensitive respiratory growth defect, decreased oxygen consumption, impaired maturation/stabilization of the Rieske Fe-S protein, and reduced <ENT2>complex III</ENT2> activity and amount.",,,,T,,,,,c,,,,,0.0,,
24014394,2645,90624,617,Association,FALSE,"Recently, human <ENT1>LYRM7</ENT1>/<ENT1>MZM1L</ENT1>, the ortholog of yeast MZM1, has been identified as a new assembly factor for <ENT2>cIII</ENT2>.",,,,T,,,,,c,,,,,0.5,,
24036311,2658,14465,22083,Association,TRUE,"Expression of some lineage specific factors is markedly reduced in <ENT2>Ctr9</ENT2> knockdown embryos, including Eomes, Elf5 and Sox2, while others are inappropriately expressed (Oct4, Nanog, <ENT1>Gata6</ENT1>, Fgf4 and Sox17).",,,,T,,,,,c,,,,,0.0,,
24036311,2662,13711,22083,Positive_Correlation,TRUE,"Expression of some lineage specific factors is markedly reduced in <ENT2>Ctr9</ENT2> knockdown embryos, including Eomes, <ENT1>Elf5</ENT1> and Sox2, while others are inappropriately expressed (Oct4, Nanog, Gata6, Fgf4 and Sox17).",,,,T,,,,,c,,,,,0.0,,
24036311;24036311,2665;2666,76246;54624,22083;22083,Bind;Bind,FALSE;FALSE,"<ENT2>CTR9</ENT2>/<ENT2><ENT1>PAF1c</ENT2></ENT1> regulates molecular lineage identity, histone H3K36 trimethylation and genomic imprinting during preimplantation development.",,,,T,,T,,,c,,,,,0.0,,
24036311,2665,76246,22083,Bind,FALSE,"Here we report that two members of the <ENT2><ENT1>RNA polymerase II associated factor, homolog (Saccharomyces cerevisiae) complex</ENT2></ENT1> (<ENT2><ENT1>PAF1 complex</ENT2></ENT1>) components, <ENT2>Ctr9</ENT2> and <ENT1>Rtf1</ENT1>, are required during mammalian preimplantation development.",,,,T,,,,,c,,,,,0.0,,
24036311,2665,76246,22083,Bind,FALSE,We document a loss of histone H3 lysine 36 trimethylation (H3K36me3) in <ENT2>Ctr9</ENT2>-deficient embryos and confirm that knockdown of either Setd2 or <ENT1>Rtf1</ENT1> results in similar phenotypes.,,,,T,,,,,c,,,,,1.0,,
24036311;24036311,2650;2651,76246;54624,260423;260423,Association;Association,TRUE;TRUE,"CTR9/<ENT1>PAF1c</ENT1> regulates molecular lineage identity, <ENT2>histone H3</ENT2>K36 trimethylation and genomic imprinting during preimplantation development.",,,,T,,,,,c,,,,,1.0,,
24036311,2650,76246,260423,Association,TRUE,We document a loss of <ENT2>histone H3</ENT2> lysine 36 trimethylation (<ENT2>H3</ENT2>K36me3) in Ctr9-deficient embryos and confirm that knockdown of either Setd2 or <ENT1>Rtf1</ENT1> results in similar phenotypes.,,,,T,,,,,c,,,,,1.0,,
24036311;24036311;24036311,2650;2651;2664,76246;54624;22083,260423;260423;260423,Association;Association;Association,TRUE;TRUE;TRUE,"These findings show that the <ENT1>PAF1 complex</ENT1> is required for mammalian development, likely through regulation of <ENT2>H3</ENT2>K36me3, and indicate functional conservation of the <ENT1>PAF1 complex</ENT1> from yeast to mammals in vivo.",,,,T,,,,,c,,,,,1.0,,
24036311,2661,20674,22083,Positive_Correlation,TRUE,"Expression of some lineage specific factors is markedly reduced in <ENT2>Ctr9</ENT2> knockdown embryos, including Eomes, Elf5 and <ENT1>Sox2</ENT1>, while others are inappropriately expressed (Oct4, Nanog, Gata6, Fgf4 and Sox17).",,,,T,,,,,c,,,,,0.0,,
24036311,2666,54624,22083,Bind,FALSE,"Here we report that two members of the <ENT2><ENT1>RNA polymerase II associated factor, homolog (Saccharomyces cerevisiae) complex</ENT2></ENT1> (<ENT2><ENT1>PAF1 complex</ENT2></ENT1>) components, <ENT2>Ctr9</ENT2> and Rtf1, are required during mammalian preimplantation development.",,,,T,,,,,w,,,"11,22",,0.0,,
24036311,2657,14175,22083,Negative_Correlation,TRUE,"Expression of some lineage specific factors is markedly reduced in <ENT2>Ctr9</ENT2> knockdown embryos, including Eomes, Elf5 and Sox2, while others are inappropriately expressed (Oct4, Nanog, Gata6, <ENT1>Fgf4</ENT1> and Sox17).",,,,T,,,,,w,,,,,0.0,,
24036311,2649,235626,260423,Association,TRUE,We document a loss of <ENT2>histone H3</ENT2> lysine 36 trimethylation (<ENT2>H3</ENT2>K36me3) in Ctr9-deficient embryos and confirm that knockdown of either <ENT1>Setd2</ENT1> or Rtf1 results in similar phenotypes.,,,,T,,,,,c,,,,,1.0,,
24036311,2660,22083,18999,Negative_Correlation,TRUE,"Expression of some lineage specific factors is markedly reduced in <ENT1>Ctr9</ENT1> knockdown embryos, including Eomes, Elf5 and Sox2, while others are inappropriately expressed (<ENT2>Oct4</ENT2>, Nanog, Gata6, Fgf4 and Sox17).",,,,T,,,,,c,,,,,1.0,,
24036311,2656,22083,20671,Negative_Correlation,TRUE,"Expression of some lineage specific factors is markedly reduced in <ENT1>Ctr9</ENT1> knockdown embryos, including Eomes, Elf5 and Sox2, while others are inappropriately expressed (Oct4, Nanog, Gata6, Fgf4 and <ENT2>Sox17</ENT2>).",,,,T,,,,,c,,,,,1.0,,
24036311,2659,22083,71950,Negative_Correlation,TRUE,"Expression of some lineage specific factors is markedly reduced in <ENT1>Ctr9</ENT1> knockdown embryos, including Eomes, Elf5 and Sox2, while others are inappropriately expressed (Oct4, <ENT2>Nanog</ENT2>, Gata6, Fgf4 and Sox17).",,,,T,,,,,c,,,,,1.0,,
24036311,2664,22083,260423,Association,TRUE,"<ENT1>CTR9</ENT1>/<ENT1>PAF1c</ENT1> regulates molecular lineage identity, <ENT2>histone H3</ENT2>K36 trimethylation and genomic imprinting during preimplantation development.",,,,T,,,,,c,,,,,1.0,,
24036311,2664,22083,260423,Association,TRUE,We document a loss of <ENT2>histone H3</ENT2> lysine 36 trimethylation (<ENT2>H3</ENT2>K36me3) in <ENT1>Ctr9</ENT1>-deficient embryos and confirm that knockdown of either Setd2 or Rtf1 results in similar phenotypes.,,,,T,,,,,c,,,,,0.0,,
24036311,2663,22083,13813,Positive_Correlation,TRUE,"Expression of some lineage specific factors is markedly reduced in <ENT1>Ctr9</ENT1> knockdown embryos, including <ENT2>Eomes</ENT2>, Elf5 and Sox2, while others are inappropriately expressed (Oct4, Nanog, Gata6, Fgf4 and Sox17).",,,,T,,,,,c,,,,,0.0,,
24055495,2675,D003704,D005947,Association,FALSE,Basic and clinical research has demonstrated that <ENT1>dementia</ENT1> of sporadic Alzheimer's disease (sAD) type is associated with dysfunction of the insulin-receptor (IR) system followed by decreased <ENT2>glucose</ENT2> transport via <ENT2>glucose</ENT2> transporter GLUT4 and decreased <ENT2>glucose</ENT2> metabolism in brain cells.,,,,T,,,,,c,,,,,0.0,,
24055495,2669,D003704,24954,Association,FALSE,Basic and clinical research has demonstrated that <ENT1>dementia</ENT1> of sporadic Alzheimer's disease (sAD) type is associated with dysfunction of the <ENT2>insulin-receptor</ENT2> (<ENT2>IR</ENT2>) system followed by decreased glucose transport via glucose transporter GLUT4 and decreased glucose metabolism in brain cells.,,,,T,,,,,c,,,,,0.5,,
24055495,2673,D013311,D003072,Positive_Correlation,FALSE,Long-term oral galactose treatment prevents <ENT2>cognitive deficits</ENT2> in male Wistar rats treated intracerebroventricularly with <ENT1>streptozotocin</ENT1>.,,,,T,,,,,c,,,,,0.0,,
24055495,2673,D013311,D003072,Positive_Correlation,FALSE,"We have investigated the effects of continuous daily oral galactose (200 mg/kg/day) treatment on <ENT2>cognitive deficits</ENT2> in <ENT1>streptozotocin</ENT1>-induced (<ENT1>STZ</ENT1>-icv) rat model of sAD, tested by Morris Water Maze and Passive Avoidance test, respectively.",,,,T,,,,,w,,,,,0.5,,
24055495,2673,D013311,D003072,Positive_Correlation,FALSE,"One month of oral galactose treatment initiated immediately after the <ENT1>STZ</ENT1>-icv administration, successfully prevented development of the <ENT1>STZ</ENT1>-icv-induced <ENT2>cognitive deficits</ENT2>.",,,,T,,,,,c,,,,,1.0,,
24055495,2672,D013311,D000544,Positive_Correlation,FALSE,"We have investigated the effects of continuous daily oral galactose (200 mg/kg/day) treatment on cognitive deficits in <ENT1>streptozotocin</ENT1>-induced (<ENT1>STZ</ENT1>-icv) rat model of <ENT2>sAD</ENT2>, tested by Morris Water Maze and Passive Avoidance test, respectively.",,,,T,,,,,c,,,,,0.5,,
24055495,2674,D013311,D005690,Negative_Correlation,TRUE,Long-term oral <ENT2>galactose</ENT2> treatment prevents cognitive deficits in male Wistar rats treated intracerebroventricularly with <ENT1>streptozotocin</ENT1>.,,,,T,Y,T,,,c,,,,,0.0,,
24055495,2674,D013311,D005690,Negative_Correlation,TRUE,"We have investigated the effects of continuous daily oral <ENT2>galactose</ENT2> (200 mg/kg/day) treatment on cognitive deficits in <ENT1>streptozotocin</ENT1>-induced (<ENT1>STZ</ENT1>-icv) rat model of sAD, tested by Morris Water Maze and Passive Avoidance test, respectively.",,,,T,Y,,,,w,,,,,0.0,,
24055495,2674,D013311,D005690,Negative_Correlation,TRUE,"One month of oral <ENT2>galactose</ENT2> treatment initiated immediately after the <ENT1>STZ</ENT1>-icv administration, successfully prevented development of the <ENT1>STZ</ENT1>-icv-induced cognitive deficits.",,,,T,,,,,c,,,,,0.0,,
24055495,2681,D003072,D005690,Negative_Correlation,TRUE,Long-term oral <ENT2>galactose</ENT2> treatment prevents <ENT1>cognitive deficits</ENT1> in male Wistar rats treated intracerebroventricularly with streptozotocin.,,,,T,,,,,c,,,,,1.0,,
24055495,2681,D003072,D005690,Negative_Correlation,TRUE,"We have investigated the effects of continuous daily oral <ENT2>galactose</ENT2> (200 mg/kg/day) treatment on <ENT1>cognitive deficits</ENT1> in streptozotocin-induced (STZ-icv) rat model of sAD, tested by Morris Water Maze and Passive Avoidance test, respectively.",,,,T,,,,,c,,,,,0.0,,
24055495,2681,D003072,D005690,Negative_Correlation,TRUE,"One month of oral <ENT2>galactose</ENT2> treatment initiated immediately after the STZ-icv administration, successfully prevented development of the STZ-icv-induced <ENT1>cognitive deficits</ENT1>.",,,,T,,,,,c,,,,,1.0,,
24055495,2681,D003072,D005690,Negative_Correlation,TRUE,Oral <ENT2>galactose</ENT2> exposure might have beneficial effects on learning and memory ability and could be worth investigating for improvement of <ENT1>cognitive deficits</ENT1> associated with glucose hypometabolism in AD.,,,,T,,Y,,,c,,,,,0.0,,
24055495,2680,25551,D005690,Association,FALSE,An alternative source of energy is <ENT2>d-galactose</ENT2> (the C-4-epimer of d-glucose) which is transported into the brain by insulin-independent <ENT1>GLUT3</ENT1> transporter where it might be metabolized to glucose via the Leloir pathway.,,,,T,,,,,w,,,,,1.0,,
24055495,2678,D000544,D005690,Association,TRUE,"We have investigated the effects of continuous daily oral <ENT2>galactose</ENT2> (200 mg/kg/day) treatment on cognitive deficits in streptozotocin-induced (STZ-icv) rat model of <ENT1>sAD</ENT1>, tested by Morris Water Maze and Passive Avoidance test, respectively.",,,,T,,,,,c,,,,,0.0,,
24055495,2678,D000544,D005690,Association,TRUE,Oral <ENT2>galactose</ENT2> exposure might have beneficial effects on learning and memory ability and could be worth investigating for improvement of cognitive deficits associated with glucose hypometabolism in <ENT1>AD</ENT1>.,,,,T,,Y,,,w,,,,,0.0,,
24055495,2671,D000544,D005947,Negative_Correlation,FALSE,Basic and clinical research has demonstrated that dementia of sporadic <ENT1>Alzheimer's disease</ENT1> (<ENT1>sAD</ENT1>) type is associated with dysfunction of the insulin-receptor (IR) system followed by decreased <ENT2>glucose</ENT2> transport via <ENT2>glucose</ENT2> transporter GLUT4 and decreased <ENT2>glucose</ENT2> metabolism in brain cells.,,,,T,,,,,c,,,"11,12,13,21,22,23",,0.0,,
24055495,2670,D000544,24954,Association,FALSE,Basic and clinical research has demonstrated that dementia of sporadic <ENT1>Alzheimer's disease</ENT1> (<ENT1>sAD</ENT1>) type is associated with dysfunction of the <ENT2>insulin-receptor</ENT2> (<ENT2>IR</ENT2>) system followed by decreased glucose transport via glucose transporter GLUT4 and decreased glucose metabolism in brain cells.,,,,T,,,,,c,,,"11,12,21,22",,1.0,,
24055495,2679,D005690,D008569,Positive_Correlation,FALSE,"Exclusively parenteral daily injections of <ENT1>galactose</ENT1> induce <ENT2>memory deterioration</ENT2> in rodents and are used to generate animal aging model, but the effects of oral <ENT1>galactose</ENT1> treatment on cognitive functions have never been tested.",,,,T,,,,,c,,,,,0.5,,
24055495,2677,D005690,D018149,Association,TRUE,Oral <ENT1>galactose</ENT1> exposure might have beneficial effects on learning and memory ability and could be worth investigating for improvement of cognitive deficits associated with <ENT2>glucose hypometabolism</ENT2> in AD.,,,,T,Y,,,,w,,,,,0.0,,
24055495,2676,25139,D005947,Association,FALSE,Basic and clinical research has demonstrated that dementia of sporadic Alzheimer's disease (sAD) type is associated with dysfunction of the insulin-receptor (IR) system followed by decreased <ENT2>glucose</ENT2> transport via <ENT2>glucose</ENT2> transporter <ENT1>GLUT4</ENT1> and decreased <ENT2>glucose</ENT2> metabolism in brain cells.,,,,T,,,,,c,,,,,0.0,,
24055495,2668,D005947,24954,Negative_Correlation,FALSE,Basic and clinical research has demonstrated that dementia of sporadic Alzheimer's disease (sAD) type is associated with dysfunction of the <ENT2>insulin-receptor</ENT2> (<ENT2>IR</ENT2>) system followed by decreased <ENT1>glucose</ENT1> transport via <ENT1>glucose</ENT1> transporter GLUT4 and decreased <ENT1>glucose</ENT1> metabolism in brain cells.,,,,T,,,,,c,,,,,1.0,,
24100257,2682,D003329,C089750,Positive_Correlation,FALSE,"Extensive literature search revealed multiple cases of <ENT1>coronary artery vasospasm</ENT1> secondary to <ENT2>zolmitriptan</ENT2>, but none of the cases were associated with TS.",,,,T,,,,,c,,,,,1.0,,
24100257,2683,D008881,C089750,Negative_Correlation,FALSE,Detailed history obtained retrospectively revealed that the patient took <ENT2>zolmitriptan</ENT2> sparingly only when she had <ENT1>migraines</ENT1>.,,,,T,,,,,c,,,,,0.0,,
24100257,2683,D008881,C089750,Negative_Correlation,FALSE,"But before this event, she was taking <ENT2>zolmitriptan</ENT2> 2-3 times daily for several days because of a persistent <ENT1>migraine headache</ENT1>.",,,,T,,,,,c,,,,,1.0,,
24100257,2684,C089750,D054549,Positive_Correlation,TRUE,<ENT2>Takotsubo syndrome</ENT2> (or <ENT2>apical ballooning syndrome</ENT2>) secondary to <ENT1>Zolmitriptan</ENT1>.,,,,T,,T,,,c,,,,,1.0,,
24100257,2684,C089750,D054549,Positive_Correlation,TRUE,"Extensive literature search revealed multiple cases of coronary artery vasospasm secondary to <ENT1>zolmitriptan</ENT1>, but none of the cases were associated with <ENT2>TS</ENT2>.",,,,T,,,,,c,,,,,1.0,,
24309294,2694,C058121,25706,Negative_Correlation,FALSE,"Pre-treatment of the <ENT2>CCK2 receptor</ENT2> antagonist <ENT1>L-365,260</ENT1> (10ug, i.c.v) reversed the effects of CCK-8, but the CCK1 receptor antagonist L-364,718 (10ug, i.c.v) did not.",,,,T,,,,,c,,,,,1.0,,
24309294,2693,C058121,D012844,Negative_Correlation,TRUE,"Pre-treatment of the CCK2 receptor antagonist <ENT1>L-365,260</ENT1> (10ug, i.c.v) reversed the effects of <ENT2>CCK-8</ENT2>, but the CCK1 receptor antagonist L-364,718 (10ug, i.c.v) did not.",,,,T,,,,,c,,,,,1.0,,
24309294,2688,25706,D009020,Association,TRUE,The present results demonstrate that CCK-8 attenuates the effect of <ENT2>morphine</ENT2> on hippocampal LTP through <ENT1>CCK2 receptors</ENT1> and suggest an ameliorative function of CCK-8 on <ENT2>morphine</ENT2>-induced memory impairment.,,,,T,,,,,w,,,,,1.0,,
24309294,2692,25706,D012844,Association,TRUE,"Pre-treatment of the <ENT1>CCK2 receptor</ENT1> antagonist L-365,260 (10ug, i.c.v) reversed the effects of <ENT2>CCK-8</ENT2>, but the CCK1 receptor antagonist L-364,718 (10ug, i.c.v) did not.",,,,T,,,,,w,,,,,0.0,,
24309294,2692,25706,D012844,Association,TRUE,The present results demonstrate that <ENT2>CCK-8</ENT2> attenuates the effect of morphine on hippocampal LTP through <ENT1>CCK2 receptors</ENT1> and suggest an ameliorative function of <ENT2>CCK-8</ENT2> on morphine-induced memory impairment.,,,,T,,,,,w,,,,,0.5,,
24309294,2686,D009020,D000647,Positive_Correlation,FALSE,We have previously reported that CCK-8 significantly alleviated <ENT1>morphine</ENT1>-induced <ENT2>amnesia</ENT2> and reversed spine density decreases in the CA1 region of the hippocampus in <ENT1>morphine</ENT1>-treated animals.,,,,T,,,,,c,,,,,0.5,,
24309294,2687,D009020,D008569,Positive_Correlation,FALSE,The present results demonstrate that CCK-8 attenuates the effect of <ENT1>morphine</ENT1> on hippocampal LTP through CCK2 receptors and suggest an ameliorative function of CCK-8 on <ENT1>morphine</ENT1>-induced <ENT2>memory impairment</ENT2>.,,,,T,,,,,c,,,,,0.5,,
24309294,2691,D009020,D012844,Negative_Correlation,FALSE,<ENT2>Cholecystokinin-octapeptide</ENT2> restored <ENT1>morphine</ENT1>-induced hippocampal long-term potentiation impairment in rats.,,,,T,,T,,,c,,,,,0.0,,
24309294,2691,D009020,D012844,Negative_Correlation,FALSE,We have previously reported that <ENT2>CCK-8</ENT2> significantly alleviated <ENT1>morphine</ENT1>-induced amnesia and reversed spine density decreases in the CA1 region of the hippocampus in <ENT1>morphine</ENT1>-treated animals.,,,,T,Y,,,,c,,,,,0.5,,
24309294,2691,D009020,D012844,Negative_Correlation,FALSE,"Here, we investigated the effects of <ENT2>CCK-8</ENT2> on long-term potentiation (LTP) in the lateral perforant path (LPP)-granule cell synapse of rat dentate gyrus (DG) in acute saline or <ENT1>morphine</ENT1>-treated rats.",,,,T,,Y,,,c,,,,,1.0,,
24309294,2691,D009020,D012844,Negative_Correlation,FALSE,"Acute <ENT1>morphine</ENT1> (30mg/kg, s.c.) treatment significantly attenuated hippocampal LTP and <ENT2>CCK-8</ENT2> (1ug, i.c.v.) restored the amplitude of PS that was attenuated by <ENT1>morphine</ENT1> injection.",,,,T,,,,,c,,,,,0.5,,
24309294,2691,D009020,D012844,Negative_Correlation,FALSE,The present results demonstrate that <ENT2>CCK-8</ENT2> attenuates the effect of <ENT1>morphine</ENT1> on hippocampal LTP through CCK2 receptors and suggest an ameliorative function of <ENT2>CCK-8</ENT2> on <ENT1>morphine</ENT1>-induced memory impairment.,,,,T,,,,,c,,,"11,22",,0.0,,
24309294,2689,D000647,D012844,Negative_Correlation,FALSE,We have previously reported that <ENT2>CCK-8</ENT2> significantly alleviated morphine-induced <ENT1>amnesia</ENT1> and reversed spine density decreases in the CA1 region of the hippocampus in morphine-treated animals.,,,,T,,,,,c,,,,,0.0,,
24309294,2685,D020109,24889,Negative_Correlation,FALSE,"Pre-treatment of the CCK2 receptor antagonist L-365,260 (10ug, i.c.v) reversed the effects of CCK-8, but the <ENT2>CCK1 receptor</ENT2> antagonist <ENT1>L-364,718</ENT1> (10ug, i.c.v) did not.",,,,T,,,,,c,,,,,0.0,,
24309294,2690,D008569,D012844,Negative_Correlation,TRUE,The present results demonstrate that <ENT2>CCK-8</ENT2> attenuates the effect of morphine on hippocampal LTP through CCK2 receptors and suggest an ameliorative function of <ENT2>CCK-8</ENT2> on morphine-induced <ENT1>memory impairment</ENT1>.,,,,T,,,,,c,,,,,1.0,,
24442316,2715,D005688,D008107,Positive_Correlation,FALSE,CMCS could protect <ENT2>LSECs from injury</ENT2> and maintain the microvasculature integration in acute <ENT2>injured liver</ENT2> of mice induced by LPS/<ENT1>D-GalN</ENT1>.,,,,T,,,,,c,,,,,0.5,,
24442316,2706,D017665,D008107,Positive_Correlation,TRUE,"Compared to that in the normal control, more severe <ENT2>liver inflammation</ENT2> and hepatocyte apoptosis, worse hepatic lipid peroxidation demonstrated by the increased ASAFR, <ENT1>.OH</ENT1> and MDA, but decreased SOD and GST, increased MMP-2/9 activities and VCAM-1, ICAM-1 and vWF expressions, which revealed obvious <ENT2>LSEC injury</ENT2> and scaffold structure broken, were shown in the model control.",,,,T,,,,,w,,,,,1.0,,
24442316,2708,15894,D008107,Association,TRUE,"Compared to that in the normal control, more severe <ENT2>liver inflammation</ENT2> and hepatocyte apoptosis, worse hepatic lipid peroxidation demonstrated by the increased ASAFR, .OH and MDA, but decreased SOD and GST, increased MMP-2/9 activities and VCAM-1, <ENT1>ICAM-1</ENT1> and vWF expressions, which revealed obvious <ENT2>LSEC injury</ENT2> and scaffold structure broken, were shown in the model control.",,,,T,,,,,c,,,,,0.0,,
24442316,2708,15894,D008107,Association,TRUE,"Compared with the model group, CMCS and 1,10-phenanthroline significantly improved serum ALT/AST, attenuated <ENT2>hepatic inflammation</ENT2> and improved peroxidative <ENT2>injury in liver</ENT2>, decreased MMP-2/9 activities in liver tissue, improved integration of scaffold structure, and decreased protein expression of VCAM-1 and <ENT1>ICAM-1</ENT1>.",,,,T,,,,,c,,,,,0.5,,
24442316,2699,15894,C025205,Negative_Correlation,TRUE,"Compared with the model group, CMCS and <ENT2>1,10-phenanthroline</ENT2> significantly improved serum ALT/AST, attenuated hepatic inflammation and improved peroxidative injury in liver, decreased MMP-2/9 activities in liver tissue, improved integration of scaffold structure, and decreased protein expression of VCAM-1 and <ENT1>ICAM-1</ENT1>.",,,,T,,,,,c,,,,,1.0,,
24442316,2712,D008107,54486,Association,TRUE,"Compared to that in the normal control, more severe <ENT1>liver inflammation</ENT1> and hepatocyte apoptosis, worse hepatic lipid peroxidation demonstrated by the increased ASAFR, .OH and MDA, but decreased SOD and <ENT2>GST</ENT2>, increased MMP-2/9 activities and VCAM-1, ICAM-1 and vWF expressions, which revealed obvious <ENT1>LSEC injury</ENT1> and scaffold structure broken, were shown in the model control.",,,,T,,,,,w,,,,,1.0,,
24442316,2703,D008107,C025205,Negative_Correlation,TRUE,"Compared with the model group, CMCS and <ENT2>1,10-phenanthroline</ENT2> significantly improved serum ALT/AST, attenuated <ENT1>hepatic inflammation</ENT1> and improved peroxidative <ENT1>injury in liver</ENT1>, decreased MMP-2/9 activities in liver tissue, improved integration of scaffold structure, and decreased protein expression of VCAM-1 and ICAM-1.",,,,T,,,,,c,,,,,1.0,,
24442316,2705,D008107,D008315,Positive_Correlation,TRUE,"Compared to that in the normal control, more severe <ENT1>liver inflammation</ENT1> and hepatocyte apoptosis, worse hepatic lipid peroxidation demonstrated by the increased ASAFR, .OH and <ENT2>MDA</ENT2>, but decreased SOD and GST, increased MMP-2/9 activities and VCAM-1, ICAM-1 and vWF expressions, which revealed obvious <ENT1>LSEC injury</ENT1> and scaffold structure broken, were shown in the model control.",,,,T,,,,,w,,,,,1.0,,
24442316,2696,D008107,76282,Association,TRUE,"Compared with the model group, CMCS and 1,10-phenanthroline significantly improved serum <ENT2>ALT</ENT2>/AST, attenuated <ENT1>hepatic inflammation</ENT1> and improved peroxidative <ENT1>injury in liver</ENT1>, decreased MMP-2/9 activities in liver tissue, improved integration of scaffold structure, and decreased protein expression of VCAM-1 and ICAM-1.",,,,T,,,,,c,,,,,1.0,,
24442316,2707,D008107,22371,Association,TRUE,"Compared to that in the normal control, more severe <ENT1>liver inflammation</ENT1> and hepatocyte apoptosis, worse hepatic lipid peroxidation demonstrated by the increased ASAFR, .OH and MDA, but decreased SOD and GST, increased MMP-2/9 activities and VCAM-1, ICAM-1 and <ENT2>vWF</ENT2> expressions, which revealed obvious <ENT1>LSEC injury</ENT1> and scaffold structure broken, were shown in the model control.",,,,T,,,,,c,,,,,0.0,,
24442316,2710,D008107,17395,Association,TRUE,"Compared to that in the normal control, more severe <ENT1>liver inflammation</ENT1> and hepatocyte apoptosis, worse hepatic lipid peroxidation demonstrated by the increased ASAFR, .OH and MDA, but decreased SOD and GST, increased <ENT2>MMP-2/9</ENT2> activities and VCAM-1, ICAM-1 and vWF expressions, which revealed obvious <ENT1>LSEC injury</ENT1> and scaffold structure broken, were shown in the model control.",,,,T,,,,,c,,,,,0.0,,
24442316,2710,D008107,17395,Association,TRUE,"Compared with the model group, CMCS and 1,10-phenanthroline significantly improved serum ALT/AST, attenuated <ENT1>hepatic inflammation</ENT1> and improved peroxidative <ENT1>injury in liver</ENT1>, decreased <ENT2>MMP-2/9</ENT2> activities in liver tissue, improved integration of scaffold structure, and decreased protein expression of VCAM-1 and ICAM-1.",,,,T,,,,,c,,,,,1.0,,
24442316,2710,D008107,17395,Association,TRUE,Its action mechanism was associated with the down-regulation of <ENT2>MMP-2/9</ENT2> activities and inhibition of peroxidation in <ENT1>injured liver</ENT1>.,,,,T,,,,,c,,,,,1.0,,
24442316,2714,D008107,D008055,Association,TRUE,"Compared to that in the normal control, more severe <ENT1>liver inflammation</ENT1> and hepatocyte apoptosis, worse hepatic <ENT2>lipid</ENT2> peroxidation demonstrated by the increased ASAFR, .OH and MDA, but decreased SOD and GST, increased MMP-2/9 activities and VCAM-1, ICAM-1 and vWF expressions, which revealed obvious <ENT1>LSEC injury</ENT1> and scaffold structure broken, were shown in the model control.",,,,T,,,,,w,,,,,1.0,,
24442316,2713,D008107,20655,Association,TRUE,"Compared to that in the normal control, more severe <ENT1>liver inflammation</ENT1> and hepatocyte apoptosis, worse hepatic lipid peroxidation demonstrated by the increased ASAFR, .OH and MDA, but decreased <ENT2>SOD</ENT2> and GST, increased MMP-2/9 activities and VCAM-1, ICAM-1 and vWF expressions, which revealed obvious <ENT1>LSEC injury</ENT1> and scaffold structure broken, were shown in the model control.",,,,T,,,,,w,,,,,0.0,,
24442316,2704,D008107,D008070,Positive_Correlation,FALSE,CMCS could protect <ENT1>LSECs from injury</ENT1> and maintain the microvasculature integration in acute <ENT1>injured liver</ENT1> of mice induced by <ENT2>LPS</ENT2>/D-GalN.,,,,T,,,,,c,,,,,0.5,,
24442316,2695,D008107,14718,Association,TRUE,"Compared with the model group, CMCS and 1,10-phenanthroline significantly improved serum ALT/<ENT2>AST</ENT2>, attenuated <ENT1>hepatic inflammation</ENT1> and improved peroxidative <ENT1>injury in liver</ENT1>, decreased MMP-2/9 activities in liver tissue, improved integration of scaffold structure, and decreased protein expression of VCAM-1 and ICAM-1.",,,,T,,,,,c,,,,,1.0,,
24442316,2709,D008107,22329,Association,TRUE,"Compared to that in the normal control, more severe <ENT1>liver inflammation</ENT1> and hepatocyte apoptosis, worse hepatic lipid peroxidation demonstrated by the increased ASAFR, .OH and MDA, but decreased SOD and GST, increased MMP-2/9 activities and <ENT2>VCAM-1</ENT2>, ICAM-1 and vWF expressions, which revealed obvious <ENT1>LSEC injury</ENT1> and scaffold structure broken, were shown in the model control.",,,,T,,,,,c,,,,,0.0,,
24442316,2709,D008107,22329,Association,TRUE,"Compared with the model group, CMCS and 1,10-phenanthroline significantly improved serum ALT/AST, attenuated <ENT1>hepatic inflammation</ENT1> and improved peroxidative <ENT1>injury in liver</ENT1>, decreased MMP-2/9 activities in liver tissue, improved integration of scaffold structure, and decreased protein expression of <ENT2>VCAM-1</ENT2> and ICAM-1.",,,,T,,,,,c,,,,,1.0,,
24442316,2698,C025205,76282,Positive_Correlation,TRUE,"Compared with the model group, CMCS and <ENT1>1,10-phenanthroline</ENT1> significantly improved serum <ENT2>ALT</ENT2>/AST, attenuated hepatic inflammation and improved peroxidative injury in liver, decreased MMP-2/9 activities in liver tissue, improved integration of scaffold structure, and decreased protein expression of VCAM-1 and ICAM-1.",,,,T,,,,,c,,,,,0.0,,
24442316,2701,C025205,17395,Negative_Correlation,TRUE,"Compared with the model group, CMCS and <ENT1>1,10-phenanthroline</ENT1> significantly improved serum ALT/AST, attenuated hepatic inflammation and improved peroxidative injury in liver, decreased <ENT2>MMP-2/9</ENT2> activities in liver tissue, improved integration of scaffold structure, and decreased protein expression of VCAM-1 and ICAM-1.",,,,T,,,,,c,,,,,0.0,,
24442316,2697,C025205,14718,Positive_Correlation,TRUE,"Compared with the model group, CMCS and <ENT1>1,10-phenanthroline</ENT1> significantly improved serum ALT/<ENT2>AST</ENT2>, attenuated hepatic inflammation and improved peroxidative injury in liver, decreased MMP-2/9 activities in liver tissue, improved integration of scaffold structure, and decreased protein expression of VCAM-1 and ICAM-1.",,,,T,,,,,c,,,,,0.0,,
24442316,2700,C025205,22329,Negative_Correlation,TRUE,"Compared with the model group, CMCS and <ENT1>1,10-phenanthroline</ENT1> significantly improved serum ALT/AST, attenuated hepatic inflammation and improved peroxidative injury in liver, decreased MMP-2/9 activities in liver tissue, improved integration of scaffold structure, and decreased protein expression of <ENT2>VCAM-1</ENT2> and ICAM-1.",,,,T,,,,,c,,,,,1.0,,
24477591,2717,D050197,D017382,Association,FALSE,<ENT2>Reactive oxygen species</ENT2> (<ENT2>ROS</ENT2>) are involved in the pathogenesis of <ENT1>atherosclerosis</ENT1> and coronary artery disease (CAD).,,,,T,,,,,c,,,,,1.0,,
24477591,2722,D009765,rs9932581,Positive_Correlation,TRUE,A synergistic effect of the <ENT2>-930G</ENT2> allele with overweight/<ENT1>obesity</ENT1> (BMI --25) and cigarette smoking was found.,,,,T,,,,,c,,,,,1.0,,
24477591,2722,D009765,rs9932581,Positive_Correlation,TRUE,Overweight/<ENT1>obesity</ENT1> was a risk factor for CAD only in the <ENT2>-930G</ENT2> allele carriers (P<10(-10)) but not in the AA homozygotes (P=1.00).,,,,T,,,,,c,,,,,1.0,,
24477591,2722,D009765,rs9932581,Positive_Correlation,TRUE,The <ENT2>-930G</ENT2> allele carriers are particularly at risk of consequences of <ENT1>obesity</ENT1> and tobacco smoke exposure.,,,,T,Y,,,,c,,,,,0.0,,
24477591,2718,D017382,D003324,Association,FALSE,<ENT1>Reactive oxygen species</ENT1> (<ENT1>ROS</ENT1>) are involved in the pathogenesis of atherosclerosis and <ENT2>coronary artery disease</ENT2> (<ENT2>CAD</ENT2>).,,,,T,,,,,c,,,"11,12,21,22",,0.0,,
24477591,2716,D017382,1666,Association,FALSE,<ENT2>NADPH oxidases</ENT2> are the main source of <ENT1>ROS</ENT1> in the vasculature.,,,,T,,,,,c,,,,,0.0,,
24477591,2721,rs9932581,D050177,Positive_Correlation,TRUE,A synergistic effect of the <ENT1>-930G</ENT1> allele with <ENT2>overweight</ENT2>/obesity (BMI --25) and cigarette smoking was found.,,,,T,,,,,c,,,,,1.0,,
24477591,2721,rs9932581,D050177,Positive_Correlation,TRUE,<ENT2>Overweight</ENT2>/obesity was a risk factor for CAD only in the <ENT1>-930G</ENT1> allele carriers (P<10(-10)) but not in the AA homozygotes (P=1.00).,,,,T,,,,,c,,,,,1.0,,
24477591,2723,rs9932581,D003324,Positive_Correlation,TRUE,The <ENT1>-930A>G</ENT1> polymorphism of the CYBA gene is associated with premature <ENT2>coronary artery disease</ENT2>. A case-control study and gene-risk factors interactions.,,,,T,,T,,,w,,,,,1.0,,
24477591,2723,rs9932581,D003324,Positive_Correlation,TRUE,The aim of the present study was to analyze a possible association between the <ENT1>-930A>G</ENT1> polymorphism and <ENT2>CAD</ENT2> and to search for gene-traditional risk factors interactions.,,,,T,,Y,,,w,,,,,0.0,,
24477591,2723,rs9932581,D003324,Positive_Correlation,TRUE,"The <ENT1>-930G</ENT1> allele carrier state was a risk factor for <ENT2>CAD</ENT2> (OR 2.03, 95% CI 1.21-3.44, P=0.007).",,,,T,,,,,c,,,,,1.0,,
24477591,2723,rs9932581,D003324,Positive_Correlation,TRUE,"The estimated <ENT2>CAD</ENT2> risk for BMI --25 and the <ENT1>-930G</ENT1> allele interaction was about 160% greater than that predicted by assuming additivity of the effects, and about 40% greater for interaction of cigarette smoking and the <ENT1>-930G</ENT1> allele.",,,,T,,,,,w,,,,,0.5,TRUE,
24477591,2723,rs9932581,D003324,Positive_Correlation,TRUE,Overweight/obesity was a risk factor for <ENT2>CAD</ENT2> only in the <ENT1>-930G</ENT1> allele carriers (P<10(-10)) but not in the AA homozygotes (P=1.00).,,,,T,Y,,,,w,,,,,1.0,,
24477591,2723,rs9932581,D003324,Positive_Correlation,TRUE,In conclusion the <ENT1>-930A>G</ENT1> CYBA polymorphism is associated with <ENT2>CAD</ENT2> in the Polish population.,,,,T,Y,,,,w,,,,,1.0,,
24477591,2725,1535,D003324,Association,TRUE,The -930A>G polymorphism of the <ENT1>CYBA</ENT1> gene is associated with premature <ENT2>coronary artery disease</ENT2>. A case-control study and gene-risk factors interactions.,,,,T,,T,,,c,,,,,0.0,,
24477591,2725,1535,D003324,Association,TRUE,In conclusion the -930A>G <ENT1>CYBA</ENT1> polymorphism is associated with <ENT2>CAD</ENT2> in the Polish population.,,,,T,,,,,c,,,,,0.0,,
24477591,2724,1535,1666,Association,FALSE,<ENT1>p22phox</ENT1> is a critical component of vascular <ENT2>NADPH oxidases</ENT2> and is encoded by the <ENT1>CYBA</ENT1> (<ENT1>cytochrome b245 alpha</ENT1>) gene.,,,,T,,,,,c,,,,,1.0,,
24587916,2726,D006861,D003907,Positive_Correlation,TRUE,<ENT2>Dexamethasone</ENT2> significantly increased SBP and plasma <ENT1>H2O2</ENT1> level and decreased thymus and body weights.,,,,T,,,,,c,,,,,1.0,,
24587916,2730,D006861,301034,Negative_Correlation,TRUE,<ENT2>LF</ENT2> prevented body weight loss and significantly reduced the elevated plasma <ENT1>H2O2</ENT1> and increased FRAP values.,,,,T,,,,,c,,,,,0.0,,
24587916,2728,D017382,301034,Negative_Correlation,TRUE,"Chronic administration of <ENT2>LF</ENT2> strongly reduced the blood pressure and production of <ENT1>ROS</ENT1> and improved antioxidant capacity in Dex-induced hypertension, suggesting the role of inhibition of oxidative stress as another mechanism of antihypertensive action of <ENT2>LF</ENT2>.",,,,T,,,,,c,,,,,0.5,,
24587916,2727,D003907,D006973,Positive_Correlation,FALSE,Antioxidant effects of bovine lactoferrin on <ENT1>dexamethasone</ENT1>-induced <ENT2>hypertension</ENT2> in rat.,,,,T,,T,,,c,,,,,1.0,,
24587916,2727,D003907,D006973,Positive_Correlation,FALSE,<ENT1>Dexamethasone</ENT1>- (<ENT1>Dex</ENT1>-) induced <ENT2>hypertension</ENT2> is associated with enhanced oxidative stress.,,,,T,,,,,c,,,,,0.5,,
24587916,2727,D003907,D006973,Positive_Correlation,FALSE,"In this study, we investigated the effect of chronic administration of LF on oxidative stress and <ENT2>hypertension</ENT2> upon <ENT1>Dex</ENT1> administration.",,,,T,,,,,w,,,,,0.0,,
24587916,2727,D003907,D006973,Positive_Correlation,FALSE,LF lowered (P < 0.01) and dose dependently prevented (P < 0.001) <ENT1>Dex</ENT1>-induced <ENT2>hypertension</ENT2>.,,,,T,,,,,c,,,,,1.0,,
24587916,2727,D003907,D006973,Positive_Correlation,FALSE,"Chronic administration of LF strongly reduced the blood pressure and production of ROS and improved antioxidant capacity in <ENT1>Dex</ENT1>-induced <ENT2>hypertension</ENT2>, suggesting the role of inhibition of oxidative stress as another mechanism of antihypertensive action of LF.",,,,T,,,,,c,,,,,1.0,,
24587916,2732,D003907,301034,Negative_Correlation,TRUE,Antioxidant effects of bovine <ENT2>lactoferrin</ENT2> on <ENT1>dexamethasone</ENT1>-induced hypertension in rat.,,,,T,,T,,,c,,,,,1.0,,
24587916,2732,D003907,301034,Negative_Correlation,TRUE,"In this study, we investigated the effect of chronic administration of <ENT2>LF</ENT2> on oxidative stress and hypertension upon <ENT1>Dex</ENT1> administration.",,,,T,,Y,,,w,,,,,0.0,,
24587916,2732,D003907,301034,Negative_Correlation,TRUE,"In a prevention study, rats received 4 days of <ENT2>LF</ENT2> treatment followed by <ENT1>Dex</ENT1> and continued during the test period.",,,,T,,,,,c,,,,,0.0,,
24587916,2732,D003907,301034,Negative_Correlation,TRUE,<ENT2>LF</ENT2> lowered (P < 0.01) and dose dependently prevented (P < 0.001) <ENT1>Dex</ENT1>-induced hypertension.,,,,T,,,,,c,,,,,1.0,,
24587916,2732,D003907,301034,Negative_Correlation,TRUE,"Chronic administration of <ENT2>LF</ENT2> strongly reduced the blood pressure and production of ROS and improved antioxidant capacity in <ENT1>Dex</ENT1>-induced hypertension, suggesting the role of inhibition of oxidative stress as another mechanism of antihypertensive action of <ENT2>LF</ENT2>.",,,,T,Y,,,,w,,,,,0.0,TRUE,
24587916,2733,D007501,301034,Association,TRUE,<ENT2>Lactoferrin</ENT2> (<ENT2>LF</ENT2>) is an <ENT1>iron</ENT1>-binding glycoprotein with antihypertensive properties.,,,,T,,,,,w,,,,,1.0,,
24587916,2729,D015431,301034,Negative_Correlation,TRUE,<ENT2>LF</ENT2> prevented body <ENT1>weight loss</ENT1> and significantly reduced the elevated plasma H2O2 and increased FRAP values.,,,,T,,,,,c,,,,,0.0,,
24587916,2731,D006973,301034,Negative_Correlation,TRUE,Antioxidant effects of bovine <ENT2>lactoferrin</ENT2> on dexamethasone-induced <ENT1>hypertension</ENT1> in rat.,,,,T,Y,T,,,w,,,,,0.0,,
24587916,2731,D006973,301034,Negative_Correlation,TRUE,"In this study, we investigated the effect of chronic administration of <ENT2>LF</ENT2> on oxidative stress and <ENT1>hypertension</ENT1> upon Dex administration.",,,,T,,,,,c,,,,,1.0,,
24587916,2731,D006973,301034,Negative_Correlation,TRUE,<ENT2>LF</ENT2> lowered (P < 0.01) and dose dependently prevented (P < 0.001) Dex-induced <ENT1>hypertension</ENT1>.,,,,T,,,,,c,,,,,1.0,,
24587916,2731,D006973,301034,Negative_Correlation,TRUE,"Chronic administration of <ENT2>LF</ENT2> strongly reduced the blood pressure and production of ROS and improved antioxidant capacity in Dex-induced <ENT1>hypertension</ENT1>, suggesting the role of inhibition of oxidative stress as another mechanism of antihypertensive action of <ENT2>LF</ENT2>.",,,,T,Y,,,,c,,,,,0.0,,
24588023,2734,D014148,D012640,Association,TRUE,The association between <ENT1>tranexamic acid</ENT1> and <ENT2>convulsive seizures</ENT2> after cardiac surgery: a multivariate analysis in 11 529 patients.,,,,T,,T,,,w,,,,,0.0,,
24588023,2734,D014148,D012640,Association,TRUE,"Independent predictors of postoperative <ENT2>seizures</ENT2> included age, female sex, redo cardiac surgery, calcification of ascending aorta, congestive heart failure, deep hypothermic circulatory arrest, duration of aortic cross-clamp and <ENT1>tranexamic acid</ENT1>.",,,,T,,,,,c,,,,,0.0,,
24588023,2734,D014148,D012640,Association,TRUE,"When tested in a multivariate regression analysis, <ENT1>tranexamic acid</ENT1> was a strong independent predictor of <ENT2>seizures</ENT2> (OR 14.3, 95% CI 5.5-36.7; p < 0.001).",,,,T,,,,,c,,,,,0.0,,
24588023,2734,D014148,D012640,Association,TRUE,"As <ENT1>tranexamic acid</ENT1> is the only modifiable factor, its administration, particularly in doses exceeding 80 mg.kg(-1), should be weighed against the risk of postoperative <ENT2>seizures</ENT2>.",,,,T,,,,,c,,,,,0.0,,
24623966,2745,85431,D017382,Positive_Correlation,FALSE,PURPOSE: <ENT1>NADPH oxidase</ENT1>-generated <ENT2>reactive oxygen species</ENT2> (<ENT2>ROS</ENT2>) are implicated in angiogenesis.,,,,T,,,,,c,,,,,0.0,,
24623966,2746,85431,25589,Association,TRUE,Endothelial <ENT1>NADPH oxidase 4</ENT1> mediates <ENT2>vascular endothelial growth factor receptor 2</ENT2>-induced intravitreal neovascularization in a rat model of retinopathy of prematurity.,,,,T,Y,T,,,c,,,,,1.0,,
24623966,2746,85431,25589,Association,TRUE,"Altogether, our results suggest that <ENT1>NOX4</ENT1> may regulate <ENT2>VEGFR2</ENT2>-mediated IVNV through activated STAT3.",,,,T,,,,,c,,,,,1.0,,
24623966,2737,7422,D017382,Positive_Correlation,FALSE,"In hRMVECs transfected with NOX4 siRNA and treated with <ENT1>VEGF</ENT1> or control, 1) <ENT2>ROS</ENT2> generation was measured using the 5-(and-6)-chloromethyl-2',7'-dichlorodihydrofluorescein diacetate, acetyl ester fluorescence assay and 2) phosphorylated VEGF receptor 2 and STAT3, and total VEGFR2 and STAT3 were measured in western blot analyses.",,,,T,,Y,,,c,,,,,1.0,,
24623966,2737,7422,D017382,Positive_Correlation,FALSE,"In cultured hRMVECs, knockdown of NOX4 by siRNA transfection inhibited <ENT1>VEGF</ENT1>-induced <ENT2>ROS</ENT2> generation.",,,,T,,,,,c,,,,,1.0,,
24623966,2741,7422,50507,Association,TRUE,"In hRMVECs transfected with <ENT2>NOX4</ENT2> siRNA and treated with <ENT1>VEGF</ENT1> or control, 1) ROS generation was measured using the 5-(and-6)-chloromethyl-2',7'-dichlorodihydrofluorescein diacetate, acetyl ester fluorescence assay and 2) phosphorylated VEGF receptor 2 and STAT3, and total VEGFR2 and STAT3 were measured in western blot analyses.",,,,T,,,,,c,,,,,1.0,,
24623966,2741,7422,50507,Association,TRUE,"<ENT1>VEGF</ENT1>-stimulated hRMVEC proliferation was measured following transfection with <ENT2>NOX4</ENT2> siRNA or STAT3 siRNA, or respective controls.",,,,T,,Y,,,w,,,,,0.0,,
24623966,2741,7422,50507,Association,TRUE,"In cultured hRMVECs, knockdown of <ENT2>NOX4</ENT2> by siRNA transfection inhibited <ENT1>VEGF</ENT1>-induced ROS generation.",,,,T,,,,,w,,,,,0.0,,
24623966,2741,7422,50507,Association,TRUE,<ENT1>VEGF</ENT1> induced a physical interaction of phosphorylated-VEGFR2 and <ENT2>NOX4</ENT2>.,,,,T,,,,,c,,,,,0.0,,
24623966,2741,7422,50507,Association,TRUE,Knockdown of <ENT2>NOX4</ENT2>: 1) reduced VEGFR2 activation but did not abolish it and 2) abolished STAT3 activation in response to <ENT1>VEGF</ENT1>.,,,,T,,,,,c,,,,,0.0,,
24623966,2741,7422,50507,Association,TRUE,Knockdown of either <ENT2>NOX4</ENT2> or STAT3 inhibited <ENT1>VEGF</ENT1>-induced EC proliferation.,,,,T,,,,,c,,,,,0.0,,
24623966,2741,7422,50507,Association,TRUE,<ENT1>VEGF</ENT1>-activated <ENT2>NOX4</ENT2> led to an interaction between <ENT1>VEGF</ENT1>-activated VEGFR2 and <ENT2>NOX4</ENT2> that mediated EC proliferation via activation of STAT3.,,,,T,,,,,c,,,,,0.25,,
24623966,2736,7422,3791,Positive_Correlation,TRUE,"In hRMVECs transfected with NOX4 siRNA and treated with <ENT1>VEGF</ENT1> or control, 1) ROS generation was measured using the 5-(and-6)-chloromethyl-2',7'-dichlorodihydrofluorescein diacetate, acetyl ester fluorescence assay and 2) phosphorylated <ENT2>VEGF receptor 2</ENT2> and STAT3, and total <ENT2>VEGFR2</ENT2> and STAT3 were measured in western blot analyses.",,,,T,,Y,,,c,,,,,1.0,,
24623966,2736,7422,3791,Positive_Correlation,TRUE,<ENT1>VEGF</ENT1> induced a physical interaction of phosphorylated-<ENT2>VEGFR2</ENT2> and NOX4.,,,,T,,,,,w,,,,,1.0,,
24623966,2736,7422,3791,Positive_Correlation,TRUE,Knockdown of NOX4: 1) reduced <ENT2>VEGFR2</ENT2> activation but did not abolish it and 2) abolished STAT3 activation in response to <ENT1>VEGF</ENT1>.,,,,T,,,,,c,,,,,1.0,,
24623966,2736,7422,3791,Positive_Correlation,TRUE,<ENT1>VEGF</ENT1>-activated NOX4 led to an interaction between <ENT1>VEGF</ENT1>-activated <ENT2>VEGFR2</ENT2> and NOX4 that mediated EC proliferation via activation of STAT3.,,,,T,,,,,c,,,,,1.0,,
24623966,2735,7422,6774,Association,TRUE,"In hRMVECs transfected with NOX4 siRNA and treated with <ENT1>VEGF</ENT1> or control, 1) ROS generation was measured using the 5-(and-6)-chloromethyl-2',7'-dichlorodihydrofluorescein diacetate, acetyl ester fluorescence assay and 2) phosphorylated VEGF receptor 2 and <ENT2>STAT3</ENT2>, and total VEGFR2 and <ENT2>STAT3</ENT2> were measured in western blot analyses.",,,,T,,Y,,,c,,,,,1.0,,
24623966,2735,7422,6774,Association,TRUE,"<ENT1>VEGF</ENT1>-stimulated hRMVEC proliferation was measured following transfection with NOX4 siRNA or <ENT2>STAT3</ENT2> siRNA, or respective controls.",,,,T,,,,,c,,,,,1.0,,
24623966,2735,7422,6774,Association,TRUE,Knockdown of NOX4: 1) reduced VEGFR2 activation but did not abolish it and 2) abolished <ENT2>STAT3</ENT2> activation in response to <ENT1>VEGF</ENT1>.,,,,T,,,,,c,,,,,0.0,,
24623966,2735,7422,6774,Association,TRUE,Knockdown of either NOX4 or <ENT2>STAT3</ENT2> inhibited <ENT1>VEGF</ENT1>-induced EC proliferation.,,,,T,,,,,c,,,,,0.0,,
24623966,2735,7422,6774,Association,TRUE,<ENT1>VEGF</ENT1>-activated NOX4 led to an interaction between <ENT1>VEGF</ENT1>-activated VEGFR2 and NOX4 that mediated EC proliferation via activation of <ENT2>STAT3</ENT2>.,,,,T,,,,,w,,,,,0.0,TRUE,
24623966;24623966;24623966,2743;2738;2742,D017382;D017382;D017382,114243;66021;50507,Positive_Correlation;Positive_Correlation;Positive_Correlation,FALSE;FALSE;FALSE,PURPOSE: <ENT2>NADPH oxidase</ENT2>-generated <ENT1>reactive oxygen species</ENT1> (<ENT1>ROS</ENT1>) are implicated in angiogenesis.,,,,T,,,,,c,,,,,0.0,,
24623966,2742,D017382,50507,Positive_Correlation,TRUE,"In hRMVECs transfected with <ENT2>NOX4</ENT2> siRNA and treated with VEGF or control, 1) <ENT1>ROS</ENT1> generation was measured using the 5-(and-6)-chloromethyl-2',7'-dichlorodihydrofluorescein diacetate, acetyl ester fluorescence assay and 2) phosphorylated VEGF receptor 2 and STAT3, and total VEGFR2 and STAT3 were measured in western blot analyses.",,,,T,,Y,,,c,,,,,1.0,,
24623966,2742,D017382,50507,Positive_Correlation,TRUE,"In cultured hRMVECs, knockdown of <ENT2>NOX4</ENT2> by siRNA transfection inhibited VEGF-induced <ENT1>ROS</ENT1> generation.",,,,T,,,,,c,,,,,0.0,,
24623966,2744,D012164,D010100,Positive_Correlation,FALSE,"Of these, NOX1 and NOX2 have been reported to contribute to intravitreal neovascularization (IVNV) in <ENT2>oxygen</ENT2>-induced <ENT1>retinopathy</ENT1> (<ENT1>OIR</ENT1>) models.",,,,T,,,,,c,,,,,0.5,,
24623966,2744,D012164,D010100,Positive_Correlation,FALSE,"Newborn rat pups and dams were placed into an <ENT1>OIR</ENT1> model that cycled <ENT2>oxygen</ENT2> concentration between 50% and 10% every 24 h for 14 days, and then were placed in room air (RA) for an additional 4 days (rat <ENT1>OIR</ENT1> model).",,,,T,,,,,c,,,,,1.0,,
24623966,2740,50507,3791,Positive_Correlation,TRUE,"In hRMVECs transfected with <ENT1>NOX4</ENT1> siRNA and treated with VEGF or control, 1) ROS generation was measured using the 5-(and-6)-chloromethyl-2',7'-dichlorodihydrofluorescein diacetate, acetyl ester fluorescence assay and 2) phosphorylated <ENT2>VEGF receptor 2</ENT2> and STAT3, and total <ENT2>VEGFR2</ENT2> and STAT3 were measured in western blot analyses.",,,,T,,Y,,,c,,,,,1.0,,
24623966,2740,50507,3791,Positive_Correlation,TRUE,VEGF induced a physical interaction of phosphorylated-<ENT2>VEGFR2</ENT2> and <ENT1>NOX4</ENT1>.,,,,T,,,,,w,,,,,0.0,,
24623966,2740,50507,3791,Positive_Correlation,TRUE,Knockdown of <ENT1>NOX4</ENT1>: 1) reduced <ENT2>VEGFR2</ENT2> activation but did not abolish it and 2) abolished STAT3 activation in response to VEGF.,,,,T,,,,,c,,,,,1.0,,
24623966,2740,50507,3791,Positive_Correlation,TRUE,VEGF-activated <ENT1>NOX4</ENT1> led to an interaction between VEGF-activated <ENT2>VEGFR2</ENT2> and <ENT1>NOX4</ENT1> that mediated EC proliferation via activation of STAT3.,,,,T,,,,,w,,,,,0.0,TRUE,
24623966,2739,50507,6774,Positive_Correlation,TRUE,"In hRMVECs transfected with <ENT1>NOX4</ENT1> siRNA and treated with VEGF or control, 1) ROS generation was measured using the 5-(and-6)-chloromethyl-2',7'-dichlorodihydrofluorescein diacetate, acetyl ester fluorescence assay and 2) phosphorylated VEGF receptor 2 and <ENT2>STAT3</ENT2>, and total VEGFR2 and <ENT2>STAT3</ENT2> were measured in western blot analyses.",,,,T,,Y,,,c,,,,,1.0,,
24623966,2739,50507,6774,Positive_Correlation,TRUE,"VEGF-stimulated hRMVEC proliferation was measured following transfection with <ENT1>NOX4</ENT1> siRNA or <ENT2>STAT3</ENT2> siRNA, or respective controls.",,,,T,,,,,c,,,,,1.0,,
24623966,2739,50507,6774,Positive_Correlation,TRUE,Knockdown of <ENT1>NOX4</ENT1>: 1) reduced VEGFR2 activation but did not abolish it and 2) abolished <ENT2>STAT3</ENT2> activation in response to VEGF.,,,,T,,,,,c,,,,,0.0,,
24623966,2739,50507,6774,Positive_Correlation,TRUE,Knockdown of either <ENT1>NOX4</ENT1> or <ENT2>STAT3</ENT2> inhibited VEGF-induced EC proliferation.,,,,T,,,,,c,,,,,1.0,,
24623966,2739,50507,6774,Positive_Correlation,TRUE,VEGF-activated <ENT1>NOX4</ENT1> led to an interaction between VEGF-activated VEGFR2 and <ENT1>NOX4</ENT1> that mediated EC proliferation via activation of <ENT2>STAT3</ENT2>.,,,,T,,,,,w,,,,,0.5,TRUE,
24632946,2757,D029502,12387,Association,TRUE,Both <ENT2>b-catenin</ENT2> loss- and gain-of-function (LOF and GOF) mutants displayed abnormal clefts in the perineal region and <ENT1>hypoplastic</ENT1> elongation of the URS.,,,,T,,,,,c,,,,,1.0,,
24632946,2747,20423,D013629,Association,FALSE,We modulated the b-catenin gene conditionally in endodermal epithelia by utilizing <ENT2>tamoxifen</ENT2>-inducible Cre driver line (<ENT1>Shh</ENT1>(CreERT2)).,,,,T,,,,,c,,,,,0.0,,
24632946,2758,20423,12387,Association,FALSE,We modulated the <ENT2>b-catenin</ENT2> gene conditionally in endodermal epithelia by utilizing tamoxifen-inducible Cre driver line (<ENT1>Shh</ENT1>(CreERT2)).,,,,T,,,,,c,,,,,0.0,,
24632946,2758,20423,12387,Association,FALSE,The <ENT1>Shh</ENT1>(CreERT2/+); <ENT2>b-catenin</ENT2>(flox(ex3)/+); BmprIA(flox/-) mutants displayed partial restoration of URS elongation compared with the <ENT2>b-catenin</ENT2> GOF mutants.,,,,T,,,,,w,,,,,0.0,TRUE,
24632946;24632946,2752;2751,D000071056;D000071056,12159;12162,Association;Association,TRUE;TRUE,These results indicate that some <ENT1>ARM</ENT1> phenotypes in the b-catenin GOF mutants were caused by abnormal <ENT2>Bmp</ENT2> signaling.,,,,T,,,,,c,,,,,1.0,,
24632946,2759,D000071056,12387,Association,TRUE,Disruption of the temporally regulated cloaca endodermal <ENT2>b-catenin</ENT2> signaling causes <ENT1>anorectal malformations</ENT1>.,,,,T,,,,,c,,,,,1.0,,
24632946,2759,D000071056,12387,Association,TRUE,These results indicate that some <ENT1>ARM</ENT1> phenotypes in the <ENT2>b-catenin</ENT2> GOF mutants were caused by abnormal Bmp signaling.,,,,T,,,,,c,,,,,1.0,,
24632946,2759,D000071056,12387,Association,TRUE,The current analysis revealed the close relation of endodermal <ENT2>b-catenin</ENT2> signaling to the <ENT1>ARM</ENT1> phenotypes.,,,,T,,,,,c,,,,,1.0,,
24632946,2750,12159,12387,Association,TRUE,"The expression of <ENT1>bone morphogenetic protein</ENT1> (<ENT1>Bmp</ENT1>) genes, such as <ENT1>Bmp4</ENT1> and Bmp7, was also ectopically induced in the epithelia of the URS in the <ENT2>b-catenin</ENT2> GOF mutants.",,,,T,,,,,c,,,,,0.0,,
24632946,2750,12159,12387,Association,TRUE,These results indicate that some ARM phenotypes in the <ENT2>b-catenin</ENT2> GOF mutants were caused by abnormal <ENT1>Bmp</ENT1> signaling.,,,,T,,,,,w,,,,,1.0,,
24632946,2748,D013629,12387,Association,FALSE,We modulated the <ENT2>b-catenin</ENT2> gene conditionally in endodermal epithelia by utilizing <ENT1>tamoxifen</ENT1>-inducible Cre driver line (Shh(CreERT2)).,,,,T,,,,,c,,,,,0.0,,
24632946,2749,12387,12162,Association,TRUE,"The expression of <ENT2>bone morphogenetic protein</ENT2> (<ENT2>Bmp</ENT2>) genes, such as Bmp4 and <ENT2>Bmp7</ENT2>, was also ectopically induced in the epithelia of the URS in the <ENT1>b-catenin</ENT1> GOF mutants.",,,,T,,,,,c,,,,,0.0,,
24632946,2749,12387,12162,Association,TRUE,These results indicate that some ARM phenotypes in the <ENT1>b-catenin</ENT1> GOF mutants were caused by abnormal <ENT2>Bmp</ENT2> signaling.,,,,T,,,,,w,,,,,1.0,,
24671324,2764,D000069283,D003907,Cotreatment,FALSE,"We report a case of a 76-year-old man with Waldenstrom macroglobulinaemia who suffered necrotising fasciitis without neutropenia after the combination treatment with bortezomib, high-dose <ENT2>dexamethasone</ENT2> and <ENT1>rituximab</ENT1>.",,,,T,,,,,c,,,,,1.0,,
24671324,2767,D000069283,D000069286,Cotreatment,FALSE,"We report a case of a 76-year-old man with Waldenstrom macroglobulinaemia who suffered necrotising fasciitis without neutropenia after the combination treatment with <ENT2>bortezomib</ENT2>, high-dose dexamethasone and <ENT1>rituximab</ENT1>.",,,,T,,,,,c,,,,,1.0,,
24671324,2762,D000069283,D008258,Negative_Correlation,FALSE,"We report a case of a 76-year-old man with <ENT2>Waldenstrom macroglobulinaemia</ENT2> who suffered necrotising fasciitis without neutropenia after the combination treatment with bortezomib, high-dose dexamethasone and <ENT1>rituximab</ENT1>.",,,,T,,,,,c,,,,,1.0,,
24671324,2760,D001424,D003907,Positive_Correlation,TRUE,Bortezomib and high-dose <ENT2>dexamethasone</ENT2>-containing regimens are considered to be generally tolerable with few severe <ENT1>bacterial infections</ENT1> in patients with B-cell malignancies.,,,,T,,,,,c,,,,,1.0,,
24671324,2760,D001424,D003907,Positive_Correlation,TRUE,"Physicians should recognise the possibility of fatal <ENT1>bacterial infections</ENT1> related to bortezomib plus high-dose <ENT2>dexamethasone</ENT2> in elderly patients, and we believe this case warrants further investigation.",,,,T,,,,,c,,,,,1.0,,
24671324,2761,D001424,D000069286,Positive_Correlation,TRUE,<ENT2>Bortezomib</ENT2> and high-dose dexamethasone-containing regimens are considered to be generally tolerable with few severe <ENT1>bacterial infections</ENT1> in patients with B-cell malignancies.,,,,T,,,,,c,,,,,1.0,,
24671324,2761,D001424,D000069286,Positive_Correlation,TRUE,"Physicians should recognise the possibility of fatal <ENT1>bacterial infections</ENT1> related to <ENT2>bortezomib</ENT2> plus high-dose dexamethasone in elderly patients, and we believe this case warrants further investigation.",,,,T,,,,,w,,,,,1.0,,
24671324,2769,D003907,D000069286,Cotreatment,FALSE,Necrotising fasciitis after <ENT2>bortezomib</ENT2> and <ENT1>dexamethasone</ENT1>-containing regimen in an elderly patient of Waldenstrom macroglobulinaemia.,,,,T,,,,,c,,,,,1.0,,
24671324,2769,D003907,D000069286,Cotreatment,FALSE,<ENT2>Bortezomib</ENT2> and high-dose <ENT1>dexamethasone</ENT1>-containing regimens are considered to be generally tolerable with few severe bacterial infections in patients with B-cell malignancies.,,,,T,,,,,c,,,,,1.0,,
24671324,2769,D003907,D000069286,Cotreatment,FALSE,"We report a case of a 76-year-old man with Waldenstrom macroglobulinaemia who suffered necrotising fasciitis without neutropenia after the combination treatment with <ENT2>bortezomib</ENT2>, high-dose <ENT1>dexamethasone</ENT1> and rituximab.",,,,T,,,,,c,,,,,1.0,,
24671324,2769,D003907,D000069286,Cotreatment,FALSE,"Physicians should recognise the possibility of fatal bacterial infections related to <ENT2>bortezomib</ENT2> plus high-dose <ENT1>dexamethasone</ENT1> in elderly patients, and we believe this case warrants further investigation.",,,,T,,,,,w,,,,,1.0,,
24671324,2765,D003907,D008258,Negative_Correlation,FALSE,Necrotising fasciitis after bortezomib and <ENT1>dexamethasone</ENT1>-containing regimen in an elderly patient of <ENT2>Waldenstrom macroglobulinaemia</ENT2>.,,,,T,,,,,c,,,,,1.0,,
24671324,2765,D003907,D008258,Negative_Correlation,FALSE,"We report a case of a 76-year-old man with <ENT2>Waldenstrom macroglobulinaemia</ENT2> who suffered necrotising fasciitis without neutropenia after the combination treatment with bortezomib, high-dose <ENT1>dexamethasone</ENT1> and rituximab.",,,,T,,,,,c,,,,,1.0,,
24671324,2770,D003907,D019115,Positive_Correlation,TRUE,<ENT2>Necrotising fasciitis</ENT2> after bortezomib and <ENT1>dexamethasone</ENT1>-containing regimen in an elderly patient of Waldenstrom macroglobulinaemia.,,,,T,,,,,w,,,,,1.0,,
24671324,2770,D003907,D019115,Positive_Correlation,TRUE,"We report a case of a 76-year-old man with Waldenstrom macroglobulinaemia who suffered <ENT2>necrotising fasciitis</ENT2> without neutropenia after the combination treatment with bortezomib, high-dose <ENT1>dexamethasone</ENT1> and rituximab.",,,,T,,,,,c,,,,,1.0,,
24671324,2763,D003907,D009369,Negative_Correlation,FALSE,Bortezomib and high-dose <ENT1>dexamethasone</ENT1>-containing regimens are considered to be generally tolerable with few severe bacterial infections in patients with B-cell <ENT2>malignancies</ENT2>.,,,,T,,,,,c,,,,,1.0,,
24671324,2768,D000069286,D008258,Negative_Correlation,FALSE,Necrotising fasciitis after <ENT1>bortezomib</ENT1> and dexamethasone-containing regimen in an elderly patient of <ENT2>Waldenstrom macroglobulinaemia</ENT2>.,,,,T,,,,,c,,,,,0.0,,
24671324,2768,D000069286,D008258,Negative_Correlation,FALSE,"We report a case of a 76-year-old man with <ENT2>Waldenstrom macroglobulinaemia</ENT2> who suffered necrotising fasciitis without neutropenia after the combination treatment with <ENT1>bortezomib</ENT1>, high-dose dexamethasone and rituximab.",,,,T,,,,,c,,,,,0.0,,
24671324,2771,D000069286,D019115,Positive_Correlation,TRUE,<ENT2>Necrotising fasciitis</ENT2> after <ENT1>bortezomib</ENT1> and dexamethasone-containing regimen in an elderly patient of Waldenstrom macroglobulinaemia.,,,,T,,,,,c,,,,,1.0,,
24671324,2771,D000069286,D019115,Positive_Correlation,TRUE,"We report a case of a 76-year-old man with Waldenstrom macroglobulinaemia who suffered <ENT2>necrotising fasciitis</ENT2> without neutropenia after the combination treatment with <ENT1>bortezomib</ENT1>, high-dose dexamethasone and rituximab.",,,,T,,,,,c,,,,,1.0,,
24671324,2766,D000069286,D009369,Negative_Correlation,FALSE,<ENT1>Bortezomib</ENT1> and high-dose dexamethasone-containing regimens are considered to be generally tolerable with few severe bacterial infections in patients with B-cell <ENT2>malignancies</ENT2>.,,,,T,,,,,c,,,,,1.0,,
24709919,2776,D036145,D000701,Association,TRUE,Effects of <ENT1>ginsenosides</ENT1> on <ENT2>opioid</ENT2>-induced hyperalgesia in mice.,,,,T,,T,,,c,,,,,0.0,,
24709919,2777,D036145,D006930,Association,TRUE,Effects of <ENT1>ginsenosides</ENT1> on opioid-induced <ENT2>hyperalgesia</ENT2> in mice.,,,,T,,T,,,c,,,,,0.0,,
24709919,2775,D000701,D006930,Positive_Correlation,FALSE,Effects of ginsenosides on <ENT1>opioid</ENT1>-induced <ENT2>hyperalgesia</ENT2> in mice.,,,,T,,T,,,c,,,,,1.0,,
24709919,2775,D000701,D006930,Positive_Correlation,FALSE,<ENT1>Opioid</ENT1>-induced <ENT2>hyperalgesia</ENT2> (<ENT2>OIH</ENT2>) is characterized by nociceptive sensitization caused by the cessation of chronic <ENT1>opioid</ENT1> use.,,,,T,,,,,c,,,,,0.5,,
24709919,2775,D000701,D006930,Positive_Correlation,FALSE,<ENT2>OIH</ENT2> can limit the clinical use of <ENT1>opioid</ENT1> analgesics and complicate withdrawal from opioid addiction.,,,,T,,,,,w,,,,,0.0,,
24709919;24709919,2774;2773,C035054;C049864,D006930;D006930,Positive_Correlation;Negative_Correlation,TRUE;TRUE,"In this study, we investigated the effects of <ENT1>Re, Rg1, and Rb1 ginsenosides</ENT1>, the bioactive components of ginseng, on <ENT2>OIH</ENT2>.",,,,T,,Y,,,c,,,,,1.0,,
24709919,2774,C035054,D006930,Positive_Correlation,TRUE,"However, the <ENT1>Rg1 and Rb1 ginsenosides</ENT1> failed to prevent <ENT2>OIH</ENT2> in either test.",,,,T,,,,,c,,,,,1.0,,
24709919,2774,C035054,D006930,Positive_Correlation,TRUE,"Furthermore, <ENT1>Rg1</ENT1> showed a tendency to aggravate <ENT2>OIH</ENT2> in the acetic acid-induced writhing test.",,,,T,,,,,c,,,,,1.0,,
24709919,2774,C035054,D006930,Positive_Correlation,TRUE,"Our data suggested that the ginsenoside Re, but not <ENT1>Rg1</ENT1> or Rb1, may contribute toward reversal of <ENT2>OIH</ENT2>.",,,,T,,,,,c,,,,,1.0,,
24709919,2773,C049864,D006930,Negative_Correlation,TRUE,<ENT1>Re</ENT1> (300 mg/kg) inhibited <ENT2>OIH</ENT2> in both the thermal sensitivity test and the acetic acid-induced writhing test.,,,,T,,,,,c,,,,,1.0,,
24709919,2773,C049864,D006930,Negative_Correlation,TRUE,"Our data suggested that the <ENT1>ginsenoside Re</ENT1>, but not Rg1 or Rb1, may contribute toward reversal of <ENT2>OIH</ENT2>.",,,,T,,,,,c,,,,,1.0,,
24742750,2778,D015283,D016171,Positive_Correlation,FALSE,"Finally, the IKr blockers, Terfenadine and <ENT1>Citalopram</ENT1>, which are reported to cause <ENT2>Torsade de Pointes</ENT2> (<ENT2>TdP</ENT2>) in clinical practice, produced early afterdepolarization (EAD).",,,,T,,,,,c,,,,,0.0,,
24742750,2779,D016171,D016593,Positive_Correlation,FALSE,"Finally, the IKr blockers, <ENT2>Terfenadine</ENT2> and Citalopram, which are reported to cause <ENT1>Torsade de Pointes</ENT1> (<ENT1>TdP</ENT1>) in clinical practice, produced early afterdepolarization (EAD).",,,,T,,,,,c,,,,,1.0,,
24743235,2786,D008070,16153,Association,TRUE,"Both populations produced a high level of <ENT2>IL-10</ENT2>, in addition to IL-1, IL-6 and TNFa, in response to <ENT1>LPS</ENT1>, and were relatively poor T cell stimulators.",,,,T,,,,,c,,,,,0.0,,
24743235,2785,12977,16187,Association,TRUE,<ENT2>IL-3</ENT2> and <ENT1>CSF-1</ENT1> interact to promote generation of CD11c+ IL-10-producing macrophages.,,,,T,,,,,c,,,,,0.0,,
24743235,2785,12977,16187,Association,TRUE,"<ENT2>IL-3</ENT2> is an allergic cytokine with the multilineage potential, while <ENT1>CSF-1</ENT1> is produced in the steady state with restricted lineage coverage.",,,,T,,,,,c,,,,,1.0,,
24743235,2785,12977,16187,Association,TRUE,"Here, we uncovered an instructive role of <ENT1>CSF-1</ENT1> in <ENT2>IL-3</ENT2>-mediated hematopoiesis.",,,,T,,,,,c,,,,,0.0,,
24743235,2785,12977,16187,Association,TRUE,<ENT1>CSF-1</ENT1> significantly promoted <ENT2>IL-3</ENT2>-driven CD11c+ cell expansion and dampened basophil and mast cell generation from C57BL/6 bone marrow.,,,,T,,,,,c,,,,,0.0,,
24743235,2785,12977,16187,Association,TRUE,Further studies indicated that the <ENT1>CSF-1</ENT1>/CSF-1R axis contributed significantly to <ENT2>IL-3</ENT2>-induced CD11c+ cell generation through enhancing c-Fos-associated monopoiesis.,,,,T,,,,,c,,,,,0.0,,
24743235,2785,12977,16187,Association,TRUE,CD11c+ cells induced by <ENT2>IL-3</ENT2> or <ENT2>IL-3</ENT2>/<ENT1>CSF-1</ENT1> were competent in cellular maturation and endocytosis.,,,,T,,,,,w,,,,,0.0,TRUE,
24743235,2785,12977,16187,Association,TRUE,Both <ENT2>IL-3</ENT2> and <ENT2>IL-3</ENT2>/<ENT1>CSF-1</ENT1> cells lacked classical dendritic cell appearance and resembled macrophages in morphology.,,,,T,,,,,w,,,,,0.0,TRUE,
24743235,2785,12977,16187,Association,TRUE,"Collectively, these findings reveal a role for <ENT1>CSF-1</ENT1> in mediating the <ENT2>IL-3</ENT2> hematopoietic pathway through monopoiesis, which regulates expansion of CD11c+ macrophages.",,,,T,,,,,w,,,,,1.0,,
24743235,2782,12977,12978,Bind,FALSE,Further studies indicated that the <ENT1>CSF-1</ENT1>/<ENT2>CSF-1R</ENT2> axis contributed significantly to IL-3-induced CD11c+ cell generation through enhancing c-Fos-associated monopoiesis.,,,,T,,,,,w,,,,,1.0,,
24743235,2781,12977,14281,Positive_Correlation,TRUE,Further studies indicated that the <ENT1>CSF-1</ENT1>/CSF-1R axis contributed significantly to IL-3-induced CD11c+ cell generation through enhancing <ENT2>c-Fos</ENT2>-associated monopoiesis.,,,,T,,,,,c,,,,,0.0,,
24743235,2783,12977,16153,Positive_Correlation,TRUE,IL-3 and <ENT1>CSF-1</ENT1> interact to promote generation of CD11c+ <ENT2>IL-10</ENT2>-producing macrophages.,,,,T,,,,,c,,,,,0.0,,
24743235,2784,12977,16411,Positive_Correlation,TRUE,IL-3 and <ENT1>CSF-1</ENT1> interact to promote generation of <ENT2>CD11c</ENT2>+ IL-10-producing macrophages.,,,,T,,,,,c,,,,,1.0,,
24743235,2784,12977,16411,Positive_Correlation,TRUE,<ENT1>CSF-1</ENT1> significantly promoted IL-3-driven <ENT2>CD11c</ENT2>+ cell expansion and dampened basophil and mast cell generation from C57BL/6 bone marrow.,,,,T,,,,,c,,,,,1.0,,
24743235,2784,12977,16411,Positive_Correlation,TRUE,Further studies indicated that the <ENT1>CSF-1</ENT1>/CSF-1R axis contributed significantly to IL-3-induced <ENT2>CD11c</ENT2>+ cell generation through enhancing c-Fos-associated monopoiesis.,,,,T,,,,,c,,,,,0.0,,
24743235,2784,12977,16411,Positive_Correlation,TRUE,<ENT2>CD11c</ENT2>+ cells induced by IL-3 or IL-3/<ENT1>CSF-1</ENT1> were competent in cellular maturation and endocytosis.,,,,T,,,,,c,,,,,0.0,,
24743235,2784,12977,16411,Positive_Correlation,TRUE,"Collectively, these findings reveal a role for <ENT1>CSF-1</ENT1> in mediating the IL-3 hematopoietic pathway through monopoiesis, which regulates expansion of <ENT2>CD11c</ENT2>+ macrophages.",,,,T,,,,,c,,,,,0.0,,
24743235,2787,16187,16153,Positive_Correlation,TRUE,<ENT1>IL-3</ENT1> and CSF-1 interact to promote generation of CD11c+ <ENT2>IL-10</ENT2>-producing macrophages.,,,,T,,T,,,c,,,,,0.0,,
24743235,2788,16187,16411,Positive_Correlation,TRUE,<ENT1>IL-3</ENT1> and CSF-1 interact to promote generation of <ENT2>CD11c</ENT2>+ IL-10-producing macrophages.,,,,T,,T,,,c,,,,,1.0,,
24743235,2788,16187,16411,Positive_Correlation,TRUE,CSF-1 significantly promoted <ENT1>IL-3</ENT1>-driven <ENT2>CD11c</ENT2>+ cell expansion and dampened basophil and mast cell generation from C57BL/6 bone marrow.,,,,T,,,,,c,,,,,1.0,,
24743235,2788,16187,16411,Positive_Correlation,TRUE,Further studies indicated that the CSF-1/CSF-1R axis contributed significantly to <ENT1>IL-3</ENT1>-induced <ENT2>CD11c</ENT2>+ cell generation through enhancing c-Fos-associated monopoiesis.,,,,T,,,,,c,,,,,1.0,,
24743235,2788,16187,16411,Positive_Correlation,TRUE,<ENT2>CD11c</ENT2>+ cells induced by <ENT1>IL-3</ENT1> or <ENT1>IL-3</ENT1>/CSF-1 were competent in cellular maturation and endocytosis.,,,,T,,,,,c,,,,,1.0,,
24743235,2788,16187,16411,Positive_Correlation,TRUE,"Collectively, these findings reveal a role for CSF-1 in mediating the <ENT1>IL-3</ENT1> hematopoietic pathway through monopoiesis, which regulates expansion of <ENT2>CD11c</ENT2>+ macrophages.",,,,T,,,,,c,,,,,0.0,,
24743235,2780,12978,14281,Positive_Correlation,TRUE,Further studies indicated that the CSF-1/<ENT1>CSF-1R</ENT1> axis contributed significantly to IL-3-induced CD11c+ cell generation through enhancing <ENT2>c-Fos</ENT2>-associated monopoiesis.,,,,T,,,,,c,,,,,0.0,,
24840785,2792,D066126,D000157,Positive_Correlation,TRUE,Emerging evidence indicates that voltage-dependent Na(+) channels have pivotal roles in the <ENT1>cardiotoxicity</ENT1> of <ENT2>aconitine</ENT2>.,,,,T,,,,,w,,,,,1.0,,
24840785,2789,D066126,D012964,Association,FALSE,Emerging evidence indicates that voltage-dependent <ENT2>Na(+)</ENT2> channels have pivotal roles in the <ENT1>cardiotoxicity</ENT1> of aconitine.,,,,T,,,,,c,,,,,0.0,,
24840785,2794,81649,D000157,Association,TRUE,<ENT2>Aconitine</ENT2>-induced Ca2+ overload causes arrhythmia and triggers apoptosis through <ENT1>p38 MAPK</ENT1> signaling pathway in rats.,,,,T,,,,,c,,,,,0.0,,
24840785,2794,81649,D000157,Association,TRUE,"Hence, our results suggest that <ENT2>aconitine</ENT2> significantly aggravates Ca(2+) overload and causes arrhythmia and finally promotes apoptotic development via phosphorylation of <ENT1>P38 mitogen-activated protein kinase</ENT1>.",,,,T,,,,,c,,,,,1.0,,
24840785,2791,81649,D001145,Association,TRUE,Aconitine-induced Ca2+ overload causes <ENT2>arrhythmia</ENT2> and triggers apoptosis through <ENT1>p38 MAPK</ENT1> signaling pathway in rats.,,,,T,,,,,c,,,,,0.0,,
24840785,2791,81649,D001145,Association,TRUE,"Hence, our results suggest that aconitine significantly aggravates Ca(2+) overload and causes <ENT2>arrhythmia</ENT2> and finally promotes apoptotic development via phosphorylation of <ENT1>P38 mitogen-activated protein kinase</ENT1>.",,,,T,,,,,c,,,,,1.0,,
24840785,2793,D000157,D009202,Positive_Correlation,TRUE,"To investigate effects of <ENT1>aconitine</ENT1> on <ENT2>myocardial injury</ENT2>, we performed cytotoxicity assay in neonatal rat ventricular myocytes (NRVMs), as well as measured lactate dehydrogenase level in the culture medium of NRVMs and activities of serum cardiac enzymes in rats.",,,,T,,Y,,,c,,,,,1.0,,
24840785,2793,D000157,D009202,Positive_Correlation,TRUE,The results showed that <ENT1>aconitine</ENT1> resulted in <ENT2>myocardial injury</ENT2> and reduced NRVMs viability dose-dependently.,,,,T,,,,,c,,,,,1.0,,
24840785,2796,D000157,D001145,Positive_Correlation,TRUE,<ENT1>Aconitine</ENT1>-induced Ca2+ overload causes <ENT2>arrhythmia</ENT2> and triggers apoptosis through p38 MAPK signaling pathway in rats.,,,,T,,T,,,c,,,,,1.0,,
24840785,2796,D000157,D001145,Positive_Correlation,TRUE,"Hence, our results suggest that <ENT1>aconitine</ENT1> significantly aggravates Ca(2+) overload and causes <ENT2>arrhythmia</ENT2> and finally promotes apoptotic development via phosphorylation of P38 mitogen-activated protein kinase.",,,,T,,,,,c,,,,,1.0,,
24840785,2795,D000157,D002118,Positive_Correlation,TRUE,<ENT1>Aconitine</ENT1>-induced <ENT2>Ca2+</ENT2> overload causes arrhythmia and triggers apoptosis through p38 MAPK signaling pathway in rats.,,,,T,,T,,,c,,,,,1.0,,
24840785,2795,D000157,D002118,Positive_Correlation,TRUE,"However, no reports are available on the role of <ENT2>Ca(2+)</ENT2> in <ENT1>aconitine</ENT1> poisoning.",,,,T,,,,,c,,,,,1.0,,
24840785,2795,D000157,D002118,Positive_Correlation,TRUE,"In this study, we explored the importance of pathological <ENT2>Ca(2+)</ENT2> signaling in <ENT1>aconitine</ENT1> poisoning in vitro and in vivo.",,,,T,,Y,,,c,,,,,1.0,,
24840785,2795,D000157,D002118,Positive_Correlation,TRUE,The expression analysis of <ENT2>Ca(2+)</ENT2> handling proteins demonstrated that <ENT1>aconitine</ENT1> promoted <ENT2>Ca(2+)</ENT2> overload through the expression regulation of <ENT2>Ca(2+)</ENT2> handling proteins.,,,,T,,,,,c,,,,,0.0,,
24840785,2795,D000157,D002118,Positive_Correlation,TRUE,"Hence, our results suggest that <ENT1>aconitine</ENT1> significantly aggravates <ENT2>Ca(2+)</ENT2> overload and causes arrhythmia and finally promotes apoptotic development via phosphorylation of P38 mitogen-activated protein kinase.",,,,T,,,,,c,,,,,1.0,,
24840785,2790,D001145,D002118,Positive_Correlation,TRUE,Aconitine-induced <ENT2>Ca2+</ENT2> overload causes <ENT1>arrhythmia</ENT1> and triggers apoptosis through p38 MAPK signaling pathway in rats.,,,,T,,T,,,c,,,,,1.0,,
24840785,2790,D001145,D002118,Positive_Correlation,TRUE,We found that <ENT2>Ca(2+)</ENT2> overload lead to accelerated beating rhythm in adult rat ventricular myocytes and caused <ENT1>arrhythmia</ENT1> in conscious freely moving rats.,,,,T,,,,,c,,,,,1.0,,
24840785,2790,D001145,D002118,Positive_Correlation,TRUE,"Hence, our results suggest that aconitine significantly aggravates <ENT2>Ca(2+)</ENT2> overload and causes <ENT1>arrhythmia</ENT1> and finally promotes apoptotic development via phosphorylation of P38 mitogen-activated protein kinase.",,,,T,,,,,c,,,,,1.0,,
24842192,2807,D007249,D008687,Negative_Correlation,TRUE,Acute treatment with <ENT2>metformin</ENT2> has a protective effect in myocardial infarction by suppression of <ENT1>inflammatory</ENT1> responses due to activation of AMP-activated protein kinase (AMPK).,,,,T,,,,,c,,,,,1.0,,
24842192,2807,D007249,D008687,Negative_Correlation,TRUE,"Chronic pre-treatment with <ENT2>metformin</ENT2> reduces post-myocardial infarction cardiac dysfunction and suppresses <ENT1>inflammatory</ENT1> responses, possibly through inhibition of TLR4 activities.",,,,T,,,,,c,,,,,1.0,,
24842192,2804,D007249,29260,Association,TRUE,"Chronic pre-treatment with metformin reduces post-myocardial infarction cardiac dysfunction and suppresses <ENT1>inflammatory</ENT1> responses, possibly through inhibition of <ENT2>TLR4</ENT2> activities.",,,,T,,,,,c,,,,,1.0,,
24842192,2797,D007249,65248,Negative_Correlation,FALSE,Acute treatment with metformin has a protective effect in myocardial infarction by suppression of <ENT1>inflammatory</ENT1> responses due to activation of <ENT2>AMP-activated protein kinase</ENT2> (<ENT2>AMPK</ENT2>).,,,,T,,,,,w,,,,,0.0,,
24842192,2811,24498,D008687,Negative_Correlation,TRUE,"<ENT2>Metfromin</ENT2> markedly lowered isoproterenol-induced elevation in the levels of TLR4 mRNA, myeloid differentiation protein 88 (MyD88), tumor necrosis factor-alpha (TNF-a), and <ENT1>interleukin 6</ENT1> (<ENT1>IL-6</ENT1>) in the heart tissues.",,,,T,,,,,c,,,,,1.0,,
24842192,2800,24498,D007545,Positive_Correlation,TRUE,"Metfromin markedly lowered <ENT2>isoproterenol</ENT2>-induced elevation in the levels of TLR4 mRNA, myeloid differentiation protein 88 (MyD88), tumor necrosis factor-alpha (TNF-a), and <ENT1>interleukin 6</ENT1> (<ENT1>IL-6</ENT1>) in the heart tissues.",,,,T,,,,,c,,,,,1.0,,
24842192,2813,D008687,D009203,Negative_Correlation,TRUE,Chronic treatment with <ENT1>metformin</ENT1> suppresses toll-like receptor 4 signaling and attenuates left ventricular dysfunction following <ENT2>myocardial infarction</ENT2>.,,,,T,,T,,,w,,,,,0.0,,
24842192,2813,D008687,D009203,Negative_Correlation,TRUE,Acute treatment with <ENT1>metformin</ENT1> has a protective effect in <ENT2>myocardial infarction</ENT2> by suppression of inflammatory responses due to activation of AMP-activated protein kinase (AMPK).,,,,T,,,,,c,,,,,1.0,,
24842192,2813,D008687,D009203,Negative_Correlation,TRUE,"In the present study, the effect of chronic pre-treatment with <ENT1>metformin</ENT1> on cardiac dysfunction and toll-like receptor 4 (TLR4) activities following <ENT2>myocardial infarction</ENT2> and their relation with AMPK were assessed.",,,,T,,,,,c,,,,,1.0,,
24842192,2813,D008687,D009203,Negative_Correlation,TRUE,"Chronic pre-treatment with <ENT1>metformin</ENT1> reduces post-<ENT2>myocardial infarction</ENT2> cardiac dysfunction and suppresses inflammatory responses, possibly through inhibition of TLR4 activities.",,,,T,,,,,c,,,,,0.0,,
24842192,2814,D008687,D007545,Negative_Correlation,TRUE,"Male Wistar rats were randomly assigned to one of 5 groups (n=6): normal control and groups were injected <ENT2>isoproterenol</ENT2> after chronic pre-treatment with 0, 25, 50, or 100mg/kg of <ENT1>metformin</ENT1> twice daily for 14 days.",,,,T,,,,,c,,,,,1.0,,
24842192,2814,D008687,D007545,Negative_Correlation,TRUE,"<ENT1>Metfromin</ENT1> markedly lowered <ENT2>isoproterenol</ENT2>-induced elevation in the levels of TLR4 mRNA, myeloid differentiation protein 88 (MyD88), tumor necrosis factor-alpha (TNF-a), and interleukin 6 (IL-6) in the heart tissues.",,,,T,,,,,c,,,,,1.0,,
24842192,2816,D008687,29260,Negative_Correlation,TRUE,Chronic treatment with <ENT1>metformin</ENT1> suppresses <ENT2>toll-like receptor 4</ENT2> signaling and attenuates left ventricular dysfunction following myocardial infarction.,,,,T,,T,,,c,,,,,1.0,,
24842192,2816,D008687,29260,Negative_Correlation,TRUE,"In the present study, the effect of chronic pre-treatment with <ENT1>metformin</ENT1> on cardiac dysfunction and <ENT2>toll-like receptor 4</ENT2> (<ENT2>TLR4</ENT2>) activities following myocardial infarction and their relation with AMPK were assessed.",,,,T,,Y,,,c,,,,,1.0,,
24842192,2816,D008687,29260,Negative_Correlation,TRUE,"<ENT1>Metfromin</ENT1> markedly lowered isoproterenol-induced elevation in the levels of <ENT2>TLR4</ENT2> mRNA, myeloid differentiation protein 88 (MyD88), tumor necrosis factor-alpha (TNF-a), and interleukin 6 (IL-6) in the heart tissues.",,,,T,,,,,c,,,,,1.0,,
24842192,2816,D008687,29260,Negative_Correlation,TRUE,"Chronic pre-treatment with <ENT1>metformin</ENT1> reduces post-myocardial infarction cardiac dysfunction and suppresses inflammatory responses, possibly through inhibition of <ENT2>TLR4</ENT2> activities.",,,,T,,,,,c,,,,,1.0,,
24842192,2812,D008687,301059,Negative_Correlation,TRUE,"<ENT1>Metfromin</ENT1> markedly lowered isoproterenol-induced elevation in the levels of TLR4 mRNA, <ENT2>myeloid differentiation protein 88</ENT2> (<ENT2>MyD88</ENT2>), tumor necrosis factor-alpha (TNF-a), and interleukin 6 (IL-6) in the heart tissues.",,,,T,,,,,c,,,,,1.0,,
24842192,2810,D008687,24835,Negative_Correlation,TRUE,"<ENT1>Metfromin</ENT1> markedly lowered isoproterenol-induced elevation in the levels of TLR4 mRNA, myeloid differentiation protein 88 (MyD88), <ENT2>tumor necrosis factor-alpha</ENT2> (<ENT2>TNF-a</ENT2>), and interleukin 6 (IL-6) in the heart tissues.",,,,T,,,,,c,,,,,1.0,,
24842192,2815,D008687,D018487,Negative_Correlation,TRUE,Chronic treatment with <ENT1>metformin</ENT1> suppresses toll-like receptor 4 signaling and attenuates <ENT2>left ventricular dysfunction</ENT2> following myocardial infarction.,,,,T,,T,,,c,,,,,0.0,,
24842192,2815,D008687,D018487,Negative_Correlation,TRUE,The <ENT2>left ventricular dysfunction</ENT2> was significantly lower in the groups treated with 25 and 50mg/kg of <ENT1>metformin</ENT1>.,,,,T,,,,,c,,,,,0.0,,
24842192,2809,D008687,65248,Positive_Correlation,TRUE,Acute treatment with <ENT1>metformin</ENT1> has a protective effect in myocardial infarction by suppression of inflammatory responses due to activation of <ENT2>AMP-activated protein kinase</ENT2> (<ENT2>AMPK</ENT2>).,,,,T,,,,,c,,,,,0.0,,
24842192,2809,D008687,65248,Positive_Correlation,TRUE,"In the present study, the effect of chronic pre-treatment with <ENT1>metformin</ENT1> on cardiac dysfunction and toll-like receptor 4 (TLR4) activities following myocardial infarction and their relation with <ENT2>AMPK</ENT2> were assessed.",,,,T,,Y,,,c,,,,,1.0,,
24842192,2809,D008687,65248,Positive_Correlation,TRUE,"Phosphorylated <ENT2>AMPKa</ENT2> (p-<ENT2>AMPK</ENT2>) in the myocardium was significantly elevated by 25mg/kg of <ENT1>metformin</ENT1>, slightly by 50mg/kg, but not by 100mg/kg.",,,,T,,,,,c,,,,,1.0,,
24842192,2808,D008687,D006331,Negative_Correlation,TRUE,"In the present study, the effect of chronic pre-treatment with <ENT1>metformin</ENT1> on <ENT2>cardiac dysfunction</ENT2> and toll-like receptor 4 (TLR4) activities following myocardial infarction and their relation with AMPK were assessed.",,,,T,,Y,,,c,,,,,0.0,,
24842192,2808,D008687,D006331,Negative_Correlation,TRUE,"Chronic pre-treatment with <ENT1>metformin</ENT1> reduces post-myocardial infarction <ENT2>cardiac dysfunction</ENT2> and suppresses inflammatory responses, possibly through inhibition of TLR4 activities.",,,,T,,,,,c,,,,,1.0,,
24842192,2802,D009203,D007545,Positive_Correlation,FALSE,<ENT2>Isoproterenol</ENT2> (100mg/kg) was injected subcutaneously on the 13th and 14th days to induce <ENT1>acute myocardial infarction</ENT1>.,,,,T,,,,,c,,,,,1.0,,
24842192,2806,D009203,29260,Association,TRUE,Chronic treatment with metformin suppresses <ENT2>toll-like receptor 4</ENT2> signaling and attenuates left ventricular dysfunction following <ENT1>myocardial infarction</ENT1>.,,,,T,,,,,w,,,,,0.0,,
24842192,2806,D009203,29260,Association,TRUE,"In the present study, the effect of chronic pre-treatment with metformin on cardiac dysfunction and <ENT2>toll-like receptor 4</ENT2> (<ENT2>TLR4</ENT2>) activities following <ENT1>myocardial infarction</ENT1> and their relation with AMPK were assessed.",,,,T,,,,,c,,,,,0.0,,
24842192,2806,D009203,29260,Association,TRUE,"Chronic pre-treatment with metformin reduces post-<ENT1>myocardial infarction</ENT1> cardiac dysfunction and suppresses inflammatory responses, possibly through inhibition of <ENT2>TLR4</ENT2> activities.",,,,T,,,,,w,,,,,0.0,,
24842192,2798,D009203,65248,Negative_Correlation,FALSE,Acute treatment with metformin has a protective effect in <ENT1>myocardial infarction</ENT1> by suppression of inflammatory responses due to activation of <ENT2>AMP-activated protein kinase</ENT2> (<ENT2>AMPK</ENT2>).,,,,T,,,,,w,,,,,0.0,,
24842192,2798,D009203,65248,Negative_Correlation,FALSE,"In the present study, the effect of chronic pre-treatment with metformin on cardiac dysfunction and toll-like receptor 4 (TLR4) activities following <ENT1>myocardial infarction</ENT1> and their relation with <ENT2>AMPK</ENT2> were assessed.",,,,T,,,,,c,,,,,1.0,,
24842192,2803,D007545,29260,Positive_Correlation,TRUE,"Metfromin markedly lowered <ENT1>isoproterenol</ENT1>-induced elevation in the levels of <ENT2>TLR4</ENT2> mRNA, myeloid differentiation protein 88 (MyD88), tumor necrosis factor-alpha (TNF-a), and interleukin 6 (IL-6) in the heart tissues.",,,,T,,,,,c,,,,,1.0,,
24842192,2801,D007545,301059,Positive_Correlation,TRUE,"Metfromin markedly lowered <ENT1>isoproterenol</ENT1>-induced elevation in the levels of TLR4 mRNA, <ENT2>myeloid differentiation protein 88</ENT2> (<ENT2>MyD88</ENT2>), tumor necrosis factor-alpha (TNF-a), and interleukin 6 (IL-6) in the heart tissues.",,,,T,,,,,c,,,,,1.0,,
24842192,2799,D007545,24835,Positive_Correlation,TRUE,"Metfromin markedly lowered <ENT1>isoproterenol</ENT1>-induced elevation in the levels of TLR4 mRNA, myeloid differentiation protein 88 (MyD88), <ENT2>tumor necrosis factor-alpha</ENT2> (<ENT2>TNF-a</ENT2>), and interleukin 6 (IL-6) in the heart tissues.",,,,T,,,,,c,,,,,1.0,,
24842192,2805,29260,D006331,Association,TRUE,"In the present study, the effect of chronic pre-treatment with metformin on <ENT2>cardiac dysfunction</ENT2> and <ENT1>toll-like receptor 4</ENT1> (<ENT1>TLR4</ENT1>) activities following myocardial infarction and their relation with AMPK were assessed.",,,,T,Y,,,,w,,,,,0.0,TRUE,
24842192,2805,29260,D006331,Association,TRUE,"Chronic pre-treatment with metformin reduces post-myocardial infarction <ENT2>cardiac dysfunction</ENT2> and suppresses inflammatory responses, possibly through inhibition of <ENT1>TLR4</ENT1> activities.",,,,T,,,,,c,,,,,0.0,,
24911645,2830,C573355,11423,Positive_Correlation,TRUE,"The present study aimed to evaluate the <ENT1>GFC</ENT1> effects at doses of 25, 50 or 75 mg/kg on seizure parameters to determine their anticonvulsant activity and its effects on amino acid (r-aminobutyric acid (GABA), glutamine, aspartate and glutathione) levels as well as on <ENT2>acetylcholinesterase</ENT2> (<ENT2>AChE</ENT2>) activity in mice hippocampus after seizures.",,,,T,,Y,,,c,,,,,1.0,,
24911645,2830,C573355,11423,Positive_Correlation,TRUE,Hippocampus mice treated with <ENT1>GFC75</ENT1> plus P400 showed an increase in <ENT2>AChE</ENT2> activity (63.30%) when compared with seized mice.,,,,T,,,,,c,,,,,1.0,,
24911645,2830,C573355,11423,Positive_Correlation,TRUE,"In conclusion, our data suggest that <ENT1>GFC</ENT1> may influence in epileptogenesis and promote anticonvulsant actions in pilocarpine model by modulating the GABA and glutamate contents and of <ENT2>AChE</ENT2> activity in seized mice hippocampus.",,,,T,,,,,c,,,,,1.0,,
24911645,2832,C573355,D012640,Negative_Correlation,TRUE,Behavioral and neurochemical studies in mice pretreated with <ENT1>garcinielliptone FC</ENT1> in pilocarpine-induced <ENT2>seizures</ENT2>.,,,,T,,T,,,w,,,,,1.0,,
24911645,2832,C573355,D012640,Negative_Correlation,TRUE,"The present study aimed to evaluate the <ENT1>GFC</ENT1> effects at doses of 25, 50 or 75 mg/kg on <ENT2>seizure</ENT2> parameters to determine their anticonvulsant activity and its effects on amino acid (r-aminobutyric acid (GABA), glutamine, aspartate and glutathione) levels as well as on acetylcholinesterase (AChE) activity in mice hippocampus after <ENT2>seizures</ENT2>.",,,,T,,Y,,,c,,,,,1.0,,
24911645,2832,C573355,D012640,Negative_Correlation,TRUE,"<ENT1>GFC</ENT1> produced an increased latency to first <ENT2>seizure</ENT2>, at doses 25mg/kg (20.12 + 2.20 min), 50mg/kg (20.95 + 2.21 min) or 75 mg/kg (23.43 + 1.99 min) when compared with seized mice.",,,,T,Y,,,,w,,,,,0.0,,
24911645,2832,C573355,D012640,Negative_Correlation,TRUE,"The results indicate that <ENT1>GFC</ENT1> can exert anticonvulsant activity and reduce the frequency of installation of pilocarpine-induced status epilepticus, as demonstrated by increase in latency to first <ENT2>seizure</ENT2> and decrease in mortality rate of animals.",,,,T,Y,,,,w,,,,,0.0,,
24911645,2828,C573355,D013226,Negative_Correlation,TRUE,"The results indicate that <ENT1>GFC</ENT1> can exert anticonvulsant activity and reduce the frequency of installation of pilocarpine-induced <ENT2>status epilepticus</ENT2>, as demonstrated by increase in latency to first seizure and decrease in mortality rate of animals.",,,,T,,,,,c,,,,,1.0,,
24911645,2829,C573355,D010862,Cotreatment,TRUE,Behavioral and neurochemical studies in mice pretreated with <ENT1>garcinielliptone FC</ENT1> in <ENT2>pilocarpine</ENT2>-induced seizures.,,,,T,,,,,c,,,,,1.0,,
24911645,2829,C573355,D010862,Cotreatment,TRUE,"In addition, GABA content of mice hippocampus treated with <ENT1>GFC75</ENT1> plus <ENT2>P400</ENT2> showed an increase of 46.90% when compared with seized mice.",,,,T,,,,,c,,,,,1.0,,
24911645,2829,C573355,D010862,Cotreatment,TRUE,"In aspartate, glutamine and glutamate levels detected a decrease of 5.21%, 13.55% and 21.80%, respectively in mice hippocampus treated with <ENT1>GFC75</ENT1> plus <ENT2>P400</ENT2> when compared with seized mice.",,,,T,,,,,c,,,,,1.0,,
24911645,2829,C573355,D010862,Cotreatment,TRUE,Hippocampus mice treated with <ENT1>GFC75</ENT1> plus <ENT2>P400</ENT2> showed an increase in AChE activity (63.30%) when compared with seized mice.,,,,T,,,,,c,,,,,1.0,,
24911645,2829,C573355,D010862,Cotreatment,TRUE,"The results indicate that <ENT1>GFC</ENT1> can exert anticonvulsant activity and reduce the frequency of installation of <ENT2>pilocarpine</ENT2>-induced status epilepticus, as demonstrated by increase in latency to first seizure and decrease in mortality rate of animals.",,,,T,,,,,w,,,,,1.0,,
24911645,2829,C573355,D010862,Cotreatment,TRUE,"In conclusion, our data suggest that <ENT1>GFC</ENT1> may influence in epileptogenesis and promote anticonvulsant actions in <ENT2>pilocarpine</ENT2> model by modulating the GABA and glutamate contents and of AChE activity in seized mice hippocampus.",,,,T,,,,,c,,,,,0.0,,
24911645,2818,C573355,D001224,Negative_Correlation,TRUE,"The present study aimed to evaluate the <ENT1>GFC</ENT1> effects at doses of 25, 50 or 75 mg/kg on seizure parameters to determine their anticonvulsant activity and its effects on amino acid (r-aminobutyric acid (GABA), glutamine, <ENT2>aspartate</ENT2> and glutathione) levels as well as on acetylcholinesterase (AChE) activity in mice hippocampus after seizures.",,,,T,,Y,,,c,,,,,1.0,,
24911645,2818,C573355,D001224,Negative_Correlation,TRUE,"In <ENT2>aspartate</ENT2>, glutamine and glutamate levels detected a decrease of 5.21%, 13.55% and 21.80%, respectively in mice hippocampus treated with <ENT1>GFC75</ENT1> plus P400 when compared with seized mice.",,,,T,,,,,c,,,,,1.0,,
24911645,2823,C573355,D018698,Negative_Correlation,TRUE,"The present study aimed to evaluate the <ENT1>GFC</ENT1> effects at doses of 25, 50 or 75 mg/kg on seizure parameters to determine their anticonvulsant activity and its effects on amino acid (r-aminobutyric acid (GABA), <ENT2>glutamine</ENT2>, aspartate and glutathione) levels as well as on acetylcholinesterase (AChE) activity in mice hippocampus after seizures.",,,,T,,Y,,,c,,,,,1.0,,
24911645,2823,C573355,D018698,Negative_Correlation,TRUE,"In aspartate, <ENT2>glutamine</ENT2> and <ENT2>glutamate</ENT2> levels detected a decrease of 5.21%, 13.55% and 21.80%, respectively in mice hippocampus treated with <ENT1>GFC75</ENT1> plus P400 when compared with seized mice.",,,,T,,,,,c,,,,,0.5,,
24911645,2823,C573355,D018698,Negative_Correlation,TRUE,"In conclusion, our data suggest that <ENT1>GFC</ENT1> may influence in epileptogenesis and promote anticonvulsant actions in pilocarpine model by modulating the GABA and <ENT2>glutamate</ENT2> contents and of AChE activity in seized mice hippocampus.",,,,T,,,,,c,,,,,0.0,,
24911645,2825,C573355,D005680,Positive_Correlation,TRUE,"The present study aimed to evaluate the <ENT1>GFC</ENT1> effects at doses of 25, 50 or 75 mg/kg on seizure parameters to determine their anticonvulsant activity and its effects on amino acid (<ENT2>r-aminobutyric acid</ENT2> (<ENT2>GABA</ENT2>), glutamine, aspartate and glutathione) levels as well as on acetylcholinesterase (AChE) activity in mice hippocampus after seizures.",,,,T,,Y,,,c,,,,,1.0,,
24911645,2825,C573355,D005680,Positive_Correlation,TRUE,"In addition, <ENT2>GABA</ENT2> content of mice hippocampus treated with <ENT1>GFC75</ENT1> plus P400 showed an increase of 46.90% when compared with seized mice.",,,,T,,,,,c,,,,,1.0,,
24911645,2825,C573355,D005680,Positive_Correlation,TRUE,"In conclusion, our data suggest that <ENT1>GFC</ENT1> may influence in epileptogenesis and promote anticonvulsant actions in pilocarpine model by modulating the <ENT2>GABA</ENT2> and glutamate contents and of AChE activity in seized mice hippocampus.",,,,T,,,,,c,,,,,0.0,,
24911645,2820,11423,D010862,Positive_Correlation,TRUE,Hippocampus mice treated with GFC75 plus <ENT2>P400</ENT2> showed an increase in <ENT1>AChE</ENT1> activity (63.30%) when compared with seized mice.,,,,T,,,,,c,,,,,1.0,,
24911645,2820,11423,D010862,Positive_Correlation,TRUE,"In conclusion, our data suggest that GFC may influence in epileptogenesis and promote anticonvulsant actions in <ENT2>pilocarpine</ENT2> model by modulating the GABA and glutamate contents and of <ENT1>AChE</ENT1> activity in seized mice hippocampus.",,,,T,,,,,c,,,,,1.0,,
24911645,2821,D012640,D010862,Positive_Correlation,FALSE,Behavioral and neurochemical studies in mice pretreated with garcinielliptone FC in <ENT2>pilocarpine</ENT2>-induced <ENT1>seizures</ENT1>.,,,,T,,T,,,c,,,,,1.0,,
24911645,2821,D012640,D010862,Positive_Correlation,FALSE,"The results indicate that GFC can exert anticonvulsant activity and reduce the frequency of installation of <ENT2>pilocarpine</ENT2>-induced status epilepticus, as demonstrated by increase in latency to first <ENT1>seizure</ENT1> and decrease in mortality rate of animals.",,,,T,,,,,c,,,,,0.0,,
24911645,2819,D013226,D010862,Positive_Correlation,FALSE,"The results indicate that GFC can exert anticonvulsant activity and reduce the frequency of installation of <ENT2>pilocarpine</ENT2>-induced <ENT1>status epilepticus</ENT1>, as demonstrated by increase in latency to first seizure and decrease in mortality rate of animals.",,,,T,,,,,c,,,,,1.0,,
24911645,2817,D010862,D001224,Negative_Correlation,TRUE,"In <ENT2>aspartate</ENT2>, glutamine and glutamate levels detected a decrease of 5.21%, 13.55% and 21.80%, respectively in mice hippocampus treated with GFC75 plus <ENT1>P400</ENT1> when compared with seized mice.",,,,T,,,,,c,,,,,0.0,,
24911645,2822,D010862,D018698,Negative_Correlation,TRUE,"In aspartate, <ENT2>glutamine</ENT2> and <ENT2>glutamate</ENT2> levels detected a decrease of 5.21%, 13.55% and 21.80%, respectively in mice hippocampus treated with GFC75 plus <ENT1>P400</ENT1> when compared with seized mice.",,,,T,,,,,c,,,,,0.5,,
24911645,2822,D010862,D018698,Negative_Correlation,TRUE,"In conclusion, our data suggest that GFC may influence in epileptogenesis and promote anticonvulsant actions in <ENT1>pilocarpine</ENT1> model by modulating the GABA and <ENT2>glutamate</ENT2> contents and of AChE activity in seized mice hippocampus.",,,,T,,,,,c,,,,,1.0,,
24911645,2824,D010862,D005680,Positive_Correlation,TRUE,"In addition, <ENT2>GABA</ENT2> content of mice hippocampus treated with GFC75 plus <ENT1>P400</ENT1> showed an increase of 46.90% when compared with seized mice.",,,,T,,,,,c,,,,,1.0,,
24911645,2824,D010862,D005680,Positive_Correlation,TRUE,"In conclusion, our data suggest that GFC may influence in epileptogenesis and promote anticonvulsant actions in <ENT1>pilocarpine</ENT1> model by modulating the <ENT2>GABA</ENT2> and glutamate contents and of AChE activity in seized mice hippocampus.",,,,T,,,,,c,,,,,1.0,,
24914936,2833,D002658,D013974,Negative_Correlation,FALSE,"In an attempt to improve <ENT1>developmental delay</ENT1> and alleviate symptoms of hypothyroidism, patients are receiving varying doses and durations of <ENT2>T4</ENT2> treatment, but responses have been inconsistent so far.",,,,T,,,,,c,,,,,1.0,,
24914936,2841,D006130,21833,Association,TRUE,"Adult female <ENT2>Thra1</ENT2>(PV/+) mice had <ENT1>short stature</ENT1>, grossly abnormal bone morphology but normal bone strength despite high bone mass.",,,,T,,,,,c,,,,,1.0,,
24914936,2842,21833,D001848,Association,TRUE,<ENT1>Thyroid hormone receptor a</ENT1> mutation causes a severe and thyroxine-resistant <ENT2>skeletal dysplasia</ENT2> in female mice.,,,,T,,,,,c,,,,,1.0,,
24914936,2838,D013974,22094,Negative_Correlation,TRUE,"Although <ENT1>T4</ENT1> treatment suppressed <ENT2>TSH</ENT2> secretion, it had no effect on skeletal maturation, linear growth, or bone mineralization, thus demonstrating profound tissue resistance to thyroid hormone.",,,,T,,,,,c,,,,,1.0,,
24914936,2840,D013974,D001848,Association,TRUE,Thyroid hormone receptor a mutation causes a severe and <ENT1>thyroxine</ENT1>-resistant <ENT2>skeletal dysplasia</ENT2> in female mice.,,,,T,,,,,w,,,,,0.0,,
24914936,2840,D013974,D001848,Association,TRUE,Affected children have a high serum T3:<ENT1>T4</ENT1> ratio and variable degrees of intellectual deficit and constipation but exhibit a consistently severe <ENT2>skeletal dysplasia</ENT2>.,,,,T,,,,,c,,,,,0.0,,
24914936,2834,D013974,D007037,Negative_Correlation,FALSE,"In an attempt to improve developmental delay and alleviate symptoms of <ENT2>hypothyroidism</ENT2>, patients are receiving varying doses and durations of <ENT1>T4</ENT1> treatment, but responses have been inconsistent so far.",,,,T,,,,,c,,,,,1.0,,
25006961,2849,D011141,D008094,Positive_Correlation,FALSE,"Targeting an alternative signaling pathway, such as PKC-mediated signaling, may be an effective method of treating <ENT2>lithium</ENT2>-induced <ENT1>polyuria</ENT1>.",,,,T,,,,,c,,,,,1.0,,
25006961,2849,D011141,D008094,Positive_Correlation,FALSE,"Our data show that ablation of PKCa preserves AQP2 and UT-A1 protein expression and localization in <ENT2>lithium</ENT2>-induced NDI, and prevents the development of the severe <ENT1>polyuria</ENT1> associated with <ENT2>lithium</ENT2> therapy.",,,,T,,,,,c,,,,,0.5,,
25006961,2845,D011141,18750,Association,TRUE,"Targeting an alternative signaling pathway, such as <ENT2>PKC</ENT2>-mediated signaling, may be an effective method of treating lithium-induced <ENT1>polyuria</ENT1>.",,,,T,,,,,c,,,,,0.0,,
25006961,2845,D011141,18750,Association,TRUE,"Our data show that ablation of <ENT2>PKCa</ENT2> preserves AQP2 and UT-A1 protein expression and localization in lithium-induced NDI, and prevents the development of the severe <ENT1>polyuria</ENT1> associated with lithium therapy.",,,,T,,,,,c,,,,,0.0,,
25006961,2850,11827,D008094,Negative_Correlation,TRUE,The decreased capacity to concentrate urine is likely due to <ENT2>lithium</ENT2> acutely disrupting the cAMP pathway and chronically reducing urea transporter (UT-A1) and water channel (<ENT1>AQP2</ENT1>) expression in the inner medulla.,,,,T,,,,,c,,,,,1.0,,
25006961,2850,11827,D008094,Negative_Correlation,TRUE,"<ENT1>AQP2</ENT1> and UT-A1 expression was lowered in 6 week <ENT2>lithium</ENT2>-treated WT animals whereas in treated PKCa KO mice, <ENT1>AQP2</ENT1> was only reduced by 2-fold and UT-A1 expression was unaffected.",,,,T,,,,,c,,,,,1.0,,
25006961,2850,11827,D008094,Negative_Correlation,TRUE,"Our data show that ablation of PKCa preserves <ENT1>AQP2</ENT1> and UT-A1 protein expression and localization in <ENT2>lithium</ENT2>-induced NDI, and prevents the development of the severe polyuria associated with <ENT2>lithium</ENT2> therapy.",,,,T,,,,,c,,,,,1.0,,
25006961,2846,11827,18750,Negative_Correlation,TRUE,"Western blot analysis revealed that <ENT1>AQP2</ENT1> expression in medullary tissues was lowered after 3 and 5 days in WT mice; however, <ENT1>AQP2</ENT1> was unchanged in <ENT2>PKCa</ENT2> KO.",,,,T,,,,,c,,,,,0.0,,keep 2 ENT2 in the sentence
25006961,2846,11827,18750,Negative_Correlation,TRUE,"<ENT1>AQP2</ENT1> and UT-A1 expression was lowered in 6 week lithium-treated WT animals whereas in treated <ENT2>PKCa</ENT2> KO mice, <ENT1>AQP2</ENT1> was only reduced by 2-fold and UT-A1 expression was unaffected.",,,,T,,,,,c,,,,,0.0,,keep 2 ENT2 in the sentence
25006961,2846,11827,18750,Negative_Correlation,TRUE,"Our data show that ablation of <ENT2>PKCa</ENT2> preserves <ENT1>AQP2</ENT1> and UT-A1 protein expression and localization in lithium-induced NDI, and prevents the development of the severe polyuria associated with lithium therapy.",,,,T,,,,,c,,,,,0.0,,
25006961,2844,D008094,27411,Negative_Correlation,TRUE,The decreased capacity to concentrate urine is likely due to <ENT1>lithium</ENT1> acutely disrupting the cAMP pathway and chronically reducing <ENT2>urea transporter</ENT2> (<ENT2>UT-A1</ENT2>) and water channel (AQP2) expression in the inner medulla.,,,,T,,,,,c,,,,,0.5,,
25006961,2844,D008094,27411,Negative_Correlation,TRUE,"AQP2 and <ENT2>UT-A1</ENT2> expression was lowered in 6 week <ENT1>lithium</ENT1>-treated WT animals whereas in treated PKCa KO mice, AQP2 was only reduced by 2-fold and <ENT2>UT-A1</ENT2> expression was unaffected.",,,,T,,,,,c,,,,,0.5,,
25006961,2844,D008094,27411,Negative_Correlation,TRUE,"Our data show that ablation of PKCa preserves AQP2 and <ENT2>UT-A1</ENT2> protein expression and localization in <ENT1>lithium</ENT1>-induced NDI, and prevents the development of the severe polyuria associated with <ENT1>lithium</ENT1> therapy.",,,,T,,,,,c,,,,,1.0,,
25006961,2853,D008094,18750,Positive_Correlation,TRUE,Absence of <ENT2>PKC-alpha</ENT2> attenuates <ENT1>lithium</ENT1>-induced nephrogenic diabetes insipidus.,,,,T,Y,,,,w,,,,,1.0,,
25006961,2853,D008094,18750,Positive_Correlation,TRUE,"Targeting an alternative signaling pathway, such as <ENT2>PKC</ENT2>-mediated signaling, may be an effective method of treating <ENT1>lithium</ENT1>-induced polyuria.",,,,T,,,,,c,,,,,1.0,,
25006961,2853,D008094,18750,Positive_Correlation,TRUE,"<ENT2>PKC-alpha</ENT2> null mice (<ENT2>PKCa</ENT2> KO) and strain-matched wild type (WT) controls were treated with <ENT1>lithium</ENT1> for 0, 3 or 5 days.",,,,T,,,,,c,,,,,1.0,,
25006961,2853,D008094,18750,Positive_Correlation,TRUE,<ENT1>Lithium</ENT1>-treated WT mice had 19-fold increased urine output whereas treated <ENT2>PKCa</ENT2> KO animals had a 4-fold increase in output.,,,,T,,,,,c,,,,,1.0,,
25006961,2853,D008094,18750,Positive_Correlation,TRUE,"AQP2 and UT-A1 expression was lowered in 6 week <ENT1>lithium</ENT1>-treated WT animals whereas in treated <ENT2>PKCa</ENT2> KO mice, AQP2 was only reduced by 2-fold and UT-A1 expression was unaffected.",,,,T,,,,,c,,,,,1.0,,
25006961,2853,D008094,18750,Positive_Correlation,TRUE,"Urinary sodium, potassium and calcium were elevated in <ENT1>lithium</ENT1>-fed WT but not in <ENT1>lithium</ENT1>-fed <ENT2>PKCa</ENT2> KO mice.",,,,T,,,,,c,,,,,1.0,,
25006961,2853,D008094,18750,Positive_Correlation,TRUE,"Our data show that ablation of <ENT2>PKCa</ENT2> preserves AQP2 and UT-A1 protein expression and localization in <ENT1>lithium</ENT1>-induced NDI, and prevents the development of the severe polyuria associated with <ENT1>lithium</ENT1> therapy.",,,,T,,,,,c,,,,,0.5,,
25006961,2847,D008094,D011188,Association,TRUE,"Urinary sodium, <ENT2>potassium</ENT2> and calcium were elevated in <ENT1>lithium</ENT1>-fed WT but not in <ENT1>lithium</ENT1>-fed PKCa KO mice.",,,,T,,,,,c,,,,,0.0,,
25006961,2851,D008094,D018500,Positive_Correlation,TRUE,Absence of PKC-alpha attenuates <ENT1>lithium</ENT1>-induced <ENT2>nephrogenic diabetes insipidus</ENT2>.,,,,T,,,,,c,,,,,1.0,,
25006961,2851,D008094,D018500,Positive_Correlation,TRUE,"<ENT1>Lithium</ENT1>, an effective antipsychotic, induces <ENT2>nephrogenic diabetes insipidus</ENT2> (<ENT2>NDI</ENT2>) in  40% of patients.",,,,T,,,,,c,,,,,1.0,,
25006961,2851,D008094,D018500,Positive_Correlation,TRUE,"Our data show that ablation of PKCa preserves AQP2 and UT-A1 protein expression and localization in <ENT1>lithium</ENT1>-induced <ENT2>NDI</ENT2>, and prevents the development of the severe polyuria associated with <ENT1>lithium</ENT1> therapy.",,,,T,,,,,c,,,,,1.0,,
25006961,2848,D008094,D012964,Association,TRUE,"Urinary <ENT2>sodium</ENT2>, potassium and calcium were elevated in <ENT1>lithium</ENT1>-fed WT but not in <ENT1>lithium</ENT1>-fed PKCa KO mice.",,,,T,,,,,c,,,,,0.0,,
25006961,2843,D008094,D002118,Association,TRUE,"Urinary sodium, potassium and <ENT2>calcium</ENT2> were elevated in <ENT1>lithium</ENT1>-fed WT but not in <ENT1>lithium</ENT1>-fed PKCa KO mice.",,,,T,,,,,c,,,,,0.0,,
25006961,2852,27411,18750,Negative_Correlation,TRUE,"AQP2 and <ENT1>UT-A1</ENT1> expression was lowered in 6 week lithium-treated WT animals whereas in treated <ENT2>PKCa</ENT2> KO mice, AQP2 was only reduced by 2-fold and <ENT1>UT-A1</ENT1> expression was unaffected.",,,,T,,,,,c,,,,,0.0,,keep 2 ENT1 in the sentence
25006961,2852,27411,18750,Negative_Correlation,TRUE,"Our data show that ablation of <ENT2>PKCa</ENT2> preserves AQP2 and <ENT1>UT-A1</ENT1> protein expression and localization in lithium-induced NDI, and prevents the development of the severe polyuria associated with lithium therapy.",,,,T,,,,,c,,,,,0.0,,
25006961,2854,18750,D018500,Positive_Correlation,TRUE,Absence of <ENT1>PKC-alpha</ENT1> attenuates lithium-induced <ENT2>nephrogenic diabetes insipidus</ENT2>.,,,,T,,,,,c,,,,,0.0,,
25006961,2854,18750,D018500,Positive_Correlation,TRUE,"Our data show that ablation of <ENT1>PKCa</ENT1> preserves AQP2 and UT-A1 protein expression and localization in lithium-induced <ENT2>NDI</ENT2>, and prevents the development of the severe polyuria associated with lithium therapy.",,,,T,,,,,c,,,,,0.0,,
25054547,2874,D002092,p|SUB|V|204|D,Association,TRUE,Kinetic analysis showed that the <ENT2>p.Val204Asp</ENT2>/p.Asp70Gly-p.Ala539Thr BChE displays a pure Michaelian behavior with <ENT1>BTC</ENT1> as the substrate.,,,,T,,,,,c,,,,,0.0,,
25054547,2860,D002092,rs1799807,Association,TRUE,Kinetic analysis showed that the p.Val204Asp/<ENT2>p.Asp70Gly</ENT2>-p.Ala539Thr BChE displays a pure Michaelian behavior with <ENT1>BTC</ENT1> as the substrate.,,,,T,,,,,c,,,,,0.0,,
25054547,2865,D002092,590,Association,TRUE,"Low activity of patient plasma <ENT2>butyrylcholinesterase</ENT2> with <ENT1>butyrylthiocholine</ENT1> (<ENT1>BTC</ENT1>) and benzoylcholine, and values of dibucaine and fluoride numbers fit with heterozygous atypical silent genotype.",,,,T,,,,,c,,,,,0.0,,
25054547,2865,D002092,590,Association,TRUE,Kinetic analysis showed that the p.Val204Asp/p.Asp70Gly-p.Ala539Thr <ENT2>BChE</ENT2> displays a pure Michaelian behavior with <ENT1>BTC</ENT1> as the substrate.,,,,T,,,,,c,,,,,1.0,,
25054547,2858,D002092,rs1803274,Association,TRUE,Kinetic analysis showed that the p.Val204Asp/p.Asp70Gly-<ENT2>p.Ala539Thr</ENT2> BChE displays a pure Michaelian behavior with <ENT1>BTC</ENT1> as the substrate.,,,,T,,,,,c,,,,,0.0,,
25054547,2870,D001049,D013390,Positive_Correlation,FALSE,"Characterization of a novel BCHE ""silent"" allele: point mutation (p.Val204Asp) causes loss of activity and prolonged <ENT1>apnea</ENT1> with <ENT2>suxamethonium</ENT2>.",,,,T,,,,,c,,,,,1.0,,
25054547,2870,D001049,D013390,Positive_Correlation,FALSE,Butyrylcholinesterase deficiency is characterized by prolonged <ENT1>apnea</ENT1> after the use of muscle relaxants (<ENT2>suxamethonium</ENT2> or mivacurium) in patients who have mutations in the BCHE gene.,,,,T,,,,,c,,,,,1.0,,
25054547,2876,D001049,p|SUB|V|204|D,Positive_Correlation,TRUE,"Characterization of a novel BCHE ""silent"" allele: point mutation (<ENT2>p.Val204Asp</ENT2>) causes loss of activity and prolonged <ENT1>apnea</ENT1> with suxamethonium.",,,,T,,,,,c,,,,,1.0,,
25054547,2871,D001049,D000077590,Positive_Correlation,FALSE,Butyrylcholinesterase deficiency is characterized by prolonged <ENT1>apnea</ENT1> after the use of muscle relaxants (suxamethonium or <ENT2>mivacurium</ENT2>) in patients who have mutations in the BCHE gene.,,,,T,,,,,c,,,,,1.0,,
25054547,2868,D001049,590,Association,FALSE,"Characterization of a novel <ENT2>BCHE</ENT2> ""silent"" allele: point mutation (p.Val204Asp) causes loss of activity and prolonged <ENT1>apnea</ENT1> with suxamethonium.",,,,T,,,,,c,,,,,0.0,,
25054547,2868,D001049,590,Association,FALSE,Butyrylcholinesterase deficiency is characterized by prolonged <ENT1>apnea</ENT1> after the use of muscle relaxants (suxamethonium or mivacurium) in patients who have mutations in the <ENT2>BCHE</ENT2> gene.,,,,T,Y,,,,c,,,,,1.0,,
25054547,2869,D013390,c|SUB|T|695|A,Association,TRUE,"Here, we report a case of prolonged neuromuscular block after administration of <ENT1>suxamethonium</ENT1> leading to the discovery of a novel BCHE variant (<ENT2>c.695T>A</ENT2>, p.Val204Asp).",,,,T,Y,,,,c,,,,,0.0,,
25054547,2875,D013390,p|SUB|V|204|D,Association,TRUE,"Characterization of a novel BCHE ""silent"" allele: point mutation (<ENT2>p.Val204Asp</ENT2>) causes loss of activity and prolonged apnea with <ENT1>suxamethonium</ENT1>.",,,,T,Y,,,,c,,,,,0.0,,
25054547,2875,D013390,p|SUB|V|204|D,Association,TRUE,"Here, we report a case of prolonged neuromuscular block after administration of <ENT1>suxamethonium</ENT1> leading to the discovery of a novel BCHE variant (c.695T>A, <ENT2>p.Val204Asp</ENT2>).",,,,T,Y,,,,c,,,,,0.0,,
25054547,2862,D013390,D055191,Positive_Correlation,TRUE,"Here, we report a case of prolonged <ENT2>neuromuscular block</ENT2> after administration of <ENT1>suxamethonium</ENT1> leading to the discovery of a novel BCHE variant (c.695T>A, p.Val204Asp).",,,,T,,,,,c,,,,,1.0,,
25054547,2856,D013390,C537417,Positive_Correlation,FALSE,<ENT2>Butyrylcholinesterase deficiency</ENT2> is characterized by prolonged apnea after the use of muscle relaxants (<ENT1>suxamethonium</ENT1> or mivacurium) in patients who have mutations in the BCHE gene.,,,,T,,,,,c,,,,,1.0,,
25054547,2867,D013390,590,Association,FALSE,"Characterization of a novel <ENT2>BCHE</ENT2> ""silent"" allele: point mutation (p.Val204Asp) causes loss of activity and prolonged apnea with <ENT1>suxamethonium</ENT1>.",,,,T,,,,,w,,,,,0.0,,
25054547,2867,D013390,590,Association,FALSE,Butyrylcholinesterase deficiency is characterized by prolonged apnea after the use of muscle relaxants (<ENT1>suxamethonium</ENT1> or mivacurium) in patients who have mutations in the <ENT2>BCHE</ENT2> gene.,,,,T,,,,,c,,,,,1.0,,
25054547,2867,D013390,590,Association,FALSE,"Here, we report a case of prolonged neuromuscular block after administration of <ENT1>suxamethonium</ENT1> leading to the discovery of a novel <ENT2>BCHE</ENT2> variant (c.695T>A, p.Val204Asp).",,,,T,,,,,c,,,,,1.0,,
25054547,2861,c|SUB|T|695|A,D055191,Positive_Correlation,TRUE,"Here, we report a case of prolonged <ENT2>neuromuscular block</ENT2> after administration of suxamethonium leading to the discovery of a novel BCHE variant (<ENT1>c.695T>A</ENT1>, p.Val204Asp).",,,,T,,,,,c,,,,,1.0,,
25054547,2863,p|SUB|V|204|D,D055191,Positive_Correlation,TRUE,"Here, we report a case of prolonged <ENT2>neuromuscular block</ENT2> after administration of suxamethonium leading to the discovery of a novel BCHE variant (c.695T>A, <ENT1>p.Val204Asp</ENT1>).",,,,T,,,,,c,,,,,0.0,,
25054547,2873,p|SUB|V|204|D,rs1799807,Association,TRUE,Kinetic analysis showed that the <ENT1>p.Val204Asp</ENT1>/<ENT2>p.Asp70Gly</ENT2>-p.Ala539Thr BChE displays a pure Michaelian behavior with BTC as the substrate.,,,,T,,,,,c,,,,,0.0,,
25054547,2872,p|SUB|V|204|D,rs1803274,Association,TRUE,Kinetic analysis showed that the <ENT1>p.Val204Asp</ENT1>/p.Asp70Gly-<ENT2>p.Ala539Thr</ENT2> BChE displays a pure Michaelian behavior with BTC as the substrate.,,,,T,,,,,c,,,,,0.0,,
25054547,2866,D055191,590,Association,TRUE,"Here, we report a case of prolonged <ENT1>neuromuscular block</ENT1> after administration of suxamethonium leading to the discovery of a novel <ENT2>BCHE</ENT2> variant (c.695T>A, p.Val204Asp).",,,,T,,,,,c,,,,,1.0,,
25054547,2859,rs1799807,rs1803274,Association,TRUE,Kinetic analysis showed that the p.Val204Asp/<ENT1>p.Asp70Gly</ENT1>-<ENT2>p.Ala539Thr</ENT2> BChE displays a pure Michaelian behavior with BTC as the substrate.,,,,T,,,,,c,,,,,0.0,,
25054547,2859,rs1799807,rs1803274,Association,TRUE,This fits with the reduced concentration of p.Ala204Asp/<ENT1>p.Asp70Gly</ENT1>-<ENT2>p.Ala539Thr</ENT2> tetrameric enzyme in the plasma and non-detectable fast moving-bands on electrophoresis gels.,,,,T,,,,,c,,,,,1.0,,
25054547,2855,C537417,D000077590,Positive_Correlation,FALSE,<ENT1>Butyrylcholinesterase deficiency</ENT1> is characterized by prolonged apnea after the use of muscle relaxants (suxamethonium or <ENT2>mivacurium</ENT2>) in patients who have mutations in the BCHE gene.,,,,T,,,,,c,,,,,1.0,,
25054547,2864,C537417,590,Negative_Correlation,FALSE,<ENT1>Butyrylcholinesterase deficiency</ENT1> is characterized by prolonged apnea after the use of muscle relaxants (suxamethonium or mivacurium) in patients who have mutations in the <ENT2>BCHE</ENT2> gene.,,,,T,,,,,c,,,,,0.0,,
25119790,2877,D011507,C030272,Positive_Correlation,TRUE,Tubular <ENT1>proteinuria</ENT1> and oxidative stress were induced by a single injection of <ENT2>maleate</ENT2> (400 mg/kg) in rats.,,,,T,,,,,c,,,,,1.0,,
25119790,2884,D010100,C030272,Association,TRUE,"Curcumin prevents <ENT2>maleate</ENT2>-induced nephrotoxicity: relation to hemodynamic alterations, oxidative stress, mitochondrial <ENT1>oxygen</ENT1> consumption and activity of respiratory complex I.",,,,T,,,,,c,,,,,1.0,,
25119790,2884,D010100,C030272,Association,TRUE,"In addition, <ENT2>maleate</ENT2> treatment reduced <ENT1>oxygen</ENT1> consumption in ADP-stimulated mitochondria and diminished respiratory control index when using malate/glutamate as substrate.",,,,T,,,,,c,,,,,0.0,,
25119790,2878,D007674,286934,Positive_Correlation,TRUE,"Maleate-induced <ENT1>renal injury</ENT1> included increase in renal vascular resistance and in the urinary excretion of total protein, glucose, sodium, neutrophil gelatinase-associated lipocalin (NGAL) and N-acetyl b-D-glucosaminidase (NAG), upregulation of <ENT2>kidney injury molecule (KIM)-1</ENT2>, decrease in renal blood flow and claudin-2 expression besides of necrosis and apoptosis of tubular cells on 24 h.",,,,T,,,,,c,,,,,0.0,,
25119790,2891,D007674,C030272,Positive_Correlation,FALSE,"Curcumin prevents <ENT2>maleate</ENT2>-induced <ENT1>nephrotoxicity</ENT1>: relation to hemodynamic alterations, oxidative stress, mitochondrial oxygen consumption and activity of respiratory complex I.",,,,T,,,,,c,,,,,1.0,,
25119790,2891,D007674,C030272,Positive_Correlation,FALSE,The potential protective effect of the dietary antioxidant curcumin (120 mg/Kg/day for 6 days) against the <ENT1>renal injury</ENT1> induced by <ENT2>maleate</ENT2> was evaluated.,,,,T,,,,,c,,,,,1.0,,
25119790,2891,D007674,C030272,Positive_Correlation,FALSE,"<ENT2>Maleate</ENT2>-induced <ENT1>renal injury</ENT1> included increase in renal vascular resistance and in the urinary excretion of total protein, glucose, sodium, neutrophil gelatinase-associated lipocalin (NGAL) and N-acetyl b-D-glucosaminidase (NAG), upregulation of kidney injury molecule (KIM)-1, decrease in renal blood flow and claudin-2 expression besides of necrosis and apoptosis of tubular cells on 24 h.",,,,T,,,,,c,,,,,1.0,,
25119790,2891,D007674,C030272,Positive_Correlation,FALSE,It is concluded that curcumin is able to attenuate in vivo <ENT2>maleate</ENT2>-induced <ENT1>nephropathy</ENT1> and in vitro cell damage.,,,,T,,,,,c,,,,,0.0,,
25119790,2880,D007674,170496,Association,TRUE,"Maleate-induced <ENT1>renal injury</ENT1> included increase in renal vascular resistance and in the urinary excretion of total protein, glucose, sodium, <ENT2>neutrophil gelatinase-associated lipocalin</ENT2> (<ENT2>NGAL</ENT2>) and N-acetyl b-D-glucosaminidase (NAG), upregulation of kidney injury molecule (KIM)-1, decrease in renal blood flow and claudin-2 expression besides of necrosis and apoptosis of tubular cells on 24 h.",,,,T,,,,,c,,,,,0.5,,
25119790,2882,D007674,D005947,Association,TRUE,"Maleate-induced <ENT1>renal injury</ENT1> included increase in renal vascular resistance and in the urinary excretion of total protein, <ENT2>glucose</ENT2>, sodium, neutrophil gelatinase-associated lipocalin (NGAL) and N-acetyl b-D-glucosaminidase (NAG), upregulation of kidney injury molecule (KIM)-1, decrease in renal blood flow and claudin-2 expression besides of necrosis and apoptosis of tubular cells on 24 h.",,,,T,,,,,c,,,,,1.0,,
25119790,2881,D007674,D012964,Association,TRUE,"Maleate-induced <ENT1>renal injury</ENT1> included increase in renal vascular resistance and in the urinary excretion of total protein, glucose, <ENT2>sodium</ENT2>, neutrophil gelatinase-associated lipocalin (NGAL) and N-acetyl b-D-glucosaminidase (NAG), upregulation of kidney injury molecule (KIM)-1, decrease in renal blood flow and claudin-2 expression besides of necrosis and apoptosis of tubular cells on 24 h.",,,,T,,,,,c,,,,,1.0,,
25119790,2879,D007674,733684,Negative_Correlation,TRUE,"Maleate-induced <ENT1>renal injury</ENT1> included increase in renal vascular resistance and in the urinary excretion of total protein, glucose, sodium, neutrophil gelatinase-associated lipocalin (NGAL) and N-acetyl b-D-glucosaminidase (NAG), upregulation of kidney injury molecule (KIM)-1, decrease in renal blood flow and <ENT2>claudin-2</ENT2> expression besides of necrosis and apoptosis of tubular cells on 24 h.",,,,T,,,,,c,,,,,0.0,,
25119790,2892,D007674,D003474,Negative_Correlation,TRUE,"<ENT2>Curcumin</ENT2> prevents maleate-induced <ENT1>nephrotoxicity</ENT1>: relation to hemodynamic alterations, oxidative stress, mitochondrial oxygen consumption and activity of respiratory complex I.",,,,T,,,,,c,,,,,1.0,,
25119790,2892,D007674,D003474,Negative_Correlation,TRUE,The potential protective effect of the dietary antioxidant <ENT2>curcumin</ENT2> (120 mg/Kg/day for 6 days) against the <ENT1>renal injury</ENT1> induced by maleate was evaluated.,,,,T,,Y,,,c,,,,,0.0,,
25119790,2892,D007674,D003474,Negative_Correlation,TRUE,It is concluded that <ENT2>curcumin</ENT2> is able to attenuate in vivo maleate-induced <ENT1>nephropathy</ENT1> and in vitro cell damage.,,,,T,,,,,c,,,,,1.0,,
25119790,2886,286934,C030272,Positive_Correlation,TRUE,"<ENT2>Maleate</ENT2>-induced renal injury included increase in renal vascular resistance and in the urinary excretion of total protein, glucose, sodium, neutrophil gelatinase-associated lipocalin (NGAL) and N-acetyl b-D-glucosaminidase (NAG), upregulation of <ENT1>kidney injury molecule (KIM)-1</ENT1>, decrease in renal blood flow and claudin-2 expression besides of necrosis and apoptosis of tubular cells on 24 h.",,,,T,,,,,c,,,,,1.0,,
25119790,2888,C030272,170496,Association,TRUE,"<ENT1>Maleate</ENT1>-induced renal injury included increase in renal vascular resistance and in the urinary excretion of total protein, glucose, sodium, <ENT2>neutrophil gelatinase-associated lipocalin</ENT2> (<ENT2>NGAL</ENT2>) and N-acetyl b-D-glucosaminidase (NAG), upregulation of kidney injury molecule (KIM)-1, decrease in renal blood flow and claudin-2 expression besides of necrosis and apoptosis of tubular cells on 24 h.",,,,T,,,,,c,,,,,0.0,,
25119790,2890,C030272,D005947,Association,TRUE,"<ENT1>Maleate</ENT1>-induced renal injury included increase in renal vascular resistance and in the urinary excretion of total protein, <ENT2>glucose</ENT2>, sodium, neutrophil gelatinase-associated lipocalin (NGAL) and N-acetyl b-D-glucosaminidase (NAG), upregulation of kidney injury molecule (KIM)-1, decrease in renal blood flow and claudin-2 expression besides of necrosis and apoptosis of tubular cells on 24 h.",,,,T,,,,,c,,,,,0.0,,
25119790,2889,C030272,D012964,Association,TRUE,"<ENT1>Maleate</ENT1>-induced renal injury included increase in renal vascular resistance and in the urinary excretion of total protein, glucose, <ENT2>sodium</ENT2>, neutrophil gelatinase-associated lipocalin (NGAL) and N-acetyl b-D-glucosaminidase (NAG), upregulation of kidney injury molecule (KIM)-1, decrease in renal blood flow and claudin-2 expression besides of necrosis and apoptosis of tubular cells on 24 h.",,,,T,,,,,c,,,,,0.0,,
25119790,2887,C030272,733684,Negative_Correlation,TRUE,"<ENT1>Maleate</ENT1>-induced renal injury included increase in renal vascular resistance and in the urinary excretion of total protein, glucose, sodium, neutrophil gelatinase-associated lipocalin (NGAL) and N-acetyl b-D-glucosaminidase (NAG), upregulation of kidney injury molecule (KIM)-1, decrease in renal blood flow and <ENT2>claudin-2</ENT2> expression besides of necrosis and apoptosis of tubular cells on 24 h.",,,,T,,,,,c,,,,,1.0,,
25119790,2893,C030272,D003474,Negative_Correlation,TRUE,"<ENT2>Curcumin</ENT2> prevents <ENT1>maleate</ENT1>-induced nephrotoxicity: relation to hemodynamic alterations, oxidative stress, mitochondrial oxygen consumption and activity of respiratory complex I.",,,,T,Y,,,,c,,,,,0.0,,
25119790,2893,C030272,D003474,Negative_Correlation,TRUE,The potential protective effect of the dietary antioxidant <ENT2>curcumin</ENT2> (120 mg/Kg/day for 6 days) against the renal injury induced by <ENT1>maleate</ENT1> was evaluated.,,,,T,,Y,,,c,,,,,0.0,,
25119790,2893,C030272,D003474,Negative_Correlation,TRUE,It is concluded that <ENT2>curcumin</ENT2> is able to attenuate in vivo <ENT1>maleate</ENT1>-induced nephropathy and in vitro cell damage.,,,,T,,,,,c,,,,,1.0,,
25119790,2885,C030272,D017382,Positive_Correlation,TRUE,<ENT1>Maleate</ENT1> induced cell damage and <ENT2>reactive oxygen species</ENT2> (<ENT2>ROS</ENT2>) production in LLC-PK1 cells in culture.,,,,T,,,,,c,,,,,1.0,,
25218136,2895,298514,287871,Bind,FALSE,"There was no sepsis or Leu effect on the protein content for <ENT1>RagA-D</ENT1>, LAMTOR-1 and -2, <ENT2>raptor</ENT2>, Rheb or mTOR in muscle.",,,,T,,,,,c,,,,,1.0,,
25218136,2895,298514,287871,Bind,FALSE,"The binding of mTOR, PRAS40 and <ENT1>RagC</ENT1> to <ENT2>raptor</ENT2> did not differ for control and septic muscle in the basal condition; however, the Leu-induced decrease in PRAS40 <ENT2>raptor</ENT2> and increase in <ENT1>RagC</ENT1> <ENT2>raptor</ENT2> seen in control muscle was absent in sepsis.",,,,T,,,,,c,,,,,0.166666667,,
25218136,2895,298514,287871,Bind,FALSE,"Hence, while alterations in select amino acid transporters are not associated with development of sepsis-induced Leu resistance, the Leu-stimulated binding of <ENT2>raptor</ENT2> with <ENT1>RagC</ENT1> and the recruitment of mTOR/<ENT2>raptor</ENT2> to the endosome-lysosomal compartment may partially explain the inability of Leu to fully activate mTOR and muscle protein synthesis.",,,,T,,,,,c,,,,,0.5,,
25218136,2898,298514,D007930,Positive_Correlation,TRUE,"There was no sepsis or <ENT2>Leu</ENT2> effect on the protein content for <ENT1>RagA-D</ENT1>, LAMTOR-1 and -2, raptor, Rheb or mTOR in muscle.",,,,T,,,,,c,,,,,0.0,,
25218136,2898,298514,D007930,Positive_Correlation,TRUE,"The binding of mTOR, PRAS40 and <ENT1>RagC</ENT1> to raptor did not differ for control and septic muscle in the basal condition; however, the <ENT2>Leu</ENT2>-induced decrease in PRAS40 raptor and increase in <ENT1>RagC</ENT1> raptor seen in control muscle was absent in sepsis.",,,,T,,,,,c,,,,,0.0,,
25218136,2898,298514,D007930,Positive_Correlation,TRUE,"Hence, while alterations in select amino acid transporters are not associated with development of sepsis-induced <ENT2>Leu</ENT2> resistance, the <ENT2>Leu</ENT2>-stimulated binding of raptor with <ENT1>RagC</ENT1> and the recruitment of mTOR/raptor to the endosome-lysosomal compartment may partially explain the inability of <ENT2>Leu</ENT2> to fully activate mTOR and muscle protein synthesis.",,,,T,,,,,w,,,,,0.333333333,TRUE,
25218136,2911,116636,56718,Association,TRUE,"Sepsis in adult male rats decreased basal protein synthesis in gastrocnemius, associated with a reduction in <ENT2>mTOR</ENT2> activation as indicated by decreased <ENT1>4E-BP1</ENT1> and S6K1 phosphorylation.",,,,T,,,,,c,,,,,1.0,,
25218136;25218136;25218136,2904;2903;2905,84551;29642;25648,D018805;D018805;D018805,Association;Association;Association,TRUE;TRUE;TRUE,<ENT2>Sepsis</ENT2>-induced changes in <ENT1>amino acid transporters</ENT1> and leucine signaling via mTOR in skeletal muscle.,,,,T,,,,,c,,,,,0.0,,
25218136;25218136;25218136,2904;2903;2905,84551;29642;25648,D018805;D018805;D018805,Association;Association;Association,TRUE;TRUE;TRUE,The present study tested the hypothesis that <ENT2>sepsis</ENT2>-induced leucine (Leu) resistance in skeletal muscle is associated with a down-regulation of <ENT1>amino acid transporters</ENT1> important in regulating Leu flux or an impairment in the formation of the Leu-sensitive mTOR-Ragulator complex.,,,,T,,,,,c,,,,,0.0,,
25218136,2904,84551,D018805,Association,TRUE,"<ENT2>Sepsis</ENT2> increased CAT1, <ENT1>LAT2</ENT1> and SNAT2 mRNA content two- to fourfold, but only the protein content for CAT1 (20 % decrease) differed significantly.",,,,T,,,,,c,,,,,0.0,,
25218136;25218136;25218136,2904;2903;2905,84551;29642;25648,D018805;D018805;D018805,Association;Association;Association,TRUE;TRUE;TRUE,"Hence, while alterations in select <ENT1>amino acid transporters</ENT1> are not associated with development of <ENT2>sepsis</ENT2>-induced Leu resistance, the Leu-stimulated binding of raptor with RagC and the recruitment of mTOR/raptor to the endosome-lysosomal compartment may partially explain the inability of Leu to fully activate mTOR and muscle protein synthesis.",,,,T,,,,,c,,,,,1.0,,
25218136,2903,29642,D018805,Association,TRUE,"<ENT2>Sepsis</ENT2> increased CAT1, LAT2 and <ENT1>SNAT2</ENT1> mRNA content two- to fourfold, but only the protein content for CAT1 (20 % decrease) differed significantly.",,,,T,,,,,c,,,,,0.0,,
25218136,2896,308869,D007930,Association,FALSE,The present study tested the hypothesis that sepsis-induced <ENT2>leucine</ENT2> (<ENT2>Leu</ENT2>) resistance in skeletal muscle is associated with a down-regulation of amino acid transporters important in regulating <ENT2>Leu</ENT2> flux or an impairment in the formation of the <ENT2>Leu</ENT2>-sensitive mTOR-<ENT1>Ragulator complex</ENT1>.,,,,T,,,,,w,,,,,0.0,,
25218136,2896,308869,D007930,Association,FALSE,"There was no sepsis or <ENT2>Leu</ENT2> effect on the protein content for RagA-D, <ENT1>LAMTOR-1 and -2</ENT1>, raptor, Rheb or mTOR in muscle.",,,,T,,,,,c,,,,,1.0,,
25218136,2907,308869,56718,Association,FALSE,The present study tested the hypothesis that sepsis-induced leucine (Leu) resistance in skeletal muscle is associated with a down-regulation of amino acid transporters important in regulating Leu flux or an impairment in the formation of the Leu-sensitive <ENT2>mTOR</ENT2>-<ENT1>Ragulator complex</ENT1>.,,,,T,,,,,w,,,,,1.0,,
25218136,2907,308869,56718,Association,FALSE,"There was no sepsis or Leu effect on the protein content for RagA-D, <ENT1>LAMTOR-1 and -2</ENT1>, raptor, Rheb or <ENT2>mTOR</ENT2> in muscle.",,,,T,,,,,c,,,,,1.0,,
25218136,2900,287871,D007930,Association,TRUE,"There was no sepsis or <ENT2>Leu</ENT2> effect on the protein content for RagA-D, LAMTOR-1 and -2, <ENT1>raptor</ENT1>, Rheb or mTOR in muscle.",,,,T,,,,,c,,,,,0.0,,
25218136,2900,287871,D007930,Association,TRUE,"The binding of mTOR, PRAS40 and RagC to <ENT1>raptor</ENT1> did not differ for control and septic muscle in the basal condition; however, the <ENT2>Leu</ENT2>-induced decrease in PRAS40 <ENT1>raptor</ENT1> and increase in RagC <ENT1>raptor</ENT1> seen in control muscle was absent in sepsis.",,,,T,,,,,c,,,,,0.0,,keep two ENT1 in the sentence
25218136,2900,287871,D007930,Association,TRUE,"Hence, while alterations in select amino acid transporters are not associated with development of sepsis-induced <ENT2>Leu</ENT2> resistance, the <ENT2>Leu</ENT2>-stimulated binding of <ENT1>raptor</ENT1> with RagC and the recruitment of mTOR/<ENT1>raptor</ENT1> to the endosome-lysosomal compartment may partially explain the inability of <ENT2>Leu</ENT2> to fully activate mTOR and muscle protein synthesis.",,,,T,,,,,c,,,,,0.0,,
25218136,2909,287871,56718,Bind,FALSE,"There was no sepsis or Leu effect on the protein content for RagA-D, LAMTOR-1 and -2, <ENT1>raptor</ENT1>, Rheb or <ENT2>mTOR</ENT2> in muscle.",,,,T,,,,,c,,,,,1.0,,
25218136,2909,287871,56718,Bind,FALSE,"The binding of <ENT2>mTOR</ENT2>, PRAS40 and RagC to <ENT1>raptor</ENT1> did not differ for control and septic muscle in the basal condition; however, the Leu-induced decrease in PRAS40 <ENT1>raptor</ENT1> and increase in RagC <ENT1>raptor</ENT1> seen in control muscle was absent in sepsis.",,,,T,,,,,c,,,,,0.0,,
25218136,2909,287871,56718,Bind,FALSE,"Hence, while alterations in select amino acid transporters are not associated with development of sepsis-induced Leu resistance, the Leu-stimulated binding of <ENT1>raptor</ENT1> with RagC and the recruitment of <ENT2>mTOR</ENT2>/<ENT1>raptor</ENT1> to the endosome-lysosomal compartment may partially explain the inability of Leu to fully activate <ENT2>mTOR</ENT2> and muscle protein synthesis.",,,,T,,,,,c,,,,,0.0,,
25218136,2894,287871,292887,Bind,FALSE,"The binding of mTOR, <ENT2>PRAS40</ENT2> and RagC to <ENT1>raptor</ENT1> did not differ for control and septic muscle in the basal condition; however, the Leu-induced decrease in <ENT2>PRAS40</ENT2> <ENT1>raptor</ENT1> and increase in RagC <ENT1>raptor</ENT1> seen in control muscle was absent in sepsis.",,,,T,,,,,c,,,,,0.0,,
25218136,2901,D007930,D018805,Association,TRUE,<ENT2>Sepsis</ENT2>-induced changes in amino acid transporters and <ENT1>leucine</ENT1> signaling via mTOR in skeletal muscle.,,,,T,Y,,,,c,,,,,0.0,,
25218136,2901,D007930,D018805,Association,TRUE,The present study tested the hypothesis that <ENT2>sepsis</ENT2>-induced <ENT1>leucine</ENT1> (<ENT1>Leu</ENT1>) resistance in skeletal muscle is associated with a down-regulation of amino acid transporters important in regulating <ENT1>Leu</ENT1> flux or an impairment in the formation of the <ENT1>Leu</ENT1>-sensitive mTOR-Ragulator complex.,,,,T,,,,,c,,,,,0.0,,
25218136,2901,D007930,D018805,Association,TRUE,The ability of oral <ENT1>Leu</ENT1> to increase protein synthesis and mTOR kinase after 1 h was largely prevented in <ENT2>sepsis</ENT2>.,,,,T,,,,,c,,,,,0.0,,
25218136,2901,D007930,D018805,Association,TRUE,"There was no <ENT2>sepsis</ENT2> or <ENT1>Leu</ENT1> effect on the protein content for RagA-D, LAMTOR-1 and -2, raptor, Rheb or mTOR in muscle.",,,,T,,,,,c,,,,,0.0,,
25218136,2901,D007930,D018805,Association,TRUE,"The binding of mTOR, PRAS40 and RagC to raptor did not differ for control and septic muscle in the basal condition; however, the <ENT1>Leu</ENT1>-induced decrease in PRAS40 raptor and increase in RagC raptor seen in control muscle was absent in <ENT2>sepsis</ENT2>.",,,,T,,,,,c,,,,,1.0,,
25218136,2901,D007930,D018805,Association,TRUE,"Hence, while alterations in select amino acid transporters are not associated with development of <ENT2>sepsis</ENT2>-induced <ENT1>Leu</ENT1> resistance, the <ENT1>Leu</ENT1>-stimulated binding of raptor with RagC and the recruitment of mTOR/raptor to the endosome-lysosomal compartment may partially explain the inability of <ENT1>Leu</ENT1> to fully activate mTOR and muscle protein synthesis.",,,,T,,,,,c,,,,,0.0,,
25218136,2902,D007930,56718,Positive_Correlation,TRUE,Sepsis-induced changes in amino acid transporters and <ENT1>leucine</ENT1> signaling via <ENT2>mTOR</ENT2> in skeletal muscle.,,,,T,,,,,w,,,,,0.0,,
25218136,2902,D007930,56718,Positive_Correlation,TRUE,The present study tested the hypothesis that sepsis-induced <ENT1>leucine</ENT1> (<ENT1>Leu</ENT1>) resistance in skeletal muscle is associated with a down-regulation of amino acid transporters important in regulating <ENT1>Leu</ENT1> flux or an impairment in the formation of the <ENT1>Leu</ENT1>-sensitive <ENT2>mTOR</ENT2>-Ragulator complex.,,,,T,,,,,w,,,,,0.25,TRUE,
25218136,2902,D007930,56718,Positive_Correlation,TRUE,The ability of oral <ENT1>Leu</ENT1> to increase protein synthesis and <ENT2>mTOR</ENT2> kinase after 1 h was largely prevented in sepsis.,,,,T,,,,,c,,,,,1.0,,
25218136,2902,D007930,56718,Positive_Correlation,TRUE,"There was no sepsis or <ENT1>Leu</ENT1> effect on the protein content for RagA-D, LAMTOR-1 and -2, raptor, Rheb or <ENT2>mTOR</ENT2> in muscle.",,,,T,,,,,c,,,,,1.0,,
25218136,2902,D007930,56718,Positive_Correlation,TRUE,"The binding of <ENT2>mTOR</ENT2>, PRAS40 and RagC to raptor did not differ for control and septic muscle in the basal condition; however, the <ENT1>Leu</ENT1>-induced decrease in PRAS40 raptor and increase in RagC raptor seen in control muscle was absent in sepsis.",,,,T,,,,,c,,,,,1.0,,
25218136,2902,D007930,56718,Positive_Correlation,TRUE,"Hence, while alterations in select amino acid transporters are not associated with development of sepsis-induced <ENT1>Leu</ENT1> resistance, the <ENT1>Leu</ENT1>-stimulated binding of raptor with RagC and the recruitment of <ENT2>mTOR</ENT2>/raptor to the endosome-lysosomal compartment may partially explain the inability of <ENT1>Leu</ENT1> to fully activate <ENT2>mTOR</ENT2> and muscle protein synthesis.",,,,T,,,,,c,,,"21,32",,0.5,,
25218136,2899,D007930,292887,Negative_Correlation,TRUE,"The binding of mTOR, <ENT2>PRAS40</ENT2> and RagC to raptor did not differ for control and septic muscle in the basal condition; however, the <ENT1>Leu</ENT1>-induced decrease in <ENT2>PRAS40</ENT2> raptor and increase in RagC raptor seen in control muscle was absent in sepsis.",,,,T,,,,,c,,,,,0.5,,
25218136,2905,25648,D018805,Association,TRUE,"<ENT2>Sepsis</ENT2> increased <ENT1>CAT1</ENT1>, LAT2 and SNAT2 mRNA content two- to fourfold, but only the protein content for <ENT1>CAT1</ENT1> (20 % decrease) differed significantly.",,,,T,,,,,c,,,,,0.0,,
25218136,2906,D018805,56718,Negative_Correlation,TRUE,<ENT1>Sepsis</ENT1>-induced changes in amino acid transporters and leucine signaling via <ENT2>mTOR</ENT2> in skeletal muscle.,,,,T,,,,,w,,,,,1.0,,
25218136,2906,D018805,56718,Negative_Correlation,TRUE,The present study tested the hypothesis that <ENT1>sepsis</ENT1>-induced leucine (Leu) resistance in skeletal muscle is associated with a down-regulation of amino acid transporters important in regulating Leu flux or an impairment in the formation of the Leu-sensitive <ENT2>mTOR</ENT2>-Ragulator complex.,,,,T,,Y,,,w,,,,,0.0,,
25218136,2906,D018805,56718,Negative_Correlation,TRUE,"<ENT1>Sepsis</ENT1> in adult male rats decreased basal protein synthesis in gastrocnemius, associated with a reduction in <ENT2>mTOR</ENT2> activation as indicated by decreased 4E-BP1 and S6K1 phosphorylation.",,,,T,,,,,c,,,,,0.0,,
25218136,2906,D018805,56718,Negative_Correlation,TRUE,The ability of oral Leu to increase protein synthesis and <ENT2>mTOR</ENT2> kinase after 1 h was largely prevented in <ENT1>sepsis</ENT1>.,,,,T,,,,,c,,,,,0.0,,
25218136,2906,D018805,56718,Negative_Correlation,TRUE,"There was no <ENT1>sepsis</ENT1> or Leu effect on the protein content for RagA-D, LAMTOR-1 and -2, raptor, Rheb or <ENT2>mTOR</ENT2> in muscle.",,,,T,,,,,c,,,,,1.0,,
25218136,2906,D018805,56718,Negative_Correlation,TRUE,"The binding of <ENT2>mTOR</ENT2>, PRAS40 and RagC to raptor did not differ for control and septic muscle in the basal condition; however, the Leu-induced decrease in PRAS40 raptor and increase in RagC raptor seen in control muscle was absent in <ENT1>sepsis</ENT1>.",,,,T,,,,,c,,,,,1.0,,
25218136,2906,D018805,56718,Negative_Correlation,TRUE,"Hence, while alterations in select amino acid transporters are not associated with development of <ENT1>sepsis</ENT1>-induced Leu resistance, the Leu-stimulated binding of raptor with RagC and the recruitment of <ENT2>mTOR</ENT2>/raptor to the endosome-lysosomal compartment may partially explain the inability of Leu to fully activate <ENT2>mTOR</ENT2> and muscle protein synthesis.",,,,T,,,,,c,,,,,1.0,,
25218136,2910,56718,83840,Association,TRUE,"Sepsis in adult male rats decreased basal protein synthesis in gastrocnemius, associated with a reduction in <ENT1>mTOR</ENT1> activation as indicated by decreased 4E-BP1 and <ENT2>S6K1</ENT2> phosphorylation.",,,,T,,,,,c,,,,,1.0,,
25277705,2917,20302,228607,Association,FALSE,"In vivo induction of airway IL-1b, IL-4, IL-5, IL-6, IL-12(p40), IFN-g, CCL2, CCL5, <ENT1>CCL3</ENT1>, CXCL1, IP-10/CXCL10, IL-22, MIG/CXCL9 and MIF were dependent on <ENT2>Mavs</ENT2> expression in mice.",,,,T,,,,,c,,,,,0.0,,
25277705,2953,4282,D018357,Positive_Correlation,TRUE,"RESULTS AND DISCUSSION: <ENT2>RSV-infected</ENT2> A549 and SAE cells release a network of cytokines, including newly identified RSV-inducible cytokines LIF, <ENT1>migration inhibitory factor</ENT1> (<ENT1>MIF</ENT1>), stem cell factor (SCF), CCL27, CXCL12 and stem cell growth factor beta (SCGF-b).",,,,T,,,,,w,,,,,0.5,,
25277705;25277705,2944;2955,D055370;D055370,3976;16878,Negative_Correlation;Negative_Correlation,TRUE;TRUE,Expression of <ENT2>LIF</ENT2> protects the lung from <ENT1>lung injury</ENT1> and enhanced pathology during RSV infection.,,,,T,,,,,c,,,,,1.0,,
25277705,2916,14825,228607,Association,FALSE,"In vivo induction of airway IL-1b, IL-4, IL-5, IL-6, IL-12(p40), IFN-g, CCL2, CCL5, CCL3, <ENT1>CXCL1</ENT1>, IP-10/CXCL10, IL-22, MIG/CXCL9 and MIF were dependent on <ENT2>Mavs</ENT2> expression in mice.",,,,T,,,,,c,,,,,0.0,,
25277705,2914,50929,228607,Association,FALSE,"In vivo induction of airway IL-1b, IL-4, IL-5, IL-6, IL-12(p40), IFN-g, CCL2, CCL5, CCL3, CXCL1, IP-10/CXCL10, <ENT1>IL-22</ENT1>, MIG/CXCL9 and MIF were dependent on <ENT2>Mavs</ENT2> expression in mice.",,,,T,,,,,c,,,,,0.0,,
25277705,2930,106759,16176,Association,TRUE,"Loss of <ENT1>Trif</ENT1> expression in mice altered the RSV induction of <ENT2>IL-1b</ENT2>, IL-5, CXCL12, MIF, LIF, CXCL12 and IFN-g. Silencing of retinoic acid-inducible gene-1 (RIG-I) expression in A549 cells had a greater impact on RSV-inducible cytokines than melanoma differentiation-associated protein 5 (MDA5) and laboratory of genetics and physiology 2 (LGP2), and Trif expression.",,,,T,,,,,c,,,,,0.0,,
25277705,2926,106759,20315,Association,TRUE,"Loss of <ENT1>Trif</ENT1> expression in mice altered the RSV induction of IL-1b, IL-5, <ENT2>CXCL12</ENT2>, MIF, LIF, <ENT2>CXCL12</ENT2> and IFN-g. Silencing of retinoic acid-inducible gene-1 (RIG-I) expression in A549 cells had a greater impact on RSV-inducible cytokines than melanoma differentiation-associated protein 5 (MDA5) and laboratory of genetics and physiology 2 (LGP2), and Trif expression.",,,,T,,,,,c,,,,,0.5,,
25277705,2927,106759,17319,Association,TRUE,"Loss of <ENT1>Trif</ENT1> expression in mice altered the RSV induction of IL-1b, IL-5, CXCL12, <ENT2>MIF</ENT2>, LIF, CXCL12 and IFN-g. Silencing of retinoic acid-inducible gene-1 (RIG-I) expression in A549 cells had a greater impact on RSV-inducible cytokines than melanoma differentiation-associated protein 5 (MDA5) and laboratory of genetics and physiology 2 (LGP2), and Trif expression.",,,,T,,,,,c,,,,,1.0,,
25277705,2929,106759,16191,Association,TRUE,"Loss of <ENT1>Trif</ENT1> expression in mice altered the RSV induction of IL-1b, <ENT2>IL-5</ENT2>, CXCL12, MIF, LIF, CXCL12 and IFN-g. Silencing of retinoic acid-inducible gene-1 (RIG-I) expression in A549 cells had a greater impact on RSV-inducible cytokines than melanoma differentiation-associated protein 5 (MDA5) and laboratory of genetics and physiology 2 (LGP2), and Trif expression.",,,,T,,,,,c,,,,,0.0,,
25277705,2928,106759,15978,Association,TRUE,"Loss of <ENT1>Trif</ENT1> expression in mice altered the RSV induction of IL-1b, IL-5, CXCL12, MIF, LIF, CXCL12 and <ENT2>IFN-g</ENT2>. Silencing of retinoic acid-inducible gene-1 (RIG-I) expression in A549 cells had a greater impact on RSV-inducible cytokines than melanoma differentiation-associated protein 5 (MDA5) and laboratory of genetics and physiology 2 (LGP2), and Trif expression.",,,,T,,,,,c,,,,,1.0,,
25277705,2931,106759,16878,Association,TRUE,"Loss of <ENT1>Trif</ENT1> expression in mice altered the RSV induction of IL-1b, IL-5, CXCL12, MIF, <ENT2>LIF</ENT2>, CXCL12 and IFN-g. Silencing of retinoic acid-inducible gene-1 (RIG-I) expression in A549 cells had a greater impact on RSV-inducible cytokines than melanoma differentiation-associated protein 5 (MDA5) and laboratory of genetics and physiology 2 (LGP2), and Trif expression.",,,,T,,,,,c,,,,,1.0,,
25277705,2925,16176,228607,Association,FALSE,"In vivo induction of airway <ENT1>IL-1b</ENT1>, IL-4, IL-5, IL-6, IL-12(p40), IFN-g, CCL2, CCL5, CCL3, CXCL1, IP-10/CXCL10, IL-22, MIG/CXCL9 and MIF were dependent on <ENT2>Mavs</ENT2> expression in mice.",,,,T,,,,,c,,,,,0.0,,
25277705,2946,3976,D018357,Positive_Correlation,TRUE,<ENT1>Leukemia inhibitory factor</ENT1> protects the lung during <ENT2>respiratory syncytial viral infection</ENT2>.,,,,T,Y,,,,w,,,,,1.0,,
25277705,2946,3976,D018357,Positive_Correlation,TRUE,Neutralizing anti-<ENT1>leukemia inhibitory factor</ENT1> (<ENT1>LIF</ENT1>) IgG or control IgG was administered to a group of wild-type animals prior to <ENT2>RSV infection</ENT2>.,,,,T,,,,,c,,,,,1.0,,
25277705,2946,3976,D018357,Positive_Correlation,TRUE,"RESULTS AND DISCUSSION: <ENT2>RSV-infected</ENT2> A549 and SAE cells release a network of cytokines, including newly identified RSV-inducible cytokines <ENT1>LIF</ENT1>, migration inhibitory factor (MIF), stem cell factor (SCF), CCL27, CXCL12 and stem cell growth factor beta (SCGF-b).",,,,T,,,,,w,,,,,1.0,,
25277705,2946,3976,D018357,Positive_Correlation,TRUE,Expression of <ENT1>LIF</ENT1> protects the lung from lung injury and enhanced pathology during <ENT2>RSV infection</ENT2>.,,,,T,Y,,,,w,,,,,0.0,,
25277705,2918,20304,228607,Association,FALSE,"In vivo induction of airway IL-1b, IL-4, IL-5, IL-6, IL-12(p40), IFN-g, CCL2, <ENT1>CCL5</ENT1>, CCL3, CXCL1, IP-10/CXCL10, IL-22, MIG/CXCL9 and MIF were dependent on <ENT2>Mavs</ENT2> expression in mice.",,,,T,,,,,c,,,,,0.0,,
25277705,2950,6387,D018357,Positive_Correlation,TRUE,"RESULTS AND DISCUSSION: <ENT2>RSV-infected</ENT2> A549 and SAE cells release a network of cytokines, including newly identified RSV-inducible cytokines LIF, migration inhibitory factor (MIF), stem cell factor (SCF), CCL27, <ENT1>CXCL12</ENT1> and stem cell growth factor beta (SCGF-b).",,,,T,,,,,w,,,,,0.0,,
25277705,2942,D007239,23586,Association,TRUE,"CONCLUSIONS: RSV infection in the epithelium induces a network of immune factors to counter <ENT1>infection</ENT1>, primarily in a <ENT2>RIG-I</ENT2> dependent manner.",,,,T,,,,,c,,,,,1.0,,
25277705,2924,16189,228607,Association,FALSE,"In vivo induction of airway IL-1b, <ENT1>IL-4</ENT1>, IL-5, IL-6, IL-12(p40), IFN-g, CCL2, CCL5, CCL3, CXCL1, IP-10/CXCL10, IL-22, MIG/CXCL9 and MIF were dependent on <ENT2>Mavs</ENT2> expression in mice.",,,,T,,,,,c,,,,,0.0,,
25277705,2922,16193,228607,Association,FALSE,"In vivo induction of airway IL-1b, IL-4, IL-5, <ENT1>IL-6</ENT1>, IL-12(p40), IFN-g, CCL2, CCL5, CCL3, CXCL1, IP-10/CXCL10, IL-22, MIG/CXCL9 and MIF were dependent on <ENT2>Mavs</ENT2> expression in mice.",,,,T,,,,,c,,,,,0.0,,
25277705,2949,6320,D018357,Positive_Correlation,TRUE,"RESULTS AND DISCUSSION: <ENT2>RSV-infected</ENT2> A549 and SAE cells release a network of cytokines, including newly identified RSV-inducible cytokines LIF, migration inhibitory factor (MIF), stem cell factor (SCF), CCL27, CXCL12 and <ENT1>stem cell growth factor beta</ENT1> (<ENT1>SCGF-b</ENT1>).",,,,T,,,,,w,,,,,1.0,,
25277705,2954,D018357,23586,Association,TRUE,"CONCLUSIONS: <ENT1>RSV infection</ENT1> in the epithelium induces a network of immune factors to counter infection, primarily in a <ENT2>RIG-I</ENT2> dependent manner.",,,,T,,,,,c,,,,,1.0,,
25277705,2956,D018357,16878,Association,TRUE,<ENT2>Leukemia inhibitory factor</ENT2> protects the lung during <ENT1>respiratory syncytial viral infection</ENT1>.,,,,T,,,,,w,,,,,0.0,,
25277705,2956,D018357,16878,Association,TRUE,"To evaluate the role of <ENT2>LIF</ENT2> in the airways during <ENT1>RSV infection</ENT1>, animals were treated with neutralizing anti-<ENT2>LIF</ENT2> IgG, which enhanced RSV pathology observed with increased airspace protein content, apoptosis and airway hyperresponsiveness compared to control IgG treatment.",,,,T,,Y,,,c,,,,,0.0,,
25277705,2956,D018357,16878,Association,TRUE,Expression of <ENT2>LIF</ENT2> protects the lung from lung injury and enhanced pathology during <ENT1>RSV infection</ENT1>.,,,,T,,,,,w,,,,,1.0,,
25277705,2951,D018357,10850,Positive_Correlation,TRUE,"RESULTS AND DISCUSSION: <ENT1>RSV-infected</ENT1> A549 and SAE cells release a network of cytokines, including newly identified RSV-inducible cytokines LIF, migration inhibitory factor (MIF), stem cell factor (SCF), <ENT2>CCL27</ENT2>, CXCL12 and stem cell growth factor beta (SCGF-b).",,,,T,,,,,w,,,,,1.0,,
25277705,2952,D018357,4254,Positive_Correlation,TRUE,"RESULTS AND DISCUSSION: <ENT1>RSV-infected</ENT1> A549 and SAE cells release a network of cytokines, including newly identified RSV-inducible cytokines LIF, migration inhibitory factor (MIF), <ENT2>stem cell factor</ENT2> (<ENT2>SCF</ENT2>), CCL27, CXCL12 and stem cell growth factor beta (SCGF-b).",,,,T,,,,,w,,,,,0.0,,
25277705,2919,20296,228607,Association,FALSE,"In vivo induction of airway IL-1b, IL-4, IL-5, IL-6, IL-12(p40), IFN-g, <ENT1>CCL2</ENT1>, CCL5, CCL3, CXCL1, IP-10/CXCL10, IL-22, MIG/CXCL9 and MIF were dependent on <ENT2>Mavs</ENT2> expression in mice.",,,,T,,,,,c,,,,,0.0,,
25277705,2913,17329,228607,Association,FALSE,"In vivo induction of airway IL-1b, IL-4, IL-5, IL-6, IL-12(p40), IFN-g, CCL2, CCL5, CCL3, CXCL1, IP-10/CXCL10, IL-22, <ENT1>MIG</ENT1>/<ENT1>CXCL9</ENT1> and MIF were dependent on <ENT2>Mavs</ENT2> expression in mice.",,,,T,,,,,c,,,,,0.5,,
25277705,2915,15945,228607,Association,FALSE,"In vivo induction of airway IL-1b, IL-4, IL-5, IL-6, IL-12(p40), IFN-g, CCL2, CCL5, CCL3, CXCL1, <ENT1>IP-10</ENT1>/<ENT1>CXCL10</ENT1>, IL-22, MIG/CXCL9 and MIF were dependent on <ENT2>Mavs</ENT2> expression in mice.",,,,T,,,,,c,,,,,0.0,,
25277705,2921,16160,228607,Association,FALSE,"In vivo induction of airway IL-1b, IL-4, IL-5, IL-6, <ENT1>IL-12</ENT1>(<ENT1>p40</ENT1>), IFN-g, CCL2, CCL5, CCL3, CXCL1, IP-10/CXCL10, IL-22, MIG/CXCL9 and MIF were dependent on <ENT2>Mavs</ENT2> expression in mice.",,,,T,,,,,c,,,,,0.0,,
25277705,2912,17319,228607,Association,FALSE,"In vivo induction of airway IL-1b, IL-4, IL-5, IL-6, IL-12(p40), IFN-g, CCL2, CCL5, CCL3, CXCL1, IP-10/CXCL10, IL-22, MIG/CXCL9 and <ENT1>MIF</ENT1> were dependent on <ENT2>Mavs</ENT2> expression in mice.",,,,T,,,,,c,,,,,0.0,,
25277705,2923,16191,228607,Association,FALSE,"In vivo induction of airway IL-1b, IL-4, <ENT1>IL-5</ENT1>, IL-6, IL-12(p40), IFN-g, CCL2, CCL5, CCL3, CXCL1, IP-10/CXCL10, IL-22, MIG/CXCL9 and MIF were dependent on <ENT2>Mavs</ENT2> expression in mice.",,,,T,,,,,c,,,,,0.0,,
25277705,2920,15978,228607,Association,FALSE,"In vivo induction of airway IL-1b, IL-4, IL-5, IL-6, IL-12(p40), <ENT1>IFN-g</ENT1>, CCL2, CCL5, CCL3, CXCL1, IP-10/CXCL10, IL-22, MIG/CXCL9 and MIF were dependent on <ENT2>Mavs</ENT2> expression in mice.",,,,T,,,,,c,,,,,0.0,,
25550469,2967,D050197,11835,Negative_Correlation,TRUE,"The <ENT2>androgen receptor</ENT2> confers protection against diet-induced <ENT1>atherosclerosis</ENT1>, obesity, and dyslipidemia in female mice.",,,,T,,,,,c,,,,,1.0,,
25550469,2967,D050197,11835,Negative_Correlation,TRUE,"To determine the physiologic <ENT2>androgen receptor</ENT2> (<ENT2>AR</ENT2>)-dependent actions of androgens on <ENT1>atherogenesis</ENT1> in female mice, we generated female <ENT2>AR</ENT2>-knockout (<ENT2>AR</ENT2>KO) mice on an <ENT1>atherosclerosis</ENT1>-prone apolipoprotein E (apoE)-deficient background.",,,,T,,Y,,,c,,,,,1.0,,
25550469,2967,D050197,11835,Negative_Correlation,TRUE,"After 8 weeks on a high-fat diet, but not on a normal chow diet, <ENT1>atherosclerosis</ENT1> in aorta was increased in <ENT2>AR</ENT2>KO females (+59% vs. control apoE-deficient mice with intact <ENT2>AR</ENT2> gene).",,,,T,,,,,w,,,,,1.0,TRUE,
25550469,2967,D050197,11835,Negative_Correlation,TRUE,"Differences in <ENT1>atherosclerosis</ENT1>, body weight, and lipid levels between <ENT2>AR</ENT2>KO and control mice were abolished in mice that were ovariectomized before puberty, consistent with a protective action of ovarian androgens mediated via the <ENT2>AR</ENT2>.",,,,T,Y,,,,w,,,,,0.5,TRUE,
25550469,2967,D050197,11835,Negative_Correlation,TRUE,"Furthermore, the <ENT2>AR</ENT2> agonist dihydrotestosterone reduced <ENT1>atherosclerosis</ENT1> (-41%; thoracic aorta), subcutaneous fat mass (-44%), and cholesterol levels (-35%) in ovariectomized mice, reduced hepatocyte lipid accumulation in hepatoma cells in vitro, and regulated mRNA expression of hepatic genes pivotal for lipid homeostasis.",,,,T,,,,,c,,,,,0.0,,
25550469,2967,D050197,11835,Negative_Correlation,TRUE,"In conclusion, we demonstrate that the <ENT2>AR</ENT2> protects against diet-induced <ENT1>atherosclerosis</ENT1> in female mice and propose that this is mediated by modulation of body composition and lipid metabolism.",,,,T,,,,,c,,,,,1.0,,
25550469,2961,D050197,D002784,Positive_Correlation,FALSE,"They also displayed increased body weight (+18%), body fat percentage (+62%), and hepatic triglyceride levels, reduced insulin sensitivity, and a marked <ENT1>atherogenic</ENT1> dyslipidemia (serum <ENT2>cholesterol</ENT2>, +52%).",,,,T,Y,,,,w,,,,,0.0,,
25550469,2961,D050197,D002784,Positive_Correlation,FALSE,"Furthermore, the AR agonist dihydrotestosterone reduced <ENT1>atherosclerosis</ENT1> (-41%; thoracic aorta), subcutaneous fat mass (-44%), and <ENT2>cholesterol</ENT2> levels (-35%) in ovariectomized mice, reduced hepatocyte lipid accumulation in hepatoma cells in vitro, and regulated mRNA expression of hepatic genes pivotal for lipid homeostasis.",,,,T,,,,,c,,,,,1.0,,
25550469,2959,D050197,D013196,Negative_Correlation,TRUE,"Furthermore, the AR agonist <ENT2>dihydrotestosterone</ENT2> reduced <ENT1>atherosclerosis</ENT1> (-41%; thoracic aorta), subcutaneous fat mass (-44%), and cholesterol levels (-35%) in ovariectomized mice, reduced hepatocyte lipid accumulation in hepatoma cells in vitro, and regulated mRNA expression of hepatic genes pivotal for lipid homeostasis.",,,,T,,,,,c,,,,,1.0,,
25550469,2960,D050197,D008055,Association,TRUE,"Differences in <ENT1>atherosclerosis</ENT1>, body weight, and <ENT2>lipid</ENT2> levels between ARKO and control mice were abolished in mice that were ovariectomized before puberty, consistent with a protective action of ovarian androgens mediated via the AR.",,,,T,,,,,c,,,,,1.0,,
25550469,2960,D050197,D008055,Association,TRUE,"Furthermore, the AR agonist dihydrotestosterone reduced <ENT1>atherosclerosis</ENT1> (-41%; thoracic aorta), subcutaneous fat mass (-44%), and cholesterol levels (-35%) in ovariectomized mice, reduced hepatocyte <ENT2>lipid</ENT2> accumulation in hepatoma cells in vitro, and regulated mRNA expression of hepatic genes pivotal for <ENT2>lipid</ENT2> homeostasis.",,,,T,,,,,c,,,,,1.0,,
25550469,2960,D050197,D008055,Association,TRUE,"In conclusion, we demonstrate that the AR protects against diet-induced <ENT1>atherosclerosis</ENT1> in female mice and propose that this is mediated by modulation of body composition and <ENT2>lipid</ENT2> metabolism.",,,,T,,,,,w,,,,,0.0,,
25550469,2969,11835,D009765,Negative_Correlation,TRUE,"The <ENT1>androgen receptor</ENT1> confers protection against diet-induced atherosclerosis, <ENT2>obesity</ENT2>, and dyslipidemia in female mice.",,,,T,,,,,c,,,,,1.0,,
25550469,2963,11835,D050171,Negative_Correlation,TRUE,"The <ENT1>androgen receptor</ENT1> confers protection against diet-induced atherosclerosis, obesity, and <ENT2>dyslipidemia</ENT2> in female mice.",,,,T,,,,,c,,,,,0.0,,
25550469,2965,11835,D013196,Positive_Correlation,FALSE,"Furthermore, the <ENT1>AR</ENT1> agonist <ENT2>dihydrotestosterone</ENT2> reduced atherosclerosis (-41%; thoracic aorta), subcutaneous fat mass (-44%), and cholesterol levels (-35%) in ovariectomized mice, reduced hepatocyte lipid accumulation in hepatoma cells in vitro, and regulated mRNA expression of hepatic genes pivotal for lipid homeostasis.",,,,T,,,,,c,,,,,1.0,,
25550469,2966,11835,D000728,Bind,FALSE,"To determine the physiologic <ENT1>androgen receptor</ENT1> (<ENT1>AR</ENT1>)-dependent actions of <ENT2>androgens</ENT2> on atherogenesis in female mice, we generated female <ENT1>AR</ENT1>-knockout (<ENT1>AR</ENT1>KO) mice on an atherosclerosis-prone apolipoprotein E (apoE)-deficient background.",,,,T,,,,,w,,,,,0.0,,
25550469,2966,11835,D000728,Bind,FALSE,"Differences in atherosclerosis, body weight, and lipid levels between <ENT1>AR</ENT1>KO and control mice were abolished in mice that were ovariectomized before puberty, consistent with a protective action of ovarian <ENT2>androgens</ENT2> mediated via the <ENT1>AR</ENT1>.",,,,T,Y,,,,w,,,,,0.0,,
25550469,2962,D050171,D002784,Positive_Correlation,FALSE,"They also displayed increased body weight (+18%), body fat percentage (+62%), and hepatic triglyceride levels, reduced insulin sensitivity, and a marked atherogenic <ENT1>dyslipidemia</ENT1> (serum <ENT2>cholesterol</ENT2>, +52%).",,,,T,,,,,c,,,,,0.0,,
25550469,2958,D002784,D013196,Negative_Correlation,TRUE,"Furthermore, the AR agonist <ENT2>dihydrotestosterone</ENT2> reduced atherosclerosis (-41%; thoracic aorta), subcutaneous fat mass (-44%), and <ENT1>cholesterol</ENT1> levels (-35%) in ovariectomized mice, reduced hepatocyte lipid accumulation in hepatoma cells in vitro, and regulated mRNA expression of hepatic genes pivotal for lipid homeostasis.",,,,T,,,,,c,,,,,1.0,,
25550469,2957,D013196,D008055,Negative_Correlation,TRUE,"Furthermore, the AR agonist <ENT1>dihydrotestosterone</ENT1> reduced atherosclerosis (-41%; thoracic aorta), subcutaneous fat mass (-44%), and cholesterol levels (-35%) in ovariectomized mice, reduced hepatocyte <ENT2>lipid</ENT2> accumulation in hepatoma cells in vitro, and regulated mRNA expression of hepatic genes pivotal for <ENT2>lipid</ENT2> homeostasis.",,,,T,,,,,c,,,,,0.5,,
25589620,2970,rs4073,D005472,Association,TRUE,"<ENT1>rs4073</ENT1> and rs1870377 may exhibit different associations with toxicity, according to the <ENT2>5-FU</ENT2> schedule.",,,,T,,,,,c,,,,,0.0,,
25589620,2977,D012004,2950,Association,TRUE,"PURPOSE: We tested whether 18 polymorphisms in 16 genes (<ENT2>GSTP1</ENT2>, COX2, IL10, EGFR, EGF, FGFR4, CCDN1, VEGFR2, VEGF, CXCR2, IL8, MMP3, ICAM1, ERCC1, RAD51, and XRCC3) would predict disease-free survival (DFS), overall survival (OS), and toxicity in the INT0144 trial, which was designed to investigate different postoperative regimens of 5-fluorouracil (5-FU)-based chemoradiation (CRT) in locally advanced <ENT1>rectal cancers</ENT1>: Arm 1 consisted of bolus 5-FU followed by 5-FU protracted venous infusion (PVI) with radiotherapy; arm 2 was induction and concomitant PVI 5-FU with radiotherapy and arm 3 was induction and concomitant bolus 5-FU with radiotherapy.",,,,T,,Y,,,c,,,,,1.0,,
25589620,2971,D012004,rs1695,Association,TRUE,CONCLUSION: <ENT2>rs1695</ENT2> may be prognostic in patients with <ENT1>rectal cancer</ENT1> treated with adjuvant CRT.,,,,T,,,,,c,,,,,1.0,,
25589620,2978,D012004,D005472,Negative_Correlation,FALSE,Pharmacogenetic Analysis of INT 0144 Trial: Association of Polymorphisms with Survival and Toxicity in <ENT1>Rectal Cancer</ENT1> Patients Treated with <ENT2>5-FU</ENT2> and Radiation.,,,,T,,,,,c,,,,,0.0,,
25589620,2978,D012004,D005472,Negative_Correlation,FALSE,"PURPOSE: We tested whether 18 polymorphisms in 16 genes (GSTP1, COX2, IL10, EGFR, EGF, FGFR4, CCDN1, VEGFR2, VEGF, CXCR2, IL8, MMP3, ICAM1, ERCC1, RAD51, and XRCC3) would predict disease-free survival (DFS), overall survival (OS), and toxicity in the INT0144 trial, which was designed to investigate different postoperative regimens of <ENT2>5-fluorouracil</ENT2> (<ENT2>5-FU</ENT2>)-based chemoradiation (CRT) in locally advanced <ENT1>rectal cancers</ENT1>: Arm 1 consisted of bolus <ENT2>5-FU</ENT2> followed by <ENT2>5-FU</ENT2> protracted venous infusion (PVI) with radiotherapy; arm 2 was induction and concomitant PVI <ENT2>5-FU</ENT2> with radiotherapy and arm 3 was induction and concomitant bolus <ENT2>5-FU</ENT2> with radiotherapy.",,,,T,,,,,c,,,,,0.333333333,,
25589620,2972,rs1870377,D052016,Positive_Correlation,TRUE,The VEGFR2 <ENT1>H472Q</ENT1> Q/Q genotype (<ENT1>rs1870377</ENT1>) was associated with a higher risk of grade 3-5 proximal upper gastrointestinal tract (PUGIT) <ENT2>mucositis</ENT2> (P = 0.04) in arm 2.,,,,T,,,,,c,,,,,1.0,,
25589620,2973,rs1870377,D005472,Association,TRUE,"rs4073 and <ENT1>rs1870377</ENT1> may exhibit different associations with toxicity, according to the <ENT2>5-FU</ENT2> schedule.",,,,T,,,,,c,,,,,0.0,,
25589620,2974,3791,D052016,Association,TRUE,The <ENT1>VEGFR2</ENT1> H472Q Q/Q genotype (rs1870377) was associated with a higher risk of grade 3-5 proximal upper gastrointestinal tract (PUGIT) <ENT2>mucositis</ENT2> (P = 0.04) in arm 2.,,,,T,,,,,c,,,,,1.0,,
25589620,2975,3791,D005472,Association,FALSE,"PURPOSE: We tested whether 18 polymorphisms in 16 genes (GSTP1, COX2, IL10, EGFR, EGF, FGFR4, CCDN1, <ENT1>VEGFR2</ENT1>, VEGF, CXCR2, IL8, MMP3, ICAM1, ERCC1, RAD51, and XRCC3) would predict disease-free survival (DFS), overall survival (OS), and toxicity in the INT0144 trial, which was designed to investigate different postoperative regimens of <ENT2>5-fluorouracil</ENT2> (<ENT2>5-FU</ENT2>)-based chemoradiation (CRT) in locally advanced rectal cancers: Arm 1 consisted of bolus <ENT2>5-FU</ENT2> followed by <ENT2>5-FU</ENT2> protracted venous infusion (PVI) with radiotherapy; arm 2 was induction and concomitant PVI <ENT2>5-FU</ENT2> with radiotherapy and arm 3 was induction and concomitant bolus <ENT2>5-FU</ENT2> with radiotherapy.",,,,T,,Y,,,w,,,,,1.0,,
25589620,2976,D005472,3576,Association,FALSE,"PURPOSE: We tested whether 18 polymorphisms in 16 genes (GSTP1, COX2, IL10, EGFR, EGF, FGFR4, CCDN1, VEGFR2, VEGF, CXCR2, <ENT2>IL8</ENT2>, MMP3, ICAM1, ERCC1, RAD51, and XRCC3) would predict disease-free survival (DFS), overall survival (OS), and toxicity in the INT0144 trial, which was designed to investigate different postoperative regimens of <ENT1>5-fluorouracil</ENT1> (<ENT1>5-FU</ENT1>)-based chemoradiation (CRT) in locally advanced rectal cancers: Arm 1 consisted of bolus <ENT1>5-FU</ENT1> followed by <ENT1>5-FU</ENT1> protracted venous infusion (PVI) with radiotherapy; arm 2 was induction and concomitant PVI <ENT1>5-FU</ENT1> with radiotherapy and arm 3 was induction and concomitant bolus <ENT1>5-FU</ENT1> with radiotherapy.",,,,T,,Y,,,w,,,,,1.0,,
25622904,2999,19823,D008175,Association,FALSE,"Our recent study showed that <ENT1>SAG</ENT1>/<ENT1>RBX2</ENT1> <ENT1>E3 ubiquitin ligase</ENT1> regulates apoptosis and vasculogenesis by promoting degradation of NOXA and NF1, and co-operates with Kras to promote <ENT2>lung tumorigenesis</ENT2> by activating NFkappaB and mTOR pathways via targeted degradation of tumor suppressive substrates including IkappaB, DEPTOR, p21 and p27.",,,,T,,,,,c,,,,,1.0,,
25622904,3002,19823,97998,Association,FALSE,"Our recent study showed that <ENT1>SAG</ENT1>/<ENT1>RBX2</ENT1> <ENT1>E3 ubiquitin ligase</ENT1> regulates apoptosis and vasculogenesis by promoting degradation of NOXA and NF1, and co-operates with Kras to promote lung tumorigenesis by activating NFkappaB and mTOR pathways via targeted degradation of tumor suppressive substrates including IkappaB, <ENT2>DEPTOR</ENT2>, p21 and p27.",,,,T,,,,,c,,,,,0.333333333,,
25622904,3004,19823,16653,Positive_Correlation,TRUE,Inactivation of <ENT1>Sag</ENT1>/<ENT1>Rbx2</ENT1>/<ENT1>Roc2</ENT1> <ENT1>e3 ubiquitin ligase</ENT1> triggers senescence and inhibits <ENT2>kras</ENT2>-induced immortalization.,,,,T,,,,,c,,,,,0.25,,
25622904,3004,19823,16653,Positive_Correlation,TRUE,"Our recent study showed that <ENT1>SAG</ENT1>/<ENT1>RBX2</ENT1> <ENT1>E3 ubiquitin ligase</ENT1> regulates apoptosis and vasculogenesis by promoting degradation of NOXA and NF1, and co-operates with <ENT2>Kras</ENT2> to promote lung tumorigenesis by activating NFkappaB and mTOR pathways via targeted degradation of tumor suppressive substrates including IkappaB, DEPTOR, p21 and p27.",,,,T,,,,,w,,,,,0.333333333,,
25622904,3004,19823,16653,Positive_Correlation,TRUE,Here we investigated the role of <ENT1>Sag</ENT1>/<ENT1>Rbx2</ENT1> <ENT1>E3 ligase</ENT1> in cellular senescence and immortalization of mouse embryonic fibroblasts (MEFs) and report that <ENT1>Sag</ENT1> is required for proper cell proliferation and <ENT2>Kras</ENT2>(G12D)-induced immortalization.,,,,T,,,,,w,,,,,0.0,,
25622904,3004,19823,16653,Positive_Correlation,TRUE,"Furthermore, <ENT2>Kras</ENT2>(G12D)-induced immortalization can also be abrogated by <ENT1>Sag</ENT1> deletion via senescence induction, which is again rescued by simultaneous deletion of Cdkn2a.",,,,T,,,,,c,,,,,0.0,,
25622904,3004,19823,16653,Positive_Correlation,TRUE,"Finally, we found that <ENT1>Sag</ENT1> deletion inactivates <ENT2>Kras</ENT2>(G12D) activity and block the MAPK signaling pathway, together with accumulated p16, to induce senescence.",,,,T,,,,,c,,,,,1.0,,
25622904,3004,19823,16653,Positive_Correlation,TRUE,"Taken together, our results demonstrated that <ENT1>Sag</ENT1> is a <ENT2>Kras</ENT2>(G12D)-cooperating oncogene required for <ENT2>Kras</ENT2>(G12D)-induced immortalization and transformation, and targeting <ENT1>SAG</ENT1>-SCF <ENT1>E3 ligase</ENT1> may, therefore, have therapeutic value for senescence-based cancer treatment.",,,,T,,,,,c,,,,,0.0,,
25622904,3003,19823,18033,Association,FALSE,"Our recent study showed that <ENT1>SAG</ENT1>/<ENT1>RBX2</ENT1> <ENT1>E3 ubiquitin ligase</ENT1> regulates apoptosis and vasculogenesis by promoting degradation of NOXA and NF1, and co-operates with Kras to promote lung tumorigenesis by activating <ENT2>NFkappaB</ENT2> and mTOR pathways via targeted degradation of tumor suppressive substrates including <ENT2>IkappaB</ENT2>, DEPTOR, p21 and p27.",,,,T,,,,,w,,,,,0.5,,
25622904,2996,19823,16477,Association,TRUE,"Mechanistically, <ENT1>Sag</ENT1> deletion caused accumulation of <ENT2>Jun-B</ENT2>, a substrate of <ENT1>Sag</ENT1>-Fbxw7 <ENT1>E3 ligase</ENT1> and a transcription factor that drives p16 transcription.",,,,T,,,,,c,,,,,0.333333333,,
25622904,2993,19823,18015,Association,FALSE,"Our recent study showed that <ENT1>SAG</ENT1>/<ENT1>RBX2</ENT1> <ENT1>E3 ubiquitin ligase</ENT1> regulates apoptosis and vasculogenesis by promoting degradation of NOXA and <ENT2>NF1</ENT2>, and co-operates with Kras to promote lung tumorigenesis by activating NFkappaB and mTOR pathways via targeted degradation of tumor suppressive substrates including IkappaB, DEPTOR, p21 and p27.",,,,T,,,,,w,,,,,1.0,,
25622904,2997,19823,12578,Negative_Correlation,TRUE,"<ENT1>Sag</ENT1> inactivation by genetic deletion remarkably suppresses cell proliferation by inducing senescence, which is associated with accumulation of <ENT2>p16</ENT2>, but not p53.",,,,T,,,,,c,,,,,1.0,,
25622904,2997,19823,12578,Negative_Correlation,TRUE,"Mechanistically, <ENT1>Sag</ENT1> deletion caused accumulation of Jun-B, a substrate of <ENT1>Sag</ENT1>-Fbxw7 <ENT1>E3 ligase</ENT1> and a transcription factor that drives <ENT2>p16</ENT2> transcription.",,,,T,,,,,c,,,,,0.333333333,,
25622904,2997,19823,12578,Negative_Correlation,TRUE,"Importantly, senescence triggered by <ENT1>Sag</ENT1> deletion can be largely rescued by simultaneous deletion of <ENT2>Cdkn2a</ENT2>, the <ENT2>p16</ENT2> encoding gene, indicating its causal role.",,,,T,,,,,c,,,,,0.0,,
25622904,2997,19823,12578,Negative_Correlation,TRUE,"Furthermore, Kras(G12D)-induced immortalization can also be abrogated by <ENT1>Sag</ENT1> deletion via senescence induction, which is again rescued by simultaneous deletion of <ENT2>Cdkn2a</ENT2>.",,,,T,,,,,c,,,,,0.0,,
25622904,2997,19823,12578,Negative_Correlation,TRUE,"Finally, we found that <ENT1>Sag</ENT1> deletion inactivates Kras(G12D) activity and block the MAPK signaling pathway, together with accumulated <ENT2>p16</ENT2>, to induce senescence.",,,,T,,,,,c,,,,,0.0,,
25622904,3001,19823,12575,Association,FALSE,"Our recent study showed that <ENT1>SAG</ENT1>/<ENT1>RBX2</ENT1> <ENT1>E3 ubiquitin ligase</ENT1> regulates apoptosis and vasculogenesis by promoting degradation of NOXA and NF1, and co-operates with Kras to promote lung tumorigenesis by activating NFkappaB and mTOR pathways via targeted degradation of tumor suppressive substrates including IkappaB, DEPTOR, <ENT2>p21</ENT2> and p27.",,,,T,,,,,c,,,,,0.333333333,,
25622904,2995,19823,26413,Positive_Correlation,TRUE,"Finally, we found that <ENT1>Sag</ENT1> deletion inactivates Kras(G12D) activity and block the <ENT2>MAPK</ENT2> signaling pathway, together with accumulated p16, to induce senescence.",,,,T,,,,,c,,,,,1.0,,
25622904,2994,19823,58801,Association,FALSE,"Our recent study showed that <ENT1>SAG</ENT1>/<ENT1>RBX2</ENT1> <ENT1>E3 ubiquitin ligase</ENT1> regulates apoptosis and vasculogenesis by promoting degradation of <ENT2>NOXA</ENT2> and NF1, and co-operates with Kras to promote lung tumorigenesis by activating NFkappaB and mTOR pathways via targeted degradation of tumor suppressive substrates including IkappaB, DEPTOR, p21 and p27.",,,,T,,,,,w,,,,,0.666666667,,
25622904,2998,19823,D009369,Association,FALSE,"Our recent study showed that <ENT1>SAG</ENT1>/<ENT1>RBX2</ENT1> <ENT1>E3 ubiquitin ligase</ENT1> regulates apoptosis and vasculogenesis by promoting degradation of NOXA and NF1, and co-operates with Kras to promote lung tumorigenesis by activating NFkappaB and mTOR pathways via targeted degradation of <ENT2>tumor</ENT2> suppressive substrates including IkappaB, DEPTOR, p21 and p27.",,,,T,,,,,c,,,,,0.333333333,,
25622904,2998,19823,D009369,Association,FALSE,"Taken together, our results demonstrated that <ENT1>Sag</ENT1> is a Kras(G12D)-cooperating oncogene required for Kras(G12D)-induced immortalization and transformation, and targeting <ENT1>SAG</ENT1>-SCF <ENT1>E3 ligase</ENT1> may, therefore, have therapeutic value for senescence-based <ENT2>cancer</ENT2> treatment.",,,,T,,,,,w,,,,,0.0,,
25622904,3000,19823,12576,Association,FALSE,"Our recent study showed that <ENT1>SAG</ENT1>/<ENT1>RBX2</ENT1> <ENT1>E3 ubiquitin ligase</ENT1> regulates apoptosis and vasculogenesis by promoting degradation of NOXA and NF1, and co-operates with Kras to promote lung tumorigenesis by activating NFkappaB and mTOR pathways via targeted degradation of tumor suppressive substrates including IkappaB, DEPTOR, p21 and <ENT2>p27</ENT2>.",,,,T,,,,,c,,,,,0.333333333,,
25622904,2992,D008175,16653,Association,FALSE,"Our recent study showed that SAG/RBX2 E3 ubiquitin ligase regulates apoptosis and vasculogenesis by promoting degradation of NOXA and NF1, and co-operates with <ENT2>Kras</ENT2> to promote <ENT1>lung tumorigenesis</ENT1> by activating NFkappaB and mTOR pathways via targeted degradation of tumor suppressive substrates including IkappaB, DEPTOR, p21 and p27.",,,,T,,,,,c,,,,,1.0,,
25622904,2988,97998,16653,Association,FALSE,"Our recent study showed that SAG/RBX2 E3 ubiquitin ligase regulates apoptosis and vasculogenesis by promoting degradation of NOXA and NF1, and co-operates with <ENT2>Kras</ENT2> to promote lung tumorigenesis by activating NFkappaB and mTOR pathways via targeted degradation of tumor suppressive substrates including IkappaB, <ENT1>DEPTOR</ENT1>, p21 and p27.",,,,T,,,,,c,,,,,1.0,,
25622904,2987,97998,D009369,Negative_Correlation,FALSE,"Our recent study showed that SAG/RBX2 E3 ubiquitin ligase regulates apoptosis and vasculogenesis by promoting degradation of NOXA and NF1, and co-operates with Kras to promote lung tumorigenesis by activating NFkappaB and mTOR pathways via targeted degradation of <ENT2>tumor</ENT2> suppressive substrates including IkappaB, <ENT1>DEPTOR</ENT1>, p21 and p27.",,,,T,,,,,w,,,,,0.0,,
25622904,2990,16653,18033,Association,FALSE,"Our recent study showed that SAG/RBX2 E3 ubiquitin ligase regulates apoptosis and vasculogenesis by promoting degradation of NOXA and NF1, and co-operates with <ENT1>Kras</ENT1> to promote lung tumorigenesis by activating <ENT2>NFkappaB</ENT2> and mTOR pathways via targeted degradation of tumor suppressive substrates including <ENT2>IkappaB</ENT2>, DEPTOR, p21 and p27.",,,,T,,,,,c,,,,,0.5,,
25622904,2986,16653,12575,Association,FALSE,"Our recent study showed that SAG/RBX2 E3 ubiquitin ligase regulates apoptosis and vasculogenesis by promoting degradation of NOXA and NF1, and co-operates with <ENT1>Kras</ENT1> to promote lung tumorigenesis by activating NFkappaB and mTOR pathways via targeted degradation of tumor suppressive substrates including IkappaB, DEPTOR, <ENT2>p21</ENT2> and p27.",,,,T,,,,,c,,,,,1.0,,
25622904,2991,16653,D009369,Association,FALSE,"Our recent study showed that SAG/RBX2 E3 ubiquitin ligase regulates apoptosis and vasculogenesis by promoting degradation of NOXA and NF1, and co-operates with <ENT1>Kras</ENT1> to promote lung tumorigenesis by activating NFkappaB and mTOR pathways via targeted degradation of <ENT2>tumor</ENT2> suppressive substrates including IkappaB, DEPTOR, p21 and p27.",,,,T,,,,,c,,,,,0.0,,
25622904,2991,16653,D009369,Association,FALSE,"Taken together, our results demonstrated that Sag is a <ENT1>Kras</ENT1>(G12D)-cooperating oncogene required for <ENT1>Kras</ENT1>(G12D)-induced immortalization and transformation, and targeting SAG-SCF E3 ligase may, therefore, have therapeutic value for senescence-based <ENT2>cancer</ENT2> treatment.",,,,T,,,,,c,,,,,0.0,,
25622904,2984,16653,12576,Association,FALSE,"Our recent study showed that SAG/RBX2 E3 ubiquitin ligase regulates apoptosis and vasculogenesis by promoting degradation of NOXA and NF1, and co-operates with <ENT1>Kras</ENT1> to promote lung tumorigenesis by activating NFkappaB and mTOR pathways via targeted degradation of tumor suppressive substrates including IkappaB, DEPTOR, p21 and <ENT2>p27</ENT2>.",,,,T,,,,,c,,,,,0.0,,
25622904,2980,50754,16477,Association,FALSE,"Mechanistically, Sag deletion caused accumulation of <ENT2>Jun-B</ENT2>, a substrate of Sag-<ENT1>Fbxw7</ENT1> E3 ligase and a transcription factor that drives p16 transcription.",,,,T,,,,,c,,,,,1.0,,
25622904,2982,50754,D009369,Association,TRUE,"Taken together, our results demonstrated that Sag is a Kras(G12D)-cooperating oncogene required for Kras(G12D)-induced immortalization and transformation, and targeting SAG-<ENT1>SCF</ENT1> E3 ligase may, therefore, have therapeutic value for senescence-based <ENT2>cancer</ENT2> treatment.",,,,T,,,,,c,,,,,0.0,,
25622904,2989,18033,D009369,Negative_Correlation,FALSE,"Our recent study showed that SAG/RBX2 E3 ubiquitin ligase regulates apoptosis and vasculogenesis by promoting degradation of NOXA and NF1, and co-operates with Kras to promote lung tumorigenesis by activating <ENT1>NFkappaB</ENT1> and mTOR pathways via targeted degradation of <ENT2>tumor</ENT2> suppressive substrates including <ENT1>IkappaB</ENT1>, DEPTOR, p21 and p27.",,,,T,,,,,c,,,,,0.0,,
25622904,2981,16477,12578,Association,FALSE,"Mechanistically, Sag deletion caused accumulation of <ENT1>Jun-B</ENT1>, a substrate of Sag-Fbxw7 E3 ligase and a transcription factor that drives <ENT2>p16</ENT2> transcription.",,,,T,,,,,w,,,,,0.0,,
25622904,2985,12575,D009369,Negative_Correlation,FALSE,"Our recent study showed that SAG/RBX2 E3 ubiquitin ligase regulates apoptosis and vasculogenesis by promoting degradation of NOXA and NF1, and co-operates with Kras to promote lung tumorigenesis by activating NFkappaB and mTOR pathways via targeted degradation of <ENT2>tumor</ENT2> suppressive substrates including IkappaB, DEPTOR, <ENT1>p21</ENT1> and p27.",,,,T,,,,,c,,,,,1.0,,
25622904,2979,rs121913529,D009369,Association,FALSE,"Taken together, our results demonstrated that Sag is a Kras(<ENT1>G12D</ENT1>)-cooperating oncogene required for Kras(<ENT1>G12D</ENT1>)-induced immortalization and transformation, and targeting SAG-SCF E3 ligase may, therefore, have therapeutic value for senescence-based <ENT2>cancer</ENT2> treatment.",,,,T,,,,,w,,,,,1.0,,
25622904,2983,D009369,12576,Negative_Correlation,FALSE,"Our recent study showed that SAG/RBX2 E3 ubiquitin ligase regulates apoptosis and vasculogenesis by promoting degradation of NOXA and NF1, and co-operates with Kras to promote lung tumorigenesis by activating NFkappaB and mTOR pathways via targeted degradation of <ENT1>tumor</ENT1> suppressive substrates including IkappaB, DEPTOR, p21 and <ENT2>p27</ENT2>.",,,,T,,,,,c,,,,,1.0,,
25874935,3013,24533,116459,Negative_Correlation,TRUE,"To confirm the neuroprotective effects of <ENT2>NSP</ENT2>, we measured the cell survival rate, relative <ENT1>lactate dehydrogenase</ENT1> (<ENT1>LDH</ENT1>) release; we also performed morphological methods, namely Hoechst 33342 staining and Annexin V assay.",,,,T,,,,,c,,,,,1.0,,
25874935,3013,24533,116459,Negative_Correlation,TRUE,We found that <ENT2>NSP</ENT2> significantly increased the cell survival rate and reduced <ENT1>LDH</ENT1> release in OGD/R-treated astrocytes.,,,,T,,,,,c,,,,,1.0,,
25874935,3008,309361,116459,Negative_Correlation,TRUE,Western blotting showed that the protein levels of p-<ENT1>IKKBalpha/beta</ENT1> and P65 were upregulated by the OGD/R treatment and such effects were significantly inhibited by <ENT2>NSP</ENT2> administration.,,,,T,,,,,c,,,,,1.0,,
25874935,3011,116459,D009569,Negative_Correlation,TRUE,"To explore the potential mechanisms of <ENT1>NSP</ENT1>, the release of <ENT2>nitric oxide</ENT2> (<ENT2>NO</ENT2>) and TNF-alpha related to <ENT1>NSP</ENT1> administration were measured by enzyme-linked immunosorbent assay.",,,,T,,Y,,,c,,,,,0.5,,
25874935,3009,116459,C118258,Positive_Correlation,TRUE,"To verify the cause-and-effect relationship between neuroprotection and the NF-kappaB pathway, a NF-kappaB pathway inhibitor <ENT2>sc3060</ENT2> was employed to observe the effects of <ENT1>NSP</ENT1>-induced neuroprotection.",,,,T,,,,,c,,,,,1.0,,
25874935,3009,116459,C118258,Positive_Correlation,TRUE,"The <ENT1>NSP</ENT1>-induced inhibition could be significantly reversed by administration of the NF-kappaB pathway inhibitor <ENT2>sc3060</ENT2>, whereas, expressions of p-ERK1, p-ERK2, and p-AKT were upregulated by the OGD/R treatment; however, their levels were unchanged by <ENT1>NSP</ENT1> administration.",,,,T,Y,,,,w,,,,,0.0,,
25874935;25874935,3006;3005,116459;5274,D002545;D002545,Negative_Correlation;Negative_Correlation,FALSE;FALSE,"<ENT1>Neuroserpin</ENT1> (<ENT1>NSP</ENT1>) reportedly exerts neuroprotective effects in <ENT2>cerebral ischemic</ENT2> animal models and patients; however, the mechanism of protection is poorly understood.",,,,T,,,,,w,,,,,0.5,,
25874935,3012,116459,D007511,Negative_Correlation,TRUE,We thus attempted to confirm neuroprotective effects of <ENT1>NSP</ENT1> on astrocytes in the <ENT2>ischemic</ENT2> state and then explored the relative mechanisms.,,,,T,,Y,,,c,,,,,1.0,,
25874935,3012,116459,D007511,Negative_Correlation,TRUE,Our results thus verified the neuroprotective effects of <ENT1>NSP</ENT1> in <ENT2>ischemic</ENT2> astrocytes.,,,,T,,,,,w,,,,,0.0,,
25874935,3014,116459,24835,Negative_Correlation,TRUE,"To explore the potential mechanisms of <ENT1>NSP</ENT1>, the release of nitric oxide (NO) and <ENT2>TNF-alpha</ENT2> related to <ENT1>NSP</ENT1> administration were measured by enzyme-linked immunosorbent assay.",,,,T,,,,,w,,,,,0.0,,
25874935,3010,309165,C118258,Negative_Correlation,FALSE,"To verify the cause-and-effect relationship between neuroprotection and the <ENT1>NF-kappaB</ENT1> pathway, a <ENT1>NF-kappaB</ENT1> pathway inhibitor <ENT2>sc3060</ENT2> was employed to observe the effects of NSP-induced neuroprotection.",,,,T,,,,,c,,,,,0.5,,
25874935,3010,309165,C118258,Negative_Correlation,FALSE,"The NSP-induced inhibition could be significantly reversed by administration of the <ENT1>NF-kappaB</ENT1> pathway inhibitor <ENT2>sc3060</ENT2>, whereas, expressions of p-ERK1, p-ERK2, and p-AKT were upregulated by the OGD/R treatment; however, their levels were unchanged by NSP administration.",,,,T,,,,,c,,,,,1.0,,
25946186,3026,D008175,79626,Negative_Correlation,TRUE,<ENT2>TIPE2</ENT2> Inhibits <ENT1>Lung Cancer</ENT1> Growth Attributing to Promotion of Apoptosis by Regulating Some Apoptotic Molecules Expression.,,,,T,,,,,c,,,,,1.0,,
25946186,3026,D008175,79626,Negative_Correlation,TRUE,"However, little is known about <ENT2>TIPE2</ENT2> in <ENT1>lung cancer</ENT1>.",,,,T,,,,,c,,,,,1.0,,
25946186,3026,D008175,79626,Negative_Correlation,TRUE,Our study aims to clarify the role of <ENT2>TIPE2</ENT2> in <ENT1>lung carcinogenesis</ENT1>.,,,,T,,,,,c,,,,,1.0,,
25946186,3026,D008175,79626,Negative_Correlation,TRUE,Overexpression of <ENT2>TIPE2</ENT2> significantly inhibited the growth of <ENT1>lung cancer</ENT1> cell H446 in vitro and even suppressed tumor formation in vivo.,,,,T,,,,,c,,,,,0.0,,
25946186,3026,D008175,79626,Negative_Correlation,TRUE,"Taken together, <ENT2>TIPE2</ENT2> promoted <ENT1>lung cancer</ENT1> cell apoptosis through affecting apoptosis-related molecules caspase-3, caspase-9, Bcl-2 and Bax, possibly via regulating P38 and Akt pathways, indicating that <ENT2>TIPE2</ENT2> might be a novel marker for <ENT1>lung cancer</ENT1> diagnosis and therapy.",,,,T,,,,,c,,,"11,22",,0.0,,
25946186,3018,D008175,836,Association,FALSE,"Taken together, TIPE2 promoted <ENT1>lung cancer</ENT1> cell apoptosis through affecting apoptosis-related molecules <ENT2>caspase-3</ENT2>, caspase-9, Bcl-2 and Bax, possibly via regulating P38 and Akt pathways, indicating that TIPE2 might be a novel marker for <ENT1>lung cancer</ENT1> diagnosis and therapy.",,,,T,,,,,c,,,,,0.0,,
25946186,3017,D008175,842,Association,FALSE,"Taken together, TIPE2 promoted <ENT1>lung cancer</ENT1> cell apoptosis through affecting apoptosis-related molecules caspase-3, <ENT2>caspase-9</ENT2>, Bcl-2 and Bax, possibly via regulating P38 and Akt pathways, indicating that TIPE2 might be a novel marker for <ENT1>lung cancer</ENT1> diagnosis and therapy.",,,,T,,,,,c,,,,,0.0,,
25946186,3015,D008175,596,Association,FALSE,"Taken together, TIPE2 promoted <ENT1>lung cancer</ENT1> cell apoptosis through affecting apoptosis-related molecules caspase-3, caspase-9, <ENT2>Bcl-2</ENT2> and Bax, possibly via regulating P38 and Akt pathways, indicating that TIPE2 might be a novel marker for <ENT1>lung cancer</ENT1> diagnosis and therapy.",,,,T,,,,,c,,,,,0.0,,
25946186,3016,D008175,581,Association,TRUE,"Taken together, TIPE2 promoted <ENT1>lung cancer</ENT1> cell apoptosis through affecting apoptosis-related molecules caspase-3, caspase-9, Bcl-2 and <ENT2>Bax</ENT2>, possibly via regulating P38 and Akt pathways, indicating that TIPE2 might be a novel marker for <ENT1>lung cancer</ENT1> diagnosis and therapy.",,,,T,,,,,c,,,,,0.0,,
25946186,3019,79626,1432,Association,TRUE,"<ENT1>TIPE2</ENT1> inhibited the phosphorylation of Akt, while promoting the phosphorylation of <ENT2>P38</ENT2>, but had no effect on IkBa and ERK pathway.",,,,T,,,,,c,,,,,0.0,,
25946186,3019,79626,1432,Association,TRUE,"Taken together, <ENT1>TIPE2</ENT1> promoted lung cancer cell apoptosis through affecting apoptosis-related molecules caspase-3, caspase-9, Bcl-2 and Bax, possibly via regulating <ENT2>P38</ENT2> and Akt pathways, indicating that <ENT1>TIPE2</ENT1> might be a novel marker for lung cancer diagnosis and therapy.",,,,T,,,,,c,,,,,0.0,,
25946186,3024,79626,836,Positive_Correlation,TRUE,"In <ENT1>TIPE2</ENT1> over-expression cells, <ENT2>caspase-3</ENT2>, caspase-9, and Bax were significantly up-regulated while Bcl-2 was down-regulated.",,,,T,,,,,c,,,,,1.0,,
25946186,3024,79626,836,Positive_Correlation,TRUE,"Taken together, <ENT1>TIPE2</ENT1> promoted lung cancer cell apoptosis through affecting apoptosis-related molecules <ENT2>caspase-3</ENT2>, caspase-9, Bcl-2 and Bax, possibly via regulating P38 and Akt pathways, indicating that <ENT1>TIPE2</ENT1> might be a novel marker for lung cancer diagnosis and therapy.",,,,T,,,,,w,,,,,0.5,,
25946186,3027,79626,D055752,Negative_Correlation,TRUE,"We examined the expression of <ENT1>TIPE2</ENT1> in lung squamous cancer (LSC), <ENT2>small cell lung cancer</ENT2> and lung adenocarcinoma (AdC) tissues and found that <ENT1>TIPE2</ENT1> expression was lost in <ENT2>small cell lung cancer</ENT2>, compared with adjacent non-tumor tissues.",,,,T,,,,,c,,,,,0.0,,
25946186,3020,79626,207,Association,TRUE,"<ENT1>TIPE2</ENT1> inhibited the phosphorylation of <ENT2>Akt</ENT2>, while promoting the phosphorylation of P38, but had no effect on IkBa and ERK pathway.",,,,T,,,,,c,,,,,1.0,,
25946186,3020,79626,207,Association,TRUE,"Taken together, <ENT1>TIPE2</ENT1> promoted lung cancer cell apoptosis through affecting apoptosis-related molecules caspase-3, caspase-9, Bcl-2 and Bax, possibly via regulating P38 and <ENT2>Akt</ENT2> pathways, indicating that <ENT1>TIPE2</ENT1> might be a novel marker for lung cancer diagnosis and therapy.",,,,T,,,,,c,,,,,0.0,,
25946186,3023,79626,842,Positive_Correlation,TRUE,"In <ENT1>TIPE2</ENT1> over-expression cells, caspase-3, <ENT2>caspase-9</ENT2>, and Bax were significantly up-regulated while Bcl-2 was down-regulated.",,,,T,,,,,c,,,,,1.0,,
25946186,3023,79626,842,Positive_Correlation,TRUE,"Taken together, <ENT1>TIPE2</ENT1> promoted lung cancer cell apoptosis through affecting apoptosis-related molecules caspase-3, <ENT2>caspase-9</ENT2>, Bcl-2 and Bax, possibly via regulating P38 and Akt pathways, indicating that <ENT1>TIPE2</ENT1> might be a novel marker for lung cancer diagnosis and therapy.",,,,T,,,,,w,,,,,0.5,,
25946186,3025,79626,D009369,Association,TRUE,Recent studies found that <ENT1>TIPE2</ENT1> was involved in <ENT2>cancer</ENT2> development.,,,,T,,,,,c,,,,,1.0,,
25946186,3025,79626,D009369,Association,TRUE,"We examined the expression of <ENT1>TIPE2</ENT1> in lung squamous cancer (LSC), small cell lung cancer and lung adenocarcinoma (AdC) tissues and found that <ENT1>TIPE2</ENT1> expression was lost in small cell lung cancer, compared with adjacent non-<ENT2>tumor</ENT2> tissues.",,,,T,,,,,w,,,,,1.0,,
25946186,3025,79626,D009369,Association,TRUE,Overexpression of <ENT1>TIPE2</ENT1> significantly inhibited the growth of lung cancer cell H446 in vitro and even suppressed <ENT2>tumor</ENT2> formation in vivo.,,,,T,,,,,c,,,,,1.0,,
25946186,3021,79626,596,Negative_Correlation,TRUE,"In <ENT1>TIPE2</ENT1> over-expression cells, caspase-3, caspase-9, and Bax were significantly up-regulated while <ENT2>Bcl-2</ENT2> was down-regulated.",,,,T,,,,,c,,,,,0.0,,
25946186,3021,79626,596,Negative_Correlation,TRUE,"Taken together, <ENT1>TIPE2</ENT1> promoted lung cancer cell apoptosis through affecting apoptosis-related molecules caspase-3, caspase-9, <ENT2>Bcl-2</ENT2> and Bax, possibly via regulating P38 and Akt pathways, indicating that <ENT1>TIPE2</ENT1> might be a novel marker for lung cancer diagnosis and therapy.",,,,T,,,,,w,,,,,0.0,,
25946186,3022,79626,581,Positive_Correlation,TRUE,"In <ENT1>TIPE2</ENT1> over-expression cells, caspase-3, caspase-9, and <ENT2>Bax</ENT2> were significantly up-regulated while Bcl-2 was down-regulated.",,,,T,,,,,c,,,,,1.0,,
25946186,3022,79626,581,Positive_Correlation,TRUE,"Taken together, <ENT1>TIPE2</ENT1> promoted lung cancer cell apoptosis through affecting apoptosis-related molecules caspase-3, caspase-9, Bcl-2 and <ENT2>Bax</ENT2>, possibly via regulating P38 and Akt pathways, indicating that <ENT1>TIPE2</ENT1> might be a novel marker for lung cancer diagnosis and therapy.",,,,T,,,,,w,,,,,0.5,,
25979836,3044,D001839,C541795,Association,TRUE,"<ENT2>IPA-3</ENT2>, which prevents PAK2 binding to small-GTPases partially inhibited PAK2-activation, as well as reduced CCK-induced ERK1/2 activation and amylase release induced by CCK or <ENT1>bombesin</ENT1>.",,,,T,,,,,c,,,,,0.0,,
25979836,3050,D001839,24203,Positive_Correlation,FALSE,"IPA-3, which prevents PAK2 binding to small-GTPases partially inhibited PAK2-activation, as well as reduced CCK-induced ERK1/2 activation and <ENT2>amylase</ENT2> release induced by CCK or <ENT1>bombesin</ENT1>.",,,,T,,,,,c,,,,,1.0,,
25979836,3071,D001839,29432,Positive_Correlation,TRUE,"<ENT2>PAK2</ENT2> was activated by some pancreatic growth-factors [EGF, PDGF, bFGF], by secretagogues activating phospholipase-C (PLC) [CCK, carbachol, <ENT1>bombesin</ENT1>] and by post-receptor stimulants activating PKC [TPA], but not agents only mobilizing cellular calcium or increasing cyclic AMP.",,,,T,,,,,c,,,,,1.0,,
25979836,3071,D001839,29432,Positive_Correlation,TRUE,"IPA-3, which prevents <ENT2>PAK2</ENT2> binding to small-GTPases partially inhibited <ENT2>PAK2</ENT2>-activation, as well as reduced CCK-induced ERK1/2 activation and amylase release induced by CCK or <ENT1>bombesin</ENT1>.",,,,T,,,,,w,,,,,0.5,,
25979836;25979836,3033;3031,29433;296078,D005768;D005768,Positive_Correlation;Positive_Correlation,TRUE;TRUE,"However, little is known about <ENT1>PAKs</ENT1> ability to be activated by <ENT2>gastrointestinal (GI) hormones</ENT2>/neurotransmitters/growth-factors.",,,,T,,Y,,,w,,,,,0.0,,
25979836,3033,29433,D005768,Positive_Correlation,TRUE,We used rat pancreatic acini to explore the ability of <ENT2>GI-hormones</ENT2>/neurotransmitters/growth-factors to activate <ENT1>Group-I-PAKs</ENT1> and the signaling cascades involved.,,,,T,,Y,,,w,,,,,1.0,,
25979836;25979836,3032;3030,29433;296078,D018377;D018377,Positive_Correlation;Positive_Correlation,TRUE;TRUE,"However, little is known about <ENT1>PAKs</ENT1> ability to be activated by gastrointestinal (GI) hormones/<ENT2>neurotransmitters</ENT2>/growth-factors.",,,,T,,Y,,,w,,,,,0.0,,
25979836,3032,29433,D018377,Positive_Correlation,TRUE,We used rat pancreatic acini to explore the ability of GI-hormones/<ENT2>neurotransmitters</ENT2>/growth-factors to activate <ENT1>Group-I-PAKs</ENT1> and the signaling cascades involved.,,,,T,,Y,,,w,,,,,0.0,,
25979836,3048,298947,D000077191,Negative_Correlation,FALSE,"It was partially reduced by PKC- or Src-inhibition, but not with <ENT1>PI3K</ENT1>-inhibitors (<ENT2>wortmannin</ENT2>, LY294002) or thapsigargin.",,,,T,,,,,c,,,,,0.0,,
25979836,3047,298947,C085911,Negative_Correlation,FALSE,"It was partially reduced by PKC- or Src-inhibition, but not with <ENT1>PI3K</ENT1>-inhibitors (wortmannin, <ENT2>LY294002</ENT2>) or thapsigargin.",,,,T,,,,,c,,,,,0.0,,
25979836,3074,D002217,29432,Positive_Correlation,TRUE,"<ENT2>PAK2</ENT2> was activated by some pancreatic growth-factors [EGF, PDGF, bFGF], by secretagogues activating phospholipase-C (PLC) [CCK, <ENT1>carbachol</ENT1>, bombesin] and by post-receptor stimulants activating PKC [TPA], but not agents only mobilizing cellular calcium or increasing cyclic AMP.",,,,T,,,,,c,,,,,1.0,,
25979836,3051,83805,25298,Association,TRUE,"<ENT2>CCK</ENT2> and other GI-hormones/neurotransmitters/growth-factors activate PAK2 via small GTPases (CDC42/Rac1), PKC and <ENT1>SFK</ENT1> but not cytosolic calcium or PI3K.",,,,T,,,,,c,,,,,1.0,,
25979836,3078,83805,D005768,Association,TRUE,"CCK and other <ENT2>GI-hormones</ENT2>/neurotransmitters/growth-factors activate PAK2 via small GTPases (CDC42/Rac1), PKC and <ENT1>SFK</ENT1> but not cytosolic calcium or PI3K.",,,,T,,,,,c,,,,,0.0,,
25979836,3058,83805,D018377,Association,TRUE,"CCK and other GI-hormones/<ENT2>neurotransmitters</ENT2>/growth-factors activate PAK2 via small GTPases (CDC42/Rac1), PKC and <ENT1>SFK</ENT1> but not cytosolic calcium or PI3K.",,,,T,,,,,c,,,,,0.0,,
25979836,3065,83805,29432,Association,TRUE,"CCK and other GI-hormones/neurotransmitters/growth-factors activate <ENT2>PAK2</ENT2> via small GTPases (CDC42/Rac1), PKC and <ENT1>SFK</ENT1> but not cytosolic calcium or PI3K.",,,,T,,,,,c,,,,,1.0,,
25979836,3045,C541795,25298,Negative_Correlation,TRUE,"<ENT1>IPA-3</ENT1>, which prevents PAK2 binding to small-GTPases partially inhibited PAK2-activation, as well as reduced <ENT2>CCK</ENT2>-induced ERK1/2 activation and amylase release induced by <ENT2>CCK</ENT2> or bombesin.",,,,T,,,,,c,,,,,1.0,,
25979836;25979836,3043;3042,C541795;C541795,363875;64465,Association;Association,TRUE;TRUE,"<ENT1>IPA-3</ENT1>, which prevents PAK2 binding to <ENT2>small-GTPases</ENT2> partially inhibited PAK2-activation, as well as reduced CCK-induced ERK1/2 activation and amylase release induced by CCK or bombesin.",,,,T,,,,,c,,,,,0.0,,
25979836,3039,C541795,24203,Negative_Correlation,TRUE,"<ENT1>IPA-3</ENT1>, which prevents PAK2 binding to small-GTPases partially inhibited PAK2-activation, as well as reduced CCK-induced ERK1/2 activation and <ENT2>amylase</ENT2> release induced by CCK or bombesin.",,,,T,,,,,c,,,,,1.0,,
25979836,3046,C541795,29432,Negative_Correlation,TRUE,"<ENT1>IPA-3</ENT1>, which prevents <ENT2>PAK2</ENT2> binding to small-GTPases partially inhibited <ENT2>PAK2</ENT2>-activation, as well as reduced CCK-induced ERK1/2 activation and amylase release induced by CCK or bombesin.",,,,T,,,,,c,,,,,0.5,,
25979836,3040,C541795,50689,Negative_Correlation,TRUE,"<ENT1>IPA-3</ENT1>, which prevents PAK2 binding to small-GTPases partially inhibited PAK2-activation, as well as reduced CCK-induced <ENT2>ERK1/2</ENT2> activation and amylase release induced by CCK or bombesin.",,,,T,,,,,c,,,,,0.0,,
25979836,3064,D010182,29432,Association,TRUE,These results show that <ENT2>PAK2</ENT2> is important in signaling cascades activated by numerous pancreatic stimuli which mediate their various physiological/pathophysiological responses and thus could be a promising target for the development of therapies in some <ENT1>pancreatic disorders</ENT1> such as pancreatitis.,,,,T,,,,,c,,,,,1.0,,
25979836,3063,D010195,29432,Association,TRUE,These results show that <ENT2>PAK2</ENT2> is important in signaling cascades activated by numerous pancreatic stimuli which mediate their various physiological/pathophysiological responses and thus could be a promising target for the development of therapies in some pancreatic disorders such as <ENT1>pancreatitis</ENT1>.,,,,T,,,,,c,,,,,1.0,,
25979836,3077,54250,29432,Positive_Correlation,TRUE,"<ENT2>PAK2</ENT2> was activated by some <ENT1>pancreatic growth-factors</ENT1> [EGF, PDGF, <ENT1>bFGF</ENT1>], by secretagogues activating phospholipase-C (PLC) [CCK, carbachol, bombesin] and by post-receptor stimulants activating PKC [TPA], but not agents only mobilizing cellular calcium or increasing cyclic AMP.",,,,T,,,,,c,,,,,1.0,,
25979836,3049,25298,24889,Association,FALSE,<ENT1>CCK</ENT1>-activation of PAK2 required both high- and low-affinity-<ENT2>CCK1-receptor</ENT2>-state activation.,,,,T,,,,,c,,,,,1.0,,
25979836,3057,25298,24655,Association,TRUE,"PAK2 was activated by some pancreatic growth-factors [EGF, PDGF, bFGF], by secretagogues activating <ENT2>phospholipase-C</ENT2> (<ENT2>PLC</ENT2>) [<ENT1>CCK</ENT1>, carbachol, bombesin] and by post-receptor stimulants activating PKC [TPA], but not agents only mobilizing cellular calcium or increasing cyclic AMP.",,,,T,,,,,w,,,,,0.0,TRUE,
25979836,3057,25298,24655,Association,TRUE,"<ENT1>CCK</ENT1>-activation of PAK2 showed several novel features being dependent on both receptor-activation states, having <ENT2>PLC</ENT2>- and PKC-dependent/independent components and small-GTPase-dependent/independent components.",,,,T,,,,,c,,,,,0.0,,
25979836,3056,25298,24681,Association,TRUE,"PAK2 was activated by some pancreatic growth-factors [EGF, PDGF, bFGF], by secretagogues activating phospholipase-C (PLC) [<ENT1>CCK</ENT1>, carbachol, bombesin] and by post-receptor stimulants activating <ENT2>PKC</ENT2> [TPA], but not agents only mobilizing cellular calcium or increasing cyclic AMP.",,,,T,,,,,c,,,,,1.0,,
25979836,3056,25298,24681,Association,TRUE,"<ENT1>CCK</ENT1> and other GI-hormones/neurotransmitters/growth-factors activate PAK2 via small GTPases (CDC42/Rac1), <ENT2>PKC</ENT2> and SFK but not cytosolic calcium or PI3K.",,,,T,,,,,c,,,,,0.0,,
25979836,3056,25298,24681,Association,TRUE,"<ENT1>CCK</ENT1>-activation of PAK2 showed several novel features being dependent on both receptor-activation states, having PLC- and <ENT2>PKC</ENT2>-dependent/independent components and small-GTPase-dependent/independent components.",,,,T,,,,,c,,,,,0.0,,
25979836;25979836,3055;3054,25298;25298,363875;64465,Association;Association,TRUE;TRUE,"IPA-3, which prevents PAK2 binding to <ENT2>small-GTPases</ENT2> partially inhibited PAK2-activation, as well as reduced <ENT1>CCK</ENT1>-induced ERK1/2 activation and amylase release induced by <ENT1>CCK</ENT1> or bombesin.",,,,T,,,,,c,,,,,0.0,,
25979836,3055,25298,363875,Association,TRUE,"<ENT1>CCK</ENT1> and other GI-hormones/neurotransmitters/growth-factors activate PAK2 via <ENT2>small GTPases</ENT2> (CDC42/<ENT2>Rac1</ENT2>), PKC and SFK but not cytosolic calcium or PI3K.",,,,T,,,,,c,,,,,1.0,,
25979836;25979836,3055;3054,25298;25298,363875;64465,Association;Association,TRUE;TRUE,"<ENT1>CCK</ENT1>-activation of PAK2 showed several novel features being dependent on both receptor-activation states, having PLC- and PKC-dependent/independent components and <ENT2>small-GTPase</ENT2>-dependent/independent components.",,,,T,,,,,c,,,,,1.0,,
25979836,3054,25298,64465,Association,TRUE,"<ENT1>CCK</ENT1> and other GI-hormones/neurotransmitters/growth-factors activate PAK2 via <ENT2>small GTPases</ENT2> (<ENT2>CDC42</ENT2>/Rac1), PKC and SFK but not cytosolic calcium or PI3K.",,,,T,,,,,c,,,,,1.0,,
25979836,3038,25298,24203,Positive_Correlation,FALSE,"IPA-3, which prevents PAK2 binding to small-GTPases partially inhibited PAK2-activation, as well as reduced <ENT1>CCK</ENT1>-induced ERK1/2 activation and <ENT2>amylase</ENT2> release induced by <ENT1>CCK</ENT1> or bombesin.",,,,T,,,,,w,,,,,1.0,,
25979836,3075,25298,29432,Positive_Correlation,TRUE,"<ENT2>PAK2</ENT2> was activated by some pancreatic growth-factors [EGF, PDGF, bFGF], by secretagogues activating phospholipase-C (PLC) [<ENT1>CCK</ENT1>, carbachol, bombesin] and by post-receptor stimulants activating PKC [TPA], but not agents only mobilizing cellular calcium or increasing cyclic AMP.",,,,T,,,,,c,,,,,1.0,,
25979836,3075,25298,29432,Positive_Correlation,TRUE,<ENT1>CCK</ENT1>-activation of <ENT2>PAK2</ENT2> required both high- and low-affinity-CCK1-receptor-state activation.,,,,T,,,,,c,,,,,1.0,,
25979836,3075,25298,29432,Positive_Correlation,TRUE,"IPA-3, which prevents <ENT2>PAK2</ENT2> binding to small-GTPases partially inhibited <ENT2>PAK2</ENT2>-activation, as well as reduced <ENT1>CCK</ENT1>-induced ERK1/2 activation and amylase release induced by <ENT1>CCK</ENT1> or bombesin.",,,,T,,,,,c,,,,,0.5,,
25979836,3075,25298,29432,Positive_Correlation,TRUE,"<ENT1>CCK</ENT1> and other GI-hormones/neurotransmitters/growth-factors activate <ENT2>PAK2</ENT2> via small GTPases (CDC42/Rac1), PKC and SFK but not cytosolic calcium or PI3K.",,,,T,,,,,c,,,,,0.0,,
25979836,3075,25298,29432,Positive_Correlation,TRUE,"<ENT1>CCK</ENT1>-activation of <ENT2>PAK2</ENT2> showed several novel features being dependent on both receptor-activation states, having PLC- and PKC-dependent/independent components and small-GTPase-dependent/independent components.",,,,T,,,,,c,,,,,0.0,,
25979836,3052,25298,50689,Positive_Correlation,FALSE,"IPA-3, which prevents PAK2 binding to small-GTPases partially inhibited PAK2-activation, as well as reduced <ENT1>CCK</ENT1>-induced <ENT2>ERK1/2</ENT2> activation and amylase release induced by <ENT1>CCK</ENT1> or bombesin.",,,,T,,,,,c,,,,,1.0,,
25979836,3081,D005768,24681,Association,TRUE,"CCK and other <ENT1>GI-hormones</ENT1>/neurotransmitters/growth-factors activate PAK2 via small GTPases (CDC42/Rac1), <ENT2>PKC</ENT2> and SFK but not cytosolic calcium or PI3K.",,,,T,,,,,c,,,,,0.0,,
25979836,3080,D005768,363875,Association,TRUE,"CCK and other <ENT1>GI-hormones</ENT1>/neurotransmitters/growth-factors activate PAK2 via <ENT2>small GTPases</ENT2> (CDC42/<ENT2>Rac1</ENT2>), PKC and SFK but not cytosolic calcium or PI3K.",,,,T,,,,,c,,,,,0.0,,
25979836,3079,D005768,64465,Association,TRUE,"CCK and other <ENT1>GI-hormones</ENT1>/neurotransmitters/growth-factors activate PAK2 via <ENT2>small GTPases</ENT2> (<ENT2>CDC42</ENT2>/Rac1), PKC and SFK but not cytosolic calcium or PI3K.",,,,T,,,,,c,,,,,0.0,,
25979836,3082,D005768,29432,Positive_Correlation,TRUE,<ENT1>Gastrointestinal hormones</ENT1>/neurotransmitters and growth factors can activate <ENT2>P21 activated kinase 2</ENT2> in pancreatic acinar cells by novel mechanisms.,,,,T,,,,,c,,,,,0.0,,
25979836,3082,D005768,29432,Positive_Correlation,TRUE,"However, little is known about <ENT2>PAKs</ENT2> ability to be activated by <ENT1>gastrointestinal (GI) hormones</ENT1>/neurotransmitters/growth-factors.",,,,T,,Y,,,c,,,,,1.0,,
25979836,3082,D005768,29432,Positive_Correlation,TRUE,We used rat pancreatic acini to explore the ability of <ENT1>GI-hormones</ENT1>/neurotransmitters/growth-factors to activate <ENT2>Group-I-PAKs</ENT2> and the signaling cascades involved.,,,,T,,Y,,,c,,,,,0.0,,
25979836,3082,D005768,29432,Positive_Correlation,TRUE,"CCK and other <ENT1>GI-hormones</ENT1>/neurotransmitters/growth-factors activate <ENT2>PAK2</ENT2> via small GTPases (CDC42/Rac1), PKC and SFK but not cytosolic calcium or PI3K.",,,,T,,,,,c,,,,,1.0,,
25979836,3068,24889,29432,Association,TRUE,CCK-activation of <ENT2>PAK2</ENT2> required both high- and low-affinity-<ENT1>CCK1-receptor</ENT1>-state activation.,,,,T,,,,,w,,,,,0.0,,
25979836,3076,24655,29432,Positive_Correlation,TRUE,"<ENT2>PAK2</ENT2> was activated by some pancreatic growth-factors [EGF, PDGF, bFGF], by secretagogues activating <ENT1>phospholipase-C</ENT1> (<ENT1>PLC</ENT1>) [CCK, carbachol, bombesin] and by post-receptor stimulants activating PKC [TPA], but not agents only mobilizing cellular calcium or increasing cyclic AMP.",,,,T,,,,,c,,,,,1.0,,
25979836,3076,24655,29432,Positive_Correlation,TRUE,"CCK-activation of <ENT2>PAK2</ENT2> showed several novel features being dependent on both receptor-activation states, having <ENT1>PLC</ENT1>- and PKC-dependent/independent components and small-GTPase-dependent/independent components.",,,,T,,,,,w,,,,,1.0,,
25979836,3061,24681,D018377,Association,TRUE,"CCK and other GI-hormones/<ENT2>neurotransmitters</ENT2>/growth-factors activate PAK2 via small GTPases (CDC42/Rac1), <ENT1>PKC</ENT1> and SFK but not cytosolic calcium or PI3K.",,,,T,,,,,c,,,,,0.0,,
25979836,3073,24681,29432,Positive_Correlation,TRUE,"<ENT2>PAK2</ENT2> was activated by some pancreatic growth-factors [EGF, PDGF, bFGF], by secretagogues activating phospholipase-C (PLC) [CCK, carbachol, bombesin] and by post-receptor stimulants activating <ENT1>PKC</ENT1> [TPA], but not agents only mobilizing cellular calcium or increasing cyclic AMP.",,,,T,,,,,w,,,,,1.0,,
25979836,3073,24681,29432,Positive_Correlation,TRUE,"CCK and other GI-hormones/neurotransmitters/growth-factors activate <ENT2>PAK2</ENT2> via small GTPases (CDC42/Rac1), <ENT1>PKC</ENT1> and SFK but not cytosolic calcium or PI3K.",,,,T,,,,,c,,,,,1.0,,
25979836,3073,24681,29432,Positive_Correlation,TRUE,"CCK-activation of <ENT2>PAK2</ENT2> showed several novel features being dependent on both receptor-activation states, having PLC- and <ENT1>PKC</ENT1>-dependent/independent components and small-GTPase-dependent/independent components.",,,,T,,,,,w,,,,,1.0,,
25979836,3060,D018377,363875,Association,TRUE,"CCK and other GI-hormones/<ENT1>neurotransmitters</ENT1>/growth-factors activate PAK2 via <ENT2>small GTPases</ENT2> (CDC42/<ENT2>Rac1</ENT2>), PKC and SFK but not cytosolic calcium or PI3K.",,,,T,,,,,c,,,,,0.0,,
25979836,3059,D018377,64465,Association,TRUE,"CCK and other GI-hormones/<ENT1>neurotransmitters</ENT1>/growth-factors activate PAK2 via <ENT2>small GTPases</ENT2> (<ENT2>CDC42</ENT2>/Rac1), PKC and SFK but not cytosolic calcium or PI3K.",,,,T,,,,,c,,,,,0.0,,
25979836,3062,D018377,29432,Positive_Correlation,TRUE,Gastrointestinal hormones/<ENT1>neurotransmitters</ENT1> and growth factors can activate <ENT2>P21 activated kinase 2</ENT2> in pancreatic acinar cells by novel mechanisms.,,,,T,,,,,c,,,,,1.0,,
25979836,3062,D018377,29432,Positive_Correlation,TRUE,"However, little is known about <ENT2>PAKs</ENT2> ability to be activated by gastrointestinal (GI) hormones/<ENT1>neurotransmitters</ENT1>/growth-factors.",,,,T,,Y,,,c,,,,,1.0,,
25979836,3062,D018377,29432,Positive_Correlation,TRUE,We used rat pancreatic acini to explore the ability of GI-hormones/<ENT1>neurotransmitters</ENT1>/growth-factors to activate <ENT2>Group-I-PAKs</ENT2> and the signaling cascades involved.,,,,T,,Y,,,c,,,,,1.0,,
25979836,3062,D018377,29432,Positive_Correlation,TRUE,"CCK and other GI-hormones/<ENT1>neurotransmitters</ENT1>/growth-factors activate <ENT2>PAK2</ENT2> via small GTPases (CDC42/Rac1), PKC and SFK but not cytosolic calcium or PI3K.",,,,T,,,,,c,,,,,1.0,,
25979836;25979836,3067;3066,363875;64465,29432;29432,Bind;Bind,TRUE;TRUE,"IPA-3, which prevents <ENT2>PAK2</ENT2> binding to <ENT1>small-GTPases</ENT1> partially inhibited <ENT2>PAK2</ENT2>-activation, as well as reduced CCK-induced ERK1/2 activation and amylase release induced by CCK or bombesin.",,,,T,,,,,c,,,,,0.5,,
25979836,3067,363875,29432,Bind,TRUE,"CCK and other GI-hormones/neurotransmitters/growth-factors activate <ENT2>PAK2</ENT2> via <ENT1>small GTPases</ENT1> (CDC42/<ENT1>Rac1</ENT1>), PKC and SFK but not cytosolic calcium or PI3K.",,,,T,,,,,c,,,,,0.0,,
25979836;25979836,3067;3066,363875;64465,29432;29432,Bind;Bind,TRUE;TRUE,"CCK-activation of <ENT2>PAK2</ENT2> showed several novel features being dependent on both receptor-activation states, having PLC- and PKC-dependent/independent components and <ENT1>small-GTPase</ENT1>-dependent/independent components.",,,,T,,,,,c,,,,,0.0,,
25979836,3072,D013755,29432,Positive_Correlation,TRUE,"<ENT2>PAK2</ENT2> was activated by some pancreatic growth-factors [EGF, PDGF, bFGF], by secretagogues activating phospholipase-C (PLC) [CCK, carbachol, bombesin] and by post-receptor stimulants activating PKC [<ENT1>TPA</ENT1>], but not agents only mobilizing cellular calcium or increasing cyclic AMP.",,,,T,,,,,w,,,,,1.0,,
25979836,3069,25266,29432,Positive_Correlation,TRUE,"<ENT2>PAK2</ENT2> was activated by some <ENT1>pancreatic growth-factors</ENT1> [EGF, <ENT1>PDGF</ENT1>, bFGF], by secretagogues activating phospholipase-C (PLC) [CCK, carbachol, bombesin] and by post-receptor stimulants activating PKC [TPA], but not agents only mobilizing cellular calcium or increasing cyclic AMP.",,,,T,,,,,c,,,,,0.5,,
25979836,3066,64465,29432,Bind,TRUE,"CCK and other GI-hormones/neurotransmitters/growth-factors activate <ENT2>PAK2</ENT2> via <ENT1>small GTPases</ENT1> (<ENT1>CDC42</ENT1>/Rac1), PKC and SFK but not cytosolic calcium or PI3K.",,,,T,,,,,w,,,,,0.0,,
25979836,3070,29432,25313,Positive_Correlation,TRUE,"<ENT1>PAK2</ENT1> was activated by some <ENT2>pancreatic growth-factors</ENT2> [<ENT2>EGF</ENT2>, PDGF, bFGF], by secretagogues activating phospholipase-C (PLC) [CCK, carbachol, bombesin] and by post-receptor stimulants activating PKC [TPA], but not agents only mobilizing cellular calcium or increasing cyclic AMP.",,,,T,,,,,c,,,,,1.0,,
26102294,3084,7157,5460,Positive_Correlation,FALSE,"Previously, we showed that following etoposide (ETO) treatment embryonal carcinoma PA-1 cells undergo a <ENT1>p53</ENT1>-dependent upregulation of <ENT2>OCT4A</ENT2> and p21Cip1 (governing self-renewal and regulating cell cycle inhibition and senescence, respectively).",,,,T,,,,,c,,,,,1.0,,
26102294,3085,7157,D018236,Association,FALSE,"Previously, we showed that following etoposide (ETO) treatment <ENT2>embryonal carcinoma</ENT2> PA-1 cells undergo a <ENT1>p53</ENT1>-dependent upregulation of OCT4A and p21Cip1 (governing self-renewal and regulating cell cycle inhibition and senescence, respectively).",,,,T,,,,,c,,,,,0.0,,
26102294,3083,7157,1026,Positive_Correlation,FALSE,"Previously, we showed that following etoposide (ETO) treatment embryonal carcinoma PA-1 cells undergo a <ENT1>p53</ENT1>-dependent upregulation of OCT4A and <ENT2>p21Cip1</ENT2> (governing self-renewal and regulating cell cycle inhibition and senescence, respectively).",,,,T,,,,,c,,,,,0.0,,
26102294,3089,7157,D005047,Association,FALSE,"Previously, we showed that following <ENT2>etoposide</ENT2> (<ENT2>ETO</ENT2>) treatment embryonal carcinoma PA-1 cells undergo a <ENT1>p53</ENT1>-dependent upregulation of OCT4A and p21Cip1 (governing self-renewal and regulating cell cycle inhibition and senescence, respectively).",,,,T,,,,,c,,,,,0.0,,
26102294,3095,5562,5460,Positive_Correlation,TRUE,"Instead, ETO-induced <ENT2>OCT4A</ENT2> was concomitant with activation of <ENT1>AMPK</ENT1>, a key component of metabolic stress and autophagy regulation.",,,,T,,,,,c,,,,,1.0,,
26102294,3095,5562,5460,Positive_Correlation,TRUE,"Together, these findings imply that <ENT2>OCT4A</ENT2> induction following DNA damage in PA-1 cells, performs a cell stress, rather than self-renewal, function by moderating the expression of p21Cip1, which alongside <ENT1>AMPK</ENT1> helps to then regulate autophagy.",,,,T,,,,,w,,,,,0.0,,
26102294,3094,5562,1026,Association,TRUE,"Together, these findings imply that OCT4A induction following DNA damage in PA-1 cells, performs a cell stress, rather than self-renewal, function by moderating the expression of <ENT2>p21Cip1</ENT2>, which alongside <ENT1>AMPK</ENT1> helps to then regulate autophagy.",,,,T,,,,,c,,,,,0.0,,
26102294,3091,5562,D005047,Positive_Correlation,TRUE,"Instead, <ENT2>ETO</ENT2>-induced OCT4A was concomitant with activation of <ENT1>AMPK</ENT1>, a key component of metabolic stress and autophagy regulation.",,,,T,,,,,c,,,,,1.0,,
26102294,3087,5460,D018236,Association,FALSE,Role of stress-activated <ENT1>OCT4A</ENT1> in the cell fate decisions of <ENT2>embryonal carcinoma</ENT2> cells treated with etoposide.,,,,T,,T,,,c,,,,,0.0,,
26102294,3087,5460,D018236,Association,FALSE,"Previously, we showed that following etoposide (ETO) treatment <ENT2>embryonal carcinoma</ENT2> PA-1 cells undergo a p53-dependent upregulation of <ENT1>OCT4A</ENT1> and p21Cip1 (governing self-renewal and regulating cell cycle inhibition and senescence, respectively).",,,,T,,,,,c,,,,,1.0,,
26102294,3096,5460,1026,Positive_Correlation,TRUE,"Previously, we showed that following etoposide (ETO) treatment embryonal carcinoma PA-1 cells undergo a p53-dependent upregulation of <ENT1>OCT4A</ENT1> and <ENT2>p21Cip1</ENT2> (governing self-renewal and regulating cell cycle inhibition and senescence, respectively).",,,,T,,,,,c,,,,,1.0,,
26102294,3096,5460,1026,Positive_Correlation,TRUE,PA-1 cells treated with ETO display highly heterogeneous increases in <ENT1>OCT4A</ENT1> and <ENT2>p21Cip1</ENT2> indicative of dis-adaptation catastrophe.,,,,T,,,,,c,,,,,1.0,,
26102294,3096,5460,1026,Positive_Correlation,TRUE,"Silencing <ENT1>OCT4A</ENT1> suppresses <ENT2>p21Cip1</ENT2>, changes cell cycle regulation and subsequently suppresses terminal senescence; <ENT2>p21Cip1</ENT2>-silencing did not affect <ENT1>OCT4A</ENT1> expression or cellular phenotype.",,,,T,,,,,c,,,,,0.0,,
26102294,3096,5460,1026,Positive_Correlation,TRUE,"Together, these findings imply that <ENT1>OCT4A</ENT1> induction following DNA damage in PA-1 cells, performs a cell stress, rather than self-renewal, function by moderating the expression of <ENT2>p21Cip1</ENT2>, which alongside AMPK helps to then regulate autophagy.",,,,T,,,,,w,,,,,0.0,,
26102294,3093,5460,D005047,Positive_Correlation,TRUE,Role of stress-activated <ENT1>OCT4A</ENT1> in the cell fate decisions of embryonal carcinoma cells treated with <ENT2>etoposide</ENT2>.,,,,T,,,,,c,,,,,1.0,,
26102294,3093,5460,D005047,Positive_Correlation,TRUE,"Previously, we showed that following <ENT2>etoposide</ENT2> (<ENT2>ETO</ENT2>) treatment embryonal carcinoma PA-1 cells undergo a p53-dependent upregulation of <ENT1>OCT4A</ENT1> and p21Cip1 (governing self-renewal and regulating cell cycle inhibition and senescence, respectively).",,,,T,,,,,w,,,,,0.0,TRUE,
26102294,3093,5460,D005047,Positive_Correlation,TRUE,PA-1 cells treated with <ENT2>ETO</ENT2> display highly heterogeneous increases in <ENT1>OCT4A</ENT1> and p21Cip1 indicative of dis-adaptation catastrophe.,,,,T,,,,,c,,,,,1.0,,
26102294,3093,5460,D005047,Positive_Correlation,TRUE,SOX2 and NANOG expression did not change following <ENT2>ETO</ENT2> treatment suggesting a dissociation of <ENT1>OCT4A</ENT1> from its pluripotency function.,,,,T,,,,,c,,,,,1.0,,
26102294,3093,5460,D005047,Positive_Correlation,TRUE,"Instead, <ENT2>ETO</ENT2>-induced <ENT1>OCT4A</ENT1> was concomitant with activation of AMPK, a key component of metabolic stress and autophagy regulation.",,,,T,,,,,c,,,,,1.0,,
26102294,3086,D018236,1026,Association,FALSE,"Previously, we showed that following etoposide (ETO) treatment <ENT1>embryonal carcinoma</ENT1> PA-1 cells undergo a p53-dependent upregulation of OCT4A and <ENT2>p21Cip1</ENT2> (governing self-renewal and regulating cell cycle inhibition and senescence, respectively).",,,,T,Y,,,,c,,,,,0.0,,
26102294,3090,D018236,D005047,Negative_Correlation,FALSE,Role of stress-activated OCT4A in the cell fate decisions of <ENT1>embryonal carcinoma</ENT1> cells treated with <ENT2>etoposide</ENT2>.,,,,T,,,,,w,,,,,1.0,,
26102294,3090,D018236,D005047,Negative_Correlation,FALSE,"Previously, we showed that following <ENT2>etoposide</ENT2> (<ENT2>ETO</ENT2>) treatment <ENT1>embryonal carcinoma</ENT1> PA-1 cells undergo a p53-dependent upregulation of OCT4A and p21Cip1 (governing self-renewal and regulating cell cycle inhibition and senescence, respectively).",,,,T,,,,,w,,,,,0.5,,
26102294,3088,1029,D005047,Association,TRUE,"<ENT1>p16ink4a</ENT1>, the inducer of terminal senescence, underwent autophagic sequestration in the cytoplasm of <ENT2>ETO</ENT2>-treated cells, allowing alternative cell fates.",,,,T,,,,,c,,,,,1.0,,
26102294,3092,1026,D005047,Positive_Correlation,FALSE,"Previously, we showed that following <ENT2>etoposide</ENT2> (<ENT2>ETO</ENT2>) treatment embryonal carcinoma PA-1 cells undergo a p53-dependent upregulation of OCT4A and <ENT1>p21Cip1</ENT1> (governing self-renewal and regulating cell cycle inhibition and senescence, respectively).",,,,T,,,,,w,,,,,0.5,TRUE,
26102294,3092,1026,D005047,Positive_Correlation,FALSE,PA-1 cells treated with <ENT2>ETO</ENT2> display highly heterogeneous increases in OCT4A and <ENT1>p21Cip1</ENT1> indicative of dis-adaptation catastrophe.,,,,T,,,,,c,,,,,1.0,,
26115410,3097,D001152,D009369,Positive_Correlation,TRUE,"There is considerable interest in identifying the molecular mechanisms that relate early-life <ENT1>iAs</ENT1> exposure to the development of these latent diseases, particularly in relationship to <ENT2>cancer</ENT2>.",,,,T,,,,,w,,,,,1.0,,
26115410,3097,D001152,D009369,Positive_Correlation,TRUE,OBJECTIVES: This work summarizes research on the molecular mechanisms that underlie the increased risk of <ENT2>cancer</ENT2> development in adulthood that is associated with early-life <ENT1>iAs</ENT1> exposure.,,,,T,,,,,c,,,,,1.0,,
26115410,3097,D001152,D009369,Positive_Correlation,TRUE,"DISCUSSION: Epigenetic reprogramming that imparts functional changes in gene expression, the development of <ENT2>cancer</ENT2> stem cells, and immunomodulation are plausible underlying mechanisms by which early-life <ENT1>iAs</ENT1> exposure elicits latent <ENT2>carcinogenic</ENT2> effects.",,,,T,,,,,c,,,,,1.0,,
26115410,3097,D001152,D009369,Positive_Correlation,TRUE,CONCLUSIONS: Evidence is mounting that relates early-life <ENT1>iAs</ENT1> exposure and <ENT2>cancer</ENT2> development later in life.,,,,T,,,,,c,,,,,0.0,,
26270232,3104,6352,D006528,Positive_Correlation,TRUE,Serum levels of <ENT1>chemokines</ENT1> CCL4 and <ENT1>CCL5</ENT1> in cirrhotic patients indicate the presence of <ENT2>hepatocellular carcinoma</ENT2>.,,,,T,,,,,w,,,,,0.0,,
26270232,3104,6352,D006528,Positive_Correlation,TRUE,"RESULTS: Patients with <ENT2>HCC</ENT2> had higher serum TPO and <ENT1>chemokines</ENT1> (P   <0.001 for TPO, CCL4, <ENT1>CCL5</ENT1> and CXCL5) and lower CCL2 (P=0.008) levels than cirrhotic patients without <ENT2>HCC</ENT2>.",,,,T,,,,,c,,,,,0.25,,
26270232,3104,6352,D006528,Positive_Correlation,TRUE,Multivariate forward stepwise regression analysis for significant parameters showed that among the studied parameters CCL4 and <ENT1>CCL5</ENT1> (P=0.001) are diagnostic markers of <ENT2>HCC</ENT2>.,,,,T,,,,,c,,,,,0.0,,
26270232,3104,6352,D006528,Positive_Correlation,TRUE,CONCLUSIONS: High serum levels of inflammatory <ENT1>chemokines</ENT1> such as CCL4 and <ENT1>CCL5</ENT1> in the serum of cirrhotic patients indicate the presence of <ENT2>HCC</ENT2>.,,,,T,,,,,c,,,,,0.0,,
26270232,3110,6352,D008103,Association,TRUE,Serum levels of <ENT1>chemokines</ENT1> CCL4 and <ENT1>CCL5</ENT1> in <ENT2>cirrhotic</ENT2> patients indicate the presence of hepatocellular carcinoma.,,,,T,,,,,w,,,,,0.0,TRUE,
26270232,3110,6352,D008103,Association,TRUE,"RESULTS: Patients with HCC had higher serum TPO and <ENT1>chemokines</ENT1> (P   <0.001 for TPO, CCL4, <ENT1>CCL5</ENT1> and CXCL5) and lower CCL2 (P=0.008) levels than <ENT2>cirrhotic</ENT2> patients without HCC.",,,,T,,,,,c,,,,,1.0,,
26270232;26270232;26270232;26270232,3110;3112;3109;3111,6352;6348;6374;6351,D008103;D008103;D008103;D008103,Association;Association;Association;Association,TRUE;TRUE;TRUE;TRUE,"Serum levels of TPO and <ENT1>chemokines</ENT1> were lower, whereas M30 was significantly higher in <ENT2>cirrhotic</ENT2> patients than in HCs.",,,,T,,,,,w,,,,,0.0,,
26270232,3110,6352,D008103,Association,TRUE,CONCLUSIONS: High serum levels of inflammatory <ENT1>chemokines</ENT1> such as CCL4 and <ENT1>CCL5</ENT1> in the serum of <ENT2>cirrhotic</ENT2> patients indicate the presence of HCC.,,,,T,,,,,w,,,,,0.0,TRUE,
26270232,3117,6352,D007249,Association,FALSE,"Serum concentrations of CRP, neopterin and IL-6 as markers of <ENT2>inflammation</ENT2> and thrombopoietin (TPO), GCSF, FGF basic and VEGF, HMGB1, CK-18 (M65) and CK18 fragment (M30) and a panel of <ENT1>proinflammatory chemokines</ENT1> (CCL2, CCL3, CCL4, <ENT1>CCL5</ENT1>, CXCL5 and IL-8) were measured.",,,,T,,,,,c,,,,,1.0,,
26270232,3117,6352,D007249,Association,FALSE,CONCLUSIONS: High serum levels of <ENT2>inflammatory</ENT2> <ENT1>chemokines</ENT1> such as CCL4 and <ENT1>CCL5</ENT1> in the serum of cirrhotic patients indicate the presence of HCC.,,,,T,,,,,w,,,,,0.5,TRUE,
26270232;26270232,3106;3103,6348;6374,D006528;D006528,Positive_Correlation;Positive_Correlation,TRUE;TRUE,Serum levels of <ENT1>chemokines</ENT1> CCL4 and CCL5 in cirrhotic patients indicate the presence of <ENT2>hepatocellular carcinoma</ENT2>.,,,,T,,,,,c,,,,,0.0,,
26270232,3106,6348,D006528,Positive_Correlation,TRUE,"RESULTS: Patients with <ENT2>HCC</ENT2> had higher serum TPO and <ENT1>chemokines</ENT1> (P   <0.001 for TPO, CCL4, CCL5 and CXCL5) and lower CCL2 (P=0.008) levels than cirrhotic patients without <ENT2>HCC</ENT2>.",,,,T,,,,,c,,,,,0.5,,
26270232;26270232,3106;3103,6348;6374,D006528;D006528,Positive_Correlation;Positive_Correlation,TRUE;TRUE,CONCLUSIONS: High serum levels of inflammatory <ENT1>chemokines</ENT1> such as CCL4 and CCL5 in the serum of cirrhotic patients indicate the presence of <ENT2>HCC</ENT2>.,,,,T,,,,,c,,,,,0.0,,
26270232;26270232,3112;3109,6348;6374,D008103;D008103,Association;Association,TRUE;TRUE,Serum levels of <ENT1>chemokines</ENT1> CCL4 and CCL5 in <ENT2>cirrhotic</ENT2> patients indicate the presence of hepatocellular carcinoma.,,,,T,,,,,w,,,,,0.0,,
26270232,3112,6348,D008103,Association,TRUE,"RESULTS: Patients with HCC had higher serum TPO and <ENT1>chemokines</ENT1> (P   <0.001 for TPO, CCL4, CCL5 and CXCL5) and lower CCL2 (P=0.008) levels than <ENT2>cirrhotic</ENT2> patients without HCC.",,,,T,,,,,c,,,,,1.0,,
26270232;26270232,3112;3109,6348;6374,D008103;D008103,Association;Association,TRUE;TRUE,CONCLUSIONS: High serum levels of inflammatory <ENT1>chemokines</ENT1> such as CCL4 and CCL5 in the serum of <ENT2>cirrhotic</ENT2> patients indicate the presence of HCC.,,,,T,,,,,c,,,,,1.0,,
26270232,3119,6348,D007249,Association,FALSE,"Serum concentrations of CRP, neopterin and IL-6 as markers of <ENT2>inflammation</ENT2> and thrombopoietin (TPO), GCSF, FGF basic and VEGF, HMGB1, CK-18 (M65) and CK18 fragment (M30) and a panel of <ENT1>proinflammatory chemokines</ENT1> (CCL2, <ENT1>CCL3</ENT1>, CCL4, CCL5, CXCL5 and IL-8) were measured.",,,,T,,Y,,,c,,,,,1.0,,
26270232;26270232,3119;3116,6348;6374,D007249;D007249,Association;Association,FALSE;FALSE,CONCLUSIONS: High serum levels of <ENT2>inflammatory</ENT2> <ENT1>chemokines</ENT1> such as CCL4 and CCL5 in the serum of cirrhotic patients indicate the presence of HCC.,,,,T,,,,,w,,,,,0.0,,
26270232,3103,6374,D006528,Positive_Correlation,TRUE,"RESULTS: Patients with <ENT2>HCC</ENT2> had higher serum TPO and <ENT1>chemokines</ENT1> (P   <0.001 for TPO, CCL4, CCL5 and <ENT1>CXCL5</ENT1>) and lower CCL2 (P=0.008) levels than cirrhotic patients without <ENT2>HCC</ENT2>.",,,,T,,,,,c,,,,,0.25,,
26270232,3109,6374,D008103,Association,TRUE,"RESULTS: Patients with HCC had higher serum TPO and <ENT1>chemokines</ENT1> (P   <0.001 for TPO, CCL4, CCL5 and <ENT1>CXCL5</ENT1>) and lower CCL2 (P=0.008) levels than <ENT2>cirrhotic</ENT2> patients without HCC.",,,,T,,,,,c,,,,,1.0,,
26270232,3116,6374,D007249,Association,FALSE,"Serum concentrations of CRP, neopterin and IL-6 as markers of <ENT2>inflammation</ENT2> and thrombopoietin (TPO), GCSF, FGF basic and VEGF, HMGB1, CK-18 (M65) and CK18 fragment (M30) and a panel of <ENT1>proinflammatory chemokines</ENT1> (CCL2, CCL3, CCL4, CCL5, <ENT1>CXCL5</ENT1> and IL-8) were measured.",,,,T,,Y,,,c,,,,,1.0,,
26270232,3105,D006528,6351,Positive_Correlation,TRUE,Serum levels of <ENT2>chemokines</ENT2> <ENT2>CCL4</ENT2> and CCL5 in cirrhotic patients indicate the presence of <ENT1>hepatocellular carcinoma</ENT1>.,,,,T,,,,,c,,,,,0.0,,
26270232,3105,D006528,6351,Positive_Correlation,TRUE,"RESULTS: Patients with <ENT1>HCC</ENT1> had higher serum TPO and <ENT2>chemokines</ENT2> (P   <0.001 for TPO, <ENT2>CCL4</ENT2>, CCL5 and CXCL5) and lower CCL2 (P=0.008) levels than cirrhotic patients without <ENT1>HCC</ENT1>.",,,,T,,,,,c,,,,,0.5,,
26270232,3105,D006528,6351,Positive_Correlation,TRUE,Multivariate forward stepwise regression analysis for significant parameters showed that among the studied parameters <ENT2>CCL4</ENT2> and CCL5 (P=0.001) are diagnostic markers of <ENT1>HCC</ENT1>.,,,,T,,,,,c,,,,,0.0,,
26270232,3105,D006528,6351,Positive_Correlation,TRUE,CONCLUSIONS: High serum levels of inflammatory <ENT2>chemokines</ENT2> such as <ENT2>CCL4</ENT2> and CCL5 in the serum of cirrhotic patients indicate the presence of <ENT1>HCC</ENT1>.,,,,T,,,,,c,,,,,0.0,,
26270232;26270232,3102;3107,D006528;D006528,3576;6347,Positive_Correlation;Positive_Correlation,TRUE;TRUE,Serum levels of <ENT2>chemokines</ENT2> CCL4 and CCL5 in cirrhotic patients indicate the presence of <ENT1>hepatocellular carcinoma</ENT1>.,,,,T,,,,,c,,,,,0.0,,
26270232,3102,D006528,3576,Positive_Correlation,TRUE,"RESULTS: Patients with <ENT1>HCC</ENT1> had higher serum TPO and <ENT2>chemokines</ENT2> (P   <0.001 for TPO, CCL4, CCL5 and CXCL5) and lower CCL2 (P=0.008) levels than cirrhotic patients without <ENT1>HCC</ENT1>.",,,,T,,,,,c,,,,,0.5,,
26270232;26270232,3102;3107,D006528;D006528,3576;6347,Positive_Correlation;Positive_Correlation,TRUE;TRUE,CONCLUSIONS: High serum levels of inflammatory <ENT2>chemokines</ENT2> such as CCL4 and CCL5 in the serum of cirrhotic patients indicate the presence of <ENT1>HCC</ENT1>.,,,,T,,,,,c,,,,,0.0,,
26270232,3107,D006528,6347,Positive_Correlation,TRUE,"RESULTS: Patients with <ENT1>HCC</ENT1> had higher serum TPO and <ENT2>chemokines</ENT2> (P   <0.001 for TPO, CCL4, CCL5 and CXCL5) and lower <ENT2>CCL2</ENT2> (P=0.008) levels than cirrhotic patients without <ENT1>HCC</ENT1>.",,,,T,,,,,w,,,,,0.5,TRUE,
26270232,3101,D006528,7066,Positive_Correlation,TRUE,"RESULTS: Patients with <ENT1>HCC</ENT1> had higher serum <ENT2>TPO</ENT2> and chemokines (P   <0.001 for <ENT2>TPO</ENT2>, CCL4, CCL5 and CXCL5) and lower CCL2 (P=0.008) levels than cirrhotic patients without <ENT1>HCC</ENT1>.",,,,T,,,,,c,,,,,0.5,,
26270232,3111,6351,D008103,Association,TRUE,Serum levels of <ENT1>chemokines</ENT1> <ENT1>CCL4</ENT1> and CCL5 in <ENT2>cirrhotic</ENT2> patients indicate the presence of hepatocellular carcinoma.,,,,T,,,,,c,,,,,1.0,,
26270232,3111,6351,D008103,Association,TRUE,"RESULTS: Patients with HCC had higher serum TPO and <ENT1>chemokines</ENT1> (P   <0.001 for TPO, <ENT1>CCL4</ENT1>, CCL5 and CXCL5) and lower CCL2 (P=0.008) levels than <ENT2>cirrhotic</ENT2> patients without HCC.",,,,T,,,,,c,,,,,1.0,,
26270232,3111,6351,D008103,Association,TRUE,CONCLUSIONS: High serum levels of inflammatory <ENT1>chemokines</ENT1> such as <ENT1>CCL4</ENT1> and CCL5 in the serum of <ENT2>cirrhotic</ENT2> patients indicate the presence of HCC.,,,,T,,,,,c,,,,,1.0,,
26270232,3118,6351,D007249,Association,FALSE,"Serum concentrations of CRP, neopterin and IL-6 as markers of <ENT2>inflammation</ENT2> and thrombopoietin (TPO), GCSF, FGF basic and VEGF, HMGB1, CK-18 (M65) and CK18 fragment (M30) and a panel of <ENT1>proinflammatory chemokines</ENT1> (CCL2, CCL3, <ENT1>CCL4</ENT1>, CCL5, CXCL5 and IL-8) were measured.",,,,T,,Y,,,c,,,,,1.0,,
26270232,3118,6351,D007249,Association,FALSE,CONCLUSIONS: High serum levels of <ENT2>inflammatory</ENT2> <ENT1>chemokines</ENT1> such as <ENT1>CCL4</ENT1> and CCL5 in the serum of cirrhotic patients indicate the presence of HCC.,,,,T,,,,,w,,,,,0.5,,
26270232;26270232,3108;3113,D008103;D008103,3576;6347,Association;Association,TRUE;TRUE,Serum levels of <ENT2>chemokines</ENT2> CCL4 and CCL5 in <ENT1>cirrhotic</ENT1> patients indicate the presence of hepatocellular carcinoma.,,,,T,,,,,c,,,,,1.0,,
26270232,3108,D008103,3576,Association,TRUE,"RESULTS: Patients with HCC had higher serum TPO and <ENT2>chemokines</ENT2> (P   <0.001 for TPO, CCL4, CCL5 and CXCL5) and lower CCL2 (P=0.008) levels than <ENT1>cirrhotic</ENT1> patients without HCC.",,,,T,,,,,c,,,,,1.0,,
26270232;26270232,3108;3113,D008103;D008103,3576;6347,Association;Association,TRUE;TRUE,"Serum levels of TPO and <ENT2>chemokines</ENT2> were lower, whereas M30 was significantly higher in <ENT1>cirrhotic</ENT1> patients than in HCs.",,,,T,,,,,c,,,,,0.0,,
26270232;26270232,3108;3113,D008103;D008103,3576;6347,Association;Association,TRUE;TRUE,CONCLUSIONS: High serum levels of inflammatory <ENT2>chemokines</ENT2> such as CCL4 and CCL5 in the serum of <ENT1>cirrhotic</ENT1> patients indicate the presence of HCC.,,,,T,,,,,c,,,,,1.0,,
26270232,3113,D008103,6347,Association,TRUE,"RESULTS: Patients with HCC had higher serum TPO and <ENT2>chemokines</ENT2> (P   <0.001 for TPO, CCL4, CCL5 and CXCL5) and lower <ENT2>CCL2</ENT2> (P=0.008) levels than <ENT1>cirrhotic</ENT1> patients without HCC.",,,,T,,,,,w,,,,,0.0,,
26270232,3100,D008103,7066,Association,TRUE,"RESULTS: Patients with HCC had higher serum <ENT2>TPO</ENT2> and chemokines (P   <0.001 for <ENT2>TPO</ENT2>, CCL4, CCL5 and CXCL5) and lower CCL2 (P=0.008) levels than <ENT1>cirrhotic</ENT1> patients without HCC.",,,,T,,,,,c,,,,,1.0,,
26270232,3100,D008103,7066,Association,TRUE,"Serum levels of <ENT2>TPO</ENT2> and chemokines were lower, whereas M30 was significantly higher in <ENT1>cirrhotic</ENT1> patients than in HCs.",,,,T,,,,,c,,,,,0.0,,
26270232,3098,2147,D009369,Association,FALSE,The prognostic value of serum <ENT2>tumour</ENT2> markers alpha-fetoprotein (AFP) and <ENT1>des-gamma-carboxy prothrombin</ENT1> (<ENT1>DCP</ENT1>) is limited.,,,,T,,,,,w,,,,,0.0,,
26270232,3121,D007249,3569,Association,FALSE,"Serum concentrations of CRP, neopterin and <ENT2>IL-6</ENT2> as markers of <ENT1>inflammation</ENT1> and thrombopoietin (TPO), GCSF, FGF basic and VEGF, HMGB1, CK-18 (M65) and CK18 fragment (M30) and a panel of proinflammatory chemokines (CCL2, CCL3, CCL4, CCL5, CXCL5 and IL-8) were measured.",,,,T,,,,,c,,,,,1.0,,
26270232,3115,D007249,3576,Association,FALSE,"Serum concentrations of CRP, neopterin and IL-6 as markers of <ENT1>inflammation</ENT1> and thrombopoietin (TPO), GCSF, FGF basic and VEGF, HMGB1, CK-18 (M65) and CK18 fragment (M30) and a panel of <ENT2>proinflammatory chemokines</ENT2> (CCL2, CCL3, CCL4, CCL5, CXCL5 and <ENT2>IL-8</ENT2>) were measured.",,,,T,,Y,,,c,,,,,1.0,,
26270232;26270232,3115;3120,D007249;D007249,3576;6347,Association;Association,FALSE;FALSE,CONCLUSIONS: High serum levels of <ENT1>inflammatory</ENT1> <ENT2>chemokines</ENT2> such as CCL4 and CCL5 in the serum of cirrhotic patients indicate the presence of HCC.,,,,T,,,,,w,,,,,0.0,,
26270232,3120,D007249,6347,Association,FALSE,"Serum concentrations of CRP, neopterin and IL-6 as markers of <ENT1>inflammation</ENT1> and thrombopoietin (TPO), GCSF, FGF basic and VEGF, HMGB1, CK-18 (M65) and CK18 fragment (M30) and a panel of <ENT2>proinflammatory chemokines</ENT2> (<ENT2>CCL2</ENT2>, CCL3, CCL4, CCL5, CXCL5 and IL-8) were measured.",,,,T,,Y,,,c,,,,,1.0,,
26270232,3122,D007249,1401,Association,FALSE,"Serum concentrations of <ENT2>CRP</ENT2>, neopterin and IL-6 as markers of <ENT1>inflammation</ENT1> and thrombopoietin (TPO), GCSF, FGF basic and VEGF, HMGB1, CK-18 (M65) and CK18 fragment (M30) and a panel of proinflammatory chemokines (CCL2, CCL3, CCL4, CCL5, CXCL5 and IL-8) were measured.",,,,T,,,,,c,,,,,0.0,,
26270232,3114,D007249,D019798,Association,FALSE,"Serum concentrations of CRP, <ENT2>neopterin</ENT2> and IL-6 as markers of <ENT1>inflammation</ENT1> and thrombopoietin (TPO), GCSF, FGF basic and VEGF, HMGB1, CK-18 (M65) and CK18 fragment (M30) and a panel of proinflammatory chemokines (CCL2, CCL3, CCL4, CCL5, CXCL5 and IL-8) were measured.",,,,T,,,,,c,,,,,1.0,,
26270232,3099,D009369,174,Association,FALSE,The prognostic value of serum <ENT1>tumour</ENT1> markers <ENT2>alpha-fetoprotein</ENT2> (<ENT2>AFP</ENT2>) and des-gamma-carboxy prothrombin (DCP) is limited.,,,,T,,,,,c,,,,,1.0,,
26411452,3123,2078,7113,Association,FALSE,We integrated chromatin-immunoprecipitation-coupled sequencing and microarray expression profiling in <ENT2>TMPRSS2</ENT2>-<ENT1>ERG</ENT1> gene rearrangement positive DUCaP cells with the GWAS PCa risk SNPs catalog to identify disease susceptibility SNPs localized within functional androgen receptor-binding sites (ARBSs).,,,,T,,,,,w,,,,,1.0,,
26411452,3127,367,D000728,Association,TRUE,"Of these, rs11891426:T>G in an intron of the melanophilin gene (MLPH) was within a novel putative auxiliary <ENT1>AR</ENT1>-binding motif, which is enriched in the neighborhood of canonical <ENT2>androgen</ENT2>-responsive elements.",,,,T,Y,,,,w,,,,,0.0,,
26411452,3127,367,D000728,Association,TRUE,"These results unravel a hidden link between <ENT1>AR</ENT1> and a functional putative PCa risk SNP, whose allele alteration affects <ENT2>androgen</ENT2> regulation of its host gene MLPH.",,,,T,,,,,w,,,,,1.0,,
26411452,3130,367,79083,Bind,TRUE,Putative Prostate Cancer Risk SNP in an <ENT1>Androgen Receptor</ENT1>-Binding Site of the <ENT2>Melanophilin</ENT2> Gene Illustrates Enrichment of Risk SNPs in <ENT1>Androgen Receptor</ENT1> Target Sites.,,,,T,,,,,c,,,,,0.0,,
26411452,3130,367,79083,Bind,TRUE,"Of these, rs11891426:T>G in an intron of the <ENT2>melanophilin</ENT2> gene (<ENT2>MLPH</ENT2>) was within a novel putative auxiliary <ENT1>AR</ENT1>-binding motif, which is enriched in the neighborhood of canonical androgen-responsive elements.",,,,T,,,,,c,,,,4226,0.0,,
26411452,3130,367,79083,Bind,TRUE,The expression of <ENT2>MLPH</ENT2> in primary prostate tumors was significantly lower in those with the G compared with the T allele and correlated significantly with <ENT1>AR</ENT1> protein.,,,,T,,,,,w,,,,1795,0.0,,
26411452,3130,367,79083,Bind,TRUE,"These results unravel a hidden link between <ENT1>AR</ENT1> and a functional putative PCa risk SNP, whose allele alteration affects androgen regulation of its host gene <ENT2>MLPH</ENT2>.",,,,T,,,,,c,,,,,0.0,,
26411452,3126,367,D011471,Association,TRUE,Putative <ENT2>Prostate Cancer</ENT2> Risk SNP in an <ENT1>Androgen Receptor</ENT1>-Binding Site of the Melanophilin Gene Illustrates Enrichment of Risk SNPs in <ENT1>Androgen Receptor</ENT1> Target Sites.,,,,T,,,,,w,,,,,0.0,TRUE,
26411452,3126,367,D011471,Association,TRUE,We integrated chromatin-immunoprecipitation-coupled sequencing and microarray expression profiling in TMPRSS2-ERG gene rearrangement positive DUCaP cells with the GWAS <ENT2>PCa</ENT2> risk SNPs catalog to identify disease susceptibility SNPs localized within functional <ENT1>androgen receptor</ENT1>-binding sites (<ENT1>AR</ENT1>BSs).,,,,T,,,,,c,,,,,0.0,,
26411452,3126,367,D011471,Association,TRUE,The expression of MLPH in primary <ENT2>prostate tumors</ENT2> was significantly lower in those with the G compared with the T allele and correlated significantly with <ENT1>AR</ENT1> protein.,,,,T,,,,,c,,,,,0.0,,
26411452,3126,367,D011471,Association,TRUE,"These results unravel a hidden link between <ENT1>AR</ENT1> and a functional putative <ENT2>PCa</ENT2> risk SNP, whose allele alteration affects androgen regulation of its host gene MLPH.",,,,T,,,,,c,,,,,1.0,,
26411452,3125,rs11891426,D000728,Association,TRUE,"Of these, <ENT1>rs11891426</ENT1>:<ENT1>T>G</ENT1> in an intron of the melanophilin gene (MLPH) was within a novel putative auxiliary AR-binding motif, which is enriched in the neighborhood of canonical <ENT2>androgen</ENT2>-responsive elements.",,,,T,Y,,,,w,,,,,0.5,,
26411452,3129,D000728,79083,Association,TRUE,"Of these, rs11891426:T>G in an intron of the <ENT2>melanophilin</ENT2> gene (<ENT2>MLPH</ENT2>) was within a novel putative auxiliary AR-binding motif, which is enriched in the neighborhood of canonical <ENT1>androgen</ENT1>-responsive elements.",,,,T,,,,,w,,,,,1.0,,
26411452,3129,D000728,79083,Association,TRUE,"These results unravel a hidden link between AR and a functional putative PCa risk SNP, whose allele alteration affects <ENT1>androgen</ENT1> regulation of its host gene <ENT2>MLPH</ENT2>.",,,,T,,,,,w,,,,,1.0,,
26411452,3128,79083,D011471,Association,TRUE,Putative <ENT2>Prostate Cancer</ENT2> Risk SNP in an Androgen Receptor-Binding Site of the <ENT1>Melanophilin</ENT1> Gene Illustrates Enrichment of Risk SNPs in Androgen Receptor Target Sites.,,,,T,,T,,,w,,,,,0.0,,
26411452,3128,79083,D011471,Association,TRUE,The expression of <ENT1>MLPH</ENT1> in primary <ENT2>prostate tumors</ENT2> was significantly lower in those with the G compared with the T allele and correlated significantly with AR protein.,,,,T,,,,,c,,,,,1.0,,
26411452,3128,79083,D011471,Association,TRUE,Higher <ENT1>melanophilin</ENT1> level in prostate tissue of patients with a favorable <ENT2>PCa</ENT2> risk profile points out a tumor-suppressive effect.,,,,T,,,,,w,,,,,0.0,,
26411452,3128,79083,D011471,Association,TRUE,"These results unravel a hidden link between AR and a functional putative <ENT2>PCa</ENT2> risk SNP, whose allele alteration affects androgen regulation of its host gene <ENT1>MLPH</ENT1>.",,,,T,,,,,w,,,,,0.0,,
26449539,3141,5166,5465,Positive_Correlation,TRUE,"RESULTS: Quantitative PCR indicated that <ENT2>PPARa</ENT2> is well expressed in human liver and human liver slices and that the classical <ENT2>PPARa</ENT2> targets PLIN2, VLDLR, ANGPTL4, CPT1A and <ENT1>PDK4</ENT1> are robustly induced by <ENT2>PPARa</ENT2> activation.",,,,T,,,,,c,,,,,0.666666667,,
26449539,3142,5465,1374,Positive_Correlation,TRUE,"RESULTS: Quantitative PCR indicated that <ENT1>PPARa</ENT1> is well expressed in human liver and human liver slices and that the classical <ENT1>PPARa</ENT1> targets PLIN2, VLDLR, ANGPTL4, <ENT2>CPT1A</ENT2> and PDK4 are robustly induced by <ENT1>PPARa</ENT1> activation.",,,,T,,,,,w,,,,,0.0,,
26449539,3149,5465,25987,Positive_Correlation,TRUE,"Finally, several putative new target genes of <ENT1>PPARa</ENT1> were identified that were commonly induced by <ENT1>PPARa</ENT1> activation in the two human liver model systems, including <ENT2>TSKU</ENT2>, RHOF, CA12 and VSIG10L.",,,,T,,,,,c,,,,,0.0,,
26449539,3155,5465,3433,Negative_Correlation,TRUE,"Among the most highly repressed genes upon <ENT1>PPARa</ENT1> activation were several chemokines (e.g. CXCL9-11, CCL8, CX3CL1, CXCL6), interferon g-induced genes (e.g. IFITM1, IFIT1, <ENT2>IFIT2</ENT2>, IFIT3) and numerous other immune-related genes (e.g. TLR3, NOS2, and LCN2).",,,,T,,,,,c,,,,,0.0,,
26449539,3143,5465,51129,Positive_Correlation,TRUE,"RESULTS: Quantitative PCR indicated that <ENT1>PPARa</ENT1> is well expressed in human liver and human liver slices and that the classical <ENT1>PPARa</ENT1> targets PLIN2, VLDLR, <ENT2>ANGPTL4</ENT2>, CPT1A and PDK4 are robustly induced by <ENT1>PPARa</ENT1> activation.",,,,T,,,,,w,,,,,0.666666667,,
26449539,3131,5465,D065626,Association,TRUE,Our data underscore the major role of <ENT1>PPARa</ENT1> in regulation of hepatic lipid and xenobiotic metabolism in human liver and reveal a marked immuno-suppressive/anti-inflammatory effect of <ENT1>PPARa</ENT1> in human liver slices that may be therapeutically relevant for <ENT2>non-alcoholic fatty liver disease</ENT2>.,,,,T,,,,,c,,,,,0.0,,
26449539,3146,5465,147645,Positive_Correlation,TRUE,"Finally, several putative new target genes of <ENT1>PPARa</ENT1> were identified that were commonly induced by <ENT1>PPARa</ENT1> activation in the two human liver model systems, including TSKU, RHOF, CA12 and <ENT2>VSIG10L</ENT2>.",,,,T,,,,,c,,,,,0.0,,
26449539,3151,5465,3934,Negative_Correlation,TRUE,"Among the most highly repressed genes upon <ENT1>PPARa</ENT1> activation were several chemokines (e.g. CXCL9-11, CCL8, CX3CL1, CXCL6), interferon g-induced genes (e.g. IFITM1, IFIT1, IFIT2, IFIT3) and numerous other immune-related genes (e.g. TLR3, NOS2, and <ENT2>LCN2</ENT2>).",,,,T,,,,,c,,,,,1.0,,
26449539,3169,5465,51703,Positive_Correlation,TRUE,"Many genes induced by <ENT1>PPARa</ENT1> activation were involved in lipid metabolism (<ENT2>ACSL5</ENT2>, AGPAT9, FADS1, SLC27A4), xenobiotic metabolism (POR, ABCC2, CYP3A5) or the unfolded protein response, whereas most of the downregulated genes were involved in immune-related pathways.",,,,T,,,,,c,,,,,1.0,,
26449539,3157,5465,8519,Negative_Correlation,TRUE,"Among the most highly repressed genes upon <ENT1>PPARa</ENT1> activation were several chemokines (e.g. CXCL9-11, CCL8, CX3CL1, CXCL6), interferon g-induced genes (e.g. <ENT2>IFITM1</ENT2>, IFIT1, IFIT2, IFIT3) and numerous other immune-related genes (e.g. TLR3, NOS2, and LCN2).",,,,T,,,,,c,,,,,1.0,,
26449539,3167,5465,3992,Positive_Correlation,TRUE,"Many genes induced by <ENT1>PPARa</ENT1> activation were involved in lipid metabolism (ACSL5, AGPAT9, <ENT2>FADS1</ENT2>, SLC27A4), xenobiotic metabolism (POR, ABCC2, CYP3A5) or the unfolded protein response, whereas most of the downregulated genes were involved in immune-related pathways.",,,,T,,,,,c,,,,,1.0,,
26449539,3150,5465,4283,Negative_Correlation,TRUE,"Among the most highly repressed genes upon <ENT1>PPARa</ENT1> activation were several <ENT2>chemokines</ENT2> (e.g. <ENT2>CXCL9-11</ENT2>, CCL8, CX3CL1, CXCL6), interferon g-induced genes (e.g. IFITM1, IFIT1, IFIT2, IFIT3) and numerous other immune-related genes (e.g. TLR3, NOS2, and LCN2).",,,,T,,,,,c,,,,,0.0,,
26449539,3163,5465,1577,Positive_Correlation,TRUE,"Many genes induced by <ENT1>PPARa</ENT1> activation were involved in lipid metabolism (ACSL5, AGPAT9, FADS1, SLC27A4), xenobiotic metabolism (POR, ABCC2, <ENT2>CYP3A5</ENT2>) or the unfolded protein response, whereas most of the downregulated genes were involved in immune-related pathways.",,,,T,,,,,c,,,,,1.0,,
26449539,3170,5465,123,Positive_Correlation,TRUE,"RESULTS: Quantitative PCR indicated that <ENT1>PPARa</ENT1> is well expressed in human liver and human liver slices and that the classical <ENT1>PPARa</ENT1> targets <ENT2>PLIN2</ENT2>, VLDLR, ANGPTL4, CPT1A and PDK4 are robustly induced by <ENT1>PPARa</ENT1> activation.",,,,T,,,,,w,,,,,0.333333333,,
26449539,3145,5465,D007249,Association,TRUE,"In particular, <ENT1>PPARa</ENT1> activation markedly suppressed immunity/<ENT2>inflammation</ENT2>-related genes in human liver slices but not in primary hepatocytes.",,,,T,,,,,w,,,,,0.0,,
26449539,3145,5465,D007249,Association,TRUE,Our data underscore the major role of <ENT1>PPARa</ENT1> in regulation of hepatic lipid and xenobiotic metabolism in human liver and reveal a marked immuno-suppressive/anti-<ENT2>inflammatory</ENT2> effect of <ENT1>PPARa</ENT1> in human liver slices that may be therapeutically relevant for non-alcoholic fatty liver disease.,,,,T,,,,,c,,,,,0.0,,
26449539,3156,5465,3434,Negative_Correlation,TRUE,"Among the most highly repressed genes upon <ENT1>PPARa</ENT1> activation were several chemokines (e.g. CXCL9-11, CCL8, CX3CL1, CXCL6), interferon g-induced genes (e.g. IFITM1, <ENT2>IFIT1</ENT2>, IFIT2, IFIT3) and numerous other immune-related genes (e.g. TLR3, NOS2, and LCN2).",,,,T,,,,,c,,,,,1.0,,
26449539,3168,5465,84803,Positive_Correlation,TRUE,"Many genes induced by <ENT1>PPARa</ENT1> activation were involved in lipid metabolism (ACSL5, <ENT2>AGPAT9</ENT2>, FADS1, SLC27A4), xenobiotic metabolism (POR, ABCC2, CYP3A5) or the unfolded protein response, whereas most of the downregulated genes were involved in immune-related pathways.",,,,T,,,,,c,,,,,1.0,,
26449539,3164,5465,1244,Positive_Correlation,TRUE,"Many genes induced by <ENT1>PPARa</ENT1> activation were involved in lipid metabolism (ACSL5, AGPAT9, FADS1, SLC27A4), xenobiotic metabolism (POR, <ENT2>ABCC2</ENT2>, CYP3A5) or the unfolded protein response, whereas most of the downregulated genes were involved in immune-related pathways.",,,,T,,,,,c,,,,,1.0,,
26449539,3154,5465,3437,Negative_Correlation,TRUE,"Among the most highly repressed genes upon <ENT1>PPARa</ENT1> activation were several chemokines (e.g. CXCL9-11, CCL8, CX3CL1, CXCL6), interferon g-induced genes (e.g. IFITM1, IFIT1, IFIT2, <ENT2>IFIT3</ENT2>) and numerous other immune-related genes (e.g. TLR3, NOS2, and LCN2).",,,,T,,,,,c,,,,,1.0,,
26449539,3160,5465,6376,Negative_Correlation,TRUE,"Among the most highly repressed genes upon <ENT1>PPARa</ENT1> activation were several <ENT2>chemokines</ENT2> (e.g. CXCL9-11, CCL8, <ENT2>CX3CL1</ENT2>, CXCL6), interferon g-induced genes (e.g. IFITM1, IFIT1, IFIT2, IFIT3) and numerous other immune-related genes (e.g. TLR3, NOS2, and LCN2).",,,,T,,,,,c,,,,,1.0,,
26449539,3162,5465,D008055,Association,TRUE,"Many genes induced by <ENT1>PPARa</ENT1> activation were involved in <ENT2>lipid</ENT2> metabolism (ACSL5, AGPAT9, FADS1, SLC27A4), xenobiotic metabolism (POR, ABCC2, CYP3A5) or the unfolded protein response, whereas most of the downregulated genes were involved in immune-related pathways.",,,,T,,,,,w,,,,,0.0,,
26449539,3162,5465,D008055,Association,TRUE,Our data underscore the major role of <ENT1>PPARa</ENT1> in regulation of hepatic <ENT2>lipid</ENT2> and xenobiotic metabolism in human liver and reveal a marked immuno-suppressive/anti-inflammatory effect of <ENT1>PPARa</ENT1> in human liver slices that may be therapeutically relevant for non-alcoholic fatty liver disease.,,,,T,,,,,c,,,,,0.5,,
26449539,3144,5465,7436,Positive_Correlation,TRUE,"RESULTS: Quantitative PCR indicated that <ENT1>PPARa</ENT1> is well expressed in human liver and human liver slices and that the classical <ENT1>PPARa</ENT1> targets PLIN2, <ENT2>VLDLR</ENT2>, ANGPTL4, CPT1A and PDK4 are robustly induced by <ENT1>PPARa</ENT1> activation.",,,,T,,,,,w,,,,,0.333333333,,
26449539,3152,5465,4843,Negative_Correlation,TRUE,"Among the most highly repressed genes upon <ENT1>PPARa</ENT1> activation were several chemokines (e.g. CXCL9-11, CCL8, CX3CL1, CXCL6), interferon g-induced genes (e.g. IFITM1, IFIT1, IFIT2, IFIT3) and numerous other immune-related genes (e.g. TLR3, <ENT2>NOS2</ENT2>, and LCN2).",,,,T,,,,,c,,,,,1.0,,
26449539,3147,5465,771,Positive_Correlation,TRUE,"Finally, several putative new target genes of <ENT1>PPARa</ENT1> were identified that were commonly induced by <ENT1>PPARa</ENT1> activation in the two human liver model systems, including TSKU, RHOF, <ENT2>CA12</ENT2> and VSIG10L.",,,,T,,,,,w,,,,,0.0,,
26449539,3148,5465,54509,Positive_Correlation,TRUE,"Finally, several putative new target genes of <ENT1>PPARa</ENT1> were identified that were commonly induced by <ENT1>PPARa</ENT1> activation in the two human liver model systems, including TSKU, <ENT2>RHOF</ENT2>, CA12 and VSIG10L.",,,,T,,,,,w,,,,,0.0,,
26449539,3161,5465,6355,Negative_Correlation,TRUE,"Among the most highly repressed genes upon <ENT1>PPARa</ENT1> activation were several <ENT2>chemokines</ENT2> (e.g. CXCL9-11, <ENT2>CCL8</ENT2>, CX3CL1, CXCL6), interferon g-induced genes (e.g. IFITM1, IFIT1, IFIT2, IFIT3) and numerous other immune-related genes (e.g. TLR3, NOS2, and LCN2).",,,,T,,,,,c,,,,,0.5,,
26449539,3165,5465,5447,Positive_Correlation,TRUE,"Many genes induced by <ENT1>PPARa</ENT1> activation were involved in lipid metabolism (ACSL5, AGPAT9, FADS1, SLC27A4), xenobiotic metabolism (<ENT2>POR</ENT2>, ABCC2, CYP3A5) or the unfolded protein response, whereas most of the downregulated genes were involved in immune-related pathways.",,,,T,,,,,c,,,,,1.0,,
26449539,3166,5465,10999,Positive_Correlation,TRUE,"Many genes induced by <ENT1>PPARa</ENT1> activation were involved in lipid metabolism (ACSL5, AGPAT9, FADS1, <ENT2>SLC27A4</ENT2>), xenobiotic metabolism (POR, ABCC2, CYP3A5) or the unfolded protein response, whereas most of the downregulated genes were involved in immune-related pathways.",,,,T,,,,,c,,,,,1.0,,
26449539,3159,5465,6372,Negative_Correlation,TRUE,"Among the most highly repressed genes upon <ENT1>PPARa</ENT1> activation were several <ENT2>chemokines</ENT2> (e.g. CXCL9-11, CCL8, CX3CL1, <ENT2>CXCL6</ENT2>), interferon g-induced genes (e.g. IFITM1, IFIT1, IFIT2, IFIT3) and numerous other immune-related genes (e.g. TLR3, NOS2, and LCN2).",,,,T,,,,,c,,,,,1.0,,
26449539,3171,5465,C006253,Positive_Correlation,FALSE,METHODS: Here we set out to study the function of <ENT1>PPARa</ENT1> in human liver via analysis of whole genome gene regulation in human liver slices treated with the <ENT1>PPARa</ENT1> agonist <ENT2>Wy14643</ENT2>.,,,,T,,,,,c,,,,,0.5,,
26449539,3171,5465,C006253,Positive_Correlation,FALSE,Comparative analysis of gene regulation by <ENT2>Wy14643</ENT2> between human liver slices and primary human hepatocytes showed that down-regulation of gene expression by <ENT1>PPARa</ENT1> is much better captured by liver slices as compared to primary hepatocytes.,,,,T,,,,,c,,,,,1.0,,
26449539,3158,5465,3458,Association,FALSE,"Among the most highly repressed genes upon <ENT1>PPARa</ENT1> activation were several chemokines (e.g. CXCL9-11, CCL8, CX3CL1, CXCL6), <ENT2>interferon g</ENT2>-induced genes (e.g. IFITM1, IFIT1, IFIT2, IFIT3) and numerous other immune-related genes (e.g. TLR3, NOS2, and LCN2).",,,,T,,,,,c,,,,,0.0,,
26449539,3153,5465,7098,Negative_Correlation,TRUE,"Among the most highly repressed genes upon <ENT1>PPARa</ENT1> activation were several chemokines (e.g. CXCL9-11, CCL8, CX3CL1, CXCL6), interferon g-induced genes (e.g. IFITM1, IFIT1, IFIT2, IFIT3) and numerous other immune-related genes (e.g. <ENT2>TLR3</ENT2>, NOS2, and LCN2).",,,,T,,,,,c,,,,,1.0,,
26449539,3133,3433,3458,Positive_Correlation,FALSE,"Among the most highly repressed genes upon PPARa activation were several chemokines (e.g. CXCL9-11, CCL8, CX3CL1, CXCL6), <ENT2>interferon g</ENT2>-induced genes (e.g. IFITM1, IFIT1, <ENT1>IFIT2</ENT1>, IFIT3) and numerous other immune-related genes (e.g. TLR3, NOS2, and LCN2).",,,,T,,,,,c,,,,,1.0,,
26449539,3136,19013,D008055,Association,FALSE,BACKGROUND: Studies in mice have shown that <ENT1>PPARa</ENT1> is an important regulator of <ENT2>lipid</ENT2> metabolism in liver and key transcription factor involved in the adaptive response to fasting.,,,,T,,,,,c,,,,,0.0,,
26449539,3140,51703,D008055,Association,FALSE,"Many genes induced by PPARa activation were involved in <ENT2>lipid</ENT2> metabolism (<ENT1>ACSL5</ENT1>, AGPAT9, FADS1, SLC27A4), xenobiotic metabolism (POR, ABCC2, CYP3A5) or the unfolded protein response, whereas most of the downregulated genes were involved in immune-related pathways.",,,,T,,,,,c,,,,,0.0,,
26449539,3135,8519,3458,Positive_Correlation,FALSE,"Among the most highly repressed genes upon PPARa activation were several chemokines (e.g. CXCL9-11, CCL8, CX3CL1, CXCL6), <ENT2>interferon g</ENT2>-induced genes (e.g. <ENT1>IFITM1</ENT1>, IFIT1, IFIT2, IFIT3) and numerous other immune-related genes (e.g. TLR3, NOS2, and LCN2).",,,,T,,,,,c,,,,,0.0,,
26449539,3138,3992,D008055,Association,FALSE,"Many genes induced by PPARa activation were involved in <ENT2>lipid</ENT2> metabolism (ACSL5, AGPAT9, <ENT1>FADS1</ENT1>, SLC27A4), xenobiotic metabolism (POR, ABCC2, CYP3A5) or the unfolded protein response, whereas most of the downregulated genes were involved in immune-related pathways.",,,,T,,,,,c,,,,,0.0,,
26449539,3134,3434,3458,Positive_Correlation,FALSE,"Among the most highly repressed genes upon PPARa activation were several chemokines (e.g. CXCL9-11, CCL8, CX3CL1, CXCL6), <ENT2>interferon g</ENT2>-induced genes (e.g. IFITM1, <ENT1>IFIT1</ENT1>, IFIT2, IFIT3) and numerous other immune-related genes (e.g. TLR3, NOS2, and LCN2).",,,,T,,,,,c,,,,,1.0,,
26449539,3139,84803,D008055,Association,FALSE,"Many genes induced by PPARa activation were involved in <ENT2>lipid</ENT2> metabolism (ACSL5, <ENT1>AGPAT9</ENT1>, FADS1, SLC27A4), xenobiotic metabolism (POR, ABCC2, CYP3A5) or the unfolded protein response, whereas most of the downregulated genes were involved in immune-related pathways.",,,,T,,,,,c,,,,,0.0,,
26449539,3132,3437,3458,Positive_Correlation,FALSE,"Among the most highly repressed genes upon PPARa activation were several chemokines (e.g. CXCL9-11, CCL8, CX3CL1, CXCL6), <ENT2>interferon g</ENT2>-induced genes (e.g. IFITM1, IFIT1, IFIT2, <ENT1>IFIT3</ENT1>) and numerous other immune-related genes (e.g. TLR3, NOS2, and LCN2).",,,,T,,,,,c,,,,,1.0,,
26449539,3137,D008055,10999,Association,FALSE,"Many genes induced by PPARa activation were involved in <ENT1>lipid</ENT1> metabolism (ACSL5, AGPAT9, FADS1, <ENT2>SLC27A4</ENT2>), xenobiotic metabolism (POR, ABCC2, CYP3A5) or the unfolded protein response, whereas most of the downregulated genes were involved in immune-related pathways.",,,,T,,,,,c,,,,,0.0,,
26615423,3172,D000077216,55165,Association,TRUE,Upregulation of <ENT2>centrosomal protein 55</ENT2> is associated with unfavorable prognosis and tumor invasion in <ENT1>epithelial ovarian carcinoma</ENT1>.,,,,T,,,,,c,,,,,0.0,,
26615423,3172,D000077216,55165,Association,TRUE,"However, characteristics of <ENT2>CEP55</ENT2> expression and its clinical/prognostic significance are unclear in human <ENT1>epithelial ovarian carcinoma</ENT1> (<ENT1>EOC</ENT1>).",,,,T,,,,,c,,,,,1.0,,
26615423,3172,D000077216,55165,Association,TRUE,"Therefore, we investigated the expression and clinicopathological significance of <ENT2>CEP55</ENT2> in patients with <ENT1>EOC</ENT1> and its role in regulating invasion and metastasis of ovarian cell lines.",,,,T,,Y,,,w,,,,,0.0,,
26615423,3172,D000077216,55165,Association,TRUE,"In the 213 <ENT1>EOC</ENT1> samples, <ENT2>CEP55</ENT2> protein levels were positively correlated with clinical stage (P < 0.001), lymph node metastasis (P < 0.001), intraperitoneal metastasis (P < 0.001), tumor recurrence (P < 0.001), differentiation grade (P < 0.001), residual tumor size (P < 0.001), ascites see tumor cells (P = 0.020), and serum CA153 level (P < 0.001).",,,,T,,,,,w,,,,,1.0,,
26615423,3172,D000077216,55165,Association,TRUE,Multivariate analysis implicated <ENT2>CEP55</ENT2> as an independent prognostic indicator for <ENT1>EOC</ENT1> patients.,,,,T,,,,,c,,,,,1.0,,
26615423,3172,D000077216,55165,Association,TRUE,Aberrant <ENT2>CEP55</ENT2> expression may predict unfavorable clinical outcomes in <ENT1>EOC</ENT1> patients and play an important role in regulating invasion in ovarian cancer cells.,,,,T,,,,,c,,,,,1.0,,
26615423,3172,D000077216,55165,Association,TRUE,"Thus, <ENT2>CEP55</ENT2> may serve as a prognostic marker and therapeutic target for <ENT1>EOC</ENT1>.",,,,T,,,,,c,,,,,1.0,,
26615423,3173,D009362,55165,Positive_Correlation,TRUE,"In the 213 EOC samples, <ENT2>CEP55</ENT2> protein levels were positively correlated with clinical stage (P < 0.001), lymph node metastasis (P < 0.001), <ENT1>intraperitoneal metastasis</ENT1> (P < 0.001), tumor recurrence (P < 0.001), differentiation grade (P < 0.001), residual tumor size (P < 0.001), ascites see tumor cells (P = 0.020), and serum CA153 level (P < 0.001).",,,,T,,,,,c,,,,,1.0,,
26615423,3174,55165,D008207,Positive_Correlation,TRUE,"In the 213 EOC samples, <ENT1>CEP55</ENT1> protein levels were positively correlated with clinical stage (P < 0.001), <ENT2>lymph node metastasis</ENT2> (P < 0.001), intraperitoneal metastasis (P < 0.001), tumor recurrence (P < 0.001), differentiation grade (P < 0.001), residual tumor size (P < 0.001), ascites see tumor cells (P = 0.020), and serum CA153 level (P < 0.001).",,,,T,,,,,c,,,,,1.0,,
26615423,3175,55165,4582,Positive_Correlation,TRUE,"In the 213 EOC samples, <ENT1>CEP55</ENT1> protein levels were positively correlated with clinical stage (P < 0.001), lymph node metastasis (P < 0.001), intraperitoneal metastasis (P < 0.001), tumor recurrence (P < 0.001), differentiation grade (P < 0.001), residual tumor size (P < 0.001), ascites see tumor cells (P = 0.020), and serum <ENT2>CA153</ENT2> level (P < 0.001).",,,,T,,,,,c,,,,,0.0,,
26615423,3177,55165,D010051,Positive_Correlation,TRUE,"Therefore, we investigated the expression and clinicopathological significance of <ENT1>CEP55</ENT1> in patients with EOC and its role in regulating invasion and <ENT2>metastasis of ovarian</ENT2> cell lines.",,,,T,,Y,,,w,,,,,0.0,,
26615423,3177,55165,D010051,Positive_Correlation,TRUE,<ENT1>CEP55</ENT1> was significantly upregulated in <ENT2>ovarian cancer</ENT2> cell lines and lesions compared with normal cells and adjacent noncancerous ovarian tissues.,,,,T,,,,,c,,,,,1.0,,
26615423,3177,55165,D010051,Positive_Correlation,TRUE,"Additionally, downregulation of <ENT1>CEP55</ENT1> in <ENT2>ovarian cancer</ENT2> cells remarkably inhibited cellular motility and invasion.",,,,T,,,,,c,,,,,1.0,,
26615423,3177,55165,D010051,Positive_Correlation,TRUE,Aberrant <ENT1>CEP55</ENT1> expression may predict unfavorable clinical outcomes in EOC patients and play an important role in regulating invasion in <ENT2>ovarian cancer</ENT2> cells.,,,,T,,,,,w,,,,,0.0,,
26615423,3176,55165,D009369,Positive_Correlation,FALSE,Upregulation of <ENT1>centrosomal protein 55</ENT1> is associated with unfavorable prognosis and <ENT2>tumor</ENT2> invasion in epithelial ovarian carcinoma.,,,,T,,,,,w,,,,,1.0,,
26615423,3176,55165,D009369,Positive_Correlation,FALSE,<ENT1>Centrosomal protein 55</ENT1> (<ENT1>CEP55</ENT1>) is a cell cycle regulator implicated in development of certain <ENT2>cancers</ENT2>.,,,,T,,,,,w,,,,,0.0,,
26615423,3176,55165,D009369,Positive_Correlation,FALSE,"In the 213 EOC samples, <ENT1>CEP55</ENT1> protein levels were positively correlated with clinical stage (P < 0.001), lymph node metastasis (P < 0.001), intraperitoneal metastasis (P < 0.001), <ENT2>tumor</ENT2> recurrence (P < 0.001), differentiation grade (P < 0.001), residual <ENT2>tumor</ENT2> size (P < 0.001), ascites see <ENT2>tumor</ENT2> cells (P = 0.020), and serum CA153 level (P < 0.001).",,,,T,,,,,w,,,,,0.666666667,TRUE,
26684240,3186,5921,D009369,Association,FALSE,"Among 12 GEP-NETs, eight showed mutations of more than one <ENT2>cancer</ENT2>-related gene, including TP53, CNBD1, RB1, APC, BCOR, BRAF, CTNNB1, EGFR, EP300, ERBB3, KDM6A, KRAS, MGA, MLL3, PTEN, <ENT1>RASA1</ENT1>, SMARCB1, SPEN, TBC1D12, and VHL.",,,,T,,,,,c,,,,,1.0,,
26684240,3210,5921,C535650,Association,TRUE,"Among 12 <ENT2>GEP-NETs</ENT2>, eight showed mutations of more than one cancer-related gene, including TP53, CNBD1, RB1, APC, BCOR, BRAF, CTNNB1, EGFR, EP300, ERBB3, KDM6A, KRAS, MGA, MLL3, PTEN, <ENT1>RASA1</ENT1>, SMARCB1, SPEN, TBC1D12, and VHL.",,,,T,,,,,c,,,,,1.0,,
26684240,3187,5728,D009369,Association,FALSE,"Among 12 GEP-NETs, eight showed mutations of more than one <ENT2>cancer</ENT2>-related gene, including TP53, CNBD1, RB1, APC, BCOR, BRAF, CTNNB1, EGFR, EP300, ERBB3, KDM6A, KRAS, MGA, MLL3, <ENT1>PTEN</ENT1>, RASA1, SMARCB1, SPEN, TBC1D12, and VHL.",,,,T,,,,,c,,,,,1.0,,
26684240,3211,5728,C535650,Association,TRUE,"Among 12 <ENT2>GEP-NETs</ENT2>, eight showed mutations of more than one cancer-related gene, including TP53, CNBD1, RB1, APC, BCOR, BRAF, CTNNB1, EGFR, EP300, ERBB3, KDM6A, KRAS, MGA, MLL3, <ENT1>PTEN</ENT1>, RASA1, SMARCB1, SPEN, TBC1D12, and VHL.",,,,T,,,,,c,,,,,1.0,,
26684240,3192,2033,D009369,Association,FALSE,"Among 12 GEP-NETs, eight showed mutations of more than one <ENT2>cancer</ENT2>-related gene, including TP53, CNBD1, RB1, APC, BCOR, BRAF, CTNNB1, EGFR, <ENT1>EP300</ENT1>, ERBB3, KDM6A, KRAS, MGA, MLL3, PTEN, RASA1, SMARCB1, SPEN, TBC1D12, and VHL.",,,,T,,,,,c,,,,,1.0,,
26684240,3217,2033,C535650,Association,TRUE,"Among 12 <ENT2>GEP-NETs</ENT2>, eight showed mutations of more than one cancer-related gene, including TP53, CNBD1, RB1, APC, BCOR, BRAF, CTNNB1, EGFR, <ENT1>EP300</ENT1>, ERBB3, KDM6A, KRAS, MGA, MLL3, PTEN, RASA1, SMARCB1, SPEN, TBC1D12, and VHL.",,,,T,,,,,c,,,,,1.0,,
26684240,3190,3845,D009369,Association,FALSE,"Among 12 GEP-NETs, eight showed mutations of more than one <ENT2>cancer</ENT2>-related gene, including TP53, CNBD1, RB1, APC, BCOR, BRAF, CTNNB1, EGFR, EP300, ERBB3, KDM6A, <ENT1>KRAS</ENT1>, MGA, MLL3, PTEN, RASA1, SMARCB1, SPEN, TBC1D12, and VHL.",,,,T,,,,,c,,,,,1.0,,
26684240,3214,3845,C535650,Association,TRUE,"Among 12 <ENT2>GEP-NETs</ENT2>, eight showed mutations of more than one cancer-related gene, including TP53, CNBD1, RB1, APC, BCOR, BRAF, CTNNB1, EGFR, EP300, ERBB3, KDM6A, <ENT1>KRAS</ENT1>, MGA, MLL3, PTEN, RASA1, SMARCB1, SPEN, TBC1D12, and VHL.",,,,T,,,,,c,,,,,1.0,,
26684240,3195,54880,D009369,Association,FALSE,"Among 12 GEP-NETs, eight showed mutations of more than one <ENT2>cancer</ENT2>-related gene, including TP53, CNBD1, RB1, APC, <ENT1>BCOR</ENT1>, BRAF, CTNNB1, EGFR, EP300, ERBB3, KDM6A, KRAS, MGA, MLL3, PTEN, RASA1, SMARCB1, SPEN, TBC1D12, and VHL.",,,,T,,,,,c,,,,,1.0,,
26684240,3220,54880,C535650,Association,TRUE,"Among 12 <ENT2>GEP-NETs</ENT2>, eight showed mutations of more than one cancer-related gene, including TP53, CNBD1, RB1, APC, <ENT1>BCOR</ENT1>, BRAF, CTNNB1, EGFR, EP300, ERBB3, KDM6A, KRAS, MGA, MLL3, PTEN, RASA1, SMARCB1, SPEN, TBC1D12, and VHL.",,,,T,,,,,c,,,,,1.0,,
26684240,3226,673,C516667,Negative_Correlation,TRUE,Three GEP-NET patients with TP53 mutations demonstrated a durable response and one small intestinal grade (G) 1 NET patient with <ENT1>BRAF</ENT1> V600E mutation showed progression after <ENT2>pazopanib</ENT2> treatment.,,,,T,Y,,,,w,,,,,0.0,,
26684240,3226,673,C516667,Negative_Correlation,TRUE,"In conclusion, <ENT1>BRAF</ENT1> V600E mutation is likely to result in resistance to <ENT2>pazopanib</ENT2> but may be a potentianally actionable mutation in metastatic GEP-NETs patients.",,,,T,Y,,,,c,,,,,0.0,,
26684240,3181,673,D007414,Association,TRUE,Three GEP-NET patients with TP53 mutations demonstrated a durable response and one small <ENT2>intestinal grade (G) 1 NET</ENT2> patient with <ENT1>BRAF</ENT1> V600E mutation showed progression after pazopanib treatment.,,,,T,Y,,,,w,,,,,0.0,,
26684240,3227,673,D009369,Association,FALSE,"Among 12 GEP-NETs, eight showed mutations of more than one <ENT2>cancer</ENT2>-related gene, including TP53, CNBD1, RB1, APC, BCOR, <ENT1>BRAF</ENT1>, CTNNB1, EGFR, EP300, ERBB3, KDM6A, KRAS, MGA, MLL3, PTEN, RASA1, SMARCB1, SPEN, TBC1D12, and VHL.",,,,T,,,,,c,,,,,1.0,,
26684240,3228,673,C535650,Association,TRUE,Identification of the <ENT1>BRAF</ENT1> V600E mutation in <ENT2>gastroenteropancreatic neuroendocrine tumors</ENT2>.,,,,T,,T,,,w,,,,,1.0,,
26684240,3228,673,C535650,Association,TRUE,"Among 12 <ENT2>GEP-NETs</ENT2>, eight showed mutations of more than one cancer-related gene, including TP53, CNBD1, RB1, APC, BCOR, <ENT1>BRAF</ENT1>, CTNNB1, EGFR, EP300, ERBB3, KDM6A, KRAS, MGA, MLL3, PTEN, RASA1, SMARCB1, SPEN, TBC1D12, and VHL.",,,,T,,,,,c,,,,,1.0,,
26684240,3228,673,C535650,Association,TRUE,Three <ENT2>GEP-NET</ENT2> patients with TP53 mutations demonstrated a durable response and one small intestinal grade (G) 1 NET patient with <ENT1>BRAF</ENT1> V600E mutation showed progression after pazopanib treatment.,,,,T,,,,,c,,,,,1.0,,
26684240,3228,673,C535650,Association,TRUE,"We found <ENT1>BRAF</ENT1> V600E (G1 NET from rectum and two G3 NETs from colon) and <ENT1>BRAF</ENT1> G593S (G2 NET from pancreas) missense mutations (9.1%) in an independent cohort of 44 <ENT2>GEP-NETs</ENT2> from the rectum (n = 26), colon (n = 7), pancreas (n = 4), small intestine (n = 3), stomach (n = 3) and appendix (n = 1) by Sanger sequencing.",,,,T,,,,,c,,,,,0.0,,
26684240,3228,673,C535650,Association,TRUE,"In conclusion, <ENT1>BRAF</ENT1> V600E mutation is likely to result in resistance to pazopanib but may be a potentianally actionable mutation in metastatic <ENT2>GEP-NETs</ENT2> patients.",,,,T,,,,,c,,,,,0.0,,
26684240,3225,673,D018358,Association,TRUE,"We found <ENT1>BRAF</ENT1> V600E (G1 <ENT2>NET</ENT2> from rectum and two G3 <ENT2>NETs</ENT2> from colon) and <ENT1>BRAF</ENT1> G593S (G2 <ENT2>NET</ENT2> from pancreas) missense mutations (9.1%) in an independent cohort of 44 GEP-NETs from the rectum (n = 26), colon (n = 7), pancreas (n = 4), small intestine (n = 3), stomach (n = 3) and appendix (n = 1) by Sanger sequencing.",,,,T,,,,,c,,,"11,12,23",,0.166666667,,
26684240,3202,C516667,rs113488022,Negative_Correlation,TRUE,Three GEP-NET patients with TP53 mutations demonstrated a durable response and one small intestinal grade (G) 1 NET patient with BRAF <ENT2>V600E</ENT2> mutation showed progression after <ENT1>pazopanib</ENT1> treatment.,,,,T,,,,,c,,,,,0.0,,
26684240,3202,C516667,rs113488022,Negative_Correlation,TRUE,"In conclusion, BRAF <ENT2>V600E</ENT2> mutation is likely to result in resistance to <ENT1>pazopanib</ENT1> but may be a potentianally actionable mutation in metastatic GEP-NETs patients.",,,,T,,,,,c,,,,,0.0,,
26684240,3179,C516667,D007414,Negative_Correlation,FALSE,"Here, we performed whole exome sequencing of 12 GEP-NETs from patients enrolled in a nonrandomized, open-labeled, single-center phase II study for <ENT1>pazopanib</ENT1>, and integrated our results with previously published results on pancreas (n = 12) and small <ENT2>intestine NETs</ENT2> (n = 50).",,,,T,,,,,c,,,,,1.0,,
26684240,3179,C516667,D007414,Negative_Correlation,FALSE,Three GEP-NET patients with TP53 mutations demonstrated a durable response and one small <ENT2>intestinal grade (G) 1 NET</ENT2> patient with BRAF V600E mutation showed progression after <ENT1>pazopanib</ENT1> treatment.,,,,T,,,,,c,,,,,0.0,,
26684240,3205,C516667,C535650,Negative_Correlation,FALSE,"Here, we performed whole exome sequencing of 12 <ENT2>GEP-NETs</ENT2> from patients enrolled in a nonrandomized, open-labeled, single-center phase II study for <ENT1>pazopanib</ENT1>, and integrated our results with previously published results on pancreas (n = 12) and small intestine NETs (n = 50).",,,,T,,,,,w,,,,,1.0,,
26684240,3205,C516667,C535650,Negative_Correlation,FALSE,Three <ENT2>GEP-NET</ENT2> patients with TP53 mutations demonstrated a durable response and one small intestinal grade (G) 1 NET patient with BRAF V600E mutation showed progression after <ENT1>pazopanib</ENT1> treatment.,,,,T,,,,,c,,,,,1.0,,
26684240,3205,C516667,C535650,Negative_Correlation,FALSE,"In conclusion, BRAF V600E mutation is likely to result in resistance to <ENT1>pazopanib</ENT1> but may be a potentianally actionable mutation in metastatic <ENT2>GEP-NETs</ENT2> patients.",,,,T,,,,,c,,,,,1.0,,
26684240,3180,rs113488022,D007414,Association,TRUE,Three GEP-NET patients with TP53 mutations demonstrated a durable response and one small <ENT2>intestinal grade (G) 1 NET</ENT2> patient with BRAF <ENT1>V600E</ENT1> mutation showed progression after pazopanib treatment.,,,,T,,,,,w,,,,,0.0,,
26684240,3203,rs113488022,C535650,Association,TRUE,Identification of the BRAF <ENT1>V600E</ENT1> mutation in <ENT2>gastroenteropancreatic neuroendocrine tumors</ENT2>.,,,,T,,,,,c,,,,,1.0,,
26684240,3203,rs113488022,C535650,Association,TRUE,Three <ENT2>GEP-NET</ENT2> patients with TP53 mutations demonstrated a durable response and one small intestinal grade (G) 1 NET patient with BRAF <ENT1>V600E</ENT1> mutation showed progression after pazopanib treatment.,,,,T,,,,,c,,,,,1.0,,
26684240,3203,rs113488022,C535650,Association,TRUE,"We found BRAF <ENT1>V600E</ENT1> (G1 NET from rectum and two G3 NETs from colon) and BRAF G593S (G2 NET from pancreas) missense mutations (9.1%) in an independent cohort of 44 <ENT2>GEP-NETs</ENT2> from the rectum (n = 26), colon (n = 7), pancreas (n = 4), small intestine (n = 3), stomach (n = 3) and appendix (n = 1) by Sanger sequencing.",,,,T,,,,,c,,,,,1.0,,
26684240,3203,rs113488022,C535650,Association,TRUE,"In conclusion, BRAF <ENT1>V600E</ENT1> mutation is likely to result in resistance to pazopanib but may be a potentianally actionable mutation in metastatic <ENT2>GEP-NETs</ENT2> patients.",,,,T,,,,,c,,,,,1.0,,
26684240,3201,rs113488022,D018358,Association,TRUE,"We found BRAF <ENT1>V600E</ENT1> (G1 <ENT2>NET</ENT2> from rectum and two G3 <ENT2>NETs</ENT2> from colon) and BRAF G593S (G2 <ENT2>NET</ENT2> from pancreas) missense mutations (9.1%) in an independent cohort of 44 GEP-NETs from the rectum (n = 26), colon (n = 7), pancreas (n = 4), small intestine (n = 3), stomach (n = 3) and appendix (n = 1) by Sanger sequencing.",,,,T,Y,,,,w,,,,,0.0,,
26684240,3196,324,D009369,Association,FALSE,"Among 12 GEP-NETs, eight showed mutations of more than one <ENT2>cancer</ENT2>-related gene, including TP53, CNBD1, RB1, <ENT1>APC</ENT1>, BCOR, BRAF, CTNNB1, EGFR, EP300, ERBB3, KDM6A, KRAS, MGA, MLL3, PTEN, RASA1, SMARCB1, SPEN, TBC1D12, and VHL.",,,,T,,,,,c,,,,,1.0,,
26684240,3221,324,C535650,Association,TRUE,"Among 12 <ENT2>GEP-NETs</ENT2>, eight showed mutations of more than one cancer-related gene, including TP53, CNBD1, RB1, <ENT1>APC</ENT1>, BCOR, BRAF, CTNNB1, EGFR, EP300, ERBB3, KDM6A, KRAS, MGA, MLL3, PTEN, RASA1, SMARCB1, SPEN, TBC1D12, and VHL.",,,,T,,,,,c,,,,,1.0,,
26684240,3197,5925,D009369,Association,FALSE,"Among 12 GEP-NETs, eight showed mutations of more than one <ENT2>cancer</ENT2>-related gene, including TP53, CNBD1, <ENT1>RB1</ENT1>, APC, BCOR, BRAF, CTNNB1, EGFR, EP300, ERBB3, KDM6A, KRAS, MGA, MLL3, PTEN, RASA1, SMARCB1, SPEN, TBC1D12, and VHL.",,,,T,,,,,c,,,,,1.0,,
26684240,3222,5925,C535650,Association,TRUE,"Among 12 <ENT2>GEP-NETs</ENT2>, eight showed mutations of more than one cancer-related gene, including TP53, CNBD1, <ENT1>RB1</ENT1>, APC, BCOR, BRAF, CTNNB1, EGFR, EP300, ERBB3, KDM6A, KRAS, MGA, MLL3, PTEN, RASA1, SMARCB1, SPEN, TBC1D12, and VHL.",,,,T,,,,,c,,,,,1.0,,
26684240,3188,58508,D009369,Association,FALSE,"Among 12 GEP-NETs, eight showed mutations of more than one <ENT2>cancer</ENT2>-related gene, including TP53, CNBD1, RB1, APC, BCOR, BRAF, CTNNB1, EGFR, EP300, ERBB3, KDM6A, KRAS, MGA, <ENT1>MLL3</ENT1>, PTEN, RASA1, SMARCB1, SPEN, TBC1D12, and VHL.",,,,T,,,,,c,,,,,1.0,,
26684240,3212,58508,C535650,Association,TRUE,"Among 12 <ENT2>GEP-NETs</ENT2>, eight showed mutations of more than one cancer-related gene, including TP53, CNBD1, RB1, APC, BCOR, BRAF, CTNNB1, EGFR, EP300, ERBB3, KDM6A, KRAS, MGA, <ENT1>MLL3</ENT1>, PTEN, RASA1, SMARCB1, SPEN, TBC1D12, and VHL.",,,,T,,,,,c,,,,,1.0,,
26684240,3183,23232,D009369,Association,FALSE,"Among 12 GEP-NETs, eight showed mutations of more than one <ENT2>cancer</ENT2>-related gene, including TP53, CNBD1, RB1, APC, BCOR, BRAF, CTNNB1, EGFR, EP300, ERBB3, KDM6A, KRAS, MGA, MLL3, PTEN, RASA1, SMARCB1, SPEN, <ENT1>TBC1D12</ENT1>, and VHL.",,,,T,,,,,c,,,,,1.0,,
26684240,3207,23232,C535650,Association,TRUE,"Among 12 <ENT2>GEP-NETs</ENT2>, eight showed mutations of more than one cancer-related gene, including TP53, CNBD1, RB1, APC, BCOR, BRAF, CTNNB1, EGFR, EP300, ERBB3, KDM6A, KRAS, MGA, MLL3, PTEN, RASA1, SMARCB1, SPEN, <ENT1>TBC1D12</ENT1>, and VHL.",,,,T,,,,,c,,,,,1.0,,
26684240,3194,1499,D009369,Association,FALSE,"Among 12 GEP-NETs, eight showed mutations of more than one <ENT2>cancer</ENT2>-related gene, including TP53, CNBD1, RB1, APC, BCOR, BRAF, <ENT1>CTNNB1</ENT1>, EGFR, EP300, ERBB3, KDM6A, KRAS, MGA, MLL3, PTEN, RASA1, SMARCB1, SPEN, TBC1D12, and VHL.",,,,T,,,,,c,,,,,0.0,,
26684240,3219,1499,C535650,Association,TRUE,"Among 12 <ENT2>GEP-NETs</ENT2>, eight showed mutations of more than one cancer-related gene, including TP53, CNBD1, RB1, APC, BCOR, BRAF, <ENT1>CTNNB1</ENT1>, EGFR, EP300, ERBB3, KDM6A, KRAS, MGA, MLL3, PTEN, RASA1, SMARCB1, SPEN, TBC1D12, and VHL.",,,,T,,,,,c,,,,,1.0,,
26684240,3199,2065,D009369,Association,FALSE,"Among 12 GEP-NETs, eight showed mutations of more than one <ENT2>cancer</ENT2>-related gene, including TP53, CNBD1, RB1, APC, BCOR, BRAF, CTNNB1, EGFR, EP300, <ENT1>ERBB3</ENT1>, KDM6A, KRAS, MGA, MLL3, PTEN, RASA1, SMARCB1, SPEN, TBC1D12, and VHL.",,,,T,,,,,c,,,,,1.0,,
26684240,3216,2065,C535650,Association,TRUE,"Among 12 <ENT2>GEP-NETs</ENT2>, eight showed mutations of more than one cancer-related gene, including TP53, CNBD1, RB1, APC, BCOR, BRAF, CTNNB1, EGFR, EP300, <ENT1>ERBB3</ENT1>, KDM6A, KRAS, MGA, MLL3, PTEN, RASA1, SMARCB1, SPEN, TBC1D12, and VHL.",,,,T,,,,,c,,,,,1.0,,
26684240,3204,p.G593S,C535650,Association,TRUE,"We found BRAF V600E (G1 NET from rectum and two G3 NETs from colon) and BRAF <ENT1>G593S</ENT1> (G2 NET from pancreas) missense mutations (9.1%) in an independent cohort of 44 <ENT2>GEP-NETs</ENT2> from the rectum (n = 26), colon (n = 7), pancreas (n = 4), small intestine (n = 3), stomach (n = 3) and appendix (n = 1) by Sanger sequencing.",,,,T,,,,,c,,,,,0.0,,
26684240,3178,p.G593S,D018358,Association,TRUE,"We found BRAF V600E (G1 <ENT2>NET</ENT2> from rectum and two G3 <ENT2>NETs</ENT2> from colon) and BRAF <ENT1>G593S</ENT1> (G2 <ENT2>NET</ENT2> from pancreas) missense mutations (9.1%) in an independent cohort of 44 GEP-NETs from the rectum (n = 26), colon (n = 7), pancreas (n = 4), small intestine (n = 3), stomach (n = 3) and appendix (n = 1) by Sanger sequencing.",,,,T,Y,,,,w,,,,,0.0,,
26684240,3182,7428,D009369,Association,FALSE,"Among 12 GEP-NETs, eight showed mutations of more than one <ENT2>cancer</ENT2>-related gene, including TP53, CNBD1, RB1, APC, BCOR, BRAF, CTNNB1, EGFR, EP300, ERBB3, KDM6A, KRAS, MGA, MLL3, PTEN, RASA1, SMARCB1, SPEN, TBC1D12, and <ENT1>VHL</ENT1>.",,,,T,,,,,c,,,,,1.0,,
26684240,3206,7428,C535650,Association,TRUE,"Among 12 <ENT2>GEP-NETs</ENT2>, eight showed mutations of more than one cancer-related gene, including TP53, CNBD1, RB1, APC, BCOR, BRAF, CTNNB1, EGFR, EP300, ERBB3, KDM6A, KRAS, MGA, MLL3, PTEN, RASA1, SMARCB1, SPEN, TBC1D12, and <ENT1>VHL</ENT1>.",,,,T,,,,,c,,,,,0.0,,
26684240,3198,168975,D009369,Association,FALSE,"Among 12 GEP-NETs, eight showed mutations of more than one <ENT2>cancer</ENT2>-related gene, including TP53, <ENT1>CNBD1</ENT1>, RB1, APC, BCOR, BRAF, CTNNB1, EGFR, EP300, ERBB3, KDM6A, KRAS, MGA, MLL3, PTEN, RASA1, SMARCB1, SPEN, TBC1D12, and VHL.",,,,T,,,,,c,,,,,1.0,,
26684240,3223,168975,C535650,Association,TRUE,"Among 12 <ENT2>GEP-NETs</ENT2>, eight showed mutations of more than one cancer-related gene, including TP53, <ENT1>CNBD1</ENT1>, RB1, APC, BCOR, BRAF, CTNNB1, EGFR, EP300, ERBB3, KDM6A, KRAS, MGA, MLL3, PTEN, RASA1, SMARCB1, SPEN, TBC1D12, and VHL.",,,,T,,,,,c,,,,,1.0,,
26684240,3200,7157,D009369,Association,FALSE,"Among 12 GEP-NETs, eight showed mutations of more than one <ENT2>cancer</ENT2>-related gene, including <ENT1>TP53</ENT1>, CNBD1, RB1, APC, BCOR, BRAF, CTNNB1, EGFR, EP300, ERBB3, KDM6A, KRAS, MGA, MLL3, PTEN, RASA1, SMARCB1, SPEN, TBC1D12, and VHL.",,,,T,,,,,c,,,,,1.0,,
26684240,3224,7157,C535650,Association,TRUE,"Among 12 <ENT2>GEP-NETs</ENT2>, eight showed mutations of more than one cancer-related gene, including <ENT1>TP53</ENT1>, CNBD1, RB1, APC, BCOR, BRAF, CTNNB1, EGFR, EP300, ERBB3, KDM6A, KRAS, MGA, MLL3, PTEN, RASA1, SMARCB1, SPEN, TBC1D12, and VHL.",,,,T,,,,,c,,,,,1.0,,
26684240,3224,7157,C535650,Association,TRUE,Three <ENT2>GEP-NET</ENT2> patients with <ENT1>TP53</ENT1> mutations demonstrated a durable response and one small intestinal grade (G) 1 NET patient with BRAF V600E mutation showed progression after pazopanib treatment.,,,,T,Y,,,,w,,,,,1.0,,
26684240,3185,6598,D009369,Association,FALSE,"Among 12 GEP-NETs, eight showed mutations of more than one <ENT2>cancer</ENT2>-related gene, including TP53, CNBD1, RB1, APC, BCOR, BRAF, CTNNB1, EGFR, EP300, ERBB3, KDM6A, KRAS, MGA, MLL3, PTEN, RASA1, <ENT1>SMARCB1</ENT1>, SPEN, TBC1D12, and VHL.",,,,T,,,,,c,,,,,1.0,,
26684240,3209,6598,C535650,Association,TRUE,"Among 12 <ENT2>GEP-NETs</ENT2>, eight showed mutations of more than one cancer-related gene, including TP53, CNBD1, RB1, APC, BCOR, BRAF, CTNNB1, EGFR, EP300, ERBB3, KDM6A, KRAS, MGA, MLL3, PTEN, RASA1, <ENT1>SMARCB1</ENT1>, SPEN, TBC1D12, and VHL.",,,,T,,,,,c,,,,,1.0,,
26684240,3189,D009369,23269,Association,FALSE,"Among 12 GEP-NETs, eight showed mutations of more than one <ENT1>cancer</ENT1>-related gene, including TP53, CNBD1, RB1, APC, BCOR, BRAF, CTNNB1, EGFR, EP300, ERBB3, KDM6A, KRAS, <ENT2>MGA</ENT2>, MLL3, PTEN, RASA1, SMARCB1, SPEN, TBC1D12, and VHL.",,,,T,,,,,c,,,,,0.0,,
26684240,3184,D009369,23013,Association,FALSE,"Among 12 GEP-NETs, eight showed mutations of more than one <ENT1>cancer</ENT1>-related gene, including TP53, CNBD1, RB1, APC, BCOR, BRAF, CTNNB1, EGFR, EP300, ERBB3, KDM6A, KRAS, MGA, MLL3, PTEN, RASA1, SMARCB1, <ENT2>SPEN</ENT2>, TBC1D12, and VHL.",,,,T,,,,,c,,,,,0.0,,
26684240,3193,D009369,1956,Association,FALSE,"Among 12 GEP-NETs, eight showed mutations of more than one <ENT1>cancer</ENT1>-related gene, including TP53, CNBD1, RB1, APC, BCOR, BRAF, CTNNB1, <ENT2>EGFR</ENT2>, EP300, ERBB3, KDM6A, KRAS, MGA, MLL3, PTEN, RASA1, SMARCB1, SPEN, TBC1D12, and VHL.",,,,T,,,,,c,,,,,1.0,,
26684240,3191,D009369,7403,Association,FALSE,"Among 12 GEP-NETs, eight showed mutations of more than one <ENT1>cancer</ENT1>-related gene, including TP53, CNBD1, RB1, APC, BCOR, BRAF, CTNNB1, EGFR, EP300, ERBB3, <ENT2>KDM6A</ENT2>, KRAS, MGA, MLL3, PTEN, RASA1, SMARCB1, SPEN, TBC1D12, and VHL.",,,,T,,,,,c,,,,,1.0,,
26684240,3213,23269,C535650,Association,TRUE,"Among 12 <ENT2>GEP-NETs</ENT2>, eight showed mutations of more than one cancer-related gene, including TP53, CNBD1, RB1, APC, BCOR, BRAF, CTNNB1, EGFR, EP300, ERBB3, KDM6A, KRAS, <ENT1>MGA</ENT1>, MLL3, PTEN, RASA1, SMARCB1, SPEN, TBC1D12, and VHL.",,,,T,,,,,c,,,,,0.0,,
26684240,3208,C535650,23013,Association,TRUE,"Among 12 <ENT1>GEP-NETs</ENT1>, eight showed mutations of more than one cancer-related gene, including TP53, CNBD1, RB1, APC, BCOR, BRAF, CTNNB1, EGFR, EP300, ERBB3, KDM6A, KRAS, MGA, MLL3, PTEN, RASA1, SMARCB1, <ENT2>SPEN</ENT2>, TBC1D12, and VHL.",,,,T,,,,,c,,,,,0.0,,
26684240,3218,C535650,1956,Association,TRUE,"Among 12 <ENT1>GEP-NETs</ENT1>, eight showed mutations of more than one cancer-related gene, including TP53, CNBD1, RB1, APC, BCOR, BRAF, CTNNB1, <ENT2>EGFR</ENT2>, EP300, ERBB3, KDM6A, KRAS, MGA, MLL3, PTEN, RASA1, SMARCB1, SPEN, TBC1D12, and VHL.",,,,T,,,,,c,,,,,1.0,,
26684240,3215,C535650,7403,Association,TRUE,"Among 12 <ENT1>GEP-NETs</ENT1>, eight showed mutations of more than one cancer-related gene, including TP53, CNBD1, RB1, APC, BCOR, BRAF, CTNNB1, EGFR, EP300, ERBB3, <ENT2>KDM6A</ENT2>, KRAS, MGA, MLL3, PTEN, RASA1, SMARCB1, SPEN, TBC1D12, and VHL.",,,,T,,,,,c,,,,,1.0,,
26847345;26847345;26847345,3234;3235;3236,6876;6876;6876,7145;55740;51361,Positive_Correlation;Positive_Correlation;Positive_Correlation,TRUE;TRUE;TRUE,"Investigation of mRNA expression patterns showed that <ENT1>transgelin</ENT1> overexpression altered the levels of approximately 250 other transcripts, with over-representation of genes that affect function of actin or other <ENT2><ENT1>cytoskeletal proteins</ENT2></ENT1>.",,,,T,,,,,w,,,,,0.5,TRUE,
26847345,3237,6876,60,Association,TRUE,"Investigation of mRNA expression patterns showed that <ENT1>transgelin</ENT1> overexpression altered the levels of approximately 250 other transcripts, with over-representation of genes that affect function of <ENT2>actin</ENT2> or other <ENT1>cytoskeletal proteins</ENT1>.",,,,T,,,,,w,,,,,0.0,,
26847345,3239,6876,D015179,Association,TRUE,<ENT1>Transgelin</ENT1> increases metastatic potential of <ENT2>colorectal cancer</ENT2> cells in vivo and alters expression of genes involved in cell motility.,,,,T,,,,,c,,,,,1.0,,
26847345,3239,6876,D015179,Association,TRUE,Here we sought to determine the role of <ENT1>transgelin</ENT1> more directly by determining whether experimental manipulation of <ENT1>transgelin</ENT1> levels in <ENT2>colorectal cancer</ENT2> (<ENT2>CRC</ENT2>) cells led to changes in metastatic potential in vivo. METHODS: Isogenic <ENT2>CRC</ENT2> cell lines that differ in <ENT1>transgelin</ENT1> expression were characterized using in vitro assays of growth and invasiveness and a mouse tail vein assay of experimental metastasis.,,,,T,,Y,,,c,,,,,0.888888889,,
26847345,3229,6876,D009369,Association,TRUE,"Although the role of <ENT1>transgelin</ENT1> in <ENT2>cancer</ENT2> is controversial, a number of studies have shown that elevated levels correlate with aggressive <ENT2>tumor</ENT2> behavior, advanced stage, and poor prognosis.",,,,T,,,,,c,,,,,0.5,,
26847345,3229,6876,D009369,Association,TRUE,"CONCLUSIONS: Increases or decreases in <ENT1>transgelin</ENT1> levels have reciprocal effects on <ENT2>tumor</ENT2> cell behavior, with higher expression promoting metastasis.",,,,T,,,,,c,,,,,1.0,,
26900322,3241,rs7356506,D002386,Association,TRUE,"Furthermore, there were significant decreases in the frequencies of the G allele and GG homozygosity in CFI-<ENT1>rs7356506</ENT1> in patients with VKH syndrome with complicated <ENT2>cataract</ENT2> compared to the controls (p<0.001, OR=0.357, 95% CI=0.197-0.648; p<0.001, OR=0.273, 95% CI=0.135-0.551, respectively).",,,,T,,,,,c,,,,,1.0,,
26900322,3241,rs7356506,D002386,Association,TRUE,"CONCLUSIONS: Our results indicate that CFI polymorphisms are not significantly associated with VKH syndrome; nevertheless, we identified a trend for the association of CFI-<ENT1>7356506</ENT1> with VKH syndrome that depends on the recurrent status and the complicated <ENT2>cataract</ENT2> status but not on the steroid-sensitive status.",,,,T,,,,,c,,,,,1.0,,
26900322,3242,rs7356506,D014607,Association,TRUE,CFI-<ENT1>rs7356506</ENT1> polymorphisms associated with <ENT2>Vogt-Koyanagi-Harada syndrome</ENT2>.,,,,T,,,,,c,,,,,0.0,,
26900322,3242,rs7356506,D014607,Association,TRUE,RESULTS: No significant association was found between CFI-<ENT1>rs7356506</ENT1> polymorphisms and <ENT2>VKH syndrome</ENT2>.,,,,T,,,,,c,,,,,1.0,,
26900322,3242,rs7356506,D014607,Association,TRUE,"However, patients with recurrent <ENT2>VKH syndrome</ENT2> had lower frequencies of the G allele and GG homozygosity in CFI-<ENT1>rs7356506</ENT1> when compared to the controls (p=0.016, odds ratio [OR]=0.429, 95% confidence interval [CI]=0.212-0.871; p=0.014, OR=0.364, 95% CI=0.158-0.837, respectively).",,,,T,,,,,c,,,,,1.0,,
26900322,3242,rs7356506,D014607,Association,TRUE,"Furthermore, there were significant decreases in the frequencies of the G allele and GG homozygosity in CFI-<ENT1>rs7356506</ENT1> in patients with <ENT2>VKH syndrome</ENT2> with complicated cataract compared to the controls (p<0.001, OR=0.357, 95% CI=0.197-0.648; p<0.001, OR=0.273, 95% CI=0.135-0.551, respectively).",,,,T,,,,,c,,,,,1.0,,
26900322,3242,rs7356506,D014607,Association,TRUE,"Nevertheless, no significant association with patients with <ENT2>VKH syndrome</ENT2> in steroid-sensitive statuses was detected for CFI-<ENT1>rs7356506</ENT1> polymorphisms.",,,,T,,,,,c,,,,,1.0,,
26900322,3242,rs7356506,D014607,Association,TRUE,"CONCLUSIONS: Our results indicate that CFI polymorphisms are not significantly associated with <ENT2>VKH syndrome</ENT2>; nevertheless, we identified a trend for the association of CFI-<ENT1>7356506</ENT1> with <ENT2>VKH syndrome</ENT2> that depends on the recurrent status and the complicated cataract status but not on the steroid-sensitive status.",,,,T,,,,,c,,,,,0.0,,
26900322,3243,3426,D014605,Association,FALSE,PURPOSE: <ENT1>Complement factor I</ENT1> (<ENT1>CFI</ENT1>) plays an important role in complement activation pathways and is known to affect the development of <ENT2>uveitis</ENT2>.,,,,T,,,,,c,,,,,1.0,,
26900322,3244,3426,D002386,Association,TRUE,"Furthermore, there were significant decreases in the frequencies of the G allele and GG homozygosity in <ENT1>CFI</ENT1>-rs7356506 in patients with VKH syndrome with complicated <ENT2>cataract</ENT2> compared to the controls (p<0.001, OR=0.357, 95% CI=0.197-0.648; p<0.001, OR=0.273, 95% CI=0.135-0.551, respectively).",,,,T,,,,,c,,,,,1.0,,
26900322,3244,3426,D002386,Association,TRUE,"CONCLUSIONS: Our results indicate that <ENT1>CFI</ENT1> polymorphisms are not significantly associated with VKH syndrome; nevertheless, we identified a trend for the association of <ENT1>CFI</ENT1>-7356506 with VKH syndrome that depends on the recurrent status and the complicated <ENT2>cataract</ENT2> status but not on the steroid-sensitive status.",,,,T,,,,,c,,,,,0.5,,
26900322,3245,3426,D014607,Association,TRUE,<ENT1>CFI</ENT1>-rs7356506 polymorphisms associated with <ENT2>Vogt-Koyanagi-Harada syndrome</ENT2>.,,,,T,,,,,c,,,,,1.0,,
26900322,3245,3426,D014607,Association,TRUE,The present study was performed to investigate the existence of an association between <ENT1>CFI</ENT1> genetic polymorphisms and <ENT2>Vogt-Koyanagi-Harada (VKH) syndrome</ENT2>.,,,,T,,Y,,,c,,,,,1.0,,
26900322,3245,3426,D014607,Association,TRUE,RESULTS: No significant association was found between <ENT1>CFI</ENT1>-rs7356506 polymorphisms and <ENT2>VKH syndrome</ENT2>.,,,,T,,,,,c,,,,,1.0,,
26900322,3245,3426,D014607,Association,TRUE,"However, patients with recurrent <ENT2>VKH syndrome</ENT2> had lower frequencies of the G allele and GG homozygosity in <ENT1>CFI</ENT1>-rs7356506 when compared to the controls (p=0.016, odds ratio [OR]=0.429, 95% confidence interval [CI]=0.212-0.871; p=0.014, OR=0.364, 95% CI=0.158-0.837, respectively).",,,,T,,,,,c,,,,,1.0,,
26900322,3245,3426,D014607,Association,TRUE,"Furthermore, there were significant decreases in the frequencies of the G allele and GG homozygosity in <ENT1>CFI</ENT1>-rs7356506 in patients with <ENT2>VKH syndrome</ENT2> with complicated cataract compared to the controls (p<0.001, OR=0.357, 95% CI=0.197-0.648; p<0.001, OR=0.273, 95% CI=0.135-0.551, respectively).",,,,T,,,,,c,,,,,1.0,,
26900322,3245,3426,D014607,Association,TRUE,"Nevertheless, no significant association with patients with <ENT2>VKH syndrome</ENT2> in steroid-sensitive statuses was detected for <ENT1>CFI</ENT1>-rs7356506 polymorphisms.",,,,T,,,,,c,,,,,1.0,,
26900322,3245,3426,D014607,Association,TRUE,"CONCLUSIONS: Our results indicate that <ENT1>CFI</ENT1> polymorphisms are not significantly associated with <ENT2>VKH syndrome</ENT2>; nevertheless, we identified a trend for the association of <ENT1>CFI</ENT1>-7356506 with <ENT2>VKH syndrome</ENT2> that depends on the recurrent status and the complicated cataract status but not on the steroid-sensitive status.",,,,T,,,,,c,,,,,0.0,,
26937641,3264,116554,6352,Association,TRUE,"Serum amyloid A induced the transcription of MCP-1, <ENT2>RANTES</ENT2> and MMP9 in an NF-kappaB- and <ENT1>JNK</ENT1>-dependent manner.",,,,T,,,,,c,,,,,0.0,,
26937641;26937641;26937641,3344;3324;3304,116554;116554;116554,20208;20210;6288,Positive_Correlation;Positive_Correlation;Positive_Correlation,TRUE;TRUE;TRUE,"<ENT2>Serum amyloid A</ENT2> potently activated IkappaB kinase, <ENT1>c-Jun N-terminal kinase</ENT1> (<ENT1>JNK</ENT1>), Erk and Akt and enhanced NF-kappaB-dependent luciferase activity in primary human and rat HSCs.",,,,T,,,,,c,,,,,0.0,,
26937641;26937641;26937641,3344;3324;3304,116554;116554;116554,20208;20210;6288,Positive_Correlation;Positive_Correlation;Positive_Correlation,TRUE;TRUE;TRUE,"<ENT2>Serum amyloid A</ENT2> induced the transcription of MCP-1, RANTES and MMP9 in an NF-kappaB- and <ENT1>JNK</ENT1>-dependent manner.",,,,T,,,,,w,,,,,0.0,,
26937641;26937641;26937641,3344;3324;3304,116554;116554;116554,20208;20210;6288,Positive_Correlation;Positive_Correlation;Positive_Correlation,TRUE;TRUE;TRUE,"<ENT2>Serum amyloid A</ENT2> induced HSC proliferation, which depended on <ENT1>JNK</ENT1>, Erk and Akt activity.",,,,T,,,,,w,,,,,1.0,,
26937641;26937641;26937641;26937641;26937641;26937641;26937641,3344;3324;3304;3315;3295;3332;3312,116554;116554;116554;5594;5594;207;207,20208;20210;6288;20210;6288;20210;6288,Positive_Correlation;Positive_Correlation;Positive_Correlation;Positive_Correlation;Positive_Correlation;Positive_Correlation;Positive_Correlation,TRUE;TRUE;TRUE;TRUE;TRUE;TRUE;TRUE,"In primary hepatocytes, <ENT2>SAA</ENT2> also activated <ENT1>MAP kinases,</ENT1> but did not induce relevant cell death after NF-kappaB inhibition.",,,,T,,,,,c,,,,,1.0,,
26937641,3252,116554,81687,Association,TRUE,"Serum amyloid A induced the transcription of MCP-1, RANTES and <ENT2>MMP9</ENT2> in an NF-kappaB- and <ENT1>JNK</ENT1>-dependent manner.",,,,T,,,,,c,,,,,0.0,,
26937641,3272,116554,24770,Association,TRUE,"Serum amyloid A induced the transcription of <ENT2>MCP-1</ENT2>, RANTES and MMP9 in an NF-kappaB- and <ENT1>JNK</ENT1>-dependent manner.",,,,T,,,,,c,,,,,0.0,,
26937641;26937641;26937641,3339;3319;3299,25591;25591;25591,20208;20210;6288,Association;Association;Association,TRUE;TRUE;TRUE,Blockade of NF-kappaB revealed cytotoxic effects of <ENT2>SAA</ENT2> in primary HSCs with signs of apoptosis such as caspase 3 and <ENT1>PARP</ENT1> cleavage and Annexin V staining.,,,,T,,,,,c,,,,,0.0,,
26937641,3277,25591,81736,Association,TRUE,Blockade of <ENT2>NF-kappaB</ENT2> revealed cytotoxic effects of SAA in primary HSCs with signs of apoptosis such as caspase 3 and <ENT1>PARP</ENT1> cleavage and Annexin V staining.,,,,T,,,,,c,,,,,0.0,,
26937641;26937641;26937641,3342;3322;3302,25402;25402;25402,20208;20210;6288,Association;Association;Association,TRUE;TRUE;TRUE,Blockade of NF-kappaB revealed cytotoxic effects of <ENT2>SAA</ENT2> in primary HSCs with signs of apoptosis such as <ENT1>caspase 3</ENT1> and PARP cleavage and Annexin V staining.,,,,T,,,,,c,,,,,0.0,,
26937641,3280,25402,81736,Association,TRUE,Blockade of <ENT2>NF-kappaB</ENT2> revealed cytotoxic effects of SAA in primary HSCs with signs of apoptosis such as <ENT1>caspase 3</ENT1> and PARP cleavage and Annexin V staining.,,,,T,,,,,c,,,,,0.0,,
26937641;26937641;26937641,3348;3328;3308,6352;6352;6352,20208;20210;6288,Positive_Correlation;Positive_Correlation;Positive_Correlation,TRUE;TRUE;TRUE,"<ENT2>Serum amyloid A</ENT2> induced the transcription of MCP-1, <ENT1>RANTES</ENT1> and MMP9 in an NF-kappaB- and JNK-dependent manner.",,,,T,,,,,c,,,,,1.0,,
26937641,3265,6352,81736,Association,TRUE,"Serum amyloid A induced the transcription of MCP-1, <ENT1>RANTES</ENT1> and MMP9 in an <ENT2>NF-kappaB</ENT2>- and JNK-dependent manner.",,,,T,,,,,c,,,,,0.0,,
26937641;26937641;26937641,3337;3317;3297,308;308;308,20208;20210;6288,Association;Association;Association,TRUE;TRUE;TRUE,Blockade of NF-kappaB revealed cytotoxic effects of <ENT2>SAA</ENT2> in primary HSCs with signs of apoptosis such as caspase 3 and PARP cleavage and <ENT1>Annexin V</ENT1> staining.,,,,T,,,,,c,,,,,0.0,,
26937641,3275,308,81736,Association,TRUE,Blockade of <ENT2>NF-kappaB</ENT2> revealed cytotoxic effects of SAA in primary HSCs with signs of apoptosis such as caspase 3 and PARP cleavage and <ENT1>Annexin V</ENT1> staining.,,,,T,,,,,c,,,,,0.0,,
26937641,3248,20208,6351,Positive_Correlation,TRUE,"In two models of hepatic fibrogenesis, <ENT2>CCl4</ENT2> treatment and bile duct ligation, hepatic mRNA levels of <ENT1>SAA1</ENT1> and SAA3 were strongly increased.",,,,T,,,,,c,,,,,1.0,,
26937641,3333,20208,9641,Positive_Correlation,TRUE,"<ENT1>Serum amyloid A</ENT1> potently activated <ENT2>IkappaB kinase</ENT2>, c-Jun N-terminal kinase (JNK), Erk and Akt and enhanced NF-kappaB-dependent luciferase activity in primary human and rat HSCs.",,,,T,,,,,c,,,,,1.0,,
26937641,3250,20208,D008107,Association,TRUE,"In two models of <ENT2>hepatic fibrogenesis</ENT2>, CCl4 treatment and bile duct ligation, hepatic mRNA levels of <ENT1>SAA1</ENT1> and SAA3 were strongly increased.",,,,T,,,,,c,,,,,1.0,,
26937641,3335,20208,5594,Positive_Correlation,TRUE,"<ENT1>Serum amyloid A</ENT1> potently activated IkappaB kinase, c-Jun N-terminal kinase (JNK), <ENT2>Erk</ENT2> and Akt and enhanced NF-kappaB-dependent luciferase activity in primary human and rat HSCs.",,,,T,,,,,c,,,,,0.0,,
26937641,3335,20208,5594,Positive_Correlation,TRUE,"<ENT1>Serum amyloid A</ENT1> induced HSC proliferation, which depended on JNK, <ENT2>Erk</ENT2> and Akt activity.",,,,T,,,,,w,,,,,1.0,,
26937641;26937641,3335;3352,20208;20208,5594;207,Positive_Correlation;Positive_Correlation,TRUE;TRUE,"In primary hepatocytes, <ENT1>SAA</ENT1> also activated <ENT2>MAP kinases,</ENT2> but did not induce relevant cell death after NF-kappaB inhibition.",,,,T,,,,,c,,,,,1.0,,
26937641,3352,20208,207,Positive_Correlation,TRUE,"<ENT1>Serum amyloid A</ENT1> potently activated IkappaB kinase, c-Jun N-terminal kinase (JNK), Erk and <ENT2>Akt</ENT2> and enhanced NF-kappaB-dependent luciferase activity in primary human and rat HSCs.",,,,T,,,,,c,,,,,1.0,,
26937641,3352,20208,207,Positive_Correlation,TRUE,"<ENT1>Serum amyloid A</ENT1> induced HSC proliferation, which depended on JNK, Erk and <ENT2>Akt</ENT2> activity.",,,,T,,,,,w,,,,,0.0,,
26937641;26937641,3345;3325,20208;20210,81687;81687,Positive_Correlation;Positive_Correlation,TRUE;TRUE,"<ENT1>Serum amyloid A</ENT1> induced the transcription of MCP-1, RANTES and <ENT2>MMP9</ENT2> in an NF-kappaB- and JNK-dependent manner.",,,,T,,,,,c,,,,,1.0,,
26937641;26937641,3283;3282,20208;20210,81736;81736,Association;Association,TRUE;TRUE,"<ENT1>Serum amyloid A</ENT1> potently activated IkappaB kinase, c-Jun N-terminal kinase (JNK), Erk and Akt and enhanced <ENT2>NF-kappaB</ENT2>-dependent luciferase activity in primary human and rat HSCs.",,,,T,,,,,c,,,,,0.0,,
26937641;26937641,3283;3282,20208;20210,81736;81736,Association;Association,TRUE;TRUE,"<ENT1>Serum amyloid A</ENT1> induced the transcription of MCP-1, RANTES and MMP9 in an <ENT2>NF-kappaB</ENT2>- and JNK-dependent manner.",,,,T,,,,,c,,,,,0.0,,
26937641;26937641,3283;3282,20208;20210,81736;81736,Association;Association,TRUE;TRUE,Blockade of <ENT2>NF-kappaB</ENT2> revealed cytotoxic effects of <ENT1>SAA</ENT1> in primary HSCs with signs of apoptosis such as caspase 3 and PARP cleavage and Annexin V staining.,,,,T,,,,,c,,,,,1.0,,
26937641;26937641,3283;3282,20208;20210,81736;81736,Association;Association,TRUE;TRUE,"In primary hepatocytes, <ENT1>SAA</ENT1> also activated MAP kinases, but did not induce relevant cell death after <ENT2>NF-kappaB</ENT2> inhibition.",,,,T,,,,,w,,,,,0.0,,
26937641;26937641,3350;3330,20208;20210,24770;24770,Positive_Correlation;Positive_Correlation,TRUE;TRUE,"<ENT1>Serum amyloid A</ENT1> induced the transcription of <ENT2>MCP-1</ENT2>, RANTES and MMP9 in an NF-kappaB- and JNK-dependent manner.",,,,T,,,,,c,,,,,1.0,,
26937641,3246,6351,D008107,Association,TRUE,"In two models of <ENT2>hepatic fibrogenesis</ENT2>, <ENT1>CCl4</ENT1> treatment and bile duct ligation, hepatic mRNA levels of SAA1 and SAA3 were strongly increased.",,,,T,,,,,w,,,,,0.0,,
26937641,3247,6351,20210,Positive_Correlation,TRUE,"In two models of hepatic fibrogenesis, <ENT1>CCl4</ENT1> treatment and bile duct ligation, hepatic mRNA levels of SAA1 and <ENT2>SAA3</ENT2> were strongly increased.",,,,T,,,,,c,,,,,0.0,,
26937641;26937641,3313;3293,9641;9641,20210;6288,Positive_Correlation;Positive_Correlation,TRUE;TRUE,"<ENT2>Serum amyloid A</ENT2> potently activated <ENT1>IkappaB kinase</ENT1>, c-Jun N-terminal kinase (JNK), Erk and Akt and enhanced NF-kappaB-dependent luciferase activity in primary human and rat HSCs.",,,,T,,,,,c,,,,,1.0,,
26937641,3249,D008107,20210,Association,TRUE,"In two models of <ENT1>hepatic fibrogenesis</ENT1>, CCl4 treatment and bile duct ligation, hepatic mRNA levels of SAA1 and <ENT2>SAA3</ENT2> were strongly increased.",,,,T,,,,,c,,,,,1.0,,
26937641;26937641,3315;3295,5594;5594,20210;6288,Positive_Correlation;Positive_Correlation,TRUE;TRUE,"<ENT2>Serum amyloid A</ENT2> potently activated IkappaB kinase, c-Jun N-terminal kinase (JNK), <ENT1>Erk</ENT1> and Akt and enhanced NF-kappaB-dependent luciferase activity in primary human and rat HSCs.",,,,T,,,,,c,,,,,1.0,,
26937641;26937641,3315;3295,5594;5594,20210;6288,Positive_Correlation;Positive_Correlation,TRUE;TRUE,"<ENT2>Serum amyloid A</ENT2> induced HSC proliferation, which depended on JNK, <ENT1>Erk</ENT1> and Akt activity.",,,,T,,,,,w,,,,,1.0,,
26937641;26937641,3332;3312,207;207,20210;6288,Positive_Correlation;Positive_Correlation,TRUE;TRUE,"<ENT2>Serum amyloid A</ENT2> potently activated IkappaB kinase, c-Jun N-terminal kinase (JNK), Erk and <ENT1>Akt</ENT1> and enhanced NF-kappaB-dependent luciferase activity in primary human and rat HSCs.",,,,T,,,,,c,,,,,0.0,,
26937641;26937641,3332;3312,207;207,20210;6288,Positive_Correlation;Positive_Correlation,TRUE;TRUE,"<ENT2>Serum amyloid A</ENT2> induced HSC proliferation, which depended on JNK, Erk and <ENT1>Akt</ENT1> activity.",,,,T,,,,,w,,,,,0.0,,
26937641,3253,81687,81736,Association,TRUE,"Serum amyloid A induced the transcription of MCP-1, RANTES and <ENT1>MMP9</ENT1> in an <ENT2>NF-kappaB</ENT2>- and JNK-dependent manner.",,,,T,,,,,c,,,,,0.0,,
26937641,3305,81687,6288,Positive_Correlation,TRUE,"<ENT2>Serum amyloid A</ENT2> induced the transcription of MCP-1, RANTES and <ENT1>MMP9</ENT1> in an NF-kappaB- and JNK-dependent manner.",,,,T,,,,,c,,,,,1.0,,
26937641,3273,81736,24770,Association,TRUE,"Serum amyloid A induced the transcription of <ENT2>MCP-1</ENT2>, RANTES and MMP9 in an <ENT1>NF-kappaB</ENT1>- and JNK-dependent manner.",,,,T,,,,,c,,,,,0.0,,
26937641,3281,81736,6288,Association,TRUE,"<ENT2>Serum amyloid A</ENT2> potently activated IkappaB kinase, c-Jun N-terminal kinase (JNK), Erk and Akt and enhanced <ENT1>NF-kappaB</ENT1>-dependent luciferase activity in primary human and rat HSCs.",,,,T,,,,,c,,,,,0.0,,
26937641,3281,81736,6288,Association,TRUE,"<ENT2>Serum amyloid A</ENT2> induced the transcription of MCP-1, RANTES and MMP9 in an <ENT1>NF-kappaB</ENT1>- and JNK-dependent manner.",,,,T,,,,,c,,,,,0.0,,
26937641,3281,81736,6288,Association,TRUE,Blockade of <ENT1>NF-kappaB</ENT1> revealed cytotoxic effects of <ENT2>SAA</ENT2> in primary HSCs with signs of apoptosis such as caspase 3 and PARP cleavage and Annexin V staining.,,,,T,,,,,c,,,,,1.0,,
26937641,3281,81736,6288,Association,TRUE,"In primary hepatocytes, <ENT2>SAA</ENT2> also activated MAP kinases, but did not induce relevant cell death after <ENT1>NF-kappaB</ENT1> inhibition.",,,,T,,,,,w,,,,,0.0,,
26937641,3310,24770,6288,Positive_Correlation,TRUE,"<ENT2>Serum amyloid A</ENT2> induced the transcription of <ENT1>MCP-1</ENT1>, RANTES and MMP9 in an NF-kappaB- and JNK-dependent manner.",,,,T,,,,,c,,,,,1.0,,
26991973,3355,835209,843915,Positive_Correlation,TRUE,"Furthermore, <ENT1>MOL1</ENT1> but not PXY is able to rescue <ENT2>CLV1</ENT2> deficiency in the shoot apical meristem.",,,,T,,,,,c,,,,,0.0,,
26991973,3354,835209,D005030,Association,TRUE,"By identifying genes mis-expressed in <ENT1>mol1</ENT1> mutants, we demonstrate that <ENT1>MOL1</ENT1> represses genes associated with stress-related <ENT2>ethylene</ENT2> and jasmonic acid hormone signaling pathways which have known roles in coordinating lateral growth of the Arabidopsis stem.",,,,T,,,,,c,,,,,0.0,,
26991973,3353,835209,C011006,Association,TRUE,"By identifying genes mis-expressed in <ENT1>mol1</ENT1> mutants, we demonstrate that <ENT1>MOL1</ENT1> represses genes associated with stress-related ethylene and <ENT2>jasmonic acid</ENT2> hormone signaling pathways which have known roles in coordinating lateral growth of the Arabidopsis stem.",,,,T,,,,,c,,,,,0.0,,
26991973,3356,836269,822075,Bind,FALSE,"By employing promoter reporter lines, we reveal that MOL1 is active in a domain that is distinct from the domain of the positively acting <ENT2>CLE41</ENT2>/<ENT1>PXY</ENT1> signaling module.",,,,T,,,,,c,,,,,0.0,,
26991973,3356,836269,822075,Bind,FALSE,"In particular, we show that MOL1 acts in an opposing manner to the <ENT2>CLE41</ENT2>/<ENT1>PXY</ENT1> module and that changing the domain or level of MOL1 expression both result in disturbed cambium organization.",,,,T,,,,,c,,,,,0.0,,
27084744,3381,7025,D003528,Association,TRUE,"CD133(+)<ENT2>ACC</ENT2> cells produced activated NOTCH1 (N1ICD) and generated CD133(-)cells that expressed JAG1 as well as neural differentiation factors <ENT1>NR2F1</ENT1>, NR2F2, and p27Kip1.",,,,T,,,,,c,,,,,1.0,,
27084744,3366,1027,55851,Negative_Correlation,TRUE,"A <ENT2>g-secretase</ENT2> inhibitor, DAPT, selectively depleted CD133(+)cells, suppressed N1ICD and SKP2, induced <ENT1>p27Kip1</ENT1>, inhibited ACC growthin vivo, and sensitized CD133(+)cells to radiation.",,,,T,,,,,c,,,,,0.0,,
27084744,3379,1027,D003528,Association,TRUE,"CD133(+)<ENT2>ACC</ENT2> cells produced activated NOTCH1 (N1ICD) and generated CD133(-)cells that expressed JAG1 as well as neural differentiation factors NR2F1, NR2F2, and <ENT1>p27Kip1</ENT1>.",,,,T,,,,,c,,,,,1.0,,
27084744,3379,1027,D003528,Association,TRUE,"A g-secretase inhibitor, DAPT, selectively depleted CD133(+)cells, suppressed N1ICD and SKP2, induced <ENT1>p27Kip1</ENT1>, inhibited <ENT2>ACC</ENT2> growthin vivo, and sensitized CD133(+)cells to radiation.",,,,T,,,,,c,,,,,1.0,,
27084744,3361,1027,C419410,Positive_Correlation,TRUE,"A g-secretase inhibitor, <ENT2>DAPT</ENT2>, selectively depleted CD133(+)cells, suppressed N1ICD and SKP2, induced <ENT1>p27Kip1</ENT1>, inhibited ACC growthin vivo, and sensitized CD133(+)cells to radiation.",,,,T,,,,,c,,,,,1.0,,
27084744,3369,1027,6502,Association,FALSE,"Among proliferation-linked NOTCH1/FABP7 targets, we identified <ENT2>SKP2</ENT2> and its substrate <ENT1>p27Kip1</ENT1>.",,,,T,,,,,c,,,,,1.0,,
27084744,3369,1027,6502,Association,FALSE,"A g-secretase inhibitor, DAPT, selectively depleted CD133(+)cells, suppressed N1ICD and <ENT2>SKP2</ENT2>, induced <ENT1>p27Kip1</ENT1>, inhibited ACC growthin vivo, and sensitized CD133(+)cells to radiation.",,,,T,,,,,c,,,,,1.0,,
27084744,3382,182,D003528,Association,TRUE,"CD133(+)<ENT2>ACC</ENT2> cells produced activated NOTCH1 (N1ICD) and generated CD133(-)cells that expressed <ENT1>JAG1</ENT1> as well as neural differentiation factors NR2F1, NR2F2, and p27Kip1.",,,,T,,,,,c,,,,,0.0,,
27084744,3372,6663,2173,Positive_Correlation,TRUE,"Knockdowns of NOTCH1, <ENT1>SOX10</ENT1>, and their common effector <ENT2>FABP7</ENT2> had negative effects on each other, inhibited spheroidogenesis, and induced cell death pointing at their essential roles in CSC maintenance.",,,,T,,,,,w,,,,,0.0,,
27084744,3372,6663,2173,Positive_Correlation,TRUE,"CONCLUSIONS: These results establish in the majority of ACC the presence of a previously uncharacterized population of CD133(+)cells with neural stem properties, which are driven by <ENT1>SOX10</ENT1>, NOTCH1, and <ENT2>FABP7</ENT2>.",,,,T,,,,,c,,,,,1.0,,
27084744,3374,6663,D003528,Association,TRUE,NOTCH1 and <ENT1>SOX10</ENT1> are Essential for Proliferation and Radiation Resistance of Cancer Stem-Like Cells in <ENT2>Adenoid Cystic Carcinoma</ENT2>.,,,,T,,,,,c,,,,,1.0,,
27084744,3374,6663,D003528,Association,TRUE,"RESULTS: We identified in <ENT2>ACC</ENT2> CD133-positive CSC that expressed NOTCH1 and <ENT1>SOX10</ENT1>, formed spheroids, and initiated tumors in nude mice.",,,,T,,,,,c,,,,,1.0,,
27084744,3374,6663,D003528,Association,TRUE,"CONCLUSIONS: These results establish in the majority of <ENT2>ACC</ENT2> the presence of a previously uncharacterized population of CD133(+)cells with neural stem properties, which are driven by <ENT1>SOX10</ENT1>, NOTCH1, and FABP7.",,,,T,,,,,c,,,,,1.0,,
27084744,3373,6663,D009369,Association,TRUE,NOTCH1 and <ENT1>SOX10</ENT1> are Essential for Proliferation and Radiation Resistance of <ENT2>Cancer</ENT2> Stem-Like Cells in Adenoid Cystic Carcinoma.,,,,T,,,,,c,,,,,1.0,,
27084744,3373,6663,D009369,Association,TRUE,"RESULTS: We identified in ACC CD133-positive CSC that expressed NOTCH1 and <ENT1>SOX10</ENT1>, formed spheroids, and initiated <ENT2>tumors</ENT2> in nude mice.",,,,T,,,,,c,,,,,0.0,,
27084744,3357,6663,8842,Positive_Correlation,TRUE,"RESULTS: We identified in ACC <ENT2>CD133</ENT2>-positive CSC that expressed NOTCH1 and <ENT1>SOX10</ENT1>, formed spheroids, and initiated tumors in nude mice.",,,,T,,,,,c,,,,,0.0,,
27084744,3357,6663,8842,Positive_Correlation,TRUE,"CONCLUSIONS: These results establish in the majority of ACC the presence of a previously uncharacterized population of <ENT2>CD133</ENT2>(+)cells with neural stem properties, which are driven by <ENT1>SOX10</ENT1>, NOTCH1, and FABP7.",,,,T,Y,,,,c,,,,,0.0,,
27084744,3368,4851,55851,Positive_Correlation,TRUE,"A <ENT2>g-secretase</ENT2> inhibitor, DAPT, selectively depleted CD133(+)cells, suppressed <ENT1>N1ICD</ENT1> and SKP2, induced p27Kip1, inhibited ACC growthin vivo, and sensitized CD133(+)cells to radiation.",,,,T,,,,,c,,,,,0.0,,
27084744,3384,4851,2173,Positive_Correlation,TRUE,"Knockdowns of <ENT1>NOTCH1</ENT1>, SOX10, and their common effector <ENT2>FABP7</ENT2> had negative effects on each other, inhibited spheroidogenesis, and induced cell death pointing at their essential roles in CSC maintenance.",,,,T,,,,,w,,,,,0.0,,
27084744,3384,4851,2173,Positive_Correlation,TRUE,"Among proliferation-linked <ENT1>NOTCH1</ENT1>/<ENT2>FABP7</ENT2> targets, we identified SKP2 and its substrate p27Kip1.",,,,T,,,,,w,,,,,1.0,,
27084744,3384,4851,2173,Positive_Correlation,TRUE,"CONCLUSIONS: These results establish in the majority of ACC the presence of a previously uncharacterized population of CD133(+)cells with neural stem properties, which are driven by SOX10, <ENT1>NOTCH1</ENT1>, and <ENT2>FABP7</ENT2>.",,,,T,,,,,c,,,,,1.0,,
27084744,3386,4851,D003528,Association,TRUE,<ENT1>NOTCH1</ENT1> and SOX10 are Essential for Proliferation and Radiation Resistance of Cancer Stem-Like Cells in <ENT2>Adenoid Cystic Carcinoma</ENT2>.,,,,T,,,,,c,,,,,1.0,,
27084744,3386,4851,D003528,Association,TRUE,"RESULTS: We identified in <ENT2>ACC</ENT2> CD133-positive CSC that expressed <ENT1>NOTCH1</ENT1> and SOX10, formed spheroids, and initiated tumors in nude mice.",,,,T,,,,,c,,,,,1.0,,
27084744,3386,4851,D003528,Association,TRUE,"CD133(+)<ENT2>ACC</ENT2> cells produced activated <ENT1>NOTCH1</ENT1> (<ENT1>N1ICD</ENT1>) and generated CD133(-)cells that expressed JAG1 as well as neural differentiation factors NR2F1, NR2F2, and p27Kip1.",,,,T,,,,,c,,,,,0.5,,
27084744,3386,4851,D003528,Association,TRUE,"A g-secretase inhibitor, DAPT, selectively depleted CD133(+)cells, suppressed <ENT1>N1ICD</ENT1> and SKP2, induced p27Kip1, inhibited <ENT2>ACC</ENT2> growthin vivo, and sensitized CD133(+)cells to radiation.",,,,T,,,,,c,,,,,1.0,,
27084744,3386,4851,D003528,Association,TRUE,"CONCLUSIONS: These results establish in the majority of <ENT2>ACC</ENT2> the presence of a previously uncharacterized population of CD133(+)cells with neural stem properties, which are driven by SOX10, <ENT1>NOTCH1</ENT1>, and FABP7.",,,,T,,,,,c,,,,,1.0,,
27084744,3386,4851,D003528,Association,TRUE,Sensitivity of these cells to <ENT1>Notch</ENT1> inhibition and their dependence on SKP2 offer new opportunities for targeted <ENT2>ACC</ENT2> therapies.,,,,T,,,,,c,,,,,1.0,,
27084744,3383,4851,C419410,Negative_Correlation,TRUE,"A g-secretase inhibitor, <ENT2>DAPT</ENT2>, selectively depleted CD133(+)cells, suppressed <ENT1>N1ICD</ENT1> and SKP2, induced p27Kip1, inhibited ACC growthin vivo, and sensitized CD133(+)cells to radiation.",,,,T,,,,,c,,,,,1.0,,
27084744,3385,4851,D009369,Association,TRUE,<ENT1>NOTCH1</ENT1> and SOX10 are Essential for Proliferation and Radiation Resistance of <ENT2>Cancer</ENT2> Stem-Like Cells in Adenoid Cystic Carcinoma.,,,,T,,,,,c,,,,,1.0,,
27084744,3385,4851,D009369,Association,TRUE,"RESULTS: We identified in ACC CD133-positive CSC that expressed <ENT1>NOTCH1</ENT1> and SOX10, formed spheroids, and initiated <ENT2>tumors</ENT2> in nude mice.",,,,T,,,,,w,,,,,0.0,,
27084744,3358,4851,8842,Association,TRUE,"RESULTS: We identified in ACC <ENT2>CD133</ENT2>-positive CSC that expressed <ENT1>NOTCH1</ENT1> and SOX10, formed spheroids, and initiated tumors in nude mice.",,,,T,,,,,c,,,,,0.0,,
27084744,3358,4851,8842,Association,TRUE,"<ENT2>CD133</ENT2>(+)ACC cells produced activated <ENT1>NOTCH1</ENT1> (<ENT1>N1ICD</ENT1>) and generated <ENT2>CD133</ENT2>(-)cells that expressed JAG1 as well as neural differentiation factors NR2F1, NR2F2, and p27Kip1.",,,,T,,,,,c,,,,,0.25,,
27084744,3358,4851,8842,Association,TRUE,"A g-secretase inhibitor, DAPT, selectively depleted <ENT2>CD133</ENT2>(+)cells, suppressed <ENT1>N1ICD</ENT1> and SKP2, induced p27Kip1, inhibited ACC growthin vivo, and sensitized <ENT2>CD133</ENT2>(+)cells to radiation.",,,,T,,,,,c,,,,,1.0,,
27084744,3358,4851,8842,Association,TRUE,"CONCLUSIONS: These results establish in the majority of ACC the presence of a previously uncharacterized population of <ENT2>CD133</ENT2>(+)cells with neural stem properties, which are driven by SOX10, <ENT1>NOTCH1</ENT1>, and FABP7.",,,,T,,,,,c,,,,,1.0,,
27084744,3380,7026,D003528,Association,TRUE,"CD133(+)<ENT2>ACC</ENT2> cells produced activated NOTCH1 (N1ICD) and generated CD133(-)cells that expressed JAG1 as well as neural differentiation factors NR2F1, <ENT1>NR2F2</ENT1>, and p27Kip1.",,,,T,,,,,c,,,,,0.0,,
27084744,3367,55851,D003528,Association,TRUE,"A <ENT1>g-secretase</ENT1> inhibitor, DAPT, selectively depleted CD133(+)cells, suppressed N1ICD and SKP2, induced p27Kip1, inhibited <ENT2>ACC</ENT2> growthin vivo, and sensitized CD133(+)cells to radiation.",,,,T,,,,,c,,,,,0.0,,
27084744,3364,55851,C419410,Negative_Correlation,FALSE,"A <ENT1>g-secretase</ENT1> inhibitor, <ENT2>DAPT</ENT2>, selectively depleted CD133(+)cells, suppressed N1ICD and SKP2, induced p27Kip1, inhibited ACC growthin vivo, and sensitized CD133(+)cells to radiation.",,,,T,,,,,c,,,,,1.0,,
27084744,3363,55851,8842,Association,TRUE,"A <ENT1>g-secretase</ENT1> inhibitor, DAPT, selectively depleted <ENT2>CD133</ENT2>(+)cells, suppressed N1ICD and SKP2, induced p27Kip1, inhibited ACC growthin vivo, and sensitized <ENT2>CD133</ENT2>(+)cells to radiation.",,,,T,,,,,c,,,,,0.0,,
27084744,3365,55851,6502,Positive_Correlation,TRUE,"A <ENT1>g-secretase</ENT1> inhibitor, DAPT, selectively depleted CD133(+)cells, suppressed N1ICD and <ENT2>SKP2</ENT2>, induced p27Kip1, inhibited ACC growthin vivo, and sensitized CD133(+)cells to radiation.",,,,T,,,,,c,,,,,0.0,,
27084744,3371,2173,D003528,Association,TRUE,"CONCLUSIONS: These results establish in the majority of <ENT2>ACC</ENT2> the presence of a previously uncharacterized population of CD133(+)cells with neural stem properties, which are driven by SOX10, NOTCH1, and <ENT1>FABP7</ENT1>.",,,,T,,,,,c,,,,,1.0,,
27084744,3362,D003528,C419410,Negative_Correlation,TRUE,"A g-secretase inhibitor, <ENT2>DAPT</ENT2>, selectively depleted CD133(+)cells, suppressed N1ICD and SKP2, induced p27Kip1, inhibited <ENT1>ACC</ENT1> growthin vivo, and sensitized CD133(+)cells to radiation.",,,,T,,,,,c,,,,,1.0,,
27084744,3378,D003528,8842,Association,FALSE,"RESULTS: We identified in <ENT1>ACC</ENT1> <ENT2>CD133</ENT2>-positive CSC that expressed NOTCH1 and SOX10, formed spheroids, and initiated tumors in nude mice.",,,,T,,,,,c,,,,,1.0,,
27084744,3378,D003528,8842,Association,FALSE,"<ENT2>CD133</ENT2>(+)<ENT1>ACC</ENT1> cells produced activated NOTCH1 (N1ICD) and generated <ENT2>CD133</ENT2>(-)cells that expressed JAG1 as well as neural differentiation factors NR2F1, NR2F2, and p27Kip1.",,,,T,Y,,,,w,,,,,0.5,TRUE,
27084744,3378,D003528,8842,Association,FALSE,"A g-secretase inhibitor, DAPT, selectively depleted <ENT2>CD133</ENT2>(+)cells, suppressed N1ICD and SKP2, induced p27Kip1, inhibited <ENT1>ACC</ENT1> growthin vivo, and sensitized <ENT2>CD133</ENT2>(+)cells to radiation.",,,,T,,,,,c,,,,,1.0,,
27084744,3378,D003528,8842,Association,FALSE,"CONCLUSIONS: These results establish in the majority of <ENT1>ACC</ENT1> the presence of a previously uncharacterized population of <ENT2>CD133</ENT2>(+)cells with neural stem properties, which are driven by SOX10, NOTCH1, and FABP7.",,,,T,,,,,c,,,,,0.0,,
27084744,3370,D003528,6502,Association,TRUE,"A g-secretase inhibitor, DAPT, selectively depleted CD133(+)cells, suppressed N1ICD and <ENT2>SKP2</ENT2>, induced p27Kip1, inhibited <ENT1>ACC</ENT1> growthin vivo, and sensitized CD133(+)cells to radiation.",,,,T,,,,,c,,,,,1.0,,
27084744,3370,D003528,6502,Association,TRUE,Sensitivity of these cells to Notch inhibition and their dependence on <ENT2>SKP2</ENT2> offer new opportunities for targeted <ENT1>ACC</ENT1> therapies.,,,,T,,,,,c,,,,,1.0,,
27084744,3377,D003528,6093,Association,FALSE,"EXPERIMENTAL DESIGN: To isolate CSC from <ENT1>ACC</ENT1> and characterize them, we used <ENT2>ROCK</ENT2> inhibitor-supplemented cell culture, immunomagnetic cell sorting, andin vitro/in vivoassays for CSC viability and tumorigenicity.",,,,T,,,,,c,,,,,1.0,,
27084744,3359,C419410,8842,Association,TRUE,"A g-secretase inhibitor, <ENT1>DAPT</ENT1>, selectively depleted <ENT2>CD133</ENT2>(+)cells, suppressed N1ICD and SKP2, induced p27Kip1, inhibited ACC growthin vivo, and sensitized <ENT2>CD133</ENT2>(+)cells to radiation.",,,,T,,,,,c,,,,,0.0,,
27084744,3360,C419410,6502,Negative_Correlation,TRUE,"A g-secretase inhibitor, <ENT1>DAPT</ENT1>, selectively depleted CD133(+)cells, suppressed N1ICD and <ENT2>SKP2</ENT2>, induced p27Kip1, inhibited ACC growthin vivo, and sensitized CD133(+)cells to radiation.",,,,T,,,,,c,,,,,1.0,,
27084744,3376,D009369,8842,Association,FALSE,"RESULTS: We identified in ACC <ENT2>CD133</ENT2>-positive CSC that expressed NOTCH1 and SOX10, formed spheroids, and initiated <ENT1>tumors</ENT1> in nude mice.",,,,T,,,,,c,,,,,1.0,,
27090298,3393,9370,57587,Association,FALSE,"Circulating FASN was assessed in 115 asymptomatic pregnant women in the second trimester of gestation along with C-peptide, fasting glucose and insulin, post-load glucose lipids, <ENT2>HMW</ENT2>-<ENT1>adiponectin</ENT1> and blood pressure (the latter was assessed in each trimester of gestation).",,,,T,,,,,w,,,,,0.0,,
27090298,3390,3043,2194,Association,TRUE,"Higher circulating <ENT2>FASN</ENT2> was associated with lower systolic blood pressure (SBP), with a more favourable metabolic phenotype (lower fasting glucose and insulin, post load glucose, <ENT1>HbAc1</ENT1>, HOMA-IR and C-peptide), and with lower placental and birth weight (all p < 0.05 to p < 0.001).",,,,T,,,,,c,,,,,0.0,,
27090298,3388,D006973,2194,Association,FALSE,The enzyme <ENT2>FASN</ENT2> (<ENT2>fatty acid synthase</ENT2>) is potentially related with <ENT1>hypertension</ENT1> and metabolic dysfunction.,,,,T,,,,,c,,,,,1.0,,
27090298,3387,2194,D008659,Association,FALSE,The enzyme <ENT1>FASN</ENT1> (<ENT1>fatty acid synthase</ENT1>) is potentially related with hypertension and <ENT2>metabolic dysfunction</ENT2>.,,,,T,,,,,c,,,,,1.0,,
27090298,3391,2194,3630,Negative_Correlation,TRUE,"Circulating <ENT1>FASN</ENT1> was assessed in 115 asymptomatic pregnant women in the second trimester of gestation along with C-peptide, fasting glucose and <ENT2>insulin</ENT2>, post-load glucose lipids, HMW-adiponectin and blood pressure (the latter was assessed in each trimester of gestation).",,,,T,,,,,c,,,,,1.0,,
27090298,3391,2194,3630,Negative_Correlation,TRUE,"Higher circulating <ENT1>FASN</ENT1> was associated with lower systolic blood pressure (SBP), with a more favourable metabolic phenotype (lower fasting glucose and <ENT2>insulin</ENT2>, post load glucose, HbAc1, HOMA-IR and C-peptide), and with lower placental and birth weight (all p < 0.05 to p < 0.001).",,,,T,,,,,c,,,,,1.0,,
27090298,3391,2194,3630,Negative_Correlation,TRUE,"Future studies will clarify whether circulating <ENT1>FASN</ENT1> of placental origin does actually regulate placental and fetal growth, and (thereby) has a favourable influence on the pregnant mother's <ENT2>insulin</ENT2> sensitivity and blood pressure.",,,,T,,,,,c,,,,,1.0,,
27090298,3392,2194,D005947,Negative_Correlation,TRUE,"Circulating <ENT1>FASN</ENT1> was assessed in 115 asymptomatic pregnant women in the second trimester of gestation along with C-peptide, fasting <ENT2>glucose</ENT2> and insulin, post-load <ENT2>glucose</ENT2> lipids, HMW-adiponectin and blood pressure (the latter was assessed in each trimester of gestation).",,,,T,,,,,c,,,,,1.0,,
27090298,3392,2194,D005947,Negative_Correlation,TRUE,"Higher circulating <ENT1>FASN</ENT1> was associated with lower systolic blood pressure (SBP), with a more favourable metabolic phenotype (lower fasting <ENT2>glucose</ENT2> and insulin, post load <ENT2>glucose</ENT2>, HbAc1, HOMA-IR and C-peptide), and with lower placental and birth weight (all p < 0.05 to p < 0.001).",,,,T,,,,,w,,,,,1.0,,
27090298,3389,2194,D002096,Association,TRUE,"Circulating <ENT1>FASN</ENT1> was assessed in 115 asymptomatic pregnant women in the second trimester of gestation along with <ENT2>C-peptide</ENT2>, fasting glucose and insulin, post-load glucose lipids, HMW-adiponectin and blood pressure (the latter was assessed in each trimester of gestation).",,,,T,,,,,c,,,,,1.0,,
27090298,3389,2194,D002096,Association,TRUE,"Higher circulating <ENT1>FASN</ENT1> was associated with lower systolic blood pressure (SBP), with a more favourable metabolic phenotype (lower fasting glucose and insulin, post load glucose, HbAc1, HOMA-IR and <ENT2>C-peptide</ENT2>), and with lower placental and birth weight (all p < 0.05 to p < 0.001).",,,,T,,,,,w,,,,,0.0,,
27103577,3394,22229,D000255,Association,TRUE,"Compared with a normoxic, chow-fed control mouse heart, hypoxia decreased PPARa expression, fatty acid oxidation, and <ENT1>mitochondrial uncoupling protein 3</ENT1> (<ENT1>UCP3</ENT1>) levels, while increasing glycolysis, all of which served to maintain normal <ENT2>ATP</ENT2> concentrations ([<ENT2>ATP</ENT2>]) and thereby, ejection fractions.",,,,T,,,,,w,,,"11,12,21,22",,0.0,,
27103577,3398,22229,D000860,Negative_Correlation,TRUE,"Compared with a normoxic, chow-fed control mouse heart, <ENT2>hypoxia</ENT2> decreased PPARa expression, fatty acid oxidation, and <ENT1>mitochondrial uncoupling protein 3</ENT1> (<ENT1>UCP3</ENT1>) levels, while increasing glycolysis, all of which served to maintain normal ATP concentrations ([ATP]) and thereby, ejection fractions.",,,,T,,,,,c,,,,,1.0,,
27103577,3396,D000255,19013,Association,TRUE,"Compared with a normoxic, chow-fed control mouse heart, hypoxia decreased <ENT2>PPARa</ENT2> expression, fatty acid oxidation, and mitochondrial uncoupling protein 3 (UCP3) levels, while increasing glycolysis, all of which served to maintain normal <ENT1>ATP</ENT1> concentrations ([<ENT1>ATP</ENT1>]) and thereby, ejection fractions.",,,,T,,,,,c,,,,,1.0,,
27103577,3396,D000255,19013,Association,TRUE,"Hypoxia was unable to alter the high <ENT2>PPARa</ENT2> expression or reverse the metabolic changes caused by the high-fat diet, with the result that [<ENT1>ATP</ENT1>] and contractile function decreased significantly.",,,,T,,,,,w,,,,,0.0,,
27103577,3395,D000255,D005227,Association,TRUE,"Compared with a normoxic, chow-fed control mouse heart, hypoxia decreased PPARa expression, <ENT2>fatty acid</ENT2> oxidation, and mitochondrial uncoupling protein 3 (UCP3) levels, while increasing glycolysis, all of which served to maintain normal <ENT1>ATP</ENT1> concentrations ([<ENT1>ATP</ENT1>]) and thereby, ejection fractions.",,,,T,Y,,,,w,,,,,0.0,,
27103577,3397,D000255,D000860,Negative_Correlation,TRUE,"Compared with a normoxic, chow-fed control mouse heart, <ENT2>hypoxia</ENT2> decreased PPARa expression, fatty acid oxidation, and mitochondrial uncoupling protein 3 (UCP3) levels, while increasing glycolysis, all of which served to maintain normal <ENT1>ATP</ENT1> concentrations ([<ENT1>ATP</ENT1>]) and thereby, ejection fractions.",,,,T,Y,,,,w,,,,,1.0,TRUE,
27103577,3397,D000255,D000860,Negative_Correlation,TRUE,"<ENT2>Hypoxia</ENT2> was unable to alter the high PPARa expression or reverse the metabolic changes caused by the high-fat diet, with the result that [<ENT1>ATP</ENT1>] and contractile function decreased significantly.",,,,T,,,,,c,,,,,1.0,,
27103577,3400,19013,D000860,Negative_Correlation,TRUE,On the pivotal role of <ENT1>PPARa</ENT1> in adaptation of the heart to <ENT2>hypoxia</ENT2> and why fat in the diet increases <ENT2>hypoxic</ENT2> injury.,,,,T,,T,,,w,,,,,0.25,TRUE,
27103577,3400,19013,D000860,Negative_Correlation,TRUE,The role of <ENT1>peroxisome proliferator-activated receptor a</ENT1> (<ENT1>PPARa</ENT1>)-mediated metabolic remodeling in cardiac adaptation to <ENT2>hypoxia</ENT2> has yet to be defined.,,,,T,,Y,,,c,,,,,1.0,,
27103577,3400,19013,D000860,Negative_Correlation,TRUE,"Compared with a normoxic, chow-fed control mouse heart, <ENT2>hypoxia</ENT2> decreased <ENT1>PPARa</ENT1> expression, fatty acid oxidation, and mitochondrial uncoupling protein 3 (UCP3) levels, while increasing glycolysis, all of which served to maintain normal ATP concentrations ([ATP]) and thereby, ejection fractions.",,,,T,,,,,c,,,,,1.0,,
27103577,3400,19013,D000860,Negative_Correlation,TRUE,"<ENT2>Hypoxia</ENT2> was unable to alter the high <ENT1>PPARa</ENT1> expression or reverse the metabolic changes caused by the high-fat diet, with the result that [ATP] and contractile function decreased significantly.",,,,T,,,,,c,,,,,1.0,,
27103577,3400,19013,D000860,Negative_Correlation,TRUE,The adaptive metabolic changes caused by <ENT2>hypoxia</ENT2> in control mouse hearts were found to have occurred already in <ENT1>PPARa</ENT1>-deficient (<ENT1>PPARa</ENT1>(-/-)) mouse hearts and sustained function in <ENT2>hypoxia</ENT2> despite an inability for further metabolic remodeling.,,,,T,,,,,c,,,,,1.0,,
27103577,3400,19013,D000860,Negative_Correlation,TRUE,"We conclude that decreased cardiac <ENT1>PPARa</ENT1> expression is essential for adaptive metabolic remodeling in <ENT2>hypoxia</ENT2>, but is prevented by dietary fat.-Cole, M. A., Abd Jamil, A. H., Heather, L. C., Murray, A. J., Sutton, E. R., Slingo, M., Sebag-Montefiore, L., Tan, S. C., Aksentijevic, D., Gildea, O. S., Stuckey, D. J., Yeoh, K. K., Carr, C. A., Evans, R. D., Aasum, E., Schofield, C. J., Ratcliffe, P. J., Neubauer, S., Robbins, P. A., Clarke, K.",,,,T,Y,,,,w,,,,,0.0,,
27103577,3399,D005227,D000860,Negative_Correlation,TRUE,"Compared with a normoxic, chow-fed control mouse heart, <ENT2>hypoxia</ENT2> decreased PPARa expression, <ENT1>fatty acid</ENT1> oxidation, and mitochondrial uncoupling protein 3 (UCP3) levels, while increasing glycolysis, all of which served to maintain normal ATP concentrations ([ATP]) and thereby, ejection fractions.",,,,T,,,,,c,,,,,0.0,,
27172902,3418,13982,D002945,Positive_Correlation,TRUE,"<ENT2>Cisplatin</ENT2> induces tolerogenic dendritic cells in response to <ENT1>TLR</ENT1> agonists via the abundant production of IL-10, thereby promoting Th2- and Tr1-biased T-cell immunity.",,,,T,,,,,w,,,,,0.0,,
27172902,3418,13982,D002945,Positive_Correlation,TRUE,"Here, we investigated the effect of <ENT2>cisplatin</ENT2> on the functionality of DCs and the changes in signaling pathways activated upon <ENT1>toll-like receptor</ENT1> (<ENT1>TLR</ENT1>) stimulation.",,,,T,,Y,,,w,,,,,0.0,TRUE,
27172902,3418,13982,D002945,Positive_Correlation,TRUE,"Upon stimulation with various <ENT1>TLR</ENT1> agonists, <ENT2>cisplatin</ENT2>-treated DCs showed markedly increased IL-10 production through activation of the p38 MAPK and NF-kappaB signaling pathways without altering the levels of TNF-alpha and IL-12p70, indicating the <ENT2>cisplatin</ENT2>-mediated induction of tolerogenic DCs.",,,,T,Y,,,,w,,,,,0.5,,
27172902,3406,13982,26416,Positive_Correlation,TRUE,"Upon stimulation with various <ENT1>TLR</ENT1> agonists, cisplatin-treated DCs showed markedly increased IL-10 production through activation of the <ENT2>p38 MAPK</ENT2> and NF-kappaB signaling pathways without altering the levels of TNF-alpha and IL-12p70, indicating the cisplatin-mediated induction of tolerogenic DCs.",,,,T,,,,,c,,,,,0.0,,
27172902,3407,13982,16153,Positive_Correlation,TRUE,"Cisplatin induces tolerogenic dendritic cells in response to <ENT1>TLR</ENT1> agonists via the abundant production of <ENT2>IL-10</ENT2>, thereby promoting Th2- and Tr1-biased T-cell immunity.",,,,T,,,,,c,,,,,1.0,,
27172902,3407,13982,16153,Positive_Correlation,TRUE,"Upon stimulation with various <ENT1>TLR</ENT1> agonists, cisplatin-treated DCs showed markedly increased <ENT2>IL-10</ENT2> production through activation of the p38 MAPK and NF-kappaB signaling pathways without altering the levels of TNF-alpha and IL-12p70, indicating the cisplatin-mediated induction of tolerogenic DCs.",,,,T,,,,,c,,,,,1.0,,
27172902,3405,13982,18033,Positive_Correlation,TRUE,"Upon stimulation with various <ENT1>TLR</ENT1> agonists, cisplatin-treated DCs showed markedly increased IL-10 production through activation of the p38 MAPK and <ENT2>NF-kappaB</ENT2> signaling pathways without altering the levels of TNF-alpha and IL-12p70, indicating the cisplatin-mediated induction of tolerogenic DCs.",,,,T,,,,,c,,,,,0.0,,
27172902,3416,D002945,12524,Negative_Correlation,TRUE,"<ENT1>Cisplatin</ENT1>-treated DCs down-regulated the expression of cell surface molecules (CD80, <ENT2>CD86</ENT2>, MHC class I and II) and up-regulated endocytic capacity in a dose-dependent manner.",,,,T,,,,,c,,,,,0.0,,
27172902,3414,D002945,14972,Negative_Correlation,TRUE,"<ENT1>Cisplatin</ENT1>-treated DCs down-regulated the expression of cell surface molecules (CD80, CD86, <ENT2>MHC class I and II</ENT2>) and up-regulated endocytic capacity in a dose-dependent manner.",,,,T,,,,,c,,,,,1.0,,
27172902,3409,D002945,D007249,Positive_Correlation,TRUE,"Taken together, our results suggest that <ENT1>cisplatin</ENT1> induces immune-suppressive tolerogenic DCs in TLR agonist-induced <ENT2>inflammatory</ENT2> conditions via abundant IL-10 production, thereby skewing Th cell differentiation towards Th2 and Tr1 cells.",,,,T,,,,,w,,,,,0.0,,
27172902,3412,D002945,26416,Positive_Correlation,TRUE,"Upon stimulation with various TLR agonists, <ENT1>cisplatin</ENT1>-treated DCs showed markedly increased IL-10 production through activation of the <ENT2>p38 MAPK</ENT2> and NF-kappaB signaling pathways without altering the levels of TNF-alpha and IL-12p70, indicating the <ENT1>cisplatin</ENT1>-mediated induction of tolerogenic DCs.",,,,T,,,,,c,,,,,0.5,,
27172902,3413,D002945,16153,Positive_Correlation,TRUE,"<ENT1>Cisplatin</ENT1> induces tolerogenic dendritic cells in response to TLR agonists via the abundant production of <ENT2>IL-10</ENT2>, thereby promoting Th2- and Tr1-biased T-cell immunity.",,,,T,,,,,c,,,,,1.0,,
27172902,3413,D002945,16153,Positive_Correlation,TRUE,"Upon stimulation with various TLR agonists, <ENT1>cisplatin</ENT1>-treated DCs showed markedly increased <ENT2>IL-10</ENT2> production through activation of the p38 MAPK and NF-kappaB signaling pathways without altering the levels of TNF-alpha and IL-12p70, indicating the <ENT1>cisplatin</ENT1>-mediated induction of tolerogenic DCs.",,,,T,,,,,c,,,,,1.0,,
27172902,3413,D002945,16153,Positive_Correlation,TRUE,"Taken together, our results suggest that <ENT1>cisplatin</ENT1> induces immune-suppressive tolerogenic DCs in TLR agonist-induced inflammatory conditions via abundant <ENT2>IL-10</ENT2> production, thereby skewing Th cell differentiation towards Th2 and Tr1 cells.",,,,T,,,,,c,,,,,1.0,,
27172902,3417,D002945,12519,Negative_Correlation,TRUE,"<ENT1>Cisplatin</ENT1>-treated DCs down-regulated the expression of cell surface molecules (<ENT2>CD80</ENT2>, CD86, MHC class I and II) and up-regulated endocytic capacity in a dose-dependent manner.",,,,T,,,,,c,,,,,1.0,,
27172902,3408,D002945,D009369,Negative_Correlation,FALSE,"Although many advantageous roles of <ENT1>cisplatin</ENT1> (<ENT1>cis-diamminedichloroplatinum</ENT1> (II), <ENT1>CDDP</ENT1>) have been reported in <ENT2>cancer</ENT2> therapy, the immunomodulatory roles of <ENT1>cisplatin</ENT1> in the phenotypic and functional alterations of dendritic cells (DCs) are poorly understood.",,,,T,,,,,c,,,,,0.5,,
27172902,3410,D002945,D008070,Cotreatment,TRUE,"Interestingly, DCs that were co-treated with <ENT1>cisplatin</ENT1> and <ENT2>lipopolysaccharide</ENT2> (<ENT2>LPS</ENT2>) exhibited a decreased immunostimulatory capacity for inducing the proliferation of Th1- and Th17-type T cells; instead, these DCs contributed to Th2-type T cell immunity.",,,,T,,,,,c,,,,,0.5,,
27172902,3411,D002945,18033,Positive_Correlation,TRUE,"Upon stimulation with various TLR agonists, <ENT1>cisplatin</ENT1>-treated DCs showed markedly increased IL-10 production through activation of the p38 MAPK and <ENT2>NF-kappaB</ENT2> signaling pathways without altering the levels of TNF-alpha and IL-12p70, indicating the <ENT1>cisplatin</ENT1>-mediated induction of tolerogenic DCs.",,,,T,,,,,c,,,,,0.0,,
27172902,3402,D007249,16153,Association,TRUE,"Taken together, our results suggest that cisplatin induces immune-suppressive tolerogenic DCs in TLR agonist-induced <ENT1>inflammatory</ENT1> conditions via abundant <ENT2>IL-10</ENT2> production, thereby skewing Th cell differentiation towards Th2 and Tr1 cells.",,,,T,,,,,w,,,,,0.0,,
27172902,3404,26416,16153,Positive_Correlation,TRUE,"Upon stimulation with various TLR agonists, cisplatin-treated DCs showed markedly increased <ENT2>IL-10</ENT2> production through activation of the <ENT1>p38 MAPK</ENT1> and NF-kappaB signaling pathways without altering the levels of TNF-alpha and IL-12p70, indicating the cisplatin-mediated induction of tolerogenic DCs.",,,,T,,,,,c,,,,,0.0,,
27172902,3403,16153,18033,Positive_Correlation,TRUE,"Upon stimulation with various TLR agonists, cisplatin-treated DCs showed markedly increased <ENT1>IL-10</ENT1> production through activation of the p38 MAPK and <ENT2>NF-kappaB</ENT2> signaling pathways without altering the levels of TNF-alpha and IL-12p70, indicating the cisplatin-mediated induction of tolerogenic DCs.",,,,T,,,,,c,,,,,0.0,,
27184800,3422,D000077157,D009369,Negative_Correlation,FALSE,"BACKGROUND: <ENT1>Sorafenib</ENT1>, a kinase inhibitor active against various solid <ENT2>tumours</ENT2>, induces oxidative stress and ferroptosis, a new form of oxidative necrosis, in some <ENT2>cancer</ENT2> cells.",,,,T,,,,,c,,,,,1.0,,
27184800,3422,D000077157,D009369,Negative_Correlation,FALSE,Clinically-applicable biomarkers that reflect the impact of <ENT1>sorafenib</ENT1> on the redox metabolism of <ENT2>cancer</ENT2> cells are lacking.,,,,T,,,,,w,,,,,0.0,,
27184800,3422,D000077157,D009369,Negative_Correlation,FALSE,"METHODS: We used gene expression microarrays, real-time PCR, immunoblot, protein-specific ELISA, and gene reporter constructs encoding the enzyme luciferase to study the response of a panel of <ENT2>cancer</ENT2> cells to <ENT1>sorafenib</ENT1>.",,,,T,,Y,,,w,,,,,0.0,,
27184800,3422,D000077157,D009369,Negative_Correlation,FALSE,<ENT2>Tumour</ENT2> explants prepared from surgical hepatocellular carcinoma (HCC) samples and serum samples obtained from HCC patients receiving <ENT1>sorafenib</ENT1> were also used.,,,,T,Y,,,,w,,,,,1.0,,
27184800,3422,D000077157,D009369,Negative_Correlation,FALSE,"<ENT1>Sorafenib</ENT1> increased the expression of MT1G mRNA in a panel of human <ENT2>cancer</ENT2> cells, an effect that was not observed with eight other clinically-approved kinase inhibitors.",,,,T,Y,,,,w,,,,,1.0,,
27184800,3422,D000077157,D009369,Negative_Correlation,FALSE,CONCLUSION: These findings indicate that MT1 constitute a biomarker adapted for exploring the impact of <ENT1>sorafenib</ENT1> on the redox metabolism of <ENT2>cancer</ENT2> cells.,,,,T,Y,,,,w,,,,,0.0,,
27184800,3423,D000077157,D006528,Negative_Correlation,FALSE,Metallothionein-1 as a biomarker of altered redox metabolism in <ENT2>hepatocellular carcinoma</ENT2> cells exposed to <ENT1>sorafenib</ENT1>.,,,,T,,,,,w,,,,,0.0,,
27184800,3423,D000077157,D006528,Negative_Correlation,FALSE,Tumour explants prepared from surgical <ENT2>hepatocellular carcinoma</ENT2> (<ENT2>HCC</ENT2>) samples and serum samples obtained from <ENT2>HCC</ENT2> patients receiving <ENT1>sorafenib</ENT1> were also used.,,,,T,,,,,w,,,,,1.0,TRUE,
27184800,3423,D000077157,D006528,Negative_Correlation,FALSE,RESULTS: We observed that genes of the metallothionein-1 (MT1) family are induced in the <ENT2>HCC</ENT2> cell line Huh7 exposed to <ENT1>sorafenib</ENT1>.,,,,T,,,,,w,,,,,1.0,,
27184800,3423,D000077157,D006528,Negative_Correlation,FALSE,"Finally, we showed that the protein levels of MT1 increase in the serum of some <ENT2>HCC</ENT2> patients receiving <ENT1>sorafenib</ENT1>, and found an association with reduced overall survival.",,,,T,,,,,w,,,,,0.0,,
27184800,3420,D000077157,4495,Positive_Correlation,TRUE,<ENT2>Metallothionein-1</ENT2> as a biomarker of altered redox metabolism in hepatocellular carcinoma cells exposed to <ENT1>sorafenib</ENT1>.,,,,T,,,,,w,,,,,0.0,,
27184800,3420,D000077157,4495,Positive_Correlation,TRUE,RESULTS: We observed that genes of the <ENT2>metallothionein-1</ENT2> (<ENT2>MT1</ENT2>) family are induced in the HCC cell line Huh7 exposed to <ENT1>sorafenib</ENT1>.,,,,T,,,,,c,,,,,1.0,,
27184800,3420,D000077157,4495,Positive_Correlation,TRUE,"<ENT1>Sorafenib</ENT1> increased the expression of <ENT2>MT1G</ENT2> mRNA in a panel of human cancer cells, an effect that was not observed with eight other clinically-approved kinase inhibitors.",,,,T,,,,,c,,,,,1.0,,
27184800,3420,D000077157,4495,Positive_Correlation,TRUE,We identified the minimal region of the <ENT2>MT1G</ENT2> promoter that confers inducibility by <ENT1>sorafenib</ENT1> to a 133 base pair region containing an Anti-oxidant Response Element (ARE) and showed the essential role of the transcription factor NRF2 (Nuclear factor erythroid 2-Related Factor 2).,,,,T,,,,,c,,,,,1.0,,
27184800,3420,D000077157,4495,Positive_Correlation,TRUE,"Finally, we showed that the protein levels of <ENT2>MT1</ENT2> increase in the serum of some HCC patients receiving <ENT1>sorafenib</ENT1>, and found an association with reduced overall survival.",,,,T,,,,,c,,,,,1.0,,
27184800,3420,D000077157,4495,Positive_Correlation,TRUE,CONCLUSION: These findings indicate that <ENT2>MT1</ENT2> constitute a biomarker adapted for exploring the impact of <ENT1>sorafenib</ENT1> on the redox metabolism of cancer cells.,,,,T,,,,,w,,,,,0.0,,
27184800,3419,D009369,4495,Association,TRUE,"Sorafenib increased the expression of <ENT2>MT1G</ENT2> mRNA in a panel of human <ENT1>cancer</ENT1> cells, an effect that was not observed with eight other clinically-approved kinase inhibitors.",,,,T,,,,,c,,,,,1.0,,
27184800,3419,D009369,4495,Association,TRUE,We examined the clinical relevance of our findings by analysing the regulation of <ENT2>MT1G</ENT2> in five <ENT1>tumour</ENT1> explants prepared from surgical HCC samples.,,,,T,,Y,,,c,,,,,1.0,,
27184800,3419,D009369,4495,Association,TRUE,CONCLUSION: These findings indicate that <ENT2>MT1</ENT2> constitute a biomarker adapted for exploring the impact of sorafenib on the redox metabolism of <ENT1>cancer</ENT1> cells.,,,,T,,,,,c,,,,,1.0,,
27184800,3421,D006528,4495,Association,TRUE,<ENT2>Metallothionein-1</ENT2> as a biomarker of altered redox metabolism in <ENT1>hepatocellular carcinoma</ENT1> cells exposed to sorafenib.,,,,T,,,,,c,,,,,1.0,,
27184800,3421,D006528,4495,Association,TRUE,RESULTS: We observed that genes of the <ENT2>metallothionein-1</ENT2> (<ENT2>MT1</ENT2>) family are induced in the <ENT1>HCC</ENT1> cell line Huh7 exposed to sorafenib.,,,,T,,,,,c,,,,,0.0,TRUE,
27184800,3421,D006528,4495,Association,TRUE,We examined the clinical relevance of our findings by analysing the regulation of <ENT2>MT1G</ENT2> in five tumour explants prepared from surgical <ENT1>HCC</ENT1> samples.,,,,T,,Y,,,c,,,,,1.0,,
27184800,3421,D006528,4495,Association,TRUE,"Finally, we showed that the protein levels of <ENT2>MT1</ENT2> increase in the serum of some <ENT1>HCC</ENT1> patients receiving sorafenib, and found an association with reduced overall survival.",,,,T,,,,,c,,,,,0.0,,
27292643,3426,56150,16653,Association,TRUE,"Here, we show that simultaneous overexpression of the mitotic checkpoint protein <ENT1>Mad2</ENT1> with <ENT2>Kras</ENT2>(<ENT2>G12D</ENT2>) or Her2 in mammary glands of adult mice results in mitotic checkpoint overactivation and a delay in tumor onset.",,,,T,,,,,c,,,,,0.0,,
27292643,3426,56150,16653,Association,TRUE,"Nonetheless, <ENT1>Mad2</ENT1> expression persists and increases karyotype complexity in <ENT2>Kras</ENT2> tumors.",,,,T,,,,,c,,,,,1.0,,
27292643,3428,56150,D001943,Association,TRUE,Negative Selection and Chromosome Instability Induced by <ENT1>Mad2</ENT1> Overexpression Delay <ENT2>Breast Cancer</ENT2> but Facilitate Oncogene-Independent Outgrowth.,,,,T,,,,,c,,,,,0.0,,
27292643,3427,56150,D009369,Association,TRUE,"Here, we show that simultaneous overexpression of the mitotic checkpoint protein <ENT1>Mad2</ENT1> with Kras(G12D) or Her2 in mammary glands of adult mice results in mitotic checkpoint overactivation and a delay in <ENT2>tumor</ENT2> onset.",,,,T,,,,,c,,,,,1.0,,
27292643,3427,56150,D009369,Association,TRUE,"Nonetheless, <ENT1>Mad2</ENT1> expression persists and increases karyotype complexity in Kras <ENT2>tumors</ENT2>.",,,,T,,,,,c,,,,,1.0,,
27292643,3427,56150,D009369,Association,TRUE,"Faced with the selective pressure of oncogene withdrawal, <ENT1>Mad2</ENT1>-positive <ENT2>tumors</ENT2> have a higher frequency of developing persistent subclones that avoid remission and continue to grow.",,,,T,Y,,,,w,,,,,0.0,,
27292643,3429,56150,D043171,Positive_Correlation,TRUE,Negative Selection and <ENT2>Chromosome Instability</ENT2> Induced by <ENT1>Mad2</ENT1> Overexpression Delay Breast Cancer but Facilitate Oncogene-Independent Outgrowth.,,,,T,,,,,c,,,,,1.0,,
27292643,3425,16653,D009369,Association,FALSE,"Here, we show that simultaneous overexpression of the mitotic checkpoint protein Mad2 with <ENT1>Kras</ENT1>(<ENT1>G12D</ENT1>) or Her2 in mammary glands of adult mice results in mitotic checkpoint overactivation and a delay in <ENT2>tumor</ENT2> onset.",,,,T,,,,,c,,,,,0.5,,
27292643,3425,16653,D009369,Association,FALSE,"Nonetheless, Mad2 expression persists and increases karyotype complexity in <ENT1>Kras</ENT1> <ENT2>tumors</ENT2>.",,,,T,,,,,w,,,,,1.0,,
27292643,3424,13866,D009369,Association,FALSE,"Here, we show that simultaneous overexpression of the mitotic checkpoint protein Mad2 with Kras(G12D) or <ENT1>Her2</ENT1> in mammary glands of adult mice results in mitotic checkpoint overactivation and a delay in <ENT2>tumor</ENT2> onset.",,,,T,,,,,c,,,,,0.0,,
27464336,3443,72508,D000438,Association,TRUE,Decreased Whole-Body Fat Mass Produced by Chronic <ENT2>Alcohol</ENT2> Consumption is Associated with Activation of <ENT1>S6K1</ENT1>-Mediated Protein Synthesis and Increased Autophagy in Epididymal White Adipose Tissue.,,,,T,,,,,c,,,,,0.0,,
27464336,3443,72508,D000438,Association,TRUE,"Instead, a selective increase in phosphorylation of <ENT1>S6K1</ENT1> and its downstream substrates, S6 and eIF4B was detected in <ENT2>alcohol</ENT2>-fed mice.",,,,T,,,,,c,,,,,1.0,,
27464336,3443,72508,D000438,Association,TRUE,CONCLUSIONS: These results demonstrate that the <ENT2>alcohol</ENT2>-induced decrease in whole-body fat mass resulted in part from activation of autophagy in eWAT as protein synthesis was increased and mediated by the specific increase in the activity of <ENT1>S6K1</ENT1>.,,,,T,Y,,,,w,,,,,0.0,,
27464336,3441,19016,D000438,Negative_Correlation,TRUE,Lipolytic enzymes (ATGL and HSL phosphorylation) were increased and lipogenic regulators (<ENT1>PPARgamma</ENT1> and C/EBPalpha) were decreased in eWAT by <ENT2>alcohol</ENT2>.,,,,T,,,,,c,,,,,1.0,,
27464336,3434,11793,D000438,Positive_Correlation,TRUE,"<ENT2>Alcohol</ENT2> increased <ENT1>Atg12-5</ENT1>, LC3B-I and -II, and ULK1 S555 phosphorylation, suggesting increased autophagy, while markers of apoptosis (cleaved caspase-3 and -9, and PARP) were unchanged.",,,,T,,,,,c,,,,,0.0,,
27464336,3430,66853,D000438,Positive_Correlation,TRUE,Lipolytic enzymes (<ENT1>ATGL</ENT1> and HSL phosphorylation) were increased and lipogenic regulators (PPARgamma and C/EBPalpha) were decreased in eWAT by <ENT2>alcohol</ENT2>.,,,,T,,,,,c,,,,,1.0,,
27464336,3439,21926,D000438,Positive_Correlation,TRUE,"Although <ENT2>alcohol</ENT2> increased <ENT1>TNF-alpha</ENT1>, IL-6, and IL-1beta mRNA, no change in key components of the NLRP3 inflammasome (NLRP3, ACS, and cleaved caspase-1) was detected suggesting <ENT2>alcohol</ENT2> did not increase pyroptosis.",,,,T,,,,,c,,,,,1.0,,
27464336,3440,D000438,12606,Negative_Correlation,TRUE,Lipolytic enzymes (ATGL and HSL phosphorylation) were increased and lipogenic regulators (PPARgamma and <ENT2>C/EBPalpha</ENT2>) were decreased in eWAT by <ENT1>alcohol</ENT1>.,,,,T,,,,,c,,,,,1.0,,
27464336,3432,D000438,22241,Positive_Correlation,TRUE,"<ENT1>Alcohol</ENT1> increased Atg12-5, LC3B-I and -II, and <ENT2>ULK1</ENT2> S555 phosphorylation, suggesting increased autophagy, while markers of apoptosis (cleaved caspase-3 and -9, and PARP) were unchanged.",,,,T,,,,,c,,,,,0.0,,
27464336,3442,D000438,16890,Positive_Correlation,TRUE,Lipolytic enzymes (ATGL and <ENT2>HSL</ENT2> phosphorylation) were increased and lipogenic regulators (PPARgamma and C/EBPalpha) were decreased in eWAT by <ENT1>alcohol</ENT1>.,,,,T,,,,,c,,,,,1.0,,
27464336,3437,D000438,16176,Positive_Correlation,TRUE,"Although <ENT1>alcohol</ENT1> increased TNF-alpha, IL-6, and <ENT2>IL-1beta</ENT2> mRNA, no change in key components of the NLRP3 inflammasome (NLRP3, ACS, and cleaved caspase-1) was detected suggesting <ENT1>alcohol</ENT1> did not increase pyroptosis.",,,,T,,,,,c,,,,,0.5,,
27464336,3435,D000438,75705,Positive_Correlation,TRUE,"Instead, a selective increase in phosphorylation of S6K1 and its downstream substrates, S6 and <ENT2>eIF4B</ENT2> was detected in <ENT1>alcohol</ENT1>-fed mice.",,,,T,,,,,c,,,,,0.0,,
27464336,3438,D000438,16193,Positive_Correlation,TRUE,"Although <ENT1>alcohol</ENT1> increased TNF-alpha, <ENT2>IL-6</ENT2>, and IL-1beta mRNA, no change in key components of the NLRP3 inflammasome (NLRP3, ACS, and cleaved caspase-1) was detected suggesting <ENT1>alcohol</ENT1> did not increase pyroptosis.",,,,T,,,,,c,,,,,1.0,,
27464336,3436,D000438,20104,Positive_Correlation,TRUE,"Instead, a selective increase in phosphorylation of S6K1 and its downstream substrates, <ENT2>S6</ENT2> and eIF4B was detected in <ENT1>alcohol</ENT1>-fed mice.",,,,T,,,,,c,,,,,0.0,,
27464336,3431,D000438,67443,Positive_Correlation,TRUE,"<ENT1>Alcohol</ENT1> increased Atg12-5, <ENT2>LC3B-I and -II</ENT2>, and ULK1 S555 phosphorylation, suggesting increased autophagy, while markers of apoptosis (cleaved caspase-3 and -9, and PARP) were unchanged.",,,,T,,,,,c,,,,,1.0,,
27491646,3454,595,C000605798,Negative_Correlation,TRUE,"<ENT2>Gartanin</ENT2>, at low micromole, led to cell cycle arrest in G1 phase accompanied by inhibited expression level of G1 cell cycle regulatory proteins <ENT1>cyclin D1</ENT1>, while increased expression level of cyclin-dependent kinase inhibitor p27Kip1.",,,,T,,,,,c,,,,,1.0,,
27491646,3458,5291,207,Association,FALSE,Gartanin induces cell cycle arrest and autophagy and suppresses migration involving <ENT1>PI3K</ENT1>/<ENT2>Akt</ENT2>/mTOR and MAPK signalling pathway in human glioma cells.,,,,T,,,,,w,,,,,1.0,,
27491646,3458,5291,207,Association,FALSE,"Gartanin treatment resulted in obvious inhibition of <ENT1>PI3K</ENT1>/<ENT2>Akt</ENT2>/mTOR signalling pathway, which is important in modulating autophagy.",,,,T,,,,,w,,,,,1.0,,
27491646,3458,5291,207,Association,FALSE,"These results indicate that anti-proliferation effect of gartanin in T98G cells is most likely via cell cycle arrest modulated by autophagy, which is regulated by <ENT1>PI3K</ENT1>/<ENT2>Akt</ENT2>/mTOR signalling pathway, while anti-migration effect is most likely via suppression of MMP-2/-9 activity which is involved in MAPK signalling pathway.",,,,T,,,,,w,,,,,1.0,,
27491646,3457,5291,2475,Association,FALSE,Gartanin induces cell cycle arrest and autophagy and suppresses migration involving <ENT1>PI3K</ENT1>/Akt/<ENT2>mTOR</ENT2> and MAPK signalling pathway in human glioma cells.,,,,T,,,,,w,,,,,1.0,,
27491646,3457,5291,2475,Association,FALSE,"Gartanin treatment resulted in obvious inhibition of <ENT1>PI3K</ENT1>/Akt/<ENT2>mTOR</ENT2> signalling pathway, which is important in modulating autophagy.",,,,T,,,,,w,,,,,1.0,,
27491646,3457,5291,2475,Association,FALSE,"These results indicate that anti-proliferation effect of gartanin in T98G cells is most likely via cell cycle arrest modulated by autophagy, which is regulated by <ENT1>PI3K</ENT1>/Akt/<ENT2>mTOR</ENT2> signalling pathway, while anti-migration effect is most likely via suppression of MMP-2/-9 activity which is involved in MAPK signalling pathway.",,,,T,,,,,w,,,,,1.0,,
27491646,3444,983,1027,Negative_Correlation,FALSE,"Gartanin, at low micromole, led to cell cycle arrest in G1 phase accompanied by inhibited expression level of G1 cell cycle regulatory proteins cyclin D1, while increased expression level of <ENT1>cyclin-dependent kinase</ENT1> inhibitor <ENT2>p27Kip1</ENT2>.",,,,T,,,,,c,,,,,0.0,,
27491646,3452,4313,C000605798,Negative_Correlation,TRUE,"In addition, the secretion and activity of <ENT1>matrix metalloproteinases 2/9</ENT1> (<ENT1>MMP-2/-9</ENT1>) were significantly suppressed in T98G cells treated with <ENT2>gartanin</ENT2>, and it might result from modulating mitogen-activated protein kinases (MAPK) signalling pathway in T98G glioma cells.",,,,T,,,,,c,,,,,1.0,,
27491646,3452,4313,C000605798,Negative_Correlation,TRUE,"These results indicate that anti-proliferation effect of <ENT2>gartanin</ENT2> in T98G cells is most likely via cell cycle arrest modulated by autophagy, which is regulated by PI3K/Akt/mTOR signalling pathway, while anti-migration effect is most likely via suppression of <ENT1>MMP-2/-9</ENT1> activity which is involved in MAPK signalling pathway.",,,,T,,,,,w,,,,,0.0,,
27491646,3456,207,2475,Association,FALSE,Gartanin induces cell cycle arrest and autophagy and suppresses migration involving PI3K/<ENT1>Akt</ENT1>/<ENT2>mTOR</ENT2> and MAPK signalling pathway in human glioma cells.,,,,T,,,,,w,,,,,1.0,,
27491646,3456,207,2475,Association,FALSE,"Gartanin treatment resulted in obvious inhibition of PI3K/<ENT1>Akt</ENT1>/<ENT2>mTOR</ENT2> signalling pathway, which is important in modulating autophagy.",,,,T,,,,,w,,,,,1.0,,
27491646,3456,207,2475,Association,FALSE,"These results indicate that anti-proliferation effect of gartanin in T98G cells is most likely via cell cycle arrest modulated by autophagy, which is regulated by PI3K/<ENT1>Akt</ENT1>/<ENT2>mTOR</ENT2> signalling pathway, while anti-migration effect is most likely via suppression of MMP-2/-9 activity which is involved in MAPK signalling pathway.",,,,T,,,,,w,,,,,1.0,,
27491646,3453,1027,C000605798,Positive_Correlation,TRUE,"<ENT2>Gartanin</ENT2>, at low micromole, led to cell cycle arrest in G1 phase accompanied by inhibited expression level of G1 cell cycle regulatory proteins cyclin D1, while increased expression level of cyclin-dependent kinase inhibitor <ENT1>p27Kip1</ENT1>.",,,,T,,,,,c,,,,,1.0,,
27491646,3450,8678,C000605798,Positive_Correlation,TRUE,"Moreover, <ENT2>gartanin</ENT2> significantly induced autophagy in T98G cells and increased GFP-LC3 punctate fluorescence accompanied by the increased expression level of <ENT1>Beclin 1</ENT1> and LC3-II, while suppressed expression level of p62.",,,,T,,,,,c,,,,,1.0,,
27491646,3448,8878,C000605798,Negative_Correlation,TRUE,"Moreover, <ENT2>gartanin</ENT2> significantly induced autophagy in T98G cells and increased GFP-LC3 punctate fluorescence accompanied by the increased expression level of Beclin 1 and LC3-II, while suppressed expression level of <ENT1>p62</ENT1>.",,,,T,,,,,c,,,,,1.0,,
27491646,3447,C000605798,C025946,Negative_Correlation,TRUE,"Notably, <ENT1>gartanin</ENT1>-mediated anti-viability was significantly abrogated by autophagy inhibitors including <ENT2>3-methyladenine</ENT2> (<ENT2>3-MA</ENT2>) and chloroquine (CQ).",,,,T,,,,,c,,,,,1.0,,
27491646,3449,C000605798,84557,Positive_Correlation,TRUE,"Moreover, <ENT1>gartanin</ENT1> significantly induced autophagy in T98G cells and increased GFP-<ENT2>LC3</ENT2> punctate fluorescence accompanied by the increased expression level of Beclin 1 and <ENT2>LC3</ENT2>-II, while suppressed expression level of p62.",,,,T,,,,,c,,,,,1.0,,
27491646,3455,C000605798,D005910,Negative_Correlation,TRUE,<ENT1>Gartanin</ENT1> induces cell cycle arrest and autophagy and suppresses migration involving PI3K/Akt/mTOR and MAPK signalling pathway in human <ENT2>glioma</ENT2> cells.,,,,T,,,,,w,,,,,1.0,,
27491646,3455,C000605798,D005910,Negative_Correlation,TRUE,"<ENT1>Gartanin</ENT1>, a natural xanthone of mangosteen, suppressed proliferation, migration and colony formation in a time- and concentration-dependent manner in T98G <ENT2>glioma</ENT2> cells but not in mouse normal neuronal HT22 cells.",,,,T,,,,,c,,,,,1.0,,
27491646,3455,C000605798,D005910,Negative_Correlation,TRUE,"In addition, the secretion and activity of matrix metalloproteinases 2/9 (MMP-2/-9) were significantly suppressed in T98G cells treated with <ENT1>gartanin</ENT1>, and it might result from modulating mitogen-activated protein kinases (MAPK) signalling pathway in T98G <ENT2>glioma</ENT2> cells.",,,,T,Y,,,,w,,,,,0.0,,
27491646,3446,C000605798,D002738,Negative_Correlation,TRUE,"Notably, <ENT1>gartanin</ENT1>-mediated anti-viability was significantly abrogated by autophagy inhibitors including 3-methyladenine (3-MA) and <ENT2>chloroquine</ENT2> (<ENT2>CQ</ENT2>).",,,,T,,,,,c,,,,,1.0,,
27491646,3445,C009689,D005910,Association,TRUE,"Gartanin, a natural <ENT1>xanthone</ENT1> of mangosteen, suppressed proliferation, migration and colony formation in a time- and concentration-dependent manner in T98G <ENT2>glioma</ENT2> cells but not in mouse normal neuronal HT22 cells.",,,,T,,,,,c,,,,,0.0,,
27509880,3469,D003110,D047630,Negative_Correlation,TRUE,Combination of the histone deacetylase inhibitor <ENT2>depsipeptide</ENT2> and 5-fluorouracil upregulates major histocompatibility complex class II and p21 genes and activates caspase-3/7 in human <ENT1>colon cancer</ENT1> HCT-116 cells.,,,,T,,,,,w,,,,,1.0,,
27509880,3469,D003110,D047630,Negative_Correlation,TRUE,"In the present study, we found that a very low concentration of <ENT2>depsipeptide</ENT2>, an HDAC inhibitor, potentiated the antitumor activity of 5-fluorouracil (5-FU) in a human <ENT1>colon cancer</ENT1> cell model using HCT-116, HT29, and SW48 cells via the inhibition of colony formation ability or cellular viability.",,,,T,,,,,c,,,,,0.0,,
27509880,3469,D003110,D047630,Negative_Correlation,TRUE,"To the best of our knowledge, this is the first study to report that the combination of 5-FU and <ENT2>depsipeptide</ENT2> induces human <ENT1>colon cancer</ENT1> cell apoptosis in a concerted manner with the induction of MHC class II gene expression.",,,,T,,,,,c,,,,,0.0,,
27509880,3461,D003110,D005472,Negative_Correlation,TRUE,Combination of the histone deacetylase inhibitor depsipeptide and <ENT2>5-fluorouracil</ENT2> upregulates major histocompatibility complex class II and p21 genes and activates caspase-3/7 in human <ENT1>colon cancer</ENT1> HCT-116 cells.,,,,T,,,,,w,,,,,0.0,,
27509880,3461,D003110,D005472,Negative_Correlation,TRUE,"In the present study, we found that a very low concentration of depsipeptide, an HDAC inhibitor, potentiated the antitumor activity of <ENT2>5-fluorouracil</ENT2> (<ENT2>5-FU</ENT2>) in a human <ENT1>colon cancer</ENT1> cell model using HCT-116, HT29, and SW48 cells via the inhibition of colony formation ability or cellular viability.",,,,T,,,,,c,,,,,0.0,,
27509880,3461,D003110,D005472,Negative_Correlation,TRUE,"To the best of our knowledge, this is the first study to report that the combination of <ENT2>5-FU</ENT2> and depsipeptide induces human <ENT1>colon cancer</ENT1> cell apoptosis in a concerted manner with the induction of MHC class II gene expression.",,,,T,,,,,c,,,,,1.0,,
27509880,3471,D047630,8850,Association,TRUE,"Furthermore, our global analysis of gene expression, which was focused on genes involved in the molecular regulation of MHC class II genes, showed enhancement of pro-apoptotic <ENT2>PCAF</ENT2> and CIITA after the combination of 5-FU and <ENT1>depsipeptide</ENT1>.",,,,T,,,,,c,,,,,0.0,,
27509880,3475,D047630,3119,Positive_Correlation,TRUE,Combination of the histone deacetylase inhibitor <ENT1>depsipeptide</ENT1> and 5-fluorouracil upregulates <ENT2>major histocompatibility complex class II</ENT2> and p21 genes and activates caspase-3/7 in human colon cancer HCT-116 cells.,,,,T,,,,,c,,,,,1.0,,
27509880,3475,D047630,3119,Positive_Correlation,TRUE,"Compared with vehicle controls, the cells treated with the combination of 5-FU and <ENT1>depsipeptide</ENT1> showed marked induction (3- to 8.5-fold) of expression of <ENT2>MHC class II genes</ENT2>, but not of MHC class I genes.",,,,T,,,,,c,,,,,1.0,,
27509880,3475,D047630,3119,Positive_Correlation,TRUE,"Furthermore, our global analysis of gene expression, which was focused on genes involved in the molecular regulation of <ENT2>MHC class II genes</ENT2>, showed enhancement of pro-apoptotic PCAF and CIITA after the combination of 5-FU and <ENT1>depsipeptide</ENT1>.",,,,T,,,,,c,,,,,0.0,,
27509880,3475,D047630,3119,Positive_Correlation,TRUE,These results may indicate a closer relationship between elevation of <ENT2>MHC class II</ENT2> expression and cellular apoptosis induced by the combination of <ENT1>depsipeptide</ENT1> and 5-FU.,,,,T,,,,,c,,,,,0.0,,
27509880,3475,D047630,3119,Positive_Correlation,TRUE,"To the best of our knowledge, this is the first study to report that the combination of 5-FU and <ENT1>depsipeptide</ENT1> induces human colon cancer cell apoptosis in a concerted manner with the induction of <ENT2>MHC class II</ENT2> gene expression.",,,,T,,,,,c,,,,,0.0,,
27509880,3460,D047630,3065,Negative_Correlation,FALSE,Combination of the <ENT2>histone deacetylase</ENT2> inhibitor <ENT1>depsipeptide</ENT1> and 5-fluorouracil upregulates major histocompatibility complex class II and p21 genes and activates caspase-3/7 in human colon cancer HCT-116 cells.,,,,T,,,,,c,,,,,1.0,,
27509880,3460,D047630,3065,Negative_Correlation,FALSE,"In the present study, we found that a very low concentration of <ENT1>depsipeptide</ENT1>, an <ENT2>HDAC</ENT2> inhibitor, potentiated the antitumor activity of 5-fluorouracil (5-FU) in a human colon cancer cell model using HCT-116, HT29, and SW48 cells via the inhibition of colony formation ability or cellular viability.",,,,T,,,,,c,,,,,1.0,,
27509880,3472,D047630,D005472,Cotreatment,FALSE,Combination of the histone deacetylase inhibitor <ENT1>depsipeptide</ENT1> and <ENT2>5-fluorouracil</ENT2> upregulates major histocompatibility complex class II and p21 genes and activates caspase-3/7 in human colon cancer HCT-116 cells.,,,,T,,,,,c,,,,,1.0,,
27509880,3472,D047630,D005472,Cotreatment,FALSE,"In the present study, we found that a very low concentration of <ENT1>depsipeptide</ENT1>, an HDAC inhibitor, potentiated the antitumor activity of <ENT2>5-fluorouracil</ENT2> (<ENT2>5-FU</ENT2>) in a human colon cancer cell model using HCT-116, HT29, and SW48 cells via the inhibition of colony formation ability or cellular viability.",,,,T,,,,,w,,,,,0.0,,
27509880,3472,D047630,D005472,Cotreatment,FALSE,"Exposure to a combination of <ENT2>5-FU</ENT2> (1.75 uM) and 1 nM <ENT1>depsipeptide</ENT1> for 24 and 48 h resulted in a 3- to 4-fold increase in activated caspase-3/7, while <ENT2>5-FU</ENT2> alone failed to activate caspase-3/7.",,,,T,,,,,c,,,,,0.0,,
27509880,3472,D047630,D005472,Cotreatment,FALSE,"Microarray and subsequent gene ontology analyses revealed that compared to <ENT2>5-FU</ENT2> or <ENT1>depsipeptide</ENT1> alone, the combination treatment of <ENT2>5-FU</ENT2> and <ENT1>depsipeptide</ENT1> upregulated genes related to cell death and the apoptotic process consistent with the inhibition of colony formation and caspase-3/7 activation.",,,,T,,,,,c,,,,,0.75,,
27509880,3472,D047630,D005472,Cotreatment,FALSE,"Compared with vehicle controls, the cells treated with the combination of <ENT2>5-FU</ENT2> and <ENT1>depsipeptide</ENT1> showed marked induction (3- to 8.5-fold) of expression of MHC class II genes, but not of MHC class I genes.",,,,T,,,,,c,,,,,1.0,,
27509880,3472,D047630,D005472,Cotreatment,FALSE,"Furthermore, our global analysis of gene expression, which was focused on genes involved in the molecular regulation of MHC class II genes, showed enhancement of pro-apoptotic PCAF and CIITA after the combination of <ENT2>5-FU</ENT2> and <ENT1>depsipeptide</ENT1>.",,,,T,,,,,c,,,,,0.0,,
27509880,3472,D047630,D005472,Cotreatment,FALSE,These results may indicate a closer relationship between elevation of MHC class II expression and cellular apoptosis induced by the combination of <ENT1>depsipeptide</ENT1> and <ENT2>5-FU</ENT2>.,,,,T,,,,,c,,,,,0.0,,
27509880,3472,D047630,D005472,Cotreatment,FALSE,"To the best of our knowledge, this is the first study to report that the combination of <ENT2>5-FU</ENT2> and <ENT1>depsipeptide</ENT1> induces human colon cancer cell apoptosis in a concerted manner with the induction of MHC class II gene expression.",,,,T,,,,,c,,,,,0.0,,
27509880,3470,D047630,4261,Association,TRUE,"Furthermore, our global analysis of gene expression, which was focused on genes involved in the molecular regulation of MHC class II genes, showed enhancement of pro-apoptotic PCAF and <ENT2>CIITA</ENT2> after the combination of 5-FU and <ENT1>depsipeptide</ENT1>.",,,,T,,,,,c,,,,,0.0,,
27509880,3468,D047630,836,Positive_Correlation,TRUE,Combination of the histone deacetylase inhibitor <ENT1>depsipeptide</ENT1> and 5-fluorouracil upregulates major histocompatibility complex class II and p21 genes and activates <ENT2>caspase-3/7</ENT2> in human colon cancer HCT-116 cells.,,,,T,,,,,c,,,,,1.0,,
27509880,3468,D047630,836,Positive_Correlation,TRUE,"Exposure to a combination of 5-FU (1.75 uM) and 1 nM <ENT1>depsipeptide</ENT1> for 24 and 48 h resulted in a 3- to 4-fold increase in activated <ENT2>caspase-3/7</ENT2>, while 5-FU alone failed to activate <ENT2>caspase-3/7</ENT2>.",,,,T,,,,,c,,,,,0.5,,
27509880,3468,D047630,836,Positive_Correlation,TRUE,"Microarray and subsequent gene ontology analyses revealed that compared to 5-FU or <ENT1>depsipeptide</ENT1> alone, the combination treatment of 5-FU and <ENT1>depsipeptide</ENT1> upregulated genes related to cell death and the apoptotic process consistent with the inhibition of colony formation and <ENT2>caspase-3/7</ENT2> activation.",,,,T,Y,,,,c,,,,,0.0,,
27509880,3473,D047630,1026,Positive_Correlation,TRUE,Combination of the histone deacetylase inhibitor <ENT1>depsipeptide</ENT1> and 5-fluorouracil upregulates major histocompatibility complex class II and <ENT2>p21</ENT2> genes and activates caspase-3/7 in human colon cancer HCT-116 cells.,,,,T,,,,,c,,,,,1.0,,
27509880,3463,8850,D005472,Association,TRUE,"Furthermore, our global analysis of gene expression, which was focused on genes involved in the molecular regulation of MHC class II genes, showed enhancement of pro-apoptotic <ENT1>PCAF</ENT1> and CIITA after the combination of <ENT2>5-FU</ENT2> and depsipeptide.",,,,T,,,,,c,,,,,0.0,,
27509880,3474,3119,D005472,Positive_Correlation,TRUE,Combination of the histone deacetylase inhibitor depsipeptide and <ENT2>5-fluorouracil</ENT2> upregulates <ENT1>major histocompatibility complex class II</ENT1> and p21 genes and activates caspase-3/7 in human colon cancer HCT-116 cells.,,,,T,,,,,c,,,,,1.0,,
27509880,3474,3119,D005472,Positive_Correlation,TRUE,"Compared with vehicle controls, the cells treated with the combination of <ENT2>5-FU</ENT2> and depsipeptide showed marked induction (3- to 8.5-fold) of expression of <ENT1>MHC class II genes</ENT1>, but not of MHC class I genes.",,,,T,,,,,c,,,,,1.0,,
27509880,3474,3119,D005472,Positive_Correlation,TRUE,"Furthermore, our global analysis of gene expression, which was focused on genes involved in the molecular regulation of <ENT1>MHC class II genes</ENT1>, showed enhancement of pro-apoptotic PCAF and CIITA after the combination of <ENT2>5-FU</ENT2> and depsipeptide.",,,,T,,,,,w,,,,,0.0,,
27509880,3474,3119,D005472,Positive_Correlation,TRUE,These results may indicate a closer relationship between elevation of <ENT1>MHC class II</ENT1> expression and cellular apoptosis induced by the combination of depsipeptide and <ENT2>5-FU</ENT2>.,,,,T,,,,,c,,,,,0.0,,
27509880,3474,3119,D005472,Positive_Correlation,TRUE,"To the best of our knowledge, this is the first study to report that the combination of <ENT2>5-FU</ENT2> and depsipeptide induces human colon cancer cell apoptosis in a concerted manner with the induction of <ENT1>MHC class II</ENT1> gene expression.",,,,T,,,,,c,,,,,1.0,,
27509880,3459,D011134,3123,Association,TRUE,These analyses indicated marked upregulation of antigen processing and presentation of peptide or <ENT1>polysaccharide</ENT1> antigen via <ENT2>major histocompatibility complex (MHC) class</ENT2> (GO:0002504) and <ENT2>MHC protein complex</ENT2> (GO:0042611).,,,,T,,,,,w,,,,,0.0,,
27509880,3462,D005472,4261,Association,TRUE,"Furthermore, our global analysis of gene expression, which was focused on genes involved in the molecular regulation of MHC class II genes, showed enhancement of pro-apoptotic PCAF and <ENT2>CIITA</ENT2> after the combination of <ENT1>5-FU</ENT1> and depsipeptide.",,,,T,,,,,c,,,,,0.0,,
27509880,3467,D005472,836,Positive_Correlation,TRUE,Combination of the histone deacetylase inhibitor depsipeptide and <ENT1>5-fluorouracil</ENT1> upregulates major histocompatibility complex class II and p21 genes and activates <ENT2>caspase-3/7</ENT2> in human colon cancer HCT-116 cells.,,,,T,,,,,c,,,,,1.0,,
27509880,3467,D005472,836,Positive_Correlation,TRUE,"Exposure to a combination of <ENT1>5-FU</ENT1> (1.75 uM) and 1 nM depsipeptide for 24 and 48 h resulted in a 3- to 4-fold increase in activated <ENT2>caspase-3/7</ENT2>, while <ENT1>5-FU</ENT1> alone failed to activate <ENT2>caspase-3/7</ENT2>.",,,,T,,,,,c,,,,,0.25,,
27509880,3467,D005472,836,Positive_Correlation,TRUE,"Microarray and subsequent gene ontology analyses revealed that compared to <ENT1>5-FU</ENT1> or depsipeptide alone, the combination treatment of <ENT1>5-FU</ENT1> and depsipeptide upregulated genes related to cell death and the apoptotic process consistent with the inhibition of colony formation and <ENT2>caspase-3/7</ENT2> activation.",,,,T,Y,,,,w,,,,,0.0,,
27509880,3464,D005472,1026,Positive_Correlation,TRUE,Combination of the histone deacetylase inhibitor depsipeptide and <ENT1>5-fluorouracil</ENT1> upregulates major histocompatibility complex class II and <ENT2>p21</ENT2> genes and activates caspase-3/7 in human colon cancer HCT-116 cells.,,,,T,,,,,c,,,,,1.0,,
27630165,3486,12504,16768,Association,TRUE,"<ENT1>CD4</ENT1>(+)YFP(+)GFP(+) T cells generally exhibited a short-lived effector rather than effector memory T cell phenotype postinfection and expressed high levels of PD-1, <ENT2>Lag-3</ENT2>, and TIGIT, indicative of cellular exhaustion.",,,,T,,,,,c,,,,,0.0,,
27630165,3488,12504,15978,Association,FALSE,Long-Lived <ENT1>CD4</ENT1>+<ENT2>IFN-g</ENT2>+ T Cells rather than Short-Lived <ENT1>CD4</ENT1>+<ENT2>IFN-g</ENT2>+IL-10+ T Cells Initiate Rapid IL-10 Production To Suppress Anamnestic T Cell Responses during Secondary Malaria Infection.,,,,T,,,,,w,,,,,1.0,,
27630165,3488,12504,15978,Association,FALSE,"<ENT1>CD4</ENT1>(+) T cells that produce <ENT2>IFN-g</ENT2> are the source of host-protective IL-10 during primary infection with a number of different pathogens, including Plasmodium spp.",,,,T,,,,,c,,,,,0.0,,
27630165,3488,12504,15978,Association,FALSE,"The fate of these <ENT1>CD4</ENT1>(+)<ENT2>IFN-g</ENT2>(+)IL-10(+) T cells following clearance of primary infection and their subsequent influence on the course of repeated infections is, however, presently unknown.",,,,T,,,,,c,,,,,1.0,,
27630165,3488,12504,15978,Association,FALSE,"In this study, utilizing <ENT2>IFN-g</ENT2>-yellow fluorescent protein (YFP) and IL-10-GFP dual reporter mice, we show that primary malaria infection-induced <ENT1>CD4</ENT1>(+)YFP(+)GFP(+) T cells have limited memory potential, do not stably express IL-10, and are disproportionately lost from the Ag-experienced <ENT1>CD4</ENT1>(+) T cell memory population during the maintenance phase postinfection.",,,,T,,,,,c,,,,,1.0,,
27630165,3489,12504,16153,Association,FALSE,Long-Lived <ENT1>CD4</ENT1>+IFN-g+ T Cells rather than Short-Lived <ENT1>CD4</ENT1>+IFN-g+<ENT2>IL-10</ENT2>+ T Cells Initiate Rapid <ENT2>IL-10</ENT2> Production To Suppress Anamnestic T Cell Responses during Secondary Malaria Infection.,,,,T,,,,,w,,,,,1.0,,
27630165,3489,12504,16153,Association,FALSE,"<ENT1>CD4</ENT1>(+) T cells that produce IFN-g are the source of host-protective <ENT2>IL-10</ENT2> during primary infection with a number of different pathogens, including Plasmodium spp.",,,,T,,,,,c,,,,,0.0,,
27630165,3489,12504,16153,Association,FALSE,"The fate of these <ENT1>CD4</ENT1>(+)IFN-g(+)<ENT2>IL-10</ENT2>(+) T cells following clearance of primary infection and their subsequent influence on the course of repeated infections is, however, presently unknown.",,,,T,,,,,c,,,,,1.0,,
27630165,3489,12504,16153,Association,FALSE,"In this study, utilizing IFN-g-yellow fluorescent protein (YFP) and <ENT2>IL-10</ENT2>-GFP dual reporter mice, we show that primary malaria infection-induced <ENT1>CD4</ENT1>(+)YFP(+)GFP(+) T cells have limited memory potential, do not stably express <ENT2>IL-10</ENT2>, and are disproportionately lost from the Ag-experienced <ENT1>CD4</ENT1>(+) T cell memory population during the maintenance phase postinfection.",,,,T,,,,,c,,,,,0.75,,
27630165,3489,12504,16153,Association,FALSE,"In contrast, <ENT1>CD4</ENT1>(+)YFP(+)GFP(-) T cell-derived cells expanded rapidly and upregulated <ENT2>IL-10</ENT2> expression during secondary infection.",,,,T,,,,,c,,,,,0.0,,
27630165,3489,12504,16153,Association,FALSE,"Correspondingly, <ENT1>CD4</ENT1>(+) T cells were the major producers within an accelerated and amplified <ENT2>IL-10</ENT2> response during the early stage of secondary malaria infection.",,,,T,,,,,c,,,,,0.0,,
27630165,3489,12504,16153,Association,FALSE,"Notably, <ENT2>IL-10</ENT2> exerted quantitatively stronger regulatory effects on innate and <ENT1>CD4</ENT1>(+) T cell responses during primary and secondary infections, respectively.",,,,T,,,,,c,,,,,0.0,,
27630165,3489,12504,16153,Association,FALSE,The results in this study significantly improve our understanding of the durability of <ENT2>IL-10</ENT2>-producing <ENT1>CD4</ENT1>(+) T cells postinfection and provide information on how <ENT2>IL-10</ENT2> may contribute to optimized parasite control and prevention of immune-mediated pathology during repeated malaria infections.,,,,T,,,,,c,,,,,0.0,,
27630165,3485,12504,100043314,Association,TRUE,"<ENT1>CD4</ENT1>(+)YFP(+)GFP(+) T cells generally exhibited a short-lived effector rather than effector memory T cell phenotype postinfection and expressed high levels of PD-1, Lag-3, and <ENT2>TIGIT</ENT2>, indicative of cellular exhaustion.",,,,T,,,,,c,,,,,0.0,,
27630165,3484,12504,D008288,Association,FALSE,Long-Lived <ENT1>CD4</ENT1>+IFN-g+ T Cells rather than Short-Lived <ENT1>CD4</ENT1>+IFN-g+IL-10+ T Cells Initiate Rapid IL-10 Production To Suppress Anamnestic T Cell Responses during Secondary <ENT2>Malaria Infection</ENT2>.,,,,T,,,,,w,,,,,1.0,TRUE,
27630165,3484,12504,D008288,Association,FALSE,"In this study, utilizing IFN-g-yellow fluorescent protein (YFP) and IL-10-GFP dual reporter mice, we show that primary <ENT2>malaria infection</ENT2>-induced <ENT1>CD4</ENT1>(+)YFP(+)GFP(+) T cells have limited memory potential, do not stably express IL-10, and are disproportionately lost from the Ag-experienced <ENT1>CD4</ENT1>(+) T cell memory population during the maintenance phase postinfection.",,,,T,,,,,c,,,,,0.0,,
27630165,3484,12504,D008288,Association,FALSE,"Correspondingly, <ENT1>CD4</ENT1>(+) T cells were the major producers within an accelerated and amplified IL-10 response during the early stage of secondary <ENT2>malaria infection</ENT2>.",,,,T,,,,,w,,,,,1.0,,
27630165,3484,12504,D008288,Association,FALSE,The results in this study significantly improve our understanding of the durability of IL-10-producing <ENT1>CD4</ENT1>(+) T cells postinfection and provide information on how IL-10 may contribute to optimized parasite control and prevention of immune-mediated pathology during repeated <ENT2>malaria infections</ENT2>.,,,,T,,,,,w,,,,,1.0,,
27630165,3487,12504,18566,Association,TRUE,"<ENT1>CD4</ENT1>(+)YFP(+)GFP(+) T cells generally exhibited a short-lived effector rather than effector memory T cell phenotype postinfection and expressed high levels of <ENT2>PD-1</ENT2>, Lag-3, and TIGIT, indicative of cellular exhaustion.",,,,T,,,,,c,,,,,0.0,,
27630165,3476,15978,D008288,Association,FALSE,Long-Lived CD4+<ENT1>IFN-g</ENT1>+ T Cells rather than Short-Lived CD4+<ENT1>IFN-g</ENT1>+IL-10+ T Cells Initiate Rapid IL-10 Production To Suppress Anamnestic T Cell Responses during Secondary <ENT2>Malaria Infection</ENT2>.,,,,T,,,,,w,,,,,1.0,TRUE,
27630165,3476,15978,D008288,Association,FALSE,"In this study, utilizing <ENT1>IFN-g</ENT1>-yellow fluorescent protein (YFP) and IL-10-GFP dual reporter mice, we show that primary <ENT2>malaria infection</ENT2>-induced CD4(+)YFP(+)GFP(+) T cells have limited memory potential, do not stably express IL-10, and are disproportionately lost from the Ag-experienced CD4(+) T cell memory population during the maintenance phase postinfection.",,,,T,,,,,c,,,,,1.0,,
27630165,3480,16153,D008288,Association,FALSE,Long-Lived CD4+IFN-g+ T Cells rather than Short-Lived CD4+IFN-g+<ENT1>IL-10</ENT1>+ T Cells Initiate Rapid <ENT1>IL-10</ENT1> Production To Suppress Anamnestic T Cell Responses during Secondary <ENT2>Malaria Infection</ENT2>.,,,,T,,,,,c,,,,,1.0,,
27630165,3480,16153,D008288,Association,FALSE,"In this study, utilizing IFN-g-yellow fluorescent protein (YFP) and <ENT1>IL-10</ENT1>-GFP dual reporter mice, we show that primary <ENT2>malaria infection</ENT2>-induced CD4(+)YFP(+)GFP(+) T cells have limited memory potential, do not stably express <ENT1>IL-10</ENT1>, and are disproportionately lost from the Ag-experienced CD4(+) T cell memory population during the maintenance phase postinfection.",,,,T,,,,,c,,,,,1.0,,
27630165,3480,16153,D008288,Association,FALSE,"Correspondingly, CD4(+) T cells were the major producers within an accelerated and amplified <ENT1>IL-10</ENT1> response during the early stage of secondary <ENT2>malaria infection</ENT2>.",,,,T,,,,,c,,,,,0.0,,
27630165,3480,16153,D008288,Association,FALSE,The results in this study significantly improve our understanding of the durability of <ENT1>IL-10</ENT1>-producing CD4(+) T cells postinfection and provide information on how <ENT1>IL-10</ENT1> may contribute to optimized parasite control and prevention of immune-mediated pathology during repeated <ENT2>malaria infections</ENT2>.,,,,T,,,,,c,,,,,0.0,,
27643404,3498,D000438,125,Association,FALSE,"Study-specific associations of 68 single nucleotide polymorphisms (SNPs) in 8 <ENT1>alcohol</ENT1>-metabolising genes (<ENT2>Alcohol Dehydrogenases</ENT2> (<ENT2>ADHs</ENT2>) and Aldehyde Dehydrogenases (ALDHs)) with prostate cancer diagnosis and prostate cancer-specific mortality, by grade, were assessed using logistic and Cox regression models, respectively.",,,,T,,,,,c,,,,,0.0,,
27643404,3497,D000438,8854,Association,FALSE,"Study-specific associations of 68 single nucleotide polymorphisms (SNPs) in 8 <ENT1>alcohol</ENT1>-metabolising genes (Alcohol Dehydrogenases (ADHs) and <ENT2>Aldehyde Dehydrogenases</ENT2> (<ENT2>ALDHs</ENT2>)) with prostate cancer diagnosis and prostate cancer-specific mortality, by grade, were assessed using logistic and Cox regression models, respectively.",,,,T,,,,,c,,,,,0.0,,
27643404,3496,D000438,D011471,Association,TRUE,<ENT1>Alcohol</ENT1> consumption and <ENT2>prostate cancer</ENT2> incidence and progression: A Mendelian randomisation study.,,,,T,,T,,,c,,,,,1.0,,
27643404,3496,D000438,D011471,Association,TRUE,"The effects of <ENT1>alcohol</ENT1> consumption on <ENT2>prostate cancer</ENT2> incidence and survival remain unclear, potentially due to methodological limitations of observational studies.",,,,T,,,,,c,,,,,1.0,,
27643404,3496,D000438,D011471,Association,TRUE,"In this study, we investigated the associations of genetic variants in <ENT1>alcohol</ENT1>-metabolising genes with <ENT2>prostate cancer</ENT2> incidence and survival.",,,,T,,Y,,,w,,,,,0.0,,
27643404,3496,D000438,D011471,Association,TRUE,"Study-specific associations of 68 single nucleotide polymorphisms (SNPs) in 8 <ENT1>alcohol</ENT1>-metabolising genes (Alcohol Dehydrogenases (ADHs) and Aldehyde Dehydrogenases (ALDHs)) with <ENT2>prostate cancer</ENT2> diagnosis and <ENT2>prostate cancer</ENT2>-specific mortality, by grade, were assessed using logistic and Cox regression models, respectively.",,,,T,,Y,,,w,,,,,1.0,,
27643404,3496,D000438,D011471,Association,TRUE,We found little evidence that variants in <ENT1>alcohol</ENT1> metabolising genes were associated with <ENT2>prostate cancer</ENT2> diagnosis.,,,,T,,,,,c,,,,,1.0,,
27643404,3496,D000438,D011471,Association,TRUE,"These results suggest that <ENT1>alcohol</ENT1> consumption is unlikely to affect <ENT2>prostate cancer</ENT2> incidence, but it may influence disease progression.",,,,T,,,,,w,,,,,0.0,,
27643404,3491,219,D011471,Association,TRUE,"In <ENT1>ALDH1B1</ENT1>, rs10973794 (HRfixed  = 1.43; 95%CI:1.14,1.79; p values = 0.002) was associated with <ENT2>prostate cancer</ENT2> mortality in men with low-grade <ENT2>prostate cancer</ENT2>.",,,,T,,,,,w,,,,,0.5,,
27643404,3494,rs1441817,D011471,Positive_Correlation,TRUE,"SNPs within ALDH1A2 associated with <ENT2>prostate cancer</ENT2> mortality were <ENT1>rs1441817</ENT1> (fixed effects hazard ratio, HRfixed  = 0.78; 95% confidence interval (95%CI):0.66,0.91; p values = 0.002); rs12910509, HRfixed  = 0.76; 95%CI:0.64,0.91; p values = 0.003); and rs8041922 (HRfixed  = 0.76; 95%CI:0.64,0.91; p values = 0.002).",,,,T,,,,,c,,,,,0.0,,
27643404,3495,8854,D011471,Association,TRUE,"Study-specific associations of 68 single nucleotide polymorphisms (SNPs) in 8 alcohol-metabolising genes (Alcohol Dehydrogenases (ADHs) and <ENT1>Aldehyde Dehydrogenases</ENT1> (<ENT1>ALDHs</ENT1>)) with <ENT2>prostate cancer</ENT2> diagnosis and <ENT2>prostate cancer</ENT2>-specific mortality, by grade, were assessed using logistic and Cox regression models, respectively.",,,,T,,Y,,,w,,,,,1.0,,
27643404,3495,8854,D011471,Association,TRUE,"SNPs within <ENT1>ALDH1A2</ENT1> associated with <ENT2>prostate cancer</ENT2> mortality were rs1441817 (fixed effects hazard ratio, HRfixed  = 0.78; 95% confidence interval (95%CI):0.66,0.91; p values = 0.002); rs12910509, HRfixed  = 0.76; 95%CI:0.64,0.91; p values = 0.003); and rs8041922 (HRfixed  = 0.76; 95%CI:0.64,0.91; p values = 0.002).",,,,T,,,,,c,,,,,1.0,,
27643404,3493,rs12910509,D011471,Positive_Correlation,TRUE,"SNPs within ALDH1A2 associated with <ENT2>prostate cancer</ENT2> mortality were rs1441817 (fixed effects hazard ratio, HRfixed  = 0.78; 95% confidence interval (95%CI):0.66,0.91; p values = 0.002); <ENT1>rs12910509</ENT1>, HRfixed  = 0.76; 95%CI:0.64,0.91; p values = 0.003); and rs8041922 (HRfixed  = 0.76; 95%CI:0.64,0.91; p values = 0.002).",,,,T,,,,,c,,,,,0.0,,
27643404,3492,rs8041922,D011471,Positive_Correlation,TRUE,"SNPs within ALDH1A2 associated with <ENT2>prostate cancer</ENT2> mortality were rs1441817 (fixed effects hazard ratio, HRfixed  = 0.78; 95% confidence interval (95%CI):0.66,0.91; p values = 0.002); rs12910509, HRfixed  = 0.76; 95%CI:0.64,0.91; p values = 0.003); and <ENT1>rs8041922</ENT1> (HRfixed  = 0.76; 95%CI:0.64,0.91; p values = 0.002).",,,,T,,,,,c,,,,,0.0,,
27643404,3490,D011471,rs10973794,Positive_Correlation,TRUE,"In ALDH1B1, <ENT2>rs10973794</ENT2> (HRfixed  = 1.43; 95%CI:1.14,1.79; p values = 0.002) was associated with <ENT1>prostate cancer</ENT1> mortality in men with low-grade <ENT1>prostate cancer</ENT1>.",,,,T,,,,,c,,,,,0.5,,
27729412,3500,20181,11450,Negative_Correlation,TRUE,Reduced <ENT2>adiponectin</ENT2> expression after high-fat diet is associated with selective up-regulation of ALDH1A1 and further <ENT1>retinoic acid receptor</ENT1> signaling in adipose tissue.,,,,T,,,,,c,,,,,0.0,,
27729412,3500,20181,11450,Negative_Correlation,TRUE,"Adipocyte cell culture revealed that endogenous and synthetic retinoic acid receptor (RAR)a- and RARg-selective agonists, as well as a synthetic <ENT1>retinoid X receptor</ENT1> agonist, efficiently reduced <ENT2>adiponectin</ENT2> expression, whereas ALDH1A1 expression only increased with <ENT1>RAR</ENT1> agonists.",,,,T,,,,,c,,,,,0.5,,
27729412,3500,20181,11450,Negative_Correlation,TRUE,"We conclude that reduced <ENT2>adiponectin</ENT2> expression under high-fat dietary conditions is dependent on 1) increased ALDH1A1 expression in adipocytes, which does not increase all-trans-retinoic acid levels; 2) further <ENT1>RAR</ENT1> ligand-induced, WAT-selective, increased retinoic acid response element-mediated signaling; and 3) <ENT1>RAR</ENT1> ligand-dependent reduction of <ENT2>adiponectin</ENT2> expression.-Landrier, J.-F., Kasiri, E., Karkeni, E., Mihaly, J., Beke, G., Weiss, K., Lucas, R., Aydemir, G., Salles, J., Walrand, S., de Lera, A. R., Ruhl, R.",,,,T,,,,,c,,,,,0.0,,
27729412;27729412,3506;3508,20181;19401,11668;11668,Positive_Correlation;Positive_Correlation,TRUE;TRUE,Reduced adiponectin expression after high-fat diet is associated with selective up-regulation of <ENT2>ALDH1A1</ENT2> and further <ENT1>retinoic acid receptor</ENT1> signaling in adipose tissue.,,,,T,,,,,c,,,,,1.0,,
27729412,3506,20181,11668,Positive_Correlation,TRUE,"Adipocyte cell culture revealed that endogenous and synthetic retinoic acid receptor (RAR)a- and RARg-selective agonists, as well as a synthetic <ENT1>retinoid X receptor</ENT1> agonist, efficiently reduced adiponectin expression, whereas <ENT2>ALDH1A1</ENT2> expression only increased with <ENT1>RAR</ENT1> agonists.",,,,T,,,,,c,,,,,0.5,,
27729412;27729412,3506;3508,20181;19401,11668;11668,Positive_Correlation;Positive_Correlation,TRUE;TRUE,"We conclude that reduced adiponectin expression under high-fat dietary conditions is dependent on 1) increased <ENT2>ALDH1A1</ENT2> expression in adipocytes, which does not increase all-trans-retinoic acid levels; 2) further <ENT1>RAR</ENT1> ligand-induced, WAT-selective, increased retinoic acid response element-mediated signaling; and 3) <ENT1>RAR</ENT1> ligand-dependent reduction of adiponectin expression.-Landrier, J.-F., Kasiri, E., Karkeni, E., Mihaly, J., Beke, G., Weiss, K., Lucas, R., Aydemir, G., Salles, J., Walrand, S., de Lera, A. R., Ruhl, R.",,,,T,,,,,c,,,,,1.0,,
27729412;27729412;27729412,3499;3503;3501,20181;19401;19411,D014212;D014212;D014212,Positive_Correlation;Positive_Correlation;Positive_Correlation,FALSE;FALSE;FALSE,"We conclude that reduced adiponectin expression under high-fat dietary conditions is dependent on 1) increased ALDH1A1 expression in adipocytes, which does not increase all-trans-<ENT2>retinoic acid</ENT2> levels; 2) further <ENT1>RAR</ENT1> ligand-induced, WAT-selective, increased <ENT2>retinoic acid</ENT2> response element-mediated signaling; and 3) <ENT1>RAR</ENT1> ligand-dependent reduction of adiponectin expression.-Landrier, J.-F., Kasiri, E., Karkeni, E., Mihaly, J., Beke, G., Weiss, K., Lucas, R., Aydemir, G., Salles, J., Walrand, S., de Lera, A. R., Ruhl, R.",,,,T,,,,,c,,,,,0.25,,
27729412,3513,11450,D014801,Negative_Correlation,TRUE,"In this study, we examined <ENT1>adiponectin</ENT1> expression as a function of dietary high-fat and high-<ENT2>vitamin A</ENT2> conditions in mice.",,,,T,,Y,,,c,,,,,1.0,,
27729412,3513,11450,D014801,Negative_Correlation,TRUE,"A decrease of <ENT1>adiponectin</ENT1> expression in addition to an up-regulation of aldehyde dehydrogenase A1 (ALDH1A1), retinoid signaling, and retinoic acid response element signaling was selectively observed in WAT of mice fed a normal-<ENT2>vitamin A</ENT2>, high-fat diet.",,,,T,,,,,c,,,,,0.0,,
27729412,3513,11450,D014801,Negative_Correlation,TRUE,Reduced <ENT1>adiponectin</ENT1> expression in WAT was also observed in mice fed a high-<ENT2>vitamin A</ENT2> diet.,,,,T,,,,,c,,,,,0.0,,
27729412;27729412,3504;3502,11450;11450,19401;19411,Negative_Correlation;Negative_Correlation,TRUE;TRUE,Reduced <ENT1>adiponectin</ENT1> expression after high-fat diet is associated with selective up-regulation of ALDH1A1 and further <ENT2>retinoic acid receptor</ENT2> signaling in adipose tissue.,,,,T,,,,,w,,,,,0.0,,
27729412,3504,11450,19401,Negative_Correlation,TRUE,"Adipocyte cell culture revealed that endogenous and synthetic <ENT2>retinoic acid receptor (RAR)a</ENT2>- and RARg-selective agonists, as well as a synthetic retinoid X receptor agonist, efficiently reduced <ENT1>adiponectin</ENT1> expression, whereas ALDH1A1 expression only increased with <ENT2>RAR</ENT2> agonists.",,,,T,,,,,c,,,,,0.5,,
27729412;27729412,3504;3502,11450;11450,19401;19411,Negative_Correlation;Negative_Correlation,TRUE;TRUE,"We conclude that reduced <ENT1>adiponectin</ENT1> expression under high-fat dietary conditions is dependent on 1) increased ALDH1A1 expression in adipocytes, which does not increase all-trans-retinoic acid levels; 2) further <ENT2>RAR</ENT2> ligand-induced, WAT-selective, increased retinoic acid response element-mediated signaling; and 3) <ENT2>RAR</ENT2> ligand-dependent reduction of <ENT1>adiponectin</ENT1> expression.-Landrier, J.-F., Kasiri, E., Karkeni, E., Mihaly, J., Beke, G., Weiss, K., Lucas, R., Aydemir, G., Salles, J., Walrand, S., de Lera, A. R., Ruhl, R.",,,,T,,,,,w,,,,,0.0,,
27729412,3512,11450,11668,Negative_Correlation,TRUE,Reduced <ENT1>adiponectin</ENT1> expression after high-fat diet is associated with selective up-regulation of <ENT2>ALDH1A1</ENT2> and further retinoic acid receptor signaling in adipose tissue.,,,,T,,,,,c,,,,,0.0,,
27729412,3512,11450,11668,Negative_Correlation,TRUE,"A decrease of <ENT1>adiponectin</ENT1> expression in addition to an up-regulation of <ENT2>aldehyde dehydrogenase A1</ENT2> (<ENT2>ALDH1A1</ENT2>), retinoid signaling, and retinoic acid response element signaling was selectively observed in WAT of mice fed a normal-vitamin A, high-fat diet.",,,,T,,,,,w,,,,,0.0,,
27729412,3512,11450,11668,Negative_Correlation,TRUE,"Adipocyte cell culture revealed that endogenous and synthetic retinoic acid receptor (RAR)a- and RARg-selective agonists, as well as a synthetic retinoid X receptor agonist, efficiently reduced <ENT1>adiponectin</ENT1> expression, whereas <ENT2>ALDH1A1</ENT2> expression only increased with RAR agonists.",,,,T,,,,,c,,,,,1.0,,
27729412,3512,11450,11668,Negative_Correlation,TRUE,"We conclude that reduced <ENT1>adiponectin</ENT1> expression under high-fat dietary conditions is dependent on 1) increased <ENT2>ALDH1A1</ENT2> expression in adipocytes, which does not increase all-trans-retinoic acid levels; 2) further RAR ligand-induced, WAT-selective, increased retinoic acid response element-mediated signaling; and 3) RAR ligand-dependent reduction of <ENT1>adiponectin</ENT1> expression.-Landrier, J.-F., Kasiri, E., Karkeni, E., Mihaly, J., Beke, G., Weiss, K., Lucas, R., Aydemir, G., Salles, J., Walrand, S., de Lera, A. R., Ruhl, R.",,,,T,,,,,w,,,,,0.5,,
27729412,3502,11450,19411,Negative_Correlation,TRUE,"Adipocyte cell culture revealed that endogenous and synthetic retinoic acid receptor (RAR)a- and <ENT2>RARg</ENT2>-selective agonists, as well as a synthetic retinoid X receptor agonist, efficiently reduced <ENT1>adiponectin</ENT1> expression, whereas ALDH1A1 expression only increased with <ENT2>RAR</ENT2> agonists.",,,,T,,,,,c,,,,,0.5,,
27729412,3511,11450,D014212,Negative_Correlation,TRUE,"A decrease of <ENT1>adiponectin</ENT1> expression in addition to an up-regulation of aldehyde dehydrogenase A1 (ALDH1A1), retinoid signaling, and <ENT2>retinoic acid</ENT2> response element signaling was selectively observed in WAT of mice fed a normal-vitamin A, high-fat diet.",,,,T,,,,,c,,,,,0.0,,
27729412,3511,11450,D014212,Negative_Correlation,TRUE,"We conclude that reduced <ENT1>adiponectin</ENT1> expression under high-fat dietary conditions is dependent on 1) increased ALDH1A1 expression in adipocytes, which does not increase all-trans-<ENT2>retinoic acid</ENT2> levels; 2) further RAR ligand-induced, WAT-selective, increased <ENT2>retinoic acid</ENT2> response element-mediated signaling; and 3) RAR ligand-dependent reduction of <ENT1>adiponectin</ENT1> expression.-Landrier, J.-F., Kasiri, E., Karkeni, E., Mihaly, J., Beke, G., Weiss, K., Lucas, R., Aydemir, G., Salles, J., Walrand, S., de Lera, A. R., Ruhl, R.",,,,T,,,,,w,,,,,0.0,,
27729412,3510,11450,D007249,Negative_Correlation,FALSE,"<ENT1>Adiponectin</ENT1> is an adipocyte-derived <ENT1>adipokine</ENT1> with potent antidiabetic, anti-<ENT2>inflammatory</ENT2>, and antiatherogenic activity.",,,,T,,,,,c,,,,,0.5,,
27729412,3510,11450,D007249,Negative_Correlation,FALSE,"Long-term, high-fat diet results in gain of body weight, adiposity, further <ENT2>inflammatory</ENT2>-based cardiovascular diseases, and reduced <ENT1>adiponectin</ENT1> secretion.",,,,T,,,,,c,,,,,1.0,,
27729412,3509,D014801,11668,Positive_Correlation,TRUE,"A decrease of adiponectin expression in addition to an up-regulation of <ENT2>aldehyde dehydrogenase A1</ENT2> (<ENT2>ALDH1A1</ENT2>), retinoid signaling, and retinoic acid response element signaling was selectively observed in WAT of mice fed a normal-<ENT1>vitamin A</ENT1>, high-fat diet.",,,,T,,,,,c,,,,,0.0,,
27729412,3505,D014801,D014212,Association,TRUE,"A decrease of adiponectin expression in addition to an up-regulation of aldehyde dehydrogenase A1 (ALDH1A1), retinoid signaling, and <ENT2>retinoic acid</ENT2> response element signaling was selectively observed in WAT of mice fed a normal-<ENT1>vitamin A</ENT1>, high-fat diet.",,,,T,,,,,c,,,,,0.0,,
27729412,3508,19401,11668,Positive_Correlation,TRUE,"Adipocyte cell culture revealed that endogenous and synthetic <ENT1>retinoic acid receptor (RAR)a</ENT1>- and RARg-selective agonists, as well as a synthetic retinoid X receptor agonist, efficiently reduced adiponectin expression, whereas <ENT2>ALDH1A1</ENT2> expression only increased with <ENT1>RAR</ENT1> agonists.",,,,T,,,,,c,,,,,0.5,,
27729412,3507,11668,19411,Positive_Correlation,TRUE,Reduced adiponectin expression after high-fat diet is associated with selective up-regulation of <ENT1>ALDH1A1</ENT1> and further <ENT2>retinoic acid receptor</ENT2> signaling in adipose tissue.,,,,T,,,,,w,,,,,1.0,,
27729412,3507,11668,19411,Positive_Correlation,TRUE,"Adipocyte cell culture revealed that endogenous and synthetic retinoic acid receptor (RAR)a- and <ENT2>RARg</ENT2>-selective agonists, as well as a synthetic retinoid X receptor agonist, efficiently reduced adiponectin expression, whereas <ENT1>ALDH1A1</ENT1> expression only increased with <ENT2>RAR</ENT2> agonists.",,,,T,,,,,c,,,,,0.5,,
27729412,3507,11668,19411,Positive_Correlation,TRUE,"We conclude that reduced adiponectin expression under high-fat dietary conditions is dependent on 1) increased <ENT1>ALDH1A1</ENT1> expression in adipocytes, which does not increase all-trans-retinoic acid levels; 2) further <ENT2>RAR</ENT2> ligand-induced, WAT-selective, increased retinoic acid response element-mediated signaling; and 3) <ENT2>RAR</ENT2> ligand-dependent reduction of adiponectin expression.-Landrier, J.-F., Kasiri, E., Karkeni, E., Mihaly, J., Beke, G., Weiss, K., Lucas, R., Aydemir, G., Salles, J., Walrand, S., de Lera, A. R., Ruhl, R.",,,,T,,,,,c,,,,,1.0,,
27798239,3526,4218,55300,Association,TRUE,<ENT2>PI4KIIb</ENT2> depletion caused increased MT1-MMP trafficking to invasive structures at the plasma membrane and was accompanied by reduced colocalization of MT1-MMP with membranes containing the endosomal markers Rab5 and Rab7 but increased localization with the exocytic <ENT1>Rab8</ENT1>.,,,,T,,,,,c,,,,,1.0,,
27798239,3521,4218,4323,Association,TRUE,PI4KIIb depletion caused increased <ENT2>MT1-MMP</ENT2> trafficking to invasive structures at the plasma membrane and was accompanied by reduced colocalization of <ENT2>MT1-MMP</ENT2> with membranes containing the endosomal markers Rab5 and Rab7 but increased localization with the exocytic <ENT1>Rab8</ENT1>.,,,,T,,,,,c,,,,,0.5,,
27798239,3524,55300,1213,Association,FALSE,"The <ENT1>type II phosphatidylinositol 4-kinase</ENT1> (<ENT1>PI4KII</ENT1>) enzymes synthesize the lipid phosphatidylinositol 4-phosphate (PI(4)P), which has been detected at the Golgi complex and endosomal compartments and recruits <ENT2>clathrin</ENT2> adaptors.",,,,T,,,,,c,,,,,0.5,,
27798239,3522,55300,60,Association,TRUE,We found that depletion of PI4KIIa and <ENT1>PI4KIIb</ENT1> using small interfering RNA led to <ENT2>actin</ENT2> remodeling.,,,,T,,,,,c,,,,,0.0,,
27798239,3528,55300,4323,Association,TRUE,Depletion of <ENT1>PI4KIIb</ENT1> also induced the formation of invadopodia containing <ENT2>membrane type I matrix metalloproteinase</ENT2> (<ENT2>MT1-MMP</ENT2>).,,,,T,,,,,c,,,,,0.0,,
27798239,3528,55300,4323,Association,TRUE,<ENT1>PI4KIIb</ENT1> depletion caused increased <ENT2>MT1-MMP</ENT2> trafficking to invasive structures at the plasma membrane and was accompanied by reduced colocalization of <ENT2>MT1-MMP</ENT2> with membranes containing the endosomal markers Rab5 and Rab7 but increased localization with the exocytic Rab8.,,,,T,,,,,c,,,,,0.0,,
27798239,3528,55300,4323,Association,TRUE,We propose that <ENT1>PI4KIIb</ENT1> synthesizes a pool of PI(4)P that maintains <ENT2>MT1-MMP</ENT2> traffic in the degradative pathway and suppresses the formation of invadopodia.,,,,T,,Y,,,w,,,,,0.0,,
27798239,3525,55300,D008055,Association,FALSE,"The <ENT1>type II phosphatidylinositol 4-kinase</ENT1> (<ENT1>PI4KII</ENT1>) enzymes synthesize the <ENT2>lipid</ENT2> phosphatidylinositol 4-phosphate (PI(4)P), which has been detected at the Golgi complex and endosomal compartments and recruits clathrin adaptors.",,,,T,,,,,c,,,,,1.0,,
27798239,3523,55300,D009369,Negative_Correlation,TRUE,Mining oncogenomic databases revealed that loss of the <ENT1>PI4K2B</ENT1> allele and underexpression of <ENT1>PI4KIIb</ENT1> mRNA are associated with human <ENT2>cancers</ENT2>.,,,,T,,,,,w,,,,,0.0,,
27798239,3527,55300,C037178,Association,TRUE,"The <ENT1>type II phosphatidylinositol 4-kinase</ENT1> (<ENT1>PI4KII</ENT1>) enzymes synthesize the lipid <ENT2>phosphatidylinositol 4-phosphate</ENT2> (<ENT2>PI(4)P</ENT2>), which has been detected at the Golgi complex and endosomal compartments and recruits clathrin adaptors.",,,,T,,,,,c,,,"11,12,21,22",,0.0,,
27798239,3527,55300,C037178,Association,TRUE,Depletion of <ENT1>PI4KII</ENT1> isoforms also differentially affected trans-Golgi network (TGN) pools of <ENT2>PI(4)P</ENT2> and post-TGN traffic.,,,,T,,,,,c,,,,,0.0,,
27798239,3527,55300,C037178,Association,TRUE,We propose that <ENT1>PI4KIIb</ENT1> synthesizes a pool of <ENT2>PI(4)P</ENT2> that maintains MT1-MMP traffic in the degradative pathway and suppresses the formation of invadopodia.,,,,T,,,,,c,,,,,0.0,,
27798239,3515,1213,55361,Association,FALSE,"The <ENT2>type II phosphatidylinositol 4-kinase</ENT2> (<ENT2>PI4KII</ENT2>) enzymes synthesize the lipid phosphatidylinositol 4-phosphate (PI(4)P), which has been detected at the Golgi complex and endosomal compartments and recruits <ENT1>clathrin</ENT1> adaptors.",,,,T,,,,,c,,,,,1.0,,
27798239,3514,60,55361,Association,TRUE,We found that depletion of <ENT2>PI4KIIa</ENT2> and PI4KIIb using small interfering RNA led to <ENT1>actin</ENT1> remodeling.,,,,T,,,,,c,,,,,1.0,,
27798239,3519,4323,338382,Association,TRUE,PI4KIIb depletion caused increased <ENT1>MT1-MMP</ENT1> trafficking to invasive structures at the plasma membrane and was accompanied by reduced colocalization of <ENT1>MT1-MMP</ENT1> with membranes containing the endosomal markers Rab5 and <ENT2>Rab7</ENT2> but increased localization with the exocytic Rab8.,,,,T,,,,,w,,,,,0.0,TRUE,
27798239,3520,4323,5868,Association,TRUE,PI4KIIb depletion caused increased <ENT1>MT1-MMP</ENT1> trafficking to invasive structures at the plasma membrane and was accompanied by reduced colocalization of <ENT1>MT1-MMP</ENT1> with membranes containing the endosomal markers <ENT2>Rab5</ENT2> and Rab7 but increased localization with the exocytic Rab8.,,,,T,,,,,w,,,,,0.0,TRUE,
27798239,3518,4323,C037178,Association,TRUE,We propose that PI4KIIb synthesizes a pool of <ENT2>PI(4)P</ENT2> that maintains <ENT1>MT1-MMP</ENT1> traffic in the degradative pathway and suppresses the formation of invadopodia.,,,,T,,,,,c,,,,,1.0,,
27798239,3516,D008055,55361,Association,FALSE,"The <ENT2>type II phosphatidylinositol 4-kinase</ENT2> (<ENT2>PI4KII</ENT2>) enzymes synthesize the <ENT1>lipid</ENT1> phosphatidylinositol 4-phosphate (PI(4)P), which has been detected at the Golgi complex and endosomal compartments and recruits clathrin adaptors.",,,,T,,,,,c,,,,,1.0,,
27798239,3517,C037178,55361,Association,TRUE,"The <ENT2>type II phosphatidylinositol 4-kinase</ENT2> (<ENT2>PI4KII</ENT2>) enzymes synthesize the lipid <ENT1>phosphatidylinositol 4-phosphate</ENT1> (<ENT1>PI(4)P</ENT1>), which has been detected at the Golgi complex and endosomal compartments and recruits clathrin adaptors.",,,,T,,,,,c,,,"11,12,21,22",,0.0,,
27798239,3517,C037178,55361,Association,TRUE,Depletion of <ENT2>PI4KII</ENT2> isoforms also differentially affected trans-Golgi network (TGN) pools of <ENT1>PI(4)P</ENT1> and post-TGN traffic.,,,,T,,,,,c,,,,,1.0,,
27840894,3554,D063730,5251,Association,FALSE,Seven novel and six de novo <ENT2>PHEX</ENT2> gene mutations in patients with <ENT1>hypophosphatemic rickets</ENT1>.,,,,T,,T,,,w,,,,,0.0,,
27840894,3553,5251,D053098,Negative_Correlation,TRUE,Inactivating mutations in <ENT1>phosphate-regulating gene with homologies to endopeptidase on the X chromosome</ENT1> (<ENT1>PHEX</ENT1>) have been identified as a cause of <ENT2>X-linked hypophosphatemic rickets</ENT2> (<ENT2>XLH</ENT2>; <ENT2>OMIM 307800</ENT2>).,,,,T,,,,,c,,,"11,12,13,21,22,23",,0.666666667,,
27860244,3568,3569,10419,Positive_Correlation,TRUE,"Inhibition of <ENT2>PRMT5</ENT2> by EPZ015666 and siRNA-mediated knockdown reduced <ENT1>IL-6</ENT1> and IL-8 production, and proliferation of RA FLSs.",,,,T,,,,,c,,,,,1.0,,
27860244,3560,3569,C000599896,Negative_Correlation,TRUE,"Inhibition of PRMT5 by <ENT2>EPZ015666</ENT2> and siRNA-mediated knockdown reduced <ENT1>IL-6</ENT1> and IL-8 production, and proliferation of RA FLSs.",,,,T,,,,,c,,,,,1.0,,
27860244,3566,5970,10419,Association,TRUE,"<ENT2>PRMT5</ENT2> regulated the production of inflammatory factors, cell proliferation, migration and invasion of RA FLS, which was mediated by the <ENT1>NF-kB</ENT1> and AKT pathways.",,,,T,,,,,c,,,,,0.0,,
27860244,3572,5970,D001172,Association,FALSE,"PRMT5 regulated the production of inflammatory factors, cell proliferation, migration and invasion of <ENT2>RA</ENT2> FLS, which was mediated by the <ENT1>NF-kB</ENT1> and AKT pathways.",,,,T,,,,,c,,,,,0.0,,
27860244,3556,5970,C000599896,Association,TRUE,"Furthermore, <ENT2>EPZ015666</ENT2> restrained the phosphorylation of IkB kinaseb and IkBa, as well as nucleus transsituation of <ENT1>p65</ENT1> as well as AKT in FLSs.",,,,T,,,,,c,,,,,0.0,,
27860244,3570,10419,3553,Positive_Correlation,TRUE,"In RA FLSs, the level of <ENT1>PRMT5</ENT1> was up-regulated by stimulation with <ENT2>IL-1b</ENT2> and TNF-a.",,,,T,,,,,c,,,,,1.0,,
27860244,3573,10419,D001172,Association,TRUE,Role of <ENT1>protein arginine methyltransferase 5</ENT1> in inflammation and migration of fibroblast-like synoviocytes in <ENT2>rheumatoid arthritis</ENT2>.,,,,T,,T,,,c,,,,,1.0,,
27860244,3573,10419,D001172,Association,TRUE,"To probe the role of <ENT1>protein arginine methyltransferase 5</ENT1> (<ENT1>PRMT5</ENT1>) in regulating inflammation, cell proliferation, migration and invasion of fibroblast-like synoviocytes (FLSs) from patients with <ENT2>rheumatoid arthritis</ENT2> (<ENT2>RA</ENT2>).",,,,T,,Y,,,c,,,,,1.0,,
27860244,3573,10419,D001172,Association,TRUE,Increased <ENT1>PRMT5</ENT1> was discovered in STs and FLSs from patients with <ENT2>RA</ENT2>.,,,,T,,,,,c,,,,,1.0,,
27860244,3573,10419,D001172,Association,TRUE,"In <ENT2>RA</ENT2> FLSs, the level of <ENT1>PRMT5</ENT1> was up-regulated by stimulation with IL-1b and TNF-a.",,,,T,,,,,c,,,,,0.0,,
27860244,3573,10419,D001172,Association,TRUE,"Inhibition of <ENT1>PRMT5</ENT1> by EPZ015666 and siRNA-mediated knockdown reduced IL-6 and IL-8 production, and proliferation of <ENT2>RA</ENT2> FLSs.",,,,T,,,,,c,,,,,1.0,,
27860244,3573,10419,D001172,Association,TRUE,"In addition, inhibition of <ENT1>PRMT5</ENT1> decreased in vitro migration and invasion of <ENT2>RA</ENT2> FLSs.",,,,T,,,,,c,,,,,1.0,,
27860244,3573,10419,D001172,Association,TRUE,"<ENT1>PRMT5</ENT1> regulated the production of inflammatory factors, cell proliferation, migration and invasion of <ENT2>RA</ENT2> FLS, which was mediated by the NF-kB and AKT pathways.",,,,T,,,,,c,,,,,1.0,,
27860244,3573,10419,D001172,Association,TRUE,Our data suggested that targeting <ENT1>PRMT5</ENT1> to prevent synovial inflammation and destruction might be a promising therapy for <ENT2>RA</ENT2>.,,,,T,,,,,c,,,,,0.0,,
27860244,3567,10419,3576,Positive_Correlation,TRUE,"Inhibition of <ENT1>PRMT5</ENT1> by EPZ015666 and siRNA-mediated knockdown reduced IL-6 and <ENT2>IL-8</ENT2> production, and proliferation of RA FLSs.",,,,T,,,,,c,,,,,1.0,,
27860244,3569,10419,7124,Positive_Correlation,TRUE,"In RA FLSs, the level of <ENT1>PRMT5</ENT1> was up-regulated by stimulation with IL-1b and <ENT2>TNF-a</ENT2>.",,,,T,,,,,c,,,,,1.0,,
27860244,3565,10419,207,Association,TRUE,"<ENT1>PRMT5</ENT1> regulated the production of inflammatory factors, cell proliferation, migration and invasion of RA FLS, which was mediated by the NF-kB and <ENT2>AKT</ENT2> pathways.",,,,T,,,,,w,,,,,0.0,,
27860244,3563,10419,D013585,Association,TRUE,Our data suggested that targeting <ENT1>PRMT5</ENT1> to prevent <ENT2>synovial inflammation</ENT2> and destruction might be a promising therapy for RA.,,,,T,,,,,c,,,,,1.0,,
27860244,3561,10419,C000599896,Negative_Correlation,FALSE,An inhibitor of <ENT1>PRMT5</ENT1> (<ENT2>EPZ015666</ENT2>) and short interference RNA (siRNA) against <ENT1>PRMT5</ENT1> were used to inhibit <ENT1>PRMT5</ENT1> expression.,,,,T,,,,,c,,,,,0.666666667,,
27860244,3561,10419,C000599896,Negative_Correlation,FALSE,"Inhibition of <ENT1>PRMT5</ENT1> by <ENT2>EPZ015666</ENT2> and siRNA-mediated knockdown reduced IL-6 and IL-8 production, and proliferation of RA FLSs.",,,,T,,,,,c,,,,,1.0,,
27860244,3564,10419,D007249,Association,TRUE,Role of <ENT1>protein arginine methyltransferase 5</ENT1> in <ENT2>inflammation</ENT2> and migration of fibroblast-like synoviocytes in rheumatoid arthritis.,,,,T,,T,,,c,,,,,0.0,,
27860244,3564,10419,D007249,Association,TRUE,"To probe the role of <ENT1>protein arginine methyltransferase 5</ENT1> (<ENT1>PRMT5</ENT1>) in regulating <ENT2>inflammation</ENT2>, cell proliferation, migration and invasion of fibroblast-like synoviocytes (FLSs) from patients with rheumatoid arthritis (RA).",,,,T,,,,,c,,,,,1.0,,
27860244,3564,10419,D007249,Association,TRUE,"<ENT1>PRMT5</ENT1> regulated the production of <ENT2>inflammatory</ENT2> factors, cell proliferation, migration and invasion of RA FLS, which was mediated by the NF-kB and AKT pathways.",,,,T,,,,,c,,,,,1.0,,
27860244,3571,D001172,207,Association,FALSE,"PRMT5 regulated the production of inflammatory factors, cell proliferation, migration and invasion of <ENT1>RA</ENT1> FLS, which was mediated by the NF-kB and <ENT2>AKT</ENT2> pathways.",,,,T,,,,,c,,,,,1.0,,
27860244,3562,D001172,C000599896,Association,TRUE,"Inhibition of PRMT5 by <ENT2>EPZ015666</ENT2> and siRNA-mediated knockdown reduced IL-6 and IL-8 production, and proliferation of <ENT1>RA</ENT1> FLSs.",,,,T,,,,,c,,,,,0.0,,
27860244,3559,3576,C000599896,Negative_Correlation,TRUE,"Inhibition of PRMT5 by <ENT2>EPZ015666</ENT2> and siRNA-mediated knockdown reduced IL-6 and <ENT1>IL-8</ENT1> production, and proliferation of RA FLSs.",,,,T,,,,,c,,,,,1.0,,
27860244,3555,207,C000599896,Association,TRUE,"Furthermore, <ENT2>EPZ015666</ENT2> restrained the phosphorylation of IkB kinaseb and IkBa, as well as nucleus transsituation of p65 as well as <ENT1>AKT</ENT1> in FLSs.",,,,T,,,,,c,,,,,0.0,,
27860244,3557,4792,C000599896,Association,TRUE,"Furthermore, <ENT2>EPZ015666</ENT2> restrained the phosphorylation of IkB kinaseb and <ENT1>IkBa</ENT1>, as well as nucleus transsituation of p65 as well as AKT in FLSs.",,,,T,,,,,c,,,,,0.0,,
27860244,3558,C000599896,3551,Association,TRUE,"Furthermore, <ENT1>EPZ015666</ENT1> restrained the phosphorylation of <ENT2>IkB kinaseb</ENT2> and IkBa, as well as nucleus transsituation of p65 as well as AKT in FLSs.",,,,T,,,,,c,,,,,0.0,,
27866394,3589,D043183,C013934,Negative_Correlation,FALSE,<ENT2>Otilonium bromide</ENT2> (<ENT2>OB</ENT2>) is a spasmolytic drug successfully used for the treatment of <ENT1>irritable bowel syndrome</ENT1> (<ENT1>IBS</ENT1>).,,,,T,,,,,c,,,"11,12,21,22",,1.0,,
27866394,3589,D043183,C013934,Negative_Correlation,FALSE,"On this basis, we investigated whether repeated <ENT2>OB</ENT2> treatment prevented the functional and neurochemical changes observed in the colon of rats underwent to wrap restrain stress (WRS) a psychosocial stressor considered suitable to reproduce the main <ENT1>IBS</ENT1> signs and symptoms.",,,,T,,Y,,,w,,,,,0.0,,
27866394,3588,C013934,D018377,Association,FALSE,Repeated <ENT1>otilonium bromide</ENT1> administration prevents <ENT2>neurotransmitter</ENT2> changes in colon of rats underwent to wrap restraint stress.,,,,T,,,,,c,,,,,0.0,,
27866394,3588,C013934,D018377,Association,FALSE,"Furthermore, in healthy rats, repeated <ENT1>OB</ENT1> administration modified <ENT2>neurotransmitter</ENT2> expression and function suggesting other mechanisms of action.",,,,T,,,,,c,,,,,0.0,,
27866394,3588,C013934,D018377,Association,FALSE,The results showed that <ENT1>OB</ENT1> counteracts most of the <ENT2>neurotransmitters</ENT2> changes caused by WRS.,,,,T,,,,,c,,,,,0.0,,
27866394,3591,C013934,81645,Positive_Correlation,TRUE,"Finally, <ENT1>OB</ENT1> per se increases the <ENT2>Mr2</ENT2> expression in the muscle wall and decreases the number of the myenteric ChAT-IR neurons.",,,,T,,,,,c,,,,,1.0,,
27866394,3590,C013934,290567,Negative_Correlation,TRUE,"Finally, <ENT1>OB</ENT1> per se increases the Mr2 expression in the muscle wall and decreases the number of the myenteric <ENT2>ChAT</ENT2>-IR neurons.",,,,T,,,,,c,,,,,1.0,,
27866394,3577,C013934,24239,Negative_Correlation,TRUE,"The ability of <ENT1>OB</ENT1> to block <ENT2>L-type Ca(2+) channels</ENT2>, also expressed by enteric neurons, might represent a possible mechanism through which <ENT1>OB</ENT1> exerts its actions.",,,,T,,,,,c,,,,,1.0,,
27930654,3600,189429,D000071700,Association,FALSE,"Further analyses of C. elegans <ENT1>RAB-28</ENT1>, recently associated with autosomal-recessive <ENT2>cone-rod dystrophy</ENT2>, reveal that this small <ENT1>GTPase</ENT1> is exclusively expressed in ciliated neurons where it dynamically associates with IFT trains.",,,,T,,,,,c,,,,,1.0,,
27930654,3598,189429,D006153,Bind,FALSE,"Whereas inactive <ENT2>GDP</ENT2>-bound <ENT1>RAB-28</ENT1> displays no IFT movement and diffuse localisation, GTP-bound (activated) <ENT1>RAB-28</ENT1> concentrates at the periciliary membrane in a BBSome-dependent manner and undergoes bidirectional IFT.",,,,T,,,,,c,,,,,0.0,,
27930654,3598,189429,D006153,Bind,FALSE,"Functional analyses reveal that whilst cilium structure, sensory function and IFT are seemingly normal in a <ENT1>rab-28</ENT1> null allele, overexpression of predicted <ENT2>GDP</ENT2> or GTP locked variants of <ENT1>RAB-28</ENT1> perturbs cilium and sensory pore morphogenesis and function.",,,,T,,,,,c,,,,,0.0,,
27930654,3597,189429,D006160,Bind,FALSE,"Whereas inactive GDP-bound <ENT1>RAB-28</ENT1> displays no IFT movement and diffuse localisation, <ENT2>GTP</ENT2>-bound (activated) <ENT1>RAB-28</ENT1> concentrates at the periciliary membrane in a BBSome-dependent manner and undergoes bidirectional IFT.",,,,T,,,,,c,,,,,0.5,,
27930654,3597,189429,D006160,Bind,FALSE,"Functional analyses reveal that whilst cilium structure, sensory function and IFT are seemingly normal in a <ENT1>rab-28</ENT1> null allele, overexpression of predicted GDP or <ENT2>GTP</ENT2> locked variants of <ENT1>RAB-28</ENT1> perturbs cilium and sensory pore morphogenesis and function.",,,,T,,,,,c,,,,,0.0,,
27930654,3601,189429,260219,Association,TRUE,Whole-Organism Developmental Expression Profiling Identifies <ENT1>RAB-28</ENT1> as a Novel Ciliary <ENT1>GTPase</ENT1> Associated with the <ENT2>BBSome</ENT2> and Intraflagellar Transport.,,,,T,,,,,c,,,,,0.5,,
27930654,3601,189429,260219,Association,TRUE,"Whereas inactive GDP-bound <ENT1>RAB-28</ENT1> displays no IFT movement and diffuse localisation, GTP-bound (activated) <ENT1>RAB-28</ENT1> concentrates at the periciliary membrane in a <ENT2>BBSome</ENT2>-dependent manner and undergoes bidirectional IFT.",,,,T,,,,,c,,,,,1.0,,
27930654,3595,D020788,9364,Association,FALSE,"Collectively, our findings present a new approach for identifying ciliary proteins, and unveil <ENT2>RAB28</ENT2>, a <ENT2>GTPase</ENT2> most closely related to the <ENT1>BBS</ENT1> protein RABL4/IFT27, as an IFT-associated cargo with BBSome-dependent cell autonomous and non-autonomous functions at the ciliary base.",,,,T,,,,,c,,,,,0.0,,
27930654,3593,D020788,11020,Association,FALSE,"Collectively, our findings present a new approach for identifying ciliary proteins, and unveil RAB28, a GTPase most closely related to the <ENT1>BBS</ENT1> protein <ENT2>RABL4</ENT2>/<ENT2>IFT27</ENT2>, as an IFT-associated cargo with BBSome-dependent cell autonomous and non-autonomous functions at the ciliary base.",,,,T,,,,,c,,,,,1.0,,
27930654,3599,D020788,260219,Association,FALSE,"Collectively, our findings present a new approach for identifying ciliary proteins, and unveil RAB28, a GTPase most closely related to the <ENT1>BBS</ENT1> protein RABL4/IFT27, as an IFT-associated cargo with <ENT2>BBSome</ENT2>-dependent cell autonomous and non-autonomous functions at the ciliary base.",,,,T,,,,,w,,,,,1.0,,
27930654,3594,9364,11020,Association,FALSE,"Collectively, our findings present a new approach for identifying ciliary proteins, and unveil <ENT1>RAB28</ENT1>, a <ENT1>GTPase</ENT1> most closely related to the BBS protein <ENT2>RABL4</ENT2>/<ENT2>IFT27</ENT2>, as an IFT-associated cargo with BBSome-dependent cell autonomous and non-autonomous functions at the ciliary base.",,,,T,,,,,c,,,"11,12,21,22",,0.25,,
27930654,3596,D006160,260219,Association,TRUE,"Whereas inactive GDP-bound RAB-28 displays no IFT movement and diffuse localisation, <ENT1>GTP</ENT1>-bound (activated) RAB-28 concentrates at the periciliary membrane in a <ENT2>BBSome</ENT2>-dependent manner and undergoes bidirectional IFT.",,,,T,,,,,c,,,,,0.0,,
27941998,3605,24887,C563319,Association,TRUE,"Meanwhile apoptosis related proteins <ENT1>bax</ENT1> and ATF2 were involved in <ENT2>desminopathy</ENT2> patients and <ENT2>desminopathy</ENT2> rat model, but not bcl-2, bcl-xl or HK2.VDAC1 and desmin are closely relevant in the tissue splices of deminopathies patients and rats with <ENT2>desminopathy</ENT2> at protein lever.",,,,T,,,,,c,,,,,1.0,,
27941998,3605,24887,C563319,Association,TRUE,"Moreover, apoptotic proteins are also involved in the <ENT2>desminopathies</ENT2>, like <ENT1>bax</ENT1>, ATF2, but not bcl-2, bcl-xl or HK2.",,,,T,,,,,w,,,,,1.0,,
27941998,3603,1386,C563319,Association,TRUE,"Meanwhile apoptosis related proteins bax and <ENT1>ATF2</ENT1> were involved in <ENT2>desminopathy</ENT2> patients and <ENT2>desminopathy</ENT2> rat model, but not bcl-2, bcl-xl or HK2.VDAC1 and desmin are closely relevant in the tissue splices of deminopathies patients and rats with <ENT2>desminopathy</ENT2> at protein lever.",,,,T,,,,,c,,,,,1.0,,
27941998,3603,1386,C563319,Association,TRUE,"Moreover, apoptotic proteins are also involved in the <ENT2>desminopathies</ENT2>, like bax, <ENT1>ATF2</ENT1>, but not bcl-2, bcl-xl or HK2.",,,,T,,,,,w,,,,,1.0,,
27941998;27941998,3607;3609,C563319;C563319,64362;1674,Association;Association,FALSE;FALSE,Immunofluorescence results showed that VDAC1 was accumulated in the <ENT2>desmin</ENT2> highly stained area of muscle fibers of <ENT1>desminopathy</ENT1> patients or <ENT1>desminopathy</ENT1> rat model compared to the normal ones.,,,,T,,,,,w,,,,,0.0,TRUE,
27941998;27941998,3607;3609,C563319;C563319,64362;1674,Association;Association,FALSE;FALSE,"Meanwhile apoptosis related proteins bax and ATF2 were involved in <ENT1>desminopathy</ENT1> patients and <ENT1>desminopathy</ENT1> rat model, but not bcl-2, bcl-xl or HK2.VDAC1 and <ENT2>desmin</ENT2> are closely relevant in the tissue splices of deminopathies patients and rats with <ENT1>desminopathy</ENT1> at protein lever.",,,,T,,,,,w,,,,,1.0,,
27941998;27941998,3607;3609,C563319;C563319,64362;1674,Association;Association,FALSE;FALSE,"This pathological analysis presents the correlation between VDAC1 and <ENT2>desmin</ENT2>, and apoptosis related proteins are correlated in the <ENT1>desminopathy</ENT1>.",,,,T,,,,,c,,,,,1.0,,
27941998,3607,C563319,64362,Association,FALSE,"Furthermore, we provide a rat model of <ENT1>desminopathy</ENT1> for the investigation of <ENT2>desmin</ENT2> related myopathy.",,,,T,,,,,w,,,,,0.0,,
27941998;27941998,3610;3614,C563319;C563319,83529;7416,Association;Association,TRUE;TRUE,<ENT2>Voltage-Dependent Anion Channel 1</ENT2>(<ENT2>VDAC1</ENT2>) Participates the Apoptosis of the Mitochondrial Dysfunction in <ENT1>Desminopathy</ENT1>.,,,,T,,T,,,w,,,,,0.0,,
27941998;27941998,3610;3614,C563319;C563319,83529;7416,Association;Association,TRUE;TRUE,Immunofluorescence results showed that <ENT2>VDAC1</ENT2> was accumulated in the desmin highly stained area of muscle fibers of <ENT1>desminopathy</ENT1> patients or <ENT1>desminopathy</ENT1> rat model compared to the normal ones.,,,,T,,,,,c,,,,,1.0,,
27941998;27941998,3610;3614,C563319;C563319,83529;7416,Association;Association,TRUE;TRUE,"Meanwhile apoptosis related proteins bax and ATF2 were involved in <ENT1>desminopathy</ENT1> patients and <ENT1>desminopathy</ENT1> rat model, but not bcl-2, bcl-xl or HK2.<ENT2>VDAC1</ENT2> and desmin are closely relevant in the tissue splices of deminopathies patients and rats with <ENT1>desminopathy</ENT1> at protein lever.",,,,T,,,,,w,,,,,0.0,,
27941998;27941998,3610;3614,C563319;C563319,83529;7416,Association;Association,TRUE;TRUE,"This pathological analysis presents the correlation between <ENT2>VDAC1</ENT2> and desmin, and apoptosis related proteins are correlated in the <ENT1>desminopathy</ENT1>.",,,,T,,,,,c,,,,,0.0,,
27941998,3614,C563319,7416,Association,TRUE,Relationships between <ENT1>desminopathies</ENT1> and <ENT2>Voltage-dependent anion channel 1</ENT2> (<ENT2>VDAC1</ENT2>) remain unclear.,,,,T,,,,,c,,,,,1.0,,
27941998,3609,C563319,1674,Association,FALSE,<ENT1>Desminopathies</ENT1> caused by the mutation in the gene coding for <ENT2>desmin</ENT2> are genetically protein aggregation myopathies.,,,,T,,,,,c,,,,,1.0,,
27941998;27941998,3613;3617,D028361;D028361,83529;7416,Association;Association,TRUE;TRUE,<ENT2>Voltage-Dependent Anion Channel 1</ENT2>(<ENT2>VDAC1</ENT2>) Participates the Apoptosis of the <ENT1>Mitochondrial Dysfunction</ENT1> in Desminopathy.,,,,T,,,,,w,,,,,0.0,,
27941998;27941998,3611;3615,64362;64362,83529;7416,Association;Association,TRUE;TRUE,Immunofluorescence results showed that <ENT2>VDAC1</ENT2> was accumulated in the <ENT1>desmin</ENT1> highly stained area of muscle fibers of desminopathy patients or desminopathy rat model compared to the normal ones.,,,,T,,,,,w,,,,,0.0,,
27941998;27941998,3611;3615,64362;64362,83529;7416,Association;Association,TRUE;TRUE,"Meanwhile apoptosis related proteins bax and ATF2 were involved in desminopathy patients and desminopathy rat model, but not bcl-2, bcl-xl or HK2.<ENT2>VDAC1</ENT2> and <ENT1>desmin</ENT1> are closely relevant in the tissue splices of deminopathies patients and rats with desminopathy at protein lever.",,,,T,,,,,c,,,,,1.0,,
27941998;27941998,3611;3615,64362;64362,83529;7416,Association;Association,TRUE;TRUE,"This pathological analysis presents the correlation between <ENT2>VDAC1</ENT2> and <ENT1>desmin</ENT1>, and apoptosis related proteins are correlated in the desminopathy.",,,,T,,,,,c,,,,,1.0,,
27941998,3606,64362,D009135,Association,FALSE,"Furthermore, we provide a rat model of desminopathy for the investigation of <ENT1>desmin</ENT1> related <ENT2>myopathy</ENT2>.",,,,T,,,,,c,,,,,1.0,,
27941998;27941998,3612;3616,83529;7416,1674;1674,Association;Association,TRUE;TRUE,Immunofluorescence results showed that <ENT1>VDAC1</ENT1> was accumulated in the <ENT2>desmin</ENT2> highly stained area of muscle fibers of desminopathy patients or desminopathy rat model compared to the normal ones.,,,,T,,,,,w,,,,,0.0,,
27941998;27941998,3612;3616,83529;7416,1674;1674,Association;Association,TRUE;TRUE,"Meanwhile apoptosis related proteins bax and ATF2 were involved in desminopathy patients and desminopathy rat model, but not bcl-2, bcl-xl or HK2.<ENT1>VDAC1</ENT1> and <ENT2>desmin</ENT2> are closely relevant in the tissue splices of deminopathies patients and rats with desminopathy at protein lever.",,,,T,,,,,c,,,,,1.0,,
27941998;27941998,3612;3616,83529;7416,1674;1674,Association;Association,TRUE;TRUE,"This pathological analysis presents the correlation between <ENT1>VDAC1</ENT1> and <ENT2>desmin</ENT2>, and apoptosis related proteins are correlated in the desminopathy.",,,,T,,,,,c,,,,,1.0,,
27941998,3608,D009135,1674,Association,FALSE,Desminopathies caused by the mutation in the gene coding for <ENT2>desmin</ENT2> are genetically protein aggregation <ENT1>myopathies</ENT1>.,,,,T,,,,,c,,,,,0.0,,
27959382,3618,D005355,12013,Association,FALSE,"<ENT2>Bach1</ENT2> knockdown by siRNA also enhanced the expression of antioxidant factors, but suppressed that of <ENT1>fibrosis</ENT1>-related cytokines in mice compared with the BLM group.",,,,T,,,,,w,,,,,1.0,,
27959382,3623,12013,15368,Negative_Correlation,TRUE,"Furthermore, the MLFs infected with <ENT1>Bach1</ENT1> siRNA exhibited increased mRNA and protein expression levels of <ENT2>heme oxygenase-1</ENT2> and glutathione peroxidase 1, but decreased levels of TGF-b1 and interleukin-6 in the cell supernatants compared with the cells exposed to TGF-b1 alone.",,,,T,,,,,w,,,,,0.0,,
27959382;27959382,3623;3622,12013;12013,15368;14775,Negative_Correlation;Negative_Correlation,TRUE;TRUE,"<ENT1>Bach1</ENT1> knockdown by siRNA also enhanced the expression of <ENT2>antioxidant factors</ENT2>, but suppressed that of fibrosis-related cytokines in mice compared with the BLM group.",,,,T,,,,,w,,,,,1.0,,
27959382,3624,12013,D011658,Positive_Correlation,TRUE,<ENT1>Bach1</ENT1> siRNA attenuates bleomycin-induced <ENT2>pulmonary fibrosis</ENT2> by modulating oxidative stress in mice.,,,,T,,,,,w,,,,,0.0,,
27959382,3624,12013,D011658,Positive_Correlation,TRUE,<ENT1>Bach1</ENT1> is an important transcriptional repressor that acts by modulating oxidative stress and represents a potential target in the treatment of <ENT2>pulmonary fibrosis</ENT2> (<ENT2>PF</ENT2>).,,,,T,,,,,w,,,,,1.0,,
27959382,3624,12013,D011658,Positive_Correlation,TRUE,"In this study, we knocked down <ENT1>Bach1</ENT1> using adenovirus-mediated small interfering RNA (siRNA) to determine whether the use of <ENT1>Bach1</ENT1> siRNA is an effective therapeutic strategy in mice with bleomycin (BLM)-induced <ENT2>PF</ENT2>.",,,,T,,Y,,,c,,,,,1.0,,
27959382,3624,12013,D011658,Positive_Correlation,TRUE,"A mouse model of BLM-induced <ENT2>PF</ENT2> was established, and <ENT1>Bach1</ENT1> siRNA (1x109 pfu) was administered to the mice via the tail vein.",,,,T,,,,,c,,,,,1.0,,
27959382,3624,12013,D011658,Positive_Correlation,TRUE,"On the whole, our findings demonstrate that <ENT1>Bach1</ENT1> siRNA exerts protective effects against BLM-induced <ENT2>PF</ENT2> in mice.",,,,T,,,,,w,,,,,0.0,,
27959382,3621,12013,21803,Positive_Correlation,TRUE,"Mouse lung fibroblasts (MLFs) were incubated with <ENT2>transforming growth factor (TGF)-b1</ENT2> (5 ng/ml) and subsequently infected with recombined adenovirus-like <ENT1>Bach1</ENT1> siRNA1 and <ENT1>Bach1</ENT1> siRNA2, while an empty adenovirus vector was used as the negative control.",,,,T,,,,,w,,,,,1.0,,
27959382,3621,12013,21803,Positive_Correlation,TRUE,"Furthermore, the MLFs infected with <ENT1>Bach1</ENT1> siRNA exhibited increased mRNA and protein expression levels of heme oxygenase-1 and glutathione peroxidase 1, but decreased levels of <ENT2>TGF-b1</ENT2> and interleukin-6 in the cell supernatants compared with the cells exposed to <ENT2>TGF-b1</ENT2> alone.",,,,T,,,,,w,,,,,1.0,TRUE,
27959382,3622,12013,14775,Negative_Correlation,TRUE,"Furthermore, the MLFs infected with <ENT1>Bach1</ENT1> siRNA exhibited increased mRNA and protein expression levels of heme oxygenase-1 and <ENT2>glutathione peroxidase 1</ENT2>, but decreased levels of TGF-b1 and interleukin-6 in the cell supernatants compared with the cells exposed to TGF-b1 alone.",,,,T,,,,,w,,,,,0.0,,
27959382,3625,12013,D001761,Positive_Correlation,FALSE,<ENT1>Bach1</ENT1> siRNA attenuates <ENT2>bleomycin</ENT2>-induced pulmonary fibrosis by modulating oxidative stress in mice.,,,,T,,,,,w,,,,,0.0,,
27959382,3625,12013,D001761,Positive_Correlation,FALSE,"In this study, we knocked down <ENT1>Bach1</ENT1> using adenovirus-mediated small interfering RNA (siRNA) to determine whether the use of <ENT1>Bach1</ENT1> siRNA is an effective therapeutic strategy in mice with <ENT2>bleomycin</ENT2> (<ENT2>BLM</ENT2>)-induced PF.",,,,T,,Y,,,c,,,,,1.0,,
27959382,3625,12013,D001761,Positive_Correlation,FALSE,"A mouse model of <ENT2>BLM</ENT2>-induced PF was established, and <ENT1>Bach1</ENT1> siRNA (1x109 pfu) was administered to the mice via the tail vein.",,,,T,,,,,c,,,,,1.0,,
27959382,3625,12013,D001761,Positive_Correlation,FALSE,"<ENT1>Bach1</ENT1> knockdown by siRNA also enhanced the expression of antioxidant factors, but suppressed that of fibrosis-related cytokines in mice compared with the <ENT2>BLM</ENT2> group.",,,,T,,,,,w,,,,,1.0,,
27959382,3625,12013,D001761,Positive_Correlation,FALSE,"Finally, the inflammatory infiltration of alveolar and interstitial cells and the destruction of lung structure were significantly attenuated in the mide administered <ENT1>Bach1</ENT1> siRNA compared with those in the <ENT2>BLM</ENT2> group.",,,,T,,,,,c,,,,,1.0,,
27959382,3625,12013,D001761,Positive_Correlation,FALSE,"On the whole, our findings demonstrate that <ENT1>Bach1</ENT1> siRNA exerts protective effects against <ENT2>BLM</ENT2>-induced PF in mice.",,,,T,,,,,w,,,,,0.0,,
27959382,3620,12013,16193,Positive_Correlation,TRUE,"Furthermore, the MLFs infected with <ENT1>Bach1</ENT1> siRNA exhibited increased mRNA and protein expression levels of heme oxygenase-1 and glutathione peroxidase 1, but decreased levels of TGF-b1 and <ENT2>interleukin-6</ENT2> in the cell supernatants compared with the cells exposed to TGF-b1 alone.",,,,T,,,,,c,,,,,0.0,,
27959382,3619,D011658,D001761,Positive_Correlation,FALSE,Bach1 siRNA attenuates <ENT2>bleomycin</ENT2>-induced <ENT1>pulmonary fibrosis</ENT1> by modulating oxidative stress in mice.,,,,T,,,,,c,,,,,1.0,,
27959382,3619,D011658,D001761,Positive_Correlation,FALSE,"In this study, we knocked down Bach1 using adenovirus-mediated small interfering RNA (siRNA) to determine whether the use of Bach1 siRNA is an effective therapeutic strategy in mice with <ENT2>bleomycin</ENT2> (<ENT2>BLM</ENT2>)-induced <ENT1>PF</ENT1>.",,,,T,,,,,c,,,,,1.0,,
27959382,3619,D011658,D001761,Positive_Correlation,FALSE,"A mouse model of <ENT2>BLM</ENT2>-induced <ENT1>PF</ENT1> was established, and Bach1 siRNA (1x109 pfu) was administered to the mice via the tail vein.",,,,T,,,,,c,,,,,1.0,,
27959382,3619,D011658,D001761,Positive_Correlation,FALSE,"On the whole, our findings demonstrate that Bach1 siRNA exerts protective effects against <ENT2>BLM</ENT2>-induced <ENT1>PF</ENT1> in mice.",,,,T,,,,,c,,,,,1.0,,
27959387,3630,5241,D009369,Association,FALSE,"Long-term exposure upregulated expression of some <ENT2>malignancy</ENT2> related genes (STEAP4, SERPINA3, SAMD9, GDF15, KRT15, ITGB6, TP63, and <ENT1>PGR</ENT1>, as well as the CEACAM, interferon related, and HLA gene families).",,,,T,,,,,c,,,,,1.0,,
27959387,3649,D001943,D000438,Positive_Correlation,FALSE,<ENT2>Alcohol</ENT2> consumption is a risk factor for <ENT1>breast cancer</ENT1>.,,,,T,,,,,c,,,,,1.0,,
27959387,3649,D001943,D000438,Positive_Correlation,FALSE,The previously shown <ENT2>alcohol</ENT2> induction of oncogenic transformation of normal breast cells is now complemented by the current results suggesting <ENT2>alcohol</ENT2>'s potential involvement in malignant progression of <ENT1>breast cancer</ENT1>.,,,,T,,,,,c,,,,,0.0,,
27959387,3656,D001943,D000431,Positive_Correlation,TRUE,Long-term exposure of MCF-7 <ENT1>breast cancer</ENT1> cells to <ENT2>ethanol</ENT2> stimulates oncogenic features.,,,,T,,,,,w,,,,,0.0,,
27959387,3656,D001943,D000431,Positive_Correlation,TRUE,"In this study, we investigated in the human <ENT1>breast cancer</ENT1> cell line MCF-7, whether a similar exposure to <ENT2>ethanol</ENT2> at concentrations ranging up to peak blood levels in heavy drinkers would increase malignant progression.",,,,T,,Y,,,c,,,,,1.0,,
27959387,3636,3866,D009369,Association,FALSE,"Long-term exposure upregulated expression of some <ENT2>malignancy</ENT2> related genes (STEAP4, SERPINA3, SAMD9, GDF15, <ENT1>KRT15</ENT1>, ITGB6, TP63, and PGR, as well as the CEACAM, interferon related, and HLA gene families).",,,,T,,,,,c,,,,,1.0,,
27959387,3642,12,D009369,Association,FALSE,"Long-term exposure upregulated expression of some <ENT2>malignancy</ENT2> related genes (STEAP4, <ENT1>SERPINA3</ENT1>, SAMD9, GDF15, KRT15, ITGB6, TP63, and PGR, as well as the CEACAM, interferon related, and HLA gene families).",,,,T,,,,,c,,,,,0.0,,
27959387,3644,79689,D009369,Association,FALSE,"Long-term exposure upregulated expression of some <ENT2>malignancy</ENT2> related genes (<ENT1>STEAP4</ENT1>, SERPINA3, SAMD9, GDF15, KRT15, ITGB6, TP63, and PGR, as well as the CEACAM, interferon related, and HLA gene families).",,,,T,,,,,c,,,,,1.0,,
27959387,3632,8626,D009369,Association,FALSE,"Long-term exposure upregulated expression of some <ENT2>malignancy</ENT2> related genes (STEAP4, SERPINA3, SAMD9, GDF15, KRT15, ITGB6, <ENT1>TP63</ENT1>, and PGR, as well as the CEACAM, interferon related, and HLA gene families).",,,,T,,,,,c,,,,,1.0,,
27959387,3626,3123,D009369,Association,FALSE,"Long-term exposure upregulated expression of some <ENT2>malignancy</ENT2> related genes (STEAP4, SERPINA3, SAMD9, GDF15, KRT15, ITGB6, TP63, and PGR, as well as the CEACAM, interferon related, and <ENT1>HLA</ENT1> gene families).",,,,T,,,,,c,,,,,0.0,,
27959387,3647,D000438,79923,Positive_Correlation,TRUE,"Short-term (1-week) incubation to ethanol at as low as 1-5 mM (corresponding to blood <ENT1>alcohol</ENT1> concentration of ~0.0048-0.024%) upregulated the stem cell related proteins Oct4 and <ENT2>Nanog</ENT2>, but they were reduced after exposure at 25 mM.",,,,T,,,,,c,,,,,1.0,,
27959387,3650,D000438,D000431,Positive_Correlation,FALSE,"We previously showed that long-term exposure to 2.5 mM <ENT2>ethanol</ENT2> (blood <ENT1>alcohol</ENT1> ~0.012%) of MCF-12A, a human normal epithelial breast cell line, induced epithelial mesenchymal transition (EMT) and oncogenic transformation.",,,,T,,,,,w,,,,,1.0,,
27959387,3650,D000438,D000431,Positive_Correlation,FALSE,"Short-term (1-week) incubation to <ENT2>ethanol</ENT2> at as low as 1-5 mM (corresponding to blood <ENT1>alcohol</ENT1> concentration of ~0.0048-0.024%) upregulated the stem cell related proteins Oct4 and Nanog, but they were reduced after exposure at 25 mM.",,,,T,,,,,w,,,,,1.0,,
27959387,3648,D000438,5460,Positive_Correlation,TRUE,"Short-term (1-week) incubation to ethanol at as low as 1-5 mM (corresponding to blood <ENT1>alcohol</ENT1> concentration of ~0.0048-0.024%) upregulated the stem cell related proteins <ENT2>Oct4</ENT2> and Nanog, but they were reduced after exposure at 25 mM.",,,,T,,,,,c,,,,,1.0,,
27959387,3653,4680,D000431,Positive_Correlation,TRUE,"Long-term (4-week) exposure to 25 mM <ENT2>ethanol</ENT2> upregulated the Oct4 and Nanog proteins, as well as the malignancy marker <ENT1>Ceacam6</ENT1>.",,,,T,,,,,c,,,,,0.0,,
27959387,3646,4680,D009369,Association,FALSE,"Long-term (4-week) exposure to 25 mM ethanol upregulated the Oct4 and Nanog proteins, as well as the <ENT2>malignancy</ENT2> marker <ENT1>Ceacam6</ENT1>.",,,,T,,,,,w,,,,,0.0,,
27959387,3646,4680,D009369,Association,FALSE,"Long-term exposure upregulated expression of some <ENT2>malignancy</ENT2> related genes (STEAP4, SERPINA3, SAMD9, GDF15, KRT15, ITGB6, TP63, and PGR, as well as the <ENT1>CEACAM</ENT1>, interferon related, and HLA gene families).",,,,T,,,,,c,,,,,0.0,,
27959387,3640,54809,D009369,Association,FALSE,"Long-term exposure upregulated expression of some <ENT2>malignancy</ENT2> related genes (STEAP4, SERPINA3, <ENT1>SAMD9</ENT1>, GDF15, KRT15, ITGB6, TP63, and PGR, as well as the CEACAM, interferon related, and HLA gene families).",,,,T,,,,,c,,,,,1.0,,
27959387,3654,79923,D000431,Positive_Correlation,TRUE,"Short-term (1-week) incubation to <ENT2>ethanol</ENT2> at as low as 1-5 mM (corresponding to blood alcohol concentration of ~0.0048-0.024%) upregulated the stem cell related proteins Oct4 and <ENT1>Nanog</ENT1>, but they were reduced after exposure at 25 mM.",,,,T,,,,,c,,,,,1.0,,
27959387,3654,79923,D000431,Positive_Correlation,TRUE,"Long-term (4-week) exposure to 25 mM <ENT2>ethanol</ENT2> upregulated the Oct4 and <ENT1>Nanog</ENT1> proteins, as well as the malignancy marker Ceacam6.",,,,T,,,,,c,,,,,1.0,,
27959387,3651,D000431,D009369,Association,TRUE,"Long-term (4-week) exposure to 25 mM <ENT1>ethanol</ENT1> upregulated the Oct4 and Nanog proteins, as well as the <ENT2>malignancy</ENT2> marker Ceacam6.",,,,T,,,,,c,,,,,0.0,,
27959387,3655,D000431,5460,Positive_Correlation,TRUE,"Short-term (1-week) incubation to <ENT1>ethanol</ENT1> at as low as 1-5 mM (corresponding to blood alcohol concentration of ~0.0048-0.024%) upregulated the stem cell related proteins <ENT2>Oct4</ENT2> and Nanog, but they were reduced after exposure at 25 mM.",,,,T,,,,,c,,,,,1.0,,
27959387,3655,D000431,5460,Positive_Correlation,TRUE,"Long-term (4-week) exposure to 25 mM <ENT1>ethanol</ENT1> upregulated the <ENT2>Oct4</ENT2> and Nanog proteins, as well as the malignancy marker Ceacam6.",,,,T,,,,,c,,,,,1.0,,
27959387,3634,D009369,3694,Association,FALSE,"Long-term exposure upregulated expression of some <ENT1>malignancy</ENT1> related genes (STEAP4, SERPINA3, SAMD9, GDF15, KRT15, <ENT2>ITGB6</ENT2>, TP63, and PGR, as well as the CEACAM, interferon related, and HLA gene families).",,,,T,,,,,c,,,,,1.0,,
27959387,3638,D009369,9518,Association,FALSE,"Long-term exposure upregulated expression of some <ENT1>malignancy</ENT1> related genes (STEAP4, SERPINA3, SAMD9, <ENT2>GDF15</ENT2>, KRT15, ITGB6, TP63, and PGR, as well as the CEACAM, interferon related, and HLA gene families).",,,,T,,,,,c,,,,,1.0,,
27959387,3628,D009369,282617,Association,FALSE,"Long-term exposure upregulated expression of some <ENT1>malignancy</ENT1> related genes (STEAP4, SERPINA3, SAMD9, GDF15, KRT15, ITGB6, TP63, and PGR, as well as the CEACAM, <ENT2>interferon</ENT2> related, and HLA gene families).",,,,T,,,,,c,,,,,0.0,,
27993978,3658,56371,268697,Association,TRUE,CenpH regulates meiotic G2/M transition by modulating the <ENT1>APC/CCdh1</ENT1>-<ENT2>cyclin B1</ENT2> pathway in oocytes.,,,,T,,,,,w,,,,,1.0,,
27993978,3658,56371,268697,Association,TRUE,CenpH protects <ENT2>cyclin B1</ENT2> from destruction by competing with the action of <ENT1>APC/C</ENT1>(<ENT1>Cdh1</ENT1>) Impaired G2/M transition after CenpH depletion could be rescued by expression of exogenous <ENT2>cyclin B1</ENT2>.,,,,T,,,,,w,,,,,0.5,TRUE,
27993978,3658,56371,268697,Association,TRUE,Our findings reveal a novel role of CenpH in regulating meiotic G2/M transition by acting via the <ENT1>APC/C</ENT1>(<ENT1>Cdh1</ENT1>)-<ENT2>cyclin B1</ENT2> pathway.,,,,T,,,,,w,,,,,0.5,TRUE,
27993978,3659,56371,26886,Association,TRUE,<ENT2>CenpH</ENT2> regulates meiotic G2/M transition by modulating the <ENT1>APC/CCdh1</ENT1>-cyclin B1 pathway in oocytes.,,,,T,,,,,c,,,,,1.0,,
27993978,3659,56371,26886,Association,TRUE,<ENT2>CenpH</ENT2> protects cyclin B1 from destruction by competing with the action of <ENT1>APC/C</ENT1>(<ENT1>Cdh1</ENT1>) Impaired G2/M transition after <ENT2>CenpH</ENT2> depletion could be rescued by expression of exogenous cyclin B1.,,,,T,,,,,c,,,,,1.0,,
27993978,3659,56371,26886,Association,TRUE,Our findings reveal a novel role of <ENT2>CenpH</ENT2> in regulating meiotic G2/M transition by acting via the <ENT1>APC/C</ENT1>(<ENT1>Cdh1</ENT1>)-cyclin B1 pathway.,,,,T,,,,,c,,,,,1.0,,
27993978,3657,D060172,268697,Negative_Correlation,TRUE,"Depletion of CenpH by <ENT1>morpholino</ENT1> injection decreased <ENT2>cyclin B1</ENT2> levels, resulting in attenuation of <ENT2>maturation-promoting factor</ENT2> (<ENT2>MPF</ENT2>) activation, and severely compromised meiotic resumption.",,,,T,,,,,w,,,,,0.666666667,TRUE,
27993978,3660,D060172,26886,Negative_Correlation,FALSE,"Depletion of <ENT2>CenpH</ENT2> by <ENT1>morpholino</ENT1> injection decreased cyclin B1 levels, resulting in attenuation of maturation-promoting factor (MPF) activation, and severely compromised meiotic resumption.",,,,T,,,,,c,,,,,1.0,,
27993978,3661,268697,26886,Positive_Correlation,TRUE,<ENT2>CenpH</ENT2> regulates meiotic G2/M transition by modulating the APC/CCdh1-<ENT1>cyclin B1</ENT1> pathway in oocytes.,,,,T,,,,,w,,,,,0.0,,
27993978,3661,268697,26886,Positive_Correlation,TRUE,"Depletion of <ENT2>CenpH</ENT2> by morpholino injection decreased <ENT1>cyclin B1</ENT1> levels, resulting in attenuation of <ENT1>maturation-promoting factor</ENT1> (<ENT1>MPF</ENT1>) activation, and severely compromised meiotic resumption.",,,,T,,,,,c,,,,,1.0,,
27993978,3661,268697,26886,Positive_Correlation,TRUE,<ENT2>CenpH</ENT2> protects <ENT1>cyclin B1</ENT1> from destruction by competing with the action of APC/C(Cdh1) Impaired G2/M transition after <ENT2>CenpH</ENT2> depletion could be rescued by expression of exogenous <ENT1>cyclin B1</ENT1>.,,,,T,,,,,c,,,,,0.0,,
27993978,3661,268697,26886,Positive_Correlation,TRUE,Our findings reveal a novel role of <ENT2>CenpH</ENT2> in regulating meiotic G2/M transition by acting via the APC/C(Cdh1)-<ENT1>cyclin B1</ENT1> pathway.,,,,T,,,,,w,,,,,0.0,,
27999109,3668,3456,D003922,Association,TRUE,"Essential components of the innate immune antiviral response, including <ENT1>type I interferon</ENT1> (IFN) and IFN receptor-mediated signaling pathways, are candidates for determining susceptibility to human <ENT2>type 1 diabetes</ENT2>.",,,,T,,,,,c,,,,,1.0,,
27999109,3666,288264,D003920,Association,TRUE,We hypothesized that disrupting the cognate <ENT1>type I IFN receptor</ENT1> (<ENT1>type I IFN a/b receptor</ENT1> [<ENT1>IFNAR</ENT1>]) to interrupt IFN signaling would prevent or delay the development of virus-induced <ENT2>diabetes</ENT2>.,,,,T,,Y,,,w,,,,,0.333333333,,
27999109,3666,288264,D003920,Association,TRUE,<ENT1>IFNAR1</ENT1> deficiency significantly delayed the onset and frequency of <ENT2>diabetes</ENT2> and greatly reduced the intensity of insulitis after poly I:C treatment.,,,,T,,,,,c,,,,,1.0,,
27999109,3666,288264,D003920,Association,TRUE,The occurrence of Kilham rat virus-induced <ENT2>diabetes</ENT2> was also diminished in <ENT1>IFNAR1</ENT1>-deficient animals.,,,,T,,,,,c,,,,,1.0,,
27999109;27999109,3671;3669,288264;686326,D003922;D003922,Association;Association,TRUE;TRUE,A Critical Role for the <ENT1>Type I Interferon Receptor</ENT1> in Virus-Induced <ENT2>Autoimmune Diabetes</ENT2> in Rats.,,,,T,,,,,c,,,,,1.0,,
27999109,3662,288264,D007410,Association,TRUE,<ENT1>IFNAR1</ENT1> deficiency significantly delayed the onset and frequency of diabetes and greatly reduced the intensity of <ENT2>insulitis</ENT2> after poly I:C treatment.,,,,T,,,,,c,,,,,1.0,,
27999109,3664,D011070,D003920,Positive_Correlation,FALSE,<ENT2>Diabetes</ENT2> can be induced in LEW.1WR1 weanling rats challenged with virus or with the viral mimetic <ENT1>polyinosinic:polycytidylic acid</ENT1> (<ENT1>poly I:C</ENT1>).,,,,T,,,,,c,,,,,1.0,,
27999109,3664,D011070,D003920,Positive_Correlation,FALSE,IFNAR1 deficiency significantly delayed the onset and frequency of <ENT2>diabetes</ENT2> and greatly reduced the intensity of insulitis after <ENT1>poly I:C</ENT1> treatment.,,,,T,,,,,w,,,,,1.0,,
27999109,3667,3454,D003922,Association,TRUE,"Essential components of the innate immune antiviral response, including type I interferon (IFN) and <ENT1>IFN receptor</ENT1>-mediated signaling pathways, are candidates for determining susceptibility to human <ENT2>type 1 diabetes</ENT2>.",,,,T,,,,,c,,,,,1.0,,
27999109,3665,D003920,686326,Association,TRUE,We hypothesized that disrupting the cognate <ENT2>type I IFN receptor</ENT2> (<ENT2>type I IFN a/b receptor</ENT2> [<ENT2>IFNAR</ENT2>]) to interrupt IFN signaling would prevent or delay the development of virus-induced <ENT1>diabetes</ENT1>.,,,,T,,Y,,,w,,,,,0.0,,
27999109,3663,D003920,25712,Association,TRUE,We hypothesized that disrupting the cognate type I IFN receptor (type I IFN a/b receptor [IFNAR]) to interrupt <ENT2>IFN</ENT2> signaling would prevent or delay the development of virus-induced <ENT1>diabetes</ENT1>.,,,,T,,Y,,,w,,,,,0.0,,
27999109,3670,D003922,3630,Association,FALSE,"The pathogenesis of human <ENT1>type 1 diabetes</ENT1>, characterized by immune-mediated damage of <ENT2>insulin</ENT2>-producing b-cells of pancreatic islets, may involve viral infection.",,,,T,,,,,c,,,,,0.0,,
28068934,3676,5290,D000077277,Association,FALSE,Concordance between <ENT1>PIK3CA</ENT1> mutations in endoscopic biopsy and surgically resected specimens of <ENT2>esophageal squamous cell carcinoma</ENT2>.,,,,T,,,,,w,,,,,1.0,,
28068934,3676,5290,D000077277,Association,FALSE,BACKGROUND: <ENT1>PIK3CA</ENT1> mutations are expected to be potential therapeutic targets for <ENT2>esophageal squamous cell carcinoma</ENT2> (<ENT2>ESCC</ENT2>).,,,,T,,,,,c,,,,,1.0,,
28068934,3676,5290,D000077277,Association,FALSE,"METHODS: We examined five hotspot mutations in the <ENT1>PIK3CA</ENT1> gene (E542K, E545K, E546K, H1047R, and H1047L) in formalin-fixed and paraffin-embedded tissue sections of paired endoscopic biopsy and surgically resected specimens from 181 patients undergoing curative resection for <ENT2>ESCC</ENT2> between 2000 and 2011 using a Luminex technology-based multiplex gene mutation detection kit.",,,,T,,Y,,,c,,,,,1.0,,
28068934,3676,5290,D000077277,Association,FALSE,"CONCLUSIONS: The <ENT1>PIK3CA</ENT1> mutation status was highly concordant between endoscopic biopsy and surgically resected specimens from the same patient, suggesting that endoscopic biopsy specimens can be clinically used to detect <ENT1>PIK3CA</ENT1> mutations in patients with <ENT2>ESCC</ENT2>.",,,,T,,,,,w,,,,,1.0,TRUE,
28068934,3675,rs121913279,D000077277,Association,FALSE,"METHODS: We examined five hotspot mutations in the PIK3CA gene (E542K, E545K, E546K, <ENT1>H1047R</ENT1>, and <ENT1>H1047L</ENT1>) in formalin-fixed and paraffin-embedded tissue sections of paired endoscopic biopsy and surgically resected specimens from 181 patients undergoing curative resection for <ENT2>ESCC</ENT2> between 2000 and 2011 using a Luminex technology-based multiplex gene mutation detection kit.",,,,T,,Y,,,c,,,,,1.0,,
28068934,3674,rs121913273,D000077277,Association,FALSE,"METHODS: We examined five hotspot mutations in the PIK3CA gene (<ENT1>E542K</ENT1>, E545K, E546K, H1047R, and H1047L) in formalin-fixed and paraffin-embedded tissue sections of paired endoscopic biopsy and surgically resected specimens from 181 patients undergoing curative resection for <ENT2>ESCC</ENT2> between 2000 and 2011 using a Luminex technology-based multiplex gene mutation detection kit.",,,,T,,Y,,,c,,,,,1.0,,
28068934,3672,p|SUB|E|546|K,D000077277,Association,FALSE,"METHODS: We examined five hotspot mutations in the PIK3CA gene (E542K, E545K, <ENT1>E546K</ENT1>, H1047R, and H1047L) in formalin-fixed and paraffin-embedded tissue sections of paired endoscopic biopsy and surgically resected specimens from 181 patients undergoing curative resection for <ENT2>ESCC</ENT2> between 2000 and 2011 using a Luminex technology-based multiplex gene mutation detection kit.",,,,T,,Y,,,c,,,,,1.0,,
28068934,3673,rs104886003,D000077277,Association,FALSE,"METHODS: We examined five hotspot mutations in the PIK3CA gene (E542K, <ENT1>E545K</ENT1>, E546K, H1047R, and H1047L) in formalin-fixed and paraffin-embedded tissue sections of paired endoscopic biopsy and surgically resected specimens from 181 patients undergoing curative resection for <ENT2>ESCC</ENT2> between 2000 and 2011 using a Luminex technology-based multiplex gene mutation detection kit.",,,,T,,Y,,,c,,,,,1.0,,
28075473,3684,83430,21898,Association,TRUE,Spirulina lipopolysaccharides inhibit tumor growth in a <ENT2>Toll-like receptor 4</ENT2>-dependent manner by altering the cytokine milieu from interleukin-17/<ENT1>interleukin-23</ENT1> to interferon-g.,,,,T,Y,,,,w,,,,,1.0,,
28075473,3684,83430,21898,Association,TRUE,"Administration of Spirulina LPS suppressed tumor growth in C3H/HeN mice, but not in <ENT2>Toll-like receptor 4</ENT2> (<ENT2>TLR4</ENT2>)-mutant C3H/HeJ mice, by reducing serum levels of IL-17 and <ENT1>IL-23</ENT1>, while increasing interferon (IFN)-g levels.",,,,T,,,,,c,,,,,1.0,,
28075473,3688,83430,D009369,Association,TRUE,Spirulina lipopolysaccharides inhibit <ENT2>tumor</ENT2> growth in a Toll-like receptor 4-dependent manner by altering the cytokine milieu from interleukin-17/<ENT1>interleukin-23</ENT1> to interferon-g.,,,,T,,,,,w,,,,,1.0,,
28075473,3688,83430,D009369,Association,TRUE,"Administration of Spirulina LPS suppressed <ENT2>tumor</ENT2> growth in C3H/HeN mice, but not in Toll-like receptor 4 (TLR4)-mutant C3H/HeJ mice, by reducing serum levels of IL-17 and <ENT1>IL-23</ENT1>, while increasing interferon (IFN)-g levels.",,,,T,,,,,c,,,,,0.0,,
28075473,3688,83430,D009369,Association,TRUE,"Thus, our results support the notion that IFN-g and IL-17/<ENT1>IL-23</ENT1> mutually regulate Th17 and Th1 responses in <ENT2>tumor</ENT2>-bearing hosts, and Spirulina LPS modulates the balance of the IFN-g-IL-17/<ENT1>IL-23</ENT1> axis towards IFN-g production, which leads to <ENT2>tumor</ENT2> inhibition.",,,,T,,,,,w,,,,,0.5,TRUE,
28075473,3680,D008070,15978,Positive_Correlation,TRUE,Spirulina <ENT1>lipopolysaccharides</ENT1> inhibit tumor growth in a Toll-like receptor 4-dependent manner by altering the cytokine milieu from interleukin-17/interleukin-23 to <ENT2>interferon-g</ENT2>.,,,,T,,,,,c,,,,,0.0,,
28075473,3680,D008070,15978,Positive_Correlation,TRUE,"Administration of Spirulina <ENT1>LPS</ENT1> suppressed tumor growth in C3H/HeN mice, but not in Toll-like receptor 4 (TLR4)-mutant C3H/HeJ mice, by reducing serum levels of IL-17 and IL-23, while increasing <ENT2>interferon (IFN)-g</ENT2> levels.",,,,T,,,,,c,,,,,1.0,,
28075473,3680,D008070,15978,Positive_Correlation,TRUE,"Of note, injection of anti-IL-17 antibody in tumor-bearing C3H/HeN mice in the absence of Spirulina <ENT1>LPS</ENT1> markedly suppressed tumor growth and augmented <ENT2>IFN-g</ENT2> responses.",,,,T,,,,,w,,,,,0.0,,
28075473,3680,D008070,15978,Positive_Correlation,TRUE,"Thus, our results support the notion that <ENT2>IFN-g</ENT2> and IL-17/IL-23 mutually regulate Th17 and Th1 responses in tumor-bearing hosts, and Spirulina <ENT1>LPS</ENT1> modulates the balance of the <ENT2>IFN-g</ENT2>-IL-17/IL-23 axis towards <ENT2>IFN-g</ENT2> production, which leads to tumor inhibition.",,,,T,,,,,w,,,,,0.0,TRUE,
28075473,3679,D008070,21898,Association,TRUE,Spirulina <ENT1>lipopolysaccharides</ENT1> inhibit tumor growth in a <ENT2>Toll-like receptor 4</ENT2>-dependent manner by altering the cytokine milieu from interleukin-17/interleukin-23 to interferon-g.,,,,T,,,,,w,,,,,0.0,,
28075473,3679,D008070,21898,Association,TRUE,"Administration of Spirulina <ENT1>LPS</ENT1> suppressed tumor growth in C3H/HeN mice, but not in <ENT2>Toll-like receptor 4</ENT2> (<ENT2>TLR4</ENT2>)-mutant C3H/HeJ mice, by reducing serum levels of IL-17 and IL-23, while increasing interferon (IFN)-g levels.",,,,T,,,,,c,,,,,0.0,,
28075473,3679,D008070,21898,Association,TRUE,"Moreover, in vitro experiments showed that Spirulina <ENT1>LPS</ENT1> impaired the antigen-presenting function that supports the generation of IL-17-producing cells in a <ENT2>toll-like receptor (TLR)4</ENT2>-dependent manner.",,,,T,,,,,c,,,,,1.0,,
28075473,3678,D008070,D001943,Negative_Correlation,TRUE,"Furthermore, Spirulina <ENT1>LPS</ENT1> effectively inhibited the spontaneous development of <ENT2>mammary tumors</ENT2>.",,,,T,,,,,c,,,,,1.0,,
28075473,3681,D008070,16171,Negative_Correlation,TRUE,Spirulina <ENT1>lipopolysaccharides</ENT1> inhibit tumor growth in a Toll-like receptor 4-dependent manner by altering the cytokine milieu from <ENT2>interleukin-17</ENT2>/interleukin-23 to interferon-g.,,,,T,,,,,c,,,,,0.0,,
28075473,3681,D008070,16171,Negative_Correlation,TRUE,"Administration of Spirulina <ENT1>LPS</ENT1> suppressed tumor growth in C3H/HeN mice, but not in Toll-like receptor 4 (TLR4)-mutant C3H/HeJ mice, by reducing serum levels of <ENT2>IL-17</ENT2> and IL-23, while increasing interferon (IFN)-g levels.",,,,T,,,,,c,,,,,1.0,,
28075473,3681,D008070,16171,Negative_Correlation,TRUE,"Moreover, in vitro experiments showed that Spirulina <ENT1>LPS</ENT1> impaired the antigen-presenting function that supports the generation of <ENT2>IL-17</ENT2>-producing cells in a toll-like receptor (TLR)4-dependent manner.",,,,T,,,,,c,,,,,0.0,,
28075473,3681,D008070,16171,Negative_Correlation,TRUE,"Of note, injection of anti-<ENT2>IL-17</ENT2> antibody in tumor-bearing C3H/HeN mice in the absence of Spirulina <ENT1>LPS</ENT1> markedly suppressed tumor growth and augmented IFN-g responses.",,,,T,,,,,c,,,,,1.0,,
28075473,3681,D008070,16171,Negative_Correlation,TRUE,"Thus, our results support the notion that IFN-g and <ENT2>IL-17</ENT2>/IL-23 mutually regulate Th17 and Th1 responses in tumor-bearing hosts, and Spirulina <ENT1>LPS</ENT1> modulates the balance of the IFN-g-<ENT2>IL-17</ENT2>/IL-23 axis towards IFN-g production, which leads to tumor inhibition.",,,,T,,,,,w,,,,,0.0,TRUE,
28075473,3682,D008070,D009369,Negative_Correlation,TRUE,Spirulina <ENT1>lipopolysaccharides</ENT1> inhibit <ENT2>tumor</ENT2> growth in a Toll-like receptor 4-dependent manner by altering the cytokine milieu from interleukin-17/interleukin-23 to interferon-g.,,,,T,,,,,c,,,,,1.0,,
28075473,3682,D008070,D009369,Negative_Correlation,TRUE,"Administration of Spirulina <ENT1>LPS</ENT1> suppressed <ENT2>tumor</ENT2> growth in C3H/HeN mice, but not in Toll-like receptor 4 (TLR4)-mutant C3H/HeJ mice, by reducing serum levels of IL-17 and IL-23, while increasing interferon (IFN)-g levels.",,,,T,,,,,c,,,,,1.0,,
28075473,3682,D008070,D009369,Negative_Correlation,TRUE,"Of note, injection of anti-IL-17 antibody in <ENT2>tumor</ENT2>-bearing C3H/HeN mice in the absence of Spirulina <ENT1>LPS</ENT1> markedly suppressed <ENT2>tumor</ENT2> growth and augmented IFN-g responses.",,,,T,,,,,c,,,,,1.0,,
28075473,3682,D008070,D009369,Negative_Correlation,TRUE,"Thus, our results support the notion that IFN-g and IL-17/IL-23 mutually regulate Th17 and Th1 responses in <ENT2>tumor</ENT2>-bearing hosts, and Spirulina <ENT1>LPS</ENT1> modulates the balance of the IFN-g-IL-17/IL-23 axis towards IFN-g production, which leads to <ENT2>tumor</ENT2> inhibition.",,,,T,,,,,w,,,,,0.5,TRUE,
28075473,3683,15978,21898,Association,TRUE,Spirulina lipopolysaccharides inhibit tumor growth in a <ENT2>Toll-like receptor 4</ENT2>-dependent manner by altering the cytokine milieu from interleukin-17/interleukin-23 to <ENT1>interferon-g</ENT1>.,,,,T,Y,,,,w,,,,,1.0,,
28075473,3683,15978,21898,Association,TRUE,"Administration of Spirulina LPS suppressed tumor growth in C3H/HeN mice, but not in <ENT2>Toll-like receptor 4</ENT2> (<ENT2>TLR4</ENT2>)-mutant C3H/HeJ mice, by reducing serum levels of IL-17 and IL-23, while increasing <ENT1>interferon (IFN)-g</ENT1> levels.",,,,T,,,,,c,,,,,1.0,,
28075473,3687,15978,D009369,Association,TRUE,Spirulina lipopolysaccharides inhibit <ENT2>tumor</ENT2> growth in a Toll-like receptor 4-dependent manner by altering the cytokine milieu from interleukin-17/interleukin-23 to <ENT1>interferon-g</ENT1>.,,,,T,,,,,w,,,,,1.0,,
28075473,3687,15978,D009369,Association,TRUE,"Administration of Spirulina LPS suppressed <ENT2>tumor</ENT2> growth in C3H/HeN mice, but not in Toll-like receptor 4 (TLR4)-mutant C3H/HeJ mice, by reducing serum levels of IL-17 and IL-23, while increasing <ENT1>interferon (IFN)-g</ENT1> levels.",,,,T,,,,,c,,,,,0.0,,
28075473,3687,15978,D009369,Association,TRUE,"Of note, injection of anti-IL-17 antibody in <ENT2>tumor</ENT2>-bearing C3H/HeN mice in the absence of Spirulina LPS markedly suppressed <ENT2>tumor</ENT2> growth and augmented <ENT1>IFN-g</ENT1> responses.",,,,T,,,,,c,,,,,1.0,,
28075473,3687,15978,D009369,Association,TRUE,"Thus, our results support the notion that <ENT1>IFN-g</ENT1> and IL-17/IL-23 mutually regulate Th17 and Th1 responses in <ENT2>tumor</ENT2>-bearing hosts, and Spirulina LPS modulates the balance of the <ENT1>IFN-g</ENT1>-IL-17/IL-23 axis towards <ENT1>IFN-g</ENT1> production, which leads to <ENT2>tumor</ENT2> inhibition.",,,,T,,,,,w,,,,,0.833333333,TRUE,
28075473,3685,21898,16171,Association,TRUE,Spirulina lipopolysaccharides inhibit tumor growth in a <ENT1>Toll-like receptor 4</ENT1>-dependent manner by altering the cytokine milieu from <ENT2>interleukin-17</ENT2>/interleukin-23 to interferon-g.,,,,T,,,,,c,,,,,0.0,,
28075473,3685,21898,16171,Association,TRUE,"Administration of Spirulina LPS suppressed tumor growth in C3H/HeN mice, but not in <ENT1>Toll-like receptor 4</ENT1> (<ENT1>TLR4</ENT1>)-mutant C3H/HeJ mice, by reducing serum levels of <ENT2>IL-17</ENT2> and IL-23, while increasing interferon (IFN)-g levels.",,,,T,,,,,c,,,,,0.5,,
28075473,3685,21898,16171,Association,TRUE,"Moreover, in vitro experiments showed that Spirulina LPS impaired the antigen-presenting function that supports the generation of <ENT2>IL-17</ENT2>-producing cells in a <ENT1>toll-like receptor (TLR)4</ENT1>-dependent manner.",,,,T,,,,,w,,,,,1.0,,
28075473,3686,21898,D009369,Association,TRUE,Spirulina lipopolysaccharides inhibit <ENT2>tumor</ENT2> growth in a <ENT1>Toll-like receptor 4</ENT1>-dependent manner by altering the cytokine milieu from interleukin-17/interleukin-23 to interferon-g.,,,,T,,,,,w,,,,,0.0,,
28075473,3686,21898,D009369,Association,TRUE,"Administration of Spirulina LPS suppressed <ENT2>tumor</ENT2> growth in C3H/HeN mice, but not in <ENT1>Toll-like receptor 4</ENT1> (<ENT1>TLR4</ENT1>)-mutant C3H/HeJ mice, by reducing serum levels of IL-17 and IL-23, while increasing interferon (IFN)-g levels.",,,,T,,,,,c,,,,,1.0,,
28075473,3686,21898,D009369,Association,TRUE,This study has important implications for the exploitation of <ENT1>TLR</ENT1>-based immunomodulators for <ENT2>cancer</ENT2> immunotherapy.,,,,T,,,,,c,,,,,1.0,,
28075473,3689,16171,D009369,Association,TRUE,Spirulina lipopolysaccharides inhibit <ENT2>tumor</ENT2> growth in a Toll-like receptor 4-dependent manner by altering the cytokine milieu from <ENT1>interleukin-17</ENT1>/interleukin-23 to interferon-g.,,,,T,,,,,w,,,,,1.0,,
28075473;28075473,3689;3677,16171;3605,D009369;D009369,Association;Association,FALSE;FALSE,"Th17 cells and the cytokine they produce, <ENT1>interleukin (IL)-17</ENT1>, play an important role in <ENT2>tumor</ENT2> progression in humans and in mice.",,,,T,,,,,c,,,,,0.0,,
28075473,3689,16171,D009369,Association,TRUE,"Administration of Spirulina LPS suppressed <ENT2>tumor</ENT2> growth in C3H/HeN mice, but not in Toll-like receptor 4 (TLR4)-mutant C3H/HeJ mice, by reducing serum levels of <ENT1>IL-17</ENT1> and IL-23, while increasing interferon (IFN)-g levels.",,,,T,,,,,w,,,,,1.0,,
28075473,3689,16171,D009369,Association,TRUE,"Of note, injection of anti-<ENT1>IL-17</ENT1> antibody in <ENT2>tumor</ENT2>-bearing C3H/HeN mice in the absence of Spirulina LPS markedly suppressed <ENT2>tumor</ENT2> growth and augmented IFN-g responses.",,,,T,,,,,w,,,,,0.5,TRUE,
28075473,3689,16171,D009369,Association,TRUE,"Thus, our results support the notion that IFN-g and <ENT1>IL-17</ENT1>/IL-23 mutually regulate Th17 and Th1 responses in <ENT2>tumor</ENT2>-bearing hosts, and Spirulina LPS modulates the balance of the IFN-g-<ENT1>IL-17</ENT1>/IL-23 axis towards IFN-g production, which leads to <ENT2>tumor</ENT2> inhibition.",,,,T,,,,,w,,,,,0.5,TRUE,
28101574,3694,4751,4130,Positive_Correlation,TRUE,<ENT1>Never in mitosis gene A (NIMA)-related kinase 2</ENT1> (<ENT1>NEK2</ENT1>) is a <ENT2>microtubule-associated protein</ENT2> that regulates spindle assembly in human cells and is overexpressed in various malignancies.,,,,T,Y,,,,w,,,,,1.0,TRUE,
28101574,3694,4751,4130,Positive_Correlation,TRUE,"The expression of <ENT1>NEK2</ENT1>, phospho-AKT and <ENT2>MMP-2</ENT2> was evaluated by immunohistochemistry in 63 cases of HCC and matched adjacent non-tumorous liver tissues.",,,,T,,Y,,,c,,,,,1.0,,
28101574,3694,4751,4130,Positive_Correlation,TRUE,"Relationships between protein expression and clinicopathological parameters were assessed, and the correlations between <ENT1>NEK2</ENT1> with phospho-AKT and <ENT2>MMP-2</ENT2> expressions were evaluated.",,,,T,,Y,,,c,,,,,1.0,,
28101574,3694,4751,4130,Positive_Correlation,TRUE,"<ENT1>NEK2</ENT1> expression was positively correlated with the expression of phospho-AKT (r=0.883, P<0.01) and <ENT2>MMP-2</ENT2> (r=0.781, P<0.01).",,,,T,,,,,c,,,,,0.0,,
28101574,3694,4751,4130,Positive_Correlation,TRUE,"Alteration of <ENT1>NEK2</ENT1> protein levels may contribute to invasion and metastasis of HCC, which may occur through activation of AKT signaling and promotion of <ENT2>MMP-2</ENT2> expression.",,,,T,,,,,c,,,,,0.0,,
28101574,3695,4751,207,Positive_Correlation,TRUE,"The expression of <ENT1>NEK2</ENT1>, phospho-<ENT2>AKT</ENT2> and MMP-2 was evaluated by immunohistochemistry in 63 cases of HCC and matched adjacent non-tumorous liver tissues.",,,,T,,Y,,,c,,,,,1.0,,
28101574,3695,4751,207,Positive_Correlation,TRUE,"Relationships between protein expression and clinicopathological parameters were assessed, and the correlations between <ENT1>NEK2</ENT1> with phospho-<ENT2>AKT</ENT2> and MMP-2 expressions were evaluated.",,,,T,,Y,,,c,,,,,1.0,,
28101574,3695,4751,207,Positive_Correlation,TRUE,"<ENT1>NEK2</ENT1> expression was positively correlated with the expression of phospho-<ENT2>AKT</ENT2> (r=0.883, P<0.01) and MMP-2 (r=0.781, P<0.01).",,,,T,,,,,c,,,,,0.0,,
28101574,3695,4751,207,Positive_Correlation,TRUE,"Alteration of <ENT1>NEK2</ENT1> protein levels may contribute to invasion and metastasis of HCC, which may occur through activation of <ENT2>AKT</ENT2> signaling and promotion of MMP-2 expression.",,,,T,,,,,c,,,,,0.0,,
28101574;28101574,3692;3696,4751;4751,D009362;D006528,Association;Association,TRUE;TRUE,"Alteration of <ENT1>NEK2</ENT1> protein levels may contribute to invasion and <ENT2>metastasis of HCC</ENT2>, which may occur through activation of AKT signaling and promotion of MMP-2 expression.",,,,T,,,,,c,,,,,0.0,,
28101574,3693,4751,D009369,Association,FALSE,<ENT1>Never in mitosis gene A (NIMA)-related kinase 2</ENT1> (<ENT1>NEK2</ENT1>) is a microtubule-associated protein that regulates spindle assembly in human cells and is overexpressed in various <ENT2>malignancies</ENT2>.,,,,T,,,,,c,,,,,1.0,,
28101574,3693,4751,D009369,Association,FALSE,The correlation between survival and <ENT1>NEK2</ENT1> expression was analyzed in 359 patients with HCC using RNASeqV2 data available from The <ENT2>Cancer</ENT2> Genome Atlas (TCGA) website (https://tcga-data.nci.nih.gov/tcga/).,,,,T,,,,,c,,,,,1.0,,
28101574,3693,4751,D009369,Association,FALSE,"Clinical analysis indicated that the overexpression of <ENT1>NEK2</ENT1> in HCC was significantly correlated with diolame complete (P<0.001), <ENT2>tumor</ENT2> nodule number (P=0.012) and recurrence (P=0.004).",,,,T,,,,,c,,,,,0.0,,
28101574,3696,4751,D006528,Association,TRUE,<ENT1>NEK2</ENT1> serves as a prognostic biomarker for <ENT2>hepatocellular carcinoma</ENT2>.,,,,T,,,,,c,,,,,1.0,,
28101574,3696,4751,D006528,Association,TRUE,"However, the role of <ENT1>NEK2</ENT1> in <ENT2>hepatocellular carcinoma</ENT2> (<ENT2>HCC</ENT2>) remains undetermined.",,,,T,,,,,c,,,,,1.0,,
28101574,3696,4751,D006528,Association,TRUE,<ENT1>NEK2</ENT1> expression was detected using quantitative reverse transcription polymerase chain reaction in two cell lines and 5 matched <ENT2>HCC</ENT2> and adjacent non-tumorous liver tissues.,,,,T,,,,,w,,,,,1.0,,
28101574,3696,4751,D006528,Association,TRUE,The correlation between survival and <ENT1>NEK2</ENT1> expression was analyzed in 359 patients with <ENT2>HCC</ENT2> using RNASeqV2 data available from The Cancer Genome Atlas (TCGA) website (https://tcga-data.nci.nih.gov/tcga/).,,,,T,,,,,w,,,,,1.0,,
28101574,3696,4751,D006528,Association,TRUE,"The expression of <ENT1>NEK2</ENT1>, phospho-AKT and MMP-2 was evaluated by immunohistochemistry in 63 cases of <ENT2>HCC</ENT2> and matched adjacent non-tumorous liver tissues.",,,,T,,,,,w,,,,,1.0,,
28101574,3696,4751,D006528,Association,TRUE,"<ENT1>NEK2</ENT1>, as the most obviously different DEG in cells and tissues from the RNA-seq data, was listed as an <ENT2>HCC</ENT2> candidate biomarker for further verification.",,,,T,,,,,c,,,,,1.0,,
28101574,3696,4751,D006528,Association,TRUE,"<ENT1>NEK2</ENT1> was overexpressed in <ENT2>HCC</ENT2> cells and tissues (P=0.002, P=0.013) and <ENT2>HCC</ENT2> patients with a high expression of <ENT1>NEK2</ENT1> had a poor prognosis (P=0.0145).",,,,T,,,,,c,,,,,0.0,,
28101574,3696,4751,D006528,Association,TRUE,"Clinical analysis indicated that the overexpression of <ENT1>NEK2</ENT1> in <ENT2>HCC</ENT2> was significantly correlated with diolame complete (P<0.001), tumor nodule number (P=0.012) and recurrence (P=0.004).",,,,T,,,,,c,,,,,0.0,,
28101574,3696,4751,D006528,Association,TRUE,"Overexpression of <ENT1>NEK2</ENT1> was associated with clinicopathological characteristics and poor patient outcomes, suggesting that <ENT1>NEK2</ENT1> serves as a prognostic biomarker for <ENT2>HCC</ENT2>.",,,,T,,,,,c,,,,,0.5,,
28101574,3690,4130,D006528,Association,TRUE,"The expression of NEK2, phospho-AKT and <ENT1>MMP-2</ENT1> was evaluated by immunohistochemistry in 63 cases of <ENT2>HCC</ENT2> and matched adjacent non-tumorous liver tissues.",,,,T,,,,,w,,,,,1.0,,
28101574,3690,4130,D006528,Association,TRUE,"Alteration of NEK2 protein levels may contribute to invasion and <ENT2>metastasis of HCC</ENT2>, which may occur through activation of AKT signaling and promotion of <ENT1>MMP-2</ENT1> expression.",,,,T,,,,,c,,,,,1.0,,
28101574,3691,207,D006528,Association,TRUE,"The expression of NEK2, phospho-<ENT1>AKT</ENT1> and MMP-2 was evaluated by immunohistochemistry in 63 cases of <ENT2>HCC</ENT2> and matched adjacent non-tumorous liver tissues.",,,,T,,,,,w,,,,,1.0,,
28101574,3691,207,D006528,Association,TRUE,"Alteration of NEK2 protein levels may contribute to invasion and <ENT2>metastasis of HCC</ENT2>, which may occur through activation of <ENT1>AKT</ENT1> signaling and promotion of MMP-2 expression.",,,,T,,,,,c,,,,,0.0,,
28148288,3701,2099,8038,Association,FALSE,BACKGROUND: <ENT2>ADAM12</ENT2> is upregulated in human breast cancers and is a predictor of chemoresistance in <ENT1>estrogen receptor</ENT1>-negative tumors.,,,,T,,,,,c,,,,,0.0,,
28148288,3705,9076,8038,Association,TRUE,<ENT2>Metalloprotease-disintegrin</ENT2> <ENT2>ADAM12</ENT2> actively promotes the stem cell-like phenotype in <ENT1>claudin</ENT1>-low breast cancer.,,,,T,Y,,,,w,,,,,1.0,TRUE,
28148288,3705,9076,8038,Association,TRUE,"<ENT2>ADAM12</ENT2> is induced during epithelial-to-mesenchymal transition, a feature associated with <ENT1>claudin</ENT1>-low breast tumors, which are enriched in cancer stem cell (CSC) markers.",,,,T,,,,,w,,,,,0.0,,
28148288,3705,9076,8038,Association,TRUE,"METHODS: <ENT2>ADAM12</ENT2> expression was downregulated in representative <ENT1>claudin</ENT1>-low breast cancer cell lines, SUM159PT and Hs578T, using siRNA transfection or inducible shRNA expression.",,,,T,,,,,w,,,,,1.0,,
28148288,3705,9076,8038,Association,TRUE,CONCLUSIONS: These results indicate that <ENT2>ADAM12</ENT2> actively supports the CSC phenotype in <ENT1>claudin</ENT1>-low breast cancer cells via modulation of the EGFR pathway.,,,,T,,,,,w,,,,,1.0,,
28148288,3700,9076,D001943,Association,FALSE,Metalloprotease-disintegrin ADAM12 actively promotes the stem cell-like phenotype in <ENT1>claudin</ENT1>-low <ENT2>breast cancer</ENT2>.,,,,T,,,,,w,,,,,1.0,,
28148288,3700,9076,D001943,Association,FALSE,"ADAM12 is induced during epithelial-to-mesenchymal transition, a feature associated with <ENT1>claudin</ENT1>-low <ENT2>breast tumors</ENT2>, which are enriched in cancer stem cell (CSC) markers.",,,,T,,,,,w,,,,,1.0,,
28148288,3700,9076,D001943,Association,FALSE,"METHODS: ADAM12 expression was downregulated in representative <ENT1>claudin</ENT1>-low <ENT2>breast cancer</ENT2> cell lines, SUM159PT and Hs578T, using siRNA transfection or inducible shRNA expression.",,,,T,,,,,w,,,,,1.0,,
28148288,3700,9076,D001943,Association,FALSE,CONCLUSIONS: These results indicate that ADAM12 actively supports the CSC phenotype in <ENT1>claudin</ENT1>-low <ENT2>breast cancer</ENT2> cells via modulation of the EGFR pathway.,,,,T,,,,,w,,,,,1.0,,
28148288,3699,C080985,8038,Negative_Correlation,FALSE,"Consequently, <ENT2>ADAM12</ENT2> knockdown lowered the basal activation level of EGFR, and this effect was abolished by <ENT1>batimastat</ENT1>, a <ENT2>metalloproteinase</ENT2> inhibitor.",,,,T,,,,,w,,,,,1.0,,
28148288,3698,C080985,1956,Association,TRUE,"Consequently, ADAM12 knockdown lowered the basal activation level of <ENT2>EGFR</ENT2>, and this effect was abolished by <ENT1>batimastat</ENT1>, a metalloproteinase inhibitor.",,,,T,,,,,w,,,,,0.0,,
28148288,3704,8038,D001943,Association,TRUE,<ENT1>Metalloprotease-disintegrin</ENT1> <ENT1>ADAM12</ENT1> actively promotes the stem cell-like phenotype in claudin-low <ENT2>breast cancer</ENT2>.,,,,T,,,,,w,,,,,0.0,TRUE,
28148288,3704,8038,D001943,Association,TRUE,BACKGROUND: <ENT1>ADAM12</ENT1> is upregulated in human <ENT2>breast cancers</ENT2> and is a predictor of chemoresistance in estrogen receptor-negative tumors.,,,,T,,,,,c,,,,,0.0,,
28148288,3704,8038,D001943,Association,TRUE,"<ENT1>ADAM12</ENT1> is induced during epithelial-to-mesenchymal transition, a feature associated with claudin-low <ENT2>breast tumors</ENT2>, which are enriched in cancer stem cell (CSC) markers.",,,,T,,,,,w,,,,,0.0,,
28148288,3704,8038,D001943,Association,TRUE,It is currently unknown whether <ENT1>ADAM12</ENT1> plays an active role in promoting the CSC phenotype in <ENT2>breast cancer</ENT2> cells.,,,,T,,,,,c,,,,,1.0,,
28148288,3704,8038,D001943,Association,TRUE,"METHODS: <ENT1>ADAM12</ENT1> expression was downregulated in representative claudin-low <ENT2>breast cancer</ENT2> cell lines, SUM159PT and Hs578T, using siRNA transfection or inducible shRNA expression.",,,,T,,,,,w,,,,,0.0,,
28148288,3704,8038,D001943,Association,TRUE,CONCLUSIONS: These results indicate that <ENT1>ADAM12</ENT1> actively supports the CSC phenotype in claudin-low <ENT2>breast cancer</ENT2> cells via modulation of the EGFR pathway.,,,,T,,,,,c,,,,,1.0,,
28148288,3702,8038,1956,Positive_Correlation,TRUE,<ENT1>ADAM12</ENT1> knockdown also diminished ALDEFLUOR(+) and CD44(hi)/CD24(-/lo) CSC-enriched populations in vitro and reduced tumorigenesis in mice in vivo. RNA sequencing identified a significant overlap between <ENT1>ADAM12</ENT1>- and <ENT2>Epidermal Growth Factor Receptor</ENT2> (<ENT2>EGFR</ENT2>)-regulated genes.,,,,T,,,,,w,,,,,0.0,TRUE,
28148288,3702,8038,1956,Positive_Correlation,TRUE,"Consequently, <ENT1>ADAM12</ENT1> knockdown lowered the basal activation level of <ENT2>EGFR</ENT2>, and this effect was abolished by batimastat, a <ENT1>metalloproteinase</ENT1> inhibitor.",,,,T,,,,,c,,,,,0.5,,
28148288,3702,8038,1956,Positive_Correlation,TRUE,CONCLUSIONS: These results indicate that <ENT1>ADAM12</ENT1> actively supports the CSC phenotype in claudin-low breast cancer cells via modulation of the <ENT2>EGFR</ENT2> pathway.,,,,T,,,,,w,,,,,1.0,,
28148288,3703,8038,D009369,Association,TRUE,BACKGROUND: <ENT1>ADAM12</ENT1> is upregulated in human breast cancers and is a predictor of chemoresistance in estrogen receptor-negative <ENT2>tumors</ENT2>.,,,,T,,,,,w,,,,,0.0,,
28148288,3703,8038,D009369,Association,TRUE,"<ENT1>ADAM12</ENT1> is induced during epithelial-to-mesenchymal transition, a feature associated with claudin-low breast tumors, which are enriched in <ENT2>cancer</ENT2> stem cell (CSC) markers.",,,,T,,,,,w,,,,,0.0,,
28148288,3703,8038,D009369,Association,TRUE,<ENT1>ADAM12</ENT1> knockdown also diminished ALDEFLUOR(+) and CD44(hi)/CD24(-/lo) CSC-enriched populations in vitro and reduced <ENT2>tumorigenesis</ENT2> in mice in vivo. RNA sequencing identified a significant overlap between <ENT1>ADAM12</ENT1>- and Epidermal Growth Factor Receptor (EGFR)-regulated genes.,,,,T,,,,,c,,,,,1.0,,
28148288,3697,8038,1950,Association,TRUE,"Furthermore, incubation of cells with exogenously added <ENT2>EGF</ENT2> prevented the downregulation of CD44(hi)/CD24(-/lo) cell population by <ENT1>ADAM12</ENT1> knockdown.",,,,T,,,,,c,,,,,0.0,,
28151486,3706,D004318,D016511,Association,FALSE,The growth of breast cancer xenografts in NOD/<ENT2>SCID</ENT2> mice was also inhibited by the <ENT1>doxycycline</ENT1>-induced Star-PAP overexpression.,,,,T,,,,,w,,,,,1.0,,
28151486,3707,D004318,D001943,Negative_Correlation,FALSE,The growth of <ENT2>breast cancer</ENT2> xenografts in NOD/SCID mice was also inhibited by the <ENT1>doxycycline</ENT1>-induced Star-PAP overexpression.,,,,T,,,,,c,,,,,0.0,,
28151486,3708,D004318,64852,Positive_Correlation,FALSE,The growth of breast cancer xenografts in NOD/SCID mice was also inhibited by the <ENT1>doxycycline</ENT1>-induced <ENT2>Star-PAP</ENT2> overexpression.,,,,T,,,,,c,,,,,1.0,,
28151486,3711,D016511,64852,Association,FALSE,The growth of breast cancer xenografts in NOD/<ENT1>SCID</ENT1> mice was also inhibited by the doxycycline-induced <ENT2>Star-PAP</ENT2> overexpression.,,,,T,,,,,w,,,,,1.0,,
28151486,3713,D009369,64852,Negative_Correlation,TRUE,"<ENT2>Star-PAP</ENT2>, a <ENT2>poly(A) polymerase</ENT2>, functions as a <ENT1>tumor</ENT1> suppressor in an orthotopic human breast cancer model.",,,,T,,,,,c,,,,,0.0,,
28151486,3713,D009369,64852,Negative_Correlation,TRUE,"However, the pathological role of <ENT2>Star-PAP</ENT2> in <ENT1>cancer</ENT1> largely remains unknown.",,,,T,,,,,c,,,,,1.0,,
28151486,3713,D009369,64852,Negative_Correlation,TRUE,These findings suggested that <ENT2>Star-PAP</ENT2> possesses <ENT1>tumor</ENT1>-suppressing activity and can be a valuable target for developing new <ENT1>cancer</ENT1> therapeutic strategies.,,,,T,,,,,c,,,,,0.5,,
28151486,3712,D001943,64852,Association,TRUE,"<ENT2>Star-PAP</ENT2>, a <ENT2>poly(A) polymerase</ENT2>, functions as a tumor suppressor in an orthotopic human <ENT1>breast cancer</ENT1> model.",,,,T,,,,,w,,,,,1.0,TRUE,
28151486,3712,D001943,64852,Association,TRUE,"In this study, we observed decreased expression of <ENT2>Star-PAP</ENT2> in <ENT1>breast cancer</ENT1> cell lines and tissues.",,,,T,,,,,c,,,,,0.0,,
28151486,3712,D001943,64852,Association,TRUE,Ectopic <ENT2>Star-PAP</ENT2> expression inhibited proliferation as well as colony-forming ability of <ENT1>breast cancer</ENT1> cells.,,,,T,,,,,c,,,,,0.0,,
28151486,3712,D001943,64852,Association,TRUE,"In <ENT1>breast cancer</ENT1> patients, high levels of <ENT2>Star-PAP</ENT2> correlated with an improved prognosis.",,,,T,,,,,c,,,,,0.0,,
28151486,3712,D001943,64852,Association,TRUE,"Moreover, by regulating the expression of BIK (BCL2-interacting killer), <ENT2>Star-PAP</ENT2> induced apoptosis of <ENT1>breast cancer</ENT1> cells through the mitochondrial pathway.",,,,T,,,,,c,,,,,0.0,,
28151486,3712,D001943,64852,Association,TRUE,The growth of <ENT1>breast cancer</ENT1> xenografts in NOD/SCID mice was also inhibited by the doxycycline-induced <ENT2>Star-PAP</ENT2> overexpression.,,,,T,,,,,c,,,,,0.0,,
28151486,3712,D001943,64852,Association,TRUE,"Furthermore, <ENT2>Star-PAP</ENT2> sensitized <ENT1>breast cancer</ENT1> cells to chemotherapy drugs both in vitro and in vivo.",,,,T,,,,,c,,,,,1.0,,
28151486,3709,D001943,638,Association,FALSE,"Moreover, by regulating the expression of <ENT2>BIK</ENT2> (<ENT2>BCL2-interacting killer</ENT2>), Star-PAP induced apoptosis of <ENT1>breast cancer</ENT1> cells through the mitochondrial pathway.",,,,T,,,,,w,,,,,0.0,TRUE,
28151486,3710,64852,638,Association,FALSE,"Moreover, by regulating the expression of <ENT2>BIK</ENT2> (<ENT2>BCL2-interacting killer</ENT2>), <ENT1>Star-PAP</ENT1> induced apoptosis of breast cancer cells through the mitochondrial pathway.",,,,T,,,,,c,,,,,1.0,,
28204828,3724,22339,21847,Association,TRUE,"Improved cardiac function and less scar formation were observed in <ENT2>TIEG1</ENT2> KO mice, and we also observed the altered expression of phosphatase and tensin homolog (Pten), Akt and Bcl-2/Bax, as well as <ENT1>vascular endothelial growth factor</ENT1> (<ENT1>VEGF</ENT1>).",,,,T,,,,,w,,,,,1.0,TRUE,
28204828,3721,D007938,21847,Association,FALSE,"The <ENT2>transforming growth factor (TGF)-b-inducible early gene-1</ENT2> (<ENT2>TIEG1</ENT2>) plays a crucial role in modulating cell apoptosis and proliferation in a number of diseases, including pancreatic cancer, <ENT1>leukaemia</ENT1> and osteoporosis.",,,,T,,,,,w,,,,,1.0,,
28204828,3725,12028,21847,Association,TRUE,"Improved cardiac function and less scar formation were observed in <ENT2>TIEG1</ENT2> KO mice, and we also observed the altered expression of phosphatase and tensin homolog (Pten), Akt and Bcl-2/<ENT1>Bax</ENT1>, as well as vascular endothelial growth factor (VEGF).",,,,T,,,,,w,,,,,1.0,,
28204828,3714,1791,C027078,Association,FALSE,"Histological analyses of apoptosis, proliferation, angiogenesis and infarct zone assessments were performed using <ENT1>terminal deoxynucleotidyltransferase</ENT1>-mediated <ENT2>dUTP</ENT2> nick-end labelling (TUNEL) staining, BrdU immunostaining, a-smooth muscle actin (a-SMA)/CD31 immunostaining and Masson's trichrome staining, respectively.",,,,T,,,,,c,,,,,0.0,,
28204828,3719,D009203,19211,Association,FALSE,TIEG1 deficiency confers enhanced myocardial protection in the <ENT1>infarcted heart</ENT1> by mediating the <ENT2>Pten</ENT2>/Akt signalling pathway.,,,,T,,,,,w,,,,,1.0,,
28204828,3729,D009203,21847,Association,TRUE,<ENT2>TIEG1</ENT2> deficiency confers enhanced myocardial protection in the <ENT1>infarcted heart</ENT1> by mediating the Pten/Akt signalling pathway.,,,,T,,,,,c,,,,,1.0,,
28204828,3729,D009203,21847,Association,TRUE,"For in vivo experiments, a model of <ENT1>myocardial infarction</ENT1> (<ENT1>MI</ENT1>) was established using both <ENT2>TIEG1</ENT2> KO and WT mice.",,,,T,,,,,w,,,,,0.0,TRUE,
28204828,3718,D009203,11651,Association,FALSE,TIEG1 deficiency confers enhanced myocardial protection in the <ENT1>infarcted heart</ENT1> by mediating the Pten/<ENT2>Akt</ENT2> signalling pathway.,,,,T,,,,,w,,,,,1.0,,
28204828,3720,D010190,21847,Association,FALSE,"The <ENT2>transforming growth factor (TGF)-b-inducible early gene-1</ENT2> (<ENT2>TIEG1</ENT2>) plays a crucial role in modulating cell apoptosis and proliferation in a number of diseases, including <ENT1>pancreatic cancer</ENT1>, leukaemia and osteoporosis.",,,,T,,,,,w,,,,,1.0,,
28204828,3728,19211,21847,Association,TRUE,<ENT2>TIEG1</ENT2> deficiency confers enhanced myocardial protection in the infarcted heart by mediating the <ENT1>Pten</ENT1>/Akt signalling pathway.,,,,T,,,,,c,,,,,0.0,,
28204828,3728,19211,21847,Association,TRUE,"Improved cardiac function and less scar formation were observed in <ENT2>TIEG1</ENT2> KO mice, and we also observed the altered expression of <ENT1>phosphatase and tensin homolog</ENT1> (<ENT1>Pten</ENT1>), Akt and Bcl-2/Bax, as well as vascular endothelial growth factor (VEGF).",,,,T,,,,,w,,,,,1.0,TRUE,
28204828,3728,19211,21847,Association,TRUE,"On the whole, our findings indicate that the absence of <ENT2>TIEG1</ENT2> plays a cardioprotective role in ischaemic heart disease by promoting changes in <ENT1>Pten</ENT1>/Akt signalling.",,,,T,,,,,c,,,,,0.0,,
28204828,3716,19211,D017202,Association,FALSE,"On the whole, our findings indicate that the absence of TIEG1 plays a cardioprotective role in <ENT2>ischaemic heart disease</ENT2> by promoting changes in <ENT1>Pten</ENT1>/Akt signalling.",,,,T,,,,,c,,,,,0.0,,
28204828,3717,19211,11651,Association,FALSE,TIEG1 deficiency confers enhanced myocardial protection in the infarcted heart by mediating the <ENT1>Pten</ENT1>/<ENT2>Akt</ENT2> signalling pathway.,,,,T,,,,,c,,,,,0.0,,
28204828,3717,19211,11651,Association,FALSE,"Improved cardiac function and less scar formation were observed in TIEG1 KO mice, and we also observed the altered expression of <ENT1>phosphatase and tensin homolog</ENT1> (<ENT1>Pten</ENT1>), <ENT2>Akt</ENT2> and Bcl-2/Bax, as well as vascular endothelial growth factor (VEGF).",,,,T,,,,,c,,,,,0.5,,
28204828,3717,19211,11651,Association,FALSE,"On the whole, our findings indicate that the absence of TIEG1 plays a cardioprotective role in ischaemic heart disease by promoting changes in <ENT1>Pten</ENT1>/<ENT2>Akt</ENT2> signalling.",,,,T,,,,,w,,,,,1.0,,
28204828,3722,D010024,21847,Association,FALSE,"The <ENT2>transforming growth factor (TGF)-b-inducible early gene-1</ENT2> (<ENT2>TIEG1</ENT2>) plays a crucial role in modulating cell apoptosis and proliferation in a number of diseases, including pancreatic cancer, leukaemia and <ENT1>osteoporosis</ENT1>.",,,,T,,,,,w,,,,,1.0,,
28204828,3723,21847,D017202,Association,TRUE,"In this study, we first investigated the role of <ENT1>TIEG1</ENT1> in <ENT2>ischaemic heart disease</ENT2>.",,,,T,,Y,,,w,,,,,0.0,,
28204828,3723,21847,D017202,Association,TRUE,"On the whole, our findings indicate that the absence of <ENT1>TIEG1</ENT1> plays a cardioprotective role in <ENT2>ischaemic heart disease</ENT2> by promoting changes in Pten/Akt signalling.",,,,T,,,,,c,,,,,1.0,,
28204828,3726,21847,12043,Association,TRUE,"Improved cardiac function and less scar formation were observed in <ENT1>TIEG1</ENT1> KO mice, and we also observed the altered expression of phosphatase and tensin homolog (Pten), Akt and <ENT2>Bcl-2</ENT2>/Bax, as well as vascular endothelial growth factor (VEGF).",,,,T,,,,,w,,,,,1.0,,
28204828,3727,21847,11651,Association,TRUE,<ENT1>TIEG1</ENT1> deficiency confers enhanced myocardial protection in the infarcted heart by mediating the Pten/<ENT2>Akt</ENT2> signalling pathway.,,,,T,,,,,c,,,,,0.0,,
28204828,3727,21847,11651,Association,TRUE,"Improved cardiac function and less scar formation were observed in <ENT1>TIEG1</ENT1> KO mice, and we also observed the altered expression of phosphatase and tensin homolog (Pten), <ENT2>Akt</ENT2> and Bcl-2/Bax, as well as vascular endothelial growth factor (VEGF).",,,,T,,,,,w,,,,,1.0,,
28204828,3727,21847,11651,Association,TRUE,"On the whole, our findings indicate that the absence of <ENT1>TIEG1</ENT1> plays a cardioprotective role in ischaemic heart disease by promoting changes in Pten/<ENT2>Akt</ENT2> signalling.",,,,T,,,,,c,,,,,0.0,,
28204828,3715,D017202,11651,Association,FALSE,"On the whole, our findings indicate that the absence of TIEG1 plays a cardioprotective role in <ENT1>ischaemic heart disease</ENT1> by promoting changes in Pten/<ENT2>Akt</ENT2> signalling.",,,,T,,,,,c,,,,,0.0,,
28259923,3738,D009369,5326,Association,FALSE,Recent studies show that <ENT2>pleomorphic adenoma gene like-2</ENT2> (<ENT2>PLAGL2</ENT2>) could induce <ENT1>tumor</ENT1> EMT and is an independent predictive factor associated with poor prognosis in <ENT1>cancer</ENT1>.,,,,T,,,,,c,,,,,1.0,,
28259923,3732,7474,D015179,Association,FALSE,Pleomorphic adenoma gene like-2 induces epithelial-mesenchymal transition via <ENT1>Wnt</ENT1>/b-catenin signaling pathway in human <ENT2>colorectal adenocarcinoma</ENT2>.,,,,T,,,,,w,,,,,1.0,,
28259923,3741,7474,5326,Association,TRUE,<ENT2>Pleomorphic adenoma gene like-2</ENT2> induces epithelial-mesenchymal transition via <ENT1>Wnt</ENT1>/b-catenin signaling pathway in human colorectal adenocarcinoma.,,,,T,,,,,c,,,,,0.0,,
28259923,3741,7474,5326,Association,TRUE,"Subsequently, through western blot assay, we found that <ENT2>PLAGL2</ENT2> could activate the <ENT1>wnt</ENT1>-signaling component b-catenin in the nuclei.",,,,T,,,,,c,,,,,1.0,,
28259923,3741,7474,5326,Association,TRUE,Our findings indicated that <ENT2>PLAGL2</ENT2> might be a very upstream key molecule regulating EMT involved in <ENT1>Wnt</ENT1>/b-catenin signaling pathway.,,,,T,,,,,c,,,,,1.0,,
28259923,3733,7474,1499,Association,FALSE,Pleomorphic adenoma gene like-2 induces epithelial-mesenchymal transition via <ENT1>Wnt</ENT1>/<ENT2>b-catenin</ENT2> signaling pathway in human colorectal adenocarcinoma.,,,,T,,,,,c,,,,,0.0,,
28259923,3733,7474,1499,Association,FALSE,"Subsequently, through western blot assay, we found that PLAGL2 could activate the <ENT1>wnt</ENT1>-signaling component <ENT2>b-catenin</ENT2> in the nuclei.",,,,T,,,,,c,,,,,1.0,,
28259923,3733,7474,1499,Association,FALSE,Our findings indicated that PLAGL2 might be a very upstream key molecule regulating EMT involved in <ENT1>Wnt</ENT1>/<ENT2>b-catenin</ENT2> signaling pathway.,,,,T,,,,,c,,,,,0.0,,
28259923,3735,7431,5326,Positive_Correlation,TRUE,"Experimental EMT induced by <ENT2>PLAGL2</ENT2> plasmid transfection proved <ENT2>PLAGL2</ENT2> protein overexpression could enhance the cell scratch wound-healing and transwell ability and significantly upregulated mesenchymal marker proteins, N-cadherin and <ENT1>vimentin</ENT1> and concurrently downregulated epithelial marker of E-cadherin.",,,,T,,,,,c,,,,,0.5,,
28259923,3734,999,5326,Negative_Correlation,TRUE,"Experimental EMT induced by <ENT2>PLAGL2</ENT2> plasmid transfection proved <ENT2>PLAGL2</ENT2> protein overexpression could enhance the cell scratch wound-healing and transwell ability and significantly upregulated mesenchymal marker proteins, N-cadherin and vimentin and concurrently downregulated epithelial marker of <ENT1>E-cadherin</ENT1>.",,,,T,,,,,c,,,,,0.5,,
28259923,3739,D015179,5326,Association,TRUE,<ENT2>Pleomorphic adenoma gene like-2</ENT2> induces epithelial-mesenchymal transition via Wnt/b-catenin signaling pathway in human <ENT1>colorectal adenocarcinoma</ENT1>.,,,,T,,,,,w,,,,,1.0,,
28259923,3739,D015179,5326,Association,TRUE,"In the present study, we confirmed the role of <ENT2>PLAGL2</ENT2> in the prognosis of <ENT1>CRC</ENT1> patients and provide molecular evidence of <ENT2>PLAGL2</ENT2> promoted EMT in <ENT1>CRC</ENT1> cell line SW480.",,,,T,,,,,c,,,,,0.5,,
28259923,3739,D015179,5326,Association,TRUE,We found that <ENT2>PLAGL2</ENT2> expression was upregulated in the paraffin-embedded <ENT1>CRC</ENT1> tissues compared to borderline or benign tissues.,,,,T,,,,,c,,,,,1.0,,
28259923,3739,D015179,5326,Association,TRUE,"More <ENT1>CRC</ENT1> cell metastasis to the lungs was observed when the <ENT2>PLAGL2</ENT2> overexpressing SW480 cells were injected into the tail vein of rats, compared with the cell control and <ENT2>PLAGL2</ENT2> silence group.",,,,T,,,,,c,,,,,1.0,,
28259923,3731,D015179,1499,Association,FALSE,Pleomorphic adenoma gene like-2 induces epithelial-mesenchymal transition via Wnt/<ENT2>b-catenin</ENT2> signaling pathway in human <ENT1>colorectal adenocarcinoma</ENT1>.,,,,T,,T,,,w,,,,,1.0,,
28259923,3730,D015179,D010232,Association,FALSE,We found that PLAGL2 expression was upregulated in the <ENT2>paraffin</ENT2>-embedded <ENT1>CRC</ENT1> tissues compared to borderline or benign tissues.,,,,T,,,,,c,,,,,0.0,,
28259923,3740,5326,1499,Positive_Correlation,TRUE,<ENT1>Pleomorphic adenoma gene like-2</ENT1> induces epithelial-mesenchymal transition via Wnt/<ENT2>b-catenin</ENT2> signaling pathway in human colorectal adenocarcinoma.,,,,T,,T,,,c,,,,,1.0,,
28259923,3740,5326,1499,Positive_Correlation,TRUE,"Subsequently, through western blot assay, we found that <ENT1>PLAGL2</ENT1> could activate the wnt-signaling component <ENT2>b-catenin</ENT2> in the nuclei.",,,,T,,,,,c,,,,,1.0,,
28259923,3740,5326,1499,Positive_Correlation,TRUE,Our findings indicated that <ENT1>PLAGL2</ENT1> might be a very upstream key molecule regulating EMT involved in Wnt/<ENT2>b-catenin</ENT2> signaling pathway.,,,,T,,,,,c,,,,,1.0,,
28259923,3736,5326,1000,Positive_Correlation,TRUE,"Experimental EMT induced by <ENT1>PLAGL2</ENT1> plasmid transfection proved <ENT1>PLAGL2</ENT1> protein overexpression could enhance the cell scratch wound-healing and transwell ability and significantly upregulated mesenchymal marker proteins, <ENT2>N-cadherin</ENT2> and vimentin and concurrently downregulated epithelial marker of E-cadherin.",,,,T,,,,,c,,,,,0.0,,
28259923,3737,5326,D010232,Association,FALSE,We found that <ENT1>PLAGL2</ENT1> expression was upregulated in the <ENT2>paraffin</ENT2>-embedded CRC tissues compared to borderline or benign tissues.,,,,T,,,,,c,,,,,1.0,,
28260056,3753,16001,D017382,Association,TRUE,"Mouse embryonic fibroblasts exhibiting disruption or overexpression of <ENT1>IGF-1R</ENT1> (R- cells and R+ cells) were used to examine the level of apoptosis, autophagy, and production of <ENT2>reactive oxygen species</ENT2> (<ENT2>ROS</ENT2>).",,,,T,,Y,,,c,,,,,1.0,,
28260056,3753,16001,D017382,Association,TRUE,"These results indicated that <ENT1>IGF-1R</ENT1> may increase cell viability under hypoxic conditions by promoting autophagy and scavenging <ENT2>ROS</ENT2> production, which is closed with PI3K/Akt/mTOR signaling pathway.",,,,T,,,,,c,,,,,0.0,,
28260056,3756,16001,18706,Association,TRUE,<ENT1>Insulin-like growth factor 1 receptor</ENT1>-mediated cell survival in hypoxia depends on the promotion of autophagy via suppression of the <ENT2>PI3K</ENT2>/Akt/mTOR signaling pathway.,,,,T,,,,,w,,,,,1.0,,
28260056,3756,16001,18706,Association,TRUE,"Furthermore, <ENT1>IGF-1R</ENT1> is related with <ENT2>PI3K</ENT2>/Akt/mTOR signaling pathway and enhanced autophagy-associated protein expression, which was verified following treatment with the <ENT2>PI3K</ENT2> inhibitor LY294002.",,,,T,,,,,c,,,,,0.5,,
28260056,3756,16001,18706,Association,TRUE,"These results indicated that <ENT1>IGF-1R</ENT1> may increase cell viability under hypoxic conditions by promoting autophagy and scavenging ROS production, which is closed with <ENT2>PI3K</ENT2>/Akt/mTOR signaling pathway.",,,,T,Y,,,,w,,,,,1.0,,
28260056,3754,16001,56717,Association,TRUE,<ENT1>Insulin-like growth factor 1 receptor</ENT1>-mediated cell survival in hypoxia depends on the promotion of autophagy via suppression of the PI3K/Akt/<ENT2>mTOR</ENT2> signaling pathway.,,,,T,,,,,w,,,,,1.0,,
28260056,3754,16001,56717,Association,TRUE,"Furthermore, <ENT1>IGF-1R</ENT1> is related with PI3K/Akt/<ENT2>mTOR</ENT2> signaling pathway and enhanced autophagy-associated protein expression, which was verified following treatment with the PI3K inhibitor LY294002.",,,,T,,,,,c,,,,,0.0,,
28260056,3754,16001,56717,Association,TRUE,"These results indicated that <ENT1>IGF-1R</ENT1> may increase cell viability under hypoxic conditions by promoting autophagy and scavenging ROS production, which is closed with PI3K/Akt/<ENT2>mTOR</ENT2> signaling pathway.",,,,T,Y,,,,w,,,,,1.0,,
28260056,3755,16001,11651,Association,TRUE,<ENT1>Insulin-like growth factor 1 receptor</ENT1>-mediated cell survival in hypoxia depends on the promotion of autophagy via suppression of the PI3K/<ENT2>Akt</ENT2>/mTOR signaling pathway.,,,,T,,,,,w,,,,,1.0,,
28260056,3755,16001,11651,Association,TRUE,"Furthermore, <ENT1>IGF-1R</ENT1> is related with PI3K/<ENT2>Akt</ENT2>/mTOR signaling pathway and enhanced autophagy-associated protein expression, which was verified following treatment with the PI3K inhibitor LY294002.",,,,T,,,,,c,,,,,0.0,,
28260056,3755,16001,11651,Association,TRUE,"These results indicated that <ENT1>IGF-1R</ENT1> may increase cell viability under hypoxic conditions by promoting autophagy and scavenging ROS production, which is closed with PI3K/<ENT2>Akt</ENT2>/mTOR signaling pathway.",,,,T,Y,,,,w,,,,,0.0,,
28260056,3757,16001,D000860,Association,TRUE,<ENT1>Insulin-like growth factor 1 receptor</ENT1>-mediated cell survival in <ENT2>hypoxia</ENT2> depends on the promotion of autophagy via suppression of the PI3K/Akt/mTOR signaling pathway.,,,,T,,,,,w,,,,,0.0,,
28260056,3757,16001,D000860,Association,TRUE,"<ENT2>Hypoxia</ENT2> is a regulatory factor of the IGF system, however the role of the <ENT1>IGF-1 receptor</ENT1> (<ENT1>IGF-1R</ENT1>) in <ENT2>hypoxia</ENT2>-induced apoptosis remains unclear.",,,,T,,,,,c,,,,,1.0,,
28260056,3757,16001,D000860,Association,TRUE,The present study investigated the potential mechanisms associated with <ENT1>IGF-1R</ENT1>-associated apoptosis under <ENT2>hypoxic</ENT2> conditions.,,,,T,,,,,c,,,,,0.0,,
28260056,3757,16001,D000860,Association,TRUE,"These results indicated that <ENT1>IGF-1R</ENT1> may increase cell viability under <ENT2>hypoxic</ENT2> conditions by promoting autophagy and scavenging ROS production, which is closed with PI3K/Akt/mTOR signaling pathway.",,,,T,,,,,w,,,,,0.0,,
28260056,3746,D017382,18706,Association,TRUE,"These results indicated that IGF-1R may increase cell viability under hypoxic conditions by promoting autophagy and scavenging <ENT1>ROS</ENT1> production, which is closed with <ENT2>PI3K</ENT2>/Akt/mTOR signaling pathway.",,,,T,,,,,c,,,,,0.0,,
28260056,3744,D017382,56717,Association,TRUE,"These results indicated that IGF-1R may increase cell viability under hypoxic conditions by promoting autophagy and scavenging <ENT1>ROS</ENT1> production, which is closed with PI3K/Akt/<ENT2>mTOR</ENT2> signaling pathway.",,,,T,,,,,c,,,,,0.0,,
28260056,3742,D017382,C025946,Association,TRUE,The autophagy inhibitor <ENT2>3-methyladenine</ENT2> was used to assess the effect of autophagy on <ENT1>ROS</ENT1> production and apoptosis under hypoxic conditions.,,,,T,,,,,w,,,,,0.0,,
28260056,3745,D017382,11651,Association,TRUE,"These results indicated that IGF-1R may increase cell viability under hypoxic conditions by promoting autophagy and scavenging <ENT1>ROS</ENT1> production, which is closed with PI3K/<ENT2>Akt</ENT2>/mTOR signaling pathway.",,,,T,,,,,c,,,,,0.0,,
28260056,3747,D017382,D000860,Positive_Correlation,TRUE,The autophagy inhibitor 3-methyladenine was used to assess the effect of autophagy on <ENT1>ROS</ENT1> production and apoptosis under <ENT2>hypoxic</ENT2> conditions.,,,,T,,,,,w,,,,,1.0,,
28260056,3747,D017382,D000860,Positive_Correlation,TRUE,"The results demonstrated that <ENT2>hypoxia</ENT2> induced apoptosis, increased <ENT1>ROS</ENT1> production, and promoted autophagy in a time-dependent manner relative to that observed under normoxia.",,,,T,,,,,c,,,,,1.0,,
28260056,3747,D017382,D000860,Positive_Correlation,TRUE,"These results indicated that IGF-1R may increase cell viability under <ENT2>hypoxic</ENT2> conditions by promoting autophagy and scavenging <ENT1>ROS</ENT1> production, which is closed with PI3K/Akt/mTOR signaling pathway.",,,,T,,,,,w,,,,,1.0,,
28260056,3748,18706,C085911,Negative_Correlation,FALSE,"Furthermore, IGF-1R is related with <ENT1>PI3K</ENT1>/Akt/mTOR signaling pathway and enhanced autophagy-associated protein expression, which was verified following treatment with the <ENT1>PI3K</ENT1> inhibitor <ENT2>LY294002</ENT2>.",,,,T,,,,,c,,,,,0.5,,
28260056,3752,18706,D000860,Association,TRUE,Insulin-like growth factor 1 receptor-mediated cell survival in <ENT2>hypoxia</ENT2> depends on the promotion of autophagy via suppression of the <ENT1>PI3K</ENT1>/Akt/mTOR signaling pathway.,,,,T,,,,,w,,,,,0.0,,
28260056,3752,18706,D000860,Association,TRUE,"These results indicated that IGF-1R may increase cell viability under <ENT2>hypoxic</ENT2> conditions by promoting autophagy and scavenging ROS production, which is closed with <ENT1>PI3K</ENT1>/Akt/mTOR signaling pathway.",,,,T,,,,,c,,,,,1.0,,
28260056,3750,56717,D000860,Association,TRUE,Insulin-like growth factor 1 receptor-mediated cell survival in <ENT2>hypoxia</ENT2> depends on the promotion of autophagy via suppression of the PI3K/Akt/<ENT1>mTOR</ENT1> signaling pathway.,,,,T,,,,,w,,,,,1.0,,
28260056,3750,56717,D000860,Association,TRUE,"These results indicated that IGF-1R may increase cell viability under <ENT2>hypoxic</ENT2> conditions by promoting autophagy and scavenging ROS production, which is closed with PI3K/Akt/<ENT1>mTOR</ENT1> signaling pathway.",,,,T,,,,,c,,,,,1.0,,
28260056,3743,C025946,D000860,Association,TRUE,The autophagy inhibitor <ENT1>3-methyladenine</ENT1> was used to assess the effect of autophagy on ROS production and apoptosis under <ENT2>hypoxic</ENT2> conditions.,,,,T,,,,,c,,,,,1.0,,
28260056,3749,16000,D000860,Association,FALSE,"<ENT2>Hypoxia</ENT2> is a regulatory factor of the <ENT1>IGF</ENT1> system, however the role of the IGF-1 receptor (IGF-1R) in <ENT2>hypoxia</ENT2>-induced apoptosis remains unclear.",,,,T,,,,,c,,,,,0.5,,
28260056,3751,11651,D000860,Association,TRUE,Insulin-like growth factor 1 receptor-mediated cell survival in <ENT2>hypoxia</ENT2> depends on the promotion of autophagy via suppression of the PI3K/<ENT1>Akt</ENT1>/mTOR signaling pathway.,,,,T,,,,,w,,,,,0.0,,
28260056,3751,11651,D000860,Association,TRUE,"These results indicated that IGF-1R may increase cell viability under <ENT2>hypoxic</ENT2> conditions by promoting autophagy and scavenging ROS production, which is closed with PI3K/<ENT1>Akt</ENT1>/mTOR signaling pathway.",,,,T,,,,,c,,,,,1.0,,
28260077,3758,3315,596,Association,TRUE,"Notably, following treatment with <ENT1>Hsp27</ENT1> siRNA or pcDNA3.1-<ENT1>Hsp27</ENT1>, it was found that iopamidol enhanced or weakened the upregulation of Bax/caspase-3 and downregulation of <ENT2>Bcl-2</ENT2> in the HK2 cells, respectively.",,,,T,,,,,c,,,,,0.0,,
28260077,3766,3315,D007479,Association,FALSE,"In vitro, the HK2 cells were treated with <ENT2>iopamidol</ENT2> in the presence or absence of atorvastatin, <ENT1>heat shock protein (Hsp)27</ENT1> small interfering (si)RNA or pcDNA3.1-<ENT1>Hsp27</ENT1>.",,,,T,,,,,c,,,,,1.0,,
28260077,3766,3315,D007479,Association,FALSE,"Notably, following treatment with <ENT1>Hsp27</ENT1> siRNA or pcDNA3.1-<ENT1>Hsp27</ENT1>, it was found that <ENT2>iopamidol</ENT2> enhanced or weakened the upregulation of Bax/caspase-3 and downregulation of Bcl-2 in the HK2 cells, respectively.",,,,T,,,,,c,,,,,0.0,,
28260077,3759,3315,836,Association,TRUE,"Notably, following treatment with <ENT1>Hsp27</ENT1> siRNA or pcDNA3.1-<ENT1>Hsp27</ENT1>, it was found that iopamidol enhanced or weakened the upregulation of Bax/<ENT2>caspase-3</ENT2> and downregulation of Bcl-2 in the HK2 cells, respectively.",,,,T,,,,,c,,,,,0.0,,
28260077,3760,3315,581,Association,TRUE,"Notably, following treatment with <ENT1>Hsp27</ENT1> siRNA or pcDNA3.1-<ENT1>Hsp27</ENT1>, it was found that iopamidol enhanced or weakened the upregulation of <ENT2>Bax</ENT2>/caspase-3 and downregulation of Bcl-2 in the HK2 cells, respectively.",,,,T,,,,,c,,,,,0.0,,
28260077,3770,D000069059,24224,Positive_Correlation,TRUE,"Furthermore, <ENT1>atorvastatin</ENT1> reduced the iopamidol-induced activity of B cell lymphoma-2 (Bcl-2)-associated X protein (Bax)/caspase-3 and increased the expression of <ENT2>Bcl-2</ENT2> in vivo and in vitro.",,,,T,,,,,c,,,,,1.0,,
28260077,3772,D000069059,D007479,Negative_Correlation,TRUE,"To determine whether <ENT1>atorvastatin</ENT1> attenuated CIN, the inflammatory response and apoptosis in vivo and in vitro, a rat model of <ENT2>iopamidol</ENT2>-induced CIN was used, and human embryonic proximal tubule (HK2) cell damage was assessed.",,,,T,,,,,c,,,,,1.0,,
28260077,3772,D000069059,D007479,Negative_Correlation,TRUE,"The rats were assigned into four groups (n=10 per group), as follows: Control rats; rats+<ENT1>atorvastatin</ENT1>; rats + <ENT2>iopamidol</ENT2>; rats+<ENT2>iopamidol</ENT2>+<ENT1>atorvastatin</ENT1>.",,,,T,,,,,c,,,,,1.0,,
28260077,3772,D000069059,D007479,Negative_Correlation,TRUE,"In vitro, the HK2 cells were treated with <ENT2>iopamidol</ENT2> in the presence or absence of <ENT1>atorvastatin</ENT1>, heat shock protein (Hsp)27 small interfering (si)RNA or pcDNA3.1-Hsp27.",,,,T,,,,,c,,,,,1.0,,
28260077,3772,D000069059,D007479,Negative_Correlation,TRUE,"Furthermore, <ENT1>atorvastatin</ENT1> reduced the <ENT2>iopamidol</ENT2>-induced activity of B cell lymphoma-2 (Bcl-2)-associated X protein (Bax)/caspase-3 and increased the expression of Bcl-2 in vivo and in vitro.",,,,T,,,,,w,,,,,1.0,,
28260077,3771,D000069059,25402,Negative_Correlation,TRUE,"Furthermore, <ENT1>atorvastatin</ENT1> reduced the iopamidol-induced activity of B cell lymphoma-2 (Bcl-2)-associated X protein (Bax)/<ENT2>caspase-3</ENT2> and increased the expression of Bcl-2 in vivo and in vitro.",,,,T,,,,,c,,,,,0.0,,
28260077,3768,D000069059,24471,Positive_Correlation,TRUE,<ENT1>Atorvastatin</ENT1> protects against contrast-induced nephropathy via anti-apoptosis by the upregulation of <ENT2>Hsp27</ENT2> in vivo and in vitro.,,,,T,,,,,c,,,,,0.0,,
28260077,3768,D000069059,24471,Positive_Correlation,TRUE,The present study aimed to investigate whether <ENT1>atorvastatin</ENT1> protects against CIN via anti-apoptotic effects by the upregulation of <ENT2>Hsp27</ENT2> in vivo and in vitro.,,,,T,,,,,c,,,,,1.0,,
28260077,3768,D000069059,24471,Positive_Correlation,TRUE,The results of the present study suggested that <ENT1>atorvastatin</ENT1> protected against contrast-induced renal tubular cell apoptosis through the upregulation of <ENT2>Hsp27</ENT2> in vivo and in vitro.,,,,T,,,,,c,,,,,0.0,,
28260077,3769,D000069059,24887,Negative_Correlation,TRUE,"Furthermore, <ENT1>atorvastatin</ENT1> reduced the iopamidol-induced activity of <ENT2>B cell lymphoma-2 (Bcl-2)-associated X protein</ENT2> (<ENT2>Bax</ENT2>)/caspase-3 and increased the expression of Bcl-2 in vivo and in vitro.",,,,T,,,,,w,,,,,0.0,TRUE,
28260077,3773,D000069059,D007674,Negative_Correlation,TRUE,<ENT1>Atorvastatin</ENT1> protects against <ENT2>contrast-induced nephropathy</ENT2> via anti-apoptosis by the upregulation of Hsp27 in vivo and in vitro.,,,,T,,,,,c,,,,,1.0,,
28260077,3773,D000069059,D007674,Negative_Correlation,TRUE,The present study aimed to investigate whether <ENT1>atorvastatin</ENT1> protects against <ENT2>CIN</ENT2> via anti-apoptotic effects by the upregulation of Hsp27 in vivo and in vitro.,,,,T,,,,,c,,,,,0.0,,
28260077,3773,D000069059,D007674,Negative_Correlation,TRUE,"To determine whether <ENT1>atorvastatin</ENT1> attenuated <ENT2>CIN</ENT2>, the inflammatory response and apoptosis in vivo and in vitro, a rat model of iopamidol-induced <ENT2>CIN</ENT2> was used, and human embryonic proximal tubule (HK2) cell damage was assessed.",,,,T,,Y,,,c,,,,,0.5,,
28260077,3773,D000069059,D007674,Negative_Correlation,TRUE,The results showed that <ENT1>atorvastatin</ENT1> ameliorated the <ENT2>apoptosis and deterioration of renal function</ENT2> (P<0.05).,,,,T,,,,,c,,,,,1.0,,
28260077,3773,D000069059,D007674,Negative_Correlation,TRUE,The results of the present study suggested that <ENT1>atorvastatin</ENT1> protected against <ENT2>contrast-induced renal tubular cell apoptosis</ENT2> through the upregulation of Hsp27 in vivo and in vitro.,,,,T,,,,,c,,,,,1.0,,
28260077,3761,596,D007479,Association,TRUE,"Notably, following treatment with Hsp27 siRNA or pcDNA3.1-Hsp27, it was found that <ENT2>iopamidol</ENT2> enhanced or weakened the upregulation of Bax/caspase-3 and downregulation of <ENT1>Bcl-2</ENT1> in the HK2 cells, respectively.",,,,T,,,,,c,,,,,0.0,,
28260077,3765,D007479,25402,Positive_Correlation,FALSE,"Furthermore, atorvastatin reduced the <ENT1>iopamidol</ENT1>-induced activity of B cell lymphoma-2 (Bcl-2)-associated X protein (Bax)/<ENT2>caspase-3</ENT2> and increased the expression of Bcl-2 in vivo and in vitro.",,,,T,,,,,c,,,,,0.0,,
28260077,3762,D007479,836,Association,TRUE,"Notably, following treatment with Hsp27 siRNA or pcDNA3.1-Hsp27, it was found that <ENT1>iopamidol</ENT1> enhanced or weakened the upregulation of Bax/<ENT2>caspase-3</ENT2> and downregulation of Bcl-2 in the HK2 cells, respectively.",,,,T,,,,,c,,,,,0.0,,
28260077,3764,D007479,24887,Positive_Correlation,TRUE,"Furthermore, atorvastatin reduced the <ENT1>iopamidol</ENT1>-induced activity of <ENT2>B cell lymphoma-2 (Bcl-2)-associated X protein</ENT2> (<ENT2>Bax</ENT2>)/caspase-3 and increased the expression of Bcl-2 in vivo and in vitro.",,,,T,,,,,c,,,,,0.5,,
28260077,3767,D007479,D007674,Positive_Correlation,FALSE,"To determine whether atorvastatin attenuated <ENT2>CIN</ENT2>, the inflammatory response and apoptosis in vivo and in vitro, a rat model of <ENT1>iopamidol</ENT1>-induced <ENT2>CIN</ENT2> was used, and human embryonic proximal tubule (HK2) cell damage was assessed.",,,,T,,,,,c,,,,,0.5,,
28260077,3763,D007479,581,Association,TRUE,"Notably, following treatment with Hsp27 siRNA or pcDNA3.1-Hsp27, it was found that <ENT1>iopamidol</ENT1> enhanced or weakened the upregulation of <ENT2>Bax</ENT2>/caspase-3 and downregulation of Bcl-2 in the HK2 cells, respectively.",,,,T,,,,,c,,,,,0.0,,
28260110,3792,D004642,D005230,Negative_Correlation,TRUE,<ENT1>Emodin</ENT1> also inhibited intracellular FASN enzymatic activity and reduced the levels of intracellular <ENT2>free fatty acids</ENT2>.,,,,T,,,,,c,,,,,1.0,,
28260110,3776,D004642,D010168,Association,TRUE,"<ENT2>Palmitate</ENT2>, the final product of the FASN reaction, rescued <ENT1>emodin</ENT1>-induced viability and apoptosis.",,,,T,,,,,c,,,,,0.0,,
28260110,3788,D004642,5594,Association,TRUE,"In addition, <ENT1>emodin</ENT1> altered FASN-involved signaling pathways, including phosphatidylinositol 3-kinase/Akt and <ENT2>mitogen-activated protein kinases/extracellular signal-regulated kinases 1/2</ENT2>.",,,,T,,,,,c,,,,,1.0,,
28260110,3790,D004642,5291,Association,TRUE,"In addition, <ENT1>emodin</ENT1> altered FASN-involved signaling pathways, including <ENT2>phosphatidylinositol 3-kinase</ENT2>/Akt and mitogen-activated protein kinases/extracellular signal-regulated kinases 1/2.",,,,T,,,,,c,,,,,1.0,,
28260110,3793,D004642,D015179,Negative_Correlation,TRUE,"Inhibitory effect of <ENT1>emodin</ENT1> on fatty acid synthase, <ENT2>colon cancer</ENT2> proliferation and apoptosis.",,,,T,,,,,c,,,,,1.0,,
28260110,3793,D004642,D015179,Negative_Correlation,TRUE,"<ENT1>Emodin</ENT1>, a naturally occurring anthraquinone, exhibits an anticancer effect in various types of human cancer, including <ENT2>colon cancer</ENT2>; however, the molecular mechanisms remain to be fully elucidated.",,,,T,,,,,c,,,,,0.0,,
28260110,3793,D004642,D015179,Negative_Correlation,TRUE,The present study was performed to investigate whether the gene expression of FASN and its enzymatic activity are regulated by <ENT1>emodin</ENT1> in a human <ENT2>colon cancer</ENT2> cell line.,,,,T,,Y,,,c,,,,,1.0,,
28260110,3793,D004642,D015179,Negative_Correlation,TRUE,These results suggested that <ENT1>emodin</ENT1>-regulated cell growth and apoptosis were mediated by inhibiting FASN and provide a molecular basis for <ENT2>colon cancer</ENT2> therapy.,,,,T,,,,,c,,,,,1.0,,
28260110,3786,D004642,2194,Negative_Correlation,TRUE,"Inhibitory effect of <ENT1>emodin</ENT1> on <ENT2>fatty acid synthase</ENT2>, colon cancer proliferation and apoptosis.",,,,T,,,,,c,,,,,1.0,,
28260110,3786,D004642,2194,Negative_Correlation,TRUE,The present study was performed to investigate whether the gene expression of <ENT2>FASN</ENT2> and its enzymatic activity are regulated by <ENT1>emodin</ENT1> in a human colon cancer cell line.,,,,T,,Y,,,c,,,,,1.0,,
28260110,3786,D004642,2194,Negative_Correlation,TRUE,"<ENT1>Emodin</ENT1> markedly inhibited the proliferation of HCT116 cells and a higher protein level of <ENT2>FASN</ENT2> was expressed, compared with that in SW480, SNU-C2A or SNU-C5 cells.",,,,T,,,,,w,,,,,1.0,,
28260110,3786,D004642,2194,Negative_Correlation,TRUE,"<ENT1>Emodin</ENT1> significantly downregulated the protein expression of <ENT2>FASN</ENT2> in HCT116 cells, which was caused by protein degradation due to elevated protein ubiquitination.",,,,T,,,,,c,,,,,1.0,,
28260110,3786,D004642,2194,Negative_Correlation,TRUE,<ENT1>Emodin</ENT1> also inhibited intracellular <ENT2>FASN</ENT2> enzymatic activity and reduced the levels of intracellular free fatty acids.,,,,T,,,,,c,,,,,1.0,,
28260110,3786,D004642,2194,Negative_Correlation,TRUE,"The combined treatment of <ENT1>emodin</ENT1> and cerulenin, a commercial <ENT2>FASN</ENT2> inhibitor, had an additive effect on these activities.",,,,T,,,,,w,,,,,1.0,,
28260110,3786,D004642,2194,Negative_Correlation,TRUE,"Palmitate, the final product of the <ENT2>FASN</ENT2> reaction, rescued <ENT1>emodin</ENT1>-induced viability and apoptosis.",,,,T,Y,,,,w,,,,,1.0,,
28260110,3786,D004642,2194,Negative_Correlation,TRUE,"In addition, <ENT1>emodin</ENT1> altered <ENT2>FASN</ENT2>-involved signaling pathways, including phosphatidylinositol 3-kinase/Akt and mitogen-activated protein kinases/extracellular signal-regulated kinases 1/2.",,,,T,,,,,w,,,,,0.0,,
28260110,3786,D004642,2194,Negative_Correlation,TRUE,These results suggested that <ENT1>emodin</ENT1>-regulated cell growth and apoptosis were mediated by inhibiting <ENT2>FASN</ENT2> and provide a molecular basis for colon cancer therapy.,,,,T,,,,,c,,,,,1.0,,
28260110,3789,D004642,207,Association,TRUE,"In addition, <ENT1>emodin</ENT1> altered FASN-involved signaling pathways, including phosphatidylinositol 3-kinase/<ENT2>Akt</ENT2> and mitogen-activated protein kinases/extracellular signal-regulated kinases 1/2.",,,,T,,,,,c,,,,,1.0,,
28260110,3791,D004642,D002569,Cotreatment,TRUE,"The combined treatment of <ENT1>emodin</ENT1> and <ENT2>cerulenin</ENT2>, a commercial FASN inhibitor, had an additive effect on these activities.",,,,T,,,,,c,,,,,0.0,,
28260110,3794,D004642,D009369,Negative_Correlation,FALSE,"<ENT1>Emodin</ENT1>, a naturally occurring anthraquinone, exhibits an anticancer effect in various types of human <ENT2>cancer</ENT2>, including colon cancer; however, the molecular mechanisms remain to be fully elucidated.",,,,T,,,,,c,,,,,0.0,,
28260110,3784,D009249,2194,Association,FALSE,"<ENT2>FASN</ENT2> activity was measured by monitoring oxidation of <ENT1>nicotinamide adenine dinucleotide phosphate</ENT1> at a wavelength of 340 nm, and intracellular free fatty acid levels were detected using a Free Fatty Acid Quantification kit.",,,,T,,,,,c,,,,,1.0,,
28260110,3775,D010168,2194,Association,FALSE,"<ENT1>Palmitate</ENT1>, the final product of the <ENT2>FASN</ENT2> reaction, rescued emodin-induced viability and apoptosis.",,,,T,,,,,c,,,,,1.0,,
28260110,3781,5594,2194,Association,FALSE,"In addition, emodin altered <ENT2>FASN</ENT2>-involved signaling pathways, including phosphatidylinositol 3-kinase/Akt and <ENT1>mitogen-activated protein kinases/extracellular signal-regulated kinases 1/2</ENT1>.",,,,T,,,,,c,,,,,0.0,,
28260110,3783,5291,2194,Association,FALSE,"In addition, emodin altered <ENT2>FASN</ENT2>-involved signaling pathways, including <ENT1>phosphatidylinositol 3-kinase</ENT1>/Akt and mitogen-activated protein kinases/extracellular signal-regulated kinases 1/2.",,,,T,,,,,c,,,,,0.0,,
28260110,3785,D015179,2194,Association,FALSE,"Inhibitory effect of emodin on <ENT2>fatty acid synthase</ENT2>, <ENT1>colon cancer</ENT1> proliferation and apoptosis.",,,,T,,,,,c,,,,,1.0,,
28260110,3785,D015179,2194,Association,FALSE,"<ENT2>Fatty acid synthase</ENT2> (<ENT2>FASN</ENT2>) is a key anabolic enzyme for de novo fatty acid synthesis, which is important in the development of <ENT1>colon carcinoma</ENT1>.",,,,T,,,,,w,,,,,1.0,,
28260110,3785,D015179,2194,Association,FALSE,The high expression of <ENT2>FASN</ENT2> is considered a promising molecular target for <ENT1>colon cancer</ENT1> therapy.,,,,T,,,,,c,,,,,1.0,,
28260110,3785,D015179,2194,Association,FALSE,The present study was performed to investigate whether the gene expression of <ENT2>FASN</ENT2> and its enzymatic activity are regulated by emodin in a human <ENT1>colon cancer</ENT1> cell line.,,,,T,,Y,,,c,,,,,1.0,,
28260110,3785,D015179,2194,Association,FALSE,These results suggested that emodin-regulated cell growth and apoptosis were mediated by inhibiting <ENT2>FASN</ENT2> and provide a molecular basis for <ENT1>colon cancer</ENT1> therapy.,,,,T,,,,,c,,,,,0.0,,
28260110,3774,D015179,D005227,Association,FALSE,"Fatty acid synthase (FASN) is a key anabolic enzyme for de novo <ENT2>fatty acid</ENT2> synthesis, which is important in the development of <ENT1>colon carcinoma</ENT1>.",,,,T,,,,,c,,,,,1.0,,
28260110,3782,2194,207,Association,FALSE,"In addition, emodin altered <ENT1>FASN</ENT1>-involved signaling pathways, including phosphatidylinositol 3-kinase/<ENT2>Akt</ENT2> and mitogen-activated protein kinases/extracellular signal-regulated kinases 1/2.",,,,T,,,,,c,,,,,0.0,,
28260110,3777,2194,D002569,Negative_Correlation,FALSE,"The combined treatment of emodin and <ENT2>cerulenin</ENT2>, a commercial <ENT1>FASN</ENT1> inhibitor, had an additive effect on these activities.",,,,T,,,,,c,,,,,1.0,,
28260110,3779,2194,D005227,Association,FALSE,"<ENT1>Fatty acid synthase</ENT1> (<ENT1>FASN</ENT1>) is a key anabolic enzyme for de novo <ENT2>fatty acid</ENT2> synthesis, which is important in the development of colon carcinoma.",,,,T,,,,,c,,,,,1.0,,
28346429,3801,22339,20869,Negative_Correlation,TRUE,Deletion of endothelial cell-specific <ENT2>liver kinase B1</ENT2> increases angiogenesis and tumor growth via <ENT1>vascular endothelial growth factor</ENT1>.,,,,T,,,,,w,,,,,1.0,,
28346429,3801,22339,20869,Negative_Correlation,TRUE,<ENT1>Vascular endothelial growth factor</ENT1> (<ENT1>VEGF</ENT1>) level was highly co-stained in endothelial cells but not in macrophages in <ENT2>LKB1</ENT2>(endo-/-) mice.,,,,T,,,,,w,,,,,1.0,TRUE,
28346429,3801,22339,20869,Negative_Correlation,TRUE,"Furthermore, <ENT2>LKB1</ENT2> deletion enhanced mouse retinal and cell angiogenesis, and knockdown of <ENT1>VEGF</ENT1> by small-interfering RNA decreased endothelial cell proliferation and migration.",,,,T,,,,,w,,,,,1.0,,
28346429,3801,22339,20869,Negative_Correlation,TRUE,"Mechanistically, <ENT2>LKB1</ENT2> could bind to the <ENT1>VEGF</ENT1> transcription factor, specificity protein 1 (Sp1), which then inhibited the binding of Sp1 to the <ENT1>VEGF</ENT1> promoter to reduce <ENT1>VEGF</ENT1> expression.",,,,T,,,,,c,,,,,0.666666667,,
28346429,3801,22339,20869,Negative_Correlation,TRUE,Endothelial <ENT2>LKB1</ENT2> may regulate endothelial angiogenesis and tumor growth by modulating Sp1-mediated <ENT1>VEGF</ENT1> expression.,,,,T,,,,,w,,,,,0.0,,
28346429,3796,22339,20683,Association,FALSE,"Mechanistically, LKB1 could bind to the <ENT1>VEGF</ENT1> transcription factor, <ENT2>specificity protein 1</ENT2> (<ENT2>Sp1</ENT2>), which then inhibited the binding of <ENT2>Sp1</ENT2> to the <ENT1>VEGF</ENT1> promoter to reduce <ENT1>VEGF</ENT1> expression.",,,,T,,,,,w,,,,,0.666666667,,
28346429,3796,22339,20683,Association,FALSE,Endothelial LKB1 may regulate endothelial angiogenesis and tumor growth by modulating <ENT2>Sp1</ENT2>-mediated <ENT1>VEGF</ENT1> expression.,,,,T,,,,,c,,,,,1.0,,
28346429,3797,22339,D009369,Association,TRUE,Deletion of endothelial cell-specific liver kinase B1 increases angiogenesis and <ENT2>tumor</ENT2> growth via <ENT1>vascular endothelial growth factor</ENT1>.,,,,T,,,,,c,,,,,0.0,,
28346429,3797,22339,D009369,Association,TRUE,Injection of <ENT1>VEGF</ENT1>-neutralizing antibody but not the isotype-matched control antibody decreased endothelial-cell angiogenesis and <ENT2>tumor</ENT2> growth in vivo.,,,,T,,,,,w,,,,,0.0,,
28346429,3797,22339,D009369,Association,TRUE,Endothelial LKB1 may regulate endothelial angiogenesis and <ENT2>tumor</ENT2> growth by modulating Sp1-mediated <ENT1>VEGF</ENT1> expression.,,,,T,,,,,c,,,,,1.0,,
28346429,3795,20869,16542,Association,TRUE,Re-expression of <ENT1>LKB1</ENT1> or knockdown of <ENT2>VEGF receptor 2</ENT2> decreased the overproliferation and -migration observed in <ENT1>LKB1</ENT1>(endo-/-) cells.,,,,T,,,,,w,,,,,1.0,TRUE,
28346429,3800,20869,20683,Bind,TRUE,"Mechanistically, <ENT1>LKB1</ENT1> could bind to the VEGF transcription factor, <ENT2>specificity protein 1</ENT2> (<ENT2>Sp1</ENT2>), which then inhibited the binding of <ENT2>Sp1</ENT2> to the VEGF promoter to reduce VEGF expression.",,,,T,,,,,c,,,,,0.0,,
28346429,3800,20869,20683,Bind,TRUE,Endothelial <ENT1>LKB1</ENT1> may regulate endothelial angiogenesis and tumor growth by modulating <ENT2>Sp1</ENT2>-mediated VEGF expression.,,,,T,,,,,w,,,,,1.0,,
28346429,3802,20869,D009369,Negative_Correlation,TRUE,Deletion of endothelial cell-specific <ENT1>liver kinase B1</ENT1> increases angiogenesis and <ENT2>tumor</ENT2> growth via vascular endothelial growth factor.,,,,T,,,,,c,,,,,1.0,,
28346429,3802,20869,D009369,Negative_Correlation,TRUE,Whether endothelial <ENT1>LKB1</ENT1> regulates angiogenesis and <ENT2>tumor</ENT2> growth is unknown.,,,,T,,Y,,,c,,,,,1.0,,
28346429,3802,20869,D009369,Negative_Correlation,TRUE,<ENT2>Tumors</ENT2> implanted in <ENT1>LKB1</ENT1>(endo-/-) mice but not macrophage-specific <ENT1>LKB1</ENT1>-knockout mice grew faster and showed enhanced vascular permeability and increased angiogenesis as compared with those implanted in wild-type mice.,,,,T,,,,,w,,,,,0.5,,
28346429,3802,20869,D009369,Negative_Correlation,TRUE,Endothelial <ENT1>LKB1</ENT1> may regulate endothelial angiogenesis and <ENT2>tumor</ENT2> growth by modulating Sp1-mediated VEGF expression.,,,,T,,,,,w,,,,,0.0,,
28346429,3798,20683,D009369,Association,TRUE,Endothelial LKB1 may regulate endothelial angiogenesis and <ENT2>tumor</ENT2> growth by modulating <ENT1>Sp1</ENT1>-mediated VEGF expression.,,,,T,,,,,c,,,,,0.0,,
28368423,3809,C551803,695,Negative_Correlation,FALSE,"Notably, Myc-overexpressing B cells maintained elevated BCR signaling despite treatment with <ENT1>ibrutinib</ENT1>, a <ENT2>Bruton's tyrosine kinase</ENT2> inhibitor.",,,,T,,,,,c,,,,,1.0,,
28368423,3811,C551803,16019,Association,FALSE,"Notably, Myc-overexpressing B cells maintained elevated <ENT2>BCR</ENT2> signaling despite treatment with <ENT1>ibrutinib</ENT1>, a Bruton's tyrosine kinase inhibitor.",,,,T,,,,,c,,,,,0.0,,
28368423,3811,C551803,16019,Association,FALSE,"In addition, experiments with Btk-null B cells revealed off-target effects of <ENT1>ibrutinib</ENT1> on <ENT2>BCR</ENT2> signaling.",,,,T,,,,,c,,,,,1.0,,
28368423,3810,C551803,17869,Association,TRUE,"Notably, <ENT2>Myc</ENT2>-overexpressing B cells maintained elevated BCR signaling despite treatment with <ENT1>ibrutinib</ENT1>, a Bruton's tyrosine kinase inhibitor.",,,,T,,,,,c,,,,,1.0,,
28368423,3810,C551803,17869,Association,TRUE,"Furthermore, PI3K/Akt pathway signaling was also increased in Eu-<ENT2>myc</ENT2> B cells, and this increase was partially suppressed with <ENT1>ibrutinib</ENT1>.",,,,T,,,,,w,,,,,1.0,,
28368423,3807,C551803,18708,Negative_Correlation,FALSE,"Furthermore, <ENT2>PI3K</ENT2>/Akt pathway signaling was also increased in Eu-myc B cells, and this increase was partially suppressed with <ENT1>ibrutinib</ENT1>.",,,,T,,,,,c,,,,,1.0,,
28368423,3804,C551803,11651,Negative_Correlation,FALSE,"Furthermore, PI3K/<ENT2>Akt</ENT2> pathway signaling was also increased in Eu-myc B cells, and this increase was partially suppressed with <ENT1>ibrutinib</ENT1>.",,,,T,,,,,c,,,,,1.0,,
28368423,3817,12518,17869,Positive_Correlation,TRUE,"B cells overexpressing <ENT2>Myc</ENT2> displayed constitutively higher levels of activated <ENT1>CD79a</ENT1>, Btk, Plcg2 and Erk1/2.",,,,T,,,,,c,,,,,1.0,,
28368423,3820,16019,17869,Positive_Correlation,TRUE,<ENT2>Myc</ENT2> enhances <ENT1>B-cell receptor</ENT1> signaling in precancerous B cells and confers resistance to Btk inhibition.,,,,T,,,,,c,,,,,1.0,,
28368423,3820,16019,17869,Positive_Correlation,TRUE,"Although genomic studies suggest a link between <ENT2>MYC</ENT2> overexpression and <ENT1>B-cell receptor</ENT1> (<ENT1>BCR</ENT1>) signaling molecules in B-NHL, signaling pathways essential to <ENT2>Myc</ENT2>-mediated B-cell transformation have not been fully elucidated.",,,,T,,,,,w,,,,,0.5,,
28368423,3820,16019,17869,Positive_Correlation,TRUE,We utilized intracellular phospho-flow cytometry to investigate the relationship between <ENT2>Myc</ENT2> and <ENT1>BCR</ENT1> signaling in pre-malignant B cells.,,,,T,,Y,,,c,,,,,1.0,,
28368423,3820,16019,17869,Positive_Correlation,TRUE,"Utilizing the Eu-<ENT2>myc</ENT2> mouse model, where <ENT2>Myc</ENT2> is overexpressed specifically in B cells, both basal and stimulated <ENT1>BCR</ENT1> signaling were increased in precancerous B lymphocytes from Eu-<ENT2>myc</ENT2> mice compared with wild-type littermates.",,,,T,,,,,c,,,,,0.0,,
28368423,3820,16019,17869,Positive_Correlation,TRUE,"Notably, <ENT2>Myc</ENT2>-overexpressing B cells maintained elevated <ENT1>BCR</ENT1> signaling despite treatment with ibrutinib, a Bruton's tyrosine kinase inhibitor.",,,,T,,,,,w,,,,,0.0,,
28368423,3820,16019,17869,Positive_Correlation,TRUE,"Our data show that in pre-malignant B cells, <ENT2>Myc</ENT2> overexpression is sufficient to activate <ENT1>BCR</ENT1> and PI3K/Akt signaling pathways and further enhances signaling following <ENT1>BCR</ENT1> ligation.",,,,T,,,,,c,,,,,0.5,,
28368423,3820,16019,17869,Positive_Correlation,TRUE,"Therefore, our results indicate that precancerous B cells have already acquired enhanced survival and growth capabilities before transformation, and that elevated <ENT2>MYC</ENT2> levels confer resistance to pharmacologic inhibitors of <ENT1>BCR</ENT1> signaling, which has significant implications for B-NHL treatment.",,,,T,,,,,w,,,,,0.0,,
28368423,3803,16019,D016393,Association,TRUE,"Although genomic studies suggest a link between MYC overexpression and <ENT1>B-cell receptor</ENT1> (<ENT1>BCR</ENT1>) signaling molecules in <ENT2>B-NHL</ENT2>, signaling pathways essential to Myc-mediated B-cell transformation have not been fully elucidated.",,,,T,,,,,c,,,,,1.0,,
28368423,3803,16019,D016393,Association,TRUE,"Therefore, our results indicate that precancerous B cells have already acquired enhanced survival and growth capabilities before transformation, and that elevated MYC levels confer resistance to pharmacologic inhibitors of <ENT1>BCR</ENT1> signaling, which has significant implications for <ENT2>B-NHL</ENT2> treatment.",,,,T,,,,,c,,,,,0.0,,
28368423,3812,16019,D011230,Association,TRUE,Myc enhances <ENT1>B-cell receptor</ENT1> signaling in <ENT2>precancerous</ENT2> B cells and confers resistance to Btk inhibition.,,,,T,,,,,c,,,,,0.0,,
28368423,3812,16019,D011230,Association,TRUE,"Utilizing the Eu-myc mouse model, where Myc is overexpressed specifically in B cells, both basal and stimulated <ENT1>BCR</ENT1> signaling were increased in <ENT2>precancerous</ENT2> B lymphocytes from Eu-myc mice compared with wild-type littermates.",,,,T,,,,,w,,,,,0.0,,
28368423,3812,16019,D011230,Association,TRUE,"Therefore, our results indicate that <ENT2>precancerous</ENT2> B cells have already acquired enhanced survival and growth capabilities before transformation, and that elevated MYC levels confer resistance to pharmacologic inhibitors of <ENT1>BCR</ENT1> signaling, which has significant implications for B-NHL treatment.",,,,T,,,,,c,,,,,1.0,,
28368423,3818,17869,12229,Positive_Correlation,TRUE,<ENT1>Myc</ENT1> enhances B-cell receptor signaling in precancerous B cells and confers resistance to <ENT2>Btk</ENT2> inhibition.,,,,T,,,,,c,,,,,0.0,,
28368423,3818,17869,12229,Positive_Correlation,TRUE,"B cells overexpressing <ENT1>Myc</ENT1> displayed constitutively higher levels of activated CD79a, <ENT2>Btk</ENT2>, Plcg2 and Erk1/2.",,,,T,,,,,c,,,,,1.0,,
28368423,3808,17869,18708,Positive_Correlation,TRUE,"Furthermore, <ENT2>PI3K</ENT2>/Akt pathway signaling was also increased in Eu-<ENT1>myc</ENT1> B cells, and this increase was partially suppressed with ibrutinib.",,,,T,,,,,w,,,,,0.0,,
28368423,3808,17869,18708,Positive_Correlation,TRUE,"Our data show that in pre-malignant B cells, <ENT1>Myc</ENT1> overexpression is sufficient to activate BCR and <ENT2>PI3K</ENT2>/Akt signaling pathways and further enhances signaling following BCR ligation.",,,,T,,,,,c,,,,,1.0,,
28368423,3814,17869,26417,Positive_Correlation,TRUE,"B cells overexpressing <ENT1>Myc</ENT1> displayed constitutively higher levels of activated CD79a, Btk, Plcg2 and <ENT2>Erk1/2</ENT2>.",,,,T,,,,,c,,,,,1.0,,
28368423,3813,17869,D016393,Association,FALSE,Dysregulation of the oncogenic transcription factor <ENT1>MYC</ENT1> induces B-cell transformation and is a driver for <ENT2>B-cell non-Hodgkin lymphoma</ENT2> (<ENT2>B-NHL</ENT2>).,,,,T,,,,,c,,,,,1.0,,
28368423,3813,17869,D016393,Association,FALSE,<ENT1>MYC</ENT1> overexpression in <ENT2>B-NHL</ENT2> is associated with more aggressive phenotypes and poor prognosis.,,,,T,,,,,w,,,,,0.0,,
28368423,3813,17869,D016393,Association,FALSE,"Although genomic studies suggest a link between <ENT1>MYC</ENT1> overexpression and B-cell receptor (BCR) signaling molecules in <ENT2>B-NHL</ENT2>, signaling pathways essential to <ENT1>Myc</ENT1>-mediated B-cell transformation have not been fully elucidated.",,,,T,,,,,c,,,,,0.5,,
28368423,3813,17869,D016393,Association,FALSE,"Therefore, our results indicate that precancerous B cells have already acquired enhanced survival and growth capabilities before transformation, and that elevated <ENT1>MYC</ENT1> levels confer resistance to pharmacologic inhibitors of BCR signaling, which has significant implications for <ENT2>B-NHL</ENT2> treatment.",,,,T,,,,,c,,,,,0.0,,
28368423,3816,17869,234779,Positive_Correlation,TRUE,"B cells overexpressing <ENT1>Myc</ENT1> displayed constitutively higher levels of activated CD79a, Btk, <ENT2>Plcg2</ENT2> and Erk1/2.",,,,T,,,,,c,,,,,1.0,,
28368423,3805,17869,11651,Positive_Correlation,TRUE,"Furthermore, PI3K/<ENT2>Akt</ENT2> pathway signaling was also increased in Eu-<ENT1>myc</ENT1> B cells, and this increase was partially suppressed with ibrutinib.",,,,T,,,,,w,,,,,1.0,,
28368423,3805,17869,11651,Positive_Correlation,TRUE,"Our data show that in pre-malignant B cells, <ENT1>Myc</ENT1> overexpression is sufficient to activate BCR and PI3K/<ENT2>Akt</ENT2> signaling pathways and further enhances signaling following BCR ligation.",,,,T,,,,,c,,,,,0.0,,
28368423,3819,17869,D011230,Association,TRUE,<ENT1>Myc</ENT1> enhances B-cell receptor signaling in <ENT2>precancerous</ENT2> B cells and confers resistance to Btk inhibition.,,,,T,,,,,c,,,,,1.0,,
28368423,3819,17869,D011230,Association,TRUE,"Utilizing the Eu-<ENT1>myc</ENT1> mouse model, where <ENT1>Myc</ENT1> is overexpressed specifically in B cells, both basal and stimulated BCR signaling were increased in <ENT2>precancerous</ENT2> B lymphocytes from Eu-<ENT1>myc</ENT1> mice compared with wild-type littermates.",,,,T,,,,,w,,,,,0.333333333,TRUE,
28368423,3819,17869,D011230,Association,TRUE,"Therefore, our results indicate that <ENT2>precancerous</ENT2> B cells have already acquired enhanced survival and growth capabilities before transformation, and that elevated <ENT1>MYC</ENT1> levels confer resistance to pharmacologic inhibitors of BCR signaling, which has significant implications for B-NHL treatment.",,,,T,,,,,c,,,,,0.0,,
28368423,3806,18708,11651,Association,FALSE,"Furthermore, <ENT1>PI3K</ENT1>/<ENT2>Akt</ENT2> pathway signaling was also increased in Eu-myc B cells, and this increase was partially suppressed with ibrutinib.",,,,T,,,,,c,,,,,0.0,,
28368423,3806,18708,11651,Association,FALSE,"Our data show that in pre-malignant B cells, Myc overexpression is sufficient to activate BCR and <ENT1>PI3K</ENT1>/<ENT2>Akt</ENT2> signaling pathways and further enhances signaling following BCR ligation.",,,,T,,,,,c,,,,,0.0,,
28368537,3821,16880,17701,Positive_Correlation,TRUE,The loss of <ENT1>Lifr</ENT1> results in both the failure for STAT3 to translocate to the LE nuclei and a reduction in the expression of the LIF regulated gene <ENT2>Msx1</ENT2> that regulates uterine receptivity.,,,,T,,,,,c,,,,,0.0,,
28368537,3823,16880,16878,Bind,FALSE,"<ENT2>LIF</ENT2>, secreted from the endometrial glands (GEs), binds to the <ENT1>LIFR</ENT1>, activating the Janus kinase-signal transducer and activation of transcription (STAT) 3 (Jak-Stat3) signaling pathway in the LE.",,,,T,,,,,c,,,,,1.0,,
28368537,3823,16880,16878,Bind,FALSE,"To specifically delete the <ENT1>LIFR</ENT1> in the LE, we derived a line of mice in which Cre recombinase was inserted into the endogenous lactoferrin gene (<ENT2>Ltf</ENT2>-Cre).",,,,T,,,,,c,,,,,1.0,,
28368537,3823,16880,16878,Bind,FALSE,Crossing <ENT2>Ltf</ENT2>-Cre mice with <ENT1>Lifr</ENT1> flx/flx mice generated <ENT1>Lifr</ENT1> flx/D:<ENT2>Ltf</ENT2> Cre/+ females that were overtly normal but infertile.,,,,T,,,,,c,,,,,1.0,,
28368537,3823,16880,16878,Bind,FALSE,"Unimplanted blastocysts were recovered from the <ENT1>Lifr</ENT1> flx/D:<ENT2>Ltf</ENT2> Cre/+ uteri and, when transferred to wild-type recipients, implanted normally, indicating that uterine receptivity rather than the embryo's competency is compromised.",,,,T,,,,,c,,,,,1.0,,
28368537,3823,16880,16878,Bind,FALSE,The loss of <ENT1>Lifr</ENT1> results in both the failure for STAT3 to translocate to the LE nuclei and a reduction in the expression of the <ENT2>LIF</ENT2> regulated gene Msx1 that regulates uterine receptivity.,,,,T,,,,,w,,,,,0.0,,
28368537,3823,16880,16878,Bind,FALSE,These results reveal that uterine expression of the <ENT1>LIFR</ENT1> is essential for embryo implantation and further define the components of the <ENT2>LIF</ENT2> signaling pathway necessary for effective implantation.,,,,T,,,,,w,,,,,1.0,,
28368537,3824,16880,20848,Association,TRUE,"LIF, secreted from the endometrial glands (GEs), binds to the <ENT1>LIFR</ENT1>, activating the Janus kinase-<ENT2>signal transducer and activation of transcription (STAT) 3</ENT2> (Jak-<ENT2>Stat3</ENT2>) signaling pathway in the LE.",,,,T,,,,,w,,,,,0.0,,
28368537,3824,16880,20848,Association,TRUE,The loss of <ENT1>Lifr</ENT1> results in both the failure for <ENT2>STAT3</ENT2> to translocate to the LE nuclei and a reduction in the expression of the LIF regulated gene Msx1 that regulates uterine receptivity.,,,,T,,,,,c,,,,,1.0,,
28368537,3826,16880,16452,Association,FALSE,"LIF, secreted from the endometrial glands (GEs), binds to the <ENT1>LIFR</ENT1>, activating the <ENT2>Janus kinase</ENT2>-signal transducer and activation of transcription (STAT) 3 (<ENT2>Jak</ENT2>-Stat3) signaling pathway in the LE.",,,,T,,,,,w,,,,,0.0,,
28368537,3822,17701,16878,Association,FALSE,The loss of Lifr results in both the failure for STAT3 to translocate to the LE nuclei and a reduction in the expression of the <ENT2>LIF</ENT2> regulated gene <ENT1>Msx1</ENT1> that regulates uterine receptivity.,,,,T,,,,,c,,,,,1.0,,
28368537,3825,16878,20848,Association,FALSE,"<ENT1>LIF</ENT1>, secreted from the endometrial glands (GEs), binds to the LIFR, activating the Janus kinase-<ENT2>signal transducer and activation of transcription (STAT) 3</ENT2> (Jak-<ENT2>Stat3</ENT2>) signaling pathway in the LE.",,,,T,,,,,c,,,,,0.0,,
28368537,3825,16878,20848,Association,FALSE,The loss of Lifr results in both the failure for <ENT2>STAT3</ENT2> to translocate to the LE nuclei and a reduction in the expression of the <ENT1>LIF</ENT1> regulated gene Msx1 that regulates uterine receptivity.,,,,T,,,,,c,,,,,1.0,,
28368537,3827,16878,16452,Association,FALSE,"<ENT1>LIF</ENT1>, secreted from the endometrial glands (GEs), binds to the LIFR, activating the <ENT2>Janus kinase</ENT2>-signal transducer and activation of transcription (STAT) 3 (<ENT2>Jak</ENT2>-Stat3) signaling pathway in the LE.",,,,T,,,,,c,,,,,0.0,,
28368537,3828,20848,16452,Association,FALSE,"LIF, secreted from the endometrial glands (GEs), binds to the LIFR, activating the <ENT2>Janus kinase</ENT2>-<ENT1>signal transducer and activation of transcription (STAT) 3</ENT1> (<ENT2>Jak</ENT2>-<ENT1>Stat3</ENT1>) signaling pathway in the LE.",,,,T,,,,,w,,,"11,22",,0.0,,
28368537,3828,20848,16452,Association,FALSE,<ENT2>JAK</ENT2>-<ENT1>STAT</ENT1> activation converts the LE to a receptive state so that juxtaposed blastocysts begin to implant.,,,,T,,,,,w,,,,,0.0,,
28393239,3834,D011565,6278,Association,FALSE,<ENT2>Psoriasin</ENT2> (<ENT2>S100A7</ENT2>) is an 11-kDa small <ENT2>calcium binding protein</ENT2> initially isolated from <ENT1>psoriatic skin lesions</ENT1>.,,,,T,,,,,c,,,,,0.666666667,,
28393239,3835,6278,D010190,Positive_Correlation,TRUE,"<ENT1>Psoriasin</ENT1> promotes invasion, aggregation and survival of <ENT2>pancreatic cancer</ENT2> cells; association with disease progression.",,,,T,,,,,c,,,,,0.0,,
28393239,3835,6278,D010190,Positive_Correlation,TRUE,This study examined the role of <ENT1>Psoriasin</ENT1> on <ENT2>pancreatic cancer</ENT2> cell functions and the implication in progression of the disease.,,,,T,,Y,,,c,,,,,1.0,,
28393239,3835,6278,D010190,Positive_Correlation,TRUE,Expression of <ENT1>Psoriasin</ENT1> was determined in a cohort of pancreatic tissues comprised of 126 <ENT2>pancreatic tumours</ENT2> and 114 adjacent non-tumour pancreatic tissues.,,,,T,,Y,,,c,,,,,1.0,,
28393239,3835,6278,D010190,Positive_Correlation,TRUE,"Knockdown and overexpression of <ENT1>Psoriasin</ENT1> in <ENT2>pancreatic cancer</ENT2> cells was performed using specifically constructed plasmids, which either had anti-<ENT1>Psoriasin</ENT1> ribozyme transgene or the full length human <ENT1>Psoriasin</ENT1> coding sequence.",,,,T,,,,,w,,,,,0.0,,
28393239,3835,6278,D010190,Positive_Correlation,TRUE,The effect of manipulating <ENT1>Psoriasin</ENT1> expression on <ENT2>pancreatic cancer</ENT2> cell functions was assessed using several in vitro cell function assays.,,,,T,,Y,,,c,,,,,1.0,,
28393239,3835,6278,D010190,Positive_Correlation,TRUE,Local invasive <ENT2>pancreatic cancers</ENT2> extended beyond the pancreas expressed higher levels of <ENT1>Psoriasin</ENT1> transcripts compared with the cancers confined to the pancreas.,,,,T,,,,,c,,,,,0.0,,
28393239,3835,6278,D010190,Positive_Correlation,TRUE,"In addition, <ENT1>Psoriasin</ENT1> overexpression resulted in increased <ENT2>pancreatic cancer</ENT2> cell invasion which was associated with upregulation of matrix metalloproteinase-2 (MMP-2) and MMP-9.",,,,T,,,,,c,,,,,0.0,,
28393239,3835,6278,D010190,Positive_Correlation,TRUE,Overexpression of <ENT1>Psoriasin</ENT1> also promoted aggregation and survival of <ENT2>pancreatic cancer</ENT2> cells when they lost anchorage.,,,,T,,,,,c,,,,,0.0,,
28393239,3835,6278,D010190,Positive_Correlation,TRUE,"Taken together, higher expression of <ENT1>Psoriasin</ENT1> was associated with local invasion in <ENT2>pancreatic cancers</ENT2>.",,,,T,,,,,w,,,,,0.0,,
28393239,3835,6278,D010190,Positive_Correlation,TRUE,"<ENT1>Psoriasin</ENT1> expression is associated with <ENT2>pancreatic cancer</ENT2> cell growth, migration, cell-matrix adhesion, and invasion via regulation of MMPs.",,,,T,,,,,w,,,,,0.0,,
28393239,3832,6278,4318,Positive_Correlation,TRUE,"In addition, <ENT1>Psoriasin</ENT1> overexpression resulted in increased pancreatic cancer cell invasion which was associated with upregulation of matrix metalloproteinase-2 (MMP-2) and <ENT2>MMP-9</ENT2>.",,,,T,,,,,c,,,,,0.0,,
28393239;28393239,3832;3833,6278;6278,4318;4313,Positive_Correlation;Positive_Correlation,TRUE;TRUE,"<ENT1>Psoriasin</ENT1> expression is associated with pancreatic cancer cell growth, migration, cell-matrix adhesion, and invasion via regulation of <ENT2>MMPs</ENT2>.",,,,T,,,,,w,,,,,0.0,,
28393239,3831,6278,D009369,Association,FALSE,Aberrant <ENT1>Psoriasin</ENT1> expression has been implicated in a range of <ENT2>cancers</ENT2> and is often associated with poor prognosis.,,,,T,,,,,c,,,,,1.0,,
28393239,3831,6278,D009369,Association,FALSE,Local invasive pancreatic cancers extended beyond the pancreas expressed higher levels of <ENT1>Psoriasin</ENT1> transcripts compared with the <ENT2>cancers</ENT2> confined to the pancreas.,,,,T,,,,,c,,,,,1.0,,
28393239,3831,6278,D009369,Association,FALSE,<ENT2>Primary tumours</ENT2> with distant metastases exhibited a reduced expression of <ENT1>Psoriasin</ENT1>.,,,,T,,,,,c,,,,,0.0,,
28393239,3833,6278,4313,Positive_Correlation,TRUE,"In addition, <ENT1>Psoriasin</ENT1> overexpression resulted in increased pancreatic cancer cell invasion which was associated with upregulation of <ENT2>matrix metalloproteinase-2</ENT2> (<ENT2>MMP-2</ENT2>) and MMP-9.",,,,T,,,,,c,,,,,1.0,,
28393239,3829,D010190,4318,Positive_Correlation,TRUE,"In addition, Psoriasin overexpression resulted in increased <ENT1>pancreatic cancer</ENT1> cell invasion which was associated with upregulation of matrix metalloproteinase-2 (MMP-2) and <ENT2>MMP-9</ENT2>.",,,,T,,,,,c,,,,,0.0,,
28393239;28393239,3829;3830,D010190;D010190,4318;4313,Positive_Correlation;Positive_Correlation,TRUE;TRUE,"Psoriasin expression is associated with <ENT1>pancreatic cancer</ENT1> cell growth, migration, cell-matrix adhesion, and invasion via regulation of <ENT2>MMPs</ENT2>.",,,,T,,,,,c,,,,,0.0,,
28393239,3830,D010190,4313,Positive_Correlation,TRUE,"In addition, Psoriasin overexpression resulted in increased <ENT1>pancreatic cancer</ENT1> cell invasion which was associated with upregulation of <ENT2>matrix metalloproteinase-2</ENT2> (<ENT2>MMP-2</ENT2>) and MMP-9.",,,,T,,,,,c,,,,,0.0,,
28398555,3840,rs550921485,D004421,Positive_Correlation,FALSE,"With the advent of next-generation sequencing technologies, the homozygous mutations T71N and <ENT1>A190T</ENT1> in the neuronal calcium sensor (NCS) hippocalcin were identified as the genetic cause of <ENT2>primary isolated dystonia</ENT2> (DYT2 <ENT2>dystonia</ENT2>).",,,,T,,,,,c,,,,,0.5,,
28398555,3837,774,D011189,Association,FALSE,"In addition, we observed an increased calcium influx in <ENT2>KCl</ENT2>-depolarised cells expressing mutated hippocalcin, mostly driven by <ENT1>N-type voltage-gated calcium channels</ENT1>.",,,,T,,,,,w,,,,,1.0,,
28398555,3842,774,3208,Association,FALSE,"In addition, we observed an increased calcium influx in KCl-depolarised cells expressing mutated <ENT2>hippocalcin</ENT2>, mostly driven by <ENT1>N-type voltage-gated calcium channels</ENT1>.",,,,T,,,,,c,,,,,0.0,,
28398555,3836,774,D002118,Positive_Correlation,TRUE,"In addition, we observed an increased <ENT2>calcium</ENT2> influx in KCl-depolarised cells expressing mutated hippocalcin, mostly driven by <ENT1>N-type voltage-gated calcium channels</ENT1>.",,,,T,,,,,c,,,,,0.0,,
28398555,3845,783,3208,Bind,TRUE,"Using a multidisciplinary approach, we demonstrated that <ENT2>hippocalcin</ENT2> oligomerises in a calcium-dependent manner and binds to <ENT1>voltage-gated calcium channels</ENT1>.",,,,T,,,,,c,,,,,0.0,,
28398555,3841,D004421,rs775863165,Positive_Correlation,FALSE,"With the advent of next-generation sequencing technologies, the homozygous mutations <ENT2>T71N</ENT2> and A190T in the neuronal calcium sensor (NCS) hippocalcin were identified as the genetic cause of <ENT1>primary isolated dystonia</ENT1> (DYT2 <ENT1>dystonia</ENT1>).",,,,T,,,,,c,,,,,1.0,,
28398555,3846,D004421,3208,Association,TRUE,Biophysical and functional characterization of <ENT2>hippocalcin</ENT2> mutants responsible for human <ENT1>dystonia</ENT1>.,,,,T,,,,,c,,,,,1.0,,
28398555,3846,D004421,3208,Association,TRUE,"With the advent of next-generation sequencing technologies, the homozygous mutations T71N and A190T in the <ENT2>neuronal calcium sensor</ENT2> (<ENT2>NCS</ENT2>) <ENT2>hippocalcin</ENT2> were identified as the genetic cause of <ENT1>primary isolated dystonia</ENT1> (<ENT2>DYT2</ENT2> <ENT1>dystonia</ENT1>).",,,,T,,,,,w,,,,,0.5,,
28398555,3846,D004421,3208,Association,TRUE,Our data demonstrate that the <ENT1>dystonia</ENT1>-causing mutations strongly affect <ENT2>hippocalcin</ENT2> cellular functions which suggest a central role for perturbed calcium signalling in <ENT2>DYT2</ENT2> <ENT1>dystonia</ENT1>.,,,,T,,,,,c,,,"11,22",,0.75,,
28398555,3839,D004421,D002118,Association,TRUE,Our data demonstrate that the <ENT1>dystonia</ENT1>-causing mutations strongly affect hippocalcin cellular functions which suggest a central role for perturbed <ENT2>calcium</ENT2> signalling in DYT2 <ENT1>dystonia</ENT1>.,,,,T,,,,,c,,,,,0.5,,
28398555,3843,D011189,3208,Association,FALSE,"In addition, we observed an increased calcium influx in <ENT1>KCl</ENT1>-depolarised cells expressing mutated <ENT2>hippocalcin</ENT2>, mostly driven by N-type voltage-gated calcium channels.",,,,T,,,,,c,,,,,0.0,,
28398555,3838,D011189,D002118,Association,TRUE,"In addition, we observed an increased <ENT2>calcium</ENT2> influx in <ENT1>KCl</ENT1>-depolarised cells expressing mutated hippocalcin, mostly driven by N-type voltage-gated calcium channels.",,,,T,,,,,c,,,,,0.0,,
28398555,3844,3208,D002118,Positive_Correlation,TRUE,"Using a multidisciplinary approach, we demonstrated that <ENT1>hippocalcin</ENT1> oligomerises in a <ENT2>calcium</ENT2>-dependent manner and binds to voltage-gated calcium channels.",,,,T,,,,,c,,,,,0.0,,
28398555,3844,3208,D002118,Positive_Correlation,TRUE,"Mutations T71N and A190T in <ENT1>hippocalcin</ENT1> did not affect stability, <ENT2>calcium</ENT2>-binding affinity or translocation to cellular membranes (Ca2+/myristoyl switch).",,,,T,,,,,c,,,,,1.0,,
28398555,3844,3208,D002118,Positive_Correlation,TRUE,"In addition, we observed an increased <ENT2>calcium</ENT2> influx in KCl-depolarised cells expressing mutated <ENT1>hippocalcin</ENT1>, mostly driven by N-type voltage-gated calcium channels.",,,,T,,,,,w,,,,,0.0,,
28398555,3844,3208,D002118,Positive_Correlation,TRUE,Our data demonstrate that the dystonia-causing mutations strongly affect <ENT1>hippocalcin</ENT1> cellular functions which suggest a central role for perturbed <ENT2>calcium</ENT2> signalling in <ENT1>DYT2</ENT1> dystonia.,,,,T,,,,,w,,,,,0.5,,
28411266,3852,D003924,rs757110,Negative_Correlation,TRUE,"The <ENT2>p.A1369S</ENT2> variant was associated with a significantly lower risk of <ENT1>type 2 diabetes</ENT1> (odds ratio [OR] 0.93; 95% CI 0.91, 0.95; P = 1.2 x 10(-11)).",,,,T,,,,,c,,,,,1.0,,
28411266,3850,D003924,D013453,Negative_Correlation,FALSE,"Despite widespread clinical use in the treatment of <ENT1>type 2 diabetes</ENT1>, the impact of <ENT2>sulfonylurea</ENT2> therapy on cardiovascular outcomes remains uncertain.",,,,T,,,,,c,,,,,1.0,,
28411266,3848,D003924,6833,Association,TRUE,"Genetic Variation at the <ENT2>Sulfonylurea Receptor</ENT2>, <ENT1>Type 2 Diabetes</ENT1>, and Coronary Heart Disease.",,,,T,,T,,,c,,,,,1.0,,
28411266,3851,rs757110,D003324,Negative_Correlation,TRUE,"Furthermore, <ENT1>p.A1369S</ENT1> was associated with a reduced risk of <ENT2>coronary heart disease</ENT2> (OR 0.98; 95% CI 0.96, 0.99; P = 5.9 x 10(-4)).",,,,T,,,,,c,,,,,1.0,,
28411266,3853,rs757110,D013453,Association,FALSE,"A common missense variant in the gene encoding a component of the sulfonylurea receptor (ABCC8 <ENT1>p.A1369S</ENT1>) promotes closure of the target channel of <ENT2>sulfonylurea</ENT2> therapy and is associated with increased insulin secretion, thus mimicking the effects of <ENT2>sulfonylurea</ENT2> therapy.",,,,T,,,,,w,,,,,0.5,,
28411266,3856,3630,D013453,Positive_Correlation,TRUE,"A common missense variant in the gene encoding a component of the sulfonylurea receptor (ABCC8 p.A1369S) promotes closure of the target channel of <ENT2>sulfonylurea</ENT2> therapy and is associated with increased <ENT1>insulin</ENT1> secretion, thus mimicking the effects of <ENT2>sulfonylurea</ENT2> therapy.",,,,T,,,,,c,,,,,0.5,,
28411266,3855,3630,6833,Positive_Correlation,FALSE,"A common missense variant in the gene encoding a component of the <ENT2>sulfonylurea receptor</ENT2> (<ENT2>ABCC8</ENT2> p.A1369S) promotes closure of the target channel of sulfonylurea therapy and is associated with increased <ENT1>insulin</ENT1> secretion, thus mimicking the effects of sulfonylurea therapy.",,,,T,,,,,c,,,,,0.5,,
28411266,3854,D003324,D013453,Negative_Correlation,TRUE,"These results suggest that, despite a known association with increased weight, long-term <ENT2>sulfonylurea</ENT2> therapy may reduce the risk of <ENT1>coronary heart disease</ENT1>.",,,,T,,,,,c,,,,,1.0,,
28411266,3847,D003324,6833,Association,TRUE,"Genetic Variation at the <ENT2>Sulfonylurea Receptor</ENT2>, Type 2 Diabetes, and <ENT1>Coronary Heart Disease</ENT1>.",,,,T,,T,,,c,,,,,1.0,,
28411266,3849,D013453,6833,Association,FALSE,"A common missense variant in the gene encoding a component of the <ENT2>sulfonylurea receptor</ENT2> (<ENT2>ABCC8</ENT2> p.A1369S) promotes closure of the target channel of <ENT1>sulfonylurea</ENT1> therapy and is associated with increased insulin secretion, thus mimicking the effects of <ENT1>sulfonylurea</ENT1> therapy.",,,,T,,,,,w,,,,,0.5,,
28416580,3872,C002125,D001927,Negative_Correlation,TRUE,"In this study, we determined the impact of a TSPO ligand, <ENT1>etifoxine</ENT1>, on <ENT2>brain injury</ENT2> and inflammation in 2 mouse models of ICH.",,,,T,,Y,,,c,,,,,1.0,,
28416580,3872,C002125,D001927,Negative_Correlation,TRUE,<ENT1>Etifoxine</ENT1> significantly reduced <ENT2>neurodeficits</ENT2> and perihematomal brain edema after ICH induction by injection of either autologous blood or collagenase.,,,,T,,,,,c,,,,,1.0,,
28416580,3872,C002125,D001927,Negative_Correlation,TRUE,These results indicate that the TSPO ligand <ENT1>etifoxine</ENT1> attenuates <ENT2>brain injury</ENT2> and inflammation after ICH.,,,,T,,,,,c,,,,,1.0,,
28416580,3865,C002125,12257,Association,FALSE,"In this study, we determined the impact of a <ENT2>TSPO</ENT2> ligand, <ENT1>etifoxine</ENT1>, on brain injury and inflammation in 2 mouse models of ICH.",,,,T,,,,,c,,,,,0.0,,
28416580,3865,C002125,12257,Association,FALSE,These results indicate that the <ENT2>TSPO</ENT2> ligand <ENT1>etifoxine</ENT1> attenuates brain injury and inflammation after ICH.,,,,T,,,,,c,,,,,0.0,,
28416580,3870,C002125,D002543,Negative_Correlation,TRUE,"In this study, we determined the impact of a TSPO ligand, <ENT1>etifoxine</ENT1>, on brain injury and inflammation in 2 mouse models of <ENT2>ICH</ENT2>.",,,,T,,Y,,,c,,,,,1.0,,
28416580,3870,C002125,D002543,Negative_Correlation,TRUE,<ENT1>Etifoxine</ENT1> significantly reduced neurodeficits and perihematomal brain edema after <ENT2>ICH</ENT2> induction by injection of either autologous blood or collagenase.,,,,T,,,,,c,,,,,0.0,,
28416580,3870,C002125,D002543,Negative_Correlation,TRUE,"In collagenase-induced <ENT2>ICH</ENT2> mice, the protection of <ENT1>etifoxine</ENT1> was associated with reduced leukocyte infiltration into the brain and microglial production of IL-6 and TNF-a.",,,,T,,,,,w,,,,,1.0,,
28416580,3870,C002125,D002543,Negative_Correlation,TRUE,These results indicate that the TSPO ligand <ENT1>etifoxine</ENT1> attenuates brain injury and inflammation after <ENT2>ICH</ENT2>.,,,,T,,,,,c,,,,,0.0,,
28416580,3866,C002125,12978,Association,TRUE,"Notably, the protective effect of <ENT1>etifoxine</ENT1> was abolished in mice depleted of microglia by using a <ENT2>colony-stimulating factor 1 receptor</ENT2> inhibitor.",,,,T,,,,,w,,,,,0.0,,
28416580,3869,C002125,D001929,Negative_Correlation,TRUE,<ENT1>Etifoxine</ENT1> significantly reduced neurodeficits and perihematomal <ENT2>brain edema</ENT2> after ICH induction by injection of either autologous blood or collagenase.,,,,T,,,,,c,,,,,0.0,,
28416580,3871,C002125,D007249,Negative_Correlation,TRUE,"In this study, we determined the impact of a TSPO ligand, <ENT1>etifoxine</ENT1>, on brain injury and <ENT2>inflammation</ENT2> in 2 mouse models of ICH.",,,,T,,Y,,,c,,,,,1.0,,
28416580,3871,C002125,D007249,Negative_Correlation,TRUE,These results indicate that the TSPO ligand <ENT1>etifoxine</ENT1> attenuates brain injury and <ENT2>inflammation</ENT2> after ICH.,,,,T,,,,,c,,,,,1.0,,
28416580,3868,C002125,16193,Positive_Correlation,TRUE,"In collagenase-induced ICH mice, the protection of <ENT1>etifoxine</ENT1> was associated with reduced leukocyte infiltration into the brain and microglial production of <ENT2>IL-6</ENT2> and TNF-a.",,,,T,,,,,c,,,,,0.0,,
28416580,3867,C002125,21926,Positive_Correlation,TRUE,"In collagenase-induced ICH mice, the protection of <ENT1>etifoxine</ENT1> was associated with reduced leukocyte infiltration into the brain and microglial production of IL-6 and <ENT2>TNF-a</ENT2>.",,,,T,,,,,c,,,,,0.0,,
28416580,3864,D001927,12257,Association,FALSE,A <ENT2>TSPO</ENT2> ligand attenuates <ENT1>brain injury</ENT1> after intracerebral hemorrhage.,,,,T,,,,,c,,,,,1.0,,
28416580,3864,D001927,12257,Association,FALSE,"In this study, we determined the impact of a <ENT2>TSPO</ENT2> ligand, etifoxine, on <ENT1>brain injury</ENT1> and inflammation in 2 mouse models of ICH.",,,,T,,,,,c,,,,,1.0,,
28416580,3864,D001927,12257,Association,FALSE,These results indicate that the <ENT2>TSPO</ENT2> ligand etifoxine attenuates <ENT1>brain injury</ENT1> and inflammation after ICH.,,,,T,,,,,c,,,,,1.0,,
28416580,3862,12257,D002543,Association,TRUE,A <ENT1>TSPO</ENT1> ligand attenuates brain injury after <ENT2>intracerebral hemorrhage</ENT2>.,,,,T,,,,,w,,,,,1.0,,
28416580,3862,12257,D002543,Association,TRUE,"After <ENT2>ICH</ENT2>, the immediate infiltration of leukocytes and activation of microglia are accompanied by a rapid up-regulation of the 18-kDa <ENT1>translocator protein</ENT1> (<ENT1>TSPO</ENT1>).",,,,T,,,,,c,,,,,0.0,,
28416580,3862,12257,D002543,Association,TRUE,"In this study, we determined the impact of a <ENT1>TSPO</ENT1> ligand, etifoxine, on brain injury and inflammation in 2 mouse models of <ENT2>ICH</ENT2>.",,,,T,,,,,c,,,,,1.0,,
28416580,3862,12257,D002543,Association,TRUE,These results indicate that the <ENT1>TSPO</ENT1> ligand etifoxine attenuates brain injury and inflammation after <ENT2>ICH</ENT2>.,,,,T,,,,,w,,,,,0.0,,
28416580,3862,12257,D002543,Association,TRUE,"<ENT1>TSPO</ENT1> may be a viable therapeutic target that requires further investigations in <ENT2>ICH</ENT2>.-Li, M., Ren, H., Sheth, K. N., Shi, F.-D., Liu, Q.",,,,T,,,,,c,,,,,0.0,,
28416580,3861,12257,D002493,Association,FALSE,<ENT1>TSPO</ENT1> ligands have shown anti-inflammatory and neuroprotective properties in models of <ENT2>CNS injury</ENT2>.,,,,T,,,,,c,,,,,0.0,,
28416580,3863,12257,D007249,Association,FALSE,<ENT1>TSPO</ENT1> ligands have shown anti-<ENT2>inflammatory</ENT2> and neuroprotective properties in models of CNS injury.,,,,T,,,,,w,,,,,0.0,,
28416580,3863,12257,D007249,Association,FALSE,"In this study, we determined the impact of a <ENT1>TSPO</ENT1> ligand, etifoxine, on brain injury and <ENT2>inflammation</ENT2> in 2 mouse models of ICH.",,,,T,,Y,,,w,,,,,0.0,,
28416580,3863,12257,D007249,Association,FALSE,These results indicate that the <ENT1>TSPO</ENT1> ligand etifoxine attenuates brain injury and <ENT2>inflammation</ENT2> after ICH.,,,,T,,,,,c,,,,,1.0,,
28416580,3858,D002543,199,Association,FALSE,TSPO was up-regulated in <ENT2>Iba1</ENT2>(+) cells from brains of patients with <ENT1>ICH</ENT1> and in CD11b(+)CD45(int) cells from mice subjected to collagenase-induced <ENT1>ICH</ENT1>.,,,,T,,,,,w,,,,,0.0,,
28416580,3859,D002543,706,Association,TRUE,<ENT2>TSPO</ENT2> was up-regulated in Iba1(+) cells from brains of patients with <ENT1>ICH</ENT1> and in CD11b(+)CD45(int) cells from mice subjected to collagenase-induced <ENT1>ICH</ENT1>.,,,,T,,,,,w,,,,,0.5,,
28416580,3857,D002543,D017364,Positive_Correlation,FALSE,TSPO was up-regulated in Iba1(+) cells from brains of patients with <ENT1>ICH</ENT1> and in CD11b(+)CD45(int) cells from mice subjected to <ENT2>collagenase</ENT2>-induced <ENT1>ICH</ENT1>.,,,,T,,,,,w,,,,,0.0,,
28416580,3857,D002543,D017364,Positive_Correlation,FALSE,Etifoxine significantly reduced neurodeficits and perihematomal brain edema after <ENT1>ICH</ENT1> induction by injection of either autologous blood or <ENT2>collagenase</ENT2>.,,,,T,,,,,c,,,,,1.0,,
28416580,3857,D002543,D017364,Positive_Correlation,FALSE,"In <ENT2>collagenase</ENT2>-induced <ENT1>ICH</ENT1> mice, the protection of etifoxine was associated with reduced leukocyte infiltration into the brain and microglial production of IL-6 and TNF-a.",,,,T,,,,,c,,,,,1.0,,
28416580,3860,199,706,Positive_Correlation,TRUE,<ENT2>TSPO</ENT2> was up-regulated in <ENT1>Iba1</ENT1>(+) cells from brains of patients with ICH and in CD11b(+)CD45(int) cells from mice subjected to collagenase-induced ICH.,,,,T,,,,,c,,,,,0.0,,
28428256,3881,7412,C100008,Negative_Correlation,TRUE,<ENT2>PGA2</ENT2> also suppressed LPS-induced inflammatory signaling by inhibiting the NFkB pathway and expression of <ENT1>EC adhesion molecules</ENT1> ICAM1 and <ENT1>VCAM1</ENT1>.,,,,T,,,,,c,,,,,0.5,,
28428256,3875,7412,D007249,Association,TRUE,PGA2 also suppressed LPS-induced <ENT2>inflammatory</ENT2> signaling by inhibiting the NFkB pathway and expression of <ENT1>EC adhesion molecules</ENT1> ICAM1 and <ENT1>VCAM1</ENT1>.,,,,T,,,,,w,,,,,1.0,,
28428256,3886,5734,C100008,Bind,FALSE,"<ENT1>EP4</ENT1> mediated barrier-protective effects of <ENT2>PGA2</ENT2> by activating Rap1/Rac1 GTPase and protein kinase A targets at cell adhesions and cytoskeleton: VE-cadherin, p120-catenin, ZO-1, cortactin, and VASP.",,,,T,,,,,w,,,,,0.0,,
28428256,3886,5734,C100008,Bind,FALSE,The results suggest a novel role for the <ENT2>PGA2</ENT2>-<ENT1>EP4</ENT1> axis in vascular EC protection that is critical for improvement of pathological states associated with increased vascular leakage and inflammation.,,,,T,,,,,c,,,,,0.0,,
28428256,3889,5734,5906,Positive_Correlation,TRUE,"<ENT1>EP4</ENT1> mediated barrier-protective effects of PGA2 by activating <ENT2>Rap1/Rac1 GTPase</ENT2> and protein kinase A targets at cell adhesions and cytoskeleton: VE-cadherin, p120-catenin, ZO-1, cortactin, and VASP.",,,,T,,,,,c,,,,,1.0,,
28428256,3887,5734,D007249,Association,TRUE,The results suggest a novel role for the PGA2-<ENT1>EP4</ENT1> axis in vascular EC protection that is critical for improvement of pathological states associated with increased vascular leakage and <ENT2>inflammation</ENT2>.,,,,T,,,,,c,,,,,1.0,,
28428256,3888,5734,5566,Positive_Correlation,TRUE,"<ENT1>EP4</ENT1> mediated barrier-protective effects of PGA2 by activating Rap1/Rac1 GTPase and <ENT2>protein kinase A</ENT2> targets at cell adhesions and cytoskeleton: VE-cadherin, p120-catenin, ZO-1, cortactin, and VASP.",,,,T,,,,,c,,,,,0.0,,
28428256,3882,C100008,3383,Negative_Correlation,TRUE,<ENT1>PGA2</ENT1> also suppressed LPS-induced inflammatory signaling by inhibiting the NFkB pathway and expression of <ENT2>EC adhesion molecules</ENT2> <ENT2>ICAM1</ENT2> and VCAM1.,,,,T,,,,,c,,,,,1.0,,
28428256,3884,C100008,5906,Association,TRUE,"EP4 mediated barrier-protective effects of <ENT1>PGA2</ENT1> by activating <ENT2>Rap1/Rac1 GTPase</ENT2> and protein kinase A targets at cell adhesions and cytoskeleton: VE-cadherin, p120-catenin, ZO-1, cortactin, and VASP.",,,,T,,,,,c,,,,,1.0,,
28428256,3880,C100008,D007249,Negative_Correlation,TRUE,Regulation of lung endothelial permeability and <ENT2>inflammatory</ENT2> responses by <ENT1>prostaglandin A2</ENT1>: role of EP4 receptor.,,,,T,,,,,c,,,,,0.0,,
28428256,3880,C100008,D007249,Negative_Correlation,TRUE,We investigated effects of <ENT1>PGA2</ENT1> on pulmonary endothelial cell (EC) permeability and <ENT2>inflammatory</ENT2> activation and identified a receptor mediating these effects.,,,,T,,,,,c,,,,,1.0,,
28428256,3880,C100008,D007249,Negative_Correlation,TRUE,<ENT1>PGA2</ENT1> enhanced the EC barrier and protected against barrier dysfunction caused by vasoactive peptide thrombin and <ENT2>proinflammatory</ENT2> bacterial wall lipopolysaccharide (LPS).,,,,T,,,,,c,,,,,1.0,,
28428256,3880,C100008,D007249,Negative_Correlation,TRUE,<ENT1>PGA2</ENT1> also suppressed LPS-induced <ENT2>inflammatory</ENT2> signaling by inhibiting the NFkB pathway and expression of EC adhesion molecules ICAM1 and VCAM1.,,,,T,,,,,c,,,,,1.0,,
28428256,3880,C100008,D007249,Negative_Correlation,TRUE,"In vivo, <ENT1>PGA2</ENT1> was protective in two distinct models of acute lung injury (ALI): LPS-induced <ENT2>inflammatory injury</ENT2> and two-hit ALI caused by suboptimal mechanical ventilation and injection of thrombin receptor-activating peptide.",,,,T,,,,,c,,,,,1.0,,
28428256,3880,C100008,D007249,Negative_Correlation,TRUE,The results suggest a novel role for the <ENT1>PGA2</ENT1>-EP4 axis in vascular EC protection that is critical for improvement of pathological states associated with increased vascular leakage and <ENT2>inflammation</ENT2>.,,,,T,,,,,c,,,,,0.0,,
28428256,3879,C100008,D055371,Association,FALSE,"In vivo, <ENT1>PGA2</ENT1> was protective in two distinct models of <ENT2>acute lung injury</ENT2> (<ENT2>ALI</ENT2>): LPS-induced inflammatory injury and two-hit <ENT2>ALI</ENT2> caused by suboptimal mechanical ventilation and injection of thrombin receptor-activating peptide.",,,,T,,,,,w,,,,,0.0,,
28428256,3877,C100008,14061,Association,FALSE,<ENT1>PGA2</ENT1> enhanced the EC barrier and protected against barrier dysfunction caused by vasoactive peptide <ENT2>thrombin</ENT2> and proinflammatory bacterial wall lipopolysaccharide (LPS).,,,,T,,,,,c,,,,,0.0,,
28428256,3883,C100008,5566,Association,TRUE,"EP4 mediated barrier-protective effects of <ENT1>PGA2</ENT1> by activating Rap1/Rac1 GTPase and <ENT2>protein kinase A</ENT2> targets at cell adhesions and cytoskeleton: VE-cadherin, p120-catenin, ZO-1, cortactin, and VASP.",,,,T,,,,,c,,,,,0.0,,
28428256,3878,C100008,D008070,Negative_Correlation,TRUE,<ENT1>PGA2</ENT1> enhanced the EC barrier and protected against barrier dysfunction caused by vasoactive peptide thrombin and proinflammatory bacterial wall <ENT2>lipopolysaccharide</ENT2> (<ENT2>LPS</ENT2>).,,,,T,,,,,c,,,,,1.0,,
28428256,3878,C100008,D008070,Negative_Correlation,TRUE,<ENT1>PGA2</ENT1> also suppressed <ENT2>LPS</ENT2>-induced inflammatory signaling by inhibiting the NFkB pathway and expression of EC adhesion molecules ICAM1 and VCAM1.,,,,T,,,,,w,,,,,1.0,,
28428256,3878,C100008,D008070,Negative_Correlation,TRUE,"In vivo, <ENT1>PGA2</ENT1> was protective in two distinct models of acute lung injury (ALI): <ENT2>LPS</ENT2>-induced inflammatory injury and two-hit ALI caused by suboptimal mechanical ventilation and injection of thrombin receptor-activating peptide.",,,,T,,,,,c,,,,,0.0,,
28428256,3876,3383,D007249,Association,TRUE,PGA2 also suppressed LPS-induced <ENT2>inflammatory</ENT2> signaling by inhibiting the NFkB pathway and expression of <ENT1>EC adhesion molecules</ENT1> <ENT1>ICAM1</ENT1> and VCAM1.,,,,T,,,,,c,,,,,1.0,,
28428256,3873,D007249,D008070,Positive_Correlation,FALSE,PGA2 enhanced the EC barrier and protected against barrier dysfunction caused by vasoactive peptide thrombin and <ENT1>proinflammatory</ENT1> bacterial wall <ENT2>lipopolysaccharide</ENT2> (<ENT2>LPS</ENT2>).,,,,T,,,,,w,,,,,0.0,,
28428256,3873,D007249,D008070,Positive_Correlation,FALSE,PGA2 also suppressed <ENT2>LPS</ENT2>-induced <ENT1>inflammatory</ENT1> signaling by inhibiting the NFkB pathway and expression of EC adhesion molecules ICAM1 and VCAM1.,,,,T,,,,,c,,,,,1.0,,
28428256,3873,D007249,D008070,Positive_Correlation,FALSE,"In vivo, PGA2 was protective in two distinct models of acute lung injury (ALI): <ENT2>LPS</ENT2>-induced <ENT1>inflammatory injury</ENT1> and two-hit ALI caused by suboptimal mechanical ventilation and injection of thrombin receptor-activating peptide.",,,,T,,,,,c,,,,,1.0,,
28428256,3874,D055371,14062,Association,FALSE,"In vivo, PGA2 was protective in two distinct models of <ENT1>acute lung injury</ENT1> (<ENT1>ALI</ENT1>): LPS-induced inflammatory injury and two-hit <ENT1>ALI</ENT1> caused by suboptimal mechanical ventilation and injection of <ENT2>thrombin receptor</ENT2>-activating peptide.",,,,T,,,,,c,,,,,0.333333333,,
28468941,3904,rs587777017,D006976,Association,FALSE,Aberrant caveolin-1-mediated Smad signaling and proliferation identified by analysis of <ENT1>adenine 474 deletion</ENT1> mutation (<ENT1>c.474delA</ENT1>) in patient fibroblasts: a new perspective on the mechanism of <ENT2>pulmonary hypertension</ENT2>.,,,,T,,T,,,w,,,,,0.0,,
28468941,3903,rs587777017,D000081029,Association,FALSE,A heterozygous caveolin-1 <ENT1>c.474delA</ENT1> mutation has been identified in a family with heritable <ENT2>pulmonary arterial hypertension</ENT2> (<ENT2>PAH</ENT2>).,,,,T,,,,,c,,,,,0.0,,
28468941,3903,rs587777017,D000081029,Association,FALSE,These results demonstrate the critical role of the final 20 amino acids of caveolin-1 in modulating fibroblast proliferation by dampening Smad signaling and suggest that augmented Smad signaling and fibroblast hyperproliferation are contributing factors in the pathogenesis of <ENT2>PAH</ENT2> in patients with caveolin-1 <ENT1>c.474delA</ENT1> mutation.,,,,T,,,,,c,,,,,0.0,,
28468941,3892,94,4090,Association,FALSE,Inhibition of <ENT1>type I TGFb receptors</ENT1> <ENT1>ALK1/2/3/6</ENT1> responsible for phosphorylation of <ENT2>Smad1/5/8</ENT2> reduced the hyperproliferation seen in c.474delA fibroblasts.,,,,T,,,,,c,,,,,0.0,,
28468941,3906,4090,D006976,Association,TRUE,Aberrant caveolin-1-mediated <ENT1>Smad</ENT1> signaling and proliferation identified by analysis of adenine 474 deletion mutation (c.474delA) in patient fibroblasts: a new perspective on the mechanism of <ENT2>pulmonary hypertension</ENT2>.,,,,T,,,,,w,,,,,0.0,,
28468941,3910,4090,D000081029,Association,TRUE,These results demonstrate the critical role of the final 20 amino acids of caveolin-1 in modulating fibroblast proliferation by dampening <ENT1>Smad</ENT1> signaling and suggest that augmented <ENT1>Smad</ENT1> signaling and fibroblast hyperproliferation are contributing factors in the pathogenesis of <ENT2>PAH</ENT2> in patients with caveolin-1 c.474delA mutation.,,,,T,,,,,c,,,,,0.5,,
28468941,3914,4090,857,Association,TRUE,Aberrant <ENT2>caveolin-1</ENT2>-mediated <ENT1>Smad</ENT1> signaling and proliferation identified by analysis of adenine 474 deletion mutation (c.474delA) in patient fibroblasts: a new perspective on the mechanism of pulmonary hypertension.,,,,T,,,,,c,,,,,1.0,,
28468941,3914,4090,857,Association,TRUE,These results demonstrate the critical role of the final 20 amino acids of <ENT2>caveolin-1</ENT2> in modulating fibroblast proliferation by dampening <ENT1>Smad</ENT1> signaling and suggest that augmented <ENT1>Smad</ENT1> signaling and fibroblast hyperproliferation are contributing factors in the pathogenesis of PAH in patients with <ENT2>caveolin-1</ENT2> c.474delA mutation.,,,,T,,,,,c,,,,,0.5,,
28468941,3908,D006976,857,Association,FALSE,Aberrant <ENT2>caveolin-1</ENT2>-mediated Smad signaling and proliferation identified by analysis of adenine 474 deletion mutation (c.474delA) in patient fibroblasts: a new perspective on the mechanism of <ENT1>pulmonary hypertension</ENT1>.,,,,T,,T,,,w,,,,,0.0,,
28468941,3912,D000081029,857,Association,FALSE,A heterozygous <ENT2>caveolin-1</ENT2> c.474delA mutation has been identified in a family with heritable <ENT1>pulmonary arterial hypertension</ENT1> (<ENT1>PAH</ENT1>).,,,,T,,,,,c,,,,,0.5,,
28468941,3912,D000081029,857,Association,FALSE,These results demonstrate the critical role of the final 20 amino acids of <ENT2>caveolin-1</ENT2> in modulating fibroblast proliferation by dampening Smad signaling and suggest that augmented Smad signaling and fibroblast hyperproliferation are contributing factors in the pathogenesis of <ENT1>PAH</ENT1> in patients with <ENT2>caveolin-1</ENT2> c.474delA mutation.,,,,T,,,,,w,,,,,1.0,,
28472177,3950,59,7345,Association,TRUE,"Transcriptome comparisons of <ENT2>UCHL1</ENT2> KDs versus vector control identified a list of 306 differentially expressed genes (at least 2-fold change; p    <0.05) which included genes known to be involved in cancer like <ENT1>ACTA2</ENT1>, POSTN, LIF, FBXL7, FBXW11, GDF15, HEY2, but also potential novel genes such us IGLL5, ABCA4, AQP3, AQP4, CALB1, and ALK.",,,,T,,,,,w,,,,,1.0,,
28472177,3934,59,D009369,Association,FALSE,"Transcriptome comparisons of UCHL1 KDs versus vector control identified a list of 306 differentially expressed genes (at least 2-fold change; p    <0.05) which included genes known to be involved in <ENT2>cancer</ENT2> like <ENT1>ACTA2</ENT1>, POSTN, LIF, FBXL7, FBXW11, GDF15, HEY2, but also potential novel genes such us IGLL5, ABCA4, AQP3, AQP4, CALB1, and ALK.",,,,T,,,,,w,,,,,1.0,,
28472177,3921,2247,7345,Association,TRUE,"While <ENT1>FGF2</ENT1>, IL1B, TNF and PDGFB were predicted as top upstream regulators (p    < 2x10-16) of the <ENT2>UCHL1</ENT2> KD-associated transcriptome.",,,,T,,,,,c,,,,,1.0,,
28472177,3943,100423062,7345,Association,TRUE,"Transcriptome comparisons of <ENT2>UCHL1</ENT2> KDs versus vector control identified a list of 306 differentially expressed genes (at least 2-fold change; p    <0.05) which included genes known to be involved in cancer like ACTA2, POSTN, LIF, FBXL7, FBXW11, GDF15, HEY2, but also potential novel genes such us <ENT1>IGLL5</ENT1>, ABCA4, AQP3, AQP4, CALB1, and ALK.",,,,T,,,,,w,,,,,1.0,,
28472177,3927,100423062,D009369,Association,FALSE,"Transcriptome comparisons of UCHL1 KDs versus vector control identified a list of 306 differentially expressed genes (at least 2-fold change; p    <0.05) which included genes known to be involved in <ENT2>cancer</ENT2> like ACTA2, POSTN, LIF, FBXL7, FBXW11, GDF15, HEY2, but also potential novel genes such us <ENT1>IGLL5</ENT1>, ABCA4, AQP3, AQP4, CALB1, and ALK.",,,,T,,,,,w,,,,,1.0,,
28472177,3951,7474,7345,Positive_Correlation,TRUE,A 70% reduction in <ENT1>Wnt</ENT1> signaling was also observed in the SF188 and SJ-GBM2 <ENT2>UCHL1</ENT2> knockdowns (KDs) using a TCF-dependent TOPflash reporter assay.,,,,T,,,,,c,,,,,0.0,,
28472177,3951,7474,7345,Positive_Correlation,TRUE,"Aberrant expression of <ENT2>UCHL1</ENT2> in pediatric high-grade gliomas may promote cell invasion, transformation, and self-renewal properties, at least in part, by modulating <ENT1>Wnt</ENT1>/Beta catenin activity.",,,,T,,,,,c,,,,,0.0,,
28472177,3917,7474,D005910,Association,FALSE,"Aberrant expression of UCHL1 in pediatric high-grade <ENT2>gliomas</ENT2> may promote cell invasion, transformation, and self-renewal properties, at least in part, by modulating <ENT1>Wnt</ENT1>/Beta catenin activity.",,,,T,,,,,c,,,,,1.0,,
28472177,3919,7124,7345,Association,TRUE,"While FGF2, IL1B, <ENT1>TNF</ENT1> and PDGFB were predicted as top upstream regulators (p    < 2x10-16) of the <ENT2>UCHL1</ENT2> KD-associated transcriptome.",,,,T,,,,,c,,,,,1.0,,
28472177,3938,238,7345,Association,TRUE,"Transcriptome comparisons of <ENT2>UCHL1</ENT2> KDs versus vector control identified a list of 306 differentially expressed genes (at least 2-fold change; p    <0.05) which included genes known to be involved in cancer like ACTA2, POSTN, LIF, FBXL7, FBXW11, GDF15, HEY2, but also potential novel genes such us IGLL5, ABCA4, AQP3, AQP4, CALB1, and <ENT1>ALK</ENT1>.",,,,T,,,,,w,,,,,1.0,,
28472177,3922,238,D009369,Association,FALSE,"Transcriptome comparisons of UCHL1 KDs versus vector control identified a list of 306 differentially expressed genes (at least 2-fold change; p    <0.05) which included genes known to be involved in <ENT2>cancer</ENT2> like ACTA2, POSTN, LIF, FBXL7, FBXW11, GDF15, HEY2, but also potential novel genes such us IGLL5, ABCA4, AQP3, AQP4, CALB1, and <ENT1>ALK</ENT1>.",,,,T,,,,,w,,,,,0.0,,
28472177,3948,3976,7345,Association,TRUE,"Transcriptome comparisons of <ENT2>UCHL1</ENT2> KDs versus vector control identified a list of 306 differentially expressed genes (at least 2-fold change; p    <0.05) which included genes known to be involved in cancer like ACTA2, POSTN, <ENT1>LIF</ENT1>, FBXL7, FBXW11, GDF15, HEY2, but also potential novel genes such us IGLL5, ABCA4, AQP3, AQP4, CALB1, and ALK.",,,,T,,,,,w,,,,,0.0,,
28472177,3932,3976,D009369,Association,FALSE,"Transcriptome comparisons of UCHL1 KDs versus vector control identified a list of 306 differentially expressed genes (at least 2-fold change; p    <0.05) which included genes known to be involved in <ENT2>cancer</ENT2> like ACTA2, POSTN, <ENT1>LIF</ENT1>, FBXL7, FBXW11, GDF15, HEY2, but also potential novel genes such us IGLL5, ABCA4, AQP3, AQP4, CALB1, and ALK.",,,,T,,,,,c,,,,,1.0,,
28472177,3939,793,7345,Association,TRUE,"Transcriptome comparisons of <ENT2>UCHL1</ENT2> KDs versus vector control identified a list of 306 differentially expressed genes (at least 2-fold change; p    <0.05) which included genes known to be involved in cancer like ACTA2, POSTN, LIF, FBXL7, FBXW11, GDF15, HEY2, but also potential novel genes such us IGLL5, ABCA4, AQP3, AQP4, <ENT1>CALB1</ENT1>, and ALK.",,,,T,,,,,w,,,,,0.0,,
28472177,3923,793,D009369,Association,FALSE,"Transcriptome comparisons of UCHL1 KDs versus vector control identified a list of 306 differentially expressed genes (at least 2-fold change; p    <0.05) which included genes known to be involved in <ENT2>cancer</ENT2> like ACTA2, POSTN, LIF, FBXL7, FBXW11, GDF15, HEY2, but also potential novel genes such us IGLL5, ABCA4, AQP3, AQP4, <ENT1>CALB1</ENT1>, and ALK.",,,,T,,,,,w,,,,,0.0,,
28472177,3918,5155,7345,Association,TRUE,"While FGF2, IL1B, TNF and <ENT1>PDGFB</ENT1> were predicted as top upstream regulators (p    < 2x10-16) of the <ENT2>UCHL1</ENT2> KD-associated transcriptome.",,,,T,,,,,c,,,,,1.0,,
28472177,3940,361,7345,Association,TRUE,"Transcriptome comparisons of <ENT2>UCHL1</ENT2> KDs versus vector control identified a list of 306 differentially expressed genes (at least 2-fold change; p    <0.05) which included genes known to be involved in cancer like ACTA2, POSTN, LIF, FBXL7, FBXW11, GDF15, HEY2, but also potential novel genes such us IGLL5, ABCA4, AQP3, <ENT1>AQP4</ENT1>, CALB1, and ALK.",,,,T,,,,,w,,,,,0.0,,
28472177,3924,361,D009369,Association,FALSE,"Transcriptome comparisons of UCHL1 KDs versus vector control identified a list of 306 differentially expressed genes (at least 2-fold change; p    <0.05) which included genes known to be involved in <ENT2>cancer</ENT2> like ACTA2, POSTN, LIF, FBXL7, FBXW11, GDF15, HEY2, but also potential novel genes such us IGLL5, ABCA4, AQP3, <ENT1>AQP4</ENT1>, CALB1, and ALK.",,,,T,,,,,w,,,,,0.0,,
28472177,3936,1499,7345,Association,TRUE,"Aberrant expression of <ENT2>UCHL1</ENT2> in pediatric high-grade gliomas may promote cell invasion, transformation, and self-renewal properties, at least in part, by modulating Wnt/<ENT1>Beta catenin</ENT1> activity.",,,,T,,,,,c,,,,,1.0,,
28472177,3916,1499,D005910,Association,FALSE,"Aberrant expression of UCHL1 in pediatric high-grade <ENT2>gliomas</ENT2> may promote cell invasion, transformation, and self-renewal properties, at least in part, by modulating Wnt/<ENT1>Beta catenin</ENT1> activity.",,,,T,,,,,c,,,,,0.0,,
28472177,3949,7345,10631,Association,TRUE,"Transcriptome comparisons of <ENT1>UCHL1</ENT1> KDs versus vector control identified a list of 306 differentially expressed genes (at least 2-fold change; p    <0.05) which included genes known to be involved in cancer like ACTA2, <ENT2>POSTN</ENT2>, LIF, FBXL7, FBXW11, GDF15, HEY2, but also potential novel genes such us IGLL5, ABCA4, AQP3, AQP4, CALB1, and ALK.",,,,T,,,,,w,,,,,0.0,,
28472177,3944,7345,23493,Association,TRUE,"Transcriptome comparisons of <ENT1>UCHL1</ENT1> KDs versus vector control identified a list of 306 differentially expressed genes (at least 2-fold change; p    <0.05) which included genes known to be involved in cancer like ACTA2, POSTN, LIF, FBXL7, FBXW11, GDF15, <ENT2>HEY2</ENT2>, but also potential novel genes such us IGLL5, ABCA4, AQP3, AQP4, CALB1, and ALK.",,,,T,,,,,w,,,,,0.0,,
28472177,3920,7345,3553,Association,TRUE,"While FGF2, <ENT2>IL1B</ENT2>, TNF and PDGFB were predicted as top upstream regulators (p    < 2x10-16) of the <ENT1>UCHL1</ENT1> KD-associated transcriptome.",,,,T,,,,,c,,,,,1.0,,
28472177,3947,7345,23194,Association,TRUE,"Transcriptome comparisons of <ENT1>UCHL1</ENT1> KDs versus vector control identified a list of 306 differentially expressed genes (at least 2-fold change; p    <0.05) which included genes known to be involved in cancer like ACTA2, POSTN, LIF, <ENT2>FBXL7</ENT2>, FBXW11, GDF15, HEY2, but also potential novel genes such us IGLL5, ABCA4, AQP3, AQP4, CALB1, and ALK.",,,,T,,,,,w,,,,,0.0,,
28472177,3941,7345,360,Association,TRUE,"Transcriptome comparisons of <ENT1>UCHL1</ENT1> KDs versus vector control identified a list of 306 differentially expressed genes (at least 2-fold change; p    <0.05) which included genes known to be involved in cancer like ACTA2, POSTN, LIF, FBXL7, FBXW11, GDF15, HEY2, but also potential novel genes such us IGLL5, ABCA4, <ENT2>AQP3</ENT2>, AQP4, CALB1, and ALK.",,,,T,,,,,w,,,,,0.0,,
28472177,3937,7345,D009369,Association,TRUE,<ENT1>Ubiquitin carboxyl-terminal esterase L1</ENT1> (<ENT1>UCHL1</ENT1>) is associated with stem-like <ENT2>cancer</ENT2> cell functions in pediatric high-grade glioma.,,,,T,,,,,c,,,,,1.0,,
28472177,3937,7345,D009369,Association,TRUE,"In this work we used SF188 and SJ-GBM2 cell lines to study the function of the <ENT1>ubiquitin carboxyl-terminal esterase L1</ENT1> (<ENT1>UCHL1</ENT1>), a deubiquitinase de-regulated in several <ENT2>cancers</ENT2>, in pediatric high-grade gliomas.",,,,T,,,,,c,,,,,0.5,,
28472177,3937,7345,D009369,Association,TRUE,"Transcriptome comparisons of <ENT1>UCHL1</ENT1> KDs versus vector control identified a list of 306 differentially expressed genes (at least 2-fold change; p    <0.05) which included genes known to be involved in <ENT2>cancer</ENT2> like ACTA2, POSTN, LIF, FBXL7, FBXW11, GDF15, HEY2, but also potential novel genes such us IGLL5, ABCA4, AQP3, AQP4, CALB1, and ALK.",,,,T,,,,,w,,,,,0.0,,
28472177,3937,7345,D009369,Association,TRUE,<ENT1>UCHL1</ENT1> might act as an oncogene in glioma within the gene network that imparts stem-like characteristics to these <ENT2>cancer</ENT2> cells.,,,,T,,,,,c,,,,,1.0,,
28472177,3942,7345,24,Association,TRUE,"Transcriptome comparisons of <ENT1>UCHL1</ENT1> KDs versus vector control identified a list of 306 differentially expressed genes (at least 2-fold change; p    <0.05) which included genes known to be involved in cancer like ACTA2, POSTN, LIF, FBXL7, FBXW11, GDF15, HEY2, but also potential novel genes such us IGLL5, <ENT2>ABCA4</ENT2>, AQP3, AQP4, CALB1, and ALK.",,,,T,,,,,w,,,,,0.0,,
28472177,3946,7345,23291,Association,TRUE,"Transcriptome comparisons of <ENT1>UCHL1</ENT1> KDs versus vector control identified a list of 306 differentially expressed genes (at least 2-fold change; p    <0.05) which included genes known to be involved in cancer like ACTA2, POSTN, LIF, FBXL7, <ENT2>FBXW11</ENT2>, GDF15, HEY2, but also potential novel genes such us IGLL5, ABCA4, AQP3, AQP4, CALB1, and ALK.",,,,T,,,,,w,,,,,0.0,,
28472177,3945,7345,9518,Association,TRUE,"Transcriptome comparisons of <ENT1>UCHL1</ENT1> KDs versus vector control identified a list of 306 differentially expressed genes (at least 2-fold change; p    <0.05) which included genes known to be involved in cancer like ACTA2, POSTN, LIF, FBXL7, FBXW11, <ENT2>GDF15</ENT2>, HEY2, but also potential novel genes such us IGLL5, ABCA4, AQP3, AQP4, CALB1, and ALK.",,,,T,,,,,w,,,,,1.0,,
28472177,3935,7345,D005910,Association,TRUE,<ENT1>Ubiquitin carboxyl-terminal esterase L1</ENT1> (<ENT1>UCHL1</ENT1>) is associated with stem-like cancer cell functions in pediatric high-grade <ENT2>glioma</ENT2>.,,,,T,,,,,c,,,,,1.0,,
28472177,3935,7345,D005910,Association,TRUE,"In this work we used SF188 and SJ-GBM2 cell lines to study the function of the <ENT1>ubiquitin carboxyl-terminal esterase L1</ENT1> (<ENT1>UCHL1</ENT1>), a deubiquitinase de-regulated in several cancers, in pediatric high-grade <ENT2>gliomas</ENT2>.",,,,T,,Y,,,w,,,,,1.0,,
28472177,3935,7345,D005910,Association,TRUE,"<ENT1>UCHL1</ENT1> depletion in SF188 and SJ-GBM2 <ENT2>glioma</ENT2> cells was associated with decreased cell proliferation and invasion, along with a reduced ability to grow in soft agar and to form spheres (i.e. self-renewal measure).",,,,T,,,,,c,,,,,1.0,,
28472177,3935,7345,D005910,Association,TRUE,"Aberrant expression of <ENT1>UCHL1</ENT1> in pediatric high-grade <ENT2>gliomas</ENT2> may promote cell invasion, transformation, and self-renewal properties, at least in part, by modulating Wnt/Beta catenin activity.",,,,T,,,,,c,,,,,1.0,,
28472177,3935,7345,D005910,Association,TRUE,<ENT1>UCHL1</ENT1> might act as an oncogene in <ENT2>glioma</ENT2> within the gene network that imparts stem-like characteristics to these cancer cells.,,,,T,,,,,c,,,,,1.0,,
28472177,3933,10631,D009369,Association,FALSE,"Transcriptome comparisons of UCHL1 KDs versus vector control identified a list of 306 differentially expressed genes (at least 2-fold change; p    <0.05) which included genes known to be involved in <ENT2>cancer</ENT2> like ACTA2, <ENT1>POSTN</ENT1>, LIF, FBXL7, FBXW11, GDF15, HEY2, but also potential novel genes such us IGLL5, ABCA4, AQP3, AQP4, CALB1, and ALK.",,,,T,,,,,c,,,,,1.0,,
28472177,3928,23493,D009369,Association,FALSE,"Transcriptome comparisons of UCHL1 KDs versus vector control identified a list of 306 differentially expressed genes (at least 2-fold change; p    <0.05) which included genes known to be involved in <ENT2>cancer</ENT2> like ACTA2, POSTN, LIF, FBXL7, FBXW11, GDF15, <ENT1>HEY2</ENT1>, but also potential novel genes such us IGLL5, ABCA4, AQP3, AQP4, CALB1, and ALK.",,,,T,,,,,c,,,,,1.0,,
28472177,3931,23194,D009369,Association,FALSE,"Transcriptome comparisons of UCHL1 KDs versus vector control identified a list of 306 differentially expressed genes (at least 2-fold change; p    <0.05) which included genes known to be involved in <ENT2>cancer</ENT2> like ACTA2, POSTN, LIF, <ENT1>FBXL7</ENT1>, FBXW11, GDF15, HEY2, but also potential novel genes such us IGLL5, ABCA4, AQP3, AQP4, CALB1, and ALK.",,,,T,,,,,c,,,,,0.0,,
28472177,3925,360,D009369,Association,FALSE,"Transcriptome comparisons of UCHL1 KDs versus vector control identified a list of 306 differentially expressed genes (at least 2-fold change; p    <0.05) which included genes known to be involved in <ENT2>cancer</ENT2> like ACTA2, POSTN, LIF, FBXL7, FBXW11, GDF15, HEY2, but also potential novel genes such us IGLL5, ABCA4, <ENT1>AQP3</ENT1>, AQP4, CALB1, and ALK.",,,,T,,,,,c,,,,,0.0,,
28472177,3926,D009369,24,Association,FALSE,"Transcriptome comparisons of UCHL1 KDs versus vector control identified a list of 306 differentially expressed genes (at least 2-fold change; p    <0.05) which included genes known to be involved in <ENT1>cancer</ENT1> like ACTA2, POSTN, LIF, FBXL7, FBXW11, GDF15, HEY2, but also potential novel genes such us IGLL5, <ENT2>ABCA4</ENT2>, AQP3, AQP4, CALB1, and ALK.",,,,T,,,,,c,,,,,0.0,,
28472177,3930,D009369,23291,Association,FALSE,"Transcriptome comparisons of UCHL1 KDs versus vector control identified a list of 306 differentially expressed genes (at least 2-fold change; p    <0.05) which included genes known to be involved in <ENT1>cancer</ENT1> like ACTA2, POSTN, LIF, FBXL7, <ENT2>FBXW11</ENT2>, GDF15, HEY2, but also potential novel genes such us IGLL5, ABCA4, AQP3, AQP4, CALB1, and ALK.",,,,T,,,,,c,,,,,1.0,,
28472177,3929,D009369,9518,Association,FALSE,"Transcriptome comparisons of UCHL1 KDs versus vector control identified a list of 306 differentially expressed genes (at least 2-fold change; p    <0.05) which included genes known to be involved in <ENT1>cancer</ENT1> like ACTA2, POSTN, LIF, FBXL7, FBXW11, <ENT2>GDF15</ENT2>, HEY2, but also potential novel genes such us IGLL5, ABCA4, AQP3, AQP4, CALB1, and ALK.",,,,T,,,,,c,,,,,1.0,,
28487437,3958,2642,D006943,Association,FALSE,<ENT1>Glucagon receptor</ENT1> (<ENT1>GcgR</ENT1>) blockade has been proposed as an alternative to insulin monotherapy for treating type 1 diabetes since deletion or inhibition of <ENT1>GcgRs</ENT1> corrects <ENT2>hyperglycemia</ENT2> in models of diabetes.,,,,T,,,,,c,,,,,1.0,,
28487437,3959,2642,D003922,Association,FALSE,<ENT1>Glucagon receptor</ENT1> (<ENT1>GcgR</ENT1>) blockade has been proposed as an alternative to insulin monotherapy for treating <ENT2>type 1 diabetes</ENT2> since deletion or inhibition of <ENT1>GcgRs</ENT1> corrects hyperglycemia in models of diabetes.,,,,T,,,,,w,,,,,1.0,,
28487437,3960,14527,D001786,Negative_Correlation,TRUE,Both <ENT1>GcgR</ENT1> knockout (<ENT1>Gcgr</ENT1>(-/-)) mice and db/db mice that were administered <ENT1>GcgR</ENT1> monoclonal antibody displayed lower <ENT2>blood glucose</ENT2> levels accompanied by elevated plasma ghrelin levels.,,,,T,,,,,c,,,,,0.0,,
28487437,3960,14527,D001786,Negative_Correlation,TRUE,"Notably, administration of a ghrelin receptor antagonist further reduced <ENT2>blood glucose</ENT2> levels into the markedly hypoglycemic range in overnight-fasted, streptozotocin-treated <ENT1>Gcgr</ENT1>(-/-) mice.",,,,T,,,,,c,,,,,1.0,,
28487437,3960,14527,D001786,Negative_Correlation,TRUE,"A lowered <ENT2>blood glucose</ENT2> level also was observed in overnight-fasted, streptozotocin-treated ghrelin receptor-null mice that were administered <ENT1>GcgR</ENT1> monoclonal antibody.",,,,T,,,,,c,,,,,0.0,,
28487437,3952,D007003,14526,Association,TRUE,"Here, we tested the hypothesis that ghrelin rises to prevent <ENT1>hypoglycemia</ENT1> in the absence of <ENT2>glucagon</ENT2> function.",,,,T,,,,,c,,,,,0.0,,
28487437,3952,D007003,14526,Association,TRUE,"These data suggest that when <ENT2>glucagon</ENT2> activity is blocked in the setting of type 1 diabetes, the plasma ghrelin level rises, preventing <ENT1>hypoglycemia</ENT1>.",,,,T,,,,,c,,,,,0.0,,
28487437,3955,D007003,58991,Negative_Correlation,TRUE,"Here, we tested the hypothesis that <ENT2>ghrelin</ENT2> rises to prevent <ENT1>hypoglycemia</ENT1> in the absence of glucagon function.",,,,T,,Y,,,w,,,,,0.0,,
28487437,3955,D007003,58991,Negative_Correlation,TRUE,"These data suggest that when glucagon activity is blocked in the setting of type 1 diabetes, the plasma <ENT2>ghrelin</ENT2> level rises, preventing <ENT1>hypoglycemia</ENT1>.",,,,T,,,,,c,,,,,0.0,,
28487437,3953,14526,58991,Negative_Correlation,TRUE,"Here, we tested the hypothesis that <ENT2>ghrelin</ENT2> rises to prevent hypoglycemia in the absence of <ENT1>glucagon</ENT1> function.",,,,T,,Y,,,w,,,,,0.0,,
28487437,3953,14526,58991,Negative_Correlation,TRUE,"These data suggest that when <ENT1>glucagon</ENT1> activity is blocked in the setting of type 1 diabetes, the plasma <ENT2>ghrelin</ENT2> level rises, preventing hypoglycemia.",,,,T,,,,,c,,,,,0.0,,
28487437,3954,3630,D003922,Negative_Correlation,FALSE,Glucagon receptor (GcgR) blockade has been proposed as an alternative to <ENT1>insulin</ENT1> monotherapy for treating <ENT2>type 1 diabetes</ENT2> since deletion or inhibition of GcgRs corrects hyperglycemia in models of diabetes.,,,,T,,,,,w,,,,,1.0,,
28487437,3961,D001786,208188,Association,TRUE,"Notably, administration of a <ENT2>ghrelin receptor</ENT2> antagonist further reduced <ENT1>blood glucose</ENT1> levels into the markedly hypoglycemic range in overnight-fasted, streptozotocin-treated Gcgr(-/-) mice.",,,,T,,,,,c,,,,,1.0,,
28487437,3961,D001786,208188,Association,TRUE,"A lowered <ENT1>blood glucose</ENT1> level also was observed in overnight-fasted, streptozotocin-treated <ENT2>ghrelin receptor</ENT2>-null mice that were administered GcgR monoclonal antibody.",,,,T,,,,,c,,,,,0.0,,
28487437,3962,D001786,D013311,Negative_Correlation,TRUE,"Notably, administration of a ghrelin receptor antagonist further reduced <ENT1>blood glucose</ENT1> levels into the markedly hypoglycemic range in overnight-fasted, <ENT2>streptozotocin</ENT2>-treated Gcgr(-/-) mice.",,,,T,,,,,c,,,,,0.0,,
28487437,3962,D001786,D013311,Negative_Correlation,TRUE,"A lowered <ENT1>blood glucose</ENT1> level also was observed in overnight-fasted, <ENT2>streptozotocin</ENT2>-treated ghrelin receptor-null mice that were administered GcgR monoclonal antibody.",,,,T,,,,,c,,,,,0.0,,
28487437,3963,D001786,51738,Association,FALSE,The factors regulating <ENT1>glycemia</ENT1> in a setting devoid of insulin and glucagon function remain unclear but may include the hormone <ENT2>ghrelin</ENT2>.,,,,T,,,,,c,,,,,1.0,,
28487437,3963,D001786,51738,Association,FALSE,Not only is <ENT2>ghrelin</ENT2> release controlled by glucose but also <ENT2>ghrelin</ENT2> has many actions that can raise or reduce falls in <ENT1>blood glucose</ENT1> level.,,,,T,,,,,c,,,,,0.0,,
28487437,3957,D006943,D013311,Positive_Correlation,FALSE,"Although treatment with the pancreatic b-cell toxin <ENT2>streptozotocin</ENT2> induced <ENT1>hyperglycemia</ENT1> and raised plasma ghrelin levels in wild-type mice, <ENT1>hyperglycemia</ENT1> was averted in similarly treated Gcgr(-/-) mice and the plasma ghrelin level was further increased.",,,,T,,,,,c,,,,,0.0,,
28487437,3956,58991,D013311,Positive_Correlation,TRUE,"Although treatment with the pancreatic b-cell toxin <ENT2>streptozotocin</ENT2> induced hyperglycemia and raised plasma <ENT1>ghrelin</ENT1> levels in wild-type mice, hyperglycemia was averted in similarly treated Gcgr(-/-) mice and the plasma <ENT1>ghrelin</ENT1> level was further increased.",,,,T,,,,,c,,,,,1.0,,
28487437,3964,D005947,51738,Association,FALSE,Not only is <ENT2>ghrelin</ENT2> release controlled by <ENT1>glucose</ENT1> but also <ENT2>ghrelin</ENT2> has many actions that can raise or reduce falls in blood glucose level.,,,,T,,,,,c,,,,,0.5,,
28512644,3995,6647,D004886,Association,TRUE,"Analysis of Serum Cytokines and Single-Nucleotide Polymorphisms of <ENT1>SOD1</ENT1>, SOD2, and CAT in <ENT2>Erysipelas</ENT2> Patients.",,,,T,,T,,,w,,,,,0.0,,
28512644,3995,6647,D004886,Association,TRUE,"Comparing 71 <ENT2>erysipelas</ENT2> patients to 55 age-matched healthy individuals, we sought for CAT, <ENT1>SOD1</ENT1>, and SOD2 single polymorphism mutation (SNPs) interactions with <ENT2>erysipelas</ENT2>' predisposition and serum cytokine levels in the acute and recovery phases of <ENT2>erysipelas infection</ENT2>.",,,,T,,Y,,,w,,,,,1.0,,
28512644,3995,6647,D004886,Association,TRUE,"The presence of <ENT1>SOD1</ENT1> G7958, SOD2 T2734, and CAT C262 alleles was linked to <ENT2>erysipelas</ENT2>' predisposition.",,,,T,,,,,c,,,,,1.0,,
28512644,3980,3578,D004886,Association,TRUE,"Serum levels of IL-1beta, CCL11, IL-2Ralpha, CXCL9, TRAIL, PDGF-BB, and CCL4 were associated with symptoms accompanying the infection, while IL-6, <ENT1>IL-9</ENT1>, IL-10, IL-13, IL-15, IL-17, G-CSF, and VEGF were associated with predisposition and recurrence of <ENT2>erysipelas</ENT2>.",,,,T,,,,,c,,,,,1.0,,
28512644,3970,6352,6648,Association,TRUE,"While variations of IL-1beta, IL-7, IL-8, IL-17, <ENT1>CCL5</ENT1>, and HGF were associated with the <ENT2>SOD2</ENT2> T2734C SNP, variations of PDFG-BB and CCL2 were associated with the CAT C262T SNP.",,,,T,,,,,c,,,,,0.0,,
28512644,3972,6648,3574,Association,TRUE,"While variations of IL-1beta, <ENT2>IL-7</ENT2>, IL-8, IL-17, CCL5, and HGF were associated with the <ENT1>SOD2</ENT1> T2734C SNP, variations of PDFG-BB and CCL2 were associated with the CAT C262T SNP.",,,,T,,,,,c,,,,,0.0,,
28512644,3969,6648,3082,Association,TRUE,"While variations of IL-1beta, IL-7, IL-8, IL-17, CCL5, and <ENT2>HGF</ENT2> were associated with the <ENT1>SOD2</ENT1> T2734C SNP, variations of PDFG-BB and CCL2 were associated with the CAT C262T SNP.",,,,T,,,,,c,,,,,0.0,,
28512644,3990,6648,3553,Association,TRUE,"While variations of <ENT2>IL-1beta</ENT2>, IL-7, IL-8, IL-17, CCL5, and HGF were associated with the <ENT1>SOD2</ENT1> T2734C SNP, variations of PDFG-BB and CCL2 were associated with the CAT C262T SNP.",,,,T,,,,,c,,,,,0.0,,
28512644,3971,6648,3576,Association,TRUE,"While variations of IL-1beta, IL-7, <ENT2>IL-8</ENT2>, IL-17, CCL5, and HGF were associated with the <ENT1>SOD2</ENT1> T2734C SNP, variations of PDFG-BB and CCL2 were associated with the CAT C262T SNP.",,,,T,,,,,c,,,,,0.0,,
28512644,3994,6648,D004886,Association,TRUE,"Analysis of Serum Cytokines and Single-Nucleotide Polymorphisms of SOD1, <ENT1>SOD2</ENT1>, and CAT in <ENT2>Erysipelas</ENT2> Patients.",,,,T,,T,,,w,,,,,0.0,,
28512644,3994,6648,D004886,Association,TRUE,"Comparing 71 <ENT2>erysipelas</ENT2> patients to 55 age-matched healthy individuals, we sought for CAT, SOD1, and <ENT1>SOD2</ENT1> single polymorphism mutation (SNPs) interactions with <ENT2>erysipelas</ENT2>' predisposition and serum cytokine levels in the acute and recovery phases of <ENT2>erysipelas infection</ENT2>.",,,,T,,Y,,,w,,,,,1.0,,
28512644,3994,6648,D004886,Association,TRUE,"The presence of SOD1 G7958, <ENT1>SOD2</ENT1> T2734, and CAT C262 alleles was linked to <ENT2>erysipelas</ENT2>' predisposition.",,,,T,,,,,c,,,,,1.0,,
28512644,3994,6648,D004886,Association,TRUE,"T and C alleles of <ENT1>SOD2</ENT1> T2734C individually were linked to patients with bullous and <ENT2>erythematous erysipelas</ENT2>, respectively.",,,,T,,,,,c,,,,,1.0,,
28512644,3975,6648,3605,Association,TRUE,"While variations of IL-1beta, IL-7, IL-8, <ENT2>IL-17</ENT2>, CCL5, and HGF were associated with the <ENT1>SOD2</ENT1> T2734C SNP, variations of PDFG-BB and CCL2 were associated with the CAT C262T SNP.",,,,T,,,,,c,,,,,0.0,,
28512644,3982,c|SYB|T2734|C,D004886,Association,TRUE,"T and C alleles of SOD2 <ENT1>T2734C</ENT1> individually were linked to patients with bullous and <ENT2>erythematous erysipelas</ENT2>, respectively.",,,,T,,,,,c,,,,,0.0,,
28512644,3988,3559,D004886,Association,TRUE,"Serum levels of IL-1beta, CCL11, <ENT1>IL-2Ralpha</ENT1>, CXCL9, TRAIL, PDGF-BB, and CCL4 were associated with symptoms accompanying the infection, while IL-6, IL-9, IL-10, IL-13, IL-15, IL-17, G-CSF, and VEGF were associated with predisposition and recurrence of <ENT2>erysipelas</ENT2>.",,,,T,,,,,w,,,,,0.0,,
28512644,3983,6351,D004886,Association,TRUE,"Serum levels of IL-1beta, CCL11, IL-2Ralpha, CXCL9, TRAIL, PDGF-BB, and <ENT1>CCL4</ENT1> were associated with symptoms accompanying the infection, while IL-6, IL-9, IL-10, IL-13, IL-15, IL-17, G-CSF, and VEGF were associated with predisposition and recurrence of <ENT2>erysipelas</ENT2>.",,,,T,,,,,w,,,,,1.0,,
28512644,3987,4283,D004886,Association,TRUE,"Serum levels of IL-1beta, CCL11, IL-2Ralpha, <ENT1>CXCL9</ENT1>, TRAIL, PDGF-BB, and CCL4 were associated with symptoms accompanying the infection, while IL-6, IL-9, IL-10, IL-13, IL-15, IL-17, G-CSF, and VEGF were associated with predisposition and recurrence of <ENT2>erysipelas</ENT2>.",,,,T,,,,,w,,,,,1.0,,
28512644,3984,847,5155,Association,TRUE,"While variations of IL-1beta, IL-7, IL-8, IL-17, CCL5, and HGF were associated with the SOD2 T2734C SNP, variations of <ENT2>PDFG-BB</ENT2> and CCL2 were associated with the <ENT1>CAT</ENT1> C262T SNP.",,,,T,,,,,c,,,,,0.0,,
28512644,3968,847,6347,Association,TRUE,"While variations of IL-1beta, IL-7, IL-8, IL-17, CCL5, and HGF were associated with the SOD2 T2734C SNP, variations of PDFG-BB and <ENT2>CCL2</ENT2> were associated with the <ENT1>CAT</ENT1> C262T SNP.",,,,T,,,,,c,,,,,0.0,,
28512644,3993,847,D004886,Association,TRUE,"Analysis of Serum Cytokines and Single-Nucleotide Polymorphisms of SOD1, SOD2, and <ENT1>CAT</ENT1> in <ENT2>Erysipelas</ENT2> Patients.",,,,T,,T,,,w,,,,,0.0,,
28512644,3993,847,D004886,Association,TRUE,"Comparing 71 <ENT2>erysipelas</ENT2> patients to 55 age-matched healthy individuals, we sought for <ENT1>CAT</ENT1>, SOD1, and SOD2 single polymorphism mutation (SNPs) interactions with <ENT2>erysipelas</ENT2>' predisposition and serum cytokine levels in the acute and recovery phases of <ENT2>erysipelas infection</ENT2>.",,,,T,,Y,,,w,,,,,1.0,,
28512644,3993,847,D004886,Association,TRUE,"The presence of SOD1 G7958, SOD2 T2734, and <ENT1>CAT</ENT1> C262 alleles was linked to <ENT2>erysipelas</ENT2>' predisposition.",,,,T,,,,,c,,,,,1.0,,
28512644,3985,5155,D004886,Association,TRUE,"Serum levels of IL-1beta, CCL11, IL-2Ralpha, CXCL9, TRAIL, <ENT1>PDGF-BB</ENT1>, and CCL4 were associated with symptoms accompanying the infection, while IL-6, IL-9, IL-10, IL-13, IL-15, IL-17, G-CSF, and VEGF were associated with predisposition and recurrence of <ENT2>erysipelas</ENT2>.",,,,T,,,,,w,,,,,1.0,,
28512644,3979,3586,D004886,Association,TRUE,"Serum levels of IL-1beta, CCL11, IL-2Ralpha, CXCL9, TRAIL, PDGF-BB, and CCL4 were associated with symptoms accompanying the infection, while IL-6, IL-9, <ENT1>IL-10</ENT1>, IL-13, IL-15, IL-17, G-CSF, and VEGF were associated with predisposition and recurrence of <ENT2>erysipelas</ENT2>.",,,,T,,,,,c,,,,,1.0,,
28512644,3977,3600,D004886,Association,TRUE,"Serum levels of IL-1beta, CCL11, IL-2Ralpha, CXCL9, TRAIL, PDGF-BB, and CCL4 were associated with symptoms accompanying the infection, while IL-6, IL-9, IL-10, IL-13, <ENT1>IL-15</ENT1>, IL-17, G-CSF, and VEGF were associated with predisposition and recurrence of <ENT2>erysipelas</ENT2>.",,,,T,,,,,c,,,,,1.0,,
28512644,3981,3569,D004886,Association,TRUE,"Serum levels of IL-1beta, CCL11, IL-2Ralpha, CXCL9, TRAIL, PDGF-BB, and CCL4 were associated with symptoms accompanying the infection, while <ENT1>IL-6</ENT1>, IL-9, IL-10, IL-13, IL-15, IL-17, G-CSF, and VEGF were associated with predisposition and recurrence of <ENT2>erysipelas</ENT2>.",,,,T,,,,,c,,,,,1.0,,
28512644,3967,c|Aelle|G|7958,D004886,Association,TRUE,"The presence of SOD1 <ENT1>G7958</ENT1>, SOD2 T2734, and CAT C262 alleles was linked to <ENT2>erysipelas</ENT2>' predisposition.",,,,T,,,,,c,,,,,1.0,,
28512644,3974,1440,D004886,Association,TRUE,"Serum levels of IL-1beta, CCL11, IL-2Ralpha, CXCL9, TRAIL, PDGF-BB, and CCL4 were associated with symptoms accompanying the infection, while IL-6, IL-9, IL-10, IL-13, IL-15, IL-17, <ENT1>G-CSF</ENT1>, and VEGF were associated with predisposition and recurrence of <ENT2>erysipelas</ENT2>.",,,,T,,,,,c,,,,,1.0,,
28512644,3991,3553,D004886,Association,TRUE,"Serum levels of <ENT1>IL-1beta</ENT1>, CCL11, IL-2Ralpha, CXCL9, TRAIL, PDGF-BB, and CCL4 were associated with symptoms accompanying the infection, while IL-6, IL-9, IL-10, IL-13, IL-15, IL-17, G-CSF, and VEGF were associated with predisposition and recurrence of <ENT2>erysipelas</ENT2>.",,,,T,,,,,w,,,,,1.0,,
28512644,3973,7422,D004886,Association,TRUE,"Serum levels of IL-1beta, CCL11, IL-2Ralpha, CXCL9, TRAIL, PDGF-BB, and CCL4 were associated with symptoms accompanying the infection, while IL-6, IL-9, IL-10, IL-13, IL-15, IL-17, G-CSF, and <ENT1>VEGF</ENT1> were associated with predisposition and recurrence of <ENT2>erysipelas</ENT2>.",,,,T,,,,,c,,,,,1.0,,
28512644,3965,c|Aelle|C|262,D004886,Association,TRUE,"The presence of SOD1 G7958, SOD2 T2734, and CAT <ENT1>C262</ENT1> alleles was linked to <ENT2>erysipelas</ENT2>' predisposition.",,,,T,,,,,c,,,,,1.0,,
28512644,3986,8743,D004886,Association,TRUE,"Serum levels of IL-1beta, CCL11, IL-2Ralpha, CXCL9, <ENT1>TRAIL</ENT1>, PDGF-BB, and CCL4 were associated with symptoms accompanying the infection, while IL-6, IL-9, IL-10, IL-13, IL-15, IL-17, G-CSF, and VEGF were associated with predisposition and recurrence of <ENT2>erysipelas</ENT2>.",,,,T,,,,,w,,,,,1.0,,
28512644,3989,6356,D004886,Association,TRUE,"Serum levels of IL-1beta, <ENT1>CCL11</ENT1>, IL-2Ralpha, CXCL9, TRAIL, PDGF-BB, and CCL4 were associated with symptoms accompanying the infection, while IL-6, IL-9, IL-10, IL-13, IL-15, IL-17, G-CSF, and VEGF were associated with predisposition and recurrence of <ENT2>erysipelas</ENT2>.",,,,T,,,,,w,,,,,1.0,,
28512644,3966,D004886,c|Aelle|T|2734,Association,TRUE,"The presence of SOD1 G7958, SOD2 <ENT2>T2734</ENT2>, and CAT C262 alleles was linked to <ENT1>erysipelas</ENT1>' predisposition.",,,,T,,,,,c,,,,,1.0,,
28512644,3976,D004886,3605,Association,TRUE,"Serum levels of IL-1beta, CCL11, IL-2Ralpha, CXCL9, TRAIL, PDGF-BB, and CCL4 were associated with symptoms accompanying the infection, while IL-6, IL-9, IL-10, IL-13, IL-15, <ENT2>IL-17</ENT2>, G-CSF, and VEGF were associated with predisposition and recurrence of <ENT1>erysipelas</ENT1>.",,,,T,,,,,c,,,,,1.0,,
28512644,3978,D004886,3596,Association,TRUE,"Serum levels of IL-1beta, CCL11, IL-2Ralpha, CXCL9, TRAIL, PDGF-BB, and CCL4 were associated with symptoms accompanying the infection, while IL-6, IL-9, IL-10, <ENT2>IL-13</ENT2>, IL-15, IL-17, G-CSF, and VEGF were associated with predisposition and recurrence of <ENT1>erysipelas</ENT1>.",,,,T,,,,,c,,,,,0.0,,
28518143,4019,24392,24247,Association,TRUE,"Here, we demonstrated that HG decreased the expression of <ENT2>CaSR</ENT2>, mitochondrial fusion proteins (Mfn1, Mfn2), cell gap junction related proteins (<ENT1>Cx43</ENT1>, beta-catenin, N-cadherin), and intracellular ATP concentration.",,,,T,,,,,c,,,,,1.0,,
28518143,3999,24392,361367,Association,TRUE,"In contrast, HG increased extracellular ATP concentration, the expression of <ENT2>gp78</ENT2>, mitochondrial fission proteins (Fis1, Drp1), and the ubiquitination levels of Mfn1, Mfn2 and <ENT1>Cx43</ENT1>.",,,,T,,,,,c,,,,,1.0,,
28518143,4023,D002311,24247,Negative_Correlation,FALSE,"In our previous study, we found that <ENT2>CaSR</ENT2> expression, intracellular calcium levels and cardiac function were all significantly decreased in <ENT1>DCM</ENT1> rats; however, the exact mechanism are not clear yet.",,,,T,,,,,c,,,,,0.0,,
28518143,4023,D002311,24247,Negative_Correlation,FALSE,"Stimulation of <ENT2>CaSR</ENT2> significantly attenuates HG-induced abnormal myocardial energy metabolism, suggesting <ENT2>CaSR</ENT2> would be a promising potential therapeutic target for <ENT1>DCM</ENT1>.",,,,T,,,,,c,,,,,0.0,,
28518143,4004,D002311,D002118,Negative_Correlation,FALSE,"In our previous study, we found that CaSR expression, intracellular <ENT2>calcium</ENT2> levels and cardiac function were all significantly decreased in <ENT1>DCM</ENT1> rats; however, the exact mechanism are not clear yet.",,,,T,,,,,c,,,,,1.0,,
28518143,3996,114114,361367,Association,TRUE,"In contrast, HG increased extracellular ATP concentration, the expression of <ENT2>gp78</ENT2>, mitochondrial fission proteins (Fis1, <ENT1>Drp1</ENT1>), and the ubiquitination levels of Mfn1, Mfn2 and Cx43.",,,,T,,,,,c,,,,,1.0,,
28518143,4026,24247,D008659,Association,TRUE,<ENT1>Calcium sensing receptor</ENT1> protects high glucose-induced energy <ENT2>metabolism disorder</ENT2> via blocking gp78-ubiquitin proteasome pathway.,,,,T,,,,,c,,,,,1.0,,
28518143,4022,24247,D009202,Association,TRUE,The present study revealed the protective role of <ENT1>CaSR</ENT1> in <ENT2>myocardial energy metabolism disorder</ENT2> induced by high glucose (HG) as well as the underlying mechanism.,,,,T,,,,,c,,,,,1.0,,
28518143,4022,24247,D009202,Association,TRUE,"Taken together, these results suggest that HG induces <ENT2>myocardial energy metabolism disorder</ENT2> via decrease of <ENT1>CaSR</ENT1> expression, and activation of gp78-ubiquitin proteasome system.",,,,T,,,,,w,,,,,1.0,,
28518143,4022,24247,D009202,Association,TRUE,"Stimulation of <ENT1>CaSR</ENT1> significantly attenuates HG-induced <ENT2>abnormal myocardial energy metabolism</ENT2>, suggesting <ENT1>CaSR</ENT1> would be a promising potential therapeutic target for DCM.",,,,T,,,,,c,,,,,0.5,,
28518143,4025,24247,D005947,Negative_Correlation,TRUE,<ENT1>Calcium sensing receptor</ENT1> protects high <ENT2>glucose</ENT2>-induced energy metabolism disorder via blocking gp78-ubiquitin proteasome pathway.,,,,T,Y,,,,c,,,,,1.0,,
28518143,4025,24247,D005947,Negative_Correlation,TRUE,The present study revealed the protective role of <ENT1>CaSR</ENT1> in myocardial energy metabolism disorder induced by high <ENT2>glucose</ENT2> (HG) as well as the underlying mechanism.,,,,T,,,,,c,,,,,1.0,,
28518143,4020,24247,64476,Association,TRUE,"Here, we demonstrated that HG decreased the expression of <ENT1>CaSR</ENT1>, mitochondrial fusion proteins (Mfn1, <ENT2>Mfn2</ENT2>), cell gap junction related proteins (Cx43, beta-catenin, N-cadherin), and intracellular ATP concentration.",,,,T,,,,,c,,,,,1.0,,
28518143,4018,24247,D000255,Association,TRUE,"Here, we demonstrated that HG decreased the expression of <ENT1>CaSR</ENT1>, mitochondrial fusion proteins (Mfn1, Mfn2), cell gap junction related proteins (Cx43, beta-catenin, N-cadherin), and intracellular <ENT2>ATP</ENT2> concentration.",,,,T,,,,,c,,,,,1.0,,
28518143,4021,24247,192647,Association,TRUE,"Here, we demonstrated that HG decreased the expression of <ENT1>CaSR</ENT1>, mitochondrial fusion proteins (<ENT2>Mfn1</ENT2>, Mfn2), cell gap junction related proteins (Cx43, beta-catenin, N-cadherin), and intracellular ATP concentration.",,,,T,,,,,c,,,,,0.0,,
28518143,4024,24247,D002118,Association,FALSE,"The <ENT1>calcium sensing receptor</ENT1> (<ENT1>CaSR</ENT1>) is a <ENT1>G protein-coupled receptor</ENT1>, which is involved in maintaining <ENT2>calcium</ENT2> homeostasis, regulating cell proliferation and apoptosis, and so on.",,,,T,,,,,c,,,,,0.333333333,,
28518143,4024,24247,D002118,Association,FALSE,"In our previous study, we found that <ENT1>CaSR</ENT1> expression, intracellular <ENT2>calcium</ENT2> levels and cardiac function were all significantly decreased in DCM rats; however, the exact mechanism are not clear yet.",,,,T,,,,,c,,,,,1.0,,
28518143,4015,D008659,D005947,Positive_Correlation,FALSE,Calcium sensing receptor protects high <ENT2>glucose</ENT2>-induced energy <ENT1>metabolism disorder</ENT1> via blocking gp78-ubiquitin proteasome pathway.,,,,T,,,,,c,,,,,1.0,,
28518143,4002,361367,D009202,Association,TRUE,"Taken together, these results suggest that HG induces <ENT2>myocardial energy metabolism disorder</ENT2> via decrease of CaSR expression, and activation of <ENT1>gp78</ENT1>-ubiquitin proteasome system.",,,,T,,,,,w,,,,,1.0,,
28518143,4007,361367,D005947,Positive_Correlation,TRUE,Calcium sensing receptor protects high <ENT2>glucose</ENT2>-induced energy metabolism disorder via blocking <ENT1>gp78</ENT1>-ubiquitin proteasome pathway.,,,,T,,,,,w,,,,,0.0,,
28518143,3997,361367,288584,Association,TRUE,"In contrast, HG increased extracellular ATP concentration, the expression of <ENT1>gp78</ENT1>, mitochondrial fission proteins (<ENT2>Fis1</ENT2>, Drp1), and the ubiquitination levels of Mfn1, Mfn2 and Cx43.",,,,T,,,,,c,,,,,1.0,,
28518143,4000,361367,64476,Association,TRUE,"In contrast, HG increased extracellular ATP concentration, the expression of <ENT1>gp78</ENT1>, mitochondrial fission proteins (Fis1, Drp1), and the ubiquitination levels of Mfn1, <ENT2>Mfn2</ENT2> and Cx43.",,,,T,,,,,c,,,,,1.0,,
28518143,3998,361367,D000255,Association,TRUE,"In contrast, HG increased extracellular <ENT2>ATP</ENT2> concentration, the expression of <ENT1>gp78</ENT1>, mitochondrial fission proteins (Fis1, Drp1), and the ubiquitination levels of Mfn1, Mfn2 and Cx43.",,,,T,,,,,c,,,,,1.0,,
28518143,4001,361367,192647,Association,TRUE,"In contrast, HG increased extracellular ATP concentration, the expression of <ENT1>gp78</ENT1>, mitochondrial fission proteins (Fis1, Drp1), and the ubiquitination levels of <ENT2>Mfn1</ENT2>, Mfn2 and Cx43.",,,,T,,,,,c,,,,,1.0,,
28518143,4014,D009202,D005947,Positive_Correlation,FALSE,The present study revealed the protective role of CaSR in <ENT1>myocardial energy metabolism disorder</ENT1> induced by high <ENT2>glucose</ENT2> (HG) as well as the underlying mechanism.,,,,T,,,,,c,,,,,1.0,,
28584052,4030,D019636,8473,Association,FALSE,"Accordingly, altered levels of protein <ENT2>O-GlcNAcylation</ENT2> have been associated with developmental defects and <ENT1>neurodegeneration</ENT1>.",,,,T,,,,,c,,,,,0.0,,
28584052,4031,8473,D003147,Association,FALSE,"Accordingly, altered levels of protein <ENT1>O-GlcNAcylation</ENT1> have been associated with <ENT2>developmental defects</ENT2> and neurodegeneration.",,,,T,,,,,c,,,,,1.0,,
28584052,4032,8473,D038901,Association,TRUE,Mutations in <ENT1>N-acetylglucosamine (O-GlcNAc) transferase</ENT1> in patients with <ENT2>X-linked intellectual disability</ENT2>.,,,,T,,T,,,w,,,,,1.0,,
28584052,4032,8473,D038901,Association,TRUE,"Here, we report on two hemizygous mutations in <ENT1>OGT</ENT1> in individuals with <ENT2>X-linked intellectual disability</ENT2> (<ENT2>XLID</ENT2>) and dysmorphic features: one missense mutation (p.Arg284Pro) and one mutation leading to a splicing defect (c.463-6T>G).",,,,T,,Y,,,w,,,,,0.0,,
28584052,4032,8473,D038901,Association,TRUE,"Recombinant <ENT1>OGT</ENT1> bearing the p.Arg284Pro mutation was prone to unfolding and exhibited reduced glycosylation activity against a complex array of glycosylation substrates and proteolytic processing of the transcription factor host cell factor 1, which is also encoded by an <ENT2>XLID</ENT2>-associated gene.",,,,T,,,,,w,,,,,1.0,,
28584052,4032,8473,D038901,Association,TRUE,We conclude that defects in <ENT1>O-GlcNAc</ENT1> homeostasis and host cell factor 1 proteolysis may play roles in mediation of <ENT2>XLID</ENT2> in individuals with <ENT1>OGT</ENT1> mutations.,,,,T,,,,,c,,,,,1.0,,
28584052,4027,c|SUB|T463-6|G,D038901,Association,TRUE,"Here, we report on two hemizygous mutations in OGT in individuals with <ENT2>X-linked intellectual disability</ENT2> (<ENT2>XLID</ENT2>) and dysmorphic features: one missense mutation (p.Arg284Pro) and one mutation leading to a splicing defect (<ENT1>c.463-6T>G</ENT1>).",,,,T,,Y,,,w,,,,,0.0,,
28584052,4028,D038901,3054,Association,TRUE,"Recombinant OGT bearing the p.Arg284Pro mutation was prone to unfolding and exhibited reduced glycosylation activity against a complex array of glycosylation substrates and proteolytic processing of the transcription factor <ENT2>host cell factor 1</ENT2>, which is also encoded by an <ENT1>XLID</ENT1>-associated gene.",,,,T,,,,,c,,,,,1.0,,
28584052,4028,D038901,3054,Association,TRUE,We conclude that defects in O-GlcNAc homeostasis and <ENT2>host cell factor 1</ENT2> proteolysis may play roles in mediation of <ENT1>XLID</ENT1> in individuals with OGT mutations.,,,,T,,,,,c,,,,,1.0,,
28584052,4029,D038901,rs1114167891,Association,TRUE,"Here, we report on two hemizygous mutations in OGT in individuals with <ENT1>X-linked intellectual disability</ENT1> (<ENT1>XLID</ENT1>) and dysmorphic features: one missense mutation (<ENT2>p.Arg284Pro</ENT2>) and one mutation leading to a splicing defect (c.463-6T>G).",,,,T,,Y,,,w,,,,,0.0,,
28584052,4029,D038901,rs1114167891,Association,TRUE,"Recombinant OGT bearing the <ENT2>p.Arg284Pro</ENT2> mutation was prone to unfolding and exhibited reduced glycosylation activity against a complex array of glycosylation substrates and proteolytic processing of the transcription factor host cell factor 1, which is also encoded by an <ENT1>XLID</ENT1>-associated gene.",,,,T,,,,,w,,,,,1.0,,
28604678,4040,128866,27243,Association,TRUE,"In vitro, the <ENT2>Vps2</ENT2>/Vps24 subunits of <ENT2><ENT1>ESCRT-III</ENT2></ENT1> formed side-by-side filaments with <ENT1>Snf7</ENT1> and inhibited further polymerization, but the growth inhibition was alleviated by the addition of Vps4 and ATP.",,,,T,,,,,c,,,,,0.5,,
28604678;28604678,4042;4039,128866;27243,27183;27183,Association;Association,TRUE;TRUE,Dynamic subunit turnover in <ENT1>ESCRT-III</ENT1> assemblies is regulated by <ENT2>Vps4</ENT2> to mediate membrane remodelling during cytokinesis.,,,,T,,,,,c,,,,,0.0,,
28604678;28604678,4042;4039,128866;27243,27183;27183,Association;Association,TRUE;TRUE,"<ENT1>ESCRT-III</ENT1> turnover depended on the <ENT2>ATPase</ENT2> <ENT2>VPS4</ENT2>, which accumulated at the midbody simultaneously with <ENT1>ESCRT-III</ENT1> subunits, and was required for assembly of functional <ENT1>ESCRT-III</ENT1> structures.",,,,T,,,,,c,,,,,0.833333333,,
28604678,4042,128866,27183,Association,TRUE,"In vitro, the Vps2/Vps24 subunits of <ENT1>ESCRT-III</ENT1> formed side-by-side filaments with <ENT1>Snf7</ENT1> and inhibited further polymerization, but the growth inhibition was alleviated by the addition of <ENT2>Vps4</ENT2> and ATP.",,,,T,,,,,w,,,,,0.0,,
28604678;28604678,4042;4039,128866;27243,27183;27183,Association;Association,TRUE;TRUE,High-speed atomic force microscopy further revealed highly dynamic arrays of growing and shrinking <ENT1>ESCRT-III</ENT1> spirals in the presence of <ENT2>Vps4</ENT2>.,,,,T,,,,,c,,,,,0.0,,
28604678,4036,128866,51652,Association,TRUE,"In vitro, the Vps2/<ENT2>Vps24</ENT2> subunits of <ENT2><ENT1>ESCRT-III</ENT2></ENT1> formed side-by-side filaments with <ENT1>Snf7</ENT1> and inhibited further polymerization, but the growth inhibition was alleviated by the addition of Vps4 and ATP.",,,,T,,,,,c,,,,,0.5,,Duplicate remove
28604678,4037,29082,27243,Association,TRUE,"In vitro, the <ENT2>Vps2</ENT2>/Vps24 subunits of <ENT2>ESCRT-III</ENT2> formed side-by-side filaments with <ENT1>Snf7</ENT1> and inhibited further polymerization, but the growth inhibition was alleviated by the addition of Vps4 and ATP.",,,,T,,,,,c,,,,,1.0,,
28604678,4033,29082,51652,Association,TRUE,"In vitro, the Vps2/<ENT2>Vps24</ENT2> subunits of <ENT2>ESCRT-III</ENT2> formed side-by-side filaments with <ENT1>Snf7</ENT1> and inhibited further polymerization, but the growth inhibition was alleviated by the addition of Vps4 and ATP.",,,,T,,,,,c,,,,,1.0,,
28604678,4039,27243,27183,Association,TRUE,"In vitro, the <ENT1>Vps2</ENT1>/Vps24 subunits of <ENT1>ESCRT-III</ENT1> formed side-by-side filaments with Snf7 and inhibited further polymerization, but the growth inhibition was alleviated by the addition of <ENT2>Vps4</ENT2> and ATP.",,,,T,,,,,w,,,,,0.0,,
28604678,4035,27183,51652,Association,TRUE,Dynamic subunit turnover in <ENT2>ESCRT-III</ENT2> assemblies is regulated by <ENT1>Vps4</ENT1> to mediate membrane remodelling during cytokinesis.,,,,T,,,,,c,,,,,1.0,,
28604678,4035,27183,51652,Association,TRUE,"<ENT2>ESCRT-III</ENT2> turnover depended on the <ENT1>ATPase</ENT1> <ENT1>VPS4</ENT1>, which accumulated at the midbody simultaneously with <ENT2>ESCRT-III</ENT2> subunits, and was required for assembly of functional <ENT2>ESCRT-III</ENT2> structures.",,,,T,,,,,c,,,,,0.666666667,,
28604678,4035,27183,51652,Association,TRUE,"In vitro, the Vps2/<ENT2>Vps24</ENT2> subunits of <ENT2>ESCRT-III</ENT2> formed side-by-side filaments with Snf7 and inhibited further polymerization, but the growth inhibition was alleviated by the addition of <ENT1>Vps4</ENT1> and ATP.",,,,T,,,,,w,,,,,0.0,,
28604678,4035,27183,51652,Association,TRUE,High-speed atomic force microscopy further revealed highly dynamic arrays of growing and shrinking <ENT2>ESCRT-III</ENT2> spirals in the presence of <ENT1>Vps4</ENT1>.,,,,T,,,,,c,,,,,0.0,,
28650467,4045,D007938,D008691,Association,TRUE,"<ENT2>Methadone</ENT2>, an agonist of OPRM1, enhances the sensitivity of parental <ENT1>leukemic</ENT1> cells, but not OPRM1-depleted cells, to L-asparaginase treatment, indicating that OPRM1 is required for the synergistic action of L-asparaginase and <ENT2>methadone</ENT2>, and that OPRM1 loss promotes <ENT1>leukemic</ENT1> cell survival likely through downregulation of the OPRM1-mediated apoptotic pathway.",,,,T,,,,,c,,,,,0.0,,
28650467,4052,D007938,D001215,Negative_Correlation,FALSE,"Therefore, we sought to identify genes that are involved in <ENT2>L-asparaginase</ENT2> resistance in primary <ENT1>leukemic</ENT1> cells.",,,,T,,,,,c,,,,,0.0,,
28650467,4052,D007938,D001215,Negative_Correlation,FALSE,"Methadone, an agonist of OPRM1, enhances the sensitivity of parental <ENT1>leukemic</ENT1> cells, but not OPRM1-depleted cells, to <ENT2>L-asparaginase</ENT2> treatment, indicating that OPRM1 is required for the synergistic action of <ENT2>L-asparaginase</ENT2> and methadone, and that OPRM1 loss promotes <ENT1>leukemic</ENT1> cell survival likely through downregulation of the OPRM1-mediated apoptotic pathway.",,,,T,,,,,w,,,,,0.0,,
28650467,4052,D007938,D001215,Negative_Correlation,FALSE,"Consistent with this premise, patient <ENT1>leukemic</ENT1> cells with relatively high levels of OPRM1 are more sensitive to <ENT2>L-asparaginase</ENT2> treatment compared to OPRM1-depleted <ENT1>leukemic</ENT1> cells, further indicating that OPRM1 loss has a crucial role in <ENT2>L-asparaginase</ENT2> resistance in <ENT1>leukemic</ENT1> patients.",,,,T,,,,,w,,,,,0.333333333,,
28650467,4054,D007938,4988,Association,TRUE,We also found that <ENT2>OPRM1</ENT2> is expressed in all <ENT1>leukemic</ENT1> cells tested.,,,,T,,,,,c,,,,,0.0,,
28650467,4054,D007938,4988,Association,TRUE,"Methadone, an agonist of <ENT2>OPRM1</ENT2>, enhances the sensitivity of parental <ENT1>leukemic</ENT1> cells, but not <ENT2>OPRM1</ENT2>-depleted cells, to L-asparaginase treatment, indicating that <ENT2>OPRM1</ENT2> is required for the synergistic action of L-asparaginase and methadone, and that <ENT2>OPRM1</ENT2> loss promotes <ENT1>leukemic</ENT1> cell survival likely through downregulation of the <ENT2>OPRM1</ENT2>-mediated apoptotic pathway.",,,,T,,,,,w,,,"11,24",,0.3,,
28650467,4054,D007938,4988,Association,TRUE,"Consistent with this premise, patient <ENT1>leukemic</ENT1> cells with relatively high levels of <ENT2>OPRM1</ENT2> are more sensitive to L-asparaginase treatment compared to <ENT2>OPRM1</ENT2>-depleted <ENT1>leukemic</ENT1> cells, further indicating that <ENT2>OPRM1</ENT2> loss has a crucial role in L-asparaginase resistance in <ENT1>leukemic</ENT1> patients.",,,,T,,,,,w,,,"11,22,33",,0.444444444,,
28650467,4047,11065,D054198,Association,TRUE,"By unbiased genome-wide RNAi screening, we found that among 10 resistant <ENT2>ALL</ENT2> clones, six hits were for opioid receptor mu 1 (oprm1), two hits were for carbonic anhydrase 1 (ca1) and another two hits were for <ENT1>ubiquitin-conjugating enzyme E2C</ENT1> (<ENT1>ube2c</ENT1>).",,,,T,,,,,c,,,,,1.0,,
28650467,4053,D054198,D001215,Negative_Correlation,FALSE,Genome-wide loss-of-function genetic screening identifies opioid receptor u1 as a key regulator of <ENT2>L-asparaginase</ENT2> resistance in pediatric <ENT1>acute lymphoblastic leukemia</ENT1>.,,,,T,,,,,c,,,,,1.0,,
28650467,4053,D054198,D001215,Negative_Correlation,FALSE,<ENT2>L-asparaginase</ENT2> is a critical chemotherapeutic agent for <ENT1>acute lymphoblastic leukemia</ENT1> (<ENT1>ALL</ENT1>).,,,,T,,,,,c,,,,,0.0,,
28650467,4053,D054198,D001215,Negative_Correlation,FALSE,The molecular mechanism by which <ENT1>ALL</ENT1> cells acquire resistance to <ENT2>L-asparaginase</ENT2> is unknown.,,,,T,,,,,c,,,,,0.0,,
28650467,4053,D054198,D001215,Negative_Correlation,FALSE,"Thus, our study demonstrates for the first time, a novel OPRM1-mediated mechanism for <ENT2>L-asparaginase</ENT2> resistance in <ENT1>ALL</ENT1>, and identifies OPRM1 as a functional biomarker for defining high-risk subpopulations and for the detection of evolving resistant clones.",,,,T,,,,,c,,,,,0.0,,
28650467,4053,D054198,D001215,Negative_Correlation,FALSE,"Oprm1 may also be utilized for effective treatment of <ENT2>L-asparaginase</ENT2>-resistant <ENT1>ALL</ENT1>.Oncogene advance online publication, 26 June 2017; doi:10.1038/onc.2017.211.",,,,T,,,,,c,,,,,1.0,,
28650467,4048,D054198,759,Association,TRUE,"By unbiased genome-wide RNAi screening, we found that among 10 resistant <ENT1>ALL</ENT1> clones, six hits were for opioid receptor mu 1 (oprm1), two hits were for <ENT2>carbonic anhydrase 1</ENT2> (<ENT2>ca1</ENT2>) and another two hits were for ubiquitin-conjugating enzyme E2C (ube2c).",,,,T,,,,,c,,,,,1.0,,
28650467,4055,D054198,4988,Negative_Correlation,TRUE,Genome-wide loss-of-function genetic screening identifies <ENT2>opioid receptor u1</ENT2> as a key regulator of L-asparaginase resistance in pediatric <ENT1>acute lymphoblastic leukemia</ENT1>.,,,,T,,,,,w,,,,,0.0,,
28650467,4055,D054198,4988,Negative_Correlation,TRUE,"By unbiased genome-wide RNAi screening, we found that among 10 resistant <ENT1>ALL</ENT1> clones, six hits were for <ENT2>opioid receptor mu 1</ENT2> (<ENT2>oprm1</ENT2>), two hits were for carbonic anhydrase 1 (ca1) and another two hits were for ubiquitin-conjugating enzyme E2C (ube2c).",,,,T,,,,,w,,,,,0.5,,
28650467,4055,D054198,4988,Negative_Correlation,TRUE,"Thus, our study demonstrates for the first time, a novel <ENT2>OPRM1</ENT2>-mediated mechanism for L-asparaginase resistance in <ENT1>ALL</ENT1>, and identifies <ENT2>OPRM1</ENT2> as a functional biomarker for defining high-risk subpopulations and for the detection of evolving resistant clones.",,,,T,,,,,w,,,,,0.0,,
28650467,4055,D054198,4988,Negative_Correlation,TRUE,"<ENT2>Oprm1</ENT2> may also be utilized for effective treatment of L-asparaginase-resistant <ENT1>ALL</ENT1>.Oncogene advance online publication, 26 June 2017; doi:10.1038/onc.2017.211.",,,,T,,,,,c,,,,,0.0,,
28650467,4051,D008691,D001215,Cotreatment,TRUE,"<ENT1>Methadone</ENT1>, an agonist of OPRM1, enhances the sensitivity of parental leukemic cells, but not OPRM1-depleted cells, to <ENT2>L-asparaginase</ENT2> treatment, indicating that OPRM1 is required for the synergistic action of <ENT2>L-asparaginase</ENT2> and <ENT1>methadone</ENT1>, and that OPRM1 loss promotes leukemic cell survival likely through downregulation of the OPRM1-mediated apoptotic pathway.",,,,T,,,,,w,,,,,0.0,,
28650467,4046,D008691,4988,Positive_Correlation,TRUE,"<ENT1>Methadone</ENT1>, an agonist of <ENT2>OPRM1</ENT2>, enhances the sensitivity of parental leukemic cells, but not <ENT2>OPRM1</ENT2>-depleted cells, to L-asparaginase treatment, indicating that <ENT2>OPRM1</ENT2> is required for the synergistic action of L-asparaginase and <ENT1>methadone</ENT1>, and that <ENT2>OPRM1</ENT2> loss promotes leukemic cell survival likely through downregulation of the <ENT2>OPRM1</ENT2>-mediated apoptotic pathway.",,,,T,,,,,w,,,,,0.3,,
28650467,4056,D001215,4988,Positive_Correlation,TRUE,Genome-wide loss-of-function genetic screening identifies <ENT2>opioid receptor u1</ENT2> as a key regulator of <ENT1>L-asparaginase</ENT1> resistance in pediatric acute lymphoblastic leukemia.,,,,T,,,,,w,,,,,0.0,,
28650467,4056,D001215,4988,Positive_Correlation,TRUE,"Specific knockdown of <ENT2>OPRM1</ENT2> confers <ENT1>L-asparaginase</ENT1> resistance, validating our genome-wide retroviral shRNA library screening data.",,,,T,,,,,w,,,,,0.0,,
28650467,4056,D001215,4988,Positive_Correlation,TRUE,"Methadone, an agonist of <ENT2>OPRM1</ENT2>, enhances the sensitivity of parental leukemic cells, but not <ENT2>OPRM1</ENT2>-depleted cells, to <ENT1>L-asparaginase</ENT1> treatment, indicating that <ENT2>OPRM1</ENT2> is required for the synergistic action of <ENT1>L-asparaginase</ENT1> and methadone, and that <ENT2>OPRM1</ENT2> loss promotes leukemic cell survival likely through downregulation of the <ENT2>OPRM1</ENT2>-mediated apoptotic pathway.",,,,T,,,,,w,,,"11,23",,0.3,,
28650467,4056,D001215,4988,Positive_Correlation,TRUE,"Consistent with this premise, patient leukemic cells with relatively high levels of <ENT2>OPRM1</ENT2> are more sensitive to <ENT1>L-asparaginase</ENT1> treatment compared to <ENT2>OPRM1</ENT2>-depleted leukemic cells, further indicating that <ENT2>OPRM1</ENT2> loss has a crucial role in <ENT1>L-asparaginase</ENT1> resistance in leukemic patients.",,,,T,,,,,w,,,,,0.0,,
28650467,4056,D001215,4988,Positive_Correlation,TRUE,"Thus, our study demonstrates for the first time, a novel <ENT2>OPRM1</ENT2>-mediated mechanism for <ENT1>L-asparaginase</ENT1> resistance in ALL, and identifies <ENT2>OPRM1</ENT2> as a functional biomarker for defining high-risk subpopulations and for the detection of evolving resistant clones.",,,,T,,,,,w,,,,,1.0,,
28650467,4056,D001215,4988,Positive_Correlation,TRUE,"<ENT2>Oprm1</ENT2> may also be utilized for effective treatment of <ENT1>L-asparaginase</ENT1>-resistant ALL.Oncogene advance online publication, 26 June 2017; doi:10.1038/onc.2017.211.",,,,T,,,,,c,,,,,1.0,,
28650467,4044,D001224,D001216,Association,FALSE,"It hydrolyzes plasma <ENT2>asparagine</ENT2> into <ENT1>aspartate</ENT1> and NH3, causing asparagine deficit and inhibition of protein synthesis and eventually, leukemic cell death.",,,,T,,,,,c,,,,,0.0,,
28650467,4043,D001216,D000641,Association,FALSE,"It hydrolyzes plasma <ENT1>asparagine</ENT1> into aspartate and <ENT2>NH3</ENT2>, causing asparagine deficit and inhibition of protein synthesis and eventually, leukemic cell death.",,,,T,,,,,c,,,,,0.0,,
28660748,4062,D004002,D008113,Negative_Correlation,TRUE,Treatment of WT with <ENT1>clodronate</ENT1> liposomes suppressed <ENT2>liver metastasis</ENT2> by diminishing TGF-b1(+) F4/80(+) cells accumulation.,,,,T,,,,,c,,,,,0.0,,
28660748,4066,11607,13733,Positive_Correlation,TRUE,"The mRNA levels of CD31, transforming growth factor- b1 (TGF-b1), and <ENT2>F4/80</ENT2> were suppressed in <ENT1>AT1a</ENT1>KO compared with WT.",,,,T,,,,,w,,,,,0.0,,
28660748,4066,11607,13733,Positive_Correlation,TRUE,Double immunofluorescence analysis showed that the number of accumulated <ENT2>F4/80</ENT2>(+) cells expressing TGF-b1 in metastatic areas was higher in WT than in <ENT1>AT1a</ENT1>KO.,,,,T,,,,,w,,,,,0.0,,
28660748,4068,11607,21803,Positive_Correlation,TRUE,"The mRNA levels of CD31, <ENT2>transforming growth factor- b1</ENT2> (<ENT2>TGF-b1</ENT2>), and F4/80 were suppressed in <ENT1>AT1a</ENT1>KO compared with WT.",,,,T,,,,,w,,,,,1.0,,
28660748,4068,11607,21803,Positive_Correlation,TRUE,Double immunofluorescence analysis showed that the number of accumulated F4/80(+) cells expressing <ENT2>TGF-b1</ENT2> in metastatic areas was higher in WT than in <ENT1>AT1a</ENT1>KO.,,,,T,,,,,c,,,,,1.0,,
28660748,4068,11607,21803,Positive_Correlation,TRUE,These results suggested that resident hepatic macrophages induced liver metastasis formation by induction of <ENT2>TGF-b1</ENT2> through <ENT1>AT1a</ENT1> signaling.,,,,T,,,,,c,,,,,0.0,,
28660748,4070,11607,18613,Positive_Correlation,TRUE,"The mRNA levels of <ENT2>CD31</ENT2>, transforming growth factor- b1 (TGF-b1), and F4/80 were suppressed in <ENT1>AT1a</ENT1>KO compared with WT.",,,,T,,,,,w,,,,,0.0,,
28660748,4069,11607,D008113,Association,TRUE,<ENT1>Angiotensin II subtype 1a receptor</ENT1> signaling in resident hepatic macrophages induces <ENT2>liver metastasis</ENT2> formation.,,,,T,,,,,c,,,,,1.0,,
28660748,4069,11607,D008113,Association,TRUE,This study was designed to evaluate the role of <ENT1>angiotensin II subtype receptor 1a</ENT1> (<ENT1>AT1a</ENT1>) in the formation of <ENT2>liver metastasis</ENT2> in CRC.,,,,T,,Y,,,w,,,,,1.0,,
28660748,4069,11607,D008113,Association,TRUE,A model of <ENT2>liver metastasis</ENT2> was developed by intrasplenic injection of mouse colon cancer (CMT-93) into <ENT1>AT1a</ENT1> knockout mice (<ENT1>AT1a</ENT1>KO) and wild-type (C57BL/6) mice (WT).,,,,T,,Y,,,w,,,,,1.0,,
28660748,4069,11607,D008113,Association,TRUE,"Compared with WT mice, the liver weight and <ENT2>liver metastatic</ENT2> rate were significantly lower in <ENT1>AT1a</ENT1>KO.",,,,T,,,,,c,,,,,0.0,,
28660748,4069,11607,D008113,Association,TRUE,The <ENT1>AT1a</ENT1>KO bone marrow (BM) (<ENT1>AT1a</ENT1>KO-BM)>WT showed suppressed formation of <ENT2>liver metastasis</ENT2> compared with WT-BM>WT.,,,,T,,,,,c,,,,,1.0,,
28660748,4069,11607,D008113,Association,TRUE,"The formation of <ENT2>liver metastasis</ENT2> correlated with collagen deposition in the metastatic area, which was dependent on <ENT1>AT1a</ENT1> signaling.",,,,T,,,,,c,,,,,1.0,,
28660748,4069,11607,D008113,Association,TRUE,These results suggested that resident hepatic macrophages induced <ENT2>liver metastasis</ENT2> formation by induction of TGF-b1 through <ENT1>AT1a</ENT1> signaling.,,,,T,,,,,w,,,,,1.0,,
28660748,4060,11607,12842,Association,TRUE,"The formation of liver metastasis correlated with <ENT2>collagen</ENT2> deposition in the metastatic area, which was dependent on <ENT1>AT1a</ENT1> signaling.",,,,T,,,,,c,,,,,1.0,,
28660748,4065,21803,11606,Positive_Correlation,TRUE,<ENT2>Angiotensin II</ENT2> enhanced <ENT1>TGF-b1</ENT1> expression in Kupffer cells.,,,,T,,,,,c,,,,,1.0,,
28660748,4067,21803,D008113,Association,TRUE,"In addition, accumulated F4/80(+) cells in the <ENT2>liver metastasis</ENT2> were not BM-derived F4/80(+) cells, but mainly resident hepatic F4/80(+) cells, and these resident hepatic F4/80(+) cells were positive for <ENT1>TGF-b1</ENT1>.",,,,T,,,,,c,,,,,0.0,,
28660748,4067,21803,D008113,Association,TRUE,Treatment of WT with clodronate liposomes suppressed <ENT2>liver metastasis</ENT2> by diminishing <ENT1>TGF-b1</ENT1>(+) F4/80(+) cells accumulation.,,,,T,,,,,w,,,,,1.0,,
28660748,4067,21803,D008113,Association,TRUE,These results suggested that resident hepatic macrophages induced <ENT2>liver metastasis</ENT2> formation by induction of <ENT1>TGF-b1</ENT1> through AT1a signaling.,,,,T,,,,,w,,,,,1.0,,
28660748,4064,11606,D009362,Association,FALSE,The renin-<ENT1>angiotensin</ENT1> system is involved in tumor growth and <ENT2>metastases</ENT2>.,,,,T,,,,,c,,,,,0.0,,
28660748,4063,11606,D009369,Association,FALSE,The renin-<ENT1>angiotensin</ENT1> system is involved in <ENT2>tumor</ENT2> growth and metastases.,,,,T,,,,,c,,,,,1.0,,
28660748,4059,11606,19701,Association,FALSE,The <ENT2>renin</ENT2>-<ENT1>angiotensin</ENT1> system is involved in tumor growth and metastases.,,,,T,,,,,w,,,,,0.0,,
28660748,4061,D008113,12842,Association,TRUE,"The formation of <ENT1>liver metastasis</ENT1> correlated with <ENT2>collagen</ENT2> deposition in the metastatic area, which was dependent on AT1a signaling.",,,,T,,,,,c,,,,,1.0,,
28660748,4058,D009362,19701,Association,FALSE,The <ENT2>renin</ENT2>-angiotensin system is involved in tumor growth and <ENT1>metastases</ENT1>.,,,,T,,,,,c,,,,,0.0,,
28660748,4057,D009369,19701,Association,FALSE,The <ENT2>renin</ENT2>-angiotensin system is involved in <ENT1>tumor</ENT1> growth and metastases.,,,,T,,,,,c,,,,,1.0,,
28747658,4090,983,155348,Association,TRUE,"Here, we show that a single Arginine (R) to Glycine (G) mutation at position 76 in the refp17 backbone (<ENT2>p17</ENT2>R76G), as in the S75X variant, is per se sufficient to confer a B-cell clonogenic potential to the viral protein and modulate, through activation of the PTEN/PI3K/Akt signaling pathway, different molecules involved in apoptosis inhibition (CASP-9, CASP-7, DFF-45, NPM, YWHAZ, Src, PAX2, MAPK8), cell cycle promotion and cancer progression (<ENT1>CDK1</ENT1>, CDK2, CDK8, CHEK1, CHEK2, GSK-3 beta, NPM, PAK1, PP2C-alpha).",,,,T,,,,,c,,,,,0.0,,
28747658,4080,983,D009369,Association,FALSE,"Here, we show that a single Arginine (R) to Glycine (G) mutation at position 76 in the refp17 backbone (p17R76G), as in the S75X variant, is per se sufficient to confer a B-cell clonogenic potential to the viral protein and modulate, through activation of the PTEN/PI3K/Akt signaling pathway, different molecules involved in apoptosis inhibition (CASP-9, CASP-7, DFF-45, NPM, YWHAZ, Src, PAX2, MAPK8), cell cycle promotion and <ENT2>cancer</ENT2> progression (<ENT1>CDK1</ENT1>, CDK2, CDK8, CHEK1, CHEK2, GSK-3 beta, NPM, PAK1, PP2C-alpha).",,,,T,,,,,w,,,,,0.0,,
28747658,4092,5599,155348,Association,TRUE,"Here, we show that a single Arginine (R) to Glycine (G) mutation at position 76 in the refp17 backbone (<ENT2>p17</ENT2>R76G), as in the S75X variant, is per se sufficient to confer a B-cell clonogenic potential to the viral protein and modulate, through activation of the PTEN/PI3K/Akt signaling pathway, different molecules involved in apoptosis inhibition (CASP-9, CASP-7, DFF-45, NPM, YWHAZ, Src, PAX2, <ENT1>MAPK8</ENT1>), cell cycle promotion and cancer progression (CDK1, CDK2, CDK8, CHEK1, CHEK2, GSK-3 beta, NPM, PAK1, PP2C-alpha).",,,,T,,,,,c,,,,,0.0,,
28747658,4083,5494,155348,Association,TRUE,"Here, we show that a single Arginine (R) to Glycine (G) mutation at position 76 in the refp17 backbone (<ENT2>p17</ENT2>R76G), as in the S75X variant, is per se sufficient to confer a B-cell clonogenic potential to the viral protein and modulate, through activation of the PTEN/PI3K/Akt signaling pathway, different molecules involved in apoptosis inhibition (CASP-9, CASP-7, DFF-45, NPM, YWHAZ, Src, PAX2, MAPK8), cell cycle promotion and cancer progression (CDK1, CDK2, CDK8, CHEK1, CHEK2, GSK-3 beta, NPM, PAK1, <ENT1>PP2C-alpha</ENT1>).",,,,T,,,,,c,,,,,0.0,,
28747658,4073,5494,D009369,Association,FALSE,"Here, we show that a single Arginine (R) to Glycine (G) mutation at position 76 in the refp17 backbone (p17R76G), as in the S75X variant, is per se sufficient to confer a B-cell clonogenic potential to the viral protein and modulate, through activation of the PTEN/PI3K/Akt signaling pathway, different molecules involved in apoptosis inhibition (CASP-9, CASP-7, DFF-45, NPM, YWHAZ, Src, PAX2, MAPK8), cell cycle promotion and <ENT2>cancer</ENT2> progression (CDK1, CDK2, CDK8, CHEK1, CHEK2, GSK-3 beta, NPM, PAK1, <ENT1>PP2C-alpha</ENT1>).",,,,T,,,,,w,,,,,0.0,,
28747658,4093,5076,155348,Association,TRUE,"Here, we show that a single Arginine (R) to Glycine (G) mutation at position 76 in the refp17 backbone (<ENT2>p17</ENT2>R76G), as in the S75X variant, is per se sufficient to confer a B-cell clonogenic potential to the viral protein and modulate, through activation of the PTEN/PI3K/Akt signaling pathway, different molecules involved in apoptosis inhibition (CASP-9, CASP-7, DFF-45, NPM, YWHAZ, Src, <ENT1>PAX2</ENT1>, MAPK8), cell cycle promotion and cancer progression (CDK1, CDK2, CDK8, CHEK1, CHEK2, GSK-3 beta, NPM, PAK1, PP2C-alpha).",,,,T,,,,,c,,,,,0.0,,
28747658,4084,155348,5058,Association,TRUE,"Here, we show that a single Arginine (R) to Glycine (G) mutation at position 76 in the refp17 backbone (<ENT1>p17</ENT1>R76G), as in the S75X variant, is per se sufficient to confer a B-cell clonogenic potential to the viral protein and modulate, through activation of the PTEN/PI3K/Akt signaling pathway, different molecules involved in apoptosis inhibition (CASP-9, CASP-7, DFF-45, NPM, YWHAZ, Src, PAX2, MAPK8), cell cycle promotion and cancer progression (CDK1, CDK2, CDK8, CHEK1, CHEK2, GSK-3 beta, NPM, <ENT2>PAK1</ENT2>, PP2C-alpha).",,,,T,,,,,c,,,,,0.0,,
28747658,4098,155348,840,Association,TRUE,"Here, we show that a single Arginine (R) to Glycine (G) mutation at position 76 in the refp17 backbone (<ENT1>p17</ENT1>R76G), as in the S75X variant, is per se sufficient to confer a B-cell clonogenic potential to the viral protein and modulate, through activation of the PTEN/PI3K/Akt signaling pathway, different molecules involved in apoptosis inhibition (CASP-9, <ENT2>CASP-7</ENT2>, DFF-45, NPM, YWHAZ, Src, PAX2, MAPK8), cell cycle promotion and cancer progression (CDK1, CDK2, CDK8, CHEK1, CHEK2, GSK-3 beta, NPM, PAK1, PP2C-alpha).",,,,T,,,,,c,,,,,0.0,,
28747658,4085,155348,2932,Association,TRUE,"Here, we show that a single Arginine (R) to Glycine (G) mutation at position 76 in the refp17 backbone (<ENT1>p17</ENT1>R76G), as in the S75X variant, is per se sufficient to confer a B-cell clonogenic potential to the viral protein and modulate, through activation of the PTEN/PI3K/Akt signaling pathway, different molecules involved in apoptosis inhibition (CASP-9, CASP-7, DFF-45, NPM, YWHAZ, Src, PAX2, MAPK8), cell cycle promotion and cancer progression (CDK1, CDK2, CDK8, CHEK1, CHEK2, <ENT2>GSK-3 beta</ENT2>, NPM, PAK1, PP2C-alpha).",,,,T,,,,,c,,,,,0.0,,
28747658,4088,155348,1024,Association,TRUE,"Here, we show that a single Arginine (R) to Glycine (G) mutation at position 76 in the refp17 backbone (<ENT1>p17</ENT1>R76G), as in the S75X variant, is per se sufficient to confer a B-cell clonogenic potential to the viral protein and modulate, through activation of the PTEN/PI3K/Akt signaling pathway, different molecules involved in apoptosis inhibition (CASP-9, CASP-7, DFF-45, NPM, YWHAZ, Src, PAX2, MAPK8), cell cycle promotion and cancer progression (CDK1, CDK2, <ENT2>CDK8</ENT2>, CHEK1, CHEK2, GSK-3 beta, NPM, PAK1, PP2C-alpha).",,,,T,,,,,c,,,,,0.0,,
28747658,4089,155348,1017,Association,TRUE,"Here, we show that a single Arginine (R) to Glycine (G) mutation at position 76 in the refp17 backbone (<ENT1>p17</ENT1>R76G), as in the S75X variant, is per se sufficient to confer a B-cell clonogenic potential to the viral protein and modulate, through activation of the PTEN/PI3K/Akt signaling pathway, different molecules involved in apoptosis inhibition (CASP-9, CASP-7, DFF-45, NPM, YWHAZ, Src, PAX2, MAPK8), cell cycle promotion and cancer progression (CDK1, <ENT2>CDK2</ENT2>, CDK8, CHEK1, CHEK2, GSK-3 beta, NPM, PAK1, PP2C-alpha).",,,,T,,,,,c,,,,,0.0,,
28747658,4091,155348,D009369,Association,FALSE,"Here, we show that a single Arginine (R) to Glycine (G) mutation at position 76 in the refp17 backbone (<ENT1>p17</ENT1>R76G), as in the S75X variant, is per se sufficient to confer a B-cell clonogenic potential to the viral protein and modulate, through activation of the PTEN/PI3K/Akt signaling pathway, different molecules involved in apoptosis inhibition (CASP-9, CASP-7, DFF-45, NPM, YWHAZ, Src, PAX2, MAPK8), cell cycle promotion and <ENT2>cancer</ENT2> progression (CDK1, CDK2, CDK8, CHEK1, CHEK2, GSK-3 beta, NPM, PAK1, PP2C-alpha).",,,,T,,,,,c,,,,,0.0,,
28747658,4094,155348,6714,Association,TRUE,"Here, we show that a single Arginine (R) to Glycine (G) mutation at position 76 in the refp17 backbone (<ENT1>p17</ENT1>R76G), as in the S75X variant, is per se sufficient to confer a B-cell clonogenic potential to the viral protein and modulate, through activation of the PTEN/PI3K/Akt signaling pathway, different molecules involved in apoptosis inhibition (CASP-9, CASP-7, DFF-45, NPM, YWHAZ, <ENT2>Src</ENT2>, PAX2, MAPK8), cell cycle promotion and cancer progression (CDK1, CDK2, CDK8, CHEK1, CHEK2, GSK-3 beta, NPM, PAK1, PP2C-alpha).",,,,T,,,,,c,,,,,0.0,,
28747658,4087,155348,1111,Association,TRUE,"Here, we show that a single Arginine (R) to Glycine (G) mutation at position 76 in the refp17 backbone (<ENT1>p17</ENT1>R76G), as in the S75X variant, is per se sufficient to confer a B-cell clonogenic potential to the viral protein and modulate, through activation of the PTEN/PI3K/Akt signaling pathway, different molecules involved in apoptosis inhibition (CASP-9, CASP-7, DFF-45, NPM, YWHAZ, Src, PAX2, MAPK8), cell cycle promotion and cancer progression (CDK1, CDK2, CDK8, <ENT2>CHEK1</ENT2>, CHEK2, GSK-3 beta, NPM, PAK1, PP2C-alpha).",,,,T,,,,,c,,,,,0.0,,
28747658,4082,155348,D008223,Association,TRUE,"Recent data highlight the presence, in HIV-1-seropositive patients with <ENT2>lymphoma</ENT2>, of <ENT1>p17</ENT1> variants (vp17s) endowed with B-cell clonogenicity, suggesting a role of vp17s in <ENT2>lymphomagenesis</ENT2>.",,,,T,,,,,w,,,,,1.0,,
28747658,4086,155348,11200,Association,TRUE,"Here, we show that a single Arginine (R) to Glycine (G) mutation at position 76 in the refp17 backbone (<ENT1>p17</ENT1>R76G), as in the S75X variant, is per se sufficient to confer a B-cell clonogenic potential to the viral protein and modulate, through activation of the PTEN/PI3K/Akt signaling pathway, different molecules involved in apoptosis inhibition (CASP-9, CASP-7, DFF-45, NPM, YWHAZ, Src, PAX2, MAPK8), cell cycle promotion and cancer progression (CDK1, CDK2, CDK8, CHEK1, <ENT2>CHEK2</ENT2>, GSK-3 beta, NPM, PAK1, PP2C-alpha).",,,,T,,,,,c,,,,,0.0,,
28747658,4099,155348,842,Association,TRUE,"Here, we show that a single Arginine (R) to Glycine (G) mutation at position 76 in the refp17 backbone (<ENT1>p17</ENT1>R76G), as in the S75X variant, is per se sufficient to confer a B-cell clonogenic potential to the viral protein and modulate, through activation of the PTEN/PI3K/Akt signaling pathway, different molecules involved in apoptosis inhibition (<ENT2>CASP-9</ENT2>, CASP-7, DFF-45, NPM, YWHAZ, Src, PAX2, MAPK8), cell cycle promotion and cancer progression (CDK1, CDK2, CDK8, CHEK1, CHEK2, GSK-3 beta, NPM, PAK1, PP2C-alpha).",,,,T,,,,,c,,,,,0.0,,
28747658,4096,155348,4869,Association,TRUE,"Here, we show that a single Arginine (R) to Glycine (G) mutation at position 76 in the refp17 backbone (<ENT1>p17</ENT1>R76G), as in the S75X variant, is per se sufficient to confer a B-cell clonogenic potential to the viral protein and modulate, through activation of the PTEN/PI3K/Akt signaling pathway, different molecules involved in apoptosis inhibition (CASP-9, CASP-7, DFF-45, <ENT2>NPM</ENT2>, YWHAZ, Src, PAX2, MAPK8), cell cycle promotion and cancer progression (CDK1, CDK2, CDK8, CHEK1, CHEK2, GSK-3 beta, <ENT2>NPM</ENT2>, PAK1, PP2C-alpha).",,,,T,,,,,c,,,,,0.0,,
28747658,4097,155348,1676,Association,TRUE,"Here, we show that a single Arginine (R) to Glycine (G) mutation at position 76 in the refp17 backbone (<ENT1>p17</ENT1>R76G), as in the S75X variant, is per se sufficient to confer a B-cell clonogenic potential to the viral protein and modulate, through activation of the PTEN/PI3K/Akt signaling pathway, different molecules involved in apoptosis inhibition (CASP-9, CASP-7, <ENT2>DFF-45</ENT2>, NPM, YWHAZ, Src, PAX2, MAPK8), cell cycle promotion and cancer progression (CDK1, CDK2, CDK8, CHEK1, CHEK2, GSK-3 beta, NPM, PAK1, PP2C-alpha).",,,,T,,,,,c,,,,,0.0,,
28747658,4095,155348,7534,Association,TRUE,"Here, we show that a single Arginine (R) to Glycine (G) mutation at position 76 in the refp17 backbone (<ENT1>p17</ENT1>R76G), as in the S75X variant, is per se sufficient to confer a B-cell clonogenic potential to the viral protein and modulate, through activation of the PTEN/PI3K/Akt signaling pathway, different molecules involved in apoptosis inhibition (CASP-9, CASP-7, DFF-45, NPM, <ENT2>YWHAZ</ENT2>, Src, PAX2, MAPK8), cell cycle promotion and cancer progression (CDK1, CDK2, CDK8, CHEK1, CHEK2, GSK-3 beta, NPM, PAK1, PP2C-alpha).",,,,T,,,,,c,,,,,0.0,,
28747658,4074,5058,D009369,Association,FALSE,"Here, we show that a single Arginine (R) to Glycine (G) mutation at position 76 in the refp17 backbone (p17R76G), as in the S75X variant, is per se sufficient to confer a B-cell clonogenic potential to the viral protein and modulate, through activation of the PTEN/PI3K/Akt signaling pathway, different molecules involved in apoptosis inhibition (CASP-9, CASP-7, DFF-45, NPM, YWHAZ, Src, PAX2, MAPK8), cell cycle promotion and <ENT2>cancer</ENT2> progression (CDK1, CDK2, CDK8, CHEK1, CHEK2, GSK-3 beta, NPM, <ENT1>PAK1</ENT1>, PP2C-alpha).",,,,T,,,,,c,,,,,0.0,,
28747658,4071,p|SUB|S|75|X,D009369,Association,FALSE,"Here, we show that a single Arginine (R) to Glycine (G) mutation at position 76 in the refp17 backbone (p17R76G), as in the <ENT1>S75X</ENT1> variant, is per se sufficient to confer a B-cell clonogenic potential to the viral protein and modulate, through activation of the PTEN/PI3K/Akt signaling pathway, different molecules involved in apoptosis inhibition (CASP-9, CASP-7, DFF-45, NPM, YWHAZ, Src, PAX2, MAPK8), cell cycle promotion and <ENT2>cancer</ENT2> progression (CDK1, CDK2, CDK8, CHEK1, CHEK2, GSK-3 beta, NPM, PAK1, PP2C-alpha).",,,,T,,,,,w,,,,,1.0,,
28747658,4072,p|SUB|R|76|G,D009369,Association,TRUE,"Here, we show that a single <ENT1>Arginine (R) to Glycine (G) mutation at position 76</ENT1> in the refp17 backbone (p17<ENT1>R76G</ENT1>), as in the S75X variant, is per se sufficient to confer a B-cell clonogenic potential to the viral protein and modulate, through activation of the PTEN/PI3K/Akt signaling pathway, different molecules involved in apoptosis inhibition (CASP-9, CASP-7, DFF-45, NPM, YWHAZ, Src, PAX2, MAPK8), cell cycle promotion and <ENT2>cancer</ENT2> progression (CDK1, CDK2, CDK8, CHEK1, CHEK2, GSK-3 beta, NPM, PAK1, PP2C-alpha).",,,,T,,,,,w,,,,,0.0,,
28747658,4075,2932,D009369,Association,FALSE,"Here, we show that a single Arginine (R) to Glycine (G) mutation at position 76 in the refp17 backbone (p17R76G), as in the S75X variant, is per se sufficient to confer a B-cell clonogenic potential to the viral protein and modulate, through activation of the PTEN/PI3K/Akt signaling pathway, different molecules involved in apoptosis inhibition (CASP-9, CASP-7, DFF-45, NPM, YWHAZ, Src, PAX2, MAPK8), cell cycle promotion and <ENT2>cancer</ENT2> progression (CDK1, CDK2, CDK8, CHEK1, CHEK2, <ENT1>GSK-3 beta</ENT1>, NPM, PAK1, PP2C-alpha).",,,,T,,,,,c,,,,,0.0,,
28747658,4078,1024,D009369,Association,FALSE,"Here, we show that a single Arginine (R) to Glycine (G) mutation at position 76 in the refp17 backbone (p17R76G), as in the S75X variant, is per se sufficient to confer a B-cell clonogenic potential to the viral protein and modulate, through activation of the PTEN/PI3K/Akt signaling pathway, different molecules involved in apoptosis inhibition (CASP-9, CASP-7, DFF-45, NPM, YWHAZ, Src, PAX2, MAPK8), cell cycle promotion and <ENT2>cancer</ENT2> progression (CDK1, CDK2, <ENT1>CDK8</ENT1>, CHEK1, CHEK2, GSK-3 beta, NPM, PAK1, PP2C-alpha).",,,,T,,,,,c,,,,,0.0,,
28747658,4079,1017,D009369,Association,FALSE,"Here, we show that a single Arginine (R) to Glycine (G) mutation at position 76 in the refp17 backbone (p17R76G), as in the S75X variant, is per se sufficient to confer a B-cell clonogenic potential to the viral protein and modulate, through activation of the PTEN/PI3K/Akt signaling pathway, different molecules involved in apoptosis inhibition (CASP-9, CASP-7, DFF-45, NPM, YWHAZ, Src, PAX2, MAPK8), cell cycle promotion and <ENT2>cancer</ENT2> progression (CDK1, <ENT1>CDK2</ENT1>, CDK8, CHEK1, CHEK2, GSK-3 beta, NPM, PAK1, PP2C-alpha).",,,,T,,,,,c,,,,,0.0,,
28747658,4077,D009369,1111,Association,FALSE,"Here, we show that a single Arginine (R) to Glycine (G) mutation at position 76 in the refp17 backbone (p17R76G), as in the S75X variant, is per se sufficient to confer a B-cell clonogenic potential to the viral protein and modulate, through activation of the PTEN/PI3K/Akt signaling pathway, different molecules involved in apoptosis inhibition (CASP-9, CASP-7, DFF-45, NPM, YWHAZ, Src, PAX2, MAPK8), cell cycle promotion and <ENT1>cancer</ENT1> progression (CDK1, CDK2, CDK8, <ENT2>CHEK1</ENT2>, CHEK2, GSK-3 beta, NPM, PAK1, PP2C-alpha).",,,,T,,,,,c,,,,,0.0,,
28747658,4076,D009369,11200,Association,FALSE,"Here, we show that a single Arginine (R) to Glycine (G) mutation at position 76 in the refp17 backbone (p17R76G), as in the S75X variant, is per se sufficient to confer a B-cell clonogenic potential to the viral protein and modulate, through activation of the PTEN/PI3K/Akt signaling pathway, different molecules involved in apoptosis inhibition (CASP-9, CASP-7, DFF-45, NPM, YWHAZ, Src, PAX2, MAPK8), cell cycle promotion and <ENT1>cancer</ENT1> progression (CDK1, CDK2, CDK8, CHEK1, <ENT2>CHEK2</ENT2>, GSK-3 beta, NPM, PAK1, PP2C-alpha).",,,,T,,,,,c,,,,,0.0,,
28747658,4081,D009369,4869,Association,FALSE,"Here, we show that a single Arginine (R) to Glycine (G) mutation at position 76 in the refp17 backbone (p17R76G), as in the S75X variant, is per se sufficient to confer a B-cell clonogenic potential to the viral protein and modulate, through activation of the PTEN/PI3K/Akt signaling pathway, different molecules involved in apoptosis inhibition (CASP-9, CASP-7, DFF-45, <ENT2>NPM</ENT2>, YWHAZ, Src, PAX2, MAPK8), cell cycle promotion and <ENT1>cancer</ENT1> progression (CDK1, CDK2, CDK8, CHEK1, CHEK2, GSK-3 beta, <ENT2>NPM</ENT2>, PAK1, PP2C-alpha).",,,,T,,,,,c,,,,,0.0,,
28777492,4109,15170,53380,Bind,TRUE,"<ENT2>Gankyrin</ENT2> binds to <ENT1>Src homology 2 domain-containing protein tyrosine phosphatase-1</ENT1> (<ENT1>SHP-1</ENT1>), mainly expressed in liver non-parenchymal cells, resulting in phosphorylation and activation of signal transducer and activator of transcription 3 (STAT3).",,,,T,,,,,c,,,,,1.0,,
28777492,4101,22339,5716,Positive_Correlation,TRUE,<ENT2>Gankyrin</ENT2> upregulates <ENT1>vascular endothelial growth factor</ENT1> expression in tumor cells.,,,,T,,,,,c,,,,,1.0,,
28777492,4110,53380,D000077157,Negative_Correlation,TRUE,<ENT1>Gankyrin</ENT1> induces STAT3 activation in tumor microenvironment and <ENT2>sorafenib</ENT2> resistance in hepatocellular carcinoma.,,,,T,,,,,c,,,,,1.0,,
28777492,4105,53380,D009369,Association,TRUE,<ENT1>Gankyrin</ENT1> induces STAT3 activation in <ENT2>tumor</ENT2> microenvironment and sorafenib resistance in hepatocellular carcinoma.,,,,T,,,,,w,,,,,1.0,,
28777492,4105,53380,D009369,Association,TRUE,We have shown that the <ENT1>oncoprotein</ENT1> <ENT1>gankyrin</ENT1> is critical for inflammation-induced <ENT2>tumorigenesis</ENT2> in the colon.,,,,T,,,,,c,,,,,1.0,,
28777492,4105,53380,D009369,Association,TRUE,We investigated the effect of <ENT1>gankyrin</ENT1> in the <ENT2>tumor</ENT2> microenvironment of mice with liver parenchymal cell-specific <ENT1>gankyrin</ENT1> ablation (Alb-Cre;<ENT1>gankyrin</ENT1>(f/f) ) and <ENT1>gankyrin</ENT1> deletion both in liver parenchymal and non-parenchymal cells (Mx1-Cre;<ENT1>gankyrin</ENT1>(f/f) ).,,,,T,,Y,,,w,,,,,1.0,,
28777492,4105,53380,D009369,Association,TRUE,"<ENT1>Gankyrin</ENT1> deficiency in non-parenchymal cells, but not in parenchymal cells, reduced STAT3 activity, interleukin (IL)-6 production, and <ENT2>cancer</ENT2> stem cell marker (Bmi1 and epithelial cell adhesion molecule [EpCAM]) expression, leading to attenuated <ENT2>tumorigenic</ENT2> potential.",,,,T,,,,,c,,,,,1.0,,
28777492,4105,53380,D009369,Association,TRUE,"Thus, <ENT1>gankyrin</ENT1> appears to play a critical oncogenic function in <ENT2>tumor</ENT2> microenvironment and may be a potential target for developing therapeutic and preventive strategies against HCC.",,,,T,,,,,w,,,,,0.0,,
28777492,4106,53380,17075,Positive_Correlation,TRUE,"<ENT1>Gankyrin</ENT1> deficiency in non-parenchymal cells, but not in parenchymal cells, reduced STAT3 activity, interleukin (IL)-6 production, and cancer stem cell marker (Bmi1 and <ENT2>epithelial cell adhesion molecule</ENT2> [<ENT2>EpCAM</ENT2>]) expression, leading to attenuated tumorigenic potential.",,,,T,,,,,c,,,,,1.0,,
28777492,4111,53380,20848,Positive_Correlation,TRUE,<ENT1>Gankyrin</ENT1> induces <ENT2>STAT3</ENT2> activation in tumor microenvironment and sorafenib resistance in hepatocellular carcinoma.,,,,T,,,,,c,,,,,1.0,,
28777492,4111,53380,20848,Positive_Correlation,TRUE,"<ENT1>Gankyrin</ENT1> binds to Src homology 2 domain-containing protein tyrosine phosphatase-1 (SHP-1), mainly expressed in liver non-parenchymal cells, resulting in phosphorylation and activation of <ENT2>signal transducer and activator of transcription 3</ENT2> (<ENT2>STAT3</ENT2>).",,,,T,,,,,c,,,,,0.0,,
28777492,4111,53380,20848,Positive_Correlation,TRUE,"<ENT1>Gankyrin</ENT1> deficiency in non-parenchymal cells, but not in parenchymal cells, reduced <ENT2>STAT3</ENT2> activity, interleukin (IL)-6 production, and cancer stem cell marker (Bmi1 and epithelial cell adhesion molecule [EpCAM]) expression, leading to attenuated tumorigenic potential.",,,,T,,,,,c,,,,,1.0,,
28777492,4107,53380,12151,Positive_Correlation,TRUE,"<ENT1>Gankyrin</ENT1> deficiency in non-parenchymal cells, but not in parenchymal cells, reduced STAT3 activity, interleukin (IL)-6 production, and cancer stem cell marker (<ENT2>Bmi1</ENT2> and epithelial cell adhesion molecule [EpCAM]) expression, leading to attenuated tumorigenic potential.",,,,T,,,,,c,,,,,1.0,,
28777492,4103,53380,D006528,Association,TRUE,<ENT1>Gankyrin</ENT1> induces STAT3 activation in tumor microenvironment and sorafenib resistance in <ENT2>hepatocellular carcinoma</ENT2>.,,,,T,,,,,w,,,,,1.0,,
28777492,4103,53380,D006528,Association,TRUE,"Thus, <ENT1>gankyrin</ENT1> appears to play a critical oncogenic function in tumor microenvironment and may be a potential target for developing therapeutic and preventive strategies against <ENT2>HCC</ENT2>.",,,,T,,,,,w,,,,,1.0,,
28777492,4104,53380,D007249,Association,FALSE,We have shown that the <ENT1>oncoprotein</ENT1> <ENT1>gankyrin</ENT1> is critical for <ENT2>inflammation</ENT2>-induced tumorigenesis in the colon.,,,,T,Y,,,,c,,,,,0.5,,
28777492,4108,53380,16193,Positive_Correlation,TRUE,"<ENT1>Gankyrin</ENT1> deficiency in non-parenchymal cells, but not in parenchymal cells, reduced STAT3 activity, <ENT2>interleukin (IL)-6</ENT2> production, and cancer stem cell marker (Bmi1 and epithelial cell adhesion molecule [EpCAM]) expression, leading to attenuated tumorigenic potential.",,,,T,,,,,c,,,,,0.0,,
28777492,4102,D000077157,D006528,Negative_Correlation,FALSE,Gankyrin induces STAT3 activation in tumor microenvironment and <ENT1>sorafenib</ENT1> resistance in <ENT2>hepatocellular carcinoma</ENT2>.,,,,T,,,,,c,,,,,1.0,,
28777492,4102,D000077157,D006528,Negative_Correlation,FALSE,Gankyrin expression in the tumor microenvironment is negatively correlated with progression-free survival in patients undergoing <ENT1>sorafenib</ENT1> treatment for <ENT2>HCC</ENT2>.,,,,T,,,,,w,,,,,1.0,,
28777492,4100,5716,D007249,Positive_Correlation,TRUE,<ENT2>Chronic inflammation</ENT2> enhances <ENT1>gankyrin</ENT1> expression in the human liver.,,,,T,,,,,c,,,,,1.0,,
28846666,4137,D044882,7124,Association,TRUE,"CONCLUSIONS <ENT2>TNF-alpha</ENT2> -857C/T SNP, hs-CRP, IL-6, IL-8, and IL-6/IL-10 were associated with GDM in women from Inner Mongolia, as was serious inflammation and <ENT1>disordered lipid and glucose metabolisms</ENT1>.",,,,T,,,,,w,,,,,1.0,,
28846666,4114,D044882,3586,Association,TRUE,"CONCLUSIONS TNF-alpha -857C/T SNP, hs-CRP, IL-6, IL-8, and IL-6/<ENT2>IL-10</ENT2> were associated with GDM in women from Inner Mongolia, as was serious inflammation and <ENT1>disordered lipid and glucose metabolisms</ENT1>.",,,,T,,,,,w,,,,,1.0,,
28846666,4120,D044882,3569,Association,TRUE,"CONCLUSIONS TNF-alpha -857C/T SNP, hs-CRP, <ENT2>IL-6</ENT2>, IL-8, and <ENT2>IL-6</ENT2>/IL-10 were associated with GDM in women from Inner Mongolia, as was serious inflammation and <ENT1>disordered lipid and glucose metabolisms</ENT1>.",,,,T,,,,,w,,,,,1.0,,
28846666,4134,D044882,rs1799724,Association,TRUE,"CONCLUSIONS TNF-alpha <ENT2>-857C/T</ENT2> SNP, hs-CRP, IL-6, IL-8, and IL-6/IL-10 were associated with GDM in women from Inner Mongolia, as was serious inflammation and <ENT1>disordered lipid and glucose metabolisms</ENT1>.",,,,T,,,,,w,,,,,0.0,,
28846666,4117,D044882,3576,Association,TRUE,"CONCLUSIONS TNF-alpha -857C/T SNP, hs-CRP, IL-6, <ENT2>IL-8</ENT2>, and IL-6/IL-10 were associated with GDM in women from Inner Mongolia, as was serious inflammation and <ENT1>disordered lipid and glucose metabolisms</ENT1>.",,,,T,,,,,w,,,,,0.0,,
28846666,4123,D044882,1401,Association,TRUE,"CONCLUSIONS TNF-alpha -857C/T SNP, hs-<ENT2>CRP</ENT2>, IL-6, IL-8, and IL-6/IL-10 were associated with GDM in women from Inner Mongolia, as was serious inflammation and <ENT1>disordered lipid and glucose metabolisms</ENT1>.",,,,T,,,,,w,,,,,0.0,,
28846666,4138,7124,D016640,Association,TRUE,"Interleukin 6 (IL-6) and <ENT1>Tumor Necrosis Factor alpha</ENT1> (<ENT1>TNF-alpha</ENT1>) Single Nucleotide Polymorphisms (SNPs), Inflammation and Metabolism in <ENT2>Gestational Diabetes Mellitus</ENT2> in Inner Mongolia.",,,,T,,T,,,w,,,,,1.0,,
28846666,4138,7124,D016640,Association,TRUE,"However, few studies have focused on the association of IL-65-72C/G and <ENT1>TNF-alpha</ENT1> -857C/T single nucleotide polymorphisms (SNPs), inflammatory biomarkers, and metabolic indexes in women with <ENT2>GDM</ENT2>, especially in the Inner Mongolia population.",,,,T,,Y,,,w,,,,,1.0,,
28846666,4138,7124,D016640,Association,TRUE,"The aim of this study was to investigate the associations of IL-65-72C/G and <ENT1>TNF-alpha</ENT1> -857C/T SNPs, and inflammation and metabolic biomarkers in women with <ENT2>GDM</ENT2> pregnancies.",,,,T,,Y,,,w,,,,,1.0,,
28846666,4138,7124,D016640,Association,TRUE,"RESULTS Distribution frequency of <ENT1>TNF-alpha</ENT1> -857CT (OR=3.316, 95% CI=1.092-8.304, p=0.025) in women with <ENT2>GDM</ENT2> pregnancies were obviously higher than that in women with healthy pregnancies.",,,,T,,,,,w,,,,,1.0,,
28846666,4138,7124,D016640,Association,TRUE,"Inflammatory biomarkers in serum (hs-CRP, IL-6, IL-8, IL-6/IL-10 ratio) and placental (NF-kappaB, IL-6, IL-8, IL-6/IL-10 ratio, IL-1b, <ENT1>TNF-alpha</ENT1>) were significantly different (p   <0.05) between women with <ENT2>GDM</ENT2> and women with healthy pregnancies.",,,,T,,,,,w,,,,,1.0,,
28846666,4138,7124,D016640,Association,TRUE,"CONCLUSIONS <ENT1>TNF-alpha</ENT1> -857C/T SNP, hs-CRP, IL-6, IL-8, and IL-6/IL-10 were associated with <ENT2>GDM</ENT2> in women from Inner Mongolia, as was serious inflammation and disordered lipid and glucose metabolisms.",,,,T,,,,,c,,,,,1.0,,
28846666,4131,7124,D007249,Association,TRUE,"Interleukin 6 (IL-6) and <ENT1>Tumor Necrosis Factor alpha</ENT1> (<ENT1>TNF-alpha</ENT1>) Single Nucleotide Polymorphisms (SNPs), <ENT2>Inflammation</ENT2> and Metabolism in Gestational Diabetes Mellitus in Inner Mongolia.",,,,T,,T,,,c,,,,,1.0,,
28846666,4131,7124,D007249,Association,TRUE,"However, few studies have focused on the association of IL-65-72C/G and <ENT1>TNF-alpha</ENT1> -857C/T single nucleotide polymorphisms (SNPs), <ENT2>inflammatory</ENT2> biomarkers, and metabolic indexes in women with GDM, especially in the Inner Mongolia population.",,,,T,,Y,,,w,,,,,0.0,,
28846666,4131,7124,D007249,Association,TRUE,"The aim of this study was to investigate the associations of IL-65-72C/G and <ENT1>TNF-alpha</ENT1> -857C/T SNPs, and <ENT2>inflammation</ENT2> and metabolic biomarkers in women with GDM pregnancies.",,,,T,,Y,,,w,,,,,1.0,,
28846666,4131,7124,D007249,Association,TRUE,"<ENT2>Inflammatory</ENT2> biomarkers in serum (hs-CRP, IL-6, IL-8, IL-6/IL-10 ratio) and placental (NF-kappaB, IL-6, IL-8, IL-6/IL-10 ratio, IL-1b, <ENT1>TNF-alpha</ENT1>) were significantly different (p   <0.05) between women with GDM and women with healthy pregnancies.",,,,T,,,,,w,,,,,1.0,,
28846666,4131,7124,D007249,Association,TRUE,"CONCLUSIONS <ENT1>TNF-alpha</ENT1> -857C/T SNP, hs-CRP, IL-6, IL-8, and IL-6/IL-10 were associated with GDM in women from Inner Mongolia, as was serious <ENT2>inflammation</ENT2> and disordered lipid and glucose metabolisms.",,,,T,,,,,w,,,,,0.0,,
28846666,4115,D016640,3586,Association,TRUE,"Inflammatory biomarkers in serum (hs-CRP, IL-6, IL-8, IL-6/<ENT2>IL-10</ENT2> ratio) and placental (NF-kappaB, IL-6, IL-8, IL-6/<ENT2>IL-10</ENT2> ratio, IL-1b, TNF-alpha) were significantly different (p   <0.05) between women with <ENT1>GDM</ENT1> and women with healthy pregnancies.",,,,T,,,,,w,,,,,1.0,,
28846666,4115,D016640,3586,Association,TRUE,"CONCLUSIONS TNF-alpha -857C/T SNP, hs-CRP, IL-6, IL-8, and IL-6/<ENT2>IL-10</ENT2> were associated with <ENT1>GDM</ENT1> in women from Inner Mongolia, as was serious inflammation and disordered lipid and glucose metabolisms.",,,,T,,,,,c,,,,,1.0,,
28846666,4121,D016640,3569,Association,TRUE,"<ENT2>Interleukin 6</ENT2> (<ENT2>IL-6</ENT2>) and Tumor Necrosis Factor alpha (TNF-alpha) Single Nucleotide Polymorphisms (SNPs), Inflammation and Metabolism in <ENT1>Gestational Diabetes Mellitus</ENT1> in Inner Mongolia.",,,,T,,T,,,c,,,,,1.0,,
28846666,4121,D016640,3569,Association,TRUE,"However, few studies have focused on the association of <ENT2>IL-65</ENT2>-72C/G and TNF-alpha -857C/T single nucleotide polymorphisms (SNPs), inflammatory biomarkers, and metabolic indexes in women with <ENT1>GDM</ENT1>, especially in the Inner Mongolia population.",,,,T,,Y,,,w,,,,,1.0,,
28846666,4121,D016640,3569,Association,TRUE,"The aim of this study was to investigate the associations of <ENT2>IL-65</ENT2>-72C/G and TNF-alpha -857C/T SNPs, and inflammation and metabolic biomarkers in women with <ENT1>GDM</ENT1> pregnancies.",,,,T,,Y,,,w,,,,,1.0,,
28846666,4121,D016640,3569,Association,TRUE,"Inflammatory biomarkers in serum (hs-CRP, <ENT2>IL-6</ENT2>, IL-8, <ENT2>IL-6</ENT2>/IL-10 ratio) and placental (NF-kappaB, <ENT2>IL-6</ENT2>, IL-8, <ENT2>IL-6</ENT2>/IL-10 ratio, IL-1b, TNF-alpha) were significantly different (p   <0.05) between women with <ENT1>GDM</ENT1> and women with healthy pregnancies.",,,,T,,,,,c,,,,,1.0,,
28846666,4121,D016640,3569,Association,TRUE,"CONCLUSIONS TNF-alpha -857C/T SNP, hs-CRP, <ENT2>IL-6</ENT2>, IL-8, and <ENT2>IL-6</ENT2>/IL-10 were associated with <ENT1>GDM</ENT1> in women from Inner Mongolia, as was serious inflammation and disordered lipid and glucose metabolisms.",,,,T,,,,,c,,,,,1.0,,
28846666,4135,D016640,rs1799724,Positive_Correlation,TRUE,"However, few studies have focused on the association of IL-65-72C/G and TNF-alpha <ENT2>-857C/T</ENT2> single nucleotide polymorphisms (SNPs), inflammatory biomarkers, and metabolic indexes in women with <ENT1>GDM</ENT1>, especially in the Inner Mongolia population.",,,,T,,Y,,,c,,,,,1.0,,
28846666,4135,D016640,rs1799724,Positive_Correlation,TRUE,"The aim of this study was to investigate the associations of IL-65-72C/G and TNF-alpha <ENT2>-857C/T</ENT2> SNPs, and inflammation and metabolic biomarkers in women with <ENT1>GDM</ENT1> pregnancies.",,,,T,,Y,,,c,,,,,1.0,,
28846666,4135,D016640,rs1799724,Positive_Correlation,TRUE,"RESULTS Distribution frequency of TNF-alpha <ENT2>-857CT</ENT2> (OR=3.316, 95% CI=1.092-8.304, p=0.025) in women with <ENT1>GDM</ENT1> pregnancies were obviously higher than that in women with healthy pregnancies.",,,,T,,,,,w,,,,,1.0,,
28846666,4135,D016640,rs1799724,Positive_Correlation,TRUE,"CONCLUSIONS TNF-alpha <ENT2>-857C/T</ENT2> SNP, hs-CRP, IL-6, IL-8, and IL-6/IL-10 were associated with <ENT1>GDM</ENT1> in women from Inner Mongolia, as was serious inflammation and disordered lipid and glucose metabolisms.",,,,T,,,,,w,,,,,1.0,,
28846666,4146,D016640,3553,Association,TRUE,"Inflammatory biomarkers in serum (hs-CRP, IL-6, IL-8, IL-6/IL-10 ratio) and placental (NF-kappaB, IL-6, IL-8, IL-6/IL-10 ratio, <ENT2>IL-1b</ENT2>, TNF-alpha) were significantly different (p   <0.05) between women with <ENT1>GDM</ENT1> and women with healthy pregnancies.",,,,T,,,,,w,,,,,1.0,,
28846666,4118,D016640,3576,Association,TRUE,"Inflammatory biomarkers in serum (hs-CRP, IL-6, <ENT2>IL-8</ENT2>, IL-6/IL-10 ratio) and placental (NF-kappaB, IL-6, <ENT2>IL-8</ENT2>, IL-6/IL-10 ratio, IL-1b, TNF-alpha) were significantly different (p   <0.05) between women with <ENT1>GDM</ENT1> and women with healthy pregnancies.",,,,T,,,,,w,,,,,0.5,,
28846666,4118,D016640,3576,Association,TRUE,"CONCLUSIONS TNF-alpha -857C/T SNP, hs-CRP, IL-6, <ENT2>IL-8</ENT2>, and IL-6/IL-10 were associated with <ENT1>GDM</ENT1> in women from Inner Mongolia, as was serious inflammation and disordered lipid and glucose metabolisms.",,,,T,,,,,w,,,,,0.0,,
28846666,4124,D016640,1401,Association,TRUE,"Inflammatory biomarkers in serum (hs-<ENT2>CRP</ENT2>, IL-6, IL-8, IL-6/IL-10 ratio) and placental (NF-kappaB, IL-6, IL-8, IL-6/IL-10 ratio, IL-1b, TNF-alpha) were significantly different (p   <0.05) between women with <ENT1>GDM</ENT1> and women with healthy pregnancies.",,,,T,,,,,w,,,,,0.0,,
28846666,4124,D016640,1401,Association,TRUE,"CONCLUSIONS TNF-alpha -857C/T SNP, hs-<ENT2>CRP</ENT2>, IL-6, IL-8, and IL-6/IL-10 were associated with <ENT1>GDM</ENT1> in women from Inner Mongolia, as was serious inflammation and disordered lipid and glucose metabolisms.",,,,T,,,,,c,,,,,1.0,,
28846666,4112,D016640,4790,Association,TRUE,"Inflammatory biomarkers in serum (hs-CRP, IL-6, IL-8, IL-6/IL-10 ratio) and placental (<ENT2>NF-kappaB</ENT2>, IL-6, IL-8, IL-6/IL-10 ratio, IL-1b, TNF-alpha) were significantly different (p   <0.05) between women with <ENT1>GDM</ENT1> and women with healthy pregnancies.",,,,T,,,,,w,,,,,1.0,,
28846666,4127,3586,D007249,Association,TRUE,"<ENT2>Inflammatory</ENT2> biomarkers in serum (hs-CRP, IL-6, IL-8, IL-6/<ENT1>IL-10</ENT1> ratio) and placental (NF-kappaB, IL-6, IL-8, IL-6/<ENT1>IL-10</ENT1> ratio, IL-1b, TNF-alpha) were significantly different (p   <0.05) between women with GDM and women with healthy pregnancies.",,,,T,,,,,w,,,,,0.0,,
28846666,4127,3586,D007249,Association,TRUE,"CONCLUSIONS TNF-alpha -857C/T SNP, hs-CRP, IL-6, IL-8, and IL-6/<ENT1>IL-10</ENT1> were associated with GDM in women from Inner Mongolia, as was serious <ENT2>inflammation</ENT2> and disordered lipid and glucose metabolisms.",,,,T,,,,,w,,,,,1.0,,
28846666,4129,D007249,3569,Association,TRUE,"<ENT2>Interleukin 6</ENT2> (<ENT2>IL-6</ENT2>) and Tumor Necrosis Factor alpha (TNF-alpha) Single Nucleotide Polymorphisms (SNPs), <ENT1>Inflammation</ENT1> and Metabolism in Gestational Diabetes Mellitus in Inner Mongolia.",,,,T,,T,,,c,,,,,1.0,,
28846666,4129,D007249,3569,Association,TRUE,"However, few studies have focused on the association of <ENT2>IL-65</ENT2>-72C/G and TNF-alpha -857C/T single nucleotide polymorphisms (SNPs), <ENT1>inflammatory</ENT1> biomarkers, and metabolic indexes in women with GDM, especially in the Inner Mongolia population.",,,,T,,Y,,,w,,,,,1.0,,
28846666,4129,D007249,3569,Association,TRUE,"The aim of this study was to investigate the associations of <ENT2>IL-65</ENT2>-72C/G and TNF-alpha -857C/T SNPs, and <ENT1>inflammation</ENT1> and metabolic biomarkers in women with GDM pregnancies.",,,,T,,Y,,,w,,,,,1.0,,
28846666,4129,D007249,3569,Association,TRUE,"<ENT1>Inflammatory</ENT1> biomarkers in serum (hs-CRP, <ENT2>IL-6</ENT2>, IL-8, <ENT2>IL-6</ENT2>/IL-10 ratio) and placental (NF-kappaB, <ENT2>IL-6</ENT2>, IL-8, <ENT2>IL-6</ENT2>/IL-10 ratio, IL-1b, TNF-alpha) were significantly different (p   <0.05) between women with GDM and women with healthy pregnancies.",,,,T,,,,,c,,,,,0.75,,
28846666,4129,D007249,3569,Association,TRUE,"CONCLUSIONS TNF-alpha -857C/T SNP, hs-CRP, <ENT2>IL-6</ENT2>, IL-8, and <ENT2>IL-6</ENT2>/IL-10 were associated with GDM in women from Inner Mongolia, as was serious <ENT1>inflammation</ENT1> and disordered lipid and glucose metabolisms.",,,,T,,,,,w,,,,,0.5,,
28846666,4132,D007249,rs1799724,Association,TRUE,"However, few studies have focused on the association of IL-65-72C/G and TNF-alpha <ENT2>-857C/T</ENT2> single nucleotide polymorphisms (SNPs), <ENT1>inflammatory</ENT1> biomarkers, and metabolic indexes in women with GDM, especially in the Inner Mongolia population.",,,,T,,Y,,,w,,,,,1.0,,
28846666,4132,D007249,rs1799724,Association,TRUE,"The aim of this study was to investigate the associations of IL-65-72C/G and TNF-alpha <ENT2>-857C/T</ENT2> SNPs, and <ENT1>inflammation</ENT1> and metabolic biomarkers in women with GDM pregnancies.",,,,T,,Y,,,w,,,,,1.0,,
28846666,4132,D007249,rs1799724,Association,TRUE,"CONCLUSIONS TNF-alpha <ENT2>-857C/T</ENT2> SNP, hs-CRP, IL-6, IL-8, and IL-6/IL-10 were associated with GDM in women from Inner Mongolia, as was serious <ENT1>inflammation</ENT1> and disordered lipid and glucose metabolisms.",,,,T,,,,,w,,,,,1.0,,
28846666,4125,D007249,3553,Association,TRUE,"<ENT1>Inflammatory</ENT1> biomarkers in serum (hs-CRP, IL-6, IL-8, IL-6/IL-10 ratio) and placental (NF-kappaB, IL-6, IL-8, IL-6/IL-10 ratio, <ENT2>IL-1b</ENT2>, TNF-alpha) were significantly different (p   <0.05) between women with GDM and women with healthy pregnancies.",,,,T,,,,,c,,,,,0.0,,
28846666,4128,D007249,3576,Association,TRUE,"<ENT1>Inflammatory</ENT1> biomarkers in serum (hs-CRP, IL-6, <ENT2>IL-8</ENT2>, IL-6/IL-10 ratio) and placental (NF-kappaB, IL-6, <ENT2>IL-8</ENT2>, IL-6/IL-10 ratio, IL-1b, TNF-alpha) were significantly different (p   <0.05) between women with GDM and women with healthy pregnancies.",,,,T,,,,,c,,,,,0.5,,
28846666,4128,D007249,3576,Association,TRUE,"CONCLUSIONS TNF-alpha -857C/T SNP, hs-CRP, IL-6, <ENT2>IL-8</ENT2>, and IL-6/IL-10 were associated with GDM in women from Inner Mongolia, as was serious <ENT1>inflammation</ENT1> and disordered lipid and glucose metabolisms.",,,,T,,,,,w,,,,,0.0,,
28846666,4130,D007249,1401,Association,TRUE,"<ENT1>Inflammatory</ENT1> biomarkers in serum (hs-<ENT2>CRP</ENT2>, IL-6, IL-8, IL-6/IL-10 ratio) and placental (NF-kappaB, IL-6, IL-8, IL-6/IL-10 ratio, IL-1b, TNF-alpha) were significantly different (p   <0.05) between women with GDM and women with healthy pregnancies.",,,,T,,,,,c,,,,,0.0,,
28846666,4130,D007249,1401,Association,TRUE,"CONCLUSIONS TNF-alpha -857C/T SNP, hs-<ENT2>CRP</ENT2>, IL-6, IL-8, and IL-6/IL-10 were associated with GDM in women from Inner Mongolia, as was serious <ENT1>inflammation</ENT1> and disordered lipid and glucose metabolisms.",,,,T,,,,,w,,,,,0.0,,
28846666,4126,D007249,4790,Association,TRUE,"<ENT1>Inflammatory</ENT1> biomarkers in serum (hs-CRP, IL-6, IL-8, IL-6/IL-10 ratio) and placental (<ENT2>NF-kappaB</ENT2>, IL-6, IL-8, IL-6/IL-10 ratio, IL-1b, TNF-alpha) were significantly different (p   <0.05) between women with GDM and women with healthy pregnancies.",,,,T,,,,,c,,,,,1.0,,
28851297,4164,3040,3047,Association,TRUE,An <ENT2>Ag-globin</ENT2> G->A gene polymorphism associated with b(0)39 thalassemia globin gene and high <ENT1>fetal hemoglobin</ENT1> production.,,,,T,,,,,c,,,,,1.0,,
28851297,4164,3040,3047,Association,TRUE,BACKGROUND: Increase of the expression of <ENT2>g-globin</ENT2> gene and high production of <ENT1>fetal hemoglobin</ENT1> (<ENT1>HbF</ENT1>) in b-thalassemia patients is widely accepted as associated with a milder or even asymptomatic disease.,,,,T,,,,,c,,,,,1.0,,
28851297,4164,3040,3047,Association,TRUE,"In agreement with the expectation that this mutation alters the LYAR binding activity, we found that the <ENT2>Ag</ENT2>(+25 G->A) and Gg-globin-XmnI polymorphisms are associated with high <ENT1>HbF</ENT1> in erythroid precursor cells isolated from b(0)39/b(0)39 thalassemia patients.",,,,T,,,,,c,,,,,1.0,,
28851297,4164,3040,3047,Association,TRUE,"CONCLUSIONS: As a potential explanation of our findings, we hypothesize that in b-thalassemia the Gg-globin-XmnI/<ENT2>Ag-globin</ENT2>-(G->A) genotype is frequently under genetic linkage with b(0)-thalassemia mutations, but not with the b(+)-thalassemia mutation here studied (i.e. b(+)IVSI-110) and that this genetic combination has been selected within the population of b(0)-thalassemia patients, due to functional association with high <ENT1>HbF</ENT1>.",,,,T,,,,,c,,,,,1.0,,
28851297,4164,3040,3047,Association,TRUE,Here we describe the characterization of the rs368698783 (+25 G->A) polymorphism of the <ENT2>Ag-globin</ENT2> gene associated in b(0)39 thalassemia patients with high <ENT1>HbF</ENT1> in erythroid precursor cells.,,,,T,,,,,c,,,,,1.0,,
28851297,4160,3040,3048,Association,TRUE,BACKGROUND: Increase of the expression of <ENT2>g-globin</ENT2> gene and high production of <ENT2><ENT1>fetal hemoglobin</ENT2></ENT1> (<ENT2><ENT1>HbF</ENT2></ENT1>) in b-thalassemia patients is widely accepted as associated with a milder or even asymptomatic disease.,,,,T,,,,,c,,,,,1.0,,Overlapping entity
28851297,4160,3040,3048,Association,TRUE,"In agreement with the expectation that this mutation alters the LYAR binding activity, we found that the Ag(+25 G->A) and <ENT2>Gg-globin</ENT2>-XmnI polymorphisms are associated with high <ENT2><ENT1>HbF</ENT2></ENT1> in erythroid precursor cells isolated from b(0)39/b(0)39 thalassemia patients.",,,,T,,,,,c,,,,,0.5,,Fix overlapping entity
28851297,4160,3040,3048,Association,TRUE,"CONCLUSIONS: As a potential explanation of our findings, we hypothesize that in b-thalassemia the <ENT2>Gg-globin</ENT2>-XmnI/Ag-globin-(G->A) genotype is frequently under genetic linkage with b(0)-thalassemia mutations, but not with the b(+)-thalassemia mutation here studied (i.e. b(+)IVSI-110) and that this genetic combination has been selected within the population of b(0)-thalassemia patients, due to functional association with high <ENT2><ENT1>HbF</ENT2></ENT1>.",,,,T,,,,,c,,,,,0.0,,Fix overlapping entity
28851297,4157,3040,D017086,Association,FALSE,BACKGROUND: Increase of the expression of g-globin gene and high production of <ENT1>fetal hemoglobin</ENT1> (<ENT1>HbF</ENT1>) in <ENT2>b-thalassemia</ENT2> patients is widely accepted as associated with a milder or even asymptomatic disease.,,,,T,,,,,w,,,,,1.0,,
28851297;28851297,4157;4163,3040;3048,D017086;D017086,Association;Association,FALSE;FALSE,"The search for <ENT1>HbF</ENT1>-associated polymorphisms (such as the XmnI, BCL11A and MYB polymorphisms) has recently gained great attention, in order to stratify <ENT2>b-thalassemia</ENT2> patients with respect to expectancy of the first transfusion, need for annual intake of blood, response to <ENT1>HbF</ENT1> inducers (the most studied of which is hydroxyurea).",,,,T,,,,,w,,,,,0.0,,
28851297,4157,3040,D017086,Association,FALSE,"In agreement with the expectation that this mutation alters the LYAR binding activity, we found that the Ag(+25 G->A) and Gg-globin-XmnI polymorphisms are associated with high <ENT1>HbF</ENT1> in erythroid precursor cells isolated from <ENT2>b(0)39/b(0)39 thalassemia</ENT2> patients.",,,,T,,,,,w,,,,,1.0,,
28851297,4157,3040,D017086,Association,FALSE,"CONCLUSIONS: As a potential explanation of our findings, we hypothesize that in <ENT2>b-thalassemia</ENT2> the Gg-globin-XmnI/Ag-globin-(G->A) genotype is frequently under genetic linkage with <ENT2>b(0)-thalassemia</ENT2> mutations, but not with the <ENT2>b(+)-thalassemia</ENT2> mutation here studied (i.e. b(+)IVSI-110) and that this genetic combination has been selected within the population of <ENT2>b(0)-thalassemia</ENT2> patients, due to functional association with high <ENT1>HbF</ENT1>.",,,,T,,,,,c,,,,,0.25,,
28851297;28851297,4157;4163,3040;3048,D017086;D017086,Association;Association,FALSE;FALSE,Here we describe the characterization of the rs368698783 (+25 G->A) polymorphism of the Ag-globin gene associated in <ENT2>b(0)39 thalassemia</ENT2> patients with high <ENT1>HbF</ENT1> in erythroid precursor cells.,,,,T,,,,,w,,,,,1.0,,
28851297;28851297,4156;4159,3040;3048,53335;53335,Association;Association,FALSE;FALSE,"The search for <ENT1>HbF</ENT1>-associated polymorphisms (such as the XmnI, <ENT2>BCL11A</ENT2> and MYB polymorphisms) has recently gained great attention, in order to stratify b-thalassemia patients with respect to expectancy of the first transfusion, need for annual intake of blood, response to <ENT1>HbF</ENT1> inducers (the most studied of which is hydroxyurea).",,,,T,,,,,c,,,,,1.0,,
28851297;28851297,4155;4158,3040;3048,4602;4602,Association;Association,FALSE;FALSE,"The search for <ENT1>HbF</ENT1>-associated polymorphisms (such as the XmnI, BCL11A and <ENT2>MYB</ENT2> polymorphisms) has recently gained great attention, in order to stratify b-thalassemia patients with respect to expectancy of the first transfusion, need for annual intake of blood, response to <ENT1>HbF</ENT1> inducers (the most studied of which is hydroxyurea).",,,,T,,,,,c,,,,,0.5,,
28851297,4165,3043,3047,Association,TRUE,An <ENT2>Ag-globin</ENT2> G->A gene polymorphism associated with <ENT1>b(0)39 thalassemia globin</ENT1> gene and high fetal hemoglobin production.,,,,T,,,,,c,,,,,1.0,,
28851297,4165,3043,3047,Association,TRUE,"This <ENT2>Ag</ENT2>(+25 G->A) polymorphism is associated with the Gg-globin-XmnI polymorphism and both are linked with the <ENT1>b(0)39-globin</ENT1> gene, but not with the <ENT1>b(+)IVSI-110-globin</ENT1> gene.",,,,T,,,,,c,,,,,0.0,,
28851297,4161,3043,3048,Association,TRUE,An Ag-globin G->A gene polymorphism associated with <ENT1>b(0)39 thalassemia globin</ENT1> gene and high <ENT2>fetal hemoglobin</ENT2> production.,,,,T,,,,,c,,,,,0.0,,
28851297,4161,3043,3048,Association,TRUE,"This Ag(+25 G->A) polymorphism is associated with the <ENT2>Gg-globin</ENT2>-XmnI polymorphism and both are linked with the <ENT1>b(0)39-globin</ENT1> gene, but not with the <ENT1>b(+)IVSI-110-globin</ENT1> gene.",,,,T,,,,,c,,,,,0.0,,
28851297,4166,3047,3048,Association,TRUE,An <ENT1>Ag-globin</ENT1> G->A gene polymorphism associated with b(0)39 thalassemia globin gene and high <ENT2>fetal hemoglobin</ENT2> production.,,,,T,,,,,c,,,,,1.0,,
28851297,4166,3047,3048,Association,TRUE,BACKGROUND: Increase of the expression of <ENT2><ENT1>g-globin</ENT2></ENT1> gene and high production of <ENT2>fetal hemoglobin</ENT2> (<ENT2>HbF</ENT2>) in b-thalassemia patients is widely accepted as associated with a milder or even asymptomatic disease.,,,,T,,,,,c,,,,,1.0,,Fix overlapping entities
28851297,4166,3047,3048,Association,TRUE,"This <ENT1>Ag</ENT1>(+25 G->A) polymorphism is associated with the <ENT2>Gg-globin</ENT2>-XmnI polymorphism and both are linked with the b(0)39-globin gene, but not with the b(+)IVSI-110-globin gene.",,,,T,,,,,c,,,,,0.0,,
28851297,4166,3047,3048,Association,TRUE,"In agreement with the expectation that this mutation alters the LYAR binding activity, we found that the <ENT1>Ag</ENT1>(+25 G->A) and <ENT2>Gg-globin</ENT2>-XmnI polymorphisms are associated with high <ENT2>HbF</ENT2> in erythroid precursor cells isolated from b(0)39/b(0)39 thalassemia patients.",,,,T,,,,,c,,,,,0.5,,
28851297,4166,3047,3048,Association,TRUE,"CONCLUSIONS: As a potential explanation of our findings, we hypothesize that in b-thalassemia the <ENT2>Gg-globin</ENT2>-XmnI/<ENT1>Ag-globin</ENT1>-(G->A) genotype is frequently under genetic linkage with b(0)-thalassemia mutations, but not with the b(+)-thalassemia mutation here studied (i.e. b(+)IVSI-110) and that this genetic combination has been selected within the population of b(0)-thalassemia patients, due to functional association with high <ENT2>HbF</ENT2>.",,,,T,,,,,w,,,,,0.0,,
28851297,4166,3047,3048,Association,TRUE,Here we describe the characterization of the rs368698783 (+25 G->A) polymorphism of the <ENT1>Ag-globin</ENT1> gene associated in b(0)39 thalassemia patients with high <ENT2>HbF</ENT2> in erythroid precursor cells.,,,,T,,,,,c,,,,,0.0,,
28851297,4169,3047,D017086,Association,TRUE,BACKGROUND: Increase of the expression of <ENT1>g-globin</ENT1> gene and high production of fetal hemoglobin (HbF) in <ENT2>b-thalassemia</ENT2> patients is widely accepted as associated with a milder or even asymptomatic disease.,,,,T,,,,,c,,,,,1.0,,
28851297,4169,3047,D017086,Association,TRUE,"METHODS: <ENT1>Ag-globin</ENT1> gene sequencing was performed on genomic DNA isolated from a total of 75 <ENT2>b-thalassemia</ENT2> patients, including 31 b(0)39/b(0)39, 33 b(0)39/b(+)IVSI-110, 9 b(+)IVSI-110/b(+)IVSI-110, one b(0)IVSI-1/b(+)IVSI-6 and one b(0)39/b(+)IVSI-6.",,,,T,,Y,,,w,,,,,1.0,,
28851297,4169,3047,D017086,Association,TRUE,"RESULTS: The results show that the rs368698783 polymorphism is present in <ENT2>b-thalassemia</ENT2> patients in the 5'UTR sequence (+25) of the <ENT1>Ag-globin</ENT1> gene, known to affect the LYAR (human homologue of mouse Ly-1 antibody reactive clone) binding site 5'-GGTTAT-3'.",,,,T,,,,,c,,,,,1.0,,
28851297,4169,3047,D017086,Association,TRUE,"In agreement with the expectation that this mutation alters the LYAR binding activity, we found that the <ENT1>Ag</ENT1>(+25 G->A) and Gg-globin-XmnI polymorphisms are associated with high HbF in erythroid precursor cells isolated from <ENT2>b(0)39/b(0)39 thalassemia</ENT2> patients.",,,,T,,,,,w,,,,,1.0,,
28851297,4169,3047,D017086,Association,TRUE,"CONCLUSIONS: As a potential explanation of our findings, we hypothesize that in <ENT2>b-thalassemia</ENT2> the Gg-globin-XmnI/<ENT1>Ag-globin</ENT1>-(G->A) genotype is frequently under genetic linkage with <ENT2>b(0)-thalassemia</ENT2> mutations, but not with the <ENT2>b(+)-thalassemia</ENT2> mutation here studied (i.e. b(+)IVSI-110) and that this genetic combination has been selected within the population of <ENT2>b(0)-thalassemia</ENT2> patients, due to functional association with high HbF.",,,,T,,,,,w,,,,,0.0,,
28851297,4169,3047,D017086,Association,TRUE,Here we describe the characterization of the rs368698783 (+25 G->A) polymorphism of the <ENT1>Ag-globin</ENT1> gene associated in <ENT2>b(0)39 thalassemia</ENT2> patients with high HbF in erythroid precursor cells.,,,,T,,,,,c,,,,,0.0,,
28851297,4168,3047,55646,Association,FALSE,"RESULTS: The results show that the rs368698783 polymorphism is present in b-thalassemia patients in the 5'UTR sequence (+25) of the <ENT1>Ag-globin</ENT1> gene, known to affect the <ENT2>LYAR</ENT2> (human homologue of mouse Ly-1 antibody reactive clone) binding site 5'-GGTTAT-3'.",,,,T,,,,,c,,,,,1.0,,
28851297,4168,3047,55646,Association,FALSE,"In agreement with the expectation that this mutation alters the <ENT2>LYAR</ENT2> binding activity, we found that the <ENT1>Ag</ENT1>(+25 G->A) and Gg-globin-XmnI polymorphisms are associated with high HbF in erythroid precursor cells isolated from b(0)39/b(0)39 thalassemia patients.",,,,T,,,,,c,,,,,0.0,,
28851297,4167,3047,17089,Association,FALSE,"RESULTS: The results show that the rs368698783 polymorphism is present in b-thalassemia patients in the 5'UTR sequence (+25) of the <ENT1>Ag-globin</ENT1> gene, known to affect the LYAR (human homologue of mouse <ENT2>Ly-1 antibody reactive clone</ENT2>) binding site 5'-GGTTAT-3'.",,,,T,,,,,c,,,,,0.0,,
28851297,4163,3048,D017086,Association,TRUE,BACKGROUND: Increase of the expression of <ENT1>g-globin</ENT1> gene and high production of <ENT1>fetal hemoglobin</ENT1> (<ENT1>HbF</ENT1>) in <ENT2>b-thalassemia</ENT2> patients is widely accepted as associated with a milder or even asymptomatic disease.,,,,T,,,,,w,,,,,1.0,,
28851297,4163,3048,D017086,Association,TRUE,"In agreement with the expectation that this mutation alters the LYAR binding activity, we found that the Ag(+25 G->A) and <ENT1>Gg-globin</ENT1>-XmnI polymorphisms are associated with high <ENT1>HbF</ENT1> in erythroid precursor cells isolated from <ENT2>b(0)39/b(0)39 thalassemia</ENT2> patients.",,,,T,,,,,c,,,,,0.5,,
28851297,4163,3048,D017086,Association,TRUE,"CONCLUSIONS: As a potential explanation of our findings, we hypothesize that in <ENT2>b-thalassemia</ENT2> the <ENT1>Gg-globin</ENT1>-XmnI/Ag-globin-(G->A) genotype is frequently under genetic linkage with <ENT2>b(0)-thalassemia</ENT2> mutations, but not with the <ENT2>b(+)-thalassemia</ENT2> mutation here studied (i.e. b(+)IVSI-110) and that this genetic combination has been selected within the population of <ENT2>b(0)-thalassemia</ENT2> patients, due to functional association with high <ENT1>HbF</ENT1>.",,,,T,,,,,w,,,,,0.125,,
28851297,4170,rs368698783,D017086,Association,TRUE,"RESULTS: The results show that the <ENT1>rs368698783</ENT1> polymorphism is present in <ENT2>b-thalassemia</ENT2> patients in the 5'UTR sequence (+25) of the Ag-globin gene, known to affect the LYAR (human homologue of mouse Ly-1 antibody reactive clone) binding site 5'-GGTTAT-3'.",,,,T,,,,,w,,,,,0.0,,
28851297,4170,rs368698783,D017086,Association,TRUE,"In agreement with the expectation that this mutation alters the LYAR binding activity, we found that the Ag(<ENT1>+25 G->A</ENT1>) and Gg-globin-XmnI polymorphisms are associated with high HbF in erythroid precursor cells isolated from <ENT2>b(0)39/b(0)39 thalassemia</ENT2> patients.",,,,T,,,,,w,,,,,1.0,,
28851297,4170,rs368698783,D017086,Association,TRUE,"CONCLUSIONS: As a potential explanation of our findings, we hypothesize that in <ENT2>b-thalassemia</ENT2> the Gg-globin-XmnI/Ag-globin-(<ENT1>G->A</ENT1>) genotype is frequently under genetic linkage with <ENT2>b(0)-thalassemia</ENT2> mutations, but not with the <ENT2>b(+)-thalassemia</ENT2> mutation here studied (i.e. b(+)IVSI-110) and that this genetic combination has been selected within the population of <ENT2>b(0)-thalassemia</ENT2> patients, due to functional association with high HbF.",,,,T,,,,,w,,,,,0.0,,
28851297,4170,rs368698783,D017086,Association,TRUE,Here we describe the characterization of the <ENT1>rs368698783</ENT1> (<ENT1>+25 G->A</ENT1>) polymorphism of the Ag-globin gene associated in <ENT2>b(0)39 thalassemia</ENT2> patients with high HbF in erythroid precursor cells.,,,,T,,,,,c,,,,,0.5,,
28883039,4175,76895,5870,Positive_Correlation,TRUE,"To investigate this question, we have developed in vitro motility assays with purified <ENT1>DDB</ENT1> and <ENT1>BICD2</ENT1>'s membrane vesicle partner, the <ENT2>GTPase Rab6a</ENT2>.",,,,T,,,,,c,,,,,0.5,,
28883039,4175,76895,5870,Positive_Correlation,TRUE,"<ENT2>Rab6a-GTP</ENT2>, either in solution or bound to artificial liposomes, released <ENT1>BICD2</ENT1> from an autoinhibited state and promoted robust dynein-dynactin transport.",,,,T,,,,,c,,,,,1.0,,
28883039;28883039;28883039,4174;4173;4172,76895;76895;76895,23299;1778;1639,Association;Association;Association,TRUE;TRUE;TRUE,"In these assays, <ENT1>BICD2</ENT1> mutants showed an enhanced ability to form motile <ENT2>DDB</ENT2> complexes.",,,,T,Y,,,,c,,,,,0.0,,
28883039;28883039;28883039,4174;4173;4172,76895;76895;76895,23299;1778;1639,Association;Association;Association,TRUE;TRUE;TRUE,Our results reveal that dominant mutations in <ENT1>BICD2</ENT1> hyperactivate <ENT2>DDB</ENT2> motility and suggest that an imbalance of minus versus plus end-directed microtubule motility in neurons may underlie spinal muscular atrophy.,,,,T,,,,,c,,,,,0.0,,
28883039;28883039,4173;4172,76895;76895,1778;1639,Association;Association,TRUE;TRUE,"To investigate this question, we have developed in vitro motility assays with purified <ENT2><ENT1>DDB</ENT2></ENT1> and <ENT1>BICD2</ENT1>'s membrane vesicle partner, the GTPase Rab6a.",,,,T,,,,,c,,,,,1.0,,Fix overlapping entity
28883039,4173,76895,1778,Association,TRUE,"Rab6a-GTP, either in solution or bound to artificial liposomes, released <ENT1>BICD2</ENT1> from an autoinhibited state and promoted robust <ENT2>dynein</ENT2>-dynactin transport.",,,,T,,,,,c,,,,,0.0,,
28883039,4171,76895,D009134,Association,FALSE,Our results reveal that dominant mutations in <ENT1>BICD2</ENT1> hyperactivate DDB motility and suggest that an imbalance of minus versus plus end-directed microtubule motility in neurons may underlie <ENT2>spinal muscular atrophy</ENT2>.,,,,T,,,,,c,,,,,1.0,,
28883039,4172,76895,1639,Association,TRUE,"Rab6a-GTP, either in solution or bound to artificial liposomes, released <ENT1>BICD2</ENT1> from an autoinhibited state and promoted robust dynein-<ENT2>dynactin</ENT2> transport.",,,,T,,,,,c,,,,,0.0,,
28883039;28883039,4177;4176,5870;5870,1778;1639,Positive_Correlation;Positive_Correlation,TRUE;TRUE,"To investigate this question, we have developed in vitro motility assays with purified <ENT2>DDB</ENT2> and BICD2's membrane vesicle partner, the <ENT1>GTPase Rab6a</ENT1>.",,,,T,,,,,w,,,,,1.0,,
28883039,4177,5870,1778,Positive_Correlation,TRUE,"<ENT1>Rab6a-GTP</ENT1>, either in solution or bound to artificial liposomes, released BICD2 from an autoinhibited state and promoted robust <ENT2>dynein</ENT2>-dynactin transport.",,,,T,,,,,c,,,,,1.0,,
28883039,4176,5870,1639,Positive_Correlation,TRUE,"<ENT1>Rab6a-GTP</ENT1>, either in solution or bound to artificial liposomes, released BICD2 from an autoinhibited state and promoted robust dynein-<ENT2>dynactin</ENT2> transport.",,,,T,,,,,c,,,,,1.0,,
28883039,4183,23299,1778,Bind,TRUE,Disease-associated mutations in human <ENT1>BICD2</ENT1> hyperactivate motility of <ENT2>dynein</ENT2>-dynactin.,,,,T,,,,,w,,,,,0.0,,
28883039,4183,23299,1778,Bind,TRUE,<ENT1>Bicaudal D2</ENT1> (<ENT1>BICD2</ENT1>) joins <ENT2>dynein</ENT2> with dynactin into a ternary complex (termed <ENT2><ENT1>DDB</ENT2></ENT1>) capable of processive movement.,,,,T,,,,,w,,,,,0.166666667,,
28883039,4181,23299,D009134,Association,FALSE,"Point mutations in the <ENT1>BICD2</ENT1> gene have been identified in patients with a dominant form of <ENT2>spinal muscular atrophy</ENT2>, but how these mutations cause disease is unknown.",,,,T,,,,,c,,,,,1.0,,
28883039;28883039,4181;4179,23299;1778,D009134;D009134,Association;Association,FALSE;FALSE,Our results reveal that dominant mutations in BICD2 hyperactivate <ENT1>DDB</ENT1> motility and suggest that an imbalance of minus versus plus end-directed microtubule motility in neurons may underlie <ENT2>spinal muscular atrophy</ENT2>.,,,,T,Y,,,,c,,,,,0.0,,
28883039,4182,23299,1639,Bind,TRUE,Disease-associated mutations in human <ENT1>BICD2</ENT1> hyperactivate motility of dynein-<ENT2>dynactin</ENT2>.,,,,T,,,,,w,,,,,1.0,,
28883039,4182,23299,1639,Bind,TRUE,<ENT1>Bicaudal D2</ENT1> (<ENT1>BICD2</ENT1>) joins dynein with <ENT2>dynactin</ENT2> into a ternary complex (termed <ENT2><ENT1>DDB</ENT2></ENT1>) capable of processive movement.,,,,T,,,,,w,,,,,0.166666667,,
28883039,4180,1778,1639,Bind,FALSE,Disease-associated mutations in human BICD2 hyperactivate motility of <ENT1>dynein</ENT1>-<ENT2>dynactin</ENT2>.,,,,T,,,,,w,,,,,1.0,,
28883039,4180,1778,1639,Bind,FALSE,Bicaudal D2 (BICD2) joins <ENT1>dynein</ENT1> with <ENT2>dynactin</ENT2> into a ternary complex (termed <ENT2><ENT1>DDB</ENT2></ENT1>) capable of processive movement.,,,,T,,,,,w,,,,,0.0,,
28883039,4180,1778,1639,Bind,FALSE,"Rab6a-GTP, either in solution or bound to artificial liposomes, released BICD2 from an autoinhibited state and promoted robust <ENT1>dynein</ENT1>-<ENT2>dynactin</ENT2> transport.",,,,T,,,,,w,,,,,0.0,,
28883039,4178,D009134,1639,Association,FALSE,Our results reveal that dominant mutations in BICD2 hyperactivate <ENT2>DDB</ENT2> motility and suggest that an imbalance of minus versus plus end-directed microtubule motility in neurons may underlie <ENT1>spinal muscular atrophy</ENT1>.,,,,T,Y,,,,w,,,,,0.0,,
29049388,4194,D011507,p|SUB|R|140|Q,Positive_Correlation,TRUE,"Within the first week of <ENT2>R140Q</ENT2> hemizygosity induction the animals developed <ENT1>proteinuria</ENT1>, which peaked after 4-5 weeks.",,,,T,,,,,c,,,,,1.0,,
29049388,4192,rs74315342,D051437,Positive_Correlation,FALSE,"Knock-in mice carrying a R140Q mutation, the mouse analogue of human <ENT1>R138Q</ENT1>, show developmental arrest of podocytes and lethal <ENT2>renal failure</ENT2> at neonatal age.",,,,T,,,,,w,,,,,0.0,,
29049388,4191,rs74315342,D007674,Positive_Correlation,FALSE,"The most common podocin mutation, <ENT1>R138Q</ENT1>, is associated with early disease onset and rapid progression to end-stage <ENT2>renal disease</ENT2>.",,,,T,,,,,w,,,,,1.0,,
29049388,4185,7827,D009404,Association,FALSE,"Mutations in the <ENT1>NPHS2</ENT1> gene, encoding <ENT1>podocin</ENT1>, cause hereditary <ENT2>nephrotic syndrome</ENT2>.",,,,T,,,,,c,,,,,1.0,,
29049388,4184,7827,D007674,Association,FALSE,"The most common <ENT1>podocin</ENT1> mutation, R138Q, is associated with early disease onset and rapid progression to end-stage <ENT2>renal disease</ENT2>.",,,,T,,,,,c,,,,,1.0,,
29049388,4188,D009404,170484,Association,FALSE,An inducible mouse model of <ENT2>podocin</ENT2>-mutation-related <ENT1>nephrotic syndrome</ENT1>.,,,,T,,,,,c,,,,,1.0,,
29049388,4188,D009404,170484,Association,FALSE,"In conclusion, the inducible R140Q-<ENT2>podocin</ENT2> mouse model is an auspicious model of the most common genetic cause of human <ENT1>nephrotic syndrome</ENT1>, with a spontaneous disease course strongly reminiscent of the human disorder.",,,,T,,,,,c,,,,,1.0,,
29049388,4193,D009404,p|SUB|R|140|Q,Positive_Correlation,TRUE,"In conclusion, the inducible <ENT2>R140Q</ENT2>-podocin mouse model is an auspicious model of the most common genetic cause of human <ENT1>nephrotic syndrome</ENT1>, with a spontaneous disease course strongly reminiscent of the human disorder.",,,,T,,,,,c,,,,,0.0,,
29049388,4195,D051437,p|SUB|R|140|Q,Positive_Correlation,TRUE,"Knock-in mice carrying a <ENT2>R140Q</ENT2> mutation, the mouse analogue of human R138Q, show developmental arrest of podocytes and lethal <ENT1>renal failure</ENT1> at neonatal age.",,,,T,,,,,w,,,,,1.0,,
29183288,4222,20540,11846,Positive_Correlation,TRUE,"RESULTS: <ENT2>Arg1</ENT2> ablation had no influence on the development of OVA-induced AHR, but attenuated OVA-induced increases in expression of Arg2 and Nos2, Slc7a1, Slc7a2, and <ENT1>Slc7a7</ENT1> (<ENT1>arginine transporters</ENT1>), Il4, Il5 and Il13 (TH2-type cytokines), Ccl2 and Ccl11 (chemokines), Ifng (TH1-type cytokine), Clca3 and Muc5ac (goblet cell markers), and OVA-specific IgE.",,,,T,,,,,w,,,,,0.5,,
29183288,4204,20540,66222,Positive_Correlation,FALSE,"RESULTS: Arg1 ablation had no influence on the development of <ENT2>OVA</ENT2>-induced AHR, but attenuated <ENT2>OVA</ENT2>-induced increases in expression of Arg2 and Nos2, Slc7a1, Slc7a2, and <ENT1>Slc7a7</ENT1> (<ENT1>arginine transporters</ENT1>), Il4, Il5 and Il13 (TH2-type cytokines), Ccl2 and Ccl11 (chemokines), Ifng (TH1-type cytokine), Clca3 and Muc5ac (goblet cell markers), and <ENT2>OVA</ENT2>-specific IgE.",,,,T,,,,,w,,,,,0.0,,
29183288,4219,11846,16163,Positive_Correlation,TRUE,"RESULTS: <ENT1>Arg1</ENT1> ablation had no influence on the development of OVA-induced AHR, but attenuated OVA-induced increases in expression of Arg2 and Nos2, Slc7a1, Slc7a2, and Slc7a7 (arginine transporters), Il4, Il5 and <ENT2>Il13</ENT2> (<ENT2>TH2-type cytokines</ENT2>), Ccl2 and Ccl11 (chemokines), Ifng (TH1-type cytokine), Clca3 and Muc5ac (goblet cell markers), and OVA-specific IgE.",,,,T,,,,,w,,,,,1.0,,
29183288,4223,11846,11988,Positive_Correlation,TRUE,"RESULTS: <ENT1>Arg1</ENT1> ablation had no influence on the development of OVA-induced AHR, but attenuated OVA-induced increases in expression of Arg2 and Nos2, Slc7a1, <ENT2>Slc7a2</ENT2>, and Slc7a7 (<ENT2>arginine transporters</ENT2>), Il4, Il5 and Il13 (TH2-type cytokines), Ccl2 and Ccl11 (chemokines), Ifng (TH1-type cytokine), Clca3 and Muc5ac (goblet cell markers), and OVA-specific IgE.",,,,T,,,,,w,,,,,0.5,,
29183288,4210,11846,D009569,Association,FALSE,BACKGROUND: (Over-)expression of <ENT1>arginase</ENT1> may limit local availability of arginine for <ENT2>nitric oxide</ENT2> synthesis.,,,,T,,,,,c,,,,,0.0,,
29183288,4228,11846,D007249,Association,TRUE,"<ENT1>Arginase 1</ENT1> deletion in myeloid cells affects the <ENT2>inflammatory</ENT2> response in allergic asthma, but not lung mechanics, in female mice.",,,,T,,,,,c,,,,,1.0,,
29183288,4228,11846,D007249,Association,TRUE,<ENT1>Arg1</ENT1> elimination also decreased number and tightness of correlations between adaptive changes in lung function and <ENT2>inflammatory</ENT2> parameters in OVA/OVA-treated female mice.,,,,T,,,,,c,,,,,1.0,,
29183288,4228,11846,D007249,Association,TRUE,"CONCLUSION: Complete ablation of <ENT1>Arg1</ENT1> in the lung affects mRNA abundance of arginine-transporting and -metabolizing genes, and pro-<ENT2>inflammatory</ENT2> genes, but not methacholine responsiveness or accumulation of <ENT2>inflammatory</ENT2> cells.",,,,T,,,,,c,,,,,0.5,,
29183288,4221,11846,16189,Positive_Correlation,TRUE,"RESULTS: <ENT1>Arg1</ENT1> ablation had no influence on the development of OVA-induced AHR, but attenuated OVA-induced increases in expression of Arg2 and Nos2, Slc7a1, Slc7a2, and Slc7a7 (arginine transporters), <ENT2>Il4</ENT2>, Il5 and Il13 (<ENT2>TH2-type cytokines</ENT2>), Ccl2 and Ccl11 (chemokines), Ifng (TH1-type cytokine), Clca3 and Muc5ac (goblet cell markers), and OVA-specific IgE.",,,,T,,,,,w,,,,,1.0,,
29183288,4226,11846,11847,Positive_Correlation,TRUE,"RESULTS: <ENT1>Arg1</ENT1> ablation had no influence on the development of OVA-induced AHR, but attenuated OVA-induced increases in expression of <ENT2>Arg2</ENT2> and Nos2, Slc7a1, Slc7a2, and Slc7a7 (arginine transporters), Il4, Il5 and Il13 (TH2-type cytokines), Ccl2 and Ccl11 (chemokines), Ifng (TH1-type cytokine), Clca3 and Muc5ac (goblet cell markers), and OVA-specific IgE.",,,,T,,,,,w,,,,,1.0,,
29183288,4218,11846,20296,Positive_Correlation,TRUE,"RESULTS: <ENT1>Arg1</ENT1> ablation had no influence on the development of OVA-induced AHR, but attenuated OVA-induced increases in expression of Arg2 and Nos2, Slc7a1, Slc7a2, and Slc7a7 (arginine transporters), Il4, Il5 and Il13 (TH2-type cytokines), <ENT2>Ccl2</ENT2> and Ccl11 (<ENT2>chemokines</ENT2>), Ifng (TH1-type cytokine), Clca3 and Muc5ac (goblet cell markers), and OVA-specific IgE.",,,,T,,,,,w,,,,,1.0,,
29183288,4213,11846,629822,Positive_Correlation,TRUE,"RESULTS: <ENT1>Arg1</ENT1> ablation had no influence on the development of OVA-induced AHR, but attenuated OVA-induced increases in expression of Arg2 and Nos2, Slc7a1, Slc7a2, and Slc7a7 (arginine transporters), Il4, Il5 and Il13 (TH2-type cytokines), Ccl2 and Ccl11 (chemokines), Ifng (TH1-type cytokine), Clca3 and Muc5ac (goblet cell markers), and OVA-specific <ENT2>IgE</ENT2>.",,,,T,,,,,w,,,,,0.0,,
29183288,4213,11846,629822,Positive_Correlation,TRUE,"<ENT1>Arg1</ENT1>-deficient OVA/OVA-treated females differed from males in a more pronounced decline of arginine-metabolizing and -transporting genes, higher plasma arginine levels, a smaller OVA-specific <ENT2>IgE</ENT2> response, and no improvement of peripheral lung function.",,,,T,,,,,w,,,,,0.0,,
29183288,4211,11846,66222,Positive_Correlation,TRUE,We investigated the significance of <ENT1>arginase1</ENT1> (<ENT1>ARG1</ENT1>) for the development of airway hyperresponsiveness (AHR) and lung inflammation in female mice with <ENT2>ovalbumin</ENT2> (<ENT2>OVA</ENT2>)-induced allergic asthma.,,,,T,,,,,w,,,,,1.0,,
29183288,4211,11846,66222,Positive_Correlation,TRUE,"RESULTS: <ENT1>Arg1</ENT1> ablation had no influence on the development of <ENT2>OVA</ENT2>-induced AHR, but attenuated <ENT2>OVA</ENT2>-induced increases in expression of Arg2 and Nos2, Slc7a1, Slc7a2, and Slc7a7 (arginine transporters), Il4, Il5 and Il13 (TH2-type cytokines), Ccl2 and Ccl11 (chemokines), Ifng (TH1-type cytokine), Clca3 and Muc5ac (goblet cell markers), and <ENT2>OVA</ENT2>-specific IgE.",,,,T,,,,,c,,,,,0.333333333,,
29183288,4211,11846,66222,Positive_Correlation,TRUE,<ENT1>Arg1</ENT1> elimination also decreased number and tightness of correlations between adaptive changes in lung function and inflammatory parameters in <ENT2>OVA</ENT2>/<ENT2>OVA</ENT2>-treated female mice.,,,,T,,,,,c,,,,,1.0,,
29183288,4211,11846,66222,Positive_Correlation,TRUE,"<ENT1>Arg1</ENT1>-deficient <ENT2>OVA</ENT2>/<ENT2>OVA</ENT2>-treated females differed from males in a more pronounced decline of arginine-metabolizing and -transporting genes, higher plasma arginine levels, a smaller <ENT2>OVA</ENT2>-specific IgE response, and no improvement of peripheral lung function.",,,,T,,,,,w,,,,,0.333333333,,
29183288,4224,11846,11987,Positive_Correlation,TRUE,"RESULTS: <ENT1>Arg1</ENT1> ablation had no influence on the development of OVA-induced AHR, but attenuated OVA-induced increases in expression of Arg2 and Nos2, <ENT2>Slc7a1</ENT2>, Slc7a2, and Slc7a7 (<ENT2>arginine transporters</ENT2>), Il4, Il5 and Il13 (TH2-type cytokines), Ccl2 and Ccl11 (chemokines), Ifng (TH1-type cytokine), Clca3 and Muc5ac (goblet cell markers), and OVA-specific IgE.",,,,T,,,,,c,,,,,0.5,,
29183288,4227,11846,D001249,Association,TRUE,"<ENT1>Arginase 1</ENT1> deletion in myeloid cells affects the inflammatory response in allergic <ENT2>asthma</ENT2>, but not lung mechanics, in female mice.",,,,T,,,,,c,,,,,1.0,,
29183288,4227,11846,D001249,Association,TRUE,We investigated the significance of <ENT1>arginase1</ENT1> (<ENT1>ARG1</ENT1>) for the development of airway hyperresponsiveness (AHR) and lung inflammation in female mice with ovalbumin (OVA)-induced allergic <ENT2>asthma</ENT2>.,,,,T,,Y,,,w,,,,,0.5,,
29183288,4220,11846,16191,Positive_Correlation,TRUE,"RESULTS: <ENT1>Arg1</ENT1> ablation had no influence on the development of OVA-induced AHR, but attenuated OVA-induced increases in expression of Arg2 and Nos2, Slc7a1, Slc7a2, and Slc7a7 (arginine transporters), Il4, <ENT2>Il5</ENT2> and Il13 (<ENT2>TH2-type cytokines</ENT2>), Ccl2 and Ccl11 (chemokines), Ifng (TH1-type cytokine), Clca3 and Muc5ac (goblet cell markers), and OVA-specific IgE.",,,,T,,,,,c,,,,,1.0,,
29183288,4217,11846,20292,Positive_Correlation,TRUE,"RESULTS: <ENT1>Arg1</ENT1> ablation had no influence on the development of OVA-induced AHR, but attenuated OVA-induced increases in expression of Arg2 and Nos2, Slc7a1, Slc7a2, and Slc7a7 (arginine transporters), Il4, Il5 and Il13 (TH2-type cytokines), Ccl2 and <ENT2>Ccl11</ENT2> (<ENT2>chemokines</ENT2>), Ifng (TH1-type cytokine), Clca3 and Muc5ac (goblet cell markers), and OVA-specific IgE.",,,,T,,,,,c,,,,,1.0,,
29183288,4225,11846,18126,Positive_Correlation,TRUE,"RESULTS: <ENT1>Arg1</ENT1> ablation had no influence on the development of OVA-induced AHR, but attenuated OVA-induced increases in expression of Arg2 and <ENT2>Nos2</ENT2>, Slc7a1, Slc7a2, and Slc7a7 (arginine transporters), Il4, Il5 and Il13 (TH2-type cytokines), Ccl2 and Ccl11 (chemokines), Ifng (TH1-type cytokine), Clca3 and Muc5ac (goblet cell markers), and OVA-specific IgE.",,,,T,,,,,c,,,,,1.0,,
29183288,4215,11846,23844,Positive_Correlation,TRUE,"RESULTS: <ENT1>Arg1</ENT1> ablation had no influence on the development of OVA-induced AHR, but attenuated OVA-induced increases in expression of Arg2 and Nos2, Slc7a1, Slc7a2, and Slc7a7 (arginine transporters), Il4, Il5 and Il13 (TH2-type cytokines), Ccl2 and Ccl11 (chemokines), Ifng (TH1-type cytokine), <ENT2>Clca3</ENT2> and Muc5ac (goblet cell markers), and OVA-specific IgE.",,,,T,,,,,c,,,,,1.0,,
29183288,4216,11846,15978,Positive_Correlation,TRUE,"RESULTS: <ENT1>Arg1</ENT1> ablation had no influence on the development of OVA-induced AHR, but attenuated OVA-induced increases in expression of Arg2 and Nos2, Slc7a1, Slc7a2, and Slc7a7 (arginine transporters), Il4, Il5 and Il13 (TH2-type cytokines), Ccl2 and Ccl11 (chemokines), <ENT2>Ifng</ENT2> (<ENT2>TH1-type cytokine</ENT2>), Clca3 and Muc5ac (goblet cell markers), and OVA-specific IgE.",,,,T,,,,,c,,,,,1.0,,
29183288,4214,11846,17833,Positive_Correlation,TRUE,"RESULTS: <ENT1>Arg1</ENT1> ablation had no influence on the development of OVA-induced AHR, but attenuated OVA-induced increases in expression of Arg2 and Nos2, Slc7a1, Slc7a2, and Slc7a7 (arginine transporters), Il4, Il5 and Il13 (TH2-type cytokines), Ccl2 and Ccl11 (chemokines), Ifng (TH1-type cytokine), Clca3 and <ENT2>Muc5ac</ENT2> (goblet cell markers), and OVA-specific IgE.",,,,T,,,,,c,,,,,0.0,,
29183288,4201,16163,66222,Positive_Correlation,FALSE,"RESULTS: Arg1 ablation had no influence on the development of <ENT2>OVA</ENT2>-induced AHR, but attenuated <ENT2>OVA</ENT2>-induced increases in expression of Arg2 and Nos2, Slc7a1, Slc7a2, and Slc7a7 (arginine transporters), Il4, Il5 and <ENT1>Il13</ENT1> (<ENT1>TH2-type cytokines</ENT1>), Ccl2 and Ccl11 (chemokines), Ifng (TH1-type cytokine), Clca3 and Muc5ac (goblet cell markers), and <ENT2>OVA</ENT2>-specific IgE.",,,,T,,,,,c,,,,,0.166666667,,
29183288,4205,11988,66222,Positive_Correlation,FALSE,"RESULTS: Arg1 ablation had no influence on the development of <ENT2>OVA</ENT2>-induced AHR, but attenuated <ENT2>OVA</ENT2>-induced increases in expression of Arg2 and Nos2, Slc7a1, <ENT1>Slc7a2</ENT1>, and Slc7a7 (<ENT1>arginine transporters</ENT1>), Il4, Il5 and Il13 (TH2-type cytokines), Ccl2 and Ccl11 (chemokines), Ifng (TH1-type cytokine), Clca3 and Muc5ac (goblet cell markers), and <ENT2>OVA</ENT2>-specific IgE.",,,,T,,,,,c,,,,,0.333333333,,
29183288,4203,16189,66222,Positive_Correlation,FALSE,"RESULTS: Arg1 ablation had no influence on the development of <ENT2>OVA</ENT2>-induced AHR, but attenuated <ENT2>OVA</ENT2>-induced increases in expression of Arg2 and Nos2, Slc7a1, Slc7a2, and Slc7a7 (arginine transporters), <ENT1>Il4</ENT1>, Il5 and Il13 (<ENT1>TH2-type cytokines</ENT1>), Ccl2 and Ccl11 (chemokines), Ifng (TH1-type cytokine), Clca3 and Muc5ac (goblet cell markers), and <ENT2>OVA</ENT2>-specific IgE.",,,,T,,,,,c,,,,,0.5,,
29183288,4208,11847,66222,Positive_Correlation,FALSE,"RESULTS: Arg1 ablation had no influence on the development of <ENT2>OVA</ENT2>-induced AHR, but attenuated <ENT2>OVA</ENT2>-induced increases in expression of <ENT1>Arg2</ENT1> and Nos2, Slc7a1, Slc7a2, and Slc7a7 (arginine transporters), Il4, Il5 and Il13 (TH2-type cytokines), Ccl2 and Ccl11 (chemokines), Ifng (TH1-type cytokine), Clca3 and Muc5ac (goblet cell markers), and <ENT2>OVA</ENT2>-specific IgE.",,,,T,,,,,c,,,,,0.333333333,,
29183288,4200,20296,66222,Positive_Correlation,FALSE,"RESULTS: Arg1 ablation had no influence on the development of <ENT2>OVA</ENT2>-induced AHR, but attenuated <ENT2>OVA</ENT2>-induced increases in expression of Arg2 and Nos2, Slc7a1, Slc7a2, and Slc7a7 (arginine transporters), Il4, Il5 and Il13 (TH2-type cytokines), <ENT1>Ccl2</ENT1> and Ccl11 (<ENT1>chemokines</ENT1>), Ifng (TH1-type cytokine), Clca3 and Muc5ac (goblet cell markers), and <ENT2>OVA</ENT2>-specific IgE.",,,,T,,,,,c,,,,,0.333333333,,
29183288,4209,629822,66222,Positive_Correlation,FALSE,"RESULTS: Arg1 ablation had no influence on the development of <ENT2>OVA</ENT2>-induced AHR, but attenuated <ENT2>OVA</ENT2>-induced increases in expression of Arg2 and Nos2, Slc7a1, Slc7a2, and Slc7a7 (arginine transporters), Il4, Il5 and Il13 (TH2-type cytokines), Ccl2 and Ccl11 (chemokines), Ifng (TH1-type cytokine), Clca3 and Muc5ac (goblet cell markers), and <ENT2>OVA</ENT2>-specific <ENT1>IgE</ENT1>.",,,,T,,,,,w,,,,,0.0,,
29183288,4209,629822,66222,Positive_Correlation,FALSE,"<ENT2>OVA</ENT2>/<ENT2>OVA</ENT2>-treated female mice mounted a higher <ENT2>OVA</ENT2>-<ENT1>IgE</ENT1> response than males, but the correlation between lung function and inflammation was lower.",,,,T,Y,,,,w,,,,,0.333333333,,
29183288,4209,629822,66222,Positive_Correlation,FALSE,"Arg1-deficient <ENT2>OVA</ENT2>/<ENT2>OVA</ENT2>-treated females differed from males in a more pronounced decline of arginine-metabolizing and -transporting genes, higher plasma arginine levels, a smaller <ENT2>OVA</ENT2>-specific <ENT1>IgE</ENT1> response, and no improvement of peripheral lung function.",,,,T,Y,,,,w,,,,,0.666666667,,
29183288,4206,66222,11987,Positive_Correlation,FALSE,"RESULTS: Arg1 ablation had no influence on the development of <ENT1>OVA</ENT1>-induced AHR, but attenuated <ENT1>OVA</ENT1>-induced increases in expression of Arg2 and Nos2, <ENT2>Slc7a1</ENT2>, Slc7a2, and Slc7a7 (<ENT2>arginine transporters</ENT2>), Il4, Il5 and Il13 (TH2-type cytokines), Ccl2 and Ccl11 (chemokines), Ifng (TH1-type cytokine), Clca3 and Muc5ac (goblet cell markers), and <ENT1>OVA</ENT1>-specific IgE.",,,,T,,,,,c,,,,,0.166666667,,
29183288,4202,66222,16191,Positive_Correlation,FALSE,"RESULTS: Arg1 ablation had no influence on the development of <ENT1>OVA</ENT1>-induced AHR, but attenuated <ENT1>OVA</ENT1>-induced increases in expression of Arg2 and Nos2, Slc7a1, Slc7a2, and Slc7a7 (arginine transporters), Il4, <ENT2>Il5</ENT2> and Il13 (<ENT2>TH2-type cytokines</ENT2>), Ccl2 and Ccl11 (chemokines), Ifng (TH1-type cytokine), Clca3 and Muc5ac (goblet cell markers), and <ENT1>OVA</ENT1>-specific IgE.",,,,T,,,,,c,,,,,0.166666667,,
29183288,4199,66222,20292,Positive_Correlation,FALSE,"RESULTS: Arg1 ablation had no influence on the development of <ENT1>OVA</ENT1>-induced AHR, but attenuated <ENT1>OVA</ENT1>-induced increases in expression of Arg2 and Nos2, Slc7a1, Slc7a2, and Slc7a7 (arginine transporters), Il4, Il5 and Il13 (TH2-type cytokines), Ccl2 and <ENT2>Ccl11</ENT2> (<ENT2>chemokines</ENT2>), Ifng (TH1-type cytokine), Clca3 and Muc5ac (goblet cell markers), and <ENT1>OVA</ENT1>-specific IgE.",,,,T,,,,,c,,,,,0.166666667,,
29183288,4207,66222,18126,Positive_Correlation,FALSE,"RESULTS: Arg1 ablation had no influence on the development of <ENT1>OVA</ENT1>-induced AHR, but attenuated <ENT1>OVA</ENT1>-induced increases in expression of Arg2 and <ENT2>Nos2</ENT2>, Slc7a1, Slc7a2, and Slc7a7 (arginine transporters), Il4, Il5 and Il13 (TH2-type cytokines), Ccl2 and Ccl11 (chemokines), Ifng (TH1-type cytokine), Clca3 and Muc5ac (goblet cell markers), and <ENT1>OVA</ENT1>-specific IgE.",,,,T,,,,,c,,,,,0.333333333,,
29183288,4197,66222,23844,Positive_Correlation,TRUE,"RESULTS: Arg1 ablation had no influence on the development of <ENT1>OVA</ENT1>-induced AHR, but attenuated <ENT1>OVA</ENT1>-induced increases in expression of Arg2 and Nos2, Slc7a1, Slc7a2, and Slc7a7 (arginine transporters), Il4, Il5 and Il13 (TH2-type cytokines), Ccl2 and Ccl11 (chemokines), Ifng (TH1-type cytokine), <ENT2>Clca3</ENT2> and Muc5ac (goblet cell markers), and <ENT1>OVA</ENT1>-specific IgE.",,,,T,,,,,c,,,,,0.0,,
29183288,4198,66222,15978,Positive_Correlation,TRUE,"RESULTS: Arg1 ablation had no influence on the development of <ENT1>OVA</ENT1>-induced AHR, but attenuated <ENT1>OVA</ENT1>-induced increases in expression of Arg2 and Nos2, Slc7a1, Slc7a2, and Slc7a7 (arginine transporters), Il4, Il5 and Il13 (TH2-type cytokines), Ccl2 and Ccl11 (chemokines), <ENT2>Ifng</ENT2> (<ENT2>TH1-type cytokine</ENT2>), Clca3 and Muc5ac (goblet cell markers), and <ENT1>OVA</ENT1>-specific IgE.",,,,T,,,,,c,,,,,0.0,,
29183288,4196,66222,17833,Positive_Correlation,TRUE,"RESULTS: Arg1 ablation had no influence on the development of <ENT1>OVA</ENT1>-induced AHR, but attenuated <ENT1>OVA</ENT1>-induced increases in expression of Arg2 and Nos2, Slc7a1, Slc7a2, and Slc7a7 (arginine transporters), Il4, Il5 and Il13 (TH2-type cytokines), Ccl2 and Ccl11 (chemokines), Ifng (TH1-type cytokine), Clca3 and <ENT2>Muc5ac</ENT2> (goblet cell markers), and <ENT1>OVA</ENT1>-specific IgE.",,,,T,,,,,c,,,,,0.0,,
30836660,4271,59,C009172,Negative_Correlation,TRUE,"Furthermore, <ENT2>Sal</ENT2> administration significantly suppresses epithelial-mesenchymal transition (EMT), as evidenced by a decreased expression of <ENT1>alpha-SMA</ENT1>, vimentin, TGF-beta1, snail, slug, and a largely restored expression of E-cadherin.",,,,T,,,,,c,,,,c,1.0,,
30836660,4266,20613,C009172,Negative_Correlation,TRUE,"Furthermore, <ENT2>Sal</ENT2> administration significantly suppresses epithelial-mesenchymal transition (EMT), as evidenced by a decreased expression of alpha-SMA, vimentin, TGF-beta1, <ENT1>snail</ENT1>, slug, and a largely restored expression of E-cadherin.",,,,T,,,,,c,,,,c,1.0,,
30836660,4270,22352,C009172,Negative_Correlation,TRUE,"Furthermore, <ENT2>Sal</ENT2> administration significantly suppresses epithelial-mesenchymal transition (EMT), as evidenced by a decreased expression of alpha-SMA, <ENT1>vimentin</ENT1>, TGF-beta1, snail, slug, and a largely restored expression of E-cadherin.",,,,T,,,,,c,,,,c,1.0,,
30836660,4262,12550,C009172,Positive_Correlation,TRUE,"Furthermore, <ENT2>Sal</ENT2> administration significantly suppresses epithelial-mesenchymal transition (EMT), as evidenced by a decreased expression of alpha-SMA, vimentin, TGF-beta1, snail, slug, and a largely restored expression of <ENT1>E-cadherin</ENT1>.",,,,T,Y,,,,c,,,,c,0.0,,
30836660,4229,7124,D007249,Association,FALSE,"Additionally, Sal also reduces the levels of serum biochemical markers (serum creatinine, Scr; blood urea nitrogen, BUN; and uric acid, UA) and decreases the release of <ENT2>inflammatory</ENT2> cytokines (IL-1beta, IL-6, <ENT1>TNF-alpha</ENT1>).",,,,T,,,,,w,,,,c,0.0,,
30836660,4253,7124,C009172,Negative_Correlation,TRUE,"Additionally, <ENT2>Sal</ENT2> also reduces the levels of serum biochemical markers (serum creatinine, Scr; blood urea nitrogen, BUN; and uric acid, UA) and decreases the release of inflammatory cytokines (IL-1beta, IL-6, <ENT1>TNF-alpha</ENT1>).",,,,T,,,,,c,,,,c,0.0,,
30836660,4236,D007674,5594,Association,TRUE,Salidroside Ameliorates <ENT1>Renal Interstitial Fibrosis</ENT1> by Inhibiting the TLR4/NF-kappaB and <ENT2>MAPK</ENT2> Signaling Pathways.,,,,T,Y,,,,w,,,,c,0.0,,
30836660,4236,D007674,5594,Association,TRUE,"Further study revealed that the effect of Sal on <ENT1>renal interstitial fibrosis</ENT1> is associated with the lower expression of TLR4, p-IkappaBalpha, p-NF-kappaB and <ENT2>mitogen-activated protein kinases</ENT2> (<ENT2>MAPK</ENT2>), both in vivo and in vitro.",,,,T,Y,,,,w,,,,c,0.0,,
30836660,4235,D007674,D005492,Positive_Correlation,FALSE,"In this study, we establish the unilateral ureteric obstruction (UUO) or <ENT2>folic acid</ENT2> (<ENT2>FA</ENT2>)-induced mice <ENT1>renal interstitial fibrosis</ENT1> in vivo and the transforming growth factor (TGF)-beta1-stimulated human proximal tubular epithelial cell (HK-2) model in vitro.",,,,T,,,,,c,,,,c,1.0,,
30836660,4279,D007674,C009172,Negative_Correlation,TRUE,<ENT2>Salidroside</ENT2> Ameliorates <ENT1>Renal Interstitial Fibrosis</ENT1> by Inhibiting the TLR4/NF-kappaB and MAPK Signaling Pathways.,,,,T,,T,,,w,,,,c,1.0,,
30836660,4279,D007674,C009172,Negative_Correlation,TRUE,"However, the role of <ENT2>Sal</ENT2> on <ENT1>renal fibrosis</ENT1> has not yet been elucidated.",,,,T,,,,,c,,,,c,1.0,,
30836660,4279,D007674,C009172,Negative_Correlation,TRUE,"Here, the purpose of the current study is to test the protective effects of <ENT2>Sal</ENT2> against <ENT1>renal interstitial fibrosis</ENT1> (<ENT1>RIF</ENT1>), and to explore the underlying mechanisms using both in vivo and in vitro models.",,,,T,,Y,,,c,,,,c,0.5,,
30836660,4279,D007674,C009172,Negative_Correlation,TRUE,Immunohistochemistry and western blotting are used to determine the mechanisms of <ENT2>Sal</ENT2> against <ENT1>RIF</ENT1>.,,,,T,,,,,c,,,,c,1.0,,
30836660,4279,D007674,C009172,Negative_Correlation,TRUE,Our results show that treatment with <ENT2>Sal</ENT2> can ameliorate <ENT1>tubular injury</ENT1> and deposition of the extracellular matrix (ECM) components (including collagen SH and collagen I).,,,,T,,,,,c,,,,c,0.0,,
30836660,4279,D007674,C009172,Negative_Correlation,TRUE,"Further study revealed that the effect of <ENT2>Sal</ENT2> on <ENT1>renal interstitial fibrosis</ENT1> is associated with the lower expression of TLR4, p-IkappaBalpha, p-NF-kappaB and mitogen-activated protein kinases (MAPK), both in vivo and in vitro.",,,,T,,,,,c,,,,w,0.0,,
30836660,4279,D007674,C009172,Negative_Correlation,TRUE,"Collectively, these results suggest that the administration of <ENT2>Sal</ENT2> could be a novel therapeutic strategy in treating <ENT1>renal fibrosis</ENT1>.",,,,T,,,,,c,,,,c,1.0,,
30836660,4243,D007674,21898,Association,TRUE,Salidroside Ameliorates <ENT1>Renal Interstitial Fibrosis</ENT1> by Inhibiting the <ENT2>TLR4</ENT2>/NF-kappaB and MAPK Signaling Pathways.,,,,T,Y,,,,w,,,,c,1.0,,
30836660,4243,D007674,21898,Association,TRUE,"Further study revealed that the effect of Sal on <ENT1>renal interstitial fibrosis</ENT1> is associated with the lower expression of <ENT2>TLR4</ENT2>, p-IkappaBalpha, p-NF-kappaB and mitogen-activated protein kinases (MAPK), both in vivo and in vitro.",,,,T,Y,,,,w,,,,c,1.0,,
30836660,4239,D007674,18033,Association,TRUE,Salidroside Ameliorates <ENT1>Renal Interstitial Fibrosis</ENT1> by Inhibiting the TLR4/<ENT2>NF-kappaB</ENT2> and MAPK Signaling Pathways.,,,,T,Y,,,,w,,,,c,0.0,,
30836660,4239,D007674,18033,Association,TRUE,"Further study revealed that the effect of Sal on <ENT1>renal interstitial fibrosis</ENT1> is associated with the lower expression of TLR4, p-IkappaBalpha, p-<ENT2>NF-kappaB</ENT2> and mitogen-activated protein kinases (MAPK), both in vivo and in vitro.",,,,T,Y,,,,w,,,,c,0.0,,
30836660,4241,D007674,18035,Association,TRUE,"Further study revealed that the effect of Sal on <ENT1>renal interstitial fibrosis</ENT1> is associated with the lower expression of TLR4, p-<ENT2>IkappaBalpha</ENT2>, p-NF-kappaB and mitogen-activated protein kinases (MAPK), both in vivo and in vitro.",,,,T,Y,,,,w,,,,c,0.0,,
30836660;30836660,4267;4268,7040;21803,C009172;C009172,Negative_Correlation;Negative_Correlation,TRUE;TRUE,"Furthermore, <ENT2>Sal</ENT2> administration significantly suppresses epithelial-mesenchymal transition (EMT), as evidenced by a decreased expression of alpha-SMA, vimentin, <ENT1>TGF-beta1</ENT1>, snail, slug, and a largely restored expression of E-cadherin.",,,,T,,,,,c,,,,c,0.0,,
30836660,4277,12825,C009172,Negative_Correlation,TRUE,Our results show that treatment with <ENT2>Sal</ENT2> can ameliorate tubular injury and deposition of the extracellular matrix (ECM) components (including <ENT1>collagen SH</ENT1> and collagen I).,,,,T,,,,,c,,,,c,1.0,,
30836660,4260,D003404,C009172,Negative_Correlation,TRUE,"Additionally, <ENT2>Sal</ENT2> also reduces the levels of serum biochemical markers (serum <ENT1>creatinine</ENT1>, Scr; blood urea nitrogen, BUN; and uric acid, UA) and decreases the release of inflammatory cytokines (IL-1beta, IL-6, TNF-alpha).",,,,T,,,,,c,,,,c,1.0,,
30836660,4275,1278,C009172,Negative_Correlation,TRUE,Our results show that treatment with <ENT2>Sal</ENT2> can ameliorate tubular injury and deposition of the extracellular matrix (ECM) components (including collagen SH and <ENT1>collagen I</ENT1>).,,,,T,,,,,c,,,,c,1.0,,
30836660,4244,5594,C009172,Negative_Correlation,TRUE,<ENT2>Salidroside</ENT2> Ameliorates Renal Interstitial Fibrosis by Inhibiting the TLR4/NF-kappaB and <ENT1>MAPK</ENT1> Signaling Pathways.,,,,T,,T,,,c,,,,c,0.0,,
30836660,4244,5594,C009172,Negative_Correlation,TRUE,"Further study revealed that the effect of <ENT2>Sal</ENT2> on renal interstitial fibrosis is associated with the lower expression of TLR4, p-IkappaBalpha, p-NF-kappaB and <ENT1>mitogen-activated protein kinases</ENT1> (<ENT1>MAPK</ENT1>), both in vivo and in vitro.",,,,T,,,,,c,,,,c,0.0,,
30836660,4244,5594,C009172,Negative_Correlation,TRUE,"Furthermore, <ENT2>Sal</ENT2> treatment significantly decreases the release of inflammatory cytokines and inhibits the TLR4/NF-kappaB and <ENT1>MAPK</ENT1> signaling pathways.",,,,T,,,,,w,,,,c,0.0,,
30836660,4234,16176,D007249,Association,FALSE,"Additionally, Sal also reduces the levels of serum biochemical markers (serum creatinine, Scr; blood urea nitrogen, BUN; and uric acid, UA) and decreases the release of <ENT2>inflammatory</ENT2> cytokines (<ENT1>IL-1beta</ENT1>, IL-6, TNF-alpha).",,,,T,,,,,w,,,,c,0.0,,
30836660,4258,16176,C009172,Negative_Correlation,TRUE,"Additionally, <ENT2>Sal</ENT2> also reduces the levels of serum biochemical markers (serum creatinine, Scr; blood urea nitrogen, BUN; and uric acid, UA) and decreases the release of inflammatory cytokines (<ENT1>IL-1beta</ENT1>, IL-6, TNF-alpha).",,,,T,,,,,c,,,,c,1.0,,
30836660,4232,D007249,16193,Association,FALSE,"Additionally, Sal also reduces the levels of serum biochemical markers (serum creatinine, Scr; blood urea nitrogen, BUN; and uric acid, UA) and decreases the release of <ENT1>inflammatory</ENT1> cytokines (IL-1beta, <ENT2>IL-6</ENT2>, TNF-alpha).",,,,T,,,,,w,,,,c,0.0,,
30836660,4252,D007249,C009172,Negative_Correlation,TRUE,"<ENT2>Salidroside</ENT2> (<ENT2>Sal</ENT2>) is an active ingredient that is isolated from Rhodiola rosea, which has been reported to have anti-<ENT1>inflammatory</ENT1> activities and a renal protective effect.",,,,T,,,,,w,,,,c,1.0,,
30836660,4252,D007249,C009172,Negative_Correlation,TRUE,"Additionally, <ENT2>Sal</ENT2> also reduces the levels of serum biochemical markers (serum creatinine, Scr; blood urea nitrogen, BUN; and uric acid, UA) and decreases the release of <ENT1>inflammatory</ENT1> cytokines (IL-1beta, IL-6, TNF-alpha).",,,,T,,,,,c,,,,c,1.0,,
30836660,4252,D007249,C009172,Negative_Correlation,TRUE,"Furthermore, <ENT2>Sal</ENT2> treatment significantly decreases the release of <ENT1>inflammatory</ENT1> cytokines and inhibits the TLR4/NF-kappaB and MAPK signaling pathways.",,,,T,,,,,c,,,,c,1.0,,
30836660,4259,D014527,C009172,Negative_Correlation,TRUE,"Additionally, <ENT2>Sal</ENT2> also reduces the levels of serum biochemical markers (serum creatinine, Scr; blood urea nitrogen, BUN; and <ENT1>uric acid</ENT1>, <ENT1>UA</ENT1>) and decreases the release of inflammatory cytokines (IL-1beta, IL-6, TNF-alpha).",,,,T,,,,,c,,,,c,1.0,,
30836660,4256,16193,C009172,Negative_Correlation,TRUE,"Additionally, <ENT2>Sal</ENT2> also reduces the levels of serum biochemical markers (serum creatinine, Scr; blood urea nitrogen, BUN; and uric acid, UA) and decreases the release of inflammatory cytokines (IL-1beta, <ENT1>IL-6</ENT1>, TNF-alpha).",,,,T,,,,,c,,,,c,1.0,,
30836660,4263,6591,C009172,Negative_Correlation,TRUE,"Furthermore, <ENT2>Sal</ENT2> administration significantly suppresses epithelial-mesenchymal transition (EMT), as evidenced by a decreased expression of alpha-SMA, vimentin, TGF-beta1, snail, <ENT1>slug</ENT1>, and a largely restored expression of E-cadherin.",,,,T,,,,,c,,,,c,0.0,,
30836660,4251,C009172,21898,Negative_Correlation,TRUE,<ENT1>Salidroside</ENT1> Ameliorates Renal Interstitial Fibrosis by Inhibiting the <ENT2>TLR4</ENT2>/NF-kappaB and MAPK Signaling Pathways.,,,,T,,T,,,c,,,,c,0.0,,
30836660,4251,C009172,21898,Negative_Correlation,TRUE,"Further study revealed that the effect of <ENT1>Sal</ENT1> on renal interstitial fibrosis is associated with the lower expression of <ENT2>TLR4</ENT2>, p-IkappaBalpha, p-NF-kappaB and mitogen-activated protein kinases (MAPK), both in vivo and in vitro.",,,,T,,,,,w,,,,c,1.0,,
30836660,4251,C009172,21898,Negative_Correlation,TRUE,"Furthermore, <ENT1>Sal</ENT1> treatment significantly decreases the release of inflammatory cytokines and inhibits the <ENT2>TLR4</ENT2>/NF-kappaB and MAPK signaling pathways.",,,,T,,,,,c,,,,c,0.0,,
30836660,4247,C009172,18033,Negative_Correlation,TRUE,<ENT1>Salidroside</ENT1> Ameliorates Renal Interstitial Fibrosis by Inhibiting the TLR4/<ENT2>NF-kappaB</ENT2> and MAPK Signaling Pathways.,,,,T,,T,,,c,,,,c,0.0,,
30836660,4247,C009172,18033,Negative_Correlation,TRUE,"Further study revealed that the effect of <ENT1>Sal</ENT1> on renal interstitial fibrosis is associated with the lower expression of TLR4, p-IkappaBalpha, p-<ENT2>NF-kappaB</ENT2> and mitogen-activated protein kinases (MAPK), both in vivo and in vitro.",,,,T,,,,,w,,,,c,0.0,,
30836660,4247,C009172,18033,Negative_Correlation,TRUE,"Furthermore, <ENT1>Sal</ENT1> treatment significantly decreases the release of inflammatory cytokines and inhibits the TLR4/<ENT2>NF-kappaB</ENT2> and MAPK signaling pathways.",,,,T,,,,,w,,,,c,0.0,,
30836660,4249,C009172,18035,Negative_Correlation,TRUE,"Further study revealed that the effect of <ENT1>Sal</ENT1> on renal interstitial fibrosis is associated with the lower expression of TLR4, p-<ENT2>IkappaBalpha</ENT2>, p-NF-kappaB and mitogen-activated protein kinases (MAPK), both in vivo and in vitro.",,,,T,,,,,w,,,,c,0.0,,